Evaluation	O
of	O
reducing	O
postoperative	O
hip	O
precautions	O
in	O
total	O
hip	O
replacement	O
:	O
a	O
randomized	O
prospective	O
study	O
.	O

Currently	O
,	O
many	O
rehabilitation	O
protocols	O
for	O
total	O
hip	O
replacements	O
(	O
THRs	O
)	O
include	O
activity	O
restrictions	O
to	O
prevent	O
postoperative	O
dislocation	O
.	O

There	O
is	O
increasing	O
demand	O
for	O
more	O
efficient	O
and	O
safe	O
rehabilitation	O
protocols	O
.	O

This	O
randomized	O
prospective	O
study	O
evaluates	O
the	O
need	O
for	O
hip	O
restrictions	O
following	O
a	O
modified	O
anterolateral	O
procedure	O
.	O

From	O
2004	O
to	O
2008	O
,	O
81	O
patients	O
seeking	O
elective	O
THRs	O
were	O
randomly	O
assigned	O
into	O
a	O
standard	O
rehabilitation	O
group	O
or	O
an	O
early	O
rehabilitation	O
group	O
.	O

The	O
standard	O
group	O
included	O
restrictions	Physical
to	Physical
avoid	Physical
hip	Physical
flexion	Physical
>	Physical
90	Physical
degrees	Physical
and	Physical
avoidance	Physical
of	Physical
riding	Physical
in	Physical
a	Physical
car	Physical
for	Physical
the	Physical
first	Physical
postoperative	Physical
month	Physical
.	Physical

The	O
early	O
group	O
had	O
no	Physical
flexion	Physical
or	Physical
car	Physical
riding	Physical
restrictions	Physical
.	O

Forty-three	O
patients	O
were	O
in	O
the	O
standard	O
group	O
and	O
38	O
patients	O
were	O
in	O
the	O
early	O
group	O
.	O

There	O
were	O
no	O
significant	O
demographic	O
differences	O
between	O
the	O
2	O
groups	O
.	O

All	O
patients	O
completed	O
the	O
Short	O
Form	O
12-question	O
Health	O
Survey	O
and	O
Harris	O
Hip	O
Score	O
preoperatively	O
and	O
at	O
4	O
weeks	O
,	O
1	O
month	O
,	O
3	O
months	O
,	O
and	O
1	O
year	O
postoperatively	O
.	O

The	O
time-points	O
at	O
which	O
the	O
patient	O
first	O
drove	O
and	O
ambulated	O
with	O
a	O
cane	O
,	O
without	O
a	O
cane	O
,	O
and	O
without	O
a	O
limp	O
were	O
also	O
collected	O
.	O

No	O
incidents	O
of	O
dislocation	O
occurred	O
.	O

Patients	O
in	O
the	O
early	O
group	O
were	O
faster	O
to	O
ambulate	O
with	O
only	O
a	O
cane	O
(	O
P=.03	O
)	O
,	O
without	O
a	O
cane	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
without	O
a	O
limp	O
(	O
P=.003	O
)	O
.	O

They	O
also	O
drove	O
earlier	O
(	O
P=.02	O
)	O
.	O

Pace	O
of	O
recovery	O
was	O
the	O
only	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
.	O

The	O
early	Physical
rehabilitation	Physical
protocol	Physical
increases	O
the	O
pace	O
of	O
recovery	O
compared	O
to	O
a	O
pathway	O
with	O
hip	O
precautions	O
without	O
increasing	O
complications	O
.	O

Improved	O
survival	O
with	O
early	Educational
intensification	Educational
:	O
combined	O
results	O
from	O
the	O
Medical	O
Research	O
Council	O
childhood	O
ALL	O
randomised	O
trials	O
,	O
UKALL	O
X	O
and	O
UKALL	O
XI	O
.	O

Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Childhood	O
Leukaemia	O
.	O

The	O
Medical	O
Research	O
Council	O
(	O
MRC	O
)	O
United	O
Kingdom	O
trial	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
UKALL	O
X	O
)	O
randomised	O
patients	O
aged	O
0-14	O
years	O
inclusive	O
with	O
an	O
initial	O
white	O
blood	O
count	O
of	O
less	O
than	O
100	O
x	O
10	O
(	O
9	O
)	O
/l	O
to	O
receive	O
an	Other
early	Other
intensification	Other
block	Other
,	O
a	O
late	Other
intensification	Other
block	Other
,	O
both	O
,	O
or	O
neither	O
.	O

The	O
next	O
trial	O
,	O
UKALL	O
XI	O
,	O
for	O
children	O
aged	O
1-14	O
years	O
,	O
randomised	O
between	O
different	Physical
central	Physical
nervous	Physical
system	Physical
(	Physical
CNS	Physical
)	Physical
directed	Physical
therapies	Physical
.	O

At	O
the	O
beginning	O
of	O
the	O
trial	O
,	O
all	O
patients	O
were	O
also	O
randomised	O
between	O
late	Educational
intensification	Educational
alone	Educational
and	O
both	Educational
early	Educational
plus	Educational
late	Educational
blocks	Educational
.	O

The	O
effects	O
of	O
both	O
the	O
early	O
and	O
the	O
late	O
block	O
in	O
UKALL	O
X	O
alone	O
have	O
been	O
reported	O
previously	O
.	O

This	O
paper	O
examines	O
the	O
effect	O
of	O
the	O
addition	O
of	O
the	O
early	O
intensification	O
block	O
to	O
treatment	O
which	O
included	O
late	O
intensification	O
,	O
combining	O
the	O
data	O
from	O
UKALL	O
X	O
and	O
the	O
first	O
part	O
of	O
UKALL	O
XI	O
.	O

Early	O
intensification	O
was	O
associated	O
with	O
fewer	O
bone	O
marrow	O
relapses	O
and	O
a	O
reduction	O
in	O
the	O
odds	O
of	O
death	O
of	O
0.63	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
0.46-0.87	O
)	O
.	O

Survival	O
was	O
significantly	O
improved	O
with	O
an	O
increase	O
at	O
5	O
years	O
of	O
8	O
%	O
,	O
from	O
79	O
to	O
87	O
%	O
.	O

Following	O
this	O
demonstration	O
that	O
early	O
intensification	O
improves	O
survival	O
,	O
the	O
effect	O
of	O
a	O
third	O
intensification	O
block	O
is	O
under	O
investigation	O
.	O

Genetic	O
associations	O
with	O
lipoprotein	Physical
subfractions	Physical
provide	O
information	O
on	O
their	O
biological	O
nature	O
.	O

Adverse	O
levels	O
of	O
lipoproteins	Pharmacological
are	O
highly	O
heritable	O
and	O
constitute	O
risk	O
factors	O
for	O
cardiovascular	O
outcomes	O
.	O

Hitherto	O
,	O
genome-wide	O
association	O
studies	O
revealed	O
95	O
lipid-associated	O
loci	O
.	O

However	O
,	O
due	O
to	O
the	O
small	O
effect	O
sizes	O
of	O
these	O
associations	O
large	O
sample	O
numbers	O
(	O
>	O
100	O
000	O
samples	O
)	O
were	O
needed	O
.	O

Here	O
we	O
show	O
that	O
analyzing	O
more	O
refined	O
lipid	O
phenotypes	O
,	O
namely	O
lipoprotein	Pharmacological
subfractions	Pharmacological
,	O
can	O
increase	O
the	O
number	O
of	O
significantly	O
associated	O
loci	O
compared	O
with	O
bulk	O
high-density	Pharmacological
lipoprotein	Pharmacological
and	O
low-density	Pharmacological
lipoprotein	Pharmacological
analysis	O
in	O
a	O
study	O
with	O
identical	O
sample	O
numbers	O
.	O

Moreover	O
,	O
lipoprotein	Pharmacological
subfractions	Pharmacological
provide	O
novel	O
insight	O
into	O
the	O
human	O
lipid	O
metabolism	O
.	O

We	O
measured	O
15	Pharmacological
lipoprotein	Pharmacological
subfractions	Pharmacological
(	Pharmacological
L1-L15	Pharmacological
)	Pharmacological
in	O
1791	O
samples	O
using	O
(	Physical
1	Physical
)	Physical
H-NMR	Physical
(	Physical
nuclear	Physical
magnetic	Physical
resonance	Physical
)	Physical
spectroscopy	Physical
.	Physical

Using	O
cluster	O
analyses	O
,	O
we	O
quantified	O
inter-relationships	O
among	O
lipoprotein	Physical
subfractions	Physical
.	O

Additionally	O
,	O
we	O
analyzed	O
associations	O
with	O
subfractions	Physical
at	O
known	O
lipid	O
loci	O
.	O

We	O
identified	O
five	O
distinct	O
groups	O
of	O
subfractions	O
:	O
one	O
(	O
L1	Pharmacological
)	O
was	O
only	O
marginally	O
captured	O
by	O
serum	O
lipids	O
and	O
therefore	O
extends	O
our	O
knowledge	O
of	O
lipoprotein	O
biochemistry	O
.	O

During	O
a	O
lipid-tolerance	O
test	O
,	O
L1	Physical
lost	O
its	O
special	O
position	O
.	O

In	O
the	O
association	O
analysis	O
,	O
we	O
found	O
that	O
eight	O
loci	O
(	O
LIPC	O
,	O
CETP	O
,	O
PLTP	O
,	O
FADS1-2-3	O
,	O
SORT1	O
,	O
GCKR	O
,	O
APOB	O
,	O
APOA1	O
)	O
were	O
associated	O
with	O
the	O
subfractions	O
,	O
whereas	O
only	O
four	O
loci	O
(	O
CETP	O
,	O
SORT1	O
,	O
GCKR	O
,	O
APOA1	O
)	O
were	O
associated	O
with	O
serum	O
lipids	O
.	O

For	O
LIPC	O
,	O
we	O
observed	O
a	O
10-fold	O
increase	O
in	O
the	O
variance	O
explained	O
by	O
our	O
regression	O
models	O
.	O

In	O
conclusion	O
,	O
NMR-based	O
fine	O
mapping	O
of	O
lipoprotein	Physical
subfractions	Physical
provides	O
novel	O
information	O
on	O
their	O
biological	O
nature	O
and	O
strengthens	O
the	O
associations	O
with	O
genetic	O
loci	O
.	O

Future	O
clinical	O
studies	O
are	O
now	O
needed	O
to	O
investigate	O
their	O
biomedical	O
relevance	O
.	O

Cophenylcaine	Pharmacological
spray	O
vs.	O
placebo	Control
in	O
flexible	O
nasendoscopy	O
:	O
a	O
prospective	O
double-blind	O
randomised	O
controlled	O
trial	O
.	O

Practices	O
vary	O
across	O
the	O
UK	O
on	O
the	O
use	O
of	O
topical	O
preparation	O
prior	O
to	O
flexible	O
fibreoptic	O
nasendoscopy	O
.	O

In	O
this	O
double-blind	O
study	O
,	O
we	O
randomised	O
98	O
patients	O
to	O
receive	O
cophenylcaine	Pharmacological
or	Control
placebo	Control
nasal	Control
spray	Control
before	O
flexible	O
nasendoscopy	O
.	O

A	O
visual	O
analogue	O
scale	O
(	O
1-100	O
)	O
was	O
used	O
to	O
record	O
pain	O
,	O
unpleasantness	O
of	O
taste	O
and	O
overall	O
discomfort	O
experienced	O
.	O

Overall	O
,	O
the	O
procedure	O
was	O
associated	O
with	O
minimal	O
pain	O
and	O
discomfort	O
in	O
both	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
pain	O
or	O
overall	O
discomfort	O
experienced	O
between	O
the	O
two	O
groups	O
;	O
however	O
,	O
the	O
sensation	O
of	O
bad	O
taste	O
was	O
significantly	O
worse	O
in	O
the	O
cophenylcaine	Pharmacological
group	O
.	O

In	O
linear	O
regression	O
,	O
factors	O
that	O
predicted	O
the	O
overall	O
unpleasantness	O
of	O
the	O
experience	O
were	O
primarily	O
pain	O
experienced	O
and	O
secondarily	O
unpleasantness	O
of	O
taste	O
.	O

We	O
conclude	O
that	O
the	O
routine	O
use	O
of	O
cophenylcaine	Pharmacological
for	O
nasal	O
preparation	O
is	O
not	O
justified	O
before	O
flexible	O
nasendoscopy	O
.	O

A	O
randomized	O
trial	O
of	O
genetic	Educational
and	Educational
environmental	Educational
risk	Educational
assessment	Educational
(	Educational
GERA	Educational
)	Educational
for	O
colorectal	O
cancer	O
risk	O
in	O
primary	O
care	O
:	O
trial	O
design	O
and	O
baseline	O
findings	O
.	O

PURPOSE	O
This	O
paper	O
describes	O
an	O
ongoing	O
randomized	O
controlled	O
trial	O
designed	O
to	O
assess	O
the	O
impact	O
of	O
genetic	Educational
and	Educational
environmental	Educational
risk	Educational
assessment	Educational
(	Educational
GERA	Educational
)	Educational
on	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
screening	O
.	O

METHODS	O
The	O
trial	O
includes	O
asymptomatic	O
patients	O
who	O
are	O
50-79years	O
and	O
are	O
not	O
up-to-date	O
with	O
CRC	O
screening	O
guidelines	O
.	O

Patients	O
who	O
responded	O
to	O
a	O
baseline	O
telephone	O
survey	O
are	O
randomized	O
to	O
a	O
GERA	Educational
or	Educational
Control	Control
group	Control
.	O

GERA	O
group	O
participants	O
meet	O
with	O
a	O
nurse	O
,	O
decide	O
whether	O
to	O
have	O
a	O
GERA	O
blood	Physical
test	Physical
(	O
a	O
combination	O
of	O
genetic	O
polymorphism	Pharmacological
and	O
folate	Pharmacological
)	O
,	O
and	O
,	O
if	O
tested	O
,	O
receive	O
GERA	O
feedback	O
.	O

Follow-up	Other
telephone	Other
surveys	Other
are	Other
conducted	Other
at	Other
1	Other
and	Other
6months	Other
.	O

A	O
chart	O
audit	O
is	O
performed	O
at	O
6months	O
.	O

RESULTS	O
Of	O
2,223	O
eligible	O
patients	O
,	O
562	O
(	O
25	O
%	O
)	O
have	O
enrolled	O
.	O

Patients	O
who	O
enrolled	O
in	O
the	O
study	O
were	O
significantly	O
younger	O
than	O
those	O
who	O
did	O
not	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Participants	O
tended	O
to	O
be	O
50-59years	O
(	O
64	O
%	O
)	O
,	O
female	O
(	O
58	O
%	O
)	O
,	O
white	O
(	O
52	O
%	O
)	O
,	O
married	O
(	O
51	O
%	O
)	O
,	O
and	O
have	O
more	O
than	O
a	O
high	O
school	O
education	O
(	O
67	O
%	O
)	O
.	O

At	O
baseline	O
,	O
most	O
participants	O
had	O
some	O
knowledge	O
of	O
CRC	O
screening	O
and	O
GERA	Physical
,	O
viewed	O
CRC	O
screening	O
favorably	O
,	O
and	O
reported	O
that	O
they	O
had	O
decided	O
to	O
do	O
screening	O
.	O

Almost	O
half	O
had	O
worries	O
and	O
concerns	O
about	O
CRC	O
.	O

CONCLUSIONS	O
One	O
in	O
four	O
eligible	O
primary	O
care	O
patients	O
enrolled	O
in	O
the	O
study	O
.	O

Age	O
was	O
negatively	O
associated	O
with	O
enrollment	O
.	O

Prospective	O
analyses	O
using	O
data	O
for	O
all	O
participants	O
will	O
provide	O
more	O
definitive	O
information	O
on	O
GERA	O
uptake	O
and	O
the	O
impact	O
of	O
GERA	O
feedback	O
.	O

Scaling	O
clinical	O
judgments	O
of	O
symptom	O
pathology	O
by	O
means	O
of	O
the	O
psychophysiological	O
method	O
of	O
magnitude	O
estimation	O
.	O

Summing	O
scores	O
across	O
heterogeneous	O
symptom	O
items	O
without	O
consideration	O
of	O
their	O
differing	O
psychopathological	O
significance	O
has	O
been	O
criticized	O
as	O
producing	O
an	O
inadequate	O
picture	O
of	O
an	O
individual	O
's	O
clinical	O
status	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
derive	O
symptom	O
item	O
weights	O
representing	O
clinically	O
judged	O
seriousness	O
of	O
each	O
symptom	O
through	O
the	O
application	O
of	O
Steven	Educational
's	Educational
psychophysical	Educational
method	Educational
of	Educational
magnitude	Educational
estimation	Educational
.	Educational

A	O
nationwide	O
sample	O
of	O
129	O
clinicians	O
rated	O
the	O
pathological	O
significance	O
of	O
221	O
symptom	O
items	O
in	O
a	O
design	O
such	O
that	O
every	O
rater	O
rated	O
121	O
items	O
,	O
21	O
of	O
which	O
were	O
rated	O
by	O
all	O
raters	O
and	O
100	O
of	O
which	O
were	O
rated	O
only	O
by	O
the	O
A	O
or	O
B	O
subgroup	O
to	O
which	O
each	O
rater	O
was	O
randomly	O
assigned	O
.	O

Each	O
item	O
was	O
rated	O
as	O
to	O
the	O
seriousness	O
of	O
the	O
pathology	O
it	O
would	O
represent	O
if	O
manifested	O
by	O
either	O
a	O
boy	O
child	O
,	O
girl	O
child	O
,	O
boy	O
adolescent	O
,	O
or	O
girl	O
adolescent	O
,	O
with	O
one-fourth	O
of	O
the	O
raters	O
assigned	O
to	O
each	O
condition	O
.	O

The	O
results	O
of	O
211	O
two-way	O
analyses	O
of	O
variance	O
revealed	O
that	O
age	O
and	O
age	O
and	O
sex	O
in	O
interaction	O
,	O
but	O
not	O
sex	O
alone	O
,	O
significantly	O
influenced	O
the	O
clinical	O
ratings	O
.	O

The	O
resulting	O
magnitude	O
estimation	O
ratings	O
of	O
symptom	O
pathology	O
ranged	O
from	O
1.0	O
to	O
9.9	O
.	O

They	O
were	O
demonstrated	O
to	O
have	O
satisfactoy	O
reliability	O
and	O
convergent	O
validity	O
and	O
to	O
have	O
the	O
psychophysical	O
characteristics	O
of	O
a	O
prothetic	O
continuum	O
.	O

Family	Educational
economic	Educational
empowerment	Educational
and	O
mental	O
health	O
among	O
AIDS-affected	O
children	O
living	O
in	O
AIDS-impacted	O
communities	O
:	O
evidence	O
from	O
a	O
randomised	O
evaluation	O
in	O
southwestern	O
Uganda	O
.	O

OBJECTIVE	O
The	O
authors	O
examine	O
whether	O
an	O
innovative	O
family	Educational
economic	Educational
empowerment	Educational
intervention	O
addresses	O
mental	O
health	O
functioning	O
of	O
AIDS-affected	O
children	O
in	O
communities	O
heavily	O
impacted	O
by	O
HIV/AIDS	O
in	O
Uganda	O
.	O

METHODS	O
A	O
cluster	O
randomised	O
controlled	O
trial	O
consisting	O
of	O
two	O
study	O
arms	O
,	O
a	O
treatment	O
condition	O
(	O
n=179	O
)	O
and	O
a	O
control	Control
condition	Control
(	O
n=118	O
)	O
,	O
was	O
used	O
to	O
examine	O
the	O
impact	O
of	O
the	O
family	Educational
economic	Educational
empowerment	Educational
intervention	Educational
on	O
children	O
's	O
levels	O
of	O
hopelessness	O
and	O
depression	O
.	O

The	O
intervention	O
comprised	O
matched	Educational
children	Educational
savings	Educational
accounts	Educational
,	Educational
financial	Educational
management	Educational
workshops	Educational
and	Educational
mentorship	Educational
.	Educational

Data	O
were	O
collected	O
at	O
baseline	O
and	O
12	O
months	O
post-intervention	O
.	O

RESULTS	O
Using	O
multivariate	O
analysis	O
with	O
several	O
socioeconomic	O
controls	O
,	O
the	O
authors	O
find	O
that	O
children	O
in	O
the	O
treatment	O
condition	O
(	O
receiving	O
the	O
intervention	O
)	O
report	O
significant	O
improvement	O
in	O
their	O
mental	O
health	O
functioning	O
.	O

Specifically	O
,	O
the	O
intervention	O
reduces	O
hopelessness	O
and	O
depression	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
children	O
in	O
the	O
control	O
condition	O
(	O
not	O
receiving	O
the	O
intervention	O
)	O
report	O
no	O
changes	O
on	O
both	O
measures	O
.	O

CONCLUSIONS	O
The	O
findings	O
indicate	O
that	O
children	O
with	O
poor	O
mental	O
health	O
functioning	O
living	O
in	O
communities	O
affected	O
by	O
HIV/AIDS	O
may	O
benefit	O
from	O
innovative	O
family	O
economic	O
empowerment	O
interventions	O
.	O

As	O
measures	O
of	O
mental	O
health	O
functioning	O
,	O
both	O
hopelessness	O
and	O
depression	O
have	O
long-term	O
negative	O
psychosocial	O
and	O
developmental	O
impacts	O
on	O
children	O
.	O

These	O
findings	O
have	O
implications	O
for	O
public	O
health	O
programmes	O
intended	O
for	O
long-term	O
care	O
and	O
support	O
of	O
children	O
living	O
in	O
resource	O
poor	O
AIDS-impacted	O
communities	O
.	O

Safety	O
of	O
the	O
combination	Pharmacological
of	Pharmacological
valsartan	Pharmacological
and	O
benazepril	Pharmacological
in	O
patients	O
with	O
chronic	O
renal	O
disease	O
.	O

European	O
Group	O
for	O
the	O
Investigation	O
of	O
Valsartan	Pharmacological
in	O
Chronic	O
Renal	O
Disease	O
.	O

OBJECTIVE	O
Several	O
experimental	O
and	O
clinical	O
studies	O
indicate	O
that	O
the	O
renin	O
system	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
progressing	O
renal	O
disease	O
.	O

The	O
combination	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
and	O
an	O
angiotensin	O
receptor	O
blocker	O
could	O
provide	O
a	O
higher	O
degree	O
of	O
blockade	O
of	O
the	O
renin-angiotensin	O
system	O
than	O
either	O
agent	O
alone	O
.	O

Such	O
enhanced	O
suppression	O
might	O
be	O
of	O
benefit	O
for	O
patients	O
exhibiting	O
a	O
progressive	O
decline	O
in	O
renal	O
function	O
because	O
of	O
chronic	O
renal	O
disease	O
.	O

METHODS	O
A	O
pilot	O
multinational	O
,	O
multicentre	O
,	O
randomized	O
,	O
active-controlled	O
,	O
parallel	O
group	O
open-label	O
study	O
has	O
been	O
conducted	O
in	O
a	O
group	O
of	O
patients	O
with	O
progressive	O
chronic	O
renal	O
failure	O
(	O
creatinine	O
clearance	O
20-45	O
ml/min	O
)	O
either	O
with	O
or	O
without	O
proteinuria	O
and	O
hypertension	O
.	O

The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
tolerability	O
of	O
the	O
combination	Pharmacological
of	Pharmacological
valsartan	Pharmacological
and	O
benazepril	Pharmacological
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
group	O
1	O
received	O
valsartan	Pharmacological
160	Pharmacological
mg	Pharmacological
once	O
daily	O
(	O
n	O
=	O
22	O
)	O
;	O
group	O
2	O
received	O
valsartan	Pharmacological
80	Pharmacological
mg	Pharmacological
once	Pharmacological
daily	Pharmacological
plus	O
benazepril	Pharmacological
5	Pharmacological
or	Pharmacological
10	Pharmacological
mg	Pharmacological
once	Pharmacological
daily	Pharmacological
(	O
n	O
=	O
42	O
)	O
;	O
group	O
3	O
received	O
valsartan	Pharmacological
160	Pharmacological
mg	Pharmacological
once	O
daily	O
plus	O
benazepril	Pharmacological
5	Pharmacological
or	Pharmacological
10	Pharmacological
mg	Pharmacological
once	O
daily	O
(	O
n	O
=	O
44	O
)	O
.	O

The	O
study	O
lasted	O
for	O
5	O
weeks	O
,	O
and	O
in	O
groups	O
2	O
and	O
3	O
benazepril	O
was	O
added	O
on	O
top	O
of	O
valsartan	O
after	O
the	O
first	O
week	O
of	O
therapy	O
with	O
the	O
angiotensin	O
receptor	O
blocker	O
.	O

RESULTS	O
Serum	O
creatinine	O
increased	O
in	O
all	O
three	O
groups	O
(	O
mean	O
change	O
within	O
a	O
group	O
:	O
11	O
micromol/l	O
in	O
group	O
1	O
,	O
P=	O
0.045	O
;	O
9	O
micromol/l	O
in	O
group	O
2	O
,	O
P=	O
0.030	O
;	O
15	O
micromol/l	O
in	O
group	O
3	O
,	O
P=	O
0.0006	O
)	O
.	O

Serum	O
potassium	O
also	O
increased	O
in	O
all	O
three	O
groups	O
of	O
patients	O
(	O
mean	O
change	O
within	O
a	O
group	O
:	O
0.28	O
mmol/l	O
in	O
group	O
1	O
,	O
P=	O
0.28	O
;	O
0.48	O
mmol/l	O
in	O
group	O
2	O
,	O
P=	O
0.0008	O
;	O
0.36	O
mmol/l	O
in	O
group	O
3	O
,	O
P=	O
0.02	O
)	O
.	O

After	O
5	O
weeks	O
of	O
treatment	O
,	O
the	O
largest	O
decrease	O
in	O
blood	O
pressure	O
was	O
observed	O
in	O
group	O
3	O
(	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
seated	O
diastolic	O
blood	O
pressure	O
(	O
SDBP	O
)	O
and	O
seated	O
systolic	O
blood	O
pressure	O
(	O
SSBP	O
)	O
,	O
respectively	O
,	O
were	O
:	O
-2.0	O
and	O
-11.5	O
mmHg	O
in	O
group	O
1	O
;	O
-7.6	O
and	O
-15.4	O
mmHg	O
in	O
group	O
2	O
;	O
-12.6	O
and	O
-21.6	O
mmHg	O
in	O
group	O
3	O
)	O
.	O

In	O
addition	O
,	O
both	O
combination	O
treatments	O
resulted	O
in	O
the	O
reduction	O
of	O
proteinuria	O
.	O

The	O
total	O
number	O
of	O
patients	O
with	O
adverse	O
experiences	O
were	O
10	O
(	O
45.5	O
%	O
)	O
,	O
14	O
(	O
33.3	O
%	O
)	O
and	O
11	O
(	O
25	O
%	O
)	O
in	O
groups	O
1,2	O
and	O
3	O
,	O
respectively	O
.	O

In	O
six	O
patients	O
(	O
5.6	O
%	O
)	O
therapy	O
was	O
discontinued	O
as	O
a	O
result	O
of	O
adverse	O
experiences	O
.	O

Only	O
one	O
patient	O
in	O
each	O
of	O
the	O
combined	O
therapy	O
groups	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
hyperkalaemia	O
and	O
no	O
patients	O
were	O
forced	O
to	O
withdraw	O
because	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	O
,	O
acute	O
renal	O
failure	O
or	O
hospitalization	O
.	O

CONCLUSIONS	O
These	O
results	O
indicate	O
that	O
short-term	O
combination	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
and	O
an	O
angiotensin	O
receptor	O
blocker	O
is	O
safe	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
moderate	O
chronic	O
renal	O
failure	O
.	O

Controlled	O
trial	O
of	O
induction	O
of	O
labor	O
by	O
vaginal	O
suppositories	Pharmacological
containing	O
prostaglandin	Pharmacological
E2	Pharmacological
.	O

A	O
group	O
of	O
84	O
women	O
at	O
39-43	O
weeks	O
of	O
pregnancy	O
were	O
randomly	O
allocated	O
to	O
a	O
blind	O
trial	O
of	O
induction	O
of	O
labor	O
with	O
vaginal	O
suppositories	Pharmacological
containing	O
inert	Control
material	Control
or	O
either	O
0.2	O
mg	O
or	O
0.4	O
mg	O
of	O
prostaglandin	Pharmacological
E2	Pharmacological
.	O

The	O
suppositories	O
were	O
self-administered	O
every	O
two	O
hours	O
during	O
waking	O
hours	O
on	O
two	O
successive	O
days	O
until	O
labor	O
started	O
or	O
15	O
had	O
been	O
used	O
.	O

Side-effects	O
were	O
absent	O
.	O

Labor	O
was	O
established	O
within	O
48	O
hr	O
of	O
insertion	O
of	O
the	O
first	O
suppository	O
in	O
9.3	O
%	O
of	O
control	O
patients	O
,	O
65.4	O
%	O
of	O
those	O
treated	O
with	O
0.2	O
mg	O
PGE2	Pharmacological
and	O
85.7	O
%	O
of	O
those	O
treated	O
with	O
0.4	O
mg	O
PGE2	Pharmacological
.	O

The	O
mean	O
Apgar	O
scores	O
in	O
the	O
three	O
groups	O
were	O
the	O
same	O
.	O

The	O
mean	O
total	O
dose	O
of	O
PGE2	Pharmacological
were	O
2.0	O
mg	O
(	O
0.2	O
mg	O
group	O
)	O
and	O
2.3	O
mg	O
(	O
0.4	O
mg	O
group	O
)	O
.	O

It	O
is	O
concluded	O
that	O
vaginal	O
PGE2	Pharmacological
is	O
an	O
effective	O
and	O
acceptable	O
method	O
of	O
inducing	O
labor	O
at	O
term	O
.	O

Circadian	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
oral	O
ketoprofen	Pharmacological
.	O

Several	O
investigations	O
which	O
have	O
taken	O
treatment	O
time	O
into	O
account	O
have	O
shown	O
that	O
the	O
pharmacokinetic	O
parameters	O
,	O
the	O
therapeutic	O
efficacy	O
and	O
even	O
the	O
toxicity	O
of	O
a	O
large	O
number	O
of	O
products	O
may	O
vary	O
according	O
to	O
the	O
administration	O
schedule	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
evaluate	O
any	O
circadian	O
changes	O
in	O
pharmacokinetic	O
parameters	O
of	O
ketoprofen	Pharmacological
,	O
a	O
new	O
non-steroidal	O
anti-inflammatory	O
drug	O
(	O
NSAID	O
)	O
.	O

This	O
randomised	O
crossover	O
study	O
consisted	O
of	O
a	O
single	O
oral	O
dose	O
of	O
ketoprofen	Pharmacological
100mg	O
administered	O
to	O
8	O
healthy	O
male	O
volunteers	O
,	O
mean	O
age	O
27.2	O
years	O
,	O
at	O
07.00	O
hours	O
,	O
13.00	O
hours	O
,	O
19.00	O
hours	O
or	O
01.00	O
hours	O
in	O
4	O
study	O
periods	O
during	O
the	O
first	O
3	O
months	O
of	O
the	O
year	O
.	O

The	O
order	O
of	O
administration	O
was	O
randomised	O
,	O
with	O
each	O
subject	O
acting	O
as	O
his	O
own	O
control	O
.	O

A	O
total	O
of	O
14	O
blood	O
and	O
4	O
urine	O
samples	O
were	O
taken	O
over	O
a	O
12-hour	O
period	O
.	O

The	O
peak	O
plasma	O
concentration	O
was	O
twice	O
as	O
high	O
after	O
drug	O
administration	O
at	O
07.00	O
hours	O
(	O
13.4	O
+/-	O
1	O
mg/L	O
)	O
than	O
after	O
other	O
administration	O
times	O
(	O
13.00	O
hours	O
:	O
6.9	O
+/-	O
1	O
;	O
19.00	O
hours	O
:	O
7.2	O
+/-	O
0.7	O
;	O
01.00	O
hours	O
:	O
6.3	O
+/-	O
0.5	O
mg/L	O
)	O
[	O
p	O
less	O
than	O
0.001	O
]	O
.	O

The	O
time	O
to	O
reach	O
peak	O
concentration	O
was	O
much	O
longer	O
after	O
drug	O
administration	O
at	O
01.00	O
hours	O
(	O
135	O
+/-	O
16.7	O
min	O
)	O
than	O
at	O
07.00	O
(	O
73.1	O
+/-	O
14.1	O
min	O
)	O
,	O
13.00	O
(	O
75	O
+/-	O
16.5	O
min	O
)	O
or	O
19.00	O
hours	O
(	O
82.5	O
+/-	O
12.7	O
min	O
)	O
[	O
p	O
less	O
than	O
0.05	O
]	O
.	O

The	O
lag	O
time	O
was	O
significantly	O
longer	O
at	O
01.00	O
hours	O
than	O
at	O
13.00	O
hours	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

The	O
absorption	O
rate	O
constant	O
after	O
treatment	O
at	O
01.00	O
hours	O
was	O
less	O
than	O
at	O
the	O
other	O
times	O
of	O
administration	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
bodyweight-corrected	O
area	O
under	O
the	O
curve	O
(	O
AUC0-12	O
)	O
was	O
greater	O
after	O
07.00	O
hours	O
than	O
after	O
13.00	O
(	O
p	O
less	O
than	O
0.01	O
)	O
or	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
greater	O
after	O
01.00	O
hours	O
than	O
after	O
13.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
elimination	O
half-life	O
was	O
significantly	O
longer	O
after	O
administration	O
at	O
01.00	O
hours	O
than	O
after	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
while	O
the	O
total	O
clearance	O
was	O
lowest	O
at	O
07.00	O
hours	O
.	O

Cosinor	O
analysis	O
demonstrated	O
statistically	O
significant	O
circadian	O
rhythms	O
for	O
all	O
pharmacokinetic	O
parameters	O
described	O
above	O
.	O

The	O
amount	O
of	O
ketoprofen	Pharmacological
eliminated	O
in	O
the	O
urine	O
was	O
delayed	O
,	O
and	O
was	O
significantly	O
greater	O
after	O
the	O
administration	O
at	O
01.00	O
hours	O
than	O
07.00	O
hours	O
or	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

The	O
relationship	O
between	O
absorption	O
,	O
diffusion	O
and/or	O
elimination	O
mechanisms	O
of	O
the	O
drug	O
are	O
discussed	O
.	O

Using	O
the	O
demand-control	O
model	O
of	O
job	O
strain	O
to	O
predict	O
caregiver	O
burden	O
and	O
caregiver	O
satisfaction	O
in	O
the	O
informal	O
caregivers	O
of	O
heart	O
failure	O
patients	O
.	O

OBJECTIVES	O
The	Other
demand-control	Other
(	Other
D-C	Other
)	Other
model	Other
of	Other
job	Other
strain	Other
has	O
generated	O
a	O
considerable	O
body	O
of	O
empirical	O
support	O
in	O
predicting	O
psychological	O
health	O
outcomes	O
in	O
the	O
context	O
of	O
work	O
.	O

This	O
study	O
aimed	O
to	O
extend	O
previous	O
work	O
using	O
the	O
D-C	Physical
model	Physical
of	Physical
job	Physical
strain	Physical
to	O
predict	O
caregiver	O
burden	O
and	O
satisfaction	O
in	O
the	O
informal	O
caregivers	O
of	O
patients	O
with	O
heart	O
failure	O
.	O

DESIGN	O
AND	O
METHOD	O
Data	O
were	O
gathered	O
from	O
60	O
caregiver/patient	O
dyads	O
in	O
a	O
cross-sectional	O
design	O
.	O

Patients	O
with	O
chronic	O
stable	O
heart	O
failure	O
were	O
recruited	O
from	O
out-patient	O
clinics	O
.	O

The	O
dependent	O
variables	O
were	O
caregiver	Educational
burden	Educational
and	Educational
satisfaction	Educational
.	Educational

Demand	O
and	O
control	O
were	O
measured	O
using	O
both	O
patient-	O
and	O
caregiver-derived	O
measures	O
.	O

RESULTS	O
The	O
D-C	Physical
model	Physical
accounted	O
for	O
15	O
and	O
19	O
%	O
of	O
the	O
variance	O
in	O
caregiver	O
burden	O
,	O
after	O
controlling	O
for	O
age	O
,	O
gender	O
and	O
relationship	O
to	O
the	O
patient	O
.	O

Lower	O
control	O
was	O
associated	O
with	O
higher	O
burden	O
.	O

The	O
D-C	Physical
model	Physical
did	O
not	O
predict	O
caregiver	O
satisfaction	O
.	O

CONCLUSION	O
The	O
D-C	Physical
model	Physical
was	O
associated	O
with	O
caregiver	O
burden	O
,	O
but	O
not	O
satisfaction	O
in	O
caregivers	O
,	O
with	O
control	O
being	O
the	O
dominant	O
predictor	O
.	O

Research	O
linking	O
the	O
theory	O
and	O
findings	O
from	O
job	O
strain	O
and	O
informal	O
caregiving	O
studies	O
may	O
elucidate	O
both	O
fields	O
of	O
research	O
.	O

Using	O
the	O
demand-control	Physical
model	Physical
of	Physical
job	Physical
strain	Physical
to	O
predict	O
caregiver	O
burden	O
and	O
caregiver	O
satisfaction	O
in	O
the	O
informal	O
caregivers	O
of	O
heart	O
failure	O
patients	O
.	O

Efficacy	O
and	O
safety	O
of	O
zidovudine	Pharmacological
and	Pharmacological
zalcitabine	Pharmacological
combined	O
with	O
a	O
combination	O
of	O
herbs	O
in	O
the	O
treatment	O
of	O
HIV-infected	O
Thai	O
patients	O
.	O

A	O
randomized	O
double	O
blind	O
placebo	Control
controlled	O
trial	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
combined-herbs	O
(	O
SH	O
)	O
given	O
with	O
zidovudine	Pharmacological
(	O
ZDV	O
)	O
and	O
zalcitabine	Pharmacological
(	O
ddC	O
)	O
for	O
the	O
treatment	O
of	O
HIV	O
infection	O
in	O
Thai	O
adults	O
was	O
conducted	O
in	O
3	O
hospitals	O
in	O
northern	O
Thailand	O
during	O
2002	O
to	O
2003	O
.	O

The	O
eligible	O
subjects	O
were	O
HIV-infected	O
Thai	O
adults	O
who	O
had	O
never	O
received	O
anti-retrovirals	Pharmacological
,	O
had	O
a	O
Karnofski	O
Performance	O
Score	O
(	O
KPS	O
)	O
of	O
>	O
or	O
=	O
70	O
,	O
and	O
had	O
no	O
opportunistic	O
infections	O
.	O

The	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
combination	O
of	O
ZDV	Pharmacological
200	O
mg	O
three	O
times	O
per	O
day	O
,	O
ddC	Pharmacological
0.75	O
mg	O
three	O
times	O
per	O
day	O
,	O
and	O
SH	Pharmacological
2.5	O
g	O
three	O
times	O
per	O
day	O
or	O
a	Pharmacological
combination	Pharmacological
of	Pharmacological
ZDV	Pharmacological
200	Pharmacological
mg	Pharmacological
three	Pharmacological
times	Pharmacological
per	Pharmacological
day	Pharmacological
,	Pharmacological
ddC	Pharmacological
0.75	Pharmacological
mg	Pharmacological
three	Pharmacological
times	Pharmacological
per	Pharmacological
day	Pharmacological
,	Pharmacological
and	Pharmacological
placebo	Control
2.5	O
g	O
three	O
times	O
per	O
day	O
for	O
24	O
weeks	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
HIV-RNA	O
,	O
CD4	O
cells	O
,	O
and	O
blood	O
chemistry	O
profiles	O
prior	O
to	O
the	O
treatment	O
and	O
then	O
every	O
4	O
weeks	O
for	O
24	O
weeks	O
.	O

The	O
baseline	O
characteristics	O
of	O
60	O
evaluable	O
subjects	O
,	O
40	O
in	O
the	O
SH	Pharmacological
group	O
and	O
20	O
in	O
the	O
placebo	Control
group	O
,	O
were	O
not	O
significantly	O
different	O
.	O

HIV	O
RNA	O
at	O
week	O
4	O
and	O
thereafter	O
was	O
significantly	O
decreased	O
from	O
the	O
baseline	O
value	O
in	O
both	O
groups	O
(	O
p	O
<	O
0.001	O
)	O
.	O

However	O
,	O
the	O
decline	O
in	O
HIV	O
RNA	O
in	O
the	O
SH	Pharmacological
group	O
was	O
significantly	O
more	O
than	O
that	O
in	O
the	O
placebo	O
group	O
.	O

The	O
CD4	O
cells	O
in	O
the	O
SH	O
group	O
at	O
week	O
12	O
and	O
thereafter	O
were	O
significantly	O
increased	O
from	O
the	O
baseline	O
value	O
.	O

Serious	O
adverse	O
events	O
in	O
the	O
two	O
groups	O
were	O
not	O
observed	O
.	O

It	O
is	O
concluded	O
that	O
an	O
addition	O
of	O
SH	O
herbs	O
to	O
two	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
has	O
greater	O
antiviral	O
activity	O
than	O
antiretrovirals	O
only	O
.	O

The	O
SH	Pharmacological
herbs	O
may	O
be	O
an	O
alternative	O
for	O
the	O
third	O
anti-retroviral	O
agent	O
in	O
the	O
triple	O
drug	O
regimen	O
for	O
the	O
treatment	O
of	O
HIV	O
infected	O
patients	O
in	O
countries	O
with	O
limited	O
resources	O
.	O

A	O
web-based	O
computer-tailored	O
smoking	Educational
prevention	Educational
programme	Educational
for	O
primary	O
school	O
children	O
:	O
intervention	O
design	O
and	O
study	O
protocol	O
.	O

BACKGROUND	O
Although	O
the	O
number	O
of	O
smokers	O
has	O
declined	O
in	O
the	O
last	O
decade	O
,	O
smoking	O
is	O
still	O
a	O
major	O
health	O
problem	O
among	O
youngsters	O
and	O
adolescents	O
.	O

For	O
this	O
reason	O
,	O
there	O
is	O
a	O
need	O
for	O
effective	O
smoking	O
prevention	O
programmes	O
targeting	O
primary	O
school	O
children	O
.	O

A	O
web-based	O
computer-tailored	O
feedback	Educational
programme	Educational
may	O
be	O
an	O
effective	O
intervention	O
to	O
stimulate	O
youngsters	O
not	O
to	O
start	O
smoking	O
,	O
and	O
increase	O
their	O
knowledge	O
about	O
the	O
adverse	O
effects	O
of	O
smoking	O
and	O
their	O
attitudes	O
and	O
self-efficacy	O
regarding	O
non-smoking	O
.	O

METHODS	O
&	O
DESIGN	O
This	O
paper	O
describes	O
the	O
development	O
and	O
evaluation	O
protocol	O
of	O
a	O
web-based	Educational
out-of-school	Educational
smoking	Educational
prevention	Educational
programme	Educational
for	O
primary	O
school	O
children	O
(	O
age	O
10-13	O
years	O
)	O
entitled	O
'Fun	O
without	O
Smokes	O
'	O
.	O

It	O
is	O
a	O
transformation	O
of	O
a	O
postal	O
mailed	O
intervention	O
to	O
a	O
web-based	O
intervention	O
.	O

Besides	O
this	O
transformation	O
the	O
effects	O
of	O
prompts	O
will	O
be	O
examined	O
.	O

This	O
web-based	O
intervention	O
will	O
be	O
evaluated	O
in	O
a	O
2-year	O
cluster	O
randomised	O
controlled	O
trial	O
(	O
c-RCT	O
)	O
with	O
three	O
study	O
arms	O
.	O

An	O
intervention	O
and	O
intervention	O
+	O
prompt	O
condition	O
will	O
be	O
evaluated	O
for	O
effects	O
on	O
smoking	O
behaviour	O
,	O
compared	O
with	O
a	O
no	O
information	O
control	O
condition	O
.	O

Information	O
about	O
pupils	O
'	O
smoking	O
status	O
and	O
other	O
factors	O
related	O
to	O
smoking	O
will	O
be	O
obtained	O
using	O
a	O
web-based	O
questionnaire	O
.	O

After	O
completing	O
the	O
questionnaire	O
pupils	O
in	O
both	O
intervention	O
conditions	O
will	O
receive	O
three	O
computer-tailored	O
feedback	O
letters	O
in	O
their	O
personal	O
e-mail	O
box	O
.	O

Attitudes	O
,	O
social	O
influences	O
and	O
self-efficacy	O
expectations	O
will	O
be	O
the	O
content	O
of	O
these	O
personalised	O
feedback	O
letters	O
.	O

Pupils	O
in	O
the	O
intervention	O
+	O
prompt	O
condition	O
will	O
-	O
in	O
addition	O
to	O
the	O
personalised	O
feedback	O
letters	O
-	O
receive	O
e-mail	O
and	O
SMS	O
messages	O
prompting	O
them	O
to	O
revisit	O
the	O
'Fun	O
without	O
Smokes	O
'	O
website	O
.	O

The	O
main	O
outcome	O
measures	O
will	O
be	O
ever	O
smoking	O
and	O
the	O
utilisation	O
of	O
the	O
'Fun	O
without	O
Smokes	O
'	O
website	O
.	O

Measurements	O
will	O
be	O
carried	O
out	O
at	O
baseline	O
,	O
12	O
months	O
and	O
24	O
months	O
of	O
follow-up	O
.	O

DISCUSSION	O
The	O
present	O
study	O
protocol	O
describes	O
the	O
purpose	O
,	O
intervention	O
design	O
and	O
study	O
protocol	O
of	O
'Fun	O
without	O
Smokes	O
'	O
.	O

Expectations	O
are	O
that	O
pupils	O
receiving	O
tailored	O
advice	O
will	O
be	O
less	O
likely	O
to	O
smoke	O
after	O
24	O
months	O
in	O
contrast	O
to	O
pupils	O
in	O
the	O
control	O
condition	O
.	O

Furthermore	O
,	O
tailored	O
feedback	O
letters	O
and	O
prompting	O
is	O
expected	O
to	O
be	O
more	O
effective	O
than	O
providing	O
tailored	O
feedback	O
letters	O
only	O
.	O

TRIAL	O
REGISTRATION	O
Dutch	O
Trial	O
Register	O
NTR3116	O
.	O

Effect	O
of	O
finasteride	Pharmacological
treatment	O
on	O
suburethral	O
prostatic	O
microvessel	O
density	O
in	O
patients	O
with	O
hematuria	O
related	O
to	O
benign	O
prostate	O
hyperplasia	O
.	O

INTRODUCTION	O
In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
effect	O
of	O
short-term	O
finasteride	Pharmacological
treatment	O
on	O
microvessel	O
density	O
(	O
MVD	O
)	O
which	O
is	O
an	O
indicator	O
of	O
prostatic	O
angiogenesis	O
in	O
patients	O
with	O
hematuria	O
secondary	O
to	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
30	O
patients	O
who	O
were	O
candidates	O
for	O
BPH	O
surgery	O
were	O
prospectively	O
included	O
in	O
the	O
study	O
.	O

All	O
patients	O
had	O
history	O
of	O
gross	O
hematuria	O
and	O
evaluated	O
by	O
ultrasonography	O
and	O
cystoscopy	O
.	O

The	O
patients	O
were	O
randomized	O
two	O
groups	O
before	O
surgery	O
.	O

The	O
treatment	O
group	O
consisted	O
of	O
13	O
patients	O
who	O
were	O
given	O
5	Pharmacological
mg	Pharmacological
finasteride	Pharmacological
daily	Pharmacological
for	O
4	O
weeks	O
before	O
surgery	O
.	O

The	O
control	O
group	O
consisted	O
of	O
17	O
patients	O
who	O
did	Pharmacological
not	Pharmacological
receive	Pharmacological
finasteride	Pharmacological
before	O
surgery	O
.	O

During	O
surgery	O
,	O
resected	O
suburethral	O
and	O
hyperplastic	O
prostate	O
specimens	O
were	O
sent	O
for	O
histopathologic	O
MVD	O
determination	O
separately	O
.	O

RESULTS	O
Mean	O
MVD	O
in	O
the	O
suburethral	O
portion	O
of	O
prostate	O
was	O
significantly	O
lower	O
in	O
patients	O
treated	O
with	O
finasteride	O
when	O
compared	O
with	O
controls	O
(	O
9.08	O
+/-	O
5.6	O
and	O
13.94	O
+/-	O
5.90	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Mean	O
MVD	O
for	O
the	O
hyperplastic	O
portion	O
of	O
prostate	O
was	O
similar	O
for	O
the	O
finasteride	O
and	O
control	O
groups	O
(	O
14.21	O
+/-	O
7.10	O
and	O
19.75	O
+/-	O
9.73	O
,	O
respectively	O
,	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
The	O
potential	O
role	O
of	O
finasteride	O
on	O
hematuria	O
related	O
to	O
BPH	O
may	O
be	O
the	O
suppressive	O
effect	O
on	O
MVD	O
in	O
the	O
suburethral	O
tissue	O
of	O
prostate	O
.	O

The	O
effect	O
of	O
posture	Physical
on	O
Cheyne-Stokes	O
respirations	O
and	O
hemodynamics	O
in	O
patients	O
with	O
heart	O
failure	O
.	O

STUDY	O
OBJECTIVES	O
Cheyne-Stokes	O
respirations	O
occur	O
in	O
40	O
%	O
of	O
patients	O
with	O
heart	O
failure	O
.	O

Orthopnea	O
is	O
a	O
cardinal	O
symptom	O
of	O
heart	O
failure	O
and	O
may	O
affect	O
the	O
patient	O
's	O
sleeping	O
angle	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
respiratory	O
and	O
hemodynamic	O
response	O
to	O
sleeping	Physical
angle	Physical
in	O
a	O
group	O
of	O
subjects	O
with	O
stable	O
heart	O
failure	O
.	O

DESIGN	O
Twenty-five	O
patients	O
underwent	O
overnight	O
polysomnography	O
with	O
simultaneous	O
and	O
continuous	O
impedance	O
cardiographic	O
monitoring	O
.	O

Sleeping	O
polysomnographic	O
and	O
impedance	O
cardiographic	O
data	O
were	O
recorded	O
.	O

SETTING	O
The	O
study	O
was	O
conducted	O
in	O
a	O
sleep	O
center	O
.	O

PATIENTS	O
All	O
25	O
patients	O
had	O
clinically	O
stable	O
heart	O
failure	O
and	O
left	O
ventricular	O
ejection	O
fractions	O
<	O
40	O
%	O
.	O

INTERVENTIONS	O
The	O
patients	O
slept	Physical
at	Physical
0	Physical
degrees	Physical
,	Physical
15	Physical
degrees	Physical
,	Physical
30	Physical
degrees	Physical
,	Physical
and	Physical
45	Physical
degrees	Physical
in	Physical
random	Physical
order	Physical
.	Physical

MEASUREMENTS	O
AND	O
RESULTS	O
Seventeen	O
patients	O
had	O
Cheyne-Stokes	O
apneas	O
(	O
index	O
>	O
5/h	O
)	O
and	O
23	O
patients	O
had	O
hypopneas	O
(	O
index	O
>	O
5/h	O
)	O
.	O

The	O
hypopnea	O
index	O
showed	O
no	O
response	O
to	O
sleeping	O
angle	O
.	O

The	O
Cheyne-Stokes	O
apnea	O
index	O
decreased	O
with	O
increasing	O
sleeping	O
angle	O
(	O
P	O
<	O
0.001	O
)	O
.	O

This	O
effect	O
was	O
seen	O
only	O
during	O
supine	O
sleep	O
and	O
non-rapid	O
eye	O
movement	O
sleep	O
and	O
was	O
absent	O
in	O
non-supine	O
sleep	O
,	O
rapid	O
eye	O
movement	O
sleep	O
,	O
and	O
during	O
periods	O
of	O
wakefulness	O
.	O

Thoracic	O
fluid	O
content	O
index	O
and	O
left	O
ventricular	O
hemodynamics	O
measured	O
by	O
impedance	O
cardiography	O
showed	O
no	O
response	O
to	O
sleeping	O
angle	O
.	O

CONCLUSIONS	O
Changing	O
the	O
heart	O
failure	O
patient	O
's	O
sleeping	O
angle	O
from	O
0	O
degrees	O
to	O
45	O
degrees	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
Cheyne-Stokes	O
apneas	O
.	O

This	O
decrease	O
occurs	O
on	O
a	O
constant	O
base	O
of	O
hypopneas	O
.	O

The	O
changes	O
in	O
Cheyne-Stokes	O
apneas	O
are	O
not	O
related	O
to	O
changes	O
in	O
lung	O
congestion	O
and	O
left	O
ventricular	O
hemodynamics	O
.	O

Amisulpride	Pharmacological
versus	O
bromocriptine	Pharmacological
in	O
infantile	O
autism	O
:	O
a	O
controlled	O
crossover	O
comparative	O
study	O
of	O
two	O
drugs	O
with	O
opposite	O
effects	O
on	O
dopaminergic	O
function	O
.	O

An	O
alteration	O
of	O
dopaminergic	O
(	O
DA	O
)	O
function	O
much	O
more	O
complex	O
than	O
simple	O
hyperactivity	O
has	O
been	O
evoked	O
in	O
infantile	O
autism	O
.	O

We	O
therefore	O
compared	O
the	O
clinical	O
efficacy	O
of	O
a	O
DA	Pharmacological
antagonist	Pharmacological
(	Pharmacological
amisulpride	Pharmacological
)	Pharmacological
and	O
a	O
DA	Pharmacological
agonist	Pharmacological
(	Pharmacological
bromocriptine	Pharmacological
)	Pharmacological
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
trial	O
in	O
9	O
children	O
with	O
autism	O
,	O
likely	O
severely	O
mentally	O
retarded	O
.	O

Amisulpride	Pharmacological
acts	O
preferentially	O
on	O
specific	O
autistic	O
symptoms	O
whereas	O
bromocriptine	Pharmacological
acts	O
more	O
on	O
motor	O
hyperactivity	O
and	O
attention	O
symptoms	O
.	O

These	O
findings	O
raise	O
the	O
specificity	O
of	O
these	O
two	O
drugs	O
which	O
appear	O
to	O
act	O
preferentially	O
on	O
some	O
target	O
symptoms	O
and	O
are	O
consistent	O
with	O
some	O
clinical	O
and	O
pharmacological	O
observations	O
showing	O
a	O
sedative	O
effect	O
with	O
low	O
doses	O
of	O
DA	Pharmacological
agonists	Pharmacological
and	O
a	O
stimulant	O
effect	O
with	O
low	O
doses	O
of	O
DA	Pharmacological
antagonists	Pharmacological
such	O
as	O
the	O
benzamides	Pharmacological
.	O

Acute	O
prolactin	Pharmacological
and	O
oxytocin	Pharmacological
responses	O
and	O
milk	O
yield	O
to	O
infant	O
suckling	O
and	O
artificial	O
methods	O
of	O
expression	O
in	O
lactating	O
women	O
.	O

Breast-feeding	O
is	O
today	O
the	O
major	O
form	O
of	O
infant	O
nutrition	O
in	O
the	O
immediate	O
postpartum	O
period	O
.	O

Despite	O
this	O
,	O
recent	O
trends	O
in	O
modern	O
life-styles	O
have	O
raised	O
obstacles	O
to	O
successful	O
lactation	O
.	O

These	O
include	O
infant	O
illness	O
and	O
maternal	O
responsibilities	O
outside	O
the	O
home	O
,	O
both	O
requiring	O
separation	O
from	O
the	O
mother	O
.	O

While	O
the	O
hormonal	O
dynamics	O
of	O
infant	O
suckling	O
are	O
understood	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
artificial	O
methods	O
of	O
milk	O
expression	O
.	O

A	O
variety	O
of	O
breast	O
pumps	O
exist	O
in	O
the	O
current	O
US	O
market	O
which	O
vary	O
considerably	O
in	O
price	O
and	O
effectiveness	O
.	O

To	O
understand	O
better	O
the	O
ability	O
of	O
these	O
pumps	O
to	O
assist	O
women	O
in	O
the	O
maintenance	O
of	O
lactation	O
,	O
the	O
current	O
study	O
was	O
undertaken	O
to	O
evaluate	O
their	O
effects	O
on	O
milk	O
yield	O
and	O
prolactin	O
and	O
oxytocin	O
release	O
when	O
compared	O
to	O
natural	O
infant	O
suckling	O
.	O

Twenty-three	O
women	O
who	O
were	O
exclusively	O
breast-feeding	O
their	O
infants	O
were	O
randomly	O
assigned	O
to	O
serially	O
use	O
several	O
pumping	O
methods	O
,	O
as	O
well	O
as	O
infant	O
suckling	O
,	O
with	O
blood	O
being	O
taken	O
at	O
10-minute	O
intervals	O
to	O
determine	O
the	O
hormonal	O
responses	O
.	O

The	O
results	O
reveal	O
variability	O
in	O
the	O
prolactin	O
responses	O
to	O
the	O
artificial	O
pumping	O
methods	O
,	O
with	O
the	O
greatest	O
responses	O
found	O
with	O
an	O
electric	O
pulsatile	O
pump	O
;	O
these	O
responses	O
compare	O
favorably	O
with	O
those	O
of	O
natural	O
infant	O
suckling	O
.	O

Other	O
methods	O
were	O
less	O
successful	O
in	O
causing	O
prolactin	O
elevations	O
.	O

No	O
differences	O
were	O
seen	O
among	O
the	O
methods	O
in	O
the	O
oxytocin	O
response	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
striking	O
differences	O
in	O
the	O
ability	O
of	O
breast-pumping	O
methods	O
to	O
produce	O
an	O
acute	O
and	O
sustained	O
prolactin	O
rise	O
in	O
breast-feeding	O
mothers	O
.	O

The	O
large	O
discrepancies	O
found	O
suggest	O
the	O
need	O
for	O
further	O
studies	O
in	O
to	O
enable	O
women	O
and	O
health	O
care	O
providers	O
to	O
choose	O
the	O
most	O
appropriate	O
method	O
for	O
milk	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Assessment	O
of	O
response	O
to	O
induction	O
therapy	O
and	O
its	O
influence	O
on	O
5-year	O
failure-free	O
survival	O
in	O
group	O
III	O
rhabdomyosarcoma	O
:	O
the	O
Intergroup	O
Rhabdomyosarcoma	O
Study-IV	O
experience	O
--	O
a	O
report	O
from	O
the	O
Soft	O
Tissue	O
Sarcoma	O
Committee	O
of	O
the	O
Children	O
's	O
Oncology	O
Group	O
.	O

PURPOSE	O
Initial	O
response	O
to	O
induction	Pharmacological
chemotherapy	Pharmacological
predicts	O
failure-free	O
survival	O
(	O
FFS	O
)	O
in	O
osteosarcoma	O
and	O
Ewing	O
's	O
sarcoma	O
.	O

For	O
Intergroup	O
Rhabdomyosarcoma	O
Study	O
(	O
IRS	O
)	O
IV	O
patients	O
with	O
group	O
III	O
rhabdomyosarcoma	O
,	O
we	O
assessed	O
whether	O
reported	O
response	O
assessed	O
by	O
anatomic	O
imaging	O
at	O
week	O
8	O
predicted	O
FFS	O
.	O

PATIENTS	O
AND	O
METHODS	O
We	O
studied	O
444	O
group	O
III	O
patients	O
who	O
received	O
induction	Pharmacological
therapy	Pharmacological
,	O
had	O
response	O
assessed	O
at	O
week	O
8	O
by	O
anatomic	Physical
imaging	Physical
,	O
and	O
continued	Physical
with	Physical
protocol	Physical
therapy	Physical
.	O

Induction	Pharmacological
chemotherapy	Pharmacological
was	O
generally	O
followed	O
by	O
radiation	Physical
therapy	Physical
(	Physical
RT	Physical
)	Physical
starting	O
after	O
week	O
9	O
.	O

Response	O
to	O
induction	O
therapy	O
was	O
determined	O
at	O
weeks	O
0	O
and	O
8	O
.	O

Local	O
institutions	O
coded	O
response	O
.	O

RESULTS	O
Response	O
rate	O
for	O
the	O
entire	O
cohort	O
at	O
week	O
8	O
was	O
77	O
%	O
(	O
95	O
%	O
CI	O
,	O
73	O
%	O
to	O
81	O
%	O
;	O
complete	O
response	O
[	O
CR	O
]	O
,	O
21	O
%	O
;	O
partial	O
response	O
[	O
PR	O
]	O
,	O
56	O
%	O
)	O
but	O
response	O
had	O
no	O
influence	O
on	O
FFS	O
(	O
P	O
=	O
.57	O
)	O
.	O

Two	O
hundred	O
seventy-two	O
patients	O
received	O
standard-timing	O
RT	O
at	O
week	O
9	O
and	O
thus	O
only	O
chemotherapy	O
during	O
induction	O
.	O

Response	O
rate	O
was	O
81	O
%	O
(	O
95	O
%	O
CI	O
,	O
76	O
%	O
to	O
86	O
%	O
;	O
CR	O
,	O
22	O
%	O
;	O
PR	O
,	O
59	O
%	O
)	O
.	O

In	O
these	O
patients	O
,	O
response	O
did	O
not	O
influence	O
FFS	O
except	O
for	O
those	O
with	O
alveolar	O
histology	O
.	O

One	O
hundred	O
thirty-two	O
other	O
patients	O
received	O
chemotherapy	O
and	O
RT	O
during	O
induction	O
(	O
up-front	O
RT	O
)	O
.	O

Response	O
rate	O
was	O
65	O
%	O
(	O
95	O
%	O
CI	O
,	O
57	O
%	O
to	O
73	O
%	O
;	O
CR	O
,	O
12	O
%	O
;	O
PR	O
,	O
53	O
%	O
)	O
,	O
but	O
response	O
had	O
no	O
influence	O
on	O
FFS	O
(	O
P	O
=	O
.69	O
)	O
.	O

Forty	O
patients	O
received	O
no	O
RT	O
at	O
all	O
(	O
protocol	O
violation	O
)	O
and	O
response	O
to	O
induction	O
therapy	O
had	O
no	O
effect	O
on	O
FFS	O
.	O

CONCLUSION	O
In	O
IRS-IV	O
,	O
response	O
rate	O
to	O
induction	O
therapy	O
was	O
77	O
%	O
in	O
group	O
III	O
patients	O
,	O
was	O
independent	O
of	O
histology	O
,	O
and	O
had	O
no	O
influence	O
on	O
FFS	O
overall	O
.	O

Blood	Physical
purification	Physical
for	O
critical	O
care	O
medicine	O
:	O
endotoxin	O
adsorption	O
.	O

Many	O
kinds	O
of	O
blood	Physical
purifying	Physical
technologies	Physical
have	O
been	O
applied	O
to	O
the	O
treatment	O
of	O
critically	O
ill	O
patients	O
since	O
1979	O
when	O
plasma	O
exchange	O
with	O
hollow-fiber	O
membranes	O
was	O
developed	O
.	O

These	O
technologies	O
have	O
been	O
applied	O
not	O
only	O
to	O
the	O
removal	O
of	O
toxic	O
substances	O
,	O
but	O
also	O
to	O
the	O
treatment	O
of	O
objective	O
diseases	O
and	O
the	O
removal	O
of	O
the	O
factors	O
relating	O
to	O
the	O
associated	O
inflammation	O
.	O

This	O
article	O
summarizes	O
these	O
methods	O
and	O
their	O
efficacies	O
for	O
critically	O
ill	O
patients	O
,	O
especially	O
those	O
with	O
severe	O
sepsis	O
.	O

Attempts	O
have	O
been	O
made	O
to	O
remove	O
endotoxin	O
,	O
the	O
main	O
cause	O
of	O
sepsis	O
,	O
from	O
the	O
circulation	O
using	O
polymyxin	O
B	O
immobilized	O
fiber	O
,	O
charcoal	O
hemoperfusion	O
,	O
and	O
plasma	Physical
or	Physical
whole	Physical
blood	Physical
exchange	Physical
.	O

Attempts	O
have	O
also	O
been	O
made	O
to	O
remove	O
proinflammatory	O
cytokines	O
,	O
eicosanoides	O
,	O
and	O
coagulative	O
factors	O
from	O
the	O
circulation	O
in	O
the	O
human	O
body	O
.	O

Continuous	O
hemofiltration	O
or	O
hemodiafiltration	O
is	O
the	O
representative	O
technology	O
.	O

The	O
efficacy	O
of	O
these	O
methods	O
has	O
been	O
established	O
,	O
but	O
several	O
issues	O
remain	O
unresolved	O
.	O

All	O
methods	O
of	O
the	O
treatment	O
of	O
severe	O
sepsis	O
are	O
discussed	O
with	O
reference	O
to	O
treatment	O
indications	O
,	O
efficacy	O
,	O
and	O
outcome	O
parameters	O
.	O

In	O
particular	O
,	O
the	O
clinical	O
results	O
of	O
endotoxin	O
removal	O
with	O
polymyxin	O
B	O
immobilized	O
fiber	O
are	O
summarized	O
in	O
this	O
article	O
.	O

Randomised	O
community-based	O
trial	O
of	O
annual	O
single-dose	O
diethylcarbamazine	Pharmacological
with	O
or	O
without	O
ivermectin	Pharmacological
against	O
Wuchereria	O
bancrofti	O
infection	O
in	O
human	O
beings	O
and	O
mosquitoes	O
.	O

BACKGROUND	O
WHO	O
has	O
targeted	O
lymphatic	O
filariasis	O
for	O
elimination	O
.	O

Studies	O
of	O
vector-parasite	O
relations	O
of	O
Wuchereria	O
bancrofti	O
suggest	O
that	O
a	O
reduction	O
in	O
the	O
microfilarial	O
reservoir	O
by	O
mass	O
chemotherapy	Pharmacological
may	O
interrupt	O
transmission	O
and	O
thereby	O
eliminate	O
infection	O
.	O

However	O
,	O
no	O
field	O
data	O
exist	O
on	O
the	O
impact	O
of	O
chemotherapy	O
alone	O
on	O
vector	O
efficiency	O
and	O
transmission	O
intensity	O
of	O
W	O
bancrofti	O
.	O

We	O
compared	O
the	O
impact	O
of	O
an	O
annual	Pharmacological
community-wide	Pharmacological
single-dose	Pharmacological
treatment	Pharmacological
with	Pharmacological
diethylcarbamazine	Pharmacological
alone	Pharmacological
or	Pharmacological
with	Pharmacological
ivermectin	Pharmacological
on	O
rate	O
and	O
intensity	O
of	O
microfilaraemia	O
,	O
and	O
transmission	O
intensity	O
in	O
an	O
area	O
of	O
Papua	O
New	O
Guinea	O
endemic	O
for	O
intense	O
W	O
bancrofti	O
transmission	O
.	O

METHODS	O
We	O
carried	O
out	O
clinical	O
and	O
parasitological	O
surveys	O
in	O
14	O
communities	O
in	O
matched	O
pairs	O
.	O

People	O
aged	O
5	O
years	O
or	O
older	O
in	O
seven	O
communities	O
received	O
randomly	O
assigned	O
diethylcarbamazine	Pharmacological
6	O
mg/kg	O
and	O
people	O
in	O
the	O
other	O
seven	O
communities	O
received	O
diethylcarbamazine	Pharmacological
6	O
mg/kg	O
plus	O
ivermectin	Pharmacological
400	O
micrograms/kg	O
.	O

We	O
made	O
physical	O
examinations	O
for	O
hydroceles	O
and	O
leg	O
oedema	O
and	O
investigated	O
microfilarial	O
densities	O
by	O
membrane	O
filtration	O
before	O
and	O
after	O
treatment	O
.	O

We	O
selected	O
five	O
communities	O
for	O
monthly	O
entomological	O
surveys	O
between	O
September	O
,	O
1993	O
,	O
and	O
September	O
,	O
1995	O
.	O

Mosquitoes	O
were	O
collected	O
in	O
these	O
communities	O
by	O
the	O
all-night	O
landing	O
catch	O
method	O
and	O
were	O
individually	O
dissected	O
to	O
identify	O
rates	O
of	O
infection	O
and	O
infectiveness	O
.	O

FINDINGS	O
2219	O
(	O
87.6	O
%	O
)	O
of	O
2534	O
eligible	O
people	O
received	O
treatment	O
.	O

Microfilarial	O
rate	O
and	O
density	O
had	O
decreased	O
1	O
year	O
after	O
treatment	O
in	O
all	O
14	O
communities	O
;	O
this	O
decrease	O
was	O
significantly	O
higher	O
in	O
communities	O
given	O
combined	O
therapy	O
than	O
in	O
those	O
given	O
diethylcarbamazine	Pharmacological
alone	O
(	O
mean	O
decreases	O
57.5	O
%	O
and	O
30.6	O
%	O
,	O
respectively	O
;	O
p	O
=	O
0.0013	O
)	O
.	O

Greater	O
decreases	O
were	O
also	O
seen	O
in	O
community-specific	O
microfilarial	O
intensity	O
with	O
combined	O
therapy	O
(	O
mean	O
reductions	O
91.1	O
%	O
and	O
69.8	O
%	O
,	O
respectively	O
;	O
p	O
=	O
0.0047	O
)	O
.	O

The	O
rate	O
of	O
leg	O
oedema	O
was	O
not	O
altered	O
,	O
but	O
the	O
frequency	O
of	O
advanced	O
hydroceles	O
decreased	O
by	O
47	O
%	O
with	O
combined	O
therapy	O
and	O
56	O
%	O
with	O
diethylcarbamazine	Pharmacological
alone	O
.	O

26,641	O
Anopheles	O
punctulatus	O
mosquitoes	O
were	O
caught	O
during	O
499	O
person-nights	O
of	O
landing	O
catches	O
.	O

Exposure	O
to	O
infective	O
third-stage	O
larvae	O
decreased	O
in	O
all	O
monitored	O
five	O
communities	O
.	O

Annual	O
transmission	O
potential	O
decreased	O
by	O
between	O
75.7	O
%	O
and	O
98.8	O
%	O
in	O
combined-therapy	O
communities	O
and	O
between	O
75.6	O
%	O
and	O
79.4	O
%	O
in	O
communities	O
given	O
diethylcarbamazine	O
alone	O
.	O

Transmission	O
was	O
almost	O
interrupted	O
in	O
two	O
communities	O
treated	O
with	O
combined	O
therapy	O
.	O

INTERPRETATION	O
Annual	O
single-dose	O
community-wide	O
treatment	O
with	O
diethylcarbamazine	O
alone	O
or	O
with	O
ivermectin	O
is	O
effective	O
for	O
the	O
control	O
of	O
lymphatic	O
filariasis	O
in	O
highly	O
endemic	O
areas	O
,	O
but	O
combination	O
therapy	O
brings	O
about	O
greater	O
decreases	O
in	O
rates	O
and	O
intensity	O
of	O
microfilaraemia	O
.	O

Gum	Physical
elastic	Physical
bougie-guided	Physical
insertion	Physical
of	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
gum	Physical
elastic-bougie-guided	Physical
insertion	Physical
of	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
is	O
more	O
frequently	O
successful	O
than	O
introducer	O
tool	O
guided	O
insertion	O
after	O
failed	O
digital	O
insertion	O
.	O

One	O
hundred	O
anaesthetized	O
patients	O
(	O
ASA	O
1-2	O
,	O
aged	O
18	O
to	O
80	O
years	O
)	O
were	O
randomized	O
for	O
the	O
second	Surgical
insertion	Surgical
attempt	Surgical
using	Surgical
either	Surgical
the	Surgical
gum	Surgical
elastic	Surgical
bougie-guided	Surgical
or	Surgical
introducer	Surgical
tool	Surgical
techniques	Surgical
.	Surgical

The	O
bougie-guided	Physical
technique	Physical
involved	O
priming	O
the	O
drain	O
tube	O
with	O
the	O
bougie	O
,	O
placing	O
the	O
bougie	O
in	O
the	O
oesophagus	O
using	O
laryngoscope	O
guidance	O
,	O
digital	O
insertion	O
along	O
the	O
palato-pharyngeal	O
curve	O
,	O
and	O
bougie	O
removal	O
.	O

The	O
introducer	Physical
tool	Physical
technique	Physical
involved	O
attaching	O
the	O
introducer	O
tool	O
,	O
single-handed	O
rotation	O
along	O
the	O
palatopharyngeal	O
curve	O
,	O
and	O
introducer	O
tool	O
removal	O
.	O

Failed	O
insertion	O
was	O
classified	O
as	O
(	O
i	O
)	O
failed	O
passage	O
into	O
the	O
pharynx	O
,	O
(	O
ii	O
)	O
malposition	O
,	O
or	O
(	O
iii	O
)	O
ineffective	O
ventilation	O
.	O

Any	O
blood	O
staining	O
was	O
documented	O
.	O

Insertion	O
was	O
more	O
frequently	O
successful	O
(	O
50/50	O
vs	O
15/50	O
,	O
P=0.0002	O
)	O
and	O
faster	O
(	O
35+/-17	O
s	O
vs	O
54+/-45	O
s	O
,	O
mean+/-SD	O
,	O
P=0.006	O
)	O
with	O
the	O
bougie-guided	O
technique	O
.	O

All	O
failed	O
insertions	O
with	O
the	O
introducer	O
tool	O
technique	O
were	O
successful	O
with	O
the	O
bougie-guided	O
technique	O
.	O

The	O
aetiology	O
of	O
failed	O
insertion	O
was	O
similar	O
for	O
the	O
digital	O
and	O
introducer	O
tool	O
techniques	O
in	O
94	O
%	O
(	O
33/35	O
)	O
of	O
patients	O
.	O

There	O
was	O
no	O
blood	O
staining	O
on	O
the	O
bougie	O
,	O
laryngoscope	O
or	O
introducer	O
tool	O
at	O
removal	O
,	O
but	O
blood	O
staining	O
was	O
more	O
common	O
on	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
with	O
the	O
introducer	O
tool	O
technique	O
(	O
9/50	O
vs	O
2/50	O
,	O
P=0.03	O
)	O
.	O

We	O
conclude	O
that	O
the	O
gum	Physical
elastic	Physical
bougie-guided	Physical
insertion	Physical
has	O
a	O
higher	O
success	O
rate	O
and	O
causes	O
less	O
trauma	O
than	O
the	O
insertion	O
tool	O
insertion	O
technique	O
after	O
failed	O
digital	O
insertion	O
of	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
.	O

The	O
effects	O
of	O
haloperidol	Pharmacological
on	O
learning	O
and	O
behavior	O
in	O
autistic	O
children	O
.	O

The	O
effects	O
of	O
haloperidol	Pharmacological
on	O
behavioral	O
symptoms	O
and	O
learning	O
were	O
critically	O
assessed	O
in	O
autistic	O
children	O
in	O
an	O
ongoing	O
double-blind	O
placebo-controlled	Control
clinical	O
trial	O
.	O

Children	O
were	O
randomly	O
assigned	O
to	O
haloperidol-placebo-haloperidol	Pharmacological
or	O
placebo-haloperidol-placebo	Pharmacological
treatment	O
sequences	O
.	O

Statistically	O
,	O
haloperidol	Pharmacological
was	O
significantly	O
superior	O
to	O
placebo	Control
in	O
reducing	O
behavioral	O
symptoms	O
.	O

In	O
discrimination	O
learning	O
paradigm	O
,	O
children	O
receiving	O
haloperidol	Pharmacological
learned	O
the	O
discrimination	O
while	O
those	O
on	O
placebo	Control
did	O
not	O
.	O

Discrimination	O
attained	O
on	O
haloperidol	Pharmacological
was	O
retained	O
when	O
the	O
children	O
were	O
switched	O
to	O
placebo	Control
.	O

Once-daily	O
amoxicillin	Pharmacological
versus	O
twice-daily	O
penicillin	Pharmacological
V	Pharmacological
in	O
group	O
A	O
beta-haemolytic	O
streptococcal	O
pharyngitis	O
.	O

BACKGROUND	O
Rheumatic	O
fever	O
is	O
a	O
preventable	O
chronic	O
disease	O
preceded	O
by	O
group	O
A	O
beta-haemolytic	O
streptococcal	O
(	O
GABHS	O
)	O
pharyngitis	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
non-inferiority	O
of	O
once-daily	O
(	O
QD	O
)	O
oral	O
amoxicillin	Pharmacological
to	O
the	O
recommended	O
twice-daily	O
(	O
BID	O
)	O
oral	O
penicillin	Pharmacological
V	Pharmacological
in	O
GABHS	O
pharyngitis	O
.	O

METHODS	O
This	O
was	O
a	O
randomised	O
non-inferiority	O
trial	O
carried	O
out	O
in	O
a	O
school-based	O
clinic	O
in	O
New	O
Zealand	O
.	O

Children	O
presenting	O
with	O
GABHS	O
pharyngitis	O
were	O
randomised	O
to	O
oral	Pharmacological
amoxicillin	Pharmacological
1500	Pharmacological
mg	Pharmacological
QD	O
(	O
or	O
750	O
mg	O
if	O
bodyweight	O
was	O
<	O
or=30	O
kg	O
)	O
or	O
to	O
oral	Pharmacological
penicillin	Pharmacological
V	Pharmacological
500	Pharmacological
mg	Pharmacological
BID	O
(	O
or	O
250	O
mg	O
if	O
bodyweight	O
was	O
<	O
or=20	O
kg	O
)	O
for	O
10	O
days	O
.	O

Observed	O
medication	O
and	O
weekend	O
diary	O
cards	O
were	O
used	O
to	O
monitor	O
adherence	O
.	O

OUTCOME	O
Eradication	O
of	O
GABHS	O
,	O
determined	O
with	O
follow-up	O
throat	O
cultures	O
on	O
days	O
3-6	O
,	O
12-16	O
and	O
26-36	O
.	O

GABHS	O
isolates	O
were	O
serotyped	O
to	O
distinguish	O
bacteriological	O
treatment	O
failures	O
(	O
and	O
relapses	O
)	O
from	O
new	O
acquisitions	O
.	O

Non-inferiority	O
was	O
defined	O
as	O
an	O
upper	O
95	O
%	O
confidence	O
limit	O
(	O
CL	O
)	O
for	O
the	O
difference	O
in	O
success	O
of	O
eradication	O
in	O
the	O
amoxicillin	Pharmacological
and	O
penicillin	Pharmacological
V	Pharmacological
treatment	O
groups	O
of	O
<	O
or=10	O
%	O
.	O

RESULTS	O
353	O
children	O
with	O
positive	O
throat	O
swabs	O
for	O
GABHS	O
were	O
randomised	O
to	O
amoxicillin	Pharmacological
(	O
n	O
=	O
177	O
)	O
or	O
penicillin	Pharmacological
V	Pharmacological
(	O
n	O
=	O
176	O
)	O
.	O

The	O
upper	O
95	O
%	O
CL	O
for	O
the	O
differences	O
in	O
positive	O
cultures	O
between	O
the	O
antibiotics	O
was	O
4.9	O
%	O
at	O
days	O
3-6	O
,	O
6.5	O
%	O
at	O
days	O
12-16	O
and	O
8.5	O
%	O
at	O
days	O
26-36	O
.	O

Treatment	O
failures	O
(	O
including	O
relapses	O
)	O
occurred	O
at	O
each	O
visit	O
in	O
5.8	O
%	O
,	O
12.7	O
%	O
and	O
10.7	O
%	O
of	O
amoxicillin	Pharmacological
recipients	O
and	O
6.2	O
%	O
,	O
11.9	O
%	O
and	O
11.3	O
%	O
of	O
penicillin	Pharmacological
V	Pharmacological
recipients	O
,	O
respectively	O
.	O

No	O
significant	O
differences	O
in	O
resolution	O
of	O
symptoms	O
were	O
noted	O
between	O
treatment	O
groups	O
.	O

One	O
case	O
of	O
unsubstantiated	O
acute	O
rheumatic	O
fever	O
occurred	O
after	O
7	O
days	O
of	O
amoxicillin	Pharmacological
.	O

CONCLUSION	O
In	O
this	O
adequately	O
powered	O
study	O
,	O
once-daily	O
oral	O
amoxicillin	Pharmacological
is	O
not	O
inferior	O
to	O
twice-daily	O
penicillin	Pharmacological
V	Pharmacological
for	O
the	O
treatment	O
and	O
eradication	O
of	O
GABHS	O
in	O
children	O
with	O
pharyngitis	O
.	O

The	O
effects	O
of	O
delay	O
in	O
standard	O
treatment	O
due	O
to	O
induction	O
chemotherapy	O
in	O
two	O
randomized	O
prospective	O
studies	O
.	O

It	O
is	O
often	O
suggested	O
that	O
tumors	O
will	O
respond	O
to	O
induction	Pharmacological
chemotherapy	Pharmacological
and	O
result	O
in	O
improved	O
survival	O
for	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

Two	O
regimens	O
of	O
induction	O
chemotherapy	O
were	O
studied	O
in	O
separate	O
randomized	O
,	O
prospective	O
trials	O
over	O
the	O
last	O
6	O
years	O
.	O

Eighty-three	O
patients	O
with	O
advanced	O
disease	O
were	O
entered	O
into	O
the	O
first	O
study	O
(	O
43/chemotherapy	O
;	O
40/control	O
)	O
,	O
and	O
60	O
into	O
the	O
second	O
(	O
27/chemotherapy	O
;	O
33/control	O
)	O
.	O

Patient	O
randomization	O
was	O
stratified	O
by	O
stage	O
(	O
III/IV	O
)	O
and	O
site	O
(	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
nasopharynx	O
,	O
hypopharynx	O
,	O
larynx	O
,	O
paranasal	O
sinuses	O
)	O
.	O

The	O
first	O
study	O
utilized	Pharmacological
bleomycin	Pharmacological
,	O
Cytoxan	Pharmacological
,	O
methotrexate	Pharmacological
and	O
5-fluorouracil	Pharmacological
in	O
two	O
cycles	O
(	O
one	O
cycle	O
if	O
no	O
tumor	O
response	O
)	O
,	O
followed	Pharmacological
by	Pharmacological
standard	Pharmacological
treatment	Pharmacological
which	Pharmacological
consisted	Pharmacological
of	Pharmacological
combined	Pharmacological
irradiation	Pharmacological
and	Pharmacological
surgery	Pharmacological
or	Pharmacological
,	Pharmacological
in	Pharmacological
some	Pharmacological
instances	Pharmacological
,	Pharmacological
primary	Pharmacological
irradiation	Pharmacological
alone	O
.	O

The	O
second	O
study	O
utilized	O
cisplatin	Pharmacological
and	Pharmacological
5-fluorouracil	Pharmacological
in	Pharmacological
three	O
cycles	O
prior	Control
to	Control
standard	Control
treatment	Control
.	O

An	O
objective	O
tumor	O
response	O
to	O
chemotherapy	O
was	O
observed	O
in	O
68	O
%	O
in	O
the	O
first	O
study	O
and	O
85	O
%	O
in	O
the	O
second	O
.	O

The	O
patient	O
survival	O
in	O
both	O
studies	O
(	O
at	O
24	O
months	O
in	O
the	O
first	O
;	O
at	O
19	O
in	O
the	O
second	O
)	O
was	O
better	O
in	O
the	O
control	O
than	O
that	O
in	O
the	O
experimental	O
groups	O
(	O
43	O
%	O
to	O
31	O
%	O
;	O
69	O
%	O
to	O
46	O
%	O
)	O
.	O

In	O
the	O
second	O
study	O
,	O
the	O
average	O
length	O
of	O
delay	O
of	O
standard	O
treatment	O
was	O
longer	O
than	O
in	O
the	O
first	O
study	O
(	O
95	O
days	O
vs.	O
66	O
days	O
;	O
P	O
less	O
than	O
.02	O
)	O
.	O

Results	O
combining	O
the	O
P-values	O
of	O
both	O
studies	O
indicate	O
that	O
the	O
relative	O
risk	O
of	O
having	O
persistent	O
disease	O
was	O
2.9	O
times	O
greater	O
for	O
patients	O
who	O
received	O
chemotherapy	O
.	O

While	O
toxicity	O
to	O
chemotherapy	O
was	O
not	O
a	O
factor	O
in	O
survival	O
,	O
the	O
number	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
studies	O
and	O
those	O
who	O
did	O
not	O
comply	O
with	O
treatment	O
were	O
greater	O
in	O
the	O
chemotherapy	O
groups	O
.	O

Except	O
for	O
new	O
drug	O
regimens	O
of	O
exceptional	O
promise	O
,	O
it	O
is	O
recommended	O
that	O
future	O
studies	O
be	O
designed	O
so	O
that	O
chemotherapy	O
is	O
given	O
concurrent	O
with	O
,	O
or	O
following	O
the	O
completion	O
of	O
standard	O
treatment	O
.	O

Bioequivalence	O
evaluation	O
of	O
a	O
fixed	O
dose	O
combination	O
lamivudine	Pharmacological
+	Pharmacological
stavudine	Pharmacological
tablet	O
with	O
concurrent	O
administration	O
of	O
lamivudine	Pharmacological
tablet	O
and	O
stavudine	Pharmacological
capsule	O
in	O
healthy	O
volunteers	O
.	O

The	O
study	O
was	O
designed	O
to	O
compare	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
a	O
fixed	O
dose	O
combination	O
tablet	O
of	O
lamivudine	Pharmacological
(	Pharmacological
CAS	Pharmacological
134678-17-4	Pharmacological
)	Pharmacological
and	O
stavudine	Pharmacological
(	Pharmacological
CAS	Pharmacological
3056-17-5	Pharmacological
)	Pharmacological
with	O
the	O
concurrent	O
administration	O
of	O
lamivudine	Pharmacological
tablet	Pharmacological
and	O
stavudine	Pharmacological
capsule	Pharmacological
in	O
24	O
healthy	O
volunteers	O
under	O
fasting	O
conditions	O
.	O

The	O
volunteers	O
were	O
randomly	O
assigned	O
to	O
the	O
test	O
or	O
reference	O
treatment	O
,	O
with	O
the	O
two	O
treatment	O
periods	O
separated	O
by	O
a	O
washout	O
period	O
of	O
at	O
least	O
7	O
days	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
for	O
both	O
analytes	O
lamivudine	Pharmacological
and	O
stavudine	Pharmacological
by	O
a	O
validated	O
analytical	O
method	O
.	O

Since	O
the	O
90	O
%	O
confidence	O
intervals	O
for	O
the	O
test/reference	O
mean	O
ratio	O
of	O
the	O
In-transformed	O
pharmacokinetic	O
variables	O
C	O
(	O
max	O
)	O
AUC	O
(	O
0-t	O
)	O
and	O
AUC	O
(	O
0-infinity	O
)	O
were	O
clearly	O
within	O
the	O
conventional	O
bioequivalence	O
range	O
of	O
80	O
%	O
to	O
125	O
%	O
,	O
the	O
two	O
treatments	O
were	O
considered	O
bioequivalent	O
.	O

The	O
safety	O
profiles	O
of	O
both	O
the	O
test	O
and	O
reference	O
formulations	O
were	O
comparable	O
.	O

A	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
,	O
multicenter	O
study	O
to	O
assess	O
the	O
safety	O
and	O
cardiovascular	O
effects	O
of	O
skeletal	Physical
myoblast	Physical
implantation	Physical
by	Physical
catheter	Physical
delivery	Physical
in	O
patients	O
with	O
chronic	O
heart	O
failure	O
after	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
We	O
sought	O
to	O
determine	O
the	O
safety	O
and	O
preliminary	O
efficacy	O
of	O
transcatheter	Physical
intramyocardial	Physical
administration	Physical
of	Physical
myoblasts	Physical
in	O
patients	O
with	O
heart	O
failure	O
(	O
HF	O
)	O
.	O

METHODS	O
MARVEL	O
is	O
a	O
randomized	O
placebo-controlled	Control
trial	O
of	O
image-guided	O
,	O
catheter-based	O
intramyocardial	O
injection	O
of	O
placebo	Control
or	O
myoblasts	Pharmacological
(	O
400	O
or	O
800	O
million	O
)	O
in	O
patients	O
with	O
class	O
II	O
to	O
IV	O
HF	O
and	O
ejection	O
fraction	O
<	O
35	O
%	O
.	O

Primary	O
end	O
points	O
were	O
frequency	O
of	O
serious	O
adverse	O
events	O
(	O
safety	O
)	O
and	O
changes	O
in	O
6-minute	O
walk	O
test	O
and	O
Minnesota	O
Living	O
With	O
HF	O
score	O
(	O
efficacy	O
)	O
.	O

Of	O
330	O
patients	O
intended	O
for	O
enrollment	O
,	O
23	O
were	O
randomized	O
(	O
MARVEL-1	O
)	O
before	O
stopping	O
the	O
study	O
for	O
financial	O
reasons	O
.	O

RESULTS	O
At	O
6	O
months	O
,	O
similar	O
numbers	O
of	O
events	O
occurred	O
in	O
each	O
group	O
:	O
8	O
(	O
placebo	Control
)	O
,	O
7	O
(	O
low	O
dose	O
)	O
,	O
and	O
8	O
(	O
high	O
dose	O
)	O
,	O
without	O
deaths	O
.	O

Ventricular	O
tachycardia	O
responsive	O
to	O
amiodarone	O
was	O
more	O
frequent	O
in	O
myoblast-treated	Pharmacological
patients	O
:	O
1	O
(	O
placebo	Control
)	O
,	O
3	O
(	O
low	O
dose	O
)	O
,	O
and	O
4	O
(	O
high	O
dose	O
)	O
.	O

A	O
trend	O
toward	O
improvement	O
in	O
functional	O
capacity	O
was	O
noted	O
in	O
myoblast-treated	Pharmacological
groups	O
(	O
?6-minute	O
walk	O
test	O
of	O
-3.6	O
vs	O
+95.6	O
vs	O
+85.5	O
m	O
[	O
placebo	O
vs	O
low	O
dose	O
vs	O
high	O
dose	O
;	O
P	O
=	O
.50	O
]	O
)	O
without	O
significant	O
changes	O
in	O
Minnesota	O
Living	O
With	O
HF	O
scores	O
.	O

CONCLUSIONS	O
In	O
HF	O
patients	O
with	O
chronic	O
postinfarction	O
cardiomyopathy	O
,	O
transcatheter	O
administration	O
of	O
myoblasts	O
in	O
doses	O
of	O
400	O
to	O
800	O
million	O
cells	O
is	O
feasible	O
and	O
may	O
lead	O
to	O
important	O
clinical	O
benefits	O
.	O

Ventricular	O
tachycardia	O
may	O
be	O
provoked	O
by	O
myoblast	O
injection	O
but	O
appears	O
to	O
be	O
a	O
transient	O
and	O
treatable	O
problem	O
.	O

A	O
large-scale	O
outcome	O
trial	O
of	O
myoblast	O
administration	O
in	O
HF	O
patients	O
with	O
postinfarction	O
cardiomyopathy	O
is	O
feasible	O
and	O
warranted	O
.	O

[	O
Application	O
of	O
tacrolimus	Pharmacological
and	O
cyclosporine	Pharmacological
A	Pharmacological
in	O
HBV-carrying	O
renal	O
transplant	O
recipients	O
]	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
long-term	O
effect	O
and	O
safety	O
of	O
tacrolimus	Pharmacological
(	Pharmacological
FK506	Pharmacological
)	Pharmacological
and	O
cyclosporine	Pharmacological
(	Pharmacological
CsA	Pharmacological
)	Pharmacological
in	O
kidney	O
transplant	O
(	O
KT	O
)	O
recipients	O
carrying	O
hepatitis	O
B	O
Virus	O
(	O
HBV	O
)	O
.	O

METHODS	O
A	O
total	O
of	O
109	O
patients	O
with	O
HBV	O
were	O
randomized	O
into	O
FK506	Pharmacological
group	O
(	O
52	O
cases	O
)	O
and	O
CsA	Pharmacological
group	O
(	O
57	O
cases	O
)	O
after	O
KT	O
,	O
and	O
a	O
2-year-long	O
follow-up	O
of	O
the	O
patients	O
was	O
conducted	O
to	O
record	O
the	O
patient	O
and	O
graft	O
survival	O
,	O
incidence	O
of	O
acute	O
graft	O
rejection	O
and	O
postoperative	O
liver	O
function	O
.	O

RESULTS	O
The	O
2-year	O
patient/graft	O
survival	O
was	O
86.0	O
%	O
/73.7	O
%	O
and	O
94.2	O
%	O
/90.3	O
%	O
in	O
CsA	O
and	O
FK506	O
groups	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
,	O
with	O
incidence	O
of	O
acute	O
rejection	O
of	O
10.5	O
%	O
and	O
9.6	O
%	O
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
rate	O
of	O
abnormal	O
liver	O
function	O
of	O
26.3	O
%	O
and	O
15.4	O
%	O
(	O
P	O
<	O
0.05	O
)	O
,	O
respectively	O
.	O

Eight	O
patients	O
(	O
14.4	O
%	O
)	O
in	O
CsA	O
group	O
required	O
a	O
drug	O
conversion	O
but	O
none	O
in	O
FK506	O
group	O
.	O

The	O
drug	O
conversion	O
resulted	O
in	O
significant	O
reduction	O
of	O
ALT/AST	O
level	O
from	O
255.13+/-31.38/201.88+/-21.25	O
U/L	O
to	O
31.25+/-11.50/25.13+/-9.68	O
U/L	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
For	O
HBV-carrying	O
renal	O
transplant	O
recipients	O
,	O
FK506	Pharmacological
as	O
the	O
primary	O
choice	O
of	O
immunosuppressant	O
can	O
be	O
more	O
effective	O
and	O
safer	O
than	O
CsA	O
.	O

Differential	O
effects	O
on	O
bone	O
density	O
of	O
progestogen-only	Pharmacological
methods	O
for	O
contraception	O
in	O
premenopausal	O
women	O
.	O

The	O
question	O
of	O
differential	O
effects	O
on	O
bone	O
density	O
by	O
two	O
different	O
types	O
of	O
progestogen-only	Pharmacological
methods	O
for	O
contraception	O
in	O
premenopausal	O
women	O
was	O
addressed	O
.	O

Data	O
from	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
among	O
22	O
premenopausal	O
women	O
,	O
age	O
32.6	O
(	O
range	O
20-45	O
years	O
)	O
,	O
who	O
were	O
randomly	O
assigned	O
to	O
either	O
of	O
two	O
treatments	O
with	O
continuous	Pharmacological
progestogens	Pharmacological
for	O
contraception	O
were	O
analyzed	O
;	O
depot-medroxyprogesterone	Pharmacological
acetate	Pharmacological
(	Pharmacological
DMPA	Pharmacological
)	Pharmacological
or	O
continuous	Control
levonorgestrel	Control
treatment	Control
with	Control
subdermal	Control
implants	Control
(	O
Norplant	O
)	O
,	O
respectively	O
.	O

Forearm	O
bone	O
density	O
(	O
BMDprox	O
)	O
increased	O
with	O
2.94	O
%	O
(	O
p	O
=	O
0.006	O
)	O
in	O
women	O
who	O
were	O
prescribed	O
levonorgestrel	O
,	O
which	O
was	O
in	O
contrast	O
to	O
stable	O
values	O
in	O
those	O
prescribed	O
depot-medroxy-progesterone	Pharmacological
acetate	Pharmacological
;	O
group	O
difference	O
at	O
6	O
months	O
for	O
BMDprox	O
3.4	O
%	O
(	O
95	O
%	O
CI	O
1.3	O
,	O
5.5	O
;	O
p	O
=	O
0.025	O
)	O
and	O
BMDdist	O
4.1	O
%	O
(	O
95	O
%	O
CI	O
-	O
1.3	O
,	O
9.6	O
;	O
p	O
=	O
0.077	O
)	O
.	O

The	O
changes	O
in	O
bone	O
density	O
were	O
consistent	O
with	O
the	O
changes	O
in	O
biochemical	O
indices	O
for	O
bone	O
metabolism	O
;	O
DMPA	Pharmacological
users	O
showed	O
signs	O
of	O
increased	O
bone	O
turnover	O
and	O
users	O
of	O
levonorgestrel	O
showed	O
increased	O
bone	O
formation	O
with	O
increased	O
levels	O
of	O
both	O
alkaline	O
phosphatase	O
(	O
p	O
=	O
0.004	O
)	O
and	O
osteocalcin	O
(	O
p	O
=	O
0.007	O
)	O
.	O

The	O
findings	O
suggest	O
an	O
increase	O
in	O
bone	O
density	O
during	O
treatment	O
with	O
levonorgestrel	Pharmacological
and	O
stable	O
values	O
during	O
short-term	O
administration	O
of	O
DMPA	Pharmacological
,	O
in	O
standard	O
clinical	O
doses	O
for	O
contraception	O
.	O

Impact	O
of	O
isotonic	Pharmacological
and	O
hypertonic	Pharmacological
saline	Pharmacological
solutions	Pharmacological
on	O
mucociliary	O
activity	O
in	O
various	O
nasal	O
pathologies	O
:	O
clinical	O
study	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
impact	O
of	O
nasal	O
irrigation	O
with	O
isotonic	Pharmacological
or	O
hypertonic	Pharmacological
sodium	Pharmacological
chloride	Pharmacological
solution	Pharmacological
on	O
mucociliary	O
clearance	O
time	O
in	O
patients	O
with	O
allergic	O
rhinitis	O
,	O
acute	O
sinusitis	O
and	O
chronic	O
sinusitis	O
.	O

PATIENTS	O
AND	O
METHODS	O
Mucociliary	O
clearance	O
time	O
was	O
measured	O
using	O
the	O
saccharine	O
clearance	O
test	O
on	O
132	O
adults	O
before	O
and	O
after	O
10	O
days	O
'	O
application	Pharmacological
of	Pharmacological
intranasal	Pharmacological
isotonic	Pharmacological
or	O
hypertonic	Pharmacological
saline	Pharmacological
.	O

Patient	O
numbers	O
were	O
as	O
follows	O
:	O
controls	O
,	O
45	O
;	O
allergic	O
rhinitis	O
,	O
21	O
;	O
acute	O
sinusitis	O
,	O
24	O
;	O
and	O
chronic	O
sinusitis	O
,	O
42	O
.	O

The	O
results	O
before	O
and	O
after	O
irrigation	O
were	O
compared	O
using	O
the	O
Wilcoxon	O
t-test	O
.	O

RESULTS	O
Before	O
application	O
of	O
saline	Pharmacological
solutions	Pharmacological
,	O
mucociliary	O
clearance	O
times	O
in	O
the	O
three	O
patient	O
treatment	O
groups	O
were	O
found	O
to	O
be	O
significantly	O
delayed	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

Irrigation	O
with	O
hypertonic	Pharmacological
saline	Pharmacological
restored	O
impaired	O
mucociliary	O
clearance	O
in	O
chronic	O
sinusitis	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
,	O
while	O
isotonic	Pharmacological
saline	Pharmacological
improved	O
mucociliary	O
clearance	O
times	O
significantly	O
in	O
allergic	O
rhinitis	O
and	O
acute	O
sinusitis	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
Nasal	O
irrigation	O
with	O
isotonic	Pharmacological
or	O
hypertonic	Pharmacological
saline	Pharmacological
can	O
improve	O
mucociliary	O
clearance	O
time	O
in	O
various	O
nasal	O
pathologies	O
.	O

However	O
,	O
these	O
solutions	O
should	O
be	O
selectively	O
prescribed	O
rather	O
than	O
used	O
based	O
on	O
anecdotal	O
evidence	O
.	O

Further	O
studies	O
should	O
be	O
conducted	O
to	O
develop	O
a	O
protocol	O
for	O
standardised	O
use	O
of	O
saline	Pharmacological
solution	Pharmacological
irrigation	Pharmacological
in	O
various	O
nasal	O
pathologies	O
.	O

Partial-area	O
method	O
in	O
bioequivalence	O
assessment	O
:	O
naproxen	Pharmacological
.	O

Regulatory	O
authorities	O
require	O
demonstration	O
of	O
bioequivalence	O
through	O
comparisons	O
of	O
different	O
pharmacokinetic	O
parameters	O
,	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
,	O
the	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
,	O
and	O
the	O
time	O
to	O
reach	O
peak	O
concentration	O
(	O
Tmax	O
)	O
.	O

The	O
applicability	O
and	O
validity	O
of	O
regulatory	O
requirements	O
have	O
been	O
widely	O
criticized	O
on	O
statistical	O
and	O
clinical	O
relevance	O
grounds	O
.	O

For	O
most	O
noncomplicated	O
absorption	O
models	O
,	O
the	O
AUC	O
correlates	O
well	O
with	O
the	O
extent	O
of	O
absorption	O
.	O

However	O
,	O
in	O
nonlinear	O
models	O
of	O
absorption	O
,	O
in	O
mechanisms	O
involving	O
recycling	O
of	O
drugs	O
,	O
and	O
for	O
drugs	O
with	O
long	O
half-life	O
,	O
the	O
use	O
of	O
total	O
AUC	O
(	O
from	O
zero	O
to	O
infinity	O
)	O
can	O
give	O
erroneous	O
and	O
clinically	O
irrelevant	O
results	O
since	O
the	O
area	O
is	O
mostly	O
determined	O
by	O
elimination	O
phase	O
or	O
by	O
recycling	O
.	O

The	O
calculation	O
of	O
total	O
AUC	O
also	O
involves	O
prolonged	O
sampling	O
,	O
adding	O
to	O
the	O
cost	O
and	O
risks	O
associated	O
with	O
bioequivalence	O
studies	O
.	O

The	O
use	O
of	O
Cmax	O
or	O
Tmax	O
as	O
a	O
measure	O
of	O
rate	O
of	O
absorption	O
,	O
to	O
correlate	O
with	O
clinical	O
relevance	O
,	O
is	O
widely	O
criticized	O
on	O
logical	O
,	O
technical	O
,	O
and	O
statistical	O
grounds	O
.	O

For	O
drugs	O
used	O
on	O
a	O
multiple-dose	O
basis	O
,	O
Cmax	O
and	O
Tmax	O
evaluations	O
become	O
redundant	O
since	O
the	O
average	O
plateau	O
concentration	O
is	O
not	O
affected	O
by	O
these	O
parameters	O
.	O

To	O
resolve	O
the	O
drawbacks	O
in	O
the	O
traditional	O
methodology	O
of	O
bioequivalence	O
evaluation	O
,	O
the	O
use	O
of	O
partial	O
areas	O
in	O
lieu	O
of	O
total	O
AUC	O
,	O
Tmax	O
,	O
and	O
Cmax	O
is	O
suggested	O
.	O

This	O
study	O
investigates	O
the	O
logic	O
and	O
robustness	O
of	O
the	O
partial-area	O
method	O
in	O
establishing	O
bioequivalence	O
.	O

We	O
conclude	O
that	O
the	O
5h	O
AUC	O
is	O
a	O
more	O
relevant	O
parameter	O
to	O
establish	O
naproxen	Pharmacological
bioequivalence	O
than	O
AUCinf	O
.	O

We	O
recommend	O
against	O
using	O
symmetrical	O
confidence	O
intervals	O
and	O
report	O
excellent	O
agreement	O
among	O
several	O
methods	O
of	O
calculating	O
confidence	O
intervals	O
,	O
probability	O
values	O
,	O
and	O
nonparametric	O
tests	O
.	O

We	O
suggest	O
that	O
a	O
single-point	O
short-term	O
AUC	O
is	O
a	O
better	O
indicator	O
of	O
the	O
bioequivalence	O
of	O
generic	O
products	O
than	O
the	O
total	O
AUC	O
,	O
Cmax	O
,	O
and	O
Tmax	O
as	O
required	O
currently	O
by	O
the	O
regulatory	O
authorities	O
.	O

2-Chloroprocaine	Pharmacological
antagonism	O
of	O
epidural	O
morphine	O
analgesia	O
.	O

BACKGROUND	O
2-Chloroprocaine	Pharmacological
(	Pharmacological
2-CP	Pharmacological
)	Pharmacological
used	O
for	O
lumbar	O
epidural	O
anesthesia	O
(	O
LEA	O
)	O
reportedly	O
decreases	O
the	O
efficacy	O
of	O
epidural	O
morphine	Pharmacological
(	Pharmacological
EM	Pharmacological
)	Pharmacological
administered	O
for	O
post-cesarean	O
section	O
(	O
CS	O
)	O
analgesia	O
.	O

The	O
amount	O
of	O
supplemental	O
i.v	O
.	O

morphine	Pharmacological
self-administered	O
by	O
the	O
patient	O
via	O
the	O
patient-controlled	O
analgesia	O
device	O
(	O
PCA	O
)	O
is	O
used	O
to	O
study	O
the	O
interaction	O
between	O
EM	Pharmacological
and	O
2-CP	Pharmacological
.	O

METHODS	O
Forty-two	O
patients	O
scheduled	O
for	O
elective	O
CS	O
were	O
randomly	O
divided	O
into	O
3	O
equal	O
groups	O
,	O
and	O
received	O
2-CP	Pharmacological
,	O
2-CP	Pharmacological
+	Pharmacological
epinephrine	Pharmacological
(	O
Epi	O
,	O
5	O
micrograms.ml-1	O
)	O
or	O
2	Pharmacological
%	Pharmacological
lidocaine	Pharmacological
(	Pharmacological
Lido	Pharmacological
)	Pharmacological
with	Pharmacological
Epi	Pharmacological
for	O
LEA	O
.	O

All	O
patients	O
received	O
5	O
mg	O
EM	Pharmacological
and	O
i.v	O
.	O

PCA	Pharmacological
morphine	Pharmacological
for	O
postoperative	O
pain	O
.	O

Cumulative	O
amount	O
of	O
i.v	O
.	O

morphine	Pharmacological
used	O
in	O
the	O
first	O
24	O
hours	O
as	O
well	O
as	O
the	O
amount	O
of	O
the	O
drug	O
used	O
during	O
each	O
2-h	O
period	O
were	O
noted	O
.	O

Nonparametric	O
analysis	O
of	O
variance	O
and	O
Chi-squared	O
analysis	O
were	O
used	O
for	O
statistical	O
comparisons	O
.	O

RESULTS	O
The	O
mean	O
cumulative	O
24-h	O
i.v	O
.	O

PCA	O
morphine	O
requirement	O
in	O
the	O
2-CP	Pharmacological
,	O
2-CP+Epi	Pharmacological
and	O
Lido+Epi	O
groups	O
respectively	O
was	O
20.5	O
+/-	O
24	O
,	O
33.1.5	O
+/-	O
27	O
and	O
4.07	O
+/-	O
(	O
mean	O
+/-	O
SD	O
)	O
.	O

The	O
Lido	O
+	O
Epi	O
group	O
used	O
significantly	O
less	O
morphine	O
(	O
P	O
=	O
0.01	O
)	O
compared	O
to	O
either	O
of	O
the	O
2-CP	Pharmacological
groups	O
with	O
no	O
significant	O
difference	O
between	O
the	O
2-CP	Pharmacological
groups	O
.	O

The	O
maximum	O
i.v	O
.	O

PCA	O
morphine	Pharmacological
use	O
occurred	O
in	O
the	O
first	O
4	O
hours	O
following	O
surgery	O
in	O
all	O
three	O
groups	O
.	O

CONCLUSION	O
Analgesic	O
efficacy	O
of	O
EM	Pharmacological
is	O
decreased	O
when	O
2-CP	Pharmacological
is	O
used	O
for	O
LEA	O
compared	O
to	O
when	O
Lido	Pharmacological
+	Pharmacological
Epi	Pharmacological
is	O
used	O
.	O

[	O
Metastatic	O
breast	O
cancer	O
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
of	O
tamoxifen	Pharmacological
and	O
the	O
sequential	O
administration	O
of	O
tamoxifen	Pharmacological
and	O
medroxyprogesterone	Pharmacological
acetate	Pharmacological
]	O
.	O

Seventy-nine	O
patients	O
with	O
an	O
histologically	O
proven	O
disseminated	O
breast	O
cancer	O
,	O
never	O
treated	O
before	O
with	O
additive	O
hormonal	O
therapy	O
,	O
entered	O
into	O
a	O
randomized	O
trial	O
between	O
june	O
1981	O
and	O
december	O
1982	O
.	O

In	O
the	O
first	O
group	O
44	O
patients	O
were	O
given	O
continually	O
a	O
daily	O
dose	O
of	O
tamoxifen	Pharmacological
(	Pharmacological
TAM	Pharmacological
)	O
of	O
20	O
mg/m2	O
.	O

In	O
the	O
2nd	O
group	O
35	O
patients	O
were	O
given	O
a	O
daily	O
dose	O
of	O
TAM	Pharmacological
of	O
20	O
mg/m2	O
for	O
15	O
days	O
and	O
then	O
an	O
oral	O
daily	O
dose	O
of	O
medroxyprogesterone	Pharmacological
acetate	Pharmacological
of	O
350	O
mg/m2	O
for	O
the	O
next	O
15	O
days	O
.	O

In	O
both	O
groups	O
I	O
and	O
II	O
,	O
the	O
treatment	O
was	O
stopped	O
at	O
the	O
first	O
manifestation	O
of	O
progression	O
of	O
the	O
disease	O
.	O

The	O
hormonal	O
receptor	O
status	O
was	O
determined	O
in	O
30	O
patients	O
of	O
the	O
group	O
I	O
and	O
23	O
patients	O
of	O
the	O
group	O
II	O
.	O

An	O
objective	O
response	O
to	O
treatment	O
was	O
observed	O
in	O
48	O
per	O
cent	O
of	O
the	O
patients	O
of	O
the	O
group	O
I	O
and	O
60	O
per	O
cent	O
of	O
the	O
group	O
II	O
.	O

This	O
difference	O
is	O
not	O
significant	O
(	O
X2	O
=	O
1,05	O
)	O
.	O

However	O
,	O
the	O
mean	O
duration	O
of	O
therapeutic	O
response	O
is	O
significantly	O
higher	O
in	O
the	O
group	O
II	O
(	O
p	O
=	O
0,01	O
)	O
.	O

Carbenicillin-trimethoprim/sulfamethoxazole	Pharmacological
versus	Pharmacological
carbenicillin-gentamicin	Pharmacological
as	O
empiric	O
therapy	O
of	O
infection	O
in	O
granulocytopenic	O
patients	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

The	O
results	O
of	O
therapy	O
with	O
carbenicillin	Pharmacological
plus	Pharmacological
trimethoprim-sulfamethoxazole	Pharmacological
(	Pharmacological
C-T/S	Pharmacological
)	Pharmacological
were	Pharmacological
compared	Pharmacological
to	Pharmacological
those	Pharmacological
obtained	Pharmacological
with	Pharmacological
carbenicillin	Pharmacological
plus	Pharmacological
gentamicin	Pharmacological
(	Pharmacological
C-G	Pharmacological
)	Pharmacological
in	O
a	O
prospective	O
double-blind	O
study	O
of	O
empiric	O
antibiotic	O
therapy	O
in	O
granulocytopenic	O
patients	O
.	O

Patients	O
were	O
stratified	O
into	O
two	O
groups	O
:	O
favorable-prognosis	O
,	O
group	O
1	O
(	O
carcinoma	O
,	O
lymphoma	O
,	O
multiple	O
myeloma	O
)	O
,	O
or	O
unfavorable-prognosis	O
,	O
group	O
2	O
(	O
acute	O
leukemia	O
,	O
bone	O
marrow	O
transplantation	O
)	O
,	O
based	O
on	O
anticipated	O
duration	O
of	O
granulocytopenia	O
.	O

Over-all	O
,	O
empiric	O
antibiotic	O
trials	O
were	O
more	O
often	O
successful	O
(	O
P	O
=	O
0.004	O
)	O
in	O
group	O
1	O
(	O
55	O
of	O
62	O
patients	O
or	O
89	O
per	O
cent	O
)	O
than	O
in	O
group	O
2	O
(	O
42	O
of	O
64	O
patients	O
,	O
66	O
per	O
cent	O
)	O
mwithin	O
group	O
1	O
,	O
there	O
was	O
a	O
favorable	O
outcome	O
in	O
30	O
of	O
32	O
(	O
94	O
per	O
cent	O
)	O
C-T/S	O
trials	O
and	O
in	O
25	O
of	O
30	O
(	O
83	O
per	O
cent	O
)	O
C-G	O
trials	O
(	O
P	O
=	O
0.25	O
)	O
;	O
within	O
group	O
2	O
,	O
there	O
was	O
a	O
favorable	O
outcome	O
in	O
23	O
of	O
30	O
(	O
77	O
per	O
cent	O
)	O
C-T/S	O
trials	O
and	O
in	O
19	O
of	O
34	O
(	O
56	O
per	O
cent	O
)	O
C-G	O
trials	O
(	O
P	O
=	O
0.14	O
)	O
,	O
Combined	O
results	O
in	O
both	O
groups	O
indicated	O
a	O
higher	O
proportion	O
of	O
favorable	O
outcome	O
in	O
C-T/S	O
trials	O
(	O
53	O
of	O
62	O
,	O
85	O
per	O
cent	O
)	O
than	O
in	O
C-G	O
trials	O
(	O
44	O
of	O
64	O
,	O
69	O
per	O
cent	O
)	O
.	O

Further	O
analysis	O
(	O
Manetl-Naenszel	O
test	O
)	O
showed	O
the	O
over-all	O
difference	O
in	O
outcome	O
to	O
be	O
significant	O
(	O
P	O
=	O
0.049	O
)	O
,	O
but	O
the	O
general	O
applicability	O
of	O
this	O
result	O
may	O
be	O
limited	O
by	O
the	O
rather	O
low	O
incidence	O
of	O
gram-negative	O
bacterial	O
infections	O
in	O
this	O
study	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
treatment	O
regimens	O
in	O
antibiotic	O
toxicity	O
,	O
and	O
serious	O
superinfection	O
occurred	O
only	O
in	O
group	O
2	O
patients	O
(	O
21	O
per	O
cent	O
of	O
trials	O
)	O
,	O
equally	O
divided	O
between	O
treatment	O
arms	O
.	O

Initial	O
protocol	O
dosing	O
achieved	O
target	O
plasma	O
levels	O
of	O
trimethoprim	O
(	O
3	O
to	O
8	O
micrograms/ml	O
)	O
or	O
gentamicin	O
(	O
4	O
to	O
10	O
micrograms/ml	O
)	O
in	O
57	O
of	O
68	O
(	O
84	O
per	O
cent	O
)	O
C-T/S	O
trials	O
compared	O
to	O
21	O
of	O
60	O
(	O
35	O
per	O
cent	O
)	O
C-G	O
trials	O
.	O

Clonidine	Pharmacological
clearance	O
matures	O
rapidly	O
during	O
the	O
early	O
postnatal	O
period	O
:	O
a	O
population	O
pharmacokinetic	O
analysis	O
in	O
newborns	O
with	O
neonatal	O
abstinence	O
syndrome	O
.	O

The	O
population	O
pharmacokinetic	O
(	O
PK	O
)	O
profile	O
of	O
oral	Pharmacological
clonidine	Pharmacological
was	O
characterized	O
in	O
newborns	O
with	O
neonatal	O
abstinence	O
syndrome	O
,	O
and	O
significant	O
covariates	O
affecting	O
its	O
PK	O
parameters	O
were	O
identified	O
.	O

Plasma	O
clonidine	Pharmacological
concentration	O
data	O
were	O
obtained	O
from	O
a	O
clinical	O
trial	O
in	O
which	O
36	O
newborns	O
,	O
aged	O
1	O
to	O
25	O
days	O
(	O
postnatal	O
age	O
,	O
PNA	O
)	O
and	O
weighing	O
2.1	O
to	O
3.9	O
kg	O
,	O
were	O
enrolled	O
to	O
take	O
multiple	O
oral	O
doses	O
of	O
clonidine	O
.	O

The	O
population	O
PK	O
model	O
of	O
clonidine	Pharmacological
was	O
developed	O
by	O
NONMEM	O
,	O
and	O
significant	O
covariates	O
were	O
identified	O
,	O
followed	O
by	O
nonparametric	O
bootstraps	O
(	O
2000	O
replicates	O
)	O
and	O
simulation	O
experiments	O
.	O

A	O
1-compartment	O
open	O
linear	O
PK	O
model	O
was	O
chosen	O
to	O
describe	O
plasma	O
concentrations	O
of	O
clonidine	Pharmacological
,	O
and	O
body	O
weight	O
and	O
PNA	O
were	O
significant	O
covariates	O
for	O
apparent	O
clearance	O
(	O
CL/F	O
)	O
as	O
follows	O
:	O
CL/F	O
(	O
L/h	O
)	O
=	O
15.2	O
?	O
[	O
body	O
weight	O
(	O
kg	O
)	O
/70	O
]	O
(	O
0.75	O
)	O
?	O
[	O
PNA	O
(	O
day	O
)	O
(	O
0.441	O
)	O
/	O
(	O
4.06	O
(	O
0.441	O
)	O
+	O
PNA	O
(	O
day	O
)	O
(	O
0.441	O
)	O
)	O
]	O
.	O

Furthermore	O
,	O
CL/F	O
of	O
clonidine	O
increased	O
rapidly	O
with	O
PNA	O
during	O
the	O
first	O
month	O
of	O
life	O
after	O
body	O
weight	O
was	O
adjusted	O
.	O

Any	O
optimal	O
dosage	O
regimen	O
for	O
clonidine	O
in	O
term	O
neonates	O
should	O
be	O
based	O
on	O
infant	O
's	O
age	O
and	O
body	O
weight	O
,	O
and	O
1.5	O
?g/kg	O
every	O
4	O
hours	O
is	O
proposed	O
starting	O
the	O
second	O
week	O
of	O
life	O
based	O
on	O
the	O
simulation	O
results	O
.	O

Prognostic	O
factor	O
analysis	O
in	O
patients	O
with	O
advanced	O
prostate	O
cancer	O
treated	O
by	O
castration	Surgical
plus	O
anandron	Pharmacological
or	O
placebo	Control
:	O
a	O
final	O
update	O
.	O

PURPOSE	O
Different	O
outcome	O
results	O
have	O
been	O
published	O
in	O
trials	O
comparing	O
maximal	O
androgen	O
blockade	O
(	O
MAB	O
)	O
with	O
chemical	Surgical
or	Surgical
surgical	Surgical
castration	Surgical
alone	Surgical
.	O

The	O
conflicting	O
results	O
could	O
be	O
explained	O
by	O
the	O
fact	O
that	O
patients	O
were	O
included	O
with	O
different	O
prognostic	O
factors	O
.	O

In	O
this	O
new	O
analysis	O
of	O
the	O
Anandron	O
European	O
Study	O
,	O
independent	O
prognostic	O
factors	O
have	O
been	O
evaluated	O
in	O
order	O
to	O
identify	O
those	O
which	O
could	O
influence	O
the	O
study	O
outcome	O
and	O
the	O
impact	O
of	O
the	O
treatment	O
.	O

MATERIAL	O
AND	O
METHODS	O
399	O
out	O
of	O
457	O
patients	O
recruited	O
in	O
this	O
study	O
were	O
divided	O
in	O
a	O
good	O
or	O
poor	O
prognostic	O
group	O
depending	O
on	O
the	O
presence	O
of	O
two	O
or	O
more	O
poor	O
prognostic	O
factors	O
,	O
these	O
were	O
pain	O
requiring	O
treatment	O
,	O
>	O
5	O
bone	O
metastases	O
,	O
hydronephrosis	O
,	O
and	O
alkaline	O
phosphatase	O
>	O
2	O
ULN	O
.	O

RESULTS	O
When	O
expressed	O
as	O
a	O
percentage	O
,	O
the	O
improvement	O
in	O
time	O
to	O
progression	O
,	O
overall	O
and	O
cancer	O
specific	O
survival	O
in	O
the	O
Anandron	Pharmacological
treated	O
patients	O
was	O
identical	O
in	O
both	O
groups	O
.	O

In	O
absolute	O
terms	O
this	O
improvement	O
,	O
however	O
,	O
was	O
greater	O
in	O
the	O
good	O
prognostic	O
group	O
.	O

CONCLUSION	O
In	O
comparison	O
with	O
surgical	Surgical
castration	Surgical
MAB	Pharmacological
using	Pharmacological
Anandron	Pharmacological
,	O
in	O
patients	O
with	O
metastatic	O
prostate	O
cancer	O
improves	O
the	O
time	O
to	O
objective	O
progression	O
,	O
overall	O
and	O
cancer	O
specific	O
survival	O
,	O
irrespective	O
of	O
certain	O
poor	O
prognostic	O
factors	O
.	O

Playing	O
on	O
the	O
typewriter	O
,	O
typing	O
on	O
the	O
piano	O
:	O
manipulation	O
knowledge	O
of	O
objects	O
.	O

Two	O
experiments	O
investigated	O
sensory/motor-based	O
functional	O
knowledge	O
of	O
man-made	O
objects	O
:	O
manipulation	O
features	O
associated	O
with	O
the	O
actual	O
usage	O
of	O
objects	O
.	O

In	O
Experiment	O
1	O
,	O
a	O
series	O
of	O
prime-target	O
pairs	O
was	O
presented	O
auditorily	O
,	O
and	O
participants	O
were	O
asked	O
to	O
make	O
a	O
lexical	Educational
decision	Educational
on	O
the	O
target	O
word	O
.	O

Participants	O
made	O
a	O
significantly	O
faster	O
decision	O
about	O
the	O
target	Educational
word	Educational
(	O
e.g	O
.	O

'typewriter	O
'	O
)	O
following	O
a	O
related	O
prime	O
that	O
shared	O
manipulation	O
features	O
with	O
the	O
target	O
(	O
e.g	O
.	O

'piano	O
'	O
)	O
than	O
an	O
unrelated	O
prime	O
(	O
e.g	O
.	O

'blanket	O
'	O
)	O
.	O

In	O
Experiment	O
2	O
,	O
participants	O
'	O
eye	O
movements	O
were	O
monitored	O
when	O
they	O
viewed	O
a	O
visual	Educational
display	Educational
on	Educational
a	Educational
computer	Educational
screen	Educational
while	Educational
listening	Educational
to	Educational
a	Educational
concurrent	Educational
auditory	Educational
input	Educational
.	O

Participants	O
were	O
instructed	O
to	O
simply	O
identify	O
the	O
auditory	O
input	O
and	O
touch	O
the	O
corresponding	O
object	O
on	O
the	O
computer	O
display	O
.	O

Participants	O
fixated	O
an	O
object	O
picture	O
(	O
e.g	O
.	O

typewriter	O
)	O
related	O
to	O
a	O
target	O
word	O
(	O
e.g	O
.	O

'piano	O
'	O
)	O
significantly	O
more	O
often	O
than	O
an	O
unrelated	O
object	O
picture	O
(	O
e.g	O
.	O

bucket	O
)	O
as	O
well	O
as	O
a	O
visually	O
matched	O
control	O
(	O
e.g	O
.	O

couch	O
)	O
.	O

Results	O
of	O
the	O
two	O
experiments	O
suggest	O
that	O
manipulation	O
knowledge	O
of	O
words	O
is	O
retrieved	O
without	O
conscious	O
effort	O
and	O
that	O
manipulation	O
knowledge	O
constitutes	O
a	O
part	O
of	O
the	O
lexical-semantic	O
representation	O
of	O
objects	O
.	O

Children	O
with	O
autism	O
's	O
response	O
to	O
novel	Educational
stimuli	Educational
while	O
participating	O
in	O
interventions	O
targeting	O
joint	Educational
attention	Educational
or	O
symbolic	Educational
play	Educational
skills	O
.	O

Thirty-five	O
children	O
diagnosed	O
with	O
autism	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
joint	Educational
attention	Educational
or	Educational
a	Educational
symbolic	Educational
play	Educational
intervention	Educational
.	Educational

During	O
the	O
5-8	O
week	O
treatment	O
,	O
three	O
novel	O
probes	O
were	O
administered	O
to	O
determine	O
mastery	O
of	O
joint	O
attention	O
skills	O
.	O

The	O
probes	O
consisted	O
of	O
auditory	O
and	O
visual	O
stimuli	O
,	O
such	O
as	O
a	O
loud	O
spider	O
crawling	O
or	O
a	O
musical	O
ball	O
bouncing	O
.	O

The	O
current	O
study	O
examined	O
affect	O
,	O
gaze	O
,	O
joint	O
attention	O
behaviors	O
,	O
and	O
verbalizations	O
at	O
three	O
different	O
time	O
points	O
of	O
intervention	O
.	O

Results	O
revealed	O
that	O
children	O
randomized	O
to	O
the	O
joint	Educational
attention	Educational
group	O
were	O
more	O
likely	O
to	O
acknowledge	O
the	O
probe	O
and	O
engage	O
in	O
shared	O
interactions	O
between	O
intervener	O
and	O
probe	O
upon	O
termination	O
of	O
intervention	O
.	O

Additionally	O
,	O
the	O
joint	O
attention	O
group	O
improved	O
in	O
the	O
proportion	O
of	O
time	O
spent	O
sharing	O
coordinated	O
joint	O
looks	O
between	O
intervener	O
and	O
probe	O
.	O

These	O
results	O
suggest	O
that	O
generalization	O
of	O
joint	O
attention	O
skills	O
to	O
a	O
novel	O
probe	O
did	O
occur	O
for	O
the	O
group	O
targeting	O
joint	O
attention	O
and	O
provides	O
further	O
evidence	O
of	O
the	O
effectiveness	O
of	O
the	O
joint	O
attention	O
intervention	O
.	O

A	O
double-blind	O
placebo-controlled	Control
study	O
to	O
evaluate	O
valacyclovir	Pharmacological
alone	Pharmacological
and	O
with	O
aspirin	Pharmacological
for	O
asymptomatic	O
HSV-1	O
DNA	O
shedding	O
in	O
human	O
tears	O
and	O
saliva	O
.	O

PURPOSE	O
To	O
test	O
the	O
effect	O
of	O
valacyclovir	Pharmacological
alone	Pharmacological
and	O
with	O
aspirin	Pharmacological
on	O
the	O
asymptomatic	O
shedding	O
of	O
HSV-1	O
DNA	O
in	O
tears	O
and	O
saliva	O
of	O
healthy	O
individuals	O
.	O

METHOD	O
.	O

The	O
subjects	O
(	O
n	O
=	O
45	O
)	O
were	O
randomized	O
into	O
three	O
groups	O
without	O
regard	O
to	O
age	O
,	O
sex	O
,	O
or	O
race	O
.	O

Group	O
1	O
(	O
n	O
=	O
14	O
)	O
received	O
the	O
placebo	Control
,	O
group	O
2	O
(	O
n	O
=	O
15	O
)	O
received	O
a	O
dose	O
of	O
500	Pharmacological
mg	Pharmacological
valacyclovir	Pharmacological
once	Pharmacological
daily	Pharmacological
,	O
and	O
group	O
3	O
(	O
n	O
=	O
16	O
)	O
received	O
a	O
dose	O
of	O
500	Pharmacological
mg	Pharmacological
valacyclovir	Pharmacological
once	Pharmacological
daily	Pharmacological
and	O
350	Pharmacological
mg	Pharmacological
aspirin	Pharmacological
twice	O
daily	O
for	O
30	O
days	O
.	O

Ocular	O
and	O
oral	O
swabs	O
were	O
collected	O
twice	O
daily	O
for	O
30	O
days	O
.	O

DNA	O
was	O
extracted	O
from	O
all	O
swabs	O
and	O
HSV-1	O
DNA	O
copy	O
numbers	O
were	O
determined	O
.	O

Statistical	O
analysis	O
was	O
performed	O
to	O
compare	O
the	O
DNA	O
copy	O
numbers	O
of	O
the	O
three	O
groups	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
HSV-1	O
DNA	O
copy	O
numbers	O
in	O
the	O
tears	O
or	O
saliva	O
among	O
any	O
of	O
the	O
three	O
treatment	O
groups	O
.	O

The	O
mean	O
copy	O
numbers	O
+/-	O
SE	O
of	O
mean	O
(	O
SEM	O
)	O
of	O
HSV-1	O
DNA	O
in	O
tears	O
were	O
340	O
+/-	O
35	O
,	O
1074	O
+/-	O
320	O
,	O
and	O
630	O
+/-	O
51	O
for	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
and	O
in	O
saliva	O
were	O
238	O
+/-	O
35	O
,	O
963	O
+/-	O
462	O
,	O
and	O
493	O
+/-	O
25	O
,	O
respectively	O
,	O
for	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

CONCLUSIONS	O
No	O
correlation	O
was	O
found	O
between	O
HSV-1	O
shedding	O
and	O
valacyclovir	Pharmacological
and	O
valacyclovir	Pharmacological
with	Pharmacological
aspirin	Pharmacological
treatment	O
.	O

The	O
HSV-1	O
DNA	O
copy	O
number	O
was	O
not	O
reduced	O
by	O
treatment	O
with	O
500	O
mg	O
of	O
valacyclovir	Pharmacological
daily	O
or	O
with	O
a	O
combination	O
of	O
daily	O
valacyclovir	Pharmacological
(	O
500	O
mg	O
)	O
plus	O
twice-daily	O
doses	O
of	O
aspirin	Pharmacological
(	O
350	O
mg	O
)	O
over	O
30	O
days	O
.	O

Infliximab	Pharmacological
in	O
ankylosing	O
spondylitis	O
:	O
alone	O
or	O
in	O
combination	O
with	O
methotrexate	Pharmacological
?	O
A	O
pharmacokinetic	O
comparative	O
study	O
.	O

INTRODUCTION	O
Methotrexate	Pharmacological
(	Pharmacological
MTX	Pharmacological
)	Pharmacological
has	O
been	O
shown	O
to	O
modify	O
infliximab	Pharmacological
pharmacokinetics	O
in	O
rheumatoid	O
arthritis	O
.	O

However	O
,	O
its	O
combination	O
with	O
infliximab	Pharmacological
in	O
the	O
treatment	O
of	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
is	O
not	O
recommended	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
MTX	Pharmacological
on	Pharmacological
infliximab	Pharmacological
exposure	O
in	O
patients	O
with	O
AS	O
.	O

METHODS	O
Patients	O
with	O
AS	O
patients	O
who	O
had	O
predominantly	O
axial	O
symptoms	O
were	O
randomised	O
to	O
receive	O
infliximab	Pharmacological
alone	Pharmacological
(	O
infusions	O
of	O
5	O
mg/kg	O
at	O
weeks	O
0	O
,	O
2	O
,	O
6	O
,	O
12	O
and	O
18	O
)	O
or	Pharmacological
infliximab	Pharmacological
combined	Pharmacological
with	Pharmacological
MTX	Pharmacological
(	O
10	O
mg/week	O
)	O
.	O

Infliximab	Pharmacological
concentrations	O
were	O
measured	O
before	O
and	O
2	O
hours	O
after	O
each	O
infusion	O
and	O
at	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
8	O
,	O
10	O
,	O
14	O
and	O
18	O
weeks	O
.	O

We	O
estimated	O
individual	O
cumulative	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curves	O
(	O
AUC	O
)	O
for	O
infliximab	Pharmacological
concentration	O
between	O
baseline	O
and	O
week	O
18	O
(	O
AUC	O
(	O
0-18	O
)	O
)	O
.	O

Clinical	O
and	O
laboratory	O
evaluations	O
were	O
performed	O
at	O
each	O
visit	O
.	O

The	O
Bath	O
Ankylosing	O
Spondylitis	O
Disease	O
Activity	O
Index	O
(	O
BASDAI	O
)	O
score	O
was	O
the	O
primary	O
end	O
point	O
for	O
clinical	O
response	O
.	O

RESULTS	O
Twenty-six	O
patients	O
were	O
included	O
(	O
infliximab	O
group	O
:	O
n	O
=	O
12	O
,	O
infliximab	Pharmacological
+	Pharmacological
MTX	Pharmacological
group	O
:	O
n	O
=	O
14	O
)	O
,	O
and	O
507	O
serum	O
samples	O
were	O
available	O
for	O
measurement	O
of	O
infliximab	Pharmacological
concentration	O
.	O

The	O
two	O
groups	O
did	O
not	O
differ	O
with	O
regard	O
to	O
AUC	O
(	O
0-18	O
)	O
or	O
evolution	O
of	O
BASDAI	O
scores	O
and	O
biomarkers	O
of	O
inflammation	O
.	O

CONCLUSIONS	O
The	O
combination	O
of	O
MTX	Educational
and	Educational
infliximab	Educational
does	O
not	O
increase	O
the	O
exposure	O
to	O
infliximab	O
over	O
infliximab	Educational
alone	O
in	O
patients	O
with	O
AS	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
:	O
NCT00507403	O
.	O

Enhancing	O
the	O
working	O
memory	O
of	O
stroke	O
patients	O
using	O
tDCS	Physical
.	O

OBJECTIVES	O
We	O
investigated	O
whether	O
anodal	O
transcranial	Physical
direct	Physical
current	Physical
stimulation	Physical
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
affected	O
the	O
working	O
memory	O
performance	O
of	O
patients	O
after	O
a	O
stroke	O
.	O

DESIGN	O
Ten	O
patients	O
(	O
mean	O
age	O
47.7	O
yrs	O
)	O
with	O
cognitive	O
deficits	O
after	O
a	O
first-ever	O
stroke	O
participated	O
in	O
this	O
single-blind	O
,	O
crossover	O
,	O
and	O
sham-controlled	Control
experiment	O
.	O

Each	O
patient	O
was	O
randomly	O
assigned	O
to	O
undergo	O
two	O
transcranial	Physical
direct	Physical
current	Physical
stimulation	Physical
sessions	O
:	O
anodal	O
dorsolateral	O
prefrontal	O
cortex	O
and	O
sham	O
stimulation	O
within	O
48	O
hrs	O
of	O
a	O
washout	O
period	O
.	O

All	O
participants	O
performed	O
a	O
two-back	O
working	O
memory	O
task	O
before	O
and	O
after	O
the	O
administration	O
of	O
the	O
transcranial	O
direct	O
current	O
stimulation	O
.	O

Accuracy	O
(	O
correction	O
rate	O
)	O
,	O
recognition	O
accuracy	O
(	O
correction	O
rate-commission	O
error	O
rate	O
)	O
,	O
and	O
response	O
time	O
were	O
measured	O
during	O
each	O
experiment	O
.	O

RESULTS	O
Repeated-measures	O
analysis	O
of	O
variance	O
indicated	O
a	O
significant	O
interaction	O
effect	O
of	O
transcranial	O
direct	O
current	O
stimulation	O
type	O
and	O
time	O
on	O
the	O
recognition	O
accuracy	O
.	O

Post	O
hoc	O
analyses	O
revealed	O
a	O
significant	O
difference	O
between	O
prestimulation	O
and	O
poststimulation	O
in	O
the	O
anodal	O
stimulation	O
group	O
but	O
not	O
in	O
the	O
sham	O
stimulation	O
group	O
.	O

Regarding	O
the	O
accuracy	O
,	O
the	O
paired	O
t	O
test	O
indicated	O
significant	O
improvement	O
only	O
after	O
anodal	O
transcranial	Physical
direct	Physical
current	Physical
stimulation	Physical
without	O
a	O
significant	O
interaction	O
effect	O
between	O
the	O
two	O
transcranial	O
direct	O
current	O
stimulation	O
types	O
.	O

The	O
response	O
time	O
was	O
not	O
significantly	O
different	O
in	O
the	O
anodal	O
and	O
sham	O
stimulation	O
groups	O
.	O

CONCLUSION	O
Our	O
results	O
demonstrated	O
that	O
anodal	O
transcranial	Physical
direct	Physical
current	Physical
stimulation	Physical
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
was	O
associated	O
with	O
enhanced	O
working	O
memory	O
performance	O
as	O
indexed	O
by	O
the	O
recognition	O
accuracy	O
in	O
patients	O
after	O
a	O
stroke	O
.	O

Comparison	O
of	O
hypnotherapy	Psychological
with	O
systematic	Other
relaxation	Other
in	O
the	O
treatment	O
of	O
cigarette	O
habituation	O
.	O

Because	O
of	O
the	O
methodological	O
deficiencies	O
in	O
this	O
area	O
of	O
research	O
,	O
it	O
is	O
impossible	O
to	O
make	O
any	O
valid	O
conclusions	O
about	O
whether	O
hypnosis	O
itself	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
cigarette	O
habituation	O
.	O

In	O
this	O
study	O
,	O
87	O
volunteers	O
who	O
wanted	O
to	O
quit	O
cigarette	O
smoking	O
were	O
assigned	O
randomly	O
to	O
the	O
experimental	Educational
hypnosis	Educational
group	Educational
,	Educational
the	Physical
comparison	Other
relaxation	Other
group	Other
,	O
and	O
the	O
waiting	Control
list	Control
control	Control
group	Control
.	O

Ss	O
in	O
the	O
treatment	O
groups	O
had	O
four	O
weekly	O
50-minute	O
,	O
individual	O
sessions	O
.	O

Four	O
months	O
after	O
the	O
completion	O
of	O
treatment	O
,	O
Ss	O
were	O
administered	O
a	O
questionnaire	O
and	O
a	O
hypnotic	O
susceptibility	O
scale	O
.	O

Ss	O
in	O
the	O
hypnosis	Psychological
group	O
who	O
were	O
in	O
the	O
upper	O
two-thirds	O
of	O
the	O
group	O
in	O
terms	O
of	O
hypnotic	O
susceptibility	O
reduced	O
their	O
cigarette	O
consumption	O
substantially	O
more	O
than	O
Ss	O
in	O
the	O
relaxation	O
group	O
who	O
were	O
in	O
the	O
upper	O
two-thirds	O
of	O
the	O
group	O
in	O
terms	O
of	O
hypnotic	O
susceptibility	O
.	O

Therefore	O
,	O
the	O
hypnotic	O
state	O
appears	O
to	O
be	O
therapeutic	O
for	O
individuals	O
who	O
can	O
enter	O
medium	O
or	O
deep	O
states	O
of	O
hypnosis	O
.	O

A	O
comparison	O
of	O
a	O
spiritually	Educational
based	Educational
and	Educational
non-spiritually	Educational
based	Educational
educational	Educational
intervention	Educational
for	O
informed	O
decision	O
making	O
for	O
prostate	O
cancer	O
screening	O
among	O
church-attending	O
African-American	O
men	O
.	O

INTRODUCTION	O
Health	Educational
communication	Educational
interventions	Educational
have	O
been	O
modestly	O
effective	O
for	O
increasing	O
informed	O
decision	O
making	O
for	O
prostate	O
cancer	O
screening	O
among	O
African-American	O
men	O
;	O
however	O
,	O
knowledge	O
and	O
informed	O
decision	O
making	O
is	O
still	O
questionable	O
even	O
with	O
screening	O
.	O

Church-based	O
programs	O
may	O
be	O
more	O
effective	O
if	O
they	O
are	O
spiritually	O
based	O
in	O
nature	O
.	O

OBJECTIVE	O
The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
implement	O
and	O
provide	O
an	O
initial	O
evaluation	O
of	O
a	O
spiritually	O
based	O
prostate	O
cancer	O
screening	O
informed	O
decision	O
making	O
intervention	O
for	O
African-American	O
men	O
who	O
attend	O
church	O
,	O
and	O
determine	O
its	O
efficacy	O
for	O
increasing	O
informed	O
decision	O
making	O
.	O

DESIGN	O
AND	O
METHOD	O
Churches	O
were	O
randomized	O
to	O
receive	O
either	O
the	O
spiritually	Educational
based	Educational
or	Educational
the	Educational
non-spiritual	Educational
intervention	Educational
.	O

Trained	O
community	O
health	O
advisors	O
,	O
who	O
were	O
African-American	O
male	O
church	O
members	O
,	O
led	O
an	O
educational	Educational
session	Educational
and	O
distributed	Educational
educational	Educational
print	Educational
materials	Educational
.	Educational

Participants	O
completed	O
baseline	O
and	O
immediate	O
follow-up	O
surveys	O
to	O
assess	O
the	O
intervention	O
impact	O
on	O
study	O
outcomes	O
.	O

RESULTS	O
The	O
spiritually	O
based	O
intervention	O
appeared	O
to	O
be	O
more	O
effective	O
in	O
areas	O
such	O
as	O
knowledge	O
,	O
and	O
men	O
read	O
more	O
of	O
their	O
materials	O
in	O
the	O
spiritually	O
based	O
group	O
than	O
in	O
the	O
non-spiritual	O
group	O
.	O

CONCLUSIONS	O
Further	O
examination	O
of	O
the	O
efficacy	O
of	O
the	O
spiritually	O
based	O
approach	O
to	O
health	O
communication	O
is	O
warranted	O
.	O

Effect	O
of	O
dietary	O
supplementation	O
with	O
n-3	O
fatty	O
acids	O
on	O
coronary	O
artery	O
bypass	O
graft	O
patency	O
.	O

Epidemiologic	O
and	O
experimental	O
data	O
suggest	O
that	O
a	O
high	O
dietary	O
intake	O
of	O
long-chain	O
polyunsaturated	O
n-3	Pharmacological
fatty	Pharmacological
acids	Pharmacological
may	O
reduce	O
the	O
risk	O
of	O
atherothrombotic	O
disease	O
.	O

In	O
a	O
randomized	O
,	O
controlled	O
study	O
,	O
610	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
were	O
assigned	O
either	O
to	O
a	O
fish	Pharmacological
oil	Pharmacological
group	Pharmacological
,	Pharmacological
receiving	Pharmacological
4	Pharmacological
g/day	Pharmacological
of	Pharmacological
fish	Pharmacological
oil	Pharmacological
concentrate	Pharmacological
,	Pharmacological
or	Pharmacological
to	Pharmacological
a	Pharmacological
control	Control
group	Control
.	Pharmacological

All	O
patients	O
received	O
antithrombotic	Pharmacological
treatment	Pharmacological
,	O
either	O
aspirin	Pharmacological
or	O
warfarin	Pharmacological
.	O

Their	O
diet	O
and	O
serum	O
phospholipid	O
fatty	O
acid	O
profiles	O
were	O
monitored	O
.	O

The	O
primary	O
end	O
point	O
was	O
1-year	O
graft	O
patency	O
,	O
which	O
was	O
assessed	O
by	O
angiography	O
in	O
95	O
%	O
of	O
patients	O
.	O

Vein	O
graft	O
occlusion	O
rates	O
per	O
distal	O
anastomoses	O
were	O
27	O
%	O
in	O
the	O
fish	Pharmacological
oil	Pharmacological
group	O
and	O
33	O
%	O
in	O
the	O
control	O
group	O
(	O
odds	O
ratio	O
0.77	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
0.60	O
to	O
0.99	O
,	O
p	O
=	O
0.034	O
)	O
.	O

In	O
the	O
fish	Pharmacological
oil	Pharmacological
group	O
,	O
43	O
%	O
of	O
the	O
patients	O
had	O
>	O
or	O
=	O
1	O
occluded	O
vein	O
graft	O
(	O
s	O
)	O
compared	O
with	O
51	O
%	O
in	O
the	O
control	O
group	O
(	O
odds	O
ratio	O
0.72	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
0.51	O
to	O
1.01	O
,	O
p	O
=	O
0.05	O
)	O
.	O

Moreover	O
,	O
in	O
the	O
entire	O
patient	O
group	O
,	O
there	O
was	O
a	O
significant	O
trend	O
to	O
fewer	O
patients	O
with	O
vein	O
graft	O
occlusions	O
with	O
increasing	O
relative	O
change	O
in	O
serum	O
phospholipid	O
n-3	O
fatty	O
acids	O
during	O
the	O
study	O
period	O
(	O
p	O
for	O
linear	O
trend	O
=	O
0.0037	O
)	O
.	O

Thus	O
,	O
in	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
,	O
dietary	O
supplementation	O
with	O
n-3	Pharmacological
fatty	Pharmacological
acids	Pharmacological
reduced	O
the	O
incidence	O
of	O
vein	O
graft	O
occlusion	O
,	O
and	O
an	O
inverse	O
relation	O
between	O
relative	O
change	O
in	O
serum	O
phospholipid	O
n-3	O
fatty	O
acids	O
and	O
vein	O
graft	O
occlusions	O
was	O
observed	O
.	O

Early	O
effects	O
of	O
continuous	O
low-dosage	O
all-norgestrel	Pharmacological
administered	O
alone	O
or	O
with	O
estrogen	O
.	O

Twenty-six	O
postmenopausal	O
women	O
participated	O
in	O
a	O
double-blind	O
trial	O
involving	O
treatment	O
according	O
to	O
a	O
Latin	O
square	O
design	O
with	O
either	O
(	O
i	O
)	O
dl-norgestrel	Pharmacological
alone	Pharmacological
(	O
0.075	O
mg/day	O
)	O
continuously	O
for	O
two	O
cycles	O
,	O
(	O
ii	O
)	O
estradiol-17	Pharmacological
beta	Pharmacological
alone	Pharmacological
(	O
1	O
mg	O
on	O
25	O
of	O
28	O
days	O
)	O
for	O
two	O
cycles	O
,	O
or	O
(	O
iii	O
)	O
the	O
combined	Pharmacological
hormones	Pharmacological
for	O
six	O
cycles	O
.	O

A	O
placebo	Control
control	O
cycle	O
followed	O
each	O
hormonal	O
treatment	O
.	O

Plasma	O
triglycerides	O
decreased	O
by	O
an	O
average	O
22	O
%	O
during	O
treatment	O
with	O
either	O
dl-norgestrel	Pharmacological
alone	O
(	O
123	O
+/-	O
11	O
vs.	O
160	O
+/-	O
10	O
mg/dl	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.005	O
)	O
or	O
combination	O
therapy	O
(	O
126	O
+/-	O
11	O
vs.	O
162	O
+/-	O
11	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.005	O
)	O
as	O
compared	O
with	O
control	O
.	O

Plasma	O
total	O
cholesterol	O
fell	O
by	O
5	O
%	O
during	O
two	O
cycles	O
of	O
treatment	O
with	O
either	O
dl-norgestrel	Pharmacological
alone	O
(	O
229	O
+/-	O
11	O
vs.	O
242	O
+/-	O
10	O
mg/dl	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.02	O
)	O
or	O
combination	O
therapy	O
(	O
233	O
+/-	O
11	O
vs.	O
246	O
+/-	O
10	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.05	O
)	O
versus	O
placebo	O
.	O

During	O
the	O
fifth	O
and	O
sixth	O
cycles	O
of	O
combination	O
therapy	O
94	O
%	O
of	O
cycles	O
were	O
free	O
of	O
flushing	O
(	O
vs.	O
31	O
%	O
for	O
control	O
,	O
P	O
<	O
0.01	O
)	O
,	O
64	O
%	O
of	O
cycles	O
were	O
free	O
of	O
spotting	O
not	O
requiring	O
protection	O
(	O
control	O
75	O
%	O
)	O
,	O
96	O
%	O
of	O
cycles	O
were	O
free	O
of	O
vaginal	O
bleeding	O
(	O
control	O
100	O
%	O
)	O
,	O
endometrial	O
biopsy	O
showed	O
inactive	O
endometrium	O
in	O
nine	O
of	O
the	O
10	O
subjects	O
re-biopsied	O
,	O
fasting	O
blood	O
pyruvate	O
decreased	O
by	O
20	O
%	O
(	O
P	O
<	O
0.05	O
)	O
and	O
diastolic	O
blood	O
pressure	O
fell	O
by	O
4	O
%	O
compared	O
with	O
control	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
glucose	O
tolerance	O
was	O
unchanged	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
vasomotor	O
flushing	O
beginning	O
with	O
the	O
third	O
to	O
fourth	O
cycles	O
of	O
combination	O
therapy	O
.	O

Intestinal	O
absorption	O
of	O
dietary	O
fat	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
.	O

Fat	O
absorption	O
was	O
studied	O
in	O
24	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	O
and	O
in	O
36	O
healthy	O
control	Control
subjects	O
.	O

Beta-carotene	O
and	O
vitamin	O
A	O
in	O
their	O
plasma	O
were	O
also	O
measured	O
.	O

This	O
double-blind	O
and	O
randomized	O
study	O
showed	O
no	O
differences	O
between	O
these	O
two	O
populations	O
with	O
regard	O
to	O
the	O
three	O
parameters	O
.	O

We	O
did	O
not	O
find	O
evidence	O
for	O
fat	O
malabsorption	O
in	O
multiple	O
sclerosis	O
.	O

Social	O
stories	O
:	O
mechanisms	O
of	O
effectiveness	O
in	O
increasing	O
game	Educational
play	Educational
skills	Educational
in	O
children	O
diagnosed	O
with	O
autism	O
spectrum	O
disorder	O
using	O
a	O
pretest	O
posttest	O
repeated	O
measures	O
randomized	O
control	O
group	O
design	O
.	O

An	O
increasing	O
body	O
of	O
literature	O
has	O
indicated	O
that	O
social	O
stories	O
are	O
an	O
effective	O
way	O
to	O
teach	O
individuals	O
diagnosed	O
with	O
autism	O
appropriate	O
social	O
behavior	O
.	O

This	O
study	O
compared	O
two	O
formats	O
of	O
a	O
social	Educational
story	Educational
targeting	Educational
the	Educational
improvement	Educational
of	Educational
social	Educational
skills	Educational
during	Educational
game	Educational
play	Educational
using	O
a	O
pretest	O
posttest	O
repeated	O
measures	O
randomized	O
control	O
group	O
design	O
.	O

A	O
total	O
of	O
45	O
children	O
diagnosed	O
with	O
Autism	O
Spectrum	O
Disorder	O
(	O
ASD	O
)	O
ages	O
7-14	O
were	O
randomly	O
assigned	O
to	O
standard	O
,	O
directive	O
,	O
or	O
control	O
story	O
conditions	O
.	O

Results	O
demonstrated	O
that	O
the	O
standard	O
and	O
directive	O
story	O
formats	O
were	O
equally	O
as	O
effective	O
in	O
eliciting	O
,	O
generalizing	O
and	O
maintaining	O
the	O
targeted	O
social	O
skills	O
in	O
participants	O
who	O
had	O
prior	O
game	O
play	O
experience	O
and	O
Verbal	O
Comprehension	O
Index	O
(	O
VCI	O
)	O
scores	O
from	O
the	O
WISC-IV	O
intelligence	O
test	O
in	O
the	O
borderline	O
range	O
or	O
above	O
.	O

Effects	O
of	O
Positive	Educational
Action	Educational
on	O
the	O
emotional	O
health	O
of	O
urban	O
youth	O
:	O
a	O
cluster-randomized	O
trial	O
.	O

PURPOSE	O
We	O
examined	O
the	O
effects	O
of	O
Positive	Educational
Action	Educational
(	Educational
PA	Educational
)	Educational
,	O
a	O
school-based	Educational
social-emotional	Educational
learning	Educational
and	Educational
health	Educational
promotion	Educational
program	Educational
,	O
on	O
the	O
emotional	O
health	O
of	O
predominately	O
low-income	O
and	O
ethnic	O
minority	O
urban	O
youth	O
.	O

METHODS	O
The	O
study	O
was	O
a	O
matched-pair	O
,	O
cluster-randomized	O
controlled	O
trial	O
involving	O
14	O
Chicago	O
public	O
schools	O
.	O

Outcomes	O
were	O
assessed	O
over	O
a	O
6-year	O
period	O
of	O
program	O
implementation	O
for	O
a	O
cohort	O
of	O
youth	O
in	O
each	O
school	O
,	O
followed	O
from	O
grades	O
3	O
to	O
8	O
.	O

Youth	O
reported	O
on	O
their	O
emotional	O
health	O
(	O
positive	O
affect	O
,	O
life	O
satisfaction	O
,	O
depression	O
,	O
anxiety	O
)	O
and	O
social-emotional	O
and	O
character	O
development	O
.	O

Growth-curve	O
and	O
structural-equation	O
modeling	O
analyses	O
assessed	O
overall	O
program	O
effects	O
on	O
the	O
emotional	O
health	O
outcomes	O
as	O
well	O
as	O
mediation	O
of	O
these	O
effects	O
via	O
the	O
program	O
's	O
impact	O
on	O
youths	O
'	O
social-emotional	O
and	O
character	O
development	O
.	O

RESULTS	O
Students	O
in	O
PA	Educational
schools	O
,	O
compared	O
with	O
those	O
in	O
control	O
schools	O
,	O
had	O
more	O
favorable	O
change	O
over	O
the	O
course	O
of	O
the	O
study	O
in	O
positive	O
affect	O
(	O
standardized	O
mean	O
difference	O
effect	O
size	O
[	O
ES	O
]	O
=	O
.17	O
)	O
and	O
life	O
satisfaction	O
(	O
ES	O
=	O
.13	O
)	O
as	O
well	O
as	O
significantly	O
lower	O
depression	O
(	O
ES	O
=	O
-.14	O
)	O
and	O
anxiety	O
(	O
ES	O
=	O
-.26	O
)	O
at	O
study	O
end	O
point	O
.	O

Program	O
effects	O
for	O
positive	O
affect	O
,	O
depression	O
,	O
and	O
anxiety	O
were	O
mediated	O
by	O
more	O
favorable	O
change	O
over	O
time	O
in	O
social-emotional	O
and	O
character	O
development	O
for	O
students	O
in	O
PA	O
schools	O
.	O

CONCLUSIONS	O
Results	O
suggest	O
that	O
universal	O
,	O
school-based	O
programs	O
can	O
benefit	O
the	O
emotional	O
health	O
of	O
youth	O
in	O
low-income	O
,	O
urban	O
settings	O
.	O

The	O
modest	O
magnitude	O
of	O
effects	O
over	O
an	O
extended	O
period	O
of	O
program	O
implementation	O
,	O
however	O
,	O
reflects	O
the	O
challenges	O
of	O
both	O
mounting	O
interventions	O
and	O
offsetting	O
formidable	O
risks	O
for	O
mental	O
health	O
problems	O
in	O
such	O
environments	O
.	O

Evaluation	O
of	O
a	O
novel	Physical
technique	Physical
for	O
wound	Physical
closure	Physical
using	Physical
a	Physical
barbed	Surgical
suture	Surgical
.	O

BACKGROUND	O
Suture	O
knots	O
present	O
several	O
disadvantages	O
in	O
wound	O
closure	O
,	O
because	O
they	O
are	O
tedious	O
to	O
tie	O
and	O
place	O
ischemic	O
demands	O
on	O
tissue	O
.	O

Bulky	O
knots	O
may	O
be	O
a	O
nidus	O
for	O
infection	O
,	O
and	O
they	O
may	O
extrude	O
through	O
skin	O
weeks	O
after	O
surgery	O
.	O

Needle	O
manipulations	O
during	O
knot-tying	O
predispose	O
the	O
surgeon	O
to	O
glove	O
perforation	O
.	O

A	O
barbed	Physical
suture	Physical
was	O
developed	O
that	O
is	O
self-anchoring	O
,	O
requiring	O
no	O
knots	O
or	O
slack	O
management	O
for	O
wound	O
closure	O
.	O

The	O
elimination	O
of	O
knot	O
tying	O
may	O
have	O
advantages	O
over	O
conventional	O
wound	O
closure	O
methods	O
.	O

METHODS	O
This	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
designed	O
to	O
show	O
that	O
the	O
use	O
of	O
barbed	Physical
suture	Physical
in	O
dermal	O
closure	O
of	O
the	O
Pfannenstiel	O
incision	O
during	O
nonemergent	O
cesarean	O
delivery	O
surgery	O
produces	O
scar	O
cosmesis	O
at	O
5	O
weeks	O
that	O
is	O
no	O
worse	O
than	O
that	O
observed	O
with	O
conventional	Physical
closure	Physical
using	O
3-0	Pharmacological
polydioxanone	Pharmacological
suture	Pharmacological
.	O

Cosmesis	O
was	O
assessed	O
by	O
review	O
of	O
postoperative	O
photographs	O
by	O
a	O
blinded	O
,	O
independent	O
plastic	O
surgeon	O
using	O
the	O
modified	O
Hollander	O
cosmesis	O
score	O
.	O

Secondary	O
endpoints	O
included	O
infection	O
,	O
dehiscence	O
,	O
pain	O
,	O
closure	O
time	O
,	O
and	O
other	O
adverse	O
events	O
.	O

RESULTS	O
The	O
study	O
enrolled	O
195	O
patients	O
,	O
of	O
whom	O
188	O
were	O
eligible	O
for	O
analysis	O
.	O

Cosmesis	O
scores	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
barbed	O
suture	O
group	O
and	O
the	O
control	O
group	O
.	O

Rates	O
of	O
infection	O
,	O
dehiscence	O
,	O
and	O
other	O
adverse	O
events	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Closure	O
time	O
and	O
pain	O
scores	O
were	O
comparable	O
between	O
the	O
groups	O
.	O

CONCLUSIONS	O
The	O
barbed	O
suture	O
represents	O
an	O
innovative	O
option	O
for	O
wound	O
closure	O
.	O

With	O
a	O
cosmesis	O
and	O
safety	O
profile	O
that	O
is	O
similar	O
to	O
that	O
of	O
conventional	Physical
suture	Physical
technique	O
,	O
it	O
avoids	O
the	O
drawbacks	O
inherent	O
to	O
suture	O
knots	O
.	O

Olanzapine	Pharmacological
versus	O
haloperidol	Pharmacological
in	O
children	O
with	O
autistic	O
disorder	O
:	O
an	O
open	O
pilot	O
study	O
.	O

OBJECTIVES	O
Conventional	O
neuroleptics	Pharmacological
ameliorate	O
symptoms	O
in	O
children	O
with	O
autistic	O
disorder	O
;	O
however	O
,	O
they	O
are	O
known	O
to	O
cause	O
dyskinesias	O
.	O

Atypical	Pharmacological
neuroleptics	Pharmacological
,	O
including	O
olanzapine	O
,	O
may	O
have	O
less	O
risk	O
for	O
dyskinesia	O
,	O
but	O
their	O
efficacy	O
in	O
autistic	O
disorder	O
is	O
not	O
established	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
safety	O
and	O
effectiveness	O
of	O
open-label	O
olanzapine	Pharmacological
as	O
a	O
treatment	O
for	O
children	O
with	O
autistic	O
disorder	O
by	O
using	O
haloperidol	Pharmacological
as	O
a	O
standard	O
comparator	O
treatment	O
.	O

METHOD	O
In	O
a	O
parallel	O
groups	O
design	O
,	O
12	O
children	O
with	O
DSM-IV	O
autistic	O
disorder	O
(	O
mean	O
age	O
7.8+/-2.1	O
years	O
)	O
were	O
randomized	O
to	O
6	O
weeks	O
of	O
open	Pharmacological
treatment	Pharmacological
with	Pharmacological
olanzapine	Pharmacological
or	O
haloperidol	Pharmacological
.	O

Mean	O
final	O
dosages	O
were	O
7.9+/-2.5	O
mg/day	O
for	O
olanzapine	Pharmacological
and	O
1.4+/-0.7	O
mg/day	O
for	O
haloperidol	Pharmacological
.	O

Outcome	O
measures	O
included	O
the	O
Clinical	O
Global	O
Impressions	O
(	O
CGI	O
)	O
and	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
(	O
CPRS	O
)	O
.	O

RESULTS	O
Both	O
groups	O
had	O
symptom	O
reduction	O
.	O

Five	O
of	O
six	O
in	O
the	O
olanzapine	Pharmacological
group	O
and	O
three	O
of	O
six	O
in	O
the	O
haloperidol	Pharmacological
group	O
were	O
rated	O
as	O
responders	O
according	O
to	O
the	O
CGI	O
Improvement	O
item	O
.	O

Subjects	O
showed	O
improvement	O
on	O
the	O
CPRS	O
Autism	O
Factor	O
(	O
F1,9	O
=	O
24.4	O
,	O
p	O
=	O
.0008	O
)	O
.	O

Side	O
effects	O
included	O
drowsiness	O
and	O
weight	O
gain	O
.	O

CONCLUSIONS	O
The	O
findings	O
suggest	O
that	O
olanzapine	Pharmacological
is	O
a	O
promising	O
treatment	O
for	O
children	O
with	O
autistic	O
disorder	O
.	O

Further	O
placebo-controlled	O
and	O
long-term	O
studies	O
of	O
olanzapine	Pharmacological
in	O
autistic	O
disorder	O
are	O
required	O
.	O

Sustained	O
effect	O
of	O
SQ-standardized	O
grass	O
allergy	O
immunotherapy	Pharmacological
tablet	Pharmacological
on	O
rhinoconjunctivitis	O
quality	O
of	O
life	O
.	O

BACKGROUND	O
The	O
prevalence	O
of	O
allergic	O
rhinoconjunctivitis	O
has	O
increased	O
significantly	O
over	O
the	O
past	O
decades	O
with	O
grass	O
pollen	O
being	O
a	O
common	O
trigger	O
.	O

The	O
impact	O
of	O
allergy	O
on	O
patient	O
's	O
quality	O
of	O
life	O
is	O
substantial	O
.	O

AIM	O
To	O
investigate	O
the	O
sustained	O
effect	O
on	O
quality	O
of	O
life	O
during	O
the	O
grass	O
pollen	O
season	O
1	O
year	O
after	O
3	O
years	O
of	O
treatment	O
with	O
the	O
SQ-standardized	O
grass	Pharmacological
allergy	Pharmacological
immunotherapy	Pharmacological
tablet	Pharmacological
(	Pharmacological
AIT	Pharmacological
)	Pharmacological
,	O
Graza	O
(	O
Phleum	O
pratense	O
75,000	O
SQ-T/2800	O
BAU	O
;	O
ALK	O
,	O
Denmark	O
)	O
.	O

METHODS	O
The	O
trial	O
was	O
a	O
randomized	O
,	O
parallel-group	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
in	O
adult	O
subjects	O
with	O
a	O
history	O
of	O
moderate-severe	O
grass	O
pollen	O
induced	O
rhinoconjunctivitis	O
inadequately	O
controlled	O
by	O
symptomatic	O
medications	O
.	O

Subjects	O
received	O
3	O
years	O
of	O
grass	Pharmacological
AIT	Pharmacological
(	O
n	O
=	O
157	O
)	O
or	O
placebo	Control
(	O
n	O
=	O
126	O
)	O
,	O
followed	O
by	O
1	O
year	O
of	O
follow-up	O
.	O

Quality	O
of	O
life	O
assessments	O
were	O
based	O
on	O
the	O
standardized	O
rhinoconjunctivitis	O
quality	O
of	O
life	O
questionnaire	O
(	O
RQLQ	O
(	O
S	O
)	O
)	O
;	O
completed	O
weekly	O
during	O
the	O
entire	O
grass	O
pollen	O
season	O
.	O

RESULTS	O
During	O
follow-up	O
,	O
the	O
overall	O
RQLQ	O
(	O
S	O
)	O
score	O
for	O
the	O
entire	O
grass	O
pollen	O
season	O
was	O
significantly	O
improved	O
in	O
the	O
active	O
group	O
(	O
relative	O
difference	O
to	O
placebo	O
:	O
23	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

The	O
improvement	O
was	O
higher	O
during	O
the	O
peak	O
pollen	O
season	O
(	O
28	O
%	O
,	O
P	O
=	O
0.001	O
)	O
.	O

The	O
treatment	O
effect	O
of	O
grass	O
AIT	O
during	O
the	O
follow-up	O
year	O
and	O
the	O
previous	O
three	O
treatment	O
years	O
was	O
similar	O
.	O

Improvements	O
were	O
found	O
in	O
all	O
seven	O
RQLQ	O
(	O
S	O
)	O
domains	O
.	O

The	O
RQLQ	O
(	O
S	O
)	O
as	O
a	O
function	O
of	O
the	O
weekly	O
average	O
pollen	O
counts	O
showed	O
a	O
clear	O
separation	O
between	O
the	O
treatment	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
In	O
subjects	O
inadequately	O
controlled	O
by	O
symptomatic	O
medications	O
,	O
grass	O
AIT	Pharmacological
provided	O
sustained	O
and	O
clinically	O
relevant	O
improvements	O
in	O
rhinoconjunctivitis	O
quality	O
of	O
life	O
compared	O
to	O
placebo	O
.	O

The	O
effect	O
increased	O
with	O
increasing	O
grass	O
pollen	O
exposure	O
.	O

A	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound-guided	Surgical
laser	Surgical
photocoagulation	Surgical
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
.	O

This	O
randomized	O
controlled	O
study	O
was	O
designed	O
to	O
test	O
the	O
efficacy	O
and	O
safety	O
of	O
percutaneous	Surgical
ultrasound	Surgical
(	Surgical
US	Surgical
)	Surgical
-guided	Surgical
laser	Surgical
photocoagulation	Surgical
(	Surgical
PLP	Surgical
)	Surgical
for	O
treatment	O
of	O
subjects	O
with	O
compressive	O
symptoms	O
due	O
to	O
benign	O
thyroid	O
nodules	O
and/or	O
at	O
high	O
surgical	O
risk	O
.	O

Twenty	O
six	O
subjects	O
were	O
randomized	O
to	O
the	O
intervention	Surgical
(	O
no	O
.	O

13	O
,	O
age	O
68+/-3	O
yr	O
,	O
mean+/-SEM	O
)	O
or	O
observation	Control
(	O
no	O
.	O

13	O
,	O
age	O
71+/-2	O
yr	O
)	O
groups	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
volume	O
of	O
nodules	O
did	O
not	O
significantly	O
change	O
over	O
the	O
30	O
week	O
period	O
of	O
observation	O
.	O

In	O
the	O
intervention	O
group	O
,	O
median	O
nodule	O
volume	O
at	O
baseline	O
was	O
8.2	O
ml	O
(	O
range	O
2.8-26.9	O
)	O
and	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

Nodules	O
decreased	O
significantly	O
(	O
p	O
<	O
0.0001	O
)	O
by	O
22	O
%	O
after	O
2	O
weeks	O
(	O
6.5	O
ml	O
;	O
range	O
2.4-16.7	O
)	O
and	O
by	O
44	O
%	O
after	O
30	O
weeks	O
(	O
4.6	O
ml	O
;	O
range	O
0.69-14.2	O
)	O
.	O

Energy	O
given	O
was	O
correlated	O
(	O
p	O
<	O
0.05	O
)	O
with	O
the	O
reduction	O
of	O
thyroid	O
nodule	O
volume	O
.	O

All	O
patients	O
tolerated	O
the	O
treatment	O
well	O
and	O
reported	O
relief	O
from	O
compressive	O
and	O
cosmetic	O
complaints	O
(	O
p	O
<	O
0.05	O
)	O
.	O

At	O
the	O
time	O
of	O
enrolment	O
7/13	O
(	O
54	O
%	O
)	O
and	O
6/13	O
(	O
46	O
%	O
)	O
of	O
patients	O
in	O
the	O
intervention	O
and	O
control	O
groups	O
,	O
respectively	O
,	O
had	O
sub	O
clinical	O
hyperthyroidism	O
.	O

PLP	O
normalized	O
thyroid	O
function	O
at	O
6	O
and	O
30	O
weeks	O
after	O
treatment	O
.	O

In	O
conclusion	O
,	O
PLP	O
is	O
a	O
promising	O
safe	O
and	O
effective	O
procedure	O
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
in	O
patients	O
at	O
high	O
surgical	O
risk	O
.	O

Single	Physical
negative	Physical
colposcopy	Physical
:	O
is	O
it	O
enough	O
to	O
rule	O
out	O
high-grade	O
disease	O
?	O
It	O
has	O
been	O
proposed	O
that	O
women	O
who	O
have	O
a	O
negative	O
colposcopic	O
examination	O
or	O
who	O
have	O
no	O
cervical	O
intraepithelial	O
neoplasia	O
(	O
CIN	O
)	O
on	O
colposcopic	Physical
biopsy	Physical
can	O
be	O
safely	O
returned	O
to	O
routine	O
screening	O
with	O
the	O
next	O
visit	O
being	O
three	O
or	O
five	O
years	O
later	O
.	O

We	O
present	O
data	O
regarding	O
551	O
women	O
who	O
had	O
colposcopy	Physical
in	O
Wales	O
for	O
a	O
low-grade	O
cytological	O
abnormality	O
and	O
who	O
were	O
followed	O
through	O
Cervical	O
Screening	O
Wales	O
for	O
subsequent	O
CIN	O
.	O

Of	O
436	O
women	O
declared	O
CIN	O
free	O
initially	O
,	O
26	O
(	O
6.0	O
%	O
)	O
had	O
high-grade	O
CIN	O
diagnosed	O
on	O
follow-up	O
.	O

We	O
suggest	O
that	O
additional	O
screening	O
at	O
an	O
interval	O
of	O
less	O
than	O
three	O
years	O
should	O
be	O
offered	O
to	O
women	O
with	O
a	O
negative	O
colposcopy	O
or	O
a	O
biopsy	O
without	O
CIN	O
.	O

Treatment	O
of	O
peri-implantitis	O
by	O
the	O
Vector	Physical
system	Physical
.	O

AIM	O
To	O
compare	O
the	O
effectiveness	O
of	O
treatment	O
of	O
peri-implantitis	O
with	O
a	O
novel	O
ultrasonic	O
device	O
,	O
the	O
Vector	Physical
system	Physical
,	O
with	O
that	O
of	O
subgingival	O
debridement	O
with	O
carbon	O
fiber	O
curettes	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
study	O
,	O
comprising	O
11	O
patients	O
with	O
at	O
least	O
two	O
screw	O
type	O
implants	O
with	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
,	O
probing	O
pocket	O
depth	O
(	O
PPD	O
)	O
>	O
or	O
=5	O
mm	O
,	O
and	O
at	O
least	O
1.5	O
mm	O
radiographic	O
bone	O
loss	O
and	O
exposed	O
implant	O
threads	O
,	O
was	O
carried	O
out	O
as	O
a	O
single	O
blind	O
randomized	O
clinical	O
trial	O
.	O

At	O
baseline	O
one	O
randomly	O
chosen	O
implant	O
in	O
each	O
patient	O
was	O
treated	O
by	O
the	O
Vector	Physical
system	Physical
(	O
test	O
)	O
while	O
the	O
other	O
implant	O
(	O
control	O
)	O
was	O
treated	O
by	O
submucosal	O
debridement	O
with	O
a	O
carbon	Other
fiber	Other
curette	Other
.	O

After	O
3	O
months	O
,	O
the	O
same	O
treatments	O
were	O
repeated	O
.	O

Plaque	O
,	O
BOP	O
,	O
and	O
PPD	O
were	O
recorded	O
on	O
all	O
implant	O
surfaces	O
at	O
baseline	O
,	O
and	O
after	O
3	O
and	O
6	O
months	O
.	O

Bone	O
levels	O
were	O
recorded	O
on	O
radiographs	O
taken	O
prior	O
to	O
the	O
start	O
of	O
the	O
study	O
,	O
and	O
after	O
6	O
months	O
.	O

RESULTS	O
Oral	O
hygiene	O
around	O
both	O
test	O
and	O
control	O
implants	O
was	O
improved	O
at	O
3	O
and	O
6	O
months	O
compared	O
with	O
baseline	O
.	O

At	O
6	O
months	O
,	O
four	O
of	O
the	O
Vector-treated	Physical
sites	Physical
,	O
and	O
only	O
one	O
site	O
treated	O
with	O
curettes	O
,	O
had	O
stopped	O
to	O
bleed	O
.	O

In	O
neither	O
the	O
test	O
nor	O
the	O
control	O
group	O
,	O
were	O
there	O
any	O
differences	O
between	O
baseline	O
and	O
6	O
months	O
regarding	O
PPD	O
and	O
bone	O
levels	O
.	O

CONCLUSION	O
Although	O
there	O
was	O
a	O
greater	O
reduction	O
in	O
the	O
number	O
of	O
sites	O
with	O
BOP	O
following	O
treatment	O
with	O
the	O
Vector	Physical
system	Physical
than	O
following	O
instrumentation	O
with	O
carbon	O
fiber	O
curettes	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
.	O

An	O
international	O
multi-clinic	O
study	O
comparing	O
the	O
therapeutic	O
efficacy	O
of	O
colloidal	Pharmacological
bismuth	Pharmacological
subcitrate	Pharmacological
coated	Pharmacological
tablets	Pharmacological
with	O
chewing	Pharmacological
tablets	Pharmacological
in	O
the	O
treatment	O
of	O
duodenal	O
ulceration	O
.	O

The	O
results	O
of	O
a	O
randomized	O
,	O
single-blind	O
,	O
multi-clinic	O
study	O
comparing	O
the	O
therapeutic	O
efficacy	O
and	O
degree	O
of	O
oral	O
staining	O
of	O
new	O
colloidal	Pharmacological
bismuth	Pharmacological
subcitrate	Pharmacological
(	Pharmacological
CBS	Pharmacological
)	Pharmacological
coated	Pharmacological
tablets	Pharmacological
over	O
4	O
weeks	O
of	O
treatment	O
in	O
patients	O
suffering	O
from	O
duodenal	O
ulceration	O
are	O
reported	O
.	O

The	O
data	O
were	O
collected	O
from	O
9	O
clinics	O
in	O
the	O
Netherlands	O
,	O
Belgium	O
,	O
Ireland	O
,	O
the	O
United	O
Kingdom	O
,	O
and	O
Italy	O
.	O

The	O
results	O
from	O
94	O
patients	O
treated	O
with	O
CBS	Pharmacological
coated	Pharmacological
tablets	Pharmacological
and	O
95	O
patients	O
treated	O
with	O
CBS	Pharmacological
chewing	Pharmacological
tablets	Pharmacological
were	O
statistically	O
evaluated	O
.	O

Healing	O
rates	O
after	O
4	O
weeks	O
of	O
therapy	O
appeared	O
to	O
be	O
76	O
%	O
for	O
CBS	Pharmacological
coated	Pharmacological
tablets	Pharmacological
and	O
72	O
%	O
for	O
CBS	Pharmacological
chewing	Pharmacological
tablets	Pharmacological
,	O
so	O
no	O
statistically	O
significant	O
difference	O
in	O
therapeutic	O
efficacy	O
was	O
seen	O
.	O

A	O
highly	O
significant	O
degree	O
of	O
discolouration	O
of	O
all	O
parts	O
of	O
the	O
oral	O
cavity	O
was	O
observed	O
in	O
patients	O
treated	O
with	O
CBS	Pharmacological
chewing	Pharmacological
tablets	Pharmacological
,	O
whereas	O
only	O
a	O
few	O
patients	O
treated	O
with	O
CBS	Pharmacological
coated	Pharmacological
tablets	Pharmacological
experienced	O
a	O
slight	O
staining	O
of	O
the	O
tongue	O
.	O

Blood	O
bismuth	O
concentrations	O
during	O
the	O
study	O
had	O
a	O
range	O
of	O
less	O
than	O
or	O
equal	O
to	O
3	O
to	O
33	O
micrograms/l	O
.	O

The	O
new	O
CBS	Pharmacological
coated	Pharmacological
tablet	Pharmacological
form	O
has	O
an	O
excellent	O
patient	O
compliance	O
as	O
compared	O
to	O
the	O
chewing	Pharmacological
tablets	Pharmacological
.	O

Relation	O
between	O
early	O
mitral	O
regurgitation	O
and	O
left	O
ventricular	O
thrombus	O
formation	O
after	O
acute	O
myocardial	O
infarction	O
:	O
results	O
of	O
the	O
GISSI-3	O
echo	O
substudy	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
prevalence	O
and	O
correlates	O
of	O
left	O
ventricular	O
thrombosis	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
,	O
and	O
whether	O
the	O
occurrence	O
of	O
early	O
mitral	O
regurgitation	O
has	O
a	O
protective	O
effect	O
against	O
the	O
formation	O
of	O
left	O
ventricular	O
thrombus	O
.	O

DESIGN	O
AND	O
SETTING	O
Multicentre	O
clinical	O
trial	O
carried	O
out	O
in	O
47	O
Italian	O
coronary	O
care	O
units	O
.	O

PATIENTS	O
AND	O
METHODS	O
757	O
patients	O
from	O
the	O
GISSI-3	O
echo	O
substudy	O
population	O
with	O
their	O
first	O
acute	O
myocardial	O
infarct	O
were	O
studied	O
by	O
echocardiography	Physical
at	O
24-48	O
hours	O
from	O
symptom	O
onset	O
(	O
S1	O
)	O
,	O
at	O
discharge	O
(	O
S2	O
)	O
,	O
at	O
six	O
weeks	O
(	O
S3	O
)	O
,	O
and	O
at	O
six	O
months	O
(	O
S4	O
)	O
.	O

The	O
diagnosis	O
of	O
left	O
ventricular	O
thrombosis	O
was	O
based	O
on	O
the	O
detection	O
of	O
an	O
echo	O
dense	O
mass	O
with	O
defined	O
margins	O
visible	O
throughout	O
the	O
cardiac	O
cycle	O
in	O
at	O
least	O
two	O
orthogonal	O
views	O
.	O

RESULTS	O
In	O
64	O
patients	O
(	O
8	O
%	O
)	O
,	O
left	O
ventricular	O
thrombosis	O
was	O
detected	O
in	O
one	O
or	O
more	O
examinations	O
.	O

Compared	O
with	O
the	O
remaining	O
693	O
patients	O
,	O
subjects	O
with	O
left	O
ventricular	O
thrombosis	O
were	O
older	O
(	O
mean	O
(	O
SD	O
)	O
age	O
:	O
64.6	O
(	O
13.0	O
)	O
v	O
59.8	O
(	O
11.7	O
)	O
years	O
,	O
p	O
<	O
0.005	O
)	O
,	O
and	O
had	O
larger	O
infarcts	O
(	O
extent	O
of	O
wall	O
motion	O
asynergy	O
:	O
40.9	O
(	O
11.5	O
)	O
%	O
v	O
24.9	O
(	O
14	O
)	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
greater	O
depression	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
at	O
S1	O
(	O
43.3	O
(	O
6.9	O
)	O
%	O
v	O
48.1	O
(	O
6.8	O
)	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
greater	O
left	O
ventricular	O
volumes	O
at	O
S1	O
(	O
end	O
diastolic	O
volume	O
:	O
87	O
(	O
22	O
)	O
v	O
78	O
(	O
18	O
)	O
ml/m	O
(	O
2	O
)	O
,	O
p	O
<	O
0.001	O
;	O
end	O
systolic	O
volume	O
:	O
50	O
(	O
17	O
)	O
v	O
41	O
(	O
14	O
)	O
ml/m	O
(	O
2	O
)	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
prevalence	O
of	O
moderate	O
to	O
severe	O
mitral	O
regurgitation	O
on	O
colour	O
Doppler	O
at	O
S1	O
was	O
greater	O
in	O
patients	O
who	O
had	O
left	O
ventricular	O
thrombosis	O
at	O
any	O
time	O
(	O
10.2	O
%	O
v	O
4.2	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

On	O
stepwise	O
multiple	O
logistic	O
regression	O
analysis	O
the	O
only	O
independent	O
variables	O
related	O
to	O
the	O
presence	O
of	O
left	O
ventricular	O
thrombosis	O
were	O
the	O
extent	O
of	O
wall	O
motion	O
asynergy	O
and	O
anterior	O
site	O
of	O
infarction	O
.	O

CONCLUSIONS	O
Left	O
ventricular	O
thrombosis	O
is	O
not	O
reduced	O
,	O
and	O
may	O
even	O
be	O
increased	O
,	O
by	O
early	O
moderate	O
to	O
severe	O
mitral	O
regurgitation	O
after	O
acute	O
myocardial	O
infarction	O
.	O

The	O
only	O
independent	O
determinant	O
of	O
left	O
ventricular	O
thrombosis	O
is	O
the	O
extent	O
of	O
the	O
akinetic-dyskinetic	O
area	O
detected	O
on	O
echocardiography	O
between	O
24-48	O
hours	O
from	O
symptom	O
onset	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	Control
study	O
of	O
fluvoxamine	Pharmacological
in	O
adults	O
with	O
autistic	O
disorder	O
.	O

BACKGROUND	O
Autistic	O
disorder	O
is	O
characterized	O
by	O
a	O
fundamental	O
disturbance	O
in	O
social	O
interaction	O
,	O
impairments	O
in	O
communication	O
,	O
and	O
a	O
markedly	O
restricted	O
repertoire	O
of	O
activities	O
and	O
interests	O
.	O

Abnormalities	O
in	O
the	O
serotonin	O
neurotransmitter	O
system	O
have	O
been	O
identified	O
in	O
some	O
persons	O
with	O
autism	O
.	O

No	O
consistently	O
effective	O
and	O
safe	O
drugs	O
have	O
been	O
developed	O
for	O
treating	O
the	O
symptoms	O
of	O
autism	O
.	O

METHODS	O
Thirty	O
adults	O
with	O
autistic	O
disorder	O
completed	O
a	O
12-week	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
of	O
the	O
potent	O
and	O
selective	Pharmacological
serotonin	Pharmacological
uptake	Pharmacological
inhibitor	Pharmacological
fluvoxamine	Pharmacological
maleate	Pharmacological
.	O

Behavioral	O
ratings	O
were	O
obtained	O
at	O
baseline	O
and	O
after	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
of	O
treatment	O
.	O

RESULTS	O
Eight	O
(	O
53	O
%	O
)	O
of	O
15	O
patients	O
in	O
the	O
fluvoxamine-treated	Pharmacological
group	O
were	O
categorized	O
as	O
responders	O
compared	O
with	O
none	O
of	O
15	O
in	O
the	O
placebo	Control
group	O
(	O
P	O
=	O
.001	O
)	O
.	O

Fluvoxamine	Pharmacological
was	O
superior	O
to	O
placebo	Control
in	O
reducing	O
repetitive	O
thoughts	O
and	O
behavior	O
(	O
P	O
<	O
.001	O
)	O
,	O
maladaptive	O
behavior	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
aggression	O
(	O
P	O
<	O
.03	O
)	O
,	O
and	O
in	O
improving	O
some	O
aspects	O
of	O
social	O
relatedness	O
(	O
P	O
<	O
.04	O
)	O
,	O
especially	O
language	O
usage	O
(	O
P	O
<	O
.008	O
)	O
.	O

Treatment	O
response	O
was	O
not	O
correlated	O
with	O
age	O
level	O
of	O
autistic	O
behavior	O
,	O
or	O
full-scale	O
IQ	O
.	O

Other	O
than	O
mild	O
sedation	O
and	O
nausea	O
in	O
a	O
few	O
patients	O
,	O
fluvoxamine	Pharmacological
was	O
well	O
tolerated	O
.	O

No	O
dyskinesias	O
,	O
adverse	O
cardiovascular	O
events	O
,	O
or	O
seizures	O
occurred	O
.	O

CONCLUSIONS	O
Fluvoxamine	Pharmacological
is	O
more	O
effective	O
than	O
placebo	Control
in	O
the	O
short-term	O
treatment	O
of	O
the	O
symptoms	O
of	O
autistic	O
disorder	O
in	O
adults	O
.	O

Controlled	O
studies	O
of	O
fluvoxamine	Pharmacological
and	O
other	O
potent	O
and	O
selective	O
serotonin	O
uptake	O
inhibitors	O
seem	O
warranted	O
in	O
children	O
and	O
adolescents	O
with	O
autism	O
.	O

The	O
effects	O
of	O
different	O
intensities	O
and	O
durations	O
of	O
the	O
general	Physical
warm-up	Physical
on	Physical
leg	Physical
press	Physical
1RM	Physical
.	O

The	O
precision	O
of	O
maximum	O
strength	O
assessments	O
(	O
1	O
repetition	O
maximum	O
;	O
1RM	O
)	O
is	O
important	O
to	O
evaluate	O
the	O
functional	O
capacity	O
and	O
to	O
prescribe	O
and	O
monitor	O
the	O
training	O
load	O
.	O

Several	O
factors	O
can	O
affect	O
the	O
precision	O
of	O
1RM	O
tests	O
,	O
including	O
the	O
warm-up	O
procedure	O
.	O

General	O
and	O
specific	O
warm-up	O
routines	O
are	O
recommended	O
to	O
enhance	O
performance	O
.	O

The	O
effects	O
of	O
a	O
specific	O
warm-up	O
have	O
already	O
been	O
acknowledged	O
in	O
improving	O
performance	O
.	O

However	O
,	O
the	O
effects	O
of	O
a	O
general	Physical
warm-up	Physical
(	Physical
GWU	Physical
)	Physical
are	O
unclear	O
but	O
seem	O
to	O
depend	O
on	O
its	O
ability	O
to	O
increase	O
muscle	O
temperature	O
while	O
avoiding	O
fatigue	O
.	O

Furthermore	O
,	O
temperature	O
elevation	O
is	O
dependent	O
on	O
both	O
the	O
duration	O
and	O
the	O
intensity	O
of	O
the	O
activity	O
,	O
which	O
may	O
eventually	O
affect	O
1RM	O
performance	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
different	O
intensities	O
and	O
durations	O
of	O
GWU	O
on	O
1RM	O
performance	O
.	O

Sixteen	O
strength-trained	O
men	O
were	O
tested	O
for	O
1RM	O
leg	O
press	O
after	O
4	O
GWU	O
conditions	O
after	O
specific	O
warm-up	O
:	O
short	O
duration	O
and	O
low	O
intensity	O
(	O
SDLI	O
;	O
i.e.	O
,	O
5	O
minutes	O
at	O
40	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
long	O
duration	O
and	O
low	O
intensity	O
(	O
LDLI	O
;	O
i.e.	O
,	O
15	O
minutes	O
at	O
40	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
short	O
duration	O
and	O
moderate	O
intensity	O
(	O
SDMI	O
;	O
i.e.	O
,	O
5	O
minutes	O
at	O
70	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
long	O
duration	O
and	O
moderate	O
intensity	O
(	O
LDMI	O
;	O
i.e.	O
,	O
15	O
minutes	O
at	O
70	O
%	O
V	O
[	O
Combining	O
Dot	O
Above	O
]	O
O2max	O
)	O
,	O
and	O
the	O
control	O
(	O
CTRL	O
)	O
no-GWU	O
condition	O
.	O

Leg	O
press	O
1RM	O
values	O
were	O
higher	O
(	O
on	O
average	O
3	O
%	O
)	O
when	O
subjects	O
performed	O
LDLI	O
(	O
367.8	O
?	O
70.1	O
kg	O
;	O
p	O
=	O
0.01	O
)	O
,	O
compared	O
with	O
the	O
other	O
4	O
conditions	O
.	O

After	O
the	O
LDMI	O
condition	O
,	O
1RM	O
values	O
were	O
lower	O
(	O
on	O
average	O
-4	O
%	O
)	O
than	O
in	O
the	O
other	O
4	O
conditions	O
(	O
345.6	O
?	O
70.5	O
kg	O
;	O
p	O
=	O
0.01	O
)	O
.	O

There	O
were	O
no	O
differences	O
between	O
SDMI	O
,	O
SDLI	O
,	O
and	O
CTRL	O
(	O
359.4	O
?	O
69.2	O
kg	O
,	O
359.1	O
?	O
69.3	O
kg	O
,	O
and	O
359.4	O
?	O
70.4	O
kg	O
,	O
respectively	O
;	O
p	O
=	O
0.99	O
)	O
.	O

According	O
to	O
our	O
results	O
,	O
long-duration	O
low-intensity	O
general	O
warm-up	O
seems	O
be	O
appropriately	O
to	O
improve	O
1RM	O
performance	O
in	O
strength-trained	O
individuals	O
.	O

Population	O
pharmacokinetic/pharmacodynamic	O
analysis	O
of	O
the	O
DPP-4	O
inhibitor	O
linagliptin	O
in	O
Japanese	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

OBJECTIVES	O
Linagliptin	Pharmacological
is	O
a	O
novel	O
,	O
highly	O
selective	O
and	O
long	O
acting	O
DPP-4	O
inhibitor	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

Linagliptin	Pharmacological
exhibits	O
non-linear	O
pharmacokinetics	O
(	O
PK	O
)	O
due	O
to	O
saturable	O
binding	O
to	O
plasma	O
and	O
tissue	O
DPP-4	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
PK	O
and	O
PK/DPP-4	O
inhibition	O
relationship	O
of	O
linagliptin	Pharmacological
in	O
Japanese	O
patients	O
with	O
T2DM	O
using	O
a	O
population	O
PK/DPP-4	O
model	O
and	O
to	O
support	O
the	O
rationale	O
for	O
the	O
therapeutic	O
dose	O
in	O
Japanese	O
patients	O
by	O
simulation	O
.	O

METHODS	O
Linagliptin	Pharmacological
plasma	O
concentration	O
and	O
DPP-4	O
inhibition	O
measurements	O
from	O
a	O
placebo-controlled	Control
,	O
parallel	O
group	O
multiple	O
(	O
28	O
days	O
)	O
dose	O
trial	O
that	O
included	O
36	O
T2DM	O
patients	O
(	O
18	O
patients	O
each	O
in	O
2.5	O
mg	O
and	O
10	O
mg	O
dose	O
group	O
)	O
were	O
used	O
for	O
analysis	O
.	O

Modeling	O
was	O
performed	O
using	O
FOCE	O
INTERACTION	O
estimation	O
method	O
implemented	O
in	O
NONMEM	O
V.	O
The	O
linagliptin	O
plasma	O
concentration-	O
and	O
DPP-4	O
inhibition-	O
time	O
profiles	O
were	O
simulated	O
for	O
Japanese	O
patients	O
receiving	O
5	O
mg	O
linagliptin	Pharmacological
once	O
daily	O
by	O
the	O
model	O
established	O
.	O

RESULTS	O
Nonlinear	O
PK	O
of	O
linagliptin	O
in	O
T2DM	O
patients	O
were	O
well	O
described	O
by	O
a	O
2-compartment	O
model	O
assuming	O
concentration-dependent	O
binding	O
to	O
DPP-4	O
in	O
the	O
central	O
and	O
peripheral	O
compartment	O
.	O

Plasma	O
DPP-4	O
inhibition	O
was	O
integrated	O
in	O
the	O
model	O
by	O
relating	O
the	O
model-predicted	O
DPP-4	O
occupancy	O
with	O
linagliptin	Pharmacological
linearly	O
to	O
DPP-4	O
inhibition	O
.	O

The	O
simulation	O
predicted	O
that	O
for	O
the	O
5	O
mg	O
dose	O
group	O
the	O
trough	O
DPP-4	O
inhibition	O
at	O
steady-state	O
was	O
84.2	O
%	O
,	O
which	O
is	O
higher	O
than	O
the	O
target	O
inhibition	O
(	O
?80	O
%	O
)	O
for	O
an	O
effective	O
dose	O
of	O
DPP-4	O
inhibitor	O
.	O

In	O
2.5	O
mg	O
dose	O
group	O
,	O
steady-state	O
DPP-4	O
inhibition	O
of	O
>	O
80	O
%	O
was	O
not	O
maintained	O
over	O
24	O
hours	O
(	O
observed	O
and	O
simulated	O
)	O
.	O

CONCLUSIONS	O
The	O
nonlinear	O
PK	O
of	O
linagliptin	O
and	O
its	O
plasma	O
DPP-4	O
inhibition	O
in	O
patients	O
were	O
well	O
characterized	O
by	O
a	O
target-mediated	O
drug	O
disposition	O
model	O
relating	O
DPP-4	O
occupancy	O
with	O
linagliptin	O
to	O
DPP-4	O
inhibition	O
.	O

Simulations	O
of	O
plasma	O
DPP-4	O
inhibition	O
suggest	O
that	O
5	O
mg	O
linagliptin	O
once	O
daily	O
is	O
an	O
appropriate	O
therapeutic	O
dose	O
for	O
Japanese	O
patients	O
with	O
T2DM	O
.	O

Oral	O
ondansetron	Pharmacological
in	O
the	O
prevention	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
.	O

The	O
effect	O
of	O
three	O
times	O
daily	O
oral	O
ondansetron	O
in	O
preventing	O
postoperative	O
nausea	O
and	O
vomiting	O
was	O
investigated	O
in	O
two	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
,	O
multi-centre	O
studies	O
.	O

The	O
first	O
study	O
compared	O
ondansetron	Pharmacological
1	Pharmacological
,	Pharmacological
8	Pharmacological
and	Pharmacological
16	Pharmacological
mg	Pharmacological
to	O
placebo	Control
,	O
and	O
the	O
second	O
study	O
compared	O
8	Pharmacological
mg	Pharmacological
ondansetron	Pharmacological
to	O
placebo	Control
.	O

Both	O
studies	O
included	O
ASA	O
Class	O
I-III	O
female	O
patients	O
about	O
to	O
undergo	O
major	O
abdominal	O
gynaecological	O
surgery	O
or	O
vaginal	O
hysterectomy	O
.	O

In	O
the	O
first	O
study	O
,	O
the	O
8	Pharmacological
and	Pharmacological
16	Pharmacological
mg	Pharmacological
ondansetron	Pharmacological
groups	Pharmacological
had	O
a	O
significantly	O
lower	O
incidence	O
of	O
nausea	O
and	O
vomiting	O
in	O
the	O
0-24	O
h	O
period	O
following	O
recovery	O
from	O
anaesthesia	O
than	O
the	O
placebo	Control
group	O
.	O

Ondansetron	Pharmacological
8	O
mg	O
three	O
times	O
daily	O
was	O
also	O
significantly	O
better	O
than	O
placebo	O
in	O
the	O
second	O
study	O
.	O

Side-effects	O
mainly	O
consisted	O
of	O
constipation	O
,	O
headache	O
,	O
and	O
asymptomatic	O
elevation	O
of	O
liver	O
enzymes	O
.	O

The	O
incidence	O
of	O
side-effects	O
was	O
similar	O
in	O
ondansetron-	O
and	O
placebo-treated	O
patients	O
.	O

There	O
appeared	O
to	O
be	O
no	O
clinically	O
important	O
benefit	O
of	O
the	O
16	O
mg	O
three	O
times	O
daily	O
ondansetron	Pharmacological
regimen	O
over	O
the	O
8	O
mg	O
three	O
times	O
daily	O
dose	O
,	O
therefore	O
8	O
mg	O
three	O
times	O
daily	O
is	O
recommended	O
as	O
the	O
optimal	O
oral	O
dose	O
in	O
the	O
prevention	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
.	O

Weekly	O
docetaxel	Pharmacological
with	O
or	O
without	O
gemcitabine	Pharmacological
as	O
second-line	Pharmacological
chemotherapy	Pharmacological
in	O
paclitaxel-pretreated	Pharmacological
patients	O
with	O
metastatic	O
breast	O
cancer	O
:	O
a	O
randomized	O
phase	O
II	O
study	O
conducted	O
by	O
the	O
Hellenic	O
Co-Operative	O
Oncology	O
Group	O
.	O

OBJECTIVE	O
A	O
randomized	O
phase	O
II	O
trial	O
was	O
conducted	O
to	O
test	O
whether	O
the	O
addition	O
of	O
gemcitabine	Pharmacological
to	O
weekly	O
docetaxel	Pharmacological
could	O
improve	O
the	O
objective	O
response	O
rate	O
and	O
survival	O
outcomes	O
as	O
second-line	O
chemotherapy	O
in	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
who	O
have	O
failed	O
a	O
paclitaxel-containing	Pharmacological
regimen	O
.	O

METHODS	O
Patients	O
were	O
randomized	O
to	O
receive	O
either	O
weekly	O
docetaxel	Pharmacological
40	Pharmacological
mg/m	Pharmacological
(	Pharmacological
2	Pharmacological
)	Pharmacological
(	O
group	O
A	O
,	O
n	O
=	O
34	O
)	O
or	O
the	O
combination	O
of	O
weekly	O
docetaxel	Pharmacological
35	Pharmacological
mg/m	Pharmacological
(	Pharmacological
2	Pharmacological
)	Pharmacological
with	Pharmacological
gemcitabine	Pharmacological
600	O
mg/m	O
(	O
2	O
)	O
(	O
group	O
B	O
,	O
n	O
=	O
41	O
)	O
.	O

Three	O
consecutive	O
weekly	O
infusions	O
followed	O
by	O
a	O
1-week	O
rest	O
period	O
represented	O
1	O
chemotherapy	Pharmacological
cycle	O
.	O

RESULTS	O
The	O
objective	O
response	O
rate	O
was	O
18	O
%	O
and	O
27.5	O
%	O
in	O
group	O
A	O
and	O
B	O
,	O
respectively	O
(	O
p	O
=	O
0.413	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
demonstrated	O
in	O
terms	O
of	O
median	O
overall	O
survival	O
and	O
time	O
to	O
disease	O
progression	O
.	O

The	O
rate	O
and	O
grade	O
3	O
and	O
4	O
neutropenia	O
were	O
higher	O
in	O
group	O
B	O
(	O
23	O
vs.	O
3	O
%	O
)	O
.	O

CONCLUSIONS	O
The	O
weekly	O
administration	O
of	O
docetaxel	Pharmacological
and	O
gemcitabine	Pharmacological
did	O
not	O
result	O
in	O
superior	O
clinical	O
outcomes	O
over	O
weekly	O
docetaxel	O
.	O

Postoperative	O
pain	O
control	O
for	O
outpatient	O
oral	O
surgery	O
.	O

16	O
healthy	O
patients	O
requiring	O
removal	O
of	O
bilateral	O
symmetrically-impacted	O
mandibular	O
third	O
molars	O
participated	O
in	O
a	O
double-blind	O
randomised	O
crossover	O
trial	O
to	O
test	O
the	O
effectiveness	O
of	O
postoperative	O
pain	O
control	O
using	O
a	O
long-acting	O
anti-inflammatory	O
agent	O
(	O
diflunisal	Pharmacological
)	O
in	O
combination	O
with	O
a	O
long-acting	O
local	O
anaesthetic	O
agent	O
(	Pharmacological
bupivacaine	Pharmacological
)	Pharmacological
.	O

Results	O
were	O
compared	O
to	O
the	O
more	O
traditional	O
method	O
of	O
using	O
an	O
oral	O
analgesic	O
with	O
shorter	O
duration	O
of	O
action	O
(	Pharmacological
paracetamol	Pharmacological
with	Pharmacological
codeine	Pharmacological
)	Pharmacological
with	O
lignocaine	Pharmacological
as	O
the	O
local	O
anaesthetic	O
.	O

Using	O
a	O
visual	O
analogue	O
pain	O
scale	O
,	O
patients	O
reported	O
that	O
significantly	O
reduced	O
pain	O
was	O
experienced	O
over	O
the	O
first	O
4	O
days	O
postoperatively	O
with	O
the	O
diflunisal/bupivacaine	Pharmacological
treatment	Pharmacological
and	O
patient	O
preference	O
for	O
this	O
treatment	O
was	O
highly	O
significant	O
.	O

This	O
report	O
represents	O
the	O
first	O
such	O
study	O
of	O
diflunisal	Pharmacological
used	O
for	O
an	O
extended	O
course	O
in	O
oral	O
surgery	O
with	O
pain	O
assessment	O
over	O
the	O
same	O
period	O
.	O

No	O
significant	O
side-effects	O
or	O
adverse	O
reactions	O
were	O
encountered	O
.	O

Ankle	Physical
cryotherapy	Physical
facilitates	O
soleus	O
function	O
.	O

STUDY	O
DESIGN	O
A	O
2-factor	O
(	O
group	O
and	O
time	O
)	O
experimental	O
design	O
with	O
repeated	O
measures	O
on	O
time	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
effects	O
of	O
ankle	Physical
cryotherapy	Physical
on	O
voluntary	O
and	O
resting	O
motor	O
function	O
of	O
the	O
soleus	O
over	O
a	O
60-minute	O
period	O
.	O

To	O
determine	O
if	O
a	O
relationship	O
exists	O
between	O
changes	O
in	O
torque	O
production	O
and	O
Hoffmann	O
reflex	O
(	O
H-reflex	O
)	O
following	O
ankle	Physical
joint	Physical
cryotherapy	Physical
treatment	O
.	O

BACKGROUND	O
Controversy	O
surrounds	O
the	O
use	O
of	O
cryotherapy	O
prior	O
to	O
activity	O
and	O
rehabilitation	O
.	O

While	O
cooling	O
muscle	O
may	O
have	O
a	O
deleterious	O
effect	O
on	O
motor	O
function	O
,	O
cooling	O
the	O
joint	O
may	O
enhance	O
motor	O
function	O
around	O
the	O
joint	O
.	O

The	O
H-reflex	O
is	O
a	O
good	O
resting	O
measure	O
of	O
motoneuronal	O
activity	O
.	O

However	O
,	O
its	O
relationship	O
to	O
voluntary	O
activity	O
is	O
unknown	O
.	O

METHODS	O
AND	O
MEASURES	O
Thirty	O
subjects	O
were	O
pretested	O
(	O
baseline	O
)	O
for	O
normalized	O
H-reflex	O
(	O
defined	O
as	O
the	O
ratio	O
of	O
maximum	O
H-reflex	O
[	O
Hmax	O
]	O
to	O
maximum	O
direct	O
motor	O
response	O
[	O
Mmax	O
]	O
)	O
and	O
peak	O
plantar	O
flexion	O
torque	O
.	O

A	Physical
crushed	Physical
ice	Physical
bag	Physical
was	Physical
placed	Physical
over	Physical
the	Physical
ankle	Physical
of	O
15	O
subjects	O
for	O
30	O
minutes	O
.	O

H-reflex	O
and	O
torque	O
measurements	O
were	O
collected	O
immediately	O
following	O
the	O
cryotherapy	O
treatment	O
at	O
30	O
,	O
60	O
,	O
and	O
90	O
minutes	O
.	O

Surface	O
temperatures	O
were	O
recorded	O
from	O
the	O
ankle	O
and	O
electrode	O
site	O
with	O
each	O
measurement	O
interval	O
.	O

RESULTS	O
Both	O
peak	O
H-reflex	O
and	O
plantar	O
flexion	O
torque	O
at	O
30	O
,	O
60	O
,	O
and	O
90	O
minutes	O
increased	O
relative	O
to	O
baseline	O
measurements	O
.	O

Each	O
measurement	O
was	O
also	O
greater	O
than	O
the	O
corresponding	O
control	O
at	O
30	O
,	O
60	O
,	O
and	O
90	O
minutes	O
.	O

A	O
weak	O
correlation	O
(	O
r	O
=	O
0.38	O
;	O
P	O
=	O
0.036	O
)	O
existed	O
between	O
changes	O
in	O
H-reflex	O
and	O
plantar	O
flexion	O
torque	O
at	O
30	O
minutes	O
.	O

CONCLUSIONS	O
The	O
soleus	O
motoneuron	O
pool	O
is	O
facilitated	O
following	O
a	O
30-minute	O
crushed	Physical
ice	Physical
application	Physical
to	O
the	O
ankle	O
and	O
over	O
a	O
60-minute	O
postcooling	O
period	O
.	O

These	O
data	O
support	O
the	O
use	O
of	O
joint	O
cooling	O
prior	O
to	O
activity	O
and	O
rehabilitation	O
.	O

[	O
Physical	O
performance	O
and	O
sedation	O
:	O
comparative	O
study	O
of	O
the	O
effects	O
of	O
a	O
benzodiazepine	Pharmacological
(	Pharmacological
temazepam	Pharmacological
)	Pharmacological
and	O
of	O
a	Pharmacological
non-benzodiazepine	Pharmacological
hypnotic	Pharmacological
(	Pharmacological
zolpidem	Pharmacological
)	Pharmacological
]	O
.	O

It	O
is	O
well-known	O
that	O
many	O
athletes	O
experience	O
some	O
form	O
of	O
precompetition	O
stress	O
that	O
may	O
result	O
in	O
insomnia	O
during	O
the	O
night	O
before	O
their	O
competition	O
.	O

Yet	O
,	O
sleep	O
withdrawal	O
even	O
if	O
only	O
partial	O
,	O
has	O
a	O
negative	O
influence	O
on	O
performance	O
,	O
particularly	O
when	O
the	O
type	O
of	O
exercise	O
requires	O
good	O
psychomotor	O
performance	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
intake	O
of	O
a	O
hypnotic	O
drug	O
would	O
have	O
negative	O
effects	O
on	O
physical	O
performance	O
capacity	O
.	O

The	O
authors	O
have	O
compared	O
the	O
effects	O
of	O
oral	Pharmacological
temazepam	Pharmacological
,	O
a	O
medium	Pharmacological
half-life	Pharmacological
benzodiazepine	Pharmacological
vs	O
oral	Pharmacological
zolpidem	Pharmacological
,	O
a	Pharmacological
short	Pharmacological
half-life	Pharmacological
non-benzodiazepine	Pharmacological
drug	Pharmacological
,	O
vs	O
placebo	Control
.	O

A	O
randomized	O
double-blind	O
trial	O
was	O
used	O
to	O
assess	O
endurance	O
,	O
resistance	O
,	O
strength	O
and	O
coordination	O
in	O
26	O
athletes	O
.	O

The	O
results	O
did	O
not	O
show	O
any	O
differences	O
between	O
the	O
three	O
groups	O
,	O
neither	O
in	O
physical	O
performance	O
characteristic	O
nor	O
in	O
coordination	O
.	O

It	O
is	O
concluded	O
that	O
as	O
regards	O
the	O
performance	O
capacity	O
,	O
there	O
is	O
no	O
risk	O
for	O
stressed	O
athletes	O
to	O
use	O
sleep	O
inducers	O
the	O
night	O
before	O
their	O
competition	O
.	O

Prospective	O
randomized	O
multicenter	O
trial	O
of	O
sevelamer	Pharmacological
hydrochloride	Pharmacological
and	Pharmacological
calcium	Pharmacological
carbonate	Pharmacological
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
in	O
hemodialysis	O
patients	O
in	O
Japan	O
.	O

A	O
prospective	O
,	O
randomized	O
open-label	O
trial	O
of	O
sevelamer	Pharmacological
hydrochloride	Pharmacological
with	Pharmacological
or	Pharmacological
without	Pharmacological
calcium	Pharmacological
carbonate	Pharmacological
(	Pharmacological
CC	Pharmacological
)	Pharmacological
involved	O
86	O
hemodialysis	O
patients	O
in	O
Japan	O
.	O

The	O
dosage	O
of	O
CC	O
was	O
fixed	O
at	O
3.0	O
g/day	O
for	O
the	O
12-week	O
study	O
.	O

After	O
the	O
first	O
4	O
weeks	O
all	O
subjects	O
were	O
changed	O
from	O
CC	Pharmacological
to	Pharmacological
sevelamer	Pharmacological
3.0	O
g/day	O
for	O
another	O
4	O
weeks	O
,	O
then	O
allocated	O
randomly	O
to	O
three	O
groups	O
for	O
the	O
final	O
4	O
weeks	O
:	O
group	Pharmacological
A	Pharmacological
,	Pharmacological
sevelamer	Pharmacological
6.0	Pharmacological
g/day	Pharmacological
;	Pharmacological
group	Pharmacological
B	Pharmacological
,	Pharmacological
sevelamer	Pharmacological
3.0	Pharmacological
g/day	Pharmacological
and	Pharmacological
CC	Pharmacological
3.0	Pharmacological
g/day	Pharmacological
;	Pharmacological
group	Pharmacological
C	Pharmacological
,	Pharmacological
CC	Pharmacological
3.0	Pharmacological
g/day	Pharmacological
.	Pharmacological

The	O
target	O
serum	O
phosphorous	O
concentration	O
(	O
P	O
)	O
=5.5	O
mg/dL	O
and	O
the	O
corrected	O
calcium	O
concentration	O
(	O
Ca	O
)	O
was	O
9.0-10.0	O
mg/dL	O
.	O

Of	O
the	O
86	O
patients	O
,	O
62	O
finished	O
the	O
study	O
without	O
a	O
change	O
of	O
dosage	O
and	O
their	O
data	O
were	O
analyzed	O
(	O
group	O
A	O
,	O
N=16	O
;	O
group	O
B	O
,	O
N=26	O
;	O
group	O
C	O
,	O
N=20	O
)	O
.	O

At	O
week	O
8	O
compared	O
with	O
week	O
4	O
,	O
the	O
concentration	O
of	O
P	O
increased	O
from	O
5.7+/-1.4	O
to	O
6.4+/-1.7	O
mg/dL	O
in	O
group	O
A	O
,	O
and	O
decreased	O
significantly	O
in	O
groups	O
B	O
and	O
C	O
,	O
and	O
in	O
group	O
B	O
compared	O
with	O
groups	O
A	O
and	O
C	O
;	O
groups	O
A	O
and	O
C	O
had	O
similar	O
concentrations	O
at	O
week	O
8	O
.	O

The	O
Ca	O
concentration	O
decreased	O
significantly	O
from	O
9.7+/-1.0	O
to	O
9.1+/-0.7	O
mg/dL	O
after	O
the	O
change	O
to	O
sevelamer	Pharmacological
.	O

At	O
week	O
8	O
Ca	O
was	O
not	O
significantly	O
changed	O
in	O
group	O
A	O
,	O
whereas	O
a	O
significant	O
increase	O
occurred	O
in	O
groups	O
B	O
and	O
C.	O
Side-effects	O
with	O
sevelamer	Pharmacological
administration	O
occurred	O
in	O
34	O
of	O
the	O
86	O
patients	O
and	O
24	O
dropped	O
out	O
of	O
the	O
study	O
,	O
with	O
a	O
high	O
frequency	O
in	O
group	O
A	O
(	O
13/29	O
;	O
44.8	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
an	O
additive	O
effect	O
of	O
sevelamer	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
with	O
CC	O
.	O

The	O
combination	O
therapy	O
was	O
better	O
tolerated	O
and	O
showed	O
higher	O
patient	O
compliance	O
than	O
CC	O
or	O
sevelamer	O
monotherapy	O
.	O

Zolmitriptan	Pharmacological
(	Pharmacological
311C90	Pharmacological
)	Pharmacological
does	O
not	O
interact	O
with	O
fluoxetine	Pharmacological
in	O
healthy	O
volunteers	O
.	O

Zolmitriptan	Pharmacological
(	Pharmacological
Zomig	Pharmacological
,	Pharmacological
formerly	Pharmacological
311C90	Pharmacological
)	Pharmacological
is	O
a	O
selective	Pharmacological
5-hydroxytryptamine	Pharmacological
(	Pharmacological
5-HT	Pharmacological
)	Pharmacological
1B/1D-receptor	Pharmacological
agonist	Pharmacological
with	O
central	O
and	O
peripheral	O
activity	O
for	O
the	O
acute	O
treatment	O
of	O
migraine	O
.	O

This	O
randomized	O
,	O
placebo-controlled	Control
,	O
crossover	O
study	O
investigated	O
the	O
effects	O
of	O
fluoxetine	Pharmacological
administration	O
on	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
zolmitriptan	Pharmacological
.	O

Twenty	O
volunteers	O
were	O
given	O
single	O
doses	O
of	O
fluoxetine	Pharmacological
20	Pharmacological
mg	Pharmacological
or	O
an	O
identical	O
placebo	Control
daily	O
for	O
28	O
days	O
prior	O
to	O
receiving	O
a	O
single	O
10	O
mg	O
oral	O
dose	O
of	O
zolmitriptan	Pharmacological
.	O

Sixteen	O
volunteers	O
completed	O
the	O
two	O
treatment	O
phases	O
.	O

The	O
pharmacokinetic	O
parameters	O
of	O
zolmitriptan	Pharmacological
and	O
its	O
metabolites	O
were	O
not	O
significantly	O
affected	O
by	O
fluoxetine	Pharmacological
pretreatment	O
.	O

The	O
pharmacodynamic	O
effects	O
of	O
zolmitriptan	Pharmacological
were	O
also	O
unaffected	O
by	O
fluoxetine	Pharmacological
pretreatment	O
.	O

There	O
were	O
small	O
,	O
clinically	O
insignificant	O
increases	O
in	O
blood	O
pressure	O
following	O
zolmitriptan	Pharmacological
which	O
were	O
unaltered	O
by	O
fluoxetine	Pharmacological
.	O

Zolmitriptan	Pharmacological
was	O
well	O
tolerated	O
when	O
given	O
alone	O
or	O
concomitantly	O
with	O
fluoxetine	Pharmacological
.	O

These	O
results	O
indicate	O
that	O
there	O
is	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
zolmitriptan	Pharmacological
in	O
patients	O
treated	O
concurrently	O
with	O
selective	Pharmacological
serotonin	Pharmacological
reuptake	Pharmacological
inhibitors	Pharmacological
and	O
that	O
no	O
adjustment	O
of	O
the	O
zolmitriptan	Pharmacological
dose	O
is	O
required	O
in	O
these	O
circumstances	O
.	O

A	O
comparison	O
of	O
high	Other
and	Other
low	Other
fat	Other
meals	Other
on	O
postprandial	O
esophageal	O
acid	O
exposure	O
.	O

Fatty	O
foods	O
have	O
been	O
identified	O
as	O
precipitating	O
factors	O
in	O
symptomatic	O
gastroesophageal	O
reflux	O
(	O
GER	O
)	O
.	O

A	O
fat	O
meal	O
has	O
also	O
been	O
found	O
to	O
decrease	O
lower	O
esophageal	O
sphincter	O
pressure	O
(	O
LESP	O
)	O
in	O
normal	O
subjects	O
.	O

We	O
used	O
the	O
ambulatory	O
24-h	O
pH	O
monitor	O
to	O
assess	O
esophageal	O
acid	O
exposure	O
in	O
10	O
normal	O
subjects	O
and	O
10	O
GER	O
patients	O
following	O
low	Pharmacological
and	Pharmacological
high	Pharmacological
fat	Pharmacological
meals	Pharmacological
eaten	O
in	O
two	Pharmacological
body	Pharmacological
positions	Pharmacological
.	O

The	O
meals	O
had	O
nearly	O
identical	O
protein	O
content	O
,	O
volumes	O
,	O
and	O
calories	O
.	O

On	O
successive	O
days	O
,	O
patients	O
ingested	O
one	O
of	O
the	O
meals	Pharmacological
twice	O
,	O
followed	O
by	O
random	O
assignment	O
to	O
3	O
h	O
upright	Other
and	Other
3	O
h	O
recumbent	Physical
position	Physical
.	O

Acid	O
exposure	O
for	O
each	O
hour	O
over	O
a	O
3-h	O
postprandial	O
(	O
PP	O
)	O
period	O
was	O
assessed	O
as	O
the	O
percent	O
time	O
pH	O
less	O
than	O
4.0	O
.	O

Increased	O
upright	O
acid	O
exposure	O
occurred	O
in	O
normals	O
after	O
the	O
high	O
fat	O
(	O
6.2	O
+/-	O
2.1	O
%	O
;	O
mean	O
+/-	O
SE	O
)	O
compared	O
with	O
the	O
low	O
fat	O
meal	O
(	O
1.5	O
+/-	O
0.5	O
%	O
;	O
p	O
less	O
than	O
0.05	O
)	O
.	O

GER	O
patients	O
had	O
greater	O
(	O
p	O
less	O
than	O
0.05	O
)	O
acid	O
exposure	O
than	O
normals	O
in	O
all	O
study	O
periods	O
,	O
but	O
no	O
differences	O
were	O
found	O
between	O
low	O
and	O
high	O
fat	O
meals	O
in	O
either	O
study	O
position	O
.	O

High	O
fat	O
meals	O
induce	O
upright	O
GER	O
in	O
normals	O
,	O
but	O
do	O
not	O
significantly	O
affect	O
the	O
abnormal	O
amount	O
of	O
GER	O
in	O
patients	O
.	O

In	O
addition	O
,	O
progressive	O
increases	O
in	O
acid	O
exposure	O
were	O
found	O
over	O
the	O
3	O
postprandial	O
hours	O
in	O
GER	O
patients	O
in	O
a	O
recumbent	O
position	O
.	O

The	O
findings	O
are	O
consistent	O
with	O
prior	O
data	O
showing	O
decreased	O
LESP	O
with	O
a	O
fat	O
meal	O
in	O
normals	O
.	O

Early	O
clinical	O
outcomes	O
and	O
toxicity	O
of	O
intensity	O
modulated	O
versus	O
conventional	O
pelvic	O
radiation	O
therapy	O
for	O
locally	O
advanced	O
cervix	O
carcinoma	O
:	O
a	O
prospective	O
randomized	O
study	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
toxicity	O
and	O
clinical	O
outcome	O
in	O
patients	O
with	O
locally	O
advanced	O
cervical	O
cancer	O
(	O
LACC	O
)	O
treated	O
with	O
whole	Pharmacological
pelvic	Pharmacological
conventional	Pharmacological
radiation	Pharmacological
therapy	Pharmacological
(	O
WP-CRT	O
)	O
versus	O
intensity	Pharmacological
modulated	Pharmacological
radiation	Pharmacological
therapy	Pharmacological
(	O
WP-IMRT	O
)	O
.	O

METHODS	O
AND	O
MATERIALS	O
Between	O
January	O
2010	O
and	O
January	O
2012	O
,	O
44	O
patients	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(	O
FIGO	O
2009	O
)	O
stage	O
IIB-IIIB	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
cervix	O
were	O
randomized	O
to	O
receive	O
50.4	O
Gy	O
in	O
28	O
fractions	O
delivered	O
via	O
either	O
WP-CRT	Physical
or	O
WP-IMRT	Physical
with	O
concurrent	O
weekly	O
cisplatin	O
40	O
mg/m	O
(	O
2	O
)	O
.	O

Acute	O
toxicity	O
was	O
graded	O
according	O
to	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
,	O
version	O
3.0	O
,	O
and	O
late	O
toxicity	O
was	O
graded	O
according	O
to	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
system	O
.	O

The	O
primary	O
and	O
secondary	O
endpoints	O
were	O
acute	O
gastrointestinal	O
toxicity	O
and	O
disease-free	O
survival	O
,	O
respectively	O
.	O

RESULTS	O
Of	O
44	O
patients	O
,	O
22	O
patients	O
received	O
WP-CRT	Pharmacological
and	O
22	O
received	O
WP-IMRT	Pharmacological
.	O

In	O
the	O
WP-CRT	Pharmacological
arm	O
,	O
13	O
patients	O
had	O
stage	O
IIB	O
disease	O
and	O
9	O
had	O
stage	O
IIIB	O
disease	O
;	O
in	O
the	O
IMRT	Pharmacological
arm	O
,	O
12	O
patients	O
had	O
stage	O
IIB	O
disease	O
and	O
10	O
had	O
stage	O
IIIB	O
disease	O
.	O

The	O
median	O
follow-up	O
time	O
in	O
the	O
WP-CRT	O
arm	O
was	O
21.7	O
months	O
(	O
range	O
,	O
10.7-37.4	O
months	O
)	O
,	O
and	O
in	O
the	O
WP-IMRT	O
arm	O
it	O
was	O
21.6	O
months	O
(	O
range	O
,	O
7.7-34.4	O
months	O
)	O
.	O

At	O
27	O
months	O
,	O
disease-free	O
survival	O
was	O
79.4	O
%	O
in	O
the	O
WP-CRT	Pharmacological
group	O
versus	O
60	O
%	O
in	O
the	O
WP-IMRT	Pharmacological
group	O
(	O
P=.651	O
)	O
,	O
and	O
overall	O
survival	O
was	O
76	O
%	O
in	O
the	O
WP-CRT	O
group	O
versus	O
85.7	O
%	O
in	O
the	O
WP-IMRT	O
group	O
(	O
P=.645	O
)	O
.	O

Patients	O
in	O
the	O
WP-IMRT	O
arm	O
experienced	O
significantly	O
fewer	O
grade	O
?2	O
acute	O
gastrointestinal	O
toxicities	O
(	O
31.8	O
%	O
vs	O
63.6	O
%	O
,	O
P=.034	O
)	O
and	O
grade	O
?3	O
gastrointestinal	O
toxicities	O
(	O
4.5	O
%	O
vs	O
27.3	O
%	O
,	O
P=.047	O
)	O
than	O
did	O
patients	O
receiving	O
WP-CRT	O
and	O
had	O
less	O
chronic	O
gastrointestinal	O
toxicity	O
(	O
13.6	O
%	O
vs	O
50	O
%	O
,	O
P=.011	O
)	O
.	O

CONCLUSION	O
WP-IMRT	O
is	O
associated	O
with	O
significantly	O
less	O
toxicity	O
compared	O
with	O
WP-CRT	O
and	O
has	O
a	O
comparable	O
clinical	O
outcome	O
.	O

Further	O
studies	O
with	O
larger	O
sample	O
sizes	O
and	O
longer	O
follow-up	O
times	O
are	O
warranted	O
to	O
justify	O
its	O
use	O
in	O
routine	O
clinical	O
practice	O
.	O

Inhibition	O
of	O
awake	O
sympathetic	O
nerve	O
activity	O
of	O
heart	O
failure	O
patients	O
with	O
obstructive	O
sleep	O
apnea	O
by	O
nocturnal	Physical
continuous	Physical
positive	Physical
airway	Physical
pressure	Physical
.	O

OBJECTIVES	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
reductions	O
in	O
morning	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
elicited	O
by	O
treatment	O
of	O
moderate	O
to	O
severe	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
in	O
heart	O
failure	O
(	O
HF	O
)	O
patients	O
are	O
associated	O
with	O
a	O
reduction	O
in	O
sympathetic	O
vasoconstrictor	O
tone	O
.	O

BACKGROUND	O
Daytime	O
muscle	O
sympathetic	O
nerve	O
activity	O
(	O
MSNA	O
)	O
is	O
elevated	O
in	O
HF	O
patients	O
with	O
coexisting	O
OSA	O
.	O

In	O
our	O
recent	O
randomized	O
trial	O
in	O
HF	O
,	O
abolition	O
of	O
OSA	O
by	O
continuous	Physical
positive	Physical
airway	Physical
pressure	Physical
(	Physical
CPAP	Physical
)	Physical
increased	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
and	O
lowered	O
morning	O
systolic	O
BP	O
.	O

METHODS	O
Muscle	O
sympathetic	O
nerve	O
activity	O
,	O
BP	O
,	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
of	O
medically	O
treated	O
HF	O
patients	O
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
OSA	O
(	O
apnea-hypopnea	O
index	O
>	O
or	O
=20/h	O
of	O
sleep	O
)	O
were	O
recorded	O
on	O
the	O
morning	O
after	O
overnight	O
polysomnography	O
,	O
and	O
again	O
one	O
month	O
after	O
patients	O
were	O
randomly	O
allocated	O
nocturnal	Physical
CPAP	Physical
treatment	Physical
or	O
no	O
CPAP	O
(	O
control	O
)	O
.	O

RESULTS	O
In	O
nine	O
control	O
patients	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
the	O
severity	O
of	O
OSA	O
,	O
MSNA	O
,	O
systolic	O
BP	O
,	O
or	O
HR	O
.	O

In	O
contrast	O
,	O
in	O
the	O
8	O
CPAP-treated	Physical
patients	O
,	O
OSA	O
was	O
attenuated	O
,	O
and	O
there	O
were	O
significant	O
reductions	O
in	O
daytime	O
MSNA	O
(	O
from	O
58	O
+/-	O
4	O
bursts/min	O
to	O
48	O
+/-	O
5	O
bursts/min	O
;	O
84	O
+/-	O
4	O
bursts/100	O
heart	O
beats	O
to	O
72	O
+/-	O
5	O
bursts/100	O
heart	O
beats	O
;	O
p	O
<	O
0.001	O
and	O
p	O
=	O
0.003	O
,	O
respectively	O
)	O
,	O
systolic	O
BP	O
(	O
from	O
135	O
+/-	O
5	O
mm	O
Hg	O
to	O
120	O
+/-	O
6	O
mm	O
Hg	O
,	O
p	O
=	O
0.03	O
)	O
,	O
and	O
HR	O
(	O
from	O
69	O
+/-	O
2	O
min	O
(	O
-1	O
)	O
to	O
66	O
+/-	O
2	O
min	O
(	O
-1	O
)	O
;	O
p	O
=	O
0.013	O
)	O
.	O

CONCLUSIONS	O
Treatment	O
of	O
coexisting	O
OSA	O
by	O
CPAP	Physical
in	O
HF	O
patients	O
lowers	O
daytime	O
MSNA	O
,	O
systolic	O
BP	O
,	O
and	O
HR	O
.	O

Inhibition	O
of	O
increased	O
central	O
sympathetic	O
vasoconstrictor	O
outflow	O
is	O
one	O
mechanism	O
by	O
which	O
nocturnal	Physical
CPAP	Physical
reduces	O
awake	O
BP	O
in	O
HF	O
patients	O
with	O
moderate	O
to	O
severe	O
OSA	O
.	O

Randomized	O
trial	O
of	O
adoptive	O
transfer	O
of	O
melanoma	O
tumor-infiltrating	Physical
lymphocytes	Physical
as	O
adjuvant	O
therapy	O
for	O
stage	O
III	O
melanoma	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
interest	O
of	O
using	O
tumor-infiltrating	Physical
lymphocytes	Physical
(	Physical
TIL	Physical
)	Physical
as	O
adjuvant	O
therapy	O
for	O
stage	O
III	O
(	O
regional	O
lymph	O
nodes	O
)	O
melanoma	O
.	O

After	O
lymph	O
node	O
excision	O
,	O
patients	O
without	O
any	O
detectable	O
metastases	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
TIL	Physical
plus	Physical
interleukin-2	Physical
(	Physical
IL-2	Physical
)	Physical
for	O
2	O
months	O
,	O
or	O
IL-2	Pharmacological
only	O
.	O

The	O
primary	O
endpoint	O
was	O
determination	O
of	O
the	O
duration	O
of	O
the	O
relapse-free	O
interval	O
.	O

Eighty-eight	O
patients	O
determined	O
as	O
eligible	O
for	O
treatment	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
46.9	O
months	O
,	O
for	O
the	O
study	O
population	O
the	O
analysis	O
did	O
not	O
show	O
a	O
significant	O
extension	O
of	O
the	O
relapse-free	O
interval	O
or	O
overall	O
survival	O
.	O

However	O
,	O
a	O
significant	O
interaction	O
(	O
P	O
<	O
0.001	O
)	O
was	O
found	O
between	O
the	O
treatment	O
and	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
.	O

In	O
the	O
group	O
with	O
only	O
one	O
invaded	O
lymph	O
node	O
,	O
the	O
estimated	O
relapse	O
rate	O
was	O
significantly	O
lower	O
(	O
P	O
(	O
adjusted	O
)	O
=0.0285	O
)	O
and	O
the	O
overall	O
survival	O
was	O
increased	O
(	O
P	O
(	O
adjusted	O
)	O
=0.039	O
)	O
in	O
the	O
TIL+IL-2	Pharmacological
arm	O
compared	O
with	O
the	O
IL-2	Pharmacological
only	O
arm	O
.	O

No	O
differences	O
between	O
the	O
two	O
arms	O
,	O
either	O
as	O
regards	O
the	O
duration	O
of	O
disease-free	O
survival	O
or	O
overall	O
survival	O
,	O
were	O
noted	O
in	O
the	O
group	O
with	O
more	O
than	O
one	O
invaded	O
lymph	O
node	O
whatever	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
.	O

Treatment	O
was	O
compatible	O
with	O
normal	O
daily	O
activity	O
.	O

This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
efficiency	O
of	O
TIL	Pharmacological
in	O
stage	O
III	O
melanoma	O
(	O
AJCC	O
)	O
is	O
directly	O
related	O
to	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
,	O
indicating	O
that	O
tumor	O
burden	O
might	O
be	O
a	O
crucial	O
factor	O
in	O
the	O
efficacy	O
and/or	O
in	O
vitro	O
expansion	O
of	O
T	O
cells	O
specific	O
for	O
autologous	O
tumor	O
antigen	O
,	O
a	O
finding	O
which	O
could	O
be	O
of	O
value	O
in	O
future	O
vaccine	O
development	O
for	O
the	O
treatment	O
of	O
melanoma	O
.	O

Comparative	O
evaluation	O
of	O
calcium	Pharmacological
hydroxide	Pharmacological
and	O
zinc	Pharmacological
oxide	Pharmacological
eugenol	Pharmacological
as	O
root	Physical
canal	Physical
filling	Physical
materials	O
for	O
primary	O
molars	O
:	O
a	O
clinical	O
and	O
radiographic	O
study	O
.	O

Calcium	Pharmacological
hydroxide	Pharmacological
,	O
a	O
material	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
permanent	O
teeth	O
has	O
not	O
been	O
used	O
frequently	O
for	O
pulpectomy	O
in	O
primary	O
teeth	O
.	O

A	O
comparative	O
evaluation	O
of	O
calcium	Pharmacological
hydroxide	Pharmacological
and	O
zinc	Pharmacological
oxide	Pharmacological
eugenol	Pharmacological
used	O
as	O
root	Physical
canal	Physical
filling	Physical
materials	Physical
in	O
primary	O
molars	O
is	O
presented	O
.	O

Psychological	O
well-being	O
correlates	O
with	O
free	O
thyroxine	O
but	O
not	O
free	O
3,5,3'-triiodothyronine	O
levels	O
in	O
patients	O
on	O
thyroid	O
hormone	O
replacement	O
.	O

CONTEXT	O
AND	O
OBJECTIVE	O
An	O
association	O
between	O
mood	O
disorders	O
and	O
overt	O
thyroid	O
dysfunction	O
is	O
well	O
established	O
,	O
but	O
there	O
are	O
few	O
data	O
on	O
the	O
potential	O
for	O
thyroid	O
hormone	O
levels	O
closer	O
to	O
the	O
reference	O
range	O
to	O
correlate	O
with	O
psychological	O
well-being	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
We	O
analyzed	O
the	O
relationship	O
between	O
psychological	O
well-being	O
and	O
free	O
T	O
(	O
4	O
)	O
(	O
fT4	O
)	O
,	O
free	O
T	O
(	O
3	O
)	O
(	O
fT3	O
)	O
,	O
TSH	O
,	O
and	O
total	O
rT	O
(	O
3	O
)	O
in	O
697	O
patients	O
on	O
thyroid	Pharmacological
hormone	Pharmacological
replacement	Pharmacological
therapy	Pharmacological
at	O
entry	O
to	O
a	O
randomized	O
,	O
controlled	O
trial	O
of	O
combined	Pharmacological
T	Pharmacological
(	Pharmacological
4	Pharmacological
)	Pharmacological
and	Pharmacological
T	Pharmacological
(	Pharmacological
3	Pharmacological
)	Pharmacological
replacement	Pharmacological
therapy	Pharmacological
.	O

All	O
patients	O
were	O
on	O
100	O
mug	O
or	O
more	O
T	O
(	O
4	O
)	O
.	O

INTERVENTIONS	O
AND	O
MAIN	O
OUTCOME	O
MEASURES	O
Psychological	O
well-being	O
was	O
assessed	O
with	O
General	O
Health	O
Questionnaire-12	O
(	O
GHQ-12	O
)	O
,	O
Thyroid	O
Symptom	O
Questionnaire	O
,	O
and	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
.	O

RESULTS	O
fT	O
(	O
4	O
)	O
and	O
TSH	O
showed	O
a	O
strong	O
correlation	O
with	O
GHQ-12	O
scores	O
(	O
fT4	O
-	O
b	O
:	O
-0.16	O
,	O
P	O
=	O
0.005	O
;	O
TSH	O
-	O
b	O
:	O
0.663	O
,	O
P	O
=	O
0.04	O
)	O
.	O

No	O
correlations	O
were	O
seen	O
between	O
the	O
GHQ	O
scores	O
and	O
fT3	O
(	O
b	O
:	O
0.318	O
,	O
P	O
=	O
0.275	O
)	O
,	O
rT	O
(	O
3	O
)	O
(	O
b	O
:	O
0.095	O
,	O
P	O
=	O
0.95	O
)	O
,	O
rT	O
(	O
3	O
)	O
to	O
fT4	O
ratio	O
(	O
b	O
:	O
71.83	O
,	O
P	O
=	O
0.09	O
)	O
or	O
fT3	O
to	O
rT	O
(	O
3	O
)	O
ratio	O
(	O
b	O
:	O
0.05	O
,	O
P	O
=	O
0.32	O
)	O
.	O

The	O
correlations	O
remained	O
when	O
the	O
data	O
set	O
was	O
limited	O
to	O
patients	O
with	O
TSH	O
in	O
the	O
range	O
0.3-4.0	O
mIU/liter	O
.	O

Similar	O
correlations	O
were	O
seen	O
with	O
the	O
Thyroid	O
Symptom	O
Questionnaire	O
,	O
although	O
not	O
with	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
scores	O
.	O

CONCLUSIONS	O
Differences	O
in	O
fT4	O
and	O
TSH	O
concentration	O
,	O
even	O
within	O
the	O
reference	O
range	O
,	O
may	O
be	O
a	O
determinant	O
of	O
psychological	O
well-being	O
in	O
treated	O
hypothyroid	O
patients	O
although	O
not	O
necessarily	O
with	O
symptoms	O
typical	O
of	O
anxiety	O
or	O
depression	O
.	O

Mexiletine	Pharmacological
for	O
HIV-infected	O
patients	O
with	O
painful	O
peripheral	O
neuropathy	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
treatment	O
trial	O
.	O

Although	O
mexiletine	Pharmacological
,	O
an	O
antiarrhythmic	O
with	O
local	O
anesthetic	O
properties	O
,	O
has	O
been	O
reported	O
to	O
relieve	O
discomfort	O
in	O
diabetic	O
neuropathy	O
,	O
its	O
usefulness	O
in	O
the	O
treatment	O
of	O
HIV-related	O
painful	O
peripheral	O
neuropathy	O
(	O
PPN	O
)	O
has	O
not	O
been	O
determined	O
.	O

The	O
tolerance	O
and	O
effectiveness	O
of	O
mexiletine	Pharmacological
in	O
HIV-related	O
PPN	O
were	O
assessed	O
in	O
22	O
patients	O
who	O
were	O
randomized	O
to	O
receive	O
mexiletine	Pharmacological
(	Pharmacological
maximum	Pharmacological
dose	Pharmacological
,	Pharmacological
600	Pharmacological
mg/day	Pharmacological
)	Pharmacological
or	O
placebo	Control
for	O
6	O
weeks	O
,	O
followed	Pharmacological
by	Pharmacological
the	Pharmacological
alternative	Pharmacological
intervention	Pharmacological
for	O
6	O
weeks	O
after	O
a	O
1-week	O
washout	O
period	O
.	O

The	O
daily	O
pain	O
response	O
was	O
assessed	O
using	O
a	O
visual	O
analogue	O
scale	O
card	O
in	O
19	O
patients	O
who	O
received	O
at	O
least	O
2	O
weeks	O
of	O
the	O
drug	O
,	O
16	O
of	O
whom	O
were	O
crossed-over	O
to	O
receive	O
the	O
alternate	O
agent	O
.	O

No	O
statistically	O
significant	O
difference	O
was	O
found	O
between	O
the	O
mean	O
daily	O
pain	O
scores	O
for	O
patients	O
receiving	O
mexiletine	Pharmacological
versus	O
placebo	O
,	O
irrespective	O
of	O
the	O
order	O
in	O
which	O
the	O
agents	O
were	O
received	O
.	O

Comparing	O
the	O
mean	O
individual	O
daily	O
pain	O
scores	O
for	O
each	O
phase	O
of	O
study	O
,	O
5	O
patients	O
(	O
31	O
%	O
)	O
had	O
significantly	O
less	O
pain	O
while	O
receiving	O
mexiletine	Pharmacological
compared	O
with	O
their	O
response	O
to	O
placebo	Pharmacological
,	O
5	O
patients	O
(	O
31	O
%	O
)	O
had	O
significantly	O
less	O
pain	O
while	O
receiving	O
placebo	Pharmacological
,	O
and	O
no	O
difference	O
was	O
noted	O
in	O
6	O
patients	O
(	O
38	O
%	O
)	O
.	O

Crossover	O
and	O
multivariate	O
analyses	O
for	O
repeated	O
measures	O
showed	O
no	O
apparent	O
difference	O
in	O
the	O
response	O
to	O
mexiletine	Pharmacological
versus	O
placebo	Pharmacological
.	O

Dose-limiting	O
adverse	O
events	O
occurred	O
in	O
39	O
%	O
of	O
those	O
receiving	O
mexiletine	Pharmacological
,	O
but	O
only	O
1	O
patient	O
(	O
5	O
%	O
)	O
discontinued	O
placebo	Pharmacological
.	O

Mexiletine	Pharmacological
was	O
only	O
modestly	O
well	O
tolerated	O
despite	O
its	O
relatively	O
brief	O
period	O
of	O
administration	O
,	O
and	O
no	O
evidence	O
was	O
found	O
to	O
support	O
its	O
benefit	O
in	O
HIV-related	O
PPN	O
.	O

Although	O
a	O
first-drug	O
effect	O
was	O
not	O
demonstrated	O
,	O
a	O
powerful	O
placebo	O
effect	O
was	O
seen	O
in	O
some	O
patients	O
.	O

Serotonergic	O
control	O
of	O
TSH	O
and	O
PRL	O
secretion	O
in	O
obese	O
men	O
.	O

To	O
evaluate	O
whether	O
the	O
inhibitory	O
control	O
of	O
TSH	O
and	O
the	O
stimulatory	O
control	O
of	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
exerted	O
by	O
endogenous	O
serotonin	O
was	O
altered	O
in	O
obesity	O
,	O
22	O
obese	O
men	O
and	O
10	O
normal	O
controls	O
were	O
tested	O
with	O
TRH	Pharmacological
(	O
200	O
micrograms	O
IV	O
bolus	O
)	O
in	O
the	O
presence	O
(	O
experimental	O
test	O
)	O
and	O
absence	O
(	O
control	O
test	O
)	O
of	O
the	O
serotonergic	Pharmacological
agonist	Pharmacological
fenfluramine	Pharmacological
(	O
60	O
mg	O
PO	O
90	O
min	O
before	O
TRH	O
)	O
.	O

Control	O
and	O
experimental	O
tests	O
were	O
also	O
performed	O
in	O
seven	O
male	O
patients	O
with	O
subclinical	O
hypothyroidism	O
and	O
were	O
repeated	O
in	O
the	O
same	O
obese	O
subjects	O
after	O
substantial	O
weight	O
loss	O
.	O

Basal	O
TSH	O
levels	O
were	O
similar	O
in	O
control	O
and	O
obese	O
men	O
.	O

Normal	O
TSH	O
responses	O
to	O
TRH	O
(	O
peak	O
less	O
than	O
or	O
equal	O
to	O
14	O
mU/L	O
)	O
were	O
observed	O
in	O
all	O
normal	O
controls	O
(	O
mean	O
peak	O
+/-	O
SE	O
9.8	O
+/-	O
0.6	O
mU/L	O
)	O
.	O

In	O
contrast	O
,	O
obese	O
men	O
were	O
divided	O
into	O
two	O
groups	O
:	O
nine	O
in	O
whom	O
the	O
TRH-induced	O
TSH	O
rise	O
was	O
higher	O
than	O
normal	O
(	O
group	O
I	O
:	O
mean	O
peak	O
=	O
16.5	O
+/-	O
0.5	O
mU/L	O
)	O
and	O
13	O
in	O
whom	O
it	O
was	O
normal	O
(	O
group	O
II	O
:	O
mean	O
peak	O
=	O
10.6	O
+/-	O
0.7	O
mU/L	O
)	O
.	O

The	O
hypothyroid	O
men	O
all	O
had	O
elevated	O
basal	O
and	O
TRH-stimulated	O
TSH	O
levels	O
.	O

Basal	O
PRL	O
concentrations	O
were	O
similar	O
in	O
the	O
normal	O
controls	O
and	O
both	O
groups	O
of	O
obese	O
subjects	O
.	O

The	O
PRL	O
response	O
to	O
TRH	O
was	O
lower	O
in	O
both	O
group	O
I	O
and	O
group	O
II	O
obese	O
men	O
than	O
in	O
normal	O
controls	O
and	O
was	O
similar	O
between	O
group	O
I	O
and	O
group	O
II	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Masticatory	O
performance	O
and	O
chewing	O
experience	O
with	O
implant-retained	O
mandibular	O
overdentures	O
.	O

The	O
relationship	O
between	O
masticatory	O
performance	O
and	O
chewing	O
experience	O
has	O
not	O
yet	O
been	O
explored	O
for	O
patients	O
with	O
implant-retained	Educational
overdentures	Educational
.	O

Although	O
many	O
relationships	O
have	O
been	O
found	O
between	O
parameters	O
of	O
objective	O
and	O
subjective	O
oral	O
function	O
,	O
the	O
structure	O
of	O
these	O
relationships	O
remain	O
unclear	O
.	O

Therefore	O
,	O
we	O
studied	O
in	O
a	O
randomized	O
clinical	O
trial	O
the	O
relationship	O
between	O
the	O
comminution	O
of	O
an	O
artificial	O
test	O
food	O
,	O
i.e	O
.	O

masticatory	Educational
performance	Educational
,	Educational
and	Educational
the	Educational
subjective	Educational
chewing	Educational
experience	Educational
.	O

The	O
trial	O
involved	O
a	O
comparison	O
between	O
two	O
groups	O
receiving	O
implant	O
treatment	O
and	O
one	O
group	O
receiving	O
conventional	O
complete	O
dentures	O
(	O
CD	O
)	O
.	O

The	O
implant	O
treatment	O
involved	O
either	O
a	O
mainly	O
implant-supported	Physical
mandibular	Physical
overdenture	Physical
on	O
a	O
transmandibular	Physical
implant	Physical
(	Physical
TMI	Physical
)	Physical
or	O
an	O
implant-tissue-supported	O
mandibular	O
overdenture	O
on	O
two	O
IMZ	O
implants	O
(	O
IMZ	O
)	O
.	O

Masticatory	O
performance	O
as	O
well	O
as	O
chewing	O
experience	O
were	O
substantially	O
better	O
for	O
the	O
implant-retained	O
overdentures	O
compared	O
with	O
the	O
complete	O
denture	O
group	O
.	O

No	O
significant	O
differences	O
emerged	O
between	O
the	O
TMI	O
and	O
the	O
IMZ	O
group	O
.	O

A	O
multiple	O
regression	O
analysis	O
did	O
not	O
provide	O
any	O
comprehensibility	O
in	O
the	O
relationship	O
between	O
masticatory	O
performance	O
and	O
the	O
variables	O
of	O
chewing	O
experience	O
.	O

In	O
the	O
linear	O
structural	O
relation	O
analysis	O
(	O
LISREL	O
)	O
no	O
direct	O
relationship	O
was	O
found	O
between	O
masticatory	O
performance	O
and	O
functional	O
complaints	O
mandibular	O
denture	O
.	O

The	O
results	O
show	O
that	O
an	O
improvement	O
in	O
masticatory	O
performance	O
does	O
not	O
imply	O
the	O
same	O
improvement	O
in	O
chewing	O
experience	O
and	O
vice	O
versa	O
.	O

Comorbidity	O
,	O
age	O
and	O
overall	O
survival	O
in	O
cetuximab-treated	Pharmacological
patients	O
with	O
advanced	O
colorectal	O
cancer	O
(	O
ACRC	O
)	O
--	O
results	O
from	O
NCIC	O
CTG	O
CO.17	O
:	O
a	O
phase	O
III	O
trial	O
of	O
cetuximab	Pharmacological
versus	O
best	Other
supportive	Other
care	Other
.	O

BACKGROUND	O
the	O
interplay	O
between	O
comorbidity	O
,	O
age	O
and	O
performance	O
status	O
(	O
PS	O
)	O
as	O
predictors	O
of	O
outcome	O
in	O
advanced	O
colorectal	O
cancer	O
(	O
ACRC	O
)	O
is	O
poorly	O
understood	O
.	O

We	O
examined	O
these	O
factors	O
as	O
predictors	O
of	O
treatment	O
toxicity	O
and	O
outcome	O
in	O
cetuximab-treated	Pharmacological
patients	O
with	O
ACRC	O
.	O

PATIENTS	O
AND	O
METHODS	O
comorbidity	O
was	O
independently	O
evaluated	O
using	O
the	O
Charlson	O
Comorbidity	O
Index	O
(	O
CCI	O
)	O
,	O
a	O
validated	O
measure	O
of	O
comorbidity	O
based	O
on	O
the	O
presence	O
of	O
medical	O
conditions	O
weighted	O
according	O
to	O
their	O
effect	O
on	O
mortality	O
.	O

CCI	O
score	O
was	O
correlated	O
with	O
clinical	O
and	O
outcome	O
data	O
.	O

RESULTS	O
five	O
hundred	O
and	O
seventy-two	O
patients	O
were	O
included	O
;	O
41	O
%	O
were	O
?	O
65	O
years	O
and	O
25	O
%	O
had	O
comorbidities	O
at	O
randomization	O
.	O

In	O
multivariate	O
analysis	O
(	O
MVA	O
)	O
of	O
all	O
covariates	O
,	O
only	O
older	O
age	O
was	O
associated	O
with	O
greater	O
comorbidity	O
(	O
P	O
=	O
0.008	O
)	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
was	O
significantly	O
better	O
for	O
patients	O
with	O
greater	O
comorbidity	O
in	O
univariate	O
analysis	O
(	O
P	O
=	O
0.047	O
)	O
.	O

Conversely	O
,	O
better	O
PS	O
was	O
associated	O
with	O
better	O
OS	O
in	O
MVA	O
(	O
hazard	O
ratio	O
1.92	O
for	O
PS	O
=	O
2	O
versus	O
PS	O
=	O
0	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Age	O
was	O
not	O
associated	O
with	O
OS	O
(	O
P	O
=	O
0.13	O
)	O
.	O

Elderly	O
patients	O
had	O
significantly	O
less	O
grade	O
?	O
3	O
vomiting	O
(	O
P	O
=	O
0.034	O
)	O
but	O
more	O
dyspnea	O
(	O
P	O
=	O
0.005	O
)	O
.	O

Patients	O
with	O
greater	O
comorbidity	O
had	O
significantly	O
less	O
grade	O
?	O
3	O
vomiting	O
(	O
P	O
=	O
0.002	O
)	O
but	O
more	O
non-neutropenic	O
fever	O
(	O
P	O
=	O
0.005	O
)	O
.	O

CONCLUSION	O
better	O
PS	O
was	O
associated	O
with	O
improved	O
OS	O
.	O

For	O
patients	O
with	O
good	O
PS	O
,	O
restricting	O
cetuximab	O
use	O
in	O
the	O
setting	O
of	O
significant	O
comorbidity	O
does	O
not	O
appear	O
justified	O
.	O

A	O
sensory	Psychological
integration	Psychological
therapy	Psychological
program	Psychological
on	O
sensory	O
problems	O
for	O
children	O
with	O
autism	O
.	O

The	O
study	O
was	O
planned	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
sensory	Psychological
integration	Psychological
therapy	Psychological
program	Psychological
on	O
sensory	O
problems	O
of	O
children	O
with	O
autism	O
.	O

This	O
study	O
was	O
conducted	O
at	O
the	O
Trakya	O
University	O
Training	O
and	O
Research	O
Center	O
for	O
Mentally	O
and	O
Physically	O
Handicapped	O
Children	O
in	O
Turkey	O
.	O

The	O
children	O
were	O
separated	O
into	O
two	O
groups	O
,	O
each	O
comprising	O
15	O
children	O
between	O
7	O
and	O
11	O
years	O
of	O
age	O
with	O
autism	O
,	O
according	O
to	O
DSM-IV	O
criteria	O
.	O

The	O
children	O
in	O
each	O
group	O
were	O
assessed	O
initially	O
on	O
a	O
checklist	O
,	O
Sensory	O
Evaluation	O
Form	O
for	O
Children	O
with	O
Autism	O
,	O
developed	O
to	O
evaluate	O
sensory	O
characteristics	O
of	O
children	O
with	O
autism	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
participants	O
were	O
assessed	O
again	O
on	O
the	O
checklist	O
.	O

Statistically	O
significant	O
differences	O
between	O
groups	O
indicated	O
that	O
the	O
sensory	Psychological
integration	Psychological
therapy	Psychological
program	Psychological
positively	O
affected	O
treated	O
children	O
.	O

Effect	O
of	O
vitamin	Pharmacological
K2	Pharmacological
on	O
the	O
recurrence	O
in	O
patients	O
with	O
hepatocellular	O
carcinoma	O
.	O

BACKGROUND/AIMS	O
Vitamin	Pharmacological
K2	Pharmacological
(	Pharmacological
VK2	Pharmacological
)	Pharmacological
appears	O
to	O
have	O
a	O
potent	O
inhibitory	O
activity	O
for	O
cell	O
growth	O
including	O
HCC	O
cells	O
.	O

We	O
investigated	O
whether	O
VK2	Pharmacological
could	O
reduce	O
incidence	O
of	O
tumor	O
recurrence	O
after	O
treatment	O
of	O
HCC	O
.	O

Forty-five	O
patients	O
with	O
cured	O
or	O
possibly	O
cured	O
HCC	O
were	O
randomly	O
selected	O
,	O
assigning	O
patients	O
to	O
treatment	O
(	O
n=21	O
)	O
or	O
control	Control
group	O
(	O
n=24	O
)	O
with	O
randomization	O
list	O
.	O

METHODOLOGY	O
For	O
the	O
treatment	O
group	O
,	O
forty-five	O
mg	O
of	O
Glakay	Pharmacological
was	O
given	O
orally	O
every	O
day	O
after	O
therapy	O
for	O
HCC	O
.	O

No	O
patients	O
complained	O
of	O
adverse	O
effects	O
.	O

Abdominal	O
ultrasonography	O
and	O
dynamic	Physical
CT	Physical
were	O
performed	O
at	O
3-month	O
intervals	O
.	O

Recurrence	O
was	O
confirmed	O
by	O
abdominal	Physical
angiography	Physical
.	O

RESULTS	O
Recurrence	O
of	O
HCC	O
occurred	O
in	O
7	O
cases	O
(	O
33.3	O
%	O
)	O
for	O
the	O
treatment	O
group	O
and	O
12	O
cases	O
(	O
50.0	O
%	O
)	O
for	O
the	O
control	O
group	O
during	O
mean	O
observation	O
periods	O
of	O
19.5	O
and	O
16.5	O
months	O
,	O
respectively	O
.	O

Administration	O
of	O
VK2	O
was	O
not	O
an	O
independent	O
variable	O
for	O
the	O
recurrence	O
on	O
univariate	O
analysis	O
.	O

Cumulative	O
incidence	O
of	O
HCC	O
recurrence	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
,	O
and	O
the	O
cumulative	O
survival	O
rate	O
tended	O
to	O
be	O
high	O
in	O
treatment	O
group	O
(	O
p	O
=0.054	O
)	O
.	O

Cox	O
regression	O
analysis	O
revealed	O
that	O
serum	O
albumin	O
concentration	O
alone	O
was	O
an	O
independent	O
factor	O
affecting	O
the	O
recurrence	O
.	O

CONCLUSIONS	O
These	O
findings	O
suggest	O
that	O
VK2	O
does	O
not	O
appear	O
to	O
prevent	O
recurrence	O
of	O
HCC	O
after	O
curative	O
treatment	O
.	O

Our	O
study	O
is	O
preliminary	O
and	O
large-scale	O
trials	O
are	O
needed	O
to	O
determine	O
whether	O
VK2	O
is	O
of	O
benefit	O
to	O
decrease	O
the	O
recurrence	O
of	O
HCC	O
.	O

[	O
Comparative	O
effects	O
of	O
nebivolol	Pharmacological
and	O
valsartan	Pharmacological
on	O
atrial	O
electromechanical	O
coupling	O
in	O
newly	O
diagnosed	O
stage	O
1	O
hypertensive	O
patients	O
]	O
.	O

OBJECTIVES	O
Hypertension	O
is	O
an	O
important	O
cardiovascular	O
risk	O
factor	O
for	O
the	O
development	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
.	O

Increased	O
atrial	O
electromechanical	O
coupling	O
time	O
interval	O
measured	O
by	O
tissue	O
Doppler	O
is	O
accepted	O
as	O
an	O
important	O
factor	O
for	O
prediction	O
of	O
AF	O
development	O
in	O
hypertensive	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
valsartan	Pharmacological
,	O
an	O
angiotensin	O
receptor	O
blocker	O
,	O
and	O
nebivolol	Pharmacological
,	O
a	O
beta-blocker	O
,	O
on	O
atrial	O
electromechanical	O
coupling	O
in	O
newly	O
diagnosed	O
stage	O
1	O
hypertensive	O
patients	O
.	O

STUDY	O
DESIGN	O
The	O
study	O
included	O
60	O
newly	O
diagnosed	O
stage	O
1	O
hypertensive	O
patients	O
with	O
no	O
other	O
systemic	O
disease	O
.	O

The	O
patients	O
were	O
randomized	O
to	O
receive	O
nebivolol	Pharmacological
5	Pharmacological
mg	Pharmacological
(	O
30	O
patients	O
;	O
21	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	O
48.4	O
?	O
11.4	O
years	O
)	O
and	O
valsartan	O
160	O
mg	O
(	O
30	O
patients	O
;	O
21	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	O
49.8	O
?	O
11.3	O
years	O
)	O
.	O

All	O
the	O
patients	O
underwent	O
tissue	O
Doppler	O
echocardiographic	O
examination	O
before	O
and	O
three	O
months	O
after	O
treatment	O
to	O
compare	O
the	O
effects	O
of	O
the	O
two	O
drugs	O
on	O
atrial	O
electromechanical	O
coupling	O
.	O

RESULTS	O
Baseline	O
blood	O
pressures	O
,	O
electrocardiographic	O
and	O
echocardiographic	O
findings	O
,	O
and	O
atrial	O
electromechanical	O
coupling	O
were	O
similar	O
in	O
both	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Both	O
drugs	O
significantly	O
reduced	O
blood	O
pressure	O
after	O
treatment	O
,	O
with	O
similar	O
efficacy	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Atrial	O
electromechanical	O
coupling	O
time	O
intervals	O
showed	O
significant	O
decreases	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
Prolonged	O
interatrial	O
electromechanical	O
time	O
intervals	O
in	O
hypertensives	O
are	O
improved	O
with	O
antihypertensive	O
treatment	O
.	O

Effects	O
of	O
a	O
dietetic	Physical
treatment	Physical
in	O
older	O
,	O
undernourished	O
,	O
community-dwelling	O
individuals	O
in	O
primary	O
care	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

PURPOSE	O
Undernutrition	O
is	O
a	O
prevalent	O
problem	O
in	O
older	O
,	O
community-dwelling	O
individuals	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
a	O
dietetic	Physical
treatment	Physical
in	O
older	O
,	O
undernourished	O
,	O
community-dwelling	O
individuals	O
.	O

METHODS	O
A	O
parallel	O
randomized	O
controlled	O
trial	O
was	O
performed	O
in	O
146	O
non-institutionalized	O
,	O
undernourished	O
individuals	O
aged	O
?65	O
years	O
in	O
primary	O
care	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
the	O
intervention	O
(	O
referral	O
to	O
and	O
treatment	O
by	O
a	O
trained	O
dietitian	O
)	O
or	O
control	O
group	O
(	O
no	O
referral	O
)	O
.	O

Body	O
weight	O
,	O
physical	O
performance	O
,	O
handgrip	O
strength	O
,	O
energy	O
intake	O
,	O
protein	O
intake	O
and	O
fat-free	O
mass	O
were	O
assessed	O
at	O
baseline	O
,	O
after	O
3	O
months	O
and	O
after	O
6	O
months	O
.	O

RESULTS	O
All	O
randomized	O
participants	O
(	O
n	O
=	O
146	O
)	O
were	O
included	O
in	O
the	O
intention-to-treat	O
generalized	O
estimating	O
equations	O
analysis	O
(	O
72	O
in	O
intervention	O
and	O
74	O
in	O
control	O
group	O
)	O
.	O

No	O
treatment	O
effect	O
was	O
found	O
on	O
the	O
primary	O
outcomes	O
body	O
weight	O
(	O
?	O
=	O
0.49	O
kg	O
,	O
95	O
%	O
CI	O
:	O
-0.15-1.12	O
)	O
,	O
physical	O
performance	O
(	O
?	O
=	O
0.15	O
points	O
,	O
95	O
%	O
CI	O
:	O
-0.33-0.64	O
)	O
and	O
handgrip	O
strength	O
(	O
?	O
=	O
0.49	O
kg	O
,	O
95	O
%	O
CI	O
:	O
-0.62-1.60	O
)	O
.	O

Furthermore	O
,	O
no	O
treatment	O
effect	O
was	O
found	O
for	O
the	O
secondary	O
outcomes	O
.	O

Predefined	O
subgroup	O
analyses	O
showed	O
a	O
treatment	O
effect	O
on	O
body	O
weight	O
in	O
physically	O
active	O
participants	O
(	O
?	O
=	O
1.25	O
kg	O
,	O
95	O
%	O
CI	O
:	O
0.70-2.11	O
)	O
and	O
not	O
in	O
inactive	O
participants	O
(	O
?	O
=	O
-0.20	O
kg	O
,	O
95	O
%	O
CI	O
:	O
-1.16-0.75	O
)	O
.	O

CONCLUSIONS	O
After	O
6	O
months	O
,	O
a	O
dietetic	O
treatment	O
by	O
trained	O
dietitians	O
does	O
not	O
lead	O
to	O
increases	O
in	O
body	O
weight	O
and	O
physical	O
functioning	O
in	O
older	O
,	O
undernourished	O
,	O
community-dwelling	O
individuals	O
.	O

Prevention	O
of	O
premature	O
labor	O
by	O
17	Pharmacological
alpha-hydroxyprogesterone	Pharmacological
caproate	Pharmacological
.	O

Eighty	O
pregnant	O
women	O
at	O
high	O
risk	O
of	O
giving	O
birth	O
prematurely	O
were	O
divided	O
randomly	O
into	O
two	O
groups	O
.	O

Treatment	O
with	O
either	O
17	Pharmacological
alpha-hydroxyprogesterone	Pharmacological
caproate	Pharmacological
,	O
250	O
mg	O
by	O
intramuscular	O
injection	O
once	O
a	O
week	O
,	O
or	O
a	O
placebo	Control
was	O
given	O
in	O
a	O
double-blind	O
fashion	O
.	O

Imminent	O
premature	O
labor	O
occurred	O
in	O
29.0	O
%	O
of	O
the	O
treated	O
group	O
and	O
in	O
59.4	O
%	O
of	O
the	O
control	Control
group	O
(	O
p	O
less	O
than	O
0.025	O
)	O
.	O

The	O
rate	O
of	O
premature	O
deliveries	O
was	O
also	O
significantly	O
lower	O
in	O
the	O
treated	O
group	O
(	O
16.1	O
%	O
)	O
than	O
in	O
the	O
control	O
group	O
(	O
37.82	O
%	O
)	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

There	O
were	O
no	O
cases	O
of	O
perinatal	O
death	O
or	O
fetal	O
malformations	O
in	O
either	O
group	O
.	O

The	O
mean	O
birth	O
weight	O
of	O
all	O
infants	O
of	O
the	O
treated	O
group	O
was	O
significantly	O
higher	O
than	O
in	O
those	O
of	O
the	O
control	O
group	O
(	O
3111.9	O
+/-	O
905	O
gm	O
versus	O
2680	O
+/-	O
813.4	O
gm	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
results	O
support	O
treatment	O
with	O
progesterone	Pharmacological
caproate	Pharmacological
for	O
the	O
prevention	O
of	O
premature	O
labor	O
.	O

A	O
randomised	O
comparison	O
of	O
the	O
self-pressurised	O
air-QTM	O
intubating	O
laryngeal	Other
airway	O
with	O
the	O
LMA	O
Unique?	O
in	O
children	O
.	O

We	O
conducted	O
a	O
randomised	O
trial	O
comparing	O
the	O
self-pressurised	O
air-Q?	O
intubating	O
laryngeal	O
airway	O
(	O
air-Q	O
SP	O
)	O
with	O
the	O
LMA-Unique	O
in	O
60	O
children	O
undergoing	O
surgery	O
.	O

Outcomes	O
measured	O
were	O
airway	O
leak	O
pressure	O
,	O
ease	O
and	O
time	O
for	O
insertion	O
,	O
fibreoptic	O
examination	O
,	O
incidence	O
of	O
gastric	O
insufflation	O
and	O
complications	O
.	O

Median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
to	O
successful	O
device	O
placement	O
was	O
faster	O
with	O
the	O
air-Q	O
SP	O
(	O
12	O
(	O
10-15	O
[	O
5-18	O
]	O
)	O
)	O
s	O
than	O
with	O
the	O
LMA-Unique	O
(	O
14	O
(	O
12-17	O
[	O
6-22	O
]	O
)	O
s	O
;	O
p=0.05	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
air-Q	O
SP	O
and	O
LMA-Unique	O
in	O
initial	O
airway	O
leak	O
pressures	O
(	O
16	O
(	O
14-18	O
[	O
10-29	O
]	O
)	O
compared	O
with	O
18	O
(	O
15-20	O
[	O
10-30	O
]	O
)	O
cmH2	O
O	O
,	O
p=0.12	O
)	O
,	O
an	O
airway	O
leak	O
pressures	O
at	O
10	O
min	O
(	O
19	O
(	O
16-22	O
[	O
12-30	O
]	O
)	O
compared	O
with	O
20	O
(	O
16-22	O
[	O
10-30	O
]	O
)	O
cmH2	O
O	O
,	O
p=0.81	O
)	O
;	O
fibreoptic	O
position	O
,	O
incidence	O
of	O
gastric	O
insufflation	O
,	O
or	O
complications	O
.	O

Both	O
devices	O
provided	O
effective	O
ventilation	O
without	O
the	O
need	O
for	O
airway	O
manipulation	O
.	O

The	O
air-Q	O
SP	O
is	O
an	O
alternative	O
to	O
the	O
LMA-Unique	O
should	O
the	O
clinician	O
prefer	O
a	O
device	O
not	O
requiring	O
cuff	O
monitoring	O
during	O
anaesthesia	O
.	O

Loss	O
of	O
tooth	O
substance	O
during	O
root	Physical
planing	Physical
with	O
various	O
periodontal	O
instruments	O
:	O
an	O
in	O
vitro	O
study	O
.	O

Ultrasonic	Physical
and	Physical
power-driven	Physical
instrumentation	Physical
is	O
gaining	O
in	O
significance	O
as	O
an	O
acceptable	O
alternative	O
to	O
manual	O
periodontal	O
root	O
treatment	O
.	O

Some	O
question	O
whether	O
they	O
do	O
not	O
remove	O
too	O
much	O
tooth	O
substance	O
.	O

Various	Educational
ultrasonic	Physical
scalers	Physical
,	Educational
hand	Physical
instruments	Physical
and	Educational
two	Physical
power-driven	Physical
systems	Physical
were	O
compared	O
by	O
assessing	O
the	O
loss	O
of	O
tooth	O
substance	O
due	O
to	O
root	O
instrumentation	O
.	O

Quantitative	O
analysis	O
of	O
this	O
effect	O
of	O
the	O
instruments	O
used	O
was	O
performed	O
on	O
20	O
freshly	O
extracted	O
,	O
non-periodontally	O
involved	O
,	O
large	O
human	O
molars	O
.	O

In	O
the	O
first	O
study	O
,	O
40	O
specimens	O
were	O
randomly	O
assigned	O
to	O
four	O
groups	O
of	O
treatment	O
:	O
combined	O
use	O
of	O
ultrasonic	Physical
scaler	Physical
and	Physical
Periopolisher	Physical
diamond-coated	Physical
inserts	Physical
(	Physical
US-POL	Physical
)	Physical
,	Educational
hand	Physical
instruments	Physical
(	Physical
MANUAL	Physical
)	Physical
,	Educational
Perioplaner-Periopolisher	Physical
system	Physical
(	Physical
PPL-POL	Physical
)	Physical
and	Educational
Periokit	Physical
ultrasonic-designed	Physical
scalers	Physical
(	Physical
PERIOKIT	Physical
)	Physical
.	Educational

The	O
second	O
study	O
involved	O
two	O
treatment	O
groups	O
,	O
ultrasonic	Physical
scaler	Physical
alone	Other
and	Other
hand	Physical
instruments	Physical
,	O
each	O
allocated	O
with	O
20	O
teeth	O
(	O
small	O
root	O
fragments	O
)	O
.	O

An	O
unpaired	O
two-tailed	O
t	O
test	O
was	O
carried	O
out	O
for	O
both	O
studies	O
to	O
compare	O
the	O
average	O
weight	O
loss	O
of	O
root	O
substance	O
with	O
the	O
modes	O
of	O
instrumentation	O
.	O

The	O
level	O
of	O
significance	O
was	O
set	O
at	O
p	O
<	O
or=0.05	O
.	O

The	O
overall	O
results	O
of	O
the	O
first	O
and	O
second	O
experimental	O
trials	O
did	O
not	O
reveal	O
obvious	O
differences	O
in	O
weight	O
loss	O
between	O
the	O
manual	O
,	O
ultrasonic	O
or	O
power-driven	O
root	O
treatments	O
.	O

Based	O
on	O
the	O
results	O
of	O
these	O
two	O
comparative	O
studies	O
,	O
the	O
power-driven	O
inserts	O
or	O
the	O
various	O
ultrasonic	O
scalers	O
tested	O
did	O
not	O
remove	O
more	O
tooth	O
substance	O
than	O
conventional	O
hand	O
instruments	O
.	O

They	O
may	O
thus	O
be	O
a	O
useful	O
alternative	O
for	O
the	O
debridement	O
of	O
root	O
surfaces	O
.	O

Controlled	O
study	O
on	O
the	O
therapeutic	O
efficacy	O
of	O
propionyl-L-carnitine	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

A	O
double-blind	O
phase	O
II	O
study	O
of	O
propionyl-L-carnitine	O
(	O
CAS	O
17298-37-2	O
)	O
versus	O
placebo	O
was	O
carried	O
out	O
on	O
a	O
group	O
of	O
60	O
patients	O
with	O
mild	O
to	O
moderate	O
(	O
II	O
and	O
III	O
NYHA	O
class	O
)	O
congestive	O
heart	O
failure	O
.	O

The	O
group	O
was	O
made	O
up	O
of	O
men	O
and	O
women	O
aged	O
between	O
48	O
and	O
73	O
years	O
in	O
chronic	O
treatment	O
with	O
digitalis	O
and	O
diuretics	O
for	O
at	O
least	O
3	O
months	O
and	O
who	O
still	O
displayed	O
symptoms	O
.	O

Thirty	O
of	O
these	O
patients	O
were	O
chosen	O
randomly	O
and	O
for	O
180	O
days	O
,	O
500	Pharmacological
mg	Pharmacological
of	Pharmacological
propionyl-L-carnitine	Pharmacological
was	O
orally	O
administered	O
,	O
3	O
times	O
a	O
day	O
in	O
addition	O
to	O
their	O
usual	O
treatment	O
.	O

At	O
basal	O
conditions	O
and	O
after	O
30	O
,	O
90	O
and	O
180	O
days	O
the	O
maximum	O
exercise	O
time	O
was	O
evaluated	O
using	O
an	O
exercise	Physical
tolerance	Physical
test	Physical
performed	O
on	O
an	O
ergometer	O
bicycle	O
and	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
was	O
tested	O
by	O
means	O
of	O
bidimensional	Surgical
echocardiography	Surgical
.	O

After	O
one	O
month	O
of	O
treatment	O
,	O
the	O
patients	O
treated	O
with	O
propionyl-L-carnitine	O
,	O
compared	O
to	O
the	O
control	O
group	O
,	O
showed	O
significant	O
increases	O
in	O
the	O
values	O
of	O
both	O
tests	O
,	O
increases	O
which	O
became	O
even	O
more	O
evident	O
after	O
90	O
and	O
180	O
days	O
.	O

At	O
the	O
stated	O
times	O
the	O
increases	O
in	O
the	O
maximum	O
exercise	O
time	O
were	O
16.4	O
%	O
,	O
22.9	O
%	O
,	O
and	O
25.9	O
%	O
,	O
respectively	O
.	O

The	O
ventricular	O
ejection	O
fraction	O
increased	O
by	O
8.4	O
%	O
,	O
11.6	O
%	O
and	O
13.6	O
%	O
,	O
respectively	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
having	O
studied	O
the	O
particular	O
mechanism	O
of	O
action	O
of	O
propionyl-L-carnitine	O
the	O
authors	O
conclude	O
that	O
it	O
represents	O
a	O
drug	O
of	O
undoubted	O
therapeutic	O
interest	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
in	O
whom	O
it	O
could	O
be	O
efficaciously	O
administered	O
along	O
with	O
a	O
standard	O
pharmacological	O
therapy	O
.	O

Effect	O
of	O
clinical	O
context	O
on	O
simulator-based	O
assessment	O
of	O
blood	O
pressure	O
taking	O
-	O
a	O
pilot	O
randomized	O
study	O
.	O

BACKGROUND	O
Blood	O
pressure	O
measurement	O
is	O
an	O
essential	O
clinical	O
skill	O
that	O
can	O
readily	O
be	O
assessed	O
in	O
objective	O
structured	O
clinical	O
examination	O
(	O
OSCE	O
)	O
.	O

While	O
the	O
use	O
of	O
simulators	Other
can	O
enhance	O
test	O
validity	O
and	O
reliability	O
,	O
the	O
given	O
clinical	O
context	O
may	O
also	O
affect	O
student	O
performance	O
.	O

AIMS	O
To	O
investigate	O
the	O
impact	O
of	O
variations	O
in	O
clinical	O
context	O
on	O
blood	O
pressure	O
measurement	O
in	O
a	O
simulator-based	Other
OSCE	Other
.	O

METHOD	O
We	O
randomized	O
162	O
first-year	O
medical	O
students	O
into	O
four	O
groups	O
that	O
received	O
different	O
lead-in	O
statements	O
before	O
measuring	O
blood	O
pressure	O
on	O
a	O
manikin	Other
simulator	Other
.	O

These	O
statements	O
described	O
hypothetical	O
patients	O
with	O
different	O
likelihoods	O
of	O
having	O
systemic	O
hypertension	O
.	O

RESULTS	O
The	O
lead-in	O
that	O
described	O
the	O
highest	O
likelihood	O
of	O
hypertension	O
was	O
associated	O
with	O
significantly	O
higher	O
reported	O
readings	O
and	O
lower	O
accuracy	O
.	O

The	O
lead-in	O
that	O
suggested	O
normality	O
yielded	O
the	O
best	O
performance	O
.	O

CONCLUSION	O
Student	O
performance	O
in	O
simulator-based	Other
OSCE	Other
may	O
be	O
affected	O
by	O
the	O
clinical	O
context	O
provided	O
.	O

However	O
,	O
we	O
argue	O
that	O
construct	O
validity	O
should	O
be	O
viewed	O
in	O
light	O
of	O
the	O
application	O
of	O
a	O
test	O
,	O
in	O
that	O
patients	O
may	O
also	O
present	O
with	O
different	O
cues	O
and	O
likelihoods	O
of	O
having	O
hypertension	O
.	O

Variations	O
in	O
construct	O
design	O
should	O
be	O
further	O
explored	O
to	O
enhance	O
the	O
training	O
and	O
assessment	O
of	O
clinical	O
competence	O
that	O
reflects	O
the	O
unpredictability	O
encountered	O
in	O
daily	O
clinical	O
practice	O
.	O

Laser	Physical
therapy	Physical
combined	Physical
with	Physical
brachytherapy	Physical
for	O
the	O
palliation	O
of	O
malignant	O
dysphagia	O
.	O

BACKGROUND/AIM	O
OF	O
STUDY	O
Laser	Physical
therapy	Physical
is	O
effective	O
in	O
relieving	O
malignant	O
dysphagia	O
,	O
but	O
repeated	O
treatments	O
at	O
4	O
to	O
6	O
week	O
intervals	O
are	O
usually	O
required	O
.	O

This	O
prospective	O
randomised	O
trial	O
is	O
designed	O
to	O
determine	O
if	O
addition	O
of	O
brachytherapy	O
offers	O
any	O
advantages	O
over	O
laser	Physical
therapy	Physical
alone	O
.	O

METHODS	O
Patients	O
with	O
inoperable	O
carcinoma	O
of	O
the	O
oesophagus	O
were	O
randomised	O
to	O
receive	O
either	O
endoscopic	Physical
Nd	Physical
:	Physical
YAG	Physical
laser	Physical
therapy	Physical
alone	O
,	O
or	O
laser	Physical
followed	O
by	O
brachytherapy	Physical
.	O

Patients	O
who	O
developed	O
worsening	O
dysphagia	O
during	O
follow-up	O
were	O
offered	O
further	O
treatment	O
as	O
appropriate	O
.	O

RESULTS	O
Fourteen	O
patients	O
were	O
randomised	O
to	O
receive	O
laser	Physical
only	Physical
,	O
and	O
12	O
to	O
receive	O
laser	O
followed	O
by	O
brachytherapy	Physical
.	O

Of	O
these	O
12	O
,	O
one	O
was	O
lost	O
to	O
follow-up	O
and	O
four	O
did	O
not	O
receive	O
brachytherapy	Physical
because	O
they	O
were	O
unfit	O
,	O
had	O
extension	O
into	O
the	O
cardia	O
or	O
had	O
mainly	O
extrinsic	O
compression	O
.	O

These	O
4	O
are	O
included	O
on	O
an	O
'intention-to-treat	O
'	O
basis	O
.	O

The	O
mean	O
therapeutic	O
interval	O
for	O
the	O
brachytherapy	O
group	O
was	O
significantly	O
longer	O
,	O
83	O
days	O
compared	O
to	O
36	O
days	O
for	O
the	O
laser	O
group	O
(	O
p	O
=	O
0.026	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
degree	O
of	O
dysphagia	O
relief	O
,	O
number	O
of	O
endoscopic	O
procedures	O
or	O
survival	O
times	O
.	O

CONCLUSION	O
The	O
preliminary	O
results	O
of	O
this	O
trial	O
suggest	O
that	O
brachytherapy	Physical
in	O
addition	O
to	O
laser	O
therapy	O
prolongs	O
the	O
first	O
therapeutic	O
interval	O
.	O

However	O
,	O
no	O
long-term	O
advantages	O
have	O
been	O
shown	O
.	O

Bites	O
by	O
the	O
saw-scaled	O
or	O
carpet	O
viper	O
(	O
Echis	O
carinatus	O
)	O
:	O
trial	O
of	O
two	O
specific	O
antivenoms	O
.	O

Echis	O
carinatus	O
is	O
the	O
most	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
from	O
snake	O
bite	O
in	O
Nigeria	O
and	O
in	O
many	O
other	O
parts	O
of	O
the	O
world	O
.	O

Forty-six	O
patients	O
with	O
systemic	O
poisoning	O
by	O
this	O
snake	O
were	O
given	O
echis	Pharmacological
antivenom	Pharmacological
made	Pharmacological
either	Pharmacological
by	Pharmacological
the	Pharmacological
South	Pharmacological
African	Pharmacological
Institute	Pharmacological
for	Pharmacological
Medical	Pharmacological
Research	Pharmacological
(	Pharmacological
S.A.I.M.R	Pharmacological
.	Pharmacological

)	Pharmacological
or	O
by	O
Behringwerke	O
(	O
North	O
and	O
West	O
African	O
polyvalent	O
antivenom	O
)	O
.	O

A	O
simple	O
test	O
of	O
blood	O
coagulability	O
was	O
used	O
to	O
assess	O
whether	O
an	O
adequate	O
neutralizing	O
dose	O
of	O
antivenom	O
had	O
been	O
given	O
.	O

An	O
average	O
of	O
15.2	O
ml	O
S.A.I.M.R	Pharmacological
.	Pharmacological

antivenom	O
restored	O
normal	O
coagulability	O
permanently	O
in	O
all	O
23	O
patients	O
in	O
one	O
group	O
,	O
but	O
in	O
the	O
other	O
group	O
receiving	O
an	O
average	O
dose	O
of	O
37.9	O
ml	O
Behringwerke	Pharmacological
antivenom	Pharmacological
normal	O
clotting	O
resulted	O
in	O
only	O
18	O
out	O
of	O
23	O
patients	O
.	O

Local	O
tissue	O
swelling	O
was	O
similar	O
in	O
both	O
groups	O
,	O
but	O
local	O
necrosis	O
occurred	O
in	O
three	O
patients	O
treated	O
with	O
Behringwerke	Pharmacological
antivenom	Pharmacological
and	O
in	O
none	O
given	O
S.A.I.M.R	O
.	O

antivenom	O
.	O

[	O
Preventive	O
use	O
of	O
Pentaglobin	Pharmacological
in	O
intensive	O
care	O
treatment	O
of	O
trauma	O
patients	O
]	O
.	O

Basing	O
on	O
50	O
posttraumatic	O
intensive-care	O
patients	O
with	O
medium	O
grade	O
lesions	O
(	O
ISS	O
criteria	O
)	O
,	O
the	O
prophylactic	O
effect	O
of	O
an	O
intravenously	O
applicable	O
IgM	O
preparation	O
(	O
Pentaglobin	Pharmacological
)	O
against	O
nosocomial	O
infections	O
was	O
investigated	O
.	O

The	O
prophylaxis	O
group	O
received	O
on	O
the	O
3rd	O
,	O
4th	O
and	O
5th	O
day	O
a	O
daily	O
dose	O
of	O
10	O
g	O
each	O
.	O

At	O
the	O
same	O
times	O
the	O
controls	O
were	O
given	O
12.5	Pharmacological
g	Pharmacological
human	Pharmacological
albumin	Pharmacological
each	O
.	O

Whereas	O
no	O
difference	O
was	O
seen	O
between	O
both	O
groups	O
regarding	O
the	O
definitive	O
outcome	O
of	O
the	O
treatment	O
,	O
the	O
prophylaxis	O
group	O
clearly	O
showed	O
fewer	O
infection	O
pointers	O
during	O
the	O
clinical	O
course	O
.	O

In	O
particular	O
,	O
the	O
incidence	O
and	O
magnitude	O
of	O
febrile	O
temperatures	O
were	O
significantly	O
lower	O
between	O
the	O
4th	O
and	O
8th	O
days	O
of	O
treatment	O
.	O

Our	O
results	O
indicate	O
,	O
however	O
,	O
that	O
the	O
prophylactic	O
use	O
those	O
patients	O
who	O
are	O
at	O
particularly	O
high	O
infection	O
exposure	O
risk	O
,	O
e.g	O
.	O

through	O
reintervention	O
surgery	O
,	O
haemorrhage	O
complications	O
or	O
extensive	O
diagnostic	O
interventions	O
.	O

The	O
effectiveness	O
of	O
a	O
calcium	O
sodium	O
phosphosilicate	O
desensitizer	O
in	O
reducing	O
cervical	O
dentin	O
hypersensitivity	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
NovaMin	O
(	O
NovaMin	O
Technology	O
,	O
Alachua	O
,	O
Fla.	O
)	O
was	O
introduced	O
into	O
the	O
dental	O
market	O
as	O
a	O
desensitizer	O
in	O
December	O
2004	O
.	O

However	O
,	O
to	O
the	O
authors	O
'	O
knowledge	O
,	O
no	O
researchers	O
yet	O
have	O
evaluated	O
the	O
effectiveness	O
of	O
100	O
percent	O
NovaMin	O
powder	O
with	O
NovaMin-containing	O
toothpaste	O
in	O
reducing	O
dentin	O
hypersensitivity	O
compared	O
with	O
the	O
effectiveness	O
of	O
NovaMin-containing	O
toothpaste	O
only	O
and	O
a	O
desensitizing	O
toothpaste	O
containing	O
potassium	O
nitrate	O
as	O
a	O
control	O
.	O

METHODS	O
The	O
authors	O
divided	O
60	O
participants	O
randomly	O
into	O
three	O
groups	O
:	O
NovaMin	Pharmacological
powder	Pharmacological
with	O
NovaMin-containing	Pharmacological
toothpaste	Pharmacological
(	O
group	O
1	O
)	O
,	O
a	O
placebo	Control
powder	Control
with	O
NovaMin-containing	Pharmacological
toothpaste	Pharmacological
(	O
group	O
2	O
)	O
and	O
a	O
placebo	Pharmacological
powder	Pharmacological
with	O
the	O
control	Pharmacological
toothpaste	Pharmacological
(	O
group	O
3	O
)	O
.	O

The	O
authors	O
used	O
tactile	O
and	O
cold	O
stimuli	O
and	O
a	O
visual	O
analog	O
scale	O
to	O
evaluate	O
participants	O
'	O
pain	O
at	O
baseline	O
,	O
immediately	O
after	O
powder	O
application	O
and	O
at	O
one	O
week	O
,	O
two	O
weeks	O
and	O
four	O
weeks	O
after	O
powder	O
application	O
.	O

They	O
analyzed	O
data	O
by	O
using	O
Friedman	O
and	O
Wilcoxon	O
signed-rank	O
tests	O
for	O
within-group	O
comparison	O
.	O

They	O
used	O
Kruskal-Wallis	O
and	O
Mann-Whitney	O
U	O
tests	O
for	O
between-group	O
comparison	O
.	O

They	O
considered	O
P	O
<	O
.05	O
to	O
be	O
statistically	O
significant	O
.	O

RESULTS	O
Groups	O
1	O
and	O
2	O
showed	O
significant	O
hypersensitivity	O
reduction	O
over	O
baseline	O
at	O
all	O
time	O
points	O
.	O

Group	O
3	O
showed	O
significant	O
hypersensitivity	O
reduction	O
at	O
one	O
week	O
onward	O
.	O

Group	O
1	O
showed	O
significant	O
improvement	O
compared	O
with	O
groups	O
2	O
and	O
3	O
,	O
except	O
for	O
response	O
to	O
tactile	O
stimulus	O
at	O
four	O
weeks	O
with	O
group	O
2	O
.	O

Between	O
groups	O
2	O
and	O
3	O
,	O
there	O
were	O
significant	O
differences	O
at	O
two	O
and	O
four	O
weeks	O
.	O

CONCLUSIONS	O
and	O
CLINICAL	O
IMPLICATIONS	O
The	O
use	O
of	O
NovaMin	O
powder	O
and	O
NovaMin-containing	O
toothpaste	O
for	O
hypersensitivity	O
reduction	O
is	O
more	O
effective	O
than	O
the	O
use	O
of	O
a	O
desensitizing	O
toothpaste	O
containing	O
potassium	O
nitrate	O
and	O
fluoride	O
.	O

Cognitive	Educational
behavioral	Educational
therapy	Educational
for	O
anxiety	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

BACKGROUND	O
Children	O
with	O
autism	O
spectrum	O
disorders	O
often	O
present	O
with	O
comorbid	O
anxiety	O
disorders	O
that	O
cause	O
significant	O
functional	O
impairment	O
.	O

This	O
study	O
tested	O
a	O
modular	O
cognitive	Educational
behavioral	Educational
therapy	Educational
(	Educational
CBT	Educational
)	Educational
program	O
for	O
children	O
with	O
this	O
profile	O
.	O

A	O
standard	O
CBT	Educational
program	O
was	O
augmented	O
with	O
multiple	O
treatment	O
components	O
designed	O
to	O
accommodate	O
or	O
remediate	O
the	O
social	O
and	O
adaptive	O
skill	O
deficits	O
of	O
children	O
with	O
ASD	O
that	O
could	O
pose	O
barriers	O
to	O
anxiety	O
reduction	O
.	O

METHOD	O
Forty	O
children	O
(	O
7-11	O
years	O
old	O
)	O
were	O
randomly	O
assigned	O
to	O
16	O
sessions	O
of	O
CBT	Educational
or	O
a	O
3-month	Educational
waitlist	Educational
(	O
36	O
completed	O
treatment	O
or	O
waitlist	O
)	O
.	O

Therapists	O
worked	O
with	O
individual	O
families	O
.	O

The	O
CBT	Educational
model	O
emphasized	O
behavioral	O
experimentation	O
,	O
parent-training	O
,	O
and	O
school	O
consultation	O
.	O

Independent	O
evaluators	O
blind	O
to	O
treatment	O
condition	O
conducted	O
structured	O
diagnostic	O
interviews	O
and	O
parents	O
and	O
children	O
completed	O
anxiety	O
symptom	O
checklists	O
at	O
baseline	O
and	O
posttreatment/postwaitlist	O
.	O

RESULTS	O
In	O
intent-to-treat	O
analyses	O
,	O
78.5	O
%	O
of	O
the	O
CBT	Educational
group	O
met	O
Clinical	O
Global	O
Impressions-Improvement	O
scale	O
criteria	O
for	O
positive	O
treatment	O
response	O
at	O
posttreatment	O
,	O
as	O
compared	O
to	O
only	O
8.7	O
%	O
of	O
the	O
waitlist	Educational
group	O
.	O

CBT	Educational
also	O
outperformed	O
the	O
waitlist	Educational
on	O
diagnostic	O
outcomes	O
and	O
parent	O
reports	O
of	O
child	O
anxiety	O
,	O
but	O
not	O
children	O
's	O
self-reports	O
.	O

Treatment	O
gains	O
were	O
maintained	O
at	O
3-month	O
follow-up	O
.	O

CONCLUSIONS	O
The	O
CBT	Educational
manual	O
employed	O
in	O
this	O
study	O
is	O
one	O
of	O
the	O
first	O
adaptations	O
of	O
an	O
evidence-based	O
treatment	O
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Remission	O
of	O
anxiety	O
disorders	O
appears	O
to	O
be	O
an	O
achievable	O
goal	O
among	O
high-functioning	O
children	O
with	O
autism	O
.	O

Combined	O
therapy	O
for	O
obese	O
type	O
2	O
diabetes	O
:	O
suppertime	Pharmacological
mixed	Pharmacological
insulin	Pharmacological
with	Pharmacological
daytime	Pharmacological
sulfonylurea	Pharmacological
.	O

Combined	Pharmacological
insulin	Pharmacological
and	Pharmacological
sulfonylurea	Pharmacological
therapy	Pharmacological
for	O
type	O
2	O
diabetes	O
may	O
improve	O
the	O
effectiveness	O
of	O
a	O
single	O
injection	Pharmacological
of	Pharmacological
insulin	Pharmacological
,	O
thereby	O
postponing	O
the	O
need	O
for	O
multiple	O
injections	O
.	O

This	O
concept	O
was	O
tested	O
in	O
21	O
obese	O
subjects	O
imperfectly	O
controlled	O
by	O
20	Pharmacological
mg	Pharmacological
of	Pharmacological
glyburide	Pharmacological
daily	Pharmacological
in	O
a	O
double	O
masked	O
,	O
placebo-controlled	Control
,	O
parallel	O
design	O
,	O
16-week	O
protocol	O
.	O

Premixed	O
70	O
%	O
NPH/30	O
%	O
Regular	Pharmacological
insulin	Pharmacological
was	O
taken	O
before	O
supper	O
,	O
and	O
the	O
dosage	O
was	O
adjusted	O
weekly	O
by	O
an	O
algorithm	O
seeking	O
nearly	O
normal	O
fasting	O
glycemia	O
.	O

Eleven	O
subjects	O
using	O
insulin	Pharmacological
plus	Pharmacological
10	O
mg	O
glyburide	Pharmacological
before	O
breakfast	O
had	O
lower	O
mean	O
fasting	O
glucose	O
at	O
10-16	O
weeks	O
than	O
10	O
subjects	O
using	O
insulin	O
with	O
placebo	Control
(	O
mean	O
+/-	O
SEM	O
;	O
5.9	O
+/-	O
0.3	O
versus	O
7.5	O
+/-	O
0.7	O
mmol/L	O
;	O
p	O
less	O
than	O
0.05	O
)	O
,	O
and	O
had	O
a	O
greater	O
decrement	O
of	O
glycosylated	O
hemoglobin	O
from	O
baseline	O
values	O
(	O
1.3	O
+/-	O
0.1	O
versus	O
0.8	O
+/-	O
0.2	O
%	O
A1	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

After	O
16	O
weeks	O
the	O
combined	O
therapy	O
group	O
used	O
half	O
as	O
much	O
insulin	O
as	O
the	O
insulin-only	O
group	O
(	O
50	O
+/-	O
5	O
versus	O
101	O
+/-	O
13	O
units/d	O
;	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Fasting	O
serum	O
free	O
insulin	O
values	O
increased	O
58	O
%	O
from	O
baseline	O
after	O
insulin	O
therapy	O
in	O
the	O
insulin-only	O
group	O
(	O
p	O
less	O
than	O
0.05	O
)	O
but	O
did	O
not	O
increase	O
with	O
combined	O
therapy	O
.	O

Weight	O
gain	O
was	O
similar	O
in	O
the	O
two	O
groups	O
.	O

These	O
data	O
support	O
this	O
form	O
of	O
combined	O
therapy	O
as	O
one	O
option	O
for	O
treating	O
obese	O
persons	O
with	O
type	O
2	O
diabetes	O
no	O
longer	O
responsive	O
to	O
oral	O
therapy	O
alone	O
.	O

Effects	O
of	O
a	O
long-term	O
vitamin	Pharmacological
D	Pharmacological
and	O
calcium	Pharmacological
supplementation	Pharmacological
on	O
falls	O
and	O
parameters	O
of	O
muscle	O
function	O
in	O
community-dwelling	O
older	O
individuals	O
.	O

UNLABELLED	O
In	O
242	O
community-dwelling	O
seniors	O
,	O
supplementation	O
with	O
either	O
1000	O
mg	O
of	O
calcium	Pharmacological
or	O
1000	O
mg	O
of	O
calcium	Pharmacological
plus	Pharmacological
vitamin	Pharmacological
D	Pharmacological
resulted	O
in	O
a	O
decrease	O
in	O
the	O
number	O
of	O
subjects	O
with	O
first	O
falls	O
of	O
27	O
%	O
at	O
month	O
12	O
and	O
39	O
%	O
at	O
month	O
20	O
.	O

Additionally	O
,	O
parameters	O
of	O
muscle	O
function	O
improved	O
significantly	O
.	O

INTRODUCTION	O
The	O
efficacy	O
of	O
vitamin	Pharmacological
D	Pharmacological
and	O
calcium	Pharmacological
supplementation	O
on	O
risk	O
of	O
falling	O
in	O
the	O
elderly	O
is	O
discussed	O
controversially	O
.	O

Randomized	O
controlled	O
trials	O
using	O
falls	O
as	O
primary	O
outcome	O
are	O
needed	O
.	O

We	O
investigated	O
long-term	O
effects	O
of	O
calcium	Pharmacological
and	O
vitamin	Pharmacological
D	Pharmacological
on	O
falls	O
and	O
parameters	O
of	O
muscle	O
function	O
in	O
community-dwelling	O
elderly	O
women	O
and	O
men	O
.	O

METHODS	O
Our	O
study	O
population	O
consisted	O
of	O
242	O
individuals	O
recruited	O
by	O
advertisements	O
and	O
mailing	O
lists	O
(	O
mean	O
[	O
+/-	O
SD	O
]	O
age	O
,	O
77	O
+/-	O
4	O
years	O
)	O
.	O

All	O
serum	O
25-hydroxyvitamin	O
D	O
(	O
25	O
[	O
OH	O
]	O
D	O
)	O
levels	O
were	O
below	O
78	O
nmol/l	O
.	O

Individuals	O
received	O
in	O
a	O
double	O
blinded	O
fashion	O
either	O
1000	O
mg	O
of	O
calcium	Pharmacological
or	O
1000	O
mg	O
of	O
calcium	Pharmacological
plus	O
800	O
IU	O
of	O
vitamin	Pharmacological
D	Pharmacological
per	O
day	O
over	O
a	O
treatment	O
period	O
of	O
12	O
months	O
,	O
which	O
was	O
followed	O
by	O
a	O
treatment-free	O
but	O
still	O
blinded	O
observation	O
period	O
of	O
8	O
months	O
.	O

Falls	O
were	O
documented	O
using	O
diaries	O
.	O

The	O
study	O
took	O
place	O
in	O
Bad	O
Pyrmont	O
,	O
Germany	O
(	O
latitude	O
52	O
degrees	O
)	O
and	O
Graz	O
,	O
Austria	O
(	O
latitude	O
46	O
degrees	O
)	O
.	O

RESULTS	O
Compared	O
to	O
calcium	O
mono	O
,	O
supplementation	O
with	O
calcium	O
plus	O
vitamin	Pharmacological
D	Pharmacological
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
number	O
of	O
subjects	O
with	O
first	O
falls	O
of	O
27	O
%	O
at	O
month	O
12	O
(	O
RR	O
=	O
0.73	O
;	O
CI	O
=	O
0.54-0.96	O
)	O
and	O
39	O
%	O
at	O
month	O
20	O
(	O
RR	O
=	O
0.61	O
;	O
CI	O
=	O
0.34-0.76	O
)	O
.	O

Concerning	O
secondary	O
endpoints	O
,	O
we	O
observed	O
significant	O
improvements	O
in	O
quadriceps	O
strength	O
of	O
8	O
%	O
,	O
a	O
decrease	O
in	O
body	O
sway	O
of	O
28	O
%	O
,	O
and	O
a	O
decrease	O
in	O
time	O
needed	O
to	O
perform	O
the	O
TUG	O
test	O
of	O
11	O
%	O
.	O

DISCUSSION	O
Combined	O
calcium	Pharmacological
and	O
vitamin	Pharmacological
D	Pharmacological
supplementation	O
proved	O
superior	O
to	O
calcium	O
alone	O
in	O
reducing	O
the	O
number	O
of	O
falls	O
and	O
improving	O
muscle	O
function	O
in	O
community-dwelling	O
older	O
individuals	O
.	O

Effects	O
of	O
flumazenil	Pharmacological
on	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
consumption	O
after	O
midazolam	Pharmacological
anaesthesia	O
for	O
craniotomy	Pharmacological
.	O

Cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	O
(	O
CMRO2	O
)	O
were	O
measured	O
by	O
a	O
modification	O
of	O
the	O
Kety-Schmidt	O
technique	O
using	O
i.v	O
.	O

xenon-133	O
in	O
20	O
patients	O
undergoing	O
craniotomy	O
for	O
supratentorial	O
cerebral	O
tumours	O
.	O

Anaesthesia	O
was	O
induced	O
and	O
maintained	O
with	O
midazolam	Pharmacological
,	O
fentanyl	Pharmacological
and	O
nitrous	Pharmacological
oxide	Pharmacological
.	O

Pancuronium	Pharmacological
was	O
given	O
for	O
neuromuscular	O
block	O
.	O

The	O
lungs	O
were	O
ventilated	O
to	O
normocapnia	O
.	O

The	O
first	O
flow	O
measurements	O
were	O
performed	O
approximately	O
1	O
h	O
after	O
induction	O
of	O
anaesthesia	O
.	O

At	O
the	O
end	O
of	O
operation	O
the	O
patients	O
were	O
allocated	O
to	O
two	O
groups	O
.	O

Ten	O
patients	O
were	O
given	O
flumazenil	Pharmacological
0.01	O
mg	O
kg-1	O
and	O
5	O
min	O
later	O
the	O
second	O
flow	O
measurement	O
was	O
performed	O
.	O

In	O
the	O
other	O
10	O
patients	O
the	O
second	O
flow	O
measurement	O
was	O
performed	O
before	O
the	O
administration	O
of	O
flumazenil	Pharmacological
.	O

Plasma	O
concentrations	O
of	O
midazolam	Pharmacological
were	O
measured	O
at	O
the	O
time	O
of	O
each	O
measurement	O
of	O
CBF	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
plasma	O
concentration	O
of	O
midazolam	Pharmacological
,	O
CBF	O
or	O
CMRO2	O
.	O

Flumazenil	Pharmacological
had	O
no	O
effect	O
on	O
CBF	O
and	O
CMRO2	O
.	O

Clinic	O
visit	O
and	O
waiting	O
:	O
patient	Educational
education	Educational
and	O
satisfaction	O
.	O

Patients	Physical
who	Physical
were	Physical
taught	Physical
about	Physical
their	Physical
health	Physical
problems	Physical
while	Physical
waiting	Physical
in	Physical
the	Physical
clinic	Physical
(	O
n	O
=	O
104	O
)	O
were	O
significantly	O
more	O
satisfied	O
with	O
the	O
education	O
received	O
during	O
that	O
visit	O
than	O
the	O
control	Control
group	Control
(	O
n	O
=	O
101	O
)	O
.	O

The	O
longer	O
patients	O
waited	O
in	O
the	O
clinic	O
to	O
see	O
their	O
providers	O
,	O
the	O
less	O
satisfied	O
they	O
were	O
with	O
the	O
clinic	O
visit	O
.	O

The	O
dud	O
effect	O
:	O
adding	O
highly	O
dissimilar	O
fillers	O
increases	O
confidence	O
in	O
lineup	O
identifications	O
.	O

Recent	O
research	O
in	O
decision-making	O
has	O
demonstrated	O
the	O
dud-alternative	O
effect	O
--	O
the	O
tendency	O
to	O
become	O
more	O
confident	O
that	O
a	O
chosen	O
response	O
option	O
is	O
correct	O
if	O
it	O
is	O
surrounded	O
by	O
implausible	O
response	O
options	O
(	O
Windschitl	O
&	O
Chambers	O
,	O
J	O
Exp	O
Psychol	O
30:198-215	O
,	O
2004	O
)	O
.	O

This	O
finding	O
may	O
be	O
applicable	O
to	O
a	O
lineup	O
task	O
:	O
The	O
presence	O
of	O
duds	O
(	O
i.e.	O
,	O
highly	O
dissimilar	O
fillers	O
)	O
may	O
increase	O
a	O
witness	O
's	O
confidence	O
that	O
an	O
identified	O
(	O
non-dud	O
)	O
lineup	O
member	O
is	O
the	O
criminal	O
.	O

Four	O
studies	O
(	O
N	O
=	O
665	O
)	O
demonstrate	O
that	O
the	O
mere	O
presence	O
of	O
highly	O
dissimilar	O
fillers	O
inflates	O
witnesses	O
'	O
confidence	O
in	O
a	O
mistaken	O
identification	O
(	O
Studies	O
1-4	O
)	O
,	O
provides	O
evidence	O
that	O
this	O
confidence	O
inflation	O
is	O
due	O
to	O
the	O
duds	O
inflating	O
the	O
perceived	O
similarity	O
of	O
the	O
other	O
lineup	O
members	O
to	O
the	O
criminal	O
(	O
Studies	O
2	O
,	O
3	O
)	O
,	O
and	O
delineates	O
some	O
conditions	O
under	O
which	O
the	O
effect	O
holds	O
(	O
Studies	O
3	O
,	O
4	O
)	O
.	O

The	O
addition	O
of	O
highly	O
dissimilar	Educational
lineup	Educational
members	Educational
,	O
far	O
from	O
being	O
inert	O
,	O
as	O
is	O
often	O
implicitly	O
assumed	O
,	O
can	O
bias	O
witnesses	O
'	O
confidence	O
reports	O
.	O

A	O
physiotherapy	Physical
service	Physical
to	O
an	O
emergency	O
extended	O
care	O
unit	O
does	O
not	O
decrease	O
admission	O
rates	O
to	O
hospital	O
:	O
a	O
randomised	O
trial	O
.	O

BACKGROUND	O
One	O
of	O
the	O
reasons	O
physiotherapy	Physical
services	Physical
are	O
provided	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
and	O
emergency	O
extended	O
care	O
units	O
(	O
EECUs	O
)	O
is	O
to	O
review	O
patients	O
'	O
mobility	O
to	O
ensure	O
they	O
are	O
safe	O
to	O
be	O
discharged	O
home	O
.	O

AIM	O
To	O
investigate	O
whether	O
a	O
physiotherapy	Physical
service	Physical
to	O
an	O
EECU	O
altered	O
the	O
rate	O
of	O
hospital	O
admission	O
,	O
rate	O
of	O
re-presentation	O
to	O
the	O
ED	O
,	O
visits	O
to	O
community	O
healthcare	O
practitioners	O
,	O
return	O
to	O
usual	O
work/home/leisure	O
activities	O
and	O
patient	O
satisfaction	O
.	O

METHODS	O
A	O
randomised	O
trial	O
with	O
concealed	O
allocation	O
,	O
assessor	O
blinding	O
and	O
intention-to-treat	O
analysis	O
was	O
undertaken	O
in	O
an	O
EECU	O
.	O

The	O
sample	O
comprised	O
186	O
patients	O
(	O
mean	O
age	O
70	O
years	O
,	O
123	O
(	O
66	O
%	O
)	O
female	O
patients	O
,	O
130	O
(	O
70	O
%	O
)	O
trauma	O
)	O
who	O
were	O
referred	O
for	O
physiotherapy	Physical
assessment/intervention	Physical
.	Physical

Referral	O
occurred	O
at	O
any	O
stage	O
of	O
the	O
patients	O
'	O
EECU	O
admission	O
.	O

All	O
participants	O
received	O
medical/nursing	Physical
care	Physical
as	O
required	O
.	O

The	O
physiotherapy	Physical
group	O
also	O
received	O
physiotherapy	Physical
assessment/intervention	Physical
.	Physical

RESULTS	O
The	O
physiotherapy	Physical
group	O
had	O
a	O
4	O
%	O
(	O
95	O
%	O
CI	O
-18	O
%	O
to	O
9	O
%	O
)	O
lower	O
rate	O
of	O
admission	O
to	O
hospital	O
than	O
the	O
control	O
group	O
and	O
a	O
4	O
%	O
(	O
95	O
%	O
CI	O
-6	O
%	O
to	O
13	O
%	O
)	O
higher	O
rate	O
of	O
re-presentation	O
to	O
the	O
ED	O
,	O
which	O
were	O
statistically	O
non-significant	O
(	O
p?0.45	O
)	O
.	O

Differences	O
between	O
groups	O
for	O
use	O
of	O
community	O
healthcare	O
resources	O
,	O
return	O
to	O
usual	O
work/home/leisure	O
activities	O
and	O
satisfaction	O
with	O
their	O
EECU	O
care	O
were	O
small	O
and	O
not	O
significant	O
.	O

CONCLUSION	O
A	O
physiotherapy	O
service	O
for	O
EECU	O
patients	O
,	O
as	O
provided	O
in	O
this	O
study	O
,	O
did	O
not	O
reduce	O
the	O
rate	O
of	O
hospital	O
admission	O
,	O
rate	O
of	O
re-presentation	O
to	O
the	O
ED	O
,	O
use	O
of	O
community	O
healthcare	O
resources	O
,	O
or	O
improve	O
the	O
rate	O
of	O
return	O
to	O
usual	O
work/home/leisure	O
activities	O
or	O
patient	O
satisfaction	O
.	O

Trial	O
registration	O
number	O
ANZCTRN12609000106235	O
.	O

A	O
randomised	O
,	O
controlled	O
study	O
of	O
dietary	O
intervention	O
in	O
autistic	O
syndromes	O
.	O

Impaired	O
social	O
interaction	O
,	O
communication	O
and	O
imaginative	O
skills	O
characterize	O
autistic	O
syndromes	O
.	O

In	O
these	O
syndromes	O
urinary	O
peptide	O
abnormalities	O
,	O
derived	O
from	O
gluten	O
,	O
gliadin	O
,	O
and	O
casein	O
,	O
are	O
reported	O
.	O

They	O
reflect	O
processes	O
with	O
opioid	O
effect	O
.	O

The	O
aim	O
of	O
this	O
single	O
blind	O
study	O
was	O
to	O
evaluate	O
effect	O
of	O
gluten	O
and	O
casein-free	O
diet	O
for	O
children	O
with	O
autistic	O
syndromes	O
and	O
urinary	O
peptide	O
abnormalities	O
.	O

A	O
randomly	O
selected	O
diet	O
and	O
control	O
group	O
with	O
10	O
children	O
in	O
each	O
group	O
participated	O
.	O

Observations	O
and	O
tests	O
were	O
done	O
before	O
and	O
after	O
a	O
period	O
of	O
1	O
year	O
.	O

The	O
development	O
for	O
the	O
group	O
of	O
children	O
on	O
diet	O
was	O
significantly	O
better	O
than	O
for	O
the	O
controls	Control
.	Control

Comparison	O
of	O
coronary	Surgical
bypass	Surgical
surgery	Surgical
with	O
angioplasty	Surgical
in	O
patients	O
with	O
multivessel	O
disease	O
.	O

The	O
Bypass	O
Angioplasty	O
Revascularization	O
Investigation	O
(	O
BARI	O
)	O
Investigators	O
.	O

BACKGROUND	O
Coronary-artery	Surgical
bypass	Surgical
grafting	Surgical
(	Surgical
CABG	Surgical
)	Surgical
and	O
percutaneous	Surgical
transluminal	Surgical
coronary	Surgical
angioplasty	Surgical
(	Surgical
PTCA	Surgical
)	Surgical
are	O
alternative	O
methods	O
of	O
revascularization	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
in	O
selected	O
patients	O
with	O
multivessel	O
disease	O
suitable	O
for	O
treatment	O
with	O
either	O
procedure	O
,	O
an	O
initial	O
strategy	O
of	O
PTCA	O
does	O
not	O
result	O
in	O
a	O
poorer	O
five-year	O
clinical	O
outcome	O
than	O
CABG	O
.	O

METHODS	O
Patients	O
with	O
multivessel	O
disease	O
were	O
randomly	O
assigned	O
to	O
an	O
initial	O
treatment	O
strategy	O
of	O
CABG	O
(	O
n	O
=	O
914	O
)	O
or	O
PTCA	O
(	O
n	O
=	O
915	O
)	O
and	O
were	O
followed	O
for	O
an	O
average	O
of	O
5.4	O
years	O
.	O

Analysis	O
of	O
outcome	O
events	O
was	O
performed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
.	O

RESULTS	O
The	O
respective	O
in-hospital	O
event	O
rates	O
for	O
CABG	O
and	O
PTCA	O
were	O
1.3	O
percent	O
and	O
1.1	O
percent	O
for	O
mortality	O
,	O
4.6	O
percent	O
and	O
2.1	O
percent	O
for	O
Q-wave	O
myocardial	O
infarction	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
0.8	O
percent	O
and	O
0.2	O
percent	O
for	O
stroke	O
.	O

The	O
five-year	O
survival	O
rate	O
was	O
89.3	O
percent	O
for	O
those	O
assigned	O
to	O
CABG	O
and	O
86.3	O
percent	O
for	O
those	O
assigned	O
to	O
PTCA	O
(	O
P	O
=	O
0.19	O
;	O
95	O
percent	O
confidence	O
interval	O
of	O
the	O
difference	O
in	O
survival	O
,	O
-0.2	O
percent	O
to	O
6.0	O
percent	O
)	O
.	O

The	O
respective	O
five-year	O
survival	O
rates	O
free	O
from	O
Q-wave	O
myocardial	O
infarction	O
were	O
80.4	O
percent	O
and	O
78.7	O
percent	O
.	O

By	O
five	O
years	O
after	O
study	O
entry	O
,	O
8	O
percent	O
of	O
the	O
patients	O
assigned	O
to	O
CABG	O
had	O
undergone	O
additional	O
revascularization	O
procedures	O
,	O
as	O
compared	O
with	O
54	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
;	O
69	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
did	O
not	O
subsequently	O
undergo	O
CABG	O
.	O

Among	O
diabetic	O
patients	O
who	O
were	O
being	O
treated	O
with	O
insulin	O
or	O
oral	O
hypoglycemic	O
agents	O
at	O
base	O
line	O
,	O
a	O
subgroup	O
not	O
specified	O
by	O
the	O
protocol	O
,	O
five-year	O
survival	O
was	O
80.6	O
percent	O
for	O
the	O
CABG	O
group	O
as	O
compared	O
with	O
65.5	O
percent	O
for	O
the	O
PTCA	O
group	O
(	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
As	O
compared	O
with	O
CABG	Surgical
,	O
an	O
initial	O
strategy	O
of	O
PTCA	Surgical
did	O
not	O
significantly	O
compromise	O
five-year	O
survival	O
in	O
patients	O
with	O
multivessel	O
disease	O
,	O
although	O
subsequent	O
revascularization	O
was	O
required	O
more	O
often	O
with	O
this	O
strategy	O
.	O

For	O
treated	O
diabetics	O
,	O
five-year	O
survival	O
was	O
significantly	O
better	O
after	O
CABG	Surgical
than	O
after	O
PTCA	Surgical
.	O

A	O
pilot	O
study	O
of	O
a	O
low-tilt	O
biphasic	O
waveform	O
for	O
transvenous	O
cardioversion	O
of	O
atrial	O
fibrillation	O
:	O
improved	O
efficacy	O
compared	O
with	O
conventional	O
capacitor-based	O
waveforms	O
in	O
patients	O
.	O

BACKGROUND	O
The	O
optimal	O
waveform	O
tilt	O
for	O
defibrillation	O
is	O
not	O
known	O
.	O

Most	O
modern	O
defibrillators	O
used	O
for	O
the	O
cardioversion	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
employ	O
high-tilt	O
,	O
capacitor-based	O
biphasic	O
waveforms	O
.	O

METHODS	O
We	O
have	O
developed	O
a	O
low-tilt	Physical
biphasic	Physical
waveform	Physical
for	O
defibrillation	O
.	O

This	O
low-tilt	Pharmacological
waveform	Pharmacological
was	O
compared	O
with	O
a	O
conventional	Pharmacological
waveform	Pharmacological
of	O
equivalent	O
duration	O
and	O
voltage	O
in	O
patients	O
with	O
AF	O
.	O

Patients	O
with	O
persistent	O
AF	O
or	O
AF	O
induced	O
during	O
a	O
routine	O
electrophysiology	O
study	O
(	O
EPS	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
the	O
low-tilt	Physical
waveform	Physical
or	O
a	O
conventional	Physical
waveform	Physical
.	O

Defibrillation	O
electrodes	O
were	O
positioned	O
in	O
the	O
right	O
atrial	O
appendage	O
and	O
distal	O
coronary	O
sinus	O
.	O

Phase	O
1	O
peak	O
voltage	O
was	O
increased	O
in	O
a	O
stepwise	O
progression	O
from	O
50	O
V	O
to	O
300V	O
.	O

Shock	O
success	O
was	O
defined	O
as	O
return	O
of	O
sinus	O
rhythm	O
for	O
>	O
/=30	O
seconds	O
.	O

RESULTS	O
The	O
low-tilt	Physical
waveform	Physical
produced	O
successful	O
termination	O
of	O
persistent	O
AF	O
at	O
a	O
mean	O
voltage	O
of	O
223	O
V	O
(	O
8.2	O
J	O
)	O
versus	O
270	O
V	O
(	O
6.7	O
J	O
)	O
with	O
the	O
conventional	Pharmacological
waveform	Pharmacological
(	O
P	O
=	O
0.002	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O

In	O
patients	O
with	O
induced	O
AF	O
the	O
mean	O
voltage	O
for	O
the	O
low-tilt	O
waveform	O
was	O
91V	O
(	O
1.6	O
J	O
)	O
and	O
for	O
the	O
conventional	O
waveform	O
was	O
158	O
V	O
(	O
2.0	O
J	O
)	O
(	O
P	O
=	O
0.005	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O

The	O
waveform	O
was	O
much	O
more	O
successful	O
at	O
very	O
low	O
voltages	O
(	O
less	O
than	O
or	O
equal	O
to	O
100	O
V	O
)	O
compared	O
with	O
the	O
conventional	O
waveform	O
(	O
Novel	O
:	O
82	O
%	O
vs	O
Conventional	O
22	O
%	O
,	O
P	O
=	O
0.008	O
)	O
.	O

CONCLUSION	O
The	O
low-tilt	Pharmacological
biphasic	Pharmacological
waveform	Pharmacological
was	O
more	O
successful	O
for	O
the	O
internal	O
cardioversion	O
of	O
both	O
persistent	O
and	O
induced	O
AF	O
in	O
patients	O
(	O
in	O
terms	O
of	O
leading	O
edge	O
voltage	O
)	O
.	O

Ambient	O
temperature	O
and	O
biomarkers	O
of	O
heart	O
failure	O
:	O
a	O
repeated	O
measures	O
analysis	O
.	O

BACKGROUND	O
Extreme	O
temperatures	O
have	O
been	O
associated	O
with	O
hospitalization	O
and	O
death	O
among	O
individuals	O
with	O
heart	O
failure	O
,	O
but	O
few	O
studies	O
have	O
explored	O
the	O
underlying	O
mechanisms	O
.	O

OBJECTIVES	O
We	O
hypothesized	O
that	O
outdoor	O
temperature	O
in	O
the	O
Boston	O
,	O
Massachusetts	O
,	O
area	O
(	O
1-	O
to	O
4-day	O
moving	O
averages	O
)	O
would	O
be	O
associated	O
with	O
higher	O
levels	O
of	O
biomarkers	O
of	O
inflammation	O
and	O
myocyte	O
injury	O
in	O
a	O
repeated-measures	O
study	O
of	O
individuals	O
with	O
stable	O
heart	O
failure	O
.	O

METHODS	O
We	O
analyzed	O
data	O
from	O
a	O
completed	O
clinical	O
trial	O
that	O
randomized	O
100	O
patients	O
to	O
12	Educational
weeks	Educational
of	Educational
tai	Educational
chi	Educational
classes	Educational
or	Educational
to	Educational
time-matched	Control
education	Control
control	Control
.	Educational

B-type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
were	O
measured	O
at	O
baseline	O
,	O
6	O
weeks	O
,	O
and	O
12	O
weeks	O
.	O

Endothelin-1	O
was	O
measured	O
at	O
baseline	O
and	O
12	O
weeks	O
.	O

We	O
used	O
fixed	O
effects	O
models	O
to	O
evaluate	O
associations	O
with	O
measures	O
of	O
temperature	O
that	O
were	O
adjusted	O
for	O
time-varying	O
covariates	O
.	O

RESULTS	O
Higher	O
apparent	O
temperature	O
was	O
associated	O
with	O
higher	O
levels	O
of	O
BNP	O
beginning	O
with	O
2-day	O
moving	O
averages	O
and	O
reached	O
statistical	O
significance	O
for	O
3-	O
and	O
4-day	O
moving	O
averages	O
.	O

CRP	O
results	O
followed	O
a	O
similar	O
pattern	O
but	O
were	O
delayed	O
by	O
1	O
day	O
.	O

A	O
5?C	O
change	O
in	O
3-	O
and	O
4-day	O
moving	O
averages	O
of	O
apparent	O
temperature	O
was	O
associated	O
with	O
11.3	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.1	O
,	O
22.5	O
;	O
p	O
=	O
0.03	O
)	O
and	O
11.4	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.2	O
,	O
22.5	O
;	O
p	O
=	O
0.03	O
)	O
higher	O
BNP	O
.	O

A	O
5?C	O
change	O
in	O
the	O
4-day	O
moving	O
average	O
of	O
apparent	O
temperature	O
was	O
associated	O
with	O
21.6	O
%	O
(	O
95	O
%	O
CI	O
:	O
2.5	O
,	O
44.2	O
;	O
p	O
=	O
0.03	O
)	O
higher	O
CRP	O
.	O

No	O
clear	O
associations	O
with	O
TNF	O
or	O
endothelin-1	O
were	O
observed	O
.	O

CONCLUSIONS	O
Among	O
patients	O
undergoing	O
treatment	O
for	O
heart	O
failure	O
,	O
we	O
observed	O
positive	O
associations	O
between	O
temperature	O
and	O
both	O
BNP	O
and	O
CRP-predictors	O
of	O
heart	O
failure	O
prognosis	O
and	O
severity	O
.	O

A	O
shortened	O
versus	O
standard	O
matched	O
postpartum	Pharmacological
magnesium	Pharmacological
sulphate	Pharmacological
regimen	Pharmacological
in	O
the	O
treatment	O
of	O
eclampsia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

Magnesium	Pharmacological
sulphate	Pharmacological
is	O
currently	O
the	O
most	O
ideal	O
drug	O
for	O
the	O
treatment	O
of	O
eclampsia	O
but	O
its	O
use	O
in	O
Nigeria	O
is	O
still	O
limited	O
due	O
its	O
cost	O
and	O
clinicians	O
inexperience	O
with	O
the	O
drug	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
a	O
shortened	O
postpartum	O
course	O
of	O
magnesium	Pharmacological
sulphate	Pharmacological
is	O
as	O
effective	O
as	O
the	O
standard	O
Pritchard	O
regimen	O
in	O
controlling	O
fits	O
in	O
eclampsia	O
Between	O
January	O
and	O
June	O
2011	O
,	O
98	O
eclamptic	O
mothers	O
presenting	O
at	O
the	O
labour	O
ward	O
of	O
the	O
University	O
of	O
Maiduguri	O
Teaching	O
Hospital	O
were	O
randomised	O
to	O
receive	O
either	O
the	O
standard	Pharmacological
Pritchard	Pharmacological
regimen	Pharmacological
of	Pharmacological
magnesium	Pharmacological
sulphate	Pharmacological
or	O
a	O
shortened	O
postpartum	O
course	O
in	O
which	O
only	O
two	O
doses	O
of	O
intramuscular	Pharmacological
magnesium	Pharmacological
sulphate	Pharmacological
is	O
given	O
four	O
hours	O
apart	O
.	O

The	O
maternal	O
and	O
fetal	O
outcomes	O
were	O
compared	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
recurrence	O
of	O
fits	O
.	O

The	O
recurrence	O
of	O
fits	O
and	O
other	O
maternal	O
complications	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

The	O
total	O
dosage	O
of	O
magnesium	Pharmacological
sulphate	Pharmacological
in	O
the	O
shortened	O
group	O
was	O
reduced	O
by	O
40	O
%	O
in	O
66	O
%	O
of	O
patients	O
.	O

The	O
shortened	O
postpartum	O
course	O
of	O
magnesium	Pharmacological
sulphate	Pharmacological
is	O
as	O
effective	O
as	O
the	O
standard	O
Pritchard	O
regimen	O
in	O
the	O
management	O
of	O
eclampsia	O
.	O

Intraoperative	Other
microscopy	Other
of	O
bile	O
--	O
is	O
it	O
useful	O
?	O
Direct	Physical
microscopy	Physical
of	Physical
the	Physical
bile	Physical
was	O
performed	O
during	O
cholecystectomy	Surgical
in	O
111	O
patients	O
in	O
an	O
attempt	O
to	O
identify	O
those	O
with	O
a	O
high	O
risk	O
of	O
wound	O
infection	O
.	O

Bacteria	O
were	O
identified	O
in	O
23	O
patients	O
,	O
11	O
of	O
83	O
undergoing	O
cholecystectomy	Surgical
alone	O
and	O
12	O
of	O
28	O
undergoing	O
exploration	O
of	O
the	O
common	O
bile	O
duct	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

These	O
23	O
patients	O
were	O
randomly	O
allocated	O
to	O
an	O
antibiotic	Pharmacological
group	Pharmacological
or	O
a	O
control	O
group	O
;	O
there	O
was	O
one	O
wound	O
infection	O
in	O
the	O
antibiotic	Pharmacological
group	Pharmacological
and	O
two	O
in	O
the	O
control	Control
group	Control
.	O

A	O
total	O
of	O
14	O
patients	O
developed	O
wound	O
sepsis	O
.	O

Infection	O
was	O
more	O
likely	O
if	O
the	O
common	O
bile	O
duct	O
was	O
explored	O
(	O
6	O
of	O
28	O
)	O
rather	O
than	O
cholecystectomy	Surgical
alone	O
(	O
8	O
of	O
83	O
)	O
.	O

There	O
was	O
a	O
poor	O
correlation	O
between	O
microscopy	O
and	O
culture	O
of	O
the	O
bile	O
for	O
bacteria	O
and	O
there	O
was	O
no	O
increase	O
in	O
sepsis	O
when	O
bacteria	O
were	O
observed	O
on	O
microscopy	O
.	O

We	O
were	O
not	O
able	O
to	O
identify	O
a	O
high	O
risk	O
group	O
of	O
patients	O
by	O
intraoperative	O
microscopy	O
of	O
bile	O
.	O

Leptin	O
levels	O
in	O
protracted	O
critical	O
illness	O
:	O
effects	O
of	O
growth	Pharmacological
hormone-secretagogues	Pharmacological
and	O
thyrotropin-releasing	Pharmacological
hormone	Pharmacological
.	Pharmacological

Prolonged	O
critical	O
illness	O
is	O
characterized	O
by	O
feeding-resistant	O
wasting	O
of	O
protein	O
,	O
whereas	O
reesterification	O
,	O
instead	O
of	O
oxidation	O
of	O
fatty	O
acids	O
,	O
allows	O
fat	O
stores	O
to	O
accrue	O
and	O
associate	O
with	O
a	O
low-activity	O
status	O
of	O
the	O
somatotropic	O
and	O
thyrotropic	O
axis	O
,	O
which	O
seems	O
to	O
be	O
partly	O
of	O
hypothalamic	O
origin	O
.	O

To	O
further	O
unravel	O
this	O
paradoxical	O
metabolic	O
condition	O
,	O
and	O
in	O
search	O
of	O
potential	O
therapeutic	O
strategies	O
,	O
we	O
measured	O
serum	O
concentrations	O
of	O
leptin	O
;	O
studied	O
the	O
relationship	O
with	O
body	O
mass	O
index	O
,	O
insulin	O
,	O
cortisol	O
,	O
thyroid	O
hormones	O
,	O
and	O
somatomedins	O
;	O
and	O
documented	O
the	O
effects	O
of	O
hypothalamic	O
releasing	O
factors	O
,	O
in	O
particular	O
,	O
GH-secretagogues	O
and	O
TRH	O
.	O

Twenty	O
adults	O
,	O
critically	O
ill	O
for	O
several	O
weeks	O
and	O
supported	O
with	O
normocaloric	O
,	O
continuously	O
administered	O
parenteral	O
and/or	O
enteral	O
feeding	O
,	O
were	O
studied	O
for	O
45	O
h.	O
They	O
had	O
been	O
randomized	O
to	O
receive	O
one	O
of	O
three	O
combinations	O
of	O
peptide	O
infusions	O
,	O
in	O
random	O
order	O
:	O
TRH	Pharmacological
(	Educational
one	Educational
day	Educational
)	Educational
and	O
placebo	Control
(	O
other	O
day	O
)	O
;	O
TRH	O
+	O
GH-releasing	O
peptide	O
(	O
GHRP	O
)	O
-2	O
and	O
GHRP-2	O
;	O
TRH	O
+	O
GHRH	O
+	O
GHRP-2	O
and	O
GHRH	O
+	O
GHRP-2	O
.	O

Peptide	O
infusions	O
were	O
started	O
after	O
a	O
1-microgram/kg	O
bolus	O
at	O
0900	O
h	O
and	O
infused	O
(	O
1	O
microgram/kg.h	O
)	O
until	O
0600	O
h	O
the	O
next	O
morning	O
.	O

Serum	O
concentrations	O
of	O
leptin	O
,	O
insulin	O
,	O
cortisol	O
,	O
T4	O
,	O
T3	O
,	O
insulin-like	O
growth	O
factor	O
(	O
IGF	O
)	O
-I	O
,	O
IGF-binding	O
protein-3	O
and	O
the	O
acid-labile	O
subunit	O
(	O
ALS	O
)	O
were	O
measured	O
at	O
0900	O
h	O
,	O
2100	O
h	O
,	O
and	O
0600	O
h	O
on	O
each	O
of	O
the	O
2	O
study	O
days	O
.	O

Baseline	O
leptin	O
levels	O
(	O
mean	O
+/-	O
SEM	O
:	O
12.4	O
+/-	O
2.1	O
micrograms/L	O
)	O
were	O
independent	O
of	O
body	O
mass	O
index	O
(	O
25	O
+/-	O
1	O
kg/m2	O
)	O
,	O
insulin	O
(	O
18.6	O
+/-	O
2.9	O
microIU/mL	O
)	O
,	O
cortisol	O
(	O
504	O
+/-	O
43	O
mmol/L	O
)	O
,	O
and	O
thyroid	O
hormones	O
(	O
T4	O
:	O
63	O
+/-	O
5	O
nmol/L	O
,	O
T3	O
:	O
0.72	O
+/-	O
0.08	O
nmol/L	O
)	O
but	O
correlated	O
positively	O
with	O
circulating	O
levels	O
of	O
IGF-I	O
[	O
86	O
+/-	O
6	O
micrograms/L	O
,	O
determination	O
coefficient	O
(	O
R2	O
)	O
=	O
0.25	O
]	O
and	O
ALS	O
(	O
7.2	O
+/-	O
0.6	O
mg/L	O
,	O
R2	O
=	O
0.32	O
)	O
.	O

Infusion	O
of	O
placebo	Control
or	O
TRH	Pharmacological
had	O
no	O
effect	O
on	O
leptin	O
.	O

In	O
contrast	O
,	O
GH-secretagogues	O
elevated	O
leptin	O
levels	O
within	O
12	O
h.	O
Infusion	O
of	O
GHRP-2	O
alone	O
induced	O
a	O
maximal	O
leptin	O
increase	O
of	O
+87	O
%	O
after	O
24	O
h	O
,	O
whereas	O
GHRH	O
+	O
GHRP-2	O
elevated	O
leptin	O
by	O
up	O
to	O
+157	O
%	O
after	O
24	O
h.	O
The	O
increase	O
in	O
leptin	O
within	O
12	O
h	O
was	O
related	O
(	O
R2	O
=	O
0.58	O
)	O
to	O
the	O
substantial	O
rise	O
in	O
insulin	O
.	O

After	O
45	O
h	O
,	O
and	O
having	O
reached	O
a	O
plateau	O
,	O
leptin	O
was	O
related	O
to	O
the	O
increased	O
IGF-I	O
(	O
R2	O
=	O
0.37	O
)	O
.	O

In	O
conclusion	O
,	O
circulating	O
leptin	O
levels	O
during	O
protracted	O
critical	O
illness	O
were	O
linked	O
to	O
the	O
activity	O
state	O
of	O
the	O
GH/IGF-I	O
axis	O
.	O

Stimulating	O
the	O
GH/IGF-I	O
axis	O
with	O
GH-secretagogues	O
increased	O
leptin	O
levels	O
within	O
12	O
h.	O
Because	O
leptin	O
may	O
stimulate	O
oxidation	O
of	O
fatty	O
acids	O
,	O
and	O
because	O
GH	O
,	O
IGF-I	O
,	O
and	O
insulin	O
have	O
a	O
protein-sparing	O
effect	O
,	O
GH-secretagogue	Pharmacological
administration	O
may	O
be	O
expected	O
to	O
result	O
in	O
increased	O
utilization	O
of	O
fat	O
as	O
preferential	O
substrate	O
and	O
to	O
restore	O
protein	O
content	O
in	O
vital	O
tissues	O
and	O
,	O
consequently	O
,	O
has	O
potential	O
as	O
a	O
strategy	O
to	O
reverse	O
the	O
paradoxical	O
metabolic	O
condition	O
of	O
protracted	O
critical	O
illness	O
.	O

A	O
comparison	O
of	O
once	O
and	O
twice	O
daily	O
atenolol	Pharmacological
for	O
angina	O
pectoris	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
four	O
doses	O
of	O
atenolol	Pharmacological
in	O
11	O
patients	O
with	O
stable	O
angina	O
pectoris	O
using	O
a	O
symptom-limited	O
exercise	O
test	O
and	O
angina	O
diaries	O
.	O

The	O
doses	O
100	O
mg	O
twice	O
daily	O
and	O
50	O
mg	O
,	O
100	O
mg	O
and	O
200	O
mg	O
once	O
daily	O
were	O
given	O
double-blind	O
and	O
randomised	O
within	O
patients	O
following	O
run-in	O
on	O
placebo	Control
.	O

Measurements	O
were	O
made	O
12	O
hours	O
after	O
the	O
last	O
twice	O
daily	O
dose	O
and	O
24	O
hours	O
after	O
the	O
last	O
once	O
daily	O
dose	O
.	O

Exercise	O
tolerance	O
was	O
improved	O
by	O
40-74	O
%	O
and	O
exercise	O
duration	O
before	O
the	O
onset	O
of	O
angina	O
by	O
61-94	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Maximal	O
heart	O
rate	O
was	O
reduced	O
further	O
by	O
a	O
total	O
daily	O
dose	O
of	O
200	O
mg	O
than	O
by	O
lower	O
doses	O
,	O
but	O
no	O
extra	O
benefit	O
was	O
derived	O
by	O
giving	O
the	O
drug	O
twice	O
daily	O
.	O

The	O
largest	O
increase	O
in	O
exercise	O
tolerance	O
was	O
obtained	O
during	O
treatment	O
with	O
50	O
mg	O
once	O
daily	O
.	O

Atenolol	Pharmacological
was	O
shown	O
to	O
be	O
an	O
effective	O
anti-anginal	O
agent	O
when	O
given	O
once	O
daily	O
,	O
and	O
there	O
were	O
no	O
major	O
differences	O
between	O
the	O
doses	O
studied	O
.	O

A	O
randomized	O
double-blind	O
comparison	O
of	O
coformulated	O
elvitegravir/cobicistat/emtricitabine/tenofovir	Pharmacological
disoproxil	Pharmacological
fumarate	Pharmacological
versus	O
efavirenz/emtricitabine/tenofovir	Pharmacological
disoproxil	Pharmacological
fumarate	Pharmacological
for	O
initial	O
treatment	O
of	O
HIV-1	O
infection	O
:	O
analysis	O
of	O
week	O
96	O
results	O
.	O

We	O
report	O
week	O
96	O
results	O
from	O
a	O
phase	O
3	O
trial	O
of	O
elvitegravir/cobicistat/emtricitabine/tenofovir	Pharmacological
disoproxil	Pharmacological
fumarate	Pharmacological
(	O
EVG/COBI/FTC/TDF	O
,	O
n	O
=	O
348	O
)	O
vs	O
efavirenz/emtricitabine/tenofovir	Pharmacological
disoproxil	Pharmacological
fumarate	Pharmacological
(	O
EFV/FTC/TDF	O
,	O
n	O
=	O
352	O
)	O
.	O

At	O
week	O
48	O
,	O
EVG/COBI/FTC/TDF	Pharmacological
was	O
noninferior	O
to	O
EFV/FTC/TDF	Pharmacological
(	O
88	O
%	O
vs	O
84	O
%	O
,	O
difference	O
+3.6	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
-1.6	O
%	O
to	O
8.8	O
%	O
)	O
.	O

Virologic	O
success	O
(	O
HIV-1	O
RNA	O
<	O
50	O
copies/mL	O
)	O
was	O
maintained	O
at	O
week	O
96	O
(	O
84	O
%	O
vs	O
82	O
%	O
,	O
difference	O
+2.7	O
%	O
,	O
95	O
%	O
CI	O
:	O
-2.9	O
%	O
to	O
8.3	O
%	O
)	O
.	O

Discontinuation	O
due	O
to	O
adverse	O
events	O
was	O
low	O
(	O
5	O
%	O
vs	O
7	O
%	O
)	O
.	O

Median	O
changes	O
in	O
serum	O
creatinine	O
(	O
mg/dL	O
)	O
at	O
week	O
96	O
were	O
similar	O
to	O
week	O
48	O
.	O

These	O
results	O
support	O
the	O
durable	O
efficacy	O
and	O
long-term	O
safety	O
of	O
EVG/COBI/FTC/TDF	Pharmacological
.	O

A	O
comparison	O
of	O
the	O
systemic	O
bioactivity	O
of	O
inhaled	O
budesonide	Pharmacological
and	O
fluticasone	Pharmacological
propionate	Pharmacological
in	O
normal	O
subjects	O
.	O

1	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
systemic	O
bioactivity	O
of	O
low	O
and	O
high	O
doses	O
of	O
inhaled	Pharmacological
budesonide	Pharmacological
and	O
fluticasone	Pharmacological
propionate	Pharmacological
given	O
by	O
respective	O
dry	O
powder	O
inhaler	O
devices	O
.	O

2	O
.	O

A	O
randomised	O
,	O
single	O
blind	O
cross-over	O
design	O
was	O
used	O
in	O
nine	O
healthy	O
subjects	O
who	O
were	O
given	O
800	Pharmacological
micrograms	Pharmacological
day-1	Pharmacological
of	Pharmacological
budesonide	Pharmacological
Turbohaler	Pharmacological
(	Pharmacological
B800	Pharmacological
)	Pharmacological
for	O
1	O
week	O
,	O
followed	O
by	O
1	O
week	O
of	O
1600	O
micrograms	O
day-1	O
(	O
B1600	O
)	O
,	O
or	O
fluticasone	Pharmacological
Diskhaler	Pharmacological
750	Pharmacological
micrograms	Pharmacological
day-1	Pharmacological
(	O
F750	O
)	O
for	O
1	O
week	O
followed	O
by	O
1	O
week	O
of	O
1500	O
micrograms	O
day-1	O
(	O
F1500	O
)	O
.	O

There	O
was	O
a	O
1	O
week	O
washout	O
between	O
treatments	O
with	O
fluticasone	O
or	O
budesonide	O
.	O

A	O
twice	O
daily	O
dosing	O
regime	O
was	O
used	O
and	O
mouth-rinsing	O
was	O
employed	O
to	O
reduce	O
gut	O
bioavailability	O
as	O
well	O
as	O
to	O
obviate	O
local	O
adverse	O
effects	O
.	O

3	O
.	O

Parameters	O
of	O
hypothalmic-pituitary	O
adrenal	O
(	O
HPA	O
)	O
axis	O
activity	O
and	O
bone	O
metabolism	O
were	O
measured	O
at	O
baseline	O
(	O
B0/F0	O
)	O
,	O
at	O
the	O
end	O
of	O
each	O
week	O
of	O
treatment	O
and	O
after	O
the	O
1	O
week	O
washout	O
(	O
F0	O
or	O
B0	O
)	O
.	O

4	O
.	O

Both	O
fluticasone	Pharmacological
and	O
budesonide	Pharmacological
significantly	O
(	O
P	O
<	O
0.05	O
)	O
attenuated	O
the	O
post	O
tetracosactrin	O
serum	O
cortisol	O
at	O
low	O
and	O
high	O
doses	O
whilst	O
early	O
morning	O
cortisol	O
was	O
unchanged	O
.	O

No	O
dose-response	O
effect	O
was	O
observed	O
with	O
either	O
drug	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
between	O
treatment	O
with	O
fluticasone	Pharmacological
or	O
budesonide	Pharmacological
.	O

5	O
.	O

Neither	O
budesonide	O
nor	O
fluticasone	O
produced	O
significant	O
suppression	O
of	O
plasma	O
osteocalcin	O
,	O
although	O
the	O
higher	O
doses	O
of	O
both	O
drugs	O
significantly	O
reduced	O
fasting	O
urinary	O
calcium	O
levels	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
In	O
vitro	O
determination	O
of	O
the	O
chromatic	O
effect	O
of	O
a	O
silver	Pharmacological
nanoparticles	Pharmacological
solution	Pharmacological
linked	O
to	O
the	O
gantrez	Pharmacological
S-97	Pharmacological
copolymer	Pharmacological
on	O
tooth	O
enamel	O
.	O

Silver	O
nanoparticles	O
(	O
NNPs	O
)	O
,	O
alone	O
or	O
in	O
combination	O
with	O
the	O
bioadhesive	O
Gantrez	O
S-97	O
,	O
have	O
demonstrated	O
their	O
efficacy	O
against	O
Streptococcus	O
mutans	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
if	O
this	O
combination	O
changes	O
the	O
color	O
of	O
teeth	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
measure	O
the	O
color	O
changes	O
occurring	O
after	O
the	O
use	O
of	O
a	O
Gantrez-NNP	Pharmacological
combination	Pharmacological
on	O
enamel	O
tooth	O
blocks	O
.	O

Two	O
study	O
groups	O
were	O
randomly	O
formed	O
:	O
enamel	O
blocks	O
brushed	O
with	O
(	O
a	O
)	O
the	O
Gantrez-NNP	Pharmacological
combination	Pharmacological
and	O
(	O
b	O
)	O
conventional	Pharmacological
toothpaste	Pharmacological
,	O
for	O
1	O
minute	O
once	O
daily	O
for	O
4	O
weeks	O
,	O
then	O
rinsed	Pharmacological
with	Pharmacological
distilled	Pharmacological
water	Pharmacological
and	Pharmacological
placed	Pharmacological
in	Pharmacological
thymol	Pharmacological
solution	Pharmacological
.	O

Color	O
changes	O
in	O
the	O
enamel	O
blocks	O
were	O
measured	O
using	O
a	O
Minolta	O
colorimeter	O
CR300	O
.	O

Analysis	O
of	O
mixed	O
models	O
was	O
performed	O
with	O
R	O
2.10.1	O
at	O
a	O
95	O
%	O
confidence	O
level	O
,	O
using	O
the	O
nonlinear	O
mixed	O
effects	O
(	O
NLME	O
)	O
package	O
.	O

The	O
results	O
showed	O
that	O
there	O
were	O
no	O
color	O
changes	O
over	O
time	O
,	O
only	O
a	O
high	O
luminosity	O
equal	O
in	O
both	O
groups	O
.	O

Our	O
study	O
showed	O
that	O
the	O
use	O
of	O
the	O
Gantrez-NNP	Pharmacological
combination	Pharmacological
is	O
safe	O
with	O
respect	O
to	O
dental	O
esthetics	O
in	O
the	O
control	O
of	O
S.	O
mutans	O
.	O

Is	O
periprostatic	O
local	O
anesthesia	Physical
for	O
transrectal	O
ultrasound	O
guided	O
prostate	O
biopsy	O
associated	O
with	O
increased	O
infectious	O
or	O
hemorrhagic	O
complications	O
?	O
A	O
prospective	O
randomized	O
trial	O
.	O

PURPOSE	O
Periprostatic	O
local	O
anesthesia	O
for	O
prostate	O
biopsy	O
requires	O
2	O
or	O
more	O
extra	O
needle	O
punctures	O
and	O
injection	O
of	O
the	O
local	O
anesthetic	O
through	O
the	O
highly	O
colonized	O
rectum	O
.	O

To	O
our	O
knowledge	O
we	O
report	O
the	O
first	O
prospective	O
randomized	O
trial	O
to	O
assess	O
the	O
infectious	O
or	O
hemorrhagic	O
complications	O
associated	O
with	O
this	O
method	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
of	O
100	O
consecutive	O
patients	O
with	O
sterile	O
urine	O
cultures	O
underwent	O
transrectal	Surgical
ultrasound	Surgical
guided	Surgical
prostate	Surgical
biopsy	Surgical
.	O

They	O
were	O
randomized	O
to	O
receive	O
a	O
periprostatic	Physical
nerve	Physical
block	Physical
or	O
no	Physical
anesthesia	Physical
.	O

Patients	O
were	O
evaluated	O
for	O
the	O
amount	O
of	O
rectal	Physical
and	Physical
urethral	Physical
bleeding	Physical
,	O
and	O
symptoms	Physical
and	Physical
signs	Physical
of	Physical
infection	Physical
after	Physical
biopsy	Surgical
.	O

RESULTS	O
The	O
amount	O
of	O
urethral	O
bleeding	O
was	O
slight	O
and	O
similar	O
in	O
the	O
2	O
groups	O
.	O

Rectal	O
bleeding	O
was	O
significantly	O
less	O
in	O
the	O
patients	O
who	O
received	O
anesthesia	O
.	O

High	O
fever	O
(	O
greater	O
than	O
37.8C	O
)	O
was	O
more	O
frequent	O
in	O
the	O
nerve	O
block	O
group	O
and	O
2	O
patients	O
in	O
this	O
group	O
required	O
rehospitalization	O
.	O

Bacteriuria	O
in	O
post-biopsy	O
urine	O
cultures	O
was	O
significantly	O
more	O
common	O
in	O
the	O
anesthesia	O
group	O
.	O

CONCLUSIONS	O
Our	O
results	O
suggest	O
that	O
periprostatic	O
local	O
anesthesia	Physical
for	O
prostate	O
biopsy	O
does	O
not	O
increase	O
the	O
risk	O
of	O
urethral	O
bleeding	O
.	O

It	O
is	O
associated	O
with	O
a	O
decreased	O
incidence	O
of	O
rectal	O
bleeding	O
,	O
presumably	O
due	O
to	O
decreased	O
patient	O
discomfort	O
.	O

The	O
incidence	O
of	O
bacteriuria	O
was	O
significantly	O
higher	O
in	O
the	O
anesthesia	O
group	O
.	O

High	O
fever	O
and	O
hospitalization	O
due	O
to	O
infectious	O
complications	O
were	O
also	O
more	O
common	O
in	O
the	O
local	O
anesthesia	O
group	O
,	O
although	O
not	O
statistically	O
significant	O
.	O

Prospective	O
randomized	O
trials	O
seem	O
warranted	O
to	O
determine	O
the	O
optimum	O
antibiotic	O
prophylaxis	O
regimen	O
in	O
patients	O
undergoing	O
biopsy	O
with	O
a	O
periprostatic	O
nerve	O
block	O
.	O

Capsaicin	Pharmacological
jelly	Pharmacological
against	O
migraine	O
pain	O
.	O

OBJECTIVE	O
Recent	O
studies	O
support	O
the	O
role	O
of	O
extracranial	O
perivascular	O
afferents	O
in	O
a	O
substantial	O
percentage	O
of	O
migraineurs	O
.	O

Perivascular	O
afferent	O
fibres	O
of	O
the	O
superficial	O
temporal	O
artery	O
contain	O
peptides	O
,	O
like	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
and	O
substance	O
P	O
(	O
SP	O
)	O
.	O

CGRP	O
and	O
SP	O
are	O
considered	O
relevant	O
in	O
the	O
genesis	O
of	O
migraine	O
pain	O
.	O

Capsaicin	Pharmacological
is	O
an	O
agonist	O
of	O
the	O
transient	O
receptor	O
potential	O
vanilloid	O
type	O
1	O
.	O

It	O
causes	O
membrane	O
depolarisation	O
of	O
sensory	O
neurons	O
,	O
which	O
release	O
CGRP	O
,	O
SP	O
and	O
other	O
pain	O
peptides	O
;	O
excitation	O
is	O
followed	O
by	O
a	O
refractory	O
state	O
,	O
causing	O
inactivation	O
.	O

Topical	Pharmacological
capsaicin	Pharmacological
has	O
been	O
found	O
to	O
be	O
efficacious	O
in	O
several	O
types	O
of	O
neuropathic	O
pain	O
.	O

We	O
attempted	O
to	O
verify	O
whether	O
topical	Pharmacological
periarterial	Pharmacological
capsaicin	Pharmacological
could	O
ameliorate	O
pain	O
in	O
absence	O
of	O
and	O
during	O
a	O
migraine	O
attack	O
.	O

METHODS	O
On	O
23	O
migraineurs	O
showing	O
pain	O
at	O
pressure	O
on	O
scalp	O
arteries	O
,	O
we	O
administered	O
topical	Pharmacological
capsaicin	Pharmacological
0.1	Pharmacological
%	Pharmacological
or	Pharmacological
vaseline	Pharmacological
jelly	Pharmacological
on	O
painful	O
arteries	O
in	O
absence	O
of	O
migraine	O
attack	O
.	O

In	O
those	O
having	O
pain	O
reduction	O
>	O
50	O
%	O
,	O
we	O
made	O
the	O
same	O
comparison	O
during	O
a	O
migraine	O
attack	O
.	O

RESULTS	O
Topical	Pharmacological
capsaicin	Pharmacological
caused	O
>	O
50	O
%	O
reduction	O
of	O
arterial	O
pain	O
in	O
absence	O
of	O
attack	O
in	O
17/23	O
patients	O
,	O
as	O
opposed	O
to	O
two	O
with	O
vaseline	O
.	O

During	O
attacks	O
of	O
mild-	O
to	O
moderate-intensity	O
,	O
>	O
50	O
%	O
improvement	O
was	O
obtained	O
in	O
11/17	O
with	O
capsaicin	Pharmacological
and	O
in	O
one	O
with	O
vaseline	Control
.	O

CONCLUSIONS	O
Although	O
referring	O
to	O
a	O
small	O
number	O
of	O
patients	O
,	O
our	O
data	O
show	O
that	O
topical	Pharmacological
capsaicin	Pharmacological
may	O
relieve	O
arterial	O
pain	O
in	O
absence	O
of	O
and	O
during	O
a	O
migraine	O
attack	O
in	O
a	O
substantial	O
number	O
of	O
patients	O
experiencing	O
scalp	O
arterial	O
tenderness	O
.	O

More	O
active	O
capsacinoids	Pharmacological
might	O
be	O
tried	O
in	O
the	O
future	O
and	O
could	O
provide	O
a	O
new	O
method	O
for	O
treating	O
migraine	O
attacks	O
.	O

Effects	O
of	O
irrigation	O
fluid	O
temperature	O
on	O
core	O
body	O
temperature	O
during	O
transurethral	Surgical
resection	Surgical
of	O
the	O
prostate	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
effect	O
irrigation	O
fluid	O
temperature	O
has	O
on	O
core	O
body	O
temperature	O
changes	O
in	O
patients	O
undergoing	O
transurethral	Surgical
resection	Surgical
of	Surgical
the	Surgical
prostate	Surgical
(	Surgical
TURP	Surgical
)	Surgical
.	O

METHODS	O
Fifty-six	O
male	O
patients	O
(	O
mean	O
age	O
71.2	O
+/-	O
8.2	O
years	O
)	O
scheduled	O
for	O
TURP	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Patients	O
were	O
randomized	O
to	O
one	O
of	O
two	O
groups	O
.	O

Group	O
1	O
consisted	O
of	O
27	O
patients	O
who	O
received	O
room	Physical
temperature	Physical
irrigation	Physical
fluid	Physical
(	Physical
70	Physical
degrees	Physical
F	Physical
)	Physical
throughout	O
TURP	Surgical
;	O
group	O
2	O
consisted	O
of	O
29	O
patients	O
whose	O
procedure	O
was	O
performed	O
with	O
warmed	Pharmacological
irrigation	Pharmacological
fluid	Pharmacological
(	O
91.5	O
degrees	O
F	O
)	O
.	O

The	O
irrigation	O
fluid	O
used	O
for	O
both	O
groups	O
was	O
glycine	O
.	O

The	O
baseline	O
temperature	O
,	O
final	O
temperature	O
,	O
total	O
time	O
in	O
the	O
operating	O
room	O
,	O
and	O
amount	O
of	O
irrigation	O
fluid	O
used	O
during	O
the	O
procedure	O
were	O
recorded	O
for	O
each	O
patient	O
.	O

RESULTS	O
No	O
significant	O
difference	O
in	O
the	O
average	O
time	O
spent	O
in	O
the	O
operating	O
room	O
or	O
in	O
the	O
total	O
irrigation	O
fluid	O
used	O
between	O
the	O
two	O
groups	O
was	O
observed	O
.	O

Of	O
the	O
27	O
patients	O
who	O
received	O
room	Physical
temperature	Physical
irrigation	Physical
fluid	Physical
,	O
15	O
(	O
55.6	O
%	O
)	O
had	O
a	O
decrease	O
in	O
body	O
temperature	O
.	O

A	O
decrease	O
in	O
temperature	O
was	O
observed	O
in	O
21	O
(	O
72.4	O
%	O
)	O
of	O
the	O
29	O
patients	O
who	O
received	O
warm	Pharmacological
irrigation	Pharmacological
fluid	Pharmacological
.	O

Groups	O
1	O
and	O
2	O
had	O
12	O
(	O
44.4	O
%	O
)	O
of	O
27	O
and	O
8	O
(	O
27.6	O
%	O
)	O
of	O
29	O
patients	O
,	O
respectively	O
,	O
who	O
demonstrated	O
an	O
elevation	O
in	O
their	O
core	O
body	O
temperature	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
irrigation	O
fluid	O
temperature	O
is	O
not	O
a	O
factor	O
responsible	O
for	O
altering	O
the	O
core	O
body	O
temperature	O
in	O
patients	O
undergoing	O
TURP	O
.	O

[	O
Postlaparoscopic	O
pain	O
syndrome	O
.	O

Results	O
of	O
a	O
prospective	O
,	O
randomized	O
study	O
]	O
.	O

The	O
so-called	O
post-laparoscopic	O
algesia	O
is	O
a	O
specific	O
impairment	O
of	O
about	O
63	O
%	O
of	O
the	O
patients	O
who	O
undergo	O
laparoscopic	Surgical
surgical	Surgical
operations	Surgical
.	O

This	O
impairment	O
takes	O
the	O
form	O
of	O
mild	O
to	O
moderate	O
shoulder	O
pain	O
.	O

Eliminating	O
the	O
causes	O
of	O
pain	O
has	O
a	O
clear	O
advantage	O
over	O
symptomatic	O
treatment	O
using	O
analgetics	O
,	O
a	O
fact	O
worth	O
a	O
good	O
consideration	O
especially	O
with	O
the	O
post-operative	O
sojourn	O
at	O
the	O
hospital	O
becoming	O
shorter	O
and	O
shorter	O
.	O

In	O
a	O
prospective	O
controlled	O
study	O
,	O
involving	O
42	O
patients	O
subdivided	O
into	O
four	O
groups	O
namely	O
,	O
higher	Physical
or	Physical
lower	Physical
insufflation	Physical
pressures	Physical
,	O
chemically	Physical
inert	Physical
insufflation	Physical
gas	Physical
and	O
control	Control
groups	O
;	O
the	O
use	O
of	O
analgetics	O
,	O
lung	O
function	O
,	O
operation	O
duration	O
,	O
amount	O
of	O
insufflated	O
gas	O
,	O
intraperitoneal	O
pH-values	O
and	O
post-operative	O
complications	O
in	O
the	O
various	O
subgroups	O
were	O
compared	O
to	O
each	O
other	O
with	O
regard	O
to	O
post-operative	O
pain	O
perception	O
.	O

The	O
results	O
did	O
not	O
show	O
any	O
significant	O
differences	O
among	O
the	O
groups	O
regarding	O
the	O
main	O
parameters	O
like	O
pH-value	O
or	O
different	O
insufflation	O
pressures	O
etc	O
.	O

These	O
results	O
led	O
to	O
the	O
termination	O
of	O
the	O
study	O
based	O
on	O
the	O
raised	O
criteria	O
since	O
we	O
anticipated	O
the	O
actual	O
cause	O
of	O
the	O
shoulder	O
pain	O
to	O
be	O
due	O
to	O
an	O
unknown	O
factor	O
.	O

By	O
the	O
evaluation	O
of	O
the	O
individual	O
data	O
,	O
it	O
became	O
apparent	O
that	O
,	O
the	O
pains	O
increase	O
with	O
increasing	O
gas	O
consumption	O
,	O
a	O
fact	O
which	O
led	O
to	O
assumption	O
that	O
the	O
pains	O
are	O
caused	O
by	O
a	O
physical	O
effect	O
such	O
as	O
the	O
cooling	O
of	O
the	O
peritoneum	O
.	O

Prediction	O
of	O
the	O
response	O
to	O
citalopram	Pharmacological
and	Pharmacological
reboxetine	Pharmacological
in	O
post-stroke	O
depressed	O
patients	O
.	O

RATIONALE	O
AND	O
OBJECTIVE	O
Depression	O
is	O
a	O
significant	O
complication	O
of	O
stroke	O
.	O

The	O
effectiveness	O
of	O
antidepressant	O
drugs	O
in	O
the	O
management	O
of	O
post-stroke	O
depression	O
(	O
PSD	O
)	O
has	O
been	O
widely	O
investigated	O
.	O

However	O
,	O
the	O
choice	O
of	O
antidepressant	O
drug	O
is	O
critically	O
influenced	O
by	O
its	O
safety	O
and	O
tolerability	O
and	O
by	O
its	O
effect	O
on	O
concurrent	O
pathologies	O
.	O

Here	O
we	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
selective	O
serotonin	Pharmacological
reuptake	Pharmacological
inhibitor	Pharmacological
(	Pharmacological
SSRI	Pharmacological
)	Pharmacological
,	Pharmacological
citalopram	Pharmacological
,	Pharmacological
and	Pharmacological
a	Pharmacological
noradrenaline	Pharmacological
reuptake	Pharmacological
inhibitor	Pharmacological
(	Pharmacological
NARI	Pharmacological
)	Pharmacological
,	Pharmacological
reboxetine	Pharmacological
,	O
in	O
post-stroke	O
patients	O
affected	O
by	O
anxious	O
depression	O
or	O
retarded	O
depression	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
double-blind	O
study	O
.	O

Seventy-four	O
post-stroke	O
depressed	O
patients	O
were	O
diagnosed	O
as	O
affected	O
by	O
anxious	O
or	O
retarded	O
depression	O
by	O
using	O
a	O
synoptic	O
table	O
.	O

Randomisation	O
was	O
planned	O
so	O
that	O
50	O
%	O
of	O
the	O
patients	O
in	O
each	O
subgroup	O
were	O
assigned	O
for	O
16	O
weeks	O
to	O
treatment	O
with	O
citalopram	Pharmacological
and	O
the	O
remaining	O
50	O
%	O
were	O
assigned	O
to	O
treatment	O
with	O
reboxetine	Pharmacological
.	O

The	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
,	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HDRS	O
)	O
and	O
a	O
synoptic	O
table	O
were	O
used	O
to	O
score	O
depressive	O
symptoms	O
.	O

RESULTS	O
Both	O
citalopram	Pharmacological
and	O
reboxetine	Pharmacological
showed	O
good	O
safety	O
and	O
tolerability	O
.	O

Citalopram	O
exhibited	O
greater	O
efficacy	O
in	O
anxious	O
depressed	O
patients	O
,	O
while	O
reboxetine	Pharmacological
was	O
more	O
effective	O
in	O
retarded	O
depressed	O
patients	O
.	O

CONCLUSIONS	O
Citalopram	Pharmacological
or	O
other	O
SSRIs	O
and	O
reboxetine	Pharmacological
may	O
be	O
of	O
first	O
choice	O
treatment	O
in	O
PSD	O
because	O
of	O
their	O
good	O
efficacy	O
and	O
lack	O
of	O
severe	O
side	O
effects	O
.	O

In	O
addition	O
,	O
PSD	O
patients	O
should	O
be	O
classified	O
according	O
to	O
their	O
clinical	O
profile	O
(	O
similarly	O
to	O
patients	O
affected	O
by	O
primary	O
depression	O
)	O
for	O
the	O
selection	O
of	O
SSRIs	O
or	O
reboxetine	O
as	O
drugs	O
of	O
choice	O
in	O
particular	O
subgroups	O
of	O
patients	O
.	O

Locomoting-to-reach	Physical
:	O
information	O
variables	O
and	O
control	O
strategies	O
for	O
nested	O
actions	O
.	O

Locomoting-to-reach	Physical
is	O
a	O
basic	O
perception/action	O
behavior	O
that	O
requires	O
visual	O
information	O
for	O
the	O
control	O
of	O
both	O
locomotion	O
and	O
reaching	O
components	O
.	O

We	O
investigated	O
the	O
visual	O
information	O
and	O
the	O
control	O
strategies	O
used	O
to	O
guide	O
both	O
the	O
head	O
and	O
the	O
hand	O
on	O
approach	O
to	O
a	O
target	O
in	O
a	O
locomotion-to-reach	Physical
task	Physical
.	O

In	O
this	O
study	O
,	O
participants	O
were	O
required	O
to	O
locomote	O
in	O
the	O
dark	O
to	O
a	O
lit	O
target	O
in	O
three	O
different	O
conditions	O
:	O
monocular	O
vision/target	O
with	O
image	O
size	O
,	O
binocular	O
vision/target	O
with	O
image	O
size	O
,	O
and	O
binocular	O
vision/point-light	O
target	O
(	O
without	O
image	O
size	O
)	O
.	O

In	O
task	O
one	O
,	O
participants	O
brought	O
their	O
eyes	O
to	O
the	O
target	O
.	O

In	O
task	O
two	O
,	O
participants	O
brought	O
their	O
outstretched	O
hand	O
to	O
the	O
target	O
.	O

Movement	O
trajectories	O
for	O
both	O
tasks	O
were	O
analyzed	O
.	O

Results	O
show	O
that	O
participants	O
were	O
significantly	O
more	O
accurate	O
when	O
binocular	O
information	O
was	O
present	O
.	O

In	O
both	O
tasks	O
,	O
participants	O
were	O
found	O
to	O
use	O
a	O
proportional	O
rate	O
control	O
strategy	O
rather	O
than	O
a	O
constant	O
?	O
strategy	O
.	O

In	O
the	O
walk-to-reach	O
task	O
,	O
they	O
used	O
monocular	O
and/or	O
binocular	O
?	O
information	O
to	O
guide	O
the	O
head	O
and	O
then	O
switched	O
to	O
using	O
relative	O
disparity	O
?	O
to	O
guide	O
the	O
hand	O
to	O
final	O
target	O
acquisition	O
,	O
switching	O
when	O
the	O
hand	O
centric	O
?	O
became	O
less	O
than	O
the	O
head	O
centric	O
?.	O
Dynamical	O
models	O
of	O
the	O
information	O
and	O
control	O
strategies	O
were	O
used	O
to	O
perform	O
simulations	O
that	O
were	O
found	O
to	O
fit	O
the	O
data	O
well	O
.	O

The	O
conclusion	O
is	O
that	O
proportional	O
rate	O
control	O
is	O
used	O
sequentially	O
with	O
head	O
centric	O
,	O
then	O
hand-centric	O
?-based	O
information	O
,	O
using	O
at	O
each	O
moment	O
the	O
?	O
with	O
the	O
smallest	O
value	O
.	O

Effects	O
of	O
fatty	Pharmacological
and	Pharmacological
lean	Pharmacological
fish	Pharmacological
intake	Pharmacological
on	O
blood	O
pressure	O
in	O
subjects	O
with	O
coronary	O
heart	O
disease	O
using	O
multiple	O
medications	O
.	O

BACKGROUND	O
Intake	O
of	O
fish	O
and	O
long-chain	O
n-3	O
fatty	O
acids	O
has	O
been	O
of	O
wide	O
interest	O
due	O
to	O
their	O
beneficial	O
effects	O
on	O
cardiovascular	O
risk	O
factors	O
and	O
lower	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
risk	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
fatty	Physical
fish	Physical
and	O
lean	Physical
(	Physical
white	Physical
)	Physical
fish	Physical
on	O
fatty	O
acid	O
composition	O
of	O
serum	O
lipids	O
and	O
cardiovascular	O
risk	O
factors	O
in	O
subjects	O
with	O
CHD	O
using	O
multiple	O
drugs	O
for	O
this	O
condition	O
.	O

METHODS	O
The	O
study	O
was	O
an	O
8-week	O
controlled	O
,	O
parallel	O
intervention	O
.	O

Inclusion	O
criteria	O
were	O
myocardial	O
infarction	O
or	O
unstable	O
ischemic	O
attack	O
,	O
age	O
under	O
70	O
years	O
,	O
use	O
of	O
betablockers	O
and	O
presence	O
of	O
sinus	O
rhythm	O
.	O

The	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
the	O
following	O
groups	O
:	O
4	Educational
meals/week	Educational
fatty	Physical
fish	Physical
(	Educational
n	Educational
=	Educational
11	Educational
)	Educational
,	Educational
4	Educational
meals/week	Educational
lean	Physical
fish	Physical
(	Educational
n	Educational
=	Educational
12	Educational
)	Educational
and	Educational
control	Control
diet	Control
including	Educational
lean	Educational
meat	Educational
(	Educational
n	Educational
=	Educational
10	Educational
)	Educational
.	Educational

RESULTS	O
The	O
mean	O
(	O
+/-SD	O
)	O
of	O
reported	O
fish	O
meals	O
per	O
week	O
was	O
4.3	O
+/-	O
0.4	O
,	O
4.7	O
+/-	O
1.1	O
and	O
0.6	O
+/-	O
0.4	O
in	O
the	O
groups	O
,	O
respectively	O
.	O

The	O
proportions	O
of	O
eicosapentaenoic	O
and	O
docosahexaenoic	O
acids	O
in	O
serum	O
lipids	O
increased	O
in	O
the	O
fatty	O
fish	O
group	O
only	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Systolic	O
and	O
diastolic	O
blood	O
pressure	O
levels	O
decreased	O
in	O
the	O
lean	O
fish	O
group	O
(	O
0	O
vs.	O
8	O
week	O
:	O
3.5	O
+/-	O
3.2	O
and	O
4.6	O
+/-	O
3.6	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
total	O
triglyceride	O
concentration	O
did	O
not	O
significantly	O
change	O
.	O

HDL	O
cholesterol	O
concentration	O
change	O
differed	O
among	O
groups	O
but	O
without	O
significant	O
post	O
hoc	O
differences	O
.	O

Apolipoprotein	O
A-1	O
concentration	O
decreased	O
in	O
the	O
control	O
group	O
(	O
0	O
vs.	O
8	O
week	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Coagulation	O
factors	O
,	O
25-hydroxy	O
vitamin	O
D	O
,	O
and	O
heart	O
rate	O
variability	O
(	O
24	O
h	O
Holter	O
)	O
did	O
not	O
change	O
among	O
the	O
groups	O
.	O

CONCLUSIONS	O
Our	O
results	O
suggest	O
that	O
intake	O
of	O
lean	Physical
fish	Physical
at	O
least	O
four	O
times	O
per	O
week	O
could	O
reduce	O
blood	O
pressure	O
levels	O
in	O
CHD	O
patients	O
.	O

Efficacy	O
and	O
safety	O
relative	O
to	O
placebo	Control
of	O
an	O
oral	O
formulation	O
of	O
cetirizine	Pharmacological
and	O
sustained-release	O
pseudoephedrine	Pharmacological
in	O
the	O
management	O
of	O
nasal	O
congestion	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
efficacy	O
of	O
an	O
oral	O
formulation	O
of	O
cetirizine	Pharmacological
5	O
mg	O
with	O
sustained-release	O
pseudoephedrine	Pharmacological
(	O
PSE	O
)	O
120	O
mg	O
relative	O
to	O
placebo	Control
in	O
patients	O
with	O
nasal	O
congestion	O
.	O

METHODS	O
Twenty-four	O
patients	O
with	O
perennial	O
rhinitis	O
due	O
to	O
house-dust-mite	O
(	O
HDM	O
)	O
allergy	O
were	O
recruited	O
in	O
this	O
crossover	O
study	O
.	O

A	O
treatment	O
period	O
of	O
1	O
week	O
,	O
in	O
which	O
cetirizine/PSE	Pharmacological
was	O
administered	O
twice	O
daily	O
,	O
was	O
followed	O
by	O
a	O
washout	O
period	O
of	O
at	O
least	O
2	O
weeks	O
and	O
a	O
further	O
period	O
of	O
1	O
week	O
in	O
which	O
the	O
alternative	O
treatment	O
was	O
given	O
to	O
each	O
patient	O
.	O

Immediately	O
after	O
the	O
first	O
dose	O
of	O
each	O
medication	O
(	O
day	O
1	O
)	O
,	O
nasal	O
congestion	O
and	O
related	O
symptoms	O
were	O
assessed	O
during	O
a	O
7-h	O
challenge	O
with	O
HDM	O
feces	O
,	O
with	O
the	O
Vienna	O
Challenge	O
Chamber	O
(	O
VCC	O
)	O
,	O
to	O
investigate	O
onset	O
of	O
action	O
of	O
the	O
preparation	O
.	O

A	O
second	O
challenge	O
of	O
3-h	O
duration	O
,	O
carried	O
out	O
at	O
least	O
12	O
h	O
after	O
the	O
final	O
dose	O
,	O
was	O
undertaken	O
after	O
1	O
week	O
(	O
mean	O
)	O
of	O
twice-daily	O
treatment	O
to	O
assess	O
residual	O
effects	O
of	O
the	O
formulation	O
after	O
achievement	O
of	O
steady	O
state	O
.	O

RESULTS	O
The	O
oral	O
formulation	O
of	O
cetirizine/PSE	Pharmacological
was	O
significantly	O
(	O
P	O
<	O
0.001	O
)	O
superior	O
to	O
placebo	Control
in	O
improving	O
nasal	O
obstruction	O
during	O
both	O
challenges	O
.	O

The	O
improvement	O
in	O
nasal	O
airflow	O
and	O
nasal	O
patency	O
was	O
significantly	O
greater	O
with	O
cetirizine/PSE	Pharmacological
than	O
with	O
placebo	Control
(	O
P	O
<	O
0.02	O
)	O
.	O

In	O
addition	O
,	O
subjective	O
assessment	O
of	O
nasal	O
symptoms	O
showed	O
that	O
cetirizine/PSE	O
was	O
significantly	O
superior	O
to	O
placebo	Control
in	O
both	O
challenges	O
for	O
the	O
sum	O
of	O
nasal	O
obstruction	O
scores	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Both	O
medications	O
were	O
well	O
tolerated	O
,	O
and	O
no	O
serious	O
adverse	O
events	O
occurred	O
during	O
the	O
study	O
.	O

CONCLUSIONS	O
In	O
this	O
study	O
,	O
cetirizine/PSE	Pharmacological
relieved	O
nasal	O
congestion	O
and	O
other	O
objective	O
and	O
subjective	O
symptoms	O
to	O
a	O
significantly	O
greater	O
extent	O
than	O
placebo	O
.	O

No	O
serious	O
adverse	O
events	O
occurred	O
,	O
and	O
both	O
regimens	O
were	O
equally	O
well	O
tolerated	O
.	O

Intravesical	Physical
seeding	Physical
of	Physical
upper	Physical
urinary	Physical
tract	Physical
urothelial	Physical
carcinoma	Physical
cells	Physical
during	O
nephroureterectomy	Physical
:	O
an	O
exploratory	O
analysis	O
from	O
the	O
THPMG	O
trial	O
.	O

OBJECTIVE	O
The	O
Pirarubicin	O
Monotherapy	O
Study	O
Group	O
trial	O
was	O
a	O
randomized	O
Phase	O
II	O
study	O
that	O
evaluated	O
the	O
efficacy	O
of	O
intravesical	O
instillation	O
of	O
pirarubicin	Pharmacological
in	O
the	O
prevention	O
of	O
bladder	O
recurrence	O
after	O
nephroureterectomy	O
for	O
upper	O
urinary	O
tract	O
urothelial	O
carcinoma	O
.	O

This	O
study	O
conducted	O
further	O
analysis	O
of	O
the	O
Pirarubicin	O
Monotherapy	O
Study	O
Group	O
cohort	O
,	O
focusing	O
on	O
intravesical	Physical
seeding	Physical
of	Physical
cancer	Physical
cells	Physical
.	O

METHODS	O
Using	O
the	O
data	O
from	O
the	O
Pirarubicin	O
Monotherapy	O
Study	O
Group	O
trial	O
,	O
bladder	O
recurrence-free	O
survival	O
rates	O
and	O
factors	O
associated	O
with	O
bladder	O
recurrence	O
in	O
the	O
control	O
group	O
were	O
analyzed	O
.	O

RESULTS	O
Of	O
36	O
patients	O
in	O
the	O
control	Control
group	O
,	O
14	O
with	O
positive	O
urine	O
cytology	O
had	O
more	O
frequent	O
recurrence	O
when	O
compared	O
with	O
the	O
22	O
patients	O
with	O
negative	O
cytology	O
(	O
P	O
=	O
0.004	O
)	O
.	O

Based	O
on	O
the	O
multivariate	O
analysis	O
in	O
the	O
control	O
group	O
,	O
voided	O
urine	O
cytology	O
was	O
an	O
independent	O
predictive	O
factor	O
of	O
bladder	O
recurrence	O
(	O
hazard	O
ratio	O
,	O
5.54	O
;	O
95	O
%	O
confidence	O
interval	O
1.12-27.5	O
;	O
P	O
=	O
0.036	O
)	O
.	O

Of	O
72	O
patients	O
in	O
the	O
Pirarubicin	O
Monotherapy	O
Study	O
Group	O
trial	O
,	O
31	O
had	O
positive	O
urine	O
cytology	O
.	O

Among	O
the	O
31	O
patients	O
,	O
17	O
patients	O
who	O
received	O
pirarubicin	Pharmacological
instillation	Pharmacological
had	O
fewer	O
recurrences	O
when	O
compared	O
with	O
14	O
patients	O
who	O
received	O
control	O
treatment	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

On	O
multivariate	O
analysis	O
,	O
pirarubicin	O
instillation	O
was	O
an	O
independent	O
predictor	O
of	O
better	O
recurrence-free	O
survival	O
rates	O
in	O
the	O
patients	O
with	O
positive	O
urine	O
cytology	O
(	O
hazard	O
ratio	O
,	O
0.02	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.00-0.53	O
;	O
P	O
=	O
0.018	O
)	O
.	O

Of	O
21	O
patients	O
with	O
bladder	O
recurrence	O
,	O
17	O
had	O
recurrent	O
tumor	O
around	O
cystotomy	O
or	O
in	O
the	O
bladder	O
neck	O
compromised	O
by	O
the	O
urethral	O
catheter	O
,	O
supporting	O
the	O
notion	O
that	O
tumor	O
cells	O
seeded	O
in	O
the	O
injured	O
urothelium	O
.	O

CONCLUSIONS	O
Intravesical	Pharmacological
instillation	Pharmacological
of	Pharmacological
pirarubicin	Pharmacological
immediately	O
after	O
nephroureterectomy	Pharmacological
significantly	O
reduced	O
the	O
bladder	O
recurrence	O
rate	O
in	O
patients	O
with	O
positive	O
voided	O
urine	O
cytology	O
.	O

The	O
results	O
suggest	O
that	O
intravesical	O
seeding	O
of	O
upper	O
urinary	O
tract	O
urothelial	O
carcinoma	O
occurs	O
during	O
nephroureterectomy	O
.	O

Diet	O
design	O
for	O
a	O
multicenter	O
controlled	O
feeding	O
trial	O
:	O
the	O
DELTA	O
program	O
.	O

Delta	O
Research	O
Group	O
.	O

OBJECTIVE	O
To	O
describe	O
the	O
process	O
and	O
results	O
of	O
diet	O
standardization	O
,	O
diet	O
validation	O
,	O
and	O
monitoring	O
of	O
diet	O
composition	O
,	O
which	O
were	O
key	O
components	O
of	O
protocol	O
1	O
of	O
Dietary	O
Effects	O
on	O
Lipoproteins	O
and	O
Thrombogenic	O
Activity	O
(	O
DELTA-1	O
)	O
,	O
the	O
initial	O
protocol	O
in	O
a	O
program	O
of	O
multicenter	O
human	O
feeding	O
studies	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
amount	O
and	O
type	O
of	O
fat	O
on	O
lipoproteins	O
and	O
hemostasis	O
parameters	O
in	O
various	O
demographic	O
groups	O
.	O

DESIGN	O
DELTA-1	O
was	O
based	O
on	O
a	O
randomized	O
,	O
blinded	O
,	O
crossover	O
experimental	O
design	O
.	O

Three	Pharmacological
diets	Pharmacological
were	O
fed	O
for	O
8	O
weeks	O
to	O
103	O
healthy	O
men	O
and	O
women	O
aged	O
22	O
to	O
67	O
years	O
at	O
4	O
field	O
centers	O
.	O

Diet	Pharmacological
A	Pharmacological
,	Pharmacological
an	Physical
average	Physical
American	Physical
diet	Physical
,	Pharmacological
was	Pharmacological
designed	Pharmacological
to	Pharmacological
provide	Pharmacological
37	Pharmacological
%	Pharmacological
of	Pharmacological
energy	Pharmacological
from	Pharmacological
fat	Pharmacological
,	Pharmacological
16	Pharmacological
%	Pharmacological
of	Pharmacological
energy	Pharmacological
from	Pharmacological
saturated	Pharmacological
fatty	Pharmacological
acids	Pharmacological
(	Pharmacological
SFAs	Pharmacological
)	Pharmacological
;	O
diet	Pharmacological
B	Pharmacological
(	Pharmacological
step	Pharmacological
1	Pharmacological
diet	Pharmacological
)	Pharmacological
was	Pharmacological
designed	Pharmacological
to	Pharmacological
provide	Pharmacological
30	Pharmacological
%	Pharmacological
of	Pharmacological
energy	Pharmacological
from	Pharmacological
fat	Pharmacological
,	Pharmacological
9	Pharmacological
%	Pharmacological
of	Pharmacological
energy	Pharmacological
from	Pharmacological
SFA	Pharmacological
;	O
and	O
diet	Pharmacological
C	Pharmacological
(	Pharmacological
low	Pharmacological
SFA	Pharmacological
diet	Pharmacological
)	Pharmacological
was	Pharmacological
designed	Pharmacological
to	Pharmacological
provide	Pharmacological
26	Pharmacological
%	Pharmacological
of	Pharmacological
energy	Pharmacological
from	Pharmacological
fat	Pharmacological
,	Pharmacological
5	Pharmacological
%	Pharmacological
of	Pharmacological
energy	Pharmacological
from	O
SFA	O
.	O

Key	O
features	O
of	O
diet	O
standardization	O
included	O
central	O
procurement	O
of	O
fat-containing	O
foods	O
,	O
inclusion	O
of	O
standard	O
ingredients	O
,	O
precision	O
weighing	O
of	O
foods	O
--	O
especially	O
sources	O
of	O
fat	O
and	O
cholesterol	O
--	O
and	O
use	O
of	O
standardized	O
written	O
procedures	O
.	O

SETTING	O
For	O
menu	O
validation	O
,	O
a	O
set	O
of	O
12	O
menus	O
for	O
each	O
diet	O
was	O
prepared	O
in	O
duplicate	O
and	O
chemically	O
assayed	O
.	O

For	O
monitoring	O
of	O
diet	O
composition	O
during	O
the	O
study	O
,	O
an	O
8-day	O
diet	O
cycle	O
(	O
6	O
weekday	O
and	O
2	O
weekend	O
menus	O
)	O
was	O
sampled	O
by	O
every	O
field	O
center	O
twice	O
during	O
each	O
of	O
3	O
feeding	O
periods	O
.	O

STATISTICAL	O
ANALYSES	O
Means	O
(	O
+/-	O
standard	O
error	O
)	O
were	O
calculated	O
and	O
compared	O
with	O
target	O
nutrient	O
specifications	O
.	O

RESULTS	O
DELTA-1	O
was	O
able	O
to	O
provide	O
a	O
standardized	O
diet	O
that	O
met	O
nutrient	O
specifications	O
across	O
4	O
field	O
centers	O
over	O
24	O
weeks	O
of	O
participant	O
feeding	O
spanning	O
a	O
total	O
of	O
8	O
months	O
.	O

APPLICATIONS	O
Prestudy	O
chemical	O
validation	O
of	O
menus	O
and	O
continuous	O
sampling	O
and	O
assay	O
of	O
diets	O
throughout	O
the	O
study	O
are	O
essential	O
to	O
standardize	O
experimental	O
diets	O
and	O
to	O
ensure	O
that	O
nutrient	O
target	O
goals	O
are	O
met	O
and	O
maintained	O
throughout	O
a	O
controlled	O
multicenter	O
feeding	O
study	O
.	O

Comparison	O
between	O
intermittent	Physical
mandatory	Physical
ventilation	Physical
and	O
synchronized	Physical
intermittent	Physical
mandatory	Physical
ventilation	Physical
with	O
pressure	Physical
support	Physical
in	O
children	O
.	O

OBJECTIVE	O
To	O
compare	O
intermittent	Physical
mandatory	Physical
ventilation	Physical
(	Physical
IMV	Physical
)	Physical
with	O
synchronized	Physical
intermittent	Physical
mandatory	Physical
ventilation	Physical
plus	Physical
pressure	Physical
support	Physical
(	Physical
SIMV+PS	Physical
)	Physical
in	O
terms	O
of	O
time	O
on	O
mechanical	O
ventilation	O
,	O
duration	O
of	O
weaning	O
and	O
length	O
of	O
stay	O
in	O
a	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
clinical	O
trial	O
that	O
enrolled	O
children	O
aged	O
28	O
days	O
to	O
4	O
years	O
who	O
were	O
admitted	O
to	O
a	O
PICU	O
between	O
October	O
of	O
2005	O
and	O
June	O
of	O
2007	O
and	O
put	O
on	O
mechanical	Physical
ventilation	Physical
(	Physical
MV	Physical
)	Physical
for	O
more	O
than	O
48	O
hours	O
.	O

These	O
patients	O
were	O
allocated	O
to	O
one	O
of	O
two	O
groups	O
by	O
drawing	O
lots	O
:	O
IMV	Physical
group	O
(	Physical
IMVG	Physical
;	O
n	O
=	O
35	O
)	O
and	O
SIMV+PS	Physical
group	O
(	O
SIMVG	Physical
;	O
n	O
=	O
35	O
)	O
.	O

Children	O
were	O
excluded	O
if	O
they	O
had	O
undergone	O
tracheotomy	O
or	O
had	O
chronic	O
respiratory	O
diseases	O
.	O

Data	O
on	O
oxygenation	O
and	O
ventilation	O
were	O
recorded	O
at	O
admission	O
and	O
at	O
the	O
start	O
of	O
weaning	O
.	O

RESULTS	O
There	O
were	O
no	O
statistical	O
differences	O
between	O
the	O
groups	O
in	O
terms	O
of	O
age	O
,	O
sex	O
,	O
indication	O
for	O
MV	O
,	O
PRISM	O
score	O
,	O
Comfort	O
scale	O
,	O
use	O
of	O
sedatives	O
or	O
ventilation	O
and	O
oxygenation	O
parameters	O
.	O

The	O
median	O
time	O
on	O
MV	O
was	O
5	O
days	O
for	O
both	O
groups	O
(	O
p	O
=	O
0.120	O
)	O
.	O

There	O
were	O
also	O
no	O
statistical	O
differences	O
between	O
the	O
two	O
groups	O
for	O
duration	O
of	O
weaning	O
[	O
IMVG	Physical
:	O
1	O
day	O
(	O
1-6	O
)	O
vs.	O
SIMVG	Physical
:	O
1	O
day	O
(	O
1-6	O
)	O
;	O
p	O
=	O
0.262	O
]	O
or	O
length	O
of	O
hospital	O
stay	O
[	O
IMVG	Physical
:	O
8	O
days	O
(	O
2-22	O
)	O
vs.	O
SIMVG	Physical
:	O
6	O
days	O
(	O
3-20	O
)	O
;	O
p	O
=	O
0.113	O
]	O
.	O

CONCLUSION	O
Among	O
the	O
children	O
studied	O
here	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
IMV	Physical
and	O
SIMV+PS	Physical
in	O
terms	O
of	O
time	O
on	O
MV	O
,	O
duration	O
of	O
weaning	O
or	O
time	O
spent	O
in	O
the	O
PICU	O
.	O

ClinicalTrials.govID	O
:	O
NCT00549809	O
.	O

Involvement	O
of	O
cholecystokininA	O
receptors	O
in	O
transient	O
lower	O
esophageal	O
sphincter	O
relaxations	O
triggered	O
by	O
gastric	O
distension	O
.	O

OBJECTIVE	O
Transient	O
lower	O
esophageal	O
sphincter	O
relaxations	O
(	O
TLESRs	O
)	O
are	O
the	O
main	O
mechanism	O
underlying	O
gastroesophageal	O
reflux	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
effect	O
of	O
loxiglumide	O
,	O
a	O
specific	O
cholecystokininA	O
(	O
CCKA	O
)	O
-receptor	O
antagonist	O
,	O
on	O
the	O
occurrence	O
of	O
TLESRs	O
evoked	O
by	O
gastric	O
distension	O
.	O

METHODS	O
Eight	O
healthy	O
subjects	O
underwent	O
esophageal	O
manometry	O
using	O
a	O
10-lumen	Physical
sleeve	Physical
assembly	Physical
during	Physical
placebo	Physical
or	O
loxiglumide	Pharmacological
(	O
10	O
mg/kg/h	O
)	O
in	O
a	O
randomized	O
double-blind	O
order	O
.	O

Gastric	O
distension	O
was	O
induced	O
by	O
inflation	O
of	O
400	O
ml	O
of	O
air	O
.	O

RESULTS	O
Basal	O
lower	O
esophageal	O
pressure	O
(	O
LESP	O
)	O
and	O
swallow-induced	O
relaxation	O
were	O
not	O
affected	O
by	O
loxiglumide	O
.	O

Loxiglumide	O
significantly	O
reduced	O
the	O
number	O
of	O
TLESRs	O
,	O
from	O
11.5	O
(	O
5.8-18.3	O
)	O
to	O
6.0	O
(	O
3.3-14.3	O
)	O
during	O
the	O
total	O
recording	O
period	O
of	O
1	O
h	O
,	O
and	O
from	O
5.5	O
(	O
4.25-7.5	O
)	O
to	O
2.0	O
(	O
0.5-6.8	O
)	O
during	O
the	O
first	O
15	O
min	O
.	O

The	O
number	O
of	O
common	O
cavities	O
was	O
significantly	O
decreased	O
by	O
loxiglumide	O
,	O
from	O
8.0	O
(	O
4.0-20.0	O
)	O
to	O
5.0	O
(	O
2.0-7.8	O
)	O
.	O

TLESRs	O
represented	O
the	O
main	O
mechanism	O
(	O
60	O
%	O
during	O
placebo	O
,	O
74	O
%	O
during	O
loxiglumide	O
)	O
underlying	O
common	O
cavities	O
,	O
followed	O
by	O
swallow-induced	O
relaxation	O
.	O

CONCLUSIONS	O
Loxiglumide	O
significantly	O
reduces	O
the	O
number	O
of	O
TLESRs	O
triggered	O
by	O
gastric	O
distension	O
without	O
interfering	O
with	O
swallow-related	O
relaxation	O
of	O
the	O
lower	O
esophageal	O
sphincter	O
,	O
suggesting	O
the	O
involvement	O
of	O
CCKA	O
receptors	O
in	O
the	O
reflex	O
pathway	O
mediating	O
TLESRs	O
.	O

The	O
Toronto	O
prehospital	O
hypertonic	O
resuscitation	O
--	O
head	O
injury	O
and	O
multiorgan	O
dysfunction	O
trial	O
:	O
feasibility	O
study	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
a	O
prehospital	O
trial	O
comparing	O
hypertonic	Pharmacological
saline	Pharmacological
and	Pharmacological
dextran	Pharmacological
(	Pharmacological
HSD	Pharmacological
)	Pharmacological
with	O
normal	Pharmacological
saline	Pharmacological
(	Pharmacological
NS	Pharmacological
)	O
in	O
blunt	O
head	O
injury	O
patients	O
.	O

DESIGN	O
The	O
study	O
used	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

SETTING	O
The	O
study	O
was	O
conducted	O
in	O
air	O
and	O
land	O
emergency	O
medical	O
services	O
and	O
2	O
trauma	O
centers	O
serving	O
a	O
population	O
of	O
4	O
million	O
people	O
.	O

PATIENTS	O
The	O
study	O
population	O
consisted	O
of	O
head	O
injured	O
,	O
blunt	O
trauma	O
adult	O
patients	O
with	O
a	O
Glasgow	O
Coma	O
Scale	O
of	O
lower	O
than	O
9	O
.	O

INTERVENTIONS	O
We	O
used	O
250	Pharmacological
mL	Pharmacological
of	Pharmacological
HSD	Pharmacological
vs	O
NS	Pharmacological
given	O
within	O
4	O
hours	O
of	O
the	O
accident	O
.	O

MEASUREMENTS	O
The	O
specific	O
objectives	O
were	O
to	O
assess	O
protocol-related	O
logistical	O
issues	O
,	O
randomization	O
,	O
HSD	Pharmacological
safety	O
,	O
and	O
follow	O
up	O
rates	O
and	O
to	O
obtain	O
survival	O
and	O
neurocognitive	O
end	O
point	O
estimates	O
.	O

MAIN	O
RESULTS	O
Of	O
132	O
eligible	O
patients	O
,	O
113	O
were	O
randomized	O
.	O

Nineteen	O
eligible	O
patients	O
were	O
missed	O
because	O
of	O
lack	O
of	O
time	O
(	O
9	O
[	O
22	O
%	O
]	O
)	O
,	O
paramedic	O
discretion	O
(	O
3	O
[	O
7	O
%	O
]	O
)	O
,	O
the	O
paramedic	O
forgot	O
(	O
6	O
[	O
15	O
%	O
]	O
)	O
,	O
and	O
the	O
paramedic	O
refused	O
(	O
1	O
[	O
2	O
%	O
]	O
)	O
.	O

Randomization	O
compliance	O
was	O
96	O
%	O
(	O
109/113	O
)	O
.	O

Four	O
randomized	O
cases	O
met	O
exclusion	O
criteria	O
:	O
penetrating	O
trauma	O
(	O
1	O
)	O
,	O
cardiac	O
arrest	O
(	O
2	O
)	O
,	O
and	O
fall	O
from	O
standing	O
(	O
1	O
)	O
.	O

Three	O
randomized	O
patients	O
were	O
excluded	O
from	O
the	O
final	O
analysis	O
:	O
2	O
patients	O
received	O
less	O
than	O
50	O
mL	O
of	O
study	O
solution	O
due	O
to	O
an	O
interstitial	O
intravenous	O
line	O
and	O
1	O
lost	O
randomization	O
identification	O
.	O

Fifty	O
patients	O
(	O
47	O
%	O
)	O
were	O
randomized	O
to	O
HSD	O
and	O
56	O
(	O
53	O
%	O
)	O
to	O
NS	O
.	O

Mean	O
injury	O
severity	O
score	O
was	O
32.7	O
for	O
HSD	O
and	O
32.6	O
for	O
NS	O
.	O

There	O
was	O
no	O
difference	O
in	O
length	O
of	O
stay	O
,	O
Sequential	O
Organ	O
Failure	O
Assessment	O
maximum	O
,	O
Multiple	O
Organ	O
Dysfunction	O
Score	O
maximum	O
,	O
delta	O
Multiple	O
Organ	O
Dysfunction	O
Score	O
,	O
or	O
Apache	O
scores	O
.	O

Initial	O
head	O
scans	O
scored	O
3	O
or	O
higher	O
by	O
Marshall	O
classification	O
for	O
12	O
HSD	O
and	O
11	O
NS	O
patients	O
.	O

Zero	O
adverse	O
events	O
occurred	O
,	O
and	O
follow-up	O
for	O
the	O
primary	O
outcome	O
was	O
100	O
%	O
.	O

Alive	O
at	O
30	O
days	O
for	O
HSD	O
and	O
NS	O
,	O
respectively	O
,	O
was	O
70	O
%	O
(	O
35/50	O
)	O
and	O
75	O
%	O
(	O
42/56	O
)	O
and	O
at	O
discharge	O
was	O
68	O
%	O
(	O
34/50	O
)	O
and	O
73	O
%	O
(	O
41/56	O
)	O
.	O

Only	O
49.3	O
%	O
(	O
37/77	O
)	O
of	O
surviving	O
patients	O
consented	O
to	O
follow-up	O
at	O
4	O
months	O
and	O
89	O
%	O
(	O
33/37	O
)	O
completed	O
the	O
assessment	O
.	O

Disability	O
rating	O
scale	O
(	O
median	O
,	O
interquartile	O
range	O
)	O
was	O
3	O
(	O
0	O
,	O
6	O
)	O
for	O
HSD	O
and	O
was	O
0	O
(	O
0	O
,	O
6	O
)	O
for	O
NS	O
.	O

Glasgow	O
Outcome	O
Scale	O
Evaluation	O
was	O
higher	O
than	O
4	O
for	O
HSD	O
(	O
12/12	O
[	O
100	O
%	O
]	O
)	O
and	O
NS	O
(	O
15/21	O
[	O
72	O
%	O
]	O
)	O
.	O

Functional	O
Independence	O
Measure	O
(	O
mean	O
,	O
SD	O
)	O
was	O
62	O
(	O
37	O
)	O
for	O
HSD	O
and	O
80	O
(	O
32	O
)	O
for	O
NS	O
.	O

CONCLUSIONS	O
It	O
is	O
feasible	O
to	O
conduct	O
a	O
prehospital	O
randomized	O
controlled	O
trial	O
with	O
HSD	O
for	O
treatment	O
of	O
blunt	O
trauma	O
patients	O
with	O
head	O
injuries	O
;	O
however	O
,	O
consent	O
for	O
neurofunctional	O
outcomes	O
in	O
this	O
cohort	O
is	O
problematic	O
and	O
threatens	O
the	O
feasibility	O
of	O
definitive	O
trials	O
using	O
these	O
potentially	O
meaningful	O
end	O
points	O
.	O

Polymorphisms	O
of	O
ADORA2A	O
modulate	O
psychomotor	O
vigilance	O
and	O
the	O
effects	O
of	O
caffeine	O
on	O
neurobehavioural	O
performance	O
and	O
sleep	O
EEG	O
after	O
sleep	O
deprivation	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Prolonged	O
wakefulness	O
impairs	O
sustained	O
vigilant	O
attention	O
,	O
measured	O
with	O
the	O
psychomotor	O
vigilance	O
task	O
(	O
PVT	O
)	O
,	O
and	O
induces	O
a	O
compensatory	O
increase	O
in	O
sleep	O
intensity	O
in	O
recovery	O
sleep	O
,	O
quantified	O
by	O
slow-wave	O
activity	O
(	O
SWA	O
)	O
in	O
the	O
sleep	O
electroencephalogram	O
(	O
EEG	O
)	O
.	O

These	O
effects	O
of	O
sleep	O
deprivation	O
are	O
counteracted	O
by	O
the	O
adenosine	O
receptor	O
antagonist	O
caffeine	O
,	O
implying	O
involvement	O
of	O
the	O
adenosine	O
neuromodulator/receptor	O
system	O
.	O

To	O
examine	O
a	O
role	O
for	O
adenosine	O
A	O
(	O
2A	O
)	O
receptors	O
,	O
we	O
investigated	O
whether	O
variation	O
of	O
the	O
A	O
(	O
2A	O
)	O
receptor	O
gene	O
(	O
ADORA2A	O
)	O
modified	O
effects	O
of	O
caffeine	Pharmacological
on	O
PVT	O
and	O
SWA	O
after	O
sleep	Physical
deprivation	Physical
.	O

EXPERIMENTAL	O
APPROACH	O
A	O
haplotype	O
analysis	O
of	O
eight	O
single-nucleotide	O
polymorphisms	O
of	O
ADORA2A	O
was	O
performed	O
in	O
82	O
volunteers	O
.	O

In	O
45	O
young	O
men	O
carrying	O
five	O
different	O
allele	O
combinations	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
prolonged	O
waking	O
and	O
2	O
?	O
200	O
mg	O
caffeine	O
or	O
2	O
?	O
100	O
mg	O
modafinil	O
on	O
psychomotor	O
vigilance	O
,	O
sleepiness	O
,	O
and	O
the	O
waking	O
and	O
sleep	O
EEG	O
.	O

KEY	O
RESULTS	O
Throughout	O
extended	O
wakefulness	O
,	O
the	O
carriers	O
of	O
haplotype	O
HT4	O
performed	O
faster	O
on	O
the	O
PVT	O
than	O
carriers	O
of	O
non-HT4	O
haplotype	O
alleles	O
.	O

In	O
haplotype	O
HT4	O
,	O
caffeine	O
failed	O
to	O
counteract	O
the	O
waking-induced	O
impairment	O
of	O
PVT	O
performance	O
and	O
the	O
rebound	O
of	O
SWA	O
in	O
recovery	O
sleep	O
.	O

However	O
,	O
caffeine	O
was	O
effective	O
in	O
non-HT4	O
allele	O
carriers	O
,	O
and	O
modafinil	O
reduced	O
the	O
consequences	O
of	O
prolonged	O
waking	O
,	O
independently	O
of	O
ADORA2A	O
haplotype	O
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
Common	O
genetic	O
variation	O
of	O
ADORA2A	O
is	O
an	O
important	O
determinant	O
of	O
psychomotor	O
vigilance	O
in	O
rested	O
and	O
sleep-deprived	O
state	O
.	O

It	O
also	O
modulates	O
individual	O
responses	O
to	O
caffeine	O
after	O
sleep	O
deprivation	O
.	O

These	O
findings	O
demonstrate	O
a	O
role	O
for	O
adenosine	O
A	O
(	O
2A	O
)	O
receptors	O
in	O
the	O
effects	O
of	O
prolonged	O
wakefulness	O
on	O
vigilant	O
attention	O
and	O
the	O
sleep	O
EEG	O
.	O

Effects	O
of	O
intravenous	Pharmacological
iron	Pharmacological
combined	Pharmacological
with	Pharmacological
low-dose	Pharmacological
recombinant	Pharmacological
human	Pharmacological
erythropoietin	Pharmacological
on	O
transfusion	O
requirements	O
in	O
iron-deficient	O
patients	O
undergoing	O
bilateral	O
total	O
knee	O
replacement	O
arthroplasty	O
.	O

BACKGROUND	O
The	O
authors	O
examined	O
the	O
impact	O
of	O
parenteral	O
iron	O
and	O
recombinant	O
human	O
erythropoietin-?	O
(	O
rHuEPO-?	O
)	O
administered	O
in	O
the	O
bilateral	O
total	O
knee	O
replacement	O
arthroplasty	O
(	O
TKRA	O
)	O
,	O
on	O
postoperative	O
anemia	O
and	O
transfusion	O
requirements	O
in	O
iron-deficient	O
patients	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
A	O
total	O
of	O
108	O
iron-deficient	O
patients	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
:	O
Group	O
C	O
(	O
control	O
)	O
or	O
Group	O
IE	O
(	O
200	O
mg	O
of	O
iron	O
sucrose	O
intravenously	O
over	O
1	O
hr	O
and	O
3000	O
IU	O
of	O
rHuEPO-?	O
subcutaneously	O
during	O
the	O
operation	O
and	O
during	O
the	O
postoperative	O
period	O
if	O
the	O
hemoglobin	O
[	O
Hb	O
]	O
level	O
was	O
70-80	O
g/L	O
)	O
.	O

One	O
or	O
2	O
units	O
of	O
blood	O
were	O
transfused	O
to	O
patients	O
in	O
both	O
groups	O
according	O
to	O
postoperative	O
Hb	O
level	O
(	O
between	O
60	O
and	O
70	O
g/L	O
or	O
betweeen	O
50	O
and	O
60	O
g/L	O
,	O
respectively	O
)	O
.	O

Perioperative	O
laboratory	O
and	O
clinical	O
outcomes	O
(	O
Hb	O
,	O
iron	O
variables	O
,	O
postoperative	O
bleeding	O
amount	O
,	O
and	O
number	O
of	O
units	O
of	O
RBCs	O
transfused	O
and	O
incidences	O
)	O
were	O
documented	O
.	O

RESULTS	O
Although	O
preoperative	O
Hb	O
and	O
the	O
amount	O
of	O
postoperative	O
bleeding	O
were	O
comparable	O
in	O
the	O
two	O
groups	O
,	O
Hb	O
levels	O
at	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
and	O
at	O
2	O
and	O
6	O
weeks	O
postoperation	O
were	O
significantly	O
higher	O
in	O
Group	O
IE	O
.	O

Furthermore	O
,	O
the	O
transfusion	O
rate	O
was	O
significantly	O
lower	O
in	O
Group	O
IE	O
(	O
20.4	O
%	O
vs.	O
53.7	O
%	O
,	O
p=0.011	O
)	O
and	O
the	O
mean	O
number	O
of	O
red	O
blood	O
cell	O
units	O
transfused	O
was	O
markedly	O
lower	O
in	O
Group	O
IE	O
(	O
0.2?0.5	O
vs.	O
0.8?0.8	O
,	O
p=0.005	O
)	O
.	O

Postoperative	O
iron	O
,	O
ferritin	O
,	O
and	O
transferrin	O
saturation	O
levels	O
were	O
significantly	O
higher	O
in	O
Group	O
IE	O
.	O

CONCLUSIONS	O
Treatment	O
with	O
parenteral	O
iron	O
and	O
low-dose	O
rHuEPO-?	O
in	O
bilateral	O
TKRA	O
effectively	O
attenuated	O
anemia	O
and	O
decreased	O
transfusion	O
requirements	O
in	O
iron-deficient	O
patients	O
.	O

Randomized	O
,	O
controlled	O
,	O
parallel-group	O
trial	O
of	O
routine	Pharmacological
prophylaxis	Pharmacological
vs.	O
on-demand	O
treatment	O
with	O
sucrose-formulated	O
recombinant	O
factor	O
VIII	O
in	O
adults	O
with	O
severe	O
hemophilia	O
A	O
(	O
SPINART	O
)	O
.	O

BACKGROUND	O
The	O
benefits	O
of	O
routine	O
prophylaxis	O
vs.	O
on-demand	O
treatment	O
with	O
factor	O
VIII	O
products	O
have	O
not	O
been	O
evaluated	O
in	O
controlled	O
clinical	O
trials	O
in	O
older	O
patients	O
with	O
hemophilia	O
A	O
.	O

OBJECTIVES	O
To	O
report	O
results	O
from	O
a	O
preplanned	O
analysis	O
of	O
data	O
from	O
the	O
first	O
year	O
of	O
the	O
3-year	O
SPINART	O
study	O
,	O
which	O
compares	O
routine	O
prophylaxis	O
with	O
on-demand	O
treatment	O
with	O
sucrose-formulated	O
recombinant	O
FVIII	O
(	O
rFVIII-FS	O
)	O
.	O

PATIENTS/METHODS	O
SPINART	O
is	O
an	O
open-label	O
,	O
randomized	O
,	O
controlled	O
,	O
parallel-group	O
,	O
multinational	O
trial	O
.	O

Males	O
aged	O
12-50	O
years	O
with	O
severe	O
hemophilia	O
A	O
,	O
?	O
150	O
days	O
of	O
exposure	O
to	O
FVIII	O
,	O
no	O
FVIII	O
inhibitors	O
,	O
no	O
prophylaxis	O
for	O
>	O
12	O
consecutive	O
months	O
in	O
the	O
past	O
5	O
years	O
and	O
6-24	O
bleeding	O
episodes	O
in	O
the	O
preceding	O
6	O
months	O
were	O
randomized	O
1	O
:	O
1	O
to	O
rFVIII-FS	O
prophylaxis	O
(	O
25	O
IU	O
kg	O
(	O
-1	O
)	O
,	O
three	O
times	O
weekly	O
)	O
or	O
on-demand	O
treatment	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
,	O
number	O
of	O
total	O
bleeding	O
episodes	O
in	O
the	O
intent-to-treat	O
population	O
,	O
was	O
analyzed	O
after	O
the	O
last	O
patient	O
had	O
completed	O
1	O
year	O
of	O
follow-up	O
.	O

A	O
negative	O
binomial	O
model	O
was	O
used	O
for	O
the	O
primary	O
endpoint	O
analysis	O
;	O
analysis	O
of	O
variance	O
was	O
used	O
for	O
confirmatory	O
analysis	O
of	O
annualized	O
bleeding	O
rates	O
.	O

RESULTS	O
Eighty-four	O
patients	O
were	O
enrolled	O
and	O
analyzed	O
(	O
n	O
=	O
42	O
per	O
group	O
;	O
mean	O
age	O
,	O
30.6	O
years	O
;	O
median	O
treatment	O
duration	O
,	O
1.7	O
years	O
)	O
.	O

The	O
median	O
number	O
of	O
total	O
bleeding	O
episodes	O
and	O
total	O
bleeding	O
episodes	O
per	O
year	O
were	O
significantly	O
lower	O
with	O
prophylaxis	O
than	O
with	O
on-demand	O
treatment	O
(	O
total	O
,	O
0	O
vs.	O
54.5	O
;	O
total	O
per	O
year	O
,	O
0	O
vs.	O
27.9	O
;	O
both	O
P	O
<	O
0.0001	O
)	O
.	O

No	O
treatment-related	O
adverse	O
events	O
occurred	O
,	O
and	O
no	O
patients	O
developed	O
FVIII	O
inhibitors	O
.	O

CONCLUSIONS	O
Routine	O
prophylaxis	O
with	O
rFVIII-FS	O
leads	O
to	O
a	O
significant	O
reduction	O
in	O
bleeding	O
as	O
compared	O
with	O
on-demand	O
treatment	O
.	O

Adverse	O
events	O
were	O
consistent	O
with	O
the	O
established	O
rFVIII-FS	O
safety	O
profile	O
.	O

Effects	O
of	O
guided	Psychological
imagery	Psychological
with	Psychological
relaxation	Psychological
training	Psychological
on	O
anxiety	O
and	O
quality	O
of	O
life	O
among	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

BACKGROUND	O
Inflammatory	O
Bowel	O
Disease	O
(	O
IBD	O
)	O
impacts	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
.	O

Psychological	O
factors	O
influence	O
the	O
course	O
of	O
the	O
disease	O
and	O
should	O
be	O
targeted	O
for	O
intervention	O
.	O

METHODS	O
Our	O
study	O
was	O
a	O
prospective	O
,	O
randomised	O
control	O
trial	O
.	O

Fifty-six	O
outpatients	O
were	O
randomly	O
chosen	O
and	O
allocated	O
to	O
a	O
treatment	Physical
group	O
or	O
a	O
waiting-list	O
control	Control
group	O
.	O

Treatment	O
group	O
patients	O
attended	O
three	Educational
relaxation-training	Educational
sessions	Educational
and	Educational
received	Educational
an	Educational
audio	Educational
disc	Educational
for	Educational
home	Educational
practice	Educational
.	Educational

Evaluations	O
performed	O
pre	O
and	O
post-treatment	O
:	O
state	O
anxiety	O
was	O
assessed	O
with	O
the	O
State-Trait	O
Anxiety	O
Inventory	O
,	O
QoL	O
with	O
the	O
IBD	O
Questionnaire	O
.	O

The	O
Visual	O
Analogue	O
Scale	O
assessed	O
pain	O
,	O
depression	O
,	O
stress	O
and	O
mood	O
.	O

Patients	O
completed	O
a	O
symptom	O
monitoring	O
diary	O
.	O

The	O
control	O
group	O
's	O
symptoms	O
were	O
monitored	O
without	O
study-related	O
treatment	O
.	O

RESULTS	O
Thirty-nine	O
subjects	O
completed	O
the	O
study	O
and	O
were	O
included	O
in	O
the	O
data	O
analysis	O
.	O

Following	O
the	O
relaxation-training	O
intervention	O
,	O
the	O
treatment	O
group	O
's	O
(	O
n	O
=	O
18	O
)	O
measured	O
results	O
showed	O
a	O
statistically	O
significant	O
improvement	O
as	O
compared	O
to	O
the	O
control	O
group	O
(	O
n	O
=	O
21	O
)	O
(	O
time	O
by	O
treatment	O
interaction	O
)	O
:	O
anxiety	O
levels	O
decreased	O
(	O
p	O
<	O
0.01	O
)	O
,	O
QoL	O
and	O
mood	O
improved	O
(	O
p	O
<	O
0.05	O
)	O
,	O
while	O
levels	O
of	O
pain	O
and	O
stress	O
decreased	O
(	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
Findings	O
indicate	O
IBD	O
patients	O
may	O
benefit	O
from	O
relaxation	O
training	O
in	O
their	O
holistic	O
care	O
.	O

New	O
studies	O
as	O
well	O
as	O
further	O
investigation	O
of	O
the	O
subject	O
are	O
warranted	O
.	O

[	O
Effect	O
analysis	O
on	O
non-and-low	O
response	O
infants	O
after	O
revaccinated	O
hepatitis	Pharmacological
B	Pharmacological
vaccine	Pharmacological
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
booster	O
immunization	O
effect	O
to	O
non-and-low	O
response	O
children	O
after	O
3	O
doses	O
HepB	O
immunization	O
.	O

METHODS	O
Non-and-low	O
response	O
infants	O
born	O
in	O
2004	O
2005	O
administered	O
3	Pharmacological
doses	Pharmacological
of	Pharmacological
HepB	Pharmacological
at	O
0	O
,	O
1	O
,	O
6	O
months	O
in	O
Guangzhou	O
,	O
Beijing	O
and	O
Zhejiang	O
were	O
divided	O
into	O
4	O
groups	O
randomly	O
,	O
and	O
boosted	O
3	O
dose	O
of	O
4	O
different	O
types	O
of	O
HepB	Pharmacological
at	O
0	O
,	O
1	O
,	O
6	O
months	O
.	O

RESULTS	O
The	O
GMC	O
of	O
non-and-low	O
response	O
children	O
in	O
group	O
A	O
(	O
before	O
booster	O
)	O
,	O
group	O
B	O
(	O
after	O
1	O
dose	O
booster	O
)	O
and	O
group	O
C	O
(	O
after	O
3	O
dose	O
booster	O
)	O
were	O
18.66	O
mIUml	O
,	O
88.82	O
mIU/ml	O
,	O
178.24	O
mIU/ml	O
respectively	O
;	O
the	O
proportion	O
of	O
non-responders	O
in	O
three	O
groups	O
were	O
20.4	O
%	O
,	O
9.1	O
%	O
,	O
1.9	O
%	O
respectively	O
.	O

In	O
103	O
non-and-low	O
response	O
children	O
,	O
proportion	O
of	O
titers	O
of	O
more	O
than	O
100	O
mIU/ml	O
of	O
group	O
B	O
and	O
group	O
C	O
were	O
61.2	O
%	O
and	O
84.5	O
%	O
,	O
and	O
there	O
was	O
statistical	O
significant	O
difference	O
(	O
chi2	O
=	O
14.13	O
,	O
P	O
<	O
0.01	O
)	O
.	O

The	O
GMC	O
after	O
3	O
doses	O
revaccination	Pharmacological
with	O
four	O
kinds	O
of	O
HepB	O
,	O
included	O
5	O
microg	O
HepB-Y	Pharmacological
,	O
10	O
microg	O
HepB-Y	Pharmacological
,	O
l0	O
microg	O
HepB-CHO	Pharmacological
,	O
10	O
microg	O
HepB-HY	Pharmacological
were	O
168.8	O
mJU/ml	O
,	O
174.7	O
mIU/ml	O
,	O
184.9	O
mIU/ml	O
,	O
182.9	O
mIU/ml	O
respectively	O
.	O

Proportion	O
of	O
titers	O
of	O
more	O
than	O
100	O
mIU/ml	O
for	O
four	O
kinds	O
HepB	O
were	O
79.0	O
%	O
,	O
85.7	O
%	O
,	O
88.2	O
%	O
and	O
84.6	O
%	O
respectively	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
(	O
chi2	O
=	O
0.75	O
,	O
0.05	O
)	O
.	O

CONCLUSION	O
There	O
were	O
no	O
different	O
of	O
seroconversion	O
rate	O
between	O
study	O
population	O
received	O
1	O
dose	O
and	O
3	O
dose	O
booster	O
(	O
P	O
>	O
0.05	O
)	O
,	O
but	O
high	O
titer	O
was	O
observed	O
after	O
3	O
dose	O
booster	O
.	O

The	O
four	O
kinds	O
of	O
HepB	O
,	O
including	O
5	O
microg	O
HepB-Y,10	O
microg	O
HepB-Y	O
,	O
10	O
microg	O
HepB-CHO	O
,	O
10	O
microg	O
HepB-HY	O
had	O
the	O
same	O
immunization	O
effect	O
after	O
3	O
doses	O
revaccination	O
at	O
0	O
,	O
1	O
,	O
6	O
months	O
to	O
non-and-low	O
response	O
children	O
.	O

Randomised	O
placebo-controlled	Control
trial	O
of	O
rhesus-human	Pharmacological
reassortant	Pharmacological
rotavirus	Pharmacological
vaccine	Pharmacological
for	O
prevention	O
of	O
severe	O
rotavirus	O
gastroenteritis	O
.	O

BACKGROUND	O
Rotavirus	O
is	O
the	O
most	O
common	O
cause	O
of	O
acute	O
childhood	O
gastroenteritis	O
.	O

Vaccination	O
with	O
live	O
oral	O
heterologous	O
rotavirus	O
vaccines	O
may	O
prevent	O
rotavirus	O
gastroenteritis	O
.	O

We	O
assessed	O
the	O
efficacy	O
of	O
rhesus-human	Pharmacological
reassortant	Pharmacological
rotavirus	Pharmacological
tetravalent	Pharmacological
vaccine	Pharmacological
(	Pharmacological
RRV-TV	Pharmacological
)	Pharmacological
against	O
severe	O
rotavirus	O
gastroenteritis	O
in	O
Finnish	O
children	O
in	O
a	O
randomised	O
placebo-controlled	Control
double-blind	O
trial	O
.	O

METHODS	O
Placebo	Control
or	O
RRV-TV	Pharmacological
(	O
titre	O
4x10	O
(	O
5	O
)	O
plaque-forming	O
units	O
)	O
was	O
given	O
to	O
infants	O
at	O
ages	O
2	O
,	O
3	O
,	O
and	O
5	O
months	O
.	O

The	O
children	O
were	O
followed	O
up	O
for	O
one	O
or	O
two	O
rotavirus	O
epidemic	O
seasons	O
.	O

The	O
main	O
outcome	O
measure	O
was	O
protection	O
against	O
severe	O
rotavirus	O
gastroenteritis	O
(	O
score	O
>	O
or	O
=11	O
on	O
a	O
20-point	O
severity	O
scale	O
)	O
.	O

2398	O
children	O
were	O
enrolled	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
RRV-TV	O
(	O
n=1191	O
)	O
or	O
placebo	Control
(	O
n=1207	O
)	O
.	O

The	O
primary	O
efficacy	O
analysis	O
was	O
based	O
on	O
children	O
who	O
received	O
three	O
doses	O
of	O
RRV-TV	O
(	O
n=1128	O
)	O
or	O
placebo	O
(	O
n=1145	O
)	O
.	O

FINDINGS	O
256	O
episodes	O
of	O
rotavirus	O
gastroenteritis	O
occurred	O
at	O
any	O
time	O
during	O
the	O
study	O
;	O
65	O
were	O
among	O
1191	O
RRV-TV	Pharmacological
recipients	O
,	O
and	O
191	O
among	O
1207	O
placebo	Control
recipients	O
(	O
vaccine	O
efficacy	O
66	O
%	O
[	O
95	O
%	O
CI	O
55-74	O
]	O
;	O
intention-to-treat	O
analysis	O
)	O
.	O

226	O
episodes	O
were	O
included	O
in	O
the	O
primary	O
efficacy	O
analysis	O
of	O
fully	O
vaccinated	O
children	O
(	O
54	O
among	O
1128	O
RRV-TV	O
recipients	O
,	O
172	O
among	O
1145	O
placebo	O
recipients	O
;	O
vaccine	O
efficacy	O
68	O
%	O
[	O
57-76	O
]	O
)	O
.	O

100	O
episodes	O
were	O
severe	O
,	O
eight	O
in	O
RRV-TV	Pharmacological
recipients	O
and	O
92	O
in	O
placebo	O
recipients	O
(	O
vaccine	O
efficacy	O
91	O
%	O
[	O
82-96	O
]	O
)	O
.	O

INTERPRETATION	O
RRV-TV	Pharmacological
vaccine	Pharmacological
was	O
highly	O
effective	O
against	O
severe	O
rotavirus	O
gastroenteritis	O
in	O
young	O
children	O
.	O

Incorporation	O
of	O
this	O
vaccine	O
into	O
routine	O
immunisation	O
schedules	O
of	O
infants	O
could	O
reduce	O
severe	O
rotavirus	O
gastroenteritis	O
by	O
90	O
%	O
and	O
severe	O
gastroenteritis	O
of	O
all	O
causes	O
in	O
young	O
children	O
by	O
60	O
%	O
.	O

Buprenorphine	O
alone	O
and	O
in	O
combination	O
with	O
naloxone	O
in	O
non-dependent	O
humans	O
.	O

This	O
study	O
evaluated	O
the	O
effects	O
of	O
concurrent	O
naloxone	Pharmacological
on	O
the	O
opioid	O
agonist	O
effects	O
of	O
buprenorphine	Pharmacological
,	O
a	O
mixed	O
agonist-antagonist	O
marketed	O
as	O
an	O
analgesic	O
and	O
under	O
development	O
as	O
a	O
treatment	O
for	O
drug	O
abuse	O
.	O

In	O
a	O
residential	O
laboratory	O
seven	O
non-physically-dependent	O
opioid	O
abuser	O
volunteers	O
received	O
intramuscular	O
buprenorphine	O
(	O
0.4	O
mg	O
or	O
0.8	O
mg/70	O
kg	O
)	O
alone	O
and	O
in	O
combination	O
with	O
naloxone	O
(	O
0.4	O
mg	O
or	O
0.8	O
mg/70	O
kg	O
)	O
versus	O
placebo	Control
.	O

Buprenorphine	O
produced	O
dose-related	O
opioid	O
agonist	O
effects	O
on	O
physiological	O
and	O
subjective	O
measures	O
.	O

Concurrent	O
naloxone	O
attenuated	O
the	O
opioid	O
agonist	O
effects	O
of	O
buprenorphine	O
.	O

Thus	O
,	O
a	O
combination	O
product	O
of	O
buprenorphine	O
and	O
naloxone	O
may	O
have	O
lower	O
abuse	O
liability	O
than	O
buprenorphine	O
alone	O
.	O

Acute	O
effects	O
of	O
caffeine	Pharmacological
ingestion	Pharmacological
on	O
signal-averaged	O
electrocardiograms	O
.	O

BACKGROUND	O
Although	O
moderate	O
caffeine	O
ingestion	O
has	O
not	O
been	O
shown	O
to	O
be	O
arrhythmogenic	O
,	O
caffeine	O
toxicity	O
can	O
cause	O
severe	O
cardiac	O
arrhythmias	O
,	O
including	O
atrial	O
fibrillation	O
and	O
ventricular	O
tachycardia	O
.	O

Atrial	O
fibrillation	O
and	O
ventricular	O
tachycardia	O
have	O
been	O
associated	O
with	O
prolongation	O
of	O
P-wave	O
and	O
QRS	O
complex	O
durations	O
on	O
signal-averaged	O
electrocardiograms	O
.	O

This	O
study	O
investigated	O
acute	O
effects	O
of	O
caffeine	O
ingestion	O
on	O
signal-averaged	O
P-wave	O
and	O
QRS	O
complexes	O
.	O

METHODS	O
AND	O
RESULTS	O
Signal-averaged	O
electrocardiograms	O
were	O
obtained	O
from	O
12	O
normal	O
subjects	O
(	O
6	O
men	O
,	O
6	O
women	O
;	O
ages	O
21	O
to	O
26	O
years	O
)	O
before	O
and	O
after	O
ingestion	O
of	O
caffeine	Pharmacological
(	O
5	O
mg/kg	O
body	O
weight	O
)	O
or	O
placebo	Control
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
fashion	O
.	O

Electrocardiograms	O
for	O
signal	O
averaging	O
were	O
recorded	O
from	O
electrodes	O
left	O
in	O
a	O
constant	O
location	O
.	O

After	O
bandpass	O
filtering	O
(	O
30	O
to	O
300	O
Hz	O
)	O
and	O
amplification	O
,	O
signals	O
were	O
sampled	O
over	O
7.2	O
minutes	O
at	O
2000	O
Hz	O
.	O

Signal-averaged	O
P-wave	O
and	O
QRS	O
complex	O
durations	O
did	O
not	O
significantly	O
change	O
after	O
placebo	O
ingestion	O
.	O

After	O
caffeine	O
ingestion	O
QRS	O
duration	O
prolonged	O
in	O
9	O
of	O
11	O
subjects	O
at	O
90	O
minutes	O
(	O
mean	O
+/-	O
SEM	O
=	O
0.8+/-0.3	O
ms	O
,	O
P	O
<	O
.02	O
)	O
and	O
in	O
8	O
of	O
9	O
after	O
3	O
hours	O
(	O
1.1+/-0.2	O
ms	O
,	O
P	O
<	O
.001	O
)	O
.	O

No	O
significant	O
change	O
in	O
P-wave	O
duration	O
or	O
heart	O
rate	O
was	O
found	O
after	O
caffeine	O
ingestion	O
at	O
any	O
test	O
interval	O
.	O

Average	O
caffeine	O
level	O
in	O
saliva	O
90	O
minutes	O
after	O
ingestion	O
was	O
6.6+/-1.6	O
(	O
SD	O
)	O
microg/dL	O
.	O

CONCLUSIONS	O
Although	O
probably	O
not	O
arrhythmogenic	O
in	O
normal	O
subjects	O
,	O
moderate	O
caffeine	O
ingestion	O
does	O
produce	O
a	O
small	O
but	O
statistically	O
significant	O
prolongation	O
of	O
signal-averaged	O
QRS	O
complexes	O
.	O

Further	O
prolongation	O
caused	O
by	O
excessive	O
caffeine	O
intake	O
may	O
be	O
a	O
factor	O
in	O
the	O
genesis	O
of	O
arrhythmias	O
associated	O
with	O
caffeine	O
toxicity	O
.	O

Sunlight	Control
exposure	Control
or	O
vitamin	Pharmacological
D	Pharmacological
supplementation	Pharmacological
for	O
vitamin	O
D-deficient	O
non-western	O
immigrants	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

UNLABELLED	O
Vitamin	Pharmacological
D	Pharmacological
deficiency	O
is	O
very	O
common	O
in	O
non-western	O
immigrants	O
.	O

In	O
this	O
randomized	O
clinical	O
trial	O
,	O
vitamin	Pharmacological
D	Pharmacological
800	O
IU/day	O
or	O
100,000	O
IU/3	O
months	O
were	O
compared	O
with	O
advised	Physical
sunlight	Physical
exposure	Physical
.	O

Vitamin	Pharmacological
D	Pharmacological
supplementation	Pharmacological
was	O
more	O
effective	O
than	O
advised	Control
sunlight	Control
exposure	Control
in	O
improving	O
vitamin	O
D	O
status	O
and	O
lowering	O
parathyroid	O
hormone	O
levels	O
.	O

INTRODUCTION	O
Vitamin	O
D	O
deficiency	O
(	O
25-hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
<	O
25	O
nmol/l	O
)	O
is	O
common	O
among	O
non-western	O
immigrants	O
.	O

It	O
can	O
be	O
treated	O
with	O
vitamin	O
D	O
supplementation	O
or	O
sunlight	O
exposure	O
.	O

METHODS	O
To	O
determine	O
whether	O
the	O
effect	O
of	O
vitamin	O
D	O
(	O
3	O
)	O
supplementation	O
(	O
daily	O
800	O
IU	O
or	O
100,000	O
IU/3	O
months	O
)	O
or	O
sunlight	O
exposure	O
advice	O
is	O
similar	O
with	O
regard	O
to	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
concentrations	O
.	O

Randomized	O
clinical	O
trial	O
in	O
11	O
general	O
practices	O
in	O
The	O
Netherlands	O
.	O

Non-western	O
immigrants	O
,	O
aged	O
18-65	O
years	O
(	O
n	O
=	O
232	O
)	O
and	O
serum	O
25	O
(	O
OH	O
)	O
D	O
<	O
25	O
nmol/l	O
were	O
randomly	O
assigned	O
to	O
supplementation	O
(	O
daily	O
800	O
IU	O
or	O
100,000	O
IU/3	O
months	O
)	O
or	O
advice	O
for	O
sunlight	O
exposure	O
for	O
6	O
months	O
(	O
March-September	O
)	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
baseline	O
,	O
during	O
treatment	O
(	O
3	O
months	O
,	O
6	O
months	O
)	O
,	O
and	O
at	O
follow-up	O
(	O
12	O
months	O
)	O
.	O

Statistical	O
analysis	O
was	O
performed	O
with	O
multilevel	O
regression	O
modelling	O
.	O

RESULTS	O
The	O
intention-to-treat	O
analysis	O
included	O
211	O
persons	O
.	O

Baseline	O
serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
22.5	O
?	O
11.1	O
nmol/l	O
.	O

After	O
6	O
months	O
,	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
increased	O
to	O
53	O
nmol/l	O
with	O
800	O
IU/day	O
,	O
to	O
50.5	O
nmol/l	O
with	O
100,000	O
IU/3	O
months	O
,	O
and	O
to	O
29.1	O
nmol/l	O
with	O
advised	O
sunlight	O
exposure	O
(	O
supplementation	O
vs	O
sunshine	O
p	O
<	O
0.001	O
)	O
.	O

Serum	O
PTH	O
decreased	O
significantly	O
in	O
all	O
groups	O
after	O
3	O
months	O
,	O
more	O
in	O
the	O
supplementation	O
groups	O
than	O
in	O
the	O
advised	O
sunlight	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
effect	O
on	O
physical	O
performance	O
and	O
functional	O
limitations	O
.	O

CONCLUSION	O
Vitamin	O
D	O
supplementation	O
is	O
more	O
effective	O
than	O
advised	O
sunlight	O
exposure	O
for	O
treating	O
vitamin	O
D	O
deficiency	O
in	O
non-western	O
immigrants	O
.	O

Dual-task-related	O
gait	O
changes	O
in	O
transitionally	O
frail	O
older	O
adults	O
:	O
the	O
type	O
of	O
the	O
walking-associated	Educational
cognitive	Educational
task	Educational
matters	O
.	O

BACKGROUND	O
Changes	O
in	O
gait	O
patterns	O
due	O
to	O
a	O
simultaneously	Educational
performed	Educational
cognitive	Educational
task	Educational
have	O
been	O
reported	O
previously	O
and	O
associated	O
with	O
an	O
increased	O
falling	O
risk	O
among	O
older	O
adults	O
.	O

Little	O
is	O
known	O
whether	O
the	O
type	O
of	O
cognitive	Educational
task	Educational
performed	O
while	O
walking	O
is	O
important	O
concerning	O
possible	O
gait	O
interference	O
in	O
older	O
fall-prone	O
individuals	O
.	O

OBJECTIVE	O
To	O
quantify	O
and	O
compare	O
the	O
effects	O
of	O
two	O
different	O
cognitive	O
tasks	O
on	O
gait	O
in	O
transitionally	O
frail	O
older	O
adults	O
.	O

MEASUREMENTS	O
Gait	O
was	O
tested	O
in	O
30	O
transitionally	O
frail	O
older	O
adults	O
(	O
mean	O
age	O
82.6	O
+/-	O
7.1	O
years	O
,	O
90	O
%	O
female	O
)	O
while	O
either	O
walking	Educational
alone	Educational
,	Educational
performing	Educational
a	Educational
simple	Educational
arithmetic	Educational
task	Educational
,	Educational
or	Educational
performing	Educational
a	Educational
task	Educational
of	Educational
verbal	Educational
fluency	Educational
.	O

Walking	O
time	O
in	O
seconds	O
,	O
number	O
of	O
steps	O
,	O
frequency	O
of	O
lateral	O
line	O
stepping-over	O
,	O
and	O
stops	O
were	O
recorded	O
.	O

Health	O
status	O
was	O
assessed	O
using	O
standard	O
instruments	O
of	O
geriatric	O
assessment	O
.	O

The	O
classification	O
of	O
Speechley	O
and	O
Tinetti	O
was	O
used	O
to	O
define	O
the	O
participants	O
'	O
degree	O
of	O
frailty	O
.	O

RESULTS	O
Walking	O
time	O
and	O
number	O
of	O
steps	O
increased	O
significantly	O
under	O
both	O
dual-task	O
conditions	O
compared	O
to	O
walking	O
alone	O
(	O
p	O
<	O
0.001	O
)	O
without	O
reaching	O
a	O
significant	O
difference	O
between	O
the	O
two	O
dual-task	O
conditions	O
(	O
respectively	O
,	O
p	O
=	O
0.131	O
and	O
p	O
=	O
0.407	O
)	O
,	O
whereas	O
lateral	O
gait	O
instability	O
(	O
frequency	O
of	O
lateral	O
line	O
stepping-over	O
)	O
increased	O
significantly	O
in	O
association	O
with	O
counting	O
backward	O
(	O
p	O
=	O
0.006	O
)	O
but	O
not	O
with	O
the	O
verbal	O
fluency	O
task	O
(	O
p	O
=	O
1	O
)	O
.	O

CONCLUSION	O
Among	O
the	O
studied	O
sample	O
of	O
transitional	O
older	O
adults	O
,	O
a	O
walking-	O
associated	O
arithmetic	O
task	O
significantly	O
interfered	O
with	O
lateral	O
gait	O
stability	O
,	O
whereas	O
no	O
lateral	O
gait	O
deviations	O
were	O
seen	O
in	O
association	O
with	O
a	O
verbal	O
fluency	O
task	O
.	O

We	O
,	O
therefore	O
,	O
suggest	O
that	O
the	O
choice	O
of	O
the	O
attention-splitting	O
task	O
in	O
dual-task	O
gait	O
assessment	O
among	O
older	O
adults	O
must	O
be	O
made	O
carefully	O
.	O

Simplified	Psychological
subjective	Psychological
workload	Psychological
assessment	Psychological
technique	Psychological
.	Educational

Although	O
the	O
subjective	Educational
workload	Educational
assessment	Educational
technique	Educational
(	Educational
SWAT	Educational
)	Educational
has	O
been	O
widely	O
used	O
,	O
it	O
has	O
two	O
main	O
problems	O
:	O
it	O
is	O
not	O
very	O
sensitive	O
for	O
low	O
mental	O
workloads	O
and	O
it	O
requires	O
a	O
time-consuming	O
card	O
sorting	O
pretask	O
procedure	O
.	O

In	O
this	O
study	O
are	O
presented	O
five	Psychological
variations	Psychological
of	Psychological
SWAT	Psychological
in	O
an	O
effort	O
to	O
overcome	O
the	O
limitations	O
.	O

Four	O
of	O
the	O
variants	O
used	O
the	O
continuous	Psychological
SWAT	Psychological
subscales	Psychological
while	O
one	O
used	O
the	O
discrete	Psychological
SWAT	Psychological
subscale	Psychological
.	Educational

Fifteen	O
subjects	O
participated	O
in	O
the	O
experiment	O
.	O

The	O
scales	O
were	O
compared	O
with	O
the	O
original	O
SWAT	Educational
scale	O
in	O
terms	O
of	O
sensitivity	O
and	O
pretask	O
procedure	O
completion	O
time	O
when	O
performing	O
arithmetic	O
tasks	O
.	O

The	O
results	O
show	O
that	O
all	O
four	O
variants	O
are	O
more	O
sensitive	O
than	O
the	O
conventional	Educational
SWAT	Educational
scale	Educational
and	O
that	O
the	O
pairwise	O
comparison	O
procedure	O
takes	O
significantly	O
less	O
pretask	O
completion	O
time	O
compared	O
with	O
the	O
original	Educational
SWAT	Educational
scale	Educational
.	Educational

Thus	O
,	O
the	O
conventional	Educational
pretask	Educational
procedure	Educational
can	O
be	O
replaced	O
by	O
a	O
simple	O
unweighted	O
averaging	O
to	O
yield	O
a	O
scale	O
of	O
high	O
sensitivity	O
.	O

Changing	O
sodium	O
intake	O
in	O
children	O
.	O

The	O
Minneapolis	O
Children	O
's	O
Blood	O
Pressure	O
Study	O
.	O

To	O
assess	O
the	O
effects	O
of	O
modifying	O
dietary	O
sodium	O
intake	O
,	O
80	O
school	O
children	O
with	O
blood	O
pressures	O
above	O
the	O
95th	O
percentile	O
for	O
age	O
and	O
sex	O
but	O
below	O
130/90	O
mm	O
Hg	O
at	O
school	O
screening	O
were	O
randomized	O
to	O
a	O
family	Educational
intervention	Educational
program	Educational
or	O
a	O
control	Control
group	Control
.	O

Twenty	O
children	O
aged	O
6	O
to	O
9	O
years	O
and	O
their	O
families	O
began	O
a	O
program	O
to	O
modify	O
the	O
family	O
diet	O
toward	O
a	O
goal	O
of	O
70	O
mEq	O
sodium	O
per	O
person	O
per	O
day	O
.	O

Adherence	O
was	O
assessed	O
by	O
3-day	O
food	O
records	O
and	O
urine	O
collections	O
in	O
children	O
and	O
adults	O
.	O

The	O
sodium	O
intakes	O
and	O
blood	O
pressures	O
of	O
the	O
intervention	O
and	O
control	O
group	O
were	O
compared	O
1	O
year	O
after	O
randomization	O
.	O

Sodium	O
intake	O
was	O
significantly	O
lower	O
in	O
the	O
intervention	O
group	O
only	O
in	O
the	O
active	O
participants	O
as	O
compared	O
to	O
dropouts	O
and	O
controls	O
(	O
87	O
vs	O
130	O
and	O
133	O
mmoles/24	O
hr	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
height	O
,	O
weight	O
,	O
or	O
blood	O
pressure	O
.	O

Effect	O
of	O
sport-tinted	Physical
contact	Physical
lenses	Physical
for	O
contrast	O
enhancement	O
on	O
retinal	O
straylight	O
measurements	O
.	O

PURPOSE	O
To	O
investigate	O
the	O
effect	O
of	O
two	O
tinted	Physical
contact	Physical
lenses	Physical
(	Physical
CL	Physical
)	Physical
designed	O
for	O
outdoor	O
sports	O
activity	O
on	O
the	O
psychometric	O
determination	O
of	O
retinal	O
straylight	O
using	O
the	O
compensation	O
comparison	O
method	O
.	O

METHODS	O
Thirteen	O
emmetropic	O
subjects	O
were	O
randomly	O
fitted	O
with	O
two	Physical
different	Physical
tinted	Physical
Nike	Physical
Maxsight	Physical
(	Physical
Bausch	Physical
&	Physical
Lomb	Physical
,	Physical
Rochester	Physical
,	Physical
NY	Physical
,	Physical
USA	Physical
)	Physical
CL	Physical
in	Physical
one	Physical
eye	Physical
,	O
while	O
the	O
contralateral	Control
eye	Control
was	Control
fitted	Control
with	Control
a	Control
clear	Control
lens	Control
made	Control
of	Control
the	Control
same	Control
material	Control
(	O
Optima	O
38	O
,	O
Bausch	O
&	O
Lomb	O
)	O
.	O

Three	O
valid	O
straylight	O
measurements	O
were	O
taken	O
on	O
each	O
eye	O
before	O
and	O
a	O
few	O
minutes	O
after	O
lens	O
insertion	O
,	O
when	O
lens	O
stabilization	O
had	O
occurred	O
.	O

RESULTS	O
The	O
subjects	O
'	O
mean	O
straylight	O
values	O
were	O
0.90	O
+/-	O
0.09	O
at	O
baseline	O
and	O
0.95	O
+/-	O
0.10	O
with	O
the	O
clear	O
Optima	O
38	O
CL	O
.	O

Straylight	O
values	O
were	O
0.97	O
+/-	O
0.10	O
and	O
1.0	O
+/-	O
0.10	O
log	O
units	O
with	O
the	O
amber	O
and	O
grey-green	O
tinted	O
CL	O
,	O
respectively	O
.	O

Differences	O
in	O
straylight	O
between	O
baseline	O
(	O
without	O
CL	O
)	O
and	O
with	O
the	O
clear	O
CL	O
in	O
place	O
were	O
neither	O
statistically	O
significant	O
(	O
p	O
=	O
0.066	O
)	O
nor	O
was	O
there	O
a	O
significant	O
difference	O
between	O
baseline	O
and	O
the	O
amber	O
CL	O
(	O
p	O
=	O
0.052	O
)	O
.	O

However	O
,	O
the	O
grey-green	O
CL	O
showed	O
a	O
statistically	O
significant	O
difference	O
from	O
baseline	O
(	O
p	O
=	O
0.006	O
)	O
.	O

Differences	O
in	O
straylight	O
with	O
the	O
clear	O
CL	O
compared	O
with	O
the	O
grey-green	O
CL	O
were	O
also	O
statistically	O
different	O
from	O
zero	O
(	O
p	O
=	O
0.002	O
)	O
showing	O
an	O
increased	O
straylight	O
value	O
for	O
the	O
tinted	O
CL	O
.	O

These	O
differences	O
were	O
variable	O
,	O
but	O
consistent	O
for	O
each	O
subject	O
,	O
thus	O
those	O
showing	O
higher	O
or	O
lower	O
changes	O
with	O
one	O
tinted	O
lens	O
tended	O
to	O
show	O
the	O
same	O
trend	O
with	O
the	O
second	O
lens	O
(	O
r	O
(	O
2	O
)	O
=	O
0.736	O
)	O
.	O

CONCLUSIONS	O
Despite	O
increases	O
having	O
been	O
found	O
in	O
straylight	O
values	O
with	O
tinted	O
contact	O
lenses	O
,	O
those	O
changes	O
are	O
not	O
likely	O
to	O
induce	O
clinically	O
significant	O
changes	O
in	O
visual	O
function	O
under	O
photopic	O
conditions	O
,	O
even	O
for	O
the	O
grey-green	O
CL	O
,	O
which	O
seems	O
to	O
increase	O
straylight	O
values	O
more	O
significantly	O
than	O
the	O
amber	O
CL	O
.	O

This	O
difference	O
between	O
the	O
tinted	O
CL	O
could	O
suggest	O
a	O
wavelength	O
dependence	O
of	O
straylight	O
values	O
,	O
although	O
this	O
should	O
be	O
investigated	O
further	O
by	O
controlling	O
for	O
pupil	O
size	O
and	O
subjects	O
'	O
pigmentation	O
,	O
as	O
well	O
as	O
by	O
using	O
neutral	O
density	O
filters	O
.	O

Differential	O
effects	O
of	O
vitamin	Pharmacological
K1	Pharmacological
on	O
AFP	O
and	O
DCP	O
levels	O
in	O
patients	O
with	O
unresectable	O
HCC	O
and	O
in	O
HCC	O
cell	O
lines	O
.	O

PURPOSE	O
DCP	O
is	O
a	O
useful	O
HCC	O
tumor	O
marker	O
,	O
which	O
reflects	O
a	O
defect	O
in	O
vitamin	O
K	O
metabolism	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
vitamin	Pharmacological
K	Pharmacological
treatment	O
of	O
HCC	O
patients	O
might	O
suppress	O
this	O
marker	O
and	O
possibly	O
AFP	O
also	O
.	O

EXPERIMENTAL	O
DESIGN	O
HCC	O
patients	O
who	O
had	O
both	O
elevated	O
AFP	O
and	O
DCP	O
were	O
included	O
.	O

A	O
phase	O
I	O
cohort	O
was	O
treated	O
with	O
escalating	O
vitamin	Pharmacological
K1	Pharmacological
intravenous	O
weekly	O
doses	O
and	O
a	O
27-patient	O
phase	O
II	O
cohort	O
was	O
then	O
treated	O
with	O
a	O
fixed	O
oral	O
daily	O
dose	O
.	O

RESULTS	O
A	O
maximum	O
tolerated	O
dose	O
was	O
not	O
reached	O
up	O
to	O
100-fold	O
the	O
normal	O
vitamin	Pharmacological
K1	Pharmacological
dose	O
.	O

No	O
toxicities	O
were	O
found	O
up	O
to	O
1,000	O
mg/infusion	O
.	O

In	O
the	O
phase	O
II	O
cohort	O
,	O
93	O
%	O
of	O
patients	O
had	O
tumor	O
marker	O
responses	O
by	O
decreased	O
DCP	O
levels	O
,	O
but	O
only	O
22	O
%	O
had	O
responses	O
by	O
decreased	O
AFP	O
levels	O
.	O

CT	O
scans	O
showed	O
11	O
%	O
of	O
patients	O
had	O
PRs	O
,	O
59	O
%	O
had	O
stable	O
tumors	O
and	O
29.6	O
%	O
had	O
tumor	O
progression	O
.	O

Mechanism	O
studies	O
showed	O
that	O
vitamin	O
K1	O
induced	O
phosphorylation	O
of	O
JNK	O
and	O
c-Jun	O
and	O
caspase-mediated	O
apoptosis	O
.	O

CONCLUSIONS	O
Vitamin	Pharmacological
K1	Pharmacological
was	O
non-toxic	O
at	O
high	O
doses	O
,	O
strongly	O
inhibited	O
plasma	O
DCP	O
levels	O
,	O
but	O
weakly	O
suppressed	O
AFP	O
levels	O
.	O

The	O
results	O
provide	O
evidence	O
that	O
the	O
two	O
tumor	O
markers	O
are	O
not	O
directly	O
linked	O
and	O
that	O
DCP	O
levels	O
may	O
not	O
reflect	O
HCC	O
cell	O
growth	O
,	O
as	O
DCP	O
levels	O
were	O
decreased	O
in	O
patients	O
without	O
AFP	O
change	O
,	O
and	O
were	O
suppressed	O
in	O
vitro	O
at	O
1	O
%	O
of	O
the	O
vitamin	O
K1	O
concentration	O
needed	O
to	O
inhibit	O
AFP	O
.	O

Effect	O
of	O
entacapone	Pharmacological
,	O
a	O
peripherally	O
acting	O
catechol-O-methyltransferase	O
inhibitor	O
,	O
on	O
the	O
motor	O
response	O
to	O
acute	O
treatment	O
with	O
levodopa	O
in	O
patients	O
with	O
Parkinson	O
's	O
disease	O
.	O

Catechol-O-methyltransferase	O
(	O
COMT	O
)	O
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
by	O
improving	O
the	O
bioavailability	O
of	O
levodopa	O
and	O
by	O
prolonging	O
its	O
effects	O
.	O

Entacapone	Pharmacological
(	Pharmacological
OR-611	Pharmacological
)	Pharmacological
,	O
a	O
novel	Pharmacological
COMT	Pharmacological
inhibitor	Pharmacological
,	O
which	O
does	O
not	O
cross	O
the	O
blood	O
brain	O
barrier	O
,	O
was	O
assessed	O
in	O
12	O
patients	O
with	O
Parkinson	O
's	O
disease	O
and	O
motor	O
fluctuations	O
in	O
a	O
randomised	O
,	O
double-blind	O
,	O
cross-over	O
,	O
single	O
dose	O
study	O
.	O

The	O
magnitude	O
and	O
duration	O
of	O
the	O
therapeutic	O
response	O
to	O
a	O
single	O
dose	O
of	O
200	O
mg	O
levodopa/50	Pharmacological
mg	O
carbidopa	Pharmacological
was	O
evaluated	O
after	O
concomitant	O
placebo	Control
,	O
or	O
200	O
or	O
800	O
mg	O
entacapone	Pharmacological
.	O

A	O
significant	O
increase	O
in	O
the	O
duration	O
of	O
the	O
motor	O
response	O
to	O
levodopa	O
was	O
seen	O
when	O
200	O
mg	O
entacapone	O
was	O
given	O
with	O
levodopa/carbidopa	O
.	O

Plasma	O
levodopa	O
concentrations	O
were	O
increased	O
with	O
both	O
doses	O
of	O
the	O
COMT	O
inhibitor	O
.	O

The	O
latency	O
to	O
onset	O
of	O
motor	O
response	O
did	O
not	O
differ	O
significantly	O
between	O
active	O
drug	O
and	O
placebo	O
.	O

Entacapone	O
may	O
prove	O
useful	O
in	O
prolonging	O
the	O
duration	O
of	O
the	O
benefit	O
obtained	O
from	O
individual	O
doses	O
of	O
levodopa	O
.	O

Antibiotic	O
elimination	O
of	O
group-B	O
streptococci	O
in	O
urine	O
in	O
prevention	O
of	O
preterm	O
labour	O
.	O

The	O
presence	O
of	O
group-B	O
streptococci	O
in	O
the	O
urine	O
of	O
pregnant	O
women	O
seems	O
to	O
be	O
associated	O
with	O
preterm	O
labour	O
.	O

Urine	O
samples	O
from	O
4122	O
women	O
at	O
27-31	O
weeks	O
'	O
gestation	O
were	O
examined	O
for	O
bacteria	O
.	O

Group-B	O
streptococci	O
were	O
found	O
in	O
the	O
urine	O
of	O
69	O
women	O
.	O

In	O
a	O
double-blind	O
,	O
controlled	O
study	O
these	O
patients	O
were	O
given	O
either	O
penicillin	Pharmacological
(	O
10	O
(	O
6	O
)	O
IU	O
three	O
times	O
daily	O
for	O
6	O
days	O
;	O
37	O
patients	O
)	O
or	O
placebo	Control
(	O
32	O
patients	O
)	O
.	O

The	O
rates	O
of	O
primary	O
rupture	O
of	O
the	O
membranes	O
(	O
11	O
%	O
v	O
53	O
%	O
;	O
p	O
less	O
than	O
0.001	O
)	O
and	O
preterm	O
labour	O
(	O
5.4	O
%	O
v	O
38	O
%	O
;	O
p	O
less	O
than	O
0.002	O
)	O
were	O
significantly	O
lower	O
in	O
the	O
penicillin	Pharmacological
group	O
than	O
in	O
the	O
placebo	Control
group	O
.	O

These	O
results	O
suggest	O
that	O
treatment	O
and	O
follow-up	O
to	O
prevent	O
recolonisation	O
in	O
pregnant	O
women	O
with	O
group-B	O
streptococci	O
in	O
the	O
urine	O
may	O
reduce	O
the	O
frequency	O
of	O
preterm	O
labour	O
in	O
these	O
patients	O
.	O

Impact	O
of	O
prior	O
pharmacotherapy	Pharmacological
on	O
remission	O
of	O
psychotic	O
depression	O
in	O
a	O
randomized	O
controlled	O
trial	O
.	O

Having	O
failed	O
to	O
respond	O
to	O
an	O
adequate	O
antidepressant	O
treatment	O
course	O
predicts	O
poorer	O
treatment	O
outcomes	O
in	O
patients	O
with	O
major	O
depression	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
impact	O
of	O
prior	O
treatment	O
on	O
the	O
outcome	O
of	O
major	O
depression	O
with	O
psychotic	O
features	O
(	O
MDpsy	O
)	O
.	O

We	O
examined	O
the	O
effect	O
of	O
prior	O
treatment	O
history	O
on	O
the	O
outcome	O
of	O
pharmacotherapy	Pharmacological
of	O
MDpsy	O
in	O
patients	O
who	O
participated	O
in	O
the	O
STOPD-PD	O
study	O
,	O
a	O
randomized	O
,	O
double-blind	O
,	O
clinical	O
trial	O
comparing	O
a	O
combination	O
of	O
olanzapine	Pharmacological
plus	Pharmacological
sertraline	Pharmacological
vs.	Pharmacological
olanzapine	Control
plus	Control
placebo	Control
.	Control

The	O
strength	O
of	O
treatment	O
courses	O
received	O
prior	O
to	O
randomization	O
was	O
classified	O
using	O
a	O
validated	O
method	O
.	O

A	O
hierarchy	O
of	O
outcomes	O
was	O
hypothesized	O
based	O
on	O
treatments	O
received	O
prior	O
to	O
randomization	O
and	O
randomized	O
treatment	O
.	O

A	O
high	O
remission	O
rate	O
was	O
observed	O
in	O
subjects	O
with	O
a	O
history	O
of	O
no	O
prior	O
treatment	O
or	O
inadequate	O
treatment	O
who	O
were	O
treated	O
with	O
a	O
combination	O
of	O
olanzapine	Pharmacological
and	O
sertraline	Pharmacological
.	O

A	O
low	O
remission	O
rate	O
was	O
observed	O
in	O
subjects	O
who	O
had	O
previously	O
failed	O
to	O
respond	O
to	O
an	O
antidepressant	O
alone	O
and	O
who	O
were	O
treated	O
with	O
olanzapine	Pharmacological
monotherapy	O
.	O

A	O
low	O
remission	O
rate	O
was	O
also	O
observed	O
in	O
subjects	O
who	O
had	O
previously	O
failed	O
to	O
respond	O
to	O
a	O
combination	O
of	O
an	O
antipsychotic	O
and	O
an	O
antidepressant	O
.	O

Similar	O
to	O
patients	O
with	O
major	O
depression	O
,	O
these	O
results	O
emphasize	O
the	O
impact	O
of	O
prior	O
pharmacotherapy	Pharmacological
on	O
treatment	O
outcomes	O
in	O
patients	O
with	O
MDpsy	O
.	O

Spinal	O
2-chloroprocaine	Pharmacological
:	O
the	O
effect	O
of	O
added	O
clonidine	Pharmacological
.	O

Preservative-free	O
2-chloroprocaine	Pharmacological
(	Pharmacological
2-CP	Pharmacological
)	Pharmacological
is	O
being	O
investigated	O
for	O
short-acting	O
spinal	O
anesthesia	O
.	O

Clonidine	Pharmacological
improves	O
the	O
quality	O
of	O
spinal	O
bupivacaine	Pharmacological
and	O
ropivacaine	Pharmacological
,	O
but	O
in	O
traditional	O
doses	O
(	O
1-2	O
microg/kg	O
)	O
it	O
produces	O
systemic	O
side	O
effects	O
.	O

It	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
2-CP	Pharmacological
.	O

In	O
this	O
double-blind	O
,	O
randomized	O
crossover	O
study	O
,	O
we	O
compared	O
spinal	Pharmacological
2-CP	Pharmacological
(	O
30	O
mg	O
)	O
with	Pharmacological
and	Pharmacological
without	Pharmacological
clonidine	Pharmacological
(	O
15	O
microg	O
)	O
in	O
eight	O
volunteers	O
.	O

Pinprick	O
anesthesia	O
,	O
motor	O
strength	O
,	O
tolerance	O
to	O
electrical	O
stimulation	O
and	O
thigh	O
tourniquet	O
,	O
and	O
time	O
to	O
ambulation	O
were	O
assessed	O
.	O

Peak	O
block	O
height	O
was	O
similar	O
between	O
2-CP	O
(	O
T8	O
[	O
range	O
,	O
T6	O
to	O
L2	O
]	O
)	O
and	O
2-CP	O
with	O
clonidine	Pharmacological
(	O
T8	O
[	O
range	O
,	O
T4	O
to	O
T11	O
]	O
)	O
(	O
P	O
=	O
0.57	O
)	O
.	O

Sensory	O
anesthesia	O
was	O
prolonged	O
with	O
clonidine	Pharmacological
at	O
L1	O
(	O
51	O
+/-	O
23	O
min	O
versus	O
76	O
+/-	O
11	O
min	O
;	O
P	O
=	O
0.002	O
)	O
,	O
as	O
was	O
complete	O
block	O
regression	O
(	O
99	O
+/-	O
18	O
min	O
versus	O
131	O
+/-	O
15	O
min	O
;	O
P	O
=	O
0.001	O
)	O
.	O

Lower	O
extremity	O
motor	O
blockade	O
was	O
increased	O
with	O
clonidine	O
(	O
return	O
to	O
baseline	O
Bromage	O
score	O
:	O
65	O
+/-	O
13	O
min	O
versus	O
79	O
+/-	O
19	O
min	O
,	O
P	O
=	O
0.004	O
;	O
return	O
to	O
90	O
%	O
gastrocnemius	O
strength	O
:	O
P	O
=	O
0.003	O
)	O
.	O

Clonidine	Pharmacological
increased	O
tourniquet	O
tolerance	O
from	O
33	O
to	O
45	O
min	O
(	O
P	O
=	O
0.06	O
)	O
and	O
increased	O
time	O
to	O
ambulation	O
,	O
spontaneous	O
voiding	O
,	O
and	O
discharge	O
(	O
99	O
+/-	O
18	O
min	O
versus	O
131	O
+/-	O
15	O
min	O
for	O
all	O
;	O
P	O
=	O
0.001	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
hemodynamic	O
measurements	O
,	O
and	O
no	O
subject	O
reported	O
transient	O
neurologic	O
symptoms	O
.	O

We	O
conclude	O
that	O
small-dose	O
clonidine	Pharmacological
increases	O
the	O
duration	O
and	O
improves	O
the	O
quality	O
of	O
2-CP	O
spinal	O
anesthesia	O
without	O
systemic	O
side	O
effects	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
COMPASS	Other
web-based	Other
and	O
face-to-face	Educational
teacher	Educational
coaching	Educational
in	O
autism	O
.	O

OBJECTIVE	O
Most	O
children	O
with	O
autism	O
rely	O
on	O
schools	O
as	O
their	O
primary	O
source	O
of	O
intervention	O
,	O
yet	O
research	O
has	O
suggested	O
that	O
teachers	O
rarely	O
use	O
evidence-based	O
practices	O
.	O

To	O
address	O
the	O
need	O
for	O
improved	O
educational	O
outcomes	O
,	O
a	O
previously	O
tested	O
consultation	O
intervention	O
called	O
the	O
Collaborative	Educational
Model	Educational
for	Educational
Promoting	Educational
Competence	Educational
and	Educational
Success	Educational
(	Educational
COMPASS	Educational
;	O
Ruble	O
,	O
Dalrymple	O
,	O
&	O
McGrew	O
,	O
2010	O
;	O
Ruble	O
,	O
Dalrymple	O
,	O
&	O
McGrew	O
,	O
2012	O
)	O
was	O
evaluated	O
in	O
a	O
2nd	O
randomized	O
controlled	O
trial	O
,	O
with	O
the	O
addition	O
of	O
a	O
web-based	O
group	O
.	O

METHOD	O
Forty-nine	O
teacher-child	O
dyads	O
were	O
randomized	O
into	O
1	O
of	O
3	O
groups	O
:	O
(	O
1	O
)	O
a	O
placebo	Control
control	O
(	O
PBO	O
)	O
group	O
,	O
(	O
2	O
)	O
COMPASS	Educational
followed	Educational
by	Educational
face-to-face	Educational
(	Educational
FF	Educational
)	Educational
coaching	Educational
sessions	Educational
,	O
and	O
(	O
3	O
)	O
COMPASS	Educational
followed	Educational
by	Educational
web-based	Educational
(	Educational
WEB	Educational
)	Educational
coaching	Educational
sessions	Educational
.	O

Three	O
individualized	O
goals	O
(	O
social	Educational
,	Educational
communication	Educational
,	Educational
and	Educational
independence	Educational
skills	Educational
)	O
were	O
selected	O
for	O
intervention	O
for	O
each	O
child	O
.	O

The	O
primary	O
outcome	O
of	O
independent	O
ratings	O
of	O
child	O
goal	O
attainment	O
and	O
several	O
process	O
measures	O
(	O
e.g.	O
,	O
consultant	O
and	O
teacher	O
fidelity	O
)	O
were	O
evaluated	O
.	O

RESULTS	O
Using	O
an	O
intent-to-treat	O
approach	O
,	O
findings	O
replicated	O
earlier	O
results	O
with	O
a	O
very	O
large	O
effect	O
size	O
(	O
d	O
=	O
1.41	O
)	O
for	O
the	O
FF	O
group	O
and	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1.12	O
)	O
for	O
the	O
WEB	O
group	O
relative	O
to	O
the	O
PBO	O
group	O
.	O

There	O
were	O
no	O
differences	O
in	O
overall	O
change	O
across	O
goal	O
domains	O
between	O
the	O
FF	O
and	O
WEB	O
groups	O
,	O
suggesting	O
the	O
efficacy	O
of	O
videoconferencing	O
technology	O
.	O

CONCLUSIONS	O
COMPASS	Other
is	O
effective	O
and	O
results	O
in	O
improved	O
educational	O
outcomes	O
for	O
young	O
children	O
with	O
autism	O
.	O

Videoconferencing	O
technology	O
,	O
as	O
a	O
scalable	O
tool	O
,	O
has	O
promise	O
for	O
facilitating	O
access	O
to	O
autism	O
specialists	O
and	O
bridging	O
the	O
research-to-practice	O
gap	O
.	O

Effect	O
of	O
cervical	Physical
spine	Physical
manipulative	Physical
therapy	Physical
on	O
judo	O
athletes	O
'	O
grip	O
strength	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
perform	O
an	O
investigation	O
evaluating	O
if	O
cervical	Physical
spinal	Physical
manipulative	Physical
therapy	Physical
(	Physical
SMT	Physical
)	Physical
can	O
increase	O
grip	O
strength	O
on	O
judo	O
athletes	O
in	O
a	O
top	O
10	O
national-ranked	O
team	O
.	O

METHODS	O
A	O
single-blinded	O
,	O
prospective	O
,	O
comparative	O
,	O
pilot	O
,	O
randomized	O
,	O
clinical	O
trial	O
was	O
performed	O
with	O
18	O
athletes	O
of	O
both	O
sexes	O
from	O
a	O
judo	O
team	O
currently	O
competing	O
on	O
a	O
national	O
level	O
.	O

The	O
athletes	O
were	O
randomly	O
assigned	O
to	O
2	O
groups	O
:	O
chiropractic	Physical
SMT	Physical
and	O
sham	Control
.	O

Three	O
interventions	O
were	O
performed	O
on	O
each	O
of	O
the	O
athletes	O
at	O
different	O
time	O
points	O
.	O

Force	O
measurements	O
were	O
obtained	O
by	O
a	O
hydraulic	O
dynamometer	O
immediately	O
before	O
and	O
after	O
each	O
intervention	O
at	O
the	O
same	O
period	O
before	O
training	O
up	O
to	O
3	O
weeks	O
with	O
at	O
least	O
36	O
hours	O
between	O
interventions	O
.	O

RESULTS	O
Analysis	O
of	O
grip	O
strength	O
data	O
revealed	O
a	O
statistically	O
significant	O
increase	O
in	O
strength	O
within	O
the	O
treatment	O
group	O
after	O
the	O
first	O
intervention	O
(	O
6.95	O
%	O
right	O
,	O
12.61	O
%	O
left	O
)	O
as	O
compared	O
with	O
the	O
second	O
(	O
11.53	O
%	O
right	O
,	O
17.02	O
%	O
left	O
)	O
and	O
the	O
third	O
interventions	O
(	O
10.53	O
%	O
right	O
,	O
16.81	O
%	O
left	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
grip	O
strength	O
comparison	O
within	O
the	O
sham	O
group	O
.	O

Overall	O
differences	O
in	O
strength	O
were	O
consistently	O
significant	O
between	O
the	O
study	O
groups	O
(	O
P	O
=	O
.0025	O
)	O
.	O

CONCLUSION	O
The	O
present	O
study	O
suggests	O
that	O
the	O
grip	O
strength	O
of	O
national	O
level	O
judo	O
athletes	O
receiving	O
chiropractic	Physical
SMT	Physical
improved	O
compared	O
to	O
those	O
receiving	O
sham	O
.	O

Effect	O
of	O
broccoli	Pharmacological
intake	Pharmacological
on	O
markers	O
related	O
to	O
oxidative	O
stress	O
and	O
cancer	O
risk	O
in	O
healthy	O
smokers	O
and	O
nonsmokers	O
.	O

Cruciferous	Pharmacological
vegetables	Pharmacological
(	Pharmacological
CVs	Pharmacological
)	Pharmacological
have	O
been	O
widely	O
studied	O
for	O
their	O
anticarcinogenic	O
properties	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
broccoli	Pharmacological
intake	O
in	O
smokers	O
and	O
nonsmokers	O
.	O

Twenty	O
young	O
healthy	O
males	O
(	O
10	O
smokers	O
and	O
10	O
nonsmokers	O
)	O
were	O
randomized	O
in	O
a	O
cross-over	O
design	O
and	O
received	O
a	O
portion	O
of	O
broccoli	Pharmacological
(	O
200	O
g	O
)	O
or	O
maintained	Control
a	Control
controlled	Control
diet	Control
for	O
10	O
days	O
each	O
.	O

The	O
two	O
periods	O
were	O
separated	O
by	O
a	O
wash-out	O
period	O
(	O
20	O
days	O
)	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
0	O
,	O
10	O
,	O
30	O
,	O
and	O
40	O
days	O
and	O
used	O
for	O
the	O
evaluation	O
of	O
DNA	O
damage	O
,	O
insulin-like	O
growth	O
factor-I	O
(	O
IGF-I	O
)	O
and	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
.	O

Ex	O
vivo	O
protection	O
from	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
-induced	O
DNA	O
damage	O
and	O
endogenous	O
DNA	O
damage	O
were	O
evaluated	O
in	O
lymphocytes	O
by	O
means	O
of	O
the	O
comet	O
assay	O
.	O

Strand	O
breaks	O
decreased	O
significantly	O
after	O
the	O
broccoli	O
diet	O
in	O
smokers	O
as	O
well	O
as	O
in	O
nonsmokers	O
(	O
-22.2	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
whereas	O
oxidized	O
purines	O
decreased	O
significantly	O
only	O
in	O
smokers	O
(	O
-51.0	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Broccoli	Pharmacological
intake	O
did	O
not	O
modify	O
HDAC	O
activity	O
and	O
IGF-I	O
serum	O
levels	O
.	O

Our	O
results	O
strengthen	O
the	O
importance	O
of	O
consuming	O
CVs	O
to	O
increase	O
cell	O
protection	O
against	O
DNA	O
damage	O
.	O

Future	O
investigation	O
,	O
with	O
different	O
amount	O
of	O
broccoli	Pharmacological
and/or	O
different	O
time	O
of	O
exposure	O
,	O
is	O
needed	O
to	O
understand	O
the	O
lack	O
of	O
effect	O
on	O
HDAC	O
activity	O
and	O
IGF-I	O
levels	O
.	O

Acceleration	O
of	O
insulin	O
pharmacodynamic	O
profile	O
by	O
a	O
novel	O
insulin	Physical
infusion	Physical
site	Physical
warming	Physical
device	Physical
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
Subcutaneously	O
injected	O
rapid-acting	O
insulin	O
analogs	O
do	O
not	O
replicate	O
physiologic	O
insulin	O
action	O
due	O
to	O
delays	O
in	O
their	O
onset	O
and	O
peak	O
action	O
resulting	O
in	O
postprandial	O
glucose	O
excursions	O
.	O

The	Physical
InsuPatch	Physical
(	Physical
IP	Physical
)	Physical
is	O
a	O
novel	O
insulin	O
infusion	O
site	O
warming	O
device	O
developed	O
to	O
accelerate	O
insulin	O
action	O
by	O
increasing	O
blood	O
flow	O
to	O
the	O
area	O
of	O
insulin	O
absorption	O
.	O

Thirteen	O
adolescents	O
with	O
type	O
1	O
diabetes	O
(	O
T1D	O
,	O
mean	O
age	O
14	O
?	O
4	O
yr	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
IP	O
on	O
the	O
pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
a	O
0.2	O
unit/kg	O
bolus	O
dose	O
of	O
aspart	O
insulin	O
using	O
the	O
euglycemic	O
clamp	O
technique	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
Each	O
subject	O
underwent	O
two	O
euglycemic	O
clamp	O
procedures	O
on	O
separate	O
occasions	O
:	O
one	O
with	O
IP	Pharmacological
and	O
one	O
without	O
IP	Pharmacological
activation	O
in	O
random	O
order	O
.	O

RESULTS	O
When	O
the	O
insulin	O
bolus	O
was	O
given	O
with	O
IP	O
activation	O
as	O
compared	O
to	O
without	O
IP	O
activation	O
,	O
time	O
to	O
reach	O
maximum	O
insulin	O
action	O
(	O
T	O
(	O
GIRmax	O
)	O
)	O
and	O
to	O
reach	O
50	O
%	O
maximum	O
action	O
(	O
T	O
(	O
50	O
%	O
GIRmax	O
)	O
)	O
were	O
35	O
and	O
18	O
min	O
earlier	O
(	O
125	O
?	O
8	O
min	O
vs.	O
90	O
?	O
6	O
min	O
,	O
p	O
=	O
0.002	O
and	O
58	O
?	O
5	O
min	O
.	O

vs.	O
40	O
?	O
3	O
min	O
,	O
p	O
=	O
0.01	O
,	O
respectively	O
)	O
,	O
and	O
the	O
area	O
under	O
curve	O
,	O
AUC	O
(	O
GIR	O
0-90	O
min	O
)	O
,	O
reflecting	O
early	O
glucodynamic	O
action	O
,	O
was	O
significantly	O
greater	O
(	O
p	O
=	O
0.001	O
)	O
.	O

IP	O
activation	O
also	O
accelerated	O
the	O
rise	O
in	O
plasma	O
insulin	O
levels	O
after	O
the	O
bolus	O
(	O
p	O
=	O
0.03	O
)	O
and	O
resulted	O
in	O
a	O
higher	O
peak	O
(	O
p	O
=	O
0.04	O
)	O
and	O
greater	O
overall	O
increase	O
(	O
p	O
=	O
0.02	O
)	O
in	O
plasma	O
insulin	O
levels	O
.	O

CONCLUSIONS	O
Our	O
results	O
show	O
that	O
insulin	O
infusion	O
site	O
warming	O
with	O
IP	O
activation	O
accelerates	O
the	O
time	O
action	O
profile	O
of	O
aspart	O
insulin	O
which	O
may	O
be	O
of	O
benefit	O
to	O
current	O
open-loop	O
and	O
future	O
closed-loop	O
insulin	O
delivery	O
in	O
patients	O
with	O
T1D	O
.	O

Predictors	O
of	O
recruited	O
melanoma	O
families	O
into	O
a	O
behavioral	Educational
intervention	Educational
project	Educational
.	O

BACKGROUND	O
Examination	O
of	O
families	O
represents	O
an	O
important	O
priority	O
in	O
health	O
research	O
.	O

In	O
this	O
paper	O
we	O
report	O
on	O
individual	O
and	O
family-level	O
factors	O
associated	O
with	O
enrollment	O
in	O
a	O
cancer	O
prevention	O
research	O
project	O
.	O

We	O
approached	O
families	O
affected	O
by	O
melanoma	O
for	O
possible	O
participation	O
in	O
a	O
randomized	O
controlled	O
trial	O
of	O
a	O
web-based	Educational
communication	Educational
and	Educational
support	Educational
intervention	Educational
.	O

METHODS	O
We	O
recruited	O
three	O
family	O
members	O
per	O
family	O
for	O
assessment	O
-	O
the	O
melanoma	O
case	O
,	O
a	O
first-degree	O
relative	O
(	O
FDR	O
)	O
,	O
and	O
a	O
relative	O
who	O
is	O
a	O
parent	O
of	O
a	O
child	O
age	O
18	O
or	O
younger	O
.	O

Recruitment	O
involved	O
three	O
steps	O
:	O
requesting	O
the	O
physician	O
's	O
consent	O
to	O
approach	O
the	O
melanoma	O
case	O
,	O
approaching	O
the	O
case	O
to	O
request	O
their	O
participation	O
and	O
family	O
contact	O
information	O
,	O
and	O
they	O
approaching	O
the	O
FDRs	O
and	O
parents	O
.	O

RESULTS	O
Of	O
the	O
1380	O
families	O
approached	O
,	O
313	O
were	O
enrolled	O
,	O
263	O
were	O
excluded	O
because	O
we	O
could	O
not	O
find	O
or	O
contact	O
a	O
family	O
member	O
(	O
FDR	O
or	O
parent	O
)	O
,	O
331	O
did	O
not	O
have	O
eligible	O
family	O
members	O
,	O
and	O
473	O
refused	O
.	O

The	O
most	O
frequently	O
noted	O
reason	O
for	O
refusal	O
was	O
being	O
too	O
busy	O
or	O
having	O
no	O
time	O
.	O

The	O
primary	O
predictors	O
of	O
participation	O
for	O
cases	O
(	O
OR=1.6	O
;	O
CI=1.01-2.51	O
)	O
and	O
FDRs	O
(	O
OR=2.15	O
;	O
CI=1.11-4.13	O
)	O
included	O
higher	O
educational	O
attainment	O
.	O

FDRs	O
were	O
more	O
likely	O
to	O
enroll	O
if	O
they	O
were	O
female	O
(	O
OR=1.77	O
;	O
CI=1.1-.85	O
)	O
and	O
parents	O
were	O
more	O
likely	O
to	O
enroll	O
if	O
the	O
case	O
had	O
been	O
diagnosed	O
more	O
recently	O
(	O
OR=3.3	O
;	O
CI=1.9-5.93	O
)	O
,	O
if	O
the	O
parent	O
was	O
partnered	O
(	O
OR=4.37	O
;	O
CI=1.86-10.26	O
)	O
,	O
and	O
if	O
the	O
parent	O
lived	O
in	O
the	O
same	O
city	O
as	O
the	O
case	O
(	O
OR=2.88	O
;	O
CI=1.08-7.68	O
)	O
.	O

CONCLUSIONS	O
The	O
results	O
can	O
provide	O
information	O
on	O
potential	O
directions	O
for	O
future	O
family	O
recruitment	O
.	O

Survey	Educational
response	O
inducements	O
for	O
registered	O
nurses	O
.	O

The	O
past	O
20	O
years	O
have	O
seen	O
an	O
overall	O
decline	O
in	O
survey	O
response	O
rates	O
and	O
an	O
even	O
more	O
pronounced	O
decline	O
in	O
samples	O
of	O
health	O
care	O
professionals	O
.	O

The	O
authors	O
tested	O
the	O
use	O
of	O
a	O
thank	Other
you	Other
or	O
reminder	Other
postcard	Other
as	O
a	O
method	O
by	O
which	O
to	O
stem	O
the	O
tide	O
of	O
declining	O
response	O
rates	O
.	O

The	O
authors	O
conducted	O
a	O
mail	Other
and	Other
telephone	Other
survey	Other
of	O
49,605	O
registered	O
nurses	O
for	O
the	O
2000	O
National	O
Sample	O
Survey	O
of	O
Registered	O
Nurses	O
and	O
sent	O
an	O
extra	O
mailing	O
to	O
a	O
random	O
subsample	O
(	O
n	O
=	O
4,968	O
)	O
.	O

They	O
then	O
compared	O
response	O
rates	O
for	O
both	O
groups	O
.	O

Contrary	O
to	O
prior	O
research	O
,	O
this	O
study	O
found	O
that	O
reminder	O
postcards	O
did	O
not	O
improve	O
response	O
rates	O
or	O
rates	O
of	O
return	O
.	O

There	O
may	O
be	O
several	O
reasons	O
for	O
this	O
finding	O
,	O
including	O
the	O
general	O
familiarity	O
with	O
,	O
and	O
high	O
saliency	O
of	O
,	O
this	O
research	O
project	O
for	O
the	O
nursing	O
community	O
.	O

These	O
results	O
suggest	O
that	O
even	O
widely	O
accepted	O
best	O
practices	O
for	O
survey	O
methods	O
deserve	O
scrutiny	O
when	O
applied	O
to	O
special	O
subpopulations	O
.	O

Single	O
and	O
short-term	O
dosing	O
effects	O
of	O
levocetirizine	Pharmacological
on	O
adenosine	O
monophosphate	O
bronchoprovocation	O
in	O
atopic	O
asthma	O
.	O

AIMS	O
Adenosine	O
monophosphate	O
(	O
AMP	O
)	O
acts	O
indirectly	O
via	O
primed	O
airway	O
mast	O
cells	O
to	O
induce	O
bronchial	O
hyper-responsiveness	O
,	O
which	O
in	O
turn	O
correlates	O
with	O
eosinophilic	O
asthmatic	O
inflammation	O
and	O
atopic	O
disease	O
expression	O
.	O

We	O
evaluated	O
single	O
and	O
short-term	O
dosing	O
effects	O
of	O
a	O
modern	O
histamine	O
H1-receptor	O
antagonist	O
,	O
levocetirizine	Pharmacological
,	O
given	O
at	O
the	O
usual	O
clinically	O
recommended	O
dose	O
,	O
on	O
the	O
primary	O
outcome	O
of	O
AMP	O
bronchoprovocation	O
.	O

METHODS	O
Fifteen	O
atopic	O
asthmatics	O
were	O
randomized	O
in	O
double-blind	O
,	O
cross-over	O
fashion	O
to	O
receive	O
for	O
1	O
week	O
either	O
levocetirizine	Pharmacological
5	Pharmacological
mg	Pharmacological
or	O
placebo	Control
.	O

There	O
was	O
a	O
1-week	O
washout	O
period	O
prior	O
to	O
each	O
randomized	O
treatment	O
.	O

The	O
provocative	O
concentration	O
of	O
AMP	O
producing	O
a	O
20	O
%	O
fall	O
in	O
FEV1	O
(	O
PC20	O
)	O
was	O
measured	O
after	O
each	O
washout	O
at	O
baseline	O
and	O
at	O
4-6	O
h	O
following	O
the	O
first	O
and	O
last	O
doses	O
of	O
each	O
randomized	O
treatment	O
.	O

RESULTS	O
Baseline	O
mean	O
+/-	O
SEM	O
values	O
after	O
washout	O
prior	O
to	O
each	O
randomized	O
treatment	O
comparing	O
levocetirizine	Pharmacological
vs	O
placebo	Control
were	O
not	O
significantly	O
different	O
for	O
prechallenge	O
FEV1	O
(	O
%	O
predicted	O
)	O
83	O
+/-	O
4	O
vs	O
82	O
+/-	O
4	O
,	O
or	O
AMP	O
PC20	O
(	O
mg	O
ml	O
(	O
-1	O
)	O
)	O
45	O
+/-	O
24	O
vs	O
45	O
+/-	O
22	O
,	O
respectively	O
.	O

Airway	O
calibre	O
as	O
prechallenge	O
FEV1	O
for	O
levocetirizine	Pharmacological
vs	O
placebo	Control
was	O
not	O
significantly	O
different	O
following	O
the	O
first	O
dose	O
86	O
+/-	O
4	O
vs	O
82	O
+/-	O
4	O
,	O
or	O
the	O
last	O
dose	O
85	O
+/-	O
4	O
vs	O
83	O
+/-	O
4	O
,	O
respectively	O
.	O

There	O
were	O
significant	O
improvements	O
(	O
P	O
<	O
0.05	O
)	O
in	O
AMP	O
PC20	O
comparing	O
levocetirizine	O
vs	O
placebo	O
following	O
the	O
first	O
dose	O
123	O
+/-	O
73	O
vs	O
48	O
+/-	O
24	O
,	O
a	O
1.4	O
doubling	O
dilution	O
difference	O
(	O
95	O
%	O
CI	O
0.8	O
,	O
1.9	O
)	O
,	O
and	O
the	O
last	O
dose	O
127	O
+/-	O
74	O
vs	O
53	O
+/-	O
29	O
,	O
a	O
1.2	O
doubling	O
dilution	O
difference	O
(	O
95	O
%	O
CI	O
0.5	O
,	O
2.0	O
)	O
.	O

AMP	O
PC20	O
was	O
also	O
improved	O
(	O
P	O
<	O
0.05	O
)	O
by	O
the	O
first	O
and	O
last	O
doses	O
of	O
levocetirizine	O
but	O
not	O
placebo	O
,	O
vs	O
respective	O
baseline	O
values	O
,	O
with	O
there	O
being	O
no	O
difference	O
in	O
the	O
degree	O
of	O
protection	O
between	O
first	O
and	O
last	O
doses	O
.	O

CONCLUSIONS	O
Single	O
and	O
short-term	O
dosing	O
with	O
levocetirizine	Pharmacological
conferred	O
similar	O
improvements	O
in	O
bronchial	O
hyper-responsiveness	O
to	O
AMP	O
challenge	O
,	O
which	O
was	O
unrelated	O
to	O
prechallenge	O
airway	O
calibre	O
.	O

Further	O
studies	O
are	O
indicated	O
to	O
evaluate	O
the	O
longer-term	O
effects	O
of	O
levocetirizine	Pharmacological
on	O
asthma	O
exacerbations	O
.	O

Effectiveness	O
of	O
a	O
clinical	Educational
intervention	Educational
in	O
improving	O
pain	O
control	O
in	O
outpatients	O
with	O
cancer	O
treated	O
by	O
radiation	Educational
therapy	Educational
.	O

PURPOSE	O
To	O
determine	O
the	O
effectiveness	O
of	O
a	O
multicomponent	Educational
clinical	Educational
intervention	Educational
to	O
reduce	O
pain	O
in	O
outpatients	O
with	O
cancer	O
.	O

METHODS	O
AND	O
MATERIALS	O
Sixty-four	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
a	O
clinical	Educational
intervention	Educational
including	O
an	O
information	Other
session	Other
,	O
the	O
use	O
of	O
a	O
pain	Physical
diary	Physical
,	O
and	O
the	O
possibility	O
to	O
contact	Physical
a	Physical
physician	Physical
to	O
adjust	O
the	O
pain	O
medication	O
,	O
or	Physical
the	Physical
usual	Physical
treatment	Physical
of	Physical
pain	Physical
by	Physical
the	Physical
staff	Physical
radiation	Physical
oncologist	Physical
.	O

All	O
patients	O
reported	O
their	O
average	O
and	O
worst	O
pain	O
levels	O
at	O
baseline	O
and	O
2	O
and	O
3	O
weeks	O
after	O
the	O
start	O
of	O
the	O
intervention	O
.	O

RESULTS	O
The	O
study	O
groups	O
were	O
similar	O
with	O
respect	O
to	O
their	O
baseline	O
characteristics	O
and	O
pain	O
levels	O
at	O
randomization	O
.	O

After	O
3	O
weeks	O
,	O
the	O
average	O
and	O
worst	O
pain	O
experienced	O
by	O
patients	O
randomized	O
to	O
the	O
clinical	Educational
intervention	Educational
group	Educational
was	O
significantly	O
inferior	O
to	O
the	O
average	O
pain	O
experienced	O
by	O
patients	O
in	O
the	O
control	O
group	O
(	O
2.9/10	O
vs.	O
4.4/10	O
and	O
4.2/10	O
vs.	O
5.5/10	O
,	O
respectively	O
)	O
.	O

Results	O
showed	O
that	O
the	O
experimental	O
group	O
patients	O
decreased	O
their	O
pain	O
levels	O
more	O
than	O
the	O
control	O
group	O
patients	O
did	O
over	O
time	O
.	O

CONCLUSION	O
An	O
intervention	O
including	O
patient	Educational
education	Educational
,	O
a	Other
pain	Other
diary	Other
,	O
and	O
defining	Educational
a	Educational
procedure	Educational
for	Educational
therapeutic	Psychological
adjustments	Psychological
can	O
be	O
effective	O
to	O
improve	O
pain	O
relief	O
in	O
outpatients	O
with	O
cancer	O
.	O

Parent-based	Educational
sleep	Educational
education	Educational
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
provided	O
sleep	Educational
education	Educational
to	Educational
parents	Educational
of	O
children	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
to	O
determine	O
whether	O
an	O
individual	Educational
or	O
group	Educational
format	Educational
was	O
more	O
effective	O
in	O
improving	O
sleep	O
and	O
aspects	O
of	O
daytime	O
behavior	O
and	O
family	O
functioning	O
.	O

Eighty	O
children	O
,	O
ages	O
2-10	O
years	O
,	O
with	O
ASD	O
and	O
sleep	O
onset	O
delay	O
completed	O
the	O
study	O
.	O

Actigraphy	O
and	O
parent	O
questionnaires	O
were	O
collected	O
at	O
baseline	O
and	O
1	O
month	O
after	O
treatment	O
.	O

Mode	O
of	O
education	O
did	O
not	O
affect	O
outcomes	O
.	O

Sleep	O
latency	O
,	O
insomnia	O
subscales	O
on	O
the	O
Children	O
's	O
Sleep	O
Habits	O
Questionnaire	O
,	O
and	O
other	O
outcomes	O
related	O
to	O
child	O
and	O
family	O
functioning	O
improved	O
with	O
treatment	O
.	O

Parent-based	O
sleep	O
education	O
,	O
delivered	O
in	O
relatively	O
few	O
sessions	O
,	O
was	O
associated	O
with	O
improved	O
sleep	O
onset	O
delay	O
in	O
children	O
with	O
ASD	O
.	O

Group	O
versus	O
individualized	O
education	O
did	O
not	O
affect	O
outcome	O
.	O

[	O
Sentinel	O
lymph	O
node	O
detection	O
in	O
colorectal	O
cancer	O
:	O
importance	O
,	O
techniques	O
and	O
results	O
]	O
.	O

BACKGROUND	O
AND	O
AIM	O
Considering	O
that	O
lymph	O
node	O
status	O
is	O
a	O
key	O
factor	O
in	O
colorectal	O
cancer	O
staging	O
,	O
and	O
the	O
main	O
determinant	O
for	O
adjuvant	Pharmacological
therapy	Pharmacological
of	O
colorectal	O
cancer	O
being	O
this	O
therapy	O
,	O
responsible	O
for	O
a	O
significant	O
increase	O
in	O
colorectal	O
cancer	O
patients	O
survival	O
,	O
the	O
staging	O
methods	O
should	O
be	O
the	O
most	O
accurate	O
possible	O
in	O
order	O
to	O
offer	O
this	O
individuals	O
the	O
opportunity	O
to	O
be	O
adequate	O
treated	O
in	O
order	O
to	O
achieve	O
the	O
best	O
survival	O
possible	O
.	O

Sentinel	O
lymph	O
node	O
study	O
is	O
progressively	O
being	O
popularized	O
as	O
a	O
method	O
that	O
increases	O
sensibility	O
in	O
detect	O
positive	O
nodes	O
to	O
reveal	O
a	O
more	O
accurate	O
stage	O
and	O
prognosis	O
in	O
colorectal	O
cancer	O
patients	O
.	O

PATIENTS	O
AND	O
METHODS	O
Thirty	O
one	O
colorectal	O
cancer	O
patients	O
were	O
prospectively	O
studied	O
and	O
sentinel	O
lymph	O
node	O
was	O
identified	O
in	O
100	O
%	O
of	O
the	O
cases	O
utilizing	Physical
either	Physical
patent	Physical
blue	Physical
alone	Physical
,	Physical
or	Physical
in	Physical
association	Physical
with	Physical
radiotracer	Physical
based	Physical
on	Physical
technetium	Physical
99m	Physical
colloid	Physical
solution	Physical
in	Physical
a	Physical
randomized	Physical
fashion	Physical
.	O

RESULTS	O
The	O
mean	O
number	O
of	O
sentinel	O
nodes	O
per	O
patient	O
was	O
1.96	O
ranging	O
from	O
1	O
to	O
3	O
nodes	O
.	O

With	O
the	O
addition	O
of	O
transoperative	O
lympho-scintigraphy	O
five	O
extra	O
sentinel	O
nodes	O
,	O
not	O
identified	O
by	O
the	O
blue	O
dye	O
alone	O
,	O
were	O
identified	O
and	O
considered	O
for	O
histopathology	O
study	O
.	O

In	O
four	O
cases	O
(	O
12.9	O
%	O
)	O
the	O
sentinel	O
lymph	O
node	O
was	O
the	O
only	O
site	O
of	O
metastasis	O
,	O
all	O
of	O
them	O
being	O
detected	O
by	O
association	O
of	O
hematoxylin	O
and	O
eosin	O
and	O
immunohistochemical	O
examination	O
.	O

CONCLUSION	O
Sentinel	O
lymph	O
node	O
detection	O
and	O
analysis	O
is	O
feasible	O
,	O
technique	O
is	O
relatively	O
simple	O
and	O
is	O
able	O
to	O
produce	O
upstage	O
in	O
colorectal	O
cancer	O
.	O

Blue	Physical
staining	Physical
and	Physical
radio	Physical
guided	Physical
techniques	Physical
are	O
both	O
safe	O
and	O
their	O
superposition	O
has	O
shown	O
good	O
results	O
in	O
terms	O
of	O
increase	O
accuracy	O
in	O
our	O
experience	O
.	O

There	O
was	O
no	O
aberrant	O
lymph	O
drainage	O
that	O
would	O
alter	O
resection	O
margins	O
in	O
patients	O
studied	O
.	O

Upstaging	O
rate	O
,	O
identifying	O
potential	O
candidates	O
for	O
adjuvant	Pharmacological
therapy	Pharmacological
was	O
12.9	O
%	O
(	O
4/31	O
)	O
.	O

To	O
this	O
individuals	O
chemotherapy	Pharmacological
could	O
be	O
a	O
chance	O
to	O
increase	O
their	O
global	O
survival	O
.	O

A	O
comparison	O
of	O
three	O
highly	O
active	O
antiretroviral	O
treatment	O
strategies	O
consisting	O
of	O
non-nucleoside	Pharmacological
reverse	Pharmacological
transcriptase	Pharmacological
inhibitors	Pharmacological
,	Pharmacological
protease	Pharmacological
inhibitors	Pharmacological
,	Pharmacological
or	Pharmacological
both	Pharmacological
in	Pharmacological
the	Pharmacological
presence	Pharmacological
of	Pharmacological
nucleoside	Pharmacological
reverse	Pharmacological
transcriptase	Pharmacological
inhibitors	Pharmacological
as	O
initial	O
therapy	O
(	O
CPCRA	O
058	O
FIRST	O
Study	O
)	O
:	O
a	O
long-term	O
randomised	O
trial	O
.	O

BACKGROUND	O
Long-term	O
data	O
from	O
randomised	O
trials	O
on	O
the	O
consequences	O
of	O
treatment	O
with	O
a	O
protease	Pharmacological
inhibitor	Pharmacological
(	Pharmacological
PI	Pharmacological
)	Pharmacological
,	Pharmacological
non-nucleoside	Pharmacological
reverse	Pharmacological
transcriptase	Pharmacological
inhibitor	Pharmacological
(	Pharmacological
NNRTI	Pharmacological
)	Pharmacological
,	Pharmacological
or	Pharmacological
both	Pharmacological
are	Pharmacological
lacking	Pharmacological
.	Pharmacological

Here	O
,	O
we	O
report	O
results	O
from	O
the	O
FIRST	O
trial	O
,	O
which	O
compared	O
initial	O
treatment	O
strategies	O
for	O
clinical	O
,	O
immunological	O
,	O
and	O
virological	O
outcomes	O
.	O

METHODS	O
Between	O
1999	O
and	O
2002	O
,	O
1397	O
antiretroviral-treatment-naive	O
patients	O
,	O
presenting	O
at	O
18	O
clinical	O
trial	O
units	O
with	O
80	O
research	O
sites	O
in	O
the	O
USA	O
,	O
were	O
randomly	O
assigned	O
in	O
a	O
ratio	O
of	O
1:1:1	O
to	O
a	O
protease	Pharmacological
inhibitor	Pharmacological
(	Pharmacological
PI	Pharmacological
)	Pharmacological
strategy	Pharmacological
(	Pharmacological
PI	Pharmacological
plus	Pharmacological
nucleoside	Pharmacological
reverse	Pharmacological
transcriptase	Pharmacological
inhibitor	Pharmacological
[	Pharmacological
NRTI	Pharmacological
]	Pharmacological
;	Pharmacological
n=470	O
)	O
,	O
a	Pharmacological
non-nucleoside	Pharmacological
reverse	Pharmacological
transcriptase	Pharmacological
inhibitor	Pharmacological
(	Pharmacological
NNRTI	Pharmacological
)	Pharmacological
strategy	Pharmacological
(	Pharmacological
NNRTI	Pharmacological
plus	Pharmacological
NRTI	Pharmacological
;	Pharmacological
n=463	O
)	O
,	O
or	Pharmacological
a	Pharmacological
three-class	Pharmacological
strategy	Pharmacological
(	Pharmacological
PI	Pharmacological
plus	Pharmacological
NNRTI	Pharmacological
plus	Pharmacological
NRTI	Pharmacological
;	Pharmacological
n=464	O
)	O
.	O

Primary	O
endpoints	O
were	O
a	O
composite	O
of	O
an	O
AIDS-defining	O
event	O
,	O
death	O
,	O
or	O
CD4	O
cell	O
count	O
decline	O
to	O
less	O
than	O
200	O
cells	O
per	O
mm3	O
for	O
the	O
PI	O
versus	O
NNRTI	O
comparison	O
,	O
and	O
average	O
change	O
in	O
CD4	O
cell	O
count	O
at	O
or	O
after	O
32	O
months	O
for	O
the	O
three-class	O
versus	O
combined	O
two-class	O
comparison	O
.	O

Analyses	O
were	O
by	O
intention-to-treat	O
.	O

This	O
study	O
is	O
registered	O
ClinicalTrials.gov	O
,	O
number	O
NCT00000922	O
.	O

FINDINGS	O
1397	O
patients	O
were	O
assessed	O
for	O
the	O
composite	O
endpoint	O
.	O

A	O
total	O
of	O
388	O
participants	O
developed	O
the	O
composite	O
endpoint	O
,	O
302	O
developed	O
AIDS	O
or	O
died	O
,	O
and	O
188	O
died	O
.	O

NNRTI	O
versus	O
PI	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
the	O
composite	O
endpoint	O
,	O
for	O
AIDS	O
or	O
death	O
,	O
for	O
death	O
,	O
and	O
for	O
virological	O
failure	O
were	O
1.02	O
(	O
95	O
%	O
CI	O
0.79-1.31	O
)	O
,	O
1.07	O
(	O
0.80-1.41	O
)	O
,	O
0.95	O
(	O
0.66-1.37	O
)	O
,	O
and	O
0.66	O
(	O
0.56-0.78	O
)	O
,	O
respectively	O
.	O

1196	O
patients	O
were	O
assessed	O
for	O
the	O
three-class	O
versus	O
combined	O
two-class	O
primary	O
endpoint	O
.	O

Mean	O
change	O
in	O
CD4	O
cell	O
count	O
at	O
or	O
after	O
32	O
months	O
was	O
+234	O
cells	O
per	O
mm3	O
and	O
+227	O
cells	O
per	O
mm3	O
for	O
the	O
three-class	O
and	O
the	O
combined	O
two-class	O
strategies	O
(	O
p=0.62	O
)	O
,	O
respectively	O
.	O

HRs	O
(	O
three-class	O
vs	O
combined	O
two-class	O
)	O
for	O
AIDS	O
or	O
death	O
and	O
virological	O
failure	O
were	O
1.15	O
(	O
0.91-1.45	O
)	O
and	O
0.87	O
(	O
0.75-1.00	O
)	O
,	O
respectively	O
.	O

HRs	O
(	O
three-class	O
vs	O
combined	O
two-class	O
)	O
for	O
AIDS	O
or	O
death	O
were	O
similar	O
for	O
participants	O
with	O
baseline	O
CD4	O
cell	O
counts	O
of	O
200	O
cells	O
per	O
mm3	O
or	O
less	O
and	O
of	O
more	O
than	O
200	O
cells	O
per	O
mm3	O
(	O
p=0.38	O
for	O
interaction	O
)	O
,	O
and	O
for	O
participants	O
with	O
baseline	O
HIV	O
RNA	O
concentrations	O
less	O
than	O
100	O
000	O
copies	O
per	O
mL	O
and	O
100,000	O
copies	O
per	O
mL	O
or	O
more	O
(	O
p=0.26	O
for	O
interaction	O
)	O
.	O

Participants	O
assigned	O
the	O
three-class	O
strategy	O
were	O
significantly	O
more	O
likely	O
to	O
discontinue	O
treatment	O
because	O
of	O
toxic	O
effects	O
than	O
were	O
those	O
assigned	O
to	O
the	O
two-class	O
strategies	O
(	O
HR	O
1.58	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

INTERPRETATION	O
Initial	O
treatment	O
with	O
either	O
an	O
NNRTI-based	Pharmacological
regimen	Pharmacological
or	O
a	O
PI-based	Pharmacological
regimen	Pharmacological
,	O
but	O
not	O
both	O
together	O
,	O
is	O
a	O
good	O
strategy	O
for	O
long-term	O
antiretroviral	O
management	O
in	O
treatment-naive	O
patients	O
with	O
HIV	O
.	O

Enrollment	O
of	O
racial	O
and	O
ethnic	O
minorities	O
in	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
and	O
Ovarian	O
Cancer	O
Screening	O
Trial	O
.	O

BACKGROUND	O
Minority	O
populations	O
in	O
the	O
United	O
States	O
,	O
especially	O
blacks	O
and	O
Hispanics	O
,	O
are	O
generally	O
underrepresented	O
among	O
participants	O
in	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
report	O
the	O
experience	O
of	O
enrolling	O
ethnic	O
minorities	O
in	O
a	O
large	O
cancer	O
screening	O
trial	O
.	O

METHODS	O
The	O
Prostate	Educational
,	Educational
Colorectal	Educational
,	Educational
Lung	Educational
and	Educational
Ovarian	Educational
(	Educational
PLCO	Educational
)	Educational
Cancer	Educational
Screening	Educational
Trial	O
is	O
a	O
multicenter	O
randomized	O
trial	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
screening	Educational
for	Educational
the	Educational
PLCO	Educational
cancers	Educational
.	O

Subjects	O
were	O
recruited	O
at	O
10	O
U.S.	O
centers	O
between	O
1993	O
and	O
2001	O
.	O

One	O
screening	O
center	O
had	O
a	O
major	O
special	Educational
recruitment	Educational
effort	Educational
for	Educational
blacks	Educational
and	O
another	O
center	O
had	O
a	O
major	O
special	Educational
recruitment	Educational
effort	Educational
for	Educational
Hispanics	Educational
.	O

RESULTS	O
Among	O
almost	O
155,000	O
subjects	O
enrolled	O
in	O
PLCO	O
,	O
minority	O
enrollment	O
was	O
as	O
follows	O
:	O
black	O
(	O
5.0	O
%	O
)	O
,	O
Hispanic	O
(	O
1.8	O
%	O
)	O
and	O
Asian	O
(	O
3.6	O
%	O
)	O
.	O

This	O
compares	O
to	O
an	O
age-eligible	O
population	O
in	O
the	O
combined	O
catchment	O
areas	O
of	O
the	O
PLCO	O
centers	O
that	O
was	O
14.0	O
%	O
black	O
,	O
2.9	O
%	O
Hispanic	O
and	O
5.4	O
%	O
Asian	O
,	O
and	O
an	O
age-eligible	O
population	O
across	O
the	O
U.S.	O
that	O
was	O
9.5	O
%	O
black	O
,	O
6.5	O
%	O
Hispanic	O
and	O
3.0	O
%	O
Asian	O
.	O

About	O
half	O
(	O
45	O
%	O
)	O
of	O
Hispanics	O
were	O
recruited	O
at	O
the	O
center	O
with	O
the	O
special	O
Hispanic	O
recruitment	O
effort	O
.	O

Seventy	O
percent	O
of	O
blacks	O
were	O
recruited	O
at	O
two	O
centers	O
;	O
the	O
one	O
with	O
the	O
major	O
special	O
recruitment	O
effort	O
and	O
a	O
center	O
in	O
Detroit	O
whose	O
catchment	O
area	O
was	O
20	O
%	O
black	O
among	O
age-eligibles	O
.	O

Blacks	O
,	O
Hispanics	O
and	O
(	O
non-Hispanic	O
)	O
whites	O
were	O
all	O
more	O
highly	O
educated	O
,	O
less	O
likely	O
to	O
currently	O
smoke	O
and	O
more	O
likely	O
to	O
get	O
regular	O
exercise	O
than	O
their	O
counterparts	O
in	O
the	O
general	O
population	O
.	O

CONCLUSION	O
Significant	O
efforts	O
were	O
made	O
to	O
recruit	O
racial/	O
ethnic	O
minorities	O
into	O
PLCO	O
,	O
and	O
these	O
efforts	O
resulted	O
in	O
enrollment	O
levels	O
that	O
were	O
comparable	O
to	O
those	O
seen	O
in	O
many	O
recent	O
cancer	O
screening	O
or	O
prevention	O
trials	O
.	O

Blacks	O
and	O
Hispanics	O
were	O
nonetheless	O
underrepresented	O
in	O
PLCO	O
compared	O
to	O
their	O
levels	O
among	O
age-eligibles	O
in	O
the	O
overall	O
U.S.	O
population	O
or	O
in	O
the	O
aggregate	O
PLCO	O
catchment	O
areas	O
.	O

A	O
prospective	O
,	O
placebo-controlled	Control
,	O
randomized	O
trial	O
of	O
intravenous	O
streptokinase	Pharmacological
and	O
angioplasty	Physical
versus	Physical
lone	Physical
angioplasty	Physical
therapy	Physical
of	O
acute	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
The	O
value	O
of	O
routine	O
administration	O
of	O
intravenous	O
thrombolytic	Pharmacological
agents	Pharmacological
during	O
percutaneous	Physical
transluminal	Physical
coronary	Physical
angioplasty	Physical
(	Physical
PTCA	Physical
)	Physical
therapy	Physical
of	O
acute	O
myocardial	O
infarction	O
(	O
MI	O
)	O
has	O
not	O
been	O
determined	O
.	O

Therefore	O
,	O
we	O
prospectively	O
randomized	O
122	O
patients	O
with	O
evolving	O
MI	O
to	O
PTCA	Physical
therapy	Physical
with	O
or	O
without	O
adjunctive	O
intravenous	Physical
streptokinase	Physical
therapy	Physical
.	O

METHODS	O
AND	O
RESULTS	O
Patients	O
with	O
ECG	O
ST	O
segment	O
elevation	O
who	O
presented	O
within	O
4	O
hours	O
of	O
symptom	O
onset	O
,	O
had	O
no	O
contraindication	O
to	O
thrombolytic	Physical
therapy	Physical
,	O
and	O
were	O
not	O
in	O
cardiogenic	O
shock	O
were	O
enrolled	O
.	O

They	O
were	O
treated	O
immediately	O
with	O
intravenous	Pharmacological
heparin	Pharmacological
(	O
10,000	O
units	O
)	O
and	O
oral	Pharmacological
aspirin	Pharmacological
(	O
325	O
mg	O
)	O
and	O
randomized	O
to	O
treatment	O
with	O
placebo	Control
or	O
streptokinase	Pharmacological
(	O
1.5	O
M	O
units	O
)	O
administered	O
intravenously	O
over	O
30	O
minutes	O
.	O

Patients	O
then	O
were	O
taken	O
immediately	O
to	O
the	O
catheterization	O
laboratory	O
,	O
and	O
those	O
with	O
suitable	O
coronary	O
anatomy	O
underwent	O
immediate	O
PTCA	O
.	O

Subsequent	O
clinical	O
course	O
,	O
serial	O
radionuclide	O
ventriculography	O
,	O
and	O
6-month	O
repeat	O
angiography	O
were	O
analyzed	O
.	O

A	O
total	O
of	O
106	O
patients	O
were	O
treated	O
with	O
PTCA	Physical
.	O

Use	O
of	O
PTCA	O
was	O
similar	O
for	O
placebo	Control
(	O
92	O
%	O
)	O
and	O
streptokinase	Pharmacological
(	O
83	O
%	O
)	O
groups	O
.	O

Angioplasty	O
was	O
successful	O
in	O
95	O
%	O
of	O
patients	O
,	O
with	O
no	O
difference	O
in	O
placebo	O
(	O
93	O
%	O
)	O
and	O
streptokinase	Pharmacological
(	O
98	O
%	O
)	O
groups	O
.	O

Serial	O
radionuclide	O
ventriculography	O
demonstrated	O
no	O
difference	O
in	O
24-hour	O
(	O
52	O
+/-	O
12	O
%	O
versus	O
50	O
+/-	O
12	O
%	O
)	O
or	O
6-week	O
(	O
51	O
+/-	O
12	O
%	O
versus	O
51	O
+/-	O
13	O
%	O
)	O
ejection	O
fraction	O
values	O
for	O
placebo	O
and	O
streptokinase	Pharmacological
groups	O
,	O
respectively	O
.	O

Contrast	O
ventriculography	O
demonstrated	O
improvement	O
in	O
immediate	O
(	O
54	O
+/-	O
12	O
%	O
)	O
versus	O
6-month	O
(	O
60	O
+/-	O
15	O
%	O
,	O
p	O
<	O
0.05	O
)	O
values	O
for	O
the	O
overall	O
group	O
.	O

No	O
differences	O
in	O
6-month	O
values	O
were	O
present	O
(	O
58	O
+/-	O
15	O
%	O
versus	O
62	O
+/-	O
15	O
%	O
,	O
p	O
=	O
NS	O
)	O
for	O
placebo	O
and	O
streptokinase	Pharmacological
groups	O
,	O
respectively	O
.	O

Coronary	Physical
angiography	Physical
was	O
performed	O
in	O
75	O
%	O
of	O
the	O
90	O
patients	O
eligible	O
for	O
restudy	O
.	O

Arterial	O
patency	O
was	O
87	O
%	O
at	O
6	O
months	O
,	O
and	O
coronary	O
restenosis	O
was	O
present	O
in	O
38	O
%	O
of	O
patients	O
.	O

No	O
differences	O
in	O
chronic	O
patency	O
or	O
restenosis	O
were	O
detected	O
for	O
the	O
two	O
treatment	O
groups	O
.	O

Although	O
adjunctive	O
intravenous	O
streptokinase	Pharmacological
therapy	O
did	O
not	O
improve	O
outcome	O
,	O
it	O
did	O
complicate	O
the	O
hospital	O
course	O
.	O

Hospitalization	O
was	O
longer	O
(	O
9.3	O
+/-	O
5.0	O
versus	O
7.7	O
+/-	O
4.4	O
days	O
,	O
p	O
=	O
0.046	O
)	O
and	O
more	O
costly	O
(	O
$	O
25,191	O
+/-	O
15,368	O
versus	O
$	O
19,643	O
+/-	O
7,250	O
,	O
p	O
<	O
0.02	O
)	O
.	O

Transfusion	O
rate	O
was	O
higher	O
(	O
39	O
%	O
versus	O
8	O
%	O
,	O
p	O
=	O
0.0001	O
)	O
and	O
need	O
for	O
emergency	O
coronary	O
bypass	O
surgery	O
was	O
greater	O
(	O
10.3	O
%	O
versus	O
1.6	O
%	O
,	O
p	O
=	O
0.03	O
)	O
for	O
the	O
streptokinase-treated	O
patients	O
.	O

CONCLUSIONS	O
Adjunctive	O
intravenous	O
streptokinase	Pharmacological
therapy	Pharmacological
does	O
not	O
enhance	O
early	O
preservation	O
of	O
ventricular	O
function	O
,	O
improve	O
arterial	O
patency	O
rates	O
,	O
or	O
lower	O
restenosis	O
rates	O
after	O
PTCA	O
therapy	O
of	O
acute	O
MI	O
.	O

Hospital	O
course	O
is	O
longer	O
,	O
more	O
expensive	O
,	O
and	O
more	O
complicated	O
.	O

For	O
these	O
reasons	O
,	O
PTCA	O
therapy	O
of	O
acute	O
MI	O
should	O
not	O
be	O
routinely	O
performed	O
with	O
adjunctive	O
intravenous	O
streptokinase	Pharmacological
therapy	Pharmacological
.	O

Randomised	O
clinical	O
trial	O
:	O
efficacy	O
of	O
a	O
new	O
synbiotic	Pharmacological
formulation	Pharmacological
containing	Pharmacological
Lactobacillus	Pharmacological
paracasei	Pharmacological
B21060	Pharmacological
plus	Pharmacological
arabinogalactan	Pharmacological
and	Pharmacological
xilooligosaccharides	Pharmacological
in	O
children	O
with	O
acute	O
diarrhoea	O
.	O

BACKGROUND	O
Acute	O
diarrhoea	O
is	O
a	O
frequent	O
problem	O
in	O
children	O
with	O
heavy	O
economic	O
burden	O
for	O
families	O
and	O
society	O
.	O

AIM	O
To	O
test	O
the	O
efficacy	O
of	O
a	O
new	O
synbiotic	Pharmacological
formulation	Pharmacological
containing	Pharmacological
Lactobacillus	Pharmacological
paracasei	Pharmacological
B21060	Pharmacological
,	Pharmacological
arabinogalactan	Pharmacological
and	Pharmacological
xilooligosaccharides	Pharmacological
in	O
children	O
with	O
acute	O
diarrhoea	O
.	O

METHODS	O
Double-blind	O
,	O
randomised	O
,	O
placebo-controlled	O
trial	O
,	O
including	O
children	O
(	O
age	O
3-36	O
m	O
)	O
with	O
acute	O
diarrhoea	O
who	O
were	O
allocated	O
to	O
placebo	O
or	O
synbiotic	O
group	O
.	O

Major	O
outcome	O
was	O
resolution	O
rate	O
of	O
diarrhoea	O
at	O
72	O
h.	O
Total	O
duration	O
of	O
diarrhoea	O
,	O
daily	O
stool	O
outputs	O
,	O
stool	O
consistency	O
,	O
working	O
days	O
lost	O
by	O
parents	O
,	O
adjunctive	O
medications	O
,	O
and	O
hospitalisation	O
were	O
also	O
assessed	O
.	O

RESULTS	O
We	O
enrolled	O
55	O
children	O
in	O
placebo	Control
group	O
and	O
52	O
in	O
synbiotic	Pharmacological
group	O
.	O

The	O
two	O
groups	O
were	O
similar	O
for	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

Resolution	O
rate	O
of	O
diarrhoea	O
at	O
72	O
h	O
was	O
significantly	O
higher	O
in	O
synbiotic	O
group	O
(	O
67	O
%	O
)	O
compared	O
to	O
placebo	Control
group	O
(	O
40	O
%	O
,	O
P	O
=	O
0.005	O
)	O
.	O

Children	O
in	O
synbiotic	O
group	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
duration	O
of	O
diarrhoea	O
(	O
90.5	O
h	O
,	O
78.1-102.9	O
vs.	O
109.8	O
h	O
,	O
96.0-123.5	O
,	O
P	O
=	O
0.040	O
)	O
,	O
daily	O
stool	O
outputs	O
(	O
3.3	O
,	O
2.8-3.8	O
vs.	O
2.4	O
,	O
1.9-2.8	O
,	O
P	O
=	O
0.005	O
)	O
and	O
stool	O
consistency	O
(	O
1.3	O
,	O
0.9-1.6	O
vs.	O
0.6	O
,	O
0.4-0.9	O
,	O
P	O
=	O
0.002	O
)	O
compared	O
to	O
placebo	Control
group	O
(	O
data	O
expressed	O
as	O
mean	O
,	O
95	O
%	O
CI	O
)	O
.	O

Rate	O
of	O
parents	O
that	O
missed	O
at	O
least	O
one	O
working	O
day	O
(	O
41.8	O
%	O
vs.	O
15.4	O
%	O
,	O
P	O
=	O
0.003	O
)	O
,	O
rate	O
of	O
children	O
that	O
needed	O
adjunctive	O
medications	O
(	O
25.5	O
%	O
vs.	O
5.8	O
%	O
,	O
P	O
=	O
0.005	O
)	O
or	O
hospitalisation	O
(	O
10.9	O
%	O
vs.	O
0	O
%	O
,	O
P	O
=	O
0.014	O
)	O
after	O
the	O
first	O
72	O
h	O
of	O
treatment	O
,	O
were	O
reduced	O
in	O
synbiotic	O
group	O
.	O

CONCLUSION	O
The	O
synbiotic	Pharmacological
formulation	Pharmacological
studied	O
is	O
effective	O
in	O
children	O
with	O
acute	O
diarrhoea	O
.	O

Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
(	O
ACTRN12611000641998	O
)	O
.	O

The	O
influence	O
of	O
epidermal	Pharmacological
growth	Pharmacological
factor	Pharmacological
receptor	Pharmacological
and	O
tumor	O
differentiation	O
on	O
the	O
response	O
to	O
accelerated	O
radiotherapy	O
of	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
in	O
the	O
randomized	O
DAHANCA	O
6	O
and	O
7	O
study	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Reduction	O
of	O
the	O
overall	O
treatment	O
time	O
of	O
radiotherapy	O
has	O
increased	O
locoregional	O
control	O
and	O
disease	O
specific	O
survival	O
in	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
(	O
HNSCC	O
)	O
,	O
but	O
the	O
response	O
is	O
heterogeneous	O
.	O

EGFr	O
is	O
often	O
overexpressed	O
in	O
HNSCC	O
and	O
has	O
been	O
related	O
to	O
the	O
repopulation	O
taking	O
place	O
during	O
radiotherapy	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
address	O
the	O
influence	O
of	O
EGFr	O
and	O
histopathological	O
differentiation	O
when	O
the	O
overall	O
treatment	O
time	O
of	O
radiotherapy	O
was	O
moderately	O
reduced	O
.	O

PATIENTS	O
AND	O
METHODS	O
Eight	O
hundred	O
and	O
three	O
patients	O
with	O
representative	O
pretreatment	O
tissue	O
samples	O
from	O
the	O
randomized	O
DAHANCA	O
6	O
and	O
7	O
study	O
of	O
5	O
vs.	O
6	O
fx/wk	O
of	O
radiotherapy	Physical
.	O

EGFr	O
was	O
visualized	O
using	O
immunohistochemistry	O
and	O
separated	O
into	O
high	O
and	O
low	O
expression	O
before	O
correlation	O
with	O
clinical	O
data	O
.	O

RESULTS	O
Tumors	O
with	O
high	O
EGFr	O
(	O
84	O
%	O
)	O
responded	O
better	O
to	O
moderately	O
accelerated	O
radiotherapy	O
,	O
than	O
carcinomas	O
with	O
low	O
EGFr	O
,	O
using	O
locoregional	O
control	O
as	O
endpoint	O
and	O
a	O
similar	O
pattern	O
was	O
seen	O
,	O
stratifying	O
by	O
well/moderate	O
vs.	O
poor	O
tumor	O
differentiation	O
.	O

Therefore	O
,	O
a	O
combined	O
parameter	O
was	O
constructed	O
showing	O
a	O
more	O
prominent	O
separation	O
of	O
response	O
:	O
tumors	O
with	O
high	O
EGFr	O
and	O
well/moderate	O
differentiation	O
did	O
benefit	O
from	O
moderate	O
acceleration	O
of	O
treatment	O
regarding	O
locoregional	O
control	O
,	O
HR	O
0.54	O
(	O
0.37-0.78	O
)	O
,	O
whereas	O
such	O
an	O
effect	O
was	O
not	O
seen	O
in	O
tumors	O
with	O
low	O
EGFr	O
and/or	O
poor	O
differentiation	O
,	O
HR	O
0.8	O
(	O
0.51-1.25	O
)	O
.	O

These	O
results	O
reflected	O
the	O
disease	O
specific	O
survival	O
as	O
well	O
and	O
were	O
confirmed	O
in	O
multivariable	O
analyses	O
.	O

CONCLUSIONS	O
Moderately	O
accelerated	O
fractionation	O
is	O
superior	O
to	O
conventional	O
treatment	O
in	O
HNSCC	O
but	O
the	O
response	O
is	O
heterogeneous	O
and	O
may	O
be	O
predicted	O
by	O
high	O
expression	O
of	O
EGFr	O
and	O
well/moderate	O
tumor	O
differentiation	O
.	O

Comparison	O
of	O
ketoconazole	Pharmacological
and	O
griseofulvin	Pharmacological
in	O
the	O
treatment	O
of	O
tinea	O
pedis	O
.	O

Twenty-nine	O
patients	O
with	O
mycologically	O
proven	O
tinea	O
pedis	O
were	O
randomly	O
allocated	O
to	O
oral	O
treatment	O
with	O
either	O
ketoconazole	Pharmacological
200	Pharmacological
mg	Pharmacological
daily	Pharmacological
or	Pharmacological
griseofulvin	Pharmacological
1	Pharmacological
g	Pharmacological
daily	O
for	O
a	O
period	O
of	O
up	O
to	O
8	O
weeks	O
.	O

Mycological	O
cure	O
rate	O
at	O
4	O
weeks	O
was	O
33	O
%	O
for	O
ketoconazole	Pharmacological
and	O
29	O
%	O
for	O
griseofulvin	Pharmacological
,	O
and	O
at	O
8	O
weeks	O
was	O
53	O
%	O
and	O
57	O
%	O
respectively	O
.	O

The	O
efficacy	O
of	O
both	O
drugs	O
in	O
the	O
treatment	O
of	O
interdigital	O
tinea	O
pedis	O
is	O
similar	O
,	O
and	O
is	O
considerably	O
lower	O
than	O
that	O
found	O
with	O
topical	O
imidazole	O
preparations	O
where	O
cure	O
rates	O
of	O
over	O
70	O
%	O
are	O
generally	O
expected	O
.	O

Six-month	O
trial	O
of	O
on-demand	O
rabeprazole	Pharmacological
10	O
mg	O
maintains	O
symptom	O
relief	O
in	O
patients	O
with	O
non-erosive	O
reflux	O
disease	O
.	O

BACKGROUND	O
Compliance	O
studies	O
have	O
shown	O
that	O
patients	O
with	O
reflux	O
symptoms	O
generally	O
take	O
their	O
medication	O
only	O
when	O
experiencing	O
these	O
symptoms	O
.	O

AIM	O
To	O
evaluate	O
the	O
efficacy	O
of	O
on-demand	O
rabeprazole	Pharmacological
maintenance	O
therapy	O
in	O
patients	O
with	O
non-erosive	O
reflux	O
disease	O
.	O

METHODS	O
This	O
multicentre	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
,	O
withdrawal	O
study	O
compared	O
6	O
months	O
of	O
on-demand	O
treatment	O
with	O
rabeprazole	Pharmacological
10	O
mg	O
vs.	O
placebo	Control
.	O

Adults	O
with	O
a	O
history	O
of	O
reflux	O
symptoms	O
,	O
a	O
negative	O
endoscopy	O
,	O
and	O
>	O
or	O
=	O
3	O
days	O
of	O
moderate	O
to	O
very	O
severe	O
heartburn	O
in	O
the	O
7	O
days	O
before	O
enrollment	O
(	O
N	O
=	O
535	O
)	O
entered	O
4	O
weeks	O
of	O
open-label	O
,	O
acute	O
treatment	O
with	O
rabeprazole	Pharmacological
10	O
mg	O
once	O
daily	O
.	O

Patients	O
with	O
complete	O
symptom	O
relief	O
then	O
entered	O
the	O
on-demand	O
phase	O
.	O

The	O
primary	O
end-point	O
was	O
discontinuation	O
due	O
to	O
lack	O
of	O
heartburn	O
control	O
during	O
the	O
on-demand	O
phase	O
.	O

RESULTS	O
Eighty-three	O
percent	O
(	O
432	O
of	O
523	O
)	O
of	O
patients	O
reported	O
complete	O
symptom	O
relief	O
at	O
the	O
end	O
of	O
the	O
acute	O
phase	O
.	O

During	O
on-demand	O
treatment	O
,	O
rates	O
of	O
discontinuation	O
because	O
of	O
inadequate	O
heartburn	O
control	O
were	O
20	O
%	O
(	O
28	O
of	O
139	O
)	O
for	O
placebo	Control
vs.	O
6	O
%	O
(	O
16	O
of	O
279	O
)	O
for	O
rabeprazole	Pharmacological
(	O
P	O
<	O
0.00001	O
)	O
.	O

Antacid	O
use	O
was	O
twofold	O
higher	O
in	O
the	O
placebo	Control
group	O
vs.	O
the	O
rabeprazole	Pharmacological
group	O
(	O
P	O
=	O
0.0009	O
)	O
.	O

CONCLUSIONS	O
Rabeprazole	Pharmacological
10	O
mg	O
once	O
daily	O
is	O
highly	O
effective	O
in	O
acute	O
symptom	O
relief	O
and	O
as	O
on-demand	O
long-term	O
maintenance	O
therapy	O
in	O
non-erosive	O
reflux	O
disease	O
patients	O
.	O

A	O
comparison	O
of	O
1-	O
and	O
3-minute	O
lockout	O
periods	O
during	O
patient-controlled	O
sedation	O
with	O
midazolam	Pharmacological
.	Pharmacological

PURPOSE	O
The	O
maximum	O
effect	O
of	O
midazolam	Pharmacological
injected	O
intravenously	O
occurs	O
in	O
about	O
3	O
minutes	O
.	O

Patient-controlled	O
sedation	O
carried	O
out	O
with	O
1-mg	O
increments	O
of	O
midazolam	Pharmacological
at	O
3-minute	O
intervals	O
provides	O
comparable	O
conditions	O
to	O
that	O
of	O
doctor-controlled	O
sedation	O
carried	O
out	O
with	O
1-mg	O
increments	O
at	O
1-minute	O
intervals	O
,	O
except	O
for	O
the	O
longer	O
duration	O
taken	O
for	O
the	O
patients	O
to	O
achieve	O
satisfactory	O
sedation	O
prior	O
to	O
surgery	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
find	O
out	O
how	O
safe	O
it	O
would	O
be	O
to	O
shorten	O
the	O
interval	O
of	O
increments	O
of	O
midazolam	Pharmacological
to	O
1	O
minute	O
in	O
patient-controlled	Pharmacological
sedation	Pharmacological
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
a	O
randomized	O
crossover	O
study	O
,	O
26	O
patients	O
undergoing	O
bilateral	O
lower	O
third	O
molar	O
surgery	O
at	O
two	O
visits	O
had	O
patient-controlled	O
sedation	O
with	O
1	O
mg	O
midazolam	Pharmacological
increments	O
at	O
1-minute	O
or	O
3-minute	O
intervals	O
at	O
one	O
visit	O
and	O
the	O
alternative	O
at	O
the	O
other	O
visit	O
.	O

RESULTS	O
The	O
time	O
taken	O
for	O
patients	O
to	O
achieve	O
a	O
degree	O
of	O
sedation	O
that	O
they	O
thought	O
was	O
sufficient	O
to	O
tolerate	O
the	O
surgery	O
was	O
significantly	O
longer	O
when	O
the	O
increment	O
interval	O
was	O
3	O
minutes	O
(	O
t	O
=	O
-4.8	O
;	O
P	O
<	O
.05	O
)	O
.	O

Both	O
techniques	O
provided	O
good	O
operating	O
conditions	O
,	O
stable	O
vital	O
signs	O
,	O
mild	O
to	O
moderate	O
sedation	O
,	O
without	O
loss	O
of	O
verbal	O
contact	O
.	O

CONCLUSION	O
A	O
significant	O
majority	O
preferred	O
the	O
sedation	O
technique	O
with	O
1-minute	O
increment	O
intervals	O
(	O
chi	O
2	O
=	O
4.6	O
;	O
P	O
<	O
.05	O
)	O
.	O

Parent-implemented	Educational
enhanced	Educational
milieu	Educational
teaching	Educational
with	O
preschool	O
children	O
who	O
have	O
intellectual	O
disabilities	O
.	O

PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
enhanced	Educational
milieu	Educational
teaching	Educational
(	Educational
EMT	Educational
)	Educational
implemented	O
by	O
parents	O
and	O
therapists	O
versus	O
therapists	O
only	O
on	O
the	O
language	O
skills	O
of	O
preschool	O
children	O
with	O
intellectual	O
disabilities	O
(	O
IDs	O
)	O
,	O
including	O
children	O
with	O
Down	O
syndrome	O
and	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

METHOD	O
Seventy-seven	O
children	O
were	O
randomly	O
assigned	O
to	O
2	O
treatments	O
(	O
parent	Educational
+	Educational
therapist	Educational
EMT	Educational
or	O
therapist-only	Educational
EMT	Educational
)	O
and	O
received	O
36	O
intervention	O
sessions	O
.	O

Children	O
were	O
assessed	O
before	O
,	O
immediately	O
after	O
,	O
6	O
months	O
after	O
,	O
and	O
12	O
months	O
after	O
intervention	O
.	O

Separate	O
linear	O
regressions	O
were	O
conducted	O
for	O
each	O
standardized	O
and	O
observational	O
measure	O
at	O
each	O
time	O
point	O
.	O

RESULTS	O
Parents	O
in	O
the	O
parent	O
+	O
therapist	O
group	O
demonstrated	O
greater	O
use	O
of	O
EMT	Educational
strategies	Educational
at	O
home	O
than	O
untrained	O
parents	O
in	O
the	O
therapist-only	O
group	O
,	O
and	O
these	O
effects	O
maintained	O
over	O
time	O
.	O

Effect	O
sizes	O
for	O
observational	O
measures	O
ranged	O
from	O
d	O
=	O
0.10	O
to	O
d	O
=	O
1.32	O
favoring	O
the	O
parent	O
+	O
therapist	O
group	O
,	O
with	O
the	O
largest	O
effect	O
sizes	O
found	O
12	O
months	O
after	O
intervention	O
.	O

CONCLUSION	O
Findings	O
from	O
this	O
study	O
indicate	O
generally	O
that	O
there	O
are	O
benefits	O
to	O
training	O
parents	O
to	O
implement	O
naturalistic	Educational
language	Educational
intervention	Educational
strategies	Educational
with	O
preschool	O
children	O
who	O
have	O
ID	O
and	O
significant	O
language	O
impairments	O
.	O

Investigation	O
of	O
erosion	O
and	O
abrasion	O
on	O
enamel	O
and	O
dentine	O
:	O
a	O
model	O
in	O
situ	O
using	O
toothpastes	Physical
of	O
different	O
abrasivity	Physical
.	O

BACKGROUND	O
Studies	O
in	O
vitro	O
suggest	O
that	O
abrasion	O
and	O
erosion	O
may	O
act	O
synergistically	O
to	O
produce	O
wear	O
of	O
enamel	O
and	O
dentine	O
.	O

Methods	O
in	O
situ	O
are	O
recently	O
available	O
to	O
study	O
separately	O
erosion	O
and	O
abrasion	O
of	O
dental	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
combine	O
two	O
in	O
situ	O
protocols	O
to	O
study	O
the	O
interplay	O
between	O
erosion	O
and	O
abrasion	O
of	O
enamel	O
and	O
dentine	O
.	O

METHOD	O
The	O
study	O
was	O
a	O
single-blind	O
,	O
randomised	O
,	O
five-treatment	O
cross-over	O
design	O
involving	O
15	O
healthy	O
volunteers	O
.	O

During	O
each	O
10-day	O
study	O
period	O
,	O
subjects	O
wore	O
from	O
0900	O
to	O
1700	O
h	O
an	O
upper	Physical
removable	Physical
acrylic	Physical
appliance	Physical
holding	Physical
one	Physical
polished	Physical
enamel	Physical
and	O
one	Physical
polished	Physical
dentine	Physical
specimen	Physical
.	O

The	O
specimen	O
treatment	O
regimens	O
were	O
:	O
1	O
.	O

Drinking	Physical
water	Physical
and	O
brushing	Physical
with	O
toothpaste	O
A	O
.	O

2	O
.	O

Drinking	O
water	O
and	O
brushing	O
with	O
toothpaste	O
B	O
.	O

3	O
.	O

Drinking	O
orange	Physical
juice	Physical
.	O

4	O
.	O

Drinking	O
orange	Physical
juice	Physical
and	O
brushing	Physical
with	Physical
toothpaste	Physical
A	O
.	O

5	O
.	O

Drinking	O
orange	O
juice	O
and	O
brushing	O
with	O
toothpaste	O
B	O
.	O

Drinking	O
and	O
brushing	O
times	O
were	O
around	O
0900	O
,	O
1100	O
,	O
1300	O
and	O
1500	O
h.	O
Drinks	O
were	O
consumed	O
as	O
250	O
ml	O
over	O
10	O
min	O
and	O
brushing	O
ex	O
vivo	O
for	O
1	O
min	O
to	O
each	O
specimen	O
.	O

Measurement	O
of	O
tissue	O
loss	O
was	O
made	O
on	O
days	O
5	O
and	O
10	O
of	O
each	O
period	O
using	O
a	O
profilometer	O
.	O

RESULTS	O
All	O
treatments	O
produced	O
increasing	O
tissue	O
loss	O
over	O
time	O
,	O
which	O
was	O
considerably	O
greater	O
for	O
dentine	O
than	O
enamel	O
.	O

For	O
enamel	O
,	O
the	O
data	O
at	O
days	O
5	O
and	O
10	O
showed	O
a	O
significant	O
effect	O
for	O
erosion	O
(	O
i.e	O
.	O

orange	O
juice	O
was	O
significantly	O
more	O
erosive	O
than	O
water	O
)	O
,	O
but	O
no	O
significant	O
effect	O
for	O
abrasion	O
(	O
i.e	O
.	O

no	O
significant	O
difference	O
between	O
the	O
two	O
toothpaste	O
treatments	O
)	O
.	O

The	O
combined	O
orange	O
juice	O
and	O
toothpaste	O
effects	O
were	O
directional	O
for	O
synergy	O
but	O
did	O
not	O
reach	O
significance	O
.	O

For	O
dentine	O
at	O
day	O
10	O
,	O
many	O
specimens	O
exceeded	O
the	O
50	O
microm	O
set	O
limit	O
of	O
the	O
profilometer	O
and	O
only	O
day	O
5	O
data	O
were	O
considered	O
.	O

There	O
were	O
significant	O
effects	O
for	O
erosion	O
(	O
orange	O
juice	O
produced	O
significantly	O
more	O
erosion	O
than	O
water	O
)	O
and	O
for	O
abrasion	O
(	O
paste	O
A	O
was	O
significantly	O
more	O
abrasive	O
to	O
dentine	O
than	O
paste	O
B	O
)	O
.	O

The	O
synergy	O
effect	O
could	O
not	O
be	O
examined	O
for	O
dentine	O
due	O
to	O
the	O
truncation	O
effect	O
as	O
the	O
set	O
limit	O
of	O
the	O
profilometer	O
was	O
exceeded	O
.	O

CONCLUSIONS	O
Erosion	O
increases	O
the	O
susceptibility	O
of	O
enamel	O
to	O
toothpaste	O
abrasion	O
.	O

Dentine	O
is	O
considerably	O
more	O
susceptible	O
than	O
enamel	O
to	O
erosion	O
and	O
abrasion	O
alone	O
or	O
combined	O
.	O

Dentine	O
loss	O
appears	O
to	O
correlate	O
with	O
toothpaste	O
abrasivity	O
(	O
RDA	O
value	O
)	O
.	O

Instant	O
Recess?	O
:	O
a	O
practical	O
tool	O
for	O
increasing	O
physical	O
activity	O
during	O
the	O
school	O
day	O
.	O

BACKGROUND	O
An	O
increased	O
prevalence	O
of	O
overweight/obesity	O
among	O
children	O
has	O
led	O
to	O
school	O
district	O
level	O
policies	O
to	O
increase	O
physical	O
activity	O
(	O
PA	O
)	O
among	O
elementary	O
school	O
students	O
.	O

Interventions	O
are	O
needed	O
that	O
increase	O
activity	O
levels	O
without	O
sacrificing	O
time	O
spent	O
in	O
academics	O
.	O

OBJECTIVES	O
We	O
evaluated	O
a	O
policy	O
implementation	O
intervention	O
for	O
to	O
increase	O
in-school	O
PA	O
in	O
elementary	O
schools	O
in	O
Forsyth	O
County	O
,	O
North	O
Carolina	O
,	O
in	O
a	O
randomized	O
study	O
with	O
a	O
delayed	O
intervention	O
control	O
group	O
.	O

METHODS	O
The	O
study	O
included	O
third-	O
through	O
fifth-grade	O
classrooms	O
in	O
eight	O
elementary	O
schools	O
.	O

Instant	O
Recess?	O
was	O
used	O
to	O
introduce	O
10-minute	O
PA	O
breaks	O
in	O
classrooms	O
on	O
schedules	O
determined	O
by	O
teachers	O
.	O

Direct	O
observation	O
was	O
used	O
to	O
measure	O
activity	O
levels	O
,	O
other	O
student	O
behaviors	O
,	O
and	O
teacher	O
behaviors	O
related	O
to	O
PA	O
in	O
the	O
classrooms	O
.	O

RESULTS	O
Twenty-eight	O
visits	O
to	O
schools	O
were	O
made	O
during	O
the	O
spring	O
and	O
fall	O
semesters	O
of	O
2009	O
.	O

At	O
baseline	O
11	O
%	O
to	O
44	O
%	O
of	O
intervention	O
and	O
control	O
schools	O
were	O
engaged	O
in	O
classroom-based	O
PA.	O
PA	O
increased	O
from	O
baseline	O
to	O
spring	O
follow-up	O
in	O
intervention	O
schools	O
and	O
was	O
maintained	O
the	O
following	O
fall	O
.	O

Control	O
schools	O
decreased	O
PA	O
from	O
baseline	O
to	O
spring	O
and	O
increased	O
PA	O
once	O
they	O
began	O
the	O
intervention	O
.	O

Students	O
in	O
classrooms	O
engaged	O
in	O
Instant	O
Recess	O
exhibited	O
statistically	O
significant	O
increases	O
in	O
light	O
(	O
51	O
%	O
)	O
and	O
moderate-intensity	O
(	O
16	O
%	O
)	O
PA	O
and	O
increases	O
in	O
time	O
spent	O
in	O
on-task	O
behavior	O
(	O
11	O
%	O
)	O
.	O

Control	O
schools	O
experienced	O
similar	O
benefits	O
after	O
they	O
began	O
implementing	O
Instant	O
Recess	O
.	O

CONCLUSIONS	O
Instant	O
Recess	O
is	O
useful	O
for	O
increasing	O
PA	O
and	O
improving	O
behavior	O
among	O
elementary	O
school	O
children	O
.	O

Additional	O
research	O
may	O
be	O
needed	O
to	O
understand	O
how	O
to	O
create	O
policies	O
supporting	O
classroom	O
activity	O
breaks	O
and	O
how	O
to	O
assess	O
policy	O
adherence	O
.	O

Chemotherapy	Pharmacological
for	O
operable	O
gastric	O
cancer	O
:	O
results	O
of	O
the	O
Dutch	O
randomised	O
FAMTX	O
trial	O
.	O

The	O
Dutch	O
Gastric	O
Cancer	O
Group	O
(	O
DGCG	O
)	O
.	O

The	O
aim	O
of	O
this	O
trial	O
was	O
to	O
investigate	O
whether	O
pre-operative	O
chemotherapy	Pharmacological
leads	O
to	O
a	O
15	O
%	O
higher	O
curative	O
resectability	O
rate	O
in	O
patients	O
with	O
operable	O
gastric	O
cancer	O
.	O

In	O
this	O
randomised	O
trial	O
,	O
patients	O
were	O
allocated	O
to	O
receive	O
either	O
four	O
courses	O
of	O
chemotherapy	O
using	O
5-fluorouracil	Pharmacological
,	Pharmacological
doxorubicin	Pharmacological
and	Pharmacological
methotrexate	Pharmacological
(	Pharmacological
FAMTX	Pharmacological
)	Pharmacological
prior	Pharmacological
to	Pharmacological
surgery	Pharmacological
or	O
to	O
undergo	O
surgery	Surgical
only	Surgical
.	O

Patients	O
younger	O
than	O
75	O
years	O
of	O
age	O
with	O
a	O
good	O
physical	O
and	O
mental	O
condition	O
and	O
a	O
histologically	O
proven	O
adenocarcinoma	O
of	O
the	O
stomach	O
without	O
clinical	O
or	O
radiographic	O
(	O
computed	O
tomography	O
scan	O
)	O
evidence	O
of	O
distant	O
metastases	O
were	O
eligible	O
for	O
this	O
trial	O
.	O

Early	O
gastric	O
cancer	O
or	O
cardia	O
carcinoma	O
were	O
excluded	O
.	O

The	O
response	O
to	O
chemotherapy	Pharmacological
was	O
evaluated	O
after	O
two	O
and	O
four	O
courses	O
.	O

In	O
case	O
of	O
progressive	O
disease	O
(	O
PD	O
)	O
after	O
two	O
courses	O
,	O
patients	O
were	O
operated	O
upon	O
as	O
soon	O
as	O
possible	O
.	O

Otherwise	O
complete	O
response	O
(	O
CR	O
)	O
partial	O
response	O
(	O
PR	O
)	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
two	O
more	O
courses	O
were	O
scheduled	O
.	O

The	O
standard	O
surgical	O
procedure	O
was	O
a	O
limited	O
lymphadenectomy	O
(	O
D1	O
)	O
with	O
staging	O
biopsy	O
of	O
the	O
para-aortic	O
lymph	O
nodes	O
.	O

Between	O
September	O
1993	O
and	O
February	O
1996	O
,	O
56	O
eligible	O
and	O
evaluable	O
patients	O
were	O
entered	O
:	O
27	O
were	O
randomised	O
to	O
receive	O
FAMTX	O
before	O
surgery	O
and	O
29	O
to	O
undergo	O
surgery	O
only	O
.	O

In	O
the	O
FAMTX	O
+	O
surgery	O
treatment	O
group	O
,	O
15/27	O
(	O
56	O
%	O
)	O
had	O
curative	O
resections	O
versus	O
18/29	O
(	O
62	O
%	O
)	O
in	O
the	O
surgery	O
only	O
arm	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
frequency	O
of	O
TNM	O
stages	O
I	O
+	O
II	O
in	O
both	O
treatment	O
arms	O
:	O
15/27	O
versus	O
15/29	O
.	O

Due	O
to	O
PD	O
and/or	O
toxicity	O
,	O
12	O
patients	O
(	O
44	O
%	O
)	O
could	O
not	O
complete	O
the	O
planned	O
four	O
courses	O
of	O
FAMTX	O
.	O

Response	O
evaluation	O
after	O
chemotherapy	O
was	O
possible	O
in	O
25	O
patients	O
:	O
2	O
CR	O
,	O
6	O
PR	O
,	O
8	O
SD	O
and	O
9	O
PD	O
.	O

The	O
difference	O
in	O
curative	O
resectability	O
rate	O
was	O
6.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
-32	O
to	O
+19	O
%	O
)	O
in	O
favour	O
of	O
surgery	O
only	O
.	O

Downstaging	O
for	O
stages	O
I	O
+	O
II	O
did	O
not	O
occur	O
.	O

PD	O
was	O
more	O
often	O
the	O
reason	O
for	O
not	O
completing	O
the	O
planned	O
four	O
courses	O
than	O
toxicity	O
.	O

More	O
active	O
regimens	O
than	O
FAMTX	Pharmacological
are	O
required	O
for	O
future	O
randomised	O
trials	O
.	O

Japan	O
useful	O
medication	O
program	O
for	O
schizophrenia	O
(	O
JUMPs	O
)	O
-long-term	O
study	O
on	O
discontinuation	O
rate	O
,	O
resolution	O
and	O
remission	O
,	O
and	O
improvement	O
in	O
social	O
functioning	O
rate	O
associated	O
with	O
atypical	Pharmacological
antipsychotic	Pharmacological
medications	Pharmacological
in	O
patients	O
with	O
schizophrenia	O
.	O

BACKGROUND	O
It	O
is	O
desirable	O
to	O
establish	O
evidence	O
for	O
the	O
selection	O
of	O
antipsychotics	Pharmacological
from	O
the	O
viewpoint	O
of	O
recovery	O
of	O
social	O
activity	O
in	O
individual	O
patient	O
with	O
schizophrenia	O
receiving	O
medication	O
.	O

From	O
this	O
perspective	O
,	O
awareness	O
of	O
the	O
importance	O
of	O
studies	O
about	O
drug	O
effectiveness	O
on	O
treatment	O
discontinuation	O
rate	O
,	O
remission	O
rate	O
,	O
and	O
improvement	O
in	O
QOL	O
has	O
grown	O
recently	O
.	O

In	O
Western	O
countries	O
,	O
numerous	O
reports	O
are	O
available	O
in	O
effectiveness	O
studies	O
,	O
which	O
are	O
related	O
to	O
olanzapine	O
and	O
risperidone	O
primarily	O
,	O
whereas	O
evidence	O
for	O
other	O
second-generation	O
antipsychotics	O
(	O
SGAs	O
)	O
is	O
poor	O
.	O

In	O
Japan	O
,	O
no	O
effectiveness	O
study	O
has	O
been	O
reported	O
:	O
thus	O
,	O
it	O
is	O
desirable	O
to	O
collect	O
data	O
that	O
will	O
serve	O
as	O
evidence	O
for	O
selection	O
of	O
the	O
3	O
SGAs	O
approved	O
after	O
olanzapine	O
.	O

METHODS	O
The	O
present	O
study	O
was	O
a	O
long-term	O
effectiveness	O
study	O
under	O
healthcare	O
setting	O
in	O
Japan	O
.	O

It	O
was	O
designed	O
as	O
an	O
open-label	O
,	O
multicenter	O
,	O
randomized	O
,	O
comparative	O
study	O
involving	O
104-week	O
oral	O
treatment	O
with	O
1	O
of	O
the	O
3	O
drugs	O
(	O
aripiprazole	Pharmacological
,	O
blonanserin	Pharmacological
,	O
and	O
paliperidone	Pharmacological
)	O
in	O
patients	O
with	O
schizophrenia	O
aged	O
20	O
years	O
or	O
over	O
who	O
required	O
antipsychotic	Pharmacological
medication	Pharmacological
or	O
switching	O
of	O
the	O
current	O
medication	O
to	O
others	O
for	O
reasons	O
such	O
as	O
lack	O
of	O
efficacy	O
and	O
intolerability	O
.	O

The	O
primary	O
endpoint	O
is	O
treatment	O
discontinuation	O
rate	O
for	O
any	O
causes	O
.	O

The	O
secondary	O
endpoints	O
include	O
remission	O
rate	O
,	O
improvement	O
of	O
social	O
activity	O
,	O
alleviation	O
,	O
aggravation	O
or	O
recurrence	O
of	O
psychiatric	O
symptoms	O
,	O
and	O
safety	O
.	O

The	O
target	O
number	O
of	O
subjects	O
was	O
set	O
at	O
300	O
.	O

DISCUSSION	O
Because	O
this	O
study	O
is	O
expected	O
to	O
yield	O
evidence	O
regarding	O
the	O
selection	O
of	O
antipsychotics	O
for	O
facilitating	O
the	O
recovery	O
of	O
social	O
activity	O
in	O
patients	O
with	O
schizophrenia	O
,	O
it	O
is	O
considered	O
highly	O
valuable	O
to	O
perform	O
this	O
effectiveness	O
study	O
under	O
ordinary	O
healthcare	O
setting	O
in	O
Japan	O
.	O

TRIAL	O
REGISTRATION	O
UMIN	O
Clinical	O
Trials	O
Registry	O
000007942	O
.	O

Effect	O
of	O
resistance	Physical
exercise	Physical
contraction	Physical
mode	Physical
and	O
protein	Physical
supplementation	Physical
on	O
members	O
of	O
the	O
STARS	O
signalling	O
pathway	O
.	O

The	O
striated	O
muscle	O
activator	O
of	O
Rho	O
signalling	O
(	O
STARS	O
)	O
pathway	O
is	O
suggested	O
to	O
provide	O
a	O
link	O
between	O
external	O
stress	O
responses	O
and	O
transcriptional	O
regulation	O
in	O
muscle	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
STARS	O
signalling	O
to	O
different	O
mechanical	O
stresses	O
has	O
not	O
been	O
investigated	O
.	O

In	O
a	O
comparative	O
study	O
,	O
we	O
examined	O
the	O
regulation	O
of	O
the	O
STARS	O
signalling	O
pathway	O
in	O
response	O
to	O
unilateral	O
resistance	Physical
exercise	Physical
performed	O
as	O
either	O
eccentric	Educational
(	Physical
ECC	Physical
)	Physical
or	Physical
concentric	Physical
(	Physical
CONC	Physical
)	Physical
contractions	Physical
as	O
well	O
as	O
prolonged	Educational
training	Educational
;	O
with	O
and	O
without	O
whey	Physical
protein	Physical
supplementation	Physical
.	O

Skeletal	O
muscle	O
STARS	O
,	O
myocardian-related	O
transcription	O
factor-A	O
(	O
MRTF-A	O
)	O
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
mRNA	O
and	O
protein	O
,	O
as	O
well	O
as	O
muscle	O
cross-sectional	O
area	O
and	O
maximal	O
voluntary	O
contraction	O
,	O
were	O
measured	O
.	O

A	O
single-bout	O
of	O
exercise	Physical
produced	O
increases	O
in	O
STARS	O
and	O
SRF	O
mRNA	O
and	O
decreases	O
in	O
MRTF-A	O
mRNA	O
with	O
both	O
ECC	Physical
and	O
CONC	Physical
exercise	Physical
,	O
but	O
with	O
an	O
enhanced	O
response	O
occurring	O
following	O
ECC	Physical
exercise	Physical
.	O

A	O
31	O
%	O
increase	O
in	O
STARS	O
protein	O
was	O
observed	O
exclusively	O
after	O
CONC	Physical
exercise	Physical
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
pSRF	O
protein	O
levels	O
increased	O
similarly	O
by	O
48	O
%	O
with	O
both	O
CONC	O
and	O
ECC	O
exercise	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Prolonged	O
ECC	O
and	O
CONC	O
training	O
equally	O
stimulated	O
muscle	O
hypertrophy	O
and	O
produced	O
increases	O
in	O
MRTF-A	O
protein	O
of	O
125	O
%	O
and	O
99	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
changes	O
occurred	O
for	O
total	O
SRF	O
protein	O
.	O

There	O
was	O
no	O
effect	O
of	O
whey	Physical
protein	Physical
supplementation	Physical
.	O

These	O
results	O
show	O
that	O
resistance	O
exercise	O
provides	O
an	O
acute	O
stimulation	O
of	O
the	O
STARS	O
pathway	O
that	O
is	O
contraction	O
mode	O
dependent	O
.	O

The	O
responses	O
to	O
acute	Physical
exercise	Physical
were	O
more	O
pronounced	O
than	O
responses	O
to	O
accumulated	Educational
training	Educational
,	O
suggesting	O
that	O
STARS	O
signalling	O
is	O
primarily	O
involved	O
in	O
the	O
initial	O
phase	O
of	O
exercise-induced	O
muscle	O
adaptations	O
.	O

The	O
effect	O
of	O
perindopril	Pharmacological
and	Pharmacological
hydrochlorothiazide	Pharmacological
alone	Pharmacological
and	Pharmacological
in	Pharmacological
combination	Pharmacological
on	O
blood	O
pressure	O
and	O
on	O
the	O
renin-angiotensin	O
system	O
in	O
hypertensive	O
subjects	O
.	O

The	O
pharmacodynamic	O
effects	O
and	O
acceptability	O
of	O
perindopril	Pharmacological
(	O
4	O
mg	O
daily	O
)	O
and	O
hydrochlorothiazide	Pharmacological
(	O
25	O
mg	O
daily	O
)	O
given	O
alone	O
or	O
in	O
combination	O
for	O
1	O
month	O
were	O
investigated	O
in	O
a	O
double-blind	O
,	O
placebo	Control
controlled	O
,	O
parallel	O
group	O
study	O
.	O

The	O
pharmacokinetics	O
of	O
perindopril	Pharmacological
and	O
its	O
active	O
metabolite	O
perindoprilat	O
and	O
the	O
time	O
course	O
of	O
angiotensin	O
converting	O
enzyme	O
inhibition	O
were	O
studied	O
for	O
72	O
h	O
following	O
the	O
last	O
dose	O
of	O
treatment	O
in	O
the	O
two	O
appropriate	O
groups	O
.	O

Similar	O
decreases	O
in	O
blood	O
pressure	O
were	O
seen	O
24	O
h	O
after	O
the	O
last	O
dose	O
of	O
perindopril	Pharmacological
or	O
hydrochlorothiazide	Pharmacological
(	O
11/7	O
mm	O
Hg	O
supine	O
)	O
given	O
alone	O
at	O
these	O
doses	O
.	O

The	O
effect	O
of	O
these	O
drugs	O
given	O
together	O
was	O
additive	O
on	O
diastolic	O
blood	O
pressure	O
and	O
synergistic	O
on	O
systolic	O
blood	O
pressure	O
(	O
24.5/12.6	O
mm	O
Hg	O
supine	O
)	O
taking	O
into	O
account	O
the	O
placebo	O
response	O
.	O

The	O
significant	O
increase	O
in	O
plasma	O
renin	O
activity	O
produced	O
by	O
perindopril	Pharmacological
alone	O
was	O
potentiated	O
by	O
concurrent	O
administration	O
of	O
hydrochlorothiazide	Pharmacological
.	O

The	O
formation	O
of	O
perindoprilat	Pharmacological
was	O
slightly	O
reduced	O
in	O
the	O
group	O
also	O
receiving	O
hydrochlorothiazide	Pharmacological
and	O
there	O
was	O
a	O
very	O
small	O
reduction	O
in	O
ACE	O
inhibition	O
in	O
this	O
group	O
.	O

Perindopril	Pharmacological
,	O
whether	O
given	O
alone	O
or	O
in	O
combination	O
with	O
hydrochlorothiazide	Pharmacological
,	O
was	O
well	O
tolerated	O
and	O
produced	O
no	O
clinically	O
significant	O
change	O
in	O
routine	O
haematology	O
or	O
serum	O
biochemistry	O
.	O

The	O
additive	O
or	O
synergistic	O
effects	O
of	O
perindopril	Pharmacological
and	O
hydrochlorothiazide	Pharmacological
on	O
blood	O
pressure	O
must	O
be	O
due	O
to	O
their	O
complementary	O
physiological	O
actions	O
and	O
not	O
to	O
a	O
pharmacokinetic	O
interaction	O
.	O

Propofol	Pharmacological
sedation	O
with	O
bispectral	O
index	O
monitoring	O
is	O
useful	O
for	O
endoscopic	O
submucosal	O
dissection	O
:	O
a	O
randomized	O
prospective	O
phase	O
II	O
clinical	O
trial	O
.	O

BACKGROUND	O
AND	O
STUDY	O
AIMS	O
Endoscopic	O
submucosal	O
dissection	O
(	O
ESD	O
)	O
has	O
become	O
a	O
standard	O
treatment	O
.	O

However	O
,	O
the	O
treatment	O
time	O
tends	O
to	O
be	O
relatively	O
long	O
and	O
insufflation	O
and	O
manipulation	O
of	O
the	O
endoscope	O
can	O
increase	O
pain	O
and	O
discomfort	O
.	O

We	O
aimed	O
to	O
find	O
an	O
optimal	O
method	O
for	O
sedation	O
during	O
ESD	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
scheduled	O
to	O
undergo	O
ESD	O
for	O
early	O
gastric	O
cancer	O
or	O
adenoma	O
were	O
randomly	O
assigned	O
to	O
sedation	O
with	O
midazolam	Pharmacological
or	Pharmacological
propofol	Pharmacological
,	O
and	O
consciousness	O
level	O
was	O
evaluated	O
by	O
bispectral	O
index	O
(	O
BIS	O
)	O
monitoring	O
.	O

Primary	O
end	O
points	O
of	O
effectiveness	O
(	O
three	O
parameters	O
)	O
and	O
secondary	O
end	O
points	O
of	O
safety	O
during	O
ESD	O
and	O
after	O
return	O
to	O
the	O
ward	O
were	O
compared	O
between	O
the	O
groups	O
.	O

Study	O
registration	O
was	O
in	O
the	O
UMIN	O
Clinical	O
Trial	O
Registry	O
(	O
UMIN	O
000001497	O
)	O
,	O
and	O
the	O
institutional	O
trial	O
number	O
was	O
KDOG	O
0801	O
.	O

RESULTS	O
From	O
June	O
2008	O
through	O
June	O
2009	O
,	O
we	O
enrolled	O
178	O
patients	O
(	O
90	O
midazolam	O
,	O
88	O
propofol	O
)	O
.	O

Regarding	O
safety	O
after	O
ESD	O
,	O
recovery	O
was	O
significantly	O
better	O
in	O
the	O
propofol	O
group	O
immediately	O
after	O
and	O
at	O
1	O
hour	O
and	O
2	O
hours	O
after	O
return	O
to	O
the	O
ward	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
number	O
of	O
patients	O
who	O
required	O
a	O
continuous	O
supply	O
of	O
oxygen	O
2	O
hours	O
after	O
returning	O
to	O
the	O
ward	O
was	O
significantly	O
lower	O
in	O
the	O
propofol	O
group	O
(	O
midazolam	O
18	O
;	O
propofol	O
6	O
;	O
P	O
=	O
0.010	O
)	O
.	O

Though	O
propofol	O
seemed	O
to	O
be	O
better	O
for	O
effectiveness	O
and	O
safety	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
for	O
all	O
three	O
primary	O
end	O
points	O
and	O
the	O
safety	O
parameters	O
(	O
hypotension	O
,	O
hypoxia	O
,	O
bradycardia	O
)	O
.	O

CONCLUSIONS	O
Propofol	Pharmacological
with	O
BIS	O
monitoring	O
improved	O
recovery	O
of	O
patients	O
after	O
ESD	O
,	O
though	O
this	O
study	O
was	O
underpowered	O
to	O
prove	O
the	O
effectiveness	O
and	O
safety	O
of	O
propofol	O
.	O

Further	O
evaluation	O
of	O
docosahexaenoic	Pharmacological
acid	Pharmacological
in	O
patients	O
with	O
retinitis	O
pigmentosa	O
receiving	O
vitamin	Pharmacological
A	Pharmacological
treatment	O
:	O
subgroup	O
analyses	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
docosahexaenoic	Pharmacological
acid	Pharmacological
will	O
slow	O
the	O
course	O
of	O
retinal	O
degeneration	O
in	O
subgroups	O
of	O
patients	O
with	O
retinitis	O
pigmentosa	O
who	O
are	O
receiving	O
vitamin	Pharmacological
A	Pharmacological
.	O

DESIGN	O
A	O
cohort	O
of	O
208	O
patients	O
with	O
retinitis	O
pigmentosa	O
,	O
aged	O
18	O
to	O
55	O
years	O
,	O
were	O
randomly	O
assigned	O
to	O
1200	O
mg	O
of	O
docosahexaenoic	Pharmacological
acid	Pharmacological
plus	Pharmacological
15	Pharmacological
000	Pharmacological
IU/d	Pharmacological
of	Pharmacological
vitamin	Pharmacological
A	Pharmacological
given	Pharmacological
as	Pharmacological
retinyl	Pharmacological
palmitate	Pharmacological
(	Pharmacological
DHA	Pharmacological
+	Pharmacological
A	Pharmacological
group	Pharmacological
)	Pharmacological
or	O
control	Control
fatty	Control
acid	Control
plus	Control
15	Control
000	Control
IU/d	Control
of	Control
vitamin	Control
A	Control
(	Control
control	Control
+	Control
A	Control
group	Control
)	Control
and	O
followed	O
up	O
over	O
4	O
years	O
.	O

Seventy	O
percent	O
of	O
the	O
patients	O
in	O
each	O
group	O
were	O
taking	O
vitamin	Pharmacological
A	Pharmacological
,	O
15	O
000	O
IU/d	O
,	O
prior	O
to	O
entry	O
.	O

We	O
compared	O
rates	O
of	O
decline	O
in	O
ocular	O
function	O
in	O
the	O
DHA	Pharmacological
+	Pharmacological
A	Pharmacological
vs	O
control	Pharmacological
+	Pharmacological
A	Pharmacological
groups	O
among	O
the	O
subgroups	O
defined	O
by	O
use	O
or	O
nonuse	O
of	O
vitamin	Pharmacological
A	Pharmacological
prior	O
to	O
entry	O
.	O

We	O
also	O
determined	O
whether	O
decline	O
in	O
ocular	O
function	O
was	O
related	O
to	O
red	O
blood	O
cell	O
phosphatidylethanolamine	O
docosahexaenoic	O
acid	O
level	O
,	O
dietary	O
omega-3	O
fatty	O
acid	O
intake	O
,	O
or	O
duration	O
of	O
vitamin	O
A	O
use	O
.	O

Main	O
outcome	O
measures	O
were	O
Humphrey	O
Field	O
Analyzer	O
visual	O
field	O
sensitivity	O
,	O
30-Hz	O
electroretinogram	O
amplitude	O
,	O
and	O
visual	O
acuity	O
.	O

RESULTS	O
Among	O
patients	O
not	Educational
taking	Educational
vitamin	Educational
A	Educational
prior	O
to	O
entry	O
,	O
those	O
in	O
the	O
DHA	Pharmacological
+	Pharmacological
A	Pharmacological
group	O
had	O
a	O
slower	O
decline	O
in	O
field	O
sensitivity	O
and	O
electroretinogram	O
amplitude	O
than	O
those	O
in	O
the	O
control	Pharmacological
+	Pharmacological
A	Pharmacological
group	O
over	O
the	O
first	O
2	O
years	O
(	O
P	O
=.01	O
and	O
P	O
=.03	O
,	O
respectively	O
)	O
;	O
these	O
differences	O
were	O
not	O
observed	O
in	O
years	O
3	O
and	O
4	O
of	O
follow-up	O
or	O
among	O
patients	O
taking	O
vitamin	Pharmacological
A	Pharmacological
prior	O
to	O
entry	O
.	O

In	O
the	O
entire	O
cohort	O
,	O
red	O
blood	O
cell	O
phosphatidylethanolamine	O
docosahexaenoic	Pharmacological
acid	Pharmacological
level	O
was	O
inversely	O
related	O
to	O
rate	O
of	O
decline	O
in	O
total	O
field	O
sensitivity	O
over	O
4	O
years	O
(	O
test	O
for	O
trend	O
,	O
P	O
=.05	O
)	O
.	O

This	O
was	O
particularly	O
evident	O
over	O
the	O
first	O
2	O
years	O
among	O
those	O
not	Pharmacological
on	Pharmacological
vitamin	Pharmacological
A	Pharmacological
prior	O
to	O
entry	O
(	O
test	O
for	O
trend	O
,	O
P	O
=.003	O
)	O
.	O

In	O
the	O
entire	O
control	O
+	O
A	O
group	O
,	O
dietary	Pharmacological
omega-3	Pharmacological
fatty	Pharmacological
acid	Pharmacological
intake	O
was	O
inversely	O
related	O
to	O
loss	O
of	O
total	O
field	O
sensitivity	O
over	O
4	O
years	O
(	O
intake	O
,	O
<	O
0.20	O
vs	O
>	O
or	O
=0.20	O
g/d	O
;	O
P	O
=.02	O
)	O
.	O

The	O
duration	O
of	O
vitamin	Pharmacological
A	Pharmacological
supplementation	Pharmacological
prior	O
to	O
entry	O
was	O
inversely	O
related	O
to	O
rate	O
of	O
decline	O
in	O
electroretinogram	O
amplitude	O
(	O
P	O
=.008	O
)	O
.	O

CONCLUSIONS	O
For	O
patients	O
with	O
retinitis	O
pigmentosa	O
beginning	O
vitamin	Physical
A	Physical
therapy	Physical
,	O
addition	O
of	O
docosahexaenoic	Pharmacological
acid	Pharmacological
,	O
1200	O
mg/d	O
,	O
slowed	O
the	O
course	O
of	O
disease	O
for	O
2	O
years	O
.	O

Among	O
patients	O
on	O
vitamin	Pharmacological
A	Pharmacological
for	O
at	O
least	O
2	O
years	O
,	O
a	O
diet	O
rich	O
in	O
omega-3	Pharmacological
fatty	Pharmacological
acids	Pharmacological
(	O
>	O
or	O
=0.20	O
g/d	O
)	O
slowed	O
the	O
decline	O
in	O
visual	O
field	O
sensitivity	O
.	O

Superior	O
fixation	O
of	O
pegged	Physical
trabecular	Physical
metal	Physical
over	O
screw-fixed	Physical
pegged	Physical
porous	Physical
titanium	Physical
fiber	Physical
mesh	Physical
:	O
a	O
randomized	O
clinical	O
RSA	O
study	O
on	O
cementless	O
tibial	O
components	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Lasting	O
stability	O
of	O
cementless	O
implants	O
depends	O
on	O
osseointegration	O
into	O
the	O
implant	O
surface	O
,	O
and	O
long-term	O
implant	O
fixation	O
can	O
be	O
predicted	O
using	O
radiostereometric	O
analysis	O
(	O
RSA	O
)	O
with	O
short-term	O
follow-up	O
.	O

We	O
hypothesized	O
that	O
there	O
would	O
be	O
improved	O
fixation	O
of	O
high-porosity	Surgical
trabecular	Surgical
metal	Surgical
(	Surgical
TM	Surgical
)	Surgical
tibial	Surgical
components	Surgical
compared	O
to	O
low-porosity	Surgical
titanium	Surgical
pegged	Surgical
porous	Surgical
fiber-metal	Surgical
(	Surgical
Ti	Surgical
)	Surgical
polyethylene	Surgical
metal	Surgical
backings	Surgical
.	Surgical

METHODS	O
In	O
a	O
prospective	O
,	O
parallel-group	O
,	O
randomized	O
unblinded	O
clinical	O
trial	O
,	O
we	O
compared	O
cementless	Surgical
tibial	Surgical
components	Surgical
in	O
patients	O
aged	O
70	O
years	O
and	O
younger	O
with	O
osteoarthritis	O
.	O

The	O
pre-study	O
sample	O
size	O
calculation	O
was	O
22	O
patients	O
per	O
group	O
.	O

25	Surgical
TM	Surgical
tibial	Surgical
components	Surgical
were	Surgical
fixed	Surgical
press-fit	Surgical
by	Surgical
2	O
hexagonal	O
pegs	O
(	O
TM	O
group	O
)	O
and	O
25	Surgical
Ti	Surgical
tibial	Surgical
components	Surgical
were	Surgical
fixed	Surgical
press-fit	Surgical
and	Surgical
by	Surgical
4	Surgical
supplemental	Surgical
screws	Surgical
(	O
Ti	O
group	O
)	O
.	O

Stereo	O
radiographs	O
for	O
evaluation	O
of	O
absolute	O
component	O
migration	O
(	O
primary	O
effect	O
size	O
)	O
and	O
single-direction	O
absolute	O
component	O
migration	O
(	O
secondary	O
effect	O
size	O
)	O
were	O
obtained	O
within	O
the	O
first	O
postoperative	O
week	O
and	O
at	O
6	O
weeks	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
2	O
years	O
.	O

American	O
Knee	O
Society	O
score	O
was	O
used	O
for	O
clinical	O
assessment	O
preoperatively	O
,	O
and	O
at	O
1	O
and	O
2	O
years	O
.	O

RESULTS	O
There	O
were	O
no	O
intraoperative	O
complications	O
,	O
and	O
no	O
postoperative	O
infections	O
or	O
revisions	O
.	O

All	O
patients	O
had	O
improved	O
function	O
and	O
regained	O
full	O
extension	O
.	O

All	O
tibial	O
components	O
migrated	O
initially	O
.	O

Most	O
migration	O
of	O
the	O
TM	Physical
components	O
(	O
n	O
=	O
24	O
)	O
occurred	O
within	O
the	O
first	O
3	O
months	O
after	O
surgery	O
whereas	O
migration	O
of	O
the	O
Ti	Physical
components	O
(	O
n	O
=	O
22	O
)	O
appeared	O
to	O
stabilize	O
first	O
after	O
1	O
year	O
.	O

The	O
TM	Physical
components	O
migrated	O
less	O
than	O
the	O
Ti	Physical
components	O
at	O
1	O
year	O
(	O
p	O
=	O
0.01	O
)	O
and	O
2	O
years	O
(	O
p	O
=	O
0.004	O
)	O
.	O

INTERPRETATION	O
We	O
conclude	O
that	O
the	O
mechanical	O
fixation	O
of	O
TM	O
tibial	O
components	O
is	O
superior	O
to	O
that	O
of	O
screw-fixed	O
Ti	Physical
tibial	O
components	O
.	O

We	O
expect	O
long-term	O
implant	O
survival	O
to	O
be	O
better	O
with	O
the	O
TM	Physical
tibial	O
component	O
.	O

Clinical	O
trial	O
:	O
exposure	O
to	O
ribavirin	O
predicts	O
EVR	O
and	O
SVR	O
in	O
patients	O
with	O
HCV	O
genotype	O
1	O
infection	O
treated	O
with	O
peginterferon	O
alpha-2a	O
plus	O
ribavirin	O
.	O

BACKGROUND	O
The	O
impact	O
of	O
reduced	O
drug	O
exposure	O
on	O
outcomes	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
has	O
not	O
been	O
determined	O
in	O
routine	O
clinical	O
practice	O
.	O

AIM	O
To	O
examine	O
the	O
impact	O
of	O
exposure	O
to	O
peginterferon	O
alpha-2a	O
and	O
ribavirin	O
on	O
early	O
virological	O
response	O
(	O
EVR	O
)	O
and	O
sustained	O
virological	O
response	O
(	O
SVR	O
)	O
in	O
treatment-naive	O
patients	O
with	O
HCV	O
genotype	O
1	O
infection	O
enrolled	O
in	O
a	O
large	O
expanded	O
access	O
programme	O
.	O

METHODS	O
Eight	O
hundred	O
and	O
ninety-one	O
patients	O
treated	O
for	O
48	O
weeks	O
with	O
an	O
initial	O
ribavirin	Pharmacological
dose	Pharmacological
of	Pharmacological
800	Pharmacological
or	Pharmacological
1000/1200	Pharmacological
mg/day	Pharmacological
were	O
evaluated	O
.	O

Ribavirin	Pharmacological
1000	O
mg/day	O
(	O
<	O
75	O
kg	O
)	O
or	O
1200	O
mg/day	O
(	O
>	O
or=75	O
kg	O
)	O
and	O
peginterferon	Pharmacological
alpha-2a	Pharmacological
180	Pharmacological
microg/week	O
were	O
considered	O
optimal	O
.	O

The	O
impact	O
of	O
reduced	O
drug	O
exposure	O
(	O
expressed	O
as	O
a	O
percentage	O
of	O
optimal	O
)	O
on	O
EVR	O
and	O
SVR	O
was	O
evaluated	O
.	O

RESULTS	O
Mean	O
ribavirin	O
exposure	O
in	O
week	O
0-12	O
was	O
70	O
%	O
and	O
96	O
%	O
in	O
patients	O
assigned	O
to	O
ribavirin	O
800	O
and	O
1000/1200	O
mg/day	O
,	O
respectively	O
.	O

EVR	O
and	O
SVR	O
rates	O
were	O
lower	O
in	O
patients	O
assigned	O
to	O
ribavirin	O
800	O
than	O
1000/1200	O
mg/day	O
(	O
EVR	O
,	O
75	O
%	O
vs.	O
84	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0.001	O
;	O
SVR	O
,	O
45	O
%	O
vs.	O
54	O
%	O
,	O
respectively	O
,	O
P	O
=	O
0.011	O
)	O
.	O

Furthermore	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
achievement	O
of	O
EVR	O
and	O
SVR	O
and	O
ribavirin	O
dose	O
over	O
the	O
first	O
12	O
weeks	O
expressed	O
either	O
as	O
absolute	O
dose	O
or	O
proportion	O
of	O
optimal	O
dose	O
received	O
(	O
P	O
<	O
0.001	O
for	O
both	O
)	O
.	O

CONCLUSIONS	O
Ribavirin	O
exposure	O
to	O
week	O
12	O
is	O
significantly	O
associated	O
with	O
EVR	O
and	O
SVR	O
in	O
genotype	O
1	O
patients	O
.	O

Maintenance	O
of	O
an	O
optimal	O
ribavirin	O
dose	O
is	O
the	O
most	O
important	O
modifiable	O
factor	O
during	O
combination	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
.	O

Plasma	O
pH	O
does	O
not	O
influence	O
the	O
cerebral	O
metabolic	O
ratio	O
during	O
maximal	O
whole	O
body	O
exercise	O
.	O

Exercise	O
lowers	O
the	O
cerebral	O
metabolic	O
ratio	O
of	O
O2	O
to	O
carbohydrate	O
(	O
glucose+1/2	O
lactate	O
)	O
and	O
metabolic	O
acidosis	O
appears	O
to	O
promote	O
cerebral	O
lactate	O
uptake	O
.	O

However	O
,	O
the	O
influence	O
of	O
pH	O
on	O
cerebral	O
lactate	O
uptake	O
and	O
,	O
in	O
turn	O
,	O
on	O
the	O
cerebral	O
metabolic	O
ratio	O
during	O
exercise	O
is	O
not	O
known	O
.	O

Sodium	Pharmacological
bicarbonate	Pharmacological
(	O
Bicarb	O
,	O
1	O
M	O
;	O
350-500	O
ml	O
)	O
or	O
an	O
equal	O
volume	O
of	O
normal	Pharmacological
saline	Pharmacological
(	O
Sal	O
)	O
was	O
infused	O
intravenously	O
at	O
a	O
constant	O
rate	O
during	O
a	O
'2000	O
m	O
'	O
maximal	O
ergometer	Pharmacological
row	Pharmacological
in	O
six	O
male	O
oarsmen	O
(	O
23?2	O
years	O
;	O
mean?S.D.	O
)	O
.	O

During	O
the	O
Sal	O
trial	O
,	O
pH	O
decreased	O
from	O
7.41?0.01	O
at	O
rest	O
to	O
7.02?0.02	O
but	O
only	O
to	O
7.36?0.02	O
(	O
P	O
<	O
0.05	O
)	O
during	O
the	O
Bicarb	O
trial	O
.	O

Arterial	O
lactate	O
increased	O
to	O
21.4?0.8	O
and	O
32.7?2.3	O
mM	O
during	O
the	O
Sal	O
and	O
Bicarb	O
trials	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Also	O
,	O
the	O
arterial-jugular	O
venous	O
lactate	O
difference	O
increased	O
from-0.03?0.01	O
mM	O
at	O
rest	O
to	O
3.2?0.9	O
mM	O
(	O
P	O
<	O
0.05	O
)	O
and	O
3.4?1.4	O
mM	O
(	O
P	O
<	O
0.05	O
)	O
following	O
the	O
Sal	O
and	O
Bicarb	O
trials	O
,	O
respectively	O
.	O

Accordingly	O
,	O
the	O
cerebral	O
metabolic	O
ratio	O
decreased	O
equally	O
during	O
the	O
Sal	O
and	O
Bicarb	O
trials	O
:	O
from	O
5.8?0.6	O
at	O
rest	O
to	O
1.7?0.1	O
and	O
1.8?0.2	O
,	O
respectively	O
.	O

The	O
enlarged	O
blood-buffering	O
capacity	O
after	O
infusion	O
of	O
Bicarb	O
eliminated	O
metabolic	O
acidosis	O
during	O
maximal	O
exercise	O
but	O
that	O
did	O
not	O
affect	O
the	O
cerebral	O
lactate	O
uptake	O
and	O
,	O
therefore	O
,	O
the	O
decrease	O
in	O
the	O
cerebral	O
metabolic	O
ratio	O
.	O

Functional	O
outcome	O
following	O
intramedullary	Surgical
nailing	Surgical
of	Surgical
the	Surgical
femur	Surgical
:	Surgical
a	O
prospective	O
randomized	O
comparison	O
of	O
piriformis	O
fossa	O
and	O
greater	O
trochanteric	O
entry	O
portals	O
.	O

BACKGROUND	O
The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
prospectively	O
compare	O
the	O
functional	O
outcome	O
of	O
intramedullary	O
nailing	O
of	O
the	O
femur	O
performed	O
with	O
use	O
of	O
a	O
trochanteric	O
and	O
a	O
piriformis	O
fossa	O
entry	O
portal	O
.	O

METHODS	O
One	O
hundred	O
and	O
ten	O
patients	O
with	O
a	O
femoral	O
shaft	O
fracture	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
study	O
.	O

Fifty-four	O
patients	O
were	O
randomized	O
to	O
Group	O
A	O
(	Surgical
piriformis	Surgical
fossa	Surgical
portal	Surgical
)	Surgical
and	O
fifty-six	O
to	O
Group	O
B	O
(	Surgical
trochanteric	Surgical
portal	Surgical
)	Surgical
.	O

Outcome	O
measures	O
included	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
(	O
WOMAC	O
)	O
Osteoarthritis	O
Index	O
hip	O
function	O
score	O
,	O
pain	O
,	O
and	O
blinded	O
functional	O
evaluation	O
by	O
a	O
physical	O
therapist	O
.	O

RESULTS	O
Most	O
measures	O
of	O
hip	O
function	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

The	O
WOMAC	O
score	O
at	O
three	O
,	O
six	O
,	O
and	O
twelve	O
months	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
piriformis	O
fossa	O
and	O
trochanteric	O
nailing	O
groups	O
.	O

Functional	O
tests	O
included	O
the	O
chair	O
stand	O
test	O
and	O
the	O
timed	O
up	O
and	O
go	O
test	O
.	O

Patients	O
in	O
Group	O
B	O
had	O
significantly	O
better	O
scores	O
on	O
the	O
chair	O
stand	O
test	O
(	O
13.3	O
compared	O
with	O
11.1	O
in	O
Group	O
A	O
,	O
p	O
=	O
0.04	O
)	O
at	O
six	O
months	O
postoperatively	O
,	O
but	O
there	O
was	O
no	O
difference	O
at	O
twelve	O
months	O
(	O
14.0	O
compared	O
with	O
13.6	O
)	O
.	O

The	O
two	O
groups	O
did	O
not	O
differ	O
significantly	O
on	O
the	O
timed	O
up	O
and	O
go	O
test	O
at	O
either	O
six	O
or	O
twelve	O
months	O
.	O

The	O
two	O
groups	O
also	O
did	O
not	O
differ	O
on	O
the	O
muscle	O
strength	O
testing	O
.	O

Intraoperative	O
parameters	O
differed	O
significantly	O
between	O
the	O
groups	O
with	O
respect	O
to	O
operative	O
time	O
,	O
fluoroscopy	O
time	O
,	O
and	O
incision	O
length	O
,	O
with	O
the	O
difference	O
favoring	O
Group	O
B	O
for	O
each	O
parameter	O
.	O

Analog	O
pain	O
scale	O
values	O
were	O
similar	O
in	O
Group	O
A	O
(	O
2.49	O
)	O
and	O
Group	O
B	O
(	O
2.15	O
)	O
at	O
twelve	O
months	O
postoperatively	O
.	O

CONCLUSIONS	O
Patients	O
in	O
our	O
prospective	O
randomized	O
study	O
who	O
were	O
treated	O
with	O
trochanteric	O
nailing	O
did	O
not	O
differ	O
in	O
hip	O
function	O
at	O
one	O
year	O
postoperatively	O
compared	O
with	O
patients	O
treated	O
with	O
intramedullary	O
nailing	O
through	O
the	O
piriformis	O
fossa	O
.	O

The	O
values	O
of	O
several	O
intraoperative	O
parameters	O
were	O
significantly	O
better	O
in	O
the	O
trochanteric	O
nailing	O
group	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
functional	O
hip	O
outcome	O
of	O
femoral	O
intramedullary	O
nailing	O
performed	O
through	O
the	O
greater	O
trochanter	O
is	O
equal	O
to	O
that	O
of	O
intramedullary	Educational
nailing	Educational
performed	O
through	O
the	O
piriformis	O
fossa	O
.	O

Milk	O
protein	O
quantity	O
and	O
quality	O
in	O
low-birth-weight	O
infants	O
.	O

IV	O
.	O

Effects	O
on	O
tyrosine	O
and	O
phenylalanine	O
in	O
plasma	O
and	O
urine	O
.	O

Well	O
,	O
appropriate-for-gestational	O
age	O
,	O
low-birth-weight	O
infants	O
were	O
divided	O
into	O
three	O
gestational	O
age	O
groups	O
and	O
assigned	O
randomly	O
within	O
each	O
age	O
group	O
to	O
one	O
of	O
five	O
feeding	O
regimens	O
:	O
pooled	Pharmacological
human	Pharmacological
milk	Pharmacological
(	Pharmacological
BM	Pharmacological
)	Pharmacological
;	Pharmacological
formula	Pharmacological
1	Pharmacological
(	Pharmacological
F1	Pharmacological
)	Pharmacological
=	Pharmacological
1.5	Pharmacological
gm/dl	Pharmacological
protein	Pharmacological
,	Pharmacological
60	Pharmacological
parts	Pharmacological
bovine	Pharmacological
whey	Pharmacological
proteins	Pharmacological
:	Pharmacological
40	Pharmacological
parts	Pharmacological
bovine	Pharmacological
caseins	Pharmacological
;	Pharmacological
F2	Pharmacological
=	Pharmacological
3.0	Pharmacological
gm/dl	Pharmacological
,	Pharmacological
60:40	Pharmacological
;	Pharmacological
F3	Pharmacological
=	Pharmacological
1.5	Pharmacological
gm/dl	Pharmacological
,	Pharmacological
18:82	Pharmacological
;	Pharmacological
F4	Pharmacological
=	Pharmacological
3.0	Pharmacological
gm/dl	Pharmacological
,	O
18:82	O
.	O

Plasma	O
and	O
urine	O
concentrations	O
of	O
tyrosine	O
and	O
phenylalanine	O
were	O
far	O
higher	O
in	O
the	O
infants	O
fed	O
F1	O
to	O
F4	O
,	O
especially	O
F2	O
and	O
F4	O
,	O
than	O
in	O
the	O
infants	O
fed	O
BM	O
.	O

These	O
findings	O
offer	O
further	O
evidence	O
for	O
the	O
limited	O
capacity	O
of	O
the	O
low-birth-weight	O
infant	O
to	O
catabolize	O
tyrosine	O
.	O

Infants	O
fed	O
F3	O
had	O
significantly	O
higher	O
plasma	O
tyrosine	O
concentrations	O
than	O
infants	O
fed	O
F1	O
,	O
and	O
those	O
fed	O
F4	O
had	O
higher	O
concentrations	O
than	O
those	O
fed	O
F2	O
.	O

Thus	O
,	O
increased	O
plasma	O
tyrosine	O
concentrations	O
in	O
low-birth-weight	O
infants	O
are	O
related	O
directly	O
both	O
to	O
the	O
quantity	O
and	O
to	O
the	O
quality	O
of	O
the	O
protein	O
in	O
their	O
diets	O
.	O

Loss	O
of	O
autonomy	O
among	O
elderly	O
patients	O
after	O
a	O
stay	O
in	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
:	O
a	O
randomized	O
study	O
of	O
the	O
benefit	O
of	O
transfer	O
to	O
a	O
geriatric	O
ward	O
.	O

In	O
order	O
to	O
evaluate	O
changes	O
in	O
the	O
functional	O
autonomy	O
of	O
elderly	O
patients	O
after	O
a	O
stay	O
in	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
,	O
and	O
the	O
impact	O
of	O
post-ICU	O
management	O
in	O
geriatric	O
ward	O
,	O
we	O
included	O
in	O
a	O
randomized	O
controlled	O
trial	O
45	O
patients	O
aged	O
>	O
or=75	O
years	O
.	O

They	O
were	O
assessed	O
for	O
functional	O
autonomy	O
before	O
ICU	O
stay	O
,	O
just	O
after	O
ICU	O
discharge	O
,	O
just	O
after	O
hospital	O
discharge	O
,	O
and	O
6	O
months	O
later	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
two	O
post-ICU	O
management	O
groups	O
:	O
geriatric	Educational
ward	Educational
and	O
standard	Educational
care	Educational
.	O

Autonomy	O
was	O
usually	O
recovered	O
rapidly	O
,	O
but	O
the	O
degree	O
of	O
recovery	O
depended	O
on	O
the	O
patient	O
's	O
previous	O
autonomy	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

At	O
the	O
last	O
assessment	O
,	O
41	O
%	O
of	O
the	O
patients	O
had	O
recovered	O
their	O
previous	O
autonomy	O
.	O

The	O
mean	O
Barthel	O
indexes	O
were	O
81.5+/-30.4	O
in	O
the	O
geriatric	O
management	O
arm	O
and	O
70.5+/-33.4	O
in	O
the	O
standard	O
management	O
arm	O
(	O
p=0.4	O
)	O
.	O

The	O
study	O
was	O
prematurely	O
ended	O
due	O
to	O
insufficient	O
recruitment	O
flow	O
.	O

These	O
results	O
underline	O
the	O
rapid	O
loss	O
of	O
autonomy	O
after	O
a	O
stay	O
in	O
a	O
medical	O
ICU	O
.	O

Early	O
specific	O
intervention	O
to	O
improve	O
the	O
autonomy	O
of	O
elderly	O
patients	O
seems	O
an	O
attractive	O
solution	O
that	O
could	O
be	O
assessed	O
by	O
randomized	O
controlled	O
trial	O
.	O

Above	O
all	O
,	O
our	O
results	O
should	O
also	O
serve	O
as	O
a	O
basis	O
for	O
further	O
controlled	O
randomized	O
studies	O
in	O
this	O
setting	O
.	O

Aspartame	Pharmacological
:	O
neuropsychologic	O
and	O
neurophysiologic	O
evaluation	O
of	O
acute	O
and	O
chronic	O
effects	O
.	O

BACKGROUND	O
Neurobehavioral	O
symptoms	O
have	O
been	O
reported	O
anecdotally	O
with	O
aspartame	Pharmacological
.	O

OBJECTIVE	O
This	O
study	O
sought	O
to	O
determine	O
whether	O
aspartame	Pharmacological
can	O
disrupt	O
cognitive	O
,	O
neurophysiologic	O
,	O
or	O
behavioral	O
functioning	O
in	O
normal	O
individuals	O
.	O

DESIGN	O
Forty-eight	O
healthy	O
volunteers	O
completed	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
,	O
crossover	O
study	O
.	O

The	O
first	O
month	O
was	O
aspartame	Pharmacological
free	O
.	O

Subjects	O
then	O
consumed	O
sodas	Control
and	Control
capsules	Control
with	Control
placebo	Control
,	O
aspartame	Pharmacological
,	O
or	O
sucrose	Pharmacological
for	O
20	O
d	O
each	O
.	O

Order	O
was	O
randomized	O
and	O
subjects	O
were	O
assigned	O
to	O
either	O
a	O
high-	O
(	O
45	O
mg	O
x	O
kg	O
body	O
wt	O
(	O
-1	O
)	O
x	O
d	O
(	O
-1	O
)	O
)	O
or	O
low-	O
(	O
15	O
mg	O
x	O
kg	O
body	O
wt	O
(	O
-1	O
)	O
x	O
d	O
(	O
-1	O
)	O
)	O
dose	O
aspartame	Pharmacological
group	O
.	O

Neuropsychologic	O
and	O
laboratory	O
testing	O
was	O
done	O
on	O
day	O
10	O
of	O
each	O
treatment	O
period	O
to	O
determine	O
possible	O
acute	O
effects	O
and	O
on	O
day	O
20	O
for	O
possible	O
chronic	O
effects	O
.	O

RESULTS	O
Plasma	O
phenylalanine	O
concentrations	O
increased	O
significantly	O
during	O
aspartame	O
treatment	O
.	O

Neuropsychologic	O
results	O
;	O
adverse	O
experiences	O
;	O
amino	O
acid	O
,	O
insulin	O
,	O
and	O
glucose	O
values	O
;	O
and	O
electroencephalograms	O
were	O
compared	O
by	O
sex	O
and	O
by	O
treatment	O
.	O

No	O
significant	O
differences	O
were	O
found	O
for	O
any	O
dependent	O
measure	O
.	O

CONCLUSION	O
Large	O
daily	O
doses	O
of	O
aspartame	Pharmacological
had	O
no	O
effect	O
on	O
neuropsychologic	O
,	O
neurophysiologic	O
,	O
or	O
behavioral	O
functioning	O
in	O
healthy	O
young	O
adults	O
.	O

Late	O
patient-reported	O
toxicity	O
after	O
preoperative	O
radiotherapy	Physical
or	O
chemoradiotherapy	Pharmacological
in	O
nonresectable	O
rectal	O
cancer	O
:	O
results	O
from	O
a	O
randomized	O
Phase	O
III	O
study	O
.	O

PURPOSE	O
Preoperative	Physical
chemoradiotherapy	Physical
(	O
CRT	O
)	O
is	O
superior	O
to	O
radiotherapy	Physical
(	O
RT	O
)	O
in	O
locally	O
advanced	O
rectal	O
cancer	O
,	O
but	O
the	O
survival	O
gain	O
is	O
limited	O
.	O

Late	O
toxicity	O
is	O
,	O
therefore	O
,	O
important	O
.	O

The	O
aim	O
was	O
to	O
compare	O
late	O
bowel	O
,	O
urinary	O
,	O
and	O
sexual	O
functions	O
after	O
CRT	O
or	O
RT	O
.	O

METHODS	O
AND	O
MATERIALS	O
Patients	O
(	O
N	O
=	O
207	O
)	O
with	O
nonresectable	O
rectal	O
cancer	O
were	O
randomized	O
to	O
preoperative	Surgical
CRT	Surgical
or	O
RT	Surgical
(	O
2	O
Gy	O
?	O
25	O
?	O
5-fluorouracil/leucovorin	O
)	O
.	O

Extended	O
surgery	O
was	O
often	O
required	O
.	O

Self-reported	O
late	O
toxicity	O
was	O
scored	O
according	O
to	O
the	O
LENT	O
SOMA	O
criteria	O
in	O
a	O
structured	O
telephone	O
interview	O
and	O
with	O
questionnaires	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
QLQ-C30	O
)	O
,	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
and	O
sexual	O
function-vaginal	O
changes	O
questionnaire	O
(	O
SVQ	O
)	O
.	O

RESULTS	O
Of	O
the	O
105	O
patients	O
alive	O
in	O
Norway	O
and	O
Sweden	O
after	O
4	O
to	O
12	O
years	O
of	O
follow-up	O
,	O
78	O
(	O
74	O
%	O
)	O
responded	O
.	O

More	O
patients	O
in	O
the	O
CRT	O
group	O
had	O
received	O
a	O
stoma	O
(	O
73	O
%	O
vs.	O
52	O
%	O
,	O
p	O
=	O
0.09	O
)	O
.	O

Most	O
patients	O
without	O
a	O
stoma	O
(	O
7	O
of	O
12	O
in	O
CRT	O
group	O
and	O
9	O
of	O
16	O
in	O
RT	O
group	O
)	O
had	O
incontinence	O
for	O
liquid	O
stools	O
or	O
gas	O
.	O

No	O
stoma	O
and	O
good	O
anal	O
function	O
were	O
seen	O
in	O
5	O
patients	O
(	O
11	O
%	O
)	O
in	O
the	O
CRT	O
group	O
and	O
in	O
11	O
(	O
30	O
%	O
)	O
in	O
the	O
RT	O
group	O
(	O
p	O
=	O
0.046	O
)	O
.	O

Of	O
44	O
patients	O
in	O
the	O
CRT	O
group	O
,	O
12	O
(	O
28	O
%	O
)	O
had	O
had	O
bowel	O
obstruction	O
compared	O
with	O
5	O
of	O
33	O
(	O
15	O
%	O
)	O
in	O
the	O
RT	O
group	O
(	O
p	O
=	O
0.27	O
)	O
.	O

One-quarter	O
of	O
the	O
patients	O
reported	O
urinary	O
incontinence	O
.	O

The	O
majority	O
of	O
men	O
had	O
severe	O
erectile	O
dysfunction	O
.	O

Few	O
women	O
reported	O
sexual	O
activity	O
during	O
the	O
previous	O
month	O
.	O

However	O
,	O
the	O
majority	O
did	O
not	O
have	O
concerns	O
about	O
their	O
sex	O
life	O
.	O

CONCLUSIONS	O
Fecal	O
incontinence	O
and	O
erectile	O
dysfunction	O
are	O
frequent	O
after	O
combined	O
treatment	O
for	O
locally	O
advanced	O
rectal	O
cancer	O
.	O

There	O
was	O
a	O
clear	O
tendency	O
for	O
the	O
problems	O
to	O
be	O
more	O
common	O
after	O
CRT	O
than	O
after	O
RT	O
.	O

Improvement	O
of	O
pain	O
related	O
self	O
management	O
for	O
oncologic	O
patients	O
through	O
a	O
trans	O
institutional	O
modular	O
nursing	O
intervention	O
:	O
protocol	O
of	O
a	O
cluster	O
randomized	O
multicenter	O
trial	O
.	O

BACKGROUND	O
Pain	O
is	O
one	O
of	O
the	O
most	O
frequent	O
and	O
distressing	O
symptoms	O
in	O
cancer	O
patients	O
.	O

For	O
the	O
majority	O
of	O
the	O
patients	O
,	O
sufficient	O
pain	O
relief	O
can	O
be	O
obtained	O
if	O
adequate	O
treatment	O
is	O
provided	O
.	O

However	O
,	O
pain	O
remains	O
often	O
undertreated	O
due	O
to	O
institutional	O
,	O
health	O
care	O
professional	O
and	O
patient	O
related	O
barriers	O
.	O

Patients	O
self	O
management	O
skills	O
are	O
affected	O
by	O
the	O
patients	O
'	O
knowledge	O
,	O
activities	O
and	O
attitude	O
to	O
pain	O
management	O
.	O

This	O
trial	O
protocol	O
is	O
aimed	O
to	O
test	O
the	O
SCION-PAIN	O
program	O
,	O
a	O
multi	O
modular	O
structured	O
intervention	O
to	O
improve	O
self	O
management	O
in	O
cancer	O
patients	O
with	O
pain	O
.	O

METHODS	O
240	O
patients	O
with	O
diagnosed	O
malignancy	O
and	O
pain	O
>	O
3	O
days	O
and	O
average	O
pain	O
>	O
or=	O
3/10	O
will	O
participate	O
in	O
a	O
cluster	O
randomized	O
trial	O
on	O
18	O
wards	O
in	O
2	O
German	O
university	O
hospitals	O
.	O

Patients	O
from	O
the	O
intervention	O
wards	O
will	O
receive	O
,	O
additionally	O
to	O
standard	Control
pain	Control
treatment	Control
,	O
the	Physical
SCION-PAIN	Physical
program	Physical
consisting	Physical
of	Physical
3	Physical
modules	Physical
:	Physical
pharmacologic	Physical
pain	Physical
management	Physical
,	Physical
nonpharmacologic	Physical
pain	Physical
management	Physical
and	Physical
discharge	Physical
management	Physical
.	O

The	O
intervention	O
will	O
be	O
conducted	O
by	O
specially	O
trained	O
oncology	O
nurses	O
and	O
includes	O
components	O
of	O
patient	Educational
education	Educational
,	Educational
skills	Educational
training	Educational
and	Educational
counseling	Educational
to	Educational
improve	Educational
self	Educational
care	Educational
regarding	Educational
pain	Educational
management	Educational
beginning	Educational
with	Educational
admission	Educational
followed	Educational
by	Educational
booster	Educational
session	Educational
every	Educational
3rd	Educational
day	Educational
and	Educational
one	Educational
follow	Educational
up	Educational
telephone	Educational
counseling	Educational
within	Educational
2	Educational
to	Educational
3	Educational
days	Educational
after	Educational
discharge	Educational
.	O

Patients	O
in	O
the	O
control	O
group	O
will	O
receive	O
standard	O
care	O
.	O

Primary	O
endpoint	O
is	O
the	O
group	O
difference	O
in	O
patient	O
related	O
barriers	O
to	O
management	O
of	O
cancer	O
pain	O
(	O
BQII	O
)	O
,	O
7	O
days	O
after	O
discharge	O
.	O

Secondary	O
endpoints	O
are	O
:	O
pain	O
intensity	O
&	O
interference	O
,	O
adherence	O
,	O
coping	O
and	O
HRQoL	O
.	O

DISCUSSION	O
The	O
study	O
will	O
determine	O
if	O
the	O
acquired	O
self	O
management	O
skills	O
of	O
the	O
patients	O
continue	O
to	O
be	O
used	O
after	O
discharge	O
from	O
hospital	O
.	O

It	O
is	O
hypothesized	O
that	O
patients	O
who	O
receive	O
the	O
multi	O
modular	O
structured	O
intervention	O
will	O
have	O
less	O
patient	O
related	O
barriers	O
and	O
a	O
better	O
self	O
management	O
of	O
cancer	O
pain	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials	O
NCT00779597	O
.	O

Regression	O
of	O
left	O
ventricular	O
hypertrophy	O
after	O
stentless	Physical
versus	O
conventional	Surgical
aortic	Surgical
valve	Surgical
replacement	Surgical
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
analyze	O
regression	O
of	O
left	O
ventricular	O
hypertrophy	O
after	O
randomization	O
to	O
conventional	Surgical
biological	Surgical
versus	O
stentless	Surgical
aortic	Surgical
valve	Surgical
replacement	Surgical
.	O

Stentless	Physical
(	O
Freestyle	O
,	O
Toronto	O
,	O
n	O
=	O
106	O
)	O
or	O
conventional	Physical
biological	Physical
aortic	Physical
valves	Physical
(	O
Carpentier-Edwards	O
,	O
n	O
=	O
74	O
)	O
were	O
evaluated	O
prospectively	O
.	O

Preoperatively	O
there	O
were	O
no	O
differences	O
with	O
regard	O
to	O
aortic	O
valve	O
pathology	O
,	O
left	O
ventricular	O
function	O
,	O
and	O
pressure	O
gradients	O
between	O
the	O
two	O
patient	O
groups	O
.	O

The	O
patient	O
annulus	O
index	O
(	O
13.55	O
vs.	O
13.46	O
mm	O
;	O
NS	O
)	O
measured	O
intraoperatively	O
was	O
used	O
as	O
baseline	O
for	O
further	O
comparison	O
.	O

Postoperatively	O
,	O
left	O
ventricular	O
mass	O
index	O
was	O
213+/-77	O
g/m2	O
(	O
stentless	O
)	O
compared	O
with	O
202+/-72	O
(	O
conventional	O
group	O
)	O
g/m2	O
(	O
NS	O
)	O
,	O
whereas	O
after	O
6	O
months	O
it	O
was	O
141+/-41	O
g/m2	O
in	O
the	O
stentless	O
and	O
170+/-43	O
g/m2	O
in	O
the	O
conventional	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

Regression	O
of	O
left	O
ventricular	O
hypertrophy	O
occurs	O
in	O
all	O
patients	O
after	O
aortic	O
valve	O
replacement	O
.	O

Nevertheless	O
,	O
the	O
use	O
of	O
stentless	Physical
bioprostheses	Physical
leads	O
to	O
a	O
significant	O
enhancement	O
,	O
which	O
may	O
result	O
in	O
a	O
reduction	O
of	O
the	O
cardiac	O
risk	O
profile	O
for	O
the	O
patient	O
.	O

Gene	O
expression	O
is	O
altered	O
in	O
piglet	O
small	O
intestine	O
by	O
weaning	O
and	O
dietary	Pharmacological
glutamine	Pharmacological
supplementation	Pharmacological
.	Pharmacological

Dietary	Pharmacological
supplementation	Pharmacological
of	Pharmacological
glutamine	Pharmacological
prevents	O
intestinal	O
dysfunction	O
and	O
atrophy	O
in	O
weanling	O
piglets	O
,	O
but	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
largely	O
unknown	O
.	O

This	O
study	O
was	O
conducted	O
to	O
test	O
the	O
hypothesis	O
that	O
weaning	O
or	O
glutamine	O
may	O
modulate	O
expression	O
of	O
genes	O
that	O
are	O
crucial	O
for	O
intestinal	O
metabolism	O
and	O
function	O
.	O

In	O
Expt	O
.	O

1	O
,	O
we	O
obtained	O
small	O
intestine	O
from	O
28-d-old	O
pigs	O
weaned	O
at	O
21	O
d	O
of	O
age	O
and	O
from	O
age-matched	O
suckling	O
piglets	O
.	O

In	O
Expt	O
.	O

2	O
,	O
piglets	O
were	O
weaned	O
at	O
21	O
d	O
of	O
age	O
and	O
then	O
had	O
free	Pharmacological
access	Pharmacological
to	Pharmacological
diets	Pharmacological
supplemented	Pharmacological
with	Pharmacological
1	Pharmacological
%	Pharmacological
L-glutamine	Pharmacological
(	Pharmacological
wt	Pharmacological
:	Pharmacological
wt	Pharmacological
)	Pharmacological
or	Pharmacological
isonitrogenous	Pharmacological
L-alanine	Pharmacological
(	Pharmacological
control	Pharmacological
)	Pharmacological
.	Pharmacological

At	O
d	O
28	O
,	O
we	O
collected	O
small	O
intestine	O
for	O
biochemical	O
and	O
morphological	O
measurements	O
and	O
microarray	O
analysis	O
of	O
gene	O
expression	O
using	O
the	O
Operon	O
Porcine	O
Genome	O
Oligo	O
set	O
.	O

Early	O
weaning	O
resulted	O
in	O
increased	O
(	O
52-346	O
%	O
)	O
expression	O
of	O
genes	O
related	O
to	O
oxidative	O
stress	O
and	O
immune	O
activation	O
but	O
decreased	O
(	O
35-77	O
%	O
)	O
expression	O
of	O
genes	O
related	O
to	O
macronutrient	O
metabolism	O
and	O
cell	O
proliferation	O
in	O
the	O
gut	O
.	O

Dietary	Pharmacological
glutamine	Pharmacological
supplementation	Pharmacological
increased	O
intestinal	O
expression	O
(	O
120-124	O
%	O
)	O
of	O
genes	O
that	O
are	O
necessary	O
for	O
cell	O
growth	O
and	O
removal	O
of	O
oxidants	O
,	O
while	O
reducing	O
(	O
34-75	O
%	O
)	O
expression	O
of	O
genes	O
that	O
promote	O
oxidative	O
stress	O
and	O
immune	O
activation	O
.	O

Functionally	O
,	O
the	Pharmacological
glutamine	Pharmacological
treatment	Pharmacological
enhanced	O
intestinal	O
oxidative-defense	O
capacity	O
(	O
indicated	O
by	O
a	O
29	O
%	O
increase	O
in	O
glutathione	O
concentration	O
)	O
,	O
prevented	O
jejunal	O
atrophy	O
,	O
and	O
promoted	O
small	O
intestine	O
growth	O
(	O
+12	O
%	O
)	O
and	O
body	O
weight	O
gain	O
(	O
+19	O
%	O
)	O
in	O
weaned	O
piglets	O
.	O

These	O
findings	O
reveal	O
coordinate	O
alterations	O
of	O
gene	O
expression	O
in	O
response	O
to	O
weaning	O
and	O
aid	O
in	O
providing	O
molecular	O
mechanisms	O
for	O
the	O
beneficial	O
effect	O
of	O
dietary	O
glutamine	Pharmacological
supplementation	Pharmacological
to	O
improve	O
nutrition	O
status	O
in	O
young	O
mammals	O
.	O

Topical	O
administration	O
of	O
diclofenac	Pharmacological
(	O
1	O
%	O
)	O
in	O
the	O
prevention	O
of	O
miosis	O
during	O
vitrectomy	O
.	O

PURPOSE	O
A	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
was	O
conducted	O
to	O
assess	O
the	O
usefulness	O
of	O
preoperative	O
diclofenac	Pharmacological
eye	O
drops	O
in	O
maintaining	O
mydriasis	O
during	O
vitrectomy	O
and	O
in	O
reducing	O
postoperative	O
inflammation	O
.	O

METHODS	O
Fifty	O
consecutive	O
patients	O
undergoing	O
vitrectomy	O
were	O
randomly	O
assigned	O
to	O
diclofenac	Pharmacological
(	O
n	O
=	O
24	O
)	O
or	O
control	Control
(	O
n	O
=	O
26	O
)	O
groups	O
.	O

All	O
patients	O
received	O
a	O
standard	O
preoperative	O
regimen	O
of	O
cyclopentolate	Pharmacological
(	O
2	O
%	O
)	O
and	O
phenylephrine	Pharmacological
hydrochloride	Pharmacological
(	O
2.5	O
%	O
)	O
.	O

The	O
diclofenac	Pharmacological
group	O
also	O
received	O
diclofenac	Pharmacological
(	O
1	O
%	O
)	O
preoperatively	O
.	O

Pupillary	O
diameter	O
was	O
recorded	O
at	O
four	O
time	O
points	O
during	O
surgery	O
.	O

Inflammatory	O
indices	O
were	O
measured	O
postoperatively	O
using	O
slit-lamp	O
examination	O
.	O

RESULTS	O
After	O
induction	O
of	O
anesthesia	O
,	O
the	O
decrease	O
in	O
pupil	O
size	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
(	O
P	O
=	O
0.112	O
)	O
,	O
but	O
for	O
the	O
next	O
two	O
stages	O
,	O
it	O
was	O
significantly	O
less	O
in	O
the	O
diclofenac	Pharmacological
group	O
(	O
P	O
=	O
0.012	O
and	O
P	O
=	O
0.003	O
,	O
respectively	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
for	O
anterior	O
chamber	O
cells	O
and	O
redness	O
in	O
the	O
eye	O
postoperatively	O
(	O
P	O
=	O
0.609	O
and	O
P	O
=	O
0.123	O
,	O
respectively	O
)	O
.	O

However	O
,	O
anterior	O
chamber	O
flare	O
was	O
significantly	O
greater	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0.035	O
)	O
,	O
and	O
patients	O
felt	O
significantly	O
more	O
pain	O
in	O
this	O
group	O
(	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSIONS	O
Topical	O
administration	O
of	O
diclofenac	Pharmacological
was	O
effective	O
in	O
maintaining	O
mydriasis	O
during	O
vitrectomy	O
and	O
in	O
reducing	O
postoperative	O
pain	O
and	O
anterior	O
chamber	O
flare	O
as	O
determined	O
by	O
slit-lamp	O
evaluations	O
.	O

Palliative	Physical
brachytherapy	Physical
with	Surgical
or	Surgical
without	Surgical
primary	Surgical
stent	Surgical
placement	Surgical
in	O
patients	O
with	O
oesophageal	O
cancer	O
,	O
a	O
randomised	O
phase	O
III	O
trial	O
.	O

PURPOSE	O
To	O
investigate	O
whether	O
a	O
combination	Physical
of	Physical
self-expanding	Surgical
metal	Surgical
stent	Surgical
(	Surgical
SEMS	Surgical
)	Surgical
and	Physical
brachytherapy	Physical
provided	O
more	O
rapid	O
and	O
prolonged	O
effect	O
on	O
dysphagia	O
without	O
increased	O
pain	O
compared	O
to	O
brachytherapy	O
alone	O
in	O
patients	O
with	O
incurable	O
oesophageal	O
cancer	O
.	O

METHODS	O
41	O
Patients	O
were	O
randomised	O
to	O
SEMS	O
followed	O
by	O
brachytherapy	O
,	O
8	O
Gy?3	O
(	O
n=21	O
)	O
or	O
brachytherapy	O
alone	O
,	O
8	O
Gy?3	O
(	O
n=20	O
)	O
.	O

Change	O
in	O
dysphagia	O
and	O
pain	O
three	O
and	O
seven	O
weeks	O
after	O
randomisation	O
(	O
FU1	O
and	O
FU2	O
)	O
was	O
assessed	O
by	O
patient-reported	O
outcome	O
.	O

Dysphagia	O
,	O
other	O
symptoms	O
and	O
health-related	O
quality	O
of	O
life	O
were	O
assessed	O
every	O
four	O
weeks	O
thereafter	O
.	O

The	O
study	O
was	O
closed	O
before	O
the	O
estimated	O
patient-number	O
was	O
reached	O
due	O
to	O
slow	O
recruitment	O
.	O

RESULTS	O
Patients	O
receiving	O
SEMS	O
followed	O
by	O
brachytherapy	O
had	O
significantly	O
improved	O
dysphagia	O
at	O
FU1	O
compared	O
to	O
patients	O
receiving	O
brachytherapy	O
alone	O
(	O
n=35	O
)	O
.	O

Difference	O
in	O
pain	O
was	O
not	O
observed	O
.	O

At	O
FU2	O
,	O
patients	O
in	O
both	O
arms	O
(	O
n=21	O
)	O
had	O
less	O
dysphagia	O
.	O

Four	O
patients	O
in	O
the	O
combined	O
treatment	O
arm	O
experienced	O
manageable	O
complications	O
,	O
no	O
complications	O
occurred	O
after	O
brachytherapy	O
alone	O
.	O

CONCLUSION	O
For	O
the	O
relief	O
of	O
dysphagia	O
,	O
SEMS	O
followed	O
by	O
brachytherapy	O
is	O
preferable	O
and	O
safe	O
for	O
patients	O
in	O
need	O
of	O
immediate	O
alleviation	O
,	O
while	O
brachytherapy	O
with	O
or	O
without	O
preceding	O
SEMS	O
provides	O
relief	O
within	O
a	O
few	O
weeks	O
after	O
treatment	O
.	O

A	O
simplified	O
score	O
for	O
transfer	O
of	O
patients	O
requiring	O
mechanical	Physical
ventilation	Physical
to	O
a	O
long-term	O
care	O
hospital	O
.	O

BACKGROUND	O
Long-term	O
care	O
hospitals	O
are	O
Medicare	O
providers	O
of	O
postacute	O
care	O
that	O
have	O
a	O
mean	O
length	O
of	O
stay	O
of	O
25	O
days	O
or	O
more	O
.	O

Early	O
identification	O
and	O
timely	O
transfer	O
of	O
patients	O
requiring	O
mechanical	O
ventilation	O
to	O
such	O
hospitals	O
may	O
improve	O
the	O
efficiency	O
of	O
inpatient	O
care	O
.	O

OBJECTIVES	O
To	O
develop	O
a	O
predictive	Educational
model	Educational
and	O
a	O
simplified	O
score	O
for	O
use	O
on	O
day	O
7	O
of	O
hospitalization	O
to	O
assess	O
whether	O
a	O
patient	O
receiving	O
mechanical	Physical
ventilation	Physical
is	O
likely	O
to	O
require	O
an	O
additional	O
25	O
days	O
of	O
hospitalization	O
(	O
ie	O
,	O
would	O
qualify	O
for	O
transfer	O
to	O
a	O
long-term	O
care	O
hospital	O
)	O
.	O

METHODS	O
A	O
retrospective	O
,	O
cross-sectional	O
study	O
using	O
hospital	O
discharge	O
and	O
billing	O
data	O
from	O
the	O
2005	O
Nationwide	O
Inpatient	O
Sample	O
for	O
54	O
686	O
Medicare	O
beneficiaries	O
admitted	O
to	O
US	O
community	O
hospitals	O
who	O
met	O
the	O
study	O
's	O
eligibility	O
criteria	O
.	O

The	O
outcome	O
was	O
overall	O
length	O
of	O
stay	O
(	O
?32	O
vs	O
<	O
32	O
days	O
)	O
.	O

Split-sample	O
validation	O
was	O
used	O
.	O

Multivariable	O
survey-logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
assess	O
predictors	O
and	O
probability	O
of	O
the	O
outcome	O
.	O

A	O
simplified	O
score	O
was	O
derived	O
from	O
the	O
final	O
predictive	O
model	O
.	O

RESULTS	O
The	O
discriminatory	O
power	O
of	O
the	O
predictive	O
model	O
was	O
0.75	O
and	O
that	O
of	O
the	O
simplified	O
score	O
was	O
0.72	O
.	O

The	O
model	O
calibrated	O
well	O
.	O

All	O
predictors	O
were	O
significantly	O
(	O
P	O
<	O
.01	O
)	O
associated	O
with	O
a	O
hospitalization	O
of	O
32	O
days	O
or	O
longer	O
;	O
having	O
a	O
tracheostomy	O
was	O
the	O
strongest	O
predictor	O
(	O
odds	O
ratio	O
,	O
4.74	O
)	O
.	O

The	O
simplified	O
scores	O
ranged	O
from	O
-5	O
to	O
110	O
points	O
and	O
were	O
categorized	O
into	O
3	O
classes	O
of	O
risk	O
.	O

CONCLUSIONS	O
Efforts	O
to	O
aid	O
discharge	O
decision	O
making	O
and	O
optimize	O
hospital	O
resource	O
planning	O
could	O
take	O
advantage	O
of	O
our	O
predictive	O
model	O
and	O
the	O
simplified	O
scoring	O
tool	O
.	O

[	O
Dexmedetomidine	Pharmacological
use	O
for	O
postoperative	O
adrenergic	O
analgesia	O
and	O
sedation	O
in	O
abdominal	O
surgery	O
]	O
.	O

Comparative	O
study	O
of	O
postoperative	O
analgesia	O
and	O
sedation	O
with	O
trimeperidine	Pharmacological
and	O
dexmedetomidine	Pharmacological
and	O
their	O
effects	O
on	O
haemodynamics	O
and	O
vegetative	O
nervous	O
system	O
was	O
performed	O
.	O

Assessment	O
of	O
analgesia	O
and	O
sedation	O
during	O
vagotonia	O
(	O
first	O
part	O
of	O
the	O
study	O
)	O
and	O
hypokinetic	O
type	O
of	O
haemodynamics	O
(	O
second	O
part	O
of	O
the	O
study	O
)	O
was	O
carried	O
out	O
with	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
Richmond	O
scale	O
.	O

Results	O
of	O
the	O
study	O
showed	O
that	O
dexmedetomidine	Pharmacological
is	O
more	O
effective	O
and	O
safer	O
than	O
trimeperidine	Pharmacological
for	O
analgesia	O
and	O
sedation	O
in	O
patients	O
with	O
spontaneous	O
breathing	O
after	O
abdominal	O
surgery	O
.	O

Dexmedetomidine	Pharmacological
use	O
allows	O
keeping	O
optimal	O
type	O
of	O
haemodynamics	O
and	O
vegetative	O
nervous	O
system	O
parameters	O
on	O
first	O
day	O
of	O
postoperative	O
period	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
R-salbutamol	Pharmacological
for	O
topical	O
treatment	O
of	O
discoid	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
In	O
a	O
recent	O
open	O
pilot	O
trial	O
,	O
R-salbutamol	Pharmacological
sulphate	Pharmacological
,	O
a	O
well-known	O
molecule	O
with	O
anti-inflammatory	O
effects	O
,	O
was	O
tested	O
successfully	O
on	O
patients	O
with	O
therapy-resistant	O
discoid	O
lupus	O
erythematosus	O
(	O
DLE	O
)	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
R-salbutamol	Pharmacological
cream	Pharmacological
0.5	O
%	O
vs.	O
placebo	Control
on	O
DLE	O
lesions	O
in	O
a	O
multicentre	O
,	O
double-blinded	O
,	O
randomized	O
,	O
placebo-controlled	O
phase	O
II	O
trial	O
.	O

METHODS	O
Thirty-seven	O
patients	O
with	O
at	O
least	O
one	O
newly	O
developed	O
DLE	O
lesion	O
were	O
randomized	O
-	O
19	Pharmacological
to	Pharmacological
the	Pharmacological
R-salbutamol	Pharmacological
cream	Pharmacological
0.5	Pharmacological
%	Pharmacological
and	O
18	O
to	O
placebo	Control
-	O
and	O
treated	O
twice	O
daily	O
for	O
8	O
weeks	O
.	O

Efficacy	O
was	O
evaluated	O
through	O
scores	O
of	O
erythema	O
,	O
scaling/hypertrophy	O
and	O
induration	O
as	O
well	O
as	O
pain	O
and	O
itching	O
;	O
general	O
improvement	O
scored	O
by	O
the	O
investigator	O
and	O
global	O
improvement	O
scored	O
by	O
patients	O
'	O
assessment	O
were	O
also	O
evaluated	O
.	O

RESULTS	O
The	O
mean	O
area	O
under	O
the	O
curve	O
of	O
improvement	O
for	O
scaling/hypertrophy	O
,	O
pain	O
,	O
itching	O
and	O
global	O
patient	O
assessment	O
was	O
significantly	O
better	O
for	O
the	O
actively	O
treated	O
patients	O
as	O
compared	O
with	O
placebo	Control
(	O
scaling/hypertrophy	O
,	O
P	O
=	O
0.0262	O
;	O
pain	O
,	O
P	O
=	O
0.0238	O
;	O
itching	O
,	O
P	O
=	O
0.0135	O
;	O
global	O
patient	O
assessment	O
,	O
P	O
=	O
0.045	O
)	O
.	O

Moreover	O
,	O
the	O
percentage	O
of	O
patients	O
without	O
induration	O
was	O
significantly	O
higher	O
in	O
the	O
active	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0.013	O
)	O
,	O
and	O
a	O
statistically	O
significantly	O
greater	O
decrease	O
in	O
the	O
size	O
of	O
the	O
lesional	O
area	O
was	O
also	O
seen	O
in	O
the	O
overall	O
analysis	O
of	O
the	O
R-salbutamol-treated	O
patients	O
(	O
P	O
=	O
0.0197	O
)	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
reported	O
.	O

CONCLUSIONS	O
Application	O
of	O
R-salbutamol	O
cream	O
0.5	O
%	O
was	O
safe	O
and	O
well	O
tolerated	O
.	O

Statistically	O
significant	O
effects	O
were	O
seen	O
on	O
scaling/hypertrophy	O
,	O
induration	O
,	O
pain	O
and	O
itching	O
as	O
well	O
as	O
patient	O
global	O
assessment	O
,	O
suggesting	O
that	O
R-salbutamol	O
could	O
be	O
a	O
promising	O
new	O
topical	O
therapy	O
alternative	O
for	O
DLE	O
.	O

Double-blind	O
placebo-controlled	Control
trial	O
of	O
aprindine	Pharmacological
and	O
digoxin	Pharmacological
for	O
the	O
prevention	O
of	O
symptomatic	O
atrial	O
fibrillation	O
.	O

A	O
multicenter	O
,	O
placebo-controlled	Control
,	O
randomized	O
,	O
double-blind	O
trial	O
compared	O
the	O
preventive	O
effect	O
of	O
aprindine	Pharmacological
and	O
digoxin	Pharmacological
on	O
the	O
recurrence	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
with	O
placebo	Control
,	O
and	O
also	O
compare	O
the	O
effectiveness	O
of	O
these	O
2	O
drugs	O
in	O
the	O
prevention	O
of	O
AF	O
.	O

Patients	O
with	O
symptomatic	O
paroxysmal	O
or	O
persistent	O
AF	O
who	O
had	O
converted	O
to	O
sinus	O
rhythm	O
(	O
SR	O
)	O
were	O
randomly	O
assigned	O
aprindine	Pharmacological
(	O
40	O
mg/day	O
)	O
,	O
digoxin	Pharmacological
(	O
0.25	O
mg/day	O
)	O
or	O
placebo	Pharmacological
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
every	O
2	O
weeks	O
for	O
6	O
months	O
.	O

Of	O
the	O
141	O
patients	O
from	O
36	O
participating	O
centers	O
,	O
47	O
were	O
given	O
aprindine	Pharmacological
,	O
47	O
digoxin	Pharmacological
,	O
and	O
47	O
were	O
on	O
placebo	Control
.	O

After	O
the	O
6-month	O
follow-up	O
,	O
the	O
Kaplan-Meier	O
estimates	O
of	O
the	O
percentage	O
of	O
patients	O
remaining	O
free	O
of	O
recurrent	O
symptomatic	O
AF	O
on	O
aprindine	Pharmacological
,	O
digoxin	Pharmacological
and	O
placebo	Control
were	O
33.3	O
%	O
,	O
29.2	O
%	O
and	O
21.5	O
%	O
,	O
respectively	O
.	O

In	O
patients	O
remaining	O
in	O
SR	O
for	O
15	O
days	O
after	O
from	O
the	O
start	O
of	O
follow-up	O
,	O
freedom	O
from	O
recurrence	O
was	O
significantly	O
more	O
prevalent	O
in	O
the	O
aprindine	O
group	O
than	O
in	O
the	O
placebo	Control
group	O
(	O
p=0.0414	O
)	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
digoxin	O
and	O
placebo	O
groups	O
.	O

The	O
rate	O
of	O
adverse	O
events	O
was	O
similar	O
in	O
the	O
3	O
groups	O
.	O

In	O
conclusion	O
,	O
neither	O
aprindine	O
nor	O
digoxin	Pharmacological
had	O
a	O
significant	O
effect	O
on	O
preventing	O
relapse	O
of	O
symptomatic	O
AF	O
;	O
however	O
,	O
recurrence	O
of	O
AF	O
occurred	O
later	O
with	O
aprindine	Pharmacological
than	O
with	O
placebo	Control
or	O
digoxin	Pharmacological
.	O

[	O
A	O
randomized	O
trial	O
of	O
PVB	Pharmacological
,	Pharmacological
VAB-6	Pharmacological
,	Pharmacological
BVP	Pharmacological
regimen	Pharmacological
versus	Pharmacological
PEB	Pharmacological
chemotherapy	Pharmacological
in	O
patients	O
with	O
disseminated	O
testicular	O
tumors	O
]	O
.	O

During	O
2	O
years	O
and	O
7	O
months	O
from	O
June	O
,	O
1985	O
to	O
December	O
,	O
1987	O
,	O
a	O
randomized	O
multi-center	O
trial	O
of	O
PVB	Pharmacological
,	Pharmacological
VAB-6	Pharmacological
,	Pharmacological
BVP	Pharmacological
regimen	Pharmacological
(	O
group	O
A	O
)	O
without	O
etoposide	Pharmacological
versus	O
PEB	Pharmacological
chemotherapy	Pharmacological
(	Pharmacological
bleomycin	Pharmacological
,	Pharmacological
etoposide	Pharmacological
and	Pharmacological
cisplatinum	Pharmacological
)	Pharmacological
(	O
group	O
B	O
)	O
was	O
given	O
to	O
patients	O
with	O
disseminated	O
testicular	O
tumors	O
.	O

Of	O
34	O
patients	O
registered	O
,	O
10	O
patients	O
were	O
with	O
minimal	O
disease	O
in	O
stages	O
IIA	O
,	O
IIIO	O
and	O
IIIA	O
and	O
24	O
with	O
extensive	O
disease	O
in	O
IIB	O
,	O
IIIB2	O
and	O
IIIC	O
.	O

Seminomas	O
were	O
found	O
in	O
10	O
patients	O
,	O
while	O
non-seminomatous	O
tumors	O
in	O
24	O
.	O

Among	O
groups	O
A	O
and	O
B	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
in	O
clinicopathological	O
profiles	O
.	O

A	O
group	O
patients	O
were	O
given	O
either	O
PVB	O
,	O
VAB-6	O
or	O
BVP	O
according	O
to	O
the	O
physician	O
's	O
discretion	O
.	O

In	O
groups	O
A	O
and	O
B	O
,	O
35	O
%	O
and	O
43	O
%	O
of	O
the	O
patients	O
achieved	O
complete	O
response	O
,	O
and	O
45	O
%	O
and	O
50	O
%	O
achieved	O
partial	O
response	O
,	O
respectively	O
.	O

The	O
difference	O
in	O
CR	O
rates	O
among	O
both	O
groups	O
was	O
not	O
statistically	O
significant	O
even	O
when	O
calculated	O
according	O
to	O
the	O
stage	O
or	O
histologic	O
grouping	O
.	O

Salvage	O
treatments	O
mainly	O
with	O
surgical	O
resection	O
of	O
residual	O
tumors	O
after	O
the	O
chemotherapy	O
,	O
however	O
,	O
were	O
more	O
successful	O
in	O
group	O
B	O
(	O
88	O
%	O
)	O
than	O
group	O
A	O
(	O
61	O
%	O
)	O
.	O

It	O
appears	O
likely	O
that	O
the	O
higher	O
response	O
of	O
induction	O
chemotherapy	Pharmacological
in	O
patients	O
with	O
extensive	O
disease	O
made	O
the	O
salvage	O
surgery	Surgical
more	O
successful	O
in	O
group	O
B	O
than	O
in	O
group	O
A	O
.	O

The	O
3	O
year	O
survival	O
rate	O
was	O
100	O
%	O
in	O
group	O
B	O
,	O
whereas	O
it	O
was	O
76	O
%	O
in	O
group	O
A	O
.	O

Although	O
the	O
incidence	O
of	O
myelosuppression	O
and	O
alopecia	O
was	O
significantly	O
higher	O
in	O
group	O
B	O
,	O
neuropathy	O
was	O
significantly	O
more	O
frequent	O
in	O
group	O
A	O
.	O

From	O
the	O
above	O
results	O
,	O
PEB	O
seems	O
to	O
be	O
a	O
better	O
induction	O
chemotherapy	O
than	O
the	O
conventional	O
one	O
for	O
advanced	O
testicular	O
tumors	O
.	O

Effect	O
of	O
acebutolol	Pharmacological
on	O
left	O
ventricular	O
performance	O
.	O

The	O
effect	O
of	O
acebutolol	Pharmacological
on	O
left	O
ventricular	O
performance	O
was	O
examined	O
by	O
various	O
noninvasive	O
means	O
in	O
three	O
studies	O
.	O

M-mode	O
echocardiographic	O
measurements	O
were	O
made	O
in	O
21	O
patients	O
with	O
coronary	O
artery	O
disease	O
who	O
were	O
receiving	O
placebo	Control
,	O
acebutolol	Pharmacological
,	O
and	O
propranolol	Pharmacological
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

In	O
these	O
patients	O
with	O
normal	O
or	O
near-normal	O
resting	O
left	O
ventricular	O
function	O
,	O
neither	O
drug	O
induced	O
depression	O
of	O
left	O
ventricular	O
function	O
.	O

In	O
26	O
patients	O
with	O
chronic	O
angina	O
pectoris	O
receiving	O
acebutolol	Pharmacological
under	O
double-blind	O
,	O
placebo-controlled	Control
conditions	O
,	O
gated	O
(	O
equilibrium	O
)	O
myocardial	O
blood	O
pool	O
imaging	O
using	O
red	O
blood	O
cells	O
labeled	O
with	O
technetium	O
99m	O
showed	O
acebutolol	Pharmacological
to	O
have	O
no	O
clinically	O
significant	O
negative	O
effect	O
on	O
left	O
ventricular	O
performance	O
at	O
rest	O
or	O
during	O
supine	O
bicycle	O
exercise	O
.	O

Acebutolol	Pharmacological
at	O
effective	O
antianginal	O
doses	O
modestly	O
improved	O
resting	O
global	O
and	O
regional	O
myocardial	O
function	O
.	O

In	O
13	O
patients	O
with	O
stable	O
angina	O
pectoris	O
,	O
single-pass	O
studies	O
of	O
left	O
ventricular	O
function	O
with	O
indium	O
113	O
under	O
double-blind	O
,	O
placebo-controlled	O
conditions	O
similarly	O
showed	O
acebutolol	Pharmacological
to	O
have	O
no	O
clinically	O
significant	O
negative	O
inotropic	O
effects	O
.	O

In	O
conclusion	O
,	O
acebutolol	Pharmacological
is	O
safe	O
for	O
use	O
in	O
patients	O
with	O
coronary	O
disease	O
and	O
a	O
wide	O
range	O
of	O
ejection	O
fractions	O
but	O
,	O
as	O
with	O
all	O
beta	O
blockers	O
,	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
markedly	O
reduced	O
resting	O
left	O
ventricular	O
function	O
.	O

[	O
Dose-effect	O
relationship	O
of	O
isosorbide	Pharmacological
dinitrate	Pharmacological
in	O
the	O
treatment	O
of	O
angina	O
pectoris	O
(	O
author	O
's	O
transl	O
)	O
]	O
.	O

Fifteen	O
males	O
with	O
angiographic	O
evidence	O
of	O
coronary	O
heart	O
disease	O
and	O
stable	O
,	O
exercise-induced	O
angina	O
pectoris	O
were	O
given	O
placebo	Control
or	O
isosorbide	Pharmacological
dinitrate	Pharmacological
(	Pharmacological
ISDN	Pharmacological
)	Pharmacological
in	O
a	O
dialy	O
dose	O
of	O
30	O
mg	O
,	O
120	O
mg	O
,	O
240	O
mg	O
and	O
480	O
mg	O
in	O
a	O
randomized	O
single-blind	O
trial	O
.	O

The	O
daily	O
doses	O
were	O
given	O
as	O
a	O
single	O
oral	O
dose	O
of	O
5	O
mg	O
,	O
20	O
mg	O
,	O
40	O
mg	O
and	O
80	O
mg	O
tablets	O
.	O

Each	O
dose	O
and	O
placebo	O
was	O
given	O
for	O
seven	O
days	O
.	O

On	O
the	O
seventh	O
day	O
an	O
exercise	O
ECG	O
of	O
standardized	O
level	O
and	O
duration	O
of	O
exercise	O
was	O
recorded	O
.	O

The	O
ischaemia	O
response	O
in	O
the	O
ECG	O
revealed	O
a	O
dose-dependent	O
reduction	O
by	O
28	O
%	O
(	O
5	O
mg	O
ISDN	O
)	O
,	O
43	O
%	O
(	O
20	O
mg	O
)	O
,	O
60	O
%	O
(	O
40	O
mg	O
)	O
and	O
73	O
%	O
(	O
80	O
mg	O
)	O
.	O

The	O
number	O
of	O
anginal	O
attacks	O
similarly	O
fell	O
parallel	O
to	O
dose	O
.	O

Plasma	O
level	O
of	O
ISDN	O
and	O
the	O
mononitrates	O
,	O
measured	O
one	O
and	O
four	O
hours	O
after	O
drug	O
intake	O
,	O
rose	O
almost	O
linearly	O
in	O
relation	O
to	O
dose	O
.	O

Oral	O
ISDN	O
thus	O
has	O
a	O
dose-dependent	O
effect	O
on	O
the	O
frequency	O
of	O
angina	O
and	O
ischaemia	O
parameters	O
during	O
ergometric	O
exercise	O
.	O

The	O
protracted	O
anti-anginal	O
effect	O
of	O
ISDN	O
is	O
largely	O
due	O
to	O
its	O
metabolites	O
.	O

At	O
high	O
doses	O
there	O
is	O
presumably	O
an	O
added	O
effect	O
of	O
the	O
high	O
blood	O
level	O
of	O
the	O
basic	O
substance.U	O
Thoracoscopic	Pharmacological
talc	Pharmacological
insufflation	Pharmacological
versus	O
talc	Pharmacological
slurry	Pharmacological
for	O
symptomatic	O
malignant	O
pleural	O
effusion	O
.	O

BACKGROUND	O
Talc	O
has	O
been	O
generally	O
accepted	O
to	O
be	O
the	O
most	O
effective	O
sclerosant	O
for	O
chemical	O
pleurodesis	O
,	O
although	O
the	O
optimal	O
route	O
of	O
administration	O
remains	O
unclear	O
.	O

METHODS	O
We	O
designed	O
a	O
prospective	O
,	O
randomized	O
study	O
to	O
compare	O
video-assisted	Pharmacological
thoracoscopic	Pharmacological
talc	Pharmacological
insufflation	Pharmacological
with	O
bedside	Pharmacological
talc	Pharmacological
slurry	Pharmacological
in	O
the	O
treatment	O
of	O
malignant	O
pleural	O
effusion	O
.	O

From	O
September	O
1993	O
to	O
November	O
1995	O
,	O
57	O
patients	O
were	O
recruited	O
and	O
randomized	O
to	O
either	O
video-assisted	Pharmacological
thoracoscopic	Pharmacological
talc	Pharmacological
insufflation	Pharmacological
under	O
general	Pharmacological
anesthesia	Pharmacological
(	O
n	O
=	O
28	O
)	O
or	O
talc	O
slurry	O
by	O
the	O
bedside	O
(	O
n	O
=	O
29	O
)	O
.	O

Patients	O
with	O
poor	O
general	O
condition	O
(	O
Karnofsky	O
score	O
less	O
than	O
30	O
%	O
)	O
,	O
poor	O
pulmonary	O
function	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
less	O
than	O
0.5	O
L	O
)	O
,	O
or	O
trapped	O
lungs	O
were	O
excluded	O
from	O
this	O
study	O
.	O

Five	O
grams	O
of	O
purified	O
talc	O
was	O
used	O
for	O
either	O
video-assisted	O
thoracoscopic	O
talc	O
insufflation	O
or	O
talc	O
slurry	O
.	O

RESULTS	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
of	O
patients	O
with	O
respect	O
to	O
age	O
,	O
sex	O
ratio	O
,	O
chest	O
drainage	O
duration	O
,	O
postprocedural	O
hospital	O
stay	O
,	O
parenteral	O
narcotics	O
requirement	O
,	O
complications	O
,	O
or	O
procedure	O
failure	O
(	O
ie	O
,	O
recurrence	O
)	O
.	O

CONCLUSIONS	O
Video-assisted	O
thoracoscopic	O
talc	O
insufflation	O
has	O
not	O
been	O
shown	O
to	O
be	O
a	O
superior	O
approach	O
compared	O
with	O
talc	O
slurry	O
in	O
our	O
study	O
.	O

Because	O
the	O
former	O
demands	O
more	O
resources	O
,	O
we	O
advocate	O
that	O
talc	O
slurry	O
should	O
be	O
considered	O
as	O
the	O
procedure	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
symptomatic	O
malignant	O
pleural	O
effusion	O
in	O
patients	O
who	O
do	O
not	O
have	O
trapped	O
lungs	O
.	O

The	O
influence	O
of	O
serum	Pharmacological
methotrexate	Pharmacological
concentrations	O
and	O
drug	O
dosage	O
on	O
outcome	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
.	O

Sequential	O
methotrexate	Pharmacological
(	O
Mtx	O
)	O
absorption	O
studies	O
were	O
undertaken	O
in	O
127	O
children	O
undergoing	O
treatment	O
for	O
childhood	O
non-T	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
ALL	O
)	O
to	O
determine	O
whether	O
serum	O
drug	O
concentration	O
,	O
clearance	O
and	O
dosage	O
affect	O
event	O
free	O
survival	O
(	O
EFS	O
)	O
.	O

Higher	O
serum	O
concentration	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
curve	O
(	O
AUC	O
)	O
were	O
not	O
associated	O
with	O
an	O
improved	O
EFS	O
.	O

Methotrexate	Pharmacological
clearance	O
was	O
not	O
found	O
to	O
be	O
of	O
prognostic	O
significance	O
.	O

Patients	O
who	O
tolerated	O
only	O
low	O
6-mercaptopurine	Pharmacological
(	Pharmacological
6-MP	Pharmacological
)	Pharmacological
doses	O
because	O
of	O
neutropaenia	O
and	O
those	O
who	O
randomly	O
were	O
prescribed	O
higher	O
doses	O
of	O
Mtx	O
had	O
a	O
lower	O
rate	O
of	O
leukaemia	O
relapse	O
after	O
the	O
completion	O
of	O
therapy	O
.	O

This	O
suggests	O
that	O
the	O
use	O
of	O
maintenance	O
therapy	O
in	O
maximally	O
tolerated	O
doses	O
may	O
be	O
associated	O
with	O
an	O
increased	O
survival	O
in	O
childhood	O
ALL	O
.	O

[	Pharmacological
Mitomycin	Pharmacological
C	Pharmacological
plus	Pharmacological
HCFU	Pharmacological
adjuvant	O
chemotherapy	O
for	O
noncuratively	O
resected	O
cases	O
of	O
colorectal	O
carcinoma	O
.	O

(	O
Second	O
report	O
)	O
:	O
5-year	O
survival	O
rate	O
.	O

Cooperative	O
Study	O
Group	O
of	O
Kyushu	O
and	O
Chugoku	O
for	O
HCFU	O
Adjuvant	O
Chemotherapy	O
]	O
.	O

In	O
order	O
to	O
examine	O
the	O
efficacy	O
of	O
adjuvant	Pharmacological
chemotherapy	Pharmacological
employing	O
mitomycin	Pharmacological
C	Pharmacological
(	Pharmacological
MMC	Pharmacological
)	Pharmacological
and	O
carmofur	Pharmacological
(	Pharmacological
HCFU	Pharmacological
)	Pharmacological
for	O
patients	O
with	O
noncuratively	O
resected	O
colorectal	O
carcinoma	O
,	O
a	O
cooperative	O
study	O
was	O
performed	O
by	O
54	O
institutions	O
in	O
the	O
Kyushu	O
and	O
Chugoku	O
areas	O
of	O
Japan	O
.	O

The	O
criteria	O
for	O
patient	O
selection	O
were	O
as	O
follows	O
:	O
1	O
)	O
Age	O
of	O
75	O
years	O
or	O
less	O
and	O
not	O
accompanied	O
by	O
any	O
serious	O
disease	O
.	O

2	O
)	O
Macroscopic	O
diagnosis	O
as	O
being	O
noncuratively	O
resected	O
on	O
completion	O
of	O
the	O
surgical	O
procedure	O
.	O

3	O
)	O
Definitive	O
diagnosis	O
of	O
colorectal	O
carcinomas	O
,	O
histologically	O
.	O

4	O
)	O
No	O
synchronous	O
or	O
metachronous	O
double	O
cancer	O
.	O

The	O
prospective	O
randomized	O
controlled	O
study	O
consisted	O
of	O
two	O
groups	O
.	O

In	O
Group	O
A	O
,	O
the	O
MMC	Pharmacological
group	O
received	O
bolus	O
intravenous	O
injections	O
of	O
20	O
mg	O
MMC	Pharmacological
on	O
the	O
day	O
of	O
operation	O
and	O
10	O
mg	O
the	O
next	O
day	O
,	O
followed	O
by	O
10	O
mg	O
every	O
4	O
weeks	O
until	O
a	O
total	O
of	O
100	O
mg	O
had	O
been	O
administered	O
.	O

In	O
Group	O
B	O
,	O
the	O
MMC	Pharmacological
+	Pharmacological
HCFU	Pharmacological
group	Pharmacological
received	O
the	O
same	O
treatment	O
in	O
Group	O
A	O
,	O
but	O
with	O
the	O
addition	O
of	O
600	O
mg/day	O
of	O
HCFU	Pharmacological
from	O
the	O
second	O
week	O
,	O
orally	O
for	O
at	O
least	O
one	O
year	O
.	O

Concerning	O
the	O
69-month	O
survival	O
rate	O
,	O
a	O
better	O
result	O
was	O
observed	O
in	O
the	O
MMC	Pharmacological
+	Pharmacological
HCFU	Pharmacological
group	O
than	O
in	O
the	O
MMC	Pharmacological
only	Pharmacological
group	O
(	O
generalized	O
Wilcoxon	O
test	O
:	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Significantly	O
better	O
survival	O
rates	O
were	O
obtained	O
in	O
those	O
cases	O
with	O
disseminating	O
peritoneal	O
metastasis	O
,	O
hepatic	O
metastasis	O
and	O
stage	O
V	O
cancer	O
in	O
the	O
MMC	Pharmacological
+	Pharmacological
HCFU	Pharmacological
group	O
as	O
when	O
compared	O
with	O
the	O
MMC	Pharmacological
only	O
group	O
.	O

No	O
significant	O
side	O
effects	O
due	O
to	O
the	O
combined	O
administration	O
of	O
HCFU	Pharmacological
were	O
recognized	O
.	O

The	O
combined	O
administration	O
of	O
MMC	Pharmacological
and	O
HCFU	Pharmacological
was	O
suggested	O
to	O
be	O
a	O
safe	O
and	O
effective	O
adjuvant	O
chemotherapy	O
for	O
noncuratively	O
resected	O
cases	O
of	O
colorectal	O
carcinoma	O
.	O

The	O
response	O
of	O
neuropathic	O
pain	O
and	O
pain	O
in	O
complex	O
regional	O
pain	O
syndrome	O
I	O
to	O
carbamazepine	Pharmacological
and	O
sustained-release	Pharmacological
morphine	Pharmacological
in	O
patients	O
pretreated	O
with	O
spinal	Pharmacological
cord	Pharmacological
stimulation	Pharmacological
:	Pharmacological
a	O
double-blinded	O
randomized	O
study	O
.	O

Forty-three	O
patients	O
with	O
peripheral	O
neuropathic	O
pain	O
,	O
exclusively	O
pain	O
reduced	O
by	O
spinal	O
cord	O
stimulation	O
(	O
SCS	O
)	O
,	O
were	O
switched	O
into	O
a	O
painful	O
state	O
after	O
SCS	Pharmacological
inactivation	O
.	O

This	O
mode	O
was	O
used	O
to	O
assess	O
the	O
pain-relieving	O
effect	O
of	O
carbamazepine	Pharmacological
(	Pharmacological
CMZ	Pharmacological
)	Pharmacological
and	O
opioids	Pharmacological
in	O
a	O
double-blinded	O
,	O
placebo-controlled	Control
trial	O
.	O

In	O
Phase	O
1	O
,	O
the	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
CMZ	Pharmacological
(	Pharmacological
600	Pharmacological
mg/d	Pharmacological
)	Pharmacological
or	O
placebo	Control
during	O
an	O
SCS-free	O
period	O
of	O
8	O
days	O
.	O

In	O
Phase	O
2	O
,	O
after	O
a	O
CMZ	Pharmacological
elimination	O
interval	O
of	O
7	O
days	O
,	O
38	O
patients	O
received	O
either	O
sustained-release	Pharmacological
morphine	Pharmacological
(	Pharmacological
90	Pharmacological
mg/d	Pharmacological
)	Pharmacological
or	O
placebo	Control
for	O
8	O
days	O
.	O

In	O
cases	O
of	O
intolerable	O
pain	O
,	O
the	O
patients	O
were	O
authorized	O
to	O
reactivate	O
their	O
SCS	Pharmacological
.	Pharmacological

The	O
pain	O
intensity	O
was	O
rated	O
on	O
a	O
numeric	O
analog	O
scale	O
.	O

In	O
38	O
patients	O
who	O
completed	O
Phase	O
1	O
,	O
significant	O
delay	O
in	O
pain	O
increase	O
was	O
observed	O
in	O
the	O
CMZ	O
group	O
as	O
compared	O
with	O
placebo	O
(	O
P	O
=	O
0.038	O
)	O
.	O

In	O
Phase	O
2	O
,	O
the	O
trend	O
observed	O
with	O
morphine	Pharmacological
was	O
insignificant	O
(	O
P	O
=	O
0.41	O
)	O
.	O

Two	O
CMZ	O
patients	O
and	O
one	O
morphine	O
patient	O
showed	O
complete	O
pain	O
relief	O
and	O
preferred	O
to	O
continue	O
the	O
medication	O
.	O

Thirty-five	O
patients	O
returned	O
to	O
SCS	O
.	O

We	O
conclude	O
that	O
CMZ	Pharmacological
is	O
effective	O
in	O
peripheral	O
neuropathic	O
pain	O
.	O

Morphine	O
obviously	O
requires	O
larger	O
individually	O
titrated	O
dosages	O
than	O
those	O
used	O
in	O
this	O
study	O
for	O
results	O
to	O
be	O
adequately	O
interpreted	O
.	O

Immunotherapy	Pharmacological
maintenance	O
in	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O

Between	O
January	O
1975	O
and	O
December	O
1977	O
,	O
264	O
adult	O
patients	O
with	O
acute	O
non-lymphocytic	O
leukaemia	O
entered	O
the	O
Australian	O
National	O
Leukaemia	O
Trial	O
.	O

Of	O
251	O
evaluable	O
patients	O
,	O
three	O
induction	O
regimens	O
achieved	O
similar	O
complete	O
response	O
(	O
CR	O
)	O
rates	O
.	O

CROP	Pharmacological
(	Pharmacological
cytosine	Pharmacological
arabinoside	Pharmacological
,	Pharmacological
daunorubicin	Pharmacological
,	Pharmacological
vincristine	Pharmacological
,	Pharmacological
prednisolone	Pharmacological
)	Pharmacological
produced	O
CR	O
in	O
41	O
%	O
of	O
patients	O
,	O
7	O
and	O
3	O
(	Pharmacological
cytosine	Pharmacological
arabinoside	Pharmacological
,	Pharmacological
daunorubicin	Pharmacological
)	Pharmacological
in	O
42	O
%	O
and	O
7	O
and	O
3	O
plus	Pharmacological
hydroxyurea	Pharmacological
in	O
52	O
%	O
.	O

Remission	O
duration	O
and	O
survival	O
were	O
similar	O
when	O
induction	O
regimens	O
were	O
compared	O
.	O

Forty-five	O
patients	O
reaching	O
maintenance	Pharmacological
therapy	Pharmacological
were	O
randomised	O
to	O
either	O
chemo-immunotherapy	Pharmacological
(	O
BCG	Pharmacological
plus	O
intradermal	Pharmacological
leukaemic	Pharmacological
blast	Pharmacological
cells	Pharmacological
)	O
or	O
chemotherapy	Pharmacological
alone	O
.	O

The	O
duration	O
of	O
CR	O
in	O
these	O
two	O
groups	O
was	O
almost	O
identical	O
,	O
though	O
patients	O
receiving	O
chemotherapy	Pharmacological
alone	O
had	O
prolonged	O
survival	O
(	O
median	O
161	O
weeks	O
)	O
when	O
compared	O
to	O
the	O
chemo-immunotherapy	Pharmacological
group	O
(	O
84	O
weeks	O
,	O
p	O
=	O
0	O
.	O

07	O
)	O
.	O

Institutions	O
with	O
less	O
developed	O
supportive	O
facilities	O
reported	O
lower	O
CR	O
rates	O
(	O
p	O
=	O
0	O
.	O

04	O
)	O
.	O

Leucocytosis	O
(	O
greater	O
than	O
100	O
X	O
10	O
(	O
9	O
)	O
/1	O
)	O
and	O
older	O
age	O
(	O
greater	O
than	O
50	O
years	O
)	O
were	O
associated	O
with	O
shortened	O
survival	O
.	O

The	O
Trial	O
has	O
failed	O
to	O
show	O
any	O
advantage	O
for	O
this	O
form	O
of	O
immunotherapy	Pharmacological
.	O

Drug	O
preference	O
in	O
normal	O
volunteers	O
:	O
effects	O
of	O
age	O
and	O
time	O
of	O
day	O
.	O

These	O
experiments	O
assessed	O
the	O
influence	O
of	O
two	O
variables	O
,	O
age	O
of	O
subjects	O
and	O
time	O
of	O
drug	O
administration	O
,	O
on	O
the	O
reinforcing	O
properties	O
of	O
amphetamine	Pharmacological
and	O
of	O
diazepam	Pharmacological
in	O
normal	O
volunteers	O
.	O

Three	O
groups	O
of	O
subjects	O
were	O
tested	O
:	O
i	O
)	O
a	O
group	O
of	O
40-55-year-old	O
subjects	O
(	O
AGE	O
group	O
;	O
N	O
=	O
11	O
)	O
who	O
were	O
tested	O
in	O
the	O
morning	O
,	O
ii	O
)	O
a	O
group	O
of	O
21-35-year-old	O
subjects	O
(	O
CTL	O
group	O
;	O
N	O
=	O
12	O
)	O
who	O
were	O
also	O
tested	O
in	O
the	O
morning	O
,	O
and	O
iii	O
)	O
a	O
group	O
of	O
21-35-year-olds	O
who	O
were	O
tested	O
in	O
the	O
late	O
afternoon	O
(	O
AFT	O
group	O
;	O
N	O
=	O
13	O
)	O
.	O

All	O
subjects	O
participated	O
in	O
three	O
separate	O
experiments	O
comparing	O
one	O
drug	O
(	O
5	O
mg	O
d	Pharmacological
,	Pharmacological
l-amphetamine	Pharmacological
,	O
5	O
mg	O
diazepam	Pharmacological
or	O
10	O
mg	O
diazepam	Pharmacological
)	O
to	O
placebo	Control
.	O

Each	O
experiment	O
consisted	O
of	O
nine	O
sessions	O
:	O
On	O
the	O
first	O
four	O
sessions	O
subjects	O
sampled	O
two	O
color-coded	O
capsules	O
on	O
alternate	O
sessions	O
and	O
on	O
the	O
following	O
five	O
sessions	O
they	O
chose	O
and	O
ingested	O
the	O
capsule	O
they	O
preferred	O
.	O

Subjective	O
effects	O
of	O
the	O
drugs	O
were	O
monitored	O
using	O
the	O
Profile	O
of	O
Mood	O
States	O
(	O
POMS	O
)	O
and	O
a	O
shortened	O
version	O
of	O
the	O
Addiction	O
Research	O
Center	O
Inventory	O
(	O
ARCI	O
)	O
.	O

Subjects	O
in	O
all	O
three	O
groups	O
chose	O
5	O
mg	O
diazepam	Pharmacological
as	O
often	O
as	O
placebo	O
but	O
preferred	O
placebo	O
to	O
10	O
mg	O
diazepam	Pharmacological
.	O

In	O
contrast	O
,	O
they	O
chose	O
amphetamine	Pharmacological
either	O
as	O
often	O
as	O
or	O
more	O
often	O
than	O
placebo	O
.	O

The	O
subjective	O
effects	O
of	O
diazepam	Pharmacological
(	O
i.e	O
.	O

sedation	O
)	O
were	O
similar	O
across	O
all	O
three	O
groups	O
,	O
but	O
after	O
amphetamine	O
the	O
AGE	O
group	O
showed	O
greater	O
stimulant	O
effects	O
.	O

In	O
addition	O
,	O
the	O
AFT	O
group	O
showed	O
fewer	O
positive	O
mood	O
effects	O
after	O
amphetamine	O
than	O
the	O
CTL	O
group	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
[	O
Using	O
gaviscon	Pharmacological
preparation	Pharmacological
for	O
relief	O
of	O
esophageal	O
,	O
extraesophageal	O
syndromes	O
and	O
functional	O
dyspepsia	O
in	O
elderly	O
patients	O
with	O
GERD	O
]	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
clinical	O
efficacy	O
of	O
alginate	O
drug	O
Geviskon	Pharmacological
and	O
aluminum-magnesium	Pharmacological
antacids	Pharmacological
to	O
relieve	O
symptoms	O
of	O
esophageal	O
,	O
extraesophageal	O
syndrome	O
and	O
functional	O
dyspepsia	O
at	O
3	O
and	O
7	O
days	O
of	O
study	O
in	O
patients	O
with	O
GERD	O
elderly	O
.	O

MATERIALS	O
AND	O
METHODS	O
An	O
open	O
,	O
longitudinal	O
,	O
randomized	O
,	O
parallel-group	O
.	O

The	O
study	O
included	O
60	O
patients	O
with	O
A	O
degree	O
of	O
ERD	O
,	O
consistently	O
received	O
in-patient	O
treatment	O
in	O
the	O
Municipal	O
KGVV	O
,	O
mean	O
age	O
79.0	O
+/-	O
6.8	O
years	O
.	O

During	O
the	O
first	O
12	O
hours	O
of	O
hospital	O
stay	O
by	O
sealed	O
envelopes	O
them	O
randomly	O
divided	O
into	O
equal	O
groups	O
of	O
comparison	O
,	O
given	O
3	O
times	O
a	O
day	O
:	O
alginate	Pharmacological
product	Pharmacological
--	Pharmacological
Geviskon	Pharmacological
forte	Pharmacological
dose	Pharmacological
of	Pharmacological
10	Pharmacological
ml	Pharmacological
and	Pharmacological
aluminum-magnesium	Pharmacological
antacid	Pharmacological
drug	Pharmacological
at	Pharmacological
a	Pharmacological
dose	Pharmacological
of	Pharmacological
1	Pharmacological
sachet	Pharmacological
.	Pharmacological

Assess	O
the	O
frequency	O
and	O
severity	O
of	O
esophageal	O
symptoms	O
,	O
extraesophageal	O
syndrome	O
,	O
functional	O
dyspepsia	O
at	O
3	O
and	O
7	O
days	O
of	O
study	O
on	O
5-point	O
scale	O
Likert	O
.	O

The	O
degree	O
of	O
esophageal	O
mucosal	O
injury	O
was	O
determined	O
during	O
endoscopy	O
before	O
the	O
study	O
.	O

RESULTS	O
The	O
technique	O
of	O
alginate	O
compared	O
with	O
antacids	Pharmacological
provided	O
significantly	O
more	O
complete	O
and	O
earlier	O
effect	O
on	O
the	O
relief	O
of	O
heartburn	O
,	O
regurgitation	O
,	O
chronic	O
cough	O
,	O
sore	O
throat	O
,	O
and	O
EBS	O
.	O

Only	O
Geviskon	Pharmacological
influenced	O
the	O
symptoms	O
of	O
PPD	O
in	O
patients	O
with	O
GERD	O
.	O

CONCLUSION	O
The	O
clinical	O
features	O
Geviskon	O
the	O
frequency	O
and	O
timing	O
of	O
relief	O
of	O
symptoms	O
of	O
esophageal	O
,	O
extraesophageal	O
syndrome	O
,	O
functional	O
dyspepsia	O
with	O
GERD	O
in	O
the	O
older	O
age	O
groups	O
is	O
higher	O
than	O
that	O
of	O
antacids	O
.	O

Suspension	O
Geviskon	O
may	O
be	O
recommended	O
in	O
patients	O
with	O
middle	O
and	O
old	O
age	O
as	O
an	O
effective	O
and	O
safe	O
symptomatic	O
funds	O
in	O
the	O
first	O
days	O
of	O
exchange	O
rate	O
earlier	O
generations	O
of	O
PPI	O
therapy	O
,	O
as	O
well	O
as	O
monotherapy	O
--	O
to	O
maintain	O
remission	O
.	O

A	O
controlled	O
trial	O
of	O
trimethoprim-sulfamethoxazole	Pharmacological
or	O
aerosolized	Pharmacological
pentamidine	Pharmacological
for	O
secondary	O
prophylaxis	O
of	O
Pneumocystis	O
carinii	O
pneumonia	O
in	O
patients	O
with	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

AIDS	O
Clinical	O
Trials	O
Group	O
Protocol	O
021	O
.	O

BACKGROUND	O
Pneumocystis	O
carinii	O
pneumonia	O
(	O
PCP	O
)	O
continues	O
to	O
be	O
the	O
most	O
common	O
index	O
diagnosis	O
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
but	O
it	O
is	O
not	O
clear	O
which	O
of	O
several	O
available	O
agents	O
is	O
the	O
most	O
effective	O
in	O
preventing	O
a	O
recurrence	O
of	O
PCP	O
.	O

METHODS	O
We	O
conducted	O
a	O
comparative	O
,	O
open-label	O
trial	O
in	O
310	O
adults	O
with	O
AIDS	O
who	O
had	O
recently	O
recovered	O
from	O
an	O
initial	O
episode	O
of	O
PCP	O
and	O
had	O
no	O
treatment-limiting	O
toxic	O
effects	O
of	O
trimethoprim-sulfamethoxazole	Pharmacological
or	O
pentamidine	Pharmacological
.	O

All	O
the	O
patients	O
were	O
treated	O
with	O
zidovudine	Pharmacological
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
800	Pharmacological
mg	Pharmacological
of	Pharmacological
sulfamethoxazole	Pharmacological
and	Pharmacological
160	Pharmacological
mg	Pharmacological
of	Pharmacological
trimethoprim	Pharmacological
once	O
daily	O
or	O
300	Pharmacological
mg	Pharmacological
of	Pharmacological
aerosolized	Pharmacological
pentamidine	Pharmacological
administered	O
every	O
four	O
weeks	O
by	O
jet	Pharmacological
nebulizer	Pharmacological
.	O

The	O
participants	O
were	O
followed	O
for	O
a	O
median	O
of	O
17.4	O
months	O
.	O

RESULTS	O
In	O
the	O
trimethoprim-sulfamethoxazole	Pharmacological
group	O
(	O
n	O
=	O
154	O
)	O
there	O
were	O
14	O
recurrences	O
of	O
PCP	O
,	O
as	O
compared	O
with	O
36	O
recurrences	O
(	O
including	O
1	O
extrapulmonary	O
recurrence	O
)	O
in	O
the	O
aerosolized-pentamidine	O
group	O
(	O
n	O
=	O
156	O
)	O
.	O

The	O
estimated	O
recurrence	O
rates	O
at	O
18	O
months	O
were	O
11.4	O
percent	O
with	O
trimethoprim-sulfamethoxazole	Pharmacological
and	O
27.6	O
percent	O
with	O
pentamidine	Pharmacological
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
risk	O
of	O
a	O
recurrence	O
(	O
adjusted	O
for	O
initial	O
CD4	O
cell	O
count	O
)	O
was	O
3.25	O
times	O
higher	O
in	O
the	O
pentamidine	Pharmacological
group	O
(	O
P	O
<	O
0.001	O
,	O
95	O
percent	O
confidence	O
interval	O
,	O
1.72	O
to	O
6.16	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
survival	O
or	O
in	O
hematologic	O
or	O
hepatic	O
toxicity	O
.	O

Crossovers	O
from	O
trimethoprim-sulfamethoxazole	Pharmacological
to	O
aerosolized	O
pentamidine	Pharmacological
were	O
more	O
common	O
than	O
the	O
reverse	O
(	O
27	O
vs.	O
4	O
percent	O
)	O
,	O
partly	O
because	O
of	O
the	O
study	O
protocols	O
for	O
the	O
management	O
of	O
leukopenia	O
.	O

There	O
were	O
19	O
serious	O
bacterial	O
infections	O
in	O
the	O
trimethoprim-sulfamethoxazole	O
group	O
and	O
38	O
in	O
the	O
pentamidine	O
group	O
.	O

The	O
time	O
to	O
a	O
first	O
bacterial	O
infection	O
was	O
significantly	O
greater	O
for	O
those	O
assigned	O
to	O
trimethoprim-sulfamethoxazole	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
AIDS	O
who	O
are	O
receiving	O
zidovudine	Pharmacological
,	O
trimethoprim-sulfamethoxazole	Pharmacological
is	O
more	O
effective	O
than	O
aerosolized	Pharmacological
pentamidine	Pharmacological
in	O
conventional	O
doses	O
for	O
the	O
prevention	O
of	O
recurrent	O
pneumocystis	O
infection	O
.	O

Dynamic	O
surface	O
electromyographic	O
responses	O
in	O
chronic	O
low	O
back	O
pain	O
treated	O
by	O
traditional	Physical
bone	Physical
setting	Physical
and	Physical
conventional	Physical
physical	Physical
therapy	Physical
.	O

OBJECTIVE	O
This	O
study	O
compared	O
the	O
dynamic	O
surface	O
electromyographic	O
(	O
EMG	O
)	O
activities	O
of	O
back	O
muscles	O
and	O
pain	O
before	O
and	O
after	O
traditional	Physical
bone	Physical
setting	Physical
and	Physical
physical	Physical
therapy	Physical
.	O

METHODS	O
This	O
study	O
was	O
a	O
prospective	O
clinical	O
trial	O
that	O
compared	O
surface	O
EMG	O
dynamic	O
activities	O
after	O
traditional	Physical
bone	Physical
setting	Physical
and	Physical
physical	Physical
therapy	Physical
.	O

Sixty-one	O
patients	O
(	O
mean	O
age	O
,	O
41	O
years	O
)	O
with	O
nonspecific	O
low	O
back	O
pain	O
were	O
randomized	O
into	O
two	O
subgroups	O
by	O
treatment	O
.	O

The	O
patients	O
underwent	O
a	O
dynamic	Physical
EMG	Physical
evaluation	Physical
for	O
which	O
they	O
were	O
asked	O
to	O
stand	O
and	O
then	O
bend	O
forward	O
as	O
far	O
as	O
possible	O
,	O
stay	O
fully	O
flexed	O
,	O
and	O
return	O
to	O
standing	O
.	O

A	O
flexion-relaxation	O
ratio	O
was	O
calculated	O
by	O
comparing	O
maximal	O
EMG	O
activity	O
while	O
flexing	O
with	O
the	O
average	O
EMG	O
activity	O
in	O
full	O
flexion	O
.	O

Concentric	O
(	O
maximal	O
EMG	O
activity	O
during	O
extension	O
)	O
and	O
eccentric	O
(	O
maximal	O
EMG	O
activity	O
during	O
flexion	O
)	O
ratios	O
were	O
also	O
used	O
in	O
the	O
analyses	O
.	O

RESULTS	O
Disability	O
,	O
depression	O
,	O
and	O
visual	O
analog	O
scale	O
scores	O
decreased	O
significantly	O
after	O
both	O
treatments	O
.	O

The	O
concentric	O
ratio	O
increased	O
statistically	O
in	O
both	O
groups	O
after	O
the	O
treatments	O
.	O

The	O
study	O
failed	O
to	O
show	O
a	O
significant	O
association	O
between	O
experienced	O
back	O
pain	O
and	O
EMG	O
parameters	O
.	O

CONCLUSIONS	O
Both	O
treatments	O
seem	O
to	O
have	O
a	O
positive	O
influence	O
on	O
back	O
muscle	O
function	O
by	O
improving	O
muscle	O
symmetry	O
;	O
however	O
,	O
the	O
treatments	O
had	O
no	O
effect	O
on	O
the	O
flexion-relaxation	O
phenomenon	O
after	O
1	O
month	O
.	O

Active	Physical
back	Physical
exercise	Physical
at	Physical
home	Physical
together	O
with	O
rehabilitation	O
treatments	Control
might	O
be	O
effective	O
and	O
improve	O
function	O
for	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
.	O

The	O
efficacy	O
of	O
melatonin	Pharmacological
for	O
sleep	O
problems	O
in	O
children	O
with	O
autism	O
,	O
fragile	O
X	O
syndrome	O
,	O
or	O
autism	O
and	O
fragile	O
X	O
syndrome	O
.	O

STUDY	O
OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
melatonin	Pharmacological
on	O
sleep	O
problems	O
in	O
children	O
with	O
autistic	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
and	O
fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
.	O

METHODS	O
A	O
4-week	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
crossover	O
design	O
was	O
conducted	O
following	O
a	O
1-week	O
baseline	O
period	O
.	O

Either	O
melatonin	Pharmacological
,	O
3	O
mg	O
,	O
or	O
placebo	Control
was	O
given	O
to	O
participants	O
for	O
2	O
weeks	O
and	O
then	O
alternated	O
for	O
another	O
2	O
weeks	O
.	O

Sleep	O
variables	O
,	O
including	O
sleep	O
duration	O
,	O
sleep-onset	O
time	O
,	O
sleep-onset	O
latency	O
time	O
,	O
and	O
the	O
number	O
of	O
night	O
awakenings	O
,	O
were	O
recorded	O
using	O
an	O
Actiwatch	O
and	O
from	O
sleep	O
diaries	O
completed	O
by	O
parents	O
.	O

All	O
participants	O
had	O
been	O
thoroughly	O
assessed	O
for	O
ASD	O
and	O
also	O
had	O
DNA	O
testing	O
for	O
the	O
diagnosis	O
of	O
FXS	O
.	O

RESULTS	O
Data	O
were	O
successfully	O
obtained	O
from	O
the	O
12	O
of	O
18	O
subjects	O
who	O
completed	O
the	O
study	O
(	O
11	O
males	O
,	O
age	O
range	O
2	O
to	O
15.25	O
years	O
,	O
mean	O
5.47	O
,	O
SD	O
3.6	O
)	O
.	O

Five	O
participants	O
met	O
diagnostic	O
criteria	O
for	O
ASD	O
,	O
3	O
for	O
FXS	O
alone	O
,	O
3	O
for	O
FXS	O
and	O
ASD	O
,	O
and	O
1	O
for	O
fragile	O
X	O
premutation	O
.	O

Eight	O
out	O
of	O
12	O
had	O
melatonin	Pharmacological
first	O
.	O

The	O
conclusions	O
from	O
a	O
nonparametric	O
repeated-measures	O
technique	O
indicate	O
that	O
mean	O
night	O
sleep	O
duration	O
was	O
longer	O
on	O
melatonin	Pharmacological
than	O
placebo	Control
by	O
21	O
minutes	O
(	O
p	O
=	O
.02	O
)	O
,	O
mean	O
sleep-onset	O
latency	O
was	O
shorter	O
by	O
28	O
minutes	O
(	O
p	O
=	O
.0001	O
)	O
,	O
and	O
mean	O
sleep-onset	O
time	O
was	O
earlier	O
by	O
42	O
minutes	O
(	O
p	O
=	O
.02	O
)	O
.	O

CONCLUSION	O
The	O
results	O
of	O
this	O
study	O
support	O
the	O
efficacy	O
and	O
tolerability	O
of	O
melatonin	Pharmacological
treatment	O
for	O
sleep	O
problems	O
in	O
children	O
with	O
ASD	O
and	O
FXS	O
.	O

[	O
Protective	O
effect	O
of	O
ischemia	Physical
postconditioning	Physical
on	O
reperfusion	O
injury	O
in	O
patients	O
with	O
ST-segment	O
elevation	O
acute	O
myocardial	O
infarction	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
effect	O
of	O
ischemia	Physical
postconditioning	Physical
during	O
the	O
first	O
minutes	O
of	O
reperfusion	O
for	O
the	O
myocardial	O
reperfusion	O
injury	O
in	O
ST-segment	O
elevation	O
acute	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
patients	O
undergoing	O
emergency	Surgical
percutaneous	Surgical
coronary	Surgical
intervention	Surgical
(	Surgical
PCI	Surgical
)	Surgical
.	Surgical

METHODS	O
STEMI	O
patients	O
undergoing	O
emergency	Surgical
PCI	Surgical
in	O
affiliated	O
hospital	O
of	O
Beihua	O
University	O
between	O
October	O
2006	O
and	O
January	O
2009	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
the	O
control	O
group	O
(	O
n	O
=	O
34	O
)	O
without	Control
any	Control
intervention	Control
after	Control
PTCA	Control
,	O
and	O
the	O
postconditioning	O
group	O
(	O
n	O
=	O
30	O
)	O
with	Physical
ischemia	Physical
postconditioning	Physical
within	O
first	O
minutes	O
of	O
reflow	O
by	O
3	O
episodes	O
of	O
30-second	O
inflation	O
and	O
30-second	O
deflation	O
with	O
the	O
angioplasty	Surgical
balloon	Surgical
.	O

Reperfusion	O
arrhythmias	O
,	O
CK	O
and	O
CKMB	O
,	O
corrected	O
TIMI	O
frame	O
count	O
(	O
CTFC	O
)	O
,	O
wall	O
motion	O
score	O
index	O
(	O
WMSI	O
)	O
and	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
by	O
echocardiography	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

MI	O
areas	O
were	O
evaluated	O
with	O
the	O
ECG-54	O
criteria/32	O
system	O
and	O
myocardial	O
blush	O
grade	O
(	O
MBG	O
)	O
was	O
measured	O
.	O

RESULTS	O
The	O
incidence	O
of	O
reperfusion	O
arrhythmias-frequent	O
ventricular	O
premature	O
(	O
26.7	O
%	O
vs.	O
52.9	O
%	O
)	O
and	O
short	O
array	O
ventricular	O
tachycardia	O
beat	O
(	O
23.3	O
%	O
vs.	O
58.8	O
%	O
)	O
as	O
well	O
as	O
values	O
of	O
peaks	O
CK	O
[	O
(	O
1162	O
?	O
548	O
)	O
U/L	O
vs.	O
(	O
1732	O
?	O
480	O
)	O
U/L	O
,	O
P	O
<	O
0.01	O
]	O
,	O
CKMB	O
[	O
(	O
165	O
?	O
70	O
)	O
U/L	O
vs.	O
(	O
280	O
?	O
99	O
)	O
U/L	O
,	O
P	O
<	O
0.01	O
]	O
,	O
CTFC	O
(	O
22.23	O
?	O
3.81	O
vs.	O
26.97	O
?	O
3.42	O
)	O
,	O
WMSI	O
(	O
1.27	O
?	O
0.52	O
vs.	O
1.82	O
?	O
0.83	O
)	O
,	O
and	O
infarction	O
areas	O
determined	O
by	O
ECG	O
methods	O
(	O
10.60	O
%	O
?	O
4.97	O
%	O
vs.14.65	O
%	O
?	O
6.88	O
%	O
,	O
all	O
P	O
<	O
0.05	O
)	O
were	O
all	O
significantly	O
lower	O
in	O
the	O
postconditioning	O
group	O
than	O
in	O
control	O
group	O
while	O
LVEF	O
(	O
0.55	O
?	O
0.08	O
vs.	O
0.47	O
?	O
0.10	O
)	O
and	O
MBG	O
(	O
2.27	O
?	O
0.64	O
vs.	O
1.47	O
?	O
0.61	O
,	O
all	O
P	O
<	O
0.05	O
)	O
were	O
significantly	O
higher	O
in	O
the	O
postconditioning	O
group	O
than	O
in	O
control	O
group	O
.	O

CONCLUSIONS	O
Ischemia	O
postconditioning	O
can	O
significantly	O
reduce	O
myocardial	O
reperfusion	O
injury	O
in	O
patients	O
with	O
STEMI	O
.	O

Effect	O
of	O
a	O
carbohydrate-protein	Pharmacological
supplement	Pharmacological
on	O
endurance	O
performance	O
during	O
exercise	O
of	O
varying	O
intensity	O
.	O

Increasing	O
the	O
plasma	O
glucose	O
and	O
insulin	O
concentrations	O
during	O
prolonged	O
variable	O
intensity	O
exercise	O
by	O
supplementing	O
with	O
carbohydrate	O
has	O
been	O
found	O
to	O
spare	O
muscle	O
glycogen	O
and	O
increase	O
aerobic	O
endurance	O
.	O

Furthermore	O
,	O
the	O
addition	O
of	O
protein	Pharmacological
to	Pharmacological
a	Pharmacological
carbohydrate	Pharmacological
supplement	Pharmacological
will	O
enhance	O
the	O
insulin	O
response	O
of	O
a	O
carbohydrate	O
supplement	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
a	O
carbohydrate	Pharmacological
and	O
a	O
carbohydrate-protein	Pharmacological
supplement	Pharmacological
on	O
aerobic	O
endurance	O
performance	O
.	O

Nine	O
trained	O
cyclists	O
exercised	O
on	O
3	O
separate	O
occasions	O
at	O
intensities	O
that	O
varied	O
between	O
45	O
%	O
and	O
75	O
%	O
VO2max	O
for	O
3	O
h	O
and	O
then	O
at	O
85	O
%	O
VO2max	O
until	O
fatigued	O
.	O

Supplements	O
(	O
200	O
ml	O
)	O
were	O
provided	O
every	O
20	O
min	O
and	O
consisted	O
of	O
placebo	Control
,	O
a	O
7.75	O
%	O
carbohydrate	Pharmacological
solution	Pharmacological
,	O
and	O
a	O
7.75	O
%	O
carbohydrate/1.94	Pharmacological
%	Pharmacological
protein	Pharmacological
solution	Pharmacological
.	O

Treatments	O
were	O
administered	O
using	O
a	O
double-blind	O
randomized	O
design	O
.	O

Carbohydrate	O
supplementation	O
significantly	O
increased	O
time	O
to	O
exhaustion	O
(	O
carbohydrate	O
19.7	O
+/-	O
4.6	O
min	O
vs.	O
placebo	O
12.7	O
+/-	O
3.1	O
min	O
)	O
,	O
while	O
the	O
addition	O
of	O
protein	O
enhanced	O
the	O
effect	O
of	O
the	O
carbohydrate	O
supplement	O
(	O
carbohydrate-protein	O
26.9	O
+/-	O
4.5	O
min	O
,	O
p	O
<	O
.05	O
)	O
.	O

Blood	O
glucose	O
and	O
plasma	O
insulin	O
levels	O
were	O
elevated	O
above	O
placebo	O
during	O
carbohydrate	Pharmacological
and	O
carbohydrate-protein	Pharmacological
supplementation	Pharmacological
,	O
but	O
no	O
differences	O
were	O
found	O
between	O
the	O
carbohydrate	O
and	O
carbohydrate-protein	Pharmacological
treatments	O
.	O

In	O
summary	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
protein	O
to	O
a	O
carbohydrate	Pharmacological
supplement	Pharmacological
enhanced	O
aerobic	O
endurance	O
performance	O
above	O
that	O
which	O
occurred	O
with	O
carbohydrate	O
alone	O
,	O
but	O
the	O
reason	O
for	O
this	O
improvement	O
in	O
performance	O
was	O
not	O
evident	O
.	O

A	O
replication	O
and	O
extension	O
of	O
the	O
PEERS	Educational
intervention	Educational
:	Educational
examining	O
effects	O
on	O
social	O
skills	O
and	O
social	O
anxiety	O
in	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
Program	Educational
for	Educational
the	Educational
Education	Educational
and	Educational
Enrichment	Educational
of	Educational
Relational	Educational
Skills	Educational
(	Educational
PEERS	Educational
:	Educational
Laugeson	O
et	O
al	O
.	O

in	O
J	O
Autism	O
Dev	O
Disord	O
39	O
(	O
4	O
)	O
:596-606	O
,	O
2009	O
)	O
.	O

PEERS	Educational
focuses	O
on	O
improving	O
friendship	O
quality	O
and	O
social	O
skills	O
among	O
adolescents	O
with	O
higher-functioning	O
ASD	O
.	O

58	O
participants	O
aged	O
11-16	O
years-old	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
immediate	Educational
treatment	Educational
or	O
waitlist	Control
comparison	Control
group	Control
.	O

Results	O
revealed	O
,	O
in	O
comparison	O
to	O
the	O
waitlist	Educational
group	O
,	O
that	O
the	O
experimental	Educational
treatment	Educational
group	O
significantly	O
improved	O
their	O
knowledge	O
of	O
PEERS	Educational
concepts	O
and	O
friendship	O
skills	O
,	O
increased	O
in	O
their	O
amount	O
of	O
get-togethers	O
,	O
and	O
decreased	O
in	O
their	O
levels	O
of	O
social	O
anxiety	O
,	O
core	O
autistic	O
symptoms	O
,	O
and	O
problem	O
behaviors	O
from	O
pre-to	O
post-PEERS	O
.	O

This	O
study	O
provides	O
the	O
first	O
independent	O
replication	O
and	O
extension	O
of	O
the	O
empirically-supported	O
PEERS	Educational
social	Educational
skills	Educational
intervention	Educational
for	O
adolescents	O
with	O
ASD	O
.	O

Bedside	O
ultrasound-guided	Surgical
celiac	Surgical
plexus	Surgical
neurolysis	Surgical
in	O
upper	O
abdominal	O
cancer	O
patients	O
:	O
a	O
randomized	O
,	O
prospective	O
study	O
for	O
comparison	O
of	O
percutaneous	O
bilateral	Surgical
paramedian	Surgical
vs.	O
unilateral	Surgical
paramedian	Surgical
needle-insertion	Surgical
technique	Surgical
.	O

INTRODUCTION	O
Percutaneous	Surgical
anterior	Surgical
abdominal	Surgical
ultrasound	Surgical
guidance	Surgical
for	O
performing	O
celiac	O
plexus	O
neurolysis	O
is	O
a	O
relatively	O
new	O
but	O
more	O
economical	O
,	O
less	O
time-consuming	O
,	O
more	O
comfortable	O
bedside	O
technique	O
for	O
interventional	O
pain	O
management	O
.	O

Paucity	O
of	O
studies	O
evaluating	O
the	O
efficacy	O
of	O
single-site	O
vs.	O
double-site	O
injections	O
at	O
celiac	O
trunk	O
for	O
ultrasound-guided	Surgical
celiac	Surgical
plexus	Surgical
neurolysis	Surgical
(	Surgical
USCPN	Surgical
)	Surgical
prompted	O
us	O
to	O
conduct	O
a	O
prospective	O
,	O
randomized	O
,	O
single-blind	O
clinical	O
trial	O
to	O
compare	O
USCPN	Surgical
using	O
bilateral	Surgical
paramedian	Surgical
(	Surgical
double	Surgical
needle	Surgical
)	Surgical
technique	Surgical
with	O
unilateral	Surgical
paramedian	Surgical
(	Surgical
single	Surgical
needle	Surgical
)	Surgical
technique	Surgical
.	O

METHODS	O
Sixty	O
patients	O
aged	O
18	O
years	O
or	O
older	O
with	O
unresectable	O
upper	O
abdominal	O
cancers	O
were	O
randomized	O
into	O
two	O
groups	O
to	O
receive	O
USCPN	O
.	O

A	O
20-mL	O
mixture	O
of	O
50	O
%	O
ethanol	Pharmacological
with	O
0.25	O
%	O
bupivacaine	Pharmacological
was	O
injected	O
either	O
unilaterally	Physical
(	O
20	O
mL?1	O
site	O
)	O
or	O
bilaterally	O
(	O
10	O
mL?2	O
sites	O
)	O
depending	O
on	O
the	O
randomization	O
group	O
.	O

Subjects	O
were	O
assessed	O
for	O
the	O
pain	O
relief	O
using	O
Numerical	O
rating	O
scale	O
(	O
NRS	O
)	O
to	O
assess	O
their	O
pain	O
relief	O
.	O

RESULTS	O
Baseline	O
parameters	O
being	O
comparable	O
(	O
P	O
>	O
0.05	O
)	O
,	O
the	O
site	O
of	O
drug	O
injections	O
(	O
single	O
or	O
double	O
needle	O
)	O
had	O
no	O
bearing	O
on	O
the	O
onset	O
of	O
pain	O
relief	O
and	O
patient	O
satisfaction	O
scores	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Pain	O
relief	O
during	O
follow-up	O
visits	O
was	O
comparable	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
discomfort	O
score	O
correlated	O
well	O
with	O
the	O
pain	O
relief	O
scoring	O
without	O
any	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
except	O
in	O
the	O
last	O
visit	O
(	O
at	O
3	O
month	O
)	O
.	O

Incidences	O
of	O
the	O
complications	O
were	O
comparable	O
in	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
Ultrasound-guided	O
celiac	O
plexus	O
neurolysis	O
using	O
unilateral	O
paramedian	O
(	O
single	O
needle	O
)	O
needle-insertion	O
technique	O
is	O
comparable	O
with	O
bilateral	O
paramedian	O
(	O
double	O
needle	O
)	O
needle-insertion	O
technique	O
with	O
regard	O
to	O
pain	O
relief	O
and	O
side	O
effects	O
.	O

Effects	O
of	O
sensory-level	O
high-volt	O
pulsed	O
electrical	O
current	O
ondelayed-onset	O
muscle	O
soreness	O
.	O

Ten	O
healthy	O
males	O
and	O
ten	O
healthy	O
females	O
aged	O
21.5	O
+/-	O
3.2	O
years	O
(	O
mean	O
+/-	O
s	O
)	O
participated	O
in	O
the	O
study	O
,	O
which	O
was	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
sensory	Physical
level-high	Physical
volt	Physical
pulsed	Physical
electrical	Physical
current	Physical
(	Physical
HVPC	Physical
)	Physical
on	O
delayed-onset	O
muscle	O
soreness	O
(	O
DOMS	O
)	O
.	O

Arm	O
discomfort	O
,	O
elbow	O
extension	O
range	O
of	O
motion	O
and	O
isometric	O
elbow	O
flexion	O
strength	O
were	O
obtained	O
as	O
baseline	O
measurements	O
.	O

Delayed-onset	O
muscle	O
soreness	O
was	O
induced	O
in	O
the	O
participants	O
'	O
dominant	O
or	O
non-dominant	O
arm	O
using	O
two	O
sets	O
of	O
20	O
maximal	O
eccentric	O
elbow	O
flexion	O
contractions	O
.	O

After	O
the	O
induction	O
of	O
DOMS	O
,	O
the	O
participants	O
were	O
randomly	O
divided	O
into	O
an	O
experimental	Physical
condition	Physical
(	Physical
HVPC	Physical
)	Physical
or	O
a	O
placebo	Control
condition	O
.	O

The	O
experimental	O
condition	O
consisted	O
of	O
20	O
min	O
of	O
HVPC	Physical
immediately	O
after	O
the	O
induction	O
of	O
DOMS	O
,	O
and	O
20	O
min	O
every	O
24	O
h	O
for	O
three	O
consecutive	O
days	O
thereafter	O
.	O

The	O
participants	O
in	O
the	O
placebo	Control
condition	O
received	O
an	O
intervention	O
similar	O
in	O
design	O
;	O
however	O
,	O
no	O
electrical	O
current	O
was	O
administered	O
.	O

Baseline	O
measurements	O
were	O
reevaluated	O
at	O
24	O
,	O
48	O
,	O
72	O
and	O
96	O
h	O
after	O
the	O
induction	O
of	O
DOMS	O
.	O

Three	O
weeks	O
later	O
,	O
the	O
participants	O
returned	O
and	O
the	O
protocol	O
was	O
repeated	O
on	O
the	O
contralateral	O
limb	O
,	O
using	O
the	O
opposite	O
intervention	O
(	O
HVPC	Physical
or	O
placebo	Control
)	O
.	O

Repeated-measures	O
analysis	O
of	O
variance	O
revealed	O
a	O
significant	O
increase	O
in	O
overall	O
arm	O
discomfort	O
,	O
decrease	O
in	O
elbow	O
extension	O
and	O
decrease	O
in	O
isometric	O
strength	O
for	O
both	O
conditions	O
over	O
time	O
.	O

No	O
significant	O
main	O
effect	O
of	O
treatment	O
,	O
or	O
time-by-treatment	O
interaction	O
,	O
was	O
found	O
for	O
the	O
HVPC	Physical
condition	O
when	O
compared	O
with	O
the	O
placebo	Control
condition	O
for	O
any	O
variable	O
.	O

Sensory-level	O
HVPC	O
,	O
as	O
utilized	O
in	O
our	O
application	O
,	O
was	O
ineffective	O
in	O
reducing	O
the	O
measured	O
variables	O
associated	O
with	O
DOMS	O
.	O

A	O
comparative	O
study	O
of	O
the	O
safety	O
and	O
efficacy	O
of	O
FemCap	Physical
,	Physical
a	Physical
new	Physical
vaginal	Physical
barrier	Physical
contraceptive	Physical
,	O
and	O
the	O
Ortho	Pharmacological
All-Flex	Pharmacological
diaphragm	Pharmacological
.	O

The	O
FemCap	O
Investigators	O
'	O
Group	O
.	O

The	O
FemCap	Physical
is	O
a	O
new	O
silicone	O
rubber	O
barrier	O
contraceptive	O
shaped	O
like	O
a	O
sailor	O
's	O
hat	O
,	O
with	O
a	O
dome	O
that	O
covers	O
the	O
cervix	O
,	O
a	O
rim	O
that	O
fits	O
into	O
the	O
fornices	O
,	O
and	O
a	O
brim	O
that	O
conforms	O
to	O
the	O
vaginal	O
walls	O
around	O
the	O
cervix	O
.	O

It	O
was	O
designed	O
to	O
result	O
in	O
fewer	O
dislodgments	O
and	O
less	O
pressure	O
on	O
the	O
urethra	O
than	O
the	O
cervical	O
cap	O
and	O
diaphragm	O
,	O
respectively	O
,	O
and	O
to	O
require	O
less	O
clinician	O
time	O
for	O
fitting	O
.	O

This	O
was	O
a	O
phase	O
II/III	O
,	O
multicenter	O
,	O
randomized	O
,	O
open-label	O
,	O
parallel	O
group	O
study	O
of	O
841	O
women	O
at	O
risk	O
for	O
pregnancy	O
.	O

A	O
subset	O
of	O
42	O
women	O
at	O
one	O
site	O
underwent	O
colposcopy	O
.	O

Women	O
were	O
randomized	O
to	O
use	O
the	O
FemCap	Pharmacological
or	Pharmacological
Ortho	Pharmacological
All-Flex	Pharmacological
contraceptive	Pharmacological
diaphragm	Pharmacological
,	Pharmacological
both	Pharmacological
with	Pharmacological
2	Pharmacological
%	Pharmacological
nonoxynol-9	Pharmacological
spermicide	Pharmacological
,	O
for	O
28	O
weeks	O
.	O

The	O
objectives	O
were	O
to	O
compare	O
the	O
two	O
devices	O
with	O
regard	O
to	O
their	O
safety	O
and	O
acceptability	O
and	O
to	O
determine	O
whether	O
the	O
probability	O
of	O
pregnancy	O
among	O
FemCap	Pharmacological
users	O
was	O
no	O
worse	O
than	O
that	O
of	O
the	O
diaphragm	Physical
(	O
meaning	O
not	O
more	O
than	O
6	O
percentage	O
points	O
higher	O
)	O
.	O

The	O
6-month	O
Kaplan-Meier	O
cumulative	O
unadjusted	O
typical	O
use	O
pregnancy	O
probabilities	O
were	O
13.5	O
%	O
among	O
FemCap	Pharmacological
users	O
and	O
7.9	O
%	O
among	O
diaphragm	Pharmacological
users	O
.	O

The	O
adjusted	O
risk	O
of	O
pregnancy	O
among	O
FemCap	Pharmacological
users	O
was	O
1.96	O
times	O
that	O
among	O
diaphragm	Pharmacological
users	O
,	O
with	O
an	O
upper	O
95	O
%	O
confidence	O
limit	O
of	O
3.01	O
.	O

Clinical	O
equivalence	O
(	O
noninferiority	O
)	O
of	O
the	O
FemCap	Pharmacological
compared	O
with	O
the	O
diaphragm	O
,	O
as	O
defined	O
in	O
this	O
study	O
,	O
would	O
mean	O
that	O
the	O
true	O
risk	O
of	O
pregnancy	O
among	O
FemCap	Pharmacological
users	O
was	O
no	O
more	O
than	O
1.73	O
times	O
the	O
pregnancy	O
risk	O
of	O
diaphragm	Pharmacological
users	O
.	O

Because	O
the	O
observed	O
upper	O
95	O
%	O
confidence	O
limit	O
(	O
and	O
even	O
the	O
point	O
estimate	O
)	O
exceeded	O
1.73	O
,	O
the	O
probability	O
of	O
pregnancy	O
among	O
FemCap	Pharmacological
users	O
,	O
compared	O
with	O
that	O
among	O
diaphragm	Pharmacological
users	O
,	O
did	O
not	O
meet	O
the	O
definition	O
of	O
clinical	O
equivalence	O
used	O
in	O
this	O
study	O
.	O

The	O
FemCap	Pharmacological
was	O
believed	O
to	O
be	O
safe	O
and	O
was	O
associated	O
with	O
significantly	O
fewer	O
urinary	O
tract	O
infections	O
.	O

More	O
women	O
reported	O
problems	O
with	O
the	O
FemCap	Pharmacological
with	O
regard	O
to	O
insertion	O
,	O
dislodgement	O
,	O
and	O
especially	O
removal	O
,	O
although	O
their	O
general	O
assessments	O
were	O
positive	O
.	O

The	O
two	O
devices	O
were	O
comparable	O
with	O
regard	O
to	O
safety	O
and	O
acceptability	O
,	O
but	O
a	O
6-point	O
difference	O
in	O
the	O
true	O
6-month	O
pregnancy	O
probabilities	O
of	O
the	O
two	O
devices	O
could	O
not	O
be	O
ruled	O
out	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
design	O
modifications	O
can	O
simplify	O
insertion	O
and	O
removal	O
.	O

Enoxaparin	Pharmacological
in	O
the	O
prevention	O
of	O
deep	O
venous	O
thrombosis	O
after	O
major	O
surgery	O
:	O
multicentric	O
study	O
.	O

The	O
Italian	O
Study	O
Group	O
.	O

DVT	O
is	O
a	O
very	O
frequent	O
complication	O
of	O
general	O
surgery	O
.	O

Heparin	O
and	O
,	O
more	O
recently	O
,	O
LMWHs	Pharmacological
can	O
successfully	O
prevent	O
post	O
surgical	O
thromboembolism	O
.	O

One	O
thousand	O
one	O
hundred	O
and	O
twenty-two	O
patients	O
(	O
533	O
males	O
and	O
589	O
females	O
;	O
mean	O
age	O
62.2	O
+/-	O
11.4	O
yrs	O
)	O
were	O
enrolled	O
in	O
a	O
multicentre	O
controlled	O
study	O
,	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
enoxaparin	Pharmacological
in	O
comparison	O
to	O
calcium	Pharmacological
heparin	Pharmacological
in	O
the	O
prevention	O
of	O
deep	O
venous	O
thrombosis	O
(	O
DVT	O
)	O
following	O
general	O
surgery	O
.	O

Patients	O
assigned	O
to	O
the	O
enoxaparin	Pharmacological
and	O
the	O
calcium	Pharmacological
heparin	Pharmacological
groups	O
received	O
1	O
daily	O
dose	O
of	O
20	O
mg	O
(	O
2000	O
I.U	O
.	O

)	O
and	O
2	O
daily	O
doses	O
of	O
0.2	O
ml	O
(	O
5000	O
I.U	O
.	O

)	O
,	O
respectively	O
starting	O
2	O
hours	O
before	O
the	O
operation	O
.	O

Both	O
drugs	O
were	O
given	O
by	O
subcutaneous	O
route	O
.	O

A	O
Doppler	O
or	O
Duplex	O
Scan	O
diagnosis	O
of	O
DVT	O
was	O
made	O
in	O
3	O
(	O
0.5	O
%	O
)	O
patients	O
in	O
the	O
enoxaparin	Pharmacological
group	O
(	O
2	O
cases	O
during	O
treatment	O
and	O
1	O
patient	O
at	O
the	O
end	O
of	O
treatment	O
)	O
and	O
in	O
6	O
(	O
1.1	O
%	O
)	O
patients	O
in	O
the	O
calcium	Pharmacological
heparin	Pharmacological
group	O
(	O
5	O
cases	O
during	O
treatment	O
and	O
1	O
,	O
bilateral	O
,	O
after	O
the	O
end	O
of	O
treatment	O
)	O
.	O

Pulmonary	O
embolism	O
(	O
PE	O
)	O
was	O
ascertained	O
by	O
angiography	O
in	O
1	O
patient	O
(	O
0.18	O
%	O
)	O
in	O
the	O
enoxaparin	Pharmacological
group	O
and	O
in	O
2	O
patients	O
(	O
0.36	O
%	O
)	O
in	O
the	O
calcium	Pharmacological
heparin	Pharmacological
one	O
.	O

Hemorrhagic	O
complications	O
occurred	O
in	O
29	O
patients	O
(	O
5.2	O
%	O
)	O
in	O
the	O
enoxaparin	Pharmacological
group	O
and	O
in	O
34	O
(	O
6.1	O
%	O
)	O
in	O
the	O
calcium	Pharmacological
heparin	Pharmacological
group	O
.	O

Haematomas	O
located	O
in	O
the	O
injection	O
site	O
were	O
reported	O
in	O
16.1	O
%	O
and	O
25.3	O
%	O
in	O
the	O
enoxaparin	Pharmacological
and	O
calcium	Pharmacological
heparin	Pharmacological
groups	O
respectively	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

Local	O
pain	O
in	O
the	O
injection	O
site	O
at	O
the	O
5th	O
day	O
of	O
treatment	O
was	O
reported	O
in	O
8.4	O
%	O
and	O
16.6	O
%	O
in	O
the	O
enoxaparin	O
and	O
calcium	O
heparin	O
groups	O
respectively	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Phase	O
III	O
,	O
randomized	O
,	O
open-label	O
study	O
of	O
daily	O
imatinib	Pharmacological
mesylate	Pharmacological
400	O
mg	O
versus	O
800	O
mg	O
in	O
patients	O
with	O
newly	O
diagnosed	O
,	O
previously	O
untreated	O
chronic	O
myeloid	O
leukemia	O
in	O
chronic	O
phase	O
using	O
molecular	O
end	O
points	O
:	O
tyrosine	O
kinase	O
inhibitor	O
optimization	O
and	O
selectivity	O
study	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
initial	O
treatment	O
with	O
imatinib	Pharmacological
mesylate	Pharmacological
800	O
mg/d	O
(	O
400	O
mg	O
twice	O
daily	O
)	O
versus	O
400	O
mg/d	O
in	O
patients	O
with	O
newly	O
diagnosed	O
chronic	O
myeloid	O
leukemia	O
in	O
chronic	O
phase	O
.	O

PATIENTS	O
AND	O
METHODS	O
A	O
total	O
of	O
476	O
patients	O
were	O
randomly	O
assigned	O
2:1	O
to	O
imatinib	Pharmacological
800	Pharmacological
mg	Pharmacological
(	O
n	O
=	O
319	O
)	O
or	Pharmacological
400	Pharmacological
mg	Pharmacological
(	O
n	O
=	O
157	O
)	O
daily	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
major	O
molecular	O
response	O
(	O
MMR	O
)	O
rate	O
at	O
12	O
months	O
.	O

RESULTS	O
At	O
12	O
months	O
,	O
differences	O
in	O
MMR	O
and	O
complete	O
cytogenetic	O
response	O
(	O
CCyR	O
)	O
rates	O
were	O
not	O
statistically	O
significant	O
(	O
MMR	O
,	O
46	O
%	O
v	O
40	O
%	O
;	O
P	O
=	O
.2035	O
;	O
CCyR	O
,	O
70	O
%	O
v	O
66	O
%	O
;	O
P	O
=	O
.3470	O
)	O
.	O

However	O
,	O
MMR	O
occurred	O
faster	O
among	O
patients	O
randomly	O
assigned	O
to	O
imatinib	Pharmacological
800	O
mg/d	O
,	O
who	O
had	O
higher	O
rates	O
of	O
MMR	O
at	O
3	O
and	O
6	O
months	O
compared	O
with	O
those	O
in	O
the	O
imatinib	O
400-mg/d	O
arm	O
(	O
P	O
=	O
.0035	O
by	O
log-rank	O
test	O
)	O
.	O

CCyR	O
also	O
occurred	O
faster	O
in	O
the	O
800-mg/d	O
arm	O
(	O
CCyR	O
at	O
6	O
months	O
,	O
57	O
%	O
v	O
45	O
%	O
;	O
P	O
=	O
.0146	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
edema	O
,	O
gastrointestinal	O
problems	O
,	O
and	O
rash	O
,	O
and	O
all	O
were	O
more	O
common	O
in	O
patients	O
in	O
the	O
800-mg/d	O
arm	O
.	O

Grades	O
3	O
to	O
4	O
hematologic	O
toxicity	O
also	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
imatinib	O
800	O
mg/d	O
.	O

CONCLUSION	O
MMR	O
rates	O
at	O
1	O
year	O
were	O
similar	O
with	O
imatinib	O
800	O
mg/d	O
and	O
400	O
mg/d	O
,	O
but	O
MMR	O
and	O
CCyR	O
occurred	O
earlier	O
in	O
patients	O
treated	O
with	O
800	O
mg/d	O
.	O

Continued	O
follow-up	O
is	O
needed	O
to	O
determine	O
the	O
clinical	O
significance	O
of	O
earlier	O
responses	O
on	O
high-dose	O
imatinib	Pharmacological
.	Pharmacological

Transthoracic	Physical
versus	O
transesophageal	Surgical
cardioversion	Surgical
of	Surgical
atrial	Surgical
fibrillation	Surgical
under	O
light	O
sedation	O
:	O
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
Electrical	O
cardioversion	O
(	O
ECV	O
)	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
is	O
limited	O
by	O
a	O
5-10	O
%	O
failure	O
rate	O
and	O
by	O
the	O
expense	O
arising	O
from	O
a	O
perceived	O
need	O
for	O
general	O
anesthesia	O
.	O

A	O
transesophageal	O
approach	O
using	O
light	O
sedation	O
has	O
been	O
proposed	O
as	O
a	O
means	O
of	O
augmenting	O
the	O
success	O
rate	O
and	O
avoiding	O
the	O
need	O
for	O
general	O
anesthesia	O
.	O

We	O
hypothesized	O
that	O
the	O
high	O
rate	O
of	O
success	O
and	O
the	O
lower	O
energy	O
requirement	O
associated	O
with	O
biphasic	O
cardioversion	O
might	O
eliminate	O
any	O
advantage	O
of	O
the	O
transesophageal	O
approach	O
.	O

METHODS	O
We	O
randomly	O
assigned	O
60	O
patients	O
attending	O
for	O
ECV	O
of	O
persistent	O
AF	O
to	O
a	O
transesophageal	Surgical
or	O
a	O
transthoracic	Physical
approach	Physical
.	O

Sedation	O
of	O
moderate	O
depth	O
was	O
achieved	O
with	O
intravenous	Pharmacological
midazolam	Pharmacological
.	O

The	O
dose	O
of	O
midazolam	O
was	O
titrated	O
in	O
the	O
same	O
manner	O
in	O
both	O
groups	O
.	O

RESULTS	O
Sinus	O
rhythm	O
was	O
restored	O
in	O
29/30	O
patients	O
(	O
97	O
%	O
)	O
in	O
each	O
group	O
using	O
a	O
similar	O
number	O
of	O
shocks	O
for	O
both	O
groups	O
(	O
1.3	O
+/-	O
0.6	O
transesophageal	O
vs	O
1.4	O
+/-	O
0.7	O
transthoracic	O
,	O
P	O
=	O
NS	O
)	O
with	O
a	O
similar	O
procedure	O
duration	O
(	O
14.1	O
+/-	O
8.2	O
minutes	O
vs	O
13.8	O
+/-	O
7.5	O
minutes	O
,	O
P	O
=	O
NS	O
)	O
.	O

Both	O
groups	O
received	O
similar	O
doses	O
of	O
midazolam	O
(	O
4.2	O
+/-	O
2.7	O
mg	O
vs	O
4.4	O
+/-	O
2.8	O
mg	O
,	O
P	O
=	O
NS	O
)	O
and	O
both	O
reported	O
a	O
similar	O
discomfort	O
score	O
in	O
(	O
0.9	O
+/-	O
1.3	O
vs	O
1.1	O
+/-	O
1.8	O
,	O
P	O
=	O
NS	O
)	O
.	O

No	O
complication	O
occurred	O
in	O
either	O
group	O
.	O

CONCLUSION	O
AF	O
may	O
be	O
cardioverted	O
safely	O
and	O
effectively	O
by	O
either	O
a	O
transthoracic	O
or	O
a	O
transesophageal	O
approach	O
.	O

The	O
use	O
of	O
sedation	O
of	O
moderate	O
depth	O
renders	O
cardioversion	O
by	O
either	O
approach	O
acceptable	O
.	O

As	O
transesophageal	O
ECV	O
shows	O
no	O
clear	O
advantage	O
,	O
transthoracic	O
cardioversion	O
should	O
remain	O
the	O
approach	O
of	O
first	O
choice	O
.	O

The	O
effect	O
of	O
levetiracetam	Pharmacological
on	O
essential	O
tremor	O
.	O

The	O
effect	O
of	O
a	O
single	O
dose	O
of	O
1,000	Pharmacological
mg	Pharmacological
of	Pharmacological
levetiracetam	Pharmacological
on	O
essential	O
tremor	O
was	O
investigated	O
in	O
24	O
patients	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
hand	O
tremor	O
for	O
at	O
least	O
2	O
hours	O
as	O
measured	O
by	O
accelerometry	O
and	O
functional	O
tests	O
.	O

To	O
share	O
or	O
not	O
to	O
share	O
:	O
a	O
randomized	O
trial	O
of	O
consent	Educational
for	Educational
data	Educational
sharing	Educational
in	O
genome	O
research	O
.	O

PURPOSE	O
Despite	O
growing	O
concerns	O
toward	O
maintaining	O
participants	O
'	O
privacy	O
,	O
individual	O
investigators	O
collecting	O
tissue	O
and	O
other	O
biological	O
specimens	O
for	O
genomic	O
analysis	O
are	O
encouraged	O
to	O
obtain	O
informed	Educational
consent	Educational
for	O
broad	O
data	O
sharing	O
.	O

Our	O
purpose	O
was	O
to	O
assess	O
the	O
effect	O
on	O
research	O
enrollment	O
and	O
data	O
sharing	O
decisions	O
of	O
three	O
different	O
consent	O
types	O
(	O
traditional	O
,	O
binary	O
,	O
or	O
tiered	O
)	O
with	O
varying	O
levels	O
of	O
control	O
and	O
choices	O
regarding	O
data	O
sharing	O
.	O

METHODS	O
A	O
single-blinded	O
,	O
randomized	O
controlled	Control
trial	O
was	O
conducted	O
with	O
323	O
eligible	O
adult	O
participants	O
being	O
recruited	O
into	O
one	O
of	O
six	O
genome	O
studies	O
at	O
Baylor	O
College	O
of	O
Medicine	O
in	O
Houston	O
,	O
Texas	O
,	O
between	O
January	O
2008	O
and	O
August	O
2009	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
experimental	Educational
consent	Educational
documents	Educational
(	O
traditional	O
,	O
n	O
=	O
110	O
;	O
binary	O
,	O
n	O
=	O
103	O
;	O
and	O
tiered	O
,	O
n	O
=	O
110	O
)	O
.	O

Debriefing	O
in	O
follow-up	O
visits	O
provided	O
participants	O
a	O
detailed	O
review	O
of	O
all	O
consent	O
types	O
and	O
the	O
chance	O
to	O
change	O
data	O
sharing	O
choices	O
or	O
decline	O
genome	O
study	O
participation	O
.	O

RESULTS	O
Before	O
debriefing	O
,	O
83.9	O
%	O
of	O
participants	O
chose	O
public	O
data	O
release	O
.	O

After	O
debriefing	O
,	O
53.1	O
%	O
chose	O
public	O
data	O
release	O
,	O
33.1	O
%	O
chose	O
restricted	O
(	O
controlled	O
access	O
database	O
)	O
release	O
,	O
and	O
13.7	O
%	O
opted	O
out	O
of	O
data	Educational
sharing	Educational
.	Educational

Only	O
one	O
participant	O
declined	O
genome	O
study	O
participation	O
due	O
to	O
data	O
sharing	O
concerns	O
.	O

CONCLUSION	O
Our	O
findings	O
indicate	O
that	O
most	O
participants	O
are	O
willing	O
to	O
publicly	O
release	O
their	O
genomic	O
data	O
;	O
however	O
,	O
a	O
significant	O
portion	O
prefers	O
restricted	O
release	O
.	O

These	O
results	O
suggest	O
discordance	O
between	O
existing	O
data	O
sharing	O
policies	O
and	O
participants	O
'	O
judgments	O
and	O
desires	O
.	O

Use	O
of	O
EORTC	O
target	O
definition	O
guidelines	O
for	O
dose-intensified	O
salvage	O
radiation	O
therapy	O
for	O
recurrent	O
prostate	O
cancer	O
:	O
results	O
of	O
the	O
quality	O
assurance	O
program	O
of	O
the	O
randomized	O
trial	O
SAKK	O
09/10	O
.	O

PURPOSE	O
Different	O
international	O
target	O
volume	O
delineation	O
guidelines	O
exist	O
and	O
different	O
treatment	O
techniques	O
are	O
available	O
for	O
salvage	O
radiation	O
therapy	O
(	O
RT	O
)	O
for	O
recurrent	O
prostate	O
cancer	O
,	O
but	O
less	O
is	O
known	O
regarding	O
their	O
respective	O
applicability	O
in	O
clinical	O
practice	O
.	O

METHODS	O
AND	O
MATERIALS	O
A	O
randomized	O
phase	O
III	O
trial	O
testing	O
64	Pharmacological
Gy	Pharmacological
vs	Pharmacological
70	Pharmacological
Gy	Pharmacological
salvage	Pharmacological
RT	Pharmacological
was	O
accompanied	O
by	O
an	O
intense	Educational
quality	Educational
assurance	Educational
program	Educational
including	O
a	O
site-specific	O
and	O
study-specific	O
questionnaire	O
and	O
a	O
dummy	Physical
run	Physical
(	Physical
DR	Physical
)	Physical
.	O

Target	O
volume	O
delineation	O
was	O
performed	O
according	O
to	O
the	O
European	O
Organisation	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
guidelines	O
,	O
and	O
a	O
DR-based	O
treatment	O
plan	O
was	O
established	O
for	O
70	O
Gy	O
.	O

Major	O
and	O
minor	O
protocol	O
deviations	O
were	O
noted	O
,	O
interobserver	O
agreement	O
of	O
delineated	O
target	O
contours	O
was	O
assessed	O
,	O
and	O
dose-volume	O
histogram	O
(	O
DVH	O
)	O
parameters	O
of	O
different	O
treatment	O
techniques	O
were	O
compared	O
.	O

RESULTS	O
Thirty	O
European	O
centers	O
participated	O
,	O
43	O
%	O
of	O
which	O
were	O
using	O
3-dimensional	Physical
conformal	Physical
RT	Physical
(	Physical
3D-CRT	Physical
)	Physical
,	O
with	O
the	O
remaining	O
centers	O
using	O
intensity	Physical
modulated	Physical
RT	Physical
(	Physical
IMRT	Physical
)	Physical
or	O
volumetric	Physical
modulated	Physical
arc	Physical
technique	Physical
(	Physical
VMAT	Physical
)	Physical
.	O

The	O
first	O
submitted	O
version	O
of	O
the	O
DR	O
contained	O
major	O
deviations	O
in	O
21	O
of	O
30	O
(	O
70	O
%	O
)	O
centers	O
,	O
mostly	O
caused	O
by	O
inappropriately	O
defined	O
or	O
lack	O
of	O
prostate	O
bed	O
(	O
PB	O
)	O
.	O

All	O
but	O
5	O
centers	O
completed	O
the	O
DR	O
successfully	O
with	O
their	O
second	O
submitted	O
version	O
.	O

The	O
interobserver	O
agreement	O
of	O
the	O
PB	O
was	O
moderate	O
and	O
was	O
improved	O
by	O
the	O
DR	O
review	O
,	O
as	O
indicated	O
by	O
an	O
increased	O
?	O
value	O
(	O
0.59	O
vs	O
0.55	O
)	O
,	O
mean	O
sensitivity	O
(	O
0.64	O
vs	O
0.58	O
)	O
,	O
volume	O
of	O
total	O
agreement	O
(	O
3.9	O
vs	O
3.3	O
cm	O
(	O
3	O
)	O
)	O
,	O
and	O
decrease	O
in	O
the	O
union	O
volume	O
(	O
79.3	O
vs	O
84.2	O
cm	O
(	O
3	O
)	O
)	O
.	O

Rectal	O
and	O
bladder	O
wall	O
DVH	O
parameters	O
of	O
IMRT	O
and	O
VMAT	O
vs	O
3D-CRT	O
plans	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
The	O
interobserver	O
agreement	O
of	O
PB	O
delineation	O
was	O
moderate	O
but	O
was	O
improved	O
by	O
the	O
DR.	O
Major	O
deviations	O
could	O
be	O
identified	O
for	O
the	O
majority	O
of	O
centers	O
.	O

The	O
DR	O
has	O
improved	O
the	O
acquaintance	O
of	O
the	O
participating	O
centers	O
with	O
the	O
trial	O
protocol	O
.	O

Tegaserod	Pharmacological
,	Pharmacological
a	Pharmacological
5-hydroxytryptamine	Pharmacological
type	Pharmacological
4	Pharmacological
receptor	Pharmacological
partial	Pharmacological
agonist	Pharmacological
,	O
is	O
devoid	O
of	O
electrocardiographic	O
effects	O
.	O

OBJECTIVES	O
Certain	O
GI	Pharmacological
prokinetic	Pharmacological
agents	Pharmacological
have	O
been	O
shown	O
to	O
affect	O
cardiac	O
repolarization	O
,	O
which	O
may	O
be	O
associated	O
with	O
life-threatening	O
arrhythmias	O
.	O

The	O
selective	Pharmacological
5-hydroxytryptamine	Pharmacological
type	Pharmacological
4	Pharmacological
receptor	Pharmacological
partial	Pharmacological
agonist	Pharmacological
tegaserod	Pharmacological
is	O
a	O
novel	O
promotile	O
agent	O
developed	O
for	O
the	O
treatment	O
of	O
functional	O
motility	O
disorders	O
such	O
as	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
cardiac	O
safety	O
profile	O
of	O
tegaserod	Pharmacological
through	O
analysis	O
of	O
electrocardiographic	O
data	O
from	O
clinical	O
studies	O
conducted	O
in	O
patients	O
with	O
IBS	O
and	O
a	O
study	O
conducted	O
in	O
healthy	O
male	O
subjects	O
.	O

METHODS	O
In	O
three	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
clinical	O
studies	O
,	O
2516	O
IBS	O
patients	O
with	O
symptoms	O
of	O
abdominal	O
pain	O
and	O
constipation	O
received	O
tegaserod	Pharmacological
2	O
or	O
6	O
mg	O
b.i.d	O
.	O

(	O
n	O
=	O
1679	O
)	O
or	O
placebo	Control
(	O
n	O
=	O
837	O
)	O
for	O
12	O
wk	O
.	O

In	O
an	O
additional	O
study	O
,	O
36	O
healthy	O
male	O
subjects	O
received	O
iv	O
.	O

single	O
doses	O
of	O
tegaserod	Pharmacological
(	O
0.8	O
mg	O
to	O
20	O
mg	O
)	O
or	O
placebo	Control
.	O

Standard	O
12-lead	O
electrocardiograms	O
were	O
recorded	O
at	O
baseline	O
and	O
during	O
treatment	O
.	O

Baseline	O
values	O
were	O
compared	O
with	O
data	O
collected	O
during	O
the	O
treatment	O
period	O
.	O

RESULTS	O
The	O
proportion	O
of	O
patients	O
with	O
prolongation	O
of	O
the	O
QTc	O
interval	O
was	O
the	O
same	O
for	O
placebo	O
and	O
tegaserod	O
,	O
as	O
was	O
the	O
frequency	O
of	O
overall	O
electrocardiographic	O
abnormalities	O
.	O

No	O
ventricular	O
or	O
supraventricular	O
tachycardia	O
was	O
observed	O
.	O

Comparable	O
electrocardiographic	O
results	O
were	O
obtained	O
during	O
placebo	O
and	O
tegaserod	O
treatment	O
.	O

In	O
healthy	O
volunteers	O
,	O
tegaserod	O
at	O
i.v	O
.	O

doses	O
resulting	O
in	O
plasma	O
concentrations	O
up	O
to	O
100	O
times	O
those	O
measured	O
after	O
therapeutic	O
doses	O
(	O
6	O
mg	O
b.i.d	O
.	O

)	O
did	O
not	O
influence	O
electrocardiographic	O
parameters	O
.	O

CONCLUSIONS	O
Tegaserod	O
is	O
devoid	O
of	O
electrocardiographic	O
effects	O
and	O
is	O
not	O
expected	O
to	O
adversely	O
influence	O
cardiac	O
function	O
.	O

These	O
data	O
confirm	O
preclinical	O
findings	O
.	O

Effects	O
of	O
psychosocial	Psychological
program	Psychological
for	O
preparing	O
long-term	O
hospitalized	O
patients	O
with	O
schizophrenia	O
for	O
discharge	O
from	O
hospital	O
:	O
randomized	O
controlled	O
trial	O
.	O

AIM	O
The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
revise	O
the	O
Community	Educational
Re-entry	Educational
Program-Japanese	Educational
version	Educational
and	O
to	O
review	O
the	O
effectiveness	O
of	O
the	O
revised	O
Program	O
,	O
named	O
the	O
Discharge	Educational
Preparation	Educational
Program	Educational
.	O

METHODS	O
This	O
study	O
was	O
a	O
randomized	O
controlled	O
trial	O
.	O

The	O
Discharge	Educational
Preparation	Educational
Program	Educational
(	Educational
DPP	Educational
)	Educational
was	O
the	O
intervention	O
condition	O
(	O
n	O
=	O
26	O
)	O
,	O
and	O
the	O
usual	Control
rehabilitation	Control
program	Control
was	O
the	O
control	O
condition	O
(	O
n	O
=	O
23	O
)	O
.	O

Outcome	O
indicators	O
included	O
factors	O
that	O
make	O
patient	O
discharge	O
difficult	O
(	O
which	O
nurses	O
evaluated	O
)	O
,	O
psychiatric	O
symptom	O
,	O
knowledge	O
about	O
the	O
illness	O
or	O
medication	O
,	O
and	O
the	O
number	O
of	O
patients	O
who	O
were	O
discharged	O
within	O
6	O
months	O
after	O
the	O
end	O
of	O
a	O
program	O
.	O

RESULTS	O
Significant	O
improvements	O
were	O
found	O
in	O
the	O
score	O
of	O
the	O
'Issues	O
on	O
treatment	O
compliance	O
'	O
factor	O
and	O
the	O
score	O
of	O
the	O
'Autistic	O
life	O
'	O
factor	O
,	O
which	O
are	O
subscales	O
of	O
the	O
Discharge	O
Difficulty	O
Scale	O
,	O
for	O
the	O
DPP	Educational
group	O
,	O
on	O
two-way	O
ANOVA	O
(	O
'Issues	O
on	O
treatment	O
compliance	O
'	O
:	O
F	O
=	O
3.818	O
,	O
P	O
<	O
0.10	O
;	O
'Autistic	O
life	O
'	O
:	O
F	O
=	O
4.155	O
,	O
P	O
<	O
0.05	O
)	O
These	O
factors	O
affected	O
discharge	O
outcome	O
.	O

Thus	O
,	O
the	O
program	O
may	O
be	O
capable	O
of	O
promoting	O
discharge	O
of	O
long-term	O
hospitalized	O
psychiatric	O
patients	O
.	O

With	O
regard	O
to	O
the	O
number	O
of	O
patients	O
discharged	O
in	O
6	O
months	O
after	O
the	O
end	O
of	O
a	O
program	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
both	O
groups	O
.	O

CONCLUSION	O
The	O
present	O
result	O
is	O
in	O
agreement	O
with	O
past	O
studies	O
,	O
and	O
the	O
DPP	Educational
is	O
useful	O
in	O
discharge	O
support	O
for	O
patients	O
with	O
schizophrenia	O
in	O
Japan	O
.	O

Randomized	O
trial	O
of	O
a	O
decision	O
aid	O
for	O
individuals	O
considering	O
genetic	O
testing	O
for	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
risk	O
.	O

BACKGROUND	O
Despite	O
the	O
potential	O
benefits	O
of	O
genetic	O
testing	O
for	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
risk	O
,	O
individuals	O
can	O
find	O
the	O
genetic	O
testing	O
decision-making	O
process	O
complicated	O
and	O
challenging	O
.	O

The	O
goal	O
of	O
the	O
current	O
study	O
was	O
to	O
measure	O
the	O
effectiveness	O
of	O
a	O
tailored	O
decision	O
aid	O
designed	O
specifically	O
to	O
assist	O
individuals	O
to	O
make	O
informed	O
decisions	O
regarding	O
genetic	O
testing	O
for	O
HNPCC	O
risk	O
.	O

METHODS	O
In	O
all	O
,	O
153	O
individuals	O
were	O
randomized	O
to	O
receive	Educational
the	Educational
decision	Educational
aid	Educational
or	Educational
a	Educational
control	Educational
pamphlet	Educational
at	Educational
the	Educational
end	Educational
of	Educational
their	Educational
first	Educational
genetic	Educational
counseling	Educational
consultation	Educational
.	O

Of	O
these	O
,	O
109	O
(	O
71.2	O
%	O
)	O
completed	O
the	O
first	O
questionnaire	O
1	O
week	O
after	O
consultation	O
,	O
whereas	O
95	O
(	O
62.1	O
%	O
)	O
completed	O
the	O
6-month	O
follow-up	O
questionnaire	O
.	O

RESULTS	O
Although	O
the	O
decision	O
aid	O
had	O
no	O
significant	O
effect	O
on	O
postdecisional	O
regret	O
or	O
actual	O
genetic	O
testing	O
decision	O
,	O
the	O
trial	O
results	O
demonstrated	O
that	O
participants	O
who	O
received	O
the	O
decision	Educational
aid	Educational
had	O
significantly	O
lower	O
levels	O
of	O
decisional	O
conflict	O
(	O
ie	O
,	O
uncertainty	O
)	O
regarding	O
genetic	O
testing	O
(	O
chi-square	O
(	O
1	O
)	O
=	O
8.97	O
;	O
P	O
=	O
.003	O
)	O
and	O
were	O
more	O
likely	O
to	O
be	O
classified	O
as	O
having	O
made	O
an	O
informed	O
choice	O
concerning	O
genetic	O
testing	O
(	O
chi-square	O
(	O
1	O
)	O
=	O
4.37	O
;	O
P	O
=	O
.037	O
)	O
than	O
participants	O
who	O
received	O
a	O
control	Control
pamphlet	Control
.	O

Also	O
,	O
men	O
who	O
received	O
the	O
decision	Educational
aid	Educational
had	O
significantly	O
higher	O
knowledge	O
levels	O
regarding	O
genetic	O
testing	O
compared	O
with	O
men	O
who	O
received	O
the	O
control	Control
pamphlet	Control
,	O
whereas	O
no	O
such	O
differences	O
were	O
found	O
for	O
women	O
(	O
chi-square	O
(	O
2	O
)	O
=	O
6.76	O
;	O
P	O
=	O
.034	O
)	O
.	O

CONCLUSIONS	O
A	O
decision	Educational
aid	Educational
for	O
individuals	O
considering	O
genetic	O
testing	O
for	O
HNPCC	O
is	O
an	O
effective	O
intervention	O
to	O
reduce	O
uncertainty	O
and	O
assist	O
individuals	O
to	O
make	O
an	O
informed	O
choice	O
regarding	O
genetic	O
testing	O
for	O
HNPCC	O
after	O
genetic	O
counseling	O
.	O

Acute	O
pressor	O
and	O
hormonal	O
effects	O
of	O
beta-endorphin	Pharmacological
at	O
high	O
doses	O
in	O
healthy	O
and	O
hypertensive	O
subjects	O
:	O
role	O
of	O
opioid	O
receptor	O
agonism	O
.	O

CONTEXT	O
The	O
opioid	O
system	O
is	O
involved	O
in	O
blood	O
pressure	O
regulation	O
in	O
both	O
normal	O
humans	O
and	O
patients	O
with	O
essential	O
hypertension	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
high-dose	O
infusion	O
of	O
beta-endorphin	Pharmacological
,	O
an	O
opioid	O
peptide	O
,	O
on	O
blood	O
pressure	O
and	O
on	O
the	O
hormonal	O
profile	O
in	O
healthy	O
subjects	O
and	O
in	O
hypertensive	O
patients	O
and	O
the	O
mediation	O
played	O
by	O
opioid	O
receptor	O
agonism	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
According	O
to	O
a	O
randomized	O
double-blind	O
design	O
,	O
11	O
healthy	O
subjects	O
(	O
controls	O
)	O
and	O
12	O
hypertensive	O
inpatients	O
(	O
mean	O
age	O
,	O
38.9	O
and	O
40.4	O
yr	O
,	O
respectively	O
)	O
received	O
1-h	Pharmacological
iv	Pharmacological
infusion	Pharmacological
of	Pharmacological
beta-endorphin	Pharmacological
(	Pharmacological
250	Pharmacological
mug/h	Pharmacological
)	Pharmacological
and	O
,	O
on	O
another	O
occasion	O
,	O
the	O
same	O
infusion	O
protocol	O
preceded	O
by	O
the	O
opioid	Pharmacological
antagonist	Pharmacological
naloxone	Pharmacological
(	Pharmacological
8	Pharmacological
mg	Pharmacological
)	Pharmacological
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Hemodynamic	O
and	O
hormonal	O
measurements	O
were	O
performed	O
at	O
established	O
times	O
during	O
the	O
infusion	O
protocols	O
.	O

RESULTS	O
At	O
baseline	O
,	O
circulating	O
beta-endorphin	O
,	O
norepinephrine	O
,	O
and	O
endothelin-1	O
in	O
hypertensive	O
patients	O
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
higher	O
than	O
in	O
controls	O
.	O

In	O
controls	O
,	O
beta-endorphin	O
reduced	O
blood	O
pressure	O
(	O
P	O
<	O
0.01	O
)	O
and	O
circulating	O
norepinephrine	O
(	O
P	O
<	O
0.02	O
)	O
and	O
increased	O
plasma	O
atrial	O
natriuretic	O
factor	O
(	O
P	O
<	O
0.003	O
)	O
and	O
GH	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
hypertensive	O
patients	O
,	O
beta-endorphin	Pharmacological
decreased	O
systemic	O
vascular	O
resistance	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
blood	O
pressure	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
plasma	O
norepinephrine	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
endothelin-1	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
raised	O
circulating	O
atrial	O
natriuretic	O
factor	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
GH	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
IGF-I	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

These	O
hemodynamic	O
and	O
hormonal	O
responses	O
to	O
beta-endorphin	O
in	O
hypertensive	O
patients	O
were	O
significantly	O
(	O
P	O
<	O
0.0001	O
)	O
greater	O
than	O
in	O
controls	O
but	O
were	O
annulled	O
in	O
all	O
individuals	O
when	O
naloxone	O
preceded	O
beta-endorphin	O
infusion	O
.	O

CONCLUSIONS	O
High	O
doses	O
of	O
beta-endorphin	Pharmacological
induce	O
hypotensive	O
and	O
beneficial	O
hormonal	O
effects	O
in	O
humans	O
,	O
which	O
are	O
enhanced	O
in	O
essential	O
hypertension	O
and	O
are	O
mediated	O
by	O
opioid	O
receptors	O
.	O

Beverage	Physical
vs.	Educational
solid	Physical
fruits	Physical
and	Physical
vegetables	Physical
:	Educational
effects	O
on	O
energy	O
intake	O
and	O
body	O
weight	O
.	O

Beverage	O
consumption	O
has	O
been	O
implicated	O
in	O
weight	O
gain	O
,	O
but	O
questions	O
remain	O
about	O
the	O
veracity	O
of	O
the	O
association	O
,	O
whether	O
the	O
relationship	O
is	O
causal	O
and	O
what	O
property	O
of	O
beverages	O
is	O
responsible	O
.	O

It	O
was	O
hypothesized	O
that	O
food	O
form	O
is	O
the	O
most	O
salient	O
attribute	O
.	O

Thus	O
,	O
a	O
randomized	O
controlled	O
trial	O
of	O
food	O
form	O
was	O
conducted	O
.	O

Energy-matched	Physical
beverage	Physical
or	Educational
solid	Physical
forms	Physical
of	Physical
fruits	Physical
and	Physical
vegetables	Physical
were	O
provided	O
to	O
34	O
,	O
lean	O
or	O
overweight/obese	O
adults	O
for	O
two	O
8-week	O
periods	O
with	O
a	O
3-week	O
washout	O
interspersed	O
.	O

Dietary	O
compensation	O
was	O
incomplete	O
(	O
beverage	O
53	O
%	O
;	O
solid	O
78	O
%	O
)	O
and	O
body	O
weight	O
increased	O
after	O
the	O
beverage	O
(	O
1.95	O
?	O
0.33	O
kg	O
)	O
(	O
77	O
%	O
fat	O
mass	O
)	O
and	O
solid	O
(	O
1.36	O
?	O
0.30	O
kg	O
)	O
(	O
85	O
%	O
fat	O
mass	O
)	O
treatments	O
(	O
both	O
P	O
<	O
0.0005	O
)	O
.	O

Differences	O
between	O
food	O
forms	O
were	O
not	O
significant	O
.	O

The	O
lean	O
group	O
had	O
the	O
highest	O
dietary	O
compensation	O
(	O
119	O
%	O
)	O
and	O
no	O
significant	O
weight	O
change	O
(	O
0.84	O
?	O
0.53	O
kg	O
)	O
after	O
consuming	O
the	O
solid	O
fruits	O
and	O
vegetables	O
whereas	O
the	O
overweight/obese	O
group	O
had	O
lower	O
compensation	O
and	O
significant	O
weight	O
gain	O
during	O
the	O
solid	O
arm	O
(	O
46	O
%	O
,	O
1.77	O
?	O
0.32	O
kg	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
contrast	O
,	O
incomplete	O
dietary	O
compensation	O
and	O
weight	O
gain	O
occurred	O
in	O
both	O
the	O
lean	O
(	O
43	O
%	O
,	O
1.61	O
?	O
0.44	O
kg	O
,	O
P	O
=	O
0.003	O
)	O
and	O
overweight/obese	O
(	O
61	O
%	O
,	O
2.22	O
?	O
0.47	O
kg	O
,	O
P	O
<	O
0.0005	O
)	O
groups	O
during	O
the	O
beverage	O
arm	O
.	O

Secondary	O
analyses	O
revealed	O
the	O
obese	O
group	O
gained	O
more	O
weight	O
than	O
the	O
lean	O
and	O
overweight	O
groups	O
during	O
the	O
beverage	O
intervention	O
(	O
P	O
=	O
0.024	O
)	O
.	O

These	O
data	O
demonstrate	O
energy	O
consumed	O
as	O
beverages	O
may	O
be	O
especially	O
problematic	O
for	O
weight	O
gain	O
.	O

They	O
also	O
indicate	O
that	O
advice	O
to	O
increase	O
fruit	O
and	O
vegetable	O
consumption	O
should	O
emphasize	O
total	O
energy	O
intake	O
because	O
the	O
additional	O
energy	O
contributed	O
may	O
promote	O
weight	O
gain	O
,	O
especially	O
among	O
overweight	O
and	O
obese	O
individuals	O
.	O

Cardiovascular	O
complications	O
to	O
treatment	O
of	O
prostate	O
cancer	O
with	O
estramustine	Pharmacological
phosphate	Pharmacological
(	Pharmacological
Estracyt	Pharmacological
)	Pharmacological
or	O
conventional	Pharmacological
estrogen	Pharmacological
.	O

A	O
follow-up	O
of	O
212	O
randomized	O
patients	O
.	O

Two	O
hundred	O
and	O
twelve	O
patients	O
treated	O
for	O
prostatic	O
cancer	O
grade	O
I	O
or	O
II	O
were	O
investigated	O
for	O
cardiovascular	O
complications	O
.	O

The	O
patients	O
were	O
part	O
of	O
a	O
multicentre	O
study	O
in	O
the	O
Stockholm	O
area	O
and	O
had	O
been	O
randomized	O
to	O
treatment	O
with	O
either	O
estramustine	Pharmacological
phosphate	Pharmacological
(	Pharmacological
Estracyt	Pharmacological
)	Pharmacological
or	O
polyestradiol	Pharmacological
phosphate	Pharmacological
and	Pharmacological
ethinyl	Pharmacological
estradiol	Pharmacological
.	O

Cardiovascular	O
complications	O
categorized	O
as	O
impaired	O
arterial	O
circulation	O
including	O
ischemic	O
heart	O
disease	O
,	O
venous	O
thromboembolism	O
,	O
cardiac	O
incompensation	O
and	O
cerebral	O
depression	O
were	O
found	O
to	O
be	O
equally	O
frequent	O
following	O
the	O
two	O
different	O
forms	O
of	O
treatment	O
.	O

Among	O
the	O
patients	O
getting	O
cardiovascular	O
complications	O
,	O
these	O
occurred	O
within	O
two	O
months	O
after	O
the	O
start	O
of	O
treatment	O
in	O
50	O
%	O
and	O
within	O
one	O
year	O
in	O
85	O
%	O
of	O
them	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
the	O
incidence	O
of	O
cardiovascular	O
complications	O
and	O
a	O
history	O
of	O
previous	O
cardiovascular	O
disease	O
.	O

This	O
criterion	O
was	O
however	O
in	O
retrospect	O
found	O
to	O
predict	O
cardiovascular	O
complications	O
in	O
only	O
67	O
of	O
the	O
126	O
patients	O
getting	O
one	O
or	O
several	O
of	O
these	O
complications	O
.	O

[	O
A	O
multicenter	O
,	O
randomized	O
clinical	O
trial	O
of	O
intravenous	O
diltiazem	Pharmacological
in	O
treatment	O
of	O
unstable	O
angina	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
intravenous	O
diltiazem	Pharmacological
compared	O
with	O
nitroglycerin	Pharmacological
in	O
the	O
patients	O
with	O
unstable	O
angina	O
pectoris	O
.	O

METHODS	O
A	O
multicenter	O
,	O
randomized	O
,	O
open-label	O
,	O
parallel	O
group	O
trial	O
was	O
conducted	O
.	O

A	O
total	O
of	O
213	O
eligible	O
patients	O
were	O
enrolled	O
.	O

They	O
were	O
randomized	O
either	O
to	O
diltiazem	Pharmacological
or	O
nitroglycerin	Pharmacological
treatment	O
.	O

The	O
diltiazem	Pharmacological
was	O
administered	O
from	O
100	O
microg/min	O
at	O
the	O
initiation	O
of	O
treatment	O
,	O
the	O
largest	O
dosage	O
was	O
200	O
-	O
300	O
microg/min	O
;	O
the	O
nitroglycerin	Pharmacological
was	O
administered	O
from	O
20	O
microg/min	O
at	O
the	O
initiation	O
of	O
treatment	O
.	O

The	O
largest	O
dosage	O
was	O
80	O
-	O
100	O
microg/min	O
.	O

Intravenous	O
infusion	O
was	O
kept	O
over	O
48	O
hours	O
.	O

The	O
endpoints	O
included	O
refractory	O
angina	O
pectoris	O
,	O
acute	O
myocardial	O
infarction	O
,	O
death	O
,	O
emergency	O
PTCA	O
and	O
CABG	O
.	O

RESULTS	O
(	O
1	O
)	O
Intravenous	O
diltiazem	O
was	O
effective	O
on	O
the	O
improvement	O
of	O
symptom	O
and	O
electrocardiogram	O
,	O
and	O
its	O
effects	O
were	O
similar	O
to	O
intravenous	O
nitroglycerin	O
.	O

(	O
2	O
)	O
Compared	O
with	O
nitroglycerin	Pharmacological
,	O
intravenous	O
diltiazem	Pharmacological
lowered	O
heart	O
rate	O
and	O
myocardial	O
oxygen	O
consumption	O
index	O
(	O
systolic	O
pressure	O
x	O
heart	O
rate	O
)	O
to	O
more	O
extent	O
significantly	O
.	O

(	O
3	O
)	O
After	O
treatment	O
,	O
the	O
onsets	O
of	O
refractory	O
angina	O
pectoris	O
were	O
reduced	O
more	O
significantly	O
in	O
the	O
diltiazem	Pharmacological
group	O
than	O
in	O
nitroglycerin	O
group	O
[	O
4	O
(	O
3.8	O
%	O
)	O
vs	O
13	O
(	O
11.9	O
%	O
)	O
,	O
RR	O
0.32	O
(	O
95	O
%	O
CI	O
0.11	O
-	O
0.96	O
)	O
,	O
P	O
<	O
0.05	O
]	O
.	O

(	O
4	O
)	O
The	O
patients	O
whose	O
heart	O
rate	O
were	O
reduced	O
significantly	O
(	O
<	O
or=	O
50	O
beats	O
per	O
minute	O
)	O
in	O
the	O
diltiazem	O
group	O
were	O
more	O
than	O
in	O
the	O
nitroglycerin	O
group	O
[	O
8	O
(	O
7.7	O
%	O
)	O
vs	O
0	O
(	O
0	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O

But	O
these	O
patients	O
could	O
tolerate	O
the	O
lower	O
heart	O
rate	O
very	O
well	O
in	O
the	O
diltiazem	O
group	O
.	O

(	O
5	O
)	O
The	O
needs	O
of	O
beta	O
receptor	O
blocker	O
or	O
calcium	O
antagonists	O
were	O
reduced	O
more	O
significantly	O
in	O
the	O
diltiazem	Pharmacological
group	O
compared	O
with	O
those	O
in	O
the	O
nitroglycerin	O
group	O
[	O
2	O
(	O
1.9	O
%	O
)	O
vs	O
13	O
(	O
11.9	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O

CONCLUSION	O
Intravenous	O
diltiazem	Pharmacological
therapy	O
is	O
effective	O
and	O
safe	O
for	O
patients	O
with	O
unstable	O
angina	O
pectoris	O
.	O

It	O
may	O
significantly	O
lower	O
the	O
risk	O
of	O
refractory	O
angina	O
pectoris	O
compared	O
with	O
intravenous	O
nitroglycerin	O
.	O

Stapled	Surgical
hemorrhoidopexy	Surgical
vs.	O
Harmonic	Surgical
Scalpel	Surgical
hemorrhoidectomy	Surgical
:	O
a	O
randomized	O
trial	O
.	O

PURPOSE	O
A	O
randomized	O
trial	O
was	O
undertaken	O
to	O
evaluate	O
and	O
compare	O
stapled	Surgical
hemorrhoidopexy	Surgical
with	Surgical
excisional	Surgical
hemorrhoidectomy	Surgical
in	O
which	O
the	O
Harmonic	O
Scalpel	O
was	O
used	O
.	O

METHODS	O
Patients	O
with	O
Grade	O
III	O
hemorrhoids	O
who	O
were	O
employed	O
during	O
the	O
trial	O
period	O
were	O
recruited	O
and	O
randomized	O
into	O
two	O
groups	O
:	O
(	O
1	O
)	O
Harmonic	Surgical
Scalpel	Surgical
hemorrhoidectomy	Surgical
,	O
and	O
(	O
2	O
)	O
stapled	Surgical
hemorrhoidopexy	Surgical
.	O

All	O
operations	O
were	O
performed	O
by	O
a	O
single	O
surgeon	O
.	O

In	O
the	O
stapled	O
group	O
,	O
the	O
doughnut	O
obtained	O
was	O
sent	O
for	O
histopathologic	O
examination	O
to	O
determine	O
whether	O
smooth	O
muscles	O
were	O
included	O
in	O
the	O
specimen	O
.	O

Operative	O
data	O
and	O
complications	O
were	O
recorded	O
,	O
and	O
patients	O
were	O
followed	O
up	O
through	O
a	O
structured	O
pro	O
forma	O
protocol	O
.	O

An	O
independent	O
assessor	O
was	O
assigned	O
to	O
obtain	O
postoperative	O
pain	O
scores	O
and	O
satisfaction	O
scores	O
at	O
six-month	O
follow-up	O
.	O

Patients	O
were	O
also	O
administered	O
a	O
simple	Educational
questionnaire	Educational
at	O
follow-up	O
to	O
assess	O
continence	O
functions	O
.	O

RESULTS	O
Over	O
a	O
20-month	O
period	O
,	O
88	O
patients	O
were	O
recruited	O
.	O

The	O
two	O
groups	O
were	O
matched	O
for	O
age	O
and	O
gender	O
distribution	O
.	O

No	O
significant	O
difference	O
was	O
identified	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
operation	O
time	O
,	O
blood	O
loss	O
,	O
day	O
of	O
first	O
bowel	O
movement	O
after	O
surgery	O
,	O
and	O
complication	O
rates	O
.	O

Despite	O
a	O
similar	O
parenteral	O
and	O
oral	O
analgesic	O
requirement	O
,	O
the	O
stapled	O
group	O
had	O
a	O
significantly	O
better	O
pain	O
score	O
(	O
P	O
=	O
0.002	O
)	O
;	O
these	O
patients	O
also	O
had	O
a	O
significantly	O
shorter	O
length	O
of	O
stay	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
on	O
average	O
resumed	O
work	O
nine	O
days	O
earlier	O
than	O
the	O
group	O
treated	O
with	O
the	O
Harmonic	O
Scalpel	O
(	O
6.7	O
vs.	O
15.6	O
,	O
P	O
=	O
0.002	O
)	O
.	O

Although	O
88	O
percent	O
of	O
doughnuts	O
obtained	O
in	O
the	O
stapled	O
group	O
contained	O
some	O
smooth	O
muscle	O
fibers	O
,	O
no	O
association	O
was	O
found	O
between	O
smooth	O
muscle	O
incorporation	O
and	O
postoperative	O
continence	O
function	O
,	O
and	O
as	O
a	O
whole	O
the	O
continence	O
outcomes	O
of	O
the	O
stapled	O
group	O
were	O
similar	O
to	O
those	O
after	O
Harmonic	O
Scalpel	O
hemorrhoidectomy	O
.	O

Finally	O
,	O
at	O
six-month	O
follow-up	O
,	O
patients	O
who	O
underwent	O
the	O
stapled	Surgical
procedure	O
had	O
significantly	O
better	O
satisfaction	O
scores	O
(	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSION	O
Stapled	Surgical
hemorrhoidopexy	Surgical
is	O
a	O
safe	O
and	O
effective	O
procedure	O
for	O
Grade	O
III	O
hemorrhoidal	O
disease	O
.	O

Patients	O
derive	O
greater	O
short-term	O
benefits	O
of	O
reduced	O
pain	O
,	O
shorter	O
length	O
of	O
stay	O
,	O
and	O
earlier	O
resumption	O
to	O
work	O
.	O

Long-term	O
follow-up	O
is	O
necessary	O
to	O
determine	O
whether	O
these	O
initial	O
results	O
are	O
lasting	O
.	O

Paromomycin	Pharmacological
for	O
cryptosporidiosis	O
in	O
AIDS	O
:	O
a	O
prospective	O
,	O
double-blind	O
trial	O
.	O

To	O
test	O
the	O
effects	O
of	O
paromomycin	Pharmacological
,	O
10	O
patients	O
with	O
AIDS	O
and	O
cryptosporidiosis	O
were	O
randomized	O
to	O
paromomycin	Pharmacological
or	O
placebo	Control
in	O
a	O
double-blind	O
trial	O
.	O

After	O
14	O
days	O
,	O
patients	O
were	O
switched	O
to	O
the	O
other	O
treatment	O
for	O
14	O
additional	O
days	O
.	O

Measures	O
included	O
the	O
number	O
and	O
character	O
of	O
each	O
stool	O
and	O
weekly	O
24-h	O
stool	O
specimens	O
for	O
weight	O
and	O
oocyst	O
excretion	O
.	O

During	O
the	O
paromomycin	Pharmacological
treatment	O
phase	O
,	O
oocyst	O
excretion	O
decreased	O
from	O
314	O
x	O
10	O
(	O
6	O
)	O
to	O
109	O
x	O
10	O
(	O
6	O
)	O
24	O
h	O
(	O
P	O
<	O
.02	O
)	O
.	O

Oocyst	O
excretion	O
increased	O
for	O
the	O
4	O
patients	O
initially	O
on	O
placebo	Control
compared	O
to	O
a	O
median	O
decrease	O
of	O
128	O
x	O
10	O
(	O
6	O
)	O
/24	O
h	O
for	O
the	O
6	O
initially	O
treated	O
with	O
drug	O
(	O
P	O
<	O
.02	O
)	O
.	O

Stool	O
frequency	O
also	O
decreased	O
more	O
in	O
those	O
treated	O
with	O
drug	Pharmacological
(	O
3.6	O
fewer	O
vs.	O
1.25	O
fewer/24	O
h	O
,	O
P	O
<	O
.05	O
)	O
.	O

Trends	O
favored	O
drug	O
over	O
placebo	Control
for	O
stool	O
weight	O
,	O
stool	O
character	O
,	O
and	O
Karnofsky	O
score	O
.	O

Paromomycin	Pharmacological
treatment	O
resulted	O
in	O
improvement	O
in	O
both	O
clinical	O
and	O
parasitologic	O
parameters	O
in	O
cryptosporidiosis	O
in	O
AIDS	O
.	O

Double-blind	O
placebo-controlled	O
trial	O
of	O
pentoxifylline	Pharmacological
added	Pharmacological
to	Pharmacological
risperidone	Pharmacological
:	O
effects	O
on	O
aberrant	O
behavior	O
in	O
children	O
with	O
autism	O
.	O

BACKGROUND	O
There	O
are	O
several	O
lines	O
of	O
evidence	O
to	O
indicate	O
that	O
the	O
immune	O
system	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
autism	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
access	O
the	O
effects	O
of	O
pentoxifylline	Pharmacological
plus	Pharmacological
risperidone	Pharmacological
in	O
the	O
treatment	O
of	O
autistic	O
disorder	O
.	O

METHODS	O
Forty	O
children	O
between	O
the	O
ages	O
4	O
and	O
12	O
years	O
with	O
a	O
DSM	O
IV-TR	O
clinical	O
diagnosis	O
of	O
autism	O
were	O
recruited	O
.	O

The	O
children	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
severely	O
disruptive	O
symptoms	O
related	O
to	O
autistic	O
disorder	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
pentoxifylline+risperidone	Pharmacological
or	O
placebo+risperidone	Pharmacological
for	O
a	O
10-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

The	O
dose	O
of	O
risperidone	Pharmacological
was	O
titrated	O
up	O
to	O
3	O
mg/day	O
,	O
pentoxifylline	Pharmacological
was	O
titrated	O
to	O
600	O
mg/day	O
.	O

Patients	O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
and	O
10	O
weeks	O
of	O
starting	O
medication	O
.	O

The	O
measure	O
of	O
the	O
outcome	O
was	O
the	O
Aberrant	O
Behavior	O
Checklist-Community	O
(	O
ABC-C	O
)	O
.	O

RESULTS	O
The	O
difference	O
between	O
the	O
two	O
protocols	O
was	O
significant	O
as	O
the	O
group	O
that	O
received	O
pentoxifylline	Pharmacological
had	O
greater	O
reduction	O
in	O
ABC-C	O
subscale	O
scores	O
for	O
Irritability	O
,	O
Lethargy/Social	O
Withdrawal	O
,	O
Stereotypic	O
Behavior	O
,	O
Hyperactivity/Noncompliance	O
and	O
Inappropriate	O
Speech	O
.	O

CONCLUSION	O
The	O
results	O
suggest	O
that	O
combination	Pharmacological
of	Pharmacological
atypical	Pharmacological
antipsychotic	Pharmacological
medications	Pharmacological
and	Pharmacological
pentoxifylline	Pharmacological
might	O
have	O
synergistic	O
effects	O
in	O
treatment	O
of	O
behavioral	O
problems	O
of	O
children	O
with	O
autism	O
.	O

Novel	O
population	O
pharmacokinetic	O
method	O
compared	O
to	O
the	O
standard	O
noncompartmental	O
approach	O
to	O
assess	O
bioequivalence	O
of	O
iron	O
gluconate	O
formulations	O
.	O

PURPOSE	O
Iron-containing	O
products	O
are	O
atypical	O
in	O
terms	O
of	O
their	O
pharmacokinetic	O
properties	O
because	O
iron	O
is	O
only	O
removed	O
by	O
plasma	O
sampling	O
and	O
is	O
non-linear	O
.	O

This	O
study	O
aims	O
to	O
present	O
a	O
novel	O
way	O
of	O
assessing	O
the	O
relative	O
bioavailability	O
of	O
two	O
sodium	Pharmacological
ferric	Pharmacological
gluconate	Pharmacological
complex	Pharmacological
(	Pharmacological
SFGC	Pharmacological
)	Pharmacological
formulations	O
and	O
compare	O
this	O
approach	O
to	O
a	O
standard	O
previously	O
published	O
noncompartmental	O
approach	O
.	O

METHODS	O
Data	O
were	O
from	O
open-label	O
,	O
randomized	O
,	O
single-dose	O
studies	O
(	O
Study	O
1	O
was	O
parallel	O
whereas	O
Study	O
2	O
was	O
crossover	O
)	O
.	O

Subjects	O
with	O
low	O
but	O
normal	O
iron	O
levels	O
were	O
infused	O
IV	Pharmacological
SFGC	Pharmacological
in	Pharmacological
sucrose	Pharmacological
by	O
GeneraMedix	O
Inc.	O
and/or	O
Ferrlecit	O
?	O
Injection	O
(	O
Watson	O
Laboratories	O
Inc.	O
)	O
.	O

In	O
Study	O
1	O
(	O
n=240	O
)	O
,	O
125	O
mg	O
was	O
infused	O
over	O
10	O
minutes	O
.	O

In	O
Study	O
2	O
(	O
n=29	O
)	O
,	O
62.5	O
mg	O
was	O
infused	O
over	O
30	O
minutes	O
.	O

Samples	O
were	O
assayed	O
for	O
total	O
iron	O
(	O
TI	O
)	O
and	O
transferrin-bound	O
iron	O
(	O
TBI	O
)	O
over	O
36	O
hours	O
(	O
Study	O
1	O
)	O
or	O
72	O
hours	O
(	O
Study	O
2	O
)	O
post-dose	O
.	O

Studies	O
1	O
and	O
2	O
used	O
standard	O
noncompartmental	O
analysis	O
.	O

Study	O
2	O
also	O
used	O
population	O
PK	O
(	O
PPK	O
)	O
analyses	O
with	O
ADAPT	O
5?	O
.	O

The	O
final	O
model	O
predicted	O
SFGC	O
area-under-the-curve	O
(	O
AUCpred	O
)	O
and	O
maximal	O
concentration	O
(	O
Cmaxpred	O
)	O
.	O

Analyses	O
of	O
variance	O
was	O
conducted	O
on	O
ln-transformed	O
PK	O
parameters	O
.	O

Ratios	O
of	O
means	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
estimated	O
.	O

Bioequivalence	O
was	O
demonstrated	O
if	O
values	O
were	O
within	O
80-125	O
%	O
.	O

RESULTS	O
For	O
Study	O
1	O
,	O
ratios	O
and	O
90	O
%	O
CIs	O
for	O
TI	O
baseline-corrected	O
Cmax	O
and	O
AUC0-36	O
were	O
100.4	O
(	O
96.5	O
-	O
104.5	O
)	O
and	O
99.7	O
(	O
94.2	O
-	O
105.5	O
)	O
.	O

For	O
TBI	O
,	O
results	O
for	O
TI	O
baseline-corrected	O
Cmax	O
and	O
AUC0-36	O
were	O
86.8	O
(	O
82.7	O
-	O
91.1	O
)	O
and	O
92.4	O
(	O
85.6	O
-	O
99.7	O
)	O
.	O

For	O
Study	O
2	O
,	O
a	O
multi-compartmental	O
model	O
simultaneously	O
described	O
the	O
PK	O
of	O
TI	O
,	O
TBI	O
and	O
SFGC	O
.	O

Ratios	O
and	O
90	O
%	O
CIs	O
for	O
SFGC	O
Cmaxpred	O
and	O
AUCpred	O
were	O
89.9	O
(	O
85.9	O
-	O
94.0	O
)	O
and	O
89.7	O
(	O
85.7	O
-	O
93.9	O
)	O
,	O
while	O
ratios	O
and	O
90	O
%	O
CI	O
obtained	O
from	O
the	O
noncompartmental	O
analysis	O
of	O
Study	O
2	O
did	O
not	O
meet	O
BE	O
criteria	O
because	O
of	O
low	O
power	O
.	O

CONCLUSIONS	O
Both	O
the	O
standard	O
and	O
PPK	O
modeling	O
approach	O
suggested	O
bioequivalence	O
between	O
the	O
iron	O
products	O
.	O

However	O
,	O
with	O
the	O
PPK	O
method	O
,	O
less	O
subjects	O
were	O
required	O
to	O
meet	O
study	O
objectives	O
compared	O
to	O
the	O
standard	O
noncompartmental	O
approach	O
which	O
required	O
considerably	O
more	O
subjects	O
(	O
29	O
vs	O
240	O
)	O
.	O

Classroom	Educational
intervention	Educational
for	O
illness-related	O
problem	O
behavior	O
in	O
children	O
with	O
developmental	O
disabilities	O
.	O

There	O
is	O
growing	O
evidence	O
of	O
an	O
association	O
between	O
physical	O
illness	O
and	O
problem	O
behavior	O
in	O
children	O
with	O
developmental	O
disabilities	O
.	O

Such	O
behavior	O
can	O
compromise	O
school	O
performance	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
,	O
using	O
a	O
group	O
design	O
,	O
the	O
effectiveness	O
of	O
medical	Pharmacological
intervention	Pharmacological
alone	Pharmacological
(	O
N	O
=	O
11	O
)	O
versus	O
behavioral	Educational
plus	Educational
medical	Other
intervention	Other
(	O
N	O
=	O
10	O
)	O
for	O
illness-related	O
problem	O
behavior	O
in	O
a	O
school	O
setting	O
.	O

Following	O
intervention	O
,	O
the	O
behavioral	O
plus	O
medical	O
intervention	O
group	O
showed	O
lower	O
levels	O
of	O
problem	O
behavior	O
and	O
completed	O
more	O
academic	O
tasks	O
than	O
did	O
the	O
medical	O
intervention	O
alone	O
group	O
.	O

The	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
concept	O
of	O
illness	O
and	O
pain	O
as	O
a	O
setting	O
event	O
for	O
problem	O
behavior	O
.	O

The	O
need	O
for	O
research	O
to	O
develop	O
algorithms	O
that	O
allow	O
one	O
to	O
select	O
the	O
best	O
combination	O
of	O
medical	Other
and	Educational
behavioral	Educational
interventions	Educational
for	O
specific	O
illnesses	O
and	O
contexts	O
is	O
noted	O
.	O

A	O
systems	O
analysis	O
of	O
obstetric	O
triage	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
examine	O
some	O
of	O
the	O
variables	O
involved	O
in	O
obstetric	O
triage	O
in	O
an	O
effort	O
to	O
develop	O
a	O
more	O
efficient	O
patient	O
care	O
delivery	O
system	O
in	O
a	O
high-volume	O
obstetric	O
unit	O
.	O

An	O
efficient	O
triage	O
system	O
is	O
essential	O
to	O
a	O
busy	O
labor	O
and	O
delivery	O
unit	O
for	O
the	O
evaluation	O
of	O
unscheduled	O
patient	O
visits	O
.	O

In	O
hospitals	O
that	O
lack	O
an	O
efficient	O
obstetric	O
triage	O
system	O
,	O
it	O
is	O
very	O
difficult	O
to	O
regulate	O
patient	O
flow	O
and	O
wait	O
times	O
.	O

METHOD	O
The	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
a	O
triage	O
room	O
and/or	O
standing	O
orders	O
decreased	O
length	O
of	O
stay	O
as	O
compared	O
to	O
the	O
existing	O
system	O
of	O
evaluating	O
women	O
in	O
labor	O
rooms	O
.	O

In	O
2	O
separate	O
phases	O
,	O
women	O
who	O
met	O
triage	O
criteria	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
triage	O
room	O
or	O
the	O
standard	O
care	O
labor	O
room	O
.	O

During	O
phase	O
1	O
,	O
the	O
effect	O
of	O
room	O
assignment	O
was	O
evaluated	O
.	O

During	O
phase	O
2	O
,	O
the	O
effect	O
of	O
room	O
assignment	O
and	O
the	O
intervention	O
of	O
standing	Physical
orders	Physical
in	Physical
common	Physical
obstetric	Physical
problems	Physical
were	O
utilized	O
.	O

The	O
total	O
sample	O
size	O
was	O
398	O
patients	O
.	O

The	O
study	O
took	O
place	O
on	O
a	O
midsize	O
labor	O
and	O
delivery	O
unit	O
,	O
in	O
an	O
academic	O
medical	O
center	O
averaging	O
3600	O
births	O
per	O
year	O
.	O

RESULTS	O
Results	O
showed	O
that	O
using	O
a	O
triage	O
room	O
and/or	O
standing	O
orders	O
did	O
not	O
significantly	O
decrease	O
length	O
of	O
stay	O
.	O

CONCLUSION	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
triage	O
process	O
in	O
this	O
setting	O
is	O
strongly	O
dependent	O
on	O
the	O
provider	O
's	O
availability	O
to	O
assess	O
,	O
triage	O
,	O
and	O
discharge	O
patients	O
.	O

Behavioral	O
and	O
physiological	O
effects	O
of	O
remifentanil	Pharmacological
and	O
alfentanil	Pharmacological
in	O
healthy	O
volunteers	O
.	O

BACKGROUND	O
The	O
subjective	O
and	O
psychomotor	O
effects	O
of	O
remifentanil	Pharmacological
have	O
not	O
been	O
evaluated	O
.	O

Accordingly	O
,	O
the	O
authors	O
used	O
mood	O
inventories	O
and	O
psychomotor	O
tests	O
to	O
characterize	O
the	O
effects	O
of	O
remifentanil	Pharmacological
in	O
healthy	O
,	O
non-drug-abusing	O
volunteers	O
.	O

Alfentanil	O
was	O
used	O
as	O
a	O
comparator	O
drug	O
.	O

METHODS	O
Ten	O
healthy	O
volunteers	O
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double-blinded	O
,	O
placebo-controlled	Control
,	O
crossover	O
trial	O
in	O
which	O
they	O
received	O
an	O
infusion	O
of	O
saline	Pharmacological
,	O
remifentanil	Pharmacological
,	O
or	O
alfentanil	Pharmacological
for	O
120	O
min	O
.	O

The	O
age-	O
and	O
weight-adjusted	O
infusions	O
(	O
determined	O
with	O
STANPUMP	Pharmacological
,	O
a	O
computer	Pharmacological
modeling	Pharmacological
software	Pharmacological
package	Pharmacological
)	O
were	O
given	O
to	O
achieve	O
three	O
predicted	O
constant	O
plasma	O
levels	O
for	O
40	O
min	O
each	O
of	O
remifentanil	Pharmacological
(	O
0.75	O
,	O
1.5	O
,	O
and	O
3	O
ng/ml	O
)	O
and	O
alfentanil	O
(	O
16	O
,	O
32	O
,	O
and	O
64	O
ng/ml	O
)	O
.	O

Mood	O
forms	O
and	O
psychomotor	O
tests	O
were	O
completed	O
,	O
and	O
miosis	O
was	O
assessed	O
,	O
during	O
and	O
after	O
the	O
infusions	O
.	O

In	O
addition	O
,	O
analgesia	O
was	O
tested	O
at	O
each	O
dose	O
level	O
using	O
a	O
cold-pressor	O
test	O
.	O

RESULTS	O
Remifentanil	Pharmacological
had	O
prototypic	O
micro-like	O
opioid	O
subjective	O
effects	O
,	O
impaired	O
psychomotor	O
performance	O
,	O
and	O
produced	O
analgesia	O
.	O

Alfentanil	O
at	O
the	O
dose	O
range	O
tested	O
had	O
more	O
mild	O
effects	O
on	O
these	O
measures	O
,	O
and	O
the	O
analgesia	O
data	O
indicated	O
that	O
a	O
40:1	O
potency	O
ratio	O
,	O
rather	O
than	O
the	O
20:1	O
ratio	O
we	O
used	O
,	O
may	O
exist	O
between	O
remifentanil	O
and	O
alfentanil	O
.	O

A	O
psychomotor	O
test	O
administered	O
60	O
min	O
after	O
the	O
remifentanil	O
infusion	O
was	O
discontinued	O
showed	O
that	O
the	O
volunteers	O
were	O
still	O
impaired	O
,	O
although	O
they	O
reported	O
feeling	O
no	O
drug	O
effects	O
.	O

CONCLUSIONS	O
The	O
notion	O
that	O
the	O
pharmacodynamic	O
effects	O
of	O
remifentanil	Pharmacological
are	O
extremely	O
short-lived	O
after	O
the	O
drug	O
is	O
no	O
longer	O
administered	O
must	O
be	O
questioned	O
given	O
our	O
findings	O
that	O
psychomotor	O
effects	O
were	O
still	O
apparent	O
1	O
h	O
after	O
the	O
infusion	O
was	O
discontinued	O
.	O

Does	O
short-term	O
treatment	O
with	O
proton	Pharmacological
pump	Pharmacological
inhibitors	Pharmacological
cause	O
rebound	O
aggravation	O
of	O
symptoms	O
?	O
BACKGROUND	O
Rebound	O
acid	O
hypersecretion	O
might	O
occur	O
after	O
treatment	O
with	O
proton	Pharmacological
pump	Pharmacological
inhibitors	Pharmacological
.	O

This	O
study	O
looks	O
for	O
a	O
rebound	O
aggravation	O
of	O
symptoms	O
after	O
short-term	O
treatment	O
with	O
lansoprazole	Pharmacological
.	Pharmacological

STUDY	O
Sixty-two	O
patients	O
(	O
19	O
men	O
and	O
43	O
women	O
;	O
mean	O
age	O
,	O
54	O
years	O
;	O
range	O
,	O
32-77	O
years	O
)	O
with	O
heartburn	O
and	O
regurgitation	O
and	O
normal	O
upper	O
endoscopy	O
findings	O
were	O
studied	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
with	O
a	O
crossover	O
design	O
.	O

There	O
were	O
two	O
5-day	O
treatment	O
periods	O
with	O
lansoprazole	Pharmacological
60	Pharmacological
mg	Pharmacological
once	Pharmacological
daily	Pharmacological
or	O
placebo	Control
in	O
random	O
order	O
,	O
separated	O
by	O
a	O
9-day	O
washout	O
period	O
.	O

Reflux	O
,	O
total	O
,	O
and	O
antacid	O
scores	O
were	O
calculated	O
for	O
each	O
of	O
the	O
treatment	O
periods	O
.	O

Higher	O
scores	O
during	O
the	O
placebo	Control
period	O
in	O
the	O
group	O
given	O
lansoprazole	Pharmacological
first	O
than	O
in	O
the	O
group	O
given	O
placebo	O
first	O
indicated	O
a	O
rebound	O
aggravation	O
of	O
symptoms	O
.	O

RESULTS	O
The	O
mean	O
symptom	O
scores	O
during	O
the	O
placebo	Control
period	O
in	O
the	O
groups	O
given	O
lansoprazole	O
first	O
and	O
placebo	O
first	O
were	O
as	O
follows	O
:	O
reflux	O
score	O
,	O
21.5	O
and	O
17.6	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
;	O
total	O
score	O
,	O
11.2	O
and	O
10.3	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
;	O
and	O
antacid	O
score	O
,	O
8.2	O
and	O
7.2	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

CONCLUSIONS	O
There	O
is	O
no	O
indication	O
of	O
a	O
rebound	O
aggravation	O
of	O
symptoms	O
12	O
to	O
14	O
days	O
after	O
a	O
5-day	O
treatment	O
with	O
lansoprazole	Pharmacological
60	O
mg	O
once	O
daily	O
in	O
patients	O
with	O
reflux	O
symptoms	O
.	O

Successful	O
treatment	O
of	O
blepharitis	O
with	O
bibrocathol	O
(	O
Posiformin?	O
2	O
%	O
)	O
.	O

BACKGROUND	O
Bibrocathol	O
is	O
a	O
well-established	O
antiseptic	O
drug	O
for	O
the	O
treatment	O
of	O
acute	O
eyelid	O
diseases	O
like	O
blepharitis	O
.	O

Despite	O
its	O
frequent	O
use	O
in	O
clinical	O
practice	O
,	O
no	O
controlled	O
clinical	O
trial	O
on	O
the	O
efficacy	O
of	O
bibrocathol	O
2	O
%	O
eye	O
ointment	O
has	O
been	O
performed	O
until	O
now	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
efficacy	O
,	O
safety	O
and	O
tolerability	O
of	O
bibrocathol	O
(	O
Posiformin?	O
2	O
%	O
)	O
eye	O
ointment	O
in	O
patients	O
diagnosed	O
with	O
blepharitis	O
.	O

METHODS	O
In	O
this	O
multi-center	O
,	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
parallel-group	O
comparison	O
,	O
the	O
change	O
of	O
signs	O
and	O
symptoms	O
(	O
sum	O
score	O
)	O
of	O
blepharitis	O
in	O
197	O
patients	O
(	O
ITT	O
(	O
intention-to-treat-group	O
)	O
;	O
mean	O
age	O
56	O
?	O
18	O
years	O
,	O
56	O
%	O
female	O
,	O
active	O
drug	O
:	O
vehicle	O
=	O
97:100	O
)	O
over	O
2	O
weeks	O
treatment	O
with	O
bibrocathol	O
2	O
%	O
eye	O
ointment	O
was	O
evaluated	O
.	O

RESULTS	O
Patients	O
receiving	O
bibrocathol	O
2	O
%	O
showed	O
greater	O
improvement	O
in	O
the	O
sum	O
score	O
than	O
the	O
placebo	O
patients	O
(	O
p	O
<	O
0.0001	O
,	O
Cohen	O
's	O
effect	O
size	O
d	O
=	O
0.73	O
)	O
.	O

Also	O
,	O
the	O
results	O
from	O
further	O
efficacy	O
assessments	O
improvement	O
of	O
single	O
symptoms	O
and	O
ocular	O
discomfort	O
measured	O
by	O
a	O
VAS	O
(	O
visual	O
analogue	O
scale	O
)	O
supported	O
treatment	O
with	O
bibrocathol	O
.	O

Patients	O
and	O
investigators	O
provided	O
favorable	O
tolerability	O
ratings	O
preferring	O
bibrocathol	O
over	O
placebo	O
.	O

No	O
safety	O
issues	O
were	O
observed	O
with	O
regard	O
to	O
intraocular	O
pressure	O
,	O
visual	O
acuity	O
,	O
or	O
occurrence	O
of	O
adverse	O
events	O
.	O

CONCLUSIONS	O
Blepharitis	O
therapy	O
with	O
the	O
antiseptic	O
bibrocathol	O
2	O
%	O
in	O
this	O
trial	O
was	O
highly	O
efficacious	O
and	O
safe	O
.	O

Evaluation	O
of	O
a	O
device	Physical
to	Physical
facilitate	Physical
female	Physical
urethral	Physical
catheterization	Physical
.	O

Urethral	Physical
catheterization	Physical
is	O
a	O
skilled	O
procedure	O
that	O
nurses	O
in	O
hospital	O
settings	O
perform	O
routinely	O
.	O

The	O
opening	O
of	O
the	O
female	O
urethra	O
is	O
located	O
within	O
the	O
vulvar	O
vestibule	O
,	O
making	O
insertion	O
of	O
urinary	O
catheters	O
into	O
females	O
a	O
greater	O
technical	O
challenge	O
than	O
in	O
males	O
.	O

Researchers	O
evaluated	O
whether	O
a	O
new	O
device	O
might	O
decrease	O
the	O
time	O
required	O
for	O
catheter	O
insertion	O
,	O
increase	O
the	O
likelihood	O
of	O
inserting	O
the	O
catheter	O
on	O
the	O
first	O
attempt	O
(	O
improved	O
accuracy	O
)	O
,	O
and	O
reduce	O
patient	O
discomfort	O
.	O

Comments	O
about	O
the	O
device	O
from	O
both	O
patients	O
and	O
nurses	O
also	O
are	O
reported	O
.	O

Atypical	O
recruitment	O
of	O
medial	O
prefrontal	O
cortex	O
in	O
autism	O
spectrum	O
disorders	O
:	O
an	O
fMRI	Physical
study	O
of	O
two	O
executive	O
function	O
tasks	O
.	O

Recent	O
studies	O
have	O
suggested	O
an	O
uneven	O
profile	O
of	O
executive	O
dysfunction	O
in	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
.	O

For	O
example	O
,	O
some	O
authors	O
have	O
reported	O
deficits	O
on	O
newly	O
developed	O
tests	O
of	O
executive	O
function	O
sensitive	O
to	O
rostral	O
prefrontal	O
function	O
,	O
despite	O
spared	O
,	O
or	O
even	O
superior	O
,	O
performance	O
on	O
other	O
tests	O
.	O

We	O
investigated	O
the	O
performance	O
of	O
a	O
group	O
of	O
high-functioning	O
participants	O
with	O
ASD	O
(	O
N=15	O
)	O
and	O
an	O
age-	O
and	O
IQ-matched	O
control	O
group	O
(	O
N=18	O
)	O
on	O
two	Physical
executive	Physical
function	Physical
tests	Physical
,	O
whilst	O
undergoing	Physical
functional	Physical
magnetic	Physical
resonance	Physical
imaging	Physical
(	Physical
fMRI	Physical
)	Physical
.	Physical

Behaviourally	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
.	O

In	O
a	O
classical	Physical
test	Physical
of	Physical
executive	Physical
function	Physical
(	O
random	O
response	O
generation	O
)	O
,	O
BOLD	O
signal	O
differed	O
between	O
the	O
groups	O
in	O
the	O
cerebellum	O
but	O
not	O
in	O
the	O
frontal	O
lobes	O
.	O

However	O
,	O
on	O
a	O
new	Physical
test	Physical
of	Physical
executive	Physical
function	Physical
(	O
selection	O
between	O
stimulus-oriented	O
and	O
stimulus-independent	O
thought	O
)	O
,	O
the	O
ASD	O
group	O
exhibited	O
significantly	O
greater	O
signal-change	O
in	O
medial	O
rostral	O
prefrontal	O
cortex	O
(	O
especially	O
Brodmann	O
Area	O
10	O
)	O
in	O
the	O
comparison	O
of	O
stimulus-oriented	O
versus	O
stimulus-independent	O
attention	O
.	O

In	O
addition	O
,	O
the	O
new	O
test	O
(	O
but	O
not	O
the	O
classical	O
test	O
)	O
provided	O
evidence	O
for	O
abnormal	O
functional	O
organisation	O
of	O
medial	O
prefrontal	O
cortex	O
in	O
ASD	O
.	O

These	O
results	O
underline	O
the	O
heterogeneity	O
of	O
different	O
tests	O
of	O
executive	O
function	O
,	O
and	O
suggest	O
that	O
executive	O
functioning	O
in	O
ASD	O
is	O
associated	O
with	O
task-specific	O
functional	O
change	O
.	O

Usefulness	O
of	O
temporal	O
changes	O
in	O
neurohormones	O
as	O
markers	O
of	O
ventricular	O
remodeling	O
and	O
prognosis	O
in	O
patients	O
with	O
left	O
ventricular	O
systolic	O
dysfunction	O
and	O
heart	O
failure	O
receiving	O
either	O
candesartan	Pharmacological
or	O
enalapril	Pharmacological
or	O
both	O
.	O

Although	O
various	O
neurohormones	O
at	O
initial	O
measurement	O
confer	O
prognostic	O
value	O
in	O
heart	O
failure	O
and	O
correlate	O
with	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
EF	O
)	O
and	O
cardiac	O
volumes	O
,	O
the	O
significance	O
of	O
their	O
temporal	O
changes	O
(	O
Delta	O
)	O
remains	O
undetermined	O
.	O

This	O
study	O
examined	O
temporal	O
changes	O
in	O
neurohormones	O
related	O
to	O
cardiac	O
remodeling	O
and	O
prognosis	O
in	O
patients	O
with	O
systolic	O
dysfunction	O
and	O
heart	O
failure	O
receiving	O
therapeutic	O
inhibition	O
of	O
the	O
renin-angiotensin-aldosterone	O
system	O
.	O

Temporal	O
changes	O
in	O
plasma	O
renin	O
,	O
angiotensin-II	O
,	O
aldosterone	O
,	O
epinephrine	O
,	O
norepinephrine	O
,	O
B-type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
,	O
and	O
N-terminal	O
atrial	O
natriuretic	O
peptide	O
(	O
NT-ANP	O
)	O
in	O
768	O
treated	O
patients	O
with	O
heart	O
failure	O
measured	O
at	O
baseline	O
and	O
17	O
and	O
43	O
weeks	O
after	O
randomization	O
were	O
examined	O
for	O
their	O
relations	O
with	O
concurrent	O
changes	O
in	O
the	O
EF	O
,	O
cardiac	O
volumes	O
,	O
and	O
risk	O
for	O
subsequent	O
adverse	O
clinical	O
outcomes	O
.	O

Increasing	O
BNP	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
NT-ANP	O
(	O
p	O
=	O
0.01	O
)	O
over	O
time	O
were	O
associated	O
with	O
a	O
concurrent	O
decreasing	O
EF	O
,	O
increasing	O
end-diastolic	O
volume	O
(	O
EDV	O
)	O
,	O
and	O
increasing	O
end-systolic	O
volume	O
(	O
ESV	O
;	O
all	O
p	O
<	O
0.0001	O
)	O
.	O

In	O
multivariable	O
analysis	O
,	O
DeltaBNP	O
and	O
DeltaNT-ANP	O
were	O
independent	O
predictors	O
of	O
DeltaESV	O
and	O
DeltaEDV	O
,	O
whereas	O
DeltaBNP	O
also	O
predicted	O
DeltaEF	O
(	O
all	O
p	O
<	O
0.0001	O
)	O
.	O

Patients	O
who	O
died	O
or	O
experienced	O
heart	O
failure	O
hospitalization	O
had	O
larger	O
antecedent	O
increases	O
in	O
NT-ANP	O
(	O
+293.7	O
vs	O
-21.5	O
pmol/ml	O
,	O
p	O
=	O
0.006	O
)	O
and	O
lesser	O
decreases	O
in	O
norepinephrine	O
(	O
-22.3	O
vs	O
-48.5	O
pg/ml	O
,	O
p	O
=	O
0.04	O
)	O
.	O

Increasing	O
NT-ANP	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
3.45	O
,	O
p	O
=	O
0.009	O
)	O
and	O
norepinephrine	O
(	O
HR	O
2.04	O
,	O
p	O
=	O
0.02	O
)	O
over	O
time	O
independently	O
predicted	O
increased	O
risk	O
for	O
subsequent	O
death	O
or	O
heart	O
failure	O
hospitalization	O
.	O

In	O
conclusion	O
,	O
in	O
treated	O
patients	O
with	O
heart	O
failure	O
,	O
increasing	O
NT-ANP	O
and	O
BNP	O
over	O
time	O
predict	O
a	O
decreasing	O
EF	O
and	O
ventricular	O
dilatation	O
,	O
while	O
increasing	O
NT-ANP	O
and	O
norepinephrine	O
independently	O
predict	O
greater	O
mortality	O
and	O
morbidity	O
.	O

Serial	O
measurements	O
of	O
these	O
neurohormones	O
may	O
serve	O
as	O
useful	O
surrogate	O
markers	O
of	O
ventricular	O
remodeling	O
and	O
prognosticators	O
for	O
clinical	O
risk	O
stratification	O
.	O

A	O
pilot	O
randomised	O
control	O
trial	O
of	O
a	O
parent	Educational
training	Educational
intervention	Educational
for	O
pre-school	O
children	O
with	O
autism	O
.	O

Preliminary	O
findings	O
and	O
methodological	O
challenges	O
.	O

Few	O
attempts	O
have	O
been	O
made	O
to	O
conduct	O
randomised	O
control	O
trials	O
(	O
RCTs	O
)	O
of	O
interventions	O
for	O
pre-school	O
children	O
with	O
autism	O
.	O

We	O
report	O
findings	O
of	O
a	O
pilot	O
RCT	O
for	O
a	O
parent	Educational
training	Educational
intervention	Educational
with	O
a	O
focus	O
on	O
the	O
development	O
of	O
joint	O
attention	O
skills	O
and	O
joint	O
action	O
routines	O
.	O

Twenty-four	O
children	O
meeting	O
ICD-10	O
criteria	O
for	O
childhood	O
autism	O
(	O
mean	O
age	O
=	O
23	O
months	O
)	O
were	O
identified	O
using	O
the	O
CHAT	O
screen	O
and	O
randomised	O
to	O
the	O
parent	Educational
training	Educational
group	O
or	O
to	O
local	Control
services	Control
only	Control
.	O

A	O
follow-up	O
was	O
conducted	O
12	O
months	O
later	O
(	O
mean	O
age	O
=	O
35	O
months	O
)	O
.	O

There	O
was	O
some	O
evidence	O
that	O
the	O
parent	O
training	O
group	O
made	O
more	O
progress	O
in	O
language	O
development	O
than	O
the	O
local	O
services	O
group	O
.	O

However	O
,	O
the	O
present	O
pilot	O
study	O
was	O
compromised	O
by	O
several	O
factors	O
:	O
a	O
reliance	O
on	O
parental	O
report	O
to	O
measure	O
language	O
,	O
non-matching	O
of	O
the	O
groups	O
on	O
initial	O
IQ	O
,	O
and	O
a	O
lack	O
of	O
systematic	O
checking	O
regarding	O
the	O
implementation	O
of	O
the	O
parent	O
training	O
intervention	O
.	O

Furthermore	O
,	O
three	O
parents	O
in	O
the	O
local	O
services	O
group	O
commenced	O
intensive	O
,	O
home-based	Educational
behavioural	Educational
intervention	Educational
during	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
difficulties	O
encountered	O
in	O
the	O
conduct	O
of	O
RCTs	O
for	O
pre-school	O
children	O
with	O
autism	O
are	O
discussed	O
.	O

Methodological	O
challenges	O
and	O
strategies	O
for	O
future	O
well-designed	O
RCTs	O
for	O
autism	O
interventions	O
are	O
highlighted	O
.	O

Prospective	O
,	O
randomized	O
comparison	O
of	O
transperitoneal	Surgical
versus	O
retroperitoneal	Surgical
laparoscopic	Surgical
adrenalectomy	Surgical
.	O

PURPOSE	O
We	O
report	O
a	O
prospective	O
,	O
randomized	O
comparison	O
of	O
transperitoneal	Surgical
laparoscopic	Surgical
adrenalectomy	Surgical
(	Surgical
TLA	Surgical
)	Surgical
vs	O
retroperitoneal	Surgical
laparoscopic	Surgical
adrenalectomy	Surgical
(	Surgical
RLA	Surgical
)	Surgical
for	O
adrenal	O
lesions	O
with	O
long-term	O
followup	O
.	O

MATERIALS	O
AND	O
METHODS	O
Between	O
December	O
1997	O
and	O
November	O
1999	O
,	O
57	O
consecutive	O
eligible	O
patients	O
with	O
surgical	O
adrenal	O
disease	O
were	O
prospectively	O
randomized	O
to	O
undergo	O
TLA	Surgical
(	O
25	O
)	O
or	O
RLA	Surgical
(	O
32	O
)	O
.	O

Study	O
exclusion	O
criteria	O
were	O
patient	O
age	O
greater	O
than	O
80	O
years	O
,	O
body	O
mass	O
index	O
greater	O
than	O
40	O
,	O
bilateral	O
adrenalectomy	O
and	O
significant	O
prior	O
abdominal	O
surgery	O
in	O
the	O
quadrant	O
of	O
interest	O
.	O

Mean	O
followup	O
was	O
5.96	O
years	O
in	O
the	O
2	O
groups	O
.	O

RESULTS	O
The	O
groups	O
were	O
matched	O
in	O
regard	O
to	O
patient	O
age	O
(	O
p	O
=	O
0.84	O
)	O
,	O
body	O
mass	O
index	O
(	O
p	O
=	O
0.43	O
)	O
,	O
American	O
Society	O
of	O
Anesthesiologists	O
class	O
(	O
p	O
=	O
0.81	O
)	O
and	O
laterality	O
(	O
p	O
=	O
0.12	O
)	O
.	O

Median	O
adrenal	O
mass	O
size	O
was	O
2.7	O
cm	O
(	O
range	O
1	O
to	O
9	O
)	O
in	O
the	O
TLA	O
group	O
and	O
2.6	O
cm	O
(	O
range	O
0.5	O
to	O
6	O
)	O
in	O
the	O
RLA	O
group	O
(	O
p	O
=	O
0.83	O
)	O
.	O

TLA	O
was	O
comparable	O
to	O
RLA	O
in	O
terms	O
of	O
operative	O
time	O
(	O
130	O
vs	O
126.5	O
minutes	O
,	O
p	O
=	O
0.64	O
)	O
,	O
estimated	O
blood	O
loss	O
(	O
p	O
=	O
0.92	O
)	O
,	O
specimen	O
weight	O
(	O
p	O
=	O
0.81	O
)	O
,	O
analgesic	O
requirements	O
(	O
p	O
=	O
0.25	O
)	O
,	O
hospital	O
stay	O
(	O
p	O
=	O
0.56	O
)	O
and	O
the	O
complication	O
rate	O
(	O
p	O
=	O
0.58	O
)	O
.	O

One	O
case	O
per	O
group	O
was	O
electively	O
converted	O
to	O
open	O
surgery	O
.	O

Pathology	O
data	O
on	O
the	O
intact	O
extracted	O
specimens	O
were	O
similar	O
between	O
the	O
groups	O
.	O

Averaged	O
convalescence	O
was	O
4.7	O
weeks	O
in	O
the	O
TLA	O
group	O
and	O
2.3	O
weeks	O
in	O
the	O
RLA	O
group	O
(	O
p	O
=	O
0.02	O
)	O
.	O

During	O
a	O
mean	O
followup	O
of	O
6	O
years	O
2	O
patients	O
in	O
the	O
TLA	O
group	O
had	O
a	O
late	O
complication	O
(	O
port	O
site	O
hernia	O
)	O
.	O

Mortality	O
occurred	O
in	O
5	O
patients	O
,	O
including	O
1	O
with	O
TLA	O
and	O
4	O
with	O
RLA	O
,	O
during	O
the	O
6-year	O
followup	O
.	O

CONCLUSIONS	O
For	O
most	O
benign	O
adrenal	O
lesions	O
requiring	O
surgery	O
laparoscopic	Surgical
adrenalectomy	Surgical
can	O
be	O
performed	O
safely	O
and	O
effectively	O
by	O
the	O
transperitoneal	O
or	O
the	O
retroperitoneal	O
approach	O
.	O

Effect	O
of	O
chelation	Pharmacological
therapy	Pharmacological
on	O
progressive	O
diabetic	O
nephropathy	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
and	O
high-normal	O
body	O
lead	O
burdens	O
.	O

BACKGROUND	O
A	O
previous	O
study	O
in	O
type	O
2	O
diabetic	O
patients	O
with	O
high-normal	O
body	O
lead	O
burdens	O
showed	O
that	O
EDTA	Pharmacological
chelation	Pharmacological
therapy	Pharmacological
for	O
3	O
months	O
slows	O
progressive	O
diabetic	O
nephropathy	O
during	O
a	O
12-month	O
follow-up	O
.	O

The	O
effect	O
of	O
a	O
longer	O
course	O
of	O
therapy	O
on	O
kidney	O
function	O
decrease	O
over	O
a	O
longer	O
follow-up	O
is	O
not	O
known	O
.	O

STUDY	O
DESIGN	O
A	O
12-month	O
run-in	O
phase	O
,	O
then	O
a	O
randomized	O
single-blind	O
study	O
with	O
a	O
27-month	O
intervention	O
.	O

SETTING	O
&	O
PARTICIPANTS	O
University	O
medical	O
center	O
;	O
50	O
patients	O
(	O
serum	O
creatinine	O
,	O
1.5-3.9	O
mg/dL	O
)	O
with	O
high-normal	O
body	O
lead	O
burden	O
(	O
?80-	O
<	O
600	O
?g	O
)	O
were	O
randomly	O
assigned	O
to	O
the	O
treatment	O
and	O
control	O
groups	O
.	O

INTERVENTION	O
The	O
treatment	O
group	O
received	O
weekly	O
chelation	O
therapy	O
for	O
3	O
months	O
to	O
reduce	O
their	O
body	O
lead	O
burden	O
to	O
<	O
60	O
?g	O
and	O
then	O
as	O
needed	O
for	O
24	O
months	O
to	O
maintain	O
this	O
level	O
.	O

The	O
control	O
group	O
received	O
placebo	O
for	O
3	O
months	O
and	O
then	O
weekly	O
for	O
5	O
weeks	O
at	O
6-month	O
intervals	O
for	O
24	O
months	O
.	O

OUTCOMES	O
The	O
primary	O
end	O
point	O
was	O
change	O
in	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
over	O
time	O
.	O

A	O
secondary	O
end	O
point	O
was	O
a	O
2-fold	O
increase	O
in	O
baseline	O
serum	O
creatinine	O
level	O
or	O
the	O
requirement	O
for	O
renal	O
replacement	O
therapy	O
.	O

MEASUREMENTS	O
Body	O
lead	O
burdens	O
were	O
assessed	O
by	O
EDTA	O
mobilization	O
tests	O
and	O
eGFR	O
was	O
calculated	O
using	O
the	O
equation	O
for	O
Chinese	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

RESULTS	O
Mean	O
baseline	O
eGFRs	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
were	O
similar	O
.	O

After	O
3	O
months	O
of	O
chelation	O
therapy	O
,	O
the	O
change	O
in	O
eGFR	O
in	O
the	O
treatment	O
group	O
(	O
+1.0	O
?	O
4.8	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
)	O
differed	O
significantly	O
from	O
that	O
in	O
the	O
control	O
group	O
(	O
-1.5	O
?	O
4.8	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
;	O
P	O
=	O
0.04	O
)	O
.	O

In	O
the	O
subsequent	O
24-month	O
intervention	O
,	O
the	O
yearly	O
rate	O
of	O
decrease	O
in	O
eGFR	O
(	O
5.6	O
?	O
5.0	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
per	O
year	O
)	O
in	O
the	O
treatment	O
group	O
was	O
slower	O
than	O
that	O
(	O
9.2	O
?	O
3.6	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
per	O
year	O
;	O
P	O
=	O
0.04	O
)	O
in	O
the	O
control	O
group	O
.	O

17	O
(	O
68	O
%	O
)	O
control-group	O
patients	O
and	O
9	O
(	O
36	O
%	O
)	O
treatment-group	O
patients	O
achieved	O
the	O
secondary	O
end	O
point	O
.	O

LIMITATIONS	O
Small	O
sample	O
size	O
,	O
not	O
double	O
blind	O
.	O

CONCLUSIONS	O
A	O
27-month	O
course	O
of	O
EDTA	O
chelation	O
therapy	O
retards	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
in	O
type	O
2	O
diabetic	O
patients	O
with	O
high-normal	O
body	O
lead	O
burdens	O
.	O

Effects	O
of	O
enflurane	Pharmacological
and	O
isoflurane	Pharmacological
on	O
splanchnic	O
oxygenation	O
in	O
humans	O
.	O

STUDY	O
OBJECTIVES	O
To	O
determine	O
the	O
effects	O
of	O
enflurane	Pharmacological
and	O
isoflurane	Pharmacological
on	O
hepatic	O
venous	O
oxygen	O
saturation	O
(	O
ShvO2	O
)	O
and	O
splanchnic	O
oxygen	O
(	O
O2	O
)	O
extraction	O
.	O

To	O
measure	O
hemodynamic	O
parameters	O
and	O
ShvO2	O
,	O
mixed	O
venous	O
,	O
and	O
arterial	O
lactate	O
concentrations	O
during	O
enflurane	Pharmacological
and	O
isoflurane	Pharmacological
anesthesia	O
.	O

DESIGN	O
Randomized	O
,	O
prospective	O
study	O
.	O

SETTING	O
University	O
hospital	O
.	O

PATIENTS	O
20	O
ASA	O
physical	O
status	O
I	O
,	O
II	O
,	O
and	O
III	O
adults	O
,	O
who	O
underwent	O
major	O
abdominal	O
surgery	O
requiring	O
mechanical	O
ventilation	O
a	O
few	O
hours	O
postoperatively	O
.	O

INTERVENTIONS	O
After	O
placement	O
of	O
catheters	O
in	O
the	O
pulmonary	O
artery	O
,	O
radial	O
artery	O
,	O
peripheral	O
and	O
right	O
hepatic	O
vein	O
,	O
one	O
hour	O
postoperatively	O
either	O
enflurane	Pharmacological
or	O
isoflurane	Pharmacological
was	O
applied	O
at	O
different	O
minimum	O
alveolar	O
concentration	O
(	O
MAC	O
)	O
of	O
0.5	O
,	O
1.0	O
,	O
and	O
1.5	O
in	O
a	O
randomized	O
order	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Before	O
and	O
10	O
minutes	O
after	O
administration	O
of	O
each	O
desired	O
end-expiratory	O
anesthetic	O
concentration	O
,	O
the	O
following	O
parameters	O
were	O
determined	O
:	O
hemodynamic	O
parameters	O
,	O
arterial	O
(	O
SaO2	O
)	O
,	O
mixed	O
venous	O
(	O
SvO2	O
)	O
,	O
and	O
hepatic	O
venous	O
oxygen	O
saturations	O
,	O
systemic	O
and	O
splanchnic	O
O2	O
extraction	O
,	O
arterial	O
,	O
mixed	O
venous	O
,	O
and	O
hepatic	O
venous	O
lactate	O
concentrations	O
.	O

Cardiac	O
output	O
(	O
CO	O
)	O
and	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
decreased	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

SaO2	O
,	O
SvO2	O
,	O
and	O
systemic	O
O2	O
extraction	O
remained	O
unchanged	O
with	O
enflurane	O
and	O
isoflurane	O
anesthesia	O
.	O

In	O
the	O
enflurane	Pharmacological
group	O
,	O
but	O
not	O
in	O
the	O
isoflurane	O
group	O
,	O
ShvO2	O
decreased	O
with	O
increasing	O
inhalational	O
concentrations	O
.	O

This	O
decrease	O
in	O
ShvO2	O
reflected	O
an	O
increase	O
in	O
splanchnic	O
O2	O
extraction	O
with	O
enflurane	Pharmacological
;	O
in	O
contrast	O
to	O
isoflurane	Pharmacological
.	O

CONCLUSIONS	O
Enflurane	Pharmacological
causes	O
a	O
decrease	O
in	O
ShvO2	O
,	O
which	O
indicates	O
an	O
impairment	O
of	O
splanchnic	O
perfusion	O
corresponding	O
to	O
the	O
reduction	O
in	O
CO	O
and	O
MAP	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Isoflurane	Pharmacological
maintains	O
splanchnic	O
perfusion	O
in	O
contrast	O
to	O
enflurane	Pharmacological
.	O

Liposome-entrapped	Pharmacological
D.	Pharmacological
pteronyssinus	Pharmacological
vaccination	Pharmacological
in	O
mild	O
asthma	O
patients	O
:	O
effect	O
of	O
1-year	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
on	O
inflammation	O
,	O
bronchial	O
hyperresponsiveness	O
and	O
immediate	O
and	O
late	O
bronchial	O
responses	O
to	O
the	O
allergen	O
.	O

BACKGROUND	O
Allergen	O
vaccination	O
is	O
effective	O
in	O
mite-allergic	O
asthma	O
.	O

Liposomes	O
are	O
immunological	O
adjuvants	O
that	O
can	O
act	O
as	O
allergen	O
carriers	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
immunological	O
and	O
functional	O
effects	O
of	O
a	O
liposome-entrapped	Pharmacological
D.	Pharmacological
pteronyssinus	Pharmacological
vaccine	Pharmacological
on	O
mite	O
monosensitive	O
,	O
mild	O
asthma	O
patients	O
.	O

METHODS	O
A	O
double-blind	O
,	O
placebo-controlled	O
trial	O
was	O
conducted	O
on	O
26	O
asthma	O
patients	O
who	O
randomly	O
received	O
vaccination	O
or	O
placebo	Control
for	O
1	O
year	O
.	O

The	O
levels	O
of	O
exposure	O
to	O
Der	O
p	O
1	O
allergen	O
were	O
constant	O
during	O
the	O
study	O
.	O

Allergen	O
bronchial	O
challenge	O
was	O
made	O
at	O
the	O
beginning	O
(	O
T0	O
)	O
and	O
after	O
1	O
year	O
of	O
treatment	O
(	O
T12	O
)	O
.	O

The	O
day	O
before	O
and	O
24	O
h	O
after	O
the	O
allergen	O
provocation	O
,	O
patients	O
were	O
challenged	O
with	O
methacholine	Pharmacological
(	O
Mth	O
)	O
(	O
until	O
FEV1	O
fell	O
by	O
40	O
%	O
)	O
and	O
blood	O
and	O
sputum	O
samples	O
were	O
obtained	O
.	O

Dose-response	O
curves	O
to	O
Mth	O
were	O
evaluated	O
in	O
terms	O
of	O
Mth-PD20	O
(	O
dose	O
of	O
Mth	O
that	O
induced	O
20	O
%	O
drop	O
in	O
FEV1	O
)	O
,	O
slope	O
(	O
Mth-DRS	O
)	O
and	O
level	O
of	O
plateau	O
.	O

Blood	O
and	O
sputum	O
eosinophils	O
and	O
serum	O
levels	O
of	O
eosinophil	O
cationic	O
protein	O
(	O
ECP	O
)	O
and	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
were	O
measured	O
.	O

RESULTS	O
Groups	O
were	O
comparable	O
at	O
the	O
start	O
of	O
the	O
trial	O
.	O

At	O
TI2	O
,	O
previous	O
to	O
the	O
allergen	O
challenge	O
,	O
the	O
active	O
group	O
showed	O
higher	O
values	O
of	O
both	O
FEV1	O
and	O
Mth-PD20	O
and	O
lower	O
values	O
of	O
Mth-DRS	O
.	O

The	O
number	O
of	O
patients	O
presenting	O
a	O
level	O
of	O
plateau	O
increased	O
in	O
the	O
active	O
group	O
(	O
from	O
two	O
to	O
four	O
)	O
and	O
decreased	O
in	O
the	O
placebo	O
group	O
(	O
from	O
two	O
to	O
one	O
)	O
.	O

At	O
T12	O
,	O
before	O
the	O
allergen	O
challenge	O
,	O
serum	O
ECP	O
levels	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
blood	O
eosinophils	O
showed	O
a	O
trend	O
towards	O
lower	O
numbers	O
in	O
the	O
active	O
one	O
.	O

The	O
immediate	O
response	O
and	O
the	O
changes	O
in	O
Mth-DRS	O
values	O
,	O
sputum	O
eosinophils	O
and	O
serum	O
ECP	O
levels	O
following	O
the	O
allergen	O
challenge	O
were	O
attenuated	O
in	O
the	O
active	O
group	O
.	O

CONCLUSION	O
Liposome-entrapped	O
D.	O
Pteronyssinus	O
vaccination	O
:	O
(	O
i	O
)	O
protects	O
mild	O
asthma	O
patients	O
from	O
the	O
worsening	O
of	O
asthma	O
due	O
to	O
sustained	O
mite	O
exposure	O
;	O
and	O
(	O
ii	O
)	O
reduces	O
the	O
functional	O
and	O
inflammatory	O
changes	O
induced	O
by	O
allergen	O
bronchial	O
provocation	O
.	O

Effect	O
of	O
soy	Pharmacological
protein	Pharmacological
containing	Pharmacological
isoflavones	Pharmacological
on	O
blood	O
lipids	O
in	O
moderately	O
hypercholesterolemic	O
adults	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Dietary	Pharmacological
intake	Pharmacological
of	Pharmacological
soy	Pharmacological
protein	Pharmacological
with	Pharmacological
isoflavones	Pharmacological
may	O
be	O
associated	O
with	O
reductions	O
in	O
serum	O
cholesterol	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
effects	O
of	O
a	O
water-washed	Pharmacological
soy	Pharmacological
protein	Pharmacological
concentrate	Pharmacological
with	O
a	O
milk-protein	Pharmacological
based	Pharmacological
control	Pharmacological
on	O
blood	O
lipid	O
levels	O
in	O
hyperlipidemic	O
men	O
and	O
women	O
.	O

METHODS	O
A	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
clinical	O
trial	O
including	O
159	O
subjects	O
.	O

After	O
a	O
3-week	O
run-in	O
period	O
during	O
which	O
all	O
subjects	O
consumed	O
a	O
milk	Pharmacological
protein-based	Pharmacological
supplement	Pharmacological
,	O
participants	O
were	O
randomized	O
into	O
one	O
of	O
two	O
groups	O
:	O
a	O
control	O
group	O
(	O
continued	Pharmacological
milk	Pharmacological
protein	Pharmacological
)	O
and	O
an	O
intervention	O
group	O
(	O
soy	Pharmacological
protein	Pharmacological
)	O
for	O
a	O
five-week	O
period	O
.	O

Fasting	O
venous	O
blood	O
draws	O
for	O
lipid	O
measurement	O
were	O
obtained	O
at	O
baseline	O
,	O
towards	O
the	O
end	O
of	O
the	O
run-in	O
period	O
and	O
at	O
the	O
end	O
of	O
the	O
intervention	O
.	O

Blood	O
isoflavone	Pharmacological
concentrations	O
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

RESULTS	O
Blood	O
lipid	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
at	O
any	O
point	O
in	O
time	O
;	O
and	O
there	O
were	O
no	O
significant	O
associations	O
between	O
blood	O
isoflavones	Pharmacological
and	O
lipid	O
levels	O
.	O

Significant	O
decreases	O
in	O
total	O
cholesterol	O
(	O
19	O
mg/dL	O
)	O
,	O
and	O
LDL-cholesterol	O
(	O
11	O
mg/dL	O
)	O
,	O
were	O
observed	O
during	O
the	O
run-in	O
period	O
,	O
with	O
no	O
further	O
decreases	O
in	O
lipids	O
during	O
the	O
intervention	O
period	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
These	O
results	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
water-washed	O
soy	Pharmacological
protein	Pharmacological
has	O
an	O
effect	O
on	O
blood	O
lipids	O
.	O

Several	O
hypotheses	O
are	O
discussed	O
,	O
highlighting	O
the	O
selective	O
nature	O
of	O
the	O
effect	O
of	O
soy	O
consumption	O
in	O
the	O
population	O
.	O

The	O
cholesterol-lowering	O
effect	O
during	O
the	O
run-in	O
period	O
may	O
be	O
explained	O
by	O
the	O
regression	O
to	O
the	O
mean	O
effect	O
and	O
by	O
other	O
factors	O
related	O
to	O
study	O
participation	O
,	O
mainly	O
nutrient	O
displacement	O
induced	O
by	O
the	O
protein	Pharmacological
supplement	Pharmacological
.	O

Mass	O
inoculation	O
in	O
a	O
community	O
:	O
the	O
effect	O
of	O
primary	O
prevention	O
of	O
stress	O
reactions	O
.	O

This	O
study	O
assessed	O
the	O
effectiveness	O
of	O
a	O
brief	O
,	O
situation-specific	O
,	O
group-administered	O
preparatory	O
intervention	O
in	O
a	O
nonclient	O
school	O
population	O
undergoing	O
mass	Physical
inoculation	Physical
against	Physical
rubella	Physical
.	O

Fifty-one	O
girls	O
were	O
randomly	O
assigned	O
to	O
practice	Physical
,	Physical
no-practice	Physical
,	Physical
or	Physical
control	Control
groups	Control
.	O

Both	O
the	O
practice	O
and	O
the	O
no-practice	O
groups	O
received	O
information	O
that	O
described	O
the	O
inoculation	O
procedure	O
and	O
how	O
to	O
cope	O
with	O
it	O
by	O
using	O
cognitive-behavioral	O
coping	O
skills	O
.	O

The	O
practice	O
group	O
was	O
encouraged	O
to	O
perform	O
coping	O
techniques	O
of	O
this	O
type	O
,	O
whereas	O
the	O
no-practice	O
group	O
was	O
told	O
only	O
that	O
the	O
intervention	O
would	O
help	O
them	O
during	O
the	O
inoculation	O
.	O

Subjects	O
in	O
both	O
practice	O
and	O
no-practice	O
groups	O
reported	O
less	O
anxiety	O
and	O
exhibited	O
more	O
cooperative	O
behavior	O
during	O
inoculation	O
than	O
subjects	O
in	O
the	O
control	O
group	O
,	O
and	O
those	O
who	O
were	O
guided	O
and	O
prompted	O
to	O
actively	O
practice	O
derived	O
greater	O
benefit	O
.	O

Tacrolimus/sirolimus	Pharmacological
vs	Pharmacological
tacrolimus/methotrexate	Pharmacological
as	O
GVHD	O
prophylaxis	O
after	O
matched	O
,	O
related	O
donor	O
allogeneic	O
HCT	O
.	O

Grades	O
2-4	O
acute	O
graft-versus-host	O
disease	O
(	O
GVHD	O
)	O
occurs	O
in	O
approximately	O
35	O
%	O
of	O
matched	O
,	O
related	O
donor	O
(	O
MRD	O
)	O
allogeneic	O
hematopoietic	O
cell	O
transplantation	O
(	O
HCT	O
)	O
recipients	O
.	O

We	O
sought	O
to	O
determine	O
if	O
the	O
combination	O
of	O
tacrolimus	Pharmacological
and	Pharmacological
sirolimus	Pharmacological
(	Pharmacological
Tac/Sir	Pharmacological
)	Pharmacological
was	O
more	O
effective	O
than	O
tacrolimus	Pharmacological
and	Pharmacological
methotrexate	Pharmacological
(	Pharmacological
Tac/Mtx	Pharmacological
)	Pharmacological
in	O
preventing	O
acute	O
GVHD	O
and	O
early	O
mortality	O
after	O
allogeneic	O
MRD	O
HCT	O
in	O
a	O
phase	O
3	O
,	O
multicenter	O
trial	O
.	O

The	O
primary	O
end	O
point	O
of	O
the	O
trial	O
was	O
to	O
compare	O
114-day	O
grades	O
2-4	O
acute	O
GVHD-free	O
survival	O
using	O
an	O
intention-to-treat	O
analysis	O
of	O
304	O
randomized	O
subjects	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
probability	O
of	O
day	O
114	O
grades	O
2-4	O
acute	O
GVHD-free	O
survival	O
(	O
67	O
%	O
vs	O
62	O
%	O
,	O
P	O
=	O
.38	O
)	O
.	O

Grades	O
2-4	O
GVHD	O
was	O
similar	O
in	O
the	O
Tac/Sir	O
and	O
Tac/Mtx	O
arms	O
(	O
26	O
%	O
vs	O
34	O
%	O
,	O
P	O
=	O
.48	O
)	O
.	O

Neutrophil	O
and	O
platelet	O
engraftment	O
were	O
more	O
rapid	O
in	O
the	O
Tac/Sir	O
arm	O
(	O
14	O
vs	O
16	O
days	O
,	O
P	O
<	O
.001	O
;	O
16	O
vs	O
19	O
days	O
,	O
P	O
=	O
.03	O
)	O
.	O

Oropharyngeal	O
mucositis	O
was	O
less	O
severe	O
in	O
the	O
Tac/Sir	O
arm	O
(	O
peak	O
Oral	O
Mucositis	O
Assessment	O
Scale	O
score	O
0.70	O
vs	O
0.96	O
,	O
P	O
<	O
.001	O
)	O
,	O
but	O
otherwise	O
toxicity	O
was	O
similar	O
.	O

Chronic	O
GVHD	O
,	O
relapse-free	O
survival	O
,	O
and	O
overall	O
survival	O
at	O
2	O
years	O
were	O
no	O
different	O
between	O
study	O
arms	O
(	O
53	O
%	O
vs	O
45	O
%	O
,	O
P	O
=	O
.06	O
;	O
53	O
%	O
vs	O
54	O
%	O
,	O
P	O
=	O
.77	O
;	O
and	O
59	O
%	O
vs	O
63	O
%	O
,	O
P	O
=	O
.36	O
)	O
.	O

Based	O
on	O
similar	O
long-term	O
outcomes	O
,	O
more	O
rapid	O
engraftment	O
,	O
and	O
less	O
oropharyngeal	O
mucositis	O
,	O
the	O
combination	O
of	O
Tac/Sir	O
is	O
an	O
acceptable	O
alternative	O
to	O
Tac/Mtx	O
after	O
MRD	O
HCT	O
.	O

This	O
study	O
was	O
funded	O
by	O
the	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
and	O
the	O
National	O
Cancer	O
Institute	O
;	O
and	O
the	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT00406393	O
.	O

Epileptogenic	O
activity	O
of	O
folic	O
acid	O
after	O
drug	O
induces	O
SLE	O
(	O
folic	O
acid	O
and	O
epilepsy	O
)	O
OBJECTIVE	O
To	O
study	O
the	O
effect	O
of	O
folic	Pharmacological
acid-containing	Pharmacological
multivitamin	Pharmacological
supplementation	Pharmacological
in	O
epileptic	O
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	O
defects	O
and	O
epilepsy-related	O
side	O
effects	O
.	O

STUDY	O
DESIGN	O
First	O
a	O
randomised	O
trial	O
,	O
later	O
periconception	O
care	O
including	O
in	O
total	O
12225	O
females	O
.	O

RESULTS	O
Of	O
60	O
epileptic	O
women	O
with	O
periconceptional	Pharmacological
folic	Pharmacological
acid	Pharmacological
(	O
0.8	O
mg	O
)	O
-containing	Pharmacological
multivitamin	Pharmacological
supplementation	Pharmacological
,	O
no	O
one	O
developed	O
epilepsy-related	O
side	O
effects	O
during	O
the	O
periconception	O
period	O
.	O

One	O
epileptic	O
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	O
lip	O
and	O
palate	O
.	O

Another	O
patient	O
exhibited	O
with	O
a	O
cluster	O
of	O
seizures	O
after	O
the	O
periconception	O
period	O
using	O
another	O
multivitamin	O
.	O

This	O
22-year-old	O
epileptic	O
woman	O
was	O
treated	O
continuously	O
by	O
carbamazepine	Pharmacological
and	Pharmacological
a	Pharmacological
folic	Pharmacological
acid	Pharmacological
(	O
1	O
mg	O
)	O
-containing	Pharmacological
multivitamin	Pharmacological
from	O
the	O
20th	O
week	O
of	O
gestation	O
.	O

She	O
developed	O
status	O
epilepticus	O
and	O
later	O
symptoms	O
of	O
systemic	O
lupus	O
erythematodes	O
.	O

Her	O
pregnancy	O
ended	O
with	O
stillbirth	O
.	O

CONCLUSIONS	O
The	O
epileptic	O
pregnant	O
patient	O
's	O
autoimmune	O
disease	O
(	O
probably	O
drug-induced	O
lupus	O
)	O
could	O
damage	O
the	O
blood-brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=1	O
mg	O
)	O
of	O
folic	O
acid	O
triggered	O
a	O
cluster	O
of	O
seizures	O
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
both	O
in	O
healthy	O
and	O
60	O
epileptic	O
women	O
,	O
all	O
without	O
any	O
autoimmune	O
disease	O
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	O
seizures	O
.	O

Predictors	O
of	O
blood	O
pressure	O
change	O
in	O
a	O
series	O
of	O
controlled	O
dietary	O
intervention	O
studies	O
.	O

Three	O
controlled	O
dietary	Physical
intervention	Physical
studies	O
were	O
carried	O
out	O
in	O
1981-1983	O
in	O
North	O
Karelia	O
,	O
Finland	O
,	O
to	O
asses	O
the	O
impact	O
of	O
dietary	O
fat	O
intake	O
modification	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O

All	O
these	O
studies	O
involved	O
middle-aged	O
men	O
and	O
women	O
in	O
rural	O
or	O
semirural	O
areas	O
and	O
comprised	O
a	O
baseline	O
period	O
,	O
a	O
six	O
week	O
(	O
or	O
12	O
weeks	O
in	O
the	O
third	O
study	O
)	O
intervention	O
period	O
and	O
a	O
four	O
to	O
six	O
week	O
return	O
to	O
baseline	O
.	O

During	O
the	O
intervention	O
period	O
the	O
total	O
fat	Other
intake	Other
was	O
reduced	O
from	O
39	O
%	O
to	O
24	O
%	O
of	O
energy	O
and	O
the	O
polyunsaturated/saturated	Pharmacological
(	Pharmacological
P/S	Pharmacological
)	Pharmacological
ratio	Pharmacological
increased	O
from	O
0.2	O
to	O
0.4-1.2	O
.	O

In	O
all	O
groups	O
energy	O
intake	O
was	O
kept	O
constant	O
.	O

For	O
the	O
present	O
report	O
data	O
from	O
the	O
three	O
studies	O
were	O
pooled	O
for	O
a	O
series	O
of	O
stepwise	O
regression	O
analyses	O
to	O
predict	O
changes	O
in	O
BP	O
with	O
different	O
dietary	O
changes	O
.	O

For	O
both	O
systolic	O
(	O
SBP	O
)	O
and	O
diastolic	O
(	O
DBP	O
)	O
blood	O
pressure	O
,	O
change	O
in	O
polyunsaturated	O
fatty	O
acid	O
intake	O
was	O
the	O
strongest	O
dietary	O
predictor	O
of	O
BP	O
change	O
.	O

Changes	O
in	O
body	O
weight	O
,	O
total	O
fat	O
intake	O
,	O
urinary	O
sodium	O
and	O
potassium	O
did	O
not	O
have	O
significant	O
predictive	O
power	O
in	O
any	O
of	O
the	O
analyses	O
.	O

The	O
findings	O
support	O
the	O
hypothesis	O
that	O
modification	O
of	O
dietary	O
fat	O
intake	O
is	O
a	O
significant	O
predictor	O
of	O
change	O
in	O
BP	O
.	O

Assisted	Physical
exercise	Physical
and	O
bone	O
strength	O
in	O
preterm	O
infants	O
.	O

Studies	O
have	O
previously	O
demonstrated	O
that	O
brief	O
(	O
4	O
weeks	O
)	O
passive	O
range-of-motion	O
exercise	Physical
is	O
beneficial	O
for	O
bone	O
development	O
in	O
very	O
low	O
birth	O
weight	O
(	O
VLBW	O
)	O
preterm	O
infants	O
.	O

However	O
,	O
the	O
optimal	O
duration	O
of	O
exercise	O
for	O
bone	O
development	O
in	O
preterm	O
infants	O
is	O
yet	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
8	O
weeks	O
of	O
assisted	Physical
exercise	Physical
on	O
bone	O
strength	O
and	O
metabolism	O
in	O
VLBW	O
premature	O
infants	O
.	O

Sixteen	O
infants	O
(	O
mean	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
birth	O
weight	O
1,009	O
+/-	O
55	O
g	O
and	O
gestational	O
age	O
27.3	O
+/-	O
0.3	O
weeks	O
)	O
were	O
randomly	O
assigned	O
into	O
exercise	O
(	O
n	O
=	O
8	O
)	O
and	O
control	Control
(	O
n	O
=	O
8	O
)	O
groups	O
.	O

The	O
intervention	O
started	O
at	O
the	O
first	O
week	O
of	O
life	O
and	O
involved	O
8	O
weeks	O
of	O
daily	Physical
passive	Physical
extension	Physical
and	Physical
flexion	Physical
range-of-motion	Physical
exercise	Physical
of	O
the	O
upper	O
and	O
lower	O
extremities	O
.	O

Biochemical	O
markers	O
of	O
bone	O
turnover	O
were	O
measured	O
at	O
enrollment	O
and	O
after	O
8	O
weeks	O
.	O

Bone	O
strength	O
was	O
measured	O
weekly	O
by	O
quantitative	O
ultrasound	O
measurement	O
of	O
tibial	O
bone	O
speed	O
of	O
sound	O
(	O
SOS	O
)	O
.	O

Bone	O
SOS	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
(	O
-108.1	O
+/-	O
33.7	O
m/second	O
,	O
P	O
<	O
0.0001	O
)	O
during	O
the	O
study	O
period	O
,	O
while	O
remaining	O
stable	O
in	O
the	O
exercise	O
group	O
(	O
11.3	O
+/-	O
22.8	O
m/second	O
)	O
.	O

The	O
main	O
beneficial	O
effect	O
of	O
exercise	O
occurred	O
in	O
the	O
first	O
4	O
weeks	O
of	O
the	O
intervention	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
bone	O
turnover	O
marker	O
changes	O
between	O
the	O
groups	O
.	O

There	O
is	O
a	O
significant	O
postnatal	O
decrease	O
in	O
bone	O
SOS	O
in	O
VLBW	O
preterm	O
infants	O
.	O

Eight	O
weeks	O
of	O
assisted	O
range-of-motion	O
exercise	Physical
attenuates	O
the	O
decrease	O
in	O
bone	O
strength	O
and	O
may	O
decrease	O
the	O
risk	O
of	O
osteopenia	O
in	O
premature	O
infants	O
.	O

Decompressive	Physical
craniectomy	Physical
in	O
traumatic	O
brain	O
injury	O
:	O
the	O
randomized	O
multicenter	O
RESCUEicp	O
study	O
(	O
www.RESCUEicp.com	O
)	O
.	O

The	O
RESCUEicp	O
(	O
Randomized	O
Evaluation	O
of	O
Surgery	O
with	O
Craniectomy	O
for	O
Uncontrollable	O
Elevation	O
of	O
intracranial	O
pressure	O
)	O
study	O
has	O
been	O
established	O
to	O
determine	O
whether	O
decompressive	Physical
craniectomy	Physical
has	O
a	O
role	O
in	O
the	O
management	O
of	O
patients	O
with	O
traumatic	O
brain	O
injury	O
and	O
raised	O
intracranial	O
pressure	O
that	O
does	O
not	O
respond	O
to	O
initial	O
treatment	O
measures	O
.	O

We	O
describe	O
the	O
concept	O
of	O
decompressive	Physical
craniectomy	Physical
in	O
traumatic	O
brain	O
injury	O
and	O
the	O
rationale	O
and	O
protocol	O
of	O
the	O
RESCUEicp	O
study	O
.	O

Oxidative	O
DNA	O
damage	O
measured	O
in	O
human	O
lymphocytes	O
:	O
large	O
differences	O
between	O
sexes	O
and	O
between	O
countries	O
,	O
and	O
correlations	O
with	O
heart	O
disease	O
mortality	O
rates	O
.	O

The	O
'antioxidant	O
hypothesis	O
'	O
proposes	O
that	O
vitamin	O
C	O
,	O
vitamin	O
E	O
,	O
carotenoids	O
,	O
and	O
other	O
antioxidants	Pharmacological
occurring	O
in	O
fruit	O
and	O
vegetables	O
afford	O
protection	O
against	O
heart	O
disease	O
and	O
cancer	O
by	O
preventing	O
oxidative	O
damage	O
to	O
lipids	O
and	O
to	O
DNA	O
,	O
respectively	O
.	O

To	O
test	O
elements	O
of	O
this	O
hypothesis	O
,	O
we	O
have	O
measured	O
blood	O
levels	O
of	O
dietary	O
antioxidants	O
,	O
and	O
8-oxodeoxyguanosine	Pharmacological
(	O
8-oxo-dG	O
)	O
concentrations	O
in	O
lymphocyte	Pharmacological
DNA	Pharmacological
,	O
in	O
healthy	O
men	O
and	O
women	O
from	O
five	O
European	O
countries	O
:	O
France	O
,	O
Ireland	O
,	O
The	O
Netherlands	O
,	O
Spain	O
,	O
and	O
the	O
U.K	O
.	O

Volunteers	O
,	O
aged	O
25	O
45	O
,	O
all	O
nonsmokers	O
,	O
gave	O
blood	O
samples	O
before	O
and	O
after	O
a	O
12-wk	Physical
carotenoid	Physical
supplementation	Physical
regime	Physical
.	Physical

Vitamin	O
C	O
was	O
measured	O
in	O
plasma	O
and	O
vitamin	O
E	O
and	O
carotenoids	O
were	O
measured	O
in	O
serum	O
by	O
high-performance	O
liquid	Pharmacological
chromatography	Pharmacological
(	O
HPLC	O
)	O
.	O

8-oxo-dG	O
was	O
assayed	O
by	O
HPLC	O
(	O
with	O
coulometric	O
detection	O
)	O
in	O
DNA	O
isolated	O
from	O
lymphocytes	O
from	O
the	O
same	O
blood	O
samples	O
.	O

Mean	O
values	O
were	O
calculated	O
for	O
groups	O
of	O
volunteers	O
at	O
each	O
sampling	O
time	O
according	O
to	O
country	O
,	O
sex	O
,	O
and	O
supplementation	O
(	O
between	O
9	O
and	O
24	O
individual	O
samples	O
contributing	O
to	O
each	O
mean	O
)	O
.	O

We	O
found	O
that	O
8-oxo-dG	O
levels	O
in	O
lymphocyte	O
DNA	O
vary	O
significantly	O
according	O
to	O
sex	O
and	O
country	O
.	O

A	O
low	O
mean	O
8-oxo-dG	O
concentration	O
is	O
seen	O
in	O
DNA	O
of	O
women	O
from	O
all	O
five	O
countries	O
,	O
and	O
of	O
men	O
from	O
France	O
and	O
Spain	O
.	O

8-oxo-dG	O
is	O
significantly	O
higher	O
(	O
up	O
to	O
about	O
threefold	O
)	O
in	O
lymphocyte	O
DNA	O
from	O
men	O
in	O
Ireland	O
and	O
the	O
U.K.	O
Oxidative	O
DNA	O
damage	O
is	O
not	O
significantly	O
affected	O
by	O
carotenoid	O
supplementation	O
;	O
nor	O
is	O
there	O
any	O
association	O
with	O
mean	O
baseline	O
levels	O
of	O
antioxidants	O
,	O
which	O
are	O
generally	O
similar	O
in	O
the	O
five	O
countries	O
.	O

The	O
five	O
countries	O
sampled	O
lie	O
on	O
an	O
axis	O
from	O
northern	O
to	O
southern	O
Europe	O
with	O
a	O
steep	O
gradient	O
in	O
terms	O
of	O
premature	O
heart	O
disease	O
.	O

There	O
is	O
a	O
strong	O
association	O
between	O
premature	O
coronary	O
heart	O
disease	O
mortality	O
in	O
men	O
and	O
the	O
mean	O
levels	O
of	O
8-oxo-dG	O
for	O
the	O
five	O
countries	O
(	O
r	O
=	O
0.95	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Women	O
have	O
low	O
coronary	O
heart	O
disease	O
mortality	O
rates	O
,	O
which	O
do	O
not	O
correlate	O
with	O
8-oxo-dG	O
.	O

In	O
terms	O
of	O
cancer	O
deaths	O
,	O
only	O
colorectal	O
cancer	O
in	O
men	O
shows	O
a	O
significant	O
positive	O
correlation	O
(	O
r	O
=	O
0.91	O
,	O
P	O
<	O
0.05	O
)	O
,	O
and	O
stomach	O
cancer	O
in	O
women	O
is	O
negatively	O
correlated	O
with	O
DNA	O
oxidation	O
(	O
r	O
=	O
-0.92	O
,	O
P	O
=	O
0.01	O
)	O
.	O

Neuromuscular	O
excitability	O
changes	O
in	O
the	O
vastus	O
medialis	O
following	O
anterior	Surgical
cruciate	Surgical
ligament	Surgical
reconstruction	Surgical
.	O

PURPOSE	O
Quadriceps	O
weakness	O
following	O
anterior	O
cruciate	Surgical
ligament	Surgical
reconstruction	Surgical
(	Surgical
ACLR	Surgical
)	Surgical
is	O
prevalent	O
despite	O
intensive	O
rehabilitation	O
.	O

Diminished	O
neuromuscular	O
excitability	O
is	O
one	O
potential	O
factor	O
that	O
may	O
limit	O
muscular	O
recovery	O
following	O
injury	O
or	O
surgery	O
.	O

The	O
H-reflex	O
provides	O
a	O
measure	O
of	O
alpha	O
motorneuron	O
(	O
neuromuscular	O
)	O
excitability	O
in	O
the	O
sensory-motor	O
pathway	O
of	O
the	O
respective	O
muscle	O
and	O
nerve	O
.	O

To	O
date	O
the	O
vastus	O
medialis	O
(	O
VM	O
)	O
and	O
soleus	O
(	O
SOL	O
)	O
H-reflexes	O
have	O
been	O
examined	O
primarily	O
in	O
control	O
subjects	O
with	O
induced	O
knee	O
joint	O
effusion	O
.	O

This	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
evaluated	O
the	O
affect	O
of	O
ACLR	Surgical
,	O
utilizing	O
hamsting	Surgical
(	Surgical
HS	Surgical
)	Surgical
or	Surgical
bone-patellar	Surgical
tendon-bone	Surgical
(	Surgical
BTB	Surgical
)	Surgical
autograft	Surgical
,	O
on	O
VM	O
and	O
SOL	O
H-reflex	O
latency	O
and	O
amplitude	O
in	O
twenty	O
subjects	O
.	O

METHODS	O
Preoperatively	O
bilateral	O
VM	O
and	O
SOL	O
H-reflex	O
tests	O
were	O
conducted	O
.	O

VM	O
and	O
SOL	O
H-reflexes	O
were	O
subsequently	O
conducted	O
on	O
the	O
involved	O
lower	O
extremity	O
at	O
1	O
and	O
3	O
months	O
post	O
surgery	O
.	O

At	O
each	O
test	O
session	O
subjects	O
completed	O
visual	O
analog	O
scales	O
and	O
knee	O
girth	O
was	O
measured	O
.	O

RESULTS	O
The	O
VM	O
H-reflex	O
amplitude	O
increased	O
in	O
the	O
HS	O
group	O
at	O
3	O
months	O
compared	O
to	O
1-month	O
post	O
surgery	O
(	O
p	O
<	O
.05	O
)	O
.	O

Significant	O
changes	O
over	O
time	O
were	O
also	O
noted	O
in	O
the	O
visual	O
analog	O
pain	O
and	O
functional	O
scales	O
and	O
the	O
mid-patella	O
girth	O
.	O

CONCLUSIONS	O
The	O
increased	O
VM	O
H-reflex	O
amplitude	O
at	O
3	O
months	O
following	O
HS	O
autograft	O
ACLR	Surgical
demonstrates	O
an	O
increase	O
in	O
VM	O
neuromuscular	O
excitability	O
.	O

Increased	O
VM	O
neuromuscular	O
excitability	O
was	O
not	O
evident	O
in	O
patients	O
following	O
BTB	O
reconstruction	O
.	O

The	O
increased	O
neuromuscular	O
excitability	O
,	O
observed	O
only	O
in	O
the	O
HS	O
group	O
,	O
warrants	O
consideration	O
when	O
selecting	O
graft	O
type	O
for	O
patients	O
with	O
extensive	O
preoperative	O
quadriceps	O
dysfunction	O
.	O

Final	O
analysis	O
of	O
the	O
UKLG	O
LY02	O
trial	O
comparing	O
6-8	O
cycles	O
of	O
CHOP	Pharmacological
with	O
3	O
cycles	O
of	O
CHOP	Pharmacological
followed	O
by	O
a	O
BEAM	Pharmacological
autograft	Pharmacological
in	O
patients	O
<	O
65	O
years	O
with	O
poor	O
prognosis	O
histologically	O
aggressive	O
NHL	O
.	O

This	O
trial	O
involved	O
457	O
patients	O
and	O
sought	O
to	O
assess	O
the	O
value	O
of	O
early	O
intensification	O
with	O
autologous	O
transplantation	O
in	O
patients	O
with	O
poor	O
prognosis	O
histologically	O
aggressive	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
showing	O
a	O
response	O
to	O
initial	O
CHOP	Pharmacological
(	Pharmacological
cyclophosphamide	Pharmacological
,	Pharmacological
doxorubicin	Pharmacological
,	Pharmacological
vincristine	Pharmacological
,	Pharmacological
prednisolone	Pharmacological
)	Pharmacological
chemotherapy	Pharmacological
.	O

Randomization	O
was	O
made	O
at	O
the	O
time	O
of	O
diagnosis	O
with	O
223	O
assigned	O
to	O
continuing	O
CHOP	Pharmacological
and	O
234	O
to	O
3	O
cycles	O
of	O
CHOP	Pharmacological
followed	O
by	O
a	O
BEAM	Pharmacological
(	Pharmacological
carmustine	Pharmacological
,	Pharmacological
etoposide	Pharmacological
,	Pharmacological
cytarabine	Pharmacological
,	Pharmacological
melphalan	Pharmacological
)	Pharmacological
autograft	Pharmacological
.	O

Analysis	O
was	O
on	O
an	O
intention	O
to	O
treat	O
basis	O
.	O

After	O
the	O
initial	O
three	O
cycles	O
of	O
CHOP	Pharmacological
19	O
%	O
of	O
the	O
whole	O
group	O
were	O
in	O
complete	O
response	O
(	O
CR	O
)	O
and	O
53	O
%	O
in	O
partial	O
remission	O
(	O
PR	O
)	O
.	O

At	O
the	O
end	O
of	O
treatment	O
86	O
%	O
of	O
patients	O
in	O
the	O
CHOP	Pharmacological
arm	O
had	O
responded	O
with	O
58	O
%	O
in	O
CR	O
.	O

In	O
the	O
high-dose	O
therapy	O
arm	O
the	O
overall	O
response	O
rate	O
was	O
83	O
%	O
with	O
64	O
%	O
in	O
CR	O
(	O
difference	O
between	O
arms	O
not	O
significant	O
)	O
.	O

The	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
at	O
5	O
years	O
for	O
the	O
continuing	O
CHOP	O
arm	O
were	O
38	O
%	O
and	O
50	O
%	O
respectively	O
,	O
and	O
for	O
the	O
autograft	O
arm	O
were	O
44	O
%	O
and	O
50	O
%	O
(	O
differences	O
not	O
significant	O
)	O
.	O

Of	O
the	O
patients	O
who	O
attained	O
CR	O
and	O
subsequently	O
relapsed	O
,	O
there	O
were	O
no	O
long-term	O
survivors	O
in	O
the	O
autograft	O
recipients	O
compared	O
to	O
46	O
%	O
of	O
the	O
continuing	O
CHOP	Pharmacological
recipients	O
(	O
P	O
=	O
0.0008	O
)	O
.	O

In	O
conclusion	O
,	O
no	O
survival	O
benefit	O
was	O
demonstrated	O
for	O
an	O
early	O
autograft	O
in	O
first	O
response	O
.	O

A	O
comparative	O
trial	O
of	O
liver	O
biopsy	O
needles	O
.	O

A	O
sheathed	Physical
needle	Physical
(	O
Tru-Cut	O
)	O
was	O
compared	O
with	O
a	O
suction	Physical
biopsy	Physical
needle	Physical
(	Physical
Menghini	Physical
)	Physical
in	O
a	O
randomised	O
prospective	O
trial	O
over	O
18	O
months	O
to	O
determine	O
whether	O
the	O
former	O
offered	O
any	O
special	O
advantages	O
in	O
routine	Physical
percutaneous	Physical
liver	Physical
biopsy	Physical
.	O

Seventy-seven	O
consecutive	O
biopsies	O
were	O
performed	O
by	O
a	O
single	O
operator	O
.	O

Although	O
biopsy	O
fragmentation	O
was	O
commoner	O
with	O
the	O
suction	Physical
needle	Physical
,	O
the	O
length	O
and	O
volume	O
of	O
the	O
largest	O
core	O
obtained	O
was	O
similar	O
to	O
results	O
with	O
the	O
sheathed	Other
needle	Other
.	O

Cytology	O
provided	O
useful	O
additional	O
information	O
with	O
the	O
Menghini	Physical
technique	Physical
.	Physical

The	O
suction	Other
needle	Other
was	O
repeatedly	O
reusable	O
and	O
considerably	O
cheaper	O
than	O
the	O
sheathed	Other
needle	Other
,	O
which	O
may	O
be	O
used	O
once	O
only	O
.	O

Enhanced	O
baroreceptor	O
control	O
of	O
the	O
cardiovascular	O
system	O
by	O
polyunsaturated	Pharmacological
Fatty	Pharmacological
acids	Pharmacological
in	O
heart	O
failure	O
patients	O
.	O

OBJECTIVES	O
The	O
intention	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
,	O
in	O
heart	O
failure	O
patients	O
,	O
dietary	Pharmacological
supplementation	Pharmacological
of	Pharmacological
polyunsaturated	Pharmacological
fatty	Pharmacological
acids	Pharmacological
(	Pharmacological
PUFA	Pharmacological
)	Pharmacological
enhances	O
arterial	O
baroreceptor	O
control	O
of	O
the	O
cardiovascular	O
system	O
.	O

BACKGROUND	O
Administration	O
of	O
PUFA	Pharmacological
reduces	O
the	O
risk	O
of	O
life-threatening	O
arrhythmias	O
in	O
patients	O
surviving	O
myocardial	O
infarction	O
.	O

This	O
might	O
result	O
from	O
potentiation	O
of	O
arterial	O
baroreflexes	O
,	O
but	O
whether	O
or	O
not	O
PUFA	Pharmacological
enhance	O
baroreflex	O
function	O
has	O
never	O
been	O
studied	O
in	O
humans	O
.	O

METHODS	O
Patients	O
with	O
post-myocardial	O
infarction	O
left	O
ventricular	O
dysfunction	O
underwent	O
beat-to-beat	O
blood	O
pressure	O
(	O
BP	O
)	O
(	O
Finapres	O
,	O
Ohmeda	O
Inc.	O
,	O
Englewood	O
,	O
Colorado	O
)	O
and	O
R-R	O
interval	O
(	O
electrocardiogram	O
)	O
recording	O
;	O
baroreceptor	O
reflexes	O
were	O
assessed	O
from	O
the	O
bradycardic	O
and	O
depressor	O
responses	O
to	O
graded	O
neck	O
suction	O
(	O
NS	O
)	O
as	O
well	O
as	O
by	O
computation	O
of	O
the	O
alpha	O
spontaneous	O
baroreflex	O
sensitivity	O
index	O
.	O

Assessments	O
were	O
repeated	O
after	O
prolonged	O
treatment	O
with	O
PUFA	Pharmacological
(	O
2	O
g/die	O
,	O
n	O
=	O
15	O
)	O
or	O
placebo	Control
(	O
n	O
=	O
10	O
)	O
.	O

RESULTS	O
Baseline	O
BP	O
and	O
R-R	O
interval	O
were	O
unaffected	O
by	O
PUFA	Pharmacological
.	Pharmacological

Both	O
reflex	O
depressor	O
and	O
bradycardic	O
responses	O
to	O
NS	O
increased	O
after	O
PUFA	Pharmacological
(	O
respectively	O
from	O
-0.09	O
+/-	O
0.01	O
to	O
-0.16	O
+/-	O
0.01	O
mm	O
Hg	O
x	O
mm	O
Hg	O
(	O
-1	O
)	O
,	O
p	O
<	O
0.01	O
,	O
and	O
from	O
1.25	O
+/-	O
0.9	O
to	O
1.76	O
+/-	O
1.1	O
ms	O
x	O
mm	O
Hg	O
(	O
-1	O
)	O
,	O
p	O
<	O
0.04	O
)	O
but	O
not	O
after	O
placebo	Control
.	Control

The	O
spontaneous	O
baroreflex	O
sensitivity	O
increased	O
in	O
the	O
PUFA	Pharmacological
(	O
from	O
8.99	O
+/-	O
1.4	O
to	O
12.2	O
+/-	O
1.2	O
ms	O
x	O
mm	O
Hg	O
(	O
-1	O
)	O
,	O
p	O
<	O
0.02	O
)	O
but	O
not	O
in	O
the	O
placebo	Control
group	O
.	O

Polyunsaturated	Pharmacological
fatty	Pharmacological
acids	Pharmacological
(	O
but	O
not	O
placebo	Control
)	O
treatment	O
also	O
significantly	O
increased	O
R-R	O
interval	O
total	O
variance	O
and	O
low-frequency	O
and	O
high-frequency	O
spectral	O
powers	O
.	O

CONCLUSIONS	O
Dietary	Pharmacological
PUFA	Pharmacological
supplementation	Pharmacological
markedly	O
potentiates	O
baroreflex	O
function	O
and	O
enhances	O
heart	O
rate	O
variability	O
in	O
patients	O
with	O
stable	O
congestive	O
heart	O
failure	O
.	O

Complement	O
activation	O
on	O
the	O
surface	O
of	O
cell-derived	O
microparticles	O
during	O
cardiac	O
surgery	O
with	O
cardiopulmonary	Surgical
bypass	Surgical
-	O
is	O
retransfusion	O
of	O
pericardial	O
blood	O
harmful	O
?	O
OBJECTIVES	O
To	O
investigate	O
whether	O
cell-derived	O
microparticles	O
play	O
a	O
role	O
in	O
complement	O
activation	O
in	O
pericardial	O
blood	O
of	O
patients	O
undergoing	O
cardiac	Surgical
surgery	Surgical
with	Surgical
cardiopulmonary	Surgical
bypass	Surgical
(	Surgical
CPB	Surgical
)	Surgical
and	Surgical
whether	O
microparticles	O
in	O
pericardial	O
blood	O
contribute	O
to	O
systemic	O
complement	O
activation	O
upon	O
retransfusion	O
.	O

METHODS	O
Pericardial	O
blood	O
of	O
13	O
patients	O
was	O
retransfused	O
in	O
9	O
and	O
discarded	O
in	O
4	O
cases	O
.	O

Microparticles	O
were	O
isolated	O
from	O
systemic	O
blood	Physical
collected	Physical
before	Physical
anesthesia	Physical
(	O
T1	O
)	O
and	O
at	O
the	O
end	O
of	O
CPB	Surgical
(	O
T2	O
)	O
,	O
and	O
from	O
pericardial	O
blood	O
.	O

The	O
microparticles	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
for	O
bound	O
complement	O
components	O
C1q	O
,	O
C4	O
and	O
C3	O
,	O
and	O
bound	O
complement	O
activator	O
molecules	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
serum	O
amyloid	O
P-component	O
(	O
SAP	O
)	O
,	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
and	O
IgG	O
.	O

Fluid-phase	O
complement	O
activation	O
products	O
(	O
C4b/c	O
,	O
C3b/c	O
)	O
and	O
activator	O
molecules	O
were	O
determined	O
by	O
ELISA	O
.	O

RESULTS	O
Compared	O
with	O
systemic	O
T1	O
blood	O
,	O
pericardial	O
blood	O
contained	O
increased	O
C4b/c	O
and	O
C3b/c	O
,	O
and	O
increased	O
levels	O
of	O
microparticles	O
with	O
bound	O
complement	O
components	O
.	O

In	O
systemic	O
T1	O
samples	O
,	O
microparticle-bound	O
CRP	O
,	O
whereas	O
in	O
pericardial	O
blood	O
,	O
microparticle-bound	O
SAP	O
and	O
IgM	O
were	O
associated	O
with	O
complement	O
activation	O
.	O

At	O
the	O
end	O
of	O
CPB	Surgical
,	O
increased	O
C3b/c	O
(	O
but	O
not	O
C4b/c	O
)	O
was	O
present	O
in	O
systemic	O
T2	O
blood	O
compared	O
with	O
T1	O
,	O
while	O
concentrations	O
of	O
microparticles	O
binding	O
complement	O
components	O
and	O
of	O
those	O
binding	O
complement	O
activator	O
molecules	O
were	O
similar	O
.	O

Concentrations	O
of	O
fluid-phase	O
complement	O
activation	O
products	O
and	O
microparticles	O
were	O
similar	O
in	O
patients	O
whether	O
or	O
not	O
retransfused	O
with	O
pericardial	O
blood	O
.	O

CONCLUSIONS	O
In	O
pericardial	O
blood	O
of	O
patients	O
undergoing	O
cardiac	O
surgery	O
with	O
CPB	Surgical
,	O
microparticles	O
contribute	O
to	O
activation	O
of	O
the	O
complement	O
system	O
via	O
bound	O
SAP	O
and	O
IgM	O
.	O

Retransfusion	O
of	O
pericardial	O
blood	O
,	O
however	O
,	O
does	O
not	O
contribute	O
to	O
systemic	O
complement	O
activation	O
.	O

RCT	O
of	O
a	O
manualized	O
social	Educational
treatment	Educational
for	O
high-functioning	O
autism	O
spectrum	O
disorders	O
.	O

This	O
RCT	O
examined	O
the	O
efficacy	O
of	O
a	O
manualized	Educational
social	Educational
intervention	Educational
for	O
children	O
with	O
HFASDs	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
treatment	Educational
or	O
wait-list	Control
conditions	Control
.	Control

Treatment	O
included	O
instruction	Educational
and	Educational
therapeutic	Educational
activities	Educational
targeting	Educational
social	Educational
skills	Educational
,	Educational
face-emotion	Educational
recognition	Educational
,	Educational
interest	Educational
expansion	Educational
,	Educational
and	Educational
interpretation	Educational
of	Educational
non-literal	Educational
language	Educational
.	Educational

A	O
response-cost	O
program	O
was	O
applied	O
to	O
reduce	O
problem	O
behaviors	O
and	O
foster	O
skills	O
acquisition	O
.	O

Significant	O
treatment	O
effects	O
were	O
found	O
for	O
five	O
of	O
seven	O
primary	O
outcome	O
measures	O
(	O
parent	O
ratings	O
and	O
direct	O
child	O
measures	O
)	O
.	O

Secondary	O
measures	O
based	O
on	O
staff	O
ratings	O
(	O
treatment	O
group	O
only	O
)	O
corroborated	O
gains	O
reported	O
by	O
parents	O
.	O

High	O
levels	O
of	O
parent	O
,	O
child	O
and	O
staff	O
satisfaction	O
were	O
reported	O
,	O
along	O
with	O
high	O
levels	O
of	O
treatment	O
fidelity	O
.	O

Standardized	O
effect	O
size	O
estimates	O
were	O
primarily	O
in	O
the	O
medium	O
and	O
large	O
ranges	O
and	O
favored	O
the	O
treatment	O
group	O
.	O

[	O
A	O
randomized	O
study	O
of	O
prophylactic	O
intravesical	O
instillation	O
of	O
pirarubicin	Pharmacological
(	Pharmacological
THP	Pharmacological
)	Pharmacological
prior	O
to	O
transurethral	O
resection	O
of	O
superficial	O
bladder	O
cancer	O
]	O
.	O

A	O
prospective	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
of	O
prophylactic	O
intravesical	Pharmacological
instillation	Pharmacological
of	Pharmacological
pirarubicin	Pharmacological
(	Pharmacological
THP	Pharmacological
)	Pharmacological
prior	O
to	O
transurethral	Surgical
resection	Surgical
(	O
TUR	O
)	O
of	O
superficial	O
bladder	O
cancer	O
.	O

A	O
total	O
of	O
63	O
patients	O
were	O
randomized	O
into	O
two	O
groups	O
,	O
the	O
THP	Pharmacological
group	O
and	O
the	O
control	O
group	O
.	O

In	O
the	O
THP	O
group	O
,	O
30	O
mg	O
of	O
THP	O
dissolved	O
in	O
50	Pharmacological
ml	Pharmacological
saline	Pharmacological
was	O
administered	O
4	O
times	O
intravesically	O
for	O
4	O
consecutive	O
days	O
before	O
TUR	O
.	O

In	O
the	O
control	O
group	O
,	O
no	Control
instillation	Control
was	O
performed	O
before	O
TUR	Surgical
.	O

The	O
patients	O
were	O
followed	O
by	O
cystoscopy	O
and	O
urinary	O
cytology	O
every	O
3	O
months	O
.	O

The	O
non-recurrence	O
rates	O
in	O
the	O
THP	O
group	O
and	O
control	O
group	O
were	O
54.1	O
%	O
versus	O
37.6	O
%	O
at	O
1	O
year	O
and	O
40.4	O
%	O
versus	O
26.8	O
%	O
at	O
2	O
years	O
,	O
respectively	O
(	O
P	O
=	O
0.086	O
)	O
.	O

Time	O
to	O
recurrence	O
for	O
tumors	O
larger	O
than	O
1	O
cm	O
was	O
significantly	O
longer	O
in	O
the	O
THP	O
group	O
(	O
P	O
=	O
0.0137	O
)	O
.	O

Time	O
to	O
recurrence	O
for	O
single	O
and	O
grade	O
1+2	O
tumors	O
tended	O
to	O
be	O
longer	O
in	O
the	O
THP	O
group	O
(	O
P	O
=	O
0.09	O
,	O
P	O
=	O
0.079	O
)	O
.	O

No	O
significant	O
adverse	O
effects	O
were	O
observed	O
in	O
any	O
patient	O
.	O

Our	O
findings	O
suggest	O
that	O
intravesical	O
THP	O
instillation	O
prior	O
to	O
TUR	O
would	O
be	O
effective	O
for	O
patients	O
with	O
single	O
,	O
low	O
grade	O
lesions	O
larger	O
than	O
1	O
cm	O
of	O
superficial	O
bladder	O
cancer	O
.	O

Durability	O
of	O
central	Physical
venous	Physical
catheters	Physical
.	O

A	O
randomized	O
trial	O
in	O
children	O
with	O
malignant	O
diseases	O
.	O

In	O
a	O
prospective	O
randomized	O
study	O
the	O
durability	O
of	O
tunnelled	Physical
and	Physical
non-tunnelled	Physical
central	Physical
venous	Physical
catheters	Physical
was	O
investigated	O
in	O
children	O
with	O
malignant	O
diseases	O
.	O

Twenty	O
children	O
were	O
included	O
in	O
the	O
study	O
but	O
four	O
(	O
two	O
in	O
each	O
group	O
)	O
had	O
to	O
be	O
excluded	O
;	O
three	O
because	O
the	O
entry	O
criteria	O
turned	O
out	O
not	O
to	O
be	O
fulfilled	O
and	O
one	O
because	O
of	O
lack	O
of	O
data	O
.	O

The	O
median	O
duration	O
of	O
the	O
tunnelled	Physical
catheters	Physical
was	O
224	O
days	O
with	O
a	O
range	O
of	O
25-846	O
days	O
which	O
was	O
significantly	O
longer	O
than	O
that	O
of	O
conventional	Physical
catheters	Physical
(	O
39.5	O
days	O
,	O
range	O
9-228	O
days	O
)	O
.	O

In	O
addition	O
six	O
of	O
eight	O
conventional	O
catheters	O
were	O
accidentally	O
removed	O
whereas	O
all	O
catheters	O
in	O
the	O
tunnelled	O
group	O
had	O
to	O
be	O
removed	O
via	O
a	O
small	O
incision	O
.	O

Three	O
cases	O
of	O
catheter	O
related	O
sepsis	O
,	O
two	O
in	O
the	O
tunnelled	O
group	O
and	O
one	O
in	O
the	O
conventional	O
group	O
,	O
were	O
registered	O
.	O

The	O
corresponding	O
number	O
of	O
infections	O
per	O
catheter	O
days	O
were	O
1	O
in	O
1189	O
days	O
and	O
1	O
in	O
522	O
days	O
,	O
respectively	O
.	O

In	O
conclusion	O
cuffed	Physical
,	Physical
tunnelled	Physical
central	Physical
venous	Physical
catheters	Physical
are	O
less	O
prone	O
to	O
displacement	O
than	O
traditional	Physical
percutaneous	Physical
central	Physical
venous	Physical
catheters	Physical
when	O
used	O
in	O
children	O
with	O
malignant	O
diseases	O
.	O

Rationale	O
and	O
design	O
of	O
the	O
Folic	Pharmacological
Acid	Pharmacological
for	O
Vascular	O
Outcome	O
Reduction	O
In	O
Transplantation	O
(	O
FAVORIT	O
)	O
trial	O
.	O

BACKGROUND	O
Patients	O
with	O
chronic	O
kidney	O
disease	O
,	O
including	O
kidney	O
transplant	O
recipients	O
,	O
are	O
at	O
high	O
risk	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

In	O
addition	O
to	O
the	O
constellation	O
of	O
traditional	O
CVD	O
risk	O
factors	O
in	O
chronic	O
kidney	O
disease	O
,	O
elevated	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
is	O
notably	O
more	O
prevalent	O
among	O
the	O
general	O
population	O
.	O

The	Pharmacological
Folic	Pharmacological
Acid	Pharmacological
for	O
Vascular	O
Outcome	O
Reduction	O
In	O
Transplantation	O
(	O
FAVORIT	O
)	O
trial	O
is	O
designed	O
to	O
evaluate	O
whether	O
lowering	O
tHcy	O
using	O
vitamin	Pharmacological
supplementation	Pharmacological
reduces	O
CVD	O
events	O
in	O
renal	O
transplant	O
recipients	O
.	O

METHODS	O
FAVORIT	O
is	O
a	O
multicenter	O
double-blind	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Participants	O
are	O
clinically	O
stable	O
renal	O
transplant	O
recipients	O
who	O
are	O
6	O
months	O
or	O
longer	O
posttransplant	O
with	O
elevated	O
tHcy	O
.	O

Patients	O
are	O
randomized	O
to	O
a	O
multivitamin	Pharmacological
that	Pharmacological
includes	Pharmacological
either	Pharmacological
a	Pharmacological
high-dose	Pharmacological
or	Pharmacological
low-dose	Pharmacological
of	Pharmacological
folic	Pharmacological
acid	Pharmacological
(	O
5	O
or	O
0	O
mg	O
)	O
,	O
vitamin	Pharmacological
B6	Pharmacological
(	O
50	O
or	O
1.4	O
mg	O
)	O
,	O
and	Pharmacological
vitamin	Pharmacological
B12	Pharmacological
(	O
1000	O
or	O
2	O
microg	O
)	O
.	O

The	O
primary	O
end	O
point	O
is	O
a	O
composite	O
of	O
incident	O
or	O
recurrent	O
CVD	O
outcomes	O
,	O
that	O
is	O
,	O
coronary	O
heart	O
,	O
cerebrovascular	O
,	O
or	O
abdominal	O
aortic/lower	O
extremity	O
arterial	O
events	O
.	O

A	O
sample	O
size	O
of	O
4000	O
is	O
estimated	O
to	O
provide	O
87	O
%	O
power	O
to	O
detect	O
a	O
20	O
%	O
treatment	O
effect	O
.	O

Recruitment	O
is	O
expected	O
to	O
continue	O
until	O
July	O
2006	O
,	O
with	O
follow-up	O
through	O
June	O
2010	O
.	O

RESULTS	O
From	O
August	O
2002	O
through	O
December	O
2004	O
,	O
2234	O
of	O
the	O
target	O
4000	O
patients	O
were	O
enrolled	O
.	O

In	O
accordance	O
with	O
trial	O
design	O
,	O
mean	O
(	O
SD	O
)	O
screening	O
tHcy	O
was	O
elevated	O
(	O
17.4	O
+/-	O
6.2	O
micromol/L	O
)	O
,	O
and	O
mean	O
(	O
SD	O
)	O
estimated	O
creatinine	O
clearance	O
was	O
consistent	O
with	O
stable	O
renal	O
function	O
(	O
58.0	O
+/-	O
18.6	O
mL/min	O
)	O
.	O

Evaluating	O
baseline	O
results	O
to	O
date	O
,	O
42	O
%	O
of	O
the	O
randomized	O
participants	O
had	O
a	O
history	O
of	O
diabetes	O
mellitus	O
,	O
and	O
21	O
%	O
had	O
prevalent	O
CVD	O
.	O

CONCLUSIONS	O
The	O
FAVORIT	O
trial	O
is	O
designed	O
with	O
sufficient	O
power	O
and	O
follow-up	O
time	O
to	O
detect	O
a	O
clinically	O
relevant	O
change	O
in	O
CVD	O
risk	O
between	O
renal	O
transplant	O
recipients	O
receiving	O
a	O
high	O
or	O
low	O
tHcy-lowering	O
folic	Pharmacological
acid	Pharmacological
multivitamin	Pharmacological
.	O

Preliminary	O
screening	O
and	O
baseline	O
data	O
support	O
the	O
trial	O
's	O
objectives	O
.	O

Etanercept	Pharmacological
plus	Pharmacological
standard	Pharmacological
therapy	Pharmacological
for	O
Wegener	O
's	O
granulomatosis	O
.	O

BACKGROUND	O
The	O
majority	O
of	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
have	O
disease	O
flares	O
after	O
conventional	O
medications	O
are	O
tapered	O
.	O

There	O
is	O
no	O
consistently	O
safe	O
,	O
effective	O
treatment	O
for	O
the	O
maintenance	O
of	O
remission	O
.	O

METHODS	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo-controlled	Control
trial	O
at	O
eight	O
centers	O
to	O
evaluate	O
etanercept	Pharmacological
for	O
the	O
maintenance	O
of	O
remission	O
in	O
180	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
.	O

The	O
primary	O
outcome	O
was	O
sustained	O
remission	O
,	O
defined	O
as	O
a	O
Birmingham	O
Vasculitis	O
Activity	O
Score	O
for	O
Wegener	O
's	O
Granulomatosis	O
of	O
0	O
for	O
at	O
least	O
six	O
months	O
(	O
scores	O
can	O
range	O
from	O
0	O
to	O
67	O
,	O
with	O
higher	O
scores	O
indicating	O
more	O
active	O
disease	O
)	O
.	O

In	O
addition	O
to	O
etanercept	Pharmacological
or	O
placebo	Control
,	O
patients	O
received	O
standard	Pharmacological
therapy	Pharmacological
(	Pharmacological
glucocorticoids	Pharmacological
plus	Pharmacological
cyclophosphamide	Pharmacological
or	Pharmacological
methotrexate	Pharmacological
)	Pharmacological
.	Pharmacological

After	O
remission	O
,	O
standard	Pharmacological
medications	Pharmacological
were	O
tapered	O
according	O
to	O
the	O
protocol	O
.	O

RESULTS	O
The	O
mean	O
follow-up	O
for	O
the	O
overall	O
cohort	O
was	O
27	O
months	O
.	O

Of	O
the	O
174	O
patients	O
who	O
could	O
be	O
evaluated	O
,	O
126	O
(	O
72.4	O
percent	O
)	O
had	O
a	O
sustained	O
remission	O
,	O
but	O
only	O
86	O
(	O
49.4	O
percent	O
)	O
remained	O
in	O
remission	O
for	O
the	O
remainder	O
of	O
the	O
trial	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
etanercept	Pharmacological
and	O
control	O
groups	O
in	O
the	O
rates	O
of	O
sustained	O
remission	O
(	O
69.7	O
percent	O
vs.	O
75.3	O
percent	O
,	O
P=0.39	O
)	O
,	O
sustained	O
periods	O
of	O
low-level	O
disease	O
activity	O
(	O
86.5	O
percent	O
vs.	O
90.6	O
percent	O
,	O
P=0.32	O
)	O
,	O
or	O
the	O
time	O
required	O
to	O
achieve	O
those	O
measures	O
.	O

Disease	O
flares	O
were	O
common	O
in	O
both	O
groups	O
,	O
with	O
118	O
flares	O
in	O
the	O
etanercept	Pharmacological
group	O
(	O
23	O
severe	O
and	O
95	O
limited	O
)	O
and	O
134	O
in	O
the	O
control	Control
group	Control
(	O
25	O
severe	O
and	O
109	O
limited	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
etanercept	Pharmacological
and	O
control	O
groups	O
in	O
the	O
relative	O
risk	O
of	O
disease	O
flares	O
per	O
100	O
person-years	O
of	O
follow-up	O
(	O
0.89	O
,	O
P=0.54	O
)	O
.	O

During	O
the	O
study	O
,	O
56.2	O
percent	O
of	O
patients	O
in	O
the	O
etanercept	Pharmacological
group	O
and	O
57.1	O
percent	O
of	O
those	O
in	O
the	O
control	O
group	O
had	O
at	O
least	O
one	O
severe	O
or	O
life-threatening	O
adverse	O
event	O
or	O
died	O
(	O
P=0.90	O
)	O
.	O

Solid	O
cancers	O
developed	O
in	O
six	O
patients	O
in	O
the	O
etanercept	Pharmacological
group	O
,	O
as	O
compared	O
with	O
none	O
in	O
the	O
control	O
group	O
(	O
P=0.01	O
)	O
.	O

CONCLUSIONS	O
Etanercept	Pharmacological
is	O
not	O
effective	O
for	O
the	O
maintenance	O
of	O
remission	O
in	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
.	O

Durable	O
remissions	O
were	O
achieved	O
in	O
only	O
a	O
minority	O
of	O
the	O
patients	O
,	O
and	O
there	O
was	O
a	O
high	O
rate	O
of	O
treatment-related	O
complications	O
.	O

Chlorthalidone	Pharmacological
does	O
not	O
increase	O
the	O
hypotensive	O
effect	O
of	O
nifedipine	Pharmacological
in	O
essential	O
hypertensives	O
:	O
a	O
crossover	O
multicentre	O
study	O
.	O

To	O
determine	O
whether	O
the	O
combination	O
of	O
nifedipine	Pharmacological
+	Pharmacological
chlorthalidone	Pharmacological
exerts	O
an	O
additive	O
antihypertensive	O
effect	O
when	O
compared	O
with	O
single-drug	O
treatment	O
,	O
we	O
studied	O
66	O
uncomplicated	O
essential	O
hypertensives	O
,	O
with	O
diastolic	O
blood	O
pressure	O
of	O
greater	O
than	O
100	O
and	O
less	O
than	O
115	O
mmHg	O
.	O

At	O
the	O
end	O
of	O
a	O
1-month	O
washout	O
placebo	Control
period	O
,	O
using	O
a	O
double-blind	O
crossover	O
design	O
,	O
the	O
patients	O
were	O
randomly	O
allocated	O
to	O
nifedipine	Pharmacological
(	O
20	O
mg	O
twice	O
a	O
day	O
)	O
,	O
chlorthalidone	Pharmacological
(	O
25	O
mg	O
once	O
a	O
day	O
)	O
,	O
the	O
two	O
drugs	O
combined	O
at	O
the	O
same	O
doses	O
and	O
the	O
corresponding	O
placebo	Control
.	O

Compared	O
with	O
the	O
randomly	O
allocated	O
placebo	O
,	O
the	O
three	O
active	O
treatments	O
significantly	O
reduced	O
blood	O
pressure	O
without	O
changing	O
the	O
heart	O
rate	O
or	O
body	O
weight	O
.	O

Both	O
the	O
absolute	O
and	O
percentage	O
decreases	O
in	O
mean	O
blood	O
pressure	O
induced	O
by	O
nifedipine	Pharmacological
and	O
the	O
combination	O
compared	O
with	O
placebo	Control
were	O
similar	O
and	O
significantly	O
greater	O
than	O
those	O
induced	O
by	O
chlorthalidone	Pharmacological
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
combination	O
of	O
nifedipine	Pharmacological
+	Pharmacological
chlorthalidone	Pharmacological
does	O
not	O
exert	O
any	O
additive	O
antihypertensive	O
effect	O
compared	O
with	O
nifedipine	Pharmacological
alone	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
combination	O
of	O
a	O
dihydropyridine	Pharmacological
calcium	Pharmacological
antagonist	Pharmacological
+	Pharmacological
a	Pharmacological
thiazide	Pharmacological
diuretic	Pharmacological
is	O
probably	O
devoid	O
of	O
any	O
particular	O
clinical	O
significance	O
in	O
the	O
treatment	O
of	O
uncomplicated	O
essential	O
hypertensives	O
.	O

Profound	O
luteinizing	O
hormone	O
suppression	O
after	O
stopping	O
the	O
gonadotropin-releasing	Pharmacological
hormone-agonist	Pharmacological
leuprolide	Pharmacological
acetate	Pharmacological
.	O

OBJECTIVE	O
To	O
compare	O
levels	O
of	O
serum	O
LH	O
during	O
continued	O
use	O
of	O
leuprolide	Pharmacological
acetate	Pharmacological
(	Pharmacological
LA	Pharmacological
)	Pharmacological
with	O
levels	O
during	O
the	O
first	O
week	O
after	O
discontinuing	O
LA	O
.	O

DESIGN	O
Prospective	O
controlled	O
study	O
.	O

SETTING	O
Clinical	O
assisted	O
conception	O
program	O
.	O

PATIENTS	O
Women	O
undergoing	O
controlled	O
ovarian	O
stimulation	O
for	O
assisted	O
conception	O
were	O
randomized	O
to	O
receive	O
LA	Pharmacological
according	O
to	O
short	O
or	O
ultrashort	O
protocols	O
.	O

The	O
alternative	O
protocol	O
was	O
used	O
then	O
in	O
a	O
second	O
cycle	O
.	O

Each	O
patient	O
was	O
thus	O
her	O
own	O
control	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Serum	O
LH	O
over	O
time	O
.	O

RESULTS	O
When	O
LA	Pharmacological
was	O
stopped	O
after	O
5	O
days	O
of	O
administration	O
,	O
LH	O
levels	O
fell	O
profoundly	O
when	O
compared	O
with	O
levels	O
when	O
LA	Pharmacological
was	O
continued	O
.	O

CONCLUSION	O
Loss	O
of	O
LH	O
after	O
stopping	O
LA	Pharmacological
is	O
likely	O
to	O
be	O
clinically	O
important	O
in	O
ovarian	O
stimulation	O
regimens	O
that	O
use	O
pure	O
FSH	O
with	O
LA	Pharmacological
in	O
ultrashort	O
protocols	O
.	O

The	O
fall	O
in	O
LH	O
lasts	O
at	O
least	O
1	O
week	O
and	O
may	O
be	O
explainable	O
by	O
persistent	O
suppression	O
of	O
endogenous	O
GnRH	O
by	O
LA	O
during	O
this	O
time	O
.	O

Nasal	O
oxytocin	Pharmacological
for	O
social	O
deficits	O
in	O
childhood	O
autism	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

The	O
last	O
two	O
decades	O
have	O
witnessed	O
a	O
surge	O
in	O
research	O
investigating	O
the	O
application	O
of	O
oxytocin	O
as	O
a	O
method	O
of	O
enhancing	O
social	O
behaviour	O
in	O
humans	O
.	O

Preliminary	O
evidence	O
suggests	O
oxytocin	O
may	O
have	O
potential	O
as	O
an	O
intervention	O
for	O
autism	O
.	O

We	O
evaluated	O
a	O
5-day	O
'live-in	O
'	O
intervention	O
using	O
a	O
double-blind	O
randomized	O
control	O
trial	O
.	O

38	O
male	O
youths	O
(	O
7-16	O
years	O
old	O
)	O
with	O
autism	O
spectrum	O
disorders	O
were	O
administered	O
24	O
or	O
12	O
international	O
units	O
(	O
depending	O
on	O
weight	O
)	O
intranasal	Control
placebo	Control
or	O
oxytocin	Pharmacological
once	O
daily	O
over	O
four	O
consecutive	O
days	O
.	O

The	O
oxytocin	O
or	O
placebo	O
was	O
administered	O
during	O
parent-child	O
interaction	O
training	O
sessions	O
.	O

Parent	O
and	O
child	O
behaviours	O
were	O
assessed	O
using	O
parent	O
reports	O
,	O
clinician	O
ratings	O
,	O
and	O
independent	O
observations	O
,	O
at	O
multiple	O
time	O
points	O
to	O
measure	O
side-effects	O
;	O
social	O
interaction	O
skills	O
;	O
repetitive	O
behaviours	O
;	O
emotion	O
recognition	O
and	O
diagnostic	O
status	O
.	O

Compared	O
to	O
placebo	O
,	O
intranasal	O
oxytocin	O
did	O
not	O
significantly	O
improve	O
emotion	O
recognition	O
,	O
social	O
interaction	O
skills	O
,	O
or	O
general	O
behavioral	O
adjustment	O
in	O
male	O
youths	O
with	O
autism	O
spectrum	O
disorders	O
.	O

The	O
results	O
show	O
that	O
the	O
benefits	O
of	O
nasal	O
oxytocin	O
for	O
young	O
individuals	O
with	O
autism	O
spectrum	O
disorders	O
may	O
be	O
more	O
circumscribed	O
than	O
suggested	O
by	O
previous	O
studies	O
,	O
and	O
suggest	O
caution	O
in	O
recommending	O
it	O
as	O
an	O
intervention	O
that	O
is	O
broadly	O
effective	O
.	O

A	O
double-blind	O
comparison	O
of	O
clomipramine	Pharmacological
,	O
desipramine	Pharmacological
,	O
and	O
placebo	Control
in	O
the	O
treatment	O
of	O
autistic	O
disorder	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
clomipramine	Pharmacological
hydrochloride	Pharmacological
,	O
a	O
serotonin	O
reuptake	O
blocker	O
with	O
unique	O
anti-obsessional	O
properties	O
,	O
is	O
differentially	O
effective	O
for	O
obsessive-compulsive	O
and	O
stereotyped	O
motor	O
behaviors	O
in	O
autistic	O
disorder	O
compared	O
with	O
placebo	Control
and	O
with	O
the	O
noradrenergic	Pharmacological
tricyclic	Pharmacological
antidepressant	Pharmacological
agent	Pharmacological
,	O
desipramine	Pharmacological
hydrochloride	Pharmacological
.	O

DESIGN	O
Following	O
a	O
2-week	O
,	O
single-blind	O
placebo	Control
washout	O
phase	O
,	O
12	O
autistic	O
subjects	O
completed	O
a	O
10-week	O
,	O
double-blind	O
,	O
crossover	O
comparison	O
of	O
clomipramine	Pharmacological
and	O
placebo	Control
,	O
and	O
12	O
different	O
subjects	O
completed	O
a	O
similar	O
comparison	O
of	O
clomipramine	Pharmacological
and	O
desipramine	Pharmacological
.	O

SETTING	O
Outpatient	O
clinic	O
.	O

PATIENTS	O
A	O
referral	O
sample	O
of	O
30	O
male	O
and	O
female	O
autistic	O
patients	O
were	O
enrolled	O
,	O
and	O
24	O
completed	O
the	O
study	O
.	O

MEASURES	O
Key	O
outcome	O
measures	O
were	O
the	O
Autism	O
Relevant	O
Subscale	O
of	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
,	O
the	O
Modified	O
Comprehensive	O
Psychopathological	O
Rating	O
Scale-Obsessive-Compulsive	O
Disorder	O
Subscale	O
,	O
and	O
the	O
Clinical	O
Global	O
Impressions	O
Scale	O
.	O

RESULTS	O
Clomipramine	Pharmacological
was	O
superior	O
to	O
both	O
placebo	O
and	O
desipramine	O
on	O
ratings	O
of	O
autistic	O
symptoms	O
(	O
including	O
stereotypies	O
)	O
,	O
anger	O
,	O
and	O
compulsive	O
,	O
ritualized	O
behaviors	O
(	O
P	O
<	O
.05	O
)	O
,	O
with	O
no	O
differences	O
between	O
desipramine	Pharmacological
and	O
placebo	Control
.	O

Clomipramine	Pharmacological
was	O
equal	O
to	O
desipramine	Pharmacological
and	O
both	O
tricyclic	O
agents	O
were	O
superior	O
to	O
placebo	O
for	O
amelioration	O
of	O
hyperactivity	O
.	O

CONCLUSION	O
Biological	O
links	O
between	O
compulsions	O
and	O
stereotyped	O
,	O
repetitive	O
behaviors	O
in	O
autistic	O
disorder	O
should	O
be	O
explored	O
.	O

Low-frequency	Physical
repetitive	Physical
transcranial	Physical
magnetic	Physical
stimulation	Physical
(	Physical
rTMS	Physical
)	Physical
affects	O
event-related	O
potential	O
measures	O
of	O
novelty	O
processing	O
in	O
autism	O
.	O

In	O
our	O
previous	O
study	O
on	O
individuals	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
(	O
Sokhadze	O
et	O
al.	O
,	O
Appl	O
Psychophysiol	O
Biofeedback	O
34:37-51	O
,	O
2009a	O
)	O
we	O
reported	O
abnormalities	O
in	O
the	O
attention-orienting	O
frontal	O
event-related	O
potentials	O
(	O
ERP	O
)	O
and	O
the	O
sustained-attention	O
centro-parietal	O
ERPs	O
in	O
a	O
visual	O
oddball	O
experiment	O
.	O

These	O
results	O
suggest	O
that	O
individuals	O
with	O
autism	O
over-process	O
information	O
needed	O
for	O
the	O
successful	O
differentiation	O
of	O
target	O
and	O
novel	O
stimuli	O
.	O

In	O
the	O
present	O
study	O
we	O
examine	O
the	O
effects	O
of	O
low-frequency	Physical
,	Physical
repetitive	Physical
Transcranial	Physical
Magnetic	Physical
Stimulation	Physical
(	Physical
rTMS	Physical
)	Physical
on	O
novelty	O
processing	O
as	O
well	O
as	O
behavior	O
and	O
social	O
functioning	O
in	O
13	O
individuals	O
with	O
ASD	O
.	O

Our	O
hypothesis	O
was	O
that	O
low-frequency	Physical
rTMS	Physical
application	O
to	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLFPC	O
)	O
would	O
result	O
in	O
an	O
alteration	O
of	O
the	O
cortical	O
excitatory/inhibitory	O
balance	O
through	O
the	O
activation	O
of	O
inhibitory	O
GABAergic	O
double	O
bouquet	O
interneurons	O
.	O

We	O
expected	O
to	O
find	O
post-TMS	O
differences	O
in	O
amplitude	O
and	O
latency	O
of	O
early	O
and	O
late	O
ERP	O
components	O
.	O

The	O
results	O
of	O
our	O
current	O
study	O
validate	O
the	O
use	O
of	O
low-frequency	O
rTMS	O
as	O
a	O
modulatory	O
tool	O
that	O
altered	O
the	O
disrupted	O
ratio	O
of	O
cortical	O
excitation	O
to	O
inhibition	O
in	O
autism	O
.	O

After	O
rTMS	O
the	O
parieto-occipital	O
P50	O
amplitude	O
decreased	O
to	O
novel	O
distracters	O
but	O
not	O
to	O
targets	O
;	O
also	O
the	O
amplitude	O
and	O
latency	O
to	O
targets	O
increased	O
for	O
the	O
frontal	O
P50	O
while	O
decreasing	O
to	O
non-target	O
stimuli	O
.	O

Low-frequency	O
rTMS	O
minimized	O
early	O
cortical	O
responses	O
to	O
irrelevant	O
stimuli	O
and	O
increased	O
responses	O
to	O
relevant	O
stimuli	O
.	O

Improved	O
selectivity	O
in	O
early	O
cortical	O
responses	O
lead	O
to	O
better	O
stimulus	O
differentiation	O
at	O
later-stage	O
responses	O
as	O
was	O
made	O
evident	O
by	O
our	O
P3b	O
and	O
P3a	O
component	O
findings	O
.	O

These	O
results	O
indicate	O
a	O
significant	O
change	O
in	O
early	O
,	O
middle-latency	O
and	O
late	O
ERP	O
components	O
at	O
the	O
frontal	O
,	O
centro-parietal	O
,	O
and	O
parieto-occipital	O
regions	O
of	O
interest	O
in	O
response	O
to	O
target	O
and	O
distracter	O
stimuli	O
as	O
a	O
result	O
of	O
rTMS	O
treatment	O
.	O

Overall	O
,	O
our	O
preliminary	O
results	O
show	O
that	O
rTMS	O
may	O
prove	O
to	O
be	O
an	O
important	O
research	O
tool	O
or	O
treatment	O
modality	O
in	O
addressing	O
the	O
stimulus	O
hypersensitivity	O
characteristic	O
of	O
autism	O
spectrum	O
disorders	O
.	O

Effects	O
of	O
water	Pharmacological
extracts	Pharmacological
of	Pharmacological
Graptopetalum	Pharmacological
paraguayense	Pharmacological
on	O
blood	O
pressure	O
,	O
fasting	O
glucose	O
,	O
and	O
lipid	O
profiles	O
of	O
subjects	O
with	O
metabolic	O
syndrome	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
water	Pharmacological
extracts	Pharmacological
of	Pharmacological
Graptopetalum	Pharmacological
paraguayense	Pharmacological
(	Pharmacological
WGP	Pharmacological
,	Pharmacological
4	Pharmacological
g/d	Pharmacological
)	Pharmacological
on	O
blood	O
pressure	O
,	O
blood	O
glucose	O
level	O
,	O
and	O
lipid	O
profiles	O
in	O
subjects	O
with	O
metabolic	O
syndrome	O
(	O
MS	O
)	O
.	O

Participants	O
with	O
MS	O
(	O
n	O
=	O
54	O
)	O
were	O
randomly	O
assigned	O
to	O
the	O
placebo	Control
(	O
n	O
=	O
28	O
)	O
and	O
WGP	Pharmacological
groups	O
(	O
n	O
=	O
26	O
)	O
,	O
and	O
the	O
intervention	O
was	O
administered	O
for	O
12	O
weeks	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
fasting	O
glucose	O
(	O
FG	O
)	O
,	O
lipid	O
profiles	O
(	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
,	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL-C	O
)	O
,	O
and	O
high	O
density	O
lipoprotein	O
(	O
HDL-C	O
)	O
)	O
,	O
and	O
antioxidant	O
enzymes	O
activities	O
(	O
catalase	O
(	O
CAT	O
)	O
,	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
,	O
and	O
glutathione	O
peroxidase	O
(	O
GPx	O
)	O
)	O
were	O
measured	O
.	O

Forty-two	O
subjects	O
completed	O
the	O
study	O
(	O
placebo	Control
,	O
n	O
=	O
19	O
;	O
WGP	Pharmacological
,	O
n	O
=	O
23	O
)	O
.	O

FG	O
,	O
SBP	O
,	O
and	O
LDL-C	O
levels	O
were	O
significantly	O
lower	O
and	O
HDL-C	O
level	O
and	O
antioxidant	O
enzymes	O
activities	O
(	O
CAT	O
and	O
SOD	O
)	O
were	O
significantly	O
higher	O
after	O
WGP	O
supplementation	O
.	O

Blood	O
pressure	O
,	O
FG	O
,	O
and	O
lipid	O
profiles	O
were	O
significantly	O
correlated	O
with	O
antioxidant	O
enzymes	O
activities	O
after	O
supplementation	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
present	O
study	O
demonstrated	O
a	O
significant	O
reduction	O
in	O
blood	O
pressure	O
,	O
blood	O
glucose	O
,	O
and	O
lipid	O
profiles	O
and	O
an	O
increase	O
in	O
antioxidant	O
enzymes	O
activities	O
in	O
subjects	O
with	O
MS	O
after	O
WGP	Pharmacological
supplementation	O
.	O

Taken	O
together	O
,	O
the	O
antioxidative	O
capacity	O
of	O
WGP	Control
might	O
exert	O
a	O
beneficial	O
effect	O
on	O
MS	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
NCT01463748	O
.	O

Antifibrinolytic	Pharmacological
therapy	Pharmacological
for	O
prevention	O
of	O
hemorrhage	O
during	O
surgery	O
of	O
the	O
thyroid	O
gland	O
.	O

The	O
amount	O
of	O
fibrinolytic	O
activity	O
in	O
the	O
thyroid	O
gland	O
equals	O
that	O
of	O
the	O
prostate	O
.	O

In	O
order	O
to	O
examine	O
the	O
effect	O
of	O
the	O
antifibrinolytic	Pharmacological
drug	Pharmacological
tranexemic	Pharmacological
acid	Pharmacological
on	O
perioperative	O
bleeding	O
saline	Pharmacological
or	O
tranexemic	Pharmacological
acid	Pharmacological
were	O
given	O
randomized	O
double	O
blind	O
to	O
76	O
consecutive	O
patients	O
who	O
came	O
for	O
scheduled	O
thyroid	O
surgery	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
perioperative	O
bleeding	O
between	O
patients	O
in	O
the	O
treatment	O
group	O
(	O
n	O
=	O
39	O
)	O
and	O
control	O
group	O
(	O
n	O
=	O
37	O
)	O
.	O

Esmolol	Pharmacological
versus	O
verapamil	Pharmacological
in	O
the	O
acute	O
treatment	O
of	O
atrial	O
fibrillation	O
or	O
atrial	O
flutter	O
.	O

The	O
effects	O
of	O
esmolol	Pharmacological
,	O
an	O
ultrashort-acting	O
beta	O
blocker	O
,	O
and	O
verapamil	Pharmacological
were	O
compared	O
in	O
controlling	O
ventricular	O
response	O
in	O
45	O
patients	O
with	O
atrial	O
fibrillation	O
or	O
atrial	O
flutter	O
,	O
in	O
a	O
randomized	O
,	O
parallel	O
,	O
open-label	O
study	O
.	O

Patients	O
with	O
either	O
new	O
onset	O
(	O
less	O
than	O
48	O
hours	O
,	O
n	O
=	O
31	O
)	O
or	O
old	O
onset	O
(	O
greater	O
than	O
48	O
hours	O
,	O
n	O
=	O
14	O
)	O
of	O
atrial	O
fibrillation	O
or	O
flutter	O
with	O
rapid	O
ventricular	O
rate	O
were	O
stratified	O
to	O
receive	O
esmolol	Pharmacological
(	O
n	O
=	O
21	O
)	O
or	O
verapamil	Pharmacological
(	O
n	O
=	O
24	O
)	O
.	O

Drug	O
efficacy	O
was	O
measured	O
by	O
ventricular	O
rate	O
reduction	O
and	O
conversion	O
to	O
sinus	O
rhythm	O
.	O

The	O
heart	O
rate	O
declined	O
with	O
esmolol	Pharmacological
from	O
139	O
to	O
100	O
beats/min	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
with	O
verapamil	Pharmacological
from	O
142	O
to	O
97	O
beats/min	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Fifty	O
percent	O
of	O
esmolol-treated	Pharmacological
patients	O
with	O
new	O
onset	O
of	O
arrhythmias	O
converted	O
to	O
sinus	O
rhythm	O
,	O
whereas	O
only	O
12	O
%	O
of	O
those	O
who	O
received	O
verapamil	Pharmacological
converted	O
(	O
p	O
less	O
than	O
0.03	O
)	O
.	O

Mild	O
hypotension	O
was	O
observed	O
in	O
both	O
treatment	O
groups	O
.	O

Esmolol	Pharmacological
compares	O
favorably	O
with	O
verapamil	Pharmacological
with	O
respect	O
to	O
both	O
efficacy	O
and	O
safety	O
in	O
acutely	O
decreasing	O
ventricular	O
response	O
during	O
atrial	O
fibrillation	O
or	O
flutter	O
.	O

Moreover	O
,	O
conversion	O
to	O
sinus	O
rhythm	O
is	O
significantly	O
more	O
likely	O
with	O
esmolol	Pharmacological
.	O

Can	O
a	O
home-visit	Educational
invitation	Educational
increase	O
Pap	O
smear	O
screening	O
in	O
Samliem	O
,	O
Khon	O
Kaen	O
,	O
Thailand	O
?	O
Our	O
objective	O
was	O
to	O
assess	O
the	O
efficiency	O
of	O
a	O
home-visit	Educational
invitation	Educational
aimed	O
to	O
increase	O
uptake	O
of	O
cervical	O
cancer	O
screening	O
in	O
women	O
between	O
35	O
and	O
60	O
years	O
of	O
age	O
.	O

From	O
May	O
,	O
2006	O
,	O
we	O
conducted	O
a	O
quasi-randomized	O
trial	O
to	O
determine	O
if	O
an	O
in-home	Educational
education	Educational
and	Educational
invitation	Educational
intervention	Educational
would	O
increase	O
uptake	O
of	O
cervical	O
cancer	O
screening	O
.	O

We	O
randomly	O
recruited	O
304	O
women	O
from	O
the	O
Samliem	O
inner-city	O
community	O
,	O
Khon	O
Kaen	O
,	O
Northeast	O
Thailand	O
,	O
and	O
assigned	O
participants	O
to	O
either	O
the	O
intervention	Educational
or	O
control	Control
zone	Control
.	Control

Baseline	O
screening	O
coverage	O
interviews	O
were	O
then	O
performed	O
:	O
58	O
of	O
158	O
women	O
in	O
the	O
intervention	O
zone	O
and	O
46	O
of	O
146	O
in	O
the	O
control	O
zone	O
were	O
excluded	O
from	O
the	O
study	O
because	O
of	O
having	O
had	O
a	O
Pap	O
smear	O
within	O
5	O
years	O
,	O
but	O
these	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O

First	O
,	O
100	O
women	O
in	O
the	O
intervention	O
group	O
were	O
visited	Educational
in	Educational
their	Educational
homes	Educational
by	Educational
one	Educational
of	Educational
the	Educational
researchers	Educational
,	Educational
who	Educational
provided	Educational
culturally-sensitive	Educational
health	Educational
education	Educational
that	Educational
emphasized	Educational
the	Educational
need	Educational
for	Educational
screening	Educational
.	Educational

Four	O
months	O
later	O
,	O
post-intervention	O
,	O
screening-coverage	Educational
interviews	Educational
were	O
again	O
performed	O
in	O
both	O
groups	O
,	O
in	O
combination	O
with	O
the	O
same	O
health	O
education	O
for	O
100	O
women	O
in	O
the	O
control	Control
group	O
for	O
a	O
comparison	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
baseline	O
Pap	O
smear	O
screening-coverage	O
rate	O
in	O
the	O
intervention	O
vs.	O
control	O
zones	O
(	O
36.7	O
vs.	O
31.5	O
%	O
,	O
p=0.339	O
)	O
.	O

One	O
hundred	O
women	O
in	O
the	O
intervention	O
group	O
completed	O
the	O
intervention	O
interviews	O
and	O
after	O
four	O
months	O
,	O
100	O
women	O
in	O
the	O
intervention	O
group	O
and	O
100	O
in	O
the	O
control	O
group	O
also	O
completed	O
the	O
post-intervention	O
interviews	O
.	O

The	O
increased	O
screening-coverage	O
rate	O
in	O
the	O
intervention	O
zone	O
was	O
similar	O
to	O
that	O
of	O
the	O
control	O
zone	O
(	O
43.6	O
vs.	O
34.9	O
%	O
,	O
p=0.119	O
)	O
;	O
however	O
,	O
there	O
was	O
a	O
borderline	O
significant	O
increase	O
in	O
the	O
intervention	O
zone	O
compared	O
with	O
baseline	O
(	O
36.7	O
to	O
43.6	O
%	O
,	O
p=0.070	O
)	O
.	O

Therefore	O
,	O
home	Educational
visit	Educational
education	Educational
and	Educational
invitation	Educational
intervention	Educational
produced	O
only	O
a	O
nominal	O
effect	O
on	O
increasing	O
Pap	O
smear	O
coverage	O
within	O
a	O
4-month	O
study	O
period	O
.	O

Perispinal	O
analgesia	O
for	O
labour	O
followed	O
by	O
patient-controlled	O
infusion	O
with	O
bupivacaine	Pharmacological
and	O
sufentanil	Pharmacological
:	O
combined	O
spinal-epidural	Pharmacological
vs.	Pharmacological
epidural	Pharmacological
analgesia	O
alone	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
Combined	O
spinal-epidural	O
is	O
an	O
alternative	O
technique	O
to	O
epidural	O
analgesia	O
for	O
labour	O
,	O
but	O
its	O
benefits	O
are	O
not	O
clearly	O
identified	O
.	O

METHODS	O
A	O
prospective	O
,	O
blinded	O
,	O
randomized	O
study	O
was	O
undertaken	O
involving	O
113	O
women	O
attending	O
a	O
university	O
hospital	O
obstetric	O
department	O
.	O

Analgesia	O
was	O
initiated	O
with	O
intrathecal	O
bupivacaine	Pharmacological
0.25	Pharmacological
%	Pharmacological
1	Pharmacological
mL	Pharmacological
+	O
sufentanil	Pharmacological
5	Pharmacological
microg	Pharmacological
in	O
the	O
combined	O
spinal-epidural	O
group	O
(	O
n	O
=	O
54	O
)	O
,	O
and	O
with	O
bupivacaine	Pharmacological
0.125	Pharmacological
%	Pharmacological
+	O
epinephrine	Pharmacological
2.5	Pharmacological
microg	Pharmacological
mL	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
+	O
sufentanil	Pharmacological
7.5	Pharmacological
microg	Pharmacological
in	O
the	O
epidural	O
group	O
(	O
n	O
=	O
59	O
)	O
.	O

In	Pharmacological
both	Pharmacological
cases	Pharmacological
this	Pharmacological
was	Pharmacological
followed	Pharmacological
by	Pharmacological
patient-controlled	Pharmacological
epidural	Pharmacological
analgesia	Pharmacological
with	Pharmacological
bupivacaine	Pharmacological
0.125	Pharmacological
%	Pharmacological
(	O
+	O
sufentanil	Pharmacological
0.25	Pharmacological
microg	Pharmacological
mL	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
)	Pharmacological
.	O

Duration	O
of	O
labour	O
,	O
quality	O
of	O
analgesia	O
and	O
side-effects	O
were	O
compared	O
between	O
groups	O
.	O

RESULTS	O
In	O
the	O
combined	O
spinal-epidural	O
group	O
,	O
the	O
onset	O
of	O
analgesia	O
was	O
faster	O
(	O
5	O
vs.	O
15	O
min	O
,	O
P	O
<	O
0.001	O
)	O
,	O
the	O
consumption	O
of	O
bupivacaine	Pharmacological
was	O
lower	O
(	O
7.5	O
vs.	O
11.3	O
mg	O
h	O
(	O
-1	O
)	O
,	O
P	O
=	O
0.003	O
)	O
and	O
there	O
was	O
less	O
unilateral	O
analgesia	O
(	O
14.8	O
%	O
vs.	O
40.7	O
%	O
,	O
P	O
=	O
0.002	O
)	O
than	O
in	O
the	O
epidural	O
group	O
.	O

The	O
characteristics	O
of	O
labour	O
were	O
similar	O
in	O
both	O
groups	O
.	O

However	O
,	O
in	O
the	O
combined	O
spinal-epidural	O
group	O
,	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
posterior	O
presentation	O
(	O
25.9	O
%	O
vs.	O
10	O
%	O
,	O
P	O
=	O
0.03	O
)	O
,	O
pruritus	O
(	O
P	O
<	O
0.001	O
)	O
,	O
hypotension	O
(	O
P	O
=	O
0.002	O
)	O
,	O
somnolence	O
(	O
P	O
=	O
0.01	O
)	O
,	O
nausea	O
(	O
P	O
=	O
0.02	O
)	O
and	O
one	O
case	O
of	O
meningitis	O
.	O

CONCLUSIONS	O
The	O
combined	O
spinal-epidural	O
technique	O
provided	O
more	O
effective	O
analgesia	O
during	O
labour	O
than	O
epidural	O
analgesia	O
alone	O
but	O
offered	O
no	O
other	O
advantage	O
.	O

It	O
induced	O
more	O
adverse	O
effects	O
and	O
this	O
should	O
be	O
considered	O
before	O
routinely	O
using	O
the	O
combined	O
spinal-epidural	O
technique	O
.	O

A	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
parallel	O
study	O
of	O
loteprednol	Pharmacological
etabonate	Pharmacological
0.2	O
%	O
in	O
patients	O
with	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
loteprednol	Pharmacological
etabonate	Pharmacological
(	Pharmacological
LE	Pharmacological
)	Pharmacological
0.2	O
%	O
in	O
reducing	O
the	O
signs	O
and	O
symptoms	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

DESIGN	O
Randomized	O
,	O
double-masked	O
,	O
placebo-controlled	Control
,	O
parallel	O
group	O
multicenter	O
study	O
of	O
6	O
weeks	O
duration	O
.	O

PARTICIPANTS	O
A	O
total	O
of	O
135	O
patients	O
with	O
signs	O
and	O
symptoms	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
participated	O
.	O

INTERVENTION	O
All	O
patients	O
received	O
either	O
LE	Pharmacological
0.2	Pharmacological
%	Pharmacological
or	O
placebo	Control
(	O
vehicle	O
)	O
four	O
times	O
a	O
day	O
in	O
both	O
eyes	O
for	O
42	O
days	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Bulbar	O
conjunctival	O
injection	O
(	O
primary	O
sign	O
)	O
and	O
itching	O
(	O
primary	O
symptom	O
)	O
over	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
was	O
measured	O
.	O

RESULTS	O
A	O
reduction	O
in	O
severity	O
was	O
seen	O
in	O
both	O
LE	O
and	O
placebo	O
groups	O
for	O
bulbar	O
conjunctival	O
injection	O
(	O
1.5	O
vs.	O
1.0	O
units	O
on	O
a	O
0-3	O
scale	O
)	O
and	O
itching	O
(	O
3.4	O
vs.	O
3.0	O
units	O
on	O
a	O
0-4	O
scale	O
)	O
over	O
the	O
first	O
2	O
weeks	O
.	O

The	O
treatment	O
effect	O
by	O
these	O
measures	O
was	O
-0.5	O
and	O
-0.4	O
units	O
in	O
favor	O
of	O
LE	O
(	O
P	O
<	O
or	O
=	O
0.008	O
)	O
.	O

Resolution	O
(	O
i.e.	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
signs	O
or	O
symptoms	O
no	O
longer	O
present	O
)	O
at	O
day	O
14	O
strongly	O
favored	O
LE-treated	O
patients	O
(	O
36	O
%	O
and	O
15	O
%	O
;	O
58	O
%	O
and	O
38	O
%	O
,	O
for	O
injection	O
and	O
itching	O
,	O
respectively	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

One	O
patient	O
in	O
each	O
treatment	O
group	O
(	O
1	O
of	O
67	O
and	O
1	O
of	O
68	O
,	O
respectively	O
)	O
had	O
an	O
elevation	O
of	O
intraocular	O
pressure	O
of	O
10	O
mmHg	O
or	O
greater	O
during	O
the	O
6	O
weeks	O
of	O
treatment	O
.	O

CONCLUSIONS	O
Loteprednol	O
etabonate	O
0.2	O
%	O
was	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

Loteprednol	O
etabonate	O
0.2	O
%	O
had	O
a	O
safety	O
profile	O
comparable	O
to	O
placebo	O
.	O

[	O
Impact	O
of	O
heparin	Pharmacological
on	O
coagulation	O
index	O
during	O
the	O
therapy	O
of	O
molecular	O
adsorbent	O
recirculating	O
system	O
in	O
patients	O
with	O
liver	O
failure	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
impact	O
of	O
coagulative	O
parameters	O
on	O
different	O
anticoagulation	O
systems	O
in	O
molecular	O
adsorbent	O
recirculating	O
system	O
(	O
MARS	O
)	O
in	O
subjects	O
with	O
liver	O
failure	O
,	O
and	O
to	O
evaluate	O
the	O
safety	O
of	O
different	O
anticoagulation	O
methods	O
.	O

METHODS	O
A	O
prospective	O
experimental	O
observation	O
was	O
designed	O
.	O

According	O
to	O
anticoagulation	O
Methods	O
,	O
174	O
MARS	Pharmacological
treatment	O
sessions	O
for	O
146	O
patients	O
with	O
liver	O
failure	O
and	O
prothrombin	O
time	O
activity	O
percentage	O
(	O
PTA	O
)	O
?	O
40	O
%	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
:	O
92	O
MARS	O
treatment	O
sessions	O
in	O
the	O
heparin-free	O
group	O
and	O
82	O
in	O
the	O
low-dose	O
heparin	O
group	O
.	O

Time	O
points	O
of	O
0	O
,	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
and	O
6	O
h	O
were	O
selected	O
to	O
observe	O
the	O
coagulation	O
changes	O
of	O
prothrombin	O
time	O
(	O
PT	O
)	O
,	O
PTA	O
,	O
thrombin	O
time	O
(	O
TT	O
)	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
and	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
dynamically	O
.	O

Adverse	O
events	O
such	O
as	O
line	O
/	O
filter	O
coagulation	O
,	O
rupture	O
and	O
bleeding	O
were	O
also	O
investigated	O
and	O
compared	O
due	O
to	O
frequency	O
and	O
severity	O
between	O
the	O
2	O
groups	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
in	O
PT	O
,	O
PTA	O
,	O
INR	O
between	O
the	O
2	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
in	O
APTT	O
and	O
TT	O
and	O
fibrinogen	O
(	O
Fbg	O
)	O
.	O

APTT	O
and	O
TT	O
levels	O
in	O
the	O
low-dose	O
heparin	O
group	O
was	O
increased	O
rapidly	O
after	O
the	O
first	O
given	O
dose	O
of	O
anticoagulant	O
heparin	O
and	O
reached	O
the	O
peak	O
within	O
30	O
min.The	O
levels	O
at	O
each	O
time	O
point	O
was	O
statistically	O
different	O
between	O
the	O
2	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
difference	O
in	O
the	O
Fbg	O
level	O
was	O
obtained	O
between	O
the	O
2	O
groups	O
.	O

In	O
the	O
low-dose	O
heparin	O
group	O
it	O
was	O
stabilized	O
and	O
increased	O
slightly	O
at	O
the	O
end	O
of	O
the	O
treatment	O
.	O

While	O
in	O
the	O
heparin-free	O
group	O
it	O
was	O
decreased	O
gradually	O
and	O
reached	O
a	O
ravine	O
at	O
the	O
end	O
of	O
the	O
treatment	O
.	O

A	O
curve	O
was	O
observed	O
after	O
2.5	O
h	O
treatment	O
between	O
the	O
2	O
groups	O
(	O
P=0.001	O
)	O
.	O

There	O
were	O
2	O
cases	O
of	O
severe	O
bleeding	O
after	O
MARS	O
was	O
finished	O
in	O
the	O
heparin	O
group	O
,	O
and	O
1	O
was	O
terminated	O
because	O
of	O
degree	O
III	O
clotting	O
in	O
the	O
heparin-free	O
group	O
.	O

CONCLUSION	O
Fibrinogen	O
should	O
be	O
adsorbed	O
while	O
the	O
blood	O
touches	O
the	O
MARS	O
circuit	O
path	O
and	O
anticoagulants	O
can	O
prevent	O
it	O
.	O

Comprehensive	O
analysis	O
of	O
blood	O
platelet	O
count	O
(	O
BPC	O
)	O
,	O
fibrin	O
degradation	O
products	O
(	O
FDP	O
)	O
,	O
D-dimer	O
and	O
clinical	O
symptoms	O
is	O
critical	O
and	O
required	O
to	O
determine	O
the	O
coagulation	O
status	O
to	O
select	O
an	O
anticoagulation	O
system	O
before	O
MARS	O
.	O

The	O
use	O
of	O
low	O
dose	O
heparin	O
in	O
MARS	O
improves	O
the	O
disorder	O
of	O
hypercoagulable	O
state	O
during	O
the	O
high	O
coaguation	O
period	O
,	O
while	O
heparin-free	O
during	O
low	O
coagulation	O
period	O
can	O
effectively	O
prevent	O
the	O
occurrence	O
of	O
bleeding	O
and	O
improve	O
the	O
mechanism	O
of	O
blood	O
coagulation	O
by	O
reducing	O
heparin-like	O
substance	O
in	O
the	O
blood	O
.	O

Liposome-encapsulated	Pharmacological
doxorubicin	Pharmacological
compared	O
with	O
conventional	Pharmacological
doxorubicin	Pharmacological
in	O
a	O
randomized	O
multicenter	O
trial	O
as	O
first-line	O
therapy	O
of	O
metastatic	O
breast	O
carcinoma	O
.	O

BACKGROUND	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
liposome-encapsulated	Pharmacological
doxorubicin	Pharmacological
,	O
TLC	Pharmacological
D-99	Pharmacological
(	Pharmacological
Myocet	Pharmacological
,	Pharmacological
Elan	Pharmacological
Pharmaceuticals	Pharmacological
,	Pharmacological
Princeton	Pharmacological
,	Pharmacological
NJ	Pharmacological
)	Pharmacological
,	O
and	O
conventional	Pharmacological
doxorubicin	Pharmacological
in	O
first-line	O
treatment	O
of	O
metastatic	O
breast	O
carcinoma	O
(	O
MBC	O
)	O
.	O

METHODS	O
Two	O
hundred	O
twenty-four	O
patients	O
with	O
MBC	O
and	O
no	O
prior	O
therapy	O
for	O
metastatic	O
disease	O
were	O
randomized	O
to	O
receive	O
either	O
TLC	Pharmacological
D-99	Pharmacological
(	Pharmacological
75	Pharmacological
mg/m	Pharmacological
(	Pharmacological
2	Pharmacological
)	Pharmacological
)	Pharmacological
or	O
doxorubicin	Pharmacological
(	O
75	O
mg/m	O
(	O
2	O
)	O
)	O
every	O
3	O
weeks	O
,	O
in	O
the	O
absence	O
of	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
response	O
rate	O
.	O

Responses	O
were	O
assessed	O
using	O
World	O
Health	O
Organization	O
criteria	O
and	O
were	O
required	O
to	O
be	O
of	O
at	O
least	O
6	O
weeks	O
'	O
duration	O
.	O

The	O
primary	O
safety	O
endpoint	O
was	O
cardiotoxicity	O
.	O

Cardiac	O
function	O
was	O
monitored	O
by	O
multiple-gated	Pharmacological
radionuclide	Pharmacological
cardioangiography	Pharmacological
scan	Pharmacological
,	O
and	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
was	O
scored	O
at	O
a	O
central	O
laboratory	O
.	O

Patients	O
were	O
removed	O
from	O
study	O
if	O
LVEF	O
declined	O
20	O
or	O
more	O
EF	O
units	O
from	O
baseline	O
to	O
a	O
final	O
value	O
of	O
greater	O
than	O
or	O
equal	O
to	O
50	O
%	O
,	O
or	O
by	O
10	O
or	O
more	O
units	O
to	O
a	O
final	O
value	O
of	O
less	O
than	O
50	O
%	O
,	O
or	O
onset	O
of	O
clinical	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

RESULTS	O
Median	O
age	O
was	O
54	O
years	O
in	O
both	O
treatment	O
groups	O
.	O

All	O
relevant	O
prognostic	O
factors	O
were	O
balanced	O
,	O
with	O
the	O
exception	O
that	O
there	O
were	O
significantly	O
more	O
progesterone	O
receptor	O
positive	O
patients	O
in	O
the	O
doxorubicin-treated	Pharmacological
group	O
.	O

Protocol-defined	O
cardiotoxicity	O
was	O
observed	O
in	O
13	O
%	O
of	O
TLC	O
D-99	O
patients	O
(	O
including	O
2	O
cases	O
of	O
CHF	O
)	O
compared	O
to	O
29	O
%	O
of	O
doxorubicin	Pharmacological
patients	O
(	O
including	O
9	O
cases	O
of	O
CHF	O
)	O
.	O

Median	O
cumulative	O
doxorubicin	Pharmacological
dose	O
at	O
onset	O
of	O
cardiotoxicity	O
was	O
785	O
mg/m	O
(	O
2	O
)	O
for	O
TLC	Pharmacological
D-99	Pharmacological
versus	O
570	O
mg/m	O
(	O
2	O
)	O
for	O
doxorubicin	Pharmacological
(	O
P	O
=	O
0.0001	O
;	O
hazard	O
ratio	O
,	O
3.56	O
)	O
.	O

The	O
overall	O
response	O
rate	O
was	O
26	O
%	O
in	O
both	O
treatment	O
groups	O
.	O

The	O
median	O
TTP	O
was	O
2.9	O
months	O
on	O
TLC	O
D-99	O
versus	O
3.1	O
months	O
on	O
doxorubicin	Pharmacological
.	O

Median	O
survival	O
was	O
16	O
versus	O
20	O
months	O
with	O
a	O
nonsignificant	O
trend	O
in	O
favor	O
of	O
doxorubicin	Pharmacological
(	O
P	O
=	O
0.09	O
)	O
.	O

Clinical	O
toxicities	O
,	O
commonly	O
associated	O
with	O
doxorubicin	O
,	O
appeared	O
less	O
common	O
with	O
TLC	O
D-99	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

There	O
was	O
only	O
one	O
report	O
of	O
palmar-plantar	O
erythrodysesthesia	O
(	O
Grade	O
2	O
)	O
with	O
this	O
liposomal	O
formulation	O
of	O
doxorubicin	Pharmacological
.	O

CONCLUSIONS	O
Single-agent	O
TLC	Pharmacological
D-99	Pharmacological
produces	O
less	O
cardiotoxicity	O
than	O
doxorubicin	Pharmacological
,	O
while	O
providing	O
comparable	O
antitumor	O
activity	O
.	O

The	O
effect	O
of	O
weight	Physical
training	Physical
on	O
bone	O
mineral	O
density	O
and	O
bone	O
turnover	O
in	O
postmenopausal	O
breast	O
cancer	O
survivors	O
with	O
bone	O
loss	O
:	O
a	O
24-month	O
randomized	O
controlled	O
trial	O
.	O

SUMMARY	O
This	O
study	O
examined	O
whether	O
24	O
months	O
of	O
weight	Physical
training	Physical
exercises	Physical
enhanced	O
the	O
effectiveness	O
of	O
risedronate	Pharmacological
,	Pharmacological
calcium	Pharmacological
,	O
and	O
vitamin	Pharmacological
D	Pharmacological
in	O
maintaining	O
or	O
improving	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
223	O
postmenopausal	O
breast	O
cancer	O
survivors	O
.	O

Subjects	O
who	O
were	O
>	O
or	O
=50	O
%	O
adherent	O
to	O
exercise	Physical
had	O
no	O
improvement	O
in	O
BMD	O
but	O
were	O
less	O
likely	O
to	O
lose	O
BMD	O
.	O

INTRODUCTION	O
This	O
study	O
examined	O
whether	O
(	O
1	O
)	O
postmenopausal	O
breast	O
cancer	O
survivors	O
(	O
BCS	O
)	O
with	O
bone	O
loss	O
taking	O
24	O
months	O
of	O
risedronate	Pharmacological
,	Pharmacological
calcium	Pharmacological
,	Pharmacological
and	Pharmacological
vitamin	Pharmacological
D	Pharmacological
had	O
increased	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
at	O
the	O
total	O
hip	O
,	O
femoral	O
neck	O
,	O
L1-L4	O
spine	O
,	O
total	O
radius	O
and	O
33	O
%	O
radius	O
,	O
and	O
decreased	O
bone	O
turnover	O
;	O
(	O
2	O
)	O
subjects	O
who	O
also	O
participated	O
in	O
strength/weight	Physical
training	Physical
(	Physical
ST	Physical
)	Physical
exercises	Physical
had	O
greater	O
increases	O
in	O
BMD	O
and	O
greater	O
decreases	O
in	O
bone	O
turnover	O
;	O
and	O
(	O
3	O
)	O
subjects	O
who	O
also	O
exercised	Physical
were	O
more	O
likely	O
to	O
preserve	O
(	O
at	O
least	O
maintain	O
)	O
BMD	O
.	O

METHODS	O
Postmenopausal	O
BCS	O
(	O
223	O
)	O
were	O
randomly	O
assigned	O
to	O
exercise	Physical
plus	Educational
medication	Pharmacological
or	O
medication	Pharmacological
only	Pharmacological
groups	O
.	O

Both	O
groups	O
received	O
24	O
months	O
of	O
1,200	O
mg	O
of	O
calcium	Pharmacological
and	O
400	O
IU	O
of	O
vitamin	Pharmacological
D	Pharmacological
daily	O
and	O
35	O
mg	O
of	O
risedronate	Pharmacological
weekly	O
,	O
and	O
the	O
exercise	Physical
group	O
additionally	O
had	O
ST	Physical
exercises	Physical
twice	O
weekly	O
.	O

RESULTS	O
After	O
24	O
months	O
,	O
women	O
who	O
took	O
medications	Physical
without	Physical
exercising	Physical
had	O
significant	O
improvements	O
in	O
BMD	O
at	O
the	O
total	O
hip	O
(	O
+1.81	O
%	O
)	O
and	O
spine	O
(	O
+2.85	O
%	O
)	O
and	O
significant	O
decreases	O
in	O
Alkphase	O
B	O
(	O
-8.7	O
%	O
)	O
and	O
serum	O
NTx	O
(	O
-16.7	O
%	O
)	O
.	O

Women	O
who	O
also	O
exercised	O
had	O
additional	O
increases	O
in	O
BMD	O
at	O
the	O
femoral	O
neck	O
(	O
+0.29	O
%	O
)	O
,	O
total	O
hip	O
(	O
+0.34	O
%	O
)	O
,	O
spine	O
(	O
+0.23	O
%	O
)	O
,	O
total	O
radius	O
(	O
+0.30	O
%	O
)	O
,	O
and	O
additional	O
decreases	O
in	O
Alkphase	O
B	O
(	O
-2.4	O
%	O
)	O
and	O
Serum	O
NTx	O
(	O
-6.5	O
%	O
)	O
.	O

Additional	O
changes	O
in	O
BMD	O
and	O
bone	O
turnover	O
with	O
exercise	O
were	O
not	O
significant	O
.	O

Subjects	O
who	O
were	O
>	O
or	O
=50	O
%	O
adherent	O
to	O
exercise	O
were	O
less	O
likely	O
to	O
lose	O
BMD	O
at	O
the	O
total	O
hip	O
(	O
chi-square	O
[	O
1	O
]	O
=	O
4.66	O
,	O
p	O
=	O
0.03	O
)	O
and	O
femoral	O
neck	O
(	O
chi-square	O
[	O
1	O
]	O
=	O
4.63	O
,	O
p	O
=	O
0.03	O
)	O
.	O

CONCLUSION	O
Strength/weight	O
training	O
exercises	O
may	O
prevent	O
loss	O
of	O
BMD	O
in	O
postmenopausal	O
BCS	O
at	O
risk	O
for	O
bone	O
loss	O
.	O

Randomized	O
clinical	O
trial	O
of	O
tamoxifen	O
plus	O
sequential	O
CMF	O
chemotherapy	O
versus	O
tamoxifen	O
alone	O
in	O
postmenopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
.	O

Eighty-eight	O
postmenopausal	O
women	O
with	O
metastatic	O
breast	O
cancer	O
,	O
in	O
whom	O
estrogen	O
receptors	O
(	O
ER	O
)	O
were	O
positive	O
or	O
unknown	O
,	O
were	O
treated	O
on	O
a	O
controlled	O
trial	O
to	O
determine	O
the	O
effectiveness	O
of	O
tamoxifen	Pharmacological
and	O
to	O
assess	O
the	O
therapeutic	O
advantage	O
of	O
sequentially	O
adding	O
low-dose	Pharmacological
cyclophosphamide-methotrexate-5-fluorouracil	Pharmacological
(	Pharmacological
CMF	Pharmacological
)	Pharmacological
chemotherapy	Pharmacological
in	Pharmacological
tamoxifen	Pharmacological
responders	Pharmacological
.	O

Patients	O
with	O
known	O
ER	O
negative	O
status	O
were	O
not	O
studied	O
.	O

After	O
the	O
initial	O
12-week	O
treatment	O
with	O
tamoxifen	Pharmacological
alone	Pharmacological
,	O
60	O
%	O
of	O
ER	O
positive	O
patients	O
achieved	O
complete	O
or	O
partial	O
response	O
as	O
did	O
35	O
%	O
in	O
whom	O
ER	O
were	O
unknown	O
.	O

Response	O
status	O
further	O
improved	O
in	O
18	O
%	O
randomized	O
to	O
continue	O
tamoxifen	O
alone	O
vs	O
31	O
%	O
in	O
whom	O
CMF	O
was	O
added	O
to	O
tamoxifen	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
time	O
to	O
the	O
development	O
of	O
progressive	O
disease	O
or	O
survival	O
between	O
the	O
ER	O
positive	O
and	O
ER	O
unknown	O
patients	O
or	O
between	O
the	O
tamoxifen	O
and	O
tamoxifen	O
plus	O
CMF	O
groups	O
.	O

We	O
conclude	O
that	O
inability	O
to	O
determine	O
ER	O
status	O
should	O
not	O
prejudice	O
against	O
the	O
use	O
of	O
tamoxifen	O
in	O
postmenopausal	O
patients	O
with	O
advanced	O
breast	O
cancer	O
.	O

No	O
benefit	O
has	O
been	O
demonstrated	O
from	O
the	O
addition	O
of	O
CMF	O
chemotherapy	O
in	O
tamoxifen	O
responders	O
.	O

Efficacy	O
and	O
tolerability	O
of	O
donepezil	Pharmacological
in	O
vascular	O
dementia	O
:	O
positive	O
results	O
of	O
a	O
24-week	O
,	O
multicenter	O
,	O
international	O
,	O
randomized	O
,	O
placebo-controlled	Control
clinical	O
trial	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Clinical	O
observations	O
suggest	O
that	O
patients	O
with	O
vascular	O
dementia	O
(	O
VaD	O
)	O
may	O
benefit	O
from	O
treatment	O
with	O
cholinesterase	Pharmacological
inhibitors	Pharmacological
.	O

This	O
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
donepezil	Pharmacological
for	O
relieving	O
symptoms	O
of	O
dementia	O
in	O
VaD	O
.	O

METHODS	O
Patients	O
(	O
n=603	O
;	O
mean	O
age	O
,	O
73.9	O
years	O
;	O
55.2	O
%	O
men	O
)	O
with	O
probable	O
(	O
70.5	O
%	O
)	O
or	O
possible	O
(	O
29.5	O
%	O
)	O
VaD	O
,	O
according	O
to	O
criteria	O
of	O
the	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
(	O
NINDS	O
)	O
and	O
the	O
Association	O
Internationale	O
pour	O
la	O
Recherche	O
et	O
l'Enseignement	O
en	O
Neurosciences	O
(	O
AIREN	O
)	O
,	O
were	O
randomized	O
to	O
24	O
weeks	O
of	O
treatment	O
with	O
donepezil	Pharmacological
5	O
mg/d	O
(	O
n=198	O
)	O
,	O
donepezil	Pharmacological
10	O
mg/d	O
(	O
5	O
mg/d	O
for	O
first	O
28	O
days	O
;	O
n=206	O
)	O
,	O
or	O
placebo	Control
(	O
n=199	O
)	O
.	O

Analyses	O
were	O
based	O
on	O
the	O
intent-to-treat	O
population	O
.	O

RESULTS	O
At	O
week	O
24	O
,	O
both	O
donepezil	Pharmacological
groups	O
showed	O
significant	O
improvement	O
in	O
cognition	O
versus	O
placebo	O
on	O
the	O
Alzheimer	O
's	O
Disease	O
Assessment	O
Scale-cognitive	O
subscale	O
(	O
mean	O
change	O
from	O
baseline	O
score	O
effect	O
size	O
:	O
donepezil	Pharmacological
5	O
mg/d	O
,	O
-1.90	O
;	O
P=0.001	O
;	O
donepezil	Pharmacological
10	O
mg/d	O
,	O
-2.33	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Significant	O
improvements	O
in	O
patients	O
'	O
global	O
function	O
were	O
seen	O
versus	O
placebo	O
at	O
week	O
24	O
(	O
observed	O
cases	O
)	O
,	O
on	O
the	O
Clinician	O
's	O
Interview-Based	O
Impression	O
of	O
Change-Plus	O
version	O
only	O
for	O
patients	O
on	O
donepezil	Pharmacological
5	O
mg/d	O
(	O
P=0.014	O
)	O
,	O
and	O
on	O
the	O
Sum	O
of	O
the	O
Boxes	O
of	O
the	O
Clinical	O
Dementia	O
Rating	O
only	O
for	O
patients	O
on	O
10	O
mg/d	O
(	O
P=0.007	O
)	O
.	O

Donepezil-treated	O
patients	O
showed	O
significant	O
benefits	O
in	O
activities	O
of	O
daily	O
living	O
over	O
placebo	O
on	O
the	O
Alzheimer	O
's	O
Disease	O
Functional	O
Assessment	O
and	O
Change	O
Scale	O
(	O
mean	O
change	O
from	O
baseline	O
score	O
effect	O
size	O
at	O
week	O
24	O
:	O
donepezil	O
5	O
mg/d	O
,	O
-1.31	O
,	O
P=0.02	O
;	O
donepezil	O
10	O
mg/d	O
,	O
-1.31	O
,	O
P=0.02	O
)	O
.	O

Donepezil	O
was	O
well	O
tolerated	O
.	O

Withdrawal	O
rates	O
due	O
to	O
adverse	O
events	O
were	O
relatively	O
low	O
(	O
placebo	O
,	O
11.1	O
%	O
;	O
donepezil	O
5	O
mg/d	O
,	O
11.1	O
%	O
;	O
donepezil	O
10	O
mg/d	O
,	O
21.8	O
%	O
;	O
P=0.005	O
versus	O
placebo	O
)	O
.	O

CONCLUSIONS	O
These	O
data	O
demonstrate	O
that	O
donepezil	O
is	O
an	O
effective	O
and	O
well-tolerated	O
treatment	O
for	O
VaD	O
and	O
show	O
it	O
may	O
have	O
an	O
important	O
place	O
in	O
the	O
management	O
of	O
this	O
condition	O
.	O

Efficacy	O
and	O
safety	O
of	O
bexarotene	Pharmacological
combined	Pharmacological
with	Pharmacological
psoralen-ultraviolet	Physical
A	Physical
(	Pharmacological
PUVA	Pharmacological
)	Pharmacological
compared	O
with	O
PUVA	Physical
treatment	Physical
alone	Physical
in	O
stage	O
IB-IIA	O
mycosis	O
fungoides	O
:	O
final	O
results	O
from	O
the	O
EORTC	O
Cutaneous	O
Lymphoma	O
Task	O
Force	O
phase	O
III	O
randomized	O
clinical	O
trial	O
(	O
NCT00056056	O
)	O
.	O

BACKGROUND	O
Psoralen	Physical
plus	Physical
ultraviolet	Physical
A	Physical
(	Physical
PUVA	Physical
)	Physical
is	O
the	O
standard	O
treatment	O
for	O
early	O
stages	O
of	O
mycosis	O
fungoides	O
.	O

There	O
have	O
been	O
no	O
adequate	O
randomized	O
controlled	O
trials	O
with	O
sufficient	O
power	O
comparing	O
this	O
modality	O
with	O
other	O
therapies	O
.	O

OBJECTIVE	O
To	O
assess	O
disease	O
response	O
and	O
to	O
compare	O
the	O
response	O
rates	O
of	O
patients	O
treated	O
with	O
PUVA	Physical
alone	Physical
or	O
PUVA	Pharmacological
and	Pharmacological
bexarotene	Pharmacological
.	O

METHODS	O
EORTC	O
21011	O
(	O
NCT	O
00056056	O
)	O
was	O
a	O
randomized	O
phase	O
III	O
study	O
comparing	O
combined	O
bexarotene	O
(	O
Targretin	O
(	O
?	O
)	O
)	O
and	O
PUVA	O
vs.	O
PUVA	O
alone	O
in	O
patients	O
with	O
stage	O
IB	O
and	O
IIA	O
mycosis	O
fungoides	O
(	O
MF	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
overall	O
response	O
rate	O
[	O
complete	O
clinical	O
response	O
(	O
CCR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
.	O

RESULTS	O
The	O
study	O
was	O
prematurely	O
closed	O
due	O
to	O
low	O
accrual	O
after	O
93	O
of	O
145	O
required	O
patients	O
(	O
65	O
%	O
)	O
were	O
randomized	O
.	O

Of	O
the	O
93	O
randomized	O
patients	O
,	O
87	O
started	O
treatment	O
,	O
41	O
received	O
PUVA	O
and	O
46	O
received	O
PUVA	O
+	O
bexarotene	O
.	O

Total	O
UVA	O
doses	O
received	O
were	O
107	O
J	O
cm	O
(	O
-2	O
)	O
(	O
range	O
1?4-489?9	O
)	O
in	O
the	O
PUVA	O
arm	O
vs.	O
101?7	O
J	O
cm	O
(	O
-2	O
)	O
(	O
0?2-529?9	O
)	O
in	O
the	O
combination	O
arm	O
.	O

The	O
safety	O
profile	O
was	O
acceptable	O
with	O
few	O
grade	O
3-4	O
toxicities	O
observed	O
in	O
either	O
arm	O
.	O

More	O
drop-outs	O
due	O
to	O
toxicity	O
were	O
observed	O
in	O
the	O
combination	O
arm	O
compared	O
with	O
the	O
PUVA-alone	O
arm	O
.	O

The	O
best	O
overall	O
response	O
(	O
CCR	O
+	O
PR	O
)	O
rate	O
was	O
71	O
%	O
for	O
PUVA	O
alone	O
and	O
77	O
%	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0?57	O
)	O
.	O

The	O
median	O
duration	O
of	O
response	O
was	O
9?7	O
months	O
for	O
PUVA	O
vs.	O
5?8	O
months	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0?33	O
)	O
.	O

CCR	O
was	O
seen	O
in	O
25	O
patients	O
of	O
whom	O
10	O
received	O
PUVA	O
alone	O
(	O
CCR	O
22	O
%	O
)	O
and	O
15	O
received	O
combination	O
therapy	O
(	O
CCR	O
31	O
%	O
)	O
(	O
P	O
=	O
0?45	O
)	O
.	O

CCR	O
was	O
sustained	O
in	O
25	O
%	O
of	O
patients	O
regardless	O
of	O
therapy	O
.	O

There	O
was	O
a	O
trend	O
towards	O
fewer	O
PUVA	O
sessions	O
needed	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
22	O
)	O
compared	O
with	O
the	O
PUVA	O
arm	O
(	O
median	O
27?5	O
)	O
(	O
P	O
=	O
0?11	O
)	O
.	O

Similarly	O
,	O
a	O
trend	O
towards	O
lower	O
UVA	O
dose	O
required	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
55?8	O
J	O
cm	O
(	O
-2	O
)	O
)	O
compared	O
with	O
the	O
PUVA	O
arm	O
alone	O
(	O
median	O
117?5	O
J	O
cm	O
(	O
-2	O
)	O
)	O
(	O
P	O
=	O
0?5	O
)	O
was	O
observed	O
.	O

CONCLUSIONS	O
No	O
significant	O
difference	O
in	O
response	O
rate	O
or	O
response	O
duration	O
was	O
observed	O
in	O
this	O
study	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
towards	O
fewer	O
PUVA	O
sessions	O
and	O
lower	O
UVA	O
dose	O
required	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
PUVA	O
+	O
bexarotene	O
)	O
but	O
this	O
did	O
not	O
achieve	O
statistical	O
significance	O
due	O
to	O
insufficient	O
power	O
.	O

Comparison	O
of	O
clinical	O
effectiveness	O
of	O
acupuncture	Physical
and	O
a	O
Western	Pharmacological
drug	Pharmacological
on	O
allergic	O
rhinitis	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
an	O
acupuncture	Physical
regimen	Physical
for	O
persistent	O
allergic	O
rhinitis	O
(	O
PER	O
)	O
,	O
aimed	O
at	O
improving	O
a	O
patient	O
's	O
mind	O
or	O
Shen	O
in	O
Traditional	Pharmacological
Chinese	Pharmacological
Medicine	Pharmacological
,	O
to	O
that	O
of	O
a	O
second-generation	Pharmacological
Hi-receptor	Pharmacological
antagonist	Pharmacological
,	Pharmacological
cetirizine	Pharmacological
hydrochloride	Pharmacological
.	Pharmacological

METHODS	O
This	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
on	O
PER	O
will	O
be	O
conducted	O
at	O
three	O
institutions	O
in	O
China	O
.	O

The	O
total	O
study	O
period	O
will	O
be	O
9	O
weeks	O
.	O

After	O
a	O
1-week	O
preparatory	O
screening	O
period	O
,	O
240	O
eligible	O
participants	O
with	O
PER	O
will	O
be	O
randomized	O
to	O
receive	O
acupuncture	Physical
or	O
pharmacotherapy	Pharmacological
(	O
1:1	O
)	O
for	O
4	O
weeks	O
with	O
a	O
4-week	O
follow-up	O
.	O

The	O
primary	O
outcome	O
will	O
be	O
changes	O
in	O
7-day	O
average	O
total	O
nasal	O
symptom	O
score	O
.	O

Secondary	O
outcome	O
measures	O
include	O
rhinoconjunctivitis	O
quality	O
of	O
life	O
questionnaire	O
score	O
and	O
total	O
non-nasal	O
symptom	O
score	O
.	O

RESULTS	O
The	O
presence	O
and	O
seriousness	O
of	O
psychological	O
and	O
emotional	O
impairments	O
should	O
be	O
considered	O
in	O
therapeutic	O
programs	O
for	O
allergic	O
rhinitis	O
.	O

No	O
clinical	O
trial	O
for	O
treating	O
allergic	O
rhinitis	O
via	O
acupuncture	Pharmacological
regulation	O
of	O
psychological	O
and	O
emotional	O
activities	O
has	O
been	O
reported	O
.	O

CONCLUSION	O
The	O
findings	O
of	O
the	O
trial	O
will	O
allow	O
us	O
to	O
determine	O
the	O
effects	O
of	O
the	O
mind	Pharmacological
(	Pharmacological
Shen	Pharmacological
)	Pharmacological
-regulation	Pharmacological
treatment	Pharmacological
approach	O
.	O

We	O
will	O
also	O
be	O
able	O
to	O
confirm	O
if	O
the	O
effects	O
of	O
acupuncture	Physical
are	O
equivalent	O
to	O
those	O
of	O
the	O
conventional	O
drug	O
cetirizine	Pharmacological
hydrochloride	Pharmacological
.	Pharmacological

Diode	Physical
laser	Physical
photocoagulation	Physical
for	O
threshold	O
retinopathy	O
of	O
prematurity	O
.	O

A	O
randomized	O
study	O
.	O

BACKGROUND	O
Although	O
peripheral	Physical
cryotherapy	Physical
decreases	O
the	O
incidence	O
of	O
unfavorable	O
anatomic	O
outcomes	O
in	O
threshold	O
retinopathy	O
of	O
prematurity	O
(	O
ROP	O
)	O
,	O
apnea	O
,	O
bradycardia	O
,	O
and	O
lid	O
edema	O
can	O
occur	O
.	O

Argon	Physical
laser	Physical
indirect	Physical
ophthalmoscope	Physical
photocoagulation	Physical
has	O
been	O
used	O
as	O
an	O
alternative	O
to	O
cryotherapy	Physical
,	O
with	O
fewer	O
adverse	O
effects	O
.	O

Retinal	O
lesions	O
placed	O
with	O
diode	Physical
lasers	Physical
are	O
deeper	O
than	O
similar	O
argon	Physical
laser	Physical
lesions	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
this	O
difference	O
could	O
influence	O
the	O
response	O
to	O
ablative	Physical
therapy	Physical
.	O

METHODS	O
Patients	O
were	O
enrolled	O
under	O
a	O
prospective	O
,	O
randomized	O
protocol	O
.	O

One	O
eye	O
of	O
each	O
patient	O
with	O
symmetric	O
,	O
threshold	O
ROP	O
was	O
treated	O
with	O
an	O
814/815	O
nm	O
diode	Physical
laser	Physical
,	O
while	O
the	O
other	O
eye	O
was	O
treated	O
with	O
cryotherapy	Physical
.	O

Patients	O
with	O
asymmetric	O
diseases	O
also	O
were	O
randomized	O
for	O
treatment	O
in	O
the	O
threshold	O
eye	O
.	O

RESULTS	O
Nineteen	O
infants	O
(	O
33	O
eyes	O
)	O
were	O
treated	O
,	O
ranging	O
from	O
485	O
to	O
863	O
g	O
birth	O
weight	O
(	O
23	O
to	O
27	O
weeks	O
gestational	O
age	O
)	O
;	O
18	O
patients	O
(	O
32	O
eyes	O
)	O
were	O
followed	O
for	O
3	O
months	O
or	O
longer	O
.	O

Four	O
patients	O
(	O
8	O
eyes	O
)	O
had	O
bilateral	O
zone	O
1	O
disease	O
.	O

Postconceptional	O
age	O
was	O
36	O
to	O
45	O
weeks	O
at	O
the	O
time	O
of	O
treatment	O
.	O

The	O
diode	Physical
laser	Physical
treatment	O
was	O
better	O
tolerated	O
than	O
cryotherapy	Physical
,	O
and	O
the	O
treatment	O
apparatus	O
was	O
more	O
easily	O
transported	O
.	O

Apneic	O
episodes	O
requiring	O
intubation	O
resulted	O
from	O
two	O
cryotherapy	Physical
sessions	O
but	O
no	O
diode	Physical
laser	Physical
sessions	O
.	O

Five	O
cryotherapy-treated	Physical
eyes	O
required	O
retreatment	O
because	O
of	O
persistent	O
disease	O
with	O
adjacent	O
skip	O
areas	O
.	O

In	O
the	O
group	O
followed	O
for	O
3	O
to	O
15	O
months	O
,	O
1	O
cryotherapy-treated	Physical
eye	O
and	O
1	O
diode	O
laser-treated	Physical
eye	O
progressed	O
to	O
stage	O
5	O
retinal	O
detachment	O
.	O

CONCLUSION	O
Compared	O
with	O
cryotherapy	Physical
,	O
the	O
diode	Physical
laser	Physical
was	O
more	O
convenient	O
,	O
technically	O
easier	O
to	O
administer	O
,	O
and	O
better	O
tolerated	O
by	O
the	O
patient	O
.	O

Although	O
the	O
number	O
of	O
patients	O
was	O
too	O
small	O
for	O
meaningful	O
statistical	O
analysis	O
of	O
outcome	O
,	O
diode	Physical
laser	Physical
peripheral	Physical
retinal	Physical
ablation	Physical
appeared	O
to	O
be	O
as	O
effective	O
as	O
cryotherapy	Physical
for	O
the	O
treatment	O
of	O
threshold	O
ROP	O
.	O

The	O
NORwegian	O
study	O
on	O
DIstrict	O
treatment	O
of	O
ST-elevation	O
myocardial	O
infarction	O
(	O
NORDISTEMI	O
)	O
.	O

OBJECTIVES	O
Thrombolysis	O
is	O
the	O
treatment	O
of	O
choice	O
for	O
patients	O
with	O
ST-elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
living	O
in	O
rural	O
areas	O
with	O
long	O
transfer	O
delays	O
to	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

This	O
trial	O
compares	O
two	O
different	O
strategies	O
following	O
thrombolysis	O
:	O
to	O
transfer	O
all	O
patients	O
for	O
immediate	O
coronary	O
angiography	O
and	O
intervention	O
,	O
or	O
to	O
manage	O
the	O
patients	O
more	O
conservatively	O
.	O

DESIGN	O
The	O
NORwegian	O
study	O
on	O
DIstrict	O
treatment	O
of	O
STEMI	O
(	O
NORDISTEMI	O
)	O
is	O
an	O
open	O
,	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
in	O
patients	O
with	O
STEMI	O
of	O
less	O
than	O
6	O
hours	O
of	O
duration	O
and	O
more	O
than	O
90	O
minutes	O
expected	O
time	O
delay	O
to	O
PCI	Surgical
.	O

A	O
total	O
of	O
266	O
patients	O
will	O
receive	Physical
full-dose	Pharmacological
thrombolysis	Pharmacological
,	O
preferably	O
pre-hospital	O
,	O
and	O
then	O
be	O
randomized	O
to	O
either	O
strategy	O
.	O

Our	O
primary	O
endpoint	O
is	O
the	O
one	O
year	O
combined	O
incidence	O
of	O
death	O
,	O
reinfarction	O
,	O
stroke	O
or	O
new	O
myocardial	O
ischaemia	O
.	O

The	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT00161005	O
.	O

RESULTS	O
By	O
April	O
2006	O
,	O
109	O
patients	O
have	O
been	O
randomized	O
.	O

Thrombolysis	O
has	O
been	O
given	O
pre-hospital	O
to	O
52	O
%	O
of	O
patients	O
.	O

The	O
median	O
transport	O
distance	O
from	O
first	O
medical	O
contact	O
to	O
catheterization	O
laboratory	O
was	O
155	O
km	O
(	O
range	O
90-396	O
km	O
)	O
.	O

Results	O
of	O
the	O
study	O
are	O
expected	O
in	O
2008	O
.	O

Does	O
3-day	O
course	O
of	O
oral	Pharmacological
amoxycillin	Pharmacological
benefit	O
children	O
of	O
non-severe	O
pneumonia	O
with	O
wheeze	O
:	O
a	O
multicentric	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
WHO-defined	O
pneumonias	O
,	O
treated	O
with	O
antibiotics	O
,	O
are	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
childhood	O
morbidity	O
and	O
mortality	O
in	O
the	O
developing	O
countries	O
.	O

Since	O
substantial	O
proportion	O
pneumonias	O
have	O
a	O
viral	O
etiology	O
,	O
where	O
children	O
are	O
more	O
likely	O
to	O
present	O
with	O
wheeze	O
,	O
there	O
is	O
a	O
concern	O
that	O
currently	O
antibiotics	O
are	O
being	O
over-prescribed	O
for	O
it	O
.	O

Hence	O
the	O
current	O
trial	O
was	O
conducted	O
with	O
the	O
objective	O
to	O
show	O
the	O
therapeutic	O
equivalence	O
of	O
two	O
treatments	O
(	O
placebo	Control
and	O
amoxycillin	Pharmacological
)	O
for	O
children	O
presenting	O
with	O
non-severe	O
pneumonia	O
with	O
wheeze	O
,	O
who	O
have	O
persistent	O
fast	O
breathing	O
after	O
nebulisation	O
with	O
salbutamol	O
,	O
and	O
have	O
normal	O
chest	O
radiograph	O
.	O

METHODOLOGY	O
This	O
multi-centric	O
,	O
randomised	O
placebo	O
controlled	O
double	O
blind	O
clinical	O
trial	O
intended	O
to	O
investigate	O
equivalent	O
efficacy	O
of	O
placebo	Control
and	O
amoxicillin	Pharmacological
and	O
was	O
conducted	O
in	O
ambulatory	O
care	O
settings	O
in	O
eight	O
government	O
hospitals	O
in	O
India	O
.	O

Participants	O
were	O
children	O
aged	O
2-59	O
months	O
of	O
age	O
,	O
who	O
received	O
either	O
oral	O
amoxycillin	Pharmacological
(	O
31-54	O
mg/Kg/day	O
,	O
in	O
three	O
divided	O
doses	O
for	O
three	O
days	O
)	O
or	O
placebo	O
,	O
and	O
standard	Pharmacological
bronchodilator	Pharmacological
therapy	Pharmacological
.	O

Primary	O
outcome	O
was	O
clinical	O
failure	O
on	O
or	O
before	O
day-	O
4	O
.	O

PRINCIPAL	O
FINDINGS	O
We	O
randomized	O
836	O
cases	O
in	O
placebo	O
and	O
835	O
in	O
amoxycillin	O
group	O
.	O

Clinical	O
failures	O
occurred	O
in	O
201	O
(	O
24.0	O
%	O
)	O
on	O
placebo	O
and	O
166	O
(	O
19.9	O
%	O
)	O
on	O
amoxycillin	Pharmacological
(	O
risk	O
difference	O
4.2	O
%	O
in	O
favour	O
of	O
antibiotic	O
,	O
95	O
%	O
CI	O
:	O
0.2	O
to	O
8.1	O
)	O
.	O

Adherence	O
for	O
both	O
placebo	O
and	O
amoxycillin	Pharmacological
was	O
>	O
96	O
%	O
and	O
98.9	O
%	O
subjects	O
were	O
followed	O
up	O
on	O
day-	O
4	O
.	O

Clinical	O
failure	O
was	O
associated	O
with	O
(	O
i	O
)	O
placebo	O
treatment	O
(	O
adjusted	O
OR	O
=	O
1.28	O
,	O
95	O
%	O
CI	O
:	O
1.01	O
to1.62	O
)	O
,	O
(	O
ii	O
)	O
excess	O
respiratory	O
rate	O
of	O
>	O
10	O
breaths	O
per	O
minute	O
(	O
adjusted	O
OR	O
=	O
1.51	O
,	O
95	O
%	O
CI	O
:	O
1.19	O
,	O
1.92	O
)	O
,	O
(	O
iii	O
)	O
vomiting	O
at	O
enrolment	O
(	O
adjusted	O
OR	O
=	O
1.49	O
,	O
95	O
%	O
CI	O
:	O
1.13	O
,	O
1.96	O
)	O
,	O
(	O
iv	O
)	O
history	O
of	O
use	O
of	O
broncho-dilators	O
(	O
adjusted	O
OR	O
=	O
1.71	O
,	O
95	O
%	O
CI	O
:	O
1.30	O
,	O
2.24	O
)	O
and	O
(	O
v	O
)	O
non-adherence	O
(	O
adjusted	O
OR	O
=	O
8.06	O
,	O
95	O
%	O
CI	O
:	O
4.36	O
,	O
14.92	O
)	O
.	O

CONCLUSIONS	O
Treating	O
children	O
with	O
non-severe	O
pneumonia	O
and	O
wheeze	O
with	O
a	O
placebo	O
is	O
not	O
equivalent	O
to	O
treatment	O
with	O
oral	O
amoxycillin	Pharmacological
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
NCT00407394	O
.	O

Bradykinin-induced	O
cough	O
reflex	O
markedly	O
increases	O
in	O
patients	O
with	O
cough	O
associated	O
with	O
captopril	O
and	O
enalapril	O
.	O

We	O
studied	O
the	O
effects	O
of	O
angiotensin	Pharmacological
converting	Pharmacological
enzyme	Pharmacological
(	Pharmacological
ACE	Pharmacological
)	Pharmacological
inhibitors	Pharmacological
on	O
cough	Pharmacological
responses	Pharmacological
to	Pharmacological
bradykinin	Pharmacological
(	Pharmacological
BK	Pharmacological
)	Pharmacological
,	O
substance	Pharmacological
P	Pharmacological
(	Pharmacological
SP	Pharmacological
)	Pharmacological
and	O
citric	Pharmacological
acid	Pharmacological
in	O
a	O
double	O
blind	O
,	O
random	O
study	O
on	O
10	O
hypertensive	O
patients	O
receiving	O
ACE	Pharmacological
inhibitors	Pharmacological
.	O

Of	O
these	O
patients	O
,	O
five	O
had	O
reported	O
cough	O
with	O
ACE	Pharmacological
inhibitors	Pharmacological
.	O

Cough	O
responses	O
to	O
citric	O
acid	O
were	O
similar	O
between	O
patients	O
with	O
and	O
without	O
cough	O
,	O
and	O
SP	O
up	O
to	O
10	O
(	O
-5	O
)	O
M	O
did	O
not	O
cause	O
cough	O
in	O
any	O
of	O
the	O
subjects	O
.	O

BK	Pharmacological
caused	O
cough	O
at	O
13.4	O
+/-	O
1.2	O
(	O
-log	O
M	O
)	O
in	O
5	O
patients	O
with	O
cough	O
associated	O
with	O
ACE	Pharmacological
inhibitors	Pharmacological
,	O
but	O
it	O
did	O
not	O
cause	O
cough	O
at	O
concentrations	O
up	O
to	O
10	O
(	O
-5	O
)	O
M	O
in	O
other	O
5	O
patients	O
.	O

One	O
month	O
after	O
the	O
withdrawal	O
of	O
ACE	O
inhibitors	O
,	O
5	O
patients	O
were	O
free	O
from	O
cough	O
symptoms	O
,	O
and	O
BK	O
did	O
not	O
cause	O
cough	O
up	O
to	O
10	O
(	O
-5	O
)	O
M	O
in	O
these	O
patients	O
,	O
except	O
for	O
one	O
who	O
coughed	O
at	O
10	O
(	O
-9	O
)	O
M	O
,	O
without	O
changes	O
in	O
responses	O
to	O
citric	O
acid	O
.	O

BK	O
caused	O
cough	O
at	O
14.3	O
+/-	O
0.7	O
(	O
-log	O
M	O
)	O
although	O
BK1-7	O
,	O
a	O
major	O
metabolite	O
of	O
BK	O
by	O
ACE	O
,	O
caused	O
cough	O
at	O
5.7	O
+/-	O
0.7	O
(	O
-log	O
M	O
)	O
in	O
another	O
3	O
patients	O
with	O
cough	O
associated	O
with	O
ACE	O
inhibitor	O
.	O

These	O
results	O
suggest	O
that	O
impaired	O
metabolism	O
of	O
BK	O
induced	O
by	O
ACE	O
inhibitors	O
may	O
relate	O
to	O
the	O
manifestation	O
of	O
cough	O
in	O
hypertensive	O
patients	O
receiving	O
ACE	O
inhibitors	O
.	O

Effect	O
of	O
diltiazem	Pharmacological
on	O
symptomatic	O
and	O
asymptomatic	O
episodes	O
of	O
ST	O
segment	O
depression	O
occurring	O
during	O
daily	O
life	O
and	O
during	O
exercise	O
.	O

BACKGROUND	O
Silent	O
myocardial	O
ischemia	O
is	O
an	O
adverse	O
prognostic	O
marker	O
in	O
patients	O
with	O
coronary	O
disease	O
;	O
however	O
,	O
controlled	O
data	O
on	O
the	O
effect	O
of	O
treatment	O
are	O
sparse	O
and	O
contradictory	O
,	O
and	O
the	O
relations	O
among	O
the	O
occurrence	O
of	O
ST	O
segment	O
depression	O
,	O
drug	O
efficacy	O
,	O
and	O
heart	O
rate	O
are	O
unclear	O
.	O

METHODS	O
AND	O
RESULTS	O
Sixty	O
patients	O
with	O
stable	O
coronary	O
artery	O
disease	O
,	O
a	O
positive	O
treadmill	O
exercise	O
test	O
and	O
asymptomatic	O
ST	O
segment	O
depression	O
on	O
ambulatory	O
electrocardiographic	O
recording	O
were	O
assessed	O
in	O
a	O
multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	Control
,	O
cross-over	O
trial	O
.	O

Treadmill	Physical
exercise	Physical
tests	O
and	O
72-hour	O
electrocardiographic	O
recordings	O
were	O
obtained	O
at	O
the	O
end	O
of	O
two	O
2-week	O
treatment	O
periods	O
with	O
sustained-release	Pharmacological
diltiazem	Pharmacological
180	O
mg	O
b.i.d	O
.	O

or	O
equivalent	O
placebo	Control
.	Control

Episodes	O
of	O
asymptomatic	O
ST	O
depression	O
decreased	O
by	O
50	O
%	O
or	O
more	O
in	O
70	O
%	O
of	O
the	O
patients	O
from	O
a	O
median	O
number	O
of	O
4.5	O
(	O
range	O
,	O
0-19	O
)	O
to	O
1.5	O
(	O
range	O
,	O
0-13	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
;	O
their	O
cumulative	O
duration	O
also	O
decreased	O
from	O
78.5	O
(	O
range	O
,	O
0-60	O
)	O
to	O
24.5	O
(	O
range	O
,	O
0-411	O
)	O
minutes	O
(	O
p	O
=	O
0.001	O
)	O
.	O

No	O
circadian	O
variation	O
was	O
found	O
in	O
the	O
efficacy	O
of	O
diltiazem	Pharmacological
.	Pharmacological

The	O
occurrence	O
of	O
ischemic	O
type	O
ST	O
segment	O
depression	O
was	O
modulated	O
by	O
changes	O
in	O
heart	O
rate	O
rather	O
than	O
by	O
absolute	O
heart	O
rate	O
.	O

Diltiazem	Pharmacological
also	O
improved	O
exercise	O
test	O
end	O
points	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Time	O
to	O
ST	O
segment	O
depression	O
increased	O
to	O
341	O
+/-	O
148	O
from	O
296	O
+/-	O
154	O
seconds	O
(	O
p	O
=	O
0.005	O
)	O
.	O

Although	O
less	O
frequent	O
with	O
diltiazem	Pharmacological
administration	O
(	O
45	O
versus	O
54	O
patients	O
,	O
p	O
less	O
than	O
0.03	O
)	O
,	O
exercise-induced	O
ST	O
depression	O
was	O
more	O
often	O
asymptomatic	O
(	O
98	O
%	O
versus	O
72	O
%	O
of	O
patients	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

CONCLUSIONS	O
Diltiazem	Pharmacological
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
ischemic	O
type	O
ST	O
depression	O
in	O
patients	O
with	O
stable	O
coronary	O
artery	O
disease	O
.	O

Monitoring	O
acute	O
effects	O
on	O
athletic	O
performance	O
with	O
mixed	O
linear	O
modeling	O
.	O

UNLABELLED	O
There	O
is	O
a	O
need	O
for	O
a	O
sophisticated	O
approach	O
to	O
track	O
athletic	O
performance	O
and	O
to	O
quantify	O
factors	O
affecting	O
it	O
in	O
practical	O
settings	O
.	O

PURPOSE	O
To	O
demonstrate	O
the	O
application	O
of	O
mixed	O
linear	O
modeling	O
for	O
monitoring	O
athletic	O
performance	O
.	O

METHODS	O
Elite	O
sprint	O
and	O
middle-distance	O
swimmers	O
(	O
three	O
females	O
and	O
six	O
males	O
;	O
aged	O
21-26	O
yr	O
)	O
performed	O
6-13	O
time	O
trials	O
in	O
training	O
and	O
competition	O
in	O
the	O
9	O
wk	O
before	O
and	O
including	O
Olympic-qualifying	O
trials	O
,	O
all	O
in	O
their	O
specialty	O
event	O
.	O

We	O
included	O
a	O
double-blind	O
,	O
randomized	O
,	O
diet-controlled	Educational
crossover	Educational
intervention	Educational
,	O
in	O
which	O
the	O
swimmers	O
consumed	O
caffeine	Pharmacological
(	O
5	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
body	O
mass	O
)	O
or	O
placebo	Control
.	O

The	O
swimmers	O
also	O
knowingly	O
consumed	O
varying	O
doses	O
of	O
caffeine	Pharmacological
in	O
some	O
time	O
trials	O
.	O

We	O
used	O
mixed	O
linear	O
modeling	O
of	O
log-transformed	O
swim	O
time	O
to	O
quantify	O
effects	O
on	O
performance	O
in	O
training	O
versus	O
competition	O
,	O
in	O
morning	O
versus	O
evening	O
swims	O
,	O
and	O
with	O
use	O
of	O
caffeine	O
.	O

Predictor	O
variables	O
were	O
coded	O
as	O
0	O
or	O
1	O
to	O
represent	O
absence	O
or	O
presence	O
,	O
respectively	O
,	O
of	O
each	O
condition	O
and	O
were	O
included	O
as	O
fixed	O
effects	O
.	O

The	O
date	O
of	O
each	O
performance	O
test	O
was	O
included	O
as	O
a	O
continuous	O
linear	O
fixed	O
effect	O
and	O
interacted	O
with	O
the	O
random	O
effect	O
for	O
the	O
athlete	O
to	O
represent	O
individual	O
differences	O
in	O
linear	O
trends	O
in	O
performance	O
.	O

RESULTS	O
Most	O
effects	O
were	O
clear	O
,	O
owing	O
to	O
the	O
high	O
reliability	O
of	O
performance	O
times	O
in	O
training	O
and	O
competition	O
(	O
typical	O
errors	O
of	O
0.9	O
%	O
and	O
0.8	O
%	O
,	O
respectively	O
)	O
.	O

Performance	O
time	O
improved	O
linearly	O
by	O
0.8	O
%	O
per	O
4	O
wk	O
.	O

The	O
swimmers	O
performed	O
substantially	O
better	O
in	O
evenings	O
versus	O
mornings	O
and	O
in	O
competition	O
versus	O
training	O
.	O

A	O
100-mg	O
dose	O
of	O
caffeine	O
enhanced	O
performance	O
in	O
training	O
and	O
competition	O
by	O
approximately	O
1.3	O
%	O
.	O

There	O
were	O
substantial	O
but	O
unclear	O
individual	O
responses	O
to	O
training	O
and	O
caffeine	O
(	O
SD	O
of	O
0.3	O
%	O
and	O
0.8	O
%	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
Mixed	O
linear	O
modeling	O
can	O
be	O
applied	O
successfully	O
to	O
monitor	O
factors	O
affecting	O
performance	O
in	O
a	O
squad	O
of	O
elite	O
athletes	O
.	O

The	O
Pain	O
Course	O
:	O
a	O
randomised	O
controlled	O
trial	O
of	O
a	O
clinician-guided	Physical
Internet-delivered	Physical
cognitive	Physical
behaviour	Physical
therapy	Physical
program	Physical
for	O
managing	O
chronic	O
pain	O
and	O
emotional	O
well-being	O
.	O

The	O
present	O
study	O
evaluated	O
the	O
efficacy	O
of	O
a	O
clinician-guided	Physical
Internet-delivered	Physical
cognitive	Physical
behaviour	Physical
therapy	Physical
(	Physical
iCBT	Physical
)	Physical
program	Physical
,	O
the	O
Pain	Educational
Course	Educational
,	O
to	O
reduce	O
disability	O
,	O
anxiety	O
,	O
and	O
depression	O
associated	O
with	O
chronic	O
pain	O
.	O

Sixty-three	O
adults	O
with	O
chronic	O
pain	O
were	O
randomised	O
to	O
either	O
a	O
Treatment	Control
Group	Control
or	Control
waitlist	Control
Control	Control
Group	Control
.	O

Treatment	O
consisted	O
of	O
5	Educational
iCBT-based	Educational
lessons	Educational
,	O
homework	Pharmacological
tasks	Pharmacological
,	O
additional	Educational
resources	Educational
,	O
weekly	O
e-mail	Educational
or	Educational
telephone	Educational
contact	Educational
from	Educational
a	Educational
Clinical	Educational
Psychologist	Educational
,	O
and	O
automated	Educational
e-mails	Educational
.	O

Twenty-nine	O
of	O
31	O
Treatment	O
Group	O
participants	O
completed	O
the	O
5	O
lessons	O
during	O
the	O
8-week	O
program	O
,	O
and	O
posttreatment	O
and	O
3-month	O
follow-up	O
data	O
were	O
collected	O
from	O
30/31	O
and	O
29/31	O
participants	O
,	O
respectively	O
.	O

Treatment	Physical
Group	Physical
participants	O
obtained	O
significantly	O
greater	O
improvements	O
than	O
Control	Control
Group	Control
participants	O
in	O
levels	O
of	O
disability	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
average	O
pain	O
levels	O
at	O
posttreatment	O
.	O

These	O
improvements	O
corresponded	O
to	O
small	O
to	O
large	O
between-groups	O
effect	O
sizes	O
(	O
Cohen	O
's	O
d	O
)	O
at	O
posttreatment	O
for	O
disability	O
(	O
d	O
=	O
.88	O
)	O
,	O
anxiety	O
(	O
d	O
=	O
.38	O
)	O
,	O
depression	O
(	O
d	O
=	O
.66	O
)	O
,	O
and	O
average	O
pain	O
(	O
d	O
=	O
.64	O
)	O
,	O
respectively	O
.	O

These	O
outcomes	O
were	O
sustained	O
at	O
follow-up	O
and	O
participants	O
rated	O
the	O
program	O
as	O
highly	O
acceptable	O
.	O

Overall	O
,	O
the	O
clinician	O
spent	O
a	O
total	O
mean	O
time	O
of	O
81.54	O
minutes	O
(	O
SD	O
30.91	O
minutes	O
)	O
contacting	O
participants	O
during	O
the	O
program	O
.	O

The	O
results	O
appear	O
better	O
than	O
those	O
reported	O
in	O
iCBT	O
studies	O
to	O
date	O
and	O
provide	O
support	O
for	O
the	O
potential	O
of	O
clinician-guided	Physical
iCBT	Physical
in	O
the	O
treatment	O
of	O
disability	O
,	O
anxiety	O
,	O
and	O
depression	O
for	O
people	O
with	O
chronic	O
pain	O
.	O

Pre-medication	O
with	O
pronase	Pharmacological
reduces	O
artefacts	O
during	O
endoscopic	O
ultrasonography	Physical
.	O

BACKGROUND	O
Gastric	O
mucus	O
usually	O
induces	O
artefacts	O
during	O
endoscopic	O
ultrasonography	O
.	O

AIM	O
To	O
investigate	O
the	O
effectiveness	O
of	O
pre-medication	O
with	O
the	O
proteolytic	Pharmacological
enzyme	Pharmacological
,	O
pronase	Pharmacological
,	O
before	O
endoscopic	Physical
ultrasonography	Physical
.	O

METHODS	O
Out-patients	O
scheduled	O
for	O
endoscopic	O
ultrasonography	O
were	O
randomly	O
assigned	O
to	O
oral	O
pre-medication	O
with	O
the	O
anti-foam	Pharmacological
agent	Pharmacological
,	O
dimethylpolysiloxane	Pharmacological
,	Pharmacological
alone	Pharmacological
(	O
treatment	O
A	O
;	O
n	O
=	O
29	O
)	O
,	O
with	O
dimethylpolysiloxane	Pharmacological
plus	Pharmacological
sodium	Pharmacological
bicarbonate	Pharmacological
(	O
treatment	O
B	O
;	O
n	O
=	O
29	O
)	O
or	O
with	O
dimethylpolysiloxane	O
,	O
sodium	O
bicarbonate	O
and	O
pronase	O
(	O
treatment	O
C	O
;	O
n	O
=	O
29	O
)	O
.	O

All	O
drinks	O
were	O
given	O
about	O
10	O
min	O
before	O
the	O
start	O
of	O
the	O
procedure	O
.	O

After	O
insertion	O
of	O
the	O
endoscope	O
,	O
endoscopists	O
recorded	O
visibility	O
scores	O
before	O
the	O
procedure	O
,	O
imaging	O
scores	O
at	O
endoscopic	O
ultrasonography	O
and	O
the	O
numbers	O
of	O
high-echo	O
spots	O
in	O
the	O
gastric	O
cavity	O
and	O
on	O
the	O
gastric	O
wall	O
surface	O
after	O
the	O
procedure	O
.	O

RESULTS	O
Pre-medication	O
with	O
pronase	Pharmacological
(	O
treatment	O
C	O
)	O
significantly	O
reduced	O
(	O
both	O
at	O
P	O
<	O
0.05	O
)	O
the	O
visibility	O
score	O
(	O
score	O
4	O
,	O
46	O
%	O
)	O
in	O
comparison	O
with	O
that	O
obtained	O
for	O
pre-medication	O
without	O
pronase	Pharmacological
(	O
10	O
%	O
for	O
both	O
treatments	O
A	O
and	O
B	O
)	O
.	O

Treatment	O
with	O
pronase	Pharmacological
significantly	O
reduced	O
(	O
both	O
at	O
P	O
<	O
0.05	O
)	O
the	O
endoscopic	O
ultrasonography	O
score	O
in	O
the	O
gastric	O
cavity	O
(	O
score	O
4	O
,	O
34	O
%	O
)	O
in	O
comparison	O
with	O
that	O
found	O
for	O
treatments	O
A	O
(	O
7	O
%	O
)	O
and	O
B	O
(	O
0	O
%	O
)	O
.	O

It	O
also	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
the	O
endoscopic	O
ultrasonography	O
score	O
on	O
the	O
gastric	O
wall	O
surface	O
(	O
score	O
4	O
,	O
14	O
%	O
)	O
in	O
comparison	O
with	O
that	O
observed	O
for	O
treatment	O
A	O
(	O
3	O
%	O
)	O
.	O

The	O
numbers	O
of	O
high-echo	O
spots	O
in	O
the	O
gastric	O
cavity	O
and	O
on	O
the	O
gastric	O
wall	O
surface	O
were	O
significantly	O
less	O
(	O
both	O
at	O
P	O
<	O
0.001	O
)	O
for	O
pre-medication	O
with	O
pronase	Pharmacological
(	O
treatment	O
C	O
)	O
than	O
for	O
pre-medication	O
with	O
treatments	O
A	O
and	O
B	O
.	O

There	O
were	O
no	O
complications	O
associated	O
with	O
the	O
solutions	O
.	O

CONCLUSIONS	O
Pre-treatment	O
with	O
pronase	Pharmacological
reduced	O
the	O
artefacts	O
during	O
endoscopic	O
ultrasonography	O
.	O

Effects	O
of	O
nifedipine	Pharmacological
and	O
nitrendipine	Pharmacological
on	O
insulin	O
secretion	O
in	O
obese	O
patients	O
.	O

Data	O
on	O
the	O
influence	O
of	O
calcium	O
antagonists	O
on	O
glucose	O
tolerance	O
and	O
insulin	O
release	O
in	O
humans	O
are	O
conflicting	O
.	O

The	O
present	O
double-blind	O
,	O
double-dummy	O
,	O
controlled	O
trial	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
short-term	O
(	O
7	O
days	O
)	O
treatment	O
with	O
nitrendipine	Pharmacological
,	Pharmacological
20	Pharmacological
mg	Pharmacological
b.i.d	Pharmacological
.	Pharmacological

;	Pharmacological
nitrendipine	Pharmacological
,	Pharmacological
20	Pharmacological
mg	Pharmacological
once	Pharmacological
daily	Pharmacological
;	Pharmacological
or	Pharmacological
placebo	Control
on	O
blood	O
glucose	O
and	O
plasma	O
insulin	O
and	O
C-peptide	O
response	O
to	O
an	O
intravenous	O
glucose	O
load	O
in	O
mildly	O
or	O
transiently	O
hypertensive	O
nondiabetic	O
obese	O
patients	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
fasting	O
glucose	O
,	O
insulin	O
,	O
and	O
C-peptide	O
,	O
or	O
in	O
the	O
glucose	O
disappearance	O
rate	O
and	O
in	O
any	O
of	O
the	O
parameters	O
for	O
insulin	O
and	O
C-peptide	O
response	O
after	O
i.v	O
.	O

glucose	O
,	O
between	O
the	O
three	O
groups	O
of	O
patients	O
.	O

However	O
,	O
a	O
slight	O
decrease	O
in	O
early	O
insulin	O
response	O
to	O
glucose	O
was	O
observed	O
in	O
the	O
nifedipine	O
and	O
the	O
nitrendipine	O
groups	O
.	O

This	O
study	O
confirms	O
that	O
calcium	O
antagonists	O
have	O
no	O
clinically	O
relevant	O
effect	O
on	O
glucose	O
homeostasis	O
even	O
if	O
a	O
slight	O
alteration	O
of	O
insulin	O
release	O
after	O
glucose	O
load	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Health-education	O
package	O
to	O
prevent	O
worm	O
infections	O
in	O
Chinese	O
schoolchildren	O
.	O

BACKGROUND	O
Soil-transmitted	O
helminths	O
are	O
among	O
the	O
most	O
prevalent	O
sources	O
of	O
human	O
infections	O
globally	O
.	O

We	O
determined	O
the	O
effect	O
of	O
an	O
educational	O
package	O
at	O
rural	O
schools	O
in	O
Linxiang	O
City	O
District	O
,	O
Hunan	O
province	O
,	O
China	O
,	O
where	O
these	O
worms	O
are	O
prevalent	O
.	O

The	O
intervention	O
aimed	O
to	O
increase	O
knowledge	O
about	O
soil-transmitted	O
helminths	O
,	O
induce	O
behavioral	O
change	O
,	O
and	O
reduce	O
the	O
rate	O
of	O
infection	O
.	O

METHODS	O
We	O
conducted	O
a	O
single-blind	O
,	O
unmatched	O
,	O
cluster-randomized	O
intervention	O
trial	O
involving	O
1718	O
children	O
,	O
9	O
to	O
10	O
years	O
of	O
age	O
,	O
in	O
38	O
schools	O
over	O
the	O
course	O
of	O
1	O
school	O
year	O
.	O

Schools	O
were	O
randomly	O
assigned	O
to	O
the	O
health-education	Educational
package	Educational
,	O
which	Educational
included	Educational
a	Educational
cartoon	Educational
video	Educational
,	Educational
or	Educational
to	Educational
a	Educational
control	Educational
package	Educational
,	Educational
which	Educational
involved	Educational
only	Educational
the	Educational
display	Educational
of	Educational
a	Educational
health-education	Educational
poster	Educational
.	O

Infection	O
rates	O
,	O
knowledge	O
about	O
soil-transmitted	O
helminths	O
(	O
as	O
assessed	O
with	O
the	O
use	O
of	O
a	O
questionnaire	O
)	O
,	O
and	O
hand-washing	O
behavior	O
were	O
assessed	O
before	O
and	O
after	O
the	O
intervention	O
.	O

Albendazole	Pharmacological
was	O
administered	O
in	O
all	O
the	O
participants	O
at	O
baseline	O
and	O
in	O
all	O
the	O
children	O
who	O
were	O
found	O
to	O
be	O
positive	O
for	O
infection	O
with	O
soil-transmitted	O
helminths	O
at	O
the	O
follow-up	O
assessment	O
at	O
the	O
end	O
of	O
the	O
school	O
year	O
.	O

RESULTS	O
At	O
the	O
follow-up	O
assessment	O
,	O
the	O
mean	O
score	O
for	O
the	O
knowledge	O
of	O
helminths	O
,	O
calculated	O
as	O
a	O
percentage	O
of	O
a	O
total	O
of	O
43	O
points	O
on	O
a	O
questionnaire	O
,	O
was	O
90	O
%	O
higher	O
in	O
the	O
intervention	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
63.3	O
vs.	O
33.4	O
,	O
P	O
<	O
0.001	O
)	O
,	O
the	O
percentage	O
of	O
children	O
who	O
washed	O
their	O
hands	O
after	O
using	O
the	O
toilet	O
was	O
nearly	O
twice	O
as	O
high	O
in	O
the	O
intervention	O
group	O
(	O
98.9	O
%	O
,	O
vs.	O
54.2	O
%	O
in	O
the	O
control	O
group	O
;	O
P	O
<	O
0.001	O
)	O
,	O
and	O
the	O
incidence	O
of	O
infection	O
with	O
soil-transmitted	O
helminths	O
was	O
50	O
%	O
lower	O
in	O
the	O
intervention	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
4.1	O
%	O
vs.	O
8.4	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

No	O
adverse	O
events	O
were	O
observed	O
immediately	O
(	O
within	O
15	O
minutes	O
)	O
after	O
albendazole	O
treatment	O
.	O

CONCLUSIONS	O
The	O
health-education	O
package	O
increased	O
students	O
'	O
knowledge	O
about	O
soil-transmitted	O
helminths	O
and	O
led	O
to	O
a	O
change	O
in	O
behavior	O
and	O
a	O
reduced	O
incidence	O
of	O
infection	O
within	O
1	O
school	O
year	O
.	O

(	O
Funded	O
by	O
UBS	O
Optimus	O
Foundation	O
,	O
Zurich	O
,	O
Switzerland	O
;	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
number	O
,	O
ACTRN12610000048088	O
.	O

)	O
.	O

Combination	O
of	O
arteriovenous	Physical
extracorporeal	Physical
lung	Physical
assist	Physical
and	O
high-frequency	Physical
oscillatory	Physical
ventilation	Physical
in	O
a	O
porcine	O
model	O
of	O
lavage-induced	O
acute	O
lung	O
injury	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
To	O
compare	O
the	O
combined	O
effects	O
of	O
arteriovenous	Physical
extracorporeal	Physical
lung	Physical
assist	Physical
(	Physical
AV-ECLA	Physical
)	Physical
and	O
high-frequency	Physical
oscillatory	Physical
ventilation	Physical
(	Physical
HFOV	Physical
)	Physical
on	O
pulmonary	O
gas	O
exchange	O
,	O
hemodynamics	O
,	O
and	O
respiratory	O
parameters	O
in	O
a	O
lavage-induced	O
porcine	O
lung	O
injury	O
model	O
.	O

METHODS	O
A	O
prospective	O
,	O
randomized	O
animal	O
study	O
.	O

Saline	Physical
lung	Physical
lavage	Physical
was	O
performed	O
in	O
33	O
healthy	O
female	O
pigs	O
,	O
weighing	O
52	O
+/-	O
4.1	O
kg	O
(	O
mean	O
+/-	O
SD	O
)	O
,	O
until	O
the	O
Pao2	O
decreased	O
to	O
53	O
+/-	O
8	O
mm	O
Hg	O
.	O

After	O
a	O
stabilization	O
period	O
of	O
60	O
minutes	O
,	O
the	O
animals	O
were	O
randomly	O
assigned	O
to	O
four	O
groups	O
:	O
group	O
1	O
,	O
pressure-controlled	Physical
ventilation	Physical
(	Physical
PCV	Physical
)	Physical
with	O
a	O
tidal	O
volume	O
of	O
6	O
mL/kg	O
;	O
group	O
2	O
,	O
PCV	Physical
with	O
a	O
tidal	O
volume	O
of	O
6	O
mL/kg	O
and	O
AV-ECLA	Physical
;	Surgical
group	O
3	O
,	O
HFOV	Physical
;	O
group	O
4	O
,	O
HFOV	Physical
and	Physical
AV-ECLA	Physical
.	O

In	O
groups	O
2	O
and	O
4	O
,	O
the	O
femoral	O
artery	O
and	O
vein	O
were	O
cannulated	O
and	O
a	O
low-resistance	O
membrane	O
lung	O
was	O
interposed	O
.	O

After	O
isolated	O
evaluation	O
of	O
AV-ECLA	Physical
,	O
the	O
mean	O
airway	O
pressure	O
was	O
increased	O
by	O
3	O
cm	O
H2O	O
from	O
16	O
to	O
34	O
cm	O
H2O	O
every	O
20	O
minutes	O
,	O
accompanied	O
by	O
blood	O
gas	O
analyses	O
and	O
measurements	O
of	O
respiratory	O
and	O
hemodynamic	O
variables	O
.	O

RESULTS	O
Only	O
in	O
AV-ECLA-treated	Physical
animals	O
was	O
normocapnia	O
achieved	O
.	O

No	O
significant	O
increase	O
of	O
Pao2	O
attributable	O
to	O
AV-ECLA	Physical
alone	O
was	O
detected	O
.	O

Mean	O
airway	O
pressure	O
augmentation	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
Pao2	O
in	O
all	O
groups	O
.	O

Peak	O
inspiratory	O
pressure	O
was	O
significantly	O
lower	O
in	O
HFOV-treated	O
animals	O
.	O

CONCLUSIONS	O
The	O
combination	O
of	O
AV-ECLA	Physical
and	O
HFOV	Physical
resulted	O
in	O
normocapnia	O
and	O
comparable	O
Pao2	O
,	O
although	O
a	O
smaller	O
ventilator	O
pressure	O
amplitude	O
was	O
applied	O
.	O

Long-term	O
animal	O
studies	O
are	O
needed	O
to	O
assess	O
whether	O
this	O
approach	O
results	O
in	O
further	O
lung	O
protection	O
.	O

The	O
individual	O
responsiveness	O
to	O
growth	Pharmacological
hormone	Pharmacological
(	Pharmacological
GH	Pharmacological
)	Pharmacological
treatment	Pharmacological
in	O
GH-deficient	O
adults	O
is	O
dependent	O
on	O
the	O
level	O
of	O
GH-binding	O
protein	O
,	O
body	O
mass	O
index	O
,	O
age	O
,	O
and	O
gender	O
.	O

The	O
aim	O
of	O
the	O
present	O
trial	O
was	O
to	O
study	O
the	O
individual	O
responsiveness	O
to	O
GH	Pharmacological
treatment	Pharmacological
in	O
terms	O
of	O
body	O
composition	O
and	O
to	O
search	O
for	O
possible	O
predictors	O
of	O
the	O
response	O
in	O
GH-deficient	O
adults	O
.	O

Sixty-eight	O
patients	O
(	O
44	O
men	O
and	O
24	O
women	O
)	O
with	O
a	O
mean	O
age	O
of	O
44.3	O
(	O
1.2	O
)	O
yr	O
and	O
verified	O
GH	O
deficiency	O
participated	O
in	O
a	O
2-phase	O
treatment	O
trial	O
with	O
an	O
initial	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	Control
,	O
6-month	O
period	O
,	O
followed	O
by	O
an	O
open	O
treatment	O
period	O
,	O
thereby	O
ensuring	O
all	O
patients	O
12	O
months	O
of	O
GH	O
treatment	O
.	O

Recombinant	Pharmacological
human	Pharmacological
GH	Pharmacological
was	O
administered	O
sc	O
daily	O
at	O
bedtime	O
,	O
with	O
a	O
target	O
dose	O
of	O
12	O
micrograms/kg	O
x	O
day	O
.	O

GHBP	O
was	O
measured	O
by	O
ligand-mediated	O
immunofunctional	O
assay	O
,	O
and	O
serum	O
insulin-like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
was	O
determined	O
by	O
RIA	O
after	O
acid-ethanol	O
extraction	O
,	O
using	O
a	O
truncated	O
IGF-I	O
analog	O
as	O
the	O
radioligand	O
.	O

Lean	O
body	O
mass	O
(	O
LBM	O
)	O
and	O
body	O
fat	O
(	O
BF	O
)	O
were	O
determined	O
by	O
dual	O
energy	O
x-ray	O
absorptiometry	O
,	O
and	O
total	O
body	O
water	O
(	O
TBW	O
)	O
was	O
determined	O
by	O
bioelectrical	O
impedance	O
.	O

During	O
the	O
placebo	O
control	O
period	O
,	O
serum	O
IGF-I	O
,	O
LBM	O
,	O
and	O
TBW	O
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
BF	O
decreased	O
(	O
P	O
<	O
0.001	O
)	O
and	O
serum	O
GHBP	O
was	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
GH	O
compared	O
with	O
the	O
patients	O
treated	O
with	O
placebo	O
.	O

After	O
12	O
months	O
of	O
GH	O
treatment	O
,	O
the	O
individual	O
changes	O
in	O
BF	O
ranged	O
from	O
-12.5	O
to	O
4.3	O
kg	O
and	O
from	O
-4.5	O
to	O
10.1	O
kg	O
in	O
LBM	O
.	O

Age	O
(	O
P	O
<	O
0.05	O
)	O
and	O
baseline	O
GHBP	O
level	O
(	O
P	O
<	O
0.01	O
)	O
were	O
inversely	O
correlated	O
with	O
the	O
increase	O
in	O
LBM	O
.	O

The	O
GH-induced	O
increment	O
in	O
IGF-I	O
and	O
TBW	O
was	O
greater	O
in	O
men	O
than	O
in	O
women	O
(	O
P	O
<	O
0.01	O
)	O
,	O
whereas	O
the	O
decreases	O
in	O
BF	O
were	O
similar	O
in	O
men	O
and	O
women	O
.	O

This	O
trial	O
demonstrates	O
the	O
variability	O
in	O
responsiveness	O
to	O
GH	Pharmacological
administration	O
in	O
GH-deficient	O
adults	O
.	O

The	O
best	O
response	O
to	O
GH	O
was	O
obtained	O
in	O
younger	O
patients	O
with	O
low	O
GHBP	O
levels	O
.	O

Furthermore	O
,	O
men	O
responded	O
better	O
than	O
women	O
.	O

A	O
phase	O
II	O
randomized	O
trial	O
comparing	O
radiotherapy	Physical
with	O
concurrent	O
weekly	O
cisplatin	Pharmacological
or	O
weekly	O
paclitaxel	Pharmacological
in	O
patients	O
with	O
advanced	O
cervical	O
cancer	O
.	O

PURPOSE/OBJECTIVE	O
This	O
is	O
a	O
prospective	O
comparison	O
of	O
weekly	O
cisplatin	Pharmacological
to	O
weekly	O
paclitaxel	Pharmacological
as	O
concurrent	O
chemotherapy	O
with	O
standard	Physical
radiotherapy	Physical
for	O
locally	O
advanced	O
cervical	O
carcinoma	O
.	O

MATERIALS/METHODS	O
Between	O
May	O
2000	O
and	O
May	O
2004	O
,	O
31	O
women	O
with	O
FIGO	O
stage	O
IB2-IVA	O
cervical	O
cancer	O
or	O
with	O
postsurgical	O
pelvic	O
recurrence	O
were	O
enrolled	O
into	O
this	O
phase	O
II	O
study	O
and	O
randomized	O
to	O
receive	O
on	O
a	O
weekly	O
basis	O
either	O
40	O
mg/m?	O
Cisplatin	O
(	O
group	O
I	O
;	O
16	O
patients	O
)	O
or	O
50	O
mg/m?	O
paclitaxel	O
(	O
group	O
II	O
;	O
15	O
patients	O
)	O
concurrently	O
with	O
radiotherapy	O
.	O

Median	O
total	O
dose	O
to	O
point	O
A	O
was	O
74	O
Gy	O
(	O
range	O
:	O
66-92	O
Gy	O
)	O
for	O
group	O
I	O
and	O
66	O
Gy	O
(	O
range	O
:	O
40-98	O
Gy	O
)	O
for	O
group	O
II	O
.	O

Median	O
follow-up	O
time	O
was	O
46	O
months	O
.	O

RESULTS	O
Patient	O
and	O
tumor	O
characteristics	O
were	O
similar	O
in	O
both	O
groups	O
.	O

The	O
mean	O
number	O
of	O
chemotherapy	O
cycles	O
was	O
also	O
comparable	O
with	O
87	O
%	O
and	O
80	O
%	O
of	O
patients	O
receiving	O
at	O
least	O
4	O
doses	O
in	O
groups	O
I	O
and	O
II	O
,	O
respectively	O
.	O

Seven	O
patients	O
(	O
44	O
%	O
)	O
of	O
group	O
I	O
and	O
8	O
patients	O
(	O
53	O
%	O
)	O
of	O
group	O
II	O
developed	O
tumor	O
recurrence	O
.	O

The	O
Median	O
Survival	O
time	O
was	O
not	O
reached	O
for	O
Group	O
I	O
and	O
53	O
months	O
for	O
group	O
II	O
.	O

The	O
proportion	O
of	O
patients	O
surviving	O
at	O
2	O
and	O
5	O
years	O
was	O
78	O
%	O
and	O
54	O
%	O
for	O
group	O
I	O
and	O
73	O
%	O
and	O
43	O
%	O
for	O
group	O
II	O
respectively	O
.	O

CONCLUSIONS	O
This	O
small	O
prospective	O
study	O
shows	O
that	O
weekly	O
paclitaxel	O
does	O
not	O
provide	O
any	O
clinical	O
advantage	O
over	O
weekly	O
cisplatin	O
for	O
concurrent	O
chemoradiation	O
for	O
advanced	O
carcinoma	O
of	O
the	O
cervix	O
.	O

Visual	O
field	O
progression	O
in	O
the	O
Collaborative	O
Initial	O
Glaucoma	O
Treatment	O
Study	O
the	O
impact	O
of	O
treatment	O
and	O
other	O
baseline	O
factors	O
.	O

PURPOSE	O
To	O
evaluate	O
factors	O
associated	O
with	O
visual	O
field	O
(	O
VF	O
)	O
progression	O
,	O
using	O
all	O
available	O
follow-up	O
through	O
9	O
years	O
after	O
treatment	O
initiation	O
,	O
in	O
the	O
Collaborative	O
Initial	O
Glaucoma	O
Treatment	O
Study	O
(	O
CIGTS	O
)	O
.	O

DESIGN	O
Longitudinal	O
follow-up	O
of	O
participants	O
enrolled	O
in	O
a	O
randomized	O
clinical	O
trial	O
.	O

PARTICIPANTS	O
Six	O
hundred	O
seven	O
newly	O
diagnosed	O
glaucoma	O
patients	O
.	O

METHODS	O
In	O
a	O
randomized	O
clinical	O
trial	O
,	O
607	O
subjects	O
with	O
newly	O
diagnosed	O
open-angle	O
glaucoma	O
initially	O
were	O
treated	Pharmacological
with	Pharmacological
either	Pharmacological
medication	Pharmacological
or	Pharmacological
trabeculectomy	Pharmacological
.	O

After	O
treatment	O
initiation	O
and	O
early	O
follow-up	O
,	O
subjects	O
were	O
evaluated	O
clinically	O
at	O
6-month	O
intervals	O
.	O

Study	O
participants	O
in	O
both	O
arms	O
of	O
the	O
CIGTS	O
were	O
treated	Physical
aggressively	Physical
in	Physical
an	Physical
effort	Physical
to	Physical
reduce	Physical
intraocular	Physical
pressure	Physical
(	Physical
IOP	Physical
)	Physical
to	Physical
a	Physical
level	Physical
at	Physical
or	Physical
below	Physical
a	Physical
predetermined	Physical
,	Physical
eye-specific	Physical
target	Physical
pressure	Physical
.	Physical

Visual	Physical
field	Physical
progression	Physical
was	Physical
analyzed	Physical
using	Physical
repeated	Physical
measures	Physical
models	Physical
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Visual	O
field	O
progression	O
,	O
measured	O
by	O
Humphrey	O
24-2	O
full-threshold	O
testing	O
and	O
assessed	O
by	O
the	O
change	O
in	O
the	O
mean	O
deviation	O
(	O
MD	O
)	O
,	O
and	O
an	O
indicator	O
of	O
substantial	O
worsening	O
of	O
the	O
VF	O
(	O
MD	O
decrease	O
of	O
>	O
or	O
=3	O
dB	O
from	O
baseline	O
)	O
,	O
assessed	O
at	O
each	O
follow-up	O
visit	O
.	O

RESULTS	O
Follow-up	O
indicated	O
minimal	O
change	O
from	O
baseline	O
in	O
each	O
initial	O
treatment	O
group	O
's	O
average	O
MD	O
.	O

However	O
,	O
at	O
the	O
8-year	O
follow-up	O
examination	O
,	O
substantial	O
worsening	O
(	O
>	O
or	O
=3	O
dB	O
)	O
of	O
MD	O
from	O
baseline	O
was	O
found	O
in	O
21.3	O
%	O
and	O
25.5	O
%	O
of	O
the	O
initial	O
surgery	O
and	O
initial	O
medicine	O
groups	O
,	O
respectively	O
.	O

The	O
effect	O
of	O
initial	O
treatment	O
on	O
subsequent	O
VF	O
loss	O
was	O
modified	O
by	O
time	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
baseline	O
MD	O
(	O
P	O
=	O
0.03	O
)	O
,	O
and	O
diabetes	O
(	O
P	O
=	O
0.01	O
)	O
.	O

Initial	Surgical
surgery	Surgical
led	O
to	O
less	O
VF	O
progression	O
than	O
initial	Pharmacological
medicine	Pharmacological
in	O
subjects	O
with	O
advanced	O
VF	O
loss	O
at	O
baseline	O
,	O
whereas	O
subjects	O
with	O
diabetes	O
had	O
more	O
VF	O
loss	O
over	O
time	O
if	O
treated	O
initially	O
with	O
surgery	O
.	O

CONCLUSIONS	O
The	O
CIGTS	O
intervention	O
protocol	O
led	O
to	O
a	O
lowering	O
of	O
IOP	O
that	O
persisted	O
over	O
time	O
in	O
both	O
treatment	O
groups	O
.	O

Progression	O
in	O
VF	O
loss	O
was	O
seen	O
in	O
a	O
subset	O
,	O
increasing	O
to	O
more	O
than	O
20	O
%	O
of	O
the	O
subjects	O
.	O

The	O
findings	O
regarding	O
initial	O
surgery	O
being	O
beneficial	O
for	O
subjects	O
with	O
more	O
advanced	O
VF	O
loss	O
at	O
presentation	O
,	O
but	O
detrimental	O
for	O
patients	O
with	O
diabetes	O
,	O
are	O
noteworthy	O
and	O
warrant	O
independent	O
confirmation	O
.	O

FINANCIAL	O
DISCLOSURE	O
(	O
S	O
)	O
The	O
author	O
(	O
s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O

Immune	O
reconstitution	O
after	O
allogeneic	Surgical
marrow	Surgical
transplantation	Surgical
compared	O
with	O
blood	Surgical
stem	Surgical
cell	Surgical
transplantation	Surgical
.	Surgical

Allogeneic	O
peripheral	O
blood	O
stem	O
cell	O
grafts	O
contain	O
about	O
10	O
times	O
more	O
T	O
and	O
B	O
cells	O
than	O
marrow	O
grafts	O
.	O

Because	O
these	O
cells	O
may	O
survive	O
in	O
transplant	O
recipients	O
for	O
a	O
long	O
time	O
,	O
recipients	O
of	O
blood	O
stem	O
cells	O
may	O
be	O
less	O
immunocompromised	O
than	O
recipients	O
of	O
marrow	O
.	O

Immune	O
reconstitution	O
was	O
studied	O
in	O
115	O
patients	O
randomly	O
assigned	O
to	O
receive	O
either	O
allogeneic	Surgical
marrow	Surgical
or	Surgical
filgrastim-mobilized	Surgical
blood	Surgical
stem	Surgical
cell	Surgical
transplantation	Surgical
.	Surgical

Between	O
day	O
30	O
and	O
365	O
after	O
transplantation	Physical
,	O
counts	O
of	O
most	O
lymphocyte	O
subsets	O
were	O
higher	O
in	O
the	O
blood	O
stem	O
cell	O
recipients	O
.	O

The	O
difference	O
was	O
most	O
striking	O
for	O
CD4	O
T	O
cells	O
(	O
about	O
4-fold	O
higher	O
counts	O
for	O
CD45RA	O
(	O
high	O
)	O
CD4	O
T	O
cells	O
and	O
about	O
2-fold	O
higher	O
counts	O
for	O
CD45RA	O
(	O
low/-	O
)	O
CD4	O
T	O
cells	O
;	O
P	O
<	O
.05	O
)	O
.	O

On	O
assessment	O
using	O
phytohemagglutinin	O
and	O
herpesvirus	O
antigen-stimulated	O
proliferation	O
,	O
T	O
cells	O
in	O
the	O
2	O
groups	O
of	O
patients	O
appeared	O
equally	O
functional	O
.	O

Median	O
serum	O
IgG	O
levels	O
were	O
similar	O
in	O
the	O
2	O
groups	O
.	O

The	O
rate	O
of	O
definite	O
infections	O
after	O
engraftment	O
was	O
1.7-fold	O
higher	O
in	O
marrow	O
recipients	O
(	O
P	O
=.001	O
)	O
.	O

The	O
rate	O
of	O
severe	O
(	O
inpatient	O
treatment	O
required	O
)	O
definite	O
infections	O
after	O
engraftment	O
was	O
2.4-fold	O
higher	O
in	O
marrow	O
recipients	O
(	O
P	O
=.002	O
)	O
.	O

The	O
difference	O
in	O
the	O
rates	O
of	O
definite	O
infections	O
was	O
greatest	O
for	O
fungal	O
infections	O
,	O
intermediate	O
for	O
bacterial	O
infections	O
,	O
and	O
lowest	O
for	O
viral	O
infections	O
.	O

Death	O
associated	O
with	O
a	O
fungal	O
or	O
bacterial	O
infection	O
occurred	O
between	O
day	O
30	O
and	O
day	O
365	O
after	O
transplantation	Physical
in	O
9	O
marrow	Physical
recipients	O
and	O
no	O
blood	Physical
stem	Physical
cell	Physical
recipients	O
(	O
P	O
=.008	O
)	O
.	O

In	O
conclusion	O
,	O
blood	O
stem	O
cell	O
recipients	O
have	O
higher	O
lymphocyte-subset	O
counts	O
and	O
this	O
appears	O
to	O
result	O
in	O
fewer	O
infections	O
.	O

(	O
Blood	O
.	O

2001	O
;	O
97:3380-3389	O
)	O
Correlates	O
of	O
cognitive	O
deficits	O
in	O
first	O
episode	O
schizophrenia	O
.	O

OBJECTIVE	O
The	O
presence	O
of	O
cognitive	O
dysfunction	O
in	O
schizophrenia	O
has	O
been	O
well	O
documented	O
,	O
but	O
questions	O
remain	O
about	O
whether	O
there	O
are	O
relationships	O
between	O
this	O
dysfunction	O
and	O
clinical	O
symptomatology	O
.	O

If	O
present	O
,	O
such	O
relationships	O
should	O
be	O
most	O
clearly	O
observable	O
in	O
patients	O
with	O
first	O
episode	O
schizophrenia	O
;	O
that	O
is	O
,	O
before	O
the	O
effects	O
of	O
chronic	O
illness	O
,	O
institutionalization	O
,	O
or	O
treatment	O
might	O
confound	O
them	O
.	O

METHOD	O
307	O
schizophrenia	O
subjects	O
in	O
their	O
first	O
episode	O
of	O
illness	O
were	O
recruited	O
to	O
participate	O
in	O
a	O
clinical	O
trial	O
comparing	O
the	O
long-term	O
efficacy	O
of	O
haloperidol	Pharmacological
and	Pharmacological
risperidone	Pharmacological
.	O

The	O
psychopathology	O
,	O
cognitive	O
functioning	O
,	O
early	O
treatment	O
history	O
,	O
and	O
duration	O
of	O
untreated	O
psychosis	O
of	O
these	O
subjects	O
were	O
assessed	O
prior	O
to	O
their	O
assignment	O
to	O
randomized	O
,	O
double-blind	O
treatment	O
.	O

Approximately	O
two-thirds	O
of	O
the	O
subjects	O
were	O
receiving	O
antipsychotic	Pharmacological
treatment	Pharmacological
at	O
the	O
time	O
of	O
assessment	O
;	O
however	O
,	O
the	O
duration	O
of	O
treatment	O
was	O
limited	O
to	O
12	O
weeks	O
or	O
less	O
.	O

RESULTS	O
The	O
severity	O
of	O
negative	O
symptoms	O
at	O
the	O
time	O
of	O
assessment	O
was	O
associated	O
with	O
deficits	O
in	O
memory	O
,	O
verbal	O
fluency	O
,	O
psychomotor	O
speed	O
and	O
executive	O
function	O
.	O

Positive	O
symptoms	O
were	O
not	O
associated	O
with	O
cognitive	O
deficits	O
.	O

Also	O
,	O
the	O
duration	O
of	O
untreated	O
illness	O
(	O
DUI	O
)	O
prior	O
to	O
assessment	O
was	O
not	O
significantly	O
associated	O
with	O
cognitive	O
impairment	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
of	O
first	O
episode	O
schizophrenia	O
patients	O
suggest	O
that	O
a	O
relationship	O
exists	O
between	O
negative	O
symptoms	O
and	O
cognitive	O
dysfunction	O
.	O

However	O
,	O
that	O
relationship	O
accounts	O
for	O
only	O
a	O
minor	O
portion	O
of	O
the	O
variance	O
(	O
i.e.	O
,	O
10-15	O
%	O
)	O
in	O
the	O
severity	O
of	O
cognitive	O
dysfunction	O
after	O
controlling	O
for	O
a	O
number	O
of	O
potentially	O
confounding	O
factors	O
.	O

This	O
finding	O
provides	O
support	O
for	O
the	O
theory	O
that	O
the	O
neurobiological	O
processes	O
that	O
give	O
rise	O
to	O
symptomatology	O
and	O
cognitive	O
dysfunction	O
in	O
schizophrenia	O
are	O
partially	O
overlapping	O
.	O

Effect	O
of	O
marine	Pharmacological
oils	Pharmacological
supplementation	Pharmacological
on	O
coagulation	O
and	O
cellular	O
activation	O
in	O
whole	O
blood	O
.	O

A	O
study	O
was	O
performed	O
to	O
explore	O
the	O
effects	O
of	O
supplemental	O
intake	O
of	O
various	O
marine	O
oils	O
known	O
to	O
be	O
part	O
of	O
the	O
Eskimo	O
diet	O
.	O

Healthy	O
men	O
and	O
women	O
(	O
134	O
)	O
were	O
randomly	O
selected	O
to	O
consume	O
15	O
mL/d	O
of	O
oil	Pharmacological
from	Pharmacological
blubber	Pharmacological
of	Pharmacological
seal	Pharmacological
,	Pharmacological
cod	Pharmacological
liver	Pharmacological
,	Pharmacological
seal/cod	Pharmacological
liver	Pharmacological
,	Physical
blubber	Pharmacological
of	Pharmacological
Minke	Pharmacological
whale	Pharmacological
,	O
or	O
no	Control
oil	Control
for	O
ten	O
weeks	O
.	O

Total	O
cholesterol	O
was	O
unchanged	O
in	O
the	O
oil	O
groups	O
,	O
whereas	O
high	O
density	O
lipoprotein	O
cholesterol	O
increased	O
7	O
%	O
in	O
the	O
seal/cod	Pharmacological
liver	Pharmacological
oil	Pharmacological
(	O
CLO	O
)	O
group	O
(	O
P	O
<	O
0.05	O
)	O
and	O
11	O
%	O
in	O
the	O
whale	Pharmacological
oil	Pharmacological
group	O
(	O
P	O
<	O
0.005	O
)	O
.	O

Triacylglycerol	O
was	O
significantly	O
reduced	O
in	O
the	O
CLO	O
group	O
only	O
.	O

The	O
concentration	O
of	O
prothrombin	O
fragment	O
1	O
+	O
2	O
was	O
reduced	O
25	O
%	O
(	O
P	O
<	O
0.05	O
)	O
after	O
whale	O
oil	O
supplementation	O
.	O

No	O
change	O
in	O
fibrinogen	O
or	O
factor	O
VIIc	O
was	O
detected	O
.	O

Tumor	O
necrosis	O
factor	O
generation	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
blood	O
was	O
30	O
%	O
reduced	O
after	O
whale	O
oil	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
was	O
unaffected	O
by	O
intake	O
of	O
seal	O
or	O
CLO	O
.	O

The	O
LPS-induced	O
tissue	O
factor	O
activity	O
in	O
monocytes	O
was	O
reduced	O
to	O
a	O
significant	O
degree	O
only	O
in	O
the	O
seal/CLO	O
group	O
(	O
34	O
%	O
)	O
and	O
whale	O
oil	O
group	O
(	O
35	O
%	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
most	O
dramatic	O
change	O
in	O
thromboxane	O
B2	O
in	O
LPS-stimulated	O
blood	O
was	O
seen	O
after	O
whale	O
oil	O
intake	O
with	O
44	O
%	O
reduction	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Supplementation	O
of	O
a	O
regular	O
diet	O
with	O
a	O
combination	O
of	O
seal	O
oil	O
and	O
CLO	O
and	O
especially	O
with	O
whale	O
oil	O
seems	O
to	O
have	O
beneficial	O
effects	O
on	O
several	O
products	O
thought	O
to	O
be	O
associated	O
with	O
cardiovascular	O
and	O
thrombotic	O
diseases	O
.	O

Supplemental	Pharmacological
perioperative	Pharmacological
oxygen	Pharmacological
and	O
the	O
risk	O
of	O
surgical	O
wound	O
infection	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
Supplemental	Pharmacological
perioperative	Pharmacological
oxygen	Pharmacological
has	O
been	O
variously	O
reported	O
to	O
halve	O
or	O
double	O
the	O
risk	O
of	O
surgical	O
wound	O
infection	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
hypothesis	O
that	O
supplemental	Pharmacological
oxygen	Pharmacological
reduces	O
infection	O
risk	O
in	O
patients	O
following	O
colorectal	O
surgery	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
A	O
double-blind	O
,	O
randomized	O
controlled	O
trial	O
of	O
300	O
patients	O
aged	O
18	O
to	O
80	O
years	O
who	O
underwent	O
elective	O
colorectal	O
surgery	O
in	O
14	O
Spanish	O
hospitals	O
from	O
March	O
1	O
,	O
2003	O
,	O
to	O
October	O
31	O
,	O
2004	O
.	O

Wound	O
infections	O
were	O
diagnosed	O
by	O
blinded	O
investigators	O
using	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
criteria	O
.	O

Baseline	O
patient	O
characteristics	O
,	O
anesthetic	O
treatment	O
,	O
and	O
potential	O
confounding	O
factors	O
were	O
recorded	O
.	O

INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
either	O
30	Pharmacological
%	Pharmacological
or	Pharmacological
80	Pharmacological
%	Pharmacological
fraction	Pharmacological
of	Pharmacological
inspired	Pharmacological
oxygen	Pharmacological
(	O
FIO2	O
)	O
intraoperatively	O
and	O
for	O
6	O
hours	O
after	O
surgery	O
.	O

Anesthetic	O
treatment	O
and	O
antibiotic	O
administration	O
were	O
standardized	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Any	O
surgical	O
site	O
infection	O
(	O
SSI	O
)	O
;	O
secondary	O
outcomes	O
included	O
return	O
of	O
bowel	O
function	O
and	O
ability	O
to	O
tolerate	O
solid	O
food	O
,	O
ambulation	O
,	O
suture	O
removal	O
,	O
and	O
duration	O
of	O
hospitalization	O
.	O

RESULTS	O
A	O
total	O
of	O
143	O
patients	O
received	O
30	Pharmacological
%	Pharmacological
perioperative	Pharmacological
oxygen	Pharmacological
and	O
148	O
received	O
80	Pharmacological
%	Pharmacological
perioperative	Pharmacological
oxygen	Pharmacological
.	O

Surgical	O
site	O
infection	O
occurred	O
in	O
35	O
patients	O
(	O
24.4	O
%	O
)	O
administered	O
30	O
%	O
FIO2	O
and	O
in	O
22	O
patients	O
(	O
14.9	O
%	O
)	O
administered	O
80	O
%	O
FIO2	O
(	O
P=.04	O
)	O
.	O

The	O
risk	O
of	O
SSI	O
was	O
39	O
%	O
lower	O
in	O
the	O
80	Pharmacological
%	Pharmacological
FIO2	Pharmacological
group	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
0.61	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.38-0.98	O
)	O
vs	O
the	O
30	Pharmacological
%	Pharmacological
FIO2	Pharmacological
group	O
.	O

After	O
adjustment	O
for	O
important	O
covariates	O
,	O
the	O
RR	O
of	O
infection	O
in	O
patients	O
administered	O
supplemental	O
oxygen	O
was	O
0.46	O
(	O
95	O
%	O
CI	O
,	O
0.22-0.95	O
;	O
P	O
=	O
.04	O
)	O
.	O

None	O
of	O
the	O
secondary	O
outcomes	O
varied	O
significantly	O
between	O
the	O
2	O
treatment	O
groups	O
.	O

CONCLUSIONS	O
Patients	O
receiving	O
supplemental	Pharmacological
inspired	Pharmacological
oxygen	Pharmacological
had	O
a	O
significant	O
reduction	O
in	O
the	O
risk	O
of	O
wound	O
infection	O
.	O

Supplemental	Pharmacological
oxygen	Pharmacological
appears	O
to	O
be	O
an	O
effective	O
intervention	O
to	O
reduce	O
SSI	O
in	O
patients	O
undergoing	O
colon	O
or	O
rectal	O
surgery	O
.	O

Trial	O
Registration	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00235456	O
.	O

Comparison	O
of	O
different	O
approaches	O
for	O
assessment	O
of	O
HER2	O
expression	O
on	O
protein	O
and	O
mRNA	O
level	O
:	O
prediction	O
of	O
chemotherapy	Pharmacological
response	O
in	O
the	O
neoadjuvant	O
GeparTrio	O
trial	O
(	O
NCT00544765	O
)	O
.	O

Human	Pharmacological
epidermal	Pharmacological
growth	Pharmacological
factor	Pharmacological
receptor	Pharmacological
2	Pharmacological
(	O
HER2	O
)	O
testing	O
is	O
an	O
essential	O
part	O
of	O
pathological	O
assessment	O
in	O
breast	O
cancer	O
patients	O
,	O
as	O
HER2	O
provides	O
not	O
only	O
prognostic	O
but	O
also	O
predictive	O
information	O
on	O
response	O
to	O
targeted	O
therapy	O
.	O

So	O
far	O
,	O
HER2	O
test	O
accuracy	O
of	O
immunohistochemistry/in	O
situ-hybridization	O
techniques	O
is	O
still	O
under	O
debate	O
,	O
and	O
more	O
reliable	O
and	O
robust	O
technologies	O
are	O
needed	O
.	O

To	O
address	O
this	O
issue	O
and	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
HER2	O
on	O
chemotherapy	Pharmacological
,	O
we	O
investigated	O
a	O
cohort	O
of	O
278	O
patients	O
from	O
the	O
GeparTrio	O
trial	O
,	O
a	O
prospective	O
neoadjuvant	O
anthracycline/taxane-based	O
multicenter	O
study	O
.	O

In	O
the	O
GeparTrio	O
trial	O
,	O
patients	O
were	O
not	O
treated	O
with	O
any	O
anti-HER2	Pharmacological
therapy	Pharmacological
,	O
as	O
this	O
was	O
not	O
standard	O
therapy	O
at	O
this	O
time	O
.	O

The	O
HER2	O
status	O
was	O
analyzed	O
by	O
three	O
different	O
approaches	O
:	O
local	O
and	O
central	O
evaluation	O
using	O
immunohistochemistry	Physical
combined	O
with	O
in	Physical
situ-hybridization	Physical
as	O
well	O
as	O
evaluation	O
of	O
HER2	O
mRNA	O
expression	O
using	O
kinetic	Physical
RT-PCR	Physical
from	O
formalin-fixed	O
,	O
paraffin-embedded	O
(	O
FFPE	O
)	O
tissue	O
samples	O
using	O
a	O
predefined	O
cutoff	O
.	O

HER2	O
overexpression/amplification	O
was	O
observed	O
in	O
37.3	O
%	O
(	O
91/244	O
)	O
and	O
17.9	O
%	O
(	O
41/229	O
)	O
of	O
the	O
informative	O
samples	O
in	O
the	O
local	O
and	O
central	O
evaluations	O
,	O
respectively	O
.	O

Positive	O
HER2	O
mRNA	O
levels	O
were	O
found	O
in	O
19.8	O
%	O
(	O
55/278	O
)	O
.	O

We	O
observed	O
a	O
highly	O
significant	O
correlation	O
between	O
central	O
HER2	O
expression	O
and	O
HER2	O
status	O
measured	O
by	O
kinetic	O
RT-PCR	O
(	O
r	O
=	O
0.856	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
an	O
overall	O
agreement	O
of	O
95.6	O
%	O
(	O
?	O
statistic	O
,	O
0.862	O
,	O
CI	O
0.77-0.94	O
)	O
.	O

Further	O
,	O
central	O
HER2	O
as	O
well	O
as	O
HER2	O
mRNA	O
expression	O
were	O
predictors	O
for	O
a	O
pathological	O
complete	O
response	O
after	O
neoadjuvant	O
anthracycline/taxane-based	O
primary	O
chemotherapy	O
in	O
a	O
univariate	O
binary	O
logistic	O
regression	O
analysis	O
(	O
OR	O
3.29	O
,	O
P	O
=	O
0.002	O
;	O
OR	O
2.65	O
,	O
P	O
=	O
0.004	O
)	O
.	O

The	O
predictive	O
value	O
could	O
be	O
confirmed	O
for	O
the	O
central	O
HER2	O
status	O
by	O
multivariate	O
analysis	O
(	O
OR	O
3.04	O
,	O
P	O
=	O
0.027	O
)	O
.	O

The	O
locally	O
assessed	O
HER2	O
status	O
was	O
not	O
predictive	O
of	O
response	O
to	O
chemotherapy	O
.	O

Our	O
results	O
suggest	O
that	O
standardized	O
methods	O
are	O
preferable	O
for	O
evaluation	O
of	O
HER2	O
status	O
.	O

The	O
kinetic	O
RT-PCR	O
from	O
FFPE	O
tissue	O
might	O
be	O
an	O
additional	O
approach	O
for	O
assessment	O
of	O
this	O
important	O
prognostic	O
and	O
predictive	O
parameter	O
but	O
has	O
to	O
be	O
confirmed	O
by	O
other	O
studies	O
.	O

Validation	O
of	O
a	O
novel	O
satisfaction	Educational
questionnaire	Educational
for	O
patients	O
with	O
rheumatoid	O
arthritis	O
receiving	O
outpatient	O
clinical	O
nurse	O
specialist	O
care	O
,	O
inpatient	O
care	O
,	O
or	O
day	O
patient	O
team	O
care	O
.	O

OBJECTIVES	O
To	O
develop	O
and	O
validate	O
a	O
questionnaire	O
for	O
measuring	O
satisfaction	O
with	O
different	O
forms	O
of	O
complex	O
multidisciplinary	O
care	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
The	O
satisfaction	Educational
questionnaire	Educational
(	O
score	O
range	O
0-100	O
)	O
comprised	O
28	O
items	O
covering	O
11	O
domains	O
.	O

Together	O
with	O
a	O
visual	O
analog	O
scale	O
(	O
VAS	O
,	O
range	O
0-100	O
)	O
on	O
overall	O
satisfaction	O
,	O
the	O
questionnaire	Educational
was	O
applied	O
in	O
210	O
RA	O
patients	O
who	O
participated	O
in	O
a	O
randomized	O
trial	O
comparing	O
3	O
types	O
of	O
multidisciplinary	O
care	O
.	O

RESULTS	O
The	O
questionnaire	O
was	O
returned	O
by	O
174	O
patients	O
(	O
83	O
%	O
)	O
.	O

The	O
questionnaire	O
and	O
VAS	O
scores	O
in	O
the	O
total	O
group	O
were	O
75	O
(	O
SD	O
12	O
)	O
and	O
83	O
(	O
SD	O
20	O
)	O
,	O
respectively	O
.	O

Reliability	O
analysis	O
showed	O
Cronbach	O
's	O
alpha	O
of	O
the	O
questionnaire	O
was	O
0.91	O
.	O

Spearman	O
's	O
correlation	O
coefficient	O
between	O
the	O
satisfaction	O
questionnaire	O
score	O
and	O
VAS	O
score	O
was	O
0.58	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Mean	O
total	O
satisfaction	O
questionnaire	O
scores	O
were	O
72	O
(	O
SD	O
9	O
)	O
,	O
76	O
(	O
SD	O
14	O
)	O
,	O
and	O
78	O
(	O
SD	O
11	O
)	O
,	O
in	O
the	O
nurse	O
specialist	O
,	O
inpatient	O
and	O
day	O
patient	O
groups	O
,	O
respectively	O
(	O
nurse	O
specialist	O
versus	O
day	O
patient	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Significant	O
differences	O
between	O
nurse	O
specialist	O
and	O
day	O
patients	O
were	O
seen	O
in	O
the	O
following	O
domains	O
:	O
waiting	O
time	O
during	O
the	O
treatment	O
,	O
autonomy	O
,	O
coordination	O
,	O
non-financial	O
access	O
,	O
and	O
quality	O
of	O
general	O
information	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
Overall	O
,	O
patients	O
were	O
highly	O
satisfied	O
with	O
the	O
multidisciplinary	O
care	O
they	O
received	O
.	O

Major	O
differences	O
regarding	O
the	O
organization	O
of	O
care	O
were	O
reflected	O
in	O
the	O
results	O
of	O
the	O
questionnaire	O
scores	O
.	O

The	O
satisfaction	O
questionnaire	O
appears	O
to	O
be	O
a	O
useful	O
instrument	O
for	O
measuring	O
satisfaction	O
with	O
complex	O
multidisciplinary	O
care	O
in	O
RA	O
patients	O
.	O

Milk	O
production	O
in	O
cows	O
with	O
endotoxin-induced	Pharmacological
mastitis	Pharmacological
treated	O
with	O
isotonic	Pharmacological
or	Pharmacological
hypertonic	Pharmacological
sodium	Pharmacological
chloride	Pharmacological
solution	Pharmacological
.	O

Milk	O
production	O
was	O
monitored	O
in	O
16	O
cows	O
for	O
6	O
milkings	O
after	O
intramammary	O
infusion	O
of	O
1	O
mg	O
of	O
endotoxin	Pharmacological
in	O
a	O
single	O
forequarter	O
.	O

The	O
cows	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
2	O
treatment	O
groups	O
;	O
8	O
cows	O
were	O
treated	O
with	O
isotonic	Pharmacological
saline	Pharmacological
solution	Pharmacological
and	O
8	O
cows	O
were	O
treated	O
with	O
hypertonic	Pharmacological
saline	Pharmacological
solution	Pharmacological
.	O

Saline	Pharmacological
solutions	O
were	O
administered	O
IV	O
(	O
5	O
ml/kg	O
of	O
body	O
weight	O
)	O
4	O
hours	O
after	O
infusion	O
of	O
endotoxin	Pharmacological
.	O

Mean	O
cumulative	O
change	O
in	O
milk	O
yield	O
and	O
interval	O
change	O
in	O
milk	O
yield	O
were	O
greater	O
in	O
cows	O
treated	O
with	O
isotonic	O
saline	O
solution	O
than	O
in	O
cows	O
treated	O
with	O
hypertonic	Pharmacological
saline	Pharmacological
solution	Pharmacological
.	O

Significant	O
differences	O
between	O
treatment	O
groups	O
were	O
not	O
detected	O
.	O

Concurrent	O
administration	O
of	O
donepezil	Pharmacological
HCl	Pharmacological
and	Pharmacological
digoxin	Pharmacological
:	Pharmacological
assessment	O
of	O
pharmacokinetic	O
changes	O
.	O

AIM	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
pharmacokinetics	O
of	O
donepezil	Pharmacological
HCl	Pharmacological
and	Pharmacological
digoxin	Pharmacological
separately	Pharmacological
,	Pharmacological
and	Pharmacological
in	Pharmacological
combination	Pharmacological
,	O
following	O
administration	O
of	O
single	O
oral	O
doses	O
.	O

Changes	O
in	O
cardiac	O
conduction	O
parameters	O
following	O
drug	O
administration	O
were	O
also	O
assessed	O
.	O

METHODS	O
This	O
was	O
an	O
open-label	O
,	O
randomized	O
,	O
three-period	O
crossover	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n=12	O
)	O
.	O

During	O
each	O
treatment	O
period	O
,	O
subjects	O
received	O
a	O
single	O
dose	O
of	O
either	O
donepezil	Pharmacological
HCl	Pharmacological
(	Pharmacological
5	Pharmacological
mg	Pharmacological
)	Pharmacological
,	O
digoxin	Pharmacological
(	Pharmacological
0.25	Pharmacological
mg	Pharmacological
)	Pharmacological
,	O
or	O
a	Pharmacological
combination	Pharmacological
of	Pharmacological
both	Pharmacological
drugs	Pharmacological
.	O

Each	O
treatment	O
period	O
was	O
followed	O
by	O
a	O
2-week	O
,	O
drug-free	O
washout	O
period	O
.	O

RESULTS	O
All	O
12	O
volunteers	O
completed	O
the	O
study	O
without	O
incident	O
.	O

No	O
statistically	O
significant	O
differences	O
in	O
donepezil	O
pharmacokinetics	O
(	O
Cmax	O
,	O
tmax	O
,	O
AUC	O
(	O
0-120	O
)	O
,	O
AUC	O
(	O
0-infinity	O
)	O
or	O
t1/2	O
)	O
were	O
observed	O
when	O
donepezil	Pharmacological
administered	Pharmacological
alone	Pharmacological
was	O
compared	O
with	O
donepezil	Pharmacological
administered	Pharmacological
in	O
combination	O
with	O
digoxin	Pharmacological
.	O

Similarly	O
,	O
no	O
statistically	O
significant	O
differences	O
in	O
digoxin	Pharmacological
pharmacokinetics	O
were	O
observed	O
when	O
digoxin	O
was	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
donepezil	O
.	O

No	O
clinically	O
relevant	O
changes	O
in	O
cardiac	O
conduction	O
(	O
lead	O
II	O
ECG	O
)	O
were	O
observed	O
in	O
any	O
subject	O
during	O
any	O
treatment	O
period	O
.	O

CONCLUSIONS	O
Co-administration	O
of	O
single	O
doses	O
of	O
donepezil	O
HCl	O
(	O
5	O
mg	O
)	O
and	O
digoxin	O
(	O
0.25	O
mg	O
)	O
produced	O
no	O
changes	O
in	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	O
.	O

In	O
addition	O
,	O
co-administration	O
produced	O
no	O
changes	O
in	O
cardiac	O
conduction	O
parameters	O
during	O
the	O
24	O
h	O
of	O
telemetry	O
monitoring	O
following	O
drug	O
administration	O
.	O

Ongoing	Pharmacological
Telmisartan	Pharmacological
Alone	Pharmacological
and	Pharmacological
in	Pharmacological
Combination	Pharmacological
With	Pharmacological
Ramipril	Pharmacological
Global	Pharmacological
Endpoint	Pharmacological
Trial	Pharmacological
(	Pharmacological
ONTARGET	Pharmacological
)	Pharmacological
:	Pharmacological
implications	O
for	O
reduced	O
cardiovascular	O
risk	O
.	O

The	O
recently	O
published	O
Ongoing	Pharmacological
Telmisartan	Pharmacological
Alone	Pharmacological
and	Pharmacological
in	Pharmacological
Combination	Pharmacological
With	Pharmacological
Ramipril	Pharmacological
Global	Pharmacological
Endpoint	Pharmacological
Trial	Pharmacological
(	Pharmacological
ONTARGET	Pharmacological
)	Pharmacological
in	O
patients	O
with	O
vascular	O
disease	O
or	O
high-risk	O
diabetes	O
,	O
as	O
the	O
largest	O
published	O
comparative	O
trial	O
of	O
these	O
agent	O
classes	O
,	O
provides	O
further	O
evidence	O
concerning	O
the	O
comparison	O
between	O
the	O
angiotensin-receptor	Pharmacological
blockers	Pharmacological
(	Pharmacological
ARBs	Pharmacological
)	Pharmacological
and	O
the	O
angiotensin-converting	Pharmacological
enzyme	Pharmacological
inhibitors	Pharmacological
(	Pharmacological
ACEIs	Pharmacological
)	Pharmacological
.	Pharmacological

In	O
this	O
trial	O
,	O
telmisartan	Pharmacological
(	Pharmacological
an	Pharmacological
ARB	Pharmacological
)	Pharmacological
was	O
non-inferior	O
to	O
ramipril	Pharmacological
(	Pharmacological
an	Pharmacological
ACEI	Pharmacological
)	Pharmacological
in	O
reducing	O
fatal	O
and	O
nonfatal	O
cardiovascular	O
events	O
.	O

Moreover	O
,	O
ONTARGET	Physical
is	O
an	O
example	O
of	O
a	O
high-quality	O
noninferiority	O
trial	O
.	O

However	O
,	O
the	O
combination	O
of	O
the	O
2	O
agents	O
was	O
associated	O
with	O
more	O
adverse	O
effects	O
without	O
an	O
increase	O
in	O
benefit	O
.	O

The	O
study	O
differed	O
from	O
several	O
other	O
comparative	O
studies	O
in	O
which	O
the	O
dose	O
and	O
choice	O
of	O
ACEI	Physical
was	O
left	O
to	O
individual	O
physicians	O
.	O

Further	O
,	O
in	O
ONTARGET	Pharmacological
,	O
the	O
ACEI	Pharmacological
was	O
not	O
titrated	O
to	O
the	O
maximum	O
dose	O
and	O
patients	O
with	O
heart	O
failure	O
were	O
excluded	O
.	O

Prevention	O
of	O
coronary	O
spasm	O
by	O
nicorandil	Pharmacological
:	Pharmacological
comparison	O
with	O
nifedipine	Pharmacological
.	Pharmacological

The	O
efficacy	O
of	O
nicorandil	Pharmacological
was	O
compared	O
with	O
that	O
of	O
nifedipine	Pharmacological
in	O
13	O
patients	O
with	O
vasospastic	O
angina	O
enrolled	O
in	O
a	O
randomized	O
,	O
placebo-controlled	Physical
,	O
crossover	O
study	O
.	O

All	O
patients	O
had	O
a	O
coronary	O
spasm	O
during	O
coronary	O
arteriography	O
,	O
either	O
spontaneously	O
or	O
ergometrine-induced	O
.	O

During	O
two	O
consecutive	O
periods	O
of	O
2	O
days	O
,	O
patients	O
received	O
active	Pharmacological
drugs	Pharmacological
or	O
placebo	Pharmacological
in	O
a	O
randomized	O
order	O
.	O

Each	O
patient	O
received	O
single	O
oral	O
doses	O
of	O
30	O
mg	O
nicorandil	Pharmacological
,	O
10	O
mg	O
nifedipine	Pharmacological
,	O
and	O
,	O
on	O
2	O
days	O
,	O
a	O
placebo	Pharmacological
.	O

One	O
hour	O
after	O
drug	O
intake	O
,	O
patients	O
underwent	O
an	O
ergometrine	O
test	O
with	O
increasing	O
doses	O
of	O
Methergin	Pharmacological
(	Pharmacological
ergometrine	Pharmacological
)	Pharmacological
(	O
0.05	O
,	O
0.10	O
,	O
0.20	O
,	O
and	O
0.40	O
mg	O
every	O
5	O
min	O
)	O
.	O

After	O
placebo	Pharmacological
,	O
the	O
tests	O
always	O
were	O
positive	O
,	O
and	O
the	O
ECG	O
changes	O
occurred	O
at	O
the	O
same	O
+/-	O
1	O
dose	O
of	O
ergometrine	Pharmacological
in	O
10	O
cases	O
,	O
showing	O
good	O
reproducibility	O
.	O

After	O
nicorandil	Pharmacological
,	O
the	O
tests	O
were	O
negative	O
in	O
nine	O
patients	O
and	O
positive	O
for	O
a	O
higher	O
or	O
lower	O
dose	O
of	O
ergometrine	Pharmacological
in	O
three	O
and	O
one	O
patient	O
,	O
respectively	O
(	O
p	O
=	O
0.0034	O
vs.	O
placebo	Pharmacological
)	Pharmacological
.	O

After	O
nifedipine	Pharmacological
,	O
the	O
tests	O
were	O
negative	O
in	O
five	O
patients	O
and	O
positive	O
for	O
a	O
higher	O
or	O
the	O
same	O
dose	O
of	O
ergometrine	Pharmacological
in	O
four	O
and	O
four	O
patients	O
,	O
respectively	O
(	O
p	O
=	O
0.0039	O
vs.	O
placebo	Pharmacological
)	O
.	O

Nifedipine	Pharmacological
(	O
10	O
mg	O
)	O
and	O
nicorandil	O
(	O
30	O
mg	O
)	O
were	O
equally	O
effective	O
in	O
eight	O
patients	O
;	O
in	O
the	O
remaining	O
five	O
patients	O
,	O
nicorandil	Pharmacological
had	O
better	O
results	O
(	O
p	O
=	O
0.06	O
)	O
.	O

Nicorandil	Pharmacological
(	O
30	O
mg	O
)	O
prevents	O
ergometrine-induced	O
coronary	O
spasm	O
.	O

This	O
compound	O
may	O
be	O
beneficial	O
in	O
patients	O
with	O
vasospastic	O
angina	O
.	O

Effect	O
of	O
phenylephrine	Pharmacological
on	O
the	O
haemodynamic	O
state	O
and	O
cerebral	O
oxygen	O
saturation	O
during	O
anaesthesia	O
in	O
the	O
upright	O
position	O
.	O

BACKGROUND	O
The	O
upright	O
sitting	O
or	O
beachchair	O
position	O
is	O
associated	O
with	O
hypotension	O
,	O
risk	O
of	O
cerebral	O
hypoperfusion	O
,	O
and	O
cerebral	O
injury	O
.	O

We	O
hypothesized	O
that	O
by	O
increasing	O
arterial	O
pressure	O
with	O
phenylephrine	Pharmacological
administration	O
,	O
cerebral	O
perfusion	O
,	O
and	O
postoperative	O
recovery	O
would	O
be	O
improved	O
.	O

METHODS	O
Thirty-four	O
patients	O
undergoing	O
elective	O
shoulder	O
surgery	O
were	O
randomized	O
to	O
receive	O
either	O
saline	Pharmacological
or	Pharmacological
phenylephrine	Pharmacological
infusion	Pharmacological
(	Pharmacological
PE	Pharmacological
)	Pharmacological
5	O
min	O
before	O
being	O
placed	O
in	O
the	O
upright	O
position	O
.	O

Simultaneous	O
measurements	O
of	O
mean	O
arterial	O
pressure	O
,	O
cerebral	O
oxygen	O
saturation	O
,	O
middle	O
cerebral	O
artery	O
velocity	O
,	O
and	O
cardiac	O
function	O
using	O
transthoracic	O
echocardiography	O
were	O
made	O
.	O

Postoperative	O
neurocognitive	O
function	O
was	O
assessed	O
.	O

RESULTS	O
At	O
the	O
commencement	O
of	O
PE	O
,	O
mean	O
(	O
SD	O
)	O
cerebral	O
oxygen	O
saturation	O
significantly	O
decreased	O
from	O
77	O
(	O
10	O
)	O
to	O
67	O
(	O
13	O
)	O
%	O
(	O
P=0.02	O
)	O
,	O
and	O
further	O
to	O
59	O
(	O
11	O
)	O
%	O
on	O
upright	O
positioning	O
.	O

The	O
level	O
of	O
cerebral	O
saturation	O
upright	O
was	O
not	O
significantly	O
different	O
to	O
patients	O
receiving	O
saline	O
(	O
P=0.07	O
)	O
,	O
with	O
values	O
remaining	O
at	O
room-air	O
levels	O
.	O

Middle	O
cerebral	O
artery	O
blood	O
velocity	O
increased	O
by	O
20	O
%	O
(	O
P=0.04	O
)	O
.	O

Phenylephrine	O
prevented	O
hypotension	O
in	O
the	O
upright	O
position	O
primarily	O
by	O
maintaining	O
preload	O
and	O
increasing	O
systemic	O
vascular	O
resistance	O
(	O
P=0.01	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
cardiac	O
output	O
.	O

No	O
postoperative	O
neurocognitive	O
dysfunction	O
was	O
identified	O
.	O

CONCLUSIONS	O
Despite	O
maintaining	O
arterial	O
pressure	O
with	O
phenylephrine	Pharmacological
,	O
cerebral	O
desaturation	O
occurred	O
with	O
upright	O
positioning	O
.	O

Cerebral	O
oxygen	O
saturation	O
can	O
provide	O
a	O
valuable	O
endpoint	O
when	O
evaluating	O
the	O
effect	O
of	O
vasopressor	O
therapy	O
on	O
cerebral	O
perfusion	O
.	O

Efficacy	O
of	O
ebrotidine	Pharmacological
and	O
ranitidine	Pharmacological
combined	O
with	O
amoxicillin	Pharmacological
and	O
metronidazole	Pharmacological
in	O
the	O
eradication	O
of	O
Helicobacter	O
pylori	O
in	O
patients	O
with	O
duodenal	O
ulcer	O
.	O

This	O
double-blind	O
,	O
randomized	O
,	O
phase	O
III	O
clinical	O
trial	O
was	O
carried	O
out	O
in	O
two	O
parallel	O
groups	O
to	O
assess	O
the	O
efficacy	O
of	O
ebrotidine	Pharmacological
(	Pharmacological
N-	Pharmacological
[	Pharmacological
(	Pharmacological
E	Pharmacological
)	Pharmacological
-	Pharmacological
[	Pharmacological
[	Pharmacological
2-	Pharmacological
[	Pharmacological
[	Pharmacological
[	Pharmacological
2-	Pharmacological
[	Pharmacological
(	Pharmacological
diaminomethylene	Pharmacological
)	Pharmacological
amino	Pharmacological
]	Pharmacological
-4-thiazolyl	Pharmacological
]	Pharmacological
methyl	Pharmacological
]	Pharmacological
thio	Pharmacological
]	Pharmacological
ethyl	Pharmacological
]	Pharmacological
amino	Pharmacological
]	Pharmacological
methylene	Pharmacological
]	Pharmacological
-4-bromo-benzenesulfonamide	Pharmacological
,	Pharmacological
CAS	Pharmacological
100981-43-9	Pharmacological
,	Pharmacological
FI-3542	Pharmacological
)	Pharmacological
400	Pharmacological
mg	Pharmacological
and	O
ranitidine	Pharmacological
300	Pharmacological
mg	Pharmacological
given	O
in	O
single	O
evening	O
dose	O
,	O
combined	O
with	O
amoxicillin	Pharmacological
750	O
mg	O
and	O
metronidazole	Pharmacological
500	O
mg	O
three	O
times	O
daily	O
for	O
14	O
days	O
,	O
in	O
the	O
eradication	O
of	O
Helicobacter	O
pylori	O
in	O
patients	O
with	O
duodenal	O
ulcer	O
.	O

Thirty	O
patients	O
were	O
included	O
,	O
divided	O
into	O
two	O
groups	O
of	O
15	O
,	O
to	O
whom	O
one	O
of	O
the	O
study	O
therapies	O
was	O
administered	O
based	O
on	O
a	O
randomization	O
code	O
.	O

Clinical	O
and	O
endoscopic	O
controls	O
were	O
performed	O
4	O
,	O
6	O
and	O
8	O
weeks	O
after	O
the	O
onset	O
of	O
the	O
treatment	O
.	O

No	O
differences	O
were	O
seen	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
regard	O
to	O
demographic	O
parameters	O
and	O
clinical	O
histories	O
.	O

They	O
were	O
both	O
perfectly	O
homogeneous	O
.	O

There	O
were	O
no	O
differences	O
between	O
the	O
eradication	O
of	O
both	O
therapies	O
in	O
both	O
the	O
antrum	O
and	O
gastric	O
body	O
samples	O
(	O
over	O
80	O
%	O
eradication	O
)	O
,	O
allowing	O
the	O
results	O
to	O
be	O
classified	O
as	O
satisfactory	O
.	O

Moreover	O
,	O
perfect	O
control	O
was	O
achieved	O
through	O
the	O
study	O
of	O
clinical	O
symptoms	O
,	O
which	O
even	O
disappeared	O
in	O
some	O
cases	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
healing	O
rate	O
of	O
the	O
duodenal	O
ulcer	O
after	O
four	O
weeks	O
,	O
86.7	O
%	O
being	O
achieved	O
for	O
both	O
groups	O
.	O

Catheter	Physical
ablation	Physical
of	Physical
stable	Physical
ventricular	Physical
tachycardia	Physical
before	O
defibrillator	Surgical
implantation	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
VTACH	O
)	O
:	O
a	O
multicentre	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
In	O
patients	O
with	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
and	O
a	O
history	O
of	O
myocardial	O
infarction	O
,	O
intervention	O
with	O
an	O
implantable	Surgical
cardioverter	Surgical
defibrillator	Surgical
(	Surgical
ICD	Surgical
)	Surgical
can	O
prevent	O
sudden	O
cardiac	O
death	O
and	O
thereby	O
reduce	O
total	O
mortality	O
.	O

However	O
,	O
ICD	O
shocks	O
are	O
painful	O
and	O
do	O
not	O
provide	O
complete	O
protection	O
against	O
sudden	O
cardiac	O
death	O
.	O

We	O
assessed	O
the	O
potential	O
benefit	O
of	O
catheter	Physical
ablation	Physical
before	O
implantation	O
of	O
a	O
cardioverter	O
defibrillator	O
.	O

METHODS	O
The	O
Ventricular	O
Tachycardia	O
Ablation	O
in	O
Coronary	O
Heart	O
Disease	O
(	O
VTACH	O
)	O
study	O
was	O
a	O
prospective	O
,	O
open	O
,	O
randomised	O
controlled	O
trial	O
,	O
undertaken	O
in	O
16	O
centres	O
in	O
four	O
European	O
countries	O
.	O

Patients	O
aged	O
18-80	O
years	O
were	O
eligible	O
for	O
enrolment	O
if	O
they	O
had	O
stable	O
VT	O
,	O
previous	O
myocardial	O
infarction	O
,	O
and	O
reduced	O
left-ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
;	O
<	O
or=50	O
%	O
)	O
.	O

110	O
patients	O
were	O
randomly	O
allocated	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	Physical
catheter	Physical
ablation	Physical
and	Physical
an	Physical
ICD	Physical
(	Physical
ablation	Physical
group	Physical
,	Physical
n=54	Physical
)	Physical
or	O
ICD	Control
alone	Control
(	Control
control	Control
group	Control
,	Control
n=56	Control
)	Control
.	O

Randomisation	O
was	O
done	O
by	O
computer-generated	O
randomly	O
permuted	O
blocks	O
and	O
stratified	O
by	O
centre	O
and	O
LVEF	O
(	O
<	O
or=30	O
%	O
or	O
>	O
30	O
%	O
)	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
at	O
least	O
1	O
year	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
time	O
to	O
first	O
recurrence	O
of	O
VT	O
or	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
(	O
ITT	O
)	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT00919373	O
.	O

FINDINGS	O
107	O
patients	O
were	O
included	O
in	O
the	O
ITT	O
population	O
(	O
ablation	Physical
group	Physical
,	O
n=52	O
;	O
control	Control
group	O
,	O
n=55	O
)	O
.	O

Two	O
patients	O
(	O
one	O
in	O
each	O
group	O
)	O
withdrew	O
consent	O
immediately	O
after	O
randomisation	O
without	O
any	O
follow-up	O
data	O
and	O
one	O
patient	O
(	O
ablation	O
group	O
)	O
was	O
excluded	O
because	O
of	O
a	O
protocol	O
violaton	O
.	O

Mean	O
follow-up	O
was	O
22.5	O
months	O
(	O
SD	O
9.0	O
)	O
.	O

Time	O
to	O
recurrence	O
of	O
VT	O
or	O
VF	O
was	O
longer	O
in	O
the	O
ablation	Physical
group	Physical
(	O
median	O
18.6	O
months	O
[	O
lower	O
quartile	O
2.4	O
,	O
upper	O
quartile	O
not	O
determinable	O
]	O
)	O
than	O
in	O
the	O
control	Control
group	Control
(	O
5.9	O
months	O
[	O
IQR	O
0.8-26.7	O
]	O
)	O
.	O

At	O
2	O
years	O
,	O
estimates	O
for	O
survival	O
free	O
from	O
VT	O
or	O
VF	O
were	O
47	O
%	O
in	O
the	O
ablation	Physical
group	Physical
and	O
29	O
%	O
in	O
the	O
control	Control
group	Control
(	O
hazard	O
ratio	O
0.61	O
;	O
95	O
%	O
CI	O
0.37-0.99	O
;	O
p=0.045	O
)	O
.	O

Complications	O
related	O
to	O
the	O
ablation	O
procedure	O
occurred	O
in	O
two	O
patients	O
;	O
no	O
deaths	O
occurred	O
within	O
30	O
days	O
after	O
ablation	O
.	O

15	O
device-related	O
complications	O
requiring	O
surgical	O
intervention	O
occurred	O
in	O
13	O
patients	O
(	O
ablation	Physical
group	Physical
,	O
four	O
;	O
control	Control
group	Control
,	O
nine	O
)	O
.	O

Nine	O
patients	O
died	O
during	O
the	O
study	O
(	O
ablation	Physical
group	O
,	O
five	O
;	O
control	Control
group	O
,	O
four	O
)	O
.	O

INTERPRETATION	O
Prophylactic	Physical
VT	Physical
ablation	Physical
before	O
defibrillator	Surgical
implantation	Surgical
seemed	O
to	O
prolong	O
time	O
to	O
recurrence	O
of	O
VT	O
in	O
patients	O
with	O
stable	O
VT	O
,	O
previous	O
myocardial	O
infarction	O
,	O
and	O
reduced	O
LVEF	O
.	O

Prophylactic	Physical
catheter	Physical
ablation	Physical
should	O
therefore	O
be	O
considered	O
before	O
implantation	O
of	O
a	O
cardioverter	Surgical
defibrillator	Surgical
in	O
such	O
patients	O
.	O

FUNDING	O
St	O
Jude	O
Medical	O
.	O

Effects	O
of	O
a	O
standardized	Educational
pamphlet	Educational
on	O
insomnia	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

OBJECTIVE	O
Sleep	O
difficulties	O
are	O
common	O
reasons	O
why	O
parents	O
seek	O
medical	O
intervention	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
.	O

We	O
determined	O
whether	O
a	O
pamphlet	Educational
alone	O
could	O
be	O
used	O
by	O
parents	O
to	O
help	O
their	O
child	O
's	O
insomnia	O
.	O

METHODS	O
Thirty-six	O
children	O
with	O
ASD	O
,	O
ages	O
2	O
to	O
10	O
years	O
,	O
were	O
enrolled	O
.	O

All	O
had	O
prolonged	O
sleep	O
latency	O
confirmed	O
by	O
actigraphy	O
showing	O
a	O
mean	O
sleep	O
latency	O
of	O
30	O
minutes	O
or	O
more	O
.	O

Parents	O
were	O
randomly	O
assigned	O
to	O
receive	O
the	O
sleep	Educational
education	Educational
pamphlet	Educational
or	Educational
no	Educational
intervention	Control
.	O

Children	O
wore	O
an	O
actigraphy	Other
device	Other
to	O
record	O
baseline	O
sleep	O
parameters	O
,	O
with	O
the	O
primary	O
outcome	O
variable	O
being	O
change	O
in	O
sleep	O
latency	O
.	O

Actigraphy	O
data	O
were	O
collected	O
a	O
second	O
time	O
2	O
weeks	O
after	O
the	O
parent	O
received	O
the	O
randomization	O
assignment	O
and	O
analyzed	O
by	O
using	O
Student	O
's	O
t	O
test	O
.	O

Parents	O
were	O
also	O
asked	O
a	O
series	O
of	O
questions	O
to	O
gather	O
information	O
about	O
the	O
pamphlet	Educational
and	O
its	O
usefulness	O
.	O

RESULTS	O
Although	O
participants	O
randomized	O
to	O
the	O
2	O
arms	O
did	O
not	O
differ	O
statistically	O
in	O
age	O
,	O
gender	O
,	O
socioeconomic	O
status	O
,	O
total	O
Children	O
's	O
Sleep	O
Habits	O
Questionnaire	O
score	O
,	O
or	O
actigraphy	O
parameters	O
,	O
some	O
differences	O
may	O
be	O
large	O
enough	O
to	O
affect	O
results	O
.	O

Mean	O
change	O
in	O
sleep-onset	O
latency	O
did	O
not	O
differ	O
between	O
the	O
randomized	O
groups	O
(	O
pamphlet	Educational
versus	Educational
no	Control
pamphlet	Control
)	O
.	O

Parents	O
commented	O
that	O
the	O
pamphlet	Educational
contained	O
good	O
information	O
,	O
but	O
indicated	O
that	O
it	O
would	O
have	O
been	O
more	O
useful	O
to	O
be	O
given	O
specific	O
examples	O
of	O
how	O
to	O
take	O
the	O
information	O
and	O
put	O
it	O
into	O
practice	O
.	O

CONCLUSIONS	O
A	O
sleep	Educational
education	Educational
pamphlet	Educational
did	O
not	O
appear	O
to	O
improve	O
sleep	O
latency	O
in	O
children	O
with	O
ASDs	O
.	O

Low	O
efficacy	O
of	O
mebendazole	Pharmacological
against	O
hookworm	O
in	O
Vietnam	O
:	O
two	O
randomized	O
controlled	O
trials	O
.	O

Vietnam	O
is	O
participating	O
in	O
a	O
global	O
de-worming	O
effort	O
that	O
aims	O
to	O
treat	O
650	O
million	O
school	O
children	O
regularly	O
by	O
2010	O
.	O

The	O
treatment	O
used	O
in	O
Vietnam	O
is	O
single	O
dose	O
oral	O
mebendazole	Pharmacological
(	Pharmacological
Phardazone	Pharmacological
)	Pharmacological
500	O
mg.	O
We	O
tested	O
the	O
efficacy	O
of	O
single	O
dose	O
mebendazole	Pharmacological
500	O
mg	O
in	O
the	O
therapy	O
of	O
hookworm	O
infection	O
in	O
a	O
randomized	O
double-blind	O
placebo-controlled	Control
trial	O
among	O
271	O
Vietnamese	O
schoolchildren	O
.	O

The	O
treatment	O
efficacy	O
of	O
single	O
dose	O
mebendazole	Pharmacological
in	O
children	O
did	O
not	O
differ	O
significantly	O
from	O
placebo	Control
,	O
with	O
a	O
reduction	O
in	O
mean	O
eggs	O
per	O
gram	O
of	O
feces	O
relative	O
to	O
placebo	Control
of	O
31	O
%	O
(	O
95	O
%	O
CI	O
-9	O
to	O
56	O
%	O
,	O
P	O
=	O
0.1	O
)	O
.	O

In	O
light	O
of	O
these	O
findings	O
we	O
then	O
carried	O
out	O
a	O
similar	O
randomized	O
trial	O
comparing	O
triple	O
dose	O
mebendazole	Pharmacological
,	O
single	O
dose	O
albendazole	Pharmacological
,	O
and	O
triple	O
dose	O
albendazole	Pharmacological
against	O
placebo	Control
in	O
209	O
adults	O
in	O
the	O
same	O
area	O
.	O

The	O
estimated	O
reduction	O
in	O
mean	O
post-treatment	O
eggs	O
per	O
gram	O
of	O
feces	O
relative	O
to	O
placebo	Control
was	O
63	O
%	O
(	O
95	O
%	O
CI	O
30-81	O
%	O
)	O
for	O
triple	O
mebendazole	Pharmacological
,	O
75	O
%	O
(	O
47-88	O
%	O
)	O
for	O
single	O
albendazole	Pharmacological
,	O
and	O
88	O
%	O
(	O
58-97	O
%	O
)	O
for	O
triple	O
albendazole	Pharmacological
.	O

Our	O
results	O
suggest	O
that	O
single	O
dose	O
oral	O
mebendazole	O
has	O
low	O
efficacy	O
against	O
hookworm	O
infection	O
in	O
Vietnam	O
,	O
and	O
that	O
it	O
should	O
be	O
replaced	O
by	O
albendazole	Pharmacological
.	O

These	O
findings	O
are	O
of	O
major	O
public	O
health	O
relevance	O
given	O
the	O
opportunity	O
costs	O
of	O
treating	O
entire	O
populations	O
with	O
ineffective	O
therapies	O
.	O

We	O
recommend	O
that	O
efficacy	O
of	O
anti-helminth	Pharmacological
therapies	Pharmacological
is	O
pilot	O
tested	O
before	O
implementation	O
of	O
national	O
gut	O
worm	O
control	O
programs	O
.	O

The	O
effect	O
of	O
inhaled	O
leukotriene	Pharmacological
D4	Pharmacological
and	O
methacholine	Pharmacological
on	O
sputum	O
cell	O
differentials	O
in	O
asthma	O
.	O

The	O
cysteinyl	Pharmacological
leukotriene	Pharmacological
LTE4	Pharmacological
has	O
been	O
shown	O
to	O
induce	O
airway	O
eosinophilia	O
in	O
asthmatics	O
in	O
vivo	O
.	O

This	O
phenomenon	O
has	O
not	O
yet	O
been	O
reported	O
for	O
LTD4	O
.	O

Hence	O
,	O
we	O
examined	O
the	O
effect	O
of	O
inhaled	O
LTD4	Pharmacological
and	O
a	O
control	O
bronchoconstrictor	O
agent	O
,	O
methacholine	O
,	O
on	O
cell	O
differentials	O
in	O
hypertonic	O
saline-induced	O
whole	O
sputum	O
samples	O
of	O
12	O
nonsmoking	O
atopic	O
asthmatic	O
subjects	O
(	O
three	O
women	O
,	O
nine	O
men	O
;	O
21	O
to	O
29	O
yr	O
of	O
age	O
;	O
FEV1	O
,	O
74	O
to	O
120	O
%	O
pred	O
;	O
PC20FEV1	O
methacholine	O
<	O
9.6	O
mg/ml	O
)	O
.	O

The	O
study	O
had	O
a	O
cross-over	O
,	O
placebo-controlled	O
design	O
consisting	O
of	O
4	O
d	O
separated	O
by	O
>	O
or	O
=	O
1	O
wk	O
.	O

On	O
each	O
randomized	O
study	O
day	O
,	O
the	O
subjects	O
inhaled	O
five	O
serial	O
doses	O
of	O
either	O
LTD4	Pharmacological
(	O
mean	O
cumulative	O
concentration	O
:	O
95.7	O
microM	O
)	O
or	O
methacholine	Pharmacological
(	O
mean	O
cumulative	O
concentration	O
:	O
542	O
mM	O
)	O
or	O
five	O
doses	O
of	O
their	O
respective	O
diluents	O
(	Pharmacological
PBS/ethanol	Pharmacological
or	O
PBS	O
)	O
.	O

The	O
airway	O
response	O
was	O
measured	O
by	O
FEV1	O
,	O
followed	O
by	O
sputum	O
induction	O
with	O
4.5	O
%	O
NaCl	O
,	O
4	O
h	O
postchallenge	O
.	O

Inflammatory	O
cells	O
(	O
>	O
or	O
=	O
250	O
)	O
were	O
counted	O
twice	O
on	O
coded	O
cytospins	O
and	O
expressed	O
as	O
percentages	O
of	O
nonsquamous	O
cells	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
maximal	O
percent	O
fall	O
in	O
FEV1	O
from	O
baseline	O
between	O
LTD4	O
(	O
mean	O
+/-	O
SEM	O
,	O
49.5	O
+/-	O
4.4	O
%	O
fall	O
)	O
and	O
methacholine	O
(	O
mean	O
+/-	O
SEM	O
,	O
55.9	O
+/-	O
3.4	O
%	O
fall	O
)	O
(	O
p	O
=	O
0.11	O
)	O
.	O

LTD4	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
percentage	O
of	O
sputum	O
eosinophils	O
as	O
compared	O
with	O
its	O
diluent	O
(	O
mean	O
+/-	O
SD	O
,	O
26.6	O
+/-	O
21.3	O
%	O
and	O
10.2	O
+/-	O
8.8	O
%	O
,	O
respectively	O
;	O
p	O
=	O
0.025	O
)	O
,	O
whereas	O
a	O
similar	O
trend	O
for	O
methacholine	O
failed	O
to	O
reach	O
significance	O
(	O
mean	O
+/-	O
SD	O
,	O
19.1	O
+/-	O
22.9	O
%	O
and	O
7.8	O
+/-	O
5.8	O
%	O
,	O
respectively	O
;	O
p	O
=	O
0.11	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
changes	O
in	O
the	O
percentage	O
of	O
sputum	O
eosinophils	O
between	O
LTD4	O
and	O
methacholine	O
(	O
mean	O
difference	O
+/-	O
SD	O
,	O
7.5	O
+/-	O
12.5	O
%	O
eosinophils	O
;	O
p	O
=	O
0.09	O
)	O
.	O

We	O
conclude	O
that	O
LTD4	O
induces	O
eosinophilia	O
in	O
sputum	O
of	O
asthmatic	O
subjects	O
4	O
h	O
after	O
inhalation	O
.	O

Our	O
data	O
suggest	O
that	O
LTD4	O
recruits	O
eosinophils	O
into	O
the	O
airways	O
of	O
asthmatics	O
in	O
vivo	O
,	O
possibly	O
by	O
virtue	O
of	O
direct	O
or	O
indirect	O
chemotactic	O
properties	O
,	O
whereas	O
an	O
additional	O
effect	O
of	O
vigourous	O
airway	O
narrowing	O
per	O
se	O
can	O
not	O
be	O
excluded	O
.	O

JobTIPS	O
:	O
a	O
transition	O
to	O
employment	O
program	O
for	O
individuals	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
evaluated	O
the	O
effectiveness	O
of	O
an	O
internet	Educational
accessed	Educational
training	Educational
program	Educational
that	O
included	O
Theory	O
of	O
Mind-based	O
guidance	O
,	O
video	O
models	O
,	O
visual	O
supports	O
,	O
and	O
virtual	O
reality	O
practice	O
sessions	O
in	O
teaching	O
appropriate	O
job	O
interview	O
skills	O
to	O
individuals	O
with	O
high	O
functioning	O
Autism	O
Spectrum	O
Disorders	O
.	O

In	O
a	O
randomized	O
study	O
,	O
twenty-two	O
youth	O
,	O
ages	O
16-19	O
,	O
were	O
evaluated	O
during	O
two	O
employment	O
interviews	O
.	O

Half	O
received	O
a	O
training	O
intervention	O
following	O
the	O
initial	O
interview	O
and	O
the	O
half	O
who	O
served	O
as	O
a	O
contrast	O
group	O
did	O
not	O
.	O

Their	O
performance	O
pre	O
and	O
post	O
intervention	O
was	O
assessed	O
by	O
four	O
independent	O
raters	O
using	O
a	O
scale	O
that	O
included	O
evaluation	O
of	O
both	O
Content	O
and	O
Delivery	O
.	O

Results	O
suggest	O
that	O
youth	O
who	O
completed	O
the	O
JobTIPS	O
employment	O
program	O
demonstrated	O
significantly	O
more	O
effective	O
verbal	O
content	O
skills	O
than	O
those	O
who	O
did	O
not	O
.	O

Safety	O
and	O
efficacy	O
of	O
oral	O
DMSA	Pharmacological
therapy	Pharmacological
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
:	O
Part	O
A	O
--	O
medical	O
results	O
.	O

BACKGROUND	O
This	O
study	O
investigated	O
the	O
effect	O
of	O
oral	Pharmacological
dimercapto	Pharmacological
succinic	Pharmacological
acid	Pharmacological
(	Pharmacological
DMSA	Pharmacological
)	Pharmacological
therapy	Pharmacological
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
ages	O
3-8	O
years	O
.	O

METHODS	O
Phase	O
1	O
involved	O
65	O
children	O
who	O
received	O
one	O
round	O
of	O
DMSA	Pharmacological
(	O
3	O
days	O
)	O
.	O

Participants	O
who	O
had	O
high	O
urinary	O
excretion	O
of	O
toxic	O
metals	O
were	O
selected	O
to	O
continue	O
on	O
to	O
phase	O
2	O
.	O

In	O
phase	O
2	O
,	O
49	O
participants	O
were	O
randomly	O
assigned	O
in	O
a	O
double-blind	O
design	O
to	O
receive	O
an	O
additional	O
6	O
rounds	O
of	O
either	O
DMSA	Pharmacological
or	O
placebo	Control
.	O

RESULTS	O
DMSA	O
greatly	O
increased	O
the	O
excretion	O
of	O
lead	O
,	O
substantially	O
increased	O
excretion	O
of	O
tin	O
and	O
bismuth	O
,	O
and	O
somewhat	O
increased	O
the	O
excretion	O
of	O
thallium	O
,	O
mercury	O
,	O
antimony	O
,	O
and	O
tungsten	O
.	O

There	O
was	O
some	O
increase	O
in	O
urinary	O
excretion	O
of	O
essential	O
minerals	O
,	O
especially	O
potassium	O
and	O
chromium	O
.	O

The	O
Phase	O
1	O
single	O
round	O
of	O
DMSA	Pharmacological
led	O
to	O
a	O
dramatic	O
normalization	O
of	O
RBC	O
glutathione	O
in	O
almost	O
all	O
cases	O
,	O
and	O
greatly	O
improved	O
abnormal	O
platelet	O
counts	O
,	O
suggesting	O
a	O
significant	O
decrease	O
in	O
inflammation	O
.	O

CONCLUSION	O
Overall	O
,	O
DMSA	Pharmacological
therapy	O
seems	O
to	O
be	O
reasonably	O
safe	O
,	O
effective	O
in	O
removing	O
several	O
toxic	O
metals	O
(	O
especially	O
lead	O
)	O
,	O
dramatically	O
effective	O
in	O
normalizing	O
RBC	O
glutathione	O
,	O
and	O
effective	O
in	O
normalizing	O
platelet	O
counts	O
.	O

Only	O
1	O
round	O
(	O
3	O
days	O
)	O
was	O
sufficient	O
to	O
improve	O
glutathione	O
and	O
platelets	O
.	O

Additional	O
rounds	O
increased	O
excretion	O
of	O
toxic	O
metals	O
.	O

Closure	O
of	O
the	O
femoral	O
artery	O
after	O
cardiac	O
catheterization	O
:	O
a	O
comparison	O
of	O
Angio-Seal	O
,	O
StarClose	O
,	O
and	O
manual	O
compression	O
.	O

OBJECTIVES	O
To	O
compare	O
Angio-Seal	Physical
(	Physical
AS	Physical
)	Physical
and	O
StarClose	Physical
(	Physical
SC	Physical
)	Physical
and	O
manual	Physical
compression	Physical
(	Physical
MC	Physical
)	Physical
on	O
efficacy	O
of	O
hemostasis	O
,	O
complication	O
rate	O
,	O
safety	O
of	O
early	O
mobilization	O
,	O
and	O
patient	O
comfort	O
.	O

BACKGROUND	O
Closure	O
of	O
the	O
femoral	O
artery	O
after	O
cardiac	O
catheterization	O
can	O
be	O
obtained	O
through	O
different	O
methods	O
.	O

Today	O
,	O
physicians	O
can	O
choose	O
from	O
a	O
number	O
of	O
different	O
devices	O
to	O
achieve	O
arterial	O
closure	O
.	O

METHODS	O
In	O
a	O
prospective	O
trial	O
450	O
patients	O
were	O
randomized	O
to	O
AS	Physical
,	O
SC	Physical
,	O
or	O
MC	Physical
.	O

Patients	O
were	O
mobilized	O
1	O
to	O
2	O
hr	O
after	O
device	O
placement	O
,	O
and	O
6	O
hr	O
after	O
MC	Physical
.	O

Data	O
were	O
collected	O
during	O
hospital	O
admission	O
and	O
by	O
telephone	O
at	O
one	O
month	O
after	O
hospital	O
discharge	O
.	O

RESULTS	O
Devices	O
were	O
used	O
in	O
138/150	O
allocated	O
to	O
AS	O
and	O
124/150	O
allocated	O
to	O
SC	O
patients	O
(	O
92	O
%	O
vs.	O
83	O
%	O
,	O
P	O
=	O
0.015	O
)	O
Patients	O
with	O
MC	O
experienced	O
more	O
pain	O
during	O
sheath	O
removal	O
than	O
patients	O
receiving	O
a	O
device	O
,	O
and	O
rated	O
their	O
period	O
of	O
bed	O
rest	O
as	O
less	O
comfortable	O
.	O

Oozing	O
and	O
need	O
for	O
pressure	O
bandage	O
at	O
the	O
puncture	O
site	O
were	O
observed	O
in	O
37	O
AS	O
patients	O
and	O
57	O
SC	O
patients	O
(	O
25	O
%	O
vs.	O
38	O
%	O
,	O
P	O
=	O
0.002	O
)	O
.	O

Hematoma	O
occurred	O
in	O
15	O
AS	O
patients	O
,	O
in	O
17	O
SC	O
patients	O
,	O
and	O
in	O
14	O
MC	O
patients	O
(	O
11	O
vs.	O
14	O
vs.	O
9	O
%	O
,	O
ns	O
)	O
.	O

CONCLUSION	O
There	O
is	O
no	O
difference	O
in	O
safety	O
between	O
the	O
three	O
methods	O
of	O
arterial	O
closure	O
.	O

SC	O
was	O
more	O
often	O
not	O
used	O
or	O
successfully	O
deployed	O
.	O

SC	O
patients	O
more	O
often	O
had	O
continuing	O
oozing	O
.	O

On	O
patient	O
comfort	O
,	O
closure	O
devices	O
performed	O
better	O
than	O
MC	O
.	O

Early	O
ambulation	O
in	O
patients	O
with	O
a	O
closure	O
device	O
is	O
safe	O
.	O

AS	O
is	O
the	O
preferred	O
method	O
of	O
arterial	O
closure	O
after	O
cardiac	O
catheterization	O
.	O

Amphotericin	Pharmacological
versus	O
pentamidine	Pharmacological
in	O
antimony-unresponsive	O
kala-azar	O
.	O

We	O
compared	O
the	O
efficacy	O
of	O
amphotericin	Pharmacological
B	Pharmacological
and	O
pentamidine	Pharmacological
isethionate	Pharmacological
in	O
a	O
prospective	O
randomised	O
trial	O
in	O
120	O
uncomplicated	O
and	O
parasitologically	O
confirmed	O
cases	O
of	O
antimony-unresponsive	O
kala-azar	O
.	O

Doses	O
were	O
twenty	O
intramuscular	O
injections	O
of	O
pentamidine	Pharmacological
4	O
mg/kg	O
on	O
alternate	O
days	O
or	O
fourteen	O
definitive	O
doses	O
of	O
amphotericin	Pharmacological
0.5	O
mg/kg	O
infused	O
in	O
5	O
%	O
dextrose	O
on	O
alternate	O
days	O
.	O

48	O
(	O
80	O
%	O
)	O
patients	O
given	O
pentamidine	Pharmacological
showed	O
initial	O
cure	O
and	O
46	O
(	O
77	O
%	O
)	O
showed	O
definitive	O
cure	O
compared	O
with	O
60	O
(	O
100	O
%	O
)	O
and	O
59	O
(	O
98	O
%	O
)	O
cases	O
,	O
respectively	O
,	O
on	O
amphotericin	Pharmacological
(	O
p	O
<	O
0.001	O
)	O
.	O

Amphotericin	Pharmacological
also	O
brought	O
about	O
quicker	O
abatement	O
of	O
fever	O
and	O
more	O
complete	O
spleen	O
regression	O
.	O

Osteocalcin	Pharmacological
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

A	O
one-year	O
followup	O
study	O
.	O

OBJECTIVE	O
To	O
analyze	O
clinical	O
,	O
radiological	O
,	O
and	O
drug	O
(	O
disease	O
modifying	O
antirheumatic	O
drug	O
,	O
DMARD	O
)	O
dependent	O
factors	O
influencing	O
bone	O
turnover	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
We	O
investigated	O
in	O
a	O
one-year	O
double	O
blind	O
randomized	O
study	O
comparing	O
intramuscular	Pharmacological
(	Pharmacological
im	Pharmacological
)	Pharmacological
gold	Pharmacological
with	Pharmacological
im	Pharmacological
methotrexate	Pharmacological
(	Pharmacological
MTX	Pharmacological
)	Pharmacological
,	O
whether	O
the	O
variation	O
of	O
inflammatory	O
activity	O
or	O
functional	O
capacity	O
,	O
the	O
ascending	O
anatomic	O
stage	O
,	O
or	O
DMARD	O
treatments	O
have	O
an	O
influence	O
on	O
bone	O
formation	O
(	O
osteocalcin	O
)	O
in	O
patients	O
with	O
RA	O
.	O

RESULTS	O
Patients	O
(	O
n	O
=	O
48	O
)	O
enrolled	O
at	O
the	O
beginning	O
of	O
our	O
study	O
had	O
significantly	O
increased	O
osteocalcin	O
levels	O
(	O
3.45	O
+/-	O
0.93	O
--	O
>	O
4.42	O
+/-	O
1.39	O
ng/ml	O
p	O
<	O
0.02	O
)	O
after	O
one	O
year	O
if	O
inflammatory	O
activity	O
decreased	O
(	O
>	O
or	O
=	O
1	O
SD	O
:	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
26.4	O
mm/h	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
3.8	O
mg/dl	O
)	O
.	O

We	O
found	O
a	O
significant	O
negative	O
correlation	O
of	O
the	O
one-year	O
CRP-	O
(	O
r	O
=	O
-0.44	O
,	O
p	O
<	O
0.001	O
)	O
or	O
ESR	O
differences	O
(	O
r	O
=	O
-0.45	O
,	O
p	O
<	O
0.001	O
)	O
with	O
the	O
corresponding	O
osteocalcin	O
differences	O
.	O

This	O
was	O
also	O
evident	O
if	O
these	O
patients	O
were	O
pooled	O
with	O
15	O
patients	O
excluded	O
from	O
the	O
double	O
blind	O
study	O
as	O
already	O
receiving	O
DMARD	Pharmacological
treatment	Pharmacological
(	O
n	O
=	O
63	O
;	O
p	O
<	O
0.01	O
)	O
.	O

Patients	O
with	O
impaired	O
functional	O
capacity	O
also	O
had	O
significantly	O
reduced	O
osteocalcin	O
levels	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
both	O
cases	O
,	O
alkaline	O
phosphatase	O
showed	O
no	O
significant	O
differences	O
.	O

CONCLUSIONS	O
Our	O
data	O
suggest	O
that	O
osteocalcin	O
,	O
a	O
useful	O
followup	O
variable	O
of	O
bone	O
turnover	O
,	O
is	O
changed	O
significantly	O
(	O
p	O
<	O
0.02	O
)	O
in	O
patients	O
with	O
RA	O
regarding	O
inflammatory	O
activity	O
and	O
functional	O
capacity	O
.	O

In	O
contrast	O
to	O
alkaline	O
phosphatase	O
,	O
a	O
fall	O
in	O
inflammatory	O
activity	O
stimulated	O
and	O
impairment	O
of	O
functional	O
capacity	O
significantly	O
decreased	O
osteocalcin	O
levels	O
in	O
patients	O
with	O
RA	O
.	O

Pre-treatment	O
proliferation	O
and	O
the	O
outcome	O
of	O
conventional	Physical
and	Physical
accelerated	Physical
radiotherapy	Physical
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
pre-treatment	O
proliferation	O
characteristics	O
,	O
assessed	Physical
by	Physical
Ki-67	Physical
staining	Physical
,	O
in	O
patients	O
treated	O
in	O
the	O
CHART	O
trial	O
of	O
accelerated	Physical
radiotherapy	Physical
in	O
head	O
and	O
neck	O
cancer	O
.	O

Histological	O
material	O
from	O
402	O
patients	O
was	O
collected	O
and	O
stained	O
for	O
the	O
presence	O
and	O
pattern	O
of	O
Ki-67	O
staining	O
.	O

Locoregional	O
control	O
and	O
overall	O
survival	O
were	O
the	O
main	O
clinical	O
endpoints	O
.	O

Increasing	O
Ki-67	O
positivity	O
was	O
associated	O
with	O
decreasing	O
differentiation	O
(	O
P	O
<	O
0.001	O
)	O
and	O
increasing	O
N-stage	O
(	O
P	O
<	O
0.004	O
)	O
.	O

Increasing	O
N-stage	O
was	O
also	O
associated	O
with	O
the	O
progression	O
of	O
proliferation	O
pattern	O
from	O
marginal	O
to	O
random	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Using	O
a	O
multivariate	O
model	O
,	O
a	O
trend	O
was	O
seen	O
towards	O
a	O
greater	O
benefit	O
from	O
CHART	O
in	O
the	O
lower	O
Ki-67	O
tumours	O
(	O
P	O
=	O
0.08	O
)	O
;	O
this	O
became	O
significant	O
by	O
pooling	O
the	O
low	O
and	O
intermediate	O
Ki-67	O
groups	O
in	O
comparison	O
with	O
the	O
high	O
Ki-67	O
group	O
(	O
P	O
=	O
0.032	O
)	O
.	O

Tumours	O
with	O
marginal	O
proliferation	O
pattern	O
showed	O
a	O
lower	O
hazard	O
ratio	O
with	O
CHART	O
versus	O
conventional	O
for	O
locoregional	O
control	O
(	O
P	O
=	O
0.005	O
)	O
.	O

The	O
data	O
presented	O
in	O
this	O
study	O
do	O
not	O
support	O
that	O
a	O
high	O
pre-treatment	O
Ki-67	O
is	O
associated	O
with	O
a	O
therapeutic	O
benefit	O
from	O
accelerated	Physical
radiotherapy	Physical
.	O

Tracheal	O
soiling	O
with	O
blood	O
during	O
intranasal	Surgical
surgery	Surgical
--	O
comparison	O
of	O
two	O
endotracheal	O
tubes	O
.	O

Sixty	O
adult	O
patients	O
,	O
ASA	O
Classes	O
I	O
&	O
II	O
,	O
were	O
involved	O
in	O
a	O
study	O
to	O
compare	O
the	O
effectiveness	O
of	O
Mallinckrodt	Surgical
Hi-Lo-Evac	Surgical
tube	Surgical
and	O
Portex	Surgical
blue	Surgical
line	Surgical
tube	Surgical
in	O
preventing	O
soiling	O
of	O
the	O
lower	O
airways	O
during	O
intranasal	O
surgery	O
.	O

The	O
Hi-Lo-Evac	O
tube	O
with	O
and	O
without	O
pack	O
was	O
significantly	O
more	O
effective	O
than	O
the	O
Portex	O
tube	O
with	O
pharyngeal	O
pack	O
(	O
P	O
less	O
than	O
0.002	O
)	O
and	O
(	O
P	O
less	O
than	O
0.01	O
respectively	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
when	O
the	O
Hi-Lo-Evac	O
tube	O
was	O
used	O
with	O
or	O
without	O
a	O
pack	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
.	O

The	O
more	O
effective	O
protection	O
of	O
the	O
lower	O
airways	O
by	O
the	O
Hi-Lo-Evac	O
tube	O
is	O
attributed	O
to	O
the	O
facility	O
of	O
subglottic	O
aspiration	O
during	O
surgery	O
.	O

It	O
is	O
suggested	O
that	O
the	O
Hi-Lo-Evac	O
tube	O
could	O
be	O
used	O
with	O
safety	O
during	O
intranasal	O
surgery	O
in	O
order	O
to	O
reduce	O
postoperative	O
morbidity	O
associated	O
with	O
the	O
use	O
of	O
pharyngeal	O
pack	O
.	O

[	O
Effect	O
of	O
branch	O
chain	O
amino	Pharmacological
acid	Pharmacological
enriched	Pharmacological
formula	Pharmacological
on	O
postoperative	O
fatigue	O
and	O
nutritional	O
status	O
after	O
digestive	O
surgery	O
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
branch	Physical
chain	Physical
amino	Physical
acid	Physical
(	Physical
BCAA	Physical
)	Physical
enriched	Physical
formula	Physical
on	O
nutritional	O
status	O
and	O
postoperative	O
fatigue	O
for	O
digestive	O
surgery	O
patients	O
.	O

METHODS	O
Forty	O
patients	O
who	O
underwent	O
digestive	O
surgery	O
were	O
randomly	O
received	O
parenteral	O
nutrition	O
with	O
either	Pharmacological
BCAA	Pharmacological
enriched	Pharmacological
(	Pharmacological
study	Pharmacological
group	Pharmacological
,	Pharmacological
n=20	Pharmacological
)	Pharmacological
or	Pharmacological
routine	Control
amino	Control
acid	Control
(	Control
control	Control
group	Control
,	Pharmacological
n=20	Pharmacological
)	Pharmacological
for	Pharmacological
seven	Pharmacological
consecutive	Pharmacological
days	Pharmacological
.	Pharmacological

Nitrogen	Pharmacological
balance	Pharmacological
,	Pharmacological
serum	Pharmacological
total	Pharmacological
protein	Pharmacological
,	Pharmacological
albumin	Pharmacological
,	Pharmacological
prealbumin	Pharmacological
,	Pharmacological
transferrin	Pharmacological
,	Pharmacological
retinol	Pharmacological
binding	Pharmacological
protein	Pharmacological
and	Pharmacological
postoperative	Pharmacological
fatigue	Pharmacological
score	Pharmacological
were	Pharmacological
monitored	Pharmacological
during	Pharmacological
the	Pharmacological
postoperative	Pharmacological
period	Pharmacological
.	Pharmacological

RESULTS	O
The	O
cumulative	O
postoperative	O
fatigue	O
scores	O
were	O
lower	O
in	O
BCAA	O
group	O
than	O
that	O
in	O
the	O
control	O
group	O
at	O
the	O
4th	O
,	O
5th	O
and	O
7th	O
day	O
after	O
operation	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Patients	O
achieved	O
positive	O
nitrogen	O
balance	O
2	O
days	O
earlier	O
in	O
the	O
study	O
group	O
than	O
that	O
in	O
the	O
control	O
group	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
cumulative	O
nitrogen	O
balance	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
elevation	O
of	O
serum	O
total	O
protein	O
,	O
albumin	O
,	O
prealbumin	O
,	O
transferrin	O
at	O
the	O
7th	O
day	O
after	O
operation	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
,	O
compared	O
with	O
those	O
at	O
the	O
first	O
day	O
after	O
operation	O
.	O

The	O
serum	O
level	O
of	O
retinol	O
binding	O
protein	O
was	O
higher	O
in	O
BCAA-enriched	Pharmacological
group	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
P=0.004	O
)	O
.	O

CONCLUSION	O
TPN	O
with	O
BCAA	Pharmacological
enriched	Pharmacological
formula	Pharmacological
can	O
reduce	O
postoperative	O
fatigue	O
score	O
and	O
improve	O
the	O
nutritional	O
status	O
for	O
digestive	O
surgery	O
patients	O
.	O

A	O
workplace	Educational
intervention	Educational
for	O
increasing	O
outdoor	O
workers	O
'	O
use	O
of	O
solar	O
protection	O
.	O

OBJECTIVES	O
Outdoor	O
workers	O
are	O
at	O
high	O
risk	O
of	O
developing	O
skin	O
cancer	O
.	O

Primary	O
prevention	O
in	O
this	O
group	O
can	O
potentially	O
reduce	O
the	O
incidence	O
of	O
skin	O
cancer	O
,	O
and	O
also	O
potentiates	O
the	O
spontaneous	O
remission	O
of	O
existing	O
solar	O
keratoses	O
.	O

A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
to	O
evaluate	O
a	O
solar	Educational
protection	Educational
intervention	Educational
targeting	O
outdoor	O
workers	O
.	O

METHODS	O
Outdoor	O
workers	O
were	O
randomly	O
allocated	O
to	O
an	O
intervention	Educational
(	O
n	O
=	O
65	O
)	O
or	O
control	Control
group	Control
(	O
n	O
=	O
77	O
)	O
.	O

The	O
intervention	O
group	O
received	O
individual	Educational
skin	Educational
screening	Educational
by	Educational
a	Educational
dermatologist	Educational
and	Educational
participated	Educational
in	Educational
an	Educational
education	Educational
session	Educational
.	Educational

Pre-	O
and	O
posttest	O
outcome	O
measures	O
included	O
solar	O
protection	O
behavior	O
(	O
assessed	O
using	O
a	O
validated	O
diary	O
)	O
,	O
knowledge	O
,	O
and	O
attitudes	O
.	O

RESULTS	O
There	O
was	O
a	O
significant	O
increase	O
(	O
16	O
%	O
)	O
in	O
the	O
percentage	O
of	O
outdoor	O
workers	O
who	O
were	O
using	O
a	O
high	O
level	O
of	O
solar	O
protection	O
at	O
posttest	O
compared	O
to	O
pretest	O
in	O
the	O
intervention	O
group	O
,	O
but	O
there	O
was	O
no	O
change	O
in	O
the	O
control	O
group	O
.	O

Although	O
both	O
groups	O
improved	O
in	O
their	O
knowledge	O
score	O
,	O
the	O
intervention	O
group	O
showed	O
a	O
significantly	O
greater	O
improvement	O
at	O
posttest	O
.	O

No	O
changes	O
in	O
attitudes	O
were	O
detected	O
.	O

CONCLUSIONS	O
The	O
findings	O
suggest	O
that	O
changes	O
in	O
solar	O
protection	O
are	O
achievable	O
with	O
outdoor	O
workers	O
.	O

A	O
randomised	O
group	O
comparison	O
controlled	O
trial	O
of	O
'preschoolers	O
with	O
autism	O
'	O
:	O
a	O
parent	Educational
education	Educational
and	Educational
skills	Educational
training	Educational
intervention	Educational
for	O
young	O
children	O
with	O
autistic	O
disorder	O
.	O

AIM	O
To	O
determine	O
the	O
effect	O
of	O
parent	Educational
education	Educational
on	Educational
adaptive	Educational
behaviour	Educational
,	Educational
autism	Educational
symptoms	Educational
and	Educational
cognitive/language	Educational
skills	Educational
of	O
young	O
children	O
with	O
autistic	O
disorder	O
.	O

METHOD	O
A	O
randomised	O
group	O
comparison	O
design	O
involving	O
a	O
parent	Educational
education	Educational
and	Educational
counselling	Educational
intervention	Educational
and	Educational
a	Educational
parent	Educational
education	Educational
and	Educational
behaviour	Educational
management	Educational
intervention	Educational
to	Educational
control	Educational
for	Educational
parent	Educational
skills	Educational
training	Educational
and	O
a	O
control	Educational
sample	Educational
.	O

Two	O
rural	O
and	O
two	O
metropolitan	O
regions	O
were	O
randomly	O
allocated	O
to	O
intervention	Educational
groups	O
(	O
n	O
=	O
70	O
)	O
or	O
control	Control
(	O
n	O
=	O
35	O
)	O
.	O

Parents	O
from	O
autism	O
assessment	O
services	O
in	O
the	O
intervention	O
regions	O
were	O
randomly	O
allocated	O
to	O
parent	Educational
education	Educational
and	Educational
behaviour	Educational
management	Educational
(	O
n	O
=	O
35	O
)	O
or	Educational
parent	Educational
education	Educational
and	Educational
counselling	Educational
(	O
n	O
=	O
35	O
)	O
.	O

RESULTS	O
Parent	O
education	O
and	O
behaviour	O
management	O
resulted	O
in	O
significant	O
improvement	O
in	O
adaptive	O
behaviour	O
and	O
autism	O
symptoms	O
at	O
6	O
months	O
follow-up	O
for	O
children	O
with	O
greater	O
delays	O
in	O
adaptive	O
behaviour	O
.	O

Parent	O
education	O
and	O
behaviour	O
management	O
was	O
superior	O
to	O
parent	O
education	O
and	O
counselling	O
.	O

We	O
conclude	O
that	O
a	O
20-week	O
parent	O
education	O
programme	O
including	O
skills	O
training	O
for	O
parents	O
of	O
young	O
children	O
with	O
autistic	O
disorder	O
provides	O
significant	O
improvements	O
in	O
child	O
adaptive	O
behaviour	O
and	O
symptoms	O
of	O
autism	O
for	O
low-functioning	O
children	O
.	O

Improved	O
acidosis	O
correction	O
and	O
recovery	O
of	O
mesothelial	O
cell	O
mass	O
with	O
neutral-pH	Pharmacological
bicarbonate	Pharmacological
dialysis	Pharmacological
solution	Pharmacological
among	O
children	O
undergoing	O
automated	Physical
peritoneal	Physical
dialysis	Physical
.	O

Acid-base	O
balance	O
and	O
peritoneal	O
membrane	O
longevity	O
are	O
of	O
utmost	O
relevance	O
for	O
pediatric	O
patients	O
undergoing	O
peritoneal	Physical
dialysis	Physical
(	Physical
PD	Physical
)	Physical
.	O

PD	O
fluids	O
with	O
neutral	O
pH	O
and	O
reduced	O
glucose	O
degradation	O
product	O
contents	O
are	O
considered	O
more	O
biocompatible	O
,	O
because	O
they	O
preserve	O
peritoneal	O
cell	O
functions	O
in	O
vitro	O
.	O

To	O
investigate	O
the	O
clinical	O
effects	O
of	O
a	O
novel	Pharmacological
PD	Pharmacological
fluid	Pharmacological
buffered	Pharmacological
with	Pharmacological
34	Pharmacological
mM	Pharmacological
pure	Pharmacological
bicarbonate	Pharmacological
at	Pharmacological
neutral	Pharmacological
pH	Pharmacological
,	O
a	O
randomized	O
,	O
prospective	O
,	O
crossover	O
comparison	O
with	O
conventional	Pharmacological
,	Pharmacological
acidic	Pharmacological
,	Pharmacological
35	Pharmacological
mM	Pharmacological
lactate	Pharmacological
PD	Pharmacological
fluid	Pharmacological
was	O
performed	O
for	O
two	O
consecutive	O
12-wk	O
periods	O
with	O
28	O
children	O
(	O
age	O
,	O
6	O
mo	O
to	O
15	O
yr	O
)	O
undergoing	O
automated	Physical
PD	Physical
(	Physical
APD	Physical
)	Physical
.	O

Blood	O
bicarbonate	O
levels	O
and	O
arterial	O
pH	O
were	O
significantly	O
higher	O
after	O
3	O
mo	O
of	O
bicarbonate	Pharmacological
PD	Pharmacological
(	O
24.6	O
+/-	O
2.3	O
mM	O
and	O
7.43	O
+/-	O
0.06	O
,	O
respectively	O
)	O
,	O
compared	O
with	O
lactate	Pharmacological
PD	Pharmacological
(	O
22.8	O
+/-	O
3.9	O
mM	O
and	O
7.38	O
+/-	O
0.05	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O

This	O
effect	O
was	O
reversible	O
among	O
patients	O
who	O
returned	O
from	O
bicarbonate	O
to	O
lactate	O
fluid	O
.	O

Low	O
initial	O
pH	O
and	O
young	O
patient	O
age	O
independently	O
predicted	O
increased	O
blood	O
pH	O
during	O
bicarbonate	O
APD	O
.	O

Peritoneal	O
equilibration	O
tests	O
revealed	O
subtle	O
changes	O
in	O
solute	O
transport	O
,	O
with	O
a	O
less	O
steep	O
creatinine	O
equilibration	O
curve	O
during	O
bicarbonate	O
dialysis	O
,	O
suggesting	O
reduced	O
peritoneal	O
vasodilation	O
.	O

The	O
peritoneal	O
release	O
of	O
carcinogen	O
antigen-125	O
increased	O
twofold	O
during	O
bicarbonate	O
APD	O
(	O
29	O
+/-	O
15	O
versus	O
15	O
+/-	O
8	O
U/ml	O
per	O
4	O
h	O
,	O
P	O
<	O
0.01	O
)	O
,	O
which	O
is	O
consistent	O
with	O
recovery	O
of	O
the	O
mesothelial	O
cell	O
layer	O
.	O

This	O
effect	O
was	O
fully	O
reversed	O
when	O
the	O
patients	O
returned	O
to	O
lactate	O
fluid	O
.	O

Effluent	O
carcinogen	O
antigen-125	O
levels	O
were	O
inversely	O
correlated	O
with	O
peritoneal	O
glucose	O
exposure	O
during	O
lactate	O
but	O
not	O
bicarbonate	O
APD	O
,	O
indicating	O
improved	O
in	O
vivo	O
mesothelial	O
cell	O
tolerance	O
of	O
high-dose	O
glucose	O
with	O
the	O
neutral-pH	Pharmacological
PD	Pharmacological
fluid	Pharmacological
with	Pharmacological
reduced	Pharmacological
glucose	Pharmacological
degradation	Pharmacological
product	Pharmacological
content	Pharmacological
.	O

Among	O
children	O
undergoing	O
APD	Pharmacological
,	Pharmacological
neutral-pH	Pharmacological
,	Pharmacological
bicarbonate-buffered	Pharmacological
PD	Pharmacological
fluid	Pharmacological
provides	O
more	O
effective	O
correction	O
of	O
metabolic	O
acidosis	O
and	O
better	O
preservation	O
of	O
peritoneal	O
cell	O
mass	O
than	O
do	O
conventional	Pharmacological
,	Pharmacological
acidic	Pharmacological
,	Pharmacological
lactate-based	Pharmacological
fluids	Pharmacological
.	O

Protective	O
effect	O
of	O
high-dose	Pharmacological
medroxyprogesterone	Pharmacological
acetate	Pharmacological
(	Pharmacological
HD-MPA	Pharmacological
)	Pharmacological
on	O
hematological	O
toxicity	O
induced	O
by	O
chemotherapy	Physical
for	O
advanced	O
solid	O
tumors	O
:	O
a	O
multicentric	O
controlled	O
clinical	O
trial	O
.	O

MPA-Hematology	O
Italian	O
Cooperative	O
Group	O
.	O

A	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
conducted	O
comparing	O
active	O
treatment	O
with	O
placebo	Control
in	O
227	O
patients	O
with	O
breast	O
,	O
colorectal	O
,	O
lung	O
and	O
other	O
solid	O
forms	O
of	O
cancer	O
.	O

Combination	Physical
therapy	Physical
,	Physical
(	Physical
CT	Physical
)	Physical
conventionally	O
employed	O
for	O
the	O
various	O
types	O
of	O
tumor	O
involved	O
,	O
was	O
associated	O
with	O
MPA	Pharmacological
(	O
117	O
patients	O
)	O
or	O
placebo	Control
(	O
110	O
patients	O
)	O
.	O

MPA	O
was	O
given	O
orally	O
as	O
tablets	O
,	O
as	O
a	O
dose	O
of	O
500	O
mg	O
b.i.d	O
.	O

for	O
6	O
months	O
.	O

The	O
results	O
were	O
,	O
briefly	O
,	O
as	O
follows	O
:	O
The	O
incidence	O
of	O
leukopenia	O
was	O
significantly	O
lower	O
in	O
the	O
groups	O
receiving	O
MPA	Pharmacological
in	O
patients	O
with	O
breast	O
and	O
colorectal	O
cancer	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Tumors	O
of	O
the	O
lung	O
and	O
other	O
solid	O
forms	O
showed	O
no	O
such	O
difference	O
.	O

The	O
incidence	O
of	O
thrombocytopenia	O
was	O
the	O
same	O
in	O
all	O
disease	O
groups	O
.	O

Objective	O
responses	O
(	O
CR	O
+	O
PR	O
)	O
were	O
observed	O
in	O
23/46	O
(	O
50	O
%	O
)	O
of	O
breast	O
cancer	O
patients	O
treated	O
with	O
CT	Physical
+	Physical
MPA	Physical
,	O
and	O
in	O
13/47	O
(	O
28	O
%	O
)	O
of	O
those	O
given	O
CT	Control
+	Control
placebo	Control
.	O

The	O
difference	O
was	O
significant	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Subjective	O
parameters	O
also	O
showed	O
more	O
improvement	O
in	O
the	O
MPA	Physical
group	O
than	O
in	O
the	O
patients	O
given	O
CT	O
alone	O
.	O

No	O
significant	O
differences	O
were	O
found	O
for	O
the	O
other	O
types	O
of	O
tumor	O
,	O
but	O
the	O
numbers	O
in	O
this	O
population	O
were	O
very	O
limited	O
.	O

In	O
a	O
group	O
of	O
45	O
patients	O
,	O
antithrombin	O
III	O
a	O
(	O
%	O
)	O
,	O
antithrombin	O
III	O
R	O
:	O
Ag	O
(	O
%	O
)	O
,	O
plasminogen	O
(	O
mg/dl	O
)	O
,	O
alpha-2	O
macroglobulin	O
(	O
%	O
)	O
,	O
factor	O
VIII	O
C	O
(	O
%	O
)	O
,	O
factor	O
VIII	O
R	O
:	O
Ag	O
(	O
%	O
)	O
and	O
factor	O
IX	O
C	O
(	O
%	O
)	O
were	O
determined	O
.	O

The	O
most	O
interesting	O
post-treatment	O
findings	O
were	O
an	O
increase	O
in	O
anti-thrombin	O
III	O
(	O
activity	O
and	O
antigen	O
level	O
)	O
and	O
in	O
plasminogen	O
.	O

This	O
suggests	O
that	O
MPA	O
does	O
not	O
increase	O
the	O
risk	O
of	O
thrombosis	O
,	O
and	O
might	O
even	O
,	O
to	O
some	O
extent	O
,	O
impede	O
tumor-induced	O
thrombophilia	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Extinction	O
of	O
over-selected	O
stimuli	O
causes	O
emergence	O
of	O
under-selected	O
cues	O
in	O
higher-functioning	O
children	O
with	O
autistic	O
spectrum	O
disorders	O
.	O

Two	O
experiments	O
examined	O
whether	O
over-selectivity	O
is	O
the	O
product	O
of	O
a	O
post-acquisition	O
performance	O
deficit	O
,	O
rather	O
than	O
an	O
attention	O
problem	O
.	O

In	O
both	O
experiments	O
,	O
children	O
with	O
Autistic	O
Spectrum	O
Disorder	O
were	O
presented	O
with	O
a	O
trial-and-error	Educational
discrimination	Educational
task	Educational
using	O
two	Educational
,	Educational
two-element	Educational
stimuli	Educational
and	O
over-selected	Educational
in	O
both	O
studies	O
.	O

After	O
behavioral	O
control	O
by	O
the	O
previously	O
over-selected	O
stimulus	O
was	O
extinguished	O
,	O
behavioral	O
control	O
by	O
the	O
previously	O
under-selected	O
cue	O
emerged	O
without	O
direct	O
training	O
.	O

However	O
,	O
this	O
effect	O
was	O
only	O
found	O
in	O
higher-functioning	O
children	O
,	O
and	O
not	O
with	O
more	O
severely	O
impaired	O
children	O
.	O

These	O
findings	O
suggest	O
that	O
over-selectivity	O
is	O
not	O
simply	O
due	O
to	O
a	O
failure	O
to	O
attend	O
to	O
all	O
of	O
the	O
stimuli	O
presented	O
.	O

They	O
also	O
suggest	O
that	O
extinction	O
of	O
over-selected	Psychological
stimuli	Psychological
may	O
be	O
a	O
fruitful	O
line	O
of	O
intervention	O
for	O
clinical	O
intervention	O
for	O
some	O
individuals	O
.	O

Multiple	O
courses	O
of	O
rituximab	Pharmacological
produce	O
sustained	O
clinical	O
and	O
radiographic	O
efficacy	O
and	O
safety	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
an	O
inadequate	O
response	O
to	O
1	O
or	O
more	O
tumor	Physical
necrosis	Physical
factor	Physical
inhibitors	Physical
:	O
5-year	O
data	O
from	O
the	O
REFLEX	O
study	O
.	O

OBJECTIVE	O
This	O
5-year	O
observational	O
posthoc	O
analysis	O
of	O
the	O
REFLEX	O
study	O
and	O
its	O
open-label	O
extension	O
assessed	O
clinical	O
efficacy	O
,	O
radiographic	O
response	O
,	O
and	O
safety	O
of	O
rituximab	Pharmacological
(	Pharmacological
RTX	Pharmacological
)	Pharmacological
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
who	O
had	O
an	O
inadequate	O
response	O
to	O
tumor	Physical
necrosis	Physical
factor	Physical
(	Physical
TNF	Physical
)	Physical
inhibitors	Physical
.	O

METHODS	O
Patients	O
in	O
REFLEX	O
were	O
originally	O
randomized	O
to	O
placebo	Control
(	O
PBO	O
)	O
+	Pharmacological
methotrexate	Pharmacological
(	Pharmacological
MTX	Pharmacological
;	Pharmacological
PBO-randomized	Pharmacological
)	Pharmacological
or	Pharmacological
RTX	Pharmacological
+	Pharmacological
MTX	Pharmacological
(	Pharmacological
RTX-randomized	Pharmacological
)	Pharmacological
.	O

PBO-randomized	O
patients	O
were	O
rescued	O
with	O
RTX	O
as	O
appropriate	O
.	O

Patients	O
responding	O
to	O
initial	O
RTX	Pharmacological
treatment	O
could	O
receive	O
further	O
RTX	Pharmacological
courses	O
.	O

For	O
clinical	O
efficacy	O
and	O
safety	O
analyses	O
,	O
PBO-randomized	O
patients	O
were	O
re-baselined	O
prior	O
to	O
first	O
RTX	Pharmacological
treatment	O
and	O
the	O
data	O
were	O
pooled	O
with	O
RTX-randomized	Pharmacological
patient	O
data	O
.	O

Efficacy	O
outcomes	O
24	O
weeks	O
after	O
each	O
course	O
were	O
calculated	O
relative	O
to	O
first	O
RTX	Pharmacological
pretreatment	O
baseline	O
.	O

Radiographic	O
outcomes	O
were	O
assessed	O
relative	O
to	O
randomization	O
baseline	O
for	O
both	O
PBO-randomized	O
and	O
RTX-randomized	Pharmacological
groups	O
.	O

RESULTS	O
A	O
total	O
of	O
480	O
patients	O
received	O
?	O
1	O
RTX	O
course	O
.	O

At	O
24	O
weeks	O
,	O
American	O
College	O
of	O
Rheumatology	O
20/50/70	O
responses	O
were	O
62.0	O
%	O
,	O
30.8	O
%	O
,	O
and	O
13.0	O
%	O
,	O
respectively	O
at	O
course	O
1	O
(	O
n	O
=	O
400	O
)	O
and	O
70.3	O
%	O
,	O
41.8	O
%	O
,	O
and	O
22.0	O
%	O
at	O
course	O
5	O
(	O
n	O
=	O
91	O
)	O
.	O

European	O
League	O
Against	O
Rheumatism	O
good/moderate	O
responses	O
were	O
77.2	O
%	O
and	O
84.4	O
%	O
at	O
courses	O
1	O
(	O
n	O
=	O
390	O
)	O
and	O
5	O
(	O
n	O
=	O
90	O
)	O
.	O

Rates	O
of	O
adverse	O
events	O
(	O
AE	O
)	O
,	O
serious	O
AE	O
,	O
and	O
infections	O
generally	O
remained	O
stable	O
.	O

Rate	O
of	O
progressive	O
joint	O
damage	O
(	O
PJD	O
;	O
change	O
in	O
mean	O
Total	O
Sharp	O
Score	O
)	O
decreased	O
over	O
time	O
in	O
both	O
PBO-randomized	O
(	O
n	O
=	O
79	O
)	O
and	O
RTX-randomized	O
(	O
n	O
=	O
105	O
)	O
groups	O
.	O

Mean	O
change	O
from	O
baseline	O
in	O
PJD	O
over	O
5	O
years	O
was	O
greater	O
in	O
PBO-randomized	O
versus	O
RTX-randomized	O
patients	O
(	O
5.51	O
vs	O
3.21	O
)	O
.	O

CONCLUSION	O
RTX	O
re-treatment	O
over	O
5	O
years	O
is	O
associated	O
with	O
maintained	O
or	O
improved	O
efficacy	O
,	O
continued	O
inhibition	O
of	O
PJD	O
,	O
and	O
a	O
safety	O
profile	O
consistent	O
with	O
that	O
previously	O
reported	O
.	O

A	O
delay	O
in	O
initiating	O
RTX	O
treatment	O
may	O
result	O
in	O
increased	O
PJD	O
.	O

Effect	O
of	O
topical	O
rh-TGF-beta	Pharmacological
1	Pharmacological
on	O
second	O
intention	O
wound	O
healing	O
in	O
horses	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
on	O
wound	O
healing	O
of	O
transforming	O
growth	Pharmacological
factor-beta	Pharmacological
1	Pharmacological
as	O
a	O
topical	O
treatment	O
to	O
full-thickness	O
,	O
excisional	O
wounds	O
of	O
the	O
distal	O
limb	O
of	O
horses	O
.	O

DESIGN	O
A	O
randomised	O
block	O
study	O
using	O
four	O
horses	O
,	O
each	O
with	O
wounds	O
assigned	O
to	O
four	O
treatment	O
groups	O
.	O

ANIMALS	O
Four	O
adult	O
Standardbred	O
geldings	O
.	O

PROCEDURE	O
Four	O
,	O
4	O
cm2	O
,	O
full-thickness	O
wounds	O
were	O
created	O
on	O
the	O
dorsomedial	O
and	O
dorsolateral	O
aspect	O
of	O
the	O
metacarpus	O
or	O
metatarsus	O
of	O
each	O
limb	O
of	O
four	O
horses	O
,	O
giving	O
a	O
total	O
of	O
64	O
wounds	O
.	O

For	O
each	O
limb	O
,	O
wounds	O
were	O
randomly	O
assigned	O
to	O
four	O
treatment	O
groups	O
:	O
no	Control
treatment	Control
(	O
control	O
)	O
,	O
carrier	Pharmacological
(	Pharmacological
Methyl	Pharmacological
Cellulose	Pharmacological
gel	Pharmacological
)	Pharmacological
,	O
50	Pharmacological
ng/wound	Pharmacological
rhTGF-beta	Pharmacological
1	Pharmacological
in	Pharmacological
carrier	Pharmacological
,	Pharmacological
and	O
500	Pharmacological
ng/wound	Pharmacological
rhTGF-beta	Pharmacological
1	Pharmacological
in	Pharmacological
carrier	Pharmacological
.	O

Wounds	O
were	O
treated	O
on	O
day	O
0	O
and	O
day	O
8	O
.	O

Effects	O
of	O
treatment	O
were	O
evaluated	O
on	O
the	O
basis	O
of	O
the	O
presence	O
of	O
exuberant	O
granulation	O
tissue	O
requiring	O
excision	O
,	O
number	O
of	O
times	O
excision	O
was	O
required	O
,	O
total	O
wound	O
area	O
,	O
area	O
of	O
epithelialisation	O
,	O
area	O
of	O
granulation	O
,	O
and	O
histological	O
evaluation	O
of	O
biopsy	O
samples	O
of	O
wounds	O
on	O
day	O
8	O
and	O
excised	O
wounds	O
on	O
day	O
21	O
.	O

RESULTS	O
Topical	O
application	O
of	O
TGF-beta	O
1	O
at	O
the	O
two	O
concentrations	O
studied	O
had	O
no	O
significant	O
effect	O
on	O
the	O
total	O
area	O
of	O
wounds	O
(	O
P	O
=	O
0.7	O
)	O
,	O
the	O
area	O
of	O
granulation	O
tissue	O
(	O
P	O
=	O
0.78	O
)	O
,	O
the	O
area	O
of	O
epithelialisation	O
(	O
P	O
=	O
0.92	O
)	O
,	O
histological	O
assessment	O
or	O
subjective	O
clinical	O
assessment	O
of	O
wounds	O
.	O

CONCLUSION	O
TGF-beta	Pharmacological
1	Pharmacological
had	O
no	O
beneficial	O
effects	O
on	O
wound	O
healing	O
.	O

Additional	O
trials	O
are	O
needed	O
to	O
test	O
if	O
it	O
has	O
value	O
for	O
wound	O
treatment	O
in	O
horses	O
.	O

Multicenter	O
randomized	O
controlled	O
trial	O
of	O
the	O
management	O
of	O
unresectable	O
malignant	O
mesothelioma	O
proposed	O
by	O
the	O
British	O
Thoracic	O
Society	O
and	O
the	O
British	O
Medical	O
Research	O
Council	O
.	O

Malignant	O
mesothelioma	O
is	O
almost	O
invariably	O
fatal	O
.	O

The	O
incidence	O
of	O
the	O
disease	O
is	O
rising	O
rapidly	O
in	O
many	O
countries	O
,	O
and	O
there	O
is	O
no	O
generally	O
accepted	O
standard	O
treatment	O
for	O
patients	O
with	O
unresectable	O
disease	O
.	O

According	O
to	O
current	O
British	O
Thoracic	O
Society	O
(	O
BTS	O
)	O
guidelines	O
,	O
patients	O
should	O
be	O
treated	O
with	O
active	O
symptom	O
control	O
(	O
ASC	O
)	O
,	O
involving	O
(	O
1	O
)	O
regular	O
follow-up	O
in	O
a	O
specialist	O
clinic	O
;	O
(	O
2	O
)	O
structured	O
assessments	O
of	O
physical	O
,	O
psychological	O
and	O
social	O
problems	O
with	O
appropriate	O
action	O
;	O
(	O
3	O
)	O
rapid	O
involvement	O
of	O
additional	O
specialists	O
;	O
and	O
(	O
4	O
)	O
parallel	O
nursing	O
support	O
.	O

Although	O
many	O
nonrandomized	O
studies	O
have	O
reported	O
tumor	O
responses	O
to	O
anticancer	O
chemotherapy	O
,	O
few	O
have	O
studied	O
palliation	O
and	O
it	O
is	O
not	O
known	O
whether	O
chemotherapy	O
prolongs	O
survival	O
or	O
provides	O
clinically	O
worthwhile	O
palliation	O
with	O
acceptable	O
toxicity	O
when	O
given	O
in	O
addition	O
to	O
ASC	O
.	O

We	O
therefore	O
plan	O
to	O
conduct	O
a	O
multicenter	O
randomized	O
controlled	O
trial	O
comparing	O
(	O
1	O
)	O
ASC	Other
alone	Other
,	O
(	O
2	O
)	O
ASC	Pharmacological
plus	Pharmacological
mitomycin	Pharmacological
vinblastine	Pharmacological
and	Pharmacological
cisplatin	Pharmacological
(	Pharmacological
MVP	Pharmacological
)	Pharmacological
,	O
and	O
(	O
3	O
)	O
ASC	Pharmacological
plus	Pharmacological
vinorelbine	Pharmacological
(	O
N	O
;	O
Navelbine	O
,	O
Pierre	O
Fabre	O
Oncology	O
,	O
Winchester	O
,	O
UK	O
)	O
.	O

We	O
chose	O
these	O
chemotherapy	O
regimens	O
because	O
they	O
have	O
been	O
shown	O
in	O
nonrandomized	O
studies	O
to	O
provide	O
good	O
symptom	O
control	O
as	O
recorded	O
by	O
patients	O
.	O

The	O
outcome	O
measures	O
are	O
overall	O
survival	O
,	O
palliation	O
of	O
symptoms	O
,	O
performance	O
status	O
,	O
analgesic	O
usage	O
,	O
toxicity	O
,	O
quality	O
of	O
life	O
,	O
tumor	O
response	O
,	O
and	O
recurrence/progression-free	O
survival	O
.	O

In	O
a	O
preliminary	O
feasibility	O
study	O
,	O
we	O
are	O
assessing	O
the	O
acceptability	O
of	O
the	O
trial	O
design	O
to	O
patients	O
and	O
the	O
suitability	O
of	O
two	O
standard	O
quality-of-life	O
instruments	O
in	O
mesothelioma	O
.	O

Data	O
will	O
help	O
us	O
to	O
decide	O
the	O
final	O
details	O
of	O
the	O
large	O
multicenter	O
trial	O
.	O

The	O
management	O
of	O
dermoid	O
cysts	O
--	O
a	O
comparative	O
study	O
of	O
laparoscopy	Surgical
and	O
laparotomy	Surgical
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
compare	O
laparoscopy	Surgical
with	O
laparotomy	Surgical
for	O
the	O
removal	O
of	O
ovarian	O
dermoid	O
cysts	O
.	O

Thirty-eight	O
women	O
with	O
benign	O
ovarian	O
dermoid	O
cyst	O
were	O
allocated	O
for	O
either	O
laparoscopy	Surgical
(	O
18	O
patients	O
)	O
or	O
laparotomy	Surgical
(	O
20	O
patients	O
)	O
.	O

The	O
two	O
groups	O
were	O
compared	O
for	O
operative	O
and	O
hospitalization	O
times	O
and	O
postoperative	O
course	O
.	O

Operating	O
time	O
was	O
longer	O
(	O
93.6	O
+/-	O
23.8	O
min	O
)	O
and	O
hospitalization	O
time	O
significantly	O
shorter	O
(	O
22.4	O
+/-	O
6.6	O
h	O
)	O
in	O
the	O
laparoscopy	O
group	O
.	O

No	O
complications	O
were	O
reported	O
in	O
either	O
group	O
.	O

We	O
conclude	O
that	O
operative	Surgical
laparoscopy	Surgical
is	O
a	O
safe	O
procedure	O
for	O
the	O
removal	O
of	O
dermoid	O
ovarian	O
cysts	O
and	O
is	O
as	O
effective	O
as	O
laparotomy	Surgical
.	O

Paracervical	O
anesthesia	O
for	O
outpatient	O
hysteroscopy	O
.	O

One	O
hundred	O
seventy-seven	O
women	O
aged	O
41	O
+/-	O
8	O
(	O
mean	O
+/-	O
SD	O
)	O
years	O
,	O
referred	O
for	O
evaluation	O
of	O
excessive	O
uterine	O
bleeding	O
,	O
were	O
enrolled	O
in	O
an	O
open-label	O
randomized	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
local	Pharmacological
anesthesia	Pharmacological
before	O
hysteroscopy	O
in	O
an	O
outpatient	O
population	O
.	O

The	O
patients	O
underwent	O
hysteroscopy	Surgical
and	Surgical
endometrial	Surgical
biopsy	Surgical
with	O
paracervical	Pharmacological
block	Pharmacological
by	Pharmacological
10	Pharmacological
mL	Pharmacological
of	Pharmacological
1	Pharmacological
%	Pharmacological
mepivacaine	Pharmacological
hydrochloride	Pharmacological
solution	Pharmacological
(	O
n	O
=	O
87	O
)	O
or	O
no	Control
local	Control
anesthesia	Control
(	O
n	O
=	O
90	O
)	O
and	O
assessed	O
lower	O
abdominal	O
and	O
pelvic	O
pain	O
according	O
to	O
a	O
10-point	O
linear	O
analog	O
scale	O
.	O

The	O
mean	O
+/-	O
SD	O
pain	O
score	O
was	O
4.5	O
+/-	O
2.0	O
at	O
hysteroscopy	O
and	O
5.2	O
+/-	O
2.1	O
at	O
endometrial	O
biopsy	O
in	O
the	O
87	O
subjects	O
given	O
a	O
paracervical	O
block	O
versus	O
4.9	O
+/-	O
2.2	O
and	O
5.7	O
+/-	O
2.4	O
in	O
the	O
90	O
women	O
not	O
given	O
local	O
anesthesia	O
,	O
without	O
statistically	O
significant	O
differences	O
.	O

Paracervical	Physical
anesthesia	Physical
for	O
routine	O
outpatient	O
hysteroscopy	O
in	O
premenopausal	O
women	O
may	O
be	O
superfluous	O
.	O

Long-term	O
effects	O
of	O
ezetimibe-plus-statin	Pharmacological
therapy	Pharmacological
on	O
low-density	O
lipoprotein	O
cholesterol	O
levels	O
as	O
compared	O
with	O
double-dose	Control
statin	Control
therapy	Control
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
mechanism	O
of	O
long-term	O
LDL-C-lowering	O
effect	O
of	O
ezetimibe-plus-statin	Pharmacological
.	O

METHODS	O
Coronary	O
artery	O
disease	O
patients	O
whose	O
LDL-C	O
?	O
70	O
mg/dL	O
after	O
treatment	O
with	O
atorvastatin	O
10	O
mg/day	O
or	O
rosuvastatin	O
2.5	O
mg/day	O
were	O
randomly	O
assigned	O
to	O
receive	O
ezetimibe	O
10	O
mg/day	O
+	O
statin	O
(	O
n	O
=	O
78	O
)	O
or	O
double-dose	O
statin	O
(	O
n	O
=	O
72	O
)	O
for	O
52	O
weeks	O
.	O

RESULTS	O
Greater	O
LDL-C	O
reduction	O
was	O
observed	O
and	O
maintained	O
until	O
52	O
weeks	O
in	O
ezetimibe-plus-statin	O
,	O
while	O
LDL-C	O
levels	O
re-increased	O
after	O
12	O
weeks	O
in	O
double-dose	O
statin	O
.	O

Although	O
lathosterol/TC	O
increased	O
,	O
campesterol/TC	O
decreased	O
more	O
in	O
ezetimibe-plus-statin	O
.	O

In	O
contrast	O
,	O
lathosterol/TC	O
unchanged	O
and	O
campesterol/TC	O
increased	O
,	O
increasing	O
campesterol/lathosterol	O
ratio	O
for	O
52	O
weeks	O
in	O
double-dose	O
statin	O
.	O

Plasma	O
PCSK9	O
levels	O
were	O
higher	O
in	O
double-dose	O
statin	O
than	O
in	O
ezetimibe-plus-statin	O
at	O
12	O
weeks	O
,	O
but	O
similar	O
at	O
52	O
weeks	O
.	O

CONCLUSION	O
Although	O
the	O
difference	O
in	O
PCSK9	O
between	O
2	O
groups	O
was	O
transient	O
,	O
that	O
in	O
both	O
campesterol	O
and	O
lathosterol	O
persisted	O
until	O
52	O
weeks	O
.	O

These	O
results	O
demonstrated	O
simultaneous	O
inhibition	O
of	O
cholesterol	O
absorption	O
and	O
synthesis	O
provides	O
stable	O
and	O
greater	O
decrease	O
in	O
LDL-C	O
levels	O
.	O

Dihydroergocryptine	Pharmacological
in	O
the	O
management	O
of	O
senile	O
psycho-organic	O
syndrome	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	Control
,	O
randomized	O
study	O
is	O
described	O
of	O
an	O
assessment	O
of	O
the	O
efficacy	O
and	O
relative	O
safety	O
of	O
the	O
ergot	O
alkaloid	O
,	O
dihydroergocryptine	Pharmacological
,	O
on	O
52	O
patients	O
with	O
mild	O
organic	O
brain	O
syndrome	O
over	O
a	O
period	O
of	O
three	O
months	O
using	O
a	O
series	O
of	O
neurophysiological	O
tests	O
.	O

The	O
results	O
indicated	O
that	O
short-term	O
treatment	O
with	O
the	O
alkaloid	O
improved	O
memory	O
impairment	O
.	O

The	O
side-effects	O
were	O
mild	O
and	O
transient	O
in	O
both	O
the	O
dihydroergocryptine	Pharmacological
and	O
placebo	O
groups	O
and	O
there	O
were	O
no	O
alterations	O
in	O
blood	O
chemistry	O
.	O

Pelvic	O
lymphocysts	O
following	O
retroperitoneal	O
lymphadenectomy	O
:	O
retroperitoneal	Physical
partial	Physical
no-closure	Physical
for	O
ovarian	O
and	O
endometrial	O
cancers	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Pelvic	O
lymphocysts	O
have	O
been	O
reported	O
mainly	O
following	O
pelvic	O
lymphadenectomy	O
for	O
cervical	O
cancer	O
.	O

We	O
attempted	O
to	O
assess	O
whether	O
retroperitoneal	Physical
partial	Physical
no-closure	Physical
reduces	O
the	O
incidence	O
of	O
lymphocyst	O
formation	O
following	O
retroperitoneal	O
lymphadenectomy	O
.	O

METHODS	O
Sixty-one	O
patients	O
with	O
ovarian	O
cancer	O
or	O
endometrial	O
cancer	O
who	O
underwent	O
retroperitoneal	O
lymph	O
node	O
resection	O
were	O
assigned	O
at	O
random	O
to	O
a	O
retroperitoneal	Physical
partial	Physical
no-closure	Physical
group	Physical
or	O
a	Surgical
closure	Physical
group	Physical
.	O

The	O
incidence	O
of	O
lymphocysts	O
in	O
the	O
two	O
groups	O
as	O
determined	O
using	O
ultrasonography	O
was	O
compared	O
.	O

RESULTS	O
Lymphocysts	O
appeared	O
in	O
23/61	O
patients	O
(	O
38	O
%	O
)	O
in	O
total	O
.	O

In	O
the	O
closure	O
group	O
,	O
the	O
incidence	O
was	O
52	O
%	O
(	O
16/31	O
)	O
,	O
but	O
in	O
the	O
no-closure	O
group	O
it	O
was	O
only	O
23	O
%	O
(	O
7/30	O
)	O
;	O
the	O
incidence	O
in	O
the	O
no-closure	O
group	O
was	O
significantly	O
lower	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
incidence	O
of	O
postoperative	O
fever	O
was	O
17	O
%	O
(	O
5/30	O
)	O
in	O
the	O
no-closure	O
group	O
,	O
which	O
was	O
lower	O
than	O
that	O
in	O
the	O
closure	O
group	O
(	O
42	O
%	O
,	O
13/31	O
)	O
,	O
but	O
not	O
significantly	O
so	O
(	O
P	O
<	O
0.1	O
)	O
.	O

No	O
patients	O
in	O
the	O
no-closure	O
group	O
required	O
surgical	O
procedures	O
such	O
as	O
needle	O
aspiration	O
or	O
cyst	O
drainage	O
.	O

CONCLUSIONS	O
Retroperitoneal	Physical
partial	Physical
no-closure	Physical
appears	O
to	O
be	O
a	O
useful	O
procedure	O
for	O
reducing	O
the	O
incidence	O
of	O
pelvic	O
lymphocysts	O
associated	O
with	O
retroperitoneal	Surgical
lymphadenectomy	Surgical
.	O

Topical	Pharmacological
retapamulin	Pharmacological
ointment	Pharmacological
(	O
1	O
%	O
,	O
wt/wt	O
)	O
twice	O
daily	O
for	O
5	O
days	O
versus	O
oral	O
cephalexin	Pharmacological
twice	O
daily	O
for	O
10	O
days	O
in	O
the	O
treatment	O
of	O
secondarily	O
infected	O
dermatitis	O
:	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
New	O
antibacterial	O
agents	O
with	O
activity	O
against	O
pathogenic	O
strains	O
resistant	O
to	O
established	O
antibiotics	O
are	O
needed	O
to	O
treat	O
patients	O
with	O
secondarily	O
infected	O
dermatitis	O
(	O
SID	O
)	O
.	O

OBJECTIVE	O
We	O
sought	O
to	O
determine	O
the	O
clinical	O
safety	O
and	O
efficacy	O
of	O
topical	Pharmacological
retapamulin	Pharmacological
ointment	Pharmacological
1	O
%	O
versus	O
oral	O
cephalexin	Pharmacological
for	O
the	O
treatment	O
of	O
SID	O
.	O

METHODS	O
Patients	O
with	O
SID	O
were	O
randomly	O
assigned	O
to	O
retapamulin	Pharmacological
ointment	Pharmacological
1	O
%	O
(	O
twice	O
daily	O
[	O
bid	O
]	O
)	O
for	O
5	O
days	O
,	O
or	O
oral	Pharmacological
cephalexin	Pharmacological
(	O
500	O
mg	O
bid	O
)	O
for	O
10	O
days	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
clinical	O
response	O
at	O
follow-up	O
.	O

Secondary	O
outcomes	O
included	O
microbiologic	O
response	O
at	O
follow-up	O
,	O
safety	O
,	O
and	O
compliance	O
.	O

RESULTS	O
Retapamulin	Pharmacological
was	O
as	O
effective	O
as	O
cephalexin	Pharmacological
(	O
clinical	O
success	O
rates	O
at	O
follow-up	O
:	O
85.9	O
%	O
and	O
89.7	O
%	O
,	O
respectively	O
)	O
.	O

Microbiologic	O
success	O
rates	O
at	O
follow-up	O
were	O
87.2	O
%	O
for	O
retapamulin	Pharmacological
and	O
91.8	O
%	O
for	O
cephalexin	Pharmacological
.	O

Retapamulin	Pharmacological
was	O
well	O
tolerated	O
and	O
the	O
topical	O
formulation	O
was	O
preferred	O
over	O
the	O
oral	Pharmacological
drug	Pharmacological
.	O

LIMITATIONS	O
An	O
imbalance	O
existed	O
in	O
the	O
number	O
of	O
patients	O
with	O
the	O
clinical	O
outcome	O
unable	O
to	O
determine	O
(	O
15	O
retapamulin	Pharmacological
,	O
2	O
cephalexin	Pharmacological
)	O
,	O
mainly	O
because	O
of	O
their	O
failure	O
to	O
attend	O
the	O
study	O
visit	O
.	O

If	O
those	O
who	O
failed	O
to	O
attend	O
visits	O
(	O
who	O
did	O
not	O
withdraw	O
as	O
a	O
result	O
of	O
drug-related	O
events	O
)	O
are	O
removed	O
from	O
the	O
analysis	O
,	O
the	O
clinical	O
success	O
rates	O
are	O
89.9	O
%	O
for	O
retapamulin	Pharmacological
and	O
89.7	O
%	O
for	O
cephalexin	Pharmacological
.	O

CONCLUSIONS	O
Retapamulin	Pharmacological
ointment	Pharmacological
1	O
%	O
(	O
bid	O
)	O
for	O
5	O
days	O
was	O
as	O
effective	O
as	O
oral	O
cephalexin	Pharmacological
(	O
bid	O
)	O
for	O
10	O
days	O
in	O
treatment	O
of	O
patients	O
with	O
SID	O
,	O
and	O
was	O
well	O
tolerated	O
.	O

Erythrocyte	O
deformability	O
,	O
endothelin	O
levels	O
,	O
and	O
renal	O
function	O
in	O
cyclosporin-treated	Pharmacological
renal	O
transplant	O
recipients	O
:	O
effects	O
of	O
intervention	O
with	O
fish	Pharmacological
oil	Pharmacological
and	O
corn	Pharmacological
oil	Pharmacological
.	O

Twenty	O
nine	O
stable	O
renal	O
transplant	O
recipients	O
,	O
10	O
receiving	O
cyclosporin	Pharmacological
,	O
10	Pharmacological
cyclosporin-prednisolone	Pharmacological
and	O
nine	O
azathioprine-prednisolone	Pharmacological
were	O
supplemented	O
in	O
a	O
double	O
blind	O
randomization	O
cross-over	O
study	O
with	O
fish	Pharmacological
oil	Pharmacological
and	O
corn	Pharmacological
oil	Pharmacological
for	O
a	O
period	O
of	O
4	O
months	O
each	O
.	O

Erythrocyte	O
deformability	O
was	O
reduced	O
in	O
the	O
cyclosporin-treated	Pharmacological
patients	O
and	O
returned	O
to	O
normal	O
values	O
after	O
supplementation	O
of	O
either	O
oil	Pharmacological
.	O

The	O
oil	O
supplementation	O
resulted	O
in	O
an	O
increased	O
polyunsaturated	O
fatty	O
acid	O
content	O
in	O
the	O
plasma	O
phospholipids	O
.	O

An	O
increased	O
erythrocyte	O
membrane	O
polyunsaturated	O
fatty	O
acid	O
content	O
might	O
correct	O
the	O
lower	O
erythrocyte	O
deformability	O
in	O
cyclosporin	Pharmacological
treated	O
patients	O
.	O

Therefore	O
,	O
it	O
is	O
probable	O
that	O
these	O
changes	O
are	O
membrane-related	O
.	O

The	O
oil	Pharmacological
supplementation	O
had	O
no	O
effect	O
on	O
glomerular	O
filtration	O
rate	O
,	O
effective	O
renal	O
plasma	O
flow	O
,	O
filtration	O
fraction	O
or	O
blood	O
pressure	O
,	O
which	O
does	O
not	O
exclude	O
effects	O
of	O
the	O
cyclosporin-induced	O
rigidified	O
erythrocytes	O
in	O
the	O
acute	O
phase	O
of	O
renal	O
transplantation	O
.	O

Decreased	O
erythrocyte	O
deformability	O
could	O
play	O
a	O
role	O
in	O
the	O
cyclosporin-induced	Pharmacological
deterioration	O
of	O
renal	O
haemodynamics	O
.	O

This	O
may	O
enhance	O
the	O
effects	O
of	O
endothelin	O
,	O
as	O
these	O
patients	O
also	O
had	O
elevated	O
endothelin	O
levels	O
.	O

Advice	O
or	O
exercise	O
for	O
chronic	O
whiplash	O
disorders	O
?	O
Design	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Whiplash-associated	O
disorder	O
(	O
or	O
whiplash	O
)	O
is	O
a	O
common	O
condition	O
incurring	O
considerable	O
expense	O
in	O
social	O
and	O
economic	O
terms	O
.	O

A	O
lack	O
of	O
research	O
on	O
effective	O
therapy	O
for	O
patients	O
with	O
chronic	O
whiplash	O
associated	O
disorders	O
prompted	O
the	O
design	O
of	O
the	O
current	O
study	O
.	O

The	O
primary	O
aim	O
of	O
this	O
randomised	O
controlled	O
trial	O
is	O
to	O
determine	O
the	O
effects	O
of	O
a	O
physical	O
activity	O
program	O
for	O
people	O
with	O
chronic	O
(	O
symptoms	O
of	O
>	O
3	O
months	O
duration	O
)	O
whiplash	O
.	O

A	O
secondary	O
aim	O
is	O
to	O
determine	O
if	O
pain	O
severity	O
,	O
level	O
of	O
disability	O
and	O
fear	O
of	O
movement/	O
(	O
re	O
)	O
injury	O
predict	O
response	O
to	O
a	O
physical	O
activity	O
program	O
.	O

METHODS/DESIGN	O
This	O
paper	O
presents	O
the	O
rationale	O
and	O
design	O
of	O
a	O
randomised	O
controlled	O
trial	O
examining	O
the	O
effects	O
of	O
advice	Educational
and	Educational
individualized	Physical
sub-maximal	Physical
exercise	Physical
programs	Physical
in	O
the	O
treatment	O
of	O
whiplash	O
associated	O
disorders	O
.	O

DISCUSSION	O
This	O
paper	O
highlights	O
the	O
design	O
,	O
methods	O
and	O
operational	O
aspects	O
of	O
a	O
significant	O
clinical	O
trial	O
in	O
the	O
area	O
of	O
whiplash	O
and	O
chronic	O
pain	O
.	O

Theophylline	Pharmacological
concentrations	O
in	O
serum	O
and	O
saliva	O
after	O
oral	O
microcrystalline	Pharmacological
and	O
sustained-release	Pharmacological
preparations	Pharmacological
in	O
asthmatics	O
.	O

Theophylline	Pharmacological
concentrations	O
in	O
saliva	O
have	O
been	O
compared	O
with	O
those	O
in	O
serum	O
in	O
13	O
asthmatic	O
patients	O
after	O
single	O
and	O
multiple	O
oral	O
dosage	O
of	O
a	O
microcrystalline	Pharmacological
theophylline	Pharmacological
tablet	Pharmacological
(	O
Nuelin	O
)	O
and	O
a	O
sustained-release	Pharmacological
preparation	Pharmacological
(	O
Nuelin	O
Retard	O
)	O
.	O

There	O
was	O
wide	O
individual	O
variation	O
in	O
the	O
ratio	O
of	O
serum	O
to	O
saliva	O
concentrations	O
indicating	O
that	O
,	O
even	O
when	O
individual	O
serum	O
to	O
saliva	O
ratios	O
have	O
been	O
established	O
,	O
the	O
use	O
of	O
saliva	O
theophylline	Pharmacological
measurements	O
alone	O
is	O
unreliable	O
for	O
the	O
routine	O
monitoring	O
of	O
theophylline	Pharmacological
therapy	O
.	O

Both	O
preparations	O
produced	O
mean	O
serum	O
theophylline	O
concentrations	O
within	O
the	O
10	O
--	O
20	O
mcg/ml	O
range	O
,	O
the	O
sustained-release	O
tablet	O
giving	O
higher	O
monitoring	O
through	O
values	O
and	O
smaller	O
through	O
to	O
peak	O
variation	O
.	O

The	O
preparations	O
were	O
equally	O
and	O
highly	O
bioavailable	O
.	O

Side	O
effects	O
were	O
reported	O
by	O
three	O
patients	O
,	O
which	O
were	O
the	O
patients	O
with	O
the	O
highest	O
AUC	O
.	O

The	O
Nuelin	Pharmacological
Retard	Pharmacological
preparation	O
appears	O
to	O
provide	O
smooth	O
,	O
sustained	O
serum	O
theophylline	O
concentrations	O
within	O
the	O
therapeutic	O
range	O
and	O
the	O
simple	O
,	O
twice-daily	O
dosage	O
should	O
result	O
in	O
improved	O
patient	O
compliance	O
.	O

CDP571	Pharmacological
,	O
a	O
humanized	O
monoclonal	O
antibody	O
to	O
tumour	O
necrosis	O
factor-alpha	O
,	O
for	O
steroid-dependent	O
Crohn	O
's	O
disease	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
.	O

BACKGROUND	O
More	O
than	O
50	O
%	O
of	O
patients	O
with	O
Crohn	O
's	O
disease	O
become	O
either	O
steroid	O
resistant	O
or	O
dependent	O
.	O

Accordingly	O
,	O
development	O
of	O
new	O
treatments	O
for	O
steroid-dependent	O
Crohn	O
's	O
disease	O
is	O
a	O
research	O
priority	O
.	O

AIM	O
To	O
evaluate	O
CDP571	Pharmacological
,	O
a	O
humanized	O
antibody	O
to	O
tumour	O
necrosis	O
factor-alpha	O
,	O
for	O
the	O
treatment	O
of	O
steroid-dependent	O
Crohn	O
's	O
disease	O
.	O

METHODS	O
Patients	O
with	O
steroid-dependent	O
Crohn	O
's	O
disease	O
(	O
n	O
=	O
271	O
)	O
were	O
enrolled	O
in	O
a	O
36-week	O
,	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
.	O

Steroid	O
dependence	O
was	O
defined	O
as	O
use	O
of	O
prednisolone	O
or	O
prednisone	Pharmacological
(	O
15-40	O
mg/day	O
)	O
or	O
budesonide	O
(	O
9	O
mg/day	O
)	O
for	O
>	O
or	O
=8	O
weeks	O
,	O
a	O
previous	O
failed	O
attempt	O
to	O
decrease	O
or	O
discontinue	O
steroids	O
within	O
8	O
weeks	O
of	O
screening	O
,	O
and	O
a	O
Crohn	O
's	O
Disease	O
Activity	O
Index	O
score	O
of	O
<	O
or	O
=150	O
points	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
intravenous	O
CDP571	Control
10	O
mg/kg	O
or	O
placebo	O
8-weekly	O
through	O
to	O
week	O
32	O
.	O

Steroids	O
were	O
then	O
tapered	O
using	O
a	O
defined	O
schedule	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
percentage	O
of	O
patients	O
with	O
steroid	O
sparing	O
,	O
defined	O
as	O
discontinuation	O
of	O
steroid	O
therapy	Pharmacological
without	O
a	O
disease	O
flare	O
(	O
Crohn	O
's	O
Disease	O
Activity	O
Index	O
score	O
>	O
or	O
=220	O
points	O
)	O
at	O
week	O
36	O
.	O

RESULTS	O
Steroid	O
sparing	O
occurred	O
in	O
53	O
of	O
181	O
(	O
29.3	O
%	O
)	O
CDP571	Pharmacological
patients	O
and	O
33	O
of	O
90	O
(	O
36.7	O
%	O
)	O
placebo	Control
patients	O
(	O
P	O
=	O
0.24	O
)	O
.	O

Adverse	O
events	O
occurred	O
at	O
similar	O
frequencies	O
in	O
both	O
treatment	O
groups	O
.	O

CONCLUSIONS	O
CDP571	Pharmacological
was	O
ineffective	O
for	O
sparing	O
steroids	O
in	O
patients	O
with	O
steroid-dependent	O
Crohn	O
's	O
disease	O
.	O

CDP571	Pharmacological
was	O
well	O
tolerated	O
.	O

Early	O
intervention	O
for	O
autism	O
with	O
a	O
parent-delivered	Educational
Qigong	Educational
massage	Educational
program	Educational
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

A	O
recent	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
of	O
a	O
dual	Educational
parent	Educational
and	Educational
trainer-delivered	Educational
qigong	Educational
massage	Educational
intervention	O
for	O
young	O
children	O
with	O
autism	O
resulted	O
in	O
improvement	O
of	O
measures	O
of	O
autism	O
as	O
well	O
as	O
improvement	O
of	O
abnormal	O
sensory	O
responses	O
and	O
self-regulation	O
.	O

The	O
RCT	O
evaluated	O
the	O
effects	O
of	O
the	O
parent-delivered	O
component	O
of	O
the	O
intervention	O
.	O

Forty-seven	O
children	O
were	O
randomly	O
assigned	O
to	O
treatment	O
and	O
wait-list	O
control	O
groups	O
.	O

Treatment	O
group	O
children	O
received	O
the	O
parent-delivered	Educational
program	Educational
for	Educational
4	Educational
mo	Educational
.	O

Trained	O
therapists	O
provided	O
parent	Educational
training	Educational
and	Educational
support	Educational
.	O

Improvement	O
was	O
evaluated	O
in	O
two	O
settings	O
--	O
preschool	O
and	O
home	O
--	O
by	O
teachers	O
(	O
blind	O
to	O
group	O
)	O
and	O
parents	O
.	O

Results	O
showed	O
that	O
the	O
parent-delivered	O
program	O
was	O
effective	O
in	O
improving	O
measures	O
of	O
autism	O
(	O
medium	O
effect	O
size	O
)	O
and	O
sensory	O
and	O
self-regulatory	O
responses	O
(	O
large	O
effect	O
size	O
)	O
.	O

Teacher	O
data	O
on	O
measures	O
of	O
autism	O
were	O
confirmed	O
by	O
parent	O
data	O
.	O

Results	O
indicate	O
that	O
the	O
parent-delivered	Educational
component	Educational
of	O
the	O
program	O
provided	O
effective	O
early	O
intervention	O
for	O
autism	O
that	O
was	O
suitable	O
for	O
delivery	O
at	O
home	O
.	O

Comparison	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
phonophoresis	Physical
and	O
iontophoresis	Physical
using	O
dexamethasone	Pharmacological
sodium	Pharmacological
phosphate	Pharmacological
in	O
the	O
management	O
of	O
patients	O
with	O
knee	O
osteoarthritis	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
Many	O
treatment	O
options	O
,	O
including	O
non-pharmacological	O
and	O
pharmacological	O
measures	O
,	O
have	O
been	O
recommended	O
in	O
the	O
management	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Among	O
the	O
non-pharmacological	O
approach	O
is	O
physiotherapy	O
,	O
which	O
involves	O
the	O
use	O
of	O
physical	O
modalities	O
like	O
,	O
heat	O
therapy	O
,	O
exercise	O
therapy	O
,	O
electrical	O
stimulation	O
,	O
therapeutic	O
ultrasound	O
,	O
iontophoresis	O
,	O
and	O
phonophoresis	O
.	O

This	O
study	O
was	O
therefore	O
designed	O
to	O
compare	O
the	O
effectiveness	O
of	O
0.4	O
%	O
Dexamethasone	Pharmacological
sodium	Pharmacological
phosphate	Pharmacological
(	Pharmacological
DEX-P	Pharmacological
)	Pharmacological
phonophoresis	Physical
(	Physical
PH	Physical
)	Physical
with	O
0.4	Pharmacological
%	Pharmacological
DEX-P	Pharmacological
iontophoresis	Physical
(	Physical
ION	Physical
)	Physical
therapy	Pharmacological
in	O
the	O
management	O
of	O
patients	O
with	O
knee	O
joint	O
OA	O
.	O

METHODS	O
Fifty	O
patients	O
(	O
19	O
males	O
and	O
31	O
females	O
)	O
with	O
a	O
mean	O
age	O
of	O
53.6	O
+/-	O
8.9	O
years	O
were	O
randomly	O
assigned	O
to	O
PH	Physical
or	O
ION	Physical
groups	O
with	O
25	O
patients	O
in	O
each	O
group	O
.	O

Ultrasound	O
waves	O
of	O
1	O
MHz	O
frequency	O
was	O
applied	O
for	O
5	O
minutes	O
to	O
the	O
target	O
knee	O
,	O
so	O
also	O
was	O
the	O
direct	O
current	O
for	O
10	O
minutes	O
for	O
10	O
sessions	O
treatment	O
period	O
.	O

Western	O
Ontario	O
and	O
McMaster	O
University	O
Osteoarthritis	O
Index	O
(	O
WOMAC	O
)	O
scores	O
,	O
20	O
meters	O
ambulatory	O
time	O
,	O
and	O
knee	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
were	O
evaluated	O
before	O
and	O
after	O
therapy	O
as	O
the	O
outcome	O
measures	O
.	O

RESULTS	O
At	O
the	O
end	O
of	O
two	O
weeks	O
,	O
significant	O
improvement	O
in	O
total	O
WOMAC	O
scores	O
was	O
observed	O
in	O
15	O
(	O
60	O
%	O
)	O
and	O
16	O
(	O
64	O
%	O
)	O
patients	O
in	O
the	O
PH	O
and	O
ION	O
groups	O
respectively	O
,	O
indicating	O
no	O
significant	O
difference	O
in	O
the	O
improvement	O
rate	O
.	O

Twenty	O
(	O
20	O
)	O
metres	O
ambulatory	O
time	O
and	O
knee	O
range	O
of	O
motion	O
also	O
improved	O
significantly	O
in	O
both	O
groups	O
,	O
yet	O
these	O
variables	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
Both	O
therapeutic	O
modalities	O
were	O
found	O
to	O
be	O
effective	O
and	O
generally	O
well	O
tolerated	O
after	O
10	O
treatment	O
sessions	O
.	O

DEX-P	Pharmacological
phonophoresis	Physical
was	O
not	O
superior	O
to	O
DEX-P	Pharmacological
iontophoresis	Physical
in	O
the	O
treatment	O
of	O
patients	O
with	O
OA	O
of	O
the	O
knee	O
.	O

Changes	O
in	O
sleep	O
quality	O
,	O
but	O
not	O
hormones	O
predict	O
time	O
to	O
postpartum	O
depression	O
recurrence	O
.	O

BACKGROUND	O
Poor	O
sleep	O
quality	O
,	O
dysregulation	O
of	O
hormones	O
and	O
increased	O
inflammatory	O
cytokines	O
are	O
all	O
associated	O
with	O
the	O
risk	O
for	O
postpartum	O
major	O
depression	O
(	O
PPMD	O
)	O
.	O

We	O
evaluated	O
change	O
over	O
time	O
in	O
sleep	O
quality	O
and	O
hormones	O
during	O
the	O
first	O
17	O
weeks	O
postpartum	O
,	O
as	O
well	O
as	O
a	O
single	O
cytokine	O
measure	O
,	O
and	O
their	O
association	O
with	O
PPMD	O
recurrence	O
.	O

METHODS	O
Participants	O
were	O
pregnant	O
women	O
(	O
N=56	O
)	O
,	O
with	O
past	O
histories	O
of	O
MDD/PPMD	O
but	O
not	O
depressed	O
in	O
their	O
current	O
pregnancy	O
.	O

The	O
Pittsburgh	Educational
Sleep	Educational
Quality	Educational
Index	Educational
(	Educational
PSQI	Educational
)	Educational
and	O
blood	Pharmacological
samples	Pharmacological
were	O
collected	O
8	O
times	O
during	O
the	O
first	O
17	O
weeks	O
postpartum	O
.	O

Estradiol	O
,	O
prolactin	O
and	O
cortisol	O
,	O
and	O
a	O
single	O
measure	O
of	O
IL-6	O
were	O
assayed	O
.	O

Recurrence	O
was	O
determined	O
by	O
two	O
consecutive	O
21-item	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
(	O
HRSD	O
)	O
scores?15	O
and	O
clinician	O
interview	O
.	O

RESULTS	O
In	O
the	O
analyses	O
of	O
time	O
to	O
PPMD	O
recurrence	O
,	O
poor	O
sleep	O
quality	O
,	O
but	O
none	O
of	O
the	O
hormones	O
,	O
was	O
associated	O
with	O
PPMD	O
recurrence	O
(	O
p	O
<	O
.05	O
)	O
after	O
controlling	O
for	O
medication	O
assignment	O
.	O

With	O
every	O
one	O
point	O
increase	O
in	O
PSQI	O
scores	O
across	O
time	O
,	O
a	O
woman	O
's	O
risk	O
for	O
recurrence	O
increased	O
by	O
approximately	O
25	O
%	O
There	O
was	O
no	O
significant	O
association	O
between	O
PSQI	O
scores	O
and	O
IL-6	O
concentrations	O
in	O
early	O
postpartum	O
(	O
?	O
(	O
2	O
)	O
=0.98	O
,	O
p=.32	O
)	O
.	O

CONCLUSIONS	O
Poor	O
sleep	O
quality	O
across	O
the	O
first	O
17	O
weeks	O
post-delivery	O
increases	O
the	O
risk	O
for	O
recurrent	O
PPMD	O
among	O
women	O
with	O
a	O
history	O
of	O
MDD	O
.	O

Changes	O
in	O
the	O
hormonal	O
milieu	O
were	O
not	O
associated	O
with	O
recurrence	O
.	O

Further	O
exploration	O
of	O
the	O
degree	O
to	O
which	O
poor	O
sleep	O
contributes	O
to	O
hormonal	O
and	O
cytokine	O
dysregulation	O
and	O
how	O
they	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
PPMD	O
is	O
warranted	O
.	O

A	O
double-blind	O
placebo	Control
controlled	O
trial	O
of	O
Ginkgo	Pharmacological
biloba	Pharmacological
added	O
to	O
risperidone	Pharmacological
in	O
patients	O
with	O
autistic	O
disorders	O
.	O

Ginkgo	O
biloba	O
has	O
been	O
reported	O
to	O
affect	O
the	O
neurotransmitter	O
system	O
and	O
to	O
have	O
antioxidant	O
properties	O
that	O
could	O
impact	O
the	O
pathogenesis	O
of	O
Autism	O
Spectrum	O
Disorder	O
.	O

Based	O
on	O
these	O
studies	O
,	O
we	O
decided	O
to	O
assess	O
the	O
effectiveness	O
of	O
Ginkgo	Pharmacological
biloba	Pharmacological
extract	O
(	O
Ginko	O
T.D.	O
,	O
Tolidaru	O
,	O
Iran	O
)	O
as	O
an	O
adjunctive	O
agent	O
to	O
risperidone	O
in	O
the	O
treatment	O
of	O
autism	O
.	O

Forty-seven	O
outpatients	O
with	O
a	O
DSM-IV-TR	O
diagnosis	O
of	O
autism	O
ages	O
between	O
4	O
and	O
12	O
years	O
were	O
assigned	O
to	O
this	O
double	O
blinded	O
clinical	O
trial	O
and	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

One	O
group	O
received	O
risperidone	Pharmacological
plus	Pharmacological
Ginko	Pharmacological
T.D	Pharmacological
and	Pharmacological
the	Pharmacological
other	Control
received	Control
risperidone	Control
plus	Control
placebo	Control
.	O

The	O
dose	O
of	O
risperidone	Pharmacological
was	O
1-3	O
mg/day	O
and	O
the	O
dose	O
of	O
Ginko	Pharmacological
T.D	Pharmacological
.	Pharmacological

was	O
80	O
mg/day	O
for	O
patients	O
under	O
30	O
kg	O
and	O
120	O
mg/day	O
for	O
patients	O
above	O
30	O
kg	O
.	O

Patients	O
were	O
assessed	O
using	O
Aberrant	O
Behavior	O
Checklist-Community	O
(	O
ABC-C	O
)	O
rating	O
scale	O
and	O
the	O
side	O
effect	O
check	O
list	O
every	O
2	O
weeks	O
until	O
the	O
endpoint	O
.	O

None	O
of	O
the	O
5	O
subscales	O
of	O
ABC-C	O
rating	O
scale	O
showed	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
.	O

Incidents	O
of	O
side	O
effects	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Adding	O
Ginkgo	Pharmacological
biloba	Pharmacological
to	Pharmacological
risperidone	Pharmacological
did	O
not	O
affect	O
the	O
treatment	O
outcome	O
of	O
ADs	O
.	O

Nevertheless	O
,	O
further	O
observations	O
are	O
needed	O
to	O
confirm	O
this	O
result	O
.	O

Custom	O
tray	O
application	O
of	O
peroxide	Pharmacological
gel	Pharmacological
as	O
an	O
adjunct	O
to	O
scaling	Surgical
and	Physical
root	Surgical
planing	Surgical
in	O
the	O
treatment	O
of	O
periodontitis	O
:	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
after	O
six	O
months	O
.	O

OBJECTIVE	O
Scaling	Surgical
and	Surgical
root	Surgical
planing	Surgical
(	Surgical
SRP	Surgical
)	Surgical
is	O
the	O
primary	O
non-surgical	O
treatment	O
for	O
periodontitis	O
,	O
but	O
its	O
effectiveness	O
is	O
limited	O
.	O

Consequently	O
,	O
various	O
adjunctive	O
therapies	O
have	O
been	O
investigated	O
to	O
improve	O
clinical	O
outcome	O
.	O

This	O
study	O
evaluated	O
the	O
clinical	O
effects	O
of	O
one	O
SRP	Surgical
procedure	O
alone	O
or	O
combined	O
with	O
local	O
administration	O
of	O
hydrogen	Pharmacological
peroxide	Pharmacological
gel	Pharmacological
using	O
customized	O
trays	O
for	O
the	O
treatment	O
of	O
subjects	O
with	O
chronic	O
periodontitis	O
over	O
a	O
period	O
of	O
six	O
months	O
.	O

METHODS	O
An	O
examiner-blind	O
clinical	O
trial	O
was	O
conducted	O
among	O
30	O
subjects	O
with	O
moderate	O
to	O
advanced	O
periodontitis	O
who	O
were	O
randomized	O
to	O
SRP	Surgical
alone	O
or	O
SRP	Surgical
combined	Physical
with	O
prescription	O
custom-tray	O
application	O
(	O
Perio	O
Tray	O
)	O
of	O
1.7	Pharmacological
%	Pharmacological
hydrogen	Pharmacological
peroxide	Pharmacological
gel	Pharmacological
(	Pharmacological
Perio	Pharmacological
Gel	Pharmacological
)	Pharmacological
for	O
a	O
period	O
of	O
three	O
months	O
,	O
then	O
extended	O
to	O
six	O
months	O
.	O

Following	O
impressions	O
for	O
the	O
test	O
group	O
,	O
all	O
subjects	O
brushed	Physical
twice	Physical
daily	Physical
with	Physical
a	Physical
regular	Physical
dentifrice	Physical
and	Physical
toothbrush	Physical
for	O
a	O
four-week	O
acclimation	O
phase	O
to	O
standardize	O
oral	O
conditions	O
(	O
while	O
trays	O
were	O
fabricated	O
)	O
prior	O
to	O
initiating	O
the	O
treatment	O
phase	O
.	O

SRP	Surgical
was	O
performed	O
three	O
weeks	O
after	O
baseline	O
,	O
and	O
clinical	O
assessments	O
,	O
i.e.	O
,	O
pocket	O
probing	O
depth	O
(	O
PPD	O
)	O
and	O
bleeding	O
index	O
(	O
BI	O
)	O
,	O
were	O
conducted	O
at	O
baseline	O
and	O
after	O
two	O
,	O
five	O
,	O
13	O
,	O
and	O
26	O
weeks	O
of	O
peroxide	Pharmacological
gel	Pharmacological
applications	O
.	O

Clinical	O
variables	O
were	O
compared	O
by	O
ANCOVA	O
and	O
paired	O
t-tests	O
after	O
each	O
treatment	O
interval	O
.	O

RESULTS	O
A	O
total	O
of	O
13	O
test	O
and	O
15	O
control	O
subjects	O
completed	O
the	O
original	O
three-month	O
trial	O
,	O
of	O
whom	O
10	O
test	O
and	O
13	O
control	O
subjects	O
finished	O
the	O
three-month	O
extension	O
.	O

After	O
two	O
weeks	O
of	O
peroxide	Pharmacological
gel	Pharmacological
use	O
prior	O
to	O
SRP	Surgical
,	O
mean	O
PPD	O
for	O
the	O
test	O
group	O
significantly	O
decreased	O
from	O
baseline	O
by	O
0.21	O
mm	O
and	O
mean	O
BI	O
significantly	O
dropped	O
by	O
0.14	O
;	O
clinical	O
parameters	O
for	O
the	O
control	O
group	O
were	O
unchanged	O
.	O

Two	O
weeks	O
following	O
SRP	Surgical
,	O
mean	O
PPD	O
significantly	O
decreased	O
from	O
baseline	O
by	O
0.65	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.17	O
mm	O
for	O
the	O
control	O
;	O
mean	O
BI	O
significantly	O
dropped	O
by	O
0.17	O
for	O
the	O
test	O
group	O
and	O
0.05	O
for	O
the	O
control	O
.	O

Ten	O
weeks	O
following	O
SRP	Surgical
,	O
mean	O
PPD	O
decreases	O
were	O
0.77	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.13	O
mm	O
for	O
the	O
control	O
,	O
and	O
mean	O
BI	O
reductions	O
were	O
0.14	O
for	O
the	O
test	O
group	O
and	O
0.00	O
for	O
the	O
control	O
.	O

For	O
subjects	O
who	O
completed	O
the	O
three-month	O
extension	O
(	O
i.e.	O
,	O
23	O
weeks	O
post-SRP	O
)	O
,	O
mean	O
PPD	O
decreases	O
were	O
0.72	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.13	O
mm	O
for	O
the	O
control	O
,	O
and	O
mean	O
BI	O
reductions	O
were	O
0.05	O
for	O
the	O
test	O
group	O
and	O
0.01	O
for	O
the	O
control	O
.	O

Analysis	O
of	O
deeper	O
pockets	O
(	O
i.e.	O
,	O
>	O
5	O
mm	O
at	O
baseline	O
)	O
showed	O
the	O
same	O
relationship	O
for	O
PPD	O
,	O
but	O
with	O
larger	O
differences	O
between	O
groups	O
.	O

For	O
example	O
,	O
after	O
two	O
weeks	O
of	O
peroxide	Pharmacological
gel	Pharmacological
use	O
prior	O
to	O
SRP	Surgical
,	O
mean	O
PPD	O
decreased	O
by	O
0.48	O
mm	O
for	O
the	O
test	O
group	O
compared	O
to	O
0.04	O
mm	O
for	O
the	O
control	O
.	O

Two	O
weeks	O
after	O
SRP	Surgical
,	O
mean	O
PPD	O
decreased	O
from	O
baseline	O
by	O
1.40	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.60	O
mm	O
for	O
the	O
control	O
,	O
and	O
10	O
weeks	O
after	O
SRP	O
by	O
1.57	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.58	O
mm	O
for	O
the	O
control	O
.	O

After	O
the	O
extension	O
(	O
i.e.	O
,	O
23	O
weeks	O
post-SRP	O
)	O
,	O
mean	O
PPD	O
changed	O
from	O
baseline	O
by	O
1.50	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.55	O
mm	O
for	O
the	O
control	O
.	O

With	O
the	O
exception	O
of	O
BI	O
at	O
23	O
weeks	O
post-SRP	O
,	O
all	O
reductions	O
cited	O
above	O
for	O
the	O
test	O
group	O
were	O
statistically	O
significantly	O
different	O
from	O
the	O
control	O
group	O
for	O
both	O
PPD	O
and	O
BI	O
for	O
all	O
comparisons	O
.	O

CONCLUSION	O
When	O
compared	O
with	O
SRP	Surgical
alone	O
,	O
clinical	O
improvements	O
in	O
PPD	O
(	O
e.g.	O
,	O
-1.0	O
mm	O
for	O
pockets	O
>	O
5	O
mm	O
at	O
baseline	O
)	O
were	O
maintained	O
for	O
up	O
to	O
six	O
months	O
after	O
SRP	Surgical
with	O
adjunctive	O
use	O
of	O
1.7	O
%	O
hydrogen	Pharmacological
peroxide	Pharmacological
gel	Pharmacological
,	O
locally	O
administered	O
using	O
prescription	O
customized	O
trays	O
in	O
the	O
treatment	O
of	O
subjects	O
with	O
moderate	O
to	O
advanced	O
periodontitis	O
.	O

Early	O
combination	O
disease-modifying	O
antirheumatic	Pharmacological
drug	Pharmacological
therapy	Pharmacological
and	O
tight	O
disease	O
control	O
improve	O
long-term	O
radiologic	O
outcome	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
:	O
the	O
11-year	O
results	O
of	O
the	O
Finnish	O
Rheumatoid	O
Arthritis	O
Combination	O
Therapy	O
trial	O
.	O

INTRODUCTION	O
Early	O
treatment	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
has	O
been	O
shown	O
to	O
retard	O
the	O
development	O
of	O
joint	O
damage	O
for	O
a	O
period	O
of	O
up	O
to	O
5	O
years	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
radiologic	O
progression	O
beyond	O
that	O
time	O
in	O
patients	O
with	O
early	O
RA	O
initially	O
treated	O
with	O
a	O
combination	O
of	O
three	Pharmacological
disease-modifying	Pharmacological
antirheumatic	Pharmacological
drugs	Pharmacological
(	Pharmacological
DMARDs	Pharmacological
)	Pharmacological
or	O
a	O
single	Pharmacological
DMARD	Pharmacological
.	O

METHODS	O
A	O
cohort	O
of	O
199	O
patients	O
with	O
early	O
active	O
RA	O
were	O
initially	O
randomized	O
to	O
receive	O
treatment	O
with	O
a	O
combination	O
of	O
methotrexate	Pharmacological
,	O
sulfasalazine	Pharmacological
,	O
and	O
hydroxychloroquine	Pharmacological
with	Pharmacological
prednisolone	Pharmacological
(	Pharmacological
FIN-RACo	Pharmacological
)	Pharmacological
,	O
or	O
treatment	O
with	O
a	O
single	Pharmacological
DMARD	Pharmacological
(	Pharmacological
initially	Pharmacological
,	Pharmacological
sulfasalazine	Pharmacological
)	Pharmacological
with	O
or	O
without	O
prednisolone	Pharmacological
(	Pharmacological
SINGLE	Pharmacological
)	Pharmacological
.	O

After	O
2	O
years	O
,	O
the	O
drug-treatment	O
strategy	O
became	O
unrestricted	O
,	O
but	O
still	O
targeted	O
remission	O
.	O

The	O
radiographs	O
of	O
hands	O
and	O
feet	O
were	O
analyzed	O
by	O
using	O
the	O
Larsen	O
score	O
at	O
baseline	O
,	O
2	O
,	O
5	O
,	O
and	O
11	O
years	O
,	O
and	O
the	O
radiographs	O
of	O
large	O
joints	O
,	O
at	O
11	O
years	O
.	O

RESULTS	O
Sixty-five	O
patients	O
in	O
the	O
FIN-RACo	Pharmacological
and	O
65	O
in	O
the	O
SINGLE	Pharmacological
group	O
had	O
radiographs	O
of	O
hands	O
and	O
feet	O
available	O
at	O
baseline	O
and	O
at	O
11	O
years	O
.	O

The	O
mean	O
change	O
from	O
baseline	O
to	O
11	O
years	O
in	O
Larsen	O
score	O
was	O
17	O
(	O
95	O
%	O
CI	O
,	O
12	O
to	O
26	O
)	O
in	O
the	O
FIN-RACo	Pharmacological
group	O
and	O
27	O
(	O
95	O
%	O
CI	O
,	O
22	O
to	O
33	O
)	O
in	O
the	O
SINGLE	Pharmacological
group	O
(	O
P=0.037	O
)	O
.	O

In	O
total	O
,	O
87	O
%	O
(	O
95	O
%	O
CI	O
,	O
74	O
to	O
94	O
)	O
and	O
72	O
%	O
(	O
95	O
%	O
CI	O
,	O
58	O
to	O
84	O
)	O
of	O
the	O
patients	O
in	O
the	O
FIN-RACo	O
and	O
the	O
SINGLE	O
treatment	O
arms	O
,	O
respectively	O
,	O
had	O
no	O
erosive	O
changes	O
in	O
large	O
joints	O
at	O
11	O
years	O
.	O

CONCLUSIONS	O
Targeting	O
to	O
remission	O
with	O
tight	O
clinical	O
controls	O
results	O
in	O
low	O
radiologic	O
progression	O
in	O
most	O
RA	O
patients	O
.	O

Patients	O
treated	O
initially	O
with	O
a	O
combination	Pharmacological
of	Pharmacological
DMARDs	Pharmacological
have	O
less	O
long-term	O
radiologic	O
damage	O
than	O
do	O
those	O
treated	O
initially	O
with	O
DMARD	Pharmacological
monotherapy	Pharmacological
.	O

TRIAL	O
REGISTRATION	O
Current	O
Controlled	O
Trials	O
ISRCTN18445519	O
.	O

The	O
adrenocorticotrophic	Pharmacological
hormone	Pharmacological
(	Pharmacological
4-9	Pharmacological
)	Pharmacological
analog	Pharmacological
ORG	Pharmacological
2766	Pharmacological
benefits	O
autistic	O
children	O
:	O
report	O
on	O
a	O
second	O
controlled	O
clinical	O
trial	O
.	O

In	O
a	O
second	O
controlled	O
crossover	O
trial	O
,	O
20	O
autistic	O
children	O
received	O
40	Pharmacological
mg/day	Pharmacological
of	Pharmacological
the	Pharmacological
neuropeptide	Pharmacological
ORG	Pharmacological
2766	Pharmacological
,	Pharmacological
a	Pharmacological
synthetic	Pharmacological
analog	Pharmacological
of	Pharmacological
ACTH	Pharmacological
(	Pharmacological
4-9	Pharmacological
)	Pharmacological
,	O
for	O
8	O
weeks	O
.	O

Parents	O
'	O
checklist	O
ratings	O
(	O
ABC	O
)	O
as	O
well	O
as	O
clinicians	O
'	O
ratings	O
(	O
CGI	O
)	O
pointed	O
to	O
significant	O
improvements	O
after	O
the	O
course	O
of	O
treatment	O
;	O
improvements	O
were	O
clearest	O
on	O
the	O
ABC	O
social	O
withdrawal	O
subscale	O
.	O

The	O
analysis	O
of	O
individual	O
target	O
symptoms	O
and	O
the	O
parents	O
'	O
treatment	O
preferences	O
substantiated	O
the	O
beneficial	O
effects	O
of	O
ORG	Pharmacological
2766	Pharmacological
.	Pharmacological

In	O
an	O
ethologically	O
analyzed	O
playroom	O
session	O
,	O
ORG	O
2766	O
treatment	O
was	O
associated	O
with	O
an	O
improvement	O
in	O
the	O
children	O
's	O
play	O
behavior	O
and	O
a	O
significant	O
increase	O
in	O
the	O
social	O
interaction	O
between	O
child	O
and	O
experimenter	O
.	O

Gaze	O
coordination	O
between	O
child	O
and	O
experimenter	O
also	O
was	O
improved	O
.	O

Effects	O
of	O
propranolol	Pharmacological
on	O
bone	O
metabolism	O
in	O
the	O
rat	O
.	O

Propranolol	Pharmacological
,	O
a	O
nonspecific	O
beta-blocker	O
has	O
many	O
physiologic	O
effects	O
.	O

Its	O
effects	O
on	O
bone	O
in	O
vivo	O
are	O
unknown	O
,	O
although	O
beta	O
receptor	O
sites	O
have	O
been	O
found	O
on	O
osteoblasts	O
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
tested	O
was	O
that	O
low	O
doses	O
of	O
propranolol	Pharmacological
could	O
alter	O
bone	O
properties	O
and	O
enhance	O
orthotopic	O
endochondral	O
bone	O
formation	O
.	O

In	O
a	O
group	O
of	O
nonsurgical	O
rats	O
,	O
propranolol	Pharmacological
treatment	O
increased	O
femoral	O
torsional	O
strength	O
on	O
biomechanical	O
testing	O
.	O

In	O
the	O
rat	O
surgical	O
model	O
used	O
,	O
right	O
femora	O
were	O
fixed	O
to	O
a	O
polyethylene	O
plate	O
and	O
then	O
defects	O
were	O
created	O
mid-diaphysis	O
and	O
subsequently	O
filled	O
with	O
demineralized	O
bone	O
matrix	O
.	O

These	O
rats	O
(	O
defect	O
rats	O
)	O
were	O
randomly	O
divided	O
into	O
groups	O
that	O
were	O
given	O
propranolol	Pharmacological
or	O
a	O
saline	Pharmacological
carrier	O
for	O
19	O
consecutive	O
days	O
.	O

In	O
the	O
defect	O
rats	O
,	O
increased	O
trabecular	O
femoral	O
metaphyseal	O
mineral	O
apposition	O
rates	O
were	O
observed	O
in	O
propranolol-treated	O
groups	O
.	O

Densitometry	O
and	O
roentgenographic	O
scoring	O
of	O
callus	O
formation	O
after	O
12	O
weeks	O
in	O
propranolol-treated	O
rats	O
revealed	O
increased	O
callus	O
and	O
bone	O
union	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
propranolol	Pharmacological
treatment	O
can	O
significantly	O
affect	O
bone	O
properties	O
.	O

Intraumbilical	O
vein	O
injection	O
of	O
prostaglandin	Pharmacological
F2	Pharmacological
alpha	Pharmacological
in	O
retained	O
placenta	O
.	O

A	O
randomized	O
protocol	O
was	O
used	O
to	O
study	O
the	O
effect	O
of	O
intraumbilical	Pharmacological
prostaglandin	Pharmacological
F2	Pharmacological
alpha	Pharmacological
(	O
Hembate	Pharmacological
,	O
Upjohn	Pharmacological
)	O
and	O
oxytocin	Pharmacological
injection	Pharmacological
in	O
women	O
with	O
retained	O
placenta	O
.	O

Prostaglandin	Pharmacological
F2	Pharmacological
alpha	Pharmacological
,	O
20	O
mg	O
,	O
diluted	Pharmacological
to	Pharmacological
20	Pharmacological
ml	Pharmacological
in	Pharmacological
normal	Pharmacological
saline	Pharmacological
solution	Pharmacological
(	O
10	O
women	O
,	O
group	O
1	O
)	O
,	O
30	Pharmacological
IU	Pharmacological
of	Pharmacological
oxytocin	Pharmacological
,	O
diluted	Pharmacological
to	Pharmacological
20	Pharmacological
ml	Pharmacological
in	Pharmacological
normal	Pharmacological
saline	Pharmacological
solution	Pharmacological
(	O
11	O
women	O
,	O
group	O
2	O
)	O
,	O
or	O
20	Pharmacological
ml	Pharmacological
of	Pharmacological
normal	Pharmacological
saline	Pharmacological
solution	Pharmacological
alone	Pharmacological
(	O
7	O
women	O
,	O
group	O
3	O
)	O
,	O
were	O
injected	O
into	O
the	O
umbilical	O
vein	O
1	O
h	O
after	O
delivery	O
.	O

Nine	O
women	O
(	O
group	O
4	O
,	O
controls	O
)	O
underwent	O
manual	O
removal	O
of	O
the	O
retained	O
placenta	O
.	O

In	O
group	O
1	O
,	O
placental	O
expulsion	O
occurred	O
in	O
all	O
patients	O
and	O
the	O
duration	O
of	O
the	O
placental	O
expulsion	O
after	O
prostaglandin	Pharmacological
F2	Pharmacological
alpha	Pharmacological
injection	O
was	O
6.8	O
+/-	O
1.36	O
(	O
mean	O
+/-	O
SE	O
)	O
min	O
:	O
in	O
group	O
2	O
,	O
six	O
placental	O
expulsions	O
occurred	O
after	O
13.3	O
+/-	O
1.97	O
min	O
(	O
mean	O
+/-	O
SE	O
)	O
;	O
and	O
in	O
group	O
3	O
,	O
no	O
effect	O
was	O
recorded	O
after	O
intraumbilical	O
saline	O
injection	O
.	O

We	O
suggest	O
that	O
intraumbilical	O
vein	O
injection	O
of	O
prostaglandin	Pharmacological
F2	Pharmacological
alpha	Pharmacological
might	O
be	O
a	O
beneficial	O
,	O
non-surgical	O
method	O
for	O
treating	O
retained	O
placenta	O
.	O

Oxytocin	Pharmacological
might	O
reduce	O
the	O
incidence	O
of	O
manual	O
lysis	O
of	O
the	O
placenta	O
and	O
achieve	O
partial	O
success	O
.	O

The	O
influence	O
of	O
preoperative	O
antibiotics	Pharmacological
on	O
success	O
of	O
endosseous	Physical
implants	Physical
up	O
to	O
and	O
including	O
stage	O
II	O
surgery	O
:	O
a	O
study	O
of	O
2,641	O
implants	O
.	O

According	O
to	O
the	O
American	O
College	O
of	O
Surgeons	O
,	O
complex	O
oral	O
surgical	O
procedures	O
,	O
including	O
the	O
transoral	O
placement	O
of	O
endosseous	O
implants	O
,	O
are	O
of	O
the	O
type	O
that	O
may	O
require	O
prophylactic	Pharmacological
antibiotics	Pharmacological
.	O

However	O
,	O
the	O
routine	O
use	O
of	O
prophylactic	Pharmacological
antibiotics	Pharmacological
in	O
the	O
field	O
of	O
dental	O
implantology	O
continues	O
to	O
be	O
controversial	O
,	O
and	O
their	O
utilization	O
varies	O
widely	O
.	O

No	O
data	O
from	O
a	O
randomized	O
prospective	O
clinical	O
study	O
of	O
the	O
prophylactic	O
use	O
of	O
antibiotics	Pharmacological
in	O
implant	O
surgery	O
have	O
been	O
previously	O
published	O
.	O

As	O
part	O
of	O
the	O
comprehensive	O
Dental	O
Implant	O
Clinical	O
Research	O
Group	O
clinical	O
implant	O
study	O
,	O
the	O
preoperative	O
or	O
postoperative	O
use	O
of	O
antibiotics	Pharmacological
,	O
the	O
type	O
used	O
,	O
and	O
the	O
duration	O
of	O
coverage	O
was	O
left	O
to	O
the	O
discretion	O
of	O
the	O
surgeon	O
.	O

These	O
data	O
were	O
recorded	O
and	O
correlated	O
with	O
failure	O
of	O
osseointegration	O
during	O
healing	O
(	O
stage	O
I	O
)	O
and	O
at	O
stage	O
II	O
surgery	O
(	O
uncovering	O
)	O
.	O

The	O
results	O
showed	O
that	O
significantly	O
fewer	O
failures	O
occurred	O
when	O
preoperative	O
antibiotics	Pharmacological
were	O
used	O
.	O

Why	O
the	O
prone	Physical
position	Physical
is	O
a	O
risk	O
factor	O
for	O
sudden	O
infant	O
death	O
syndrome	O
.	O

INTRODUCTION	O
The	O
laryngeal	O
chemoreflex	O
may	O
explain	O
why	O
prone	O
sleeping	O
increases	O
the	O
risk	O
of	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
)	O
.	O

Swallowing	O
and	O
arousal	O
are	O
crucial	O
to	O
prevent	O
laryngeal	O
chemoreflex	O
stimulation	O
.	O

Our	O
aim	O
was	O
to	O
examine	O
these	O
reflexes	O
and	O
breathing	O
responses	O
in	O
healthy	O
neonates	O
after	O
pharyngeal	O
infusion	O
of	O
water	O
in	O
the	O
supine	O
versus	O
the	O
prone	O
position	O
,	O
controlling	O
for	O
sleep	O
state	O
.	O

METHODS	O
A	O
total	O
of	O
10	O
term	O
infants	O
were	O
recruited	O
after	O
parental	O
consent	O
and	O
ethics	O
approval	O
.	O

Polygraphic	O
recordings	O
included	O
sleep	O
state	O
(	O
active	O
and	O
quiet	O
sleep	O
by	O
electroencephalogram	O
,	O
eye	O
movements	O
,	O
breathing	O
,	O
and	O
behavior	O
)	O
,	O
cardiorespiratory	O
measurements	O
(	O
nasal	O
airflow	O
,	O
chest	O
wall	O
movements	O
,	O
heart	O
rate	O
,	O
and	O
oxygen	O
saturation	O
)	O
,	O
swallowing	O
,	O
and	O
esophageal	O
activity	O
(	O
solid	O
state	O
pressure	O
catheter	O
)	O
.	O

Initial	Physical
sleeping	Physical
position	Physical
was	Physical
assigned	Physical
randomly	Physical
.	O

Measurements	O
were	O
made	O
for	O
1	Physical
minute	Physical
before	Physical
and	Physical
after	Physical
0.4	Physical
mL	Physical
of	Physical
water	Physical
was	Physical
instilled	Physical
into	Physical
the	Physical
oropharynx	Physical
.	O

To	O
detect	O
a	O
30	O
%	O
decrease	O
in	O
swallowing	O
,	O
power	O
analysis	O
indicated	O
that	O
>	O
/=10	O
babies	O
were	O
required	O
.	O

Analysis	O
,	O
blinded	O
to	O
position	O
,	O
was	O
made	O
using	O
nonparametric	O
statistics	O
.	O

RESULTS	O
Of	O
the	O
164	O
infusions	O
,	O
the	O
most	O
commonly	O
evoked	O
airway	O
protective	O
responses	O
to	O
pharyngeal	O
infusion	O
were	O
swallowing	O
(	O
95	O
%	O
)	O
and	O
arousal	O
(	O
54	O
%	O
)	O
.	O

After	O
infusion	O
in	O
active	O
sleep	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
swallowing	O
and	O
breathing	O
when	O
the	O
prone	O
position	O
was	O
compared	O
with	O
the	O
supine	O
position	O
(	O
prone	O
:	O
21.3	O
[	O
1.0	O
]	O
swallows/min	O
and	O
-9.6	O
[	O
2.1	O
]	O
breaths/min	O
;	O
and	O
supine	O
:	O
32	O
(	O
2.2	O
)	O
and	O
-2	O
.	O

9	O
(	O
1.5	O
)	O
,	O
respectively	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
occurrence	O
of	O
arousal	O
after	O
water	O
infusion	O
.	O

CONCLUSION	O
These	O
data	O
suggest	O
that	O
airway	O
protection	O
is	O
compromised	O
in	O
the	O
prone	O
sleeping	O
position	O
during	O
active	O
sleep	O
,	O
even	O
in	O
healthy	O
infants	O
exposed	O
to	O
minute	O
pharyngeal	O
fluid	O
volumes	O
of	O
0.4	O
mL	O
.	O

This	O
is	O
because	O
swallowing	O
rate	O
is	O
reduced	O
significantly	O
,	O
and	O
there	O
is	O
no	O
compensatory	O
increase	O
in	O
arousal	O
.	O

The	O
reduction	O
in	O
airway	O
protective	O
reflexes	O
when	O
in	O
the	O
prone	O
position	O
and	O
in	O
active	O
sleep	O
may	O
be	O
the	O
mechanism	O
for	O
the	O
increased	O
risk	O
of	O
SIDS	O
in	O
the	O
prone	O
position	O
.	O

Non-contrast-enhanced	Physical
4D	Physical
MR	Physical
angiography	Physical
with	O
STAR	O
spin	O
labeling	O
and	O
variable	O
flip	O
angle	O
sampling	O
:	O
a	O
feasibility	O
study	O
for	O
the	O
assessment	O
of	O
Dural	O
Arteriovenous	O
Fistula	O
.	O

INTRODUCTION	O
This	O
study	O
aimed	O
to	O
evaluate	O
the	O
feasibility	O
of	O
non-contrast-enhanced	O
4D	O
magnetic	O
resonance	O
angiography	O
(	O
NCE	O
4D	O
MRA	O
)	O
with	O
signal	O
targeting	O
with	O
alternative	O
radiofrequency	O
(	O
STAR	O
)	O
spin	O
labeling	O
and	O
variable	O
flip	O
angle	O
(	O
VFA	O
)	O
sampling	O
in	O
the	O
assessment	O
of	O
dural	O
arteriovenous	O
fistula	O
(	O
DAVF	O
)	O
in	O
the	O
transverse	O
sinus	O
.	O

METHODS	O
Nine	O
patients	O
underwent	O
NCE	Physical
4D	Physical
MRA	Physical
for	O
the	O
evaluation	O
of	O
DAVF	O
in	O
the	O
transverse	O
sinus	O
at	O
3	O
T.	O
One	O
patient	O
was	O
examined	O
twice	O
,	O
once	O
before	O
and	O
once	O
after	O
the	O
interventional	O
treatment	O
.	O

All	O
patients	O
also	O
underwent	O
digital	O
subtraction	O
angiography	O
(	O
DSA	O
)	O
and/or	O
contrast-enhanced	O
magnetic	O
resonance	O
angiography	O
(	O
CEMRA	O
)	O
.	O

For	O
the	O
acquisition	O
of	O
NCE	O
4D	O
MRA	O
,	O
a	O
STAR	O
spin	O
tagging	O
method	O
was	O
used	O
,	O
and	O
a	O
VFA	O
sampling	O
was	O
applied	O
in	O
the	O
data	O
readout	O
module	O
instead	O
of	O
a	O
constant	O
flip	O
angle	O
.	O

Two	O
readers	O
evaluated	O
the	O
NCE	O
4D	O
MRA	O
data	O
for	O
the	O
diagnosis	O
of	O
DAVF	O
and	O
its	O
type	O
with	O
consensus	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
from	O
DSA	O
and/or	O
CEMRA	O
.	O

RESULTS	O
All	O
patients	O
underwent	O
NCE	Physical
4D	Physical
MRA	Physical
without	O
any	O
difficulty	O
.	O

Among	O
seven	O
patients	O
with	O
patent	O
DAVFs	O
,	O
all	O
cases	O
showed	O
an	O
early	O
visualization	O
of	O
the	O
transverse	O
sinus	O
on	O
NCE	O
4D	O
MRA	O
.	O

Except	O
for	O
one	O
case	O
,	O
the	O
type	O
of	O
DAVF	O
of	O
NCE	O
4D	O
MRA	O
was	O
agreed	O
with	O
that	O
of	O
reference	O
standard	O
study	O
.	O

Cortical	O
venous	O
reflux	O
(	O
CVR	O
)	O
was	O
demonstrated	O
in	O
two	O
cases	O
out	O
of	O
three	O
patients	O
with	O
CVR	O
.	O

CONCLUSION	O
NCE	O
4D	O
MRA	O
with	O
STAR	O
tagging	O
and	O
VFA	O
sampling	O
is	O
technically	O
and	O
clinically	O
feasible	O
and	O
represents	O
a	O
promising	O
technique	O
for	O
assessment	O
of	O
DAVF	O
in	O
the	O
transverse	O
sinus	O
.	O

Further	O
technical	O
developments	O
should	O
aim	O
at	O
improvements	O
of	O
spatial	O
and	O
temporal	O
coverage	O
.	O

Why	O
are	O
there	O
sometimes	O
concreteness	O
effects	O
in	O
memory	O
for	O
prose	O
?	O
Four	O
experiments	O
explored	O
on-line	O
encoding	O
strategies	O
and	O
memory	O
for	O
high	O
imagery	O
and	O
low	O
imagery	O
texts	O
.	O

Results	O
consistently	O
indicated	O
that	O
concreteness	O
effects	O
in	O
memory	O
for	O
text	O
depend	O
on	O
how	O
materials	O
are	O
presented	O
in	O
several	O
different	O
respects	O
.	O

Most	O
importantly	O
,	O
the	O
experiments	O
clarified	O
apparently	O
contradictory	O
results	O
of	O
previous	O
studies	O
by	O
indicating	O
that	O
concreteness	O
effects	O
generally	O
do	O
not	O
occur	O
in	O
memory	O
for	O
prose	O
when	O
imageability	O
is	O
manipulated	O
between-subjects	O
,	O
and	O
that	O
their	O
occurrence	O
when	O
imageability	O
is	O
manipulated	O
within-subjects	O
depends	O
on	O
the	O
order	O
occurrence	O
when	O
imageability	O
is	O
manipulated	O
within-subjects	O
depends	O
on	O
the	O
order	O
of	O
presentation	O
.	O

In	O
addition	O
,	O
moving	O
window	O
analyses	O
of	O
text	Educational
processing	Educational
strategies	Educational
indicated	O
that	O
differential	O
strategies	O
observed	O
in	O
previous	O
studies	O
when	O
subjects	O
listened	O
to	O
high	O
vs	O
low	O
imagery	O
text	O
do	O
not	O
generalize	O
to	O
reading	O
of	O
the	O
same	O
materials	O
.	O

Potential	O
explanations	O
for	O
the	O
pattern	O
of	O
results	O
are	O
evaluated	O
,	O
and	O
implications	O
for	O
theories	O
of	O
mental	O
imagery	O
and	O
memory	O
are	O
considered	O
.	O

Randomized	O
,	O
double-blind	O
,	O
multicenter	O
trial	O
comparing	O
two	O
doses	O
of	O
arzoxifene	Pharmacological
(	Pharmacological
LY353381	Pharmacological
)	Pharmacological
in	O
hormone-sensitive	O
advanced	O
or	O
metastatic	O
breast	O
cancer	O
patients	O
.	O

BACKGROUND	O
This	O
randomized	O
,	O
double-blind	O
,	O
phase	O
II	O
study	O
assessed	O
two	O
doses	O
of	O
the	O
selective	Pharmacological
estrogen	Pharmacological
receptor	Pharmacological
modulator	Pharmacological
arzoxifene	Pharmacological
in	O
women	O
with	O
advanced	O
breast	O
cancer	O
.	O

The	O
primary	O
end	O
point	O
was	O
to	O
choose	O
the	O
best	O
of	O
two	O
doses	O
of	O
arzoxifene	Pharmacological
based	O
on	O
the	O
response	O
rate	O
or	O
the	O
clinical	O
benefit	O
rate	O
(	O
CBR	O
)	O
.	O

Pharmacokinetics	O
and	O
toxicities	O
were	O
also	O
assessed	O
.	O

PATIENTS	O
AND	O
METHODS	O
Ninety-two	O
patients	O
with	O
advanced	O
breast	O
cancer	O
received	O
arzoxifene	Pharmacological
20	Pharmacological
or	Pharmacological
50	Pharmacological
mg/day	Pharmacological
.	O

Tumor	O
response	O
was	O
assessed	O
using	O
World	Physical
Health	Physical
Organization	Physical
criteria	Physical
.	O

Toxicities	O
were	O
graded	O
according	O
to	O
the	O
National	Physical
Cancer	Physical
Institute	Physical
Common	Physical
Toxicity	Physical
Criteria	Physical
(	Physical
NCI-CTC	Physical
)	Physical
system	Physical
.	O

Pharmacokinetic	O
data	O
were	O
analyzed	O
using	O
the	O
NONMEM	O
software	O
program	O
(	O
GloboMax	O
,	O
Hanover	O
,	O
MD	O
,	O
USA	O
)	O
.	O

RESULTS	O
Response	O
rates	O
in	O
the	O
20	O
mg	O
arm	O
were	O
numerically	O
higher	O
than	O
the	O
50-mg	O
arm	O
according	O
to	O
the	O
investigator	O
(	O
40.5	O
%	O
versus	O
36.4	O
%	O
)	O
and	O
the	O
independent	O
review	O
panel	O
(	O
42.9	O
%	O
versus	O
27.3	O
%	O
)	O
.	O

CBR	O
was	O
higher	O
in	O
the	O
20	O
mg	O
arm	O
according	O
to	O
the	O
investigator	O
(	O
64.3	O
%	O
versus	O
61.4	O
%	O
)	O
and	O
the	O
independent	O
review	O
panel	O
(	O
59.5	O
%	O
versus	O
47.7	O
%	O
)	O
.	O

Arzoxifene	Pharmacological
was	O
well	O
tolerated	O
.	O

There	O
were	O
no	O
study	O
drug-related	O
deaths	O
.	O

Mean	O
observed	O
steady-state	O
plasma	O
concentrations	O
of	O
arzoxifene	Pharmacological
were	O
3.62	O
and	O
7.48	O
ng/ml	O
for	O
the	O
20	O
and	O
50	O
mg	O
doses	O
,	O
respectively	O
.	O

CONCLUSIONS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
efficacy	O
or	O
safety	O
between	O
20	O
and	O
50	O
mg	O
of	O
arzoxifene	Pharmacological
.	O

Accordingly	O
,	O
arzoxifene	Pharmacological
20	O
mg/day	O
was	O
selected	O
for	O
further	O
study	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Development	O
of	O
renal	O
disease	O
in	O
people	O
at	O
high	O
cardiovascular	O
risk	O
:	O
results	O
of	O
the	O
HOPE	O
randomized	O
study	O
.	O

In	O
people	O
with	O
diabetes	O
,	O
renal	O
disease	O
tends	O
to	O
progress	O
from	O
microalbuminuria	O
to	O
clinical	O
proteinuria	O
to	O
renal	O
insufficiency	O
.	O

Little	O
evidence	O
has	O
been	O
published	O
for	O
the	O
nondiabetic	O
population	O
.	O

This	O
study	O
retrospectively	O
analyzed	O
changes	O
of	O
proteinuria	O
over	O
4.5	O
yr	O
in	O
the	O
HOPE	O
(	O
Heart	O
Outcomes	O
and	O
Prevention	O
Evaluation	O
)	O
study	O
,	O
which	O
compared	O
ramipril	Pharmacological
's	Pharmacological
effects	O
to	O
placebo	Control
in	O
9297	O
participants	O
,	O
including	O
3577	O
with	O
diabetes	O
and	O
1956	O
with	O
microalbuminuria	O
.	O

This	O
report	O
is	O
restricted	O
to	O
7674	O
participants	O
with	O
albuminuria	O
data	O
at	O
baseline	O
and	O
at	O
follow-up	O
.	O

Inclusion	O
criteria	O
were	O
known	O
vascular	O
disease	O
or	O
diabetes	O
plus	O
one	O
other	O
cardiovascular	O
risk	O
factor	O
,	O
exclusion	O
criteria	O
included	O
heart	O
failure	O
or	O
known	O
impaired	O
left	O
ventricular	O
function	O
,	O
dipstick-positive	O
proteinuria	O
(	O
>	O
1+	O
)	O
,	O
and	O
serum	O
creatinine	O
>	O
2.3	O
mg/dl	O
(	O
200	O
microM	O
)	O
.	O

Baseline	O
microalbuminuria	O
predicted	O
subsequent	O
clinical	O
proteinuria	O
for	O
the	O
study	O
participants	O
overall	O
(	O
adjusted	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
17.5	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
12.6	O
to	O
24.4	O
)	O
,	O
in	O
participants	O
without	O
diabetes	O
(	O
OR	O
,	O
16.7	O
;	O
95	O
%	O
CI	O
,	O
8.6	O
to	O
32.4	O
)	O
,	O
and	O
in	O
participants	O
with	O
diabetes	O
(	O
OR	O
,	O
18.2	O
;	O
95	O
%	O
CI	O
,	O
12.4	O
to	O
26.7	O
)	O
.	O

Any	O
progression	O
of	O
albuminuria	O
(	O
defined	O
as	O
new	O
microalbuminuria	O
or	O
new	O
clinical	O
proteinuria	O
)	O
occurred	O
in	O
1859	O
participants	O
;	O
1542	O
developed	O
new	O
microalbuminuria	O
,	O
and	O
317	O
participants	O
developed	O
clinical	O
proteinuria	O
.	O

Ramipril	Pharmacological
reduced	O
the	O
risk	O
for	O
any	O
progression	O
(	O
OR	O
,	O
0.87	O
;	O
95	O
%	O
CI	O
,	O
0.78	O
to	O
0.97	O
;	O
P	O
=	O
0.0146	O
)	O
.	O

People	O
without	O
and	O
with	O
diabetes	O
who	O
are	O
at	O
high	O
risk	O
for	O
cardiovascular	O
disease	O
are	O
also	O
at	O
risk	O
for	O
a	O
progressive	O
rise	O
in	O
albuminuria	O
.	O

Microalbuminuria	O
itself	O
predicts	O
clinical	O
proteinuria	O
in	O
nondiabetic	O
and	O
in	O
diabetic	O
people	O
.	O

Ramipril	Pharmacological
prevents	O
or	O
delays	O
the	O
progression	O
of	O
albuminuria	O
.	O

Measurement	O
of	O
health-related	O
quality	O
of	O
life	O
in	O
multiple	O
myeloma	O
.	O

Nordic	O
Myeloma	O
Study	O
Group	O
.	O

When	O
a	O
randomized	O
trial	O
(	O
NMSG	O
4/90	O
)	O
comparing	O
treatment	O
with	O
melphalan/prednisone	Pharmacological
to	O
melphalan/	Pharmacological
prednisone	Pharmacological
+	Pharmacological
interferon	Pharmacological
alpha-2b	Pharmacological
in	O
newly	O
diagnosed	O
multiple	O
myeloma	O
was	O
initiated	O
in	O
1990	O
,	O
a	O
quality-of-life	O
assessment	O
was	O
integrated	O
into	O
the	O
study	O
.	O

We	O
used	O
the	O
questionnaire	O
(	O
QLQ-C30	O
)	O
developed	O
by	O
the	O
European	O
Organization	O
of	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Study	O
Group	O
on	O
Quality	O
of	O
Life	O
.	O

The	O
QLQ-C30	O
incorporates	O
five	O
functional	O
scales	O
,	O
three	O
symptom	O
scales	O
,	O
a	O
global	O
health	O
and	O
quality-of	O
life	O
scale	O
and	O
some	O
single	O
symptom	O
measures	O
.	O

The	O
questionnaire	O
was	O
completed	O
prior	O
to	O
treatment	O
and	O
after	O
1	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
36	O
and	O
48	O
months	O
.	O

524	O
(	O
90.2	O
%	O
)	O
of	O
581	O
patients	O
enrolled	O
in	O
the	O
NMSG	O
4/90	O
completed	O
the	O
first	O
questionnaire	O
,	O
and	O
484	O
(	O
83.3	O
%	O
)	O
completed	O
all	O
questionnaires	O
given	O
to	O
them	O
.	O

All	O
but	O
one	O
of	O
the	O
scales	O
met	O
the	O
minimum	O
criteria	O
of	O
reliability	O
(	O
Cronbach	O
's	O
alpha	O
>	O
/	O
0.70	O
)	O
.	O

Validity	O
was	O
shown	O
by	O
(	O
1	O
)	O
the	O
ability	O
of	O
the	O
scales	O
to	O
discriminate	O
clearly	O
between	O
patients	O
differing	O
in	O
clinical	O
status	O
as	O
defined	O
by	O
pretreatment	O
W.H.O	O
.	O

performance	O
index	O
and	O
Durie	O
&	O
Salmon	O
stage	O
,	O
and	O
(	O
2	O
)	O
the	O
sensitivity	O
to	O
changes	O
in	O
objective	O
disease	O
status	O
(	O
response	O
and	O
relapse	O
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
measurement	O
of	O
health-related	O
quality	O
of	O
life	O
in	O
a	O
prospective	O
clinical	O
trial	O
in	O
multiple	O
myeloma	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
QLQ-C30	O
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
for	O
the	O
measurement	O
of	O
quality	O
of	O
life	O
in	O
these	O
patients	O
.	O

The	O
data	O
will	O
be	O
used	O
for	O
a	O
cost-utility	O
analysis	O
of	O
the	O
results	O
of	O
the	O
NMSG	O
4/90	O
trial	O
.	O

Cognitive-behavioral	Psychological
therapy	Psychological
for	O
psychogenic	O
nonepileptic	O
seizures	O
:	O
a	O
pilot	O
RCT	O
.	O

OBJECTIVE	O
To	O
compare	O
cognitive-behavioral	Psychological
therapy	Psychological
(	O
CBT	Psychological
)	O
and	O
standard	Pharmacological
medical	Pharmacological
care	Pharmacological
(	Pharmacological
SMC	Pharmacological
)	Pharmacological
as	O
treatments	O
for	O
psychogenic	O
nonepileptic	O
seizures	O
(	O
PNES	O
)	O
.	O

METHODS	O
Our	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
compared	O
CBT	Psychological
with	O
SMC	Pharmacological
in	O
an	O
outpatient	O
neuropsychiatric	O
setting	O
.	O

Sixty-six	O
PNES	O
patients	O
were	O
randomized	O
to	O
either	O
CBT	Educational
(	O
plus	O
SMC	Pharmacological
)	O
or	O
SMC	Pharmacological
alone	O
,	O
scheduled	O
to	O
occur	O
over	O
4	O
months	O
.	O

PNES	O
diagnosis	O
was	O
established	O
by	O
video-EEG	O
telemetry	O
for	O
most	O
patients	O
.	O

Exclusion	O
criteria	O
included	O
comorbid	O
history	O
of	O
epilepsy	O
,	O
<	O
2	O
PNES/month	O
,	O
and	O
IQ	O
<	O
70	O
.	O

The	O
primary	O
outcome	O
was	O
seizure	O
frequency	O
at	O
end	O
of	O
treatment	O
and	O
at	O
6-month	O
follow-up	O
.	O

Secondary	O
outcomes	O
included	O
3	O
months	O
of	O
seizure	O
freedom	O
at	O
6-month	O
follow-up	O
,	O
measures	O
of	O
psychosocial	O
functioning	O
,	O
health	O
service	O
use	O
,	O
and	O
employment	O
.	O

RESULTS	O
In	O
an	O
intention-to-treat	O
analysis	O
,	O
seizure	O
reduction	O
following	O
CBT	Educational
was	O
superior	O
at	O
treatment	O
end	O
(	O
group	O
x	O
time	O
interaction	O
p	O
<	O
0.0001	O
;	O
large	O
to	O
medium	O
effect	O
sizes	O
)	O
.	O

At	O
follow-up	O
,	O
the	O
CBT	Educational
group	O
tended	O
to	O
be	O
more	O
likely	O
to	O
have	O
experienced	O
3	O
months	O
of	O
seizure	O
freedom	O
(	O
odds	O
ratio	O
3.125	O
,	O
p	O
=	O
0.086	O
)	O
.	O

Both	O
groups	O
improved	O
in	O
some	O
health	O
service	O
use	O
measures	O
and	O
on	O
the	O
Work	O
and	O
Social	O
Adjustment	O
Scale	O
.	O

Mood	O
and	O
employment	O
status	O
showed	O
no	O
change	O
.	O

CONCLUSIONS	O
Our	O
findings	O
suggest	O
that	O
cognitive-behavioral	Psychological
therapy	Psychological
is	O
more	O
effective	O
than	O
standard	O
medical	O
care	O
alone	O
in	O
reducing	O
seizure	O
frequency	O
in	O
PNES	O
patients	O
.	O

CLASSIFICATION	O
OF	O
EVIDENCE	O
This	O
study	O
provides	O
Class	O
III	O
evidence	O
that	O
CBT	Educational
in	O
addition	O
to	O
SMC	Pharmacological
,	O
as	O
compared	O
to	O
SMC	Pharmacological
alone	O
,	O
significantly	O
reduces	O
seizure	O
frequency	O
in	O
patients	O
with	O
PNES	O
(	O
change	O
in	O
median	O
monthly	O
seizure	O
frequency	O
:	O
baseline	O
to	O
6	O
months	O
follow-up	O
,	O
CBT	O
group	O
,	O
12	O
to	O
1.5	O
;	O
SMC	O
alone	O
group	O
,	O
8	O
to	O
5	O
)	O
.	O

Entomological	O
determinants	O
of	O
insecticide-treated	O
bed	O
net	O
effectiveness	O
in	O
Western	O
Myanmar	O
.	O

BACKGROUND	O
In	O
a	O
large	O
cluster	O
randomized	O
control	O
trial	O
of	O
insecticide-treated	Pharmacological
bed	Pharmacological
nets	Pharmacological
(	Pharmacological
ITN	Pharmacological
)	Pharmacological
in	O
Western	O
Myanmar	O
the	O
malaria	O
protective	O
effect	O
of	O
ITN	Pharmacological
was	O
found	O
to	O
be	O
highly	O
variable	O
and	O
,	O
in	O
aggregate	O
,	O
the	O
effect	O
was	O
not	O
statistically	O
significant	O
.	O

A	O
coincident	O
entomological	O
investigation	O
measured	O
malaria	O
vector	O
abundance	O
and	O
biting	O
behaviour	O
and	O
the	O
human	O
population	O
sleeping	O
habits	O
,	O
factors	O
relevant	O
to	O
ITN	Pharmacological
effectiveness	O
.	O

METHODS	O
Entomological	O
surveys	O
were	O
carried	O
out	O
using	O
different	O
catching	O
methods	O
to	O
identify	O
potential	O
malaria	O
vector	O
species	O
and	O
characterise	O
their	O
biting	O
habits	O
.	O

The	O
salivary	Surgical
glands	Surgical
were	Surgical
dissected	Surgical
from	O
all	O
female	O
anophelines	O
caught	O
to	O
identify	O
sporozoites	O
by	O
microscopy	Physical
.	O

FINDINGS	O
Between	O
1995	O
and	O
2000	O
a	O
total	O
of	O
4,824	O
female	O
anopheline	O
mosquitoes	O
were	O
caught	O
with	O
various	O
catching	O
methods	O
.	O

A	O
total	O
of	O
916	O
person	O
nights	O
yielded	O
3,009	O
female	O
anopheline	O
mosquitoes	O
between	O
6	O
pm	O
and	O
6	O
am	O
.	O

Except	O
for	O
Anopheles	O
annularis	O
,	O
which	O
showed	O
no	O
apparent	O
preference	O
(	O
51	O
%	O
outdoor	O
biting	O
)	O
,	O
all	O
major	O
species	O
showed	O
a	O
strong	O
preference	O
for	O
outdoor	O
biting	O
;	O
Anopheles	O
epiroticus	O
(	O
79	O
%	O
)	O
,	O
Anopheles	O
subpictus	O
(	O
72	O
%	O
)	O
,	O
Anopheles	O
maculatus	O
(	O
92	O
%	O
)	O
,	O
Anopheles	O
aconitus	O
(	O
85	O
%	O
)	O
and	O
Anopheles	O
vagus	O
(	O
72	O
%	O
)	O
.	O

Most	O
human	O
biting	O
occurred	O
in	O
the	O
early	O
evening	O
with	O
the	O
peak	O
biting	O
time	O
between	O
6	O
pm	O
and	O
7	O
pm	O
(	O
35	O
%	O
)	O
.	O

Overall	O
51	O
%	O
(	O
1447/2837	O
)	O
of	O
all	O
bites	O
recorded	O
were	O
between	O
6	O
pm	O
and	O
8	O
pm	O
.	O

A	O
large	O
proportion	O
of	O
children	O
were	O
not	O
sleeping	O
under	O
an	O
ITN	Pharmacological
during	O
peak	O
biting	O
times	O
.	O

Only	O
one	O
An	O
.	O

annularis	O
mosquito	O
(	O
0.02	O
%	O
)	O
had	O
malaria	O
sporozoites	O
identified	O
in	O
the	O
salivary	O
glands	O
.	O

CONCLUSIONS	O
Peak	O
vector	O
biting	O
occurred	O
early	O
in	O
the	O
evening	O
and	O
mainly	O
occurred	O
outdoors	O
.	O

The	O
limited	O
efficacy	O
of	O
ITN	Pharmacological
in	O
this	O
area	O
of	O
Western	O
Myanmar	O
may	O
be	O
explained	O
by	O
the	O
biting	O
behaviour	O
of	O
the	O
prevalent	O
Anopheles	O
mosquito	O
vectors	O
in	O
this	O
area	O
.	O

Simvastatin	Pharmacological
blunts	O
endotoxin-induced	O
tissue	O
factor	O
in	O
vivo	O
.	O

BACKGROUND	O
Beyond	O
lipid	O
lowering	O
,	O
various	O
antiinflammatory	O
properties	O
have	O
been	O
ascribed	O
to	O
statins	O
.	O

Moreover	O
,	O
in	O
vitro	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
anticoagulant	O
effects	O
of	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitors	O
,	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
monocyte	O
tissue	O
factor	O
(	O
TF	O
)	O
was	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
statins	Pharmacological
in	O
experimental	O
endotoxemia	O
on	O
inflammatory	O
and	O
procoagulant	O
responses	O
in	O
vivo	O
.	O

METHODS	O
AND	O
RESULTS	O
In	O
this	O
double-blind	O
,	O
placebo-controlled	Control
,	O
parallel-group	O
study	O
,	O
20	O
healthy	O
,	O
male	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
simvastatin	Pharmacological
(	O
80	O
mg/d	O
)	O
or	O
placebo	Control
for	O
4	O
days	O
before	O
intravenous	O
administration	O
of	O
LPS	O
(	O
20	O
IU/kg	O
IV	O
)	O
.	O

Plasma	O
high-sensitive	O
C-reactive	O
protein	O
(	O
hsCRP	O
)	O
,	O
monocyte	O
chemoattractant	O
protein	O
(	O
MCP-1	O
)	O
,	O
sCD40L	O
,	O
sCD40	O
,	O
and	O
prothrombin	O
fragment	O
F1+2	O
(	O
F1.2	O
)	O
were	O
determined	O
by	O
ELISAs	O
at	O
baseline	O
and	O
at	O
4	O
and	O
8	O
hours	O
after	O
LPS	O
administration	O
.	O

Monocyte	O
TF	O
expression	O
and	O
monocyte-platelet	O
aggregates	O
were	O
measured	O
by	O
whole-blood	O
flow	O
cytometry	O
over	O
the	O
same	O
time	O
course	O
.	O

The	O
increases	O
in	O
hsCRP	O
and	O
MCP-1	O
,	O
both	O
known	O
inducers	O
of	O
TF	O
,	O
were	O
significantly	O
suppressed	O
by	O
statin	O
treatment	O
after	O
LPS	O
challenge	O
.	O

Statin	Pharmacological
premedication	O
blunted	O
the	O
increase	O
of	O
monocyte	O
TF	O
expression	O
in	O
response	O
to	O
LPS	O
.	O

In	O
parallel	O
,	O
endotoxin-induced	O
formation	O
of	O
F1.2	O
was	O
significantly	O
reduced	O
by	O
simvastatin	Pharmacological
after	O
4	O
and	O
8	O
hours	O
.	O

LPS	O
infusion	O
affected	O
neither	O
the	O
formation	O
and	O
activation	O
of	O
monocyte-platelet	O
aggregates	O
nor	O
plasma	O
levels	O
of	O
sCD40	O
and	O
sCD40L	O
.	O

CONCLUSIONS	O
Simvastatin	Pharmacological
suppresses	O
the	O
inflammatory	O
response	O
to	O
endotoxin	O
and	O
blunts	O
monocyte	O
TF	O
expression	O
but	O
does	O
not	O
affect	O
platelet	O
activation	O
.	O

Development	O
of	O
an	O
adaptive	O
low-pass	O
filtered	O
speech	O
test	O
for	O
the	O
identification	O
of	O
auditory	O
processing	O
disorders	O
.	O

OBJECTIVE	O
One	O
type	O
of	O
test	O
commonly	O
used	O
to	O
examine	O
auditory	O
processing	O
disorders	O
(	O
APD	O
)	O
is	O
the	O
low-pass	Physical
filtered	Physical
speech	Physical
test	Physical
(	O
LPFST	O
)	O
,	O
of	O
which	O
there	O
are	O
various	O
versions	O
.	O

In	O
LPFSTs	O
,	O
a	O
monaural	O
,	O
low-redundancy	O
speech	O
sample	O
is	O
distorted	O
by	O
using	O
filtering	O
to	O
modify	O
its	O
frequency	O
content	O
.	O

Due	O
to	O
the	O
richness	O
of	O
the	O
neural	O
pathways	O
in	O
the	O
auditory	O
system	O
and	O
the	O
redundancy	O
of	O
acoustic	O
information	O
in	O
spoken	O
language	O
,	O
a	O
normal	O
listener	O
is	O
able	O
to	O
recognize	O
speech	O
even	O
when	O
parts	O
of	O
the	O
signal	O
are	O
missing	O
,	O
whereas	O
this	O
ability	O
is	O
often	O
impaired	O
in	O
listeners	O
with	O
APD	O
.	O

One	O
limitation	O
of	O
the	O
various	O
versions	O
of	O
the	O
LPFST	Physical
is	O
that	O
they	O
are	O
carried	O
out	O
using	O
a	O
constant	O
level	O
of	O
low-pass	O
filtering	O
(	O
e.g	O
.	O

a	O
fixed	O
1kHz	O
corner	O
frequency	O
)	O
which	O
makes	O
them	O
prone	O
to	O
ceiling	O
and	O
floor	O
effects	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
counter	O
these	O
effects	O
by	O
modifying	O
the	O
LPFST	O
using	O
a	O
computer-based	O
adaptive	O
procedure	O
,	O
and	O
to	O
evaluate	O
the	O
performance	O
of	O
normal-hearing	O
participants	O
of	O
varying	O
ages	O
on	O
the	O
test	O
.	O

METHODS	O
In	O
this	O
preliminary	O
study	O
,	O
33	O
adults	O
and	O
30	O
children	O
(	O
aged	O
8-11	O
years	O
)	O
with	O
no	O
known	O
history	O
of	O
listening	O
difficulties	O
were	O
tested	O
.	O

The	Educational
University	Educational
of	Educational
Canterbury	Educational
Adaptive	Educational
Speech	Educational
Test	Educational
(	Educational
UCAST	Educational
)	Educational
platform	Educational
was	Educational
used	Educational
to	Educational
administer	Educational
a	Educational
four-alternative	Educational
forced-choice	Educational
adaptive	Educational
test	Educational
that	Educational
altered	Educational
a	Educational
low-pass	Educational
filter	Educational
(	Educational
LPF	Educational
)	Educational
to	Educational
track	Educational
the	Educational
corner	Educational
frequency	Educational
at	Educational
which	Educational
participants	Educational
correctly	Educational
identified	Educational
a	Educational
certain	Educational
percentage	Educational
of	Educational
the	Educational
word	Educational
stimuli	Educational
.	Educational

RESULTS	O
Findings	O
on	O
the	O
University	O
of	O
Canterbury	O
Adaptive	O
Speech	O
Test-Filtered	O
Words	O
(	O
UCAST-FW	O
)	O
indicated	O
a	O
significant	O
maturational	O
effect	O
.	O

Adult	O
participants	O
performed	O
significantly	O
better	O
on	O
the	O
UCAST-FW	O
in	O
comparison	O
to	O
the	O
child	O
participants	O
.	O

The	O
UCAST-FW	O
test	O
was	O
reliable	O
over	O
repeated	O
administrations	O
.	O

CONCLUSIONS	O
An	O
adaptive	O
low-pass	O
filtered	O
speech	O
test	O
such	O
as	O
the	O
UCAST-FW	O
is	O
sensitive	O
to	O
maturational	O
changes	O
in	O
auditory	O
processing	O
ability	O
.	O

Efficiency	O
of	O
anaferon	Pharmacological
in	O
complex	Pharmacological
therapy	Pharmacological
of	O
genital	O
herpes	O
.	O

We	O
studied	O
clinical	O
efficiency	O
and	O
IFN-inducing	O
activity	O
of	O
anaferon	Pharmacological
in	O
chronic	O
recurrent	O
genital	O
herpes	O
with	O
high	O
incidence	O
of	O
relapses	O
.	O

The	O
use	O
of	O
anaferon	Pharmacological
in	O
complex	Pharmacological
therapy	Pharmacological
reduced	O
the	O
duration	O
of	O
intoxication	O
symptoms	O
and	O
local	O
symptoms	O
,	O
shortened	O
the	O
duration	O
of	O
the	O
relapse	O
,	O
activated	O
expression	O
of	O
IFN-gamma	O
mRNA	O
,	O
and	O
improved	O
IFN-gamma-producing	O
capacity	O
of	O
blood	O
leukocytes	O
.	O

The	O
effect	O
of	O
reinforcement	O
or	O
stimulus	O
control	O
to	O
reduce	O
sedentary	O
behavior	O
in	O
the	O
treatment	O
of	O
pediatric	O
obesity	O
.	O

Obese	O
children	O
were	O
randomly	O
assigned	O
to	O
a	O
family-based	Educational
behavioral	Educational
treatment	Educational
that	O
included	O
either	O
stimulus	O
control	O
or	O
reinforcement	O
to	O
reduce	O
sedentary	O
behaviors	O
.	O

Significant	O
and	O
equivalent	O
decreases	O
in	O
sedentary	O
behavior	O
and	O
high	O
energy	O
density	O
foods	O
,	O
increases	O
in	O
physical	O
activity	O
and	O
fruits	O
and	O
vegetables	O
,	O
and	O
decreases	O
in	O
standardized	O
body	O
mass	O
index	O
(	O
z-BMI	O
)	O
were	O
observed	O
.	O

Children	O
who	O
substituted	O
active	O
for	O
sedentary	O
behaviors	O
had	O
significantly	O
greater	O
z-BMI	O
changes	O
at	O
6	O
(	O
-1.21	O
vs.	O
-0.76	O
)	O
and	O
12	O
(	O
-1.05	O
vs.	O
-0.51	O
)	O
months	O
,	O
respectively	O
.	O

Substitution	O
of	O
physically	O
active	O
for	O
sedentary	O
behaviors	O
and	O
changes	O
in	O
activity	O
level	O
predicted	O
6-	O
and	O
12-month	O
z-BMI	O
changes	O
.	O

Results	O
suggest	O
stimulus	O
control	O
and	O
reinforcing	O
reduced	O
sedentary	O
behaviors	O
are	O
equivalent	O
ways	O
to	O
decrease	O
sedentary	O
behaviors	O
,	O
and	O
behavioral	O
economic	O
relationships	O
in	O
eating	O
and	O
activity	O
may	O
mediate	O
the	O
effects	O
of	O
treatment	O
.	O

[	O
Case-controll	O
study	O
on	O
the	O
synergistic	O
effects	O
of	O
electroacupuncture	Physical
on	O
knee	O
osteoarthritis	O
after	O
arthroscopic	Physical
debridement	Physical
]	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
synergistic	O
effects	O
of	O
electroacupuncture	Physical
on	O
the	O
treatment	O
of	O
knee	O
osteoarthritis	O
after	O
arthroscopic	Physical
debridement	Physical
.	O

METHODS	O
From	O
May	O
2008	O
to	O
July	O
2010	O
,	O
78	O
patients	O
with	O
knee	O
osteoarthritis	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

There	O
were	O
42	O
patients	O
in	O
the	O
experimental	O
group	O
,	O
including	O
16	O
males	O
and	O
26	O
females	O
,	O
ranging	O
in	O
age	O
from	O
41	O
to	O
63	O
years	O
,	O
with	O
an	O
average	O
of	O
(	O
53.62	O
+/-	O
6.53	O
)	O
years	O
;	O
the	O
disease	O
course	O
ranged	O
from	O
8	O
to	O
24	O
months	O
,	O
with	O
an	O
average	O
of	O
(	O
10.35	O
+/-	O
6.42	O
)	O
months	O
.	O

The	O
patients	O
were	O
treated	O
with	O
arthroscopic	Physical
debridement	Physical
combined	O
with	O
electroacupuncture	Physical
after	O
operation	O
.	O

There	O
were	O
36	O
patients	O
in	O
the	O
control	O
group	O
,	O
including	O
14	O
males	O
and	O
22	O
females	O
,	O
ranging	O
in	O
age	O
from	O
40	O
to	O
62	O
years	O
,	O
with	O
an	O
average	O
of	O
(	O
54.34	O
+/-	O
7.67	O
)	O
years	O
;	O
the	O
disease	O
course	O
ranged	O
from	O
6	O
to	O
25	O
months	O
,	O
with	O
an	O
average	O
of	O
(	O
11.94	O
+/-	O
5.13	O
)	O
months	O
.	O

Those	O
patients	O
were	O
treated	O
only	O
with	O
arthroscopic	Physical
debridment	Physical
.	O

All	O
the	O
patients	O
performed	O
isometric	Physical
quadriceps	Physical
femoris	Physical
contraction	Physical
exercise	Physical
and	O
knee	Physical
flexion	Physical
and	O
extension	Physical
activities	Physical
after	O
operation	O
.	O

The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
score	O
and	O
Lysholm	O
knee	O
score	O
were	O
used	O
to	O
evaluate	O
the	O
therapeutic	O
effects	O
.	O

RESULTS	O
All	O
the	O
patients	O
were	O
followed	O
up	O
,	O
and	O
the	O
duration	O
ranged	O
from	O
12	O
to	O
30	O
months	O
,	O
with	O
an	O
average	O
of	O
15.6	O
months	O
.	O

At	O
the	O
final	O
follow-up	O
,	O
VAS	O
score	O
was	O
significantly	O
decreased	O
,	O
and	O
the	O
Lysholm	O
score	O
,	O
except	O
for	O
the	O
item	O
demanding	O
for	O
support	O
,	O
significantly	O
increased	O
,	O
compared	O
with	O
those	O
before	O
surgery	O
respectively	O
in	O
both	O
groups	O
.	O

There	O
was	O
significant	O
difference	O
in	O
VAS	O
score	O
between	O
two	O
groups	O
after	O
treatment	O
.	O

As	O
to	O
Lysholm	O
score	O
,	O
there	O
were	O
significant	O
differences	O
in	O
limp	O
,	O
pain	O
,	O
swelling	O
,	O
stair	O
activity	O
and	O
squat	O
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
in	O
items	O
of	O
interlocking	O
and	O
instability	O
between	O
two	O
groups	O
after	O
treatment	O
.	O

CONCLUSION	O
Electroacupuncture	O
can	O
effectively	O
improve	O
the	O
clinical	O
symptoms	O
and	O
knee	O
joint	O
's	O
motor	O
function	O
of	O
knee	O
joints	O
in	O
patients	O
with	O
knee	O
osteoarthritis	O
,	O
as	O
well	O
as	O
the	O
synergistic	O
effects	O
on	O
the	O
treatment	O
of	O
knee	O
osteoarthritis	O
after	O
arthroscopic	O
debridement	O
,	O
leading	O
to	O
a	O
much	O
better	O
long-term	O
therapeutic	O
effect	O
with	O
respect	O
of	O
improving	O
the	O
function	O
of	O
knee	O
joint	O
.	O

This	O
therapy	O
,	O
combined	O
with	O
traditional	O
Chinese	O
medicine	O
and	O
Western	O
Medicine	O
,	O
is	O
worth	O
of	O
clinical	O
application	O
in	O
the	O
treatment	O
of	O
knee	O
osteoarthritis	O
.	O

Veterans	O
Administration	O
Cooperative	O
Study	O
on	O
antiplatelet	Pharmacological
agents	Pharmacological
in	O
diabetic	O
patients	O
after	O
amputation	O
for	O
gangrene	O
:	O
II	O
.	O

Effects	O
of	O
aspirin	Pharmacological
and	O
dipyridamole	Pharmacological
on	O
atherosclerotic	O
vascular	O
disease	O
rates	O
.	O

We	O
report	O
the	O
results	O
of	O
a	O
randomized	O
multicenter	O
clinical	O
trial	O
on	O
the	O
effects	O
of	O
aspirin	Pharmacological
plus	Pharmacological
dipyridamole	Pharmacological
versus	O
placebo	Control
on	O
major	O
vascular	O
end	O
points	O
in	O
231	O
non-insulin-dependent	O
diabetic	O
men	O
with	O
either	O
a	O
recent	O
amputation	O
for	O
gangrene	O
or	O
active	O
gangrene	O
.	O

Primary	O
end	O
points	O
were	O
death	O
from	O
atherosclerotic	O
vascular	O
disease	O
plus	O
amputation	O
of	O
the	O
opposite	O
extremity	O
for	O
gangrene	O
.	O

There	O
were	O
24	O
atherosclerotic	O
deaths	O
in	O
the	O
drug	O
treatment	O
group	O
(	O
21.8	O
%	O
)	O
and	O
23	O
in	O
the	O
placebo	Control
group	O
(	O
19.0	O
%	O
)	O
.	O

There	O
were	O
22	O
patients	O
in	O
the	O
drug	O
treatment	O
group	O
(	O
20.0	O
%	O
)	O
and	O
29	O
patients	O
in	O
the	O
placebo	O
group	O
(	O
24.0	O
%	O
)	O
with	O
opposite-side	O
amputations	O
.	O

Survival	O
curve	O
analyses	O
revealed	O
little	O
difference	O
between	O
these	O
groups	O
for	O
major	O
vascular	O
end	O
points	O
,	O
total	O
mortality	O
,	O
all	O
amputations	O
,	O
or	O
myocardial	O
infarctions	O
.	O

The	O
most	O
noteworthy	O
group	O
difference	O
was	O
observed	O
for	O
cerebrovascular	O
end	O
points	O
(	O
strokes	O
and	O
transient	O
ischemic	O
attacks	O
)	O
,	O
with	O
an	O
incidence	O
of	O
8.2	O
%	O
(	O
9	O
patients	O
)	O
in	O
the	O
drug	O
treatment	O
group	O
and	O
19.0	O
%	O
(	O
23	O
patients	O
)	O
in	O
the	O
placebo	O
group	O
.	O

We	O
conclude	O
from	O
this	O
study	O
that	O
antiplatelet	O
agents	O
have	O
no	O
effect	O
on	O
the	O
primary	O
vascular	O
end	O
points	O
,	O
vascular	O
deaths	O
and/or	O
amputation	O
of	O
the	O
opposite	O
extremity	O
,	O
in	O
this	O
population	O
.	O

Similarly	O
,	O
no	O
effects	O
were	O
seen	O
on	O
secondary	O
vascular	O
end	O
points	O
,	O
except	O
for	O
a	O
suggestion	O
of	O
protection	O
versus	O
strokes	O
and	O
transient	O
ischemic	O
attacks	O
.	O

However	O
,	O
this	O
finding	O
must	O
be	O
interpreted	O
with	O
caution	O
,	O
since	O
it	O
is	O
a	O
secondary	O
end	O
point	O
and	O
was	O
found	O
only	O
after	O
multiple	O
analyses	O
of	O
the	O
data	O
.	O

Effect	O
of	O
ibuprofen	Pharmacological
on	O
cyclooxygenase	O
and	O
nitric	O
oxide	O
synthase	O
of	O
gastric	O
mucosa	O
:	O
correlation	O
with	O
endoscopic	O
lesions	O
and	O
adverse	O
reactions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
ibuprofen	Pharmacological
on	O
gastric	O
mucosa	O
and	O
enzymes	O
involved	O
in	O
gastroprotection	O
in	O
healthy	O
volunteers	O
.	O

Twenty-four	O
Helicobacter	O
pylori-negative	O
subjects	O
were	O
randomized	O
to	O
treatment	O
with	O
ibuprofen	Pharmacological
or	O
ibuprofen-arginate	Pharmacological
(	O
each	O
600	O
mg/6	O
hr	O
during	O
3	O
days	O
)	O
.	O

Endoscopies	Physical
were	O
performed	O
1	O
week	O
before	O
and	O
after	O
treatment	O
.	O

Biopsies	O
were	O
taken	O
from	O
the	O
gastric	O
antrum	O
and	O
corpus	O
for	O
determination	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
by	O
ELISA	Physical
and	O
cyclooxygenase	O
(	O
COX-1	O
and	O
COX-2	O
)	O
and	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
and	O
iNOS	O
)	O
by	O
western	O
blot	O
.	O

All	O
subjects	O
had	O
at	O
least	O
one	O
gastric	O
lesion	O
except	O
for	O
two	O
individuals	O
taking	O
ibuprofen-arginate	O
.	O

Ibuprofen-arginate	O
caused	O
a	O
lower	O
rate	O
of	O
clinical	O
adverse	O
reactions	O
than	O
ibuprofen	O
.	O

Subjects	O
with	O
gastric	O
lesions	O
or	O
adverse	O
reactions	O
had	O
lower	O
PGE2	O
levels	O
.	O

COX-1	O
,	O
COX-2	O
,	O
eNOS	O
,	O
and	O
iNOS	O
were	O
detectable	O
in	O
all	O
subjects	O
.	O

The	O
constitutive	O
enzymes	O
(	O
COX-1	O
and	O
eNOS	O
)	O
did	O
not	O
change	O
after	O
treatment	O
.	O

COX-2	O
was	O
higher	O
in	O
corpus	O
than	O
antrum	O
and	O
it	O
increased	O
after	O
ibuprofen	O
treatment	O
.	O

iNOS	O
tended	O
to	O
increase	O
mildly	O
in	O
the	O
corpus	O
in	O
subjects	O
with	O
adverse	O
reactions	O
or	O
endoscopic	O
lesions	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
ibuprofen	O
and	O
ibuprofen-arginate	O
in	O
PGE2	O
,	O
or	O
enzymes	O
.	O

Rapid-sequence	Physical
intubation	Physical
of	O
head	O
trauma	O
patients	O
:	O
prevention	O
of	O
fasciculations	O
with	O
pancuronium	Pharmacological
versus	O
minidose	Pharmacological
succinylcholine	Pharmacological
.	O

INTRODUCTION	O
Fasciculations	O
during	O
rapid-sequence	O
intubation	O
may	O
lead	O
to	O
increased	O
intracranial	O
pressure	O
and	O
emesis	O
with	O
aspiration	O
.	O

Standard	O
rapid-sequence	O
intubation	O
requires	O
a	O
nondepolarizing	O
blocking	O
agent	O
before	O
succinylcholine	Pharmacological
administration	Pharmacological
.	O

HYPOTHESIS	O
Prevention	O
of	O
fasciculations	O
during	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
can	O
be	O
accomplished	O
as	O
safely	O
and	O
effectively	O
with	O
minidose	O
succinylcholine	Pharmacological
as	O
with	O
a	O
defasciculating	O
dose	O
of	O
pancuronium	O
.	O

DESIGN	O
A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

SETTING	O
An	O
inner-city	O
county	O
trauma	O
center	O
with	O
70,000	O
patient	O
visits	O
per	O
year	O
.	O

PARTICIPANTS	O
Sequential	O
adult	O
head	O
trauma	O
patients	O
requiring	O
rapid-sequence	O
intubation	O
who	O
had	O
no	O
contraindications	O
to	O
succinylcholine	Pharmacological
or	O
pancuronium	Pharmacological
.	O

INTERVENTIONS	O
Each	O
head	O
trauma	O
patient	O
requiring	O
rapid-sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid-sequence	Physical
intubation	Physical
maneuvers	Physical
and	O
lidocaine	Pharmacological
(	O
1	O
mg/kg	O
)	O
IV	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
minidose	Pharmacological
succinylcholine	Pharmacological
(	Pharmacological
0.1	Pharmacological
mg/kg	Pharmacological
)	Pharmacological
or	O
pancuronium	Pharmacological
(	O
0.03	O
mg/kg	O
)	O
IV	O
one	O
minute	O
prior	O
to	O
the	O
full	Pharmacological
paralytic	Pharmacological
dose	Pharmacological
of	Pharmacological
succinylcholine	Pharmacological
(	O
1.5	O
mg/kg	O
)	O
IV	O
.	O

Fasciculations	O
were	O
recorded	O
using	O
a	O
graded	O
visual	O
scale	O
.	O

RESULTS	O
Of	O
46	O
patients	O
,	O
eight	O
of	O
19	O
(	O
42	O
%	O
)	O
in	O
the	O
pancuronium	Pharmacological
group	O
and	O
six	O
of	O
27	O
(	O
22	O
%	O
)	O
in	O
the	O
succinylcholine	Pharmacological
group	O
experienced	O
fasciculations	O
.	O

No	O
statistically	O
significant	O
difference	O
in	O
fasciculations	O
was	O
detected	O
between	O
the	O
two	O
groups	O
using	O
chi	O
2	O
analysis	O
.	O

Complete	O
relaxation	O
of	O
the	O
cords	O
was	O
present	O
in	O
all	O
but	O
two	O
patients	O
,	O
one	O
in	O
each	O
group	O
.	O

No	O
patient	O
in	O
either	O
group	O
experienced	O
emesis	O
or	O
significant	O
dysrhythmias	O
.	O

CONCLUSION	O
Pretreatment	O
with	O
minidose	O
succinylcholine	Pharmacological
causes	O
no	O
greater	O
incidence	O
of	O
fasciculations	O
than	O
pancuronium	Pharmacological
in	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
in	O
an	O
ED	O
setting	O
.	O

Thus	O
succinylcholine	Pharmacological
may	O
be	O
used	O
as	O
the	O
sole	O
paralytic	O
agent	O
in	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
.	O

Leukocyte-depleted	Physical
reperfusion	Physical
of	O
transplanted	O
human	O
hearts	O
:	O
a	O
randomized	O
,	O
double-blind	O
clinical	O
trial	O
.	O

Standard	O
methods	O
of	O
myocardial	O
preservation	O
for	O
heart	O
transplantation	O
have	O
generally	O
provided	O
good	O
results	O
.	O

Preservation	O
times	O
beyond	O
3	O
hours	O
,	O
however	O
,	O
have	O
been	O
associated	O
with	O
decreased	O
survival	O
.	O

Leukocyte-mediated	O
reperfusion	O
injury	O
is	O
partly	O
responsible	O
for	O
decreased	O
graft	O
function	O
after	O
prolonged	O
graft	O
ischemia	O
.	O

Leukocyte-depleted	Physical
reperfusion	Physical
has	O
been	O
shown	O
experimentally	O
to	O
improve	O
cardiac	O
function	O
after	O
cold	O
ischemic	O
arrest	O
.	O

To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
leukocyte-depleted	Physical
reperfusion	Physical
,	O
20	O
patients	O
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double-blind	O
clinical	O
trial	O
to	O
be	O
treated	O
with	O
either	O
warm	Physical
whole	Physical
blood	Physical
reperfusion	Physical
(	O
group	O
I	O
;	O
n	O
=	O
9	O
)	O
or	O
warm	Physical
leukocyte-depleted	Physical
blood	Physical
reperfusion	Physical
(	O
group	O
II	O
;	O
n	O
=	O
11	O
)	O
.	O

Reperfusion	Pharmacological
with	Pharmacological
leukocyte-depleted	Pharmacological
blood	Pharmacological
or	O
whole	Pharmacological
blood	Pharmacological
was	O
carried	O
out	O
for	O
10	O
minutes	O
,	O
with	O
enriched	O
cardioplegic	O
solution	O
added	O
for	O
the	O
first	O
3	O
minutes	O
of	O
reperfusion	O
.	O

The	O
mean	O
donor	O
and	O
recipient	O
age	O
and	O
the	O
ischemic	O
time	O
(	O
142	O
versus	O
153	O
minutes	O
)	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Coronary	O
sinus	O
release	O
of	O
creatinine	O
phosphokinase-MB	O
5	O
minutes	O
after	O
reperfusion	O
was	O
significantly	O
less	O
in	O
group	O
II	O
(	O
1.65	O
EU/min	O
)	O
than	O
in	O
group	O
I	O
(	O
3.83	O
units/min	O
;	O
p	O
=	O
0.05	O
)	O
.	O

Thromboxane	O
B2	O
release	O
was	O
also	O
significantly	O
less	O
(	O
p	O
=	O
0.05	O
)	O
in	O
group	O
II	O
(	O
33.6	O
pg/min	O
)	O
than	O
in	O
group	O
I	O
(	O
67.0	O
pg/min	O
)	O
.	O

All	O
hearts	O
functioned	O
adequately	O
in	O
both	O
groups	O
.	O

The	O
duration	O
of	O
inotropic	O
support	O
was	O
shorter	O
in	O
group	O
II	O
than	O
in	O
group	O
I	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Postoperative	O
hemodynamics	O
,	O
rejection	O
episodes	O
,	O
and	O
infectious	O
complications	O
were	O
also	O
not	O
significantly	O
different	O
between	O
groups	O
in	O
a	O
mean	O
follow-up	O
of	O
9	O
months	O
.	O

Mean	O
ejection	O
fraction	O
1	O
month	O
after	O
operation	O
was	O
65	O
%	O
in	O
both	O
groups	O
.	O

One	O
early	O
death	O
occurred	O
at	O
66	O
days	O
secondary	O
to	O
infection	O
;	O
two	O
late	O
deaths	O
occurred	O
in	O
group	O
II	O
,	O
both	O
from	O
rejection	O
.	O

Leukocyte-depleted	Physical
reperfusion	Physical
is	O
safe	O
and	O
easily	O
applied	O
in	O
the	O
operating	O
room	O
.	O

Furthermore	O
,	O
leukocyte-depleted	O
reperfusion	O
decreases	O
biochemical	O
evidence	O
of	O
reperfusion	O
injury	O
.	O

Although	O
not	O
influencing	O
postoperative	O
cardiac	O
function	O
when	O
the	O
ischemic	O
time	O
is	O
short	O
,	O
less	O
than	O
3	O
hours	O
,	O
leukocyte-depleted	O
reperfusion	O
may	O
prevent	O
significant	O
reperfusion	O
injury	O
and	O
improve	O
posttransplantation	O
graft	O
function	O
when	O
ischemic	O
times	O
are	O
long	O
.	O

Safe	O
extension	O
of	O
the	O
ischemic	O
time	O
would	O
expand	O
the	O
donor	O
pool	O
and	O
allow	O
for	O
better	O
crossmatching	O
.	O

Short-term	O
effects	O
of	O
systemic	O
antibiotics	Pharmacological
during	O
periodontal	O
healing	O
.	O

OBJECTIVES	O
To	O
investigate	O
the	O
short-term	O
effects	O
of	O
nonsurgical	O
therapy	O
(	O
scaling	O
and	O
root	O
planing	O
,	O
SRP	O
)	O
on	O
the	O
subgingival	O
microbiota	O
in	O
chronic	O
(	O
CP	O
)	O
and	O
aggressive	O
(	O
AP	O
)	O
periodontal	O
disease	O
.	O

METHOD	O
AND	O
MATERIALS	O
Ninety-seven	O
CP	O
and	O
AP	O
subjects	O
underwent	O
full-mouth	O
SRP	O
on	O
2	O
consecutive	O
days	O
.	O

AP	O
patients	O
were	O
randomly	O
assigned	O
to	O
either	O
receive	O
systemic	Pharmacological
metronidazole	Pharmacological
plus	Pharmacological
amoxicillin	Pharmacological
(	Pharmacological
AP+AB	Pharmacological
)	Pharmacological
or	O
were	O
treated	Pharmacological
mechanically	Pharmacological
alone	Pharmacological
(	Pharmacological
AP	Pharmacological
)	Pharmacological
.	O

Pathogens	O
were	O
identified	O
with	O
16S	O
rRNA	O
oligodeoxynucleotide	O
probes	O
and	O
dot-blot	O
hybridization	O
before	O
and	O
at	O
days	O
2	O
,	O
3	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
and	O
21	O
of	O
healing	O
.	O

CP	O
subjects	O
were	O
treated	O
by	O
scaling	O
and	O
root	O
planing	O
along	O
with	O
placebo	Control
tablets	Control
.	Control

RESULTS	O
Initially	O
,	O
AP	O
cell	O
counts	O
were	O
69.9-	O
(	O
Porphyromonas	O
gingivalis	O
)	O
,	O
10.2-	O
(	O
Aggregatibacter	O
actinomycetemcomitans	O
)	O
,	O
5.7-	O
(	O
Tannerella	O
forsythia	O
)	O
,	O
and	O
3.3-fold	O
(	O
Prevotella	O
intermedia	O
)	O
enhanced	O
compared	O
to	O
CP	O
cell	O
counts	O
.	O

Following	O
SRP	O
,	O
immediate	O
elimination	O
occurred	O
in	O
single	O
individuals	O
of	O
all	O
three	O
treatment	O
groups	O
at	O
day	O
2	O
.	O

After	O
SRP	Pharmacological
plus	Pharmacological
antibiotic	Pharmacological
therapy	Pharmacological
(	O
AP+AB	O
)	O
,	O
the	O
prevalence	O
scores	O
dropped	O
beyond	O
the	O
levels	O
of	O
AP	O
and	O
CP	O
,	O
beginning	O
at	O
day	O
7	O
,	O
and	O
remained	O
low	O
until	O
day	O
21	O
(	O
P	O
=or	O
<	O
.05	O
)	O
.	O

Clinical	O
healing	O
statistically	O
benefited	O
from	O
SRP	O
with	O
no	O
differences	O
among	O
the	O
three	O
treatment	O
groups	O
.	O

CONCLUSION	O
Nonsurgical	O
therapy	O
resulted	O
in	O
both	O
a	O
suppression	O
and	O
early	O
elimination	O
of	O
single	O
taxa	O
immediately	O
after	O
completion	O
of	O
active	O
treatment	O
.	O

Systemic	O
antibiotics	O
significantly	O
accelerate	O
the	O
suppression	O
of	O
the	O
periodontal	O
microflora	O
,	O
but	O
have	O
limited	O
effect	O
on	O
the	O
elimination	O
of	O
target	O
isolates	O
during	O
healing	O
.	O

Diazoxide	Pharmacological
and	O
labetalol	Pharmacological
in	O
acute	O
hypertension	O
during	O
haemodialysis	O
.	O

The	O
antihypertensive	O
effect	O
of	O
the	O
peripheral	Pharmacological
vasodilator	Pharmacological
diazoxide	Pharmacological
in	O
13	O
patients	O
and	O
the	O
alpha-beta	Pharmacological
adrenoceptor	Pharmacological
blocking	Pharmacological
agent	Pharmacological
labetalol	Pharmacological
in	O
12	O
patients	O
were	O
compared	O
in	O
46	O
severe	O
acute	O
hypertensive	O
episodes	O
during	O
haemodialysis	O
.	O

A	O
single	O
dose	O
of	O
diazoxide	Pharmacological
150	Pharmacological
mg	Pharmacological
or	O
labetalol	Pharmacological
50	Pharmacological
mg	Pharmacological
was	O
effective	O
in	O
74	O
%	O
and	O
70	O
%	O
of	O
the	O
hypertensive	O
episodes	O
,	O
respectively	O
.	O

In	O
the	O
diazoxide-treated	Pharmacological
patients	O
blood	O
pressure	O
fell	O
from	O
192	O
+/-	O
3/115	O
+/-	O
4	O
mmHg	O
to	O
141	O
+/-	O
8/85	O
+/-	O
4	O
mmHg	O
2	O
h	O
after	O
injection	O
.	O

In	O
7	O
hypertensive	O
episodes	O
a	O
second	O
dose	O
of	O
diazoxide	Pharmacological
150	O
mg	O
was	O
given	O
60	O
+/-	O
11	O
min	O
after	O
the	O
first	O
injection	O
.	O

The	O
reduction	O
in	O
mean	O
arterial	O
blood	O
pressure	O
at	O
the	O
end	O
of	O
haemodialysis	O
was	O
21.5	O
+/-	O
2.6	O
%	O
in	O
patients	O
treated	O
with	O
a	O
single	O
dose	O
and	O
24.8	O
+/-	O
3.5	O
%	O
in	O
patients	O
treated	O
with	O
the	O
repeated	O
dose	O
of	O
diazoxide	Pharmacological
.	O

In	O
the	O
labetalol-treated	Pharmacological
patients	O
blood	O
pressure	O
in	O
17	O
instances	O
fell	O
from	O
198	O
+/-	O
5/104	O
+/-	O
4	O
mmHg	O
to	O
143	O
+/-	O
7/89	O
+/-	O
5	O
mmHg	O
180	O
min	O
following	O
injection	O
of	O
labetalol	Pharmacological
50	O
mg	O
.	O

In	O
6	O
episodes	O
a	O
second	O
dose	O
labetalol	Pharmacological
50	O
mg	O
was	O
given	O
41	O
+/-	O
9	O
min	O
after	O
the	O
first	O
injection	O
.	O

At	O
the	O
end	O
of	O
haemodialysis	O
the	O
decrease	O
in	O
mean	O
arterial	O
blood	O
pressure	O
was	O
17.2	O
%	O
in	O
patients	O
treated	O
with	O
a	O
single	O
dose	O
and	O
18	O
+/-	O
5	O
%	O
in	O
patients	O
given	O
the	O
repeated	O
dose	O
of	O
labetalol	Pharmacological
.	O

The	O
reduction	O
in	O
blood	O
pressure	O
caused	O
by	O
diazoxide	Pharmacological
was	O
slightly	O
greater	O
than	O
that	O
due	O
to	O
labetalol	O
.	O

At	O
the	O
end	O
of	O
haemodialysis	O
the	O
percentage	O
reduction	O
in	O
mean	O
arterial	O
blood	O
pressure	O
was	O
23	O
+/-	O
2	O
%	O
in	O
the	O
diazoxide-treated	O
group	O
and	O
17	O
+/-	O
2	O
%	O
after	O
labetalol	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Efficacy	O
and	O
safety	O
of	O
recombinant	Educational
human	Educational
nerve	Educational
growth	Educational
factor	Educational
in	O
patients	O
with	O
diabetic	O
polyneuropathy	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

rhNGF	O
Clinical	O
Investigator	O
Group	O
.	O

CONTEXT	O
Nerve	O
growth	O
factor	O
is	O
a	O
neurotrophic	O
factor	O
that	O
promotes	O
the	O
survival	O
of	O
small	O
fiber	O
sensory	O
neurons	O
and	O
sympathetic	O
neurons	O
in	O
the	O
peripheral	O
nervous	O
system	O
.	O

Recombinant	Educational
human	Educational
nerve	Educational
growth	Educational
factor	Educational
(	Educational
rhNGF	Educational
)	Educational
has	O
demonstrated	O
efficacy	O
as	O
treatment	O
for	O
peripheral	O
neuropathy	O
in	O
experimental	O
models	O
and	O
phase	O
2	O
clinical	O
trials	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
12-month	O
regimen	O
of	O
rhNGF	O
in	O
patients	O
with	O
diabetic	O
polyneuropathy	O
.	O

DESIGN	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
phase	O
3	O
trial	O
conducted	O
from	O
July	O
1997	O
through	O
May	O
1999	O
.	O

SETTING	O
Eighty-four	O
outpatient	O
centers	O
throughout	O
the	O
United	O
States	O
.	O

PATIENTS	O
A	O
total	O
of	O
1019	O
men	O
and	O
women	O
aged	O
18	O
to	O
74	O
years	O
with	O
either	O
type	O
1	O
or	O
type	O
2	O
diabetes	O
and	O
a	O
sensory	O
polyneuropathy	O
attributable	O
to	O
diabetes	O
.	O

INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
rhNGF	Pharmacological
,	O
0.1	O
microg/kg	O
(	O
n	O
=	O
504	O
)	O
,	O
or	O
placebo	Control
(	O
n	O
=	O
515	O
)	O
by	O
subcutaneous	O
injection	O
3	O
times	O
per	O
week	O
for	O
48	O
weeks	O
.	O

Patients	O
were	O
assessed	O
at	O
baseline	O
,	O
12	O
weeks	O
,	O
24	O
weeks	O
,	O
and	O
48	O
weeks	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
outcome	O
measure	O
was	O
a	O
change	O
in	O
neuropathy	O
between	O
baseline	O
and	O
week	O
48	O
,	O
demonstrated	O
by	O
the	O
Neuropathy	O
Impairment	O
Score	O
for	O
the	O
Lower	O
Limbs	O
,	O
compared	O
between	O
the	O
2	O
groups	O
.	O

Secondary	O
outcome	O
measures	O
included	O
quantitative	O
sensory	O
tests	O
using	O
the	O
CASE	O
IV	O
System	O
,	O
the	O
Neuropathy	O
Symptom	O
and	O
Change	O
questionnaire	O
,	O
the	O
Patient	O
Benefit	O
Questionnaire	O
(	O
PBQ	O
)	O
,	O
and	O
a	O
global	O
symptom	O
assessment	O
,	O
as	O
well	O
as	O
nerve	O
conduction	O
studies	O
and	O
occurrence	O
of	O
new	O
plantar	O
foot	O
ulcers	O
.	O

Patients	O
also	O
were	O
evaluated	O
for	O
presence	O
of	O
adverse	O
events	O
.	O

RESULTS	O
Among	O
patients	O
who	O
received	O
rhNGF	Educational
,	O
418	O
(	O
83	O
%	O
)	O
completed	O
the	O
regimen	O
compared	O
with	O
461	O
(	O
90	O
%	O
)	O
who	O
received	O
placebo	Control
.	O

Administration	O
of	O
rhNGF	Pharmacological
was	O
safe	O
,	O
with	O
few	O
adverse	O
events	O
attributed	O
to	O
treatment	O
apart	O
from	O
injection	O
site	O
pain/hyperalgesia	O
and	O
other	O
pain	O
syndromes	O
.	O

However	O
,	O
neither	O
the	O
primary	O
end	O
point	O
(	O
P	O
=.25	O
)	O
nor	O
most	O
of	O
the	O
secondary	O
end	O
points	O
demonstrated	O
a	O
significant	O
benefit	O
of	O
rhNGF	Pharmacological
.	O

Exceptions	O
were	O
the	O
global	O
symptom	O
assessment	O
(	O
P	O
=.03	O
)	O
and	O
2	O
of	O
32	O
comparisons	O
within	O
the	O
PBQ	O
,	O
which	O
showed	O
a	O
modest	O
but	O
significant	O
benefit	O
of	O
rhNGF	Pharmacological
(	O
P	O
=.05	O
for	O
severity	O
of	O
pain	O
in	O
the	O
legs	O
and	O
P	O
=.003	O
for	O
6-month	O
symptoms	O
in	O
the	O
feet	O
and	O
legs	O
)	O
.	O

CONCLUSION	O
Unlike	O
previous	O
phase	O
2	O
trials	O
,	O
this	O
phase	O
3	O
clinical	O
trial	O
failed	O
to	O
demonstrate	O
a	O
significant	O
beneficial	O
effect	O
of	O
rhNGF	O
on	O
diabetic	O
polyneuropathy	O
.	O

JAMA	O
.	O

2000	O
;	O
284:2215-2221	O
.	O

Effect	O
of	O
secretin	Pharmacological
on	O
children	O
with	O
autism	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

To	O
determine	O
the	O
effect	O
of	O
intravenous	Pharmacological
porcine	Pharmacological
secretin	Pharmacological
on	O
autistic	O
behaviours	O
in	O
children	O
aged	O
2	O
to	O
7	O
years	O
,	O
the	O
effects	O
of	O
secretin	O
on	O
(	O
1	O
)	O
performance	O
on	O
a	O
standardized	O
language	O
measure	O
,	O
and	O
(	O
2	O
)	O
autistic	O
behaviours	O
,	O
as	O
rated	O
by	O
parents	O
and	O
child	O
development	O
professionals	O
was	O
examined	O
.	O

Employing	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
design	O
,	O
95	O
participants	O
were	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
and	O
administered	O
a	O
single	O
dose	O
of	O
either	O
secretin	Pharmacological
or	O
placebo	Control
.	O

A	O
follow-up	O
assessment	O
was	O
conducted	O
3	O
weeks	O
after	O
the	O
injection	O
.	O

No	O
significant	O
differences	O
in	O
language	O
or	O
autistic	O
behaviour	O
measures	O
were	O
observed	O
at	O
the	O
3-week	O
follow-up	O
between	O
the	O
groups	O
.	O

Also	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
proportion	O
of	O
individuals	O
who	O
improved	O
by	O
>	O
or	O
=	O
6	O
points	O
on	O
the	O
language	O
measure	O
at	O
follow-up	O
.	O

This	O
study	O
showed	O
no	O
significant	O
effects	O
of	O
secretin	O
on	O
children	O
with	O
autism	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
a	O
systematic	O
review	O
of	O
randomized	O
controlled	O
trials	O
evaluating	O
the	O
effect	O
of	O
secretin	O
in	O
children	O
with	O
autism	O
.	O

Impact	O
of	O
disease	O
severity	O
on	O
outcome	O
of	O
antiviral	Pharmacological
therapy	Pharmacological
for	O
chronic	O
hepatitis	O
C	O
:	O
Lessons	O
from	O
the	O
HALT-C	O
trial	O
.	O

In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
advanced	O
fibrosis	O
and	O
cirrhosis	O
are	O
associated	O
with	O
lower	O
rates	O
of	O
sustained	O
virologic	O
response	O
(	O
SVR	O
)	O
to	O
interferon	O
(	O
IFN	O
)	O
-based	O
therapy	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
virologic	O
response	O
to	O
retreatment	O
with	O
peginterferon	Pharmacological
alfa-2a	Pharmacological
and	O
ribavirin	Pharmacological
(	Pharmacological
RBV	Pharmacological
)	Pharmacological
,	O
as	O
a	O
function	O
of	O
the	O
baseline	O
fibrosis	O
score	O
(	O
Ishak	O
staging	O
)	O
and	O
platelet	O
count	O
,	O
in	O
1,046	O
patients	O
enrolled	O
in	O
the	O
Hepatitis	O
C	O
Antiviral	O
Long-term	O
Treatment	O
against	O
Cirrhosis	O
(	O
HALT-C	O
)	O
Trial	O
.	O

All	O
patients	O
had	O
failed	O
prior	O
treatment	O
with	O
IFN	Pharmacological
or	O
peginterferon	Pharmacological
+/-	Pharmacological
RBV	Pharmacological
and	O
had	O
Ishak	O
fibrosis	O
scores	O
>	O
or	O
=	O
3	O
.	O

Four	O
groups	O
of	O
patients	O
with	O
increasingly	O
severe	O
liver	O
disease	O
were	O
compared	O
:	O
(	O
A	O
)	O
bridging	O
fibrosis	O
(	O
Ishak	O
3	O
and	O
4	O
)	O
with	O
platelet	O
counts	O
>	O
125,000/mm3	O
(	O
n	O
=	O
559	O
)	O
;	O
(	O
B	O
)	O
bridging	O
fibrosis	O
with	O
platelet	O
counts	O
<	O
or	O
=125,000/mm3	O
(	O
n	O
=	O
96	O
)	O
;	O
(	O
C	O
)	O
cirrhosis	O
(	O
Ishak	O
5	O
and	O
6	O
)	O
with	O
platelet	O
counts	O
>	O
125,000/mm3	O
(	O
n	O
=	O
198	O
)	O
;	O
and	O
(	O
D	O
)	O
cirrhosis	O
with	O
platelet	O
counts	O
<	O
or	O
=125,000/mm3	O
(	O
n	O
=	O
193	O
)	O
.	O

SVR	O
rates	O
were	O
23	O
%	O
,	O
17	O
%	O
,	O
10	O
%	O
,	O
and	O
9	O
%	O
in	O
groups	O
A	O
,	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
respectively	O
(	O
P	O
<	O
.0001	O
for	O
trend	O
)	O
.	O

Reduction	O
in	O
SVR	O
as	O
a	O
function	O
of	O
increasingly	O
severe	O
disease	O
was	O
independent	O
of	O
age	O
,	O
percent	O
African	O
American	O
,	O
HCV	O
genotype	O
,	O
HCV	O
level	O
,	O
and	O
type	O
of	O
prior	O
therapy	O
.	O

Dose	O
reduction	O
lowered	O
SVR	O
frequencies	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
than	O
disease	O
severity	O
.	O

By	O
logistic	O
regression	O
,	O
cirrhosis	O
(	O
P	O
<	O
.0001	O
)	O
was	O
the	O
major	O
determinant	O
that	O
impaired	O
virologic	O
response	O
,	O
independent	O
of	O
dose	O
reduction	O
or	O
platelet	O
count	O
.	O

In	O
conclusion	O
,	O
disease	O
severity	O
is	O
a	O
major	O
independent	O
determinant	O
of	O
rate	O
of	O
SVR	O
in	O
patients	O
with	O
advanced	O
chronic	O
hepatitis	O
C.	O
New	O
strategies	O
are	O
needed	O
to	O
optimize	O
antiviral	O
therapy	O
in	O
these	O
difficult-to-cure	O
patients	O
.	O

Necessary	O
but	O
not	O
sufficient	O
:	O
the	O
effect	O
of	O
screening	Educational
and	Educational
feedback	Educational
on	O
outcomes	O
of	O
primary	O
care	O
patients	O
with	O
untreated	O
anxiety	O
.	O

OBJECTIVE	O
To	O
consider	O
the	O
impact	O
on	O
primary	O
care	O
patient	O
outcomes	O
of	O
using	O
both	O
a	O
screener	O
to	O
determine	O
elevated	O
anxiety	O
levels	O
among	O
patients	O
with	O
previously	O
undetected	O
anxiety	O
and	O
a	O
physician	O
intervention	O
to	O
inform	O
physicians	O
of	O
their	O
patients	O
'	O
conditions	O
.	O

DESIGN	O
Participating	O
physicians	O
were	O
randomized	O
to	O
either	O
the	O
demonstration	Educational
or	O
the	O
control	O
arm	O
,	O
and	O
patients	O
were	O
assigned	O
to	O
a	O
study	O
arm	O
based	O
on	O
the	O
randomization	O
of	O
their	O
physicians	O
.	O

The	O
patients	O
were	O
followed	O
for	O
change	O
in	O
outcome	O
measures	O
during	O
the	O
five-month	O
study	O
period	O
.	O

SETTING	O
A	O
mixed-model	O
health	O
maintenance	O
organization	O
serving	O
approximately	O
110,000	O
enrollees	O
in	O
central	O
Colorado	O
.	O

PATIENTS/PARTICIPANTS	O
573	O
patients	O
who	O
had	O
unrecognized	O
and	O
untreated	O
anxiety	O
identified	O
from	O
the	O
approximately	O
8,000	O
patients	O
who	O
completed	O
the	O
waiting	Educational
room	Educational
screening	Educational
questionnaire	Educational
.	O

INTERVENTIONS	O
A	O
physician	Educational
intervention	Educational
served	O
the	O
dual	O
function	O
of	O
1	O
)	O
providing	Educational
an	Educational
educational	Educational
demonstration	Educational
of	Educational
anxiety	Educational
in	Educational
the	Educational
primary	Educational
care	Educational
setting	Educational
and	O
2	O
)	O
providing	Educational
a	Educational
reporting	Educational
system	Educational
for	Educational
summarizing	Educational
the	Educational
anxiety	Educational
symptom	Educational
levels	Educational
and	Educational
functioning	Educational
status	Educational
of	Educational
the	Educational
patients	Educational
enrolled	Educational
in	Educational
the	Educational
study	Educational
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Patient	O
outcomes	O
were	O
measured	O
as	O
changes	O
in	O
global	O
anxiety	O
scores	O
,	O
functioning	O
and	O
well-being	O
,	O
and	O
patients	O
'	O
reports	O
of	O
global	O
improvements	O
.	O

CONCLUSIONS	O
The	O
findings	O
indicate	O
that	O
this	O
method	O
of	O
reporting	O
symptoms	O
and	O
functioning	O
status	O
to	O
primary	O
care	O
physicians	O
did	O
not	O
significantly	O
change	O
patient	O
outcomes	O
.	O

Improvement	O
in	O
outcomes	O
appeared	O
to	O
be	O
more	O
closely	O
associated	O
with	O
the	O
patient	O
's	O
severity	O
of	O
psychological	O
distress	O
.	O

Early	O
treatment	O
of	O
cold	O
sores	O
with	O
topical	O
ME-609	Pharmacological
decreases	O
the	O
frequency	O
of	O
ulcerative	O
lesions	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
patient-initiated	O
clinical	O
trial	O
.	O

BACKGROUND	O
Prior	O
pilot	O
studies	O
support	O
the	O
use	O
of	O
antiviral	O
medications	O
with	O
topical	O
corticosteroids	O
for	O
herpes	O
simplex	O
labialis	O
(	O
HSL	O
)	O
.	O

ME-609	Pharmacological
(	Pharmacological
Xerese	Pharmacological
,	Pharmacological
Xerclear	Pharmacological
)	Pharmacological
is	O
a	O
combination	O
of	O
5	O
%	O
acyclovir	Pharmacological
and	O
1	O
%	O
hydrocortisone	Pharmacological
developed	O
for	O
the	O
topical	O
treatment	O
of	O
HSL	O
.	O

OBJECTIVES	O
The	O
primary	O
study	O
end	O
point	O
was	O
the	O
prevention	O
of	O
ulcerative	O
HSL	O
lesions	O
.	O

METHODS	O
In	O
all	O
,	O
2437	O
patients	O
with	O
a	O
history	O
of	O
HSL	O
were	O
randomized	Pharmacological
to	Pharmacological
self-initiate	Pharmacological
treatment	Pharmacological
with	Pharmacological
ME-609	Pharmacological
,	O
5	Pharmacological
%	Pharmacological
acyclovir	Pharmacological
in	Pharmacological
ME-609	Pharmacological
vehicle	Pharmacological
,	O
or	O
ME-609	Physical
vehicle	Physical
(	Physical
placebo	Physical
)	Physical
at	O
the	O
earliest	O
sign	O
of	O
a	O
cold	O
sore	O
recurrence	O
.	O

Cream	Pharmacological
was	Pharmacological
applied	Pharmacological
5	Pharmacological
times/d	Pharmacological
for	Pharmacological
5	Pharmacological
days	Pharmacological
.	O

A	O
total	O
of	O
1443	O
patients	O
experienced	O
a	O
recurrence	O
and	O
initiated	O
treatment	O
with	O
ME-609	Pharmacological
(	O
n	O
=	O
601	O
)	O
,	O
acyclovir	Pharmacological
(	O
n	O
=	O
610	O
)	O
,	O
or	O
placebo	Control
(	O
n	O
=	O
232	O
)	O
.	O

RESULTS	O
Of	O
patients	O
receiving	O
ME-609	O
,	O
42	O
%	O
did	O
not	O
develop	O
an	O
ulcerative	O
lesion	O
compared	O
with	O
35	O
%	O
of	O
patients	O
receiving	O
acyclovir	Pharmacological
in	Pharmacological
ME-609	Pharmacological
vehicle	Pharmacological
(	O
P	O
=	O
.014	O
)	O
and	O
26	O
%	O
of	O
patients	O
receiving	O
placebo	O
(	O
P	O
<	O
.0001	O
)	O
.	O

In	O
patients	O
with	O
ulcerative	O
lesions	O
,	O
healing	O
times	O
were	O
reduced	O
in	O
the	O
ME-609	O
and	O
acyclovir	O
groups	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
.01	O
for	O
both	O
)	O
.	O

The	O
cumulative	O
lesion	O
area	O
for	O
all	O
lesions	O
was	O
reduced	O
50	O
%	O
in	O
patients	O
receiving	O
ME-609	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
P	O
<	O
.0001	O
)	O
.	O

There	O
were	O
no	O
differences	O
among	O
groups	O
in	O
the	O
number	O
of	O
patients	O
with	O
positive	O
herpes	O
simplex	O
virus	O
cultures	O
.	O

The	O
side-effect	O
profile	O
was	O
similar	O
among	O
treatments	O
.	O

LIMITATIONS	O
The	O
study	O
did	O
not	O
contain	O
a	O
group	O
treated	O
with	O
a	O
topical	O
corticosteroid	O
alone	O
.	O

CONCLUSIONS	O
ME-609	O
prevented	O
progression	O
of	O
cold	O
sores	O
to	O
ulcerative	O
lesions	O
and	O
significantly	O
reduced	O
the	O
cumulative	O
lesion	O
area	O
compared	O
with	O
acyclovir	O
and	O
placebo	O
.	O

ME-609	O
treatment	O
offers	O
additional	O
therapeutic	O
benefit	O
compared	O
with	O
therapy	O
with	O
topical	O
acyclovir	O
alone	O
.	O

Calcium	Pharmacological
acetate	Pharmacological
versus	O
calcium	Pharmacological
carbonate	Pharmacological
as	O
phosphate	O
binders	O
in	O
hemodialysis	O
patients	O
.	O

We	O
conducted	O
a	O
randomized	O
unblinded	O
parallel	O
clinical	O
trial	O
to	O
compare	O
the	O
effectiveness	O
,	O
side	O
effects	O
and	O
tolerance	O
between	O
calcium	Pharmacological
acetate	Pharmacological
(	Pharmacological
CA	Pharmacological
)	Pharmacological
and	O
calcium	Pharmacological
carbonate	Pharmacological
(	Pharmacological
CC	Pharmacological
)	Pharmacological
in	O
80	O
stable	O
chronic	O
hemodialysis	O
patients	O
selected	O
on	O
the	O
basis	O
of	O
their	O
acceptable	O
control	O
of	O
serum	O
phosphorus	O
(	O
P	O
)	O
levels	O
with	O
aluminum	O
hydroxide	O
(	O
AH	O
)	O
.	O

All	O
patients	O
were	O
dialyzed	O
against	O
the	O
same	O
calcium	Pharmacological
dialyzate	Pharmacological
(	O
1.62	O
mmol/l	O
)	O
.	O

The	O
serum	O
analytical	O
tests	O
included	O
:	O
calcium	O
corrected	O
to	O
total	O
protein	O
,	O
P	O
,	O
PTH	O
(	O
intact	O
molecule	O
)	O
and	O
bicarbonate	O
.	O

The	O
study	O
was	O
divided	O
into	O
the	O
following	O
periods	O
:	O
P0	O
:	O
baseline	O
measurements	O
;	O
P1	O
:	O
washout	O
(	O
withdrawal	O
of	O
AH	O
for	O
15	O
days	O
)	O
;	O
P2	O
:	O
random	O
allocation	O
to	O
CA	Pharmacological
and	O
CC	Pharmacological
treatment	O
at	O
doses	O
equivalent	O
to	O
75	O
mEq	O
of	O
elemental	O
calcium	O
,	O
stratified	O
according	O
to	O
previous	O
doses	O
of	O
AH	O
(	O
2	O
months	O
)	O
;	O
P3	O
:	O
adjustment	O
of	O
doses	O
until	O
control	O
P	O
(	O
2	O
months	O
)	O
.	O

CA	O
was	O
poorly	O
tolerated	O
in	O
7	O
patients	O
and	O
CC	O
in	O
2	O
(	O
NS	O
)	O
.	O

The	O
changes	O
in	O
serum	O
P	O
levels	O
between	O
P0	O
and	O
P2	O
periods	O
were	O
lower	O
in	O
the	O
CA	O
group	O
(	O
1.73	O
+/-	O
0.25	O
vs.	O
1.80	O
+/-	O
0.50	O
mmol/l	O
;	O
p	O
=	O
0.26	O
)	O
than	O
in	O
the	O
CC	O
group	O
(	O
1.77	O
+/-	O
0.35	O
vs.	O
1.93	O
+/-	O
0.48	O
mmol/l	O
;	O
p	O
=	O
0.03	O
,	O
paired	O
t	O
test	O
)	O
.	O

Serum	O
calcium	O
was	O
hardly	O
modified	O
by	O
CA	O
(	O
2.42	O
+/-	O
0.20	O
vs.	O
2.47	O
+/-	O
0.17	O
mmol/l	O
;	O
NS	O
)	O
while	O
in	O
the	O
CC	O
group	O
,	O
it	O
rose	O
significantly	O
(	O
2.40	O
+/-	O
0.12	O
vs.	O
2.55	O
+/-	O
0.22	O
mmol/l	O
;	O
p	O
=	O
0.0004	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
control	O
of	O
PTH	O
or	O
bicarbonate	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Dose-response	O
comparison	O
of	O
RRR-alpha-tocopherol	Pharmacological
and	Pharmacological
all-racemic	Pharmacological
alpha-tocopherol	Pharmacological
on	O
LDL	O
oxidation	O
.	O

Much	O
data	O
have	O
accrued	O
in	O
support	O
of	O
the	O
concept	O
that	O
oxidation	O
of	O
LDL	O
is	O
a	O
key	O
early	O
step	O
in	O
atherogenesis	O
.	O

The	O
most	O
consistent	O
data	O
with	O
respect	O
to	O
micronutrient	O
antioxidants	O
and	O
atherosclerosis	O
appear	O
to	O
relate	O
to	O
alpha-tocopherol	Pharmacological
(	O
AT	O
)	O
,	O
the	O
predominant	O
lipid-soluble	O
antioxidant	O
in	O
LDL	O
.	O

There	O
are	O
scant	O
data	O
on	O
the	O
direct	O
comparison	O
of	O
RRR-AT	O
and	O
all-racemic	O
(	O
rac	O
)	O
-AT	O
on	O
LDL	O
oxidizability	O
.	O

Hence	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
relative	O
effects	O
of	O
RRR-AT	O
and	O
all-rac-AT	O
on	O
plasma	O
antioxidant	O
levels	O
and	O
LDL	O
oxidation	O
in	O
healthy	O
persons	O
in	O
a	O
dose-response	O
study	O
.	O

The	O
effect	O
of	O
RRR-AT	Pharmacological
and	Pharmacological
all-rac-AT	Pharmacological
at	O
doses	O
of	O
100	O
,	O
200	O
,	O
400	O
,	O
and	O
800	O
IU/d	O
on	O
plasma	O
and	O
LDL	O
AT	O
levels	O
and	O
LDL	O
oxidation	O
was	O
tested	O
in	O
a	O
randomized	O
,	O
placebo-controlled	O
study	O
of	O
79	O
healthy	O
subjects	O
.	O

Copper-catalyzed	O
oxidation	O
of	O
LDL	O
was	O
monitored	O
by	O
measuring	O
the	O
formation	O
of	O
conjugated	O
dienes	O
and	O
lipid	O
peroxides	O
over	O
an	O
8-hour	O
time	O
course	O
at	O
baseline	O
and	O
again	O
after	O
8	O
weeks	O
.	O

Plasma	O
AT	O
,	O
lipid-standardized	O
AT	O
,	O
and	O
LDL	O
AT	O
levels	O
rose	O
in	O
a	O
dose-dependent	O
fashion	O
in	O
both	O
the	O
RRR-AT	O
and	O
all-rac-AT	O
groups	O
compared	O
with	O
baseline	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
plasma	O
,	O
lipid-standardized	O
,	O
and	O
LDL	O
AT	O
levels	O
between	O
RRR-AT	O
and	O
all-rac-AT	O
supplementation	O
at	O
any	O
dose	O
comparison	O
.	O

The	O
lag	O
phases	O
of	O
oxidation	O
were	O
significantly	O
prolonged	O
with	O
doses	O
>	O
or	O
=	O
400	O
IU/d	O
of	O
RRR-AT	O
and	O
all-rac-AT	O
,	O
as	O
measured	O
by	O
conjugated-dienes	O
assay	O
and	O
at	O
400	O
IU/d	O
of	O
RRR-AT	O
and	O
800	O
IU/d	O
of	O
both	O
forms	O
of	O
AT	O
by	O
lipid	O
peroxide	O
assay	O
.	O

Again	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
lag	O
phase	O
of	O
oxidation	O
at	O
each	O
dose	O
for	O
RRR-AT	O
when	O
compared	O
with	O
all-rac-AT	O
.	O

Also	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
LDL	O
oxidation	O
after	O
in	O
vitro	O
enrichment	O
of	O
LDL	O
with	O
RRR-AT	O
and	O
all-rac-AT	O
.	O

Thus	O
,	O
supplementation	O
with	O
either	O
RRR-AT	O
or	O
all-rac-AT	O
resulted	O
in	O
similar	O
increases	O
in	O
plasma	O
and	O
LDL	O
AT	O
levels	O
at	O
equivalent	O
IU	O
doses	O
,	O
and	O
the	O
degree	O
of	O
protection	O
against	O
copper-catalyzed	O
LDL	O
oxidation	O
was	O
only	O
evident	O
at	O
doses	O
>	O
or	O
=	O
400	O
IU/d	O
for	O
both	O
forms	O
.	O

Efficacy	O
and	O
safety	O
of	O
selamectin	Pharmacological
against	O
fleas	O
and	O
heartworms	O
in	O
dogs	O
and	O
cats	O
presented	O
as	O
veterinary	O
patients	O
in	O
North	O
America	O
.	O

A	O
series	O
of	O
randomized	O
,	O
controlled	O
,	O
masked	O
field	O
studies	O
was	O
conducted	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
selamectin	Pharmacological
in	O
the	O
treatment	O
of	O
flea	O
infestations	O
on	O
dogs	O
and	O
cats	O
,	O
and	O
in	O
the	O
prevention	O
of	O
heartworm	O
infection	O
in	O
dogs	O
.	O

In	O
addition	O
,	O
observations	O
were	O
made	O
on	O
the	O
beneficial	O
effect	O
of	O
selamectin	Pharmacological
treatment	O
on	O
dogs	O
and	O
cats	O
showing	O
signs	O
of	O
flea	O
allergy	O
dermatitis	O
(	O
FAD	O
)	O
.	O

In	O
all	O
studies	O
selamectin	Pharmacological
was	O
applied	O
topically	O
,	O
once	O
per	O
month	O
,	O
in	O
unit	O
doses	O
providing	O
a	O
minimum	O
dosage	O
of	O
6mgkg	O
(	O
-1	O
)	O
.	O

Dogs	O
and	O
cats	O
with	O
naturally	O
occurring	O
flea	O
infestations	O
,	O
some	O
of	O
which	O
also	O
had	O
signs	O
associated	O
with	O
FAD	O
,	O
were	O
assigned	O
randomly	O
to	O
receive	O
three	Pharmacological
months	Pharmacological
of	Pharmacological
topical	Pharmacological
treatment	Pharmacological
with	Pharmacological
selamectin	Pharmacological
(	O
220	O
dogs	O
,	O
189	O
cats	O
)	O
or	O
a	O
positive-control	Pharmacological
product	Pharmacological
(	O
dogs	O
:	O
fenthion	Pharmacological
,	O
n=81	O
;	O
cats	O
:	O
pyrethrins	Pharmacological
,	O
n=66	O
)	O
.	O

Selamectin	Pharmacological
was	O
administered	O
on	O
days	O
0	O
,	O
30	O
,	O
and	O
60	O
.	O

Day	O
0	O
was	O
defined	O
as	O
the	O
day	O
that	O
the	O
animal	O
first	O
received	O
treatment	O
.	O

Flea	O
burdens	O
were	O
assessed	O
by	O
flea	O
comb	O
counts	O
and	O
clinical	O
evaluations	O
of	O
FAD	O
were	O
performed	O
before	O
treatment	O
,	O
and	O
on	O
days	O
14	O
,	O
30	O
,	O
60	O
,	O
and	O
90	O
.	O

On	O
days	O
30	O
,	O
60	O
,	O
and	O
90	O
,	O
mean	O
flea	O
counts	O
in	O
selamectin-treated	Pharmacological
dogs	O
were	O
reduced	O
by	O
92.1	O
,	O
99.0	O
,	O
and	O
99.8	O
%	O
,	O
and	O
mean	O
flea	O
counts	O
in	O
fenthion-treated	O
dogs	O
were	O
reduced	O
by	O
81.5	O
,	O
86.8	O
,	O
and	O
86.1	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
day	O
0	O
counts	O
.	O

Also	O
,	O
on	O
days	O
30	O
,	O
60	O
,	O
and	O
90	O
,	O
mean	O
flea	O
counts	O
in	O
selamectin-treated	O
cats	O
were	O
reduced	O
by	O
92.5	O
,	O
98.3	O
,	O
and	O
99.3	O
%	O
,	O
and	O
mean	O
flea	O
counts	O
in	O
pyrethrin-treated	O
cats	O
were	O
reduced	O
by	O
66.4	O
,	O
73.9	O
,	O
and	O
81.3	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
day	O
0	O
counts	O
.	O

Selamectin	Pharmacological
also	O
was	O
beneficial	O
in	O
alleviating	O
signs	O
in	O
dogs	O
and	O
cats	O
diagnosed	O
clinically	O
with	O
FAD	O
.	O

A	O
total	O
of	O
397	O
dogs	O
free	O
of	O
adult	O
heartworm	O
infection	O
from	O
four	O
heartworm-endemic	O
areas	O
of	O
the	O
USA	O
were	O
allocated	O
randomly	O
to	O
six	O
months	O
of	O
treatment	O
with	O
selamectin	O
(	O
n=298	O
)	O
or	O
ivermectin	Pharmacological
(	O
n=99	O
)	O
.	O

Selamectin	O
achieved	O
a	O
heartworm	O
prevention	O
rate	O
of	O
100	O
%	O
,	O
with	O
all	O
dogs	O
testing	O
negative	O
for	O
microfilariae	O
and	O
adult	O
heartworm	O
antigen	O
on	O
days	O
180	O
and	O
300	O
.	O

Selamectin	O
was	O
administered	O
to	O
a	O
total	O
of	O
673	O
dogs	O
and	O
347	O
cats	O
having	O
an	O
age	O
range	O
of	O
6	O
weeks	O
to	O
19	O
years	O
(	O
3954	O
doses	O
)	O
.	O

The	O
animals	O
included	O
19	O
purebred	O
or	O
crossbred	O
Collies	O
(	O
Bearded	O
,	O
Border	O
,	O
and	O
unspecified	O
)	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
events	O
.	O

Results	O
of	O
these	O
studies	O
indicated	O
that	O
selamectin	O
was	O
highly	O
effective	O
in	O
the	O
control	O
of	O
flea	O
infestations	O
in	O
dogs	O
and	O
cats	O
without	O
the	O
need	O
for	O
simultaneous	O
treatment	O
of	O
the	O
environment	O
or	O
of	O
in-contact	O
animals	O
and	O
also	O
was	O
beneficial	O
in	O
alleviating	O
signs	O
associated	O
with	O
FAD	O
.	O

Selamectin	O
also	O
was	O
100	O
%	O
effective	O
in	O
preventing	O
the	O
development	O
of	O
canine	O
heartworms	O
and	O
was	O
safe	O
for	O
topical	O
use	O
in	O
dogs	O
and	O
cats	O
.	O

Hypericum	Pharmacological
treatment	Pharmacological
of	O
mild	O
depressions	O
with	O
somatic	O
symptoms	O
.	O

In	O
a	O
randomized	O
,	O
placebo-controlled	Control
,	O
double-blind	O
study	O
,	O
39	O
patients	O
with	O
depression	O
with	O
somatic	O
symptoms	O
were	O
treated	O
with	O
hypericum	Pharmacological
extract	Pharmacological
LI	Pharmacological
160	Pharmacological
.	Pharmacological

The	O
therapy	O
lasted	O
for	O
4	O
weeks	O
;	O
the	O
dosage	O
was	O
300	O
mg	O
three	O
times	O
daily	O
.	O

At	O
the	O
onset	O
of	O
the	O
study	O
as	O
well	O
as	O
after	O
2	O
and	O
4	O
weeks	O
,	O
the	O
following	O
criteria	O
were	O
analyzed	O
:	O
HAMD	O
,	O
B-L	O
,	O
CGI	O
,	O
and	O
vegetative	O
symptoms	O
.	O

The	O
results	O
show	O
a	O
significant	O
improvement	O
in	O
the	O
active	O
treatment	O
group	O
at	O
the	O
5	O
%	O
level	O
as	O
compared	O
to	O
placebo	O
.	O

Seventy	O
percent	O
of	O
the	O
patients	O
treated	O
with	O
LI	O
160	O
were	O
free	O
of	O
symptoms	O
after	O
4	O
weeks	O
.	O

Typical	O
symptoms	O
of	O
the	O
depression	O
such	O
as	O
lack	O
of	O
activity	O
,	O
tiredness	O
,	O
fatigue	O
,	O
and	O
disturbed	O
sleep	O
,	O
were	O
especially	O
responsive	O
.	O

In	O
no	O
case	O
were	O
any	O
undesirable	O
side	O
effects	O
observed	O
.	O

Intravenous	O
pretreatment	O
of	O
hypertonic	Pharmacological
saline	Pharmacological
can	O
prevent	O
systemic	O
hypotension	O
induced	O
by	O
spinal	O
anesthesia	O
.	O

BACKGROUND	O
Hypertonic	O
saline	O
improves	O
organ	O
perfusion	O
and	O
patient	O
survival	O
during	O
hemorrhagic	O
shock	O
because	O
it	O
expands	O
plasma	O
volume	O
and	O
increases	O
tissue	O
oxygenation	O
.	O

Its	O
beneficial	O
results	O
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
hypotension	O
during	O
spinal	O
anesthesia	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
influence	O
between	O
prehydration	O
with	O
3	O
%	O
hypertonic	Pharmacological
saline	Pharmacological
and	Pharmacological
with	Pharmacological
isotonic	Pharmacological
lactated	Pharmacological
Ringer	Pharmacological
's	Pharmacological
solution	Pharmacological
on	O
the	O
hemodynamic	O
changes	O
and	O
serum	O
electrolyte	O
concentrations	O
in	O
patients	O
undergoing	O
spinal	O
anesthesia	O
.	O

METHODS	O
Sixty	O
ASA	O
class	O
I	O
patients	O
scheduled	O
for	O
herniorrhapy	Surgical
under	O
spinal	O
anesthesia	O
were	O
assigned	O
randomly	O
into	O
two	O
groups	O
.	O

Group	O
1	O
=	O
patients	O
were	O
prehydrated	Pharmacological
with	Pharmacological
isotonic	Pharmacological
lactated	Pharmacological
Ringer	Pharmacological
's	Pharmacological
solution	Pharmacological
at	Pharmacological
7	Pharmacological
mg/kg	Pharmacological
(	O
n	O
=	O
30	O
)	O
;	O
Group	O
2	O
=	O
patients	O
were	O
given	O
prehydration	Pharmacological
with	Pharmacological
3	Pharmacological
%	Pharmacological
hypertonic	Pharmacological
saline	Pharmacological
at	Pharmacological
7	Pharmacological
ml/kg	Pharmacological
(	O
n	O
=	O
30	O
)	O
.	O

Following	O
prehydration	O
,	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
recorded	O
and	O
serum	O
electrolyte	O
concentrations	O
were	O
measured	O
.	O

RESULTS	O
The	O
incidence	O
of	O
hypotension	O
was	O
17/30	O
(	O
57	O
%	O
)	O
in	O
the	O
isotonic	O
lactated	O
Ringer	O
's	O
solution	O
group	O
as	O
against	O
7/30	O
(	O
23	O
%	O
)	O
in	O
the	O
hypertonic	O
saline	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
two	O
groups	O
in	O
relation	O
to	O
the	O
level	O
of	O
anesthesia	O
or	O
maximal	O
heart	O
rate	O
,	O
and	O
electrolyte	O
imbalance	O
did	O
not	O
occur	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
Prior	O
to	O
spinal	O
anesthesia	O
,	O
hydration	O
with	O
small	O
amount	O
of	O
hypertonic	Pharmacological
saline	Pharmacological
is	O
effective	O
to	O
minimize	O
hypotension	O
associated	O
with	O
spinal	O
anesthesia	O
.	O

If	O
so	O
administered	O
it	O
would	O
not	O
increase	O
bodily	O
sodium	O
load	O
and	O
unlike	O
isotonic	O
crystalloid	O
solution	O
it	O
dose	O
not	O
cause	O
accumulation	O
of	O
water	O
in	O
the	O
body	O
on	O
equipollent	O
basis	O
.	O

Side	O
branch	O
occlusion	O
with	O
everolimus-eluting	Surgical
and	Surgical
paclitaxel-eluting	Surgical
stents	Surgical
:	O
three-year	O
results	O
from	O
the	O
SPIRIT	O
III	O
randomised	O
trial	O
.	O

AIMS	O
AND	O
METHODS	O
The	O
rates	O
of	O
side	O
branch	O
occlusion	O
and	O
subsequent	O
periprocedural	O
MI	O
during	O
everolimus-eluting	Surgical
stent	Surgical
(	Surgical
EES	Surgical
)	Surgical
and	O
paclitaxel-eluting	Surgical
stent	Surgical
(	Surgical
PES	Surgical
)	Surgical
placement	O
were	O
examined	O
in	O
the	O
randomised	O
SPIRIT	O
III	O
trial	O
.	O

Periprocedural	O
myocardial	O
infarction	O
(	O
MI	O
)	O
following	O
drug-eluting	O
stent	O
placement	O
is	O
associated	O
with	O
long-term	O
adverse	O
outcomes	O
.	O

Occlusion	O
of	O
side	O
branches	O
may	O
be	O
an	O
important	O
factor	O
contributing	O
to	O
periprocedural	O
MIs	O
.	O

Consecutive	O
procedural	O
angiograms	O
of	O
patients	O
randomly	O
assigned	O
to	O
EES	Surgical
(	O
n=669	O
)	O
or	O
PES	Surgical
(	O
n=333	O
)	O
were	O
analysed	O
by	O
an	O
independent	O
angiographic	O
core	O
laboratory	O
.	O

Side	O
branch	O
occlusion	O
was	O
defined	O
as	O
Thrombolysis	O
In	O
Myocardial	O
Infarction	O
(	O
TIMI	O
)	O
flow	O
grade	O
0	O
or	O
1	O
.	O

Clinical	O
outcomes	O
through	O
three	O
years	O
were	O
compared	O
by	O
stent	O
type	O
and	O
presence	O
of	O
side	O
branch	O
occlusion	O
.	O

CONCLUSIONS	O
A	O
total	O
of	O
2,048	O
side	O
branches	O
were	O
evaluated	O
(	O
EES	O
N=1,345	O
side	O
branches	O
in	O
688	O
stented	O
lesions	O
,	O
PES	O
N=703	O
side	O
branches	O
in	O
346	O
stented	O
lesions	O
)	O
.	O

Patients	O
with	O
compared	O
to	O
those	O
without	O
transient	O
or	O
final	O
side	O
branch	O
occlusion	O
had	O
significantly	O
higher	O
non-Q-wave	O
MI	O
(	O
NQMI	O
)	O
rates	O
in-hospital	O
(	O
9.0	O
%	O
vs.	O
0.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

By	O
multivariable	O
analysis	O
side	O
branch	O
occlusion	O
was	O
an	O
independent	O
predictor	O
of	O
NQMI	O
(	O
OR	O
4.45	O
;	O
95	O
%	O
CI	O
[	O
1.82	O
,	O
10.85	O
]	O
)	O
.	O

Transient	O
or	O
final	O
side	O
branch	O
occlusion	O
occurred	O
less	O
frequently	O
in	O
patients	O
receiving	O
EES	O
compared	O
to	O
PES	O
(	O
2.8	O
%	O
vs.	O
5.2	O
%	O
,	O
p=0.009	O
)	O
,	O
contributing	O
to	O
the	O
numerically	O
lower	O
rates	O
of	O
in-hospital	O
NQMI	O
with	O
EES	O
arm	O
compared	O
to	O
PES	O
(	O
0.7	O
%	O
vs.	O
2.3	O
%	O
,	O
p=0.05	O
)	O
.	O

Patients	O
treated	O
with	O
EES	Surgical
rather	O
than	O
PES	Surgical
were	O
less	O
likely	O
to	O
develop	O
side	O
branch	O
occlusion	O
during	O
stent	O
placement	O
,	O
contributing	O
to	O
lower	O
rates	O
of	O
periprocedural	O
MI	O
with	O
EES	Surgical
compared	O
to	O
PES	Surgical
.	O

Intravenous	O
platelet	O
blockade	O
with	O
cangrelor	Pharmacological
during	O
PCI	O
.	O

BACKGROUND	O
Intravenous	O
cangrelor	Pharmacological
,	O
a	O
rapid-acting	O
,	O
reversible	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
receptor	O
antagonist	O
,	O
might	O
reduce	O
ischemic	O
events	O
during	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

METHODS	O
In	O
this	O
double-blind	O
,	O
placebo-controlled	O
study	O
,	O
we	O
randomly	O
assigned	O
5362	O
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
clopidogrel	O
to	O
receive	O
either	O
cangrelor	Pharmacological
or	O
placebo	Control
at	O
the	O
time	O
of	O
PCI	O
,	O
followed	O
by	O
600	O
mg	O
of	O
clopidogrel	Pharmacological
.	O

The	O
primary	O
end	O
point	O
was	O
a	O
composite	O
of	O
death	O
,	O
myocardial	O
infarction	O
,	O
or	O
ischemia-driven	O
revascularization	O
at	O
48	O
hours	O
.	O

Enrollment	O
was	O
stopped	O
when	O
an	O
interim	O
analysis	O
concluded	O
that	O
the	O
trial	O
would	O
be	O
unlikely	O
to	O
show	O
superiority	O
for	O
the	O
primary	O
end	O
point	O
.	O

RESULTS	O
The	O
primary	O
end	O
point	O
occurred	O
in	O
185	O
of	O
2654	O
patients	O
receiving	O
cangrelor	Pharmacological
(	O
7.0	O
%	O
)	O
and	O
in	O
210	O
of	O
2641	O
patients	O
receiving	O
placebo	Control
(	O
8.0	O
%	O
)	O
(	O
odds	O
ratio	O
in	O
the	O
cangrelor	O
group	O
,	O
0.87	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.71	O
to	O
1.07	O
;	O
P=0.17	O
)	O
(	O
modified	O
intention-to-treat	O
population	O
adjusted	O
for	O
missing	O
data	O
)	O
.	O

In	O
the	O
cangrelor	Pharmacological
group	O
,	O
as	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
two	O
prespecified	O
secondary	O
end	O
points	O
were	O
significantly	O
reduced	O
at	O
48	O
hours	O
:	O
the	O
rate	O
of	O
stent	O
thrombosis	O
,	O
from	O
0.6	O
%	O
to	O
0.2	O
%	O
(	O
odds	O
ratio	O
,	O
0.31	O
;	O
95	O
%	O
CI	O
,	O
0.11	O
to	O
0.85	O
;	O
P=0.02	O
)	O
,	O
and	O
the	O
rate	O
of	O
death	O
from	O
any	O
cause	O
,	O
from	O
0.7	O
%	O
to	O
0.2	O
%	O
(	O
odds	O
ratio	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
,	O
0.13	O
to	O
0.83	O
;	O
P=0.02	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	O
of	O
blood	O
transfusion	O
(	O
1.0	O
%	O
in	O
the	O
cangrelor	Pharmacological
group	O
and	O
0.6	O
%	O
in	O
the	O
placebo	Control
group	O
,	O
P=0.13	O
)	O
,	O
though	O
major	O
bleeding	O
on	O
one	O
scale	O
was	O
increased	O
in	O
the	O
cangrelor	O
group	O
,	O
from	O
3.5	O
%	O
to	O
5.5	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
because	O
of	O
more	O
groin	O
hematomas	O
.	O

CONCLUSIONS	O
The	O
use	O
of	O
periprocedural	O
cangrelor	Pharmacological
during	O
PCI	O
was	O
not	O
superior	O
to	O
placebo	O
in	O
reducing	O
the	O
primary	O
end	O
point	O
.	O

The	O
prespecified	O
secondary	O
end	O
points	O
of	O
stent	O
thrombosis	O
and	O
death	O
were	O
lower	O
in	O
the	O
cangrelor	Pharmacological
group	O
,	O
with	O
no	O
significant	O
increase	O
in	O
the	O
rate	O
of	O
transfusion	O
.	O

Further	O
study	O
of	O
intravenous	O
ADP	Pharmacological
blockade	Pharmacological
with	Pharmacological
cangrelor	Pharmacological
may	O
be	O
warranted	O
.	O

(	O
ClinicalTrials.gov	O
number	O
,	O
NCT00385138	O
.	O

)	O
Plasma	O
3,4-dihydroxyphenylethyleneglycol	O
and	O
3-methoxy-4-hydroxyphenylethyleneglycol	O
as	O
indicators	O
of	O
central	O
noradrenergic	O
activity	O
.	O

A	O
comparative	O
study	O
on	O
control	O
subjects	O
and	O
depressed	O
patients	O
.	O

Animal	O
studies	O
have	O
suggested	O
interspecies	O
differences	O
in	O
brain	O
norepinephrine	O
(	O
NE	O
)	O
metabolism	O
,	O
especially	O
with	O
regard	O
to	O
the	O
relative	O
proportions	O
of	O
3,4-dihydroxyphenylethyleneglycol	O
(	O
DOPEG	O
)	O
compared	O
to	O
3-methoxy-4-hydroxyphenylethyleneglycol	O
(	O
MOPEG	O
)	O
.	O

In	O
order	O
to	O
question	O
the	O
value	O
of	O
both	O
glycol	O
metabolites	O
as	O
peripheral	O
indices	O
of	O
central	O
noradrenergic	O
activity	O
,	O
a	O
comparative	O
study	O
of	O
plasma	O
DOPEG	O
and	O
MOPEG	O
(	O
measured	O
by	O
HPLC	O
)	O
related	O
to	O
depression	O
,	O
sex	O
,	O
age	O
and	O
diagnostic	O
categories	O
(	O
DSM-III	O
)	O
was	O
carried	O
out	O
on	O
depressed	O
and	O
control	O
subjects	O
.	O

In	O
addition	O
,	O
two	O
groups	O
of	O
8	O
patients	O
were	O
randomly	O
submitted	O
to	O
a	O
desipramine	Pharmacological
150	Pharmacological
mg/day	Pharmacological
,	O
or	O
a	Pharmacological
metapramine	Pharmacological
450	Pharmacological
mg/day	Pharmacological
antidepressant	Pharmacological
treatment	Pharmacological
influencing	O
the	O
formation	O
of	O
DOPEG	O
and	O
MOPEG	O
in	O
a	O
different	O
way	O
.	O

The	O
study	O
did	O
not	O
demonstrate	O
any	O
difference	O
between	O
DOPEG	O
and	O
MOPEG	O
for	O
most	O
of	O
the	O
experimental	O
factors	O
.	O

We	O
found	O
also	O
a	O
significant	O
positive	O
correlation	O
between	O
plasma	O
levels	O
of	O
DOPEG	O
and	O
MOPEG	O
.	O

Our	O
results	O
support	O
the	O
idea	O
that	O
each	O
of	O
these	O
two	O
biological	O
indices	O
can	O
be	O
used	O
in	O
the	O
assessment	O
of	O
central	O
noradrenergic	O
activity	O
.	O

Desogestrel	O
and	O
gestodene	O
in	O
oral	O
contraceptives	O
:	O
12	O
months	O
'	O
assessment	O
of	O
carbohydrate	O
and	O
lipoprotein	O
metabolism	O
.	O

We	O
examined	O
the	O
influence	O
on	O
carbohydrate	O
and	O
lipoprotein	O
metabolism	O
of	O
oral	Pharmacological
contraceptives	Pharmacological
(	Pharmacological
OCs	Pharmacological
)	Pharmacological
containing	O
two	O
new	O
third-generation	O
progestogens	Pharmacological
,	O
desogestrel	Pharmacological
and	O
gestodene	Pharmacological
.	O

This	O
was	O
a	O
prospective	O
randomized	O
study	O
in	O
which	O
monophasic	O
combinations	O
of	O
20	O
micrograms	O
ethinyl	Pharmacological
estradiol	Pharmacological
(	Pharmacological
E2	Pharmacological
)	Pharmacological
and	O
150	O
micrograms	O
desogestrel	Pharmacological
or	O
30	O
micrograms	O
ethinyl	Pharmacological
E2	Pharmacological
plus	Pharmacological
75	Pharmacological
micrograms	Pharmacological
gestodene	Pharmacological
were	O
administered	O
to	O
15	O
and	O
19	O
healthy	O
women	O
,	O
respectively	O
.	O

An	O
oral	O
glucose	O
tolerance	O
test	O
including	O
measurement	O
of	O
insulin	O
response	O
was	O
performed	O
before	O
treatment	O
and	O
after	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
of	O
treatment	O
.	O

We	O
also	O
determined	O
fasting	O
plasma	O
concentrations	O
of	O
total	O
cholesterol	O
;	O
high-density	O
lipoprotein	O
cholesterol	O
,	O
including	O
the	O
subfractions	O
high-density	O
lipoprotein2	O
cholesterol	O
and	O
high-density	O
lipoprotein3	O
cholesterol	O
;	O
low-density	O
lipoprotein	O
cholesterol	O
;	O
very	O
low-density	O
lipoprotein	O
cholesterol	O
;	O
and	O
triglycerides	O
.	O

A	O
transient	O
deterioration	O
of	O
glucose	O
tolerance	O
was	O
observed	O
despite	O
unchanged	O
levels	O
of	O
insulin	O
after	O
treatment	O
with	O
both	O
compounds	O
for	O
3	O
months	O
.	O

In	O
both	O
groups	O
plasma	O
levels	O
of	O
triglycerides	O
,	O
very	O
low-density	O
lipoprotein	O
cholesterol	O
,	O
and	O
high-density	O
lipoprotein	O
cholesterol	O
increased	O
significantly	O
after	O
3	O
months	O
.	O

After	O
12	O
months	O
,	O
a	O
significant	O
increase	O
in	O
the	O
high-density	O
lipoprotein	O
cholesterol/total	O
cholesterol	O
ratio	O
was	O
observed	O
in	O
the	O
ethinyl	O
E2-desogestrel	O
group	O
,	O
and	O
no	O
persistent	O
changes	O
in	O
low-density	O
lipoprotein	O
cholesterol	O
could	O
be	O
demonstrated	O
in	O
any	O
of	O
the	O
groups	O
.	O

Our	O
results	O
indicate	O
that	O
treatment	O
with	O
either	O
compound	O
for	O
12	O
months	O
has	O
no	O
effect	O
on	O
carbohydrate	O
or	O
lipoprotein	O
metabolism	O
known	O
to	O
increase	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

A	O
cluster	O
randomised	O
trial	O
to	O
evaluate	O
a	O
physical	Physical
activity	Physical
intervention	Physical
among	O
3-5	O
year	O
old	O
children	O
attending	O
long	O
day	O
care	O
services	O
:	O
study	O
protocol	O
.	O

BACKGROUND	O
Young	O
children	O
are	O
not	O
participating	O
in	O
recommended	O
levels	O
of	O
physical	O
activity	O
and	O
exhibit	O
high	O
levels	O
of	O
sedentary	O
behaviour	O
.	O

Childcare	O
services	O
provide	O
access	O
to	O
large	O
numbers	O
of	O
young	O
children	O
for	O
prolonged	O
periods	O
,	O
yet	O
there	O
is	O
limited	O
experimental	O
evidence	O
regarding	O
the	O
effectiveness	O
of	O
physical	O
activity	O
interventions	O
implemented	O
in	O
this	O
setting	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
effectiveness	O
and	O
acceptability	O
of	O
a	O
multi-component	O
physical	Physical
activity	Physical
intervention	Physical
,	O
delivered	O
by	O
childcare	O
service	O
staff	O
,	O
in	O
increasing	O
the	O
physical	O
activity	O
levels	O
of	O
children	O
attending	O
long	O
day	O
care	O
services	O
.	O

METHODS/DESIGN	O
The	O
study	O
will	O
employ	O
a	O
cluster	O
randomised	O
controlled	O
trial	O
design	O
.	O

Three	O
hundred	O
children	O
aged	O
between	O
3-5	O
years	O
from	O
twenty	O
randomly	O
selected	O
long	O
day	O
care	O
services	O
in	O
the	O
Hunter	O
Region	O
of	O
New	O
South	O
Wales	O
,	O
Australia	O
will	O
be	O
invited	O
to	O
participate	O
in	O
the	O
trial	O
.	O

Ten	O
of	O
the	O
20	O
long	O
day	O
care	O
services	O
will	O
be	O
randomly	O
allocated	O
to	O
deliver	O
the	O
intervention	O
with	O
the	O
remaining	O
ten	O
services	O
allocated	O
to	O
a	O
wait	Control
list	Control
control	Control
group	O
.	O

The	O
physical	Physical
activity	Physical
intervention	Physical
will	Physical
consist	Physical
of	Physical
a	Physical
number	Physical
of	Physical
strategies	Physical
including	Physical
:	O
delivering	Physical
structured	Physical
fundamental	Physical
movement	Physical
skill	Physical
activities	Physical
,	Physical
increasing	Physical
physical	Physical
activity	Physical
opportunities	Physical
,	Physical
increasing	Physical
staff	Physical
role	Physical
modelling	Physical
,	Physical
providing	Physical
children	Physical
with	Physical
a	Physical
physical	Physical
activity	Physical
promoting	Physical
indoor	Physical
and	Physical
outdoor	Physical
environment	Physical
and	Physical
limiting	Physical
children	Physical
's	Physical
small	Physical
screen	Physical
recreation	Physical
and	Physical
sedentary	Physical
behaviours	Physical
.	O

Intervention	O
effectiveness	O
will	O
be	O
measured	O
via	O
child	O
physical	O
activity	O
levels	O
during	O
attendance	O
at	O
long	O
day	O
care	O
.	O

The	O
study	O
also	O
seeks	O
to	O
determine	O
the	O
acceptability	O
and	O
extent	O
of	O
implementation	O
of	O
the	O
intervention	O
by	O
services	O
and	O
their	O
staff	O
participating	O
in	O
the	O
study	O
.	O

DISCUSSION	O
The	O
trial	O
will	O
address	O
current	O
gaps	O
in	O
the	O
research	O
evidence	O
base	O
and	O
contribute	O
to	O
the	O
design	O
and	O
delivery	O
of	O
future	O
interventions	O
promoting	O
physical	O
activity	O
for	O
young	O
children	O
in	O
long	O
day	O
care	O
settings	O
.	O

TRIAL	O
REGISTRATION	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
ACTRN12610000087055	O
.	O

Comparison	O
of	O
neurocognitive	O
functioning	O
in	O
children	O
previously	O
randomly	O
assigned	O
to	O
intrathecal	Pharmacological
methotrexate	Pharmacological
compared	O
with	O
triple	Pharmacological
intrathecal	Pharmacological
therapy	Pharmacological
for	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
.	O

PURPOSE	O
For	O
the	O
majority	O
of	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
CNS	O
prophylaxis	O
consists	O
of	O
either	O
intrathecal	Pharmacological
(	Pharmacological
IT	Pharmacological
)	Pharmacological
methotrexate	Pharmacological
or	O
triple	Pharmacological
IT	Pharmacological
therapy	Pharmacological
(	Pharmacological
ie	Pharmacological
,	Pharmacological
methotrexate	Pharmacological
with	Pharmacological
both	Pharmacological
cytarabine	Pharmacological
and	Pharmacological
hydrocortisone	Pharmacological
)	O
.	O

The	O
long-term	O
neurotoxicities	O
of	O
these	O
two	O
IT	O
strategies	O
have	O
not	O
yet	O
been	O
directly	O
compared	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
multisite	O
study	O
,	O
171	O
children	O
with	O
standard-risk	O
ALL	O
,	O
age	O
1	O
to	O
9.99	O
years	O
at	O
diagnosis	O
,	O
previously	O
randomly	O
assigned	O
to	O
IT	Pharmacological
methotrexate	Pharmacological
(	O
n	O
=	O
82	O
)	O
or	O
to	O
triple	Pharmacological
IT	Pharmacological
therapy	Pharmacological
(	O
n	O
=	O
89	O
)	O
on	O
CCG	O
1952	O
,	O
underwent	O
neurocognitive	O
evaluation	O
by	O
a	O
licensed	O
psychologist	O
at	O
a	O
mean	O
of	O
5.9	O
years	O
after	O
random	O
assignment	O
.	O

RESULTS	O
Patients	O
who	O
received	O
IT	Pharmacological
methotrexate	Pharmacological
had	O
a	O
mean	O
Processing	O
Speed	O
Index	O
that	O
was	O
3.6	O
points	O
lower	O
,	O
about	O
one	O
fourth	O
of	O
a	O
standard	O
deviation	O
,	O
than	O
those	O
who	O
received	O
triple	Pharmacological
IT	Pharmacological
therapy	Pharmacological
(	O
P	O
=	O
.04	O
)	O
after	O
analysis	O
was	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
and	O
time	O
since	O
diagnosis	O
.	O

Likewise	O
,	O
19.5	O
%	O
of	O
children	O
in	O
the	O
IT	Pharmacological
methotrexate	Pharmacological
group	O
had	O
a	O
Processing	O
Speed	O
Index	O
score	O
in	O
the	O
below-average	O
range	O
compared	O
with	O
6.9	O
%	O
in	O
the	O
triple	Pharmacological
IT	Pharmacological
therapy	Pharmacological
group	Pharmacological
(	O
P	O
=	O
.02	O
)	O
.	O

Otherwise	O
,	O
the	O
groups	O
performed	O
similarly	O
on	O
tests	O
of	O
full-scale	O
intelligence	O
quotient	O
,	O
academic	O
achievement	O
,	O
attention/concentration	O
,	O
memory	O
,	O
and	O
visual	O
motor	O
integration	O
.	O

The	O
association	O
of	O
treatment	O
with	O
measures	O
of	O
cognitive	O
functioning	O
was	O
not	O
modified	O
by	O
sex	O
or	O
age	O
at	O
diagnosis	O
.	O

In	O
the	O
post-therapy	O
period	O
,	O
there	O
were	O
no	O
group	O
differences	O
in	O
special	O
education	O
services	O
,	O
neurologic	O
events	O
,	O
or	O
use	O
of	O
psychotropic	O
medications	O
.	O

CONCLUSION	O
This	O
study	O
did	O
not	O
show	O
any	O
clinically	O
meaningful	O
differences	O
in	O
neurocognitive	O
functioning	O
between	O
patients	O
previously	O
randomly	O
assigned	O
to	O
IT	Pharmacological
methotrexate	Pharmacological
or	O
triple	Pharmacological
IT	Pharmacological
therapy	Pharmacological
except	O
for	O
a	O
small	O
difference	O
in	O
processing	O
speed	O
in	O
the	O
IT	Pharmacological
methotrexate	Pharmacological
group	Pharmacological
.	Pharmacological

Effect	O
of	O
CX516	Pharmacological
,	O
an	O
AMPA-modulating	Pharmacological
compound	Pharmacological
,	O
on	O
cognition	O
and	O
behavior	O
in	O
fragile	O
X	O
syndrome	O
:	O
a	O
controlled	O
trial	O
.	O

A	O
Phase	O
II	O
,	O
4-week	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
clinical	O
trial	O
was	O
conducted	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
Ampakine	Pharmacological
compound	O
CX516	Pharmacological
as	O
a	O
potential	O
treatment	O
for	O
the	O
underlying	O
disorder	O
in	O
fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
.	O

After	O
baseline	O
screening	O
,	O
subjects	O
with	O
FXS	O
(	O
n	O
=	O
49	O
)	O
underwent	O
a	O
1-week	O
placebo	Control
lead-in	O
and	O
then	O
were	O
randomized	O
to	O
study	O
drug	O
or	O
placebo	Control
for	O
a	O
4-week	O
period	O
.	O

Cognitive	O
and	O
behavioral	O
outcome	O
measures	O
were	O
administered	O
prior	O
to	O
treatment	O
,	O
at	O
the	O
end	O
of	O
treatment	O
,	O
and	O
2	O
weeks	O
posttreatment	O
.	O

There	O
were	O
minimal	O
side	O
effects	O
,	O
no	O
significant	O
changes	O
in	O
safety	O
parameters	O
,	O
and	O
no	O
serious	O
adverse	O
events	O
.	O

There	O
was	O
a	O
12.5	O
%	O
frequency	O
of	O
allergic	O
rash	O
in	O
the	O
CX516	Pharmacological
group	O
and	O
1	O
subject	O
developed	O
a	O
substantial	O
rash	O
.	O

There	O
was	O
also	O
no	O
significant	O
improvement	O
in	O
memory	O
,	O
the	O
primary	O
outcome	O
measure	O
,	O
or	O
in	O
secondary	O
measures	O
of	O
language	O
,	O
attention/executive	O
function	O
,	O
behavior	O
,	O
and	O
overall	O
functioning	O
in	O
CX516-treated	Pharmacological
subjects	O
compared	O
to	O
placebo	Control
.	O

This	O
study	O
did	O
demonstrate	O
that	O
many	O
outcome	O
measures	O
were	O
reproducible	O
in	O
this	O
test-retest	O
setting	O
for	O
the	O
FXS	O
population	O
,	O
yet	O
some	O
were	O
too	O
difficult	O
or	O
variable	O
.	O

Adult	O
subjects	O
with	O
FXS	O
were	O
able	O
to	O
complete	O
an	O
intensive	O
clinical	O
trial	O
,	O
and	O
some	O
valid	O
outcome	O
measures	O
were	O
identified	O
for	O
future	O
FXS	O
trial	O
design	O
.	O

Problems	O
with	O
potency	O
of	O
CX516	Pharmacological
in	O
other	O
studies	O
have	O
suggested	O
dosing	O
may	O
have	O
been	O
inadequate	O
for	O
therapeutic	O
effect	O
and	O
thus	O
it	O
remains	O
unclear	O
whether	O
modulation	O
of	O
AMPA-mediated	O
neurotransmission	O
is	O
a	O
viable	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
FXS	O
.	O

Principal	O
results	O
of	O
the	O
Japanese	O
trial	O
to	O
assess	O
optimal	O
systolic	O
blood	O
pressure	O
in	O
elderly	O
hypertensive	O
patients	O
(	O
JATOS	O
)	O
.	O

The	O
benefits	O
of	O
lowering	O
a	O
systolic	O
blood	O
pressure	O
below	O
140	O
mmHg	O
in	O
elderly	O
hypertension	O
remain	O
controversial	O
.	O

This	O
study	O
is	O
a	O
prospective	O
,	O
randomized	O
,	O
open-label	O
study	O
with	O
blinded	O
assessment	O
of	O
endpoints	O
to	O
compare	O
the	O
2-year	O
effect	O
of	O
strict	Physical
treatment	Physical
to	Physical
maintain	Physical
systolic	Physical
blood	Physical
pressure	Physical
below	O
140	O
mmHg	O
with	O
that	O
of	O
mild	Physical
treatment	Physical
to	Physical
maintain	Physical
systolic	Physical
blood	Physical
pressure	Physical
below	O
160	O
but	O
at	O
or	O
above	O
140	O
mmHg	O
in	O
elderly	O
hypertensive	O
patients	O
.	O

Patients	O
with	O
essential	O
hypertension	O
(	O
65-85	O
years	O
old	O
,	O
with	O
a	O
pretreatment	O
systolic	O
blood	O
pressure	O
of	O
above	O
160	O
mmHg	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
strict	Physical
treatment	Physical
(	O
n=2,212	O
)	O
or	O
mild	Physical
treatment	Physical
(	O
n=2,206	O
)	O
.	O

The	O
baseline	O
drug	O
was	O
efonidipine	Physical
hydrochloride	Physical
,	O
a	O
long-acting	O
calcium	O
antagonist	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
combined	O
incidence	O
of	O
cardiovascular	O
disease	O
and	O
renal	O
failure	O
,	O
and	O
the	O
secondary	O
endpoints	O
were	O
total	O
deaths	O
and	O
any	O
safety	O
problems	O
.	O

Although	O
final	O
blood	O
pressures	O
(	O
systolic/diastolic	O
)	O
were	O
significantly	O
lower	O
in	O
the	O
strict-treatment	O
group	O
compared	O
with	O
the	O
mild-treatment	O
group	O
(	O
135.9/74.8	O
vs.	O
145.6/78.1	O
mmHg	O
;	O
p	O
<	O
0.001	O
)	O
,	O
the	O
incidence	O
of	O
the	O
primary	O
endpoint	O
was	O
similar	O
in	O
the	O
two	O
groups	O
(	O
86	O
patients	O
in	O
each	O
group	O
;	O
p=0.99	O
)	O
.	O

Total	O
deaths	O
were	O
54	O
in	O
the	O
strict-treatment	O
group	O
vs.	O
42	O
in	O
the	O
mild-treatment	O
group	O
(	O
p=0.22	O
)	O
,	O
and	O
treatment	O
was	O
withdrawn	O
because	O
of	O
adverse	O
events	O
in	O
36	O
patients	O
in	O
each	O
group	O
(	O
p=0.99	O
)	O
.	O

An	O
interaction	O
between	O
age	O
and	O
treatment	O
for	O
the	O
primary	O
endpoints	O
(	O
p=0.03	O
)	O
was	O
seen	O
.	O

Complex	O
clinical	O
features	O
associated	O
with	O
aging	O
seem	O
to	O
have	O
obscured	O
the	O
difference	O
in	O
effect	O
between	O
the	O
two	O
treatments	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
optimal	O
treatment	O
strategy	O
for	O
hypertension	O
in	O
the	O
elderly	O
.	O

Treatment	O
with	O
coumarin	Pharmacological
to	O
prevent	O
or	O
delay	O
recurrence	O
of	O
malignant	O
melanoma	O
.	O

Both	O
coumarin	Pharmacological
(	Pharmacological
1,2-benzopyrone	Pharmacological
)	Pharmacological
and	O
warfarin	Pharmacological
(	Pharmacological
4-hydroxycoumarin	Pharmacological
)	Pharmacological
have	O
been	O
shown	O
to	O
prevent	O
the	O
recurrence	O
of	O
malignant	O
melanoma	O
.	O

Their	O
action	O
is	O
macrophage-dependent	O
and	O
the	O
dosage	O
is	O
critical	O
.	O

In	O
1984	O
a	O
multicentre	O
,	O
prospective	O
,	O
randomised	O
,	O
double-blind	O
trial	O
of	O
coumarin	Pharmacological
,	O
given	O
as	O
a	O
daily	O
50-mg	O
dose	O
for	O
2	O
years	O
after	O
surgery	O
in	O
patients	O
with	O
high-risk	O
melanoma	O
,	O
was	O
started	O
.	O

the	O
patients	O
had	O
lesions	O
greater	O
than	O
1.70	O
mm	O
thick	O
and	O
TNM	O
stage	O
IB	O
or	O
stage	O
II	O
disease	O
.	O

To	O
date	O
there	O
are	O
4	O
recurrences	O
in	O
the	O
coumarin-treated	O
group	O
of	O
13	O
patients	O
,	O
and	O
10	O
recurrences	O
in	O
the	O
placebo-treated	O
group	O
of	O
14	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
.	O

There	O
were	O
no	O
toxic	O
effects	O
.	O

Randomized	O
study	O
of	O
six	O
umbilical	Pharmacological
cord	Pharmacological
care	Pharmacological
regimens	Pharmacological
.	Pharmacological

Comparing	O
length	O
of	O
attachment	O
,	O
microbial	O
control	O
,	O
and	O
satisfaction	O
.	O

Two	O
hundred	O
and	O
seventy	O
one	O
infants	O
were	O
enrolled	O
in	O
a	O
study	O
to	O
compare	O
six	O
different	O
methods	O
of	O
treating	O
the	O
umbilical	O
cord	O
.	O

Antimicrobial	O
control	O
was	O
equal	O
for	O
all	O
methods	O
.	O

Repeated	O
triple	Pharmacological
dye	Pharmacological
application	Pharmacological
was	O
considered	O
least	O
acceptable	O
by	O
staff	O
and	O
parents	O
and	O
had	O
the	O
longest	O
attachment	O
time	O
.	O

Povidone-iodine	Pharmacological
was	O
associated	O
with	O
the	O
shortest	O
attachment	O
time	O
and	O
was	O
most	O
liked	O
.	O

If	O
there	O
is	O
no	O
special	O
need	O
to	O
treat	O
a	O
specific	O
nosocomial	O
outbreak	O
,	O
duration	O
of	O
cord	O
attachment	O
and	O
satisfaction	O
of	O
staff	O
and	O
parents	O
can	O
help	O
clinicians	O
decide	O
on	O
a	O
cord	O
care	O
regimen	O
.	O

Bismuth	Pharmacological
subsalicylate	Pharmacological
in	O
the	O
treatment	O
of	O
gastritis	O
due	O
to	O
Campylobacter	O
pylori	O
.	O

Fifty	O
patients	O
completed	O
an	O
investigator-blind	O
trial	O
comparing	O
bismuth	Pharmacological
subsalicylate	Pharmacological
,	O
erythromycin	Pharmacological
ethylsuccinate	Pharmacological
,	O
and	O
placebo	Control
matched	O
to	O
the	O
bismuth	Pharmacological
salt	O
in	O
the	O
treatment	O
of	O
gastritis	O
associated	O
with	O
Campylobacter	O
pylori	O
.	O

C.	O
pylori	O
was	O
cleared	O
from	O
14	O
(	O
77.8	O
%	O
)	O
of	O
18	O
patients	O
given	O
locally	O
active	Pharmacological
bismuth	Pharmacological
,	O
from	O
one	O
(	O
6.7	O
%	O
)	O
of	O
15	O
patients	O
given	O
erythromycin	Pharmacological
,	O
and	O
from	O
none	O
of	O
17	O
patients	O
given	O
placebo	Control
.	O

Gastritis	O
resolved	O
in	O
13	O
(	O
81	O
%	O
)	O
of	O
16	O
patients	O
treated	O
with	O
bismuth	Pharmacological
but	O
in	O
only	O
three	O
of	O
13	O
receiving	O
erythromycin	Pharmacological
and	O
in	O
none	O
of	O
16	O
patients	O
given	O
placebo	Control
.	O

Results	O
of	O
endoscopic	O
examination	O
showed	O
greater	O
improvement	O
in	O
patients	O
cleared	O
of	O
C.	O
pylori	O
than	O
in	O
those	O
with	O
persistent	O
infection	O
.	O

Heartburn	O
improved	O
in	O
50	O
%	O
of	O
patients	O
who	O
received	O
bismuth	Pharmacological
compared	O
with	O
17	O
%	O
of	O
those	O
given	O
placebo	Control
.	O

The	O
success	O
of	O
bismuth	Pharmacological
is	O
probably	O
due	O
to	O
its	O
local	O
antimicrobial	O
activity	O
.	O

Erythromycin	Pharmacological
may	O
have	O
been	O
inactivated	O
by	O
the	O
low	O
pH	O
in	O
the	O
areas	O
colonized	O
with	O
C.	O
pylori	O
.	O

Relapse	O
is	O
less	O
frequent	O
when	O
a	O
combination	O
of	O
bismuth	Pharmacological
and	O
an	O
antimicrobial	O
agent	O
is	O
used	O
;	O
such	O
a	O
combination	O
is	O
characterized	O
by	O
local	O
and	O
systemic	O
activity	O
,	O
stability	O
at	O
low	O
pH	O
,	O
and	O
good	O
penetration	O
into	O
gastric	O
mucus	O
.	O

A	O
simplified	O
4-site	O
economical	O
intradermal	O
post-exposure	O
rabies	Pharmacological
vaccine	Pharmacological
regimen	O
:	O
a	O
randomised	O
controlled	O
comparison	O
with	O
standard	O
methods	O
.	O

BACKGROUND	O
The	O
need	O
for	O
economical	O
rabies	O
post-exposure	O
prophylaxis	O
(	O
PEP	O
)	O
is	O
increasing	O
in	O
developing	O
countries	O
.	O

Implementation	O
of	O
the	O
two	O
currently	O
approved	O
economical	O
intradermal	O
(	O
ID	O
)	O
vaccine	O
regimens	O
is	O
restricted	O
due	O
to	O
confusion	O
over	O
different	O
vaccines	O
,	O
regimens	O
and	O
dosages	O
,	O
lack	O
of	O
confidence	O
in	O
intradermal	O
technique	O
,	O
and	O
pharmaceutical	O
regulations	O
.	O

We	O
therefore	O
compared	O
a	O
simplified	O
4-site	O
economical	O
PEP	O
regimen	O
with	O
standard	O
methods	O
.	O

METHODS	O
Two	O
hundred	O
and	O
fifty-four	O
volunteers	O
were	O
randomly	O
allocated	O
to	O
a	O
single	O
blind	O
controlled	O
trial	O
.	O

Each	O
received	O
purified	Pharmacological
vero	Pharmacological
cell	Pharmacological
rabies	Pharmacological
vaccine	Pharmacological
by	O
one	O
of	O
four	O
PEP	O
regimens	O
:	O
the	O
currently	O
accepted	O
2-site	O
ID	O
;	O
the	O
8-site	O
regimen	O
using	O
0.05	O
ml	O
per	O
ID	O
site	O
;	O
a	O
new	O
4-site	O
ID	O
regimen	O
(	O
on	O
day	O
0	O
,	O
approximately	O
0.1	O
ml	O
at	O
4	O
ID	O
sites	O
,	O
using	O
the	O
whole	O
0.5	O
ml	O
ampoule	O
of	O
vaccine	O
;	O
on	O
day	O
7	O
,	O
0.1	O
ml	O
ID	O
at	O
2	O
sites	O
and	O
at	O
one	O
site	O
on	O
days	O
28	O
and	O
90	O
)	O
;	O
or	O
the	O
standard	Pharmacological
5-dose	Pharmacological
intramuscular	O
regimen	O
.	O

All	O
ID	O
regimens	O
required	O
the	O
same	O
total	O
amount	O
of	O
vaccine	O
,	O
60	O
%	O
less	O
than	O
the	O
intramuscular	O
method	O
.	O

Neutralising	O
antibody	O
responses	O
were	O
measured	O
five	O
times	O
over	O
a	O
year	O
in	O
229	O
people	O
,	O
for	O
whom	O
complete	O
data	O
were	O
available	O
.	O

FINDINGS	O
All	O
ID	O
regimens	O
showed	O
similar	O
immunogenicity	O
.	O

The	O
intramuscular	O
regimen	O
gave	O
the	O
lowest	O
geometric	O
mean	O
antibody	O
titres	O
.	O

Using	O
the	O
rapid	O
fluorescent	O
focus	O
inhibition	O
test	O
,	O
some	O
sera	O
had	O
unexpectedly	O
high	O
antibody	O
levels	O
that	O
were	O
not	O
attributable	O
to	O
previous	O
vaccination	O
.	O

The	O
results	O
were	O
confirmed	O
using	O
the	O
fluorescent	O
antibody	O
virus	O
neutralisation	O
method	O
.	O

CONCLUSIONS	O
This	O
4-site	O
PEP	O
regimen	O
proved	O
as	O
immunogenic	O
as	O
current	O
regimens	O
,	O
and	O
has	O
the	O
advantages	O
of	O
requiring	O
fewer	O
clinic	O
visits	O
,	O
being	O
more	O
practicable	O
,	O
and	O
having	O
a	O
wider	O
margin	O
of	O
safety	O
,	O
especially	O
in	O
inexperienced	O
hands	O
,	O
than	O
the	O
2-site	O
regimen	O
.	O

It	O
is	O
more	O
convenient	O
than	O
the	O
8-site	O
method	O
,	O
and	O
can	O
be	O
used	O
economically	O
with	O
vaccines	O
formulated	O
in	O
1.0	O
or	O
0.5	O
ml	O
ampoules	O
.	O

The	O
4-site	O
regimen	O
now	O
meets	O
all	O
requirements	O
of	O
immunogenicity	O
for	O
PEP	O
and	O
can	O
be	O
introduced	O
without	O
further	O
studies	O
.	O

TRIAL	O
REGISTRATION	O
Controlled-Trials.com	O
ISRCTN	O
30087513	O
.	O

Propranolol	Pharmacological
in	O
acute	O
myocardial	O
infarction	O
:	O
the	O
MILIS	O
experience	O
.	O

The	O
results	O
of	O
the	O
propranolol	Pharmacological
limb	O
of	O
the	O
Multicenter	O
Investigation	O
of	O
the	O
Limitation	O
of	O
Infarct	O
Size	O
are	O
reviewed	O
.	O

A	O
total	O
of	O
269	O
patients	O
,	O
who	O
presented	O
with	O
symptoms	O
and	O
electrocardiographic	O
signs	O
suggesting	O
acute	O
myocardial	O
infarction	O
were	O
randomized	O
to	O
acute	O
intravenous	O
and	O
subsequent	O
oral	O
therapy	O
with	O
propranolol	Pharmacological
(	O
n	O
=	O
134	O
)	O
or	O
placebo	Control
(	O
n	O
=	O
135	O
)	O
.	O

Eligibility	O
for	O
acute	O
beta-blocker	O
therapy	O
was	O
determined	O
on	O
the	O
basis	O
of	O
readily	O
available	O
,	O
noninvasive	O
tests	O
.	O

Therapy	O
was	O
started	O
at	O
an	O
average	O
time	O
of	O
8.5	O
hours	O
after	O
onset	O
of	O
symptoms	O
.	O

The	O
full	O
induction	O
dose	O
of	O
intravenous	O
propranolol	Pharmacological
(	O
0.1	O
mg/kg	O
)	O
was	O
tolerated	O
by	O
90	O
%	O
of	O
treated	O
patients	O
,	O
and	O
oral	O
maintenance	O
therapy	O
was	O
being	O
continued	O
in	O
82	O
%	O
of	O
treated	O
patients	O
on	O
the	O
second	O
hospital	O
day	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
heart	O
rate	O
throughout	O
maintenance	O
therapy	O
with	O
propranolol	O
,	O
which	O
continued	O
through	O
the	O
tenth	O
hospital	O
day	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
congestive	O
heart	O
failure	O
between	O
propranolol-	Pharmacological
and	O
placebo-treated	Control
groups	O
.	O

There	O
was	O
also	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
in	O
infarct	O
size	O
estimated	O
by	O
measurement	O
of	O
serum	O
CK-MB	O
,	O
planimetry	O
of	O
infarct	O
area	O
on	O
technetium	O
pyrophosphate	O
myocardial	O
scintigrams	O
or	O
R-wave	O
measurements	O
in	O
patients	O
with	O
transmural	O
anterior	O
and	O
inferior	O
infarcts	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
mortality	O
between	O
the	O
2	O
groups	O
during	O
an	O
average	O
of	O
36	O
months	O
'	O
follow-up	O
.	O

Although	O
propranolol	Pharmacological
can	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
who	O
are	O
selected	O
on	O
the	O
basis	O
of	O
simple	O
clinical	O
criteria	O
,	O
there	O
is	O
no	O
evidence	O
of	O
reduction	O
of	O
infarct	O
size	O
when	O
beta	O
blockade	O
is	O
begun	O
8.5	O
hours	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
of	O
intravenous	Pharmacological
immunoglobulin	Pharmacological
therapy	Pharmacological
in	O
patients	O
with	O
chronic	O
fatigue	O
syndrome	O
.	O

PURPOSE	O
The	O
chronic	O
fatigue	O
syndrome	O
(	O
CFS	O
)	O
is	O
characterized	O
by	O
profound	O
fatigue	O
,	O
neuropsychiatric	O
dysfunction	O
,	O
and	O
frequent	O
abnormalities	O
in	O
cell-mediated	O
immunity	O
.	O

No	O
effective	O
therapy	O
is	O
known	O
.	O

PATIENTS	O
AND	O
METHODS	O
Forty-nine	O
patients	O
(	O
40	O
with	O
abnormal	O
cell-mediated	O
immunity	O
)	O
participated	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
to	O
determine	O
the	O
effectiveness	O
of	O
high-dose	O
intravenously	Pharmacological
administered	Pharmacological
immunoglobulin	Pharmacological
G.	Pharmacological
The	O
patients	O
received	O
three	O
intravenous	O
infusions	O
of	O
a	O
placebo	Control
solution	Control
or	O
immunoglobulin	Pharmacological
at	O
a	O
dose	O
of	O
2	O
g/kg/month	O
.	O

Assessment	O
of	O
the	O
severity	O
of	O
symptoms	O
and	O
associated	O
disability	O
,	O
both	O
before	O
and	O
after	O
treatment	O
,	O
was	O
completed	O
at	O
detailed	O
interviews	O
by	O
a	O
physician	O
and	O
psychiatrist	O
,	O
who	O
were	O
unaware	O
of	O
the	O
treatment	O
status	O
.	O

In	O
addition	O
,	O
any	O
change	O
in	O
physical	O
symptoms	O
and	O
functional	O
capacity	O
was	O
recorded	O
using	O
visual	O
analogue	O
scales	O
,	O
while	O
changes	O
in	O
psychologic	O
morbidity	O
were	O
assessed	O
using	O
patient-rated	O
indices	O
of	O
depression	O
.	O

Cell-mediated	O
immunity	O
was	O
evaluated	O
by	O
T-cell	O
subset	O
analysis	O
,	O
delayed-type	O
hypersensitivity	O
skin	O
testing	O
,	O
and	O
lymphocyte	O
transformation	O
with	O
phytohemagglutinin	O
.	O

RESULTS	O
At	O
the	O
interview	O
conducted	O
by	O
the	O
physician	O
3	O
months	O
after	O
the	O
final	O
infusion	O
,	O
10	O
of	O
23	O
(	O
43	O
%	O
)	O
immunoglobulin	O
recipients	O
and	O
three	O
of	O
the	O
26	O
(	O
12	O
%	O
)	O
placebo	O
recipients	O
were	O
assessed	O
as	O
having	O
responded	O
with	O
a	O
substantial	O
reduction	O
in	O
their	O
symptoms	O
and	O
recommencement	O
of	O
work	O
,	O
leisure	O
,	O
and	O
social	O
activities	O
.	O

The	O
patients	O
designated	O
as	O
having	O
responded	O
had	O
improvement	O
in	O
physical	O
,	O
psychologic	O
,	O
and	O
immunologic	O
measures	O
(	O
p	O
less	O
than	O
0.01	O
for	O
each	O
)	O
.	O

CONCLUSION	O
Immunomodulatory	Pharmacological
treatment	Pharmacological
with	O
immunoglobulin	Pharmacological
is	O
effective	O
in	O
a	O
significant	O
number	O
of	O
patients	O
with	O
CFS	O
,	O
a	O
finding	O
that	O
supports	O
the	O
concept	O
that	O
an	O
immunologic	O
disturbance	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
this	O
disorder	O
.	O

Mapping	O
from	O
disease-specific	O
measures	O
to	O
health-state	O
utility	O
values	O
in	O
individuals	O
with	O
migraine	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
empirical	O
algorithms	O
that	O
estimate	O
health-state	O
utility	O
values	O
from	O
disease-specific	O
quality-of-life	O
scores	O
in	O
individuals	O
with	O
migraine	O
.	O

METHODS	O
Data	O
from	O
a	O
cross-sectional	O
,	O
multicountry	O
study	O
were	O
used	O
.	O

Individuals	O
with	O
episodic	O
and	O
chronic	O
migraine	O
were	O
randomly	O
assigned	O
to	O
training	O
or	O
validation	O
samples	O
.	O

Spearman	O
's	O
correlation	O
coefficients	O
between	O
paired	O
EuroQol	Educational
five-dimensional	Educational
(	Educational
EQ-5D	Educational
)	Educational
questionnaire	Educational
utility	O
values	O
and	O
both	O
Headache	O
Impact	O
Test	O
(	O
HIT-6	O
)	O
scores	O
and	O
Migraine-Specific	Educational
Quality-of-Life	Educational
Questionnaire	Educational
version	Educational
2.1	Educational
(	Educational
MSQ	Educational
)	Educational
domain	O
scores	O
(	O
role	O
restrictive	O
,	O
role	O
preventive	O
,	O
and	O
emotional	O
function	O
)	O
were	O
examined	O
.	O

Regression	O
models	O
were	O
constructed	O
to	O
estimate	O
EQ-5D	O
questionnaire	O
utility	O
values	O
from	O
the	O
HIT-6	O
score	O
or	O
the	O
MSQ	O
domain	O
scores	O
.	O

Preferred	O
algorithms	O
were	O
confirmed	O
in	O
the	O
validation	O
samples	O
.	O

RESULTS	O
In	O
episodic	O
migraine	O
,	O
the	O
preferred	O
HIT-6	Educational
and	O
MSQ	Educational
algorithms	Educational
explained	O
22	O
%	O
and	O
25	O
%	O
of	O
the	O
variance	O
(	O
R	O
(	O
2	O
)	O
)	O
in	O
the	O
training	O
samples	O
,	O
respectively	O
,	O
and	O
had	O
similar	O
prediction	O
errors	O
(	O
root	O
mean	O
square	O
errors	O
of	O
0.30	O
)	O
.	O

In	O
chronic	O
migraine	O
,	O
the	O
preferred	O
HIT-6	Educational
and	O
MSQ	Educational
algorithms	Educational
explained	O
36	O
%	O
and	O
45	O
%	O
of	O
the	O
variance	O
in	O
the	O
training	O
samples	O
,	O
respectively	O
,	O
and	O
had	O
similar	O
prediction	O
errors	O
(	O
root	O
mean	O
square	O
errors	O
0.31	O
and	O
0.29	O
)	O
.	O

In	O
episodic	O
and	O
chronic	O
migraine	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
mean	O
observed	O
and	O
the	O
mean	O
estimated	O
EQ-5D	O
questionnaire	O
utility	O
values	O
for	O
the	O
preferred	O
HIT-6	Educational
and	O
MSQ	Educational
algorithms	O
in	O
the	O
validation	O
samples	O
.	O

CONCLUSIONS	O
The	O
relationship	O
between	O
the	O
EQ-5D	O
questionnaire	O
and	O
the	O
HIT-6	O
or	O
the	O
MSQ	O
is	O
adequate	O
to	O
use	O
regression	O
equations	O
to	O
estimate	O
EQ-5D	O
questionnaire	O
utility	O
values	O
.	O

The	O
preferred	O
HIT-6	Educational
and	O
MSQ	Educational
algorithms	O
will	O
be	O
useful	O
in	O
estimating	O
health-state	O
utilities	O
in	O
migraine	O
trials	O
in	O
which	O
no	O
preference-based	O
measure	O
is	O
present	O
.	O

Efficacy	O
of	O
latanoprost	Pharmacological
when	O
stored	O
at	O
room	O
temperature	O
.	O

We	O
compared	O
the	O
ocular	O
hypotensive	O
effect	O
for	O
24	O
hours	O
and	O
the	O
tolerability	O
of	O
latanoprost	Pharmacological
stored	O
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C.	O
Seventeen	O
healthy	O
volunteers	O
were	O
included	O
in	O
this	O
crossover	O
trial	O
.	O

Latanoprost	Pharmacological
0.005	O
%	O
(	O
Xalatan	Pharmacological
)	O
was	O
stored	O
at	O
4	O
degrees	O
C	O
or	O
30	O
degrees	O
C	O
for	O
4	O
weeks	O
in	O
the	O
dark	O
.	O

The	O
subjects	O
enrolled	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
latanoprost	Pharmacological
stored	O
at	O
4	O
degrees	O
C	O
or	O
that	O
stored	O
at	O
30	O
degrees	O
C.	O
The	O
eye	O
drop	O
was	O
applied	O
to	O
the	O
right	O
eye	O
of	O
each	O
subject	O
for	O
3	O
days	O
.	O

The	O
left	O
eye	O
served	O
as	O
a	O
control	O
without	O
administration	O
.	O

Slit-lamp	Surgical
biomicroscopy	Surgical
and	O
circadian	Surgical
intra	Surgical
ocular	Surgical
pressure	Surgical
(	Surgical
IOP	Surgical
)	Surgical
curve	Surgical
was	O
performed	O
at	O
Day	O
3	O
,	O
every	O
3	O
hours	O
from	O
6	O
pm	O
.	O

This	O
procedure	O
was	O
repeated	O
7	O
days	O
after	O
changing	O
the	O
drug	O
from	O
4	O
degrees	O
C	O
to	O
30	O
degrees	O
C	O
or	O
vice	O
versa	O
,	O
and	O
application	O
to	O
the	O
left	O
eye	O
for	O
3	O
days	O
.	O

Eyes	O
treated	O
with	O
latanoprost	O
,	O
stored	O
both	O
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C	O
,	O
achieved	O
statistically	O
significantly	O
lower	O
mean	O
IOPs	O
than	O
untreated	O
eyes	O
at	O
all	O
time	O
points	O
,	O
except	O
at	O
21	O
hours	O
treated	O
by	O
the	O
drug	O
stored	O
at	O
30	O
degrees	O
C.	O
We	O
subtracted	O
the	O
IOP	O
of	O
eyes	O
receiving	O
latanoprost	O
from	O
the	O
IOP	O
of	O
untreated	O
eyes	O
for	O
each	O
time	O
point	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
eye	O
drops	O
(	O
delta	O
IOP	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
delta	O
IOPs	O
with	O
the	O
drug	O
stored	O
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C.	O
During	O
the	O
study	O
,	O
no	O
subject	O
developed	O
a	O
serious	O
adverse	O
event	O
.	O

These	O
results	O
suggest	O
that	O
latanoprost	O
stored	O
at	O
30	O
degrees	O
C	O
for	O
4	O
weeks	O
after	O
opening	O
the	O
bottle	O
remains	O
as	O
effective	O
and	O
safe	O
as	O
latanoprost	O
stored	O
under	O
cold	O
conditions	O
.	O

Comparison	O
of	O
provocative	O
tests	O
for	O
unexplained	O
syncope	O
:	O
isoprenaline	Pharmacological
and	O
glyceryl	Pharmacological
trinitrate	Pharmacological
for	O
diagnosing	O
vasovagal	O
syncope	O
.	O

AIMS	O
To	O
compare	O
the	O
sensitivity	O
,	O
specificity	O
and	O
adverse	O
event	O
profile	O
of	O
glyceryl	Pharmacological
trinitrate	Pharmacological
head-up	O
tilt	O
with	O
isoprenaline	Pharmacological
head-up	O
tilt	O
in	O
the	O
diagnosis	O
of	O
vasovagal	O
syncope	O
in	O
patients	O
with	O
unexplained	O
syncope	O
and	O
healthy	O
controls	O
.	O

METHODS	O
AND	O
RESULTS	O
Forty-eight	O
patients	O
with	O
unexplained	O
syncope	O
and	O
negative	O
passive	O
head-up	O
tilt	O
at	O
70	O
degrees	O
for	O
40	O
min	O
,	O
and	O
14	O
healthy	O
controls	O
underwent	O
glyceryl	Pharmacological
trinitrate	Pharmacological
head-up	Pharmacological
tilt	Pharmacological
and	O
isoprenaline	Pharmacological
head-up	Pharmacological
tilt	Pharmacological
(	O
maximum	O
dose	O
5	O
microg	O
x	O
min	O
(	O
-1	O
)	O
)	O
one	O
week	O
apart	O
in	O
random	O
order	O
.	O

Outcome	O
measures	O
were	O
production	O
of	O
symptoms	O
(	O
syncope	O
,	O
pre-syncope	O
)	O
with	O
development	O
of	O
hypotension	O
.	O

In	O
those	O
with	O
negative	O
passive	O
head-up	O
tilt	O
,	O
the	O
sensitivity	O
of	O
glyceryl	Pharmacological
trinitrate	Pharmacological
for	O
diagnosing	O
vasovagal	O
syncope	O
was	O
48	O
%	O
and	O
the	O
specificity	O
was	O
71	O
%	O
.	O

Glyceryl	O
trinitrate	O
was	O
well	O
tolerated	O
.	O

Isoprenaline	Pharmacological
sensitivity	O
was	O
21	O
%	O
with	O
specificity	O
64	O
%	O
.	O

Side-effects	O
prevented	O
completion	O
of	O
the	O
test	O
in	O
68	O
%	O
.	O

Commonest	O
adverse	O
events	O
were	O
the	O
development	O
of	O
hypertension	O
or	O
tachycardia	O
and	O
intolerable	O
flushing	O
or	O
nausea	O
.	O

CONCLUSIONS	O
Glyceryl	Pharmacological
trinitrate	Pharmacological
head-up	Pharmacological
tilt	Pharmacological
is	O
as	O
effective	O
as	O
isoprenaline	Pharmacological
head-up	Pharmacological
tilt	Pharmacological
as	O
a	O
provocative	O
agent	O
for	O
vasovagal	O
syncope	O
and	O
has	O
a	O
lower	O
incidence	O
of	O
adverse	O
events	O
.	O

Dose-response	O
relationship	O
of	O
sertindole	Pharmacological
and	O
haloperidol	Pharmacological
using	O
the	O
pharmacopsychometric	O
triangle	O
.	O

OBJECTIVE	O
Renewed	O
insight	O
into	O
dose-related	O
effects	O
of	O
sertindole	Pharmacological
and	O
haloperidol	Pharmacological
was	O
sought	O
by	O
re-analysing	O
published	O
data	O
for	O
antipsychotic	O
effect	O
,	O
extrapyramidal	O
effect	O
,	O
and	O
patient	O
wellbeing	O
-	O
i.e.	O
,	O
the	O
important	O
pharmacopsychometric	O
triangle	O
domains	O
.	O

METHOD	O
Selected	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
subscales	O
and	O
the	O
Simpson-Angus	O
scale	O
were	O
tested	O
for	O
validity	O
.	O

Standardized	O
effect	O
sizes	O
[	O
last	O
observation	O
carried	O
forward	O
(	O
LOCF	O
)	O
]	O
at	O
endpoint	O
were	O
calculated	O
.	O

RESULTS	O
The	O
scales	O
were	O
found	O
to	O
be	O
valid	O
instruments	O
.	O

The	O
PANSS	O
(	O
11	O
)	O
psychotic	O
subscale	O
showed	O
clinically	O
significant	O
effect	O
sizes	O
for	O
all	O
doses	O
of	O
sertindole	Pharmacological
(	O
12	O
,	O
20	O
,	O
and	O
24	O
mg	O
)	O
and	O
haloperidol	Pharmacological
(	O
4	O
,	O
8	O
,	O
and	O
16	O
mg	O
)	O
.	O

Extrapyramidal	O
effects	O
were	O
evident	O
for	O
all	O
doses	O
of	O
haloperidol	Pharmacological
,	O
but	O
absent	O
for	O
the	O
lower	O
doses	O
of	O
sertindole	Pharmacological
.	O

The	O
PANSS	O
(	O
6	O
)	O
depression	O
subscale	O
,	O
a	O
proxy	O
measure	O
of	O
quality	O
of	O
life	O
,	O
showed	O
a	O
clinically	O
significant	O
effect	O
for	O
sertindole	Pharmacological
20	O
mg	O
and	O
no	O
effect	O
for	O
haloperidol	Pharmacological
.	O

CONCLUSION	O
This	O
re-analysis	O
confirmed	O
the	O
antipsychotic	O
effect	O
and	O
absence	O
of	O
extrapyramidal	O
effects	O
for	O
sertindole	Pharmacological
and	O
,	O
in	O
addition	O
,	O
showed	O
a	O
clinically	O
significant	O
antidepressant	O
effect	O
.	O

A	O
profile	O
for	O
bipolar	O
states	O
emerged	O
.	O

Response	O
prediction	O
in	O
metastasised	O
colorectal	O
cancer	O
using	O
intratumoural	O
thymidylate	O
synthase	O
:	O
results	O
of	O
a	O
randomised	O
multicentre	O
trial	O
.	O

BACKGROUND	O
Molecular	O
markers	O
to	O
predict	O
response	O
to	O
5-fluorouracil	Pharmacological
(	Pharmacological
FU	Pharmacological
)	Pharmacological
-based	Pharmacological
treatment	O
of	O
recurrent	O
or	O
metastasised	O
colorectal	O
cancer	O
(	O
mCRC	O
)	O
are	O
not	O
established	O
.	O

The	O
aim	O
of	O
this	O
trial	O
was	O
to	O
determine	O
the	O
value	O
of	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
,	O
a	O
key	O
enzyme	O
of	O
DNA	O
synthesis	O
and	O
target	O
of	O
5-FU	O
,	O
to	O
predict	O
response	O
to	O
chemotherapy	O
of	O
mCRC	O
.	O

METHODS	O
Tumour	O
tissue	O
was	O
obtained	O
from	O
168	O
patients	O
with	O
mCRC	O
for	O
relative	O
thymidylate	Pharmacological
synthase	Pharmacological
(	O
TS	O
)	O
mRNA	O
quantitation	O
.	O

Patients	O
were	O
randomised	O
to	O
receive	O
either	O
5-FU/folinic	Pharmacological
acid	Pharmacological
(	Pharmacological
FA	Pharmacological
,	Pharmacological
FUFA	Pharmacological
)	Pharmacological
alone	Pharmacological
or	Pharmacological
in	Pharmacological
combination	Pharmacological
with	Pharmacological
irinotecan	Pharmacological
5-fluorouracil/folinic	Pharmacological
acid	Pharmacological
and	Pharmacological
irinotecan	Pharmacological
(	Pharmacological
FOLFIRI	Pharmacological
)	Pharmacological
stratified	Pharmacological
by	Pharmacological
TS	Pharmacological
(	Pharmacological
low	Pharmacological
versus	Pharmacological
high	Pharmacological
)	Pharmacological
.	O

Primary	O
end-point	O
was	O
overall	O
response	O
to	O
first-line	O
treatment	O
among	O
TS	O
high	O
patients	O
.	O

All	O
parties	O
,	O
except	O
for	O
the	O
randomisation	O
centre	O
,	O
were	O
blinded	O
for	O
TS	O
status	O
.	O

RESULTS	O
Biopsies	O
(	O
n=168	O
)	O
were	O
taken	O
without	O
complications	O
.	O

TS	O
levels	O
were	O
available	O
for	O
147	O
patients	O
(	O
87.5	O
%	O
)	O
.	O

Analysing	O
response	O
to	O
FUFA	O
and	O
FOLFIRI	O
in	O
the	O
per	O
protocol	O
set	O
(	O
n=119	O
)	O
after	O
un-blinding	O
TS	O
in	O
the	O
data	O
base	O
revealed	O
a	O
trend	O
to	O
better	O
overall	O
response	O
to	O
FOLFIRI	O
(	O
9/19	O
,	O
47	O
%	O
)	O
in	O
TS	O
high	O
compared	O
to	O
FUFA	O
(	O
5/23	O
,	O
22	O
%	O
,	O
p=0.077	O
)	O
.	O

In	O
patients	O
with	O
biopsies	O
taken	O
from	O
liver	O
lesions	O
(	O
n=91	O
)	O
overall	O
response	O
to	O
FOLFIRI	O
and	O
FUFA	O
in	O
TS	O
high	O
was	O
53	O
%	O
(	O
9/17	O
)	O
and	O
18	O
%	O
(	O
3/17	O
)	O
,	O
respectively	O
(	O
p=0.035	O
)	O
.	O

In	O
patients	O
with	O
low	O
TS	O
,	O
no	O
remarkable	O
difference	O
in	O
overall	O
response	O
to	O
FOLFIRI	O
and	O
FUFA	O
was	O
observed	O
.	O

CONCLUSIONS	O
Taking	O
a	O
pre-treatment	O
biopsy	O
is	O
a	O
safe	O
and	O
feasible	O
procedure	O
in	O
mCRC	O
.	O

After	O
validation	O
of	O
our	O
data	O
in	O
a	O
larger	O
group	O
TS	O
determination	O
may	O
have	O
the	O
potential	O
to	O
better	O
help	O
direct	O
systemic	O
treatment	O
in	O
patients	O
with	O
primarily	O
non-resectable	O
mCRC	O
.	O

Are	O
PRO	Physical
discharge	Physical
screens	Physical
associated	O
with	O
postdischarge	O
adverse	O
outcomes	O
?	O
OBJECTIVE	O
We	O
evaluate	O
whether	O
patient	O
outcomes	O
may	O
be	O
affected	O
by	O
possible	O
errors	O
in	O
care	O
at	O
discharge	O
as	O
assessed	O
by	O
Peer	O
Review	O
Organizations	O
(	O
PROs	O
)	O
.	O

DATA	O
SOURCES/STUDY	O
SETTING	O
The	O
three	O
data	O
sources	O
for	O
the	O
study	O
were	O
(	O
1	O
)	O
the	O
generic	Physical
screen	Physical
results	Physical
of	O
a	O
3	O
percent	O
random	O
sample	O
of	O
Medicare	O
beneficiaries	O
age	O
65	O
years	O
or	O
older	O
who	O
were	O
admitted	O
to	O
California	O
hospitals	O
between	O
1	O
July	O
1987	O
and	O
30	O
June	O
1988	O
(	O
n	O
=	O
20,136	O
patients	O
)	O
;	O
(	O
2	O
)	O
the	O
1987	O
and	O
1988	O
California	O
Medicare	O
Provided	O
Analysis	Educational
and	Educational
Review	Educational
(	Educational
MEDPAR	Educational
)	Educational
data	Educational
files	Educational
;	Educational
and	O
(	O
3	O
)	O
the	O
American	O
Hospital	O
Association	O
(	O
AHA	O
)	O
1988	O
Annual	O
Survey	O
of	O
Hospitals	O
.	O

STUDY	O
DESIGN	O
Multivariate	Other
logistic	Other
regression	Other
analysis	Other
was	O
used	O
to	O
evaluate	O
the	O
association	O
between	O
the	O
results	O
of	O
generic	O
discharge	O
administered	O
by	O
the	O
PROs	O
and	O
two	O
patient	O
outcomes	O
:	O
mortality	O
and	O
readmission	O
within	O
30	O
days	O
.	O

The	O
analysis	O
was	O
adjusted	O
for	O
other	O
patient	O
characteristics	O
recorded	O
on	O
the	O
uniform	O
discharge	O
abstract	O
.	O

PRINCIPAL	O
FINDINGS	O
Four	O
discharge	O
screens	O
indicated	O
an	O
increased	O
risk	O
of	O
an	O
adverse	O
outcome-absence	O
of	O
documentation	O
of	O
discharge	O
planning	O
,	O
elevated	O
temperature	O
,	O
abnormal	O
pulse	O
,	O
and	O
unaddressed	O
abnormal	O
test	O
results	O
at	O
discharge	O
.	O

The	O
other	O
three	O
discharge	O
screens	O
examined-abnormal	O
blood	O
pressure	O
,	O
IV	O
fluids	O
or	O
drugs	O
,	O
and	O
wound	O
drainage	O
before	O
discharge-were	O
unrelated	O
to	O
postdischarge	O
adverse	O
outcomes	O
.	O

CONCLUSIONS	O
Generic	Other
discharge	Other
screens	Other
based	O
on	O
inadequate	O
discharge	O
planning	O
,	O
abnormal	O
pulse	O
,	O
increased	O
temperature	O
,	O
or	O
unaddressed	O
abnormal	O
tests	O
may	O
be	O
important	O
indicators	O
of	O
substandard	O
care	O
.	O

Other	O
discharge	O
screens	O
apparently	O
do	O
not	O
detect	O
errors	O
in	O
care	O
associated	O
with	O
major	O
consequences	O
for	O
patients	O
.	O

Effects	O
of	O
frusemide	Pharmacological
and	O
hypoxia	O
on	O
the	O
pulmonary	O
vascular	O
bed	O
in	O
man	O
.	O

AIMS	O
Diuretic	Pharmacological
therapy	O
is	O
conventionally	O
used	O
to	O
treat	O
oedema	O
in	O
patients	O
with	O
hypoxic	O
cor	O
pulmonale	O
.	O

This	O
condition	O
is	O
associated	O
with	O
activation	O
of	O
the	O
renin	O
angiotensin	O
system	O
(	O
RAS	O
)	O
with	O
elevated	O
levels	O
of	O
angiotensin	O
II	O
(	O
ANG	O
II	O
)	O
,	O
a	O
potent	O
pulmonary	O
pressor	O
agent	O
.	O

We	O
explored	O
the	O
hypothesis	O
that	O
RAS	O
activation	O
by	O
diuretic	O
therapy	O
might	O
therefore	O
worsen	O
hypoxic	O
pulmonary	O
vasoconstriction	O
via	O
the	O
effects	O
of	O
ANG	O
II	O
on	O
the	O
pulmonary	O
vascular	O
bed	O
.	O

METHODS	O
Eight	O
normal	O
volunteers	O
were	O
studied	O
on	O
2	O
separate	O
days	O
.	O

They	O
either	O
received	O
40	Pharmacological
mg	Pharmacological
frusemide	Pharmacological
daily	Pharmacological
or	Pharmacological
placebo	Pharmacological
for	O
4	O
days	O
and	O
were	O
then	O
rendered	O
hypoxaemic	O
,	O
by	O
breathing	O
an	O
N2/O2	O
mixture	O
for	O
20	O
min	O
to	O
achieve	O
an	O
SaO2	O
of	O
85-90	O
%	O
adjusted	O
for	O
a	O
further	O
20	O
min	O
to	O
achieve	O
an	O
SaO2	O
of	O
75-80	O
%	O
.	O

Pulsed	O
wave	O
doppler	O
echocardiography	O
was	O
used	O
to	O
measure	O
mean	O
pulmonary	O
artery	O
pressure	O
,	O
cardiac	O
output	O
and	O
hence	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
.	O

RESULTS	O
Plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
was	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
after	O
prior	O
treatment	O
with	O
frusemide	Pharmacological
compared	O
with	O
placebo	Pharmacological
at	O
all	O
time	O
points	O
.	O

Prior	O
treatment	O
with	O
frusemide	Pharmacological
significantly	O
(	O
P	O
<	O
0.05	O
)	O
increased	O
PVR	O
compared	O
with	O
placebo	Pharmacological
at	O
baseline	O
:	O
185	O
+/-	O
17	O
vs	O
132	O
+/-	O
10	O
dyn	O
s	O
cm-5	O
at	O
an	O
SaO2	O
of	O
85-90	O
%	O
:	O
291	O
+/-	O
18	O
vs	O
229	O
+/-	O
16	O
dyn	O
s	O
cm-5	O
and	O
at	O
SaO2	O
of	O
75-80	O
%	O
:	O
356	O
+/-	O
12	O
vs	O
296	O
+/-	O
17	O
dyn	O
s	O
cm-5	O
respectively	O
.	O

However	O
,	O
the	O
delta-PVR	O
response	O
to	O
hypoxaemia	O
was	O
not	O
significantly	O
altered	O
by	O
frusemide	Pharmacological
compared	O
with	O
placebo	Pharmacological
.	O

In	O
contrast	O
to	O
its	O
effect	O
on	O
the	O
pulmonary	O
vasculature	O
prior	O
treatment	O
with	O
frusemide	Pharmacological
did	O
not	O
significantly	O
alter	O
systemic	O
haemodynamic	O
parameters	O
either	O
at	O
baseline	O
or	O
during	O
hypoxia	O
.	O

CONCLUSIONS	O
Thus	O
,	O
prior	O
treatment	O
with	O
frusemide	Pharmacological
increased	O
baseline	O
pulmonary	O
vascular	O
resistance	O
and	O
significantly	O
augmented	O
the	O
hypoxaemic	O
pulmonary	O
vascular	O
response	O
in	O
additive	O
fashion	O
.	O

It	O
is	O
hypothesised	O
that	O
this	O
effect	O
of	O
frusemide	Pharmacological
may	O
be	O
due	O
to	O
RAS	O
activation	O
with	O
ANG	O
II	O
mediated	O
pulmonary	O
vasoconstriction	O
.	O

Expectancies	O
,	O
not	O
aroma	O
,	O
explain	O
impact	O
of	O
lavender	Pharmacological
aromatherapy	Pharmacological
on	O
psychophysiological	O
indices	O
of	O
relaxation	O
in	O
young	O
healthy	O
women	O
.	O

OBJECTIVES	O
In	O
aromatherapy	Pharmacological
,	Pharmacological
lavender	Pharmacological
aroma	Pharmacological
is	O
reputed	O
to	O
assist	O
with	O
relaxation	O
.	O

However	O
,	O
while	O
there	O
is	O
much	O
anecdotal	O
evidence	O
to	O
that	O
effect	O
,	O
the	O
empirical	O
literature	O
is	O
very	O
inconsistent	O
.	O

Failure	O
to	O
employ	O
adequate	O
placebos	Control
,	O
proper	O
blinding	O
,	O
objective	O
measures	O
,	O
or	O
screening	O
of	O
prior	O
beliefs	O
about	O
aromatherapy	O
means	O
that	O
many	O
previous	O
findings	O
could	O
have	O
been	O
influenced	O
by	O
expectancy	O
biases	O
.	O

The	O
present	O
study	O
sought	O
to	O
establish	O
whether	O
lavender	Pharmacological
aroma	Pharmacological
and/or	O
expectancies	O
affect	O
post-stress	O
relaxation	O
.	O

DESIGN	O
A	O
double-blind	O
,	O
3	O
(	O
aroma	O
)	O
x	O
3	O
(	O
instruction	O
)	O
x	O
10	O
(	O
time	O
in	O
minutes	O
)	O
mixed-factorial	Control
placebo-controlled	Control
trial	O
.	O

METHOD	O
In	O
a	O
laboratory	O
,	O
96	O
healthy	O
undergraduate	O
women	O
were	O
exposed	Pharmacological
to	Pharmacological
lavender	Pharmacological
,	O
placebo	Control
,	O
or	O
no	Other
aroma	Other
during	O
physiologically	O
assessed	O
relaxation	O
after	O
an	O
arousing	O
cognitive	O
task	O
.	O

Where	O
an	O
aroma	O
was	O
presented	O
,	O
an	O
instructional	O
priming	O
procedure	O
was	O
used	O
to	O
manipulate	O
participants	O
'	O
expectancies	O
about	O
the	O
aroma	O
's	O
likely	O
impact	O
on	O
their	O
ability	O
to	O
relax	O
.	O

RESULTS	O
Results	O
showed	O
no	O
effect	O
of	O
aroma	O
on	O
galvanic	O
skin	O
response	O
during	O
relaxation	O
.	O

However	O
,	O
the	O
nature	O
of	O
instructional	O
prime	O
was	O
associated	O
with	O
relaxation	O
patterns	O
:	O
when	O
expecting	O
the	O
aroma	O
to	O
inhibit	O
them	O
,	O
participants	O
relaxed	O
more	O
;	O
when	O
expecting	O
facilitation	O
,	O
participants	O
relaxed	O
less	O
.	O

The	O
effect	O
was	O
not	O
seen	O
with	O
regard	O
to	O
self-reported	O
relaxation	O
(	O
as	O
represented	O
by	O
changes	O
in	O
state	O
anxiety	O
)	O
and	O
was	O
independent	O
of	O
ratings	O
of	O
attitudes	O
towards	O
aromatherapy	O
.	O

CONCLUSIONS	O
The	O
findings	O
imply	O
that	O
the	O
previous	O
associations	O
of	O
lavender	Control
aroma	Control
with	O
assisted	O
relaxation	O
may	O
have	O
been	O
influenced	O
by	O
expectancy	O
biases	O
,	O
and	O
that	O
the	O
relevant	O
expectancies	O
are	O
easily	O
manipulable	O
.	O

[	O
The	O
effect	O
of	O
ionic	Physical
and	Physical
nonionic	Physical
x-ray	Physical
contrast	Physical
media	Physical
on	O
myocardial	O
perfusion	O
and	O
myocardial	O
function	O
]	O
.	O

The	O
influence	O
of	O
injections	O
of	O
Amidotrizoate	Pharmacological
and	O
Iopromide	Pharmacological
into	O
the	O
left	O
coronary	O
artery	O
on	O
global	O
myocardial	O
perfusion	O
and	O
function	O
(	O
pressures	O
in	O
the	O
left	O
ventricle	O
,	O
heart	O
rate	O
)	O
as	O
well	O
as	O
excitation	O
formation	O
and	O
transmission	O
was	O
studied	O
in	O
16	O
patients	O
with	O
ischaemic	O
heart	O
disease	O
.	O

No	O
statistically	O
significant	O
differences	O
in	O
myocardial	O
perfusion	O
measured	O
were	O
found	O
with	O
xenon-133	Pharmacological
in	O
this	O
small	O
group	O
between	O
rest	O
and	O
dipyridamole	O
load	O
for	O
ionic	Pharmacological
and	O
non-ionic	Physical
contrast	Physical
media	Physical
.	O

The	O
effectiveness	O
and	O
cost	O
of	O
passive	O
warming	O
in	O
adult	O
ambulatory	O
surgery	O
patients	O
.	O

Hypothermia	O
is	O
a	O
common	O
problem	O
for	O
surgical	O
patients	O
and	O
can	O
result	O
in	O
many	O
complications	O
.	O

Because	O
few	O
studies	O
compare	O
methods	O
of	O
passive	O
warming	O
,	O
we	O
used	O
an	O
unblinded	O
,	O
prospective	O
,	O
experimental	O
,	O
randomized	O
design	O
to	O
compare	O
the	O
effectiveness	O
of	O
two	O
passive	O
methods	O
of	O
normothermia	O
management	O
in	O
the	O
postanesthesia	O
care	O
unit	O
(	O
PACU	O
)	O
.	O

We	O
assigned	O
a	O
total	O
of	O
578	O
adult	O
ambulatory	O
surgery	O
patients	O
to	O
either	O
a	O
control	Control
group	Control
that	O
was	O
given	O
two	Control
folded	Control
,	Control
warmed	Control
cotton	Control
blankets	Control
or	Physical
a	Physical
treatment	Physical
group	Physical
that	Physical
was	Physical
given	Physical
a	Physical
warmed	Physical
,	Physical
unfolded	Physical
cotton	Physical
sheet	Physical
and	Physical
cotton	Physical
blanket	Physical
.	O

We	O
recorded	O
patients	O
'	O
temperatures	O
on	O
their	O
arrival	O
in	O
the	O
PACU	O
and	O
at	O
30	O
minutes	O
after	O
arrival	O
.	O

The	O
treatment	O
group	O
had	O
temperatures	O
that	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
control	O
group	O
30	O
minutes	O
after	O
arrival	O
in	O
the	O
PACU	O
,	O
and	O
the	O
treatment	O
group	O
experienced	O
a	O
greater	O
change	O
in	O
temperature	O
from	O
baseline	O
measurements	O
to	O
those	O
taken	O
at	O
30	O
minutes	O
.	O

The	O
treatment	O
group	O
also	O
used	O
fewer	O
warmed	O
blankets	O
,	O
resulting	O
in	O
cost	O
savings	O
for	O
the	O
PACU	O
.	O

Plasma	O
Epstein-Barr	O
virus	O
DNA	O
predicts	O
outcome	O
in	O
advanced	O
Hodgkin	O
lymphoma	O
:	O
correlative	O
analysis	O
from	O
a	O
large	O
North	O
American	O
cooperative	O
group	O
trial	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
associated	O
with	O
Hodgkin	O
lymphoma	O
(	O
HL	O
)	O
and	O
can	O
be	O
detected	O
by	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
of	O
viral	O
nucleic	O
acid	O
(	O
EBER	O
)	O
in	O
tumor	O
cells	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
plasma	O
EBV-DNA	O
could	O
serve	O
as	O
a	O
surrogate	O
for	O
EBER-ISH	O
and	O
to	O
explore	O
its	O
prognostic	O
utility	O
in	O
HL	O
.	O

Specimens	O
from	O
the	O
Cancer	O
Cooperative	O
Intergroup	O
Trial	O
E2496	O
were	O
used	O
to	O
compare	O
pretreatment	Physical
plasma	Physical
EBV-DNA	Physical
quantification	Physical
with	O
EBV	Physical
tumor	Physical
status	Physical
by	Physical
EBER-ISH	Physical
.	O

A	O
cutoff	O
of	O
>	O
60	O
viral	O
copies/100	O
?L	O
plasma	O
yielded	O
96	O
%	O
concordance	O
with	O
EBER-ISH	O
.	O

Pretreatment	O
and	O
month	O
6	O
plasma	O
specimens	O
were	O
designated	O
EBV	O
(	O
-	O
)	O
or	O
EBV	O
(	O
+	O
)	O
by	O
this	O
cutoff	O
.	O

Patients	O
with	O
pretreatment	O
EBV	O
(	O
+	O
)	O
plasma	O
(	O
n	O
=	O
54	O
)	O
had	O
inferior	O
failure-free	O
survival	O
(	O
FFS	O
)	O
compared	O
with	O
those	O
with	O
pretreatment	O
EBV	O
(	O
-	O
)	O
plasma	O
(	O
n	O
=	O
274	O
)	O
,	O
log-rank	O
P	O
=	O
.009	O
.	O

By	O
contrast	O
,	O
no	O
difference	O
in	O
FFS	O
was	O
observed	O
when	O
patients	O
were	O
stratified	O
by	O
EBER-ISH	O
.	O

Pretreatment	O
plasma	O
EBV	O
positivity	O
was	O
an	O
independent	O
predictor	O
of	O
treatment	O
failure	O
on	O
multivariate	O
analyses	O
.	O

At	O
month	O
6	O
,	O
plasma	O
EBV	O
(	O
+	O
)	O
patients	O
(	O
n	O
=	O
7	O
)	O
had	O
inferior	O
FFS	O
compared	O
with	O
plasma	O
EBV	O
(	O
-	O
)	O
patients	O
(	O
n	O
=	O
125	O
)	O
,	O
log-rank	O
P	O
=	O
.007	O
.	O

These	O
results	O
confirm	O
that	O
plasma	O
EBV-DNA	O
is	O
highly	O
concordant	O
with	O
EBER-ISH	O
in	O
HL	O
and	O
suggest	O
that	O
it	O
may	O
have	O
prognostic	O
utility	O
both	O
at	O
baseline	O
and	O
after	O
therapy	O
.	O

This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT00003389	O
.	O

Histopathologic	O
changes	O
of	O
the	O
eyelid	O
skin	O
following	O
trichloroacetic	Physical
acid	Physical
chemical	Physical
peel	Physical
.	O

The	O
use	O
of	O
trichloroacetic	Pharmacological
acid	Pharmacological
(	Pharmacological
TCA	Pharmacological
)	Pharmacological
as	O
a	O
periorbital	O
and	O
eyelid	O
peel	O
for	O
skin	O
rejuvenation	O
is	O
gaining	O
significant	O
acceptance	O
among	O
oculoplastic	O
surgeons	O
,	O
dermatologists	O
,	O
and	O
other	O
surgery	O
groups	O
.	O

In	O
spite	O
of	O
the	O
current	O
enthusiasm	O
,	O
there	O
remain	O
potentially	O
serious	O
complications	O
resulting	O
from	O
any	O
periorbital	O
peel	O
.	O

Cases	O
of	O
cicatricial	O
ectropion	O
have	O
been	O
reported	O
in	O
phenol-peeled	O
patients	O
,	O
and	O
lower	O
eyelid	O
ectropion	O
has	O
reportedly	O
occurred	O
in	O
patients	O
undergoing	O
deep	O
eyelid	O
peel	O
in	O
conjunction	O
with	O
a	O
blepharoplasty	Surgical
(	O
1,2	O
)	O
.	O

To	O
avoid	O
this	O
complication	O
,	O
it	O
is	O
necessary	O
to	O
better	O
understand	O
the	O
depth	O
of	O
the	O
wound	O
produced	O
by	O
different	O
strengths	O
and	O
combinations	O
of	O
peeling	O
agents	O
applied	O
to	O
living	O
eyelid	O
tissue	O
and	O
,	O
more	O
important	O
,	O
to	O
determine	O
the	O
concentrations	O
of	O
TCA	Pharmacological
that	O
are	O
likely	O
to	O
lead	O
to	O
cicatricial	O
ectropion	O
when	O
applied	O
in	O
a	O
consistent	O
fashion	O
.	O

We	O
chose	O
upper-eyelid	O
skin	O
because	O
it	O
is	O
easier	O
to	O
obtain	O
for	O
histopathologic	O
study	O
than	O
lower-eyelid	O
skin	O
and	O
,	O
in	O
our	O
experience	O
,	O
is	O
more	O
sensitive	O
to	O
hypertrophic	O
changes	O
after	O
chemical	O
peeling	O
or	O
carbon	O
dioxide	O
laser	O
resurfacing	O
.	O

We	O
applied	O
TCA	Pharmacological
to	O
the	O
preseptal	O
skin	O
of	O
10	O
patients	O
48	O
h	O
before	O
standard	O
upper-eyelid	O
blepharoplasty	O
.	O

The	O
acid	O
was	O
applied	O
to	O
produce	O
a	O
frost	O
,	O
using	O
varying	O
concentrations	O
of	O
acid	O
,	O
ranging	O
from	O
20	O
to	O
50	O
%	O
.	O

The	O
treated	O
skin	O
removed	O
at	O
the	O
time	O
of	O
blepharoplasty	O
was	O
reviewed	O
in	O
a	O
masked	O
fashion	O
by	O
a	O
dermatopathologist	O
to	O
determine	O
the	O
depth	O
of	O
necrosis	O
.	O

We	O
found	O
that	O
superficial	O
peels	O
with	O
necrosis	O
involving	O
30	O
%	O
of	O
the	O
epidermis	O
were	O
produced	O
by	O
the	O
lowest-concentration	O
combination	O
of	O
TCA	Pharmacological
applied	O
(	O
20	O
%	O
followed	O
by	O
0	O
%	O
)	O
.	O

As	O
the	O
strength	O
increased	O
,	O
so	O
did	O
the	O
depth	O
of	O
peel	O
.	O

The	O
combination	O
of	O
50	O
%	O
followed	O
by	O
a	O
second	O
application	O
of	O
50	O
%	O
produced	O
the	O
deepest	O
peel	O
,	O
with	O
necrosis	O
into	O
the	O
papillary	O
dermis	O
.	O

This	O
finding	O
would	O
indicate	O
that	O
the	O
chance	O
of	O
developing	O
cicatricial	O
ectropion	O
with	O
any	O
of	O
the	O
tested	O
combinations	O
of	O
TCA	Pharmacological
should	O
be	O
very	O
remote	O
.	O

Pharmacist	O
directed	O
home	Pharmacological
medication	Pharmacological
reviews	O
in	O
patients	O
with	O
chronic	O
heart	O
failure	O
:	O
a	O
randomised	O
clinical	O
trial	O
.	O

BACKGROUND	O
Chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
accounts	O
for	O
significant	O
morbidity	O
,	O
mortality	O
and	O
health	O
expenditure	O
.	O

Furthermore	O
,	O
patients	O
with	O
CHF	O
are	O
often	O
on	O
numerous	O
pharmacological	O
agents	O
for	O
their	O
comorbidities	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
a	O
pharmacist	O
directed	O
home	Pharmacological
medication	Pharmacological
review	O
intervention	O
had	O
positive	O
effects	O
on	O
CHF	O
patient	O
outcomes	O
.	O

METHODS	O
A	O
total	O
of	O
120	O
patients	O
hospitalised	O
for	O
CHF	O
were	O
randomised	O
to	O
receive	O
a	O
pharmacist	O
directed	O
post-discharge	O
home	Pharmacological
medication	Pharmacological
review	O
(	O
n	O
=	O
64	O
,	O
53.3	O
%	O
)	O
or	O
standard	Control
care	Control
(	O
n	O
=	O
56	O
,	O
46.7	O
%	O
)	O
.	O

Participants	O
were	O
followed	O
for	O
6	O
months	O
.	O

Primary	O
outcomes	O
were	O
death	O
,	O
CHF	O
hospitalisation	O
and	O
length	O
of	O
hospital	O
stay	O
.	O

RESULTS	O
There	O
were	O
no	O
between	O
group	O
differences	O
in	O
mortality	O
(	O
hazard	O
ratio	O
=	O
1.41	O
,	O
0.50	O
to	O
3.97	O
;	O
P	O
=	O
0.514	O
)	O
or	O
CHF	O
hospitalizations	O
(	O
incidence	O
rate	O
ratio	O
[	O
IRR	O
]	O
=	O
1.74	O
95	O
%	O
CI	O
:	O
0.85-3.60	O
P	O
=	O
0.131	O
)	O
over	O
the	O
6	O
month	O
follow-up	O
period	O
.	O

Days	O
of	O
hospital	O
stay	O
for	O
CHF	O
exacerbations	O
in	O
the	O
6	O
month	O
follow-up	O
were	O
significantly	O
greater	O
in	O
the	O
intervention	O
group	O
(	O
IRR	O
=	O
2.34	O
95	O
%	O
CI	O
:	O
1.80-3.05	O
P	O
=	O
0.000	O
)	O
.	O

CONCLUSIONS	O
Post-discharge	O
pharmacy	O
directed	O
home	Pharmacological
medication	Pharmacological
review	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
mortality	O
and	O
health	O
care	O
utilisation	O
above	O
that	O
achieved	O
with	O
standard	O
care	O
.	O

The	O
post-acute	O
management	O
of	O
CHF	O
must	O
be	O
a	O
collaborative	O
multi-disciplinary	O
effort	O
by	O
the	O
health	O
care	O
team	O
as	O
it	O
is	O
the	O
additive	O
effect	O
of	O
interventions	O
that	O
are	O
most	O
effective	O
.	O

Experimental	O
hyaline	O
membrane	O
disease	O
in	O
the	O
premature	O
monkey	O
:	O
effects	O
of	O
antenatal	Pharmacological
dexamethasone	Pharmacological
.	O

A	O
blind	O
,	O
randomized	O
trial	O
of	O
antenatal	Pharmacological
glucocorticoid	Pharmacological
treatment	Pharmacological
was	O
conducted	O
using	O
the	O
premature	O
monkey	O
(	O
Macaca	O
nemestrina	O
)	O
model	O
of	O
hyaline	O
membrane	O
disease	O
(	O
HMD	O
)	O
.	O

Twelve	O
dams	O
received	O
dexamethasone	Pharmacological
(	O
2	O
mg/dose	O
)	O
72	O
,	O
48	O
,	O
and	O
24	O
h	O
before	O
abdominal	O
delivery	O
at	O
135	O
+/-	O
1	O
days	O
of	O
gestation	O
.	O

Twelve	O
control	O
animals	O
received	O
saline	Control
.	O

Infants	O
of	O
dexamethasone-treated	Pharmacological
dams	O
had	O
significantly	O
lower	O
incidence	O
and	O
severity	O
of	O
HMD	O
than	O
did	O
infants	O
of	O
control	O
animals	O
(	O
50	O
versus	O
92	O
%	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Improvement	O
with	O
treatment	O
was	O
markedly	O
greater	O
for	O
males	O
than	O
for	O
females	O
.	O

Differences	O
in	O
volume-pressure	O
behavior	O
of	O
the	O
excised	O
lungs	O
included	O
greater	O
distensibility	O
in	O
the	O
infants	O
from	O
dexamethasone-treated	Pharmacological
dams	O
(	O
20.6	O
+/-	O
7.1	O
ml/g	O
dry	O
lung	O
versus	O
14.7	O
+/-	O
6.1	O
,	O
p	O
less	O
than	O
0.05	O
)	O
and	O
enhanced	O
deflation	O
stability	O
with	O
treatment	O
.	O

Accelerated	O
production	O
of	O
surface	O
active	O
material	O
(	O
SAM	O
)	O
phospholipids	O
in	O
infants	O
from	O
dexamethasone-treated	Pharmacological
dams	O
was	O
indicated	O
by	O
increases	O
in	O
total	O
lung	O
phospholipid	O
(	O
84.5	O
+/-	O
8.1	O
mg/g	O
dry	O
lung	O
versus	O
75.1	O
+/-	O
9.9	O
,	O
p	O
less	O
than	O
0.025	O
)	O
,	O
alveolar	O
lavage	O
fluid	O
phospholipid	O
(	O
5.65	O
+/-	O
3.33	O
mg/g	O
dry	O
lung	O
versus	O
3.01	O
+/-	O
1.84	O
,	O
p	O
less	O
than	O
0.05	O
)	O
,	O
and	O
alveolar	O
lavage	O
fluid	O
disaturated	O
phosphatidylcholine	O
(	O
DPC	O
)	O
(	O
2.47	O
+/-	O
1.84	O
mg/g	O
dry	O
lung	O
versus	O
1.06	O
+/-	O
1.05	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Incorporation	O
of	O
14C-palmitate	O
into	O
lung	O
lipid	O
was	O
not	O
influenced	O
by	O
dexamethasone	Pharmacological
,	O
but	O
a	O
significantly	O
greater	O
portion	O
of	O
the	O
label	O
appeared	O
in	O
the	O
DPC	O
fraction	O
with	O
treatment	O
.	O

Antenatal	Pharmacological
dexamethasone	Pharmacological
treatment	Pharmacological
was	O
successful	O
in	O
reducing	O
the	O
incidence	O
and	O
severity	O
of	O
experimental	O
HMD	O
in	O
this	O
animal	O
model	O
;	O
the	O
beneficial	O
effects	O
of	O
treatment	O
were	O
associated	O
with	O
accelerated	O
maturation	O
of	O
fetal	O
pulmonary	O
functions	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
synthetic	O
metabolism	O
of	O
SAM	O
phospholipid	O
.	O

The	O
clinical	O
and	O
biochemical	O
effects	O
of	O
propofol	Pharmacological
infusion	O
with	Pharmacological
and	Pharmacological
without	Pharmacological
EDTA	Pharmacological
for	O
maintenance	O
anesthesia	O
in	O
healthy	O
children	O
undergoing	O
ambulatory	O
surgery	O
.	O

UNLABELLED	O
We	O
conducted	O
this	O
randomized	O
,	O
double-blinded	O
,	O
comparative	O
,	O
parallel-group	O
study	O
to	O
determine	O
whether	O
adding	O
EDTA	Pharmacological
to	Pharmacological
propofol	Pharmacological
would	O
affect	O
the	O
clinical	O
profile	O
,	O
calcium	O
and	O
magnesium	O
homeostasis	O
,	O
or	O
renal	O
function	O
in	O
healthy	O
children	O
.	O

After	O
the	O
induction	Pharmacological
of	Pharmacological
anesthesia	Pharmacological
with	Pharmacological
halothane	Pharmacological
,	O
69	O
ambulatory	O
surgical	O
patients	O
(	O
1	O
mo	O
to	O
<	O
17	O
yr	O
old	O
)	O
,	O
received	O
propofol	Pharmacological
without	Pharmacological
EDTA	Pharmacological
(	O
n	O
=	O
33	O
)	O
or	O
propofol	Pharmacological
with	Pharmacological
EDTA	Pharmacological
(	O
n	O
=	O
36	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
for	O
the	O
measurement	O
of	O
ionized	O
calcium	O
,	O
ionized	O
magnesium	O
,	O
and	O
laboratory	O
indicators	O
of	O
renal	O
function	O
.	O

Hemodynamic	O
measurements	O
,	O
recovery	O
,	O
and	O
adverse	O
events	O
were	O
recorded	O
.	O

Propofol	Pharmacological
with	Pharmacological
EDTA	Pharmacological
produced	O
no	O
significant	O
effects	O
on	O
clinical	O
efficacy	O
or	O
renal	O
function	O
.	O

Propofol	Pharmacological
and	O
propofol	Pharmacological
EDTA	Pharmacological
produced	O
a	O
statistically	O
significant	O
decrease	O
from	O
baseline	O
in	O
serum	O
concentrations	O
of	O
ionized	O
calcium	O
and	O
magnesium	O
during	O
infusion	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
with	O
no	O
apparent	O
clinical	O
effect	O
.	O

Hemodynamic	O
measurements	O
generally	O
remained	O
stable	O
and	O
were	O
similar	O
for	O
both	O
groups	O
.	O

Statistically	O
significant	O
changes	O
in	O
systolic	O
blood	O
pressure	O
,	O
mean	O
arterial	O
pressure	O
,	O
and	O
heart	O
rate	O
were	O
not	O
considered	O
clinically	O
significant	O
.	O

Adverse	O
events	O
were	O
mild	O
or	O
moderate	O
.	O

The	O
addition	O
of	O
EDTA	Pharmacological
does	O
not	O
alter	O
the	O
clinical	O
profile	O
of	O
propofol	O
in	O
pediatric	O
ambulatory	O
surgical	O
patients	O
.	O

With	O
or	O
without	O
EDTA	Pharmacological
,	O
propofol	Pharmacological
is	O
associated	O
with	O
a	O
decrease	O
in	O
ionized	O
calcium	O
with	O
no	O
apparent	O
clinical	O
effect	O
.	O

IMPLICATIONS	O
The	O
addition	O
of	O
EDTA	O
does	O
not	O
alter	O
the	O
clinical	O
profile	O
of	O
propofol	O
in	O
pediatric	O
ambulatory	O
surgical	O
patients	O
.	O

With	O
or	O
without	O
EDTA	O
,	O
propofol	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
ionized	O
calcium	O
with	O
no	O
apparent	O
clinical	O
effect	O
.	O

Impact	O
on	O
learning	O
of	O
an	O
e-learning	Educational
module	Educational
on	O
leukaemia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
e-learning	Educational
resources	O
may	O
be	O
beneficial	O
for	O
complex	O
or	O
conceptually	O
difficult	O
topics	O
.	O

Leukaemia	O
is	O
one	O
such	O
topic	O
,	O
yet	O
there	O
are	O
no	O
reports	O
on	O
the	O
efficacy	O
of	O
e-learning	O
for	O
leukaemia	O
.	O

This	O
study	O
compared	O
the	O
learning	O
impact	O
on	O
senior	O
medical	O
students	O
of	O
a	O
purpose-built	O
e-learning	Educational
module	Educational
on	O
leukaemia	O
,	O
compared	O
with	O
existing	Educational
online	Educational
resources	Educational
.	Educational

METHODS	O
A	O
randomised	O
controlled	O
trial	O
was	O
performed	O
utilising	O
volunteer	O
senior	O
medical	O
students	O
.	O

Participants	O
were	O
randomly	O
allocated	O
to	O
Study	O
and	O
Control	O
groups	O
.	O

Following	O
a	O
pre-test	O
on	O
leukaemia	O
administered	O
to	O
both	O
groups	O
,	O
the	O
Study	O
group	O
was	O
provided	O
with	O
access	O
to	O
the	O
new	Educational
e-learning	Educational
module	Educational
,	O
while	O
the	O
Control	O
group	O
was	O
directed	Educational
to	Educational
existing	Educational
online	Educational
resources	Educational
.	O

A	O
post-test	O
and	O
an	O
evaluation	O
questionnaire	O
were	O
administered	O
to	O
both	O
groups	O
at	O
the	O
end	O
of	O
the	O
trial	O
period	O
.	O

RESULTS	O
Study	O
and	O
Control	O
groups	O
were	O
equivalent	O
in	O
gender	O
distribution	O
,	O
mean	O
academic	O
ability	O
,	O
pre-test	O
performance	O
and	O
time	O
studying	O
leukaemia	O
during	O
the	O
trial	O
.	O

The	O
Study	O
group	O
performed	O
significantly	O
better	O
than	O
the	O
Control	O
group	O
in	O
the	O
post-test	O
,	O
in	O
which	O
the	O
group	O
to	O
which	O
the	O
students	O
had	O
been	O
allocated	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
performance	O
.	O

The	O
Study	O
group	O
's	O
evaluation	O
of	O
the	O
module	O
was	O
overwhelmingly	O
positive	O
.	O

CONCLUSIONS	O
A	O
targeted	O
e-learning	Educational
module	Educational
on	O
leukaemia	O
had	O
a	O
significant	O
effect	O
on	O
learning	O
in	O
this	O
cohort	O
,	O
compared	O
with	O
existing	O
online	O
resources	O
.	O

We	O
believe	O
that	O
the	O
interactivity	O
,	O
dialogic	O
feedback	O
and	O
integration	O
with	O
the	O
curriculum	O
offered	O
by	O
the	O
e-learning	Educational
module	Educational
contributed	O
to	O
its	O
impact	O
.	O

This	O
has	O
implications	O
for	O
e-learning	Educational
design	O
in	O
medicine	O
and	O
other	O
disciplines	O
.	O

The	O
effect	O
of	O
leukocyte	Physical
reduction	Physical
filters	Physical
on	O
inflammatory	O
mediator	O
release	O
during	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

BACKGROUND	O
Extracorporeal	O
circulation	O
used	O
during	O
coronary	O
artery	O
bypass	O
grafting	O
triggers	O
systemic	O
inflammatory	O
response	O
with	O
neutrophil	O
activation	O
which	O
adversely	O
affects	O
ischaemic/reperfused	O
myocardium	O
.	O

One	O
method	O
of	O
myocardial	O
protection	O
during	O
cardiac	O
surgery	O
is	O
the	O
use	O
of	O
blood	O
cardioplegia	O
.	O

Its	O
protective	O
effect	O
is	O
related	O
to	O
cardiac	O
cooling	O
and	O
metabolism	O
reduction	O
,	O
oxygen	O
supply	O
from	O
erythrocytes	O
,	O
and	O
reactive	O
oxygen	O
species	O
scavenging	O
.	O

However	O
,	O
blood	O
cardioplegia	O
is	O
also	O
associated	O
with	O
myocardial	O
damage	O
induced	O
by	O
undesirable	O
morphotic	O
blood	O
elements	O
.	O

AIM	O
To	O
evaluate	O
the	O
effect	O
of	O
the	O
use	O
of	O
leukocyte	Physical
reduction	Physical
filters	Physical
on	O
the	O
activity	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
in	O
patients	O
undergoing	O
surgical	O
myocardial	O
revascularisation	O
.	O

PMN	O
activity	O
was	O
evaluated	O
based	O
on	O
measurements	O
of	O
plasma	O
activity	O
of	O
granulocyte	O
enzymes	O
,	O
lysozyme	O
and	O
beta-glucuronidase	O
.	O

METHODS	O
We	O
studied	O
40	O
patients	O
who	O
underwent	O
myocardial	O
revascularisation	O
using	O
extracorporeal	Physical
circulation	Physical
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
two	O
equal	O
groups	O
:	O
in	O
Group	O
I	O
,	O
blood	O
cardioplegia	O
was	O
administered	O
using	O
leukocyte	O
reduction	O
filters	O
,	O
and	O
in	O
Group	O
II	O
,	O
leukocyte	Physical
reduction	Physical
filters	Physical
were	Physical
not	Physical
used	Physical
for	Physical
blood	Physical
cardioplegia	Physical
.	O

Measurements	O
were	O
performed	O
in	O
plasma	O
of	O
arterial	O
and	O
coronary	O
sinus	O
blood	O
samples	O
collected	O
before	O
aortic	O
clamping	O
,	O
immediately	O
after	O
unclamping	O
,	O
and	O
after	O
25	O
min	O
of	O
reperfusion	O
.	O

In	O
addition	O
,	O
blood	O
cardioplegic	O
solution	O
samples	O
were	O
collected	O
in	O
Group	O
I	O
from	O
the	O
lines	O
proximal	O
and	O
distal	O
to	O
the	O
filter	O
during	O
first	O
and	O
last	O
administration	O
.	O

Plasma	O
levels	O
of	O
lysozyme	O
and	O
beta-glucuronidase	O
were	O
determined	O
using	O
previously	O
described	O
methods	O
.	O

RESULTS	O
We	O
found	O
a	O
significant	O
decrease	O
in	O
PMN	O
count	O
in	O
filtered	O
blood	O
cardioplegic	O
solution	O
during	O
its	O
first	O
administration	O
(	O
0.27	O
?	O
0.07	O
G/L	O
)	O
compared	O
to	O
samples	O
collected	O
before	O
filter	O
passage	O
(	O
1.73	O
?	O
0.049	O
G/L	O
)	O
.	O

Also	O
during	O
last	O
administration	O
,	O
PMN	O
count	O
in	O
filtered	O
blood	O
cardioplegic	O
solution	O
was	O
decreased	O
compared	O
to	O
samples	O
collected	O
before	O
filter	O
passage	O
(	O
0.66	O
?	O
0.35	O
G/L	O
vs.	O
3.64	O
?	O
1.14	O
G/L	O
,	O
respectively	O
)	O
.	O

Significantly	O
lower	O
(	O
p	O
<	O
0.02	O
)	O
plasma	O
beta-glucuronidase	O
levels	O
were	O
found	O
in	O
arterial	O
blood	O
samples	O
in	O
Group	O
I	O
compared	O
to	O
Group	O
II	O
(	O
5.59	O
?	O
1.63	O
?g/mL	O
immediately	O
after	O
aortic	O
unclamping	O
and	O
6.59	O
?	O
1.98	O
?g/mL	O
after	O
25	O
min	O
of	O
reperfusion	O
in	O
Group	O
I	O
vs.	O
10.19	O
?	O
2.66	O
and	O
12.83	O
?	O
1.88	O
?g/mL	O
,	O
respectively	O
,	O
in	O
Group	O
II	O
)	O
.	O

Beta-glucuronidase	O
levels	O
in	O
coronary	O
sinus	O
blood	O
samples	O
collected	O
after	O
aortic	O
unclamping	O
and	O
at	O
the	O
end	O
of	O
reperfusion	O
were	O
significantly	O
higher	O
in	O
Group	O
II	O
compared	O
to	O
Group	O
I	O
(	O
p	O
<	O
0.04	O
)	O
.	O

In	O
Group	O
I	O
,	O
plasma	O
lysozyme	O
levels	O
in	O
arterial	O
and	O
venous	O
blood	O
samples	O
did	O
not	O
show	O
significant	O
changes	O
during	O
the	O
surgery	O
.	O

In	O
contrast	O
,	O
plasma	O
lysozyme	O
level	O
in	O
coronary	O
sinus	O
blood	O
samples	O
at	O
the	O
end	O
of	O
reperfusion	O
in	O
Group	O
II	O
was	O
significantly	O
higher	O
compared	O
to	O
that	O
in	O
pre-clamping	O
samples	O
(	O
p	O
<	O
0.014	O
)	O
.	O

CONCLUSIONS	O
With	O
the	O
use	O
of	O
leukocyte	O
reduction	O
filters	O
,	O
we	O
found	O
significantly	O
lower	O
beta-glucuronidase	O
levels	O
in	O
arterial	O
and	O
coronary	O
sinus	O
blood	O
samples	O
.	O

These	O
findings	O
seem	O
to	O
confirm	O
reduced	O
PMN	O
activation	O
and/or	O
reduced	O
myocardial	O
infiltration	O
by	O
activated	O
PMN	O
.	O

Plasma	O
levels	O
of	O
lysozyme	O
,	O
a	O
characteristic	O
product	O
of	O
PMN	O
degranulation	O
,	O
did	O
not	O
show	O
significant	O
differences	O
between	O
the	O
study	O
groups	O
.	O

Once-daily	O
topical	Pharmacological
brimonidine	Pharmacological
tartrate	Pharmacological
gel	Pharmacological
0?5	O
%	O
is	O
a	O
novel	O
treatment	O
for	O
moderate	O
to	O
severe	O
facial	O
erythema	O
of	O
rosacea	O
:	O
results	O
of	O
two	O
multicentre	O
,	O
randomized	O
and	O
vehicle-controlled	O
studies	O
.	O

BACKGROUND	O
Erythema	O
of	O
rosacea	O
is	O
thought	O
to	O
result	O
from	O
abnormal	O
cutaneous	O
vasomotor	O
activity	O
.	O

Brimonidine	O
tartrate	O
(	O
BT	O
)	O
is	O
a	O
highly	O
selective	O
?	O
(	O
2	O
)	O
-adrenergic	O
receptor	O
agonist	O
with	O
vasoconstrictive	O
activity	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
optimal	O
concentration	O
and	O
dose	O
regimen	O
of	O
topical	O
BT	O
gel	O
for	O
the	O
treatment	O
of	O
erythema	O
of	O
rosacea	O
and	O
to	O
evaluate	O
its	O
efficacy	O
and	O
safety	O
.	O

METHODS	O
In	O
study	O
A	O
,	O
122	O
subjects	O
were	O
randomized	O
to	O
receive	O
a	O
single	O
application	O
of	O
BT	O
0?07	O
%	O
,	O
0?18	O
%	O
,	O
0?5	O
%	O
or	O
vehicle	O
.	O

In	O
study	O
B	O
(	O
4-week	O
treatment	O
and	O
4-week	O
follow-up	O
)	O
,	O
269	O
subjects	O
were	O
randomized	O
to	O
receive	O
BT	O
0?5	O
%	O
once	O
daily	O
,	O
BT	O
0?18	O
%	O
once	O
daily	O
,	O
vehicle	O
once	O
daily	O
,	O
BT	O
0?18	O
%	O
twice	O
daily	O
or	O
vehicle	O
twice	O
daily	O
.	O

Evaluations	O
included	O
Clinician	O
's	O
Erythema	O
Assessment	O
(	O
CEA	O
)	O
,	O
Patient	O
's	O
Self-Assessment	O
(	O
PSA	O
)	O
,	O
Chroma	O
Meter	O
measurements	O
and	O
adverse	O
events	O
.	O

RESULTS	O
In	O
study	O
A	O
,	O
a	O
single	O
application	O
of	O
topical	O
BT	O
gel	O
reduced	O
facial	O
erythema	O
in	O
a	O
dose-dependent	O
fashion	O
.	O

A	O
significant	O
difference	O
between	O
BT	O
0?5	O
%	O
and	O
vehicle	O
in	O
Chroma	O
Meter	O
redness	O
value	O
was	O
observed	O
from	O
30min	O
to	O
12h	O
after	O
application	O
.	O

In	O
study	O
B	O
,	O
BT	O
0?5	O
%	O
once	O
daily	O
had	O
a	O
statistically	O
superior	O
success	O
profile	O
(	O
defined	O
as	O
a	O
two-grade	O
improvement	O
on	O
both	O
CEA	O
and	O
PSA	O
over	O
12h	O
)	O
compared	O
with	O
vehicle	O
once	O
daily	O
on	O
days	O
1	O
,	O
15	O
and	O
29	O
(	O
all	O
P	O
<	O
0?001	O
)	O
.	O

No	O
tachyphylaxis	O
,	O
rebound	O
of	O
erythema	O
or	O
aggravation	O
of	O
other	O
disease	O
signs	O
(	O
telangiectasia	O
,	O
inflammatory	O
lesions	O
)	O
was	O
observed	O
.	O

All	O
regimens	O
were	O
safe	O
and	O
well	O
tolerated	O
with	O
similarly	O
low	O
incidence	O
of	O
adverse	O
events	O
.	O

CONCLUSIONS	O
Once-daily	O
BT	O
gel	O
0?5	O
%	O
is	O
well	O
tolerated	O
and	O
provides	O
significantly	O
greater	O
efficacy	O
than	O
vehicle	O
gel	O
for	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
erythema	O
of	O
rosacea	O
.	O

Engagement	Educational
with	Educational
electronic	Educational
screen	Educational
media	Educational
among	O
students	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
investigated	O
the	O
relative	O
engagement	O
potential	O
of	O
four	O
types	O
of	O
electronic	Educational
screen	Educational
media	Educational
(	Educational
ESM	Educational
)	Educational
:	Educational
animated	Educational
video	Educational
,	Educational
video	Educational
of	Educational
self	Educational
,	Educational
video	Educational
of	Educational
a	Educational
familiar	Educational
person	Educational
engaged	Educational
with	Educational
an	Educational
immersive	Educational
virtual	Educational
reality	Educational
(	Educational
VR	Educational
)	Educational
game	Educational
,	Educational
and	Educational
immersion	Educational
of	Educational
self	Educational
in	Educational
the	Educational
VR	Educational
game	Educational
.	Educational

Forty-two	O
students	O
with	O
autism	O
,	O
varying	O
in	O
age	O
and	O
expressive	O
communication	O
ability	O
,	O
were	O
randomly	O
assigned	O
to	O
the	O
experimental	O
conditions	O
.	O

Gaze	O
duration	O
and	O
vocalization	O
served	O
as	O
dependent	O
measures	O
of	O
engagement	O
.	O

The	O
results	O
reveal	O
differential	O
responding	O
across	O
ESM	Educational
,	O
with	O
some	O
variation	O
related	O
to	O
the	O
engagement	O
metric	O
employed	O
.	O

Preferences	O
for	O
seeing	O
themselves	O
on	O
the	O
screen	O
,	O
as	O
well	O
as	O
for	O
viewing	O
the	O
VR	Educational
scenarios	O
,	O
emerged	O
from	O
the	O
data	O
.	O

While	O
the	O
study	O
did	O
not	O
yield	O
definitive	O
data	O
about	O
the	O
relative	O
engagement	O
potential	O
of	O
ESM	Educational
alternatives	O
,	O
it	O
does	O
provide	O
a	O
foundation	O
for	O
future	O
research	O
,	O
including	O
guidance	O
related	O
to	O
participant	O
profiles	O
,	O
stimulus	O
characteristics	O
,	O
and	O
data	O
coding	O
challenges	O
.	O

Activation	O
of	O
the	O
carotid	O
chemoreflex	O
secondary	O
to	O
muscle	O
metaboreflex	O
stimulation	O
in	O
men	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
the	O
carotid	O
chemoreceptor	O
(	O
CC	O
)	O
contributes	O
to	O
sympathetic	O
control	O
of	O
cardiovascular	O
function	O
during	O
exercise	O
,	O
despite	O
no	O
evidence	O
of	O
increased	O
circulating	O
CC	O
stimuli	O
,	O
suggesting	O
enhanced	O
CC	O
activity/sensitivity	O
.	O

As	O
interactions	O
between	O
metaboreceptors	O
and	O
chemoreceptors	O
have	O
been	O
previously	O
observed	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
isolate	O
the	O
metaboreflex	O
while	O
acutely	O
stimulating	O
or	O
inhibiting	O
the	O
CC	O
to	O
determine	O
whether	O
the	O
metaboreflex	O
increased	O
CC	O
activity/sensitivity	O
.	O

Fourteen	O
young	O
healthy	O
men	O
(	O
height	O
:	O
177.0	O
?	O
2.1	O
cm	O
,	O
weight	O
:	O
85.8	O
?	O
5.5	O
kg	O
,	O
age	O
:	O
24.6	O
?	O
1.1	O
yr	O
)	O
performed	O
three	O
trials	O
of	O
40	O
%	O
maximal	O
voluntary	O
contraction	O
handgrip	O
for	O
2	O
min	O
,	O
followed	O
by	O
3	O
min	O
of	O
postexercise	O
circulatory	O
occlusion	O
(	O
PECO	O
)	O
to	O
stimulate	O
the	O
metaboreflex	O
.	O

In	O
random	O
order	O
,	O
subjects	O
either	O
breathed	O
room	O
air	O
,	O
hypoxia	O
(	O
target	O
SPo2	O
=	O
85	O
%	O
)	O
,	O
or	O
hyperoxia	O
(	O
FiO2	O
=	O
1.0	O
)	O
during	O
the	O
PECO	O
to	O
modulate	O
the	O
chemoreflex	O
.	O

After	O
these	O
trials	O
,	O
a	O
resting	O
hypoxia	O
trial	O
was	O
conducted	O
without	O
handgrip	O
or	O
PECO	O
.	O

Ventilation	O
(	O
Ve	O
)	O
,	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
blood	O
pressure	O
,	O
and	O
muscle	O
sympathetic	O
nervous	O
activity	O
(	O
MSNA	O
)	O
data	O
were	O
continuously	O
obtained	O
.	O

Relative	O
to	O
normoxic	O
PECO	O
,	O
inhibition	O
of	O
the	O
CC	O
during	O
hyperoxic	O
PECO	O
resulted	O
in	O
lower	O
MSNA	O
(	O
P	O
=	O
0.038	O
)	O
and	O
HR	O
(	O
P	O
=	O
0.021	O
)	O
.	O

Relative	O
to	O
normoxic	O
PECO	O
,	O
stimulation	O
of	O
the	O
CC	O
during	O
hypoxic	O
PECO	O
resulted	O
in	O
higher	O
HR	O
(	O
P	O
<	O
0.001	O
)	O
and	O
Ve	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
ventilatory	O
and	O
MSNA	O
responses	O
to	O
hypoxic	O
PECO	O
were	O
not	O
greater	O
than	O
the	O
sum	O
of	O
the	O
responses	O
to	O
hypoxia	O
and	O
PECO	O
individually	O
,	O
indicating	O
that	O
the	O
CC	O
are	O
not	O
sensitized	O
during	O
metaboreflex	O
activation	O
.	O

These	O
results	O
demonstrate	O
that	O
stimulation	O
of	O
the	O
metaboreflex	O
activates	O
,	O
but	O
does	O
not	O
sensitize	O
the	O
CC	O
,	O
and	O
help	O
explain	O
the	O
enhanced	O
CC	O
activity	O
with	O
exercise	O
.	O

[	Pharmacological
Local	Pharmacological
therapy	Pharmacological
of	Pharmacological
grade	Pharmacological
1	Pharmacological
and	Pharmacological
2	Pharmacological
hemorrhoids	Pharmacological
.	Pharmacological

Effectiveness	O
of	O
a	O
combination	Pharmacological
preparation	Pharmacological
with	Pharmacological
standardized	Pharmacological
blood	Pharmacological
leech	Pharmacological
extract	Pharmacological
]	Pharmacological
.	O

AIMS	O
Testing	O
the	O
effectiveness	O
of	O
a	O
topical	Pharmacological
combination	Pharmacological
preparation	Pharmacological
containing	Pharmacological
standardized	Pharmacological
leech	Pharmacological
extract	Pharmacological
,	Pharmacological
polidocanol	Pharmacological
and	Pharmacological
allantoin	Pharmacological
.	Pharmacological

STUDY	O
DESIGN	O
Placebo-controlled	Control
,	O
double-blind	O
study	O
in	O
80	O
patients	O
with	O
first	O
and	O
second	O
degree	O
hemorrhoids	O
;	O
duration	O
of	O
treatment	O
one	O
week	O
;	O
examinations	O
performed	O
on	O
admission	O
and	O
on	O
days	O
3	O
,	O
4	O
,	O
5	O
and	O
8	O
.	O

RESULTS	O
Both	O
the	O
subjective	O
and	O
objective	O
symptoms	O
and	O
signs	O
improved	O
during	O
the	O
one	O
week	O
of	O
treatment	O
statistically	O
significantly	O
more	O
rapidly	O
under	O
the	O
test	Educational
preparation	Educational
as	O
compared	O
with	O
placebo	O
.	O

Histologically	O
demonstrable	O
signs	O
of	O
inflammation	O
were	O
more	O
clearly	O
improved	O
in	O
the	O
preparation	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

No	O
side	O
effects	O
were	O
observed	O
.	O

CONCLUSIONS	O
The	O
good	O
efficacy	O
and	O
tolerability	O
of	O
a	O
topical	Pharmacological
therapeutic	Pharmacological
preparation	Pharmacological
in	O
first	O
and	O
second	O
degree	O
hemorrhoids	O
have	O
been	O
convincingly	O
demonstrated	O
.	O

Efficiency	Physical
of	Physical
adjuvant	Physical
immunochemotherapy	Physical
following	O
curative	O
resection	O
in	O
patients	O
with	O
locally	O
advanced	O
gastric	O
cancer	O
.	O

BACKGROUND	O
Despite	O
curative	O
resection	O
,	O
50	O
%	O
-90	O
%	O
of	O
gastric	O
cancer	O
patients	O
die	O
of	O
disease	O
relapse	O
.	O

Although	O
some	O
clinical	O
trials	O
have	O
indicated	O
that	O
chemotherapy	O
and	O
immunochemotherapy	O
may	O
be	O
effective	O
modalities	O
,	O
more	O
recent	O
studies	O
have	O
not	O
been	O
able	O
to	O
define	O
the	O
standard	O
treatment	O
for	O
advanced	O
gastric	O
cancer	O
.	O

The	O
present	O
study	O
evaluated	O
the	O
effect	O
of	O
adjuvant	Physical
immunochemotherapy	Physical
with	Physical
the	Physical
use	Physical
of	Physical
BCG	Pharmacological
(	Pharmacological
bacille	Pharmacological
Calmette-Guerin	Pharmacological
)	Pharmacological
and	O
FAM	Pharmacological
(	O
5-fluorouracil	Pharmacological
,	O
adriamycin	Pharmacological
,	O
mitomycin	Pharmacological
C	Pharmacological
)	O
chemotherapy	Pharmacological
on	O
the	O
survival	O
of	O
patients	O
with	O
locally	O
advanced	O
resectable	O
gastric	O
cancer	O
.	O

METHODS	O
A	O
total	O
of	O
156	O
patients	O
with	O
stage	O
III	O
or	O
IV	O
gastric	O
cancer	O
who	O
had	O
undergone	O
curative	O
resection	O
were	O
randomly	Pharmacological
assigned	Pharmacological
to	Pharmacological
three	Pharmacological
treatment	Pharmacological
groups	Pharmacological
:	Pharmacological
BCG	Pharmacological
+	Pharmacological
FAM	Pharmacological
(	O
immunochemotherapy	Pharmacological
)	O
,	O
FAM	O
(	O
chemotherapy	Pharmacological
)	O
,	O
and	O
control	Surgical
(	Surgical
surgery	Surgical
only	Surgical
)	Surgical
.	O

Treatment	Other
was	Other
continued	Other
for	Other
2	Other
years	Other
or	Other
until	Other
death	Other
.	O

Further	Other
postsurgical	Other
follow	Other
up	Other
was	Other
carried	Other
on	Other
for	Other
up	Other
to	Other
10	Other
years	Other
.	O

RESULTS	O
Overall	O
10-year	O
survival	O
was	O
47.1	O
%	O
for	O
the	O
immunochemotherapy	O
group	O
(	O
P	O
<	O
0.037	O
vs	O
FAM	Physical
and	O
P	O
<	O
0.0006	O
vs	O
control	O
)	O
,	O
30	O
%	O
for	O
the	O
chemotherapy	Physical
group	O
(	O
vs	O
control	O
,	O
NS	O
)	O
,	O
and	O
15.2	O
%	O
for	O
the	O
control	O
group	O
.	O

In	O
patients	O
with	O
pT2/T3	O
primary	O
tumors	O
,	O
10-year	O
survival	O
was	O
55.3	O
%	O
for	O
BCG	Physical
+	Physical
FAM	Physical
vs	O
28.2	O
%	O
for	O
FAM	O
(	O
P	O
<	O
0.01	O
)	O
and	O
14.6	O
%	O
for	O
the	O
control	O
group	O
(	O
P	O
<	O
0.00018	O
)	O
.	O

BCG	O
+	O
FAM	O
significantly	O
improved	O
the	O
survival	O
of	O
patients	O
with	O
intestinal-type	O
but	O
not	O
diffuse-type	O
cancer	O
.	O

Immunochemotherapy	O
was	O
well	O
tolerated	O
.	O

CONCLUSION	O
This	O
study	O
,	O
based	O
on	O
a	O
limited	O
number	O
of	O
patients	O
,	O
indicates	O
that	O
adjuvant	O
immunochemotherapy	O
(	O
BCG	O
+	O
FAM	O
)	O
may	O
prolong	O
the	O
survival	O
of	O
gastric	O
cancer	O
patients	O
after	O
curative	O
gastrectomy	O
;	O
in	O
particular	O
,	O
in	O
patients	O
with	O
pT2/T3	O
tumors	O
and	O
intestinal-type	O
primary	O
tumors	O
.	O

There	O
was	O
no	O
survival	O
benefit	O
from	O
FAM	O
adjuvant	O
chemotherapy	O
.	O

[	O
Effect	O
of	O
zengjing	O
no	O
.	O

1	O
capsule	O
on	O
morphology	O
and	O
motility	O
of	O
sperm	O
in	O
patients	O
with	O
oligospermia	O
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
effect	O
of	O
Zengjing	Pharmacological
Capsule	Pharmacological
No	Pharmacological
.	Pharmacological

1	Pharmacological
(	Pharmacological
ZJC1	Pharmacological
)	Pharmacological
on	O
morphology	O
and	O
motility	O
of	O
sperm	O
in	O
patients	O
with	O
oligospermia	O
(	O
OSM	O
)	O
.	O

METHODS	O
Seventy-two	O
OSM	O
patients	O
were	O
assigned	O
to	O
2	O
groups	O
by	O
a	O
randomizing	O
digital	O
table	O
,	O
the	O
treated	O
group	O
and	O
the	O
control	O
group	O
,	O
they	O
were	O
treated	O
respectively	O
by	O
ZJC1	Pharmacological
and	O
Wuzi	Pharmacological
Yanzong	Pharmacological
Pill	Pharmacological
(	O
WYP	O
)	O
.	O

The	O
changes	O
of	O
density	O
,	O
motility	O
and	O
morphology	O
of	O
sperm	O
in	O
patients	O
before	O
and	O
after	O
3-month	O
treatment	O
were	O
examined	O
using	O
computerized	O
WLJY-9000	O
colour	O
semen	O
analysis	O
system	O
with	O
refined	O
Papanicolaou	O
's	O
stain	O
.	O

RESULTS	O
The	O
density	O
,	O
motility	O
and	O
morphology	O
of	O
sperm	O
were	O
improved	O
and	O
sperm	O
deformity	O
rate	O
was	O
significantly	O
decreased	O
after	O
treatment	O
in	O
both	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
the	O
effects	O
in	O
the	O
treated	O
group	O
were	O
better	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
ZJC1	Pharmacological
can	O
enhance	O
the	O
density	O
and	O
motility	O
of	O
sperm	O
and	O
reduce	O
the	O
sperm	O
deformity	O
rate	O
in	O
patients	O
with	O
OSM	O
.	O

Assessment	O
of	O
therapeutic	O
response	O
of	O
Plasmodium	O
falciparum	O
to	O
chloroquine	Pharmacological
and	O
sulfadoxine-pyrimethamine	Pharmacological
in	O
an	O
area	O
of	O
low	O
malaria	O
transmission	O
in	O
Colombia	O
.	O

Although	O
chloroquine	Pharmacological
(	O
CQ	O
)	O
resistance	O
was	O
first	O
reported	O
in	O
Colombia	O
in	O
1961	O
and	O
sulfadoxine-pyrimethamine	Pharmacological
(	O
SP	O
)	O
resistance	O
in	O
1981	O
,	O
the	O
frequency	O
of	O
treatment	O
failures	O
to	O
these	O
drugs	O
in	O
Colombia	O
is	O
unclear	O
.	O

A	O
modified	O
World	O
Health	O
Organization	O
14-day	O
in	O
vivo	O
drug	O
efficacy	O
test	O
for	O
uncomplicated	O
Plasmodium	O
falciparum	O
malaria	O
in	O
areas	O
with	O
intense	O
malaria	O
transmission	O
was	O
adapted	O
to	O
reflect	O
the	O
clinical	O
and	O
epidemiologic	O
features	O
of	O
a	O
low-intensity	O
malaria	O
transmission	O
area	O
in	O
the	O
Pacific	O
Coast	O
Region	O
of	O
Colombia	O
.	O

Patients	O
>	O
or	O
=1	O
year	O
of	O
age	O
with	O
a	O
parasite	O
density	O
>	O
or	O
=1,000	O
asexual	O
parasites	O
per	O
microliter	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Forty-four	O
percent	O
(	O
24	O
of	O
54	O
)	O
of	O
the	O
CQ-treated	Pharmacological
patients	O
were	O
therapeutic	O
failures	O
,	O
including	O
7	O
early	O
treatment	O
failures	O
(	O
ETFs	O
)	O
and	O
17	O
late	O
treatment	O
failures	O
(	O
LTFs	O
)	O
.	O

Four	O
(	O
6	O
%	O
)	O
of	O
67	O
SP-treated	O
patients	O
were	O
therapeutic	O
failures	O
(	O
2	O
ETFs	O
and	O
2	O
LTFs	O
)	O
.	O

Therapeutic	O
failure	O
in	O
the	O
CQ-treated	Pharmacological
group	O
was	O
associated	O
with	O
an	O
age	O
<	O
15	O
years	O
old	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
was	O
not	O
associated	O
with	O
initial	O
parasite	O
density	O
,	O
the	O
presence	O
of	O
CQ	Pharmacological
or	O
sulfa-containing	O
drugs	O
in	O
urine	O
,	O
or	O
a	O
history	O
of	O
malaria	O
.	O

The	O
high	O
level	O
of	O
therapeutic	O
failures	O
to	O
CQ	Pharmacological
detected	O
in	O
this	O
study	O
underscores	O
the	O
need	O
and	O
importance	O
of	O
drug	O
efficacy	O
evaluation	O
in	O
the	O
development	O
of	O
a	O
rational	O
national	O
antimalarial	O
drug	O
policy	O
.	O

The	O
relatively	O
low	O
level	O
of	O
therapeutic	O
failures	O
to	O
SP	O
compared	O
with	O
other	O
South	O
American	O
countries	O
raises	O
further	O
questions	O
regarding	O
factors	O
that	O
might	O
have	O
prevented	O
the	O
rapid	O
development	O
of	O
in	O
vivo	O
resistance	O
to	O
this	O
drug	O
combination	O
.	O

Effect	O
of	O
membrane	O
permeability	O
on	O
inflammation	O
and	O
arterial	O
stiffness	O
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Both	O
larger	O
molecule	O
removal	O
and	O
dialyzer	O
biocompatibility	O
have	O
been	O
implicated	O
in	O
the	O
high-flux	Physical
hemodialysis	Physical
(	O
HD	O
)	O
-associated	O
favorable	O
outcome	O
.	O

In	O
an	O
attempt	O
to	O
delineate	O
the	O
effect	O
of	O
membrane	O
permeability	O
,	O
we	O
performed	O
a	O
randomized	O
,	O
crossover	O
study	O
to	O
compare	O
the	O
inflammatory	O
biomarkers	O
,	O
lipid	O
profile	O
,	O
and	O
aortic	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
of	O
two	O
dialyzers	O
that	O
are	O
composed	O
of	O
identical	O
membranes	O
but	O
with	O
different	O
flux	O
characteristics	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
PARTICIPANTS	O
,	O
&	O
MEASUREMENTS	O
Stable	O
patients	O
who	O
had	O
anuria	O
and	O
were	O
on	O
low-flux	O
polysulfone	O
membrane	O
were	O
randomly	O
allocated	O
either	O
to	O
HD	Physical
with	Physical
high-flux	Physical
polyamide	Physical
membrane	Physical
(	O
group	O
A	O
;	O
22	O
patients	O
)	O
or	O
to	O
HD	Physical
with	Physical
low-flux	Physical
polyamide	Physical
membrane	Physical
(	O
group	O
B	O
;	O
24	O
patients	O
)	O
for	O
24	O
weeks	O
,	O
then	O
they	O
were	O
started	O
on	O
24	O
weeks	O
of	O
the	O
alternative	Physical
HD	Physical
treatment	Physical
.	O

Apart	O
from	O
the	O
dialyzer	O
,	O
the	O
dialysis	O
prescription	O
remained	O
unchanged	O
.	O

RESULTS	O
Nineteen	O
patients	O
from	O
group	O
A	O
and	O
23	O
patients	O
from	O
group	O
B	O
completed	O
the	O
study	O
.	O

Predialysis	O
beta	O
(	O
2	O
)	O
-microglobulin	O
levels	O
decreased	O
significantly	O
when	O
using	O
the	O
high-flux	Physical
polyamide	Physical
membrane	Physical
.	O

No	O
difference	O
between	O
membranes	O
was	O
observed	O
for	O
serum	O
albumin	O
,	O
high-sensitivity	O
C-reactive	O
protein	O
,	O
fibrinogen	O
,	O
IL-6	O
,	O
triglycerides	O
,	O
HDL	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
and	O
lipoprotein	O
(	O
a	O
)	O
during	O
the	O
study	O
.	O

A	O
significant	O
increase	O
in	O
aortic	O
PWV	O
,	O
a	O
marker	O
of	O
aortic	O
stiffness	O
,	O
was	O
noted	O
after	O
patients	O
switched	O
from	O
high-flux	Physical
to	O
low-flux	Physical
polyamide	Physical
membranes	Physical
.	O

Similarly	O
,	O
the	O
rate	O
of	O
change	O
in	O
aortic	O
PWV	O
was	O
significantly	O
decreased	O
with	O
the	O
use	O
of	O
the	O
high-flux	Physical
polyamide	Physical
membrane	Physical
.	O

CONCLUSIONS	O
Our	O
findings	O
suggest	O
that	O
dialysis	O
with	O
polyamide	Physical
membranes	Physical
with	O
different	O
flux	O
characteristics	O
did	O
not	O
modify	O
the	O
inflammatory	O
indices	O
and	O
lipid	O
profile	O
in	O
stable	O
HD	O
patients	O
;	O
however	O
,	O
a	O
seemingly	O
beneficial	O
effect	O
on	O
aortic	O
stiffness	O
was	O
noted	O
for	O
patients	O
who	O
were	O
maintained	O
on	O
high-flux	Physical
polyamide	Physical
membrane	Physical
.	O

The	O
relationship	O
between	O
physical	O
activity	O
level	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
functional	O
ability	O
in	O
children	O
and	O
adolescents	O
with	O
juvenile	O
idiopathic	O
arthritis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
relationships	O
between	O
physical	O
activity	O
level	O
and	O
anxiety	O
,	O
depression	O
,	O
and	O
functional	O
ability	O
in	O
children	O
and	O
adolescents	O
with	O
juvenile	O
idiopathic	O
arthritis	O
(	O
JIA	O
)	O
.	O

Cross-sectional	Educational
study	Educational
design	O
including	O
patients	O
with	O
JIA	O
aged	O
between	O
8	O
and	O
17	O
years	O
and	O
healthy	O
controls	O
was	O
used	O
.	O

Sociodemographic	O
data	O
and	O
clinical	O
features	O
were	O
assessed	O
.	O

Physical	O
activity	O
level	O
and	O
energy	O
expenditure	O
were	O
assessed	O
with	O
a	O
1-day	O
activity	O
diary	O
.	O

Anxiety	O
was	O
screened	O
by	O
The	O
Screen	O
for	O
Child	O
Anxiety	O
Related	O
Emotional	O
Disorders	O
(	O
SCARED	O
)	O
questionnaire	O
.	O

Depressive	O
symptoms	O
were	O
assessed	O
by	O
the	O
Children	O
's	O
Depression	O
Inventory	O
(	O
CDI	O
)	O
.	O

Functional	O
ability	O
was	O
assessed	O
with	O
the	O
Childhood	O
Health	O
Assessment	O
Questionnaire	O
(	O
CHAQ	O
)	O
.	O

Pain	O
and	O
overall	O
well-being	O
were	O
measured	O
using	O
a	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
.	O

Fifty-two	O
patients	O
and	O
48	O
controls	O
were	O
included	O
with	O
a	O
mean	O
age	O
of	O
12.13	O
?	O
2.92	O
and	O
11.27	O
?	O
1.59	O
years	O
,	O
respectively	O
.	O

The	O
mean	O
disease	O
duration	O
was	O
64	O
months	O
.	O

The	O
JIA	O
group	O
had	O
significantly	O
less	O
time	O
in	O
physical	O
activity	O
(	O
p	O
=	O
0.000	O
)	O
,	O
decrease	O
in	O
energy	O
expenditure	O
(	O
p	O
=	O
0.04	O
)	O
,	O
and	O
higher	O
CHAQ	O
scores	O
(	O
p	O
=	O
0.000	O
)	O
compared	O
with	O
the	O
control	O
group	O
.	O

In	O
the	O
JIA	O
group	O
,	O
significant	O
relationships	O
were	O
found	O
between	O
the	O
number	O
of	O
active	O
joint	O
and	O
disease	O
duration	O
(	O
r	O
=	O
0.44	O
,	O
p	O
=	O
0.000	O
)	O
and	O
VAS	O
pain	O
(	O
r	O
=	O
0.30	O
,	O
p	O
=	O
0.02	O
)	O
,	O
between	O
SCARED	O
and	O
CDI	O
(	O
r	O
=	O
0.54	O
,	O
p	O
=	O
0.000	O
)	O
.	O

Significant	O
relationships	O
were	O
found	O
between	O
VAS	O
overall	O
well-being	O
and	O
CDI	O
(	O
r	O
=	O
0.29	O
,	O
p	O
=	O
0.03	O
)	O
,	O
CHAQ	O
(	O
r	O
=	O
0.37	O
,	O
p	O
=	O
0.000	O
)	O
,	O
and	O
VAS	O
pain	O
(	O
r	O
=	O
0.41	O
,	O
p	O
=	O
0.000	O
)	O
.	O

Correlation	O
between	O
CHAQ	O
and	O
CDI	O
(	O
r	O
=	O
0.34	O
,	O
p	O
=	O
0.01	O
)	O
was	O
significant	O
.	O

The	O
result	O
of	O
our	O
study	O
suggested	O
that	O
only	O
depression	O
was	O
related	O
to	O
anxiety	O
,	O
functional	O
ability	O
,	O
and	O
well-being	O
in	O
children	O
and	O
adolescents	O
with	O
JIA	O
.	O

The	O
effect	O
of	O
knee	Physical
position	Physical
on	O
blood	O
loss	O
and	O
range	O
of	O
motion	O
following	O
total	O
knee	O
arthroplasty	O
.	O

PURPOSE	O
This	O
study	O
prospectively	O
assessed	O
the	O
effects	O
of	O
knee	Physical
position	Physical
on	O
blood	O
loss	O
and	O
range	O
of	O
motion	O
after	O
primary	O
total	O
knee	O
arthroplasty	O
(	O
TKA	O
)	O
.	O

METHODS	O
One	O
hundred	O
and	O
ten	O
consecutive	O
TKA	O
patients	O
were	O
randomized	O
into	O
flexion	O
group	O
and	O
extension	O
group	O
.	O

Both	O
groups	O
had	O
the	O
leg	O
elevated	O
30?	O
at	O
the	O
hip	O
over	O
an	O
inactive	O
CPM	O
for	O
72	O
h	O
postoperatively	O
.	O

The	O
flexion	O
group	O
had	O
the	O
knee	O
flexed	O
to	O
30?	O
during	O
this	O
period	O
.	O

The	O
extension	O
group	O
had	O
the	O
knee	O
extended	O
fully	O
.	O

Perioperative	O
blood	O
loss	O
,	O
hidden	O
blood	O
loss	O
,	O
knee	O
swelling	O
,	O
ecchymosis	O
,	O
analgesia	O
requirements	O
,	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
,	O
fixed	O
flexion	O
deformity	O
(	O
FFD	O
)	O
,	O
straight-leg	O
raising	O
action	O
,	O
and	O
postoperative	O
complications	O
within	O
6	O
weeks	O
of	O
surgery	O
were	O
measured	O
for	O
evaluation	O
and	O
comparison	O
.	O

RESULTS	O
The	O
postoperative	O
hidden	O
blood	O
loss	O
,	O
knee	O
swelling	O
,	O
and	O
scope	O
of	O
ecchymosis	O
were	O
significantly	O
lower	O
in	O
the	O
flexion	O
group	O
than	O
in	O
the	O
extension	O
group	O
,	O
and	O
ROM	O
and	O
straight-leg	O
raising	O
action	O
were	O
significantly	O
higher	O
during	O
the	O
early	O
period	O
after	O
operation	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
perioperative	O
blood	O
loss	O
,	O
the	O
amount	O
of	O
morphine	O
used	O
,	O
or	O
FFD	O
in	O
the	O
early	O
postoperative	O
period	O
or	O
in	O
ROM	O
and	O
FFD	O
at	O
6	O
weeks	O
postoperatively	O
.	O

CONCLUSIONS	O
The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
flexion	O
of	O
the	O
knee	O
to	O
30?	O
with	O
the	O
leg	O
elevated	O
30?	O
at	O
the	O
hip	O
after	O
total	O
knee	O
arthroplasty	O
may	O
mitigate	O
knee	O
swelling	O
and	O
provide	O
other	O
beneficial	O
results	O
during	O
the	O
early	O
rehabilitation	O
following	O
TKA	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
Prospective	O
comparative	O
study	O
,	O
Level	O
I	O
.	O

Alternative	O
voice	O
after	O
laryngectomy	Physical
using	O
a	O
sound-producing	Other
voice	Other
prosthesis	Other
.	O

OBJECTIVE	O
To	O
improve	O
the	O
voice	O
quality	O
of	O
female	O
laryngectomees	O
and/or	O
laryngectomees	O
with	O
a	O
hypotonic	O
pharyngoesophageal	O
(	O
PE	O
)	O
segment	O
by	O
means	O
of	O
a	O
pneumatic	Physical
artificial	Physical
source	Physical
of	Physical
voice	Physical
incorporated	Physical
in	Physical
a	Physical
regular	Physical
tracheoesophageal	Physical
(	Physical
TE	Physical
)	Physical
shunt	Physical
valve	Physical
.	O

STUDY	O
DESIGN	O
Experimental	O
,	O
randomized	O
,	O
crossover	O
trial	O
.	O

METHODS	O
The	O
new	O
sound	O
source	O
consists	O
of	O
a	O
single	O
silicone	O
lip	O
,	O
which	O
performs	O
an	O
oscillatory	O
movement	O
driven	O
by	O
expired	O
pulmonary	O
air	O
flowing	O
along	O
the	O
outward-striking	O
lip	O
through	O
the	O
TE	O
shunt	O
valve	O
.	O

A	O
prototype	O
of	O
this	O
pneumatic	Other
sound	Other
source	Other
is	O
evaluated	O
in	O
vitro	O
and	O
in	O
six	O
laryngectomees	O
.	O

In	O
vivo	O
evaluation	O
includes	O
speech	O
rate	O
,	O
maximal	O
phonation	O
time	O
,	O
perceptual	O
voice	O
evaluation	O
of	O
read-aloud	O
prose	O
by	O
an	O
expert	O
listener	O
,	O
speech	O
intelligibility	O
measurements	O
with	O
12	O
listeners	O
,	O
and	O
self-assessment	O
by	O
the	O
patients	O
.	O

Moreover	O
,	O
extensive	O
acoustical	O
and	O
aerodynamic	O
in	O
vivo	O
registrations	O
are	O
performed	O
using	O
a	O
newly	O
developed	O
data	O
acquisition	O
system	O
.	O

RESULTS	O
The	O
current	O
prototype	O
seems	O
beneficial	O
in	O
female	O
laryngectomees	O
with	O
a	O
hypotonic	O
PE	O
segment	O
only	O
.	O

For	O
them	O
the	O
sound-producing	Other
voice	Other
prosthesis	Other
improves	O
voice	O
quality	O
and	O
increases	O
the	O
average	O
pitch	O
of	O
voice	O
,	O
without	O
decreasing	O
intelligibility	O
or	O
necessitating	O
other	O
pressure	O
and	O
airflow	O
rates	O
than	O
regular	O
TE	O
shunt	O
speech	O
.	O

Pitch	O
regulation	O
of	O
this	O
prosthetic	O
voice	O
is	O
possible	O
,	O
yet	O
limited	O
.	O

CONCLUSIONS	O
The	O
mechanism	O
is	O
feasible	O
and	O
does	O
not	O
result	O
in	O
unacceptable	O
airflow	O
resistance	O
.	O

For	O
this	O
new	O
mechanism	O
of	O
alaryngeal	O
voice	O
to	O
become	O
an	O
established	O
technique	O
for	O
postlaryngectomy	O
voice	O
restoration	O
,	O
a	O
voice	O
suitably	O
pitched	O
for	O
male	O
laryngectomees	O
has	O
to	O
be	O
generated	O
and	O
a	O
large	O
part	O
of	O
the	O
melodic	O
and	O
dynamic	O
range	O
of	O
the	O
sound	O
source	O
has	O
to	O
be	O
attainable	O
within	O
physiological	O
airflow	O
rates	O
.	O

Potential	O
effect	O
of	O
the	O
risk	O
of	O
ovarian	Physical
cancer	Physical
algorithm	Physical
(	Physical
ROCA	Physical
)	Physical
on	O
the	O
mortality	O
outcome	O
of	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
and	O
Ovarian	O
(	O
PLCO	O
)	O
trial	O
.	O

Recently	O
,	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
and	O
Ovarian	O
(	O
PLCO	O
)	O
Trial	O
reported	O
no	O
mortality	O
benefit	O
for	O
annual	O
screening	O
with	O
CA-125	O
and	O
transvaginal	O
ultrasound	O
(	O
TVU	O
)	O
.	O

Currently	O
ongoing	O
is	O
the	O
UK	O
Collaborative	O
Trial	O
of	O
Ovarian	O
Cancer	O
Screening	O
(	O
UKCTOCS	O
)	O
,	O
which	O
utilizes	O
the	O
risk	O
of	O
ovarian	Physical
cancer	Physical
algorithm	Physical
(	Physical
ROCA	Physical
)	Physical
,	O
a	O
statistical	O
tool	O
that	O
considers	O
current	O
and	O
past	O
CA125	O
values	O
to	O
determine	O
ovarian	O
cancer	O
risk	O
.	O

In	O
contrast	O
,	O
PLCO	O
used	O
a	O
single	O
cutoff	O
for	O
CA125	O
,	O
based	O
on	O
current	O
levels	O
alone	O
.	O

We	O
investigated	O
whether	O
having	O
had	O
used	O
ROCA	Physical
in	Physical
PLCO	Physical
could	O
have	O
,	O
under	O
optimal	O
assumptions	O
,	O
resulted	O
in	O
a	O
significant	O
mortality	O
benefit	O
by	O
applying	O
ROCA	O
to	O
PLCO	O
CA125	O
screening	O
values	O
.	O

A	O
best-case	O
scenario	O
assumed	O
that	O
all	O
cancers	O
showing	O
a	O
positive	O
screen	O
result	O
earlier	O
with	O
ROCA	O
than	O
under	O
the	O
PLCO	O
protocol	O
would	O
have	O
avoided	O
mortality	O
;	O
under	O
a	O
stage-shift	O
scenario	O
,	O
such	O
women	O
were	O
assigned	O
survival	O
equivalent	O
to	O
Stage	O
I/II	O
screen-detected	O
cases	O
.	O

Updated	O
PLCO	O
data	O
show	O
132	O
intervention	O
arm	O
ovarian	O
cancer	O
deaths	O
versus	O
119	O
in	O
usual	O
care	O
(	O
relative	O
risk	O
,	O
RR	O
=	O
1.11	O
)	O
.	O

Forty-three	O
ovarian	O
cancer	O
cases	O
,	O
25	O
fatal	O
,	O
would	O
have	O
been	O
detected	O
earlier	O
with	O
ROCA	Physical
,	O
with	O
a	O
median	O
(	O
minimum	O
)	O
advance	O
time	O
for	O
fatal	O
cases	O
of	O
344	O
(	O
147	O
)	O
days	O
.	O

Best-case	O
and	O
stage-shift	O
scenarios	O
gave	O
25	O
and	O
19	O
deaths	O
prevented	O
with	O
ROCA	Physical
,	O
for	O
RRs	O
of	O
0.90	O
(	O
95	O
%	O
CI	O
:	O
0.69-1.17	O
)	O
and	O
0.95	O
(	O
95	O
%	O
CI	O
:	O
0.74-1.23	O
)	O
,	O
respectively	O
.	O

Having	O
utilized	O
ROCA	Physical
in	O
PLCO	O
would	O
not	O
have	O
led	O
to	O
a	O
significant	O
mortality	O
benefit	O
of	O
screening	O
.	O

However	O
,	O
ROCA	Physical
could	O
still	O
show	O
a	O
significant	O
effect	O
in	O
other	O
screening	O
trials	O
,	O
including	O
UKCTOCS	O
.	O

Kata	Physical
techniques	Physical
training	Physical
consistently	O
decreases	O
stereotypy	O
in	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

The	O
effects	O
of	O
14	O
weeks	O
of	O
Kata	Physical
techniques	Physical
training	Physical
on	O
stereotypic	O
behaviors	O
of	O
children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
were	O
investigated	O
.	O

The	O
study	O
included	O
30	O
eligible	O
(	O
diagnosed	O
ASD	O
,	O
school	O
age	O
)	O
children	O
with	O
ages	O
ranging	O
from	O
5	O
to	O
16	O
years	O
whom	O
they	O
assigned	O
to	O
an	O
exercise	O
(	O
n=15	O
)	O
or	O
a	O
no-exercise	Control
control	Control
group	Control
(	O
n=15	O
)	O
.	O

Participants	O
of	O
the	O
exercise	O
group	O
received	O
Kata	Physical
techniques	Physical
instruction	Physical
four	O
times	O
per	O
week	O
for	O
14	O
weeks	O
(	O
56	O
sessions	O
)	O
.	O

Stereotypy	Physical
was	O
assessed	O
at	O
baseline	O
(	O
pre-intervention	O
)	O
,	O
week	O
14	O
(	O
post-intervention	O
)	O
,	O
and	O
at	O
one	O
month	O
follow	O
up	O
in	O
both	O
groups	O
.	O

Results	O
showed	O
that	O
Kata	O
techniques	O
training	O
significantly	O
reduced	O
stereotypy	O
in	O
the	O
exercise	O
group	O
.	O

Following	O
participation	O
in	O
Kata	O
techniques	O
training	O
,	O
stereotypy	O
decreased	O
from	O
baseline	O
levels	O
by	O
a	O
M	O
of	O
42.54	O
%	O
across	O
participants	O
.	O

Interestingly	O
,	O
after	O
30	O
days	O
of	O
no	O
practice	O
,	O
stereotypy	O
in	O
the	O
exercise	O
group	O
remained	O
significantly	O
decreased	O
compared	O
to	O
pre-intervention	O
time	O
.	O

The	O
participants	O
of	O
the	O
control	O
group	O
did	O
not	O
show	O
significant	O
changes	O
in	O
the	O
stereotypy	O
.	O

Teaching	O
martial	O
arts	O
techniques	O
to	O
children	O
with	O
ASD	O
for	O
a	O
long	O
period	O
of	O
time	O
consistently	O
decreased	O
their	O
stereotypic	O
behaviors	O
.	O

The	O
interaction	O
between	O
propofol	Pharmacological
and	Pharmacological
clonidine	Pharmacological
for	O
loss	O
of	O
consciousness	O
.	O

UNLABELLED	O
Clonidine	Pharmacological
premedication	O
reduces	O
the	O
intraoperative	O
requirement	O
for	O
opioids	O
and	O
volatile	O
anesthetics	O
.	O

Clonidine	Pharmacological
also	O
reduces	O
the	O
induction	O
dose	O
of	O
IV	O
anesthetics	O
.	O

There	O
is	O
no	O
information	O
,	O
however	O
,	O
regarding	O
the	O
effect	O
of	O
oral	O
clonidine	Pharmacological
premedication	O
on	O
the	O
propofol	Pharmacological
blood	O
concentrations	O
required	O
for	O
loss	O
of	O
consciousness	O
,	O
and	O
the	O
interaction	O
between	O
propofol	Pharmacological
and	Pharmacological
clonidine	Pharmacological
.	Pharmacological

We	O
randomly	O
administered	O
target	O
effect-site	O
concentrations	O
of	O
propofol	Pharmacological
ranging	O
from	O
0.5	O
to	O
5	O
.	O

0	O
microg/mL	O
by	O
using	O
computer-assisted	O
target-controlled	O
infusion	O
to	O
3	O
groups	O
of	O
healthy	O
male	O
patients	O
:	O
Control	Control
(	O
n	O
=	O
35	O
)	O
,	O
2.5	O
microg/kg	O
Clonidine	Pharmacological
(	O
n	O
=	O
36	O
)	O
,	O
and	O
5.0	O
microg/kg	O
Clonidine	Pharmacological
(	O
n	O
=	O
36	O
)	O
groups	O
.	O

Nothing	Control
was	Control
administered	Control
to	Control
the	Control
Control	Control
group	Control
.	Control

Clonidine	Pharmacological
(	O
2.5	O
or	O
5.0	O
microg/kg	O
)	O
was	O
administered	O
orally	O
90	O
min	O
before	O
the	O
induction	O
of	O
anesthesia	O
in	O
the	O
Clonidine	Pharmacological
groups	O
.	O

After	O
equilibration	O
between	O
the	O
blood	O
and	O
effect-site	O
for	O
15	O
min	O
,	O
a	O
verbal	O
command	O
to	O
open	O
their	O
eyes	O
was	O
given	O
two	O
times	O
to	O
the	O
patients	O
.	O

Arterial	O
blood	O
samples	O
for	O
analysis	O
of	O
the	O
serum	O
propofol	Pharmacological
and	Pharmacological
clonidine	Pharmacological
concentrations	O
were	O
taken	O
immediately	O
before	O
verbal	O
commands	O
were	O
given	O
.	O

Measured	O
serum	O
propofol	Pharmacological
concentrations	O
in	O
equilibrium	O
with	O
the	O
effect-site	O
at	O
which	O
50	O
%	O
of	O
the	O
patients	O
did	O
not	O
respond	O
to	O
verbal	O
commands	O
(	O
EC50	O
for	O
loss	O
of	O
consciousness	O
)	O
were	O
determined	O
by	O
logistic	O
regression	O
.	O

The	O
EC50	O
+/-	O
SE	O
values	O
in	O
the	O
Control	O
,	O
2.5	O
microg/kg	O
Clonidine	Pharmacological
,	O
and	O
5.0	O
microg/kg	O
Clonidine	Pharmacological
groups	O
were	O
2.67	O
+/-	O
0.18	O
,	O
1.31	O
+/-	O
0.12	O
,	O
and	O
0.91	O
+/-	O
0.13	O
microg/mL	O
,	O
respectively	O
.	O

The	O
EC50	O
in	O
the	O
2.5	O
and	O
5.0	O
microg/kg	O
clonidine	O
groups	O
was	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
Control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
use	O
of	O
a	O
response	O
surface	O
modeling	O
analysis	O
indicated	O
that	O
there	O
was	O
an	O
additive	O
interaction	O
between	O
measured	O
arterial	O
propofol	Pharmacological
and	Pharmacological
clonidine	Pharmacological
concentrations	O
in	O
relation	O
to	O
loss	O
of	O
consciousness	O
.	O

These	O
results	O
indicate	O
that	O
propofol	O
and	O
clonidine	O
act	O
additively	O
for	O
loss	O
of	O
consciousness	O
.	O

IMPLICATIONS	O
Oral	O
clonidine	Pharmacological
2.5	O
and	O
5.0	O
microg/kg	O
premedication	O
decreases	O
the	O
propofol	Pharmacological
concentration	O
required	O
for	O
loss	O
of	O
consciousness	O
.	O

The	O
pulsed-dye	Surgical
laser	Surgical
as	O
an	O
adjuvant	O
treatment	O
modality	O
in	O
acne	O
vulgaris	O
:	O
a	O
randomized	O
controlled	O
single-blinded	O
trial	O
.	O

BACKGROUND	O
Acne	O
vulgaris	O
is	O
the	O
most	O
common	O
skin	O
disease	O
and	O
can	O
pose	O
a	O
substantial	O
therapeutic	O
challenge	O
.	O

Recently	O
,	O
several	O
phototherapeutic	O
modalities	O
,	O
most	O
notably	O
pulsed-dye	Surgical
laser	Surgical
(	Surgical
PDL	Surgical
)	Surgical
treatment	O
,	O
have	O
been	O
introduced	O
,	O
but	O
the	O
published	O
results	O
-	O
albeit	O
promising	O
-	O
are	O
controversial	O
.	O

OBJECTIVES	O
To	O
assess	O
the	O
efficacy	O
of	O
an	O
adjuvant	O
PDL	Surgical
treatment	O
when	O
combined	O
with	O
a	O
proven	O
topical	O
treatment	O
[	O
fixed-combination	O
clindamycin	O
1	O
%	O
-benzoyl	O
peroxide	O
5	O
%	O
hydrating	O
gel	O
(	O
C/BPO	O
)	O
]	O
.	O

METHODS	O
Eighty	O
patients	O
(	O
38	O
males	O
and	O
42	O
females	O
,	O
mean	O
+/-	O
SD	O
age	O
19.7	O
+/-	O
5.9	O
years	O
)	O
were	O
randomized	O
in	O
a	O
1	O
:	O
2	O
ratio	O
to	O
receive	O
C/BPO	Surgical
alone	Surgical
or	Surgical
in	Surgical
combination	Surgical
with	Surgical
PDL	Surgical
treatment	Surgical
(	O
wavelength	O
585	O
nm	O
,	O
energy	O
fluence	O
3	O
J	O
cm	O
(	O
-2	O
)	O
,	O
pulse	O
duration	O
0.35	O
ms	O
,	O
spot	O
size	O
7	O
mm	O
)	O
.	O

Patients	O
were	O
evaluated	O
at	O
baseline	O
and	O
at	O
2	O
and	O
4	O
weeks	O
after	O
initial	O
treatment	O
.	O

The	O
primary	O
end	O
points	O
were	O
the	O
Investigator	O
's	O
Static	O
Global	O
Assessment	O
(	O
ISGA	O
)	O
score	O
and	O
lesion	O
count	O
;	O
the	O
secondary	O
end	O
point	O
was	O
the	O
Dermatology	O
Life	O
Quality	O
Index	O
(	O
DLQI	O
)	O
.	O

RESULTS	O
Both	O
groups	O
showed	O
a	O
significant	O
improvement	O
during	O
observation	O
[	O
ISGA	O
27.1	O
%	O
(	O
C/BPO	Surgical
)	O
and	O
24.6	O
%	O
(	O
C/BPO	Surgical
+	Surgical
laser	Surgical
)	O
,	O
total	O
lesion	O
count	O
9.2	O
%	O
and	O
9.0	O
%	O
,	O
inflammatory	O
lesion	O
count	O
36.3	O
%	O
and	O
36.9	O
%	O
,	O
DLQI	O
54.5	O
%	O
and	O
42.5	O
%	O
]	O
,	O
but	O
there	O
was	O
no	O
significant	O
or	O
otherwise	O
appreciable	O
difference	O
between	O
treatment	O
modalities	O
as	O
far	O
as	O
the	O
extent	O
of	O
improvement	O
was	O
concerned	O
.	O

Patients	O
with	O
more	O
severe	O
findings	O
at	O
baseline	O
had	O
a	O
greater	O
benefit	O
from	O
either	O
therapy	O
regimen	O
.	O

CONCLUSIONS	O
Our	O
findings	O
do	O
not	O
support	O
the	O
concept	O
of	O
a	O
substantial	O
benefit	O
of	O
PDL	Surgical
treatment	O
in	O
acne	O
vulgaris	O
.	O

Immunoenhanced	Pharmacological
enteral	Pharmacological
nutrition	Pharmacological
formulas	Pharmacological
in	O
head	O
and	O
neck	O
cancer	O
surgery	O
:	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
.	O

INTRODUCTION	O
Significant	O
malnutrition	O
exists	O
in	O
a	O
high	O
percentage	O
of	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
.	O

Malnutrition	O
is	O
associated	O
with	O
defects	O
in	O
immune	O
function	O
that	O
may	O
impair	O
the	O
host	O
response	O
to	O
malignancy	O
.	O

Malnutrition	O
and	O
immunosupression	O
make	O
patients	O
highly	O
susceptible	O
to	O
postoperative	O
infections	O
and	O
complications	O
.	O

OBJECTIVES	O
Compare	O
two	O
immunoenhanced	Pharmacological
enteral	Pharmacological
nutritions	Pharmacological
with	O
a	O
control	O
diet	O
,	O
and	O
evaluate	O
the	O
effect	O
in	O
postoperative	O
infections	O
,	O
length	O
of	O
stay	O
and	O
inflammatory	O
markers	O
.	O

PATIENTS	O
A	O
population	O
of	O
44	O
patients	O
with	O
oral	O
and	O
laryngeal	O
cancer	O
was	O
enrolled	O
in	O
a	O
randomized	O
trial	O
.	O

At	O
surgery	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
three	O
groups	O
:	O
(	O
group	O
I	O
)	O
;	O
patients	O
receiving	O
an	O
arginine-enhanced	Pharmacological
formula	Pharmacological
(	O
group	O
II	O
)	O
;	O
patients	O
receiving	O
a	O
standard	O
polymeric	O
formula	O
,	O
and	O
(	O
group	O
III	O
)	O
patients	O
receiving	O
an	O
arginine	Pharmacological
,	Pharmacological
RNA	Pharmacological
and	Pharmacological
omega-3	Pharmacological
fatty	Pharmacological
acids	Pharmacological
enhanced	Pharmacological
formula	Pharmacological
,	O
in	O
an	O
isonitrogenous	O
way	O
.	O

RESULTS	O
The	O
duration	O
of	O
enteral	O
nutrition	O
in	O
the	O
three	O
groups	O
was	O
similar	O
with	O
an	O
average	O
duration	O
of	O
14,5	O
+/-	O
8	O
days	O
.	O

The	O
length	O
of	O
postoperative	O
stay	O
was	O
similar	O
,	O
with	O
an	O
average	O
of	O
19,8	O
+/-	O
8,5	O
days	O
.	O

Wound	O
infections	O
and	O
general	O
infections	O
were	O
more	O
frequent	O
in	O
the	O
control	O
group	O
.	O

Fistula	O
rates	O
were	O
not	O
improved	O
in	O
the	O
enhanced	O
diet	O
groups	O
.	O

No	O
significant	O
intergroup	O
differences	O
in	O
the	O
trend	O
of	O
the	O
two	O
plasma	O
proteins	O
(	O
albumin	O
,	O
transferrin	O
)	O
,	O
lymphocytes	O
,	O
weight	O
,	O
IL-6	O
,	O
CPR	O
and	O
TNFalpha	O
were	O
detected	O
.	O

The	O
control	O
group	O
showed	O
the	O
highest	O
levels	O
of	O
TNFalpha	O
at	O
the	O
fourteenth	O
postoperative	O
day	O
.	O

Gastrointestinal	O
tolerance	O
and	O
diarrhoea	O
rate	O
were	O
similar	O
in	O
all	O
the	O
patients	O
.	O

CONCLUSIONS	O
Immunoenhanced	O
enteral	O
nutrition	O
formulas	O
improved	O
the	O
infection	O
rate	O
in	O
the	O
postoperative	O
of	O
head	O
and	O
neck	O
cancer	O
patients	O
.	O

In	O
the	O
fistula	O
rates	O
,	O
we	O
observed	O
that	O
technical	O
problems	O
and	O
nutritional	O
status	O
might	O
have	O
played	O
an	O
equally	O
important	O
role	O
,	O
and	O
therefore	O
the	O
positive	O
effect	O
of	O
immunonutrition	O
in	O
this	O
parameter	O
might	O
have	O
been	O
overestimated	O
.	O

Beneficial	O
effect	O
of	O
etidronate	Pharmacological
therapy	Pharmacological
in	O
chronically	O
hospitalized	O
,	O
disabled	O
patients	O
with	O
stroke	O
.	O

Incidence	O
of	O
hip	O
fractures	O
is	O
high	O
in	O
chronically	O
hospitalized	O
,	O
disabled	O
,	O
elderly	O
patients	O
after	O
stroke	O
.	O

Duration	O
of	O
hospitalization	O
was	O
more	O
than	O
1	O
year	O
because	O
of	O
insufficiency	O
of	O
nursing	O
homes	O
.	O

Our	O
study	O
showed	O
that	O
immobilization-induced	O
hypercalcemia	O
and	O
25-hydroxyvitamin	O
D	O
deficiency	O
contribute	O
to	O
reduced	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
address	O
the	O
possibility	O
that	O
treatment	O
with	O
etidronate	Pharmacological
may	O
reduce	O
the	O
bone	O
resorption	O
and	O
lower	O
the	O
incidence	O
of	O
fractures	O
in	O
elderly	O
patients	O
who	O
are	O
chronically	O
hospitalized	O
and	O
disabled	O
as	O
a	O
result	O
of	O
hemiparesis	O
after	O
stroke	O
.	O

Patients	O
with	O
stroke	O
were	O
randomly	O
assigned	O
to	O
daily	O
treatment	O
with	O
400	O
mg	O
of	O
etidronate	Pharmacological
(	O
n	O
=	O
40	O
)	O
or	O
a	O
placebo	Control
(	O
n	O
=	O
40	O
)	O
,	O
and	O
followed	O
up	O
for	O
2	O
years	O
.	O

At	O
baseline	O
,	O
both	O
groups	O
had	O
low	O
BMD	O
with	O
high	O
levels	O
of	O
serum	O
ionized	O
calcium	O
and	O
urinary	O
deoxypyridinoline	O
.	O

In	O
the	O
etidronate	Pharmacological
group	O
,	O
serum	O
calcium	O
and	O
urinary	O
deoxypyridinoline	O
levels	O
decreased	O
significantly	O
during	O
the	O
study	O
period	O
,	O
whereas	O
the	O
levels	O
in	O
the	O
placebo	Control
group	O
were	O
increased	O
.	O

BMD	O
on	O
the	O
hemiplegic	O
side	O
increased	O
by	O
1.4	O
%	O
in	O
the	O
etidronate	O
group	O
and	O
decreased	O
by	O
2.2	O
%	O
in	O
the	O
placebo	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

Two	O
patients	O
sustained	O
hip	O
fractures	O
in	O
the	O
placebo	Control
group	O
,	O
and	O
no	O
hip	O
fracture	O
occurred	O
in	O
the	O
etidronate	Pharmacological
group	O
.	O

Treatment	O
with	O
etidronate	Pharmacological
increases	O
BMD	O
in	O
chronically	O
hospitalized	O
patients	O
poststroke	O
,	O
and	O
may	O
prevent	O
hip	O
fracture	O
.	O

Effects	O
of	O
pindolol	Pharmacological
and	O
clopamide	Pharmacological
on	O
blood	O
lipids	O
in	O
arterial	O
hypertensive	O
patients	O
.	O

The	O
effects	O
of	O
clopamide	Pharmacological
,	O
pindolol	Pharmacological
and	O
its	O
combination	Pharmacological
on	Pharmacological
plasma	Pharmacological
lipids	Pharmacological
in	O
49	O
hypertensive	O
patients	O
(	O
WHO	O
I-II	O
)	O
,	O
divided	O
into	O
three	O
parallel	O
randomized	O
groups	O
,	O
were	O
studied	O
over	O
a	O
6	O
months	O
period	O
.	O

Total	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
and	O
LDL	O
cholesterol	O
fractions	O
were	O
determined	O
twice	O
during	O
an	O
initial	O
4-week	O
washout	O
phase	O
,	O
and	O
after	O
a	O
1-	O
,	O
3-	O
and	O
6-month	O
active	O
hypotensive	O
drug	O
phase	O
.	O

Patients	O
were	O
instructed	O
to	O
maintain	O
their	O
usual	O
dietary	O
habits	O
.	O

Daily	O
drug	O
doses	O
were	O
adjusted	O
progressively	O
to	O
attain	O
optimal	O
hypotensive	O
effects	O
.	O

In	O
the	O
clopamide	O
monotherapy	O
group	O
,	O
total	O
cholesterol	O
increased	O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
;	O
triglycerides	O
and	O
LDL	O
showed	O
a	O
tendency	O
to	O
increase	O
while	O
for	O
HDL	O
a	O
tendency	O
to	O
decrease	O
was	O
observed	O
.	O

In	O
the	O
pindolol	O
monotherapy	O
group	O
,	O
a	O
significant	O
reduction	O
of	O
triglycerides	O
(	O
p	O
less	O
than	O
0.01	O
)	O
and	O
a	O
significant	O
increase	O
of	O
HDL	O
cholesterol	O
(	O
p	O
less	O
than	O
0.05	O
)	O
were	O
recorded	O
.	O

No	O
significant	O
changes	O
in	O
total	O
cholesterol	O
or	O
LDL	O
fraction	O
were	O
observed	O
.	O

Combined	O
pindolol-clopamide	O
therapy	O
decreased	O
total	O
triglycerides	O
(	O
NS	O
)	O
,	O
increased	O
HDL	O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
did	O
not	O
influence	O
total	O
cholesterol	O
and	O
LDL	O
fraction	O
.	O

It	O
is	O
concluded	O
that	O
pindolol	O
does	O
not	O
negatively	O
influence	O
blood	O
lipids	O
as	O
the	O
thiazide-type	O
diuretic	O
clopamide	O
does	O
,	O
and	O
that	O
when	O
both	O
drugs	O
are	O
used	O
together	O
,	O
the	O
beta-blocker	O
can	O
probably	O
counterbalance	O
the	O
diuretic-induced	O
negative	O
effects	O
on	O
blood	O
lipids	O
.	O

Accordingly	O
,	O
it	O
is	O
suggested	O
that	O
pindolol	O
could	O
be	O
a	O
more	O
favorable	O
beta-blocker	O
drug	O
to	O
be	O
used	O
on	O
hypertensive	O
subjects	O
with	O
metabolic	O
coronary	O
risk	O
factors	O
.	O

A	O
30-month	O
longitudinal	O
study	O
of	O
the	O
effects	O
of	O
some	O
oral	Physical
hygiene	Physical
measures	Physical
on	O
Streptococcus	O
mutans	O
and	O
approximal	O
dental	O
caries	O
.	O

The	O
effects	O
of	O
some	O
oral	Physical
hygiene	Physical
measures	Physical
on	O
Streptococcus	O
mutants	O
and	O
approximal	O
dental	O
caries	O
were	O
evaluated	O
.	O

One	O
hundred	O
and	O
eighty-seven	O
13-year-old	O
individuals	O
with	O
high	O
levels	O
of	O
salivary	O
S.	O
mutans	O
(	O
greater	O
than	O
10	O
(	O
6	O
)	O
/mL	O
)	O
were	O
selected	O
.	O

They	O
were	O
randomly	O
distributed	O
into	O
three	O
groups	O
.	O

Group	O
I	O
initially	O
received	O
professional	Physical
mechanical	Physical
tooth-cleaning	Physical
,	Educational
tongue-scraping	Physical
,	Educational
chlorhexidine	Control
treatment	Control
,	Educational
and	Educational
oral	Educational
hygiene	Educational
instructions	Educational
concentrated	O
on	O
the	O
approximal	O
surfaces	O
most	O
colonized	O
by	O
S.	O
mutans	O
.	O

The	O
treatment	O
was	O
given	O
four	O
times	O
with	O
intervals	O
of	O
two	O
days	O
,	O
followed	O
by	O
one	O
single	O
treatment	O
every	O
six	O
months	O
throughout	O
the	O
experimental	O
period	O
.	O

The	O
initial	O
treatment	O
period	O
for	O
group	O
II	O
,	O
also	O
consisting	O
of	O
four	O
visits	O
,	O
included	O
the	O
same	O
oral	Educational
hygiene	Educational
instructions	Educational
as	O
for	O
group	O
I	O
.	O

The	O
instructions	O
were	O
repeated	O
every	O
six	O
months	O
.	O

Group	O
III	O
was	O
maintained	O
in	O
the	O
preventive	Educational
program	Educational
provided	Educational
by	Educational
the	Educational
local	Educational
Dental	Educational
Health	Educational
Office	Educational
,	O
based	O
on	O
mechanical	Physical
plaque	Physical
control	Physical
and	O
topical	Pharmacological
use	Pharmacological
of	Pharmacological
fluorides	Pharmacological
and	Pharmacological
chlorhexidine	Pharmacological
at	O
individualized	O
intervals	O
.	O

Group	O
I	O
showed	O
a	O
significant	O
immediate	O
reduction	O
of	O
S.	O
mutans	O
in	O
saliva	O
as	O
well	O
as	O
an	O
approximal	O
tooth	O
surfaces	O
.	O

After	O
six	O
months	O
,	O
there	O
were	O
no	O
differences	O
among	O
the	O
three	O
groups	O
regarding	O
these	O
variables	O
.	O

Compared	O
with	O
baseline	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
of	O
S.	O
mutans	O
in	O
all	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
caries	O
progression	O
among	O
the	O
three	O
groups	O
.	O

However	O
,	O
the	O
selected	O
high-risk	O
individuals	O
in	O
group	O
I	O
developed	O
0.25	O
new	O
manifest	O
caries	O
lesions	O
approximally/year	O
,	O
compared	O
with	O
0.27	O
for	O
all	O
children	O
of	O
the	O
same	O
age	O
group	O
in	O
the	O
area	O
.	O

Seventeen	O
individuals	O
had	O
approximal	O
surfaces	O
with	O
consistently	O
high	O
or	O
consistently	O
low	O
S.	O
mutans	O
levels	O
.	O

Forty-six	O
percent	O
of	O
the	O
surfaces	O
with	O
high	O
values	O
developed	O
new	O
or	O
progressive	O
caries	O
,	O
compared	O
with	O
2	O
%	O
of	O
the	O
surfaces	O
with	O
low	O
values	O
.	O

Thrombin-activatable	Physical
fibrinolysis	Physical
inhibitor	Physical
in	O
hypothyroidism	O
and	O
hyperthyroxinaemia	O
.	O

Endocrine	O
disorders	O
affect	O
both	O
the	O
coagulation	O
and	O
fibrinolytic	O
systems	O
,	O
and	O
have	O
been	O
associated	O
with	O
the	O
development	O
of	O
cardiovascular	O
diseases	O
.	O

Thrombin-activatable	Physical
fibrinolysis	Physical
inhibitor	Physical
(	Physical
TAFI	Physical
)	Physical
is	O
a	O
link	O
between	O
coagulation	O
and	O
the	O
fibrinolytic	O
system	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
thyroid	O
hormone	O
excess	O
and	O
deficiency	O
on	O
TAFI	Physical
levels	O
and	O
function	O
.	O

The	O
effect	O
of	O
hyperthyroxinemia	O
on	O
TAFI	Pharmacological
was	O
studied	O
in	O
healthy	O
volunteers	O
who	O
were	O
randomised	O
to	O
receive	O
levothyroxine	Pharmacological
or	O
no	Control
medication	Control
for	O
14	O
days	O
in	O
a	O
crossover	O
design	O
.	O

The	O
effect	O
of	O
hypothyroidism	O
on	O
TAFI	Pharmacological
was	O
studied	O
in	O
a	O
multicentre	O
observational	O
cohort	O
study	O
.	O

Blood	O
was	O
drawn	O
before	O
treatment	O
of	O
patients	O
with	O
newly	O
diagnosed	O
hypothyroidism	O
and	O
when	O
euthyroidism	O
was	O
achieved	O
.	O

Plasma	O
clot-lysis	O
times	O
,	O
activated	O
TAFI	Physical
(	Physical
TAFIa	Physical
)	Physical
-dependent	Physical
prolongation	O
of	O
clot-lysis	O
and	O
TAFI	O
levels	O
were	O
measured	O
.	O

Thyroid	O
hormone	O
excess	O
resulted	O
in	O
a	O
hypofibrinolytic	O
condition	O
and	O
in	O
an	O
enhanced	O
TAFIa-dependent	O
prolongation	O
of	O
clot	O
lysis	O
.	O

A	O
trend	O
towards	O
decreased	O
plasma	O
TAFI	Pharmacological
levels	O
was	O
observed	O
in	O
healthy	O
volunteers	O
who	O
used	O
levothyroxine	Pharmacological
.	O

Hypothyroidism	O
resulted	O
in	O
hyperfibrinolysis	O
and	O
a	O
reduced	O
TAFIa-dependent	O
prolongation	O
of	O
clot	O
lysis	O
.	O

In	O
conclusion	O
,	O
alterations	O
of	O
TAFIa-dependent	Pharmacological
prolongation	O
of	O
clot	O
lysis	O
in	O
patients	O
with	O
thyroid	O
disorders	O
may	O
cause	O
an	O
impaired	O
haemostatic	O
balance	O
.	O

The	O
disturbed	O
haemostatic	O
balance	O
in	O
patients	O
with	O
hyperthyroidism	O
might	O
make	O
them	O
prone	O
to	O
thrombosis	O
,	O
while	O
the	O
risk	O
for	O
bleeding	O
may	O
increase	O
in	O
patients	O
with	O
hypothyroidism	O
.	O

A	O
selective	Physical
angiotensin	Physical
receptor	Physical
antagonist	Physical
,	O
Valsartan	Pharmacological
,	O
produced	O
regression	O
of	O
left	O
ventricular	O
hypertrophy	O
associated	O
with	O
a	O
reduction	O
of	O
arterial	O
stiffness	O
.	O

We	O
investigated	O
whether	O
a	O
selective	Pharmacological
angiotensin	Pharmacological
II	Pharmacological
receptor	Pharmacological
blocker	Pharmacological
(	Pharmacological
ARB	Pharmacological
)	Pharmacological
would	O
have	O
a	O
regressive	O
effect	O
on	O
left	O
ventricular	O
hypertrophy	O
(	O
LVH	O
)	O
in	O
patients	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

In	O
a	O
double-blind	O
study	O
,	O
24	O
CAPD	O
patients	O
with	O
LVH	O
[	O
left	O
ventricular	O
mass	O
index	O
(	O
LVMi	O
)	O
>	O
110	O
g/m2	O
for	O
women	O
and	O
LVMi	O
>	O
137	O
g/m2	O
for	O
men	O
]	O
were	O
randomized	O
to	O
12	O
months	O
'	O
administration	O
of	O
either	O
the	O
ARB	Pharmacological
valsartan	Pharmacological
(	O
n	O
=	O
14	O
)	O
or	Control
a	Control
placebo	Control
(	O
n	O
=	O
10	O
)	O
.	O

The	O
target	O
blood	O
pressure	O
(	O
BP	O
)	O
was	O
140/90	O
mmHg	O
or	O
lower	O
in	O
both	O
groups	O
.	O

The	O
following	O
parameters	O
were	O
measured	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
:	O
aortic	O
and	O
large-artery	O
compliance	O
and	O
arterial	O
wave	O
reflections	O
[	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
and	O
augmentation	O
index	O
(	O
AI	O
)	O
application	O
tonometry	O
]	O
and	O
cardiac	O
echocardiography	O
.	O

Periodically	O
recorded	O
were	O
body	O
weight	O
,	O
BP	O
(	O
mercury	O
sphygmomanometer	O
)	O
,	O
serum	O
creatinine	O
,	O
electrolytes	O
,	O
complete	O
blood	O
cell	O
counts	O
,	O
urine	O
volume	O
,	O
drainage	O
volume	O
,	O
and	O
weekly	O
creatinine	O
clearance	O
.	O

Two-way	O
analysis	O
of	O
variance	O
for	O
repeated	O
measurements	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O

Systolic	O
and	O
diastolic	O
BP	O
were	O
both	O
reduced	O
in	O
patients	O
treated	O
with	O
ARB	O
.	O

The	O
LVMi	O
was	O
significantly	O
reduced	O
in	O
patients	O
treated	O
with	O
ARB	O
(	O
to	O
121	O
+/-	O
4	O
from	O
145	O
+/-	O
5	O
)	O
but	O
not	O
in	O
those	O
receiving	O
placebo	O
(	O
to	O
137	O
+/-	O
3	O
from	O
152	O
+/-	O
3	O
,	O
p	O
<	O
0.05	O
)	O
.	O

The	O
decrease	O
in	O
LVMi	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
PWV	O
and	O
AI	O
.	O

In	O
CAPD	O
patients	O
with	O
LVH	O
,	O
ARB	O
reduced	O
LVMi	O
in	O
association	O
with	O
alterations	O
in	O
arterial	O
hemodynamics	O
.	O

Mending	O
the	O
rhythm	O
does	O
not	O
improve	O
prognosis	O
in	O
patients	O
with	O
persistent	O
atrial	O
fibrillation	O
:	O
a	O
subanalysis	O
of	O
the	O
RACE	O
study	O
.	O

AIMS	O
To	O
compare	O
outcome	O
of	O
AF	O
patients	O
with	O
effective	O
rhythm	O
control	O
with	O
patients	O
treated	O
with	O
rate	O
control	O
.	O

METHODS	O
AND	O
RESULTS	O
Out	O
of	O
the	O
266	O
AF	O
patients	O
randomized	O
to	O
rhythm	Physical
control	Physical
in	O
the	O
RACE	O
study	O
,	O
49	O
patients	O
turned	O
to	O
long-term	Physical
sinus	Physical
rhythm	Physical
and	O
were	O
continuously	O
treated	O
with	O
oral	Pharmacological
anticoagulation	Pharmacological
.	O

The	O
incidence	O
of	O
the	O
primary	O
endpoint	O
in	O
these	O
patients	O
was	O
compared	O
to	O
that	O
in	O
178	O
patients	O
out	O
of	O
the	O
initial	O
256	O
rate-control	O
patients	O
of	O
RACE	O
who	O
were	O
in	O
AF	O
and	O
using	O
oral	O
anticoagulation	O
continuously	O
.	O

Baseline	O
characteristics	O
of	O
both	O
groups	O
were	O
not	O
different	O
.	O

After	O
a	O
mean	O
follow-up	O
of	O
2.3+/-0.6	O
years	O
,	O
the	O
primary	O
endpoint	O
(	O
a	O
composite	O
of	O
cardiovascular	O
mortality	O
,	O
heart	O
failure	O
,	O
thrombo-embolic	O
complications	O
(	O
TECs	O
)	O
,	O
bleeding	O
,	O
serious	O
adverse	O
effects	O
of	O
antiarrhythmic	O
drugs	O
and	O
pacemaker	O
implants	O
)	O
was	O
22.4	O
%	O
in	O
the	O
rhythm-control	O
group	O
vs.	O
15.2	O
%	O
in	O
the	O
rate-control	O
group	O
.	O

Multivariable	O
regression	O
analysis	O
indicated	O
coronary	O
artery	O
disease	O
,	O
heart	O
failure	O
,	O
and	O
digitalis	O
as	O
independent	O
risk	O
indicators	O
of	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O

Chronic	O
sinus	O
rhythm	O
did	O
not	O
matter	O
.	O

CONCLUSION	O
Among	O
patients	O
who	O
remained	O
on	O
warfarin	Pharmacological
,	O
those	O
who	O
mostly	O
were	O
maintained	O
in	O
sinus	O
rhythm	O
under	O
a	O
rhythm-control	O
strategy	O
did	O
not	O
have	O
a	O
superior	O
prognosis	O
compared	O
to	O
those	O
who	O
remained	O
in	O
AF	O
under	O
a	O
rate-control	O
strategy	O
.	O

Pathological	O
features	O
and	O
inhaled	O
corticosteroid	O
response	O
of	O
eosinophilic	O
and	O
non-eosinophilic	O
asthma	O
.	O

BACKGROUND	O
Non-eosinophilic	O
asthma	O
is	O
a	O
potentially	O
important	O
clinicopathological	O
phenotype	O
since	O
there	O
is	O
evidence	O
that	O
it	O
responds	O
poorly	O
to	O
inhaled	O
corticosteroid	O
therapy	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
underlying	O
airway	O
immunopathology	O
and	O
there	O
are	O
no	O
data	O
from	O
placebo-controlled	O
studies	O
examining	O
the	O
effect	O
of	O
inhaled	O
corticosteroids	O
.	O

METHODS	O
Airway	O
immunopathology	O
was	O
investigated	O
using	O
induced	O
sputum	O
,	O
bronchial	O
biopsies	O
,	O
bronchial	O
wash	O
and	O
bronchoalveolar	O
lavage	O
in	O
12	O
patients	O
with	O
symptomatic	O
eosinophilic	O
asthma	O
,	O
11	O
patients	O
with	O
non-eosinophilic	O
asthma	O
and	O
10	O
healthy	O
controls	O
.	O

The	O
patients	O
with	O
non-eosinophilic	O
asthma	O
and	O
6	O
different	O
patients	O
with	O
eosinophilic	O
asthma	O
entered	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	Control
crossover	O
study	O
in	O
which	O
the	O
effects	O
of	O
inhaled	Pharmacological
mometasone	Pharmacological
400	Pharmacological
microg	Pharmacological
once	O
daily	O
for	O
8	O
weeks	O
on	O
airway	O
responsiveness	O
and	O
asthma	O
quality	O
of	O
life	O
were	O
investigated	O
.	O

RESULTS	O
Patients	O
with	O
non-eosinophilic	O
asthma	O
had	O
absence	O
of	O
eosinophils	O
in	O
the	O
mucosa	O
(	O
median	O
4.4	O
cells/mm	O
(	O
2	O
)	O
vs	O
23	O
cells/mm	O
(	O
2	O
)	O
in	O
eosinophilic	O
asthma	O
and	O
0	O
cells/mm	O
(	O
2	O
)	O
in	O
normal	O
controls	O
;	O
p	O
=	O
0.03	O
)	O
and	O
normal	O
subepithelial	O
layer	O
thickness	O
(	O
5.8	O
microm	O
vs	O
10.3	O
microm	O
in	O
eosinophilic	O
asthma	O
and	O
5.1	O
microm	O
in	O
controls	O
,	O
p	O
=	O
0.002	O
)	O
.	O

Non-eosinophilic	O
and	O
eosinophilic	O
asthma	O
groups	O
had	O
increased	O
mast	O
cell	O
numbers	O
in	O
the	O
airway	O
smooth	O
muscle	O
compared	O
with	O
normal	O
controls	O
(	O
9	O
vs	O
8	O
vs	O
0	O
cells/mm	O
(	O
2	O
)	O
,	O
p	O
=	O
0.016	O
)	O
.	O

Compared	O
with	O
placebo	O
,	O
8	O
weeks	O
of	O
treatment	O
with	O
inhaled	O
mometasone	O
led	O
to	O
less	O
improvement	O
in	O
methacholine	O
PC	O
(	O
20	O
)	O
(	O
0.5	O
vs	O
5.5	O
doubling	O
concentrations	O
,	O
95	O
%	O
CI	O
of	O
difference	O
1.1	O
to	O
9.1	O
;	O
p	O
=	O
0.018	O
)	O
and	O
asthma	O
quality	O
of	O
life	O
(	O
0.2	O
vs	O
1.0	O
points	O
,	O
95	O
%	O
CI	O
of	O
difference	O
0.27	O
to	O
1.43	O
;	O
p	O
=	O
0.008	O
)	O
.	O

CONCLUSIONS	O
Non-eosinophilic	O
asthma	O
represents	O
a	O
pathologically	O
distinct	O
disease	O
phenotype	O
which	O
is	O
characterised	O
by	O
the	O
absence	O
of	O
airway	O
eosinophilia	O
,	O
normal	O
subepithelial	O
layer	O
thickness	O
and	O
a	O
poor	O
short-term	O
response	O
to	O
treatment	O
with	O
inhaled	O
corticosteroids	O
.	O

Effect	O
of	O
diuresis	O
on	O
extracorporeal	O
shockwave	O
lithotripsy	O
treatment	O
of	O
ureteric	O
calculi	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
diuresis	Physical
during	O
extracorporeal	Physical
shockwave	Physical
lithotripsy	Physical
(	Physical
ESWL	Physical
)	Physical
treatment	O
of	O
ureteric	O
calculi	O
.	O

The	O
purpose	O
is	O
to	O
improve	O
stone	O
fragmentation	O
and	O
clearance	O
rates	O
.	O

MATERIALS	O
AND	O
METHODS	O
One	O
hundred	O
and	O
six	O
consecutive	O
patients	O
with	O
ureteric	O
calculi	O
at	O
different	O
levels	O
were	O
treated	O
by	O
ESWL	Surgical
using	O
Siemens	O
Lithostar	O
2	O
machine	O
.	O

Patients	O
have	O
been	O
randomized	O
into	O
two	O
treatment	O
groups	O
.	O

The	O
first	O
group	O
was	O
treated	O
by	O
standard	Surgical
ESWL	Surgical
and	O
included	O
54	O
patients	O
.	O

The	O
second	O
group	O
was	O
treated	O
by	O
ESWL	Surgical
with	Surgical
diuresis	Surgical
during	Surgical
the	Surgical
ESWL	Surgical
session	Surgical
.	O

Shock	O
waves	O
were	O
given	O
at	O
a	O
rate	O
of	O
90	O
shocks/minute	O
with	O
energy	O
starting	O
from	O
10	O
up	O
to	O
18	O
KV	O
.	O

During	O
the	O
ESWL	O
session	O
the	O
patient	O
belonging	O
to	O
the	O
second	O
group	O
received	O
i.v	O
.	O

infusion	O
of	O
500	O
ml	O
normal	O
saline	O
containing	O
40	O
mg	O
furosemide	O
as	O
a	O
diuretic	O
.	O

The	O
stone	O
fragmentation	O
and	O
clearance	O
rates	O
were	O
the	O
two	O
end	O
points	O
for	O
evaluation	O
.	O

RESULTS	O
The	O
average	O
number	O
of	O
sessions	O
per	O
stone	O
was	O
1.92	O
and	O
1.5	O
and	O
the	O
average	O
number	O
of	O
shocks	O
per	O
stone	O
was	O
6295	O
and	O
5300	O
for	O
the	O
first	O
and	O
second	O
treatment	O
groups	O
respectively	O
.	O

Stone	O
fragmentation	O
rate	O
was	O
47/54	O
(	O
87	O
%	O
)	O
and	O
50/52	O
(	O
96.2	O
%	O
)	O
and	O
the	O
stone	O
clearance	O
(	O
success	O
)	O
rate	O
was	O
47/54	O
(	O
87	O
%	O
)	O
and	O
48/52	O
(	O
92.3	O
%	O
)	O
for	O
the	O
first	O
and	O
the	O
second	O
groups	O
respectively	O
.	O

Analysis	O
of	O
the	O
results	O
in	O
relation	O
to	O
stone	O
location	O
showed	O
that	O
the	O
two	O
treatment	O
groups	O
were	O
comparable	O
for	O
upper	O
and	O
middle	O
ureteric	O
calculi	O
.	O

However	O
for	O
distal	O
ureteric	O
stones	O
,	O
the	O
addition	O
of	O
diuresis	O
during	O
ESWL	O
was	O
associated	O
with	O
a	O
lower	O
mean	O
number	O
of	O
ESWL	O
sessions	O
and	O
shocks	O
per	O
stone	O
compared	O
with	O
standard	O
ESWL	O
:	O
1.38	O
and	O
4950	O
for	O
ESWL	O
with	O
diuresis	O
compared	O
with	O
2.9	O
and	O
8544	O
for	O
standard	O
ESWL	O
respectively	O
.	O

The	O
stone	O
fragmentation	O
and	O
3-month	O
clearance	O
(	O
success	O
)	O
rates	O
were	O
clearly	O
higher	O
:	O
93.8	O
%	O
and	O
87.5	O
%	O
respectively	O
for	O
ESWL	O
with	O
diuresis	O
compared	O
with	O
70.6	O
%	O
(	O
for	O
both	O
fragmentation	O
and	O
clearance	O
)	O
with	O
standard	O
ESWL	O
.	O

CONCLUSIONS	O
Diuresis	O
is	O
a	O
useful	O
,	O
inexpensive	O
and	O
safe	O
adjunct	O
to	O
ESWL	O
of	O
ureteric	O
stones	O
.	O

It	O
markedly	O
improves	O
the	O
results	O
of	O
ESWL	O
treatment	O
of	O
distal	O
ureteric	O
stones	O
compared	O
with	O
standard	O
ESWL	O
.	O

A	O
controlled	O
study	O
of	O
the	O
effect	O
of	O
indomethacin	O
in	O
uremic	O
pericarditis	O
.	O

To	O
determine	O
the	O
impact	O
of	O
indomethacin	O
on	O
the	O
course	O
of	O
uremic	O
pericarditis	O
we	O
performed	O
a	O
prospective	O
,	O
double	O
blind	O
study	O
in	O
which	O
24	O
patients	O
with	O
endstage	O
chronic	O
renal	O
failure	O
and	O
pericarditis	O
randomly	O
received	O
indomethacin	O
,	O
25	O
mg	O
four	O
times	O
daily	O
,	O
(	O
11	O
patients	O
)	O
or	O
a	O
placebo	Control
(	O
13	O
patients	O
)	O
for	O
a	O
3-week	O
period	O
.	O

All	O
patients	O
received	O
peritoneal	O
or	O
hemodialysis	O
treatment	O
concurrently	O
with	O
the	O
study	O
drug	O
.	O

In	O
contrast	O
to	O
the	O
placebo	Control
,	O
indomethacin	O
produced	O
an	O
immediate	O
and	O
sustained	O
reduction	O
of	O
fever	O
in	O
all	O
but	O
one	O
patient	O
.	O

On	O
the	O
other	O
hand	O
,	O
indomethacin	O
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
chest	O
pain	O
(	O
mean	O
days	O
+/-	O
SE	O
:	O
placebo	Control
1.4	O
+/-	O
0.6	O
,	O
indomethacin	Pharmacological
5.5	O
+/-	O
3.3	O
)	O
,	O
duration	O
of	O
pericardial	O
friction	O
rub	O
(	O
placebo	O
10.3	O
+/-	O
1.7	O
,	O
indomethacin	O
16.0	O
+/-	O
3.8	O
)	O
,	O
or	O
on	O
the	O
amount	O
of	O
pericardial	O
effusion	O
.	O

Further	O
,	O
indomethacin	O
did	O
not	O
diminish	O
the	O
need	O
for	O
invasive	O
surgical	O
procedures	O
for	O
relief	O
of	O
tamponade	O
(	O
three	O
of	O
13	O
placebo	O
patients	O
,	O
two	O
of	O
11	O
indomethacin	O
patients	O
)	O
or	O
result	O
in	O
decreased	O
mortality	O
rate	O
.	O

Death	O
(	O
not	O
due	O
to	O
pericarditis	O
)	O
occurred	O
in	O
two	O
patients	O
treated	O
with	O
indomethacin	O
and	O
one	O
patient	O
who	O
received	O
the	O
placebo	O
.	O

In	O
our	O
patients	O
pericarditis	O
encompassed	O
a	O
wide	O
spectrum	O
ranging	O
from	O
a	O
mild	O
illness	O
of	O
several	O
days	O
duration	O
to	O
a	O
painful	O
and	O
debilitating	O
disease	O
lasting	O
weeks	O
and	O
requiring	O
surgical	O
intervention	O
.	O

Although	O
the	O
size	O
of	O
our	O
population	O
prohibits	O
definitive	O
conclusions	O
,	O
it	O
would	O
appear	O
that	O
,	O
except	O
for	O
fever	O
,	O
the	O
manifestations	O
and	O
natural	O
history	O
of	O
this	O
illness	O
are	O
unaffected	O
by	O
indomethacin	O
.	O

What	O
is	O
the	O
optimum	O
maximal	O
gonadotropin	Pharmacological
dosage	O
used	O
in	O
microdose	O
flare-up	O
cycles	O
in	O
poor	O
responders	O
?	O
OBJECTIVE	O
To	O
find	O
out	O
the	O
optimum	O
maximal	O
dosage	O
of	O
recombinant	O
follicle	O
stimulating	O
hormone	O
(	O
rFSH	O
)	O
in	O
microdose	O
gonadotropin-releasing	Pharmacological
hormone	Pharmacological
analog	Pharmacological
(	Pharmacological
GnRH-a	Pharmacological
)	Pharmacological
flare	O
cycles	O
in	O
poor	O
responders	O
.	O

DESIGN	O
Prospective	O
randomized	O
study	O
.	O

SETTING	O
Private	O
infertility	O
clinic	O
.	O

PATIENT	O
(	O
S	O
)	O
A	O
total	O
of	O
119	O
women	O
were	O
taken	O
into	O
the	O
study	O
.	O

INTERVENTION	O
(	O
S	O
)	O
The	O
study	O
group	O
underwent	O
a	O
microdose	O
protocol	O
with	O
a	O
GnRH-agonist	Physical
followed	O
by	O
rFSH	Physical
administration	Physical
.	O

On	O
the	O
third	O
day	O
of	O
GnRH-a	Pharmacological
administration	O
,	O
119	O
patients	O
were	O
randomized	O
in	O
three	O
groups	O
to	O
receive	O
daily	O
fixed	O
doses	O
of	O
300	O
IU	O
of	O
rFSH	Physical
(	O
group	O
A	O
,	O
n	O
=	O
38	O
)	O
,	O
or	O
450	O
IU	O
of	O
rFSH	O
(	O
group	O
B	O
,	O
n	O
=	O
39	O
)	O
,	O
or	O
600	O
IU	O
of	O
rFSH	O
(	O
group	O
C	O
,	O
n	O
=	O
42	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Peak	O
E	O
(	O
2	O
)	O
levels	O
,	O
days	O
of	O
stimulation	O
with	O
rFSH	O
,	O
total	O
rFSH	O
dosage	O
,	O
total	O
number	O
of	O
oocytes	O
retrieved	O
,	O
M2	O
oocytes	O
retrieved	O
,	O
total	O
number	O
of	O
embryos	O
,	O
number	O
of	O
embryos	O
transferred	O
,	O
number	O
of	O
Grade-1	O
embryos	O
transferred	O
,	O
clinical	O
pregnancy	O
rate	O
(	O
positive	O
fetal	O
cardiac	O
activity	O
)	O
,	O
and	O
cancellation	O
rates	O
of	O
stimulation	O
and	O
embryo	O
transfer	O
.	O

RESULT	O
(	O
S	O
)	O
Clinical	O
pregnancy	O
rates	O
were	O
13.1	O
%	O
,	O
15.3	O
%	O
,	O
and	O
16.1	O
%	O
for	O
group	O
A	O
,	O
group	O
B	O
,	O
and	O
group	O
C	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
age	O
,	O
peak	O
serum	O
E	O
(	O
2	O
)	O
concentration	O
,	O
days	O
of	O
stimulation	O
with	O
rFSH	O
,	O
total	O
number	O
of	O
M2	O
oocytes	O
retrieved	O
,	O
number	O
of	O
embryos	O
transferred	O
,	O
clinical	O
pregnancy	O
rates	O
,	O
and	O
cancellation	O
rates	O
of	O
stimulation	O
and	O
embryo	O
transfer	O
between	O
the	O
three	O
groups	O
except	O
for	O
total	O
rFSH	O
dosage	O
.	O

CONCLUSION	O
(	O
S	O
)	O
There	O
is	O
no	O
need	O
to	O
use	O
doses	O
above	O
300	O
IU	O
of	O
rFSH	O
to	O
increase	O
the	O
pregnancy	O
rate	O
in	O
microdose	O
cycles	O
.	O

In	O
addition	O
,	O
because	O
the	O
duration	O
of	O
stimulation	O
does	O
not	O
differ	O
between	O
the	O
groups	O
,	O
the	O
usage	O
of	O
300	O
IU	O
rFSH	O
in	O
microdose	O
cycles	O
results	O
in	O
less	O
total	O
amount	O
of	O
rFSH	O
consumed	O
in	O
a	O
cycle	O
compared	O
with	O
higher	O
dosages	O
,	O
and	O
this	O
would	O
obviously	O
cost	O
less	O
money	O
to	O
the	O
patients	O
.	O

Effect	O
of	O
enalapril	Pharmacological
on	O
myocardial	O
infarction	O
and	O
unstable	O
angina	O
in	O
patients	O
with	O
low	O
ejection	O
fractions	O
.	O

An	O
association	O
between	O
raised	O
renin	O
levels	O
and	O
myocardial	O
infarction	O
has	O
been	O
reported	O
.	O

We	O
studied	O
the	O
effects	O
of	O
enalapril	Pharmacological
,	O
an	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
myocardial	O
infarction	O
and	O
unstable	O
angina	O
in	O
6797	O
patients	O
with	O
ejection	O
fractions	O
<	O
or	O
=	O
0.35	O
enrolled	O
into	O
the	O
two	O
Studies	O
of	O
Left	O
Ventricular	O
Dysfunction	O
(	O
SOLVD	O
)	O
trials	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
placebo	Control
(	O
n	O
=	O
3401	O
)	O
or	O
enalapril	Pharmacological
(	O
n	O
=	O
3396	O
)	O
at	O
doses	O
of	O
2.5-20	O
mg	O
per	O
day	O
in	O
two	O
concurrent	O
double-blind	O
trials	O
with	O
the	O
same	O
protocol	O
.	O

Patients	O
with	O
heart	O
failure	O
entered	O
the	O
treatment	O
trial	O
(	O
n	O
=	O
2569	O
)	O
and	O
those	O
without	O
heart	O
failure	O
entered	O
the	O
prevention	O
trial	O
(	O
n	O
=	O
4228	O
)	O
.	O

Follow-up	O
averaged	O
40	O
months	O
.	O

In	O
each	O
trial	O
there	O
were	O
significant	O
reductions	O
in	O
the	O
number	O
of	O
patients	O
developing	O
myocardial	O
infarction	O
(	O
treatment	O
trial	O
:	O
158	O
placebo	Control
vs	O
127	O
enalapril	Pharmacological
,	O
p	O
<	O
0.02	O
;	O
prevention	O
trial	O
:	O
204	O
vs	O
161	O
p	O
<	O
0.01	O
)	O
or	O
unstable	O
angina	O
(	O
240	O
vs	O
187	O
p	O
<	O
0.001	O
;	O
355	O
vs	O
312	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Combined	O
,	O
there	O
were	O
362	O
placebo	Control
group	O
patients	O
with	O
myocardial	O
infarction	O
compared	O
with	O
288	O
in	O
the	O
enalapril	Pharmacological
group	O
(	O
risk	O
reduction	O
23	O
%	O
,	O
95	O
%	O
CI	O
11-34	O
%	O
;	O
p	O
<	O
0.001	O
)	O
.	O

595	O
placebo	Control
group	O
patients	O
developed	O
unstable	O
angina	O
compared	O
with	O
499	O
in	O
the	O
enalapril	Pharmacological
group	O
(	O
risk	O
reduction	O
20	O
%	O
,	O
95	O
%	O
CI	O
9-29	O
%	O
,	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
also	O
a	O
reduction	O
in	O
cardiac	O
deaths	O
(	O
711	O
placebo	Control
,	O
615	O
enalapril	Pharmacological
;	O
p	O
<	O
0.003	O
)	O
,	O
so	O
that	O
the	O
reduction	O
in	O
the	O
combined	O
endpoint	O
of	O
deaths	O
,	O
myocardial	O
infarction	O
,	O
and	O
unstable	O
angina	O
was	O
highly	O
significant	O
(	O
20	O
%	O
risk	O
reduction	O
,	O
95	O
%	O
CI	O
14-26	O
%	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Enalapril	Control
treatment	O
significantly	O
reduced	O
myocardial	O
infarction	O
,	O
unstable	O
angina	O
,	O
and	O
cardiac	O
mortality	O
in	O
patients	O
with	O
low	O
ejection	O
fractions	O
.	O

Endoscopic	Surgical
ligation	Surgical
compared	O
with	O
sclerotherapy	Pharmacological
for	O
bleeding	O
esophageal	O
varices	O
in	O
children	O
with	O
extrahepatic	O
portal	O
venous	O
obstruction	O
.	O

Endoscopic	Pharmacological
sclerotherapy	Pharmacological
is	O
an	O
effective	O
treatment	O
for	O
bleeding	O
esophageal	O
varices	O
,	O
but	O
it	O
is	O
associated	O
with	O
significant	O
complications	O
.	O

Endoscopic	Surgical
ligation	Surgical
,	O
a	O
new	O
form	O
of	O
endoscopic	O
treatment	O
for	O
bleeding	O
varices	O
,	O
has	O
been	O
shown	O
to	O
be	O
superior	O
to	O
sclerotherapy	O
in	O
adult	O
patients	O
with	O
cirrhosis	O
.	O

To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
endoscopic	O
sclerotherapy	O
and	O
ligation	O
,	O
the	O
2	O
methods	O
were	O
compared	O
in	O
a	O
randomized	O
control	O
trial	O
in	O
49	O
children	O
with	O
extrahepatic	O
portal	O
venous	O
obstruction	O
who	O
had	O
proven	O
bleeding	O
from	O
esophageal	O
varices	O
.	O

Twenty-four	O
patients	O
were	O
treated	O
with	O
sclerotherapy	Pharmacological
and	O
25	O
with	O
band	Surgical
ligation	Surgical
.	Surgical

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
sclerotherapy	O
and	O
ligation	O
groups	O
in	O
arresting	O
active	O
index	O
bleeding	O
(	O
100	O
%	O
each	O
)	O
and	O
achieving	O
variceal	O
eradication	O
(	O
91.7	O
%	O
vs.	O
96	O
%	O
,	O
P	O
=.61	O
)	O
.	O

Band	O
ligation	O
eradicated	O
varices	O
in	O
fewer	O
endoscopic	O
sessions	O
than	O
did	O
sclerotherapy	O
(	O
3.9	O
+/-	O
1.1	O
vs.	O
6.1	O
+/-	O
1.7	O
,	O
respectively	O
,	O
P	O
<	O
.0001	O
)	O
.	O

The	O
rebleeding	O
rate	O
was	O
significantly	O
higher	O
in	O
the	O
sclerotherapy	O
group	O
(	O
25	O
%	O
vs.	O
4	O
%	O
,	O
P	O
=.049	O
)	O
,	O
as	O
was	O
the	O
rate	O
of	O
major	O
complications	O
(	O
25	O
%	O
vs.	O
4	O
%	O
,	O
P	O
=.049	O
)	O
.	O

After	O
eradication	O
,	O
esophageal	O
variceal	O
recurrence	O
was	O
not	O
significantly	O
different	O
in	O
patients	O
treated	O
by	O
ligation	O
than	O
by	O
sclerotherapy	O
(	O
17.4	O
%	O
vs.	O
10	O
%	O
,	O
P	O
=.67	O
)	O
.	O

In	O
conclusion	O
,	O
variceal	Surgical
band	Surgical
ligation	Surgical
in	O
children	O
is	O
a	O
safe	O
and	O
effective	O
technique	O
that	O
achieves	O
variceal	O
eradication	O
more	O
quickly	O
,	O
with	O
a	O
lower	O
rebleeding	O
rate	O
and	O
fewer	O
complications	O
compared	O
with	O
sclerotherapy	O
.	O

Parent-mediated	Educational
communication-focused	Educational
treatment	Educational
in	O
children	O
with	O
autism	O
(	O
PACT	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Results	O
of	O
small	O
trials	O
suggest	O
that	O
early	O
interventions	O
for	O
social	O
communication	O
are	O
effective	O
for	O
the	O
treatment	O
of	O
autism	O
in	O
children	O
.	O

We	O
therefore	O
investigated	O
the	O
efficacy	O
of	O
such	O
an	O
intervention	O
in	O
a	O
larger	O
trial	O
.	O

METHODS	O
Children	O
with	O
core	O
autism	O
(	O
aged	O
2	O
years	O
to	O
4	O
years	O
and	O
11	O
months	O
)	O
were	O
randomly	O
assigned	O
in	O
a	O
one-to-one	O
ratio	O
to	O
a	O
parent-mediated	Educational
communication-focused	Educational
(	Educational
Preschool	Educational
Autism	Educational
Communication	Educational
Trial	Educational
[	Educational
PACT	Educational
]	Educational
)	Educational
intervention	Educational
or	O
treatment	Control
as	Control
usual	Control
at	O
three	O
specialist	O
centres	O
in	O
the	O
UK	O
.	O

Those	O
assigned	O
to	O
PACT	O
were	O
also	O
given	O
treatment	O
as	O
usual	O
.	O

Randomisation	O
was	O
by	O
use	O
of	O
minimisation	O
of	O
probability	O
in	O
the	O
marginal	O
distribution	O
of	O
treatment	O
centre	O
,	O
age	O
(	O
<	O
/=42	O
months	O
or	O
>	O
42	O
months	O
)	O
,	O
and	O
autism	O
severity	O
(	O
Autism	O
Diagnostic	O
Observation	O
Schedule-Generic	O
[	O
ADOS-G	O
]	O
algorithm	O
score	O
12-17	O
or	O
18-24	O
)	O
.	O

Primary	O
outcome	O
was	O
severity	O
of	O
autism	O
symptoms	O
(	O
a	O
total	O
score	O
of	O
social	O
communication	O
algorithm	O
items	O
from	O
ADOS-G	O
,	O
higher	O
score	O
indicating	O
greater	O
severity	O
)	O
at	O
13	O
months	O
.	O

Complementary	O
secondary	O
outcomes	O
were	O
measures	O
of	O
parent-child	O
interaction	O
,	O
child	O
language	O
,	O
and	O
adaptive	O
functioning	O
in	O
school	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
as	O
an	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
,	O
number	O
ISRCTN58133827	O
.	O

RESULTS	O
152	O
children	O
were	O
recruited	O
.	O

77	O
were	O
assigned	O
to	O
PACT	Educational
(	O
London	O
[	O
n=26	O
]	O
,	O
Manchester	O
[	O
n=26	O
]	O
,	O
and	O
Newcastle	O
[	O
n=25	O
]	O
)	O
;	O
and	O
75	O
to	O
treatment	Other
as	Other
usual	Other
(	O
London	O
[	O
n=26	O
]	O
,	O
Manchester	O
[	O
n=26	O
]	O
,	O
and	O
Newcastle	O
[	O
n=23	O
]	O
)	O
.	O

At	O
the	O
13-month	O
endpoint	O
,	O
the	O
severity	O
of	O
symptoms	O
was	O
reduced	O
by	O
3.9	O
points	O
(	O
SD	O
4.7	O
)	O
on	O
the	O
ADOS-G	O
algorithm	O
in	O
the	O
group	O
assigned	O
to	O
PACT	O
,	O
and	O
2.9	O
(	O
3.9	O
)	O
in	O
the	O
group	O
assigned	O
to	O
treatment	O
as	O
usual	O
,	O
representing	O
a	O
between-group	O
effect	O
size	O
of	O
-0.24	O
(	O
95	O
%	O
CI	O
-0.59	O
to	O
0.11	O
)	O
,	O
after	O
adjustment	O
for	O
centre	O
,	O
sex	O
,	O
socioeconomic	O
status	O
,	O
age	O
,	O
and	O
verbal	O
and	O
non-verbal	O
abilities	O
.	O

Treatment	O
effect	O
was	O
positive	O
for	O
parental	O
synchronous	O
response	O
to	O
child	O
(	O
1.22	O
,	O
0.85	O
to	O
1.59	O
)	O
,	O
child	O
initiations	O
with	O
parent	O
(	O
0.41	O
,	O
0.08	O
to	O
0.74	O
)	O
,	O
and	O
for	O
parent-child	O
shared	O
attention	O
(	O
0.33	O
,	O
-0.02	O
to	O
0.68	O
)	O
.	O

Effects	O
on	O
directly	O
assessed	O
language	O
and	O
adaptive	O
functioning	O
in	O
school	O
were	O
small	O
.	O

INTERPRETATION	O
On	O
the	O
basis	O
of	O
our	O
findings	O
,	O
we	O
can	O
not	O
recommend	O
the	O
addition	O
of	O
the	O
PACT	Educational
intervention	Educational
to	O
treatment	O
as	O
usual	O
for	O
the	O
reduction	O
of	O
autism	O
symptoms	O
;	O
however	O
,	O
a	O
clear	O
benefit	O
was	O
noted	O
for	O
parent-child	O
dyadic	O
social	O
communication	O
.	O

FUNDING	O
UK	O
Medical	O
Research	O
Council	O
,	O
and	O
UK	O
Department	O
for	O
Children	O
,	O
Schools	O
and	O
Families	O
.	O

Amiprilose	Pharmacological
hydrochloride	Pharmacological
for	O
rheumatoid	O
arthritis	O
.	O

STUDY	O
OBJECTIVE	O
To	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
amiprilose	Pharmacological
hydrochloride	Pharmacological
(	Pharmacological
HCl	Pharmacological
)	Pharmacological
,	O
a	O
novel	O
synthetic	O
carbohydrate	O
with	O
anti-inflammatory	O
and	O
immunomodulatory	O
properties	O
,	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

DESIGN	O
Prospective	O
,	O
multicenter	O
,	O
randomized	O
,	O
parallel	O
group	O
,	O
double-blind	O
placebo-controlled	O
12-week	O
trial	O
.	O

PATIENTS	O
Two	O
hundred	O
and	O
one	O
functional	O
class	O
I	O
and	O
II	O
patients	O
with	O
definite	O
or	O
classic	O
rheumatoid	O
arthritis	O
,	O
previously	O
untreated	O
with	O
disease	O
modifying	O
antirheumatic	O
drugs	O
.	O

INTERVENTIONS	O
Patients	O
were	O
withdrawn	O
from	O
nonsteroidal	O
anti-inflammatory	O
drug	O
therapy	O
.	O

Those	O
who	O
flared	O
were	O
randomly	O
assigned	O
to	O
amiprilose	Pharmacological
HCl	Pharmacological
,	Pharmacological
6	Pharmacological
g/d	Pharmacological
,	O
or	O
placebo	O
for	O
12	O
weeks	O
.	O

No	O
concomitant	O
anti-inflammatory	O
or	O
antirheumatic	O
drug	O
therapy	O
was	O
permitted	O
during	O
the	O
study	O
.	O

Combination	O
acetaminophen	O
and	O
propoxyphene	O
napsylate	O
was	O
the	O
only	O
supplemental	O
analgesic	O
medication	O
allowed	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
The	O
number	O
of	O
painful	O
joints	O
and	O
swollen	O
joints	O
,	O
joint	O
pain	O
and	O
joint	O
swelling	O
indices	O
,	O
left	O
and	O
right	O
grip	O
strength	O
,	O
investigator	O
global	O
assessment	O
,	O
and	O
patient	O
global	O
assessment	O
returned	O
to	O
baseline	O
for	O
the	O
amiprilose	Pharmacological
group	O
and	O
showed	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0.05	O
)	O
differences	O
from	O
the	O
placebo	Control
group	O
within	O
4	O
to	O
6	O
weeks	O
.	O

The	O
protocol	O
criteria	O
for	O
overall	O
therapeutic	O
response	O
were	O
satisfied	O
by	O
41	O
%	O
of	O
the	O
amiprilose	Pharmacological
patients	O
,	O
compared	O
with	O
21	O
%	O
of	O
the	O
placebo	Control
group	O
(	O
P	O
=	O
0.003	O
)	O
.	O

Approximately	O
0.5	O
tablet	O
per	O
day	O
less	O
analgesic	O
medication	O
was	O
taken	O
by	O
the	O
amiprilose	O
group	O
(	O
P	O
less	O
than	O
0.05	O
at	O
weeks	O
6	O
and	O
12	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
morning	O
stiffness	O
,	O
walking	O
time	O
,	O
erythrocyte	O
sedimentation	O
rate	O
,	O
C-reactive	O
protein	O
,	O
or	O
rheumatoid	O
factor	O
between	O
the	O
groups	O
.	O

A	O
similar	O
number	O
of	O
adverse	O
experiences	O
were	O
reported	O
by	O
the	O
patients	O
on	O
amiprilose	Pharmacological
(	O
67	O
%	O
)	O
and	O
on	O
placebo	Control
(	O
63	O
%	O
)	O
.	O

One	O
patient	O
on	O
amiprilose	Pharmacological
developed	O
thrombocytopenia	O
of	O
unknown	O
cause	O
;	O
no	O
other	O
reported	O
adverse	O
effects	O
were	O
serious	O
.	O

CONCLUSIONS	O
Amiprilose	Pharmacological
HCl	Pharmacological
has	O
significant	O
anti-inflammatory	O
activity	O
and	O
a	O
favorable	O
safety	O
profile	O
when	O
used	O
as	O
the	O
sole	O
antirheumatic	O
therapy	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
.	O

Synthetic	O
carbohydrates	O
may	O
represent	O
an	O
important	O
new	O
class	O
of	O
drugs	O
for	O
the	O
treatment	O
of	O
inflammatory	O
,	O
autoimmune	O
diseases	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
comparative	O
trial	O
of	O
a	O
COX-2	Pharmacological
selective	Pharmacological
nonsteroidal	Pharmacological
anti-inflammatory	Pharmacological
drug	Pharmacological
versus	O
placebo	Control
in	O
inguinal	O
herniorrhaphy	O
patients	O
.	O

OBJECTIVE	O
The	O
standard	O
opioid	O
treatment	O
for	O
postoperative	O
pain	O
can	O
be	O
associated	O
with	O
nausea	O
,	O
vomiting	O
,	O
and	O
constipation	O
.	O

In	O
addition	O
,	O
opioids	O
often	O
provide	O
insufficient	O
pain	O
relief	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
postoperative	O
pain	O
and	O
functional	O
outcomes	O
in	O
patients	O
undergoing	O
inguinal	O
herniorrhaphy	O
who	O
receive	O
a	O
COX-2	O
selective	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(	O
COX-2	O
)	O
or	O
placebo	O
preoperatively	O
and	O
for	O
4	O
days	O
postoperatively	O
.	O

METHODS	O
A	O
prospective	O
,	O
randomized	O
,	O
blinded	O
,	O
placebo-controlled	Control
trial	O
was	O
conducted	O
in	O
adults	O
undergoing	O
elective	O
,	O
outpatient	O
,	O
unilateral	O
inguinal	O
herniorrhaphy	O
.	O

Patients	O
received	O
rofecoxib	Pharmacological
(	O
50	O
mg	O
,	O
1	O
h	O
prior	O
to	O
incision	O
)	O
or	O
placebo	Control
.	O

Doses	O
were	O
re-administered	O
once	O
daily	O
on	O
postoperative	O
days	O
1-4	O
.	O

Patients	O
were	O
also	O
given	O
hydrocodone	Pharmacological
bitartrate	Pharmacological
for	O
use	O
as	O
needed	O
in	O
the	O
postoperative	O
period	O
.	O

Pain	O
outcomes	O
were	O
assessed	O
,	O
including	O
pain	O
intensity	O
(	O
1-10	O
visual-analogue	O
scale	O
)	O
and	O
the	O
use	O
of	O
hydrocodone	O
bitartrate	O
.	O

In	O
addition	O
,	O
functional	O
outcomes	O
such	O
as	O
activity	O
and	O
return	O
of	O
bowel	O
function	O
were	O
examined	O
for	O
5	O
postoperative	O
days	O
.	O

Incidence	O
and	O
severity	O
of	O
side	O
effects	O
were	O
examined	O
.	O

Statistics	O
are	O
mean	O
+/-	O
standard	O
deviation	O
.	O

RESULTS	O
Fifty-five	O
subjects	O
completed	O
the	O
study	O
.	O

Twenty-six	O
patients	O
received	O
rofecoxib	O
and	O
29	O
patients	O
received	O
placebo	O
.	O

Patients	O
who	O
received	O
COX-2	O
demonstrated	O
improved	O
bowel	O
function	O
as	O
reflected	O
by	O
more	O
bowel	O
movements	O
on	O
postoperative	O
day	O
2	O
and	O
postoperative	O
day	O
3	O
.	O

COX-2-treated	O
patients	O
also	O
reported	O
better	O
oral	O
intake	O
on	O
these	O
same	O
days	O
.	O

In	O
addition	O
,	O
COX-2-treated	O
patients	O
had	O
less	O
difficulty	O
coughing	O
on	O
postoperative	O
day	O
1	O
.	O

Overall	O
satisfaction	O
with	O
pain	O
management	O
was	O
better	O
in	O
COX-2-treated	O
patients	O
(	O
very	O
satisfied	O
vs.	O
satisfied	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
amount	O
of	O
hydrocodone	O
bitartrate	O
consumption	O
.	O

There	O
were	O
no	O
complications	O
during	O
the	O
study	O
period	O
.	O

CONCLUSIONS	O
Administration	O
of	O
a	O
COX-2	O
selective	O
nonsteroidal	O
anti-inflammatory	O
drug	O
prior	O
to	O
and	O
following	O
outpatient	O
inguinal	O
herniorrhaphy	O
improves	O
functional	O
outcomes	O
when	O
compared	O
with	O
placebo	O
and	O
increases	O
patient	O
satisfaction	O
.	O

These	O
results	O
suggest	O
that	O
multimodal	O
pain	O
therapy	O
with	O
COX-2	O
inhibitors	O
may	O
have	O
a	O
role	O
in	O
outpatient	O
inguinal	O
hernia	O
repair	O
.	O

Lower	O
extremity	O
deep	O
vein	O
thrombosis	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
in	O
comatose	O
or	O
sedated	O
patients	O
undergoing	O
femoral	Surgical
vein	Surgical
catheterization	Surgical
.	O

OBJECTIVES	O
To	O
determine	O
the	O
rate	O
of	O
lower	O
extremity	O
deep	O
vein	O
thrombosis	O
after	O
the	O
use	O
of	O
femoral	Physical
catheters	Physical
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
comatose	O
or	O
sedated	O
adults	O
.	O

Results	O
were	O
then	O
compared	O
with	O
results	O
of	O
patients	O
undergoing	O
superior	Surgical
vena	Surgical
cava	Surgical
catheterization	Surgical
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
,	O
unblinded	O
study	O
.	O

SETTING	O
A	O
mixed	O
medical/surgical	O
ICU	O
in	O
a	O
university	O
hospital	O
.	O

PATIENTS	O
Sixty-one	O
comatose	O
or	O
sedated	O
patients	O
admitted	O
to	O
the	O
ICU	O
who	O
underwent	O
central	Surgical
venous	Surgical
catheterization	Surgical
.	O

INTERVENTIONS	O
Patients	O
were	O
monitored	O
for	O
signs	O
of	O
thrombotic	O
complications	O
.	O

On	O
catheter	O
removal	O
,	O
a	O
lower-extremity	O
bilateral	O
phlebographic	O
examination	O
was	O
performed	O
in	O
each	O
patient	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
After	O
randomization	O
,	O
31	O
patients	O
underwent	O
femoral	Surgical
vein	Surgical
catheterization	Surgical
and	O
30	O
patients	O
underwent	O
superior	Surgical
vena	Surgical
cava	Surgical
catheterization	Surgical
,	O
either	O
by	O
axillary	O
(	O
21	O
patients	O
)	O
or	O
internal	O
jugular	O
vein	O
(	O
10	O
patients	O
)	O
cannulation	O
.	O

Single	Physical
lumen	Physical
polyurethane	Physical
catheters	Physical
were	O
inserted	O
for	O
a	O
mean	O
duration	O
of	O
7.1	O
+/-	O
4.6	O
(	O
SD	O
)	O
days	O
in	O
the	O
femoral	Surgical
vein	Surgical
group	Surgical
and	O
9.9	O
+/-	O
5.5	O
days	O
in	O
the	O
superior	Physical
vena	Physical
cava	Physical
group	O
(	O
p	O
=	O
NS	O
)	O
.	O

No	O
patient	O
had	O
clinical	O
signs	O
of	O
leg	O
venous	O
thrombosis	O
or	O
pulmonary	O
embolism	O
during	O
the	O
study	O
period	O
.	O

In	O
each	O
patient	O
,	O
lower	Physical
extremity	Physical
bilateral	Physical
phlebography	Physical
was	O
performed	O
at	O
the	O
time	O
of	O
catheter	O
removal	O
.	O

Leg	O
phlebographies	O
were	O
normal	O
in	O
18	O
(	O
60	O
%	O
)	O
patients	O
in	O
the	O
femoral	O
vein	O
group	O
and	O
26	O
(	O
84	O
%	O
)	O
patients	O
in	O
the	O
superior	O
vena	O
cava	O
group	O
.	O

Fibrin	O
sleeves	O
which	O
developed	O
around	O
the	O
femoral	O
catheters	O
were	O
seen	O
in	O
seven	O
(	O
23.3	O
%	O
)	O
patients	O
in	O
the	O
femoral	Physical
vein	Physical
group	O
and	O
in	O
no	O
patients	O
in	O
the	O
superior	Physical
vena	Physical
cava	Physical
cannulation	Physical
group	O
.	O

Three	O
patients	O
had	O
femoral	O
vein	O
thrombosis	O
,	O
two	O
(	O
6.6	O
%	O
)	O
patients	O
in	O
the	O
femoral	Physical
vein	Physical
group	O
(	O
two	O
nonobstructive	O
thromboses	O
,	O
adherent	O
to	O
the	O
common	O
femoral	O
vein	O
wall	O
)	O
and	O
one	O
(	O
3.0	O
%	O
)	O
patient	O
in	O
the	O
superior	Physical
vena	Physical
cava	Physical
group	O
(	O
nonobstructive	O
thrombosis	O
which	O
developed	O
in	O
the	O
superficial	O
femoral	O
vein	O
)	O
(	O
p	O
=	O
NS	O
)	O
.	O

Lower	O
deep	O
extremities	O
thrombosis	O
developed	O
in	O
five	O
(	O
16.7	O
%	O
)	O
patients	O
in	O
the	O
femoral	O
vein	O
group	O
and	O
in	O
five	O
(	O
16	O
%	O
)	O
patients	O
in	O
the	O
superior	O
vena	O
cava	O
group	O
(	O
p	O
=	O
NS	O
)	O
.	O

CONCLUSIONS	O
Femoral	Surgical
vein	Surgical
catheterization	Surgical
with	O
a	O
polyurethane	O
catheter	O
is	O
associated	O
with	O
a	O
lower	O
rate	O
of	O
extremity	O
deep	O
vein	O
thrombosis	O
which	O
is	O
similar	O
to	O
the	O
rate	O
observed	O
after	O
superior	O
vena	O
cannulation	O
in	O
comatose	O
or	O
sedated	O
patients	O
.	O

Femoral	O
vein	O
thrombosis	O
was	O
observed	O
at	O
a	O
rate	O
of	O
6.6	O
%	O
after	O
femoral	Surgical
vein	Surgical
cannulation	Surgical
and	O
a	O
rate	O
of	O
3	O
%	O
after	O
superior	Surgical
vena	Surgical
cava	Surgical
cannulation	Surgical
.	O

Given	O
the	O
acceptable	O
rate	O
of	O
this	O
clinically	O
important	O
complication	O
,	O
femoral	Surgical
vein	Surgical
cannulation	Surgical
offers	O
an	O
attractive	O
alternative	O
to	O
insertion	O
via	O
the	O
vena	Physical
cava	Physical
in	O
the	O
critically	O
ill	O
.	O

An	O
exploratory	O
,	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
of	O
practice	Educational
nurse	Educational
training	Educational
in	O
the	O
use	O
of	O
asthma	O
action	O
plans	O
.	O

INTRODUCTION	O
To	O
investigate	O
the	O
feasibility	O
of	O
improving	O
asthma	O
management	O
-	O
in	O
particular	O
,	O
the	O
implementation	O
of	O
individualised	Physical
asthma	Physical
action	Physical
plans	Physical
(	Physical
AAPs	Physical
)	Physical
for	O
poorly-controlled	O
adult	O
asthma	O
patients	O
-	O
by	O
providing	O
training	O
in	O
asthma-focused	O
clinical	O
and	O
communication	O
skills	O
for	O
practice	O
nurses	O
who	O
deliver	O
asthma	O
clinics	O
.	O

METHODS	O
A	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
with	O
an	O
intervention	O
(	O
an	O
interactive	O
seminar	O
)	O
delivered	O
at	O
practice	O
level	O
(	O
n=13	O
practices	O
;	O
6=intervention	O
,	O
7=control	O
)	O
.	O

The	O
impact	O
of	O
the	O
intervention	O
was	O
assessed	O
against	O
patient	O
outcomes	O
:	O
routinely	O
available	O
asthma	O
outcome	O
measures	O
(	O
beta2-agonist	O
prescription	O
rate	O
and	O
number	O
of	O
oral	O
steroid	O
courses	O
)	O
for	O
asthma	O
patients	O
identified	O
as	O
being	O
poorly-controlled	O
from	O
practice	O
records	O
;	O
and	O
questionnaire	O
data	O
-	O
Mini	O
Asthma	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
AQLQ	O
)	O
and	O
the	O
Asthma	O
Control	O
Questionnaire	O
(	O
ACQ	O
)	O
-	O
from	O
a	O
subset	O
of	O
consenting	O
patients	O
.	O

Data	O
was	O
collected	O
at	O
baseline	O
and	O
at	O
6-month	O
follow-up	O
.	O

ANALYSISs	O
:	O
Routine	O
data	O
was	O
analysed	O
for	O
629	O
patients	O
.	O

236	O
(	O
37	O
%	O
)	O
of	O
these	O
patients	O
consented	O
to	O
provide	O
questionnaire	O
data	O
at	O
baseline	O
,	O
with	O
75	O
%	O
returning	O
questionnaires	O
at	O
follow-up	O
.	O

After	O
adjustment	O
for	O
baseline	O
and	O
practice	O
,	O
there	O
was	O
a	O
significant	O
difference	O
at	O
followup	O
between	O
intervention	O
and	O
control	O
practices	O
on	O
the	O
Mini	O
AQLQ	O
only	O
(	O
p=0.03	O
)	O
.	O

Estimates	O
for	O
subsequent	O
sample	O
sizes	O
to	O
inform	O
future	O
trials	O
of	O
asthma	O
training	O
were	O
identified	O
.	O

CONCLUSION	O
Training	O
designed	O
to	O
support	O
practice	O
nurses	O
in	O
implementing	O
individualised	O
AAPs	O
impacted	O
on	O
one	O
patient	O
outcome	O
only	O
.	O

This	O
disappointing	O
outcome	O
may	O
have	O
been	O
due	O
to	O
many	O
different	O
factors	O
such	O
as	O
outcome	O
measure	O
limitations	O
,	O
data	O
collection	O
problems	O
,	O
and	O
underestimating	O
the	O
complexity	O
of	O
supporting	O
practice	O
nurses	O
in	O
behaviour	O
change	O
.	O

Effect	O
of	O
nitazoxanide	Pharmacological
on	O
morbidity	O
and	O
mortality	O
in	O
Zambian	O
children	O
with	O
cryptosporidiosis	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Cryptosporidiosis	O
in	O
children	O
in	O
developing	O
countries	O
causes	O
persistent	O
diarrhoea	O
and	O
malnutrition	O
and	O
is	O
associated	O
with	O
increased	O
mortality	O
,	O
but	O
there	O
is	O
no	O
effective	O
treatment	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
nitazoxanide-a	Physical
new	O
broad-spectrum	O
antiparasitic	O
drug-on	O
morbidity	O
and	O
mortality	O
in	O
Zambian	O
children	O
with	O
diarrhoea	O
due	O
to	O
Cryptosporidium	O
parvum	O
.	O

METHODS	O
Children	O
with	O
cryptosporidial	O
diarrhoea	O
who	O
were	O
admitted	O
to	O
the	O
University	O
Teaching	O
Hospital	O
,	O
Lusaka	O
,	O
Zambia	O
,	O
between	O
November	O
,	O
2000	O
,	O
and	O
July	O
,	O
2001	O
,	O
and	O
whose	O
parents	O
consented	O
to	O
their	O
having	O
an	O
HIV	O
test	O
were	O
randomly	O
assigned	O
nitazoxanide	Pharmacological
(	O
100	O
mg	O
twice	O
daily	O
orally	O
for	O
3	O
days	O
)	O
or	O
placebo	Control
.	O

The	O
primary	O
endpoint	O
was	O
clinical	O
response	O
on	O
day	O
7	O
after	O
the	O
start	O
of	O
treatment	O
.	O

Secondary	O
endpoints	O
included	O
parasitological	O
response	O
by	O
day	O
10	O
and	O
mortality	O
at	O
day	O
8	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
,	O
with	O
exclusion	O
of	O
patients	O
subsequently	O
found	O
to	O
be	O
negative	O
for	O
C	O
parvum	O
or	O
co-infected	O
at	O
baseline	O
.	O

The	O
trial	O
was	O
stratified	O
by	O
HIV	O
serology	O
.	O

FINDINGS	O
50	O
HIV-seropositive	O
and	O
50	O
HIV-seronegative	O
children	O
were	O
recruited	O
for	O
the	O
study	O
,	O
four	O
of	O
whom	O
were	O
subsequently	O
excluded	O
.	O

In	O
HIV-seronegative	O
children	O
,	O
diarrhoea	O
resolved	O
in	O
14	O
(	O
56	O
%	O
)	O
of	O
25	O
receiving	O
nitazoxanide	O
and	O
5	O
(	O
23	O
%	O
)	O
of	O
22	O
receiving	O
placebo	O
(	O
difference	O
33	O
%	O
,	O
95	O
%	O
CI	O
7-59	O
;	O
p=0.037	O
)	O
.	O

C	O
parvum	O
was	O
eradicated	O
from	O
stool	O
in	O
13	O
(	O
52	O
%	O
)	O
of	O
25	O
receiving	O
nitazoxanide	O
and	O
three	O
(	O
14	O
%	O
)	O
of	O
22	O
receiving	O
placebo	O
(	O
38	O
%	O
,	O
95	O
%	O
CI	O
14-63	O
;	O
p=0.007	O
)	O
.	O

Four	O
children	O
(	O
18	O
%	O
)	O
of	O
22	O
in	O
the	O
placebo	O
group	O
had	O
died	O
by	O
day	O
8	O
,	O
compared	O
with	O
none	O
of	O
25	O
in	O
the	O
nitazoxanide	O
group	O
(	O
-18	O
%	O
,	O
-34	O
to	O
2	O
;	O
p=0.041	O
)	O
.	O

HIV-seropositive	O
children	O
did	O
not	O
benefit	O
from	O
nitazoxanide	O
.	O

Nitazoxanide	O
was	O
not	O
significantly	O
associated	O
with	O
adverse	O
events	O
in	O
either	O
stratum	O
.	O

INTERPRETATION	O
A	O
3-day	O
course	O
of	O
nitazoxanide	O
significantly	O
improved	O
the	O
resolution	O
of	O
diarrhoea	O
,	O
parasitological	O
eradication	O
,	O
and	O
mortality	O
in	O
HIV-seronegative	O
,	O
but	O
not	O
HIV-seropositive	O
,	O
children	O
.	O

Cost-effectiveness	O
of	O
clopidogrel	Pharmacological
in	O
acute	O
coronary	O
syndromes	O
in	O
Canada	O
:	O
a	O
long-term	O
analysis	O
based	O
on	O
the	O
CURE	O
trial	O
.	O

BACKGROUND	O
Cardiovascular	O
diseases	O
account	O
for	O
nearly	O
20	O
%	O
of	O
all	O
hospitalizations	O
in	O
Canada	O
and	O
consume	O
12	O
%	O
of	O
the	O
total	O
cost	O
of	O
all	O
illnesses	O
.	O

With	O
increasing	O
trends	O
of	O
cardiovascular	O
disease	O
and	O
increasing	O
costs	O
of	O
care	O
,	O
development	O
of	O
cost-effective	O
strategies	O
is	O
vital	O
.	O

The	O
Clopidogrel	Pharmacological
in	O
Unstable	O
angina	O
to	O
prevent	O
Recurrent	O
Events	O
(	O
CURE	O
)	O
trial	O
demonstrated	O
the	O
effectiveness	O
of	O
clopidogrel	Pharmacological
plus	Pharmacological
acetylsalicylic	Pharmacological
acid	Pharmacological
(	Pharmacological
ASA	Pharmacological
)	Pharmacological
compared	O
with	O
ASA	Pharmacological
alone	Pharmacological
in	O
reducing	O
cardiovascular	O
events	O
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
and	O
,	O
in	O
addition	O
,	O
patients	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
in	O
the	O
Percutaneous	O
Coronary	O
Intervention	O
in	O
CURE	O
(	O
PCI-CURE	O
)	O
trial	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
cost-effectiveness	O
of	O
clopidogrel	Pharmacological
in	O
the	O
Canadian	O
health	O
care	O
system	O
.	O

METHODS	O
Estimates	O
of	O
hospitalization	O
costs	O
were	O
based	O
on	O
the	O
2003	O
cost	O
schedules	O
released	O
by	O
the	O
Health	O
Funding	O
and	O
Costing	O
Branch	O
of	O
the	O
Alberta	O
Health	O
and	O
Wellness	O
,	O
as	O
well	O
as	O
on	O
the	O
Case	O
Mix	O
Group	O
classification	O
system	O
.	O

Life	O
expectancy	O
beyond	O
the	O
trial	O
was	O
estimated	O
from	O
the	O
Saskatchewan	O
Health	O
Database	O
.	O

Cost-effectiveness	O
was	O
expressed	O
as	O
the	O
incremental	O
cost-effectiveness	O
ratio	O
,	O
and	O
bootstrap	O
methods	O
were	O
used	O
to	O
estimate	O
the	O
joint	O
distribution	O
of	O
costs	O
and	O
effectiveness	O
.	O

RESULTS	O
Clopidogrel	Pharmacological
was	O
shown	O
to	O
be	O
cost-effective	O
,	O
with	O
incremental	O
cost-effectiveness	O
ratios	O
less	O
than	O
$	O
10,000	O
per	O
event	O
prevented	O
and	O
less	O
than	O
$	O
4,000	O
per	O
life-year	O
gained	O
.	O

The	O
probability	O
of	O
clopidogrel	O
resulting	O
in	O
cost	O
per	O
life-year	O
gained	O
of	O
less	O
than	O
$	O
20,000	O
was	O
0.975	O
for	O
CURE	O
patients	O
and	O
0.904	O
for	O
PCI-CURE	O
patients	O
.	O

CONCLUSIONS	O
The	O
economic	O
analysis	O
demonstrated	O
that	O
clopidogrel	Pharmacological
combination	Pharmacological
therapy	Pharmacological
is	O
not	O
only	O
cost-effective	O
as	O
antiplatelet	O
therapy	O
compared	O
with	O
ASA	Physical
alone	O
,	O
but	O
it	O
is	O
also	O
cost-effective	O
compared	O
with	O
other	O
commonly	O
used	O
and	O
openly	O
reimbursed	O
cardiovascular	O
therapies	O
in	O
the	O
Canadian	O
health	O
care	O
system	O
.	O

Altered	O
growth	O
hormone	O
response	O
after	O
growth	Pharmacological
hormone	Pharmacological
releasing	Pharmacological
hormone	Pharmacological
administration	O
in	O
chronic	O
renal	O
failure	O
.	O

Eleven	O
chronic	O
renal	O
failure	O
patients	O
and	O
11	O
matched	O
controls	O
,	O
received	O
growth	Pharmacological
hormone	Pharmacological
GHRH	Pharmacological
(	O
1	O
microgram/kg	O
iv	O
)	O
or	O
TRH	Pharmacological
(	O
400	O
microgram	O
iv	O
)	O
on	O
separate	O
occasions	O
,	O
immediately	O
before	O
undergoing	O
hemodialysis	O
.	O

GHRH-induced	Pharmacological
GH	O
peak	O
in	O
uremics	O
(	O
22.7	O
+/-	O
5.2	O
micrograms/l	O
)	O
was	O
not	O
different	O
from	O
that	O
obtained	O
in	O
control	O
subjects	O
(	O
16.0	O
+/-	O
4.3	O
micrograms/l	O
)	O
.	O

However	O
,	O
the	O
uremic	O
patients	O
did	O
not	O
show	O
the	O
habitual	O
post-peak	O
fall	O
,	O
remaining	O
GH	O
levels	O
over	O
10	O
micrograms/l	O
till	O
the	O
end	O
of	O
the	O
test	O
.	O

Differences	O
between	O
the	O
two	O
groups	O
were	O
significant	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Uremic	O
patients	O
showed	O
PRL	O
values	O
higher	O
than	O
in	O
controls	O
,	O
however	O
their	O
TRH-induced	Pharmacological
PRL	O
peak	O
(	O
20.6	O
+/-	O
6.6	O
micrograms/l	O
)	O
was	O
not	O
different	O
from	O
that	O
of	O
controls	O
(	O
26.5	O
+/-	O
3.0	O
micrograms/l	O
)	O
.	O

Again	O
chronic	O
renal	O
failure	O
patients	O
showed	O
PRL	O
plasma	O
values	O
abnormally	O
elevated	O
till	O
the	O
end	O
of	O
the	O
test	O
.	O

Differences	O
between	O
the	O
two	O
groups	O
were	O
significant	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Administration	O
of	O
placebo	Control
to	O
a	O
different	O
group	O
of	O
seven	O
uremic	O
patients	O
did	O
not	O
alter	O
GH	O
and	O
PRL	O
plasma	O
levels	O
.	O

This	O
sustained	O
secretion	O
of	O
both	O
GH	O
and	O
PRL	O
in	O
uremia	O
could	O
be	O
attributed	O
to	O
reduced	O
kidney	O
clearance	O
.	O

However	O
,	O
when	O
subjects	O
were	O
examined	O
individually	O
both	O
the	O
GHRH-	Pharmacological
and	O
the	O
TRH-induced	Pharmacological
hormonal	O
peaks	O
and	O
the	O
subsequent	O
fall	O
were	O
not	O
different	O
in	O
both	O
groups	O
.	O

Unlike	O
with	O
controls	O
,	O
in	O
uremic	O
patients	O
GHRH-stimulated	Pharmacological
GH	O
and	O
TRH-stimulated	Pharmacological
PRL/GH	O
peaks	O
were	O
dispersed	O
throughout	O
the	O
120	O
min	O
period	O
.	O

In	O
controls	O
GH	O
and	O
PRL	O
peaks	O
clustered	O
around	O
15-30	O
min	O
.	O

The	O
peak	O
dispersion	O
created	O
a	O
false	O
impression	O
of	O
flattened	O
curves	O
or	O
sustained	O
hypersecretion	O
in	O
uremia	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
An	O
assessment	O
of	O
beta-adrenoceptor	O
blockade	O
in	O
man	O
by	O
prizidilol	Pharmacological
hydrochloride	Pharmacological
.	Pharmacological

1	O
Prizidilol	Pharmacological
hydrochloride	Pharmacological
(	O
SK	O
&	O
F	O
92657	O
)	O
is	O
a	O
new	O
compound	O
which	O
causes	O
both	O
arteriolar	O
dilatation	O
and	O
beta-adrenoceptor	O
blockade	O
.	O

The	O
effect	O
of	O
a	O
single	O
oral	O
dose	O
on	O
the	O
responses	O
of	O
heart	O
rate	O
and	O
blood	O
pressure	O
to	O
isoprenaline	O
infusion	O
has	O
been	O
studied	O
in	O
healthy	O
volunteers	O
.	O

2	O
Isoprenaline	Pharmacological
heart	O
rate	O
dose-response	O
curves	O
showed	O
parallel	O
shifts	O
to	O
the	O
right	O
after	O
oral	O
prizidilol	Pharmacological
,	O
indicating	O
antagonism	O
by	O
this	O
compound	O
at	O
beta-adrenoceptors	O
in	O
the	O
heart	O
.	O

3	O
Isoprenaline	O
dose-response	O
curves	O
for	O
decreases	O
in	O
diastolic	O
blood	O
pressure	O
also	O
showed	O
shifts	O
to	O
the	O
right	O
after	O
oral	O
prizidilol	Pharmacological
,	O
providing	O
evidence	O
of	O
beta-adrenoceptor	O
antagonism	O
by	O
this	O
drug	O
in	O
peripheral	O
resistance	O
vessels	O
.	O

4	O
The	O
peak	O
effect	O
of	O
a	O
40	O
mg	O
dose	O
of	O
propranolol	Pharmacological
was	O
greater	O
than	O
that	O
of	O
a	O
200	O
mg	O
dose	O
of	O
prizidilol	Pharmacological
but	O
both	O
drugs	O
caused	O
persistent	O
beta-adrenoceptor	O
blockade	O
for	O
at	O
least	O
7	O
h	O
after	O
ingestion	O
.	O

The	O
effect	O
of	O
calcium	Pharmacological
supplementation	Pharmacological
on	O
bone	O
density	O
in	O
premenarcheal	O
females	O
:	O
a	O
co-twin	O
approach	O
.	O

The	O
age	O
and	O
developmental	O
stage	O
at	O
which	O
calcium	Pharmacological
supplementation	Pharmacological
produces	O
the	O
greatest	O
bone	O
effects	O
remain	O
controversial	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
calcium	Pharmacological
supplementation	Pharmacological
may	O
improve	O
bone	O
accrual	O
in	O
premenarcheal	O
females	O
.	O

Fifty-one	O
pairs	O
of	O
premenarcheal	O
female	O
twins	O
(	O
27	O
monozygotic	O
and	O
24	O
dizygotic	O
;	O
mean	O
+/-	O
sd	O
age	O
,	O
10.3	O
+/-	O
1.5	O
yr	O
)	O
participated	O
in	O
a	O
randomized	O
,	O
single-blind	O
,	O
placebo-controlled	Control
trial	O
with	O
one	O
twin	O
of	O
each	O
pair	O
receiving	Pharmacological
a	Pharmacological
1200-mg	Pharmacological
calcium	Pharmacological
carbonate	Pharmacological
(	Pharmacological
Caltrate	Pharmacological
)	Pharmacological
supplement	Pharmacological
.	Pharmacological

Areal	O
bone	O
mineral	O
density	O
(	O
aBMD	O
)	O
was	O
measured	O
at	O
baseline	O
and	O
6	O
,	O
12	O
,	O
18	O
and	O
24	O
months	O
.	O

There	O
were	O
no	O
within-pair	O
differences	O
in	O
height	O
,	O
weight	O
,	O
or	O
calcium	O
intake	O
at	O
baseline	O
.	O

Calcium	O
supplementation	O
was	O
associated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
increased	O
aBMD	O
compared	O
with	O
placebo	O
,	O
adjusted	O
for	O
age	O
,	O
height	O
,	O
and	O
weight	O
at	O
the	O
following	O
time	O
points	O
from	O
baseline	O
:	O
total	O
hip	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
,	O
12	O
months	O
(	O
1.6	O
%	O
)	O
,	O
and	O
18	O
months	O
(	O
2.4	O
%	O
)	O
;	O
lumbar	O
spine	O
,	O
12	O
months	O
(	O
1.0	O
%	O
)	O
;	O
femoral	O
neck	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
.	O

Adjusted	O
total	O
body	O
bone	O
mineral	O
content	O
was	O
higher	O
in	O
the	O
calcium	O
group	O
at	O
6	O
months	O
(	O
2.0	O
%	O
)	O
,	O
12	O
months	O
(	O
2.5	O
%	O
)	O
,	O
18	O
months	O
(	O
4.6	O
%	O
)	O
,	O
and	O
24	O
months	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O

Calcium	Pharmacological
supplementation	Pharmacological
was	O
effective	O
in	O
increasing	O
aBMD	O
at	O
regional	O
sites	O
over	O
the	O
first	O
12-18	O
months	O
,	O
but	O
these	O
gains	O
were	O
not	O
maintained	O
to	O
24	O
months	O
.	O

Need	O
the	O
thumb	Physical
be	Physical
immobilised	Physical
in	O
scaphoid	O
fractures	O
?	O
A	O
randomised	O
prospective	O
trial	O
.	O

Immobilisation	Physical
of	Physical
the	Physical
thumb	Physical
is	O
widely	O
believed	O
to	O
be	O
important	O
in	O
the	O
management	O
of	O
fractures	O
of	O
the	O
carpal	O
scaphoid	O
.	O

To	O
assess	O
the	O
need	O
for	O
this	O
,	O
we	O
randomly	O
allocated	O
392	O
fresh	O
fractures	O
for	O
treatment	O
by	O
either	O
a	O
forearm	Physical
gauntlet	Physical
(	Physical
Colles	Physical
'	Physical
)	Physical
cast	Physical
,	O
leaving	O
the	O
thumb	O
free	O
,	O
or	O
by	O
a	O
conventional	Physical
'scaphoid	Physical
'	Physical
plaster	Physical
incorporating	Physical
the	Physical
thumb	Physical
as	Physical
far	Physical
as	Physical
its	Physical
interphalangeal	Physical
joint	Physical
.	O

In	O
the	O
292	O
fractures	O
which	O
were	O
followed	O
for	O
six	O
months	O
,	O
the	O
incidence	O
of	O
nonunion	O
was	O
independent	O
of	O
the	O
type	O
of	O
cast	O
used	O
.	O

Epidural	Pharmacological
morphine	Pharmacological
in	O
the	O
elderly	O
.	O

A	O
controlled	O
trial	O
after	O
upper	O
abdominal	O
surgery	O
.	O

The	O
effectiveness	O
of	O
epidurally	Pharmacological
administered	Pharmacological
morphine	Pharmacological
in	O
the	O
relief	O
of	O
pain	O
after	O
upper	O
abdominal	O
surgery	O
was	O
assessed	O
in	O
a	O
controlled	O
study	O
involving	O
20	O
patients	O
aged	O
61	O
to	O
78	O
years	O
.	O

Analgesia	O
provided	O
by	O
epidural	Pharmacological
morphine	Pharmacological
was	O
comparable	O
to	O
that	O
obtained	O
in	O
matched	O
patients	O
given	O
an	O
intramuscular	Pharmacological
regime	Pharmacological
.	O

The	O
total	O
dose	O
required	O
by	O
the	O
epidural	O
route	O
was	O
less	O
than	O
one-fifth	O
that	O
required	O
intramuscularly	O
,	O
and	O
sedation	O
was	O
correspondingly	O
reduced	O
.	O

Postoperative	O
respiratory	O
mechanics	O
,	O
however	O
,	O
were	O
not	O
significantly	O
improved	O
and	O
delayed	O
respiratory	O
depression	O
was	O
observed	O
in	O
one	O
patient	O
.	O

It	O
is	O
concluded	O
that	O
in	O
elderly	O
patients	O
undergoing	O
upper	O
abdominal	O
surgery	O
the	O
risks	O
related	O
to	O
the	O
use	O
of	O
morphine	Pharmacological
by	O
the	O
epidural	O
route	O
outweigh	O
the	O
marginal	O
advantages	O
it	O
may	O
offer	O
over	O
conventional	O
analgesic	O
techniques	O
.	O

Comparison	O
of	O
analgesic	O
effect	O
of	O
locally	O
and	O
systemically	O
administered	O
ketorolac	Pharmacological
in	O
mastectomy	O
patients	O
.	O

BACKGROUND	O
Ketorolac	Pharmacological
is	O
a	O
parenteral	O
nonsteroidal	O
antiinflammatory	O
drug	O
(	O
NSAID	O
)	O
.	O

Two	O
features	O
have	O
limited	O
its	O
clinical	O
utility	O
:	O
tendency	O
to	O
elicit	O
kidney	O
failure	O
and	O
inability	O
to	O
produce	O
complete	O
analgesia	O
.	O

Because	O
most	O
NSAIDs	Pharmacological
are	O
weak	O
acids	O
(	O
pKa	O
3-5	O
)	O
and	O
become	O
concentrated	O
in	O
acidic	O
tissues	O
,	O
such	O
as	O
injured	O
and	O
inflamed	O
tissues	O
,	O
we	O
hypothesized	O
that	O
local	O
administration	O
may	O
enhance	O
its	O
analgesic	O
efficacy	O
while	O
lowering	O
the	O
potential	O
for	O
systemic	O
complications	O
.	O

METHODS	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo-controlled	Control
study	O
of	O
60	O
group	O
I-II	O
(	O
American	O
Society	O
of	O
Anesthesiology	O
criteria	O
)	O
mastectomy	O
patients	O
,	O
20	O
in	O
each	O
group	O
.	O

Near	O
the	O
end	O
of	O
surgery	O
and	O
every	O
6	O
h	O
postoperatively	O
,	O
20	O
ml	O
of	O
the	O
study	O
solution	O
containing	O
normal	Pharmacological
saline	Pharmacological
with	Pharmacological
or	Pharmacological
without	Pharmacological
30	Pharmacological
mg	Pharmacological
of	Pharmacological
ketorolac	Pharmacological
were	O
administered	O
simultaneously	O
either	O
via	O
a	O
Jackson-Pratt	O
drain	O
or	O
intravenously	O
in	O
a	O
double-blind	O
fashion	O
.	O

The	O
quality	O
of	O
pain	O
control	O
,	O
the	O
amount	O
and	O
character	O
of	O
the	O
drain	O
fluid	O
,	O
incidence	O
of	O
nausea	O
and	O
vomiting	O
,	O
length	O
of	O
stay	O
in	O
the	O
postoperative	O
care	O
unit	O
,	O
and	O
amount	O
of	O
morphine	O
used	O
for	O
treatment	O
of	O
break-through	O
pain	O
were	O
recorded	O
.	O

RESULTS	O
Intraoperative	O
administration	O
of	O
ketorolac	Pharmacological
resulted	O
in	O
better	O
quality	O
of	O
pain	O
control	O
in	O
the	O
immediate	O
postoperative	O
period	O
regardless	O
of	O
route	O
of	O
administration	O
.	O

The	O
incidence	O
of	O
nausea	O
was	O
significantly	O
higher	O
in	O
the	O
placebo	O
group	O
,	O
and	O
drain	O
output	O
in	O
the	O
ketorolac	Pharmacological
groups	O
did	O
not	O
exceed	O
the	O
output	O
in	O
the	O
placebo	Control
group	O
.	O

CONCLUSION	O
Analgesic	O
of	O
the	O
locally	O
administered	O
ketorolac	Pharmacological
is	O
equally	O
effective	O
to	O
the	O
efficacy	O
of	O
ketorolac	Pharmacological
administered	O
intravenously	O
.	O

Clinical	O
evaluation	O
of	O
two	O
adhesive	O
composite	Physical
cements	Physical
for	O
the	O
suppression	O
of	O
dentinal	O
cold	O
sensitivity	O
.	O

STATEMENT	O
OF	O
PROBLEMS	O
Postoperative	O
cold	O
sensitivity	O
after	O
the	O
cementation	O
of	O
indirect	O
restorations	O
with	O
composite	O
cements	O
has	O
been	O
reported	O
frequently	O
but	O
not	O
scientifically	O
documented	O
.	O

PURPOSE	O
This	O
controlled	O
clinical	O
study	O
was	O
designed	O
to	O
simulate	O
the	O
dentin/composite	O
cement	O
interface	O
immediately	O
after	O
cementation	O
of	O
a	O
cast	O
restoration	O
.	O

The	O
desensitizing	O
capabilities	O
of	O
a	O
composite	O
cement	O
that	O
contains	O
a	O
self-etching	O
,	O
dual-polymerizing	O
resin	O
adhesive	O
system	O
were	O
compared	O
with	O
those	O
of	O
a	O
composite	O
cement	O
that	O
use	O
phosphoric	Pharmacological
acid	Pharmacological
etching	O
followed	O
by	O
a	O
single-bottle	O
,	O
light-activated	O
primer/resin-based	O
adhesive	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
hypersensitive	O
root	O
surfaces	O
of	O
selected	O
teeth	O
were	O
randomized	O
to	O
receive	O
1	O
of	O
3	O
treatments	O
:	O
coating	Physical
with	Physical
a	Physical
self-etching	Physical
adhesive	Physical
(	Physical
Linkmax	Physical
)	Physical
and	Physical
its	Physical
respective	Physical
cement	Physical
,	O
coating	Physical
with	Physical
a	Physical
conventionally	Physical
etched	Physical
adhesive	Physical
(	Physical
RelyX	Physical
ARC	Physical
)	Physical
and	Physical
its	Physical
cement	Physical
,	O
or	O
no	O
treatment	O
(	O
negative	O
control	O
)	O
.	O

The	O
sample	O
size	O
was	O
22	O
.	O

Dentin	O
sensitivity	O
was	O
ascertained	O
with	O
an	O
accurate	O
cold	O
testing	O
device	O
that	O
slowly	O
decreased	O
in	O
temperature	O
.	O

Tooth	O
sensitivity	O
was	O
measured	O
both	O
immediately	O
and	O
at	O
7	O
days	O
after	O
placement	O
.	O

Two-way	O
analysis	O
of	O
variance	O
and	O
Fisher	O
's	O
least	O
significant	O
difference	O
test	O
(	O
P	O
<	O
.05	O
)	O
were	O
used	O
to	O
determine	O
whether	O
significant	O
differences	O
existed	O
as	O
a	O
function	O
of	O
treatment	O
type	O
or	O
time	O
.	O

RESULTS	O
Immediately	O
after	O
placement	O
,	O
the	O
self-etching	Physical
adhesive	Physical
and	Physical
its	Physical
respective	Physical
cement	Physical
resulted	O
in	O
more	O
suppression	O
of	O
cold	O
sensitivity	O
than	O
no	O
treatment	O
(	O
control	O
)	O
;	O
with	O
Linkmax	O
treatment	O
,	O
the	O
temperature	O
at	O
which	O
teeth	O
responded	O
was	O
reduced	O
by	O
8.4	O
degrees	O
C.	O
The	O
conventionally	O
etched	Physical
adhesive	Physical
and	Physical
its	Physical
cement	Physical
reduced	O
the	O
temperature	O
at	O
which	O
teeth	O
responded	O
by	O
9.4	O
degrees	O
C.	O
After	O
1	O
week	O
,	O
these	O
temperature	O
reductions	O
were	O
7.0	O
degrees	O
C	O
and	O
4.3	O
degrees	O
C	O
,	O
respectively	O
.	O

Untreated	O
controls	O
at	O
the	O
2	O
intervals	O
showed	O
a	O
mean	O
decrease	O
in	O
sensitivity	O
to	O
cold	O
of	O
3.6	O
degrees	O
C	O
and	O
4.1	O
degrees	O
C.	O
Statistical	O
analysis	O
showed	O
type	O
of	O
composite	O
cement	O
to	O
be	O
a	O
significant	O
factor	O
.	O

CONCLUSION	O
Within	O
the	O
limitations	O
of	O
this	O
study	O
and	O
in	O
comparison	O
to	O
untreated	O
control	O
teeth	O
,	O
Linkmax	Physical
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
tooth	O
root	O
sensitivity	O
over	O
1	O
week	O
(	O
P=.02	O
)	O
,	O
whereas	O
RelyX	O
ARC	O
did	O
not	O
(	O
P=.066	O
)	O
.	O

Nizatidine	Pharmacological
versus	O
ranitidine	Pharmacological
in	O
the	O
treatment	O
of	O
peptic	O
ulcer	O
disease	O
:	O
report	O
on	O
the	O
Dutch	O
investigation	O
as	O
part	O
of	O
a	O
European	O
multicentre	O
trial	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
nizatidine	Pharmacological
was	O
evaluated	O
in	O
comparison	O
with	O
ranitidine	Pharmacological
in	O
230	O
patients	O
with	O
endoscopically	O
documented	O
gastric	O
(	O
71	O
)	O
or	O
duodenal	O
(	O
159	O
)	O
ulcers	O
.	O

Gastric	O
ulcer	O
patients	O
who	O
satisfied	O
all	O
criteria	O
for	O
inclusion	O
and	O
exclusion	O
were	O
randomly	O
allocated	O
to	O
nizatidine	Pharmacological
300	Pharmacological
mg	Pharmacological
nocte	Pharmacological
,	Pharmacological
150	Pharmacological
mg	Pharmacological
b.d	Pharmacological
.	Pharmacological

or	Pharmacological
ranitidine	Pharmacological
150	Pharmacological
mg	Pharmacological
b.d.	O
,	O
duodenal	O
ulcer	O
patients	O
to	O
nizatidine	Pharmacological
300	Pharmacological
mg	Pharmacological
nocte	Pharmacological
or	Pharmacological
ranitidine	Pharmacological
300	Pharmacological
mg	Pharmacological
nocte	Pharmacological
.	Pharmacological

Endoscopic	O
healing	O
was	O
defined	O
as	O
complete	O
epithelialisation	O
of	O
all	O
mucosal	O
lesions	O
.	O

Endoscopy	O
was	O
performed	O
at	O
4	O
and	O
,	O
if	O
not	O
healed	O
,	O
at	O
8	O
weeks	O
.	O

Healing	O
rates	O
were	O
shown	O
to	O
be	O
comparable	O
for	O
all	O
treatment	O
regimens	O
.	O

In	O
both	O
duodenal	O
ulcer	O
treatment	O
groups	O
,	O
and	O
with	O
both	O
drugs	O
,	O
healing	O
was	O
negatively	O
influenced	O
by	O
ulcer	O
size	O
,	O
ulcer	O
number	O
,	O
smoking	O
habits	O
and	O
a	O
disease	O
duration	O
of	O
5	O
years	O
or	O
more	O
.	O

Few	O
side	O
effects	O
were	O
noted	O
.	O

Nizatidine	Pharmacological
,	O
administered	O
as	O
a	O
300	O
mg	O
nocte	O
and	O
as	O
a	O
150	O
mg	O
b.d	O
.	O

dose	O
appeared	O
to	O
be	O
a	O
safe	O
H2	O
antagonist	O
and	O
was	O
as	O
effective	O
as	O
ranitidine	Pharmacological
in	O
the	O
treatment	O
of	O
duodenal	O
and	O
gastric	O
ulceration	O
.	O

Antipyrine	O
clearance	O
and	O
response	O
to	O
interferon	Pharmacological
treatment	O
in	O
patients	O
with	O
chronic	O
active	O
hepatitis	O
C.	O
To	O
determine	O
whether	O
hepatic	O
metabolic	O
function	O
affects	O
the	O
response	O
to	O
interferon	Pharmacological
treatment	O
,	O
we	O
measured	O
antipyrine	O
clearance	O
(	O
APC	O
)	O
in	O
85	O
patients	O
with	O
chronic	O
active	O
hepatitis	O
C	O
and	O
compared	O
the	O
results	O
with	O
treatment	O
outcome	O
.	O

Among	O
55	O
patients	O
who	O
responded	O
to	O
interferon	Physical
by	O
normalization	O
of	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
,	O
median	O
APC	O
before	O
treatment	O
was	O
0.47	O
(	O
range	O
,	O
0.12	O
to	O
0.98	O
;	O
normal	O
range	O
,	O
0.34	O
to	O
1.02	O
mL/min/kg	O
body	O
wt	O
)	O
,	O
a	O
value	O
that	O
was	O
significantly	O
greater	O
than	O
in	O
30	O
nonresponders	O
(	O
0.23	O
;	O
0.08	O
to	O
0.67	O
mL/min/kg	O
body	O
wt	O
,	O
P	O
<	O
.001	O
)	O
.	O

APC	O
was	O
closely	O
associated	O
with	O
response	O
to	O
interferon	Physical
.	O

The	O
response	O
rate	O
among	O
cases	O
with	O
values	O
>	O
0.25	O
mL/min/kg	O
body	O
weight	O
was	O
79	O
%	O
,	O
the	O
same	O
as	O
in	O
cases	O
without	O
cirrhosis	O
.	O

Cases	O
without	O
cirrhosis	O
and	O
with	O
APC	O
of	O
>	O
0.25	O
mL/min/kg	O
body	O
weight	O
had	O
an	O
85	O
%	O
chance	O
of	O
responding	O
to	O
interferon	Physical
;	O
this	O
was	O
unlikely	O
a	O
simple	O
reflection	O
of	O
histological	O
activity	O
,	O
because	O
the	O
correlation	O
with	O
Scheuer	O
score	O
was	O
poor	O
in	O
this	O
subgroup	O
(	O
r	O
=	O
-.31	O
,	O
P	O
<	O
.05	O
)	O
.	O

A	O
second	O
,	O
independent	O
group	O
of	O
43	O
patients	O
was	O
used	O
to	O
test	O
the	O
predictive	O
value	O
of	O
APC	O
(	O
using	O
0.25	O
mL/min/kg	O
body	O
wt	O
as	O
a	O
cut-off	O
)	O
for	O
response	O
to	O
interferon	Pharmacological
treatment	O
.	O

In	O
this	O
group	O
,	O
APC	O
correctly	O
predicted	O
positive	O
response	O
to	O
interferon	Pharmacological
in	O
75	O
%	O
of	O
cases	O
.	O

APC	O
was	O
also	O
used	O
to	O
measure	O
the	O
effects	O
of	O
treatment	O
on	O
hepatic	O
metabolic	O
function	O
.	O

Regardless	O
of	O
outcome	O
,	O
there	O
was	O
no	O
change	O
in	O
APC	O
at	O
the	O
end	O
of	O
a	O
6-month	O
course	O
of	O
interferon	Pharmacological
treatment	O
.	O

Six	O
months	O
later	O
,	O
however	O
,	O
improvement	O
in	O
APC	O
(	O
14	O
%	O
;	O
P	O
<	O
.05	O
)	O
was	O
evident	O
among	O
responders	O
but	O
not	O
in	O
those	O
who	O
had	O
failed	O
to	O
respond	O
to	O
interferon	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
[	O
Clinical	O
efficiency	O
of	O
cytokines	Pharmacological
in	O
prophylactics	O
and	O
treatment	O
of	O
infectious	O
and	O
inflammatory	O
complications	O
after	O
oral	O
surgery	O
procedures	O
]	O
.	O

The	O
study	O
presents	O
the	O
results	O
of	O
prevention	O
and	O
treatment	O
of	O
infectious	O
and	O
inflammatory	O
complications	O
after	O
oral	O
surgery	O
procedures	O
.	O

Combined	Pharmacological
therapy	Pharmacological
with	Pharmacological
antibiotics	Pharmacological
and	Pharmacological
superlimf	Pharmacological
promotes	O
a	O
more	O
rapid	O
reduction	O
in	O
the	O
duration	O
of	O
clinical	O
symptoms	O
and	O
duration	O
of	O
treatment	O
than	O
monotherapy	Control
with	Control
antibiotics	Control
.	O

Results	O
of	O
the	O
study	O
substantiate	O
the	O
feasibility	O
of	O
using	O
superlimf	Pharmacological
in	O
outpatient	O
oral	O
surgical	O
procedures	O
for	O
infectious	O
and	O
inflammatory	O
complications	O
treatment	O
.	O

[	O
Effect	O
of	O
Selaginella	Pharmacological
combined	O
with	O
radiotherapy	Physical
on	O
nasopharyngeal	O
carcinoma	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
Chinese	O
herbal	O
medicine	O
Selaginella-induced	O
radiosensitization	O
of	O
terminal	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

METHODS	O
Totally	O
180	O
patients	O
with	O
NPC	O
were	O
divided	O
equally	O
into	O
3	O
groups	O
with	O
the	O
same	O
radiotherapeutic	O
protocols	O
.	O

The	O
patients	O
in	O
group	O
A	O
received	O
radiotherapy	Physical
alone	Physical
,	O
those	O
in	O
group	O
B	O
were	O
given	O
daily	Pharmacological
Selaginella	Pharmacological
(	Pharmacological
30	Pharmacological
g	Pharmacological
)	Pharmacological
prepared	Pharmacological
into	Pharmacological
50	Pharmacological
ml	Pharmacological
decoction	Pharmacological
during	Pharmacological
the	Pharmacological
entire	Pharmacological
course	Pharmacological
of	Pharmacological
radiotherapy	Pharmacological
,	O
and	O
those	O
in	O
group	Pharmacological
C	Pharmacological
had	Pharmacological
Selaginella	Pharmacological
30	Pharmacological
g	Pharmacological
daily	Pharmacological
in	O
the	O
late	O
course	O
of	O
radiotherapy	Pharmacological
.	O

RESULTS	O
The	O
complete	O
remission	O
rate	O
of	O
nasopharyngeal	O
primary	O
lesions	O
in	O
groups	O
B	O
and	O
C	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
group	O
A	O
,	O
with	O
also	O
significantly	O
higher	O
complete	O
remission	O
rates	O
of	O
the	O
cervical	O
lymph	O
nodes	O
.	O

The	O
acute	O
toxicity	O
of	O
the	O
skin	O
and	O
mucous	O
membrane	O
was	O
milder	O
in	O
the	O
latter	O
two	O
groups	O
,	O
but	O
the	O
differences	O
were	O
not	O
significant	O
.	O

CONCLUSION	O
Selaginella	Pharmacological
may	O
induce	O
radiosensitization	O
for	O
terminal	O
NPC	O
and	O
does	O
not	O
increase	O
the	O
acute	O
toxicity	O
of	O
radiotherapy	O
.	O

Relaxation	Educational
and	Educational
imagery	Educational
and	Educational
cognitive-behavioral	Educational
training	Educational
reduce	O
pain	O
during	O
cancer	O
treatment	O
:	O
a	O
controlled	O
clinical	O
trial	O
.	O

Few	O
controlled	O
clinical	O
trials	O
of	O
psychological	O
interventions	O
for	O
cancer	O
pain	O
relief	O
exist	O
in	O
spite	O
of	O
frequent	O
support	O
for	O
their	O
importance	O
as	O
adjuncts	O
to	O
medical	O
treatment	O
.	O

This	O
study	O
compared	O
oral	O
mucositis	O
pain	O
levels	O
in	O
4	O
groups	O
of	O
cancer	O
patients	O
receiving	O
bone	O
marrow	O
transplants	O
(	O
BMT	O
)	O
:	O
(	O
1	O
)	O
treatment	Control
as	Control
usual	Control
control	Control
,	O
(	O
2	O
)	O
therapist	Educational
support	Educational
,	Educational
(	Educational
3	Educational
)	Educational
relaxation	Educational
and	Educational
imagery	Educational
training	Educational
,	Educational
and	Educational
(	Educational
4	Educational
)	Educational
training	Educational
in	Educational
a	Educational
package	Educational
of	Educational
cognitive-behavioral	Educational
coping	Educational
skills	Educational
which	Educational
included	Educational
relaxation	Educational
and	Educational
imagery	Educational
.	O

A	O
total	O
of	O
94	O
patients	O
completed	O
the	O
study	O
which	O
involved	O
two	O
training	O
sessions	O
prior	O
to	O
treatment	O
and	O
twice	O
a	O
week	O
'booster	O
'	O
sessions	O
during	O
the	O
first	O
5	O
weeks	O
of	O
treatment	O
.	O

Results	O
confirmed	O
our	O
hypothesis	O
that	O
patients	O
who	O
received	O
either	O
relaxation	O
and	O
imagery	O
alone	O
or	O
patients	O
who	O
received	O
the	O
package	O
of	O
cognitive-behavioral	O
coping	O
skills	O
would	O
report	O
less	O
pain	O
than	O
patients	O
in	O
the	O
other	O
2	O
groups	O
.	O

The	O
hypothesis	O
that	O
the	O
cognitive-behavioral	O
skills	O
package	O
would	O
have	O
an	O
additive	O
effect	O
beyond	O
relaxation	O
and	O
imagery	O
alone	O
was	O
not	O
confirmed	O
.	O

Average	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
report	O
of	O
pain	O
within	O
the	O
therapist	O
support	O
group	O
was	O
not	O
significantly	O
lower	O
than	O
the	O
control	O
group	O
(	O
P	O
=	O
0.103	O
)	O
nor	O
significantly	O
higher	O
than	O
the	O
training	O
groups	O
.	O

Patient	O
reports	O
of	O
relative	O
helpfulness	O
of	O
the	O
interventions	O
for	O
managing	O
pain	O
and	O
nausea	O
matched	O
the	O
results	O
of	O
VAS	O
reports	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
relaxation	O
and	O
imagery	O
training	O
reduces	O
cancer	O
treatment-related	O
pain	O
;	O
adding	O
cognitive-behavioral	O
skills	O
to	O
the	O
relaxation	O
with	O
imagery	O
does	O
not	O
,	O
on	O
average	O
,	O
further	O
improve	O
pain	O
relief	O
.	O

The	O
effects	O
of	O
strength	Physical
training	Physical
on	O
central	O
arterial	O
compliance	O
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

BACKGROUND	O
Contrary	O
to	O
aerobic	O
exercise	O
,	O
strength	Physical
training	Physical
(	Physical
ST	Physical
)	Physical
is	O
associated	O
with	O
decreased	O
central	O
arterial	O
compliance	O
in	O
young	O
men	O
.	O

It	O
is	O
unknown	O
whether	O
ST	Physical
,	O
with	O
or	O
without	O
concurrent	O
endurance	O
training	O
,	O
would	O
have	O
a	O
similar	O
effect	O
in	O
older	O
adults	O
with	O
reduced	O
baseline	O
arterial	O
compliance	O
.	O

OBJECTIVE	O
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
a	O
ST	Physical
program	O
on	O
central	O
arterial	O
compliance	O
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

DESIGN	O
Randomized	O
,	O
controlled	O
intervention	O
study	O
in	O
which	O
37	O
healthy	O
,	O
sedentary	O
men	O
and	O
women	O
(	O
52+/-2	O
years	O
)	O
performed	O
13	O
weeks	O
of	O
ST	O
(	O
n=13	O
)	O
,	O
ST+aerobic	Physical
exercise	Physical
(	O
n=12	O
)	O
or	Control
stretching	Control
exercises	Control
as	Control
a	Control
control	Control
group	Control
(	O
n=12	O
)	O
.	O

METHODS	O
Participants	O
were	O
rigorously	O
screened	O
for	O
cardiovascular	O
disease	O
and	O
underwent	O
pre-post	O
testing	O
for	O
carotid	O
arterial	O
compliance	O
(	O
via	O
simultaneous	O
ultrasound	O
and	O
applanation	O
tonometry	O
)	O
,	O
carotid-femoral	O
pulse	O
wave	O
velocity	O
,	O
plasma	O
endothelin-1	O
and	O
angiotensin	O
II	O
concentrations	O
and	O
carotid	O
artery	O
vasoreactivity	O
(	O
cold	O
pressor	O
test	O
)	O
.	O

RESULTS	O
ST	O
performed	O
alone	O
,	O
or	O
in	O
conjunction	O
with	O
aerobic	Physical
exercise	Physical
,	O
improved	O
maximal	O
muscle	O
strength	O
and	O
increased	O
total	O
lean	O
body	O
mass	O
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
carotid	O
artery	O
compliance	O
or	O
carotid-femoral	O
pulse	O
wave	O
velocity	O
following	O
ST	Physical
or	Physical
ST+aerobic	Physical
exercise	Physical
.	O

Carotid	O
artery	O
compliance	O
increased	O
significantly	O
(	O
23	O
%	O
)	O
following	O
stretching	O
which	O
may	O
be	O
attributed	O
to	O
a	O
reduction	O
in	O
carotid	O
pulse	O
pressure	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
plasma	O
vasoconstrictor	O
hormones	O
or	O
carotid	O
artery	O
vasoreactivity	O
following	O
the	O
interventions	O
.	O

CONCLUSION	O
Thirteen	O
weeks	O
of	O
moderate	O
ST	Physical
two	O
or	O
three	O
times	O
per	O
week	O
does	O
not	O
reduce	O
central	O
arterial	O
compliance	O
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

Hitting	O
the	O
target	O
:	O
relatively	O
easy	O
,	O
yet	O
absolutely	O
difficult	O
.	O

It	O
is	O
generally	O
agreed	O
that	O
absolute-direction	O
judgments	O
require	O
information	O
about	O
eye	O
position	O
,	O
whereas	O
relative-direction	O
judgments	O
do	O
not	O
.	O

The	O
source	O
of	O
this	O
eye-position	O
information	O
,	O
particularly	O
during	O
monocular	O
viewing	O
,	O
is	O
a	O
matter	O
of	O
debate	O
.	O

It	O
may	O
be	O
either	O
binocular	O
eye	O
position	O
,	O
or	O
the	O
position	O
of	O
the	O
viewing-eye	O
only	O
,	O
that	O
is	O
crucial	O
.	O

Using	O
more	O
ecologically	O
valid	O
stimulus	O
situations	O
than	O
the	O
traditional	O
LED	O
in	O
the	O
dark	O
,	O
we	O
performed	O
two	O
experiments	O
.	O

In	O
experiment	O
1	O
,	O
observers	Educational
threw	Educational
darts	Other
at	Other
targets	Other
that	Other
were	Other
fixated	Other
either	Other
monocularly	Other
or	Other
binocularly	Other
.	O

In	O
experiment	O
2	O
,	O
observers	Educational
aimed	Educational
a	Educational
laser	Other
gun	Other
at	Other
targets	Other
while	Other
fixating	Other
either	Other
the	Other
rear	Other
or	Other
the	Other
front	Other
gunsight	Other
monocularly	Other
,	Other
or	Other
the	Other
target	Other
either	Other
monocularly	Other
or	Other
binocularly	Other
.	O

We	O
measured	O
the	O
accuracy	O
and	O
precision	O
of	O
the	O
observers	O
'	O
absolute-	O
and	O
relative-direction	O
judgments	O
.	O

We	O
found	O
that	O
(	O
a	O
)	O
relative-direction	O
judgments	O
were	O
precise	O
and	O
independent	O
of	O
phoria	O
,	O
and	O
(	O
b	O
)	O
monocular	O
absolute-direction	O
judgments	O
were	O
inaccurate	O
,	O
and	O
the	O
magnitude	O
of	O
the	O
inaccuracy	O
was	O
predictable	O
from	O
the	O
magnitude	O
of	O
phoria	O
.	O

These	O
results	O
confirm	O
that	O
relative-direction	O
judgments	O
do	O
not	O
require	O
information	O
about	O
eye	O
position	O
.	O

Moreover	O
,	O
they	O
show	O
that	O
binocular	O
eye-position	O
information	O
is	O
crucial	O
when	O
judging	O
the	O
absolute	O
direction	O
of	O
both	O
monocular	O
and	O
binocular	O
targets	O
.	O

Effect	O
of	O
a	O
high-protein	Pharmacological
,	Pharmacological
energy-restricted	Pharmacological
diet	Pharmacological
on	O
weight	O
loss	O
and	O
energy	O
expenditure	O
after	O
weight	O
stabilization	O
in	O
hyperinsulinemic	O
subjects	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
replacing	O
some	O
dietary	O
carbohydrate	O
with	O
protein	O
,	O
during	O
energy	O
restriction	O
,	O
on	O
weight	O
loss	O
,	O
total	O
energy	O
expenditure	O
(	O
TEE	O
)	O
,	O
resting	O
energy	O
expenditure	O
(	O
REE	O
)	O
,	O
respiratory	O
quotient	O
(	O
RQ	O
)	O
,	O
and	O
the	O
thermic	O
effect	O
of	O
feeding	O
(	O
TEF	O
)	O
in	O
subjects	O
with	O
hyperinsulinemia	O
.	O

DESIGN	O
Parallel	O
,	O
clinical	O
intervention	O
study	O
of	O
12	O
weeks	O
energy	Other
restriction	Other
(	O
6.5	O
MJ/day	O
)	O
and	O
4	O
weeks	O
energy	Other
balance	Other
(	O
8.2	O
MJ/day	O
)	O
in	O
two	O
groups	O
of	O
subjects	O
randomly	O
assigned	O
to	O
either	O
a	O
high-protein	Pharmacological
(	Pharmacological
HP	Pharmacological
)	Pharmacological
diet	Pharmacological
(	O
27	O
%	O
of	O
energy	O
(	O
%	O
E	O
)	O
as	O
protein	O
,	O
45	O
%	O
E	O
as	O
carbohydrate	O
)	O
or	O
a	O
lower-protein	Pharmacological
(	Pharmacological
LP	Pharmacological
)	Pharmacological
diet	Pharmacological
(	O
16	O
%	O
E	O
as	O
protein	O
,	O
57	O
%	O
E	O
as	O
carbohydrate	O
)	O
.	O

SUBJECTS	O
A	O
total	O
of	O
36	O
obese	O
nondiabetic	O
volunteers	O
with	O
hyperinsulinemia	O
(	O
10	O
males/26	O
females	O
,	O
aged	O
34-65	O
y	O
,	O
BMI	O
28-43	O
kg/m	O
(	O
2	O
)	O
,	O
fasting	O
insulin	O
12-45	O
mU/l	O
)	O
.	O

MEASUREMENTS	O
Body	O
weight	O
and	O
composition	O
,	O
TEE	O
,	O
REE	O
,	O
and	O
RQ	O
were	O
measured	O
at	O
baseline	O
and	O
at	O
week	O
16	O
.	O

In	O
addition	O
,	O
the	O
TEF	O
to	O
an	O
HP	Other
or	O
LP	Other
meal	O
was	O
determined	O
for	O
3	O
h	O
,	O
at	O
baseline	O
and	O
at	O
week	O
16	O
.	O

RESULTS	O
After	O
16	O
weeks	O
,	O
weight	O
loss	O
was	O
similar	O
in	O
response	O
to	O
each	O
diet	O
;	O
the	O
overall	O
decrease	O
was	O
7.9+/-0.6	O
kg	O
(	O
P	O
<	O
0.001	O
)	O
,	O
of	O
which	O
6.8+/-0.5	O
kg	O
was	O
fat	O
(	O
P	O
<	O
0.001	O
)	O
.	O

REE	O
fell	O
similarly	O
with	O
each	O
diet	O
;	O
the	O
overall	O
decrease	O
was	O
719+/-106	O
kJ/day	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
TEF	O
was	O
2	O
%	O
greater	O
after	O
the	O
HP	Physical
than	O
after	O
the	O
LP	Physical
meal	O
at	O
baseline	O
(	O
P	O
<	O
0.01	O
)	O
and	O
0.8	O
%	O
greater	O
at	O
week	O
16	O
(	O
P=0.35	O
)	O
.	O

After	O
16	O
weeks	O
,	O
the	O
TEF	O
was	O
not	O
reduced	O
in	O
either	O
dietary	O
group	O
.	O

There	O
was	O
no	O
change	O
in	O
TEE	O
after	O
16	O
weeks	O
.	O

CONCLUSION	O
In	O
subjects	O
with	O
hyperinsulinemia	O
an	O
energy-restrictive	O
diet	O
containing	O
an	O
increased	O
protein-to-carbohydrate	O
ratio	O
does	O
not	O
enhance	O
weight	O
loss	O
or	O
significantly	O
affect	O
energy	O
expenditure	O
.	O

Caloric	O
restriction	O
,	O
rather	O
than	O
the	O
macronutrient	O
composition	O
of	O
the	O
diet	O
,	O
is	O
the	O
most	O
important	O
determinant	O
of	O
weight	O
loss	O
.	O

Postoperative	O
magnesium	Pharmacological
sulphate	Pharmacological
infusion	Pharmacological
reduces	O
analgesic	O
requirements	O
in	O
spinal	O
anaesthesia	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Magnesium	Pharmacological
sulphate	Pharmacological
infusion	O
during	O
general	O
anaesthesia	O
reduces	O
anaesthetic	O
consumption	O
and	O
analgesic	O
requirements	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
postoperative	O
magnesium	Pharmacological
infusion	O
on	O
duration	O
of	O
block	O
,	O
sedation	O
and	O
analgesic	O
consumption	O
after	O
spinal	O
anaesthesia	O
.	O

METHODS	O
Fifty	O
ASA	O
I-II	O
patients	O
were	O
included	O
in	O
the	O
randomized	O
double	O
blind	O
study	O
.	O

Spinal	Surgical
anaesthesia	Surgical
was	Surgical
performed	Surgical
at	Surgical
L3-4	Surgical
or	Surgical
L4-5	Surgical
interspace	Surgical
with	Surgical
12.5	Surgical
mg	Surgical
0.5	Surgical
%	Surgical
heavy	Surgical
bupivacaine	Surgical
,	Surgical
using	Surgical
a	Surgical
25	Surgical
G	Surgical
Quincke	Surgical
needle	Surgical
.	O

Patients	O
received	O
a	O
5	Pharmacological
mg	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
bolus	Pharmacological
of	Pharmacological
magnesium	Pharmacological
sulphate	Pharmacological
followed	Pharmacological
by	Pharmacological
a	Pharmacological
500	Pharmacological
mg	Pharmacological
h	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
infusion	Pharmacological
or	Pharmacological
saline	Pharmacological
in	O
the	O
same	O
volumes	O
for	O
24	O
h.	O
Time	O
to	O
first	O
pain	O
,	O
analgesic	O
request	O
,	O
return	O
of	O
motor	O
function	O
,	O
visual	O
analogue	O
pain	O
and	O
sedation	O
scores	O
were	O
evaluated	O
every	O
4	O
h	O
during	O
the	O
24	O
h	O
postoperative	O
period	O
.	O

The	O
t-	O
and	O
U-tests	O
were	O
used	O
for	O
statistical	O
analyses	O
.	O

Data	O
were	O
expressed	O
as	O
mean	O
+/-	O
SD	O
,	O
with	O
P	O
<	O
0.05	O
being	O
considered	O
significant	O
.	O

RESULTS	O
Vital	O
signs	O
were	O
stable	O
during	O
spinal	O
anaesthesia	O
and	O
postoperative	O
period	O
.	O

When	O
compared	O
to	O
the	O
control	O
group	O
,	O
time	O
to	O
analgesic	O
need	O
was	O
increased	O
and	O
total	O
analgesic	O
consumption	O
was	O
reduced	O
in	O
the	O
magnesium	O
group	O
(	O
meperidine	O
consumption	O
60.0	O
+/-	O
73.1	O
mg	O
control	O
group	O
,	O
31.8	O
+/-	O
30.7	O
mg	O
magnesium	O
group	O
,	O
P	O
=	O
0.02	O
)	O
.	O

CONCLUSIONS	O
Magnesium	Pharmacological
sulphate	Pharmacological
infusion	O
may	O
be	O
used	O
as	O
an	O
adjunct	O
for	O
reducing	O
analgesic	O
consumption	O
after	O
spinal	O
anaesthesia	O
.	O

A	O
double-blind	O
placebo-controlled	O
trial	O
of	O
zonisamide	Pharmacological
(	Pharmacological
zonegran	Pharmacological
)	Pharmacological
in	O
the	O
treatment	O
of	O
essential	O
tremor	O
.	O

Medical	O
therapy	O
for	O
essential	O
tremor	O
(	O
ET	O
)	O
,	O
a	O
common	O
movement	O
disorder	O
,	O
is	O
often	O
inadequate	O
.	O

We	O
performed	O
a	O
double-blind	O
placebo-controlled	O
randomized	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
zonisamide	Pharmacological
(	Pharmacological
ZNS	Pharmacological
)	Pharmacological
,	O
an	O
antiepileptic	O
agent	O
,	O
in	O
treating	O
ET	O
.	O

Twenty	O
patients	O
(	O
mean	O
age	O
,	O
60	O
+/-	O
15	O
years	O
)	O
with	O
ET	O
were	O
randomized	O
to	O
receive	O
ZNS	Pharmacological
or	O
placebo	Control
.	O

ZNS	Pharmacological
was	Pharmacological
initiated	Pharmacological
at	Pharmacological
a	Pharmacological
dosage	Pharmacological
of	Pharmacological
100	Pharmacological
mg/day	Pharmacological
and	Pharmacological
escalated	Pharmacological
to	Pharmacological
200	Pharmacological
mg/day	Pharmacological
at	Pharmacological
day	Pharmacological
14	Pharmacological
.	O

Patients	O
were	O
evaluated	O
by	O
accelerometry	O
and	O
the	O
Fahn-Tolosa-Marin	O
(	O
FTM	O
)	O
rating	O
scale	O
at	O
baseline	O
and	O
days	O
14	O
and	O
28	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	O
Impression	O
(	O
CGI-C	O
)	O
scale	O
at	O
day	O
28	O
.	O

At	O
endpoint	O
,	O
subjects	O
assigned	O
to	O
ZNS	Pharmacological
were	O
taking	O
a	O
mean	O
dosage	O
of	O
160	O
+/-	O
50	O
mg/day	O
.	O

There	O
were	O
no	O
significant	O
improvements	O
in	O
the	O
FTM	O
total	O
score	O
or	O
its	O
subsections	O
.	O

Tremor	O
amplitude	O
as	O
assessed	O
by	O
accelerometry	O
significantly	O
improved	O
in	O
the	O
ZNS	Pharmacological
group	O
compared	O
to	O
the	O
placebo	O
group	O
at	O
endpoint	O
relative	O
to	O
baseline	O
(	O
-0.50	O
+/-	O
0.72	O
vs.	O
0.30	O
+/-	O
0.79	O
m/s	O
(	O
2	O
)	O
;	O
P	O
=	O
0.03	O
)	O
.	O

On	O
the	O
CGI-C	O
,	O
60	O
%	O
(	O
n	O
=	O
6	O
)	O
of	O
patients	O
in	O
the	O
ZNS	O
group	O
felt	O
that	O
their	O
tremor	O
was	O
unchanged	O
,	O
while	O
the	O
remaining	O
patients	O
felt	O
that	O
their	O
tremor	O
was	O
minimally	O
improved	O
.	O

Thirty	O
percent	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	O
taking	O
ZNS	O
discontinued	O
the	O
study	O
due	O
to	O
side	O
effects	O
(	O
fatigue	O
,	O
headache	O
,	O
paresthesias	O
)	O
while	O
taking	O
100	O
mg	O
per	O
day	O
.	O

ZNS	Pharmacological
did	O
not	O
provide	O
significant	O
improvements	O
in	O
clinical	O
rating	O
scales	O
at	O
study	O
endpoint	O
compared	O
to	O
placebo	O
and	O
was	O
only	O
modestly	O
well	O
tolerated	O
.	O

ZNS	Pharmacological
was	O
effective	O
in	O
reducing	O
tremor	O
amplitude	O
as	O
measured	O
by	O
accelerometry	O
.	O

Oxytocin	Pharmacological
infusion	Pharmacological
reduces	O
repetitive	O
behaviors	O
in	O
adults	O
with	O
autistic	O
and	O
Asperger	O
's	O
disorders	O
.	O

Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
dysfunction	O
in	O
three	O
core	O
behavioral	O
domains	O
:	O
repetitive	O
behaviors	O
,	O
social	O
deficits	O
,	O
and	O
language	O
abnormalities	O
.	O

There	O
is	O
evidence	O
that	O
abnormalities	O
exist	O
in	O
peptide	O
systems	O
,	O
particularly	O
the	O
oxytocin	O
system	O
,	O
in	O
autism	O
spectrum	O
patients	O
.	O

Furthermore	O
,	O
oxytocin	O
and	O
the	O
closely	O
related	O
peptide	O
vasopressin	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
social	O
and	O
repetitive	O
behaviors	O
.	O

This	O
study	O
examined	O
the	O
impact	O
of	O
oxytocin	Pharmacological
on	O
repetitive	O
behaviors	O
in	O
15	O
adults	O
with	O
autism	O
or	O
Asperger	O
's	O
disorder	O
via	O
randomized	O
double-blind	O
oxytocin	Pharmacological
and	O
placebo	Control
challenges	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
an	O
instrument	O
rating	O
six	O
repetitive	O
behaviors	O
:	O
need	O
to	O
know	O
,	O
repeating	O
,	O
ordering	O
,	O
need	O
to	O
tell/ask	O
,	O
self-injury	O
,	O
and	O
touching	O
.	O

Patients	O
with	O
autism	O
spectrum	O
disorders	O
showed	O
a	O
significant	O
reduction	O
in	O
repetitive	O
behaviors	O
following	O
oxytocin	O
infusion	O
in	O
comparison	O
to	O
placebo	O
infusion	O
.	O

Repetitive	O
behavior	O
in	O
autism	O
spectrum	O
disorders	O
may	O
be	O
related	O
to	O
abnormalities	O
in	O
the	O
oxytocin	O
system	O
,	O
and	O
may	O
be	O
partially	O
ameliorated	O
by	O
synthetic	O
oxytocin	O
infusion	O
.	O

Subcutaneous	O
low-molecular-weight	Pharmacological
heparin	Pharmacological
compared	O
with	O
continuous	O
intravenous	O
unfractionated	Pharmacological
heparin	Pharmacological
in	O
the	O
treatment	O
of	O
proximal	O
deep	O
vein	O
thrombosis	O
.	O

BACKGROUND	O
A	O
low-molecular-weight	Pharmacological
heparin	Pharmacological
,	O
enoxaparin	Pharmacological
sodium	Pharmacological
,	O
has	O
been	O
shown	O
to	O
be	O
effective	O
and	O
safe	O
in	O
preventing	O
deep	O
vein	O
thrombosis	O
both	O
in	O
general	O
surgery	O
and	O
in	O
high-risk	O
orthopedic	O
surgery	O
.	O

We	O
conducted	O
a	O
controlled	O
,	O
randomized	O
trial	O
with	O
enoxaparin	O
in	O
the	O
treatment	O
of	O
established	O
deep	O
vein	O
thrombosis	O
.	O

METHODS	O
In	O
a	O
multicenter	O
trial	O
,	O
we	O
compared	O
fixed-dose	O
subcutaneous	O
enoxaparin	Pharmacological
,	O
given	O
twice	O
daily	O
,	O
with	O
adjusted-dose	O
intravenous	O
unfractionated	Pharmacological
heparin	Pharmacological
(	Pharmacological
UFH	Pharmacological
)	Pharmacological
given	O
by	O
continuous	O
intravenous	O
infusion	O
for	O
the	O
initial	O
10	O
days	O
of	O
treatment	O
of	O
patients	O
with	O
proximal	O
vein	O
thrombosis	O
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
the	O
change	O
of	O
the	O
size	O
of	O
the	O
thrombus	O
assessed	O
by	O
repeated	O
venograms	O
between	O
day	O
0	O
and	O
day	O
10	O
.	O

The	O
primary	O
analysis	O
of	O
safety	O
was	O
based	O
on	O
the	O
incidence	O
of	O
major	O
bleeding	O
during	O
10	O
days	O
of	O
treatment	O
.	O

RESULTS	O
There	O
were	O
67	O
patients	O
in	O
each	O
group	O
.	O

Venographic	O
assessment	O
of	O
clot	O
size	O
evolution	O
between	O
day	O
0	O
and	O
day	O
10	O
showed	O
a	O
statistically	O
significant	O
superiority	O
(	O
P	O
<	O
.002	O
)	O
of	O
enoxaparin	Pharmacological
over	O
the	O
reference	O
treatment	O
with	O
UFH	Pharmacological
.	O

Moreover	O
,	O
the	O
incidence	O
of	O
overall	O
recurrent	O
thromboembolic	O
events	O
during	O
10	O
days	O
of	O
treatment	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
.002	O
)	O
in	O
the	O
UFH	Pharmacological
group	O
(	O
seven	O
of	O
67	O
)	O
than	O
in	O
the	O
enoxaparin	Pharmacological
group	O
(	O
one	O
of	O
67	O
)	O
.	O

There	O
were	O
no	O
serious	O
bleeding	O
complications	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
Enoxaparin	Pharmacological
is	O
at	O
least	O
as	O
effective	O
and	O
safe	O
as	O
UFH	Pharmacological
under	O
the	O
conditions	O
of	O
this	O
study	O
.	O

Moreover	O
,	O
it	O
is	O
more	O
comfortable	O
for	O
patients	O
and	O
less	O
time-consuming	O
for	O
nurses	O
and	O
laboratories	O
.	O

Thus	O
,	O
our	O
study	O
confirmed	O
,	O
with	O
the	O
use	O
of	O
enoxaparin	Pharmacological
,	O
other	O
observations	O
that	O
low-molecular-weight	Pharmacological
heparin	Pharmacological
provides	O
a	O
real	O
therapeutic	O
advance	O
in	O
the	O
treatment	O
of	O
deep	O
vein	O
thrombosis	O
.	O

Effects	O
of	O
10	O
Hz	O
repetitive	Surgical
transcranial	Surgical
magnetic	Surgical
stimulation	Surgical
(	Surgical
rTMS	Surgical
)	Surgical
on	O
clinical	O
global	O
impression	O
in	O
chronic	O
schizophrenia	O
.	O

UNLABELLED	O
We	O
conducted	O
a	O
randomized	O
,	O
sham-controlled	O
repetitive	Surgical
transcranial	Surgical
magnetic	Surgical
stimulation	Surgical
(	Surgical
rTMS	Surgical
)	O
study	O
in	O
chronic	O
schizophrenia	O
in-patients	O
(	O
n=35	O
)	O
to	O
evaluate	O
the	O
therapeutic	O
efficacy	O
of	O
10	Surgical
Hz	Surgical
stimulation	O
.	O

Patients	O
,	O
who	O
were	O
on	O
stable	O
antipsychotic	O
treatment	O
,	O
were	O
randomly	O
assigned	O
to	O
the	O
active	O
or	O
sham	O
condition	O
.	O

In	O
the	O
active	O
rTMS	Surgical
group	O
,	O
ten	O
sessions	O
with	O
a	O
total	O
of	O
10,000	O
stimuli	O
were	O
applied	O
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
at	O
110	O
%	O
of	O
motor	O
threshold	O
.	O

The	O
sham	O
group	O
received	O
corresponding	O
sham	Control
stimulation	Control
.	O

Clinical	O
improvement	O
was	O
measured	O
by	O
the	O
Clinical	O
Global	O
Impression	O
scale	O
(	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
Global	O
Assessment	O
of	O
Functioning	O
Scale	O
(	O
GAF	O
)	O
and	O
the	O
Positive	O
and	O
Negative	O
Symptom	O
Scale	O
(	O
PANSS	O
;	O
secondary	O
outcome	O
measures	O
)	O
.	O

Between-group	O
comparisons	O
revealed	O
no	O
significant	O
differences	O
in	O
clinical	O
outcome	O
variables	O
.	O

Only	O
a	O
subgroup	O
of	O
patients	O
with	O
pronounced	O
negative	O
symptoms	O
developed	O
some	O
clinical	O
improvement	O
as	O
indicated	O
by	O
significant	O
changes	O
in	O
the	O
GAF-scale	O
.	O

Besides	O
there	O
is	O
some	O
evidence	O
for	O
a	O
more	O
favourable	O
clinical	O
outcome	O
within	O
this	O
subgroup	O
after	O
rTMS	Surgical
in	O
the	O
CGI-S	O
and	O
PANSS	O
negative	O
scale	O
,	O
too	O
.	O

In	O
line	O
with	O
earlier	O
investigations	O
,	O
our	O
results	O
suggest	O
a	O
moderate	O
-	O
potentially	O
clinically	O
relevant	O
-	O
treatment	O
effect	O
of	O
prefrontal	Surgical
10	Surgical
Hz	Surgical
rTMS	Surgical
stimulation	O
in	O
chronic	O
patients	O
.	O

However	O
,	O
in	O
our	O
study	O
this	O
beneficial	O
effect	O
was	O
restricted	O
to	O
subjects	O
with	O
pronounced	O
negative	O
symptoms	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
INFORMATION	O
ClinicalTrial.gov	O
Identifier	O
:	O
NCT00169689	O
,	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Short-course	O
nitrofurantoin	Pharmacological
for	O
the	O
treatment	O
of	O
acute	O
uncomplicated	O
cystitis	O
in	O
women	O
.	O

BACKGROUND	O
There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
the	O
efficacy	O
of	O
nitrofurantoin	Pharmacological
for	O
the	O
treatment	O
of	O
acute	O
uncomplicated	O
cystitis	O
in	O
regimens	O
shorter	O
than	O
7	O
days	O
.	O

Evidence-based	O
use	O
of	O
this	O
drug	O
is	O
increasingly	O
important	O
as	O
trimethoprim-sulfamethoxazole	Pharmacological
resistance	O
among	O
uropathogens	O
increases	O
.	O

METHODS	O
To	O
assess	O
the	O
efficacy	O
of	O
nitrofurantoin	Pharmacological
vs	O
trimethoprim-sulfamethoxazole	Pharmacological
,	O
338	O
women	O
aged	O
18	O
to	O
45	O
years	O
with	O
acute	O
uncomplicated	O
cystitis	O
were	O
randomized	O
to	O
open-label	O
treatment	O
with	O
either	O
trimethoprim-sulfamethoxazole	Pharmacological
,	O
1	O
double-strength	O
tablet	O
twice	O
daily	O
for	O
3	O
days	O
,	O
or	O
nitrofurantoin	Pharmacological
,	O
100	O
mg	O
twice	O
daily	O
for	O
5	O
days	O
.	O

Clinical	O
cure	O
30	O
days	O
after	O
therapy	O
was	O
the	O
main	O
outcome	O
measure	O
.	O

Secondary	O
outcomes	O
included	O
clinical	O
and	O
microbiological	O
cure	O
rates	O
5	O
to	O
9	O
days	O
after	O
therapy	O
and	O
,	O
for	O
trimethoprim-sulfamethoxazole-treated	Pharmacological
women	O
,	O
clinical	O
cure	O
stratified	O
by	O
the	O
trimethoprim-sulfamethoxazole	Pharmacological
susceptibility	O
of	O
the	O
uropathogen	O
.	O

RESULTS	O
Clinical	O
cure	O
was	O
achieved	O
in	O
79	O
%	O
of	O
the	O
trimethoprim-sulfamethoxazole	O
group	O
and	O
in	O
84	O
%	O
of	O
the	O
nitrofurantoin	O
group	O
,	O
for	O
a	O
difference	O
of	O
-5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-13	O
%	O
to	O
4	O
%	O
)	O
.	O

Clinical	O
and	O
microbiological	O
cure	O
rates	O
at	O
the	O
first	O
follow-up	O
visit	O
were	O
also	O
equivalent	O
between	O
the	O
2	O
groups	O
.	O

In	O
the	O
trimethoprim-sulfamethoxazole	Pharmacological
arm	O
,	O
7	O
of	O
17	O
women	O
(	O
41	O
%	O
)	O
with	O
a	O
trimethoprim-sulfamethoxazole-nonsusceptible	O
isolate	O
had	O
a	O
clinical	O
cure	O
compared	O
with	O
84	O
%	O
of	O
women	O
with	O
a	O
trimethoprim-sulfamethoxazole-susceptible	O
isolate	O
(	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSION	O
A	O
5-day	O
course	O
of	O
nitrofurantoin	O
is	O
equivalent	O
clinically	O
and	O
microbiologically	O
to	O
a	O
3-day	O
course	O
of	O
trimethoprim-sulfamethoxazole	O
and	O
should	O
be	O
considered	O
an	O
effective	O
fluoroquinolone-sparing	O
alternative	O
for	O
the	O
treatment	O
of	O
acute	O
cystitis	O
in	O
women	O
.	O

Early	O
behavioral	O
intervention	O
is	O
associated	O
with	O
normalized	O
brain	O
activity	O
in	O
young	O
children	O
with	O
autism	O
.	O

OBJECTIVE	O
A	O
previously	O
published	O
randomized	O
clinical	O
trial	O
indicated	O
that	O
a	O
developmental	O
behavioral	Educational
intervention	Educational
,	O
the	O
Early	O
Start	O
Denver	O
Model	O
(	O
ESDM	O
)	O
,	O
resulted	O
in	O
gains	O
in	O
IQ	O
,	O
language	O
,	O
and	O
adaptive	O
behavior	O
of	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

This	O
report	O
describes	O
a	O
secondary	O
outcome	O
measurement	O
from	O
this	O
trial	O
,	O
EEG	O
activity	O
.	O

METHOD	O
Forty-eight	O
18-	O
to	O
30-month-old	O
children	O
with	O
autism	O
spectrum	O
disorder	O
were	O
randomized	O
to	O
receive	Educational
the	Educational
ESDM	Educational
or	O
referral	Other
to	Other
community	Other
intervention	Other
for	Educational
2	Educational
years	Educational
.	O

After	O
the	O
intervention	O
(	O
age	O
48	O
to	O
77	O
months	O
)	O
,	O
EEG	Physical
activity	Physical
(	O
event-related	O
potentials	O
and	O
spectral	O
power	O
)	O
was	O
measured	O
during	O
the	O
presentation	O
of	O
faces	O
versus	O
objects	O
.	O

Age-matched	O
typical	O
children	O
were	O
also	O
assessed	O
.	O

RESULTS	O
The	O
ESDM	Educational
group	O
exhibited	O
greater	O
improvements	O
in	O
autism	O
symptoms	O
,	O
IQ	O
,	O
language	O
,	O
and	O
adaptive	O
and	O
social	O
behaviors	O
than	O
the	O
community	O
intervention	O
group	O
.	O

The	O
ESDM	O
group	O
and	O
typical	O
children	O
showed	O
a	O
shorter	O
Nc	O
latency	O
and	O
increased	O
cortical	O
activation	O
(	O
decreased	O
?	O
power	O
and	O
increased	O
?	O
power	O
)	O
when	O
viewing	O
faces	O
,	O
whereas	O
the	O
community	O
intervention	O
group	O
showed	O
the	O
opposite	O
pattern	O
(	O
shorter	O
latency	O
event-related	O
potential	O
[	O
ERP	O
]	O
and	O
greater	O
cortical	O
activation	O
when	O
viewing	O
objects	O
)	O
.	O

Greater	O
cortical	O
activation	O
while	O
viewing	O
faces	O
was	O
associated	O
with	O
improved	O
social	O
behavior	O
.	O

CONCLUSIONS	O
This	O
was	O
the	O
first	O
trial	O
to	O
demonstrate	O
that	O
early	O
behavioral	O
intervention	O
is	O
associated	O
with	O
normalized	O
patterns	O
of	O
brain	O
activity	O
,	O
which	O
is	O
associated	O
with	O
improvements	O
in	O
social	O
behavior	O
,	O
in	O
young	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Variations	O
in	O
EEG	Physical
discharges	Physical
predict	O
ADHD	O
severity	O
within	O
individual	O
Smith-Lemli-Opitz	O
patients	O
.	O

OBJECTIVE	O
We	O
sought	O
to	O
examine	O
the	O
prevalence	O
of	O
EEG	O
abnormalities	O
in	O
Smith-Lemli-Opitz	O
syndrome	O
(	O
SLOS	O
)	O
as	O
well	O
as	O
the	O
relationship	O
between	O
interictal	O
epileptiform	O
discharges	O
(	O
IEDs	O
)	O
and	O
within-subject	O
variations	O
in	O
attentional	O
symptom	O
severity	O
.	O

METHODS	O
In	O
the	O
context	O
of	O
a	O
clinical	O
trial	O
for	O
SLOS	O
,	O
we	O
performed	O
cross-sectional	O
and	O
repeated-measure	O
observational	O
studies	O
of	O
the	O
relationship	O
between	O
EEG	Physical
findings	O
and	O
cognitive/behavioral	O
factors	O
on	O
23	O
children	O
(	O
aged	O
4-17	O
years	O
)	O
.	O

EEGs	Physical
were	O
reviewed	O
for	O
clinical	O
abnormalities	O
,	O
including	O
IEDs	O
,	O
by	O
readers	O
blinded	O
to	O
participants	O
'	O
behavioral	O
symptoms	O
.	O

Between-group	O
differences	O
in	O
baseline	O
characteristics	O
of	O
participants	O
with	O
and	O
without	O
IEDs	O
were	O
analyzed	O
.	O

Within-subject	O
analyses	O
examined	O
the	O
association	O
between	O
the	O
presence	O
of	O
IEDs	O
and	O
changes	O
in	O
attention-deficit/hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
symptoms	O
.	O

RESULTS	O
Of	O
85	O
EEGs	O
,	O
43	O
(	O
51	O
%	O
)	O
were	O
abnormal	O
,	O
predominantly	O
because	O
of	O
IEDs	O
.	O

Only	O
one	O
subject	O
had	O
documented	O
clinical	O
seizures	O
.	O

IEDs	O
clustered	O
in	O
13	O
subjects	O
(	O
57	O
%	O
)	O
,	O
whereas	O
9	O
subjects	O
(	O
39	O
%	O
)	O
had	O
EEGs	O
consistently	O
free	O
of	O
IEDs	O
.	O

While	O
there	O
were	O
no	O
significant	O
group	O
differences	O
in	O
sex	O
,	O
age	O
,	O
intellectual	O
disability	O
,	O
language	O
level	O
,	O
or	O
baseline	O
ADHD	O
symptoms	O
,	O
autistic	O
symptoms	O
tended	O
to	O
be	O
more	O
prevalent	O
in	O
the	O
IED	O
group	O
(	O
according	O
to	O
Autism	O
Diagnostic	O
Observation	O
Schedule-2	O
criteria	O
)	O
.	O

Within	O
individuals	O
,	O
the	O
presence	O
of	O
IEDs	O
on	O
a	O
particular	O
EEG	O
predicted	O
,	O
on	O
average	O
,	O
a	O
27	O
%	O
increase	O
in	O
ADHD	O
symptom	O
severity	O
.	O

CONCLUSIONS	O
Epileptiform	O
discharges	O
are	O
common	O
in	O
SLOS	O
,	O
despite	O
a	O
relatively	O
low	O
prevalence	O
of	O
epilepsy	O
.	O

Fluctuations	O
in	O
the	O
presence	O
of	O
epileptiform	O
discharges	O
within	O
individual	O
children	O
with	O
a	O
developmental	O
disability	O
syndrome	O
may	O
be	O
associated	O
with	O
fluctuations	O
in	O
ADHD	O
symptomatology	O
,	O
even	O
in	O
the	O
absence	O
of	O
clinical	O
seizures	O
.	O

Efficacy	O
,	O
safety	O
,	O
and	O
steady-state	O
pharmacokinetics	O
of	O
once-a-day	O
controlled-release	O
morphine	Pharmacological
(	O
MS	O
Contin	O
XL	O
)	O
in	O
cancer	O
pain	O
.	O

The	O
efficacy	O
,	O
safety	O
,	O
and	O
pharmacokinetics	O
of	O
a	O
novel	O
once-daily	O
morphine	Pharmacological
formulation	Pharmacological
(	Pharmacological
OAD	Pharmacological
morphine	Pharmacological
)	Pharmacological
and	O
a	O
12-hourly	O
formulation	O
(	O
twice-daily	O
CR	O
morphine	Pharmacological
)	O
were	O
compared	O
in	O
a	O
double-blind	O
,	O
multi-centered	O
crossover	O
study	O
.	O

Chronic	O
cancer	O
pain	O
patients	O
(	O
n=25	O
)	O
were	O
randomized	O
to	O
OAD	Pharmacological
morphine	Pharmacological
(	O
mean	O
238	O
+/-	O
319	O
mg	O
q24h	O
)	O
or	O
twice-daily	Pharmacological
CR	Pharmacological
morphine	Pharmacological
(	O
mean	O
119	O
+/-	O
159	O
mg	O
q12h	O
)	O
for	O
one	O
week	O
.	O

They	O
then	O
crossed	O
over	O
to	O
the	O
alternate	O
drug	O
,	O
which	O
also	O
was	O
taken	O
for	O
one	O
week	O
.	O

There	O
was	O
no	O
difference	O
between	O
treatments	O
for	O
evaluations	O
of	O
overall	O
pain	O
intensity	O
,	O
analgesic	O
efficacy	O
,	O
or	O
adverse	O
events	O
.	O

However	O
,	O
whereas	O
pain	O
scores	O
increased	O
during	O
the	O
day	O
on	O
twice-daily	O
CR	O
morphine	Pharmacological
(	O
P=0.0108	O
)	O
,	O
they	O
remained	O
stable	O
on	O
OAD	O
morphine	O
.	O

Most	O
patients	O
(	O
68	O
%	O
)	O
chose	O
once-daily	O
dosing	O
for	O
continuing	O
pain	O
management	O
(	O
P=0.015	O
)	O
.	O

The	O
AUC	O
ratio	O
was	O
100.3	O
%	O
,	O
indicating	O
equivalent	O
absorption	O
.	O

Fluctuation	O
indices	O
were	O
93.5	O
+/-	O
28.8	O
%	O
and	O
179.3	O
+/-	O
41.3	O
%	O
(	O
P=0.0001	O
)	O
for	O
OAD	O
morphine	Pharmacological
and	O
twice-daily	O
CR	O
morphine	Pharmacological
,	O
respectively	O
.	O

OAD	O
morphine	Pharmacological
provides	O
analgesia	O
similar	O
to	O
twice-daily	O
CR	O
morphine	O
with	O
reduced	O
fluctuation	O
in	O
plasma	O
morphine	O
concentration	O
and	O
more	O
stable	O
pain	O
control	O
.	O

The	O
effect	O
of	O
quality	O
and	O
amount	O
of	O
dietary	O
fat	O
on	O
the	O
susceptibility	O
of	O
low	O
density	O
lipoprotein	O
to	O
oxidation	O
in	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
.	O

OBJECTIVES	O
We	O
examined	O
the	O
effects	O
of	O
a	O
high	Pharmacological
fat	Pharmacological
diet	Pharmacological
rich	Pharmacological
in	Pharmacological
monounsaturated	Pharmacological
fat	Pharmacological
(	Pharmacological
MUFA-diet	Pharmacological
)	Pharmacological
and	O
a	O
moderate	Pharmacological
fat	Pharmacological
diet	Pharmacological
rich	Pharmacological
in	Pharmacological
polyunsaturated	Pharmacological
fat	Pharmacological
(	Pharmacological
PUFA-diet	Pharmacological
)	Pharmacological
on	O
the	O
susceptibility	O
of	O
LDL	O
to	O
oxidation	O
.	O

SUBJECTS	O
29	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
.	O

METHODS	O
After	O
consuming	O
a	O
run-in	O
diet	O
[	O
37	O
%	O
of	O
energy	O
(	O
E	O
%	O
)	O
fat	O
,	O
18	O
E	O
%	O
saturated	O
fat	O
]	O
for	O
three	O
weeks	O
,	O
subjects	O
were	O
randomly	O
assigned	O
either	O
to	O
a	O
MUFA-diet	O
(	O
40	O
E	O
%	O
fat	O
,	O
19	O
E	O
%	O
monounsaturated	O
fatty	O
acids	O
)	O
or	O
a	O
PUFA-diet	O
(	O
34	O
E	O
%	O
fat	O
,	O
10	O
E	O
%	O
polyunsaturated	O
fat	O
)	O
for	O
eight	O
weeks	O
.	O

The	O
susceptibility	O
of	O
LDL	O
to	O
oxidation	O
was	O
measured	O
by	O
challenging	O
LDL	O
with	O
hemin	O
and	O
H2O2	O
and	O
measuring	O
the	O
time	O
for	O
the	O
reaction	O
to	O
reach	O
maximum	O
velocity	O
.	O

Results	O
are	O
expressed	O
as	O
lag	O
time	O
to	O
oxidation	O
in	O
minutes	O
.	O

RESULTS	O
In	O
the	O
PUFA-diet	O
group	O
(	O
n	O
=	O
15	O
)	O
lag	O
time	O
tended	O
to	O
decrease	O
during	O
the	O
experimental	O
diet	O
(	O
97	O
+/-	O
28	O
vs	O
90	O
+/-	O
25	O
min	O
,	O
mean	O
+/-	O
s.d.	O
,	O
P	O
=	O
0.073	O
)	O
,	O
whereas	O
in	O
the	O
MUFA-diet	O
group	O
(	O
n	O
=	O
14	O
)	O
there	O
was	O
no	O
significant	O
change	O
(	O
lag	O
time	O
96	O
+/-	O
24	O
vs	O
100	O
+/-	O
16	O
min	O
,	O
P	O
=	O
0.408	O
)	O
.	O

The	O
mean	O
change	O
in	O
lag	O
time	O
was	O
-7	O
+/-	O
14	O
min	O
(	O
-7.2	O
%	O
)	O
in	O
the	O
PUFA-diet	O
group	O
and	O
+4	O
+/-	O
16	O
min	O
(	O
+4.0	O
%	O
)	O
in	O
the	O
MUFA-diet	O
group	O
(	O
P	O
=	O
0.029	O
,	O
PUFA-diet	O
group	O
vs	O
MUFA-diet	O
group	O
)	O
.	O

The	O
alpha-tocopherol	O
concentration	O
in	O
LDL	O
increased	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
in	O
both	O
diet	O
groups	O
relative	O
to	O
the	O
run-in	O
diet	O
period	O
,	O
but	O
LDL	O
particle	O
score	O
did	O
not	O
change	O
in	O
either	O
of	O
the	O
diet	O
groups	O
during	O
the	O
dietary	O
intervention	O
.	O

In	O
subjects	O
with	O
impaired	O
glucose	O
tolerance	O
a	O
PUFA-rich	Pharmacological
diet	O
with	O
a	O
moderate	O
amount	O
of	O
fat	O
tended	O
to	O
increase	O
the	O
susceptibility	O
of	O
LDL	O
to	O
oxidation	O
as	O
compared	O
to	O
a	O
higher	O
fat	O
diet	O
rich	O
in	O
MUFA	Pharmacological
.	O

Furthermore	O
,	O
the	O
negative	O
mean	O
change	O
in	O
lag	O
time	O
to	O
oxidation	O
found	O
in	O
the	O
PUFA-diet	O
group	O
differed	O
significantly	O
from	O
the	O
slightly	O
positive	O
mean	O
change	O
found	O
in	O
the	O
MUFA-diet	O
group	O
.	O

Single-use	O
plaque	O
removal	O
efficacy	O
of	O
three	O
power	Other
toothbrushes	Other
.	O

OBJECTIVES	O
To	O
compare	O
the	O
safety	O
and	O
plaque	O
removal	O
efficacy	O
of	O
two	Other
oscillating/rotating/pulsating	Other
toothbrushes	Other
(	O
Oral-B	Other
ProfessionalCare	Other
7000	Other
[	Other
PC	Other
7000	Other
]	O
and	O
Oral-B	Other
3D	Other
Excel	Other
[	Other
3DE	Other
]	O
)	O
and	O
a	O
high-frequency	O
toothbrush	O
(	O
Sonicare	O
Advance	O
,	O
Philips	O
Oral	O
Healthcare	O
;	O
SA	O
)	O
in	O
a	O
single-use	O
,	O
examiner-blind	O
,	O
three	O
period	O
crossover	O
study	O
.	O

METHODS	O
After	O
refraining	O
from	O
all	O
oral	O
hygiene	O
procedures	O
for	O
23-25	O
hours	O
,	O
subjects	O
received	O
an	O
oral	O
tissue	O
examination	O
and	O
those	O
with	O
pre-brushing	O
whole	O
mouth	O
mean	O
plaque	O
scores	O
>	O
or	O
=	O
0.6	O
based	O
on	O
the	O
Rustogi	O
et	O
al	O
.	O

Modified	O
Navy	O
Plaque	O
Index	O
were	O
randomly	O
assigned	O
to	O
treatment	O
sequence	O
.	O

After	O
brushing	O
with	O
the	O
assigned	O
toothbrush	O
and	O
a	O
commercially	O
available	O
dentifrice	O
for	O
2	O
minutes	O
,	O
oral	O
tissues	O
were	O
then	O
re-examined	O
and	O
post-brushing	O
plaque	O
scores	O
recorded	O
.	O

Following	O
a	O
brief	O
washout	O
period	O
between	O
two	O
additional	O
visits	O
,	O
the	O
above	O
procedures	O
were	O
repeated	O
with	O
the	O
two	O
alternate	O
toothbrushes	O
.	O

One	O
examiner	O
,	O
blinded	O
to	O
the	O
treatment	O
sequence	O
,	O
performed	O
all	O
clinical	O
measurements	O
.	O

RESULTS	O
A	O
total	O
of	O
79	O
subjects	O
(	O
28	O
males	O
and	O
51	O
females	O
)	O
were	O
enrolled	O
and	O
completed	O
the	O
study	O
.	O

Each	O
toothbrush	O
was	O
found	O
to	O
be	O
safe	O
and	O
significantly	O
reduced	O
plaque	O
levels	O
after	O
a	O
single	O
brushing	O
.	O

The	O
PC	O
7000	O
and	O
3DE	O
were	O
equally	O
more	O
effective	O
in	O
plaque	O
removal	O
than	O
the	O
SA	O
,	O
at	O
all	O
tooth	O
areas	O
,	O
reducing	O
plaque	O
by	O
59.0	O
%	O
,	O
59.7	O
%	O
and	O
51.8	O
%	O
,	O
respectively	O
on	O
whole	O
mouth	O
surfaces	O
,	O
and	O
by	O
67.5	O
%	O
,	O
67.8	O
%	O
and	O
59.4	O
%	O
,	O
respectively	O
on	O
approximal	O
surfaces	O
.	O

CONCLUSIONS	O
The	O
action	O
of	O
the	O
oscillating/rotating/pulsating	O
toothbrushes	O
(	O
Oral-B	O
ProfessionalCare	O
7000	O
and	O
Oral-B	O
3D	O
Excel	O
)	O
was	O
more	O
effective	O
in	O
plaque	O
removal	O
than	O
the	O
high-frequency	O
toothbrush	O
(	O
Sonicare	O
Advance	O
)	O
.	O

A	O
comparison	O
of	O
the	O
effects	O
of	O
anticholinergic	Pharmacological
and	Pharmacological
beta	Pharmacological
2-agonist	Pharmacological
and	O
combination	Pharmacological
therapy	Pharmacological
on	O
respiratory	O
impedance	O
in	O
COPD	O
.	O

The	O
effects	O
of	O
three	O
different	O
regimens	O
of	O
inhaled	Pharmacological
bronchodilators	Pharmacological
on	O
spirometry	O
and	O
respiratory	O
impedance	O
as	O
measured	O
with	O
the	O
technique	O
of	O
forced	O
oscillations	O
were	O
compared	O
in	O
a	O
double-blind	O
crossover	O
study	O
in	O
22	O
patients	O
with	O
stable	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
FEV1	O
less	O
than	O
70	O
percent	O
predicted	O
)	O
.	O

On	O
three	O
trial	O
days	O
,	O
patients	O
inhaled	O
,	O
in	O
random	O
order	O
,	O
40	O
micrograms	O
ipratropium	Pharmacological
bromide	Pharmacological
,	O
200	O
micrograms	O
fenoterol	Pharmacological
hydrobromide	Pharmacological
,	O
or	O
a	O
combination	Pharmacological
of	Pharmacological
40	Pharmacological
micrograms	Pharmacological
ipratropium	Pharmacological
and	Pharmacological
100	Pharmacological
micrograms	Pharmacological
fenoterol	Pharmacological
from	O
a	O
powder	O
inhaler	O
,	O
followed	O
by	O
a	O
second	O
dose	O
of	O
the	O
same	O
drug	O
after	O
60	O
min	O
.	O

The	O
effects	O
were	O
measured	O
at	O
baseline	O
and	O
20	O
,	O
40	O
,	O
60	O
,	O
and	O
120	O
min	O
after	O
the	O
first	O
inhalation	O
.	O

No	O
significant	O
decrease	O
in	O
total	O
respiratory	O
resistance	O
at	O
8	O
Hz	O
(	O
Rrs	O
[	O
8	O
]	O
)	O
was	O
observed	O
after	O
ipratropium	Pharmacological
,	O
whereas	O
Rrs	O
(	O
8	O
)	O
decreased	O
significantly	O
20	O
min	O
after	O
fenoterol	Pharmacological
and	O
40	O
min	O
after	O
the	O
combination	Pharmacological
regimen	Pharmacological
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

All	O
three	O
studied	O
drugs	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
reactance	O
(	O
p	O
less	O
than	O
0.01	O
)	O
and	O
decrease	O
in	O
resonant	O
frequency	O
.	O

Both	O
fenoterol	O
(	O
delta	O
FEV1	O
34	O
percent	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
and	O
the	O
combination	Pharmacological
regimen	Pharmacological
(	O
delta	O
FEV1	O
38	O
percent	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
resulted	O
in	O
a	O
significantly	O
larger	O
increase	O
in	O
FEV1	O
than	O
ipratropium	Pharmacological
alone	O
(	O
delta	O
FEV1	O
17	O
percent	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

A	O
second	O
dose	O
of	O
fenoterol	Pharmacological
and	O
of	O
the	O
combination	Pharmacological
regimen	Pharmacological
resulted	O
in	O
a	O
further	O
significant	O
increase	O
in	O
FEV1	O
after	O
120	O
min	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

A	O
second	O
dose	O
of	O
ipratropium	Pharmacological
did	O
not	O
result	O
in	O
a	O
further	O
significant	O
increase	O
in	O
FEV1	O
.	O

The	O
changes	O
in	O
respiratory	O
impedance	O
were	O
qualitatively	O
similar	O
for	O
all	O
three	O
drug	O
regimens	O
,	O
but	O
larger	O
in	O
absolute	O
terms	O
after	O
fenoterol	Pharmacological
and	O
the	O
combination	Pharmacological
regimen	Pharmacological
than	O
after	O
ipratropium	Pharmacological
.	O

The	O
similar	O
effect	O
of	O
these	O
drugs	O
on	O
the	O
reactance	O
can	O
be	O
explained	O
by	O
an	O
increase	O
in	O
the	O
capacitance	O
of	O
the	O
respiratory	O
system	O
,	O
and	O
in	O
combination	O
with	O
a	O
decrease	O
in	O
frequency	O
dependence	O
of	O
resistance	O
,	O
by	O
assuming	O
a	O
decrease	O
in	O
peripheral	O
airway	O
resistance	O
.	O

Age-related	O
response	O
to	O
two	O
Haemophilus	Pharmacological
influenzae	Pharmacological
type	Pharmacological
b	Pharmacological
vaccines	Pharmacological
.	Pharmacological

Two	O
types	O
of	O
Hib	Pharmacological
vaccines	Pharmacological
were	O
compared	O
for	O
efficacy	O
and	O
safety	O
in	O
71	O
normal	O
children	O
in	O
three	O
age	O
groups	O
:	O
36	O
to	O
72	O
months	O
,	O
15	O
to	O
18	O
months	O
,	O
and	O
6	O
to	O
8	O
months	O
.	O

One	O
vaccine	O
contained	O
the	O
Hib-specific	Pharmacological
capsular	Pharmacological
polysaccharide	Pharmacological
,	Pharmacological
PRP	Pharmacological
;	Pharmacological
the	O
second	O
vaccine	O
contained	O
PRP	Pharmacological
combined	O
with	O
pertussis	Pharmacological
vaccine	Pharmacological
,	Pharmacological
PRP-P.	Pharmacological
A	O
third	O
vaccine	O
,	O
DTP	Pharmacological
,	O
was	O
administered	O
to	O
a	O
control	Control
group	O
for	O
each	O
age	O
.	O

Anti-PRP	O
antibody	O
levels	O
were	O
greater	O
after	O
vaccination	O
with	O
PRP-P	O
than	O
after	O
PRP	O
in	O
all	O
three	O
age	O
groups	O
.	O

Immunoresponsiveness	O
to	O
both	O
vaccines	O
increased	O
with	O
age	O
.	O

A	O
lower	O
incidence	O
of	O
side	O
effects	O
was	O
seen	O
with	O
both	O
PRP	Pharmacological
(	O
15	O
%	O
)	O
and	O
PRP-P	Pharmacological
(	O
20	O
%	O
)	O
than	O
with	O
DTP	O
(	O
56	O
%	O
)	O
.	O

The	O
results	O
suggest	O
that	O
PRP-P	Pharmacological
is	O
both	O
well	O
tolerated	O
clinically	O
and	O
has	O
greater	O
immunogenicity	O
than	O
PRP	O
.	O

Improvement	O
in	O
sensory	O
impairment	O
and	O
social	O
interaction	O
in	O
young	O
children	O
with	O
autism	O
following	O
treatment	O
with	O
an	O
original	Other
Qigong	Other
massage	Other
methodology	Other
.	O

In	O
clinical	O
research	O
,	O
sensory	O
impairment	O
is	O
considered	O
one	O
of	O
the	O
core	O
deficits	O
in	O
autism	O
and	O
is	O
associated	O
with	O
impaired	O
socialization	O
,	O
behavioral	O
disturbances	O
and	O
bowel	O
and	O
sleep	O
problems	O
.	O

The	O
effectiveness	O
of	O
the	O
Cignolini	Other
methodology	Other
,	Physical
an	Physical
original	Other
Qigong	Other
massage	Other
methodology	Other
,	O
in	O
treating	O
sensory	O
impairment	O
in	O
young	O
children	O
with	O
autism	O
was	O
evaluated	O
in	O
a	O
small	O
,	O
controlled	O
study	O
.	O

Thirteen	O
children	O
with	O
autism	O
between	O
the	O
ages	O
of	O
three	O
and	O
six	O
received	O
daily	O
treatment	O
according	O
to	O
the	O
methodology	O
for	O
5	O
months	O
.	O

Compared	O
with	O
untreated	O
children	O
,	O
treated	O
children	O
experienced	O
significant	O
improvement	O
of	O
their	O
sensory	O
impairment	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
demonstrated	O
increased	O
social	O
skills	O
(	O
p	O
<	O
0.04	O
)	O
and	O
basic	O
living	O
skills	O
(	O
p	O
<	O
0.02	O
)	O
on	O
standardized	O
measures	O
.	O

In	O
addition	O
,	O
all	O
of	O
the	O
children	O
with	O
bowel	O
and	O
sleep	O
abnormalities	O
demonstrated	O
improvement	O
after	O
treatment	O
.	O

Treatment	O
of	O
acute	O
ischaemic	O
stroke	O
with	O
the	O
low-affinity	O
,	O
use-dependent	O
NMDA	Pharmacological
antagonist	Pharmacological
AR-R15896AR	Pharmacological
.	O

A	O
safety	O
and	O
tolerability	O
study	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
A	O
low-affinity	O
,	O
use-dependent	O
N-Methyl-D-Aspartate	Pharmacological
(	Pharmacological
NMDA	Pharmacological
)	Pharmacological
antagonist	Pharmacological
AR-R15896AR	Pharmacological
has	O
neuroprotective	O
properties	O
in	O
animal	O
models	O
of	O
ischaemic	O
stroke	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
a	O
new	O
and	O
higher	O
dosage	O
regimen	O
that	O
would	O
enable	O
acute	O
stroke	O
patients	O
to	O
achieve	O
and	O
maintain	O
neuroprotective	O
plasma	O
concentrations	O
.	O

METHODS	O
A	O
randomised	O
,	O
multi-centre	O
,	O
double-blind	O
,	O
placebo-controlled	Control
,	O
parallel	O
group	O
study	O
was	O
carried	O
out	O
at	O
19	O
centres	O
in	O
France	O
,	O
Germany	O
and	O
the	O
Netherlands	O
in	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
acute	O
ischaemic	O
stroke	O
,	O
and	O
onset	O
of	O
symptoms	O
within	O
12	O
hours	O
before	O
start	O
of	O
study	O
drug	O
administration	O
.	O

Two	Pharmacological
loading	Pharmacological
doses	Pharmacological
of	Pharmacological
3.5	Pharmacological
mg/kg	Pharmacological
of	Pharmacological
AR-R15896AR	Pharmacological
over	O
60	O
minutes	O
,	O
followed	O
by	O
a	O
2.5	O
mg/kg	O
infusion	O
over	O
the	O
next	O
120	O
minutes	O
were	O
given	O
.	O

Eight	O
hours	O
after	O
the	O
start	O
of	O
the	O
loading	O
dose	O
infusion	O
,	O
the	O
first	O
maintenance	O
dose	O
(	O
120	O
mg	O
)	O
was	O
administered	O
over	O
60	O
minutes	O
.	O

Eight	O
further	O
maintenance	O
infusions	O
were	O
administered	O
at	O
intervals	O
of	O
8	O
hours	O
over	O
a	O
total	O
treatment	O
period	O
of	O
3	O
days	O
.	O

Main	O
variables	O
were	O
safety	O
,	O
tolerability	O
and	O
pharmacokinetics	O
.	O

Follow-up	O
assessments	O
also	O
included	O
the	O
Barthel	O
Index	O
(	O
BI	O
)	O
and	O
the	O
NIH	O
Stroke	O
Scale	O
(	O
NIHSS	O
)	O
at	O
4-7	O
days	O
after	O
the	O
end	O
of	O
the	O
last	O
infusion	O
and	O
at	O
30	O
days	O
after	O
the	O
onset	O
of	O
stroke	O
.	O

RESULTS	O
103	O
patients	O
with	O
acute	O
ischaemic	O
stroke	O
were	O
randomised	O
to	O
either	O
treatment	O
with	O
AR-R15896AR	Pharmacological
(	O
70	O
patients	O
)	O
or	O
placebo	Control
(	O
33	O
patients	O
)	O
.	O

Mortality	O
was	O
not	O
significantly	O
different	O
in	O
the	O
AR-R15896AR	Pharmacological
group	O
compared	O
with	O
the	O
placebo	Control
group	O
(	O
10	O
%	O
vs.	O
6	O
%	O
)	O
.	O

Serious	O
adverse	O
events	O
during	O
treatment	O
due	O
to	O
psychiatric	O
conditions	O
were	O
associated	O
with	O
AR-R15896AR	Pharmacological
(	O
3	O
vs.	O
0	O
)	O
.	O

Other	O
side	O
effects	O
were	O
more	O
common	O
in	O
the	O
group	O
treated	O
with	O
AR-R15896AR	Pharmacological
:	O
vomiting	O
(	O
29	O
%	O
vs.	O
9	O
%	O
)	O
,	O
nausea	O
(	O
23	O
%	O
vs.	O
12	O
%	O
)	O
,	O
fever	O
(	O
17	O
%	O
vs.	O
12	O
%	O
)	O
,	O
agitation	O
(	O
7	O
%	O
vs.	O
3	O
%	O
)	O
,	O
dizziness	O
(	O
7	O
%	O
vs.	O
0	O
%	O
)	O
,	O
and	O
hallucinations	O
(	O
6	O
%	O
vs.	O
0	O
%	O
)	O
.	O

No	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
with	O
respect	O
to	O
the	O
proportions	O
of	O
patients	O
with	O
favourable	O
outcome	O
)	O
was	O
detected	O
in	O
either	O
the	O
analysis	O
of	O
the	O
BI	O
or	O
the	O
NIHSS	O
.	O

Pharmacokinetic	O
data	O
showed	O
that	O
plasma	O
concentrations	O
of	O
AR-R15896AR	Pharmacological
were	O
in	O
the	O
expected	O
neuroprotective	O
range	O
.	O

CONCLUSION	O
In	O
most	O
of	O
the	O
patients	O
with	O
acute	O
stroke	O
receiving	O
AR-R15896AR	Pharmacological
the	O
intended	O
high	O
plasma	O
levels	O
were	O
reached	O
within	O
a	O
short	O
time	O
period	O
.	O

However	O
,	O
active	O
treatment	O
produced	O
more	O
side	O
effects	O
than	O
placebo	Control
,	O
thus	O
indicating	O
safety	O
concerns	O
and	O
tolerability	O
issues	O
for	O
use	O
in	O
high	O
doses	O
in	O
an	O
acute	O
stroke	O
population	O
.	O

Stability	O
,	O
tipping	O
and	O
relapse	O
of	O
bone-borne	O
versus	O
tooth-borne	O
surgically	Surgical
assisted	Surgical
rapid	Surgical
maxillary	Surgical
expansion	Surgical
;	O
a	O
prospective	O
randomized	O
patient	O
trial	O
.	O

This	O
study	O
evaluated	O
stability	O
,	O
tipping	O
and	O
relapse	O
after	O
surgically	Surgical
assisted	Surgical
rapid	Surgical
maxillary	Surgical
expansion	Surgical
(	Surgical
SARME	Surgical
)	Surgical
,	O
comparing	O
bone-borne	Physical
and	Other
tooth-borne	Physical
devices	Physical
,	O
in	O
skeletally	O
matured	O
non-syndromal	O
patients	O
with	O
transverse	O
maxillary	O
hypoplasia	O
.	O

The	O
study	O
is	O
a	O
randomized	O
,	O
open-label	O
,	O
clinical	O
trial	O
.	O

Patients	O
were	O
randomized	O
to	O
bone-borne	O
(	O
n=25	O
)	O
and	O
tooth-borne	O
(	O
n=21	O
)	O
groups	O
.	O

The	O
surgical	O
technique	O
for	O
corticotomy	O
was	O
the	O
same	O
in	O
both	O
groups	O
.	O

Expansion	O
was	O
performed	O
using	O
a	O
bone-borne	O
or	O
tooth-borne	O
device	O
.	O

Dental	O
study	O
casts	O
,	O
lateral	O
and	O
postero-anterior	O
cephalograms	O
were	O
taken	O
before	O
treatment	O
,	O
after	O
the	O
distraction	O
phase	O
and	O
at	O
12-month	O
follow	O
up	O
.	O

Stability	O
,	O
segmental	O
maxillary	O
tipping	O
and	O
relapse	O
were	O
studied	O
.	O

23	O
bone-borne	O
and	O
19	O
tooth-borne	O
patients	O
were	O
analyzed	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
.	O

Widening	O
was	O
comparable	O
at	O
canine	O
,	O
premolar	O
and	O
molar	O
level	O
.	O

Relapse	O
was	O
not	O
significant	O
and	O
at	O
follow	O
up	O
the	O
significant	O
increase	O
in	O
distance	O
was	O
sustained	O
.	O

A	O
significant	O
increase	O
in	O
palatal	O
width	O
,	O
at	O
premolar	O
and	O
molar	O
level	O
,	O
occurred	O
in	O
both	O
groups	O
.	O

The	O
maxilla	O
moves	O
slightly	O
downward	O
in	O
SARME	O
.	O

Segmental	O
maxillary	O
tipping	O
occurred	O
in	O
both	O
groups	O
and	O
did	O
not	O
affect	O
relapse	O
.	O

There	O
is	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

In	O
SARME	Surgical
,	O
the	O
widening	O
achieved	O
at	O
dental	O
level	O
is	O
stable	O
after	O
12	O
months	O
.	O

Over-correction	O
is	O
not	O
necessary	O
.	O

Tipping	O
of	O
the	O
maxillary	O
segments	O
and	O
increases	O
in	O
the	O
retention	O
period	O
are	O
equal	O
in	O
both	O
groups	O
.	O

A	O
high	O
intake	O
of	O
trans	Pharmacological
fatty	Pharmacological
acids	Pharmacological
has	O
little	O
effect	O
on	O
markers	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
in	O
humans	O
.	O

Consumption	O
of	O
industrial	Pharmacological
trans	Pharmacological
fatty	Pharmacological
acids	Pharmacological
(	Pharmacological
iTFA	Pharmacological
)	Pharmacological
increases	O
LDL	O
cholesterol	O
,	O
decreases	O
HDL	O
cholesterol	O
,	O
and	O
is	O
strongly	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

However	O
,	O
changes	O
in	O
circulating	O
cholesterol	O
can	O
not	O
explain	O
the	O
entire	O
effect	O
.	O

Therefore	O
,	O
we	O
studied	O
whether	O
iTFA	Pharmacological
and	O
conjugated	Pharmacological
linoleic	Pharmacological
acid	Pharmacological
(	Pharmacological
CLA	Pharmacological
)	Pharmacological
affect	O
markers	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
.	O

Sixty-one	O
healthy	O
adults	O
consumed	O
each	O
of	O
3	O
diets	Other
for	O
3	O
wk	O
,	O
in	O
random	O
order	O
.	O

Diets	O
were	O
identical	O
except	O
for	O
7	O
%	O
of	O
energy	O
provided	O
by	O
oleic	Control
acid	Control
(	Control
control	Control
diet	Control
)	Control
,	O
iTFA	Pharmacological
,	O
or	O
CLA	Pharmacological
.	O

At	O
the	O
end	O
of	O
the	O
3	O
wk	O
,	O
we	O
measured	O
plasma	O
inflammatory	O
markers	O
IL-6	O
,	O
C-reactive	O
protein	O
,	O
tumor	O
necrosis	O
factor	O
receptors	O
I	O
and	O
II	O
(	O
TNF-RI	O
and	O
-RII	O
)	O
,	O
monocyte	O
chemotactic	O
protein-1	O
and	O
E-selectin	O
,	O
and	O
urinary	O
8-iso-PGF	O
(	O
2?	O
)	O
,	O
a	O
marker	O
of	O
lipid	O
peroxidation	O
.	O

Consumption	O
of	O
iTFA	O
caused	O
4	O
%	O
lower	O
TNF-RI	O
concentrations	O
and	O
6	O
%	O
higher	O
E-selectin	O
concentrations	O
compared	O
with	O
oleic	O
acid	O
(	O
control	O
)	O
and	O
had	O
no	O
significant	O
effect	O
on	O
other	O
inflammatory	O
markers	O
.	O

CLA	O
did	O
not	O
significantly	O
affect	O
inflammatory	O
markers	O
.	O

The	O
urine	O
concentration	O
of	O
8-iso-PGF	O
(	O
2?	O
)	O
[	O
geometric	O
mean	O
(	O
95	O
%	O
CI	O
)	O
]	O
was	O
greater	O
after	O
the	O
iTFA	O
[	O
0.54	O
(	O
0.48	O
,	O
0.60	O
)	O
nmol/mmol	O
creatinine	O
]	O
and	O
the	O
CLA	O
[	O
1.2	O
(	O
1.1	O
,	O
1.3	O
)	O
nmol/mmol	O
creatinine	O
]	O
diet	O
periods	O
than	O
after	O
the	O
control	O
period	O
[	O
0.45	O
(	O
0.41	O
,	O
0.50	O
)	O
nmol/mmol	O
creatinine	O
;	O
P	O
<	O
0.05	O
]	O
.	O

In	O
conclusion	O
,	O
high	O
intakes	O
of	O
iTFA	O
and	O
CLA	O
did	O
not	O
substantially	O
affect	O
plasma	O
concentrations	O
of	O
inflammatory	O
markers	O
,	O
but	O
they	O
increased	O
the	O
urine	O
8-iso-PGF	O
(	O
2?	O
)	O
concentration	O
.	O

However	O
,	O
it	O
is	O
unlikely	O
this	O
plays	O
a	O
major	O
role	O
in	O
the	O
mechanism	O
by	O
which	O
iTFA	O
increase	O
the	O
risk	O
of	O
CVD	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
to	O
fully	O
understand	O
the	O
implications	O
of	O
these	O
findings	O
.	O

The	O
TOM	Other
test	Other
:	O
a	O
new	O
instrument	O
for	O
assessing	O
theory	O
of	O
mind	O
in	O
normal	O
children	O
and	O
children	O
with	O
pervasive	O
developmental	O
disorders	O
.	O

This	O
article	O
describes	O
a	O
first	O
attempt	O
to	O
investigate	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
TOM	Other
test	Other
,	O
a	O
new	O
instrument	O
for	O
assessing	O
theory	O
of	O
mind	O
ability	O
in	O
normal	O
children	O
and	O
children	O
with	O
pervasive	O
developmental	O
disorders	O
(	O
PDDs	O
)	O
.	O

In	O
Study	O
1	O
,	O
TOM	Other
test	Other
scores	O
of	O
normal	O
children	O
(	O
n	O
=	O
70	O
)	O
correlated	O
positively	O
with	O
their	O
performance	O
on	O
other	O
theory	O
of	O
mind	O
tasks	O
.	O

Furthermore	O
,	O
young	O
children	O
only	O
succeeded	O
on	O
TOM	O
items	O
that	O
tap	O
the	O
basic	O
domains	O
of	O
theory	O
of	O
mind	O
(	O
e.g.	O
,	O
emotion	O
recognition	O
)	O
,	O
whereas	O
older	O
children	O
also	O
passed	O
items	O
that	O
measure	O
the	O
more	O
mature	O
areas	O
of	O
theory	O
of	O
mind	O
(	O
e.g.	O
,	O
understanding	O
of	O
humor	O
,	O
understanding	O
of	O
second-order	O
beliefs	O
)	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
Study	O
1	O
suggest	O
that	O
the	O
TOM	Other
test	Other
is	O
a	O
valid	O
measure	O
.	O

Study	O
2	O
showed	O
for	O
a	O
separate	O
sample	O
of	O
normal	O
children	O
(	O
n	O
=	O
12	O
)	O
that	O
the	O
TOM	Other
test	Other
possesses	O
sufficient	O
test-retest	O
stability	O
.	O

Study	O
3	O
demonstrated	O
for	O
a	O
sample	O
of	O
children	O
with	O
PDDs	O
(	O
n	O
=	O
10	O
)	O
that	O
the	O
interrater	O
reliability	O
of	O
the	O
TOM	Other
test	Other
is	O
good	O
.	O

Study	O
4	O
found	O
that	O
children	O
with	O
PDDs	O
(	O
n	O
=	O
20	O
)	O
had	O
significantly	O
lower	O
TOM	Other
test	Other
scores	O
than	O
children	O
with	O
other	O
psychiatric	O
disorders	O
(	O
e.g.	O
,	O
children	O
with	O
Attention-deficit	O
Hyperactivity	O
Disorder	O
;	O
n	O
=	O
32	O
)	O
,	O
a	O
finding	O
that	O
underlines	O
the	O
discriminant	O
validity	O
of	O
the	O
TOM	Other
test	Other
.	O

Furthermore	O
,	O
Study	O
4	O
showed	O
that	O
intelligence	O
as	O
indexed	O
by	O
the	O
Wechsler	O
Intelligence	O
Scale	O
for	O
Children	O
was	O
positively	O
associated	O
with	O
TOM	Other
test	Other
scores	O
.	O

Finally	O
,	O
in	O
all	O
studies	O
,	O
the	O
TOM	Other
test	Other
was	O
found	O
to	O
be	O
reliable	O
in	O
terms	O
of	O
internal	O
consistency	O
.	O

Altogether	O
,	O
results	O
indicate	O
that	O
the	O
TOM	Other
test	Other
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
that	O
can	O
be	O
employed	O
to	O
measure	O
various	O
aspects	O
of	O
theory	O
of	O
mind	O
.	O

An	O
exposure	Physical
prevention	Physical
rating	Physical
method	Physical
for	O
intervention	O
needs	O
assessment	O
and	O
effectiveness	O
evaluation	O
.	O

This	O
article	O
describes	O
a	O
new	O
method	O
for	O
(	O
1	O
)	O
systematically	O
prioritizing	O
needs	O
for	O
intervention	O
on	O
hazardous	O
substance	O
exposures	O
in	O
manufacturing	O
work	O
sites	O
,	O
and	O
(	O
2	O
)	O
evaluating	O
intervention	O
effectiveness	O
.	O

We	O
developed	O
a	O
checklist	Other
containing	Educational
six	O
unique	O
sets	O
of	O
yes/no	O
variables	O
organized	O
in	O
a	O
2	O
x	O
3	O
matrix	O
of	O
exposure	O
potential	O
versus	O
protection	O
(	O
two	O
columns	O
)	O
at	O
the	O
levels	O
of	O
materials	O
,	O
processes	O
,	O
and	O
human	O
interface	O
(	O
three	O
rows	O
)	O
.	O

The	O
three	O
levels	O
correspond	O
to	O
a	O
simplified	O
hierarchy	O
of	O
controls	O
.	O

Each	O
of	O
the	O
six	O
sets	O
of	O
indicator	O
variables	O
was	O
reduced	O
to	O
a	O
high/moderate/low	O
rating	O
.	O

Ratings	O
from	O
the	O
matrix	O
were	O
then	O
combined	O
to	O
generate	O
a	O
single	O
overall	O
exposure	O
prevention	O
rating	O
for	O
each	O
area	O
.	O

Reflecting	O
the	O
hierarchy	O
of	O
controls	O
,	O
material	O
factors	O
were	O
weighted	O
highest	O
,	O
followed	O
by	O
process	O
,	O
and	O
then	O
human	O
interface	O
.	O

The	O
checklist	O
was	O
filled	O
out	O
by	O
an	O
industrial	O
hygienist	O
while	O
conducting	O
a	O
walk-through	O
inspection	O
(	O
N	O
=	O
131	O
manufacturing	O
processes/areas	O
in	O
17	O
large	O
work	O
sites	O
)	O
.	O

One	O
area	O
or	O
process	O
per	O
manufacturing	O
department	O
was	O
assessed	O
and	O
rated	O
.	O

Based	O
on	O
the	O
resulting	O
Exposure	O
Prevention	O
ratings	O
,	O
we	O
concluded	O
that	O
exposures	O
were	O
well	O
controlled	O
in	O
the	O
majority	O
of	O
areas	O
assessed	O
(	O
64	O
%	O
with	O
rating	O
of	O
1	O
or	O
2	O
on	O
a	O
6-point	O
scale	O
)	O
,	O
that	O
there	O
is	O
some	O
room	O
for	O
improvement	O
in	O
26	O
percent	O
of	O
areas	O
(	O
rating	O
of	O
3	O
or	O
4	O
)	O
,	O
and	O
that	O
roughly	O
10	O
percent	O
of	O
the	O
areas	O
assessed	O
are	O
urgently	O
in	O
need	O
of	O
intervention	O
(	O
rated	O
as	O
5	O
or	O
6	O
)	O
.	O

A	O
second	O
hygienist	O
independently	O
assessed	O
a	O
subset	O
of	O
areas	O
to	O
evaluate	O
inter-rater	O
reliability	O
.	O

The	O
reliability	O
of	O
the	O
overall	O
exposure	O
prevention	O
ratings	O
was	O
excellent	O
(	O
weighted	O
kappa	O
=	O
0.84	O
)	O
.	O

The	O
rating	O
scheme	O
has	O
good	O
discriminatory	O
power	O
and	O
reliability	O
and	O
shows	O
promise	O
as	O
a	O
broadly	O
applicable	O
and	O
inexpensive	O
tool	O
for	O
intervention	O
needs	O
assessment	O
and	O
effectiveness	O
evaluation	O
.	O

Validation	O
studies	O
are	O
needed	O
as	O
a	O
next	O
step	O
.	O

This	O
assessment	O
method	O
complements	O
quantitative	O
exposure	O
assessment	O
with	O
an	O
upstream	O
prevention	O
focus	O
.	O

Comparative	O
efficacy	O
of	O
intravenous	O
ibutilide	Pharmacological
versus	O
procainamide	Pharmacological
for	O
enhancing	O
termination	O
of	O
atrial	O
flutter	O
by	O
atrial	O
overdrive	O
pacing	O
.	O

This	O
study	O
compares	O
the	O
influence	O
of	O
intravenous	O
ibutilide	Pharmacological
,	O
a	O
class	O
III	O
antiarrhythmic	O
agent	O
,	O
with	O
procainamide	Pharmacological
,	O
a	O
class	O
IA	O
antiarrhythmic	O
agent	O
,	O
and	O
with	O
placebo	Control
on	O
its	O
ability	O
to	O
terminate	O
atrial	O
flutter	O
using	O
rapid	O
atrial	O
pacing	O
.	O

Fifty-nine	O
episodes	O
of	O
atrial	O
flutter	O
in	O
54	O
patients	O
who	O
failed	O
to	O
terminate	O
with	O
an	O
intravenous	O
infusion	O
of	O
ibutilide	Pharmacological
,	O
procainamide	Pharmacological
,	O
or	O
placebo	Control
alone	O
underwent	O
attempts	O
at	O
pacing	O
termination	O
using	O
a	O
standard	O
protocol	O
of	O
burst	O
atrial	O
overdrive	O
pacing	O
.	O

Atrial	O
flutter	O
cycle	O
length	O
and	O
atrial	O
monophasic	O
action	O
potential	O
duration	O
recorded	O
from	O
the	O
right	O
atrium	O
during	O
atrial	O
flutter	O
were	O
measured	O
at	O
baseline	O
and	O
following	O
infusion	O
of	O
ibutilide	Pharmacological
,	O
procainamide	Pharmacological
,	O
or	O
placebo	Control
.	Control

Both	O
ibutilide	Pharmacological
and	O
procainamide	Pharmacological
significantly	O
enhanced	O
(	O
p	O
<	O
0.001	O
)	O
pacing-induced	O
termination	O
of	O
atrial	O
flutter	O
compared	O
with	O
placebo	Control
.	Control

Pacing	O
converted	O
2	O
of	O
11	O
patients	O
(	O
18	O
%	O
)	O
who	O
received	O
placebo	Control
,	O
13	O
of	O
15	O
patients	O
(	O
87	O
%	O
)	O
who	O
received	O
ibutilide	Pharmacological
,	O
and	O
29	O
of	O
33	O
patients	O
(	O
88	O
%	O
)	O
who	O
received	O
procainamide	Pharmacological
to	O
sinus	O
rhythm	O
.	O

Ibutilide	Pharmacological
and	O
procainamide	Pharmacological
compared	O
with	O
placebo	Control
markedly	O
reduced	O
(	O
p	O
<	O
0.001	O
)	O
the	O
incidence	O
of	O
pacing-induced	O
atrial	O
fibrillation	O
.	O

The	O
atrial	O
flutter	O
cycle	O
length	O
was	O
prolonged	O
significantly	O
less	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
the	O
atrial	O
monophasic	O
action	O
potential	O
duration	O
was	O
increased	O
significantly	O
more	O
(	O
p	O
<	O
0.001	O
)	O
by	O
ibutilide	Pharmacological
than	O
by	O
procainamide	Pharmacological
.	Pharmacological

Although	O
the	O
electrophysiologic	O
changes	O
induced	O
by	O
these	O
antiarrhythmic	O
agents	O
contributed	O
to	O
facilitating	O
pacing-induced	O
termination	O
,	O
neither	O
tachycardia	O
cycle	O
length	O
nor	O
action	O
potential	O
duration	O
were	O
useful	O
predictors	O
of	O
the	O
ability	O
of	O
pacing	O
to	O
terminate	O
atrial	O
flutter	O
.	O

In	O
conclusion	O
,	O
despite	O
differing	O
electrophysiologic	O
effects	O
,	O
the	O
use	O
of	O
intravenous	O
ibutilide	Pharmacological
or	O
procainamide	Pharmacological
enhances	O
the	O
termination	O
of	O
atrial	O
flutter	O
by	O
atrial	O
overdrive	O
pacing	O
.	O

Metformin	Pharmacological
does	O
not	O
enhance	O
ovulation	O
induction	O
in	O
clomiphene	O
resistant	O
polycystic	O
ovary	O
syndrome	O
in	O
clinical	O
practice	O
.	O

AIMS	O
To	O
determine	O
whether	O
metformin	Pharmacological
pretreatment	Pharmacological
has	O
beneficial	O
effects	O
in	O
clomiphene	O
resistant	O
infertile	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
in	O
an	O
infertility	O
clinic	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
placebo	O
controlled	O
double-blind	O
crossover	O
study	O
of	O
3	O
months	O
metformin	Pharmacological
(	O
1500	O
mg	O
day-1	O
)	O
/placebo	Control
,	O
followed	O
by	O
3	O
months	O
metformin/placebo	Pharmacological
together	O
with	O
clomiphene	Pharmacological
(	O
50-100	O
mg	O
for	O
5	O
days	O
)	O
for	O
three	O
cycles	O
in	O
clomiphene	O
resistant	O
women	O
with	O
PCOS	O
.	O

The	O
primary	O
outcomes	O
were	O
restoration	O
of	O
spontaneous	O
menses	O
,	O
ovulation	O
induction	O
(	O
spontaneous	O
or	O
clomiphene	O
induced	O
)	O
and	O
pregnancy	O
.	O

Secondary	O
endpoints	O
were	O
changes	O
in	O
biochemical	O
parameters	O
related	O
to	O
androgens	O
and	O
insulin	O
.	O

RESULTS	O
Twelve	O
women	O
completed	O
the	O
metformin	Pharmacological
arm	O
and	O
14	O
the	O
placebo	Control
arm	O
.	O

Spontaneous	O
menstruation	O
resumed	O
in	O
five	O
metformin	Pharmacological
treated	O
patients	O
and	O
in	O
six	O
placebo	Control
treated	O
women	O
,	O
P=0.63	O
.	O

No	O
women	O
given	O
metformin	O
spontaneously	O
ovulated	O
,	O
although	O
one	O
patient	O
given	O
placebo	Control
did	O
,	O
P=0.30	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
efficacy	O
of	O
clomiphene	O
between	O
the	O
two	O
groups	O
with	O
ovulation	O
being	O
induced	O
in	O
five	O
(	O
out	O
of	O
12	O
)	O
metformin	Pharmacological
treated	O
women	O
and	O
four	O
(	O
out	O
of	O
14	O
)	O
placebo	Control
treated	O
women	O
,	O
P=0.63	O
.	O

Pregnancy	O
occurred	O
in	O
three	O
(	O
out	O
of	O
12	O
)	O
women	O
given	O
metformin	Pharmacological
and	O
two	O
(	O
out	O
of	O
14	O
)	O
women	O
given	O
placebo	Control
,	O
P=0.59	O
.	O

CONCLUSIONS	O
Metformin	Pharmacological
is	O
not	O
always	O
beneficial	O
when	O
given	O
to	O
clomiphene	O
resistant	O
infertile	O
women	O
with	O
PCOS	O
in	O
clinical	O
practice	O
.	O

Oxytocin	Pharmacological
promotes	O
facial	O
emotion	O
recognition	O
and	O
amygdala	O
reactivity	O
in	O
adults	O
with	O
asperger	O
syndrome	O
.	O

The	O
neuropeptide	Pharmacological
oxytocin	Pharmacological
has	O
recently	O
been	O
shown	O
to	O
enhance	O
eye	O
gaze	O
and	O
emotion	O
recognition	O
in	O
healthy	O
men	O
.	O

Here	O
,	O
we	O
report	O
a	O
randomized	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
that	O
examined	O
the	O
neural	O
and	O
behavioral	O
effects	O
of	O
a	O
single	O
dose	O
of	O
intranasal	Pharmacological
oxytocin	Pharmacological
on	O
emotion	O
recognition	O
in	O
individuals	O
with	O
Asperger	O
syndrome	O
(	O
AS	O
)	O
,	O
a	O
clinical	O
condition	O
characterized	O
by	O
impaired	O
eye	O
gaze	O
and	O
facial	O
emotion	O
recognition	O
.	O

Using	O
functional	Physical
magnetic	Physical
resonance	Physical
imaging	Physical
,	O
we	O
examined	O
whether	O
oxytocin	Pharmacological
would	O
enhance	O
emotion	O
recognition	O
from	O
facial	O
sections	O
of	O
the	O
eye	O
vs	O
the	O
mouth	O
region	O
and	O
modulate	O
regional	O
activity	O
in	O
brain	O
areas	O
associated	O
with	O
face	O
perception	O
in	O
both	O
adults	O
with	O
AS	O
,	O
and	O
a	O
neurotypical	Control
control	Control
group	O
.	O

Intranasal	O
administration	O
of	O
the	O
neuropeptide	Pharmacological
oxytocin	Pharmacological
improved	O
performance	O
in	O
a	O
facial	O
emotion	O
recognition	O
task	O
in	O
individuals	O
with	O
AS	O
.	O

This	O
was	O
linked	O
to	O
increased	O
left	O
amygdala	O
reactivity	O
in	O
response	O
to	O
facial	O
stimuli	O
and	O
increased	O
activity	O
in	O
the	O
neural	O
network	O
involved	O
in	O
social	O
cognition	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
amygdala	O
,	O
together	O
with	O
functionally	O
associated	O
cortical	O
areas	O
mediate	O
the	O
positive	O
effect	O
of	O
oxytocin	Pharmacological
on	O
social	O
cognitive	O
functioning	O
in	O
AS	O
.	O

Effect	O
of	O
simvastatin	Pharmacological
and	O
fenofibrate	Pharmacological
on	O
endothelium	O
in	O
Type	O
2	O
diabetes	O
.	O

Statins	O
and	O
fibrates	O
influence	O
endothelial	O
activity	O
and	O
consequently	O
atherogenesis	O
but	O
the	O
mechanisms	O
are	O
not	O
well	O
understood	O
.	O

Twenty	O
Type	O
2	O
diabetic	O
patients	O
with	O
dyslipidemia	O
were	O
treated	O
3	O
months	O
with	O
simvastatin	Pharmacological
(	O
20	O
mg	O
daily	O
)	O
and	O
then	O
3	O
months	O
with	O
fenofibrate	Pharmacological
(	O
200	O
mg	O
daily	O
)	O
with	O
2	O
months	O
of	O
wash-out	O
between	O
the	O
two	O
treatments	O
.	O

Laboratory	O
parameters	O
of	O
oxidative	O
stress	O
,	O
fibrinolysis	O
and	O
endothelial	O
function	O
were	O
evaluated	O
before	O
and	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
.	O

The	O
significant	O
decrease	O
in	O
serum	O
total	O
and	O
LDL-cholesterol	O
concentrations	O
(	O
P	O
<	O
0.0001	O
)	O
caused	O
by	O
simvastatin	O
was	O
associated	O
with	O
an	O
increase	O
in	O
serum	O
N-acetyl-beta-glucosaminidase	O
activity	O
(	O
P	O
<	O
0.001	O
)	O
,	O
ascorbic	O
acid	O
(	O
P	O
<	O
0.001	O
)	O
,	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI-1	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
vonWillebrand	O
factor	O
(	O
P	O
<	O
0.05	O
)	O
,	O
E-selectin	O
(	O
P	O
<	O
0.01	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
P	O
<	O
0.05	O
)	O
concentrations	O
and	O
with	O
a	O
decrease	O
in	O
plasma	O
glutathione	O
(	O
P	O
<	O
0.01	O
)	O
levels	O
.	O

Fenofibrate	O
caused	O
a	O
significant	O
decrease	O
in	O
serum	O
triglyceride	O
concentration	O
(	O
P	O
<	O
0.0001	O
)	O
associated	O
with	O
a	O
decrease	O
in	O
plasma	O
malondialdehyde	O
(	O
P	O
<	O
0.001	O
)	O
and	O
an	O
increase	O
in	O
plasma	O
PAI-1	O
(	O
P	O
<	O
0.05	O
)	O
and	O
P-selectin	O
(	O
P	O
<	O
0.05	O
)	O
concentrations	O
.	O

We	O
conclude	O
that	O
simvastatin	O
and	O
fenofibrate	O
interact	O
,	O
by	O
different	O
mechanisms	O
,	O
with	O
oxidative	O
stress	O
,	O
a	O
key	O
factor	O
in	O
the	O
modification	O
of	O
fibrinolysis	O
and	O
endothelial	O
function	O
in	O
Type	O
2	O
diabetes	O
.	O

Effect	O
of	O
indomethacin	Pharmacological
phonophoresis	Pharmacological
on	O
the	O
relief	O
of	O
temporomandibular	O
joint	O
pain	O
.	O

The	O
pain-relieving	O
effect	O
of	O
indomethacin	Pharmacological
phonophoresis	Pharmacological
on	O
temporomandibular	O
(	O
TMJ	O
)	O
joint	O
pain	O
was	O
evaluated	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	Control
clinical	O
trial	O
.	O

Twenty	O
subjects	O
,	O
who	O
have	O
TMJ	O
pain	O
,	O
were	O
included	O
for	O
this	O
study	O
and	O
randomly	O
assigned	O
to	O
either	O
the	O
experimental	O
group	O
(	O
n	O
=	O
10	O
)	O
or	O
the	O
control	Control
group	Control
(	O
n	O
=	O
10	O
)	O
.	O

Each	O
treatment	O
consisted	O
of	O
the	O
application	O
of	O
ultrasound	Physical
massage	Physical
(	O
1.0	O
MHz	O
,	O
0.8	O
to	O
1.5	O
W/cm2	O
continuous	O
output	O
)	O
for	O
15	O
minutes	O
to	O
the	O
painful	O
temporomandibular	O
joint	O
.	O

As	O
a	O
conducting	O
medium	O
,	O
1	Pharmacological
%	Pharmacological
indomethacin	Pharmacological
cream	Pharmacological
was	O
used	O
for	O
the	O
experimental	O
group	O
and	O
placebo	Control
cream	Control
for	O
the	O
control	O
group	O
respectively	O
.	O

Pre-	O
and	O
post-treatment	O
pain	O
levels	O
and	O
pain	O
sensitivity	O
were	O
assessed	O
with	O
visual	O
analogue	O
scales	O
(	O
VAS	O
)	O
and	O
pressure	O
pain	O
threshold	O
(	O
PPT	O
)	O
.	O

Mean	O
data	O
indicated	O
that	O
post-treatment	O
VAS	O
was	O
significantly	O
decreased	O
and	O
post-treatment	O
PPT	O
was	O
significantly	O
increased	O
in	O
the	O
experimental	O
group	O
,	O
not	O
in	O
the	O
control	O
group	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
indomethacin	Pharmacological
phonophoresis	Pharmacological
provides	O
significant	O
pain	O
relieving	O
effect	O
over	O
the	O
TMJ	O
pain	O
.	O

Bovine	Pharmacological
pericardium	Pharmacological
vs	O
dacron	Pharmacological
for	O
patch	O
angioplasty	O
after	O
carotid	O
endarterectomy	O
:	O
a	O
prospective	O
randomized	O
study	O
.	O

HYPOTHESIS	O
Bovine	Pharmacological
pericardium	Pharmacological
(	Pharmacological
BP	Pharmacological
)	Pharmacological
demonstrates	O
improved	O
intraoperative	O
hemostasis	O
and	O
equivalent	O
perioperative	O
morbidity	O
compared	O
with	O
Dacron	Pharmacological
when	O
used	O
as	O
patch	O
material	O
for	O
angioplasty	O
following	O
carotid	Surgical
endarterectomy	Surgical
.	O

OBJECTIVE	O
To	O
prospectively	O
compare	O
BP	Pharmacological
and	O
Dacron	Surgical
patch	Surgical
angioplasty	Surgical
after	O
carotid	O
endarterectomy	O
in	O
a	O
randomized	O
fashion	O
.	O

METHODS	O
Ninety-five	O
consecutive	O
primary	O
carotid	O
endarterectomies	O
were	O
performed	O
in	O
a	O
prospective	O
randomized	O
fashion	O
in	O
92	O
patients	O
.	O

Fifty-one	O
procedures	O
were	O
performed	O
using	O
BP	Pharmacological
and	O
44	O
using	O
Dacron	Surgical
.	O

Intraoperative	O
suture	O
line	O
bleeding	O
was	O
subjectively	O
evaluated	O
by	O
observing	O
bleeding	O
at	O
3	O
and	O
4	O
minutes	O
following	O
carotid	Surgical
cross-clamp	Surgical
removal	Surgical
and	O
then	O
objectively	O
weighing	O
the	O
sponge	O
used	O
to	O
tamponade	O
bleeding	O
during	O
these	O
time	O
intervals	O
.	O

Perioperative	O
morbidity	O
,	O
including	O
cervical	O
wound	O
hematoma	O
,	O
transient	O
ischemic	O
attack	O
,	O
and	O
stroke	O
,	O
and	O
perioperative	O
mortality	O
were	O
recorded	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
paired	O
t	O
tests	O
,	O
chi	O
(	O
2	O
)	O
analysis	O
,	O
Fisher	O
exact	O
test	O
,	O
or	O
multiple	O
linear	O
regression	O
as	O
appropriate	O
.	O

RESULTS	O
Suture	O
line	O
bleeding	O
at	O
3	O
minutes	O
was	O
present	O
in	O
7	O
(	O
14	O
%	O
)	O
of	O
51	O
patients	O
in	O
the	O
BP	Pharmacological
group	O
and	O
24	O
(	O
55	O
%	O
)	O
of	O
44	O
patients	O
in	O
the	O
Dacron	Surgical
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

Suture	O
line	O
bleeding	O
evaluated	O
at	O
4	O
minutes	O
was	O
present	O
in	O
2	O
(	O
4	O
%	O
)	O
of	O
51	O
patients	O
in	O
the	O
BP	Pharmacological
group	O
and	O
13	O
(	O
30	O
%	O
)	O
of	O
44	O
patients	O
in	O
the	O
Dacron	Surgical
group	O
(	O
P	O
=.001	O
)	O
.	O

Net	O
+/-	O
SEM	O
sponge	O
weight	O
(	O
total	O
intraoperative	O
suture	O
line	O
bleeding	O
)	O
was	O
6.25	O
+/-	O
0.55	O
g	O
in	O
the	O
BP	Pharmacological
group	O
and	O
16.34	O
+/-	O
1.85	O
g	O
in	O
the	O
Dacron	Surgical
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

Total	O
suture	O
line	O
bleeding	O
was	O
significantly	O
affected	O
by	O
activated	O
clotting	O
time	O
;	O
however	O
,	O
multivariate	O
analysis	O
demonstrated	O
that	O
bleeding	O
was	O
significantly	O
less	O
with	O
BP	Pharmacological
(	O
P	O
<	O
.001	O
)	O
even	O
after	O
adjusting	O
for	O
differences	O
in	O
activated	O
clotting	O
time	O
.	O

CONCLUSIONS	O
Bovine	Pharmacological
pericardium	Pharmacological
demonstrated	O
a	O
statistically	O
significant	O
decrease	O
in	O
intraoperative	O
suture	O
line	O
bleeding	O
compared	O
with	O
Dacron	Surgical
.	O

Handling	O
characteristics	O
were	O
judged	O
by	O
the	O
surgeons	O
to	O
be	O
superior	O
for	O
BP	Pharmacological
.	O

Therefore	O
,	O
we	O
believe	O
BP	Pharmacological
may	O
be	O
an	O
alternative	O
to	O
Dacron	Surgical
when	O
performing	O
patch	O
angioplasty	O
of	O
the	O
carotid	O
artery	O
after	O
endarterectomy	O
.	O

Management	O
of	O
the	O
thyroid	O
isthmus	O
in	O
tracheostomy	Surgical
:	O
a	O
prospective	O
and	O
retrospective	O
study	O
.	O

The	O
thyroid	O
isthmus	O
is	O
often	O
encountered	O
while	O
a	O
tracheostomy	Physical
is	O
being	O
performed	O
.	O

This	O
study	O
details	O
retrospective	O
and	O
prospective	O
comparison	O
of	O
electrocautery	Surgical
division	Surgical
of	Surgical
the	Surgical
isthmus	Surgical
with	O
older	O
techniques	O
.	O

In	O
this	O
study	O
,	O
electrocautery	Physical
division	Physical
of	Physical
the	Physical
thyroid	Physical
isthmus	Physical
during	O
tracheostomy	O
is	O
faster	O
and	O
as	O
safe	O
as	O
other	O
techniques	O
with	O
respect	O
to	O
blood	O
loss	O
,	O
perioperative	O
complications	O
,	O
and	O
airway	O
outcome	O
.	O

Clofibrate	Pharmacological
and	O
diabetes	O
control	O
in	O
patients	O
treated	O
with	O
oral	Pharmacological
hypoglycaemic	Pharmacological
agents	Pharmacological
.	O

1	O
.	O

Twenty-two	O
maturity-onset	O
type	O
diabetics	O
treated	O
with	O
oral	Pharmacological
hypoglycaemic	Pharmacological
agents	Pharmacological
entered	O
a	O
single-blind	O
crossover	O
study	O
using	O
placebo	Control
(	O
periods	O
A	O
and	O
C	O
,	O
2	O
months	O
each	O
)	O
and	O
clofibrate	Pharmacological
(	O
2	O
g/day	O
;	O
period	O
B	O
;	O
2	O
months	O
)	O
.	O

2	O
.	O

In	O
thirteen	O
patients	O
,	O
under	O
reasonably	O
good	O
control	O
,	O
clofibrate	Pharmacological
did	O
not	O
reduce	O
fasting	O
or	O
post-prandial	O
blood	O
glucose	O
,	O
nor	O
24	O
h	O
glycosuria	O
;	O
no	O
improvement	O
was	O
noted	O
in	O
the	O
M-value	O
,	O
an	O
index	O
of	O
diabetes	O
control	O
.	O

3	O
.	O

In	O
contrast	O
,	O
in	O
nine	O
patients	O
,	O
with	O
poor	O
diabetes	O
control	O
,	O
clofibrate	Pharmacological
reduced	O
24	O
h	O
glycosuria	O
and	O
significantly	O
improved	O
the	O
M-value	O
.	O

4	O
.	O

In	O
all	O
patients	O
,	O
clofibrate	Physical
therapy	Physical
was	O
associated	O
with	O
a	O
significant	O
19-23	O
%	O
reduction	O
in	O
plasma	O
fibrinogen	O
.	O

5	O
.	O

It	O
is	O
suggested	O
that	O
addition	O
of	O
clofibrate	Pharmacological
may	O
be	O
useful	O
in	O
maturity-onset	O
diabetics	O
not	O
adequately	O
controlled	O
by	O
diet	O
combined	O
with	O
oral	Pharmacological
hypoglycaemic	Pharmacological
agents	Pharmacological
.	O

Short-term	O
metformin	Pharmacological
treatment	O
for	O
clomiphene	O
citrate-resistant	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
short-course	O
pretreatment	O
with	O
metformin	Pharmacological
on	O
hyperandrogenism	O
,	O
insulin	O
resistance	O
,	O
cervical	O
scores	O
,	O
and	O
pregnancy	O
rates	O
in	O
women	O
with	O
clomiphene	Pharmacological
citrate	Pharmacological
(	O
CC	O
)	O
-resistant	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

METHODS	O
Thirty-seven	O
women	O
with	O
CC-resistant	O
PCOS	O
were	O
randomly	O
assigned	O
to	O
be	O
pretreated	O
with	O
500	O
mg	O
of	O
metformin	Pharmacological
or	O
placebo	Pharmacological
3	O
times	O
per	O
day	O
for	O
2	O
cycles	O
,	O
and	O
100	O
mg	O
of	O
CC	Pharmacological
was	O
given	O
on	O
days	O
5	O
through	O
9	O
of	O
the	O
second	O
cycle	O
in	O
both	O
groups	O
.	O

Luteinizing	O
hormone	O
(	O
LH	O
)	O
,	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
,	O
dehydroepiandrostendione	O
sulfate	O
(	O
DHEAS	O
)	O
,	O
total	O
testosterone	O
(	O
T	O
)	O
,	O
glucose	O
,	O
and	O
insulin	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
the	O
first	O
cycle	O
,	O
as	O
well	O
as	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
cervical	O
score	O
,	O
and	O
pregnancy	O
rate	O
.	O

RESULTS	O
After	O
1	O
cycle	O
,	O
BMI	O
,	O
total	O
T	O
level	O
,	O
and	O
percentage	O
of	O
participants	O
with	O
insulin	O
resistance	O
were	O
significantly	O
decreased	O
in	O
the	O
metformin	Pharmacological
group	O
,	O
without	O
any	O
significant	O
decrease	O
in	O
LH	O
,	O
FSH	O
,	O
and	O
DHEAS	O
levels	O
;	O
and	O
in	O
the	O
second	O
cycle	O
,	O
CC	Pharmacological
treatment	O
resulted	O
in	O
a	O
higher	O
ovulation	O
rate	O
and	O
a	O
thicker	O
endometrium	O
in	O
the	O
metformin	Pharmacological
group	O
.	O

The	O
pregnancy	O
rate	O
and	O
cervical	O
scores	O
were	O
also	O
higher	O
in	O
that	O
group	O
.	O

CONCLUSION	O
The	O
short-course	O
pretreatment	O
with	O
metformin	Pharmacological
decreased	O
hyperandrogenism	O
and	O
insulin	O
resistance	O
and	O
improved	O
cervical	O
sores	O
,	O
ovulation	O
rate	O
,	O
and	O
pregnancy	O
rate	O
among	O
women	O
with	O
CC-resistant	O
PCOS	O
.	O

Effect	O
of	O
perioperative	O
parecoxib	Pharmacological
on	O
postoperative	O
pain	O
and	O
local	O
inflammation	O
factors	O
PGE2	O
and	O
IL-6	O
for	O
total	O
knee	O
arthroplasty	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	Control
study	O
.	O

To	O
assess	O
the	O
efficacy	O
of	O
postoperative	O
pain	O
management	O
and	O
the	O
concentration	O
change	O
of	O
PGE-2	O
and	O
IL-6	O
of	O
joint	O
fluid	O
with	O
parecoxib	Pharmacological
after	O
postoperative	O
total	O
knee	O
arthroplasty	O
.	O

In	O
the	O
study	O
,	O
100	O
patients	O
experiencing	O
primary	O
TKA	O
were	O
randomly	O
divided	O
into	O
study	O
group	O
,	O
receiving	O
parecoxib	Pharmacological
sodium	Pharmacological
(	O
40	O
mg	O
)	O
intravenously	O
(	O
IV	O
)	O
at	O
the	O
completion	O
of	O
surgery	O
and	O
once	O
every	O
12	O
h	O
for	O
totally	O
6	O
times	O
postoperatively	O
,	O
and	O
placebo	O
group	O
,	O
receiving	O
normal	O
saline	O
2	O
mL	O
IV	O
at	O
the	O
same	O
time	O
points	O
.	O

Efficacy	O
was	O
assessed	O
by	O
total	O
amount	O
of	O
morphine	O
consumed	O
,	O
pain	O
intensity	O
,	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
,	O
the	O
concentration	O
change	O
of	O
PGE-2	O
and	O
IL-6	O
of	O
joint	O
fluid	O
,	O
and	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
postoperatively	O
.	O

Patients	O
in	O
study	O
group	O
consumed	O
significantly	O
less	O
morphine	O
,	O
experienced	O
significant	O
less	O
pain	O
scores	O
,	O
and	O
obtained	O
significantly	O
more	O
ROM	O
(	O
P	O
<	O
0.01	O
)	O
compared	O
with	O
that	O
in	O
placebo	O
group	O
during	O
3	O
days	O
postoperatively	O
.	O

The	O
concentration	O
of	O
PGE-2	O
and	O
IL-6	O
of	O
joint	O
fluid	O
in	O
study	O
group	O
are	O
significantly	O
lower	O
than	O
that	O
in	O
placebo	O
group	O
(	O
P	O
<	O
0.01	O
)	O
during	O
24	O
h	O
postoperatively	O
.	O

The	O
overall	O
incidence	O
of	O
PONV	O
was	O
low	O
and	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
the	O
perioperative	O
administration	O
of	O
parecoxib	O
after	O
primary	O
TKA	O
resulted	O
in	O
significantly	O
improved	O
postoperative	O
analgesic	O
management	O
as	O
defined	O
by	O
reduction	O
in	O
opioid	O
requirement	O
,	O
lower	O
pain	O
scores	O
and	O
ROM	O
,	O
and	O
significantly	O
lowered	O
local	O
inflammation	O
factors	O
PGE2	O
and	O
IL-6	O
.	O

Lack	O
of	O
lipotoxicity	O
effect	O
on	O
{	O
beta	O
}	O
-cell	O
dysfunction	O
in	O
ketosis-prone	O
type	O
2	O
diabetes	O
.	O

OBJECTIVE	O
Over	O
half	O
of	O
newly	O
diagnosed	O
obese	O
African	O
Americans	O
with	O
diabetic	O
ketoacidosis	O
(	O
DKA	O
)	O
discontinue	O
insulin	O
therapy	O
and	O
go	O
through	O
a	O
period	O
of	O
near-normoglycemia	O
remission	O
.	O

This	O
subtype	O
of	O
diabetes	O
is	O
known	O
as	O
ketosis-prone	O
type	O
2	O
diabetes	O
(	O
KPDM	O
)	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
To	O
investigate	O
the	O
role	O
of	O
lipotoxicity	O
on	O
beta-cell	O
function	O
,	O
eight	O
obese	O
African	O
Americans	O
with	O
KPDM	O
,	O
eight	O
obese	O
subjects	O
with	O
type	O
2	O
diabetes	O
with	O
severe	O
hyperglycemia	O
without	O
ketosis	O
(	O
ketosis-resistant	O
type	O
2	O
diabetes	O
)	O
,	O
and	O
nine	O
nondiabetic	O
obese	O
control	O
subjects	O
underwent	O
intravenous	Pharmacological
infusion	Pharmacological
of	Pharmacological
20	Pharmacological
%	Pharmacological
intralipid	Pharmacological
at	Pharmacological
40	Pharmacological
ml/h	Pharmacological
for	O
48	O
h.	O
beta-Cell	O
function	O
was	O
assessed	O
by	O
changes	O
in	O
insulin	O
and	O
C-peptide	O
concentration	O
during	O
infusions	O
and	O
by	O
changes	O
in	O
acute	O
insulin	O
response	O
to	O
arginine	O
stimulation	O
(	O
AIR	O
(	O
arg	O
)	O
)	O
before	O
and	O
after	O
lipid	Pharmacological
infusion	Pharmacological
.	O

RESULTS	O
The	O
mean	O
time	O
to	O
discontinue	O
insulin	O
therapy	O
was	O
11.0	O
+/-	O
8.0	O
weeks	O
in	O
KPDM	O
and	O
9.6	O
+/-	O
2.2	O
weeks	O
in	O
ketosis-resistant	O
type	O
2	O
diabetes	O
(	O
P	O
=	O
NS	O
)	O
.	O

At	O
remission	O
,	O
KPDM	O
and	O
ketosis-resistant	O
type	O
2	O
diabetes	O
had	O
similar	O
glucose	O
(	O
94	O
+/-	O
14	O
vs.	O
109	O
+/-	O
20	O
mg/dl	O
)	O
,	O
A1C	O
(	O
5.7	O
+/-	O
0.4	O
vs.	O
6.3	O
+/-	O
1.1	O
%	O
)	O
,	O
and	O
baseline	O
AIR	O
(	O
arg	O
)	O
response	O
(	O
34.8	O
+/-	O
30	O
vs.	O
64	O
+/-	O
69	O
microU/ml	O
)	O
.	O

P	O
=	O
NS	O
despite	O
a	O
fourfold	O
increase	O
in	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
levels	O
(	O
0.4	O
+/-	O
0.3	O
to	O
1.8	O
+/-	O
1.1	O
mmol/l	O
,	O
P	O
<	O
0.01	O
)	O
during	O
the	O
48-h	O
intralipid	Pharmacological
infusion	Pharmacological
;	O
the	O
response	O
to	O
AIR	O
(	O
arg	O
)	O
stimulation	O
,	O
as	O
well	O
as	O
changes	O
in	O
insulin	O
and	O
C-peptide	O
levels	O
,	O
were	O
similar	O
among	O
obese	O
patients	O
with	O
KPDM	O
,	O
patients	O
with	O
ketosis-resistant	O
type	O
2	O
diabetes	O
,	O
and	O
nondiabetic	O
control	O
subjects	O
.	O

CONCLUSIONS	O
Near-normoglycemia	O
remission	O
in	O
obese	O
African	O
American	O
patients	O
with	O
KPDM	O
and	O
ketosis-resistant	O
type	O
2	O
diabetes	O
is	O
associated	O
with	O
a	O
remarkable	O
recovery	O
in	O
basal	O
and	O
stimulated	O
insulin	O
secretion	O
.	O

A	O
high	O
FFA	O
level	O
by	O
intralipid	Pharmacological
infusion	Pharmacological
for	O
48	O
h	O
was	O
not	O
associated	O
with	O
beta-cell	O
decompensation	O
(	O
lipotoxicity	O
)	O
in	O
KPDM	O
patients	O
.	O

Effect	O
of	O
intravenous	Pharmacological
fructose-1,6-diphosphate	Pharmacological
on	O
myocardial	O
contractility	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
.	O

STUDY	O
OBJECTIVE	O
To	O
examine	O
the	O
effects	O
of	O
fructose-1,6-diphosphate	Pharmacological
on	O
myocardial	O
performance	O
using	O
nuclear	O
scintigraphy	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
single-blind	O
,	O
parallel	O
study	O
.	O

SETTING	O
Urban	O
teaching	O
hospital	O
clinical	O
research	O
center	O
.	O

PATIENTS	O
Individuals	O
with	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
II-III	O
heart	O
failure	O
(	O
mild	O
to	O
moderate	O
)	O
.	O

INTERVENTIONS	O
Subjects	O
received	O
either	O
intravenous	Pharmacological
fructose-1,6-diphosphate	Pharmacological
125	Pharmacological
mg/kg	Pharmacological
or	O
normal	Pharmacological
saline	Pharmacological
1.3	O
ml/kg	O
every	O
12	O
hours	O
over	O
10	O
minutes	O
for	O
four	O
consecutive	O
doses	O
.	O

Left	O
ventricular	O
performance	O
was	O
assessed	O
by	O
radionuclide	Physical
ventriculography	Physical
at	O
baseline	O
and	O
within	O
60	O
minutes	O
after	O
the	O
fourth	O
infusion	O
.	O

Vital	O
signs	O
were	O
monitored	O
throughout	O
the	O
study	O
period	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Fructose-1,6-diphosphate	Pharmacological
resulted	O
in	O
a	O
modest	O
7	O
%	O
increase	O
in	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Peak	O
ejection	O
rate	O
and	O
peak	O
diastolic	O
filling	O
rate	O
did	O
not	O
change	O
significantly	O
.	O

There	O
were	O
no	O
changes	O
in	O
blood	O
pressure	O
or	O
heart	O
rate	O
with	O
either	O
fructose-1,6-diphosphate	Pharmacological
or	O
placebo	Control
.	O

CONCLUSIONS	O
Fructose-1,6-diphosphate	Pharmacological
produces	O
a	O
modest	O
but	O
significant	O
increase	O
in	O
left	O
ventricular	O
ejection	O
fraction	O
in	O
patients	O
with	O
mild	O
to	O
moderate	O
heart	O
failure	O
.	O

A	O
randomised	O
trial	O
comparing	O
holmium	Surgical
laser	Surgical
enucleation	Surgical
versus	O
transurethral	Surgical
resection	Surgical
in	O
the	O
treatment	O
of	O
prostates	O
larger	O
than	O
40	O
grams	O
:	O
results	O
at	O
2	O
years	O
.	O

OBJECTIVE	O
To	O
compare	O
holmium	Surgical
laser	Surgical
enucleation	Surgical
of	Surgical
the	Surgical
prostate	Surgical
(	Surgical
HoLEP	Surgical
)	Surgical
with	O
transurethral	Surgical
resection	Surgical
of	Surgical
the	Surgical
prostate	Surgical
(	Surgical
TURP	Surgical
)	Surgical
for	O
treatment	O
of	O
men	O
with	O
bladder	O
outflow	O
obstruction	O
(	O
BOO	O
)	O
secondary	O
to	O
benign	O
prostatic	O
hyperplasia	O
with	O
a	O
minimum	O
of	O
24-month	O
follow-up	O
.	O

PATIENTS	O
AND	O
METHODS	O
Sixty-one	O
patients	O
were	O
randomised	O
to	O
either	O
HoLEP	Surgical
or	O
TURP	Surgical
.	Surgical

All	O
patients	O
had	O
BOO	O
proven	O
on	O
urodynamic	O
studies	O
pre-operatively	O
(	O
prostate	O
size	O
40-200	O
g	O
)	O
.	O

One	O
patient	O
died	O
before	O
treatment	O
,	O
which	O
left	O
30	O
patients	O
in	O
each	O
group	O
.	O

Perioperative	O
data	O
,	O
as	O
well	O
as	O
symptom	O
scores	O
,	O
Quality	O
of	O
Life	O
(	O
QoL	O
)	O
scores	O
,	O
and	O
maximum	O
urinary	O
flow	O
rates	O
(	O
Qmax	O
)	O
were	O
obtained	O
at	O
one	O
,	O
three	O
,	O
six,12	O
,	O
and	O
24	O
months	O
.	O

Post-void	O
residual	O
volumes	O
,	O
transrectal	O
ultrasound	O
(	O
TRUS	O
)	O
volumes	O
,	O
and	O
pressure	O
flow	O
studies	O
were	O
obtained	O
six	O
months	O
post-operatively	O
.	O

Continence	O
and	O
potency	O
data	O
were	O
also	O
recorded	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
surgical	O
groups	O
pre-operatively	O
.	O

Mean	O
pre-operative	O
TRUS	O
volume	O
was	O
77.8+/-5.6	O
g	O
(	O
42-152	O
)	O
in	O
the	O
HoLEP	O
group	O
and	O
70.0+/-5.0	O
g	O
(	O
46-156	O
)	O
in	O
the	O
TURP	Physical
group	O
.	O

Patients	O
in	O
the	O
HoLEP	Physical
group	O
had	O
shorter	O
catheter	O
times	O
and	O
hospital	O
stays	O
.	O

More	O
prostate	O
tissue	O
was	O
retrieved	O
in	O
the	O
HoLEP	Physical
group	O
.	O

At	O
six	O
months	O
,	O
HoLEP	Physical
was	O
urodynamically	O
superior	O
to	O
TURP	Physical
in	O
relieving	O
BOO	O
.	O

At	O
24	O
months	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
surgical	O
groups	O
with	O
respect	O
to	O
American	O
Urology	O
Association	O
scores	O
,	O
QoL	O
scores	O
,	O
or	O
Qmax	O
values	O
;	O
however	O
,	O
two	O
patients	O
in	O
the	O
TURP	O
group	O
required	O
re-operation	O
.	O

CONCLUSIONS	O
HoLEP	Physical
has	O
less	O
perioperative	O
morbidity	O
and	O
produces	O
superior	O
urodynamic	O
outcomes	O
than	O
TURP	Physical
,	O
when	O
treating	O
prostates	O
>	O
40	O
g.	O
At	O
24	O
months	O
of	O
follow-up	O
,	O
HoLEP	Physical
is	O
equivalent	O
to	O
TURP	Physical
.	O

Sinemet	Pharmacological
CR	Pharmacological
in	O
Parkinson	O
's	O
disease	O
.	O

Sinemet	Pharmacological
CR	Pharmacological
,	O
a	O
controlled	O
release	O
carbidopa/levodopa	Pharmacological
preparation	Pharmacological
,	O
was	O
compared	O
to	O
conventional	O
carbidopa/levodopa	Pharmacological
in	O
a	O
double	O
blind	O
,	O
placebo-controlled	Control
trial	O
.	O

Comparable	O
clinical	O
benefits	O
and	O
adverse	O
effects	O
were	O
noted	O
with	O
the	O
two	O
medications	O
.	O

However	O
significantly	O
less	O
frequent	O
dosing	O
was	O
necessary	O
with	O
Sinemet	O
CR	O
.	O

Prognostic	O
value	O
of	O
clinical	O
,	O
laboratory	O
,	O
and	O
histological	O
characteristics	O
in	O
multiple	O
myeloma	O
:	O
improved	O
definition	O
of	O
risk	O
groups	O
.	O

Follow-up	O
data	O
of	O
320	O
multiple	O
myeloma	O
(	O
MM	O
)	O
patients	O
entering	O
the	Pharmacological
German	Pharmacological
Myeloma	Pharmacological
Treatment	Pharmacological
Group	Pharmacological
(	Pharmacological
GMTG	Pharmacological
)	Pharmacological
trial	O
MM01	O
were	O
analysed	O
for	O
factors	O
predicting	O
overall	O
(	O
OAS	O
)	O
and	O
tumour	O
related	O
survival	O
(	O
TRS	O
)	O
.	O

Response	O
to	O
primary	Pharmacological
induction	Pharmacological
chemotherapy	Pharmacological
was	O
relevant	O
for	O
prognosis	O
if	O
a	O
limit	O
of	O
25	O
%	O
tumour	O
cell	O
mass	O
(	O
TCM	O
)	O
reduction	O
was	O
used	O
to	O
separate	O
responders	O
from	O
non-responders	O
.	O

Furthermore	O
,	O
TCM	O
,	O
histological	O
grading	O
of	O
myeloma	O
cells	O
,	O
degree	O
of	O
bone	O
marrow	O
infiltration	O
,	O
haemoglobin	O
,	O
platelet	O
counts	O
,	O
calcium	O
,	O
creatinine	O
,	O
albumin	O
,	O
beta	O
2M	O
,	O
and	O
Bence	O
Jones	O
proteinuria	O
correlated	O
to	O
both	O
OAS	O
and	O
TRS	O
.	O

Age	O
was	O
relevant	O
for	O
OAS	O
only	O
.	O

The	O
multivariate	O
analysis	O
revealed	O
histological	O
grading	O
,	O
TCM	O
and	O
platelets	O
as	O
the	O
most	O
reliable	O
prognostic	O
factors	O
.	O

Based	O
on	O
these	O
data	O
the	O
Durie/Salmon	O
classification	O
could	O
be	O
improved	O
by	O
defining	O
poor	Educational
prognosis	Educational
patients	O
(	O
50	O
%	O
TRS	O
:	O
16	O
months	O
)	O
characterised	O
by	O
pretreatment	O
platelets	O
of	O
<	O
or	O
=	O
150,000	O
and/or	O
poorly	O
differentiated	O
myeloma	O
cell	O
morphology	O
.	O

Patients	O
lacking	O
both	O
risk	O
factors	O
displayed	O
50	O
%	O
survival	O
times	O
of	O
46	O
months	O
in	O
stage	O
III	O
and	O
88	O
months	O
in	O
stage	O
II	O
.	O

[	O
A	O
prospective	O
randomized	O
study	O
of	O
the	O
radiotherapy	Physical
volume	Physical
for	O
limited-stage	O
small	O
cell	O
lung	O
cancer	O
:	O
a	O
preliminary	O
report	O
]	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
Controversies	O
exists	O
with	O
regard	O
to	O
target	O
volumes	O
as	O
far	O
as	O
thoracic	Physical
radiotherapy	Physical
(	Physical
TRT	Physical
)	Physical
is	O
concerned	O
in	O
the	O
multimodality	O
treatment	O
for	O
limited-stage	O
small	O
cell	O
lung	O
cancer	O
(	O
LSCLC	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
prospectively	O
compare	O
the	O
local	O
control	O
rate	O
,	O
toxicity	O
profiles	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
between	O
patients	O
received	O
different	Pharmacological
target	Pharmacological
volumes	Pharmacological
irradiation	Pharmacological
after	Pharmacological
induction	Pharmacological
chemotherapy	Pharmacological
.	O

METHODS	O
LSCLC	O
patients	O
received	O
2	O
cycles	O
of	O
etoposide	Pharmacological
and	Pharmacological
cisplatin	Pharmacological
(	Pharmacological
EP	Pharmacological
)	Pharmacological
induction	Pharmacological
chemotherapy	Pharmacological
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
TRT	Physical
to	O
either	O
the	O
post-	O
or	O
pre-chemotherapy	O
tumor	O
extent	O
(	O
GTV-T	O
)	O
as	O
study	O
arm	O
and	O
control	O
arm	O
,	O
CTV-N	O
included	O
the	O
positive	O
nodal	O
drainage	O
area	O
for	O
both	O
arms	O
.	O

One	O
to	O
2	O
weeks	O
after	O
induction	Pharmacological
chemotherapy	Pharmacological
,	Pharmacological
45	Physical
Gy/30	Physical
Fx/19	Physical
d	Physical
TRT	Physical
was	O
administered	O
concurrently	O
with	O
the	O
third	O
cycle	O
of	O
EP	Pharmacological
regimen	Pharmacological
.	O

After	O
that	O
,	O
additional	O
3	O
cycles	O
of	O
EP	Pharmacological
consolidation	O
were	O
administered	O
.	O

Prophylactic	Physical
cranial	Physical
irradiation	Physical
(	Physical
PCI	Physical
)	Physical
was	O
administered	O
to	O
patients	O
with	O
a	O
complete	O
response	O
.	O

RESULTS	O
Thirty-seven	O
and	O
40	O
patients	O
were	O
randomly	O
assigned	O
to	O
study	O
arm	O
and	O
control	O
arm	O
.	O

The	O
local	O
recurrence	O
rates	O
were	O
32.4	O
%	O
and	O
28.2	O
%	O
respectively	O
(	O
P	O
=	O
0.80	O
)	O
;	O
the	O
isolated	O
nodal	O
failure	O
(	O
INF	O
)	O
rates	O
were	O
3.0	O
%	O
and	O
2.6	O
%	O
respectively	O
(	O
P	O
=	O
0.91	O
)	O
;	O
all	O
INF	O
sites	O
were	O
in	O
the	O
ipsilateral	O
supraclavicular	O
fossa	O
.	O

Medastinal	O
N3	O
disease	O
was	O
the	O
risk	O
factor	O
for	O
INF	O
(	O
P	O
=	O
0.02	O
,	O
OR	O
=	O
14.13	O
,	O
95	O
%	O
CI	O
:	O
1.47-136.13	O
)	O
.	O

During	O
radiotherapy	O
,	O
grade	O
I	O
,	O
II	O
weight	O
loss	O
was	O
observed	O
in	O
29.4	O
%	O
,	O
5.9	O
%	O
and	O
56.4	O
%	O
,	O
7.7	O
%	O
patients	O
respectively	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Grade	O
0-I	O
and	O
II-III	O
late	O
pulmonary	O
injury	O
was	O
developed	O
in	O
97.1	O
%	O
,	O
2.9	O
%	O
and	O
86.4	O
%	O
,	O
15.4	O
%	O
patients	O
respectively	O
(	O
P	O
=	O
0.07	O
)	O
.	O

Median	O
survival	O
time	O
was	O
22.1	O
months	O
and	O
26.9	O
months	O
respectively	O
.	O

The	O
1	O
to	O
3-year	O
OS	O
were	O
77.9	O
%	O
,	O
44.4	O
%	O
,	O
37.3	O
%	O
and	O
75.8	O
%	O
,	O
56.3	O
%	O
,	O
41.7	O
%	O
respectively	O
(	O
P	O
=	O
0.79	O
)	O
.	O

CONCLUSIONS	O
The	O
preliminary	O
results	O
of	O
this	O
study	O
indicate	O
that	O
irradiant	O
the	O
post-chemotherapy	O
tumor	O
extent	O
(	O
GTV-T	O
)	O
and	O
positive	O
nodal	O
drainage	O
area	O
did	O
not	O
decrease	O
local	O
control	O
and	O
overall	O
survival	O
while	O
radiation	O
toxicity	O
was	O
reduced	O
.	O

But	O
the	O
current	O
sample	O
size	O
has	O
not	O
met	O
designed	O
requirements	O
,	O
and	O
further	O
investigation	O
is	O
warranted	O
before	O
final	O
conclusions	O
could	O
be	O
drawn	O
.	O

Moderate-intensity	Physical
exercise	Physical
training	Physical
with	O
elements	O
of	O
step	O
aerobics	O
in	O
patients	O
with	O
severe	O
chronic	O
heart	O
failure	O
.	O

OBJECTIVE	O
To	O
evaluate	O
whether	O
a	O
specific	O
program	O
of	O
moderate-intensity	Physical
step	Physical
aerobics	Physical
training	Physical
may	O
be	O
sufficient	O
to	O
improve	O
the	O
exercise	O
tolerance	O
of	O
patients	O
with	O
severe	O
chronic	O
heart	O
failure	O
.	O

PATIENTS	O
Twenty-six	O
patients	O
(	O
22	O
men	O
,	O
4	O
women	O
;	O
mean	O
+/-	O
SD	O
age	O
,	O
54	O
+/-	O
9yrs	O
)	O
with	O
a	O
history	O
of	O
severe	O
chronic	O
heart	O
failure	O
(	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
18	O
%	O
+/-	O
8	O
%	O
)	O
.	O

STUDY	O
DESIGN	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

Patients	O
were	O
randomized	O
into	O
exercise	O
and	O
control	O
groups	O
.	O

All	O
patients	O
underwent	O
a	O
clinical	O
examination	O
and	O
a	O
ramp	O
pattern	O
cycle	O
exercise	O
test	O
before	O
and	O
after	O
the	O
observation	O
period	O
.	O

The	O
exercise	O
group	O
underwent	O
a	O
moderate-intensity	Physical
(	Physical
50	Physical
%	Physical
of	Physical
peak	Physical
oxygen	Physical
uptake	Physical
)	Physical
12-week	Physical
training	Physical
program	Physical
,	O
progressing	Physical
to	Physical
100	Physical
minutes	Physical
per	Physical
week	Physical
of	Physical
step	Physical
aerobics	Physical
and	Physical
50	Physical
minutes	Physical
per	Physical
week	Physical
of	Physical
cycling	Physical
.	O

The	O
control	O
group	O
did	O
not	O
perform	Physical
a	Physical
training	Physical
program	Physical
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Peak	O
oxygen	O
uptake	O
,	O
peak	O
workload	O
,	O
percent	O
of	O
predicted	O
power	O
ability	O
.	O

RESULTS	O
Significant	O
increases	O
in	O
peak	O
oxygen	O
uptake	O
(	O
15	O
+/-	O
3.4	O
to	O
18.5	O
+/-	O
2.9mL/kg/min	O
;	O
p	O
=	O
.001	O
)	O
,	O
peak	O
workload	O
(	O
77	O
+/-	O
26	O
to	O
99	O
+/-	O
31	O
watts	O
;	O
p	O
=	O
.000	O
)	O
,	O
and	O
percent	O
of	O
predicted	O
power	O
ability	O
(	O
43	O
%	O
+/-	O
10	O
%	O
to	O
56	O
%	O
+/-	O
13	O
%	O
;	O
p	O
=	O
.000	O
)	O
were	O
observed	O
in	O
the	O
exercise	O
group	O
.	O

No	O
significant	O
changes	O
in	O
baseline	O
parameters	O
occurred	O
in	O
the	O
control	O
group	O
.	O

There	O
were	O
no	O
critical	O
changes	O
in	O
heart	O
rate	O
or	O
blood	O
pressure	O
in	O
either	O
group	O
.	O

CONCLUSION	O
Moderate-intensity	O
step	O
aerobics	O
training	O
significantly	O
increases	O
peak	O
oxygen	O
uptake	O
and	O
peak	O
workloads	O
in	O
patients	O
with	O
severe	O
chronic	O
heart	O
failure	O
.	O

[	O
Cannulation	Surgical
of	Surgical
the	Surgical
internal	Surgical
jugular	Surgical
vein	Surgical
using	Surgical
2	Surgical
ultrasonic	Surgical
technics	Surgical
.	O

A	O
comparative	O
controlled	O
study	O
]	O
.	O

The	O
internal	O
jugular	O
vein	O
(	O
IJV	O
)	O
is	O
a	O
common	O
access	O
route	O
to	O
the	O
central	O
venous	O
system	O
.	O

Anatomical	O
landmarks	O
(	O
group	O
I	O
)	O
are	O
normally	O
used	O
for	O
localization	O
of	O
the	O
IJV	O
.	O

We	O
have	O
compared	O
this	O
method	O
with	O
two	O
other	O
methods	O
based	O
on	O
ultrasonic	O
waves	O
to	O
identify	O
the	O
IJV	O
and	O
the	O
carotid	O
artery	O
(	O
CA	O
)	O
(	O
even	O
in	O
atypical	O
positions	O
)	O
.	O

We	O
employed	O
an	O
ultrasound	Physical
Doppler	Physical
device	Physical
in	Physical
group	Physical
II	Physical
and	Physical
a	Physical
real-time	Physical
ultrasonograph	Physical
in	Physical
group	Physical
III	Physical
.	O

Central	Surgical
venous	Surgical
catheters	Surgical
were	Surgical
placed	Surgical
into	Surgical
the	Surgical
right	Surgical
IJV	Surgical
by	Surgical
the	Surgical
Seldinger	Surgical
technique	Surgical
.	O

The	O
IJV	O
could	O
be	O
located	O
in	O
all	O
patients	O
with	O
both	O
ultrasound	O
methods	O
,	O
but	O
the	O
course	O
of	O
the	O
IJV	O
could	O
only	O
be	O
identified	O
by	O
ultrasonography	O
.	O

For	O
this	O
reason	O
,	O
the	O
direction	O
of	O
the	O
IJV	O
was	O
classified	O
as	O
typical	O
in	O
80	O
%	O
of	O
group	O
I	O
,	O
in	O
85	O
%	O
of	O
group	O
II	O
,	O
but	O
in	O
only	O
45	O
%	O
of	O
group	O
III	O
.	O

No	O
intergroup	O
differences	O
were	O
found	O
with	O
respect	O
to	O
the	O
number	O
of	O
punctures	O
(	O
mean	O
value	O
1.6	O
+/-	O
0.83	O
)	O
and	O
the	O
incidence	O
of	O
complications	O
.	O

The	O
time	O
required	O
to	O
locate	O
the	O
site	O
and	O
direction	O
of	O
puncture	O
increased	O
with	O
technical	O
sophistication	O
.	O

There	O
was	O
,	O
however	O
,	O
no	O
difference	O
in	O
the	O
total	O
time	O
for	O
catheter	O
placement	O
,	O
because	O
puncture	O
was	O
performed	O
faster	O
when	O
aided	O
by	O
sonography	O
.	O

In	O
four	O
patients	O
in	O
groups	O
I	O
and	O
II	O
,	O
in	O
whom	O
attempts	O
to	O
puncture	O
the	O
IJV	O
had	O
not	O
been	O
successful	O
,	O
this	O
could	O
subsequently	O
be	O
achieved	O
with	O
ultrasonographic	O
aid	O
.	O

One	O
patient	O
(	O
group	O
I	O
)	O
displayed	O
a	O
hematoma	O
following	O
inadvertent	O
puncture	O
of	O
the	O
CA	O
.	O

In	O
one	O
patient	O
in	O
group	O
II	O
the	O
IJV	O
and	O
CA	O
could	O
not	O
be	O
distinguished	O
as	O
one	O
was	O
overlying	O
the	O
other	O
.	O

The	O
echocamera	O
provided	O
improved	O
localization	O
of	O
the	O
IJV	O
and	O
the	O
CA	O
in	O
comparison	O
with	O
the	O
Doppler	O
ultrasound	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Dacarbazine	Pharmacological
versus	O
dacarbazine-vindesine	Pharmacological
in	O
disseminated	O
malignant	O
melanoma	O
:	O
a	O
randomized	O
phase	O
II	O
study	O
.	O

In	O
a	O
phase	O
II	O
study	O
119	O
patients	O
with	O
disseminated	O
malignant	O
melanoma	O
were	O
randomized	O
to	O
receive	O
treatment	O
with	O
dacarbazine	Pharmacological
alone	O
or	O
in	O
combination	O
with	O
vindesine	O
.	O

The	O
study	O
was	O
designed	O
to	O
reveal	O
an	O
additive	O
response	O
rate	O
when	O
the	O
drugs	O
were	O
combined	O
.	O

Dacarbazine	Pharmacological
was	Pharmacological
given	Pharmacological
i.v	Pharmacological
.	O

at	O
250	O
mg	O
m-2	O
per	O
day	O
X	O
V	O
every	O
4	O
weeks	O
.	O

In	O
the	O
combination	O
regimen	O
vindesine	Pharmacological
given	O
at	O
3	O
mg	O
m-2	O
per	O
week	O
was	O
included	O
.	O

One	O
hundred	O
and	O
ten	O
patients	O
were	O
available	O
for	O
evaluation	O
of	O
response	O
.	O

With	O
dacarbazine	Pharmacological
4/51	O
patients	O
obtained	O
a	O
complete	O
remission	O
(	O
8	O
%	O
)	O
and	O
5/51	O
patients	O
a	O
partial	O
remission	O
(	O
10	O
%	O
)	O
.	O

Overall	O
response	O
rate	O
was	O
18	O
%	O
.	O

With	O
dacarbazine-vindesine	Pharmacological
8/59	O
patients	O
obtained	O
a	O
complete	O
remission	O
(	O
13	O
%	O
)	O
and	O
7/59	O
patients	O
a	O
partial	O
remission	O
(	O
12	O
%	O
)	O
.	O

Overall	O
response	O
rate	O
was	O
25	O
%	O
.	O

The	O
difference	O
in	O
response	O
rates	O
observed	O
between	O
the	O
treatment	O
arms	O
is	O
not	O
statistically	O
significant	O
.	O

Median	O
response	O
duration	O
was	O
123	O
days	O
for	O
dacarbazine	O
patients	O
and	O
171	O
days	O
for	O
patients	O
receiving	O
dacarbazine-vindesine	O
(	O
difference	O
not	O
statistically	O
significant	O
)	O
.	O

Efficient	O
tetanus	Pharmacological
toxoid	Pharmacological
immunization	Pharmacological
on	O
vitamin	Pharmacological
D	Pharmacological
supplementation	O
.	O

BACKGROUND/OBJECTIVES	O
Vitamin	O
D	O
mediates	O
immunomodulatory	O
functions	O
,	O
and	O
its	O
deficiency	O
has	O
been	O
associated	O
with	O
an	O
increased	O
prevalence	O
of	O
immunological	O
diseases	O
.	O

The	O
supplementation	O
of	O
vitamin	Pharmacological
D	Pharmacological
might	O
be	O
therapeutically	O
beneficial	O
,	O
for	O
example	O
,	O
in	O
lupus	O
erythematosus	O
patients	O
.	O

However	O
,	O
its	O
affect	O
on	O
established	O
recall	O
immune	O
responses	O
is	O
undefined	O
.	O

SUBJECTS/METHODS	O
In	O
all	O
,	O
32	O
individuals	O
were	O
randomized	O
in	O
a	O
placebo	Control
controlled	O
,	O
double-blind	O
setting	O
,	O
and	O
received	O
vitamin	Pharmacological
D	Pharmacological
(	O
daily	O
2000	O
IU	O
)	O
for	O
10	O
weeks	O
followed	O
by	O
tetanus	Pharmacological
toxoid	Pharmacological
(	Pharmacological
TT	Pharmacological
)	Pharmacological
booster	Pharmacological
immunization	Pharmacological
.	Pharmacological

RESULTS	O
During	O
vitamin	O
D	O
supplementation	O
the	O
median	O
25-hydroxyvitamin	O
D	O
serum	O
concentration	O
increased	O
to	O
80.3	O
nM	O
,	O
which	O
as	O
expected	O
decreased	O
in	O
the	O
placebo	O
group	O
to	O
29.1	O
nM	O
during	O
the	O
ultraviolet-deprived	O
winter	O
months	O
.	O

The	O
TT-specific	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
boost	O
efficiency	O
was	O
marginal	O
higher	O
in	O
the	O
vitamin	O
D	O
group	O
(	O
P	O
=	O
0.04	O
)	O
.	O

The	O
increase	O
of	O
the	O
25-hydroxyvitamin	O
D	O
levels	O
correlated	O
with	O
the	O
increase	O
of	O
TT-IgG	O
serum	O
concentrations	O
.	O

The	O
induction	O
of	O
specific	O
serum	O
IgA	O
and	O
specific	O
antibody	O
secreting	O
cells	O
was	O
comparable	O
between	O
both	O
groups	O
.	O

Accordingly	O
,	O
the	O
TT-specific	O
and	O
polyclonally	O
triggered	O
T-cell	O
cytokine	O
profiles	O
were	O
stable	O
as	O
well	O
.	O

CONCLUSIONS	O
Vitamin	O
D	O
supplementation	O
was	O
successful	O
and	O
booster	O
immunization	O
induced	O
efficiently	O
specific	O
antibodies	O
titers	O
.	O

Effects	O
of	O
iron	Pharmacological
on	O
the	O
pharmacokinetics	O
of	O
paracetamol	Pharmacological
in	O
saliva	O
.	O

Paracetamol	Pharmacological
has	O
been	O
reported	O
to	O
chelate	O
with	O
iron	Pharmacological
.	O

It	O
was	O
found	O
that	O
no	O
in	O
vitro	O
reaction	O
between	O
ferrous	O
ion	O
and	O
paracetamol	O
.	O

Other	O
studies	O
found	O
that	O
there	O
is	O
an	O
aerobic	O
(	O
in	O
the	O
gastrointestinal	O
tract	O
)	O
oxidation	O
of	O
ferrous	O
ion	O
to	O
ferric	O
ion	O
caused	O
in	O
iron-paracetamol	O
in	O
vivo	O
reactions	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
iron	O
interacts	O
with	O
paracetamol	O
and	O
reduces	O
paracetamol	O
absorption	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
cross-over	O
study	O
design	O
was	O
used	O
to	O
assess	O
the	O
in	O
vivo	O
interaction	O
of	O
paracetamol	Pharmacological
and	O
ferrous	Pharmacological
ion	Pharmacological
.	O

Paracetamol	Pharmacological
(	O
1.0	O
g	O
)	O
was	O
co-ignested	O
alone	O
or	O
with	O
(	O
300	O
mg	O
)	O
ferrous	Pharmacological
sulphate	Pharmacological
by	O
ten	O
healthy	O
male	O
volunteers	O
,	O
using	O
saliva	O
drug	O
levels	O
as	O
a	O
parameter	O
.	O

Concomitant	O
administration	O
of	O
ferrous	Pharmacological
sulphate	Pharmacological
and	O
paracetamol	Pharmacological
,	O
decreased	O
AUC8	O
from	O
42.88	O
+/-	O
3.8-34.25	O
+/-	O
2.8	O
microg	O
h	O
mL	O
(	O
-1	O
)	O
(	O
p	O
=	O
0.04	O
)	O
and	O
Cmax	O
from	O
18.75	O
+/-	O
1.9	O
to	O
15.9	O
+/-	O
1.7	O
microg	O
mL	O
(	O
-1	O
)	O
(	O
p	O
=	O
0.11	O
)	O
,	O
while	O
no	O
change	O
in	O
tmax	O
(	O
p	O
=	O
0.5	O
)	O
was	O
originated	O
.	O

A	O
significant	O
difference	O
was	O
found	O
in	O
the	O
paracetamol	O
pharmacokinetic	O
parameter	O
oral	O
clearance	O
(	O
C1/F	O
)	O
(	O
p	O
=	O
0.02	O
)	O
and	O
slightly	O
increased	O
in	O
volume	O
of	O
distribution	O
(	O
V	O
(	O
d	O
)	O
/F	O
)	O
(	O
p	O
=	O
0.10	O
)	O
.	O

Co-administration	O
of	O
iron	Pharmacological
and	O
paracetamol	Pharmacological
results	O
in	O
decreased	O
paracetamol	O
absorption	O
due	O
to	O
an	O
interaction	O
between	O
iron	O
and	O
paracetamol	O
.	O

[	O
Stent	Surgical
and	Surgical
surgery	Surgical
for	O
symptomatic	O
carotid	O
stenosis	O
.	O

SPACE	O
study	O
results	O
]	O
.	O

The	O
SPACE	O
trial	O
compared	O
risk	O
and	O
effectiveness	O
of	O
stent-supported	Surgical
angioplasty	Surgical
(	Surgical
CAS	Surgical
)	Surgical
vs	O
carotid	Surgical
endarterectomy	Surgical
(	Surgical
CEA	Surgical
)	Surgical
using	O
a	O
noninferiority	O
design	O
in	O
patients	O
with	O
symptomatic	O
stenoses	O
.	O

Intention-to-treat	O
analysis	O
of	O
the	O
entire	O
study	O
population	O
of	O
1,214	O
patients	O
showed	O
that	O
primary	O
endpoint	O
events	O
(	O
ipsilateral	O
stroke	O
or	O
death	O
between	O
randomisation	O
and	O
day	O
30	O
)	O
occurred	O
in	O
6.92	O
%	O
of	O
the	O
CAS	Surgical
group	O
and	O
6.45	O
%	O
of	O
the	O
CEA	Surgical
group	O
.	O

The	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
the	O
absolute	O
risk	O
difference	O
ranged	O
from	O
-1.94	O
%	O
to	O
+2.87	O
%	O
,	O
therefore	O
the	O
noninferiority	O
was	O
not	O
proven	O
.	O

The	O
same	O
was	O
true	O
for	O
the	O
analysis	O
of	O
protocols	O
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
treatment	O
methods	O
were	O
found	O
in	O
primary	O
or	O
any	O
of	O
the	O
secondary	O
endpoints	O
.	O

There	O
were	O
also	O
no	O
differences	O
in	O
short-term	O
prevention	O
.	O

The	O
endpoint	O
'ipsilateral	O
ischemic	O
stroke	O
or	O
vascular	O
death	O
between	O
randomisation	O
and	O
6	O
months	O
'	O
occurred	O
in	O
7.4	O
%	O
of	O
the	O
CAS	Surgical
and	O
6.5	O
%	O
of	O
the	O
CEA	Surgical
patients	O
(	O
odds	O
ratio	O
1.16	O
,	O
95	O
%	O
confidence	O
interval	O
0.74-1.82	O
)	O
.	O

Instent	O
restenoses	O
were	O
significantly	O
more	O
common	O
in	O
the	O
CAS	Surgical
group	O
(	O
4.6	O
%	O
vs	O
2.2	O
%	O
,	O
odds	O
ratio	O
2.14	O
,	O
95	O
%	O
CI	O
1.10-4.18	O
)	O
.	O

Surgery	O
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
patients	O
with	O
symptomatic	O
carotid	O
artery	O
stenosis	O
.	O

Stent-supported	Surgical
angioplasty	Surgical
can	O
be	O
an	O
alternative	O
only	O
in	O
the	O
hands	O
of	O
an	O
experienced	O
interventionalist	O
with	O
proven	O
low	O
periprocedural	O
complication	O
rate	O
.	O

Effect	O
of	O
micronutrient	Pharmacological
supplement	Pharmacological
on	O
health	O
and	O
nutritional	O
status	O
of	O
schoolchildren	O
:	O
study	O
design	O
.	O

OBJECTIVE	O
We	O
tested	O
the	O
hypothesis	O
that	O
supplementation	O
with	O
a	O
micronutrient-fortified	Pharmacological
beverage	Pharmacological
improves	O
micronutrient	O
status	O
and	O
physical	O
and	O
mental	O
development	O
in	O
apparently	O
healthy	O
schoolchildren	O
.	O

METHODS	O
The	O
study	O
was	O
carried	O
out	O
in	O
middle-income	O
students	O
in	O
two	O
residential	O
schools	O
that	O
catered	O
to	O
children	O
from	O
a	O
semi-urban	O
population	O
near	O
Hyderabad	O
,	O
India	O
.	O

Included	O
were	O
869	O
children	O
who	O
were	O
6	O
to	O
16	O
y	O
of	O
age	O
in	O
grades	O
1	O
to	O
10	O
.	O

Because	O
children	O
at	O
each	O
grade	O
were	O
distributed	O
across	O
two	O
classrooms	O
(	O
clusters	O
)	O
and	O
were	O
homogeneous	O
,	O
each	O
grade	O
was	O
considered	O
to	O
consist	O
of	O
a	O
matched	O
pair	O
.	O

There	O
were	O
thus	O
10	O
pairs	O
available	O
for	O
the	O
study	O
.	O

Classes	O
in	O
each	O
grade	O
were	O
randomized	O
to	O
receive	O
a	O
micronutrient-enriched	Pharmacological
beverage	Pharmacological
or	O
a	O
placebo	Control
without	Control
added	Control
micronutrients	Control
.	O

The	O
study	O
was	O
double	O
blinded	O
and	O
the	O
duration	O
was	O
14	O
mo	O
,	O
with	O
supervised	O
feeding	O
of	O
the	O
micronutrient-enriched	Pharmacological
beverage	Pharmacological
.	O

The	O
effect	O
of	O
the	O
micronutrients	Pharmacological
on	O
the	O
outcome	O
variables	O
growth	O
,	O
biochemical	O
status	O
,	O
mental	O
function	O
,	O
and	O
bone	O
health	O
were	O
assessed	O
.	O

RESULTS	O
The	O
number	O
of	O
matched	O
pairs	O
varied	O
between	O
seven	O
and	O
eight	O
,	O
and	O
the	O
required	O
number	O
of	O
children	O
per	O
treatment	O
group	O
ranged	O
from	O
32	O
in	O
the	O
case	O
of	O
bone	O
heath	O
to	O
177	O
for	O
body	O
weight	O
.	O

The	O
power	O
of	O
the	O
outcome	O
variables	O
ranged	O
from	O
74	O
%	O
to	O
100	O
%	O
and	O
was	O
adequate	O
for	O
successful	O
pairing	O
.	O

The	O
effect	O
assessed	O
at	O
the	O
end	O
of	O
supplementation	Pharmacological
showed	O
that	O
the	O
intervention	O
was	O
beneficial	O
.	O

CONCLUSIONS	O
Designing	O
an	O
intervention	O
,	O
choosing	O
outcome	O
variables	O
,	O
and	O
implementing	O
the	O
protocol	O
in	O
a	O
typical	O
Indian	O
school	O
setting	O
were	O
achieved	O
.	O

HOXB13	Physical
G84E	Physical
mutation	Physical
in	O
Finland	O
:	O
population-based	O
analysis	O
of	O
prostate	O
,	O
breast	O
,	O
and	O
colorectal	O
cancer	O
risk	O
.	O

BACKGROUND	O
A	O
recently	O
identified	O
germline	O
mutation	O
G84E	Physical
in	Physical
HOXB13	Physical
was	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
prostate	O
cancer	O
.	O

In	O
a	O
family-based	O
analysis	O
by	O
The	O
International	O
Consortium	O
for	O
Prostate	O
Cancer	O
Genetics	O
(	O
ICPCG	O
)	O
,	O
the	O
G84E	Physical
mutation	Physical
was	O
most	O
prevalent	O
in	O
families	O
from	O
the	O
Nordic	O
countries	O
of	O
Finland	O
(	O
22.4	O
%	O
)	O
and	O
Sweden	O
(	O
8.2	O
%	O
)	O
.	O

METHODS	O
To	O
further	O
investigate	O
the	O
importance	O
of	O
G84E	O
in	O
the	O
Finns	O
,	O
we	O
determined	O
its	O
frequency	O
in	O
more	O
than	O
4,000	O
prostate	O
cancer	O
cases	O
and	O
5,000	O
controls	O
.	O

In	O
addition	O
,	O
986	O
breast	O
cancer	O
and	O
442	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
cases	O
were	O
studied	O
.	O

Genotyping	Physical
was	O
conducted	O
using	O
TaqMan	O
,	O
MassARRAY	O
iPLEX	O
,	O
and	O
sequencing	O
.	O

Statistical	O
analyses	O
were	O
conducted	O
using	O
Fisher	O
exact	O
test	O
,	O
and	O
overall	O
survival	O
was	O
analyzed	O
using	O
Cox	O
modeling	O
.	O

RESULTS	O
The	O
frequency	O
of	O
the	O
G84E	O
mutation	O
was	O
significantly	O
higher	O
among	O
patients	O
with	O
prostate	O
cancer	O
and	O
highest	O
among	O
patients	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
hereditary	O
prostate	O
cancer	O
[	O
8.4	O
%	O
vs.	O
1.0	O
%	O
in	O
controls	O
;	O
OR	O
8.8	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
4.9-15.7	O
]	O
.	O

The	O
mutation	O
contributed	O
significantly	O
to	O
younger	O
age	O
(	O
?55	O
years	O
)	O
at	O
onset	O
and	O
high	O
prostate-specific	O
antigen	O
(	O
PSA	O
;	O
?20	O
ng/mL	O
)	O
at	O
diagnosis	O
.	O

An	O
association	O
with	O
increased	O
prostate	O
cancer	O
risk	O
in	O
patients	O
with	O
prior	O
benign	O
prostate	O
hyperplasia	O
(	O
BPH	O
)	O
diagnosis	O
was	O
also	O
revealed	O
.	O

No	O
statistically	O
significant	O
evidence	O
for	O
a	O
contribution	O
in	O
CRC	O
risk	O
was	O
detected	O
,	O
but	O
a	O
suggestive	O
role	O
for	O
the	O
mutation	O
was	O
observed	O
in	O
familial	O
BRCA1/2-negative	O
breast	O
cancer	O
.	O

CONCLUSIONS	O
These	O
findings	O
confirm	O
an	O
increased	O
cancer	O
risk	O
associated	O
with	O
the	O
G84E	O
mutation	O
in	O
the	O
Finnish	O
population	O
,	O
particularly	O
for	O
early-onset	O
prostate	O
cancer	O
and	O
cases	O
with	O
substantially	O
elevated	O
PSA	O
.	O

IMPACT	O
This	O
study	O
confirms	O
the	O
overall	O
importance	O
of	O
the	O
HOXB13	O
G84E	O
mutation	O
in	O
prostate	O
cancer	O
susceptibility	O
.	O

Effects	O
of	O
ursodeoxycholic	Pharmacological
acid	Pharmacological
on	O
serum	O
liver	O
enzymes	O
in	O
patients	O
with	O
hepatitis	O
C	O
virus-related	O
chronic	O
liver	O
disease	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
effect	O
of	O
ursodeoxycholic	Pharmacological
acid	Pharmacological
(	Pharmacological
UDCA	Pharmacological
)	Pharmacological
on	O
serum	O
liver	O
enzyme	O
levels	O
[	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
gamma-glutamyl	O
transferase	O
(	O
GGT	O
)	O
]	O
in	O
101	O
patients	O
with	O
hepatitis	O
C	O
virus-related	O
chronic	O
liver	O
disease	O
.	O

METHODS	O
Forty-nine	O
patients	O
were	O
assigned	O
to	O
receive	O
UDCA	Pharmacological
(	O
450	O
mg/day	O
)	O
over	O
a	O
period	O
of	O
6	O
months	O
and	O
52	O
to	O
receive	O
no	Control
treatment	Control
.	O

RESULTS	O
In	O
the	O
UDCA	Pharmacological
group	O
,	O
serum	O
ALT	O
and	O
GGT	O
levels	O
significantly	O
improved	O
.	O

ALT	O
values	O
decreased	O
from	O
pre-treatment	O
levels	O
of	O
157.0	O
+/-	O
62.6	O
IU/l	O
to	O
82.5	O
+/-	O
46.4	O
IU/l	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
GGT	O
fell	O
from	O
141.3	O
+/-	O
86.2	O
IU/l	O
to	O
66.0	O
+/-	O
49.5	O
IU/l	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
change	O
occurred	O
in	O
the	O
mean	O
ALT	O
and	O
GGT	O
levels	O
in	O
the	O
control	O
group	O
.	O

CONCLUSION	O
Although	O
our	O
encouraging	O
preliminary	O
results	O
must	O
be	O
validated	O
by	O
double-blind	O
histological	O
trials	O
,	O
UDCA	Pharmacological
may	O
be	O
an	O
alternative	O
treatment	O
for	O
patients	O
who	O
fail	O
to	O
respond	O
to	O
interferon	Pharmacological
therapy	Pharmacological
.	O

A	O
drug	O
interaction	O
study	O
between	O
ticlopidine	Pharmacological
and	O
cyclosporin	Pharmacological
in	O
heart	O
transplant	O
recipients	O
.	O

OBJECTIVES	O
Previous	O
uncontrolled	O
studies	O
have	O
suggested	O
an	O
interaction	O
between	O
ticlopidine	Pharmacological
,	O
a	O
major	O
antiplatelet	O
agent	O
,	O
and	O
cyclosporin	Pharmacological
in	O
heart-	O
and	O
kidney-transplant	O
recipients	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
in	O
a	O
randomised	O
,	O
double-blind	O
fashion	O
,	O
the	O
possible	O
interaction	O
between	O
cyclosporin	Pharmacological
A	Pharmacological
and	Pharmacological
ticlopidine	Pharmacological
(	O
250	O
mg	O
per	O
day	O
)	O
and	O
the	O
tolerability	O
of	O
this	O
combination	O
in	O
heart-transplant	O
recipients	O
.	O

METHODS	O
Twenty	O
heart-transplant	O
recipients	O
were	O
randomised	O
into	O
either	O
a	O
treated	O
or	O
a	O
placebo	Pharmacological
group	O
.	O

Blood	O
samples	O
were	O
drawn	O
for	O
time-course	O
evaluation	O
of	O
cyclosporin	O
blood	O
levels	O
over	O
a	O
period	O
of	O
12	O
h	O
,	O
following	O
the	O
morning	O
intake	O
of	O
cyclosporin	Pharmacological
and	O
,	O
for	O
platelet	O
aggregation	O
studies	O
,	O
before	O
and	O
after	O
14	O
days	O
of	O
ticlopidine	Pharmacological
administration	O
.	O

Twenty	O
four-hour	O
urine	O
samples	O
were	O
collected	O
for	O
6-beta-hydroxycortisol	O
measurements	O
,	O
before	O
and	O
after	O
14	O
days	O
of	O
ticlopidine	O
.	O

RESULTS	O
Although	O
given	O
at	O
half	O
the	O
recommended	O
daily	O
dosage	O
,	O
ticlopidine	O
significantly	O
reduced	O
platelet	O
aggregation	O
.	O

Pharmacokinetic	O
parameters	O
indicate	O
that	O
the	O
bioavailability	O
of	O
cyclosporin	Pharmacological
A	Pharmacological
was	O
not	O
significantly	O
modified	O
by	O
ticlopidine	Pharmacological
.	O

However	O
,	O
one	O
patient	O
in	O
the	O
ticlopidine	O
group	O
was	O
withdrawn	O
because	O
of	O
a	O
major	O
fall	O
in	O
cyclosporin	O
blood	O
level	O
within	O
3	O
days	O
of	O
treatment	O
.	O

Urinary	O
excretion	O
of	O
6-beta-hydroxycortisol	O
was	O
augmented	O
after	O
treatment	O
in	O
the	O
ticlopidine	Pharmacological
group	O
compared	O
with	O
the	O
placebo	Pharmacological
group	O
,	O
suggesting	O
that	O
induction	O
of	O
drug	O
metabolism	O
might	O
have	O
occurred	O
.	O

Data	O
also	O
show	O
quite	O
a	O
large	O
intra-individual	O
variability	O
in	O
cyclosporin	Pharmacological
bioavailability	O
in	O
the	O
placebo	Pharmacological
group	O
,	O
suggesting	O
that	O
poor	O
absorption	O
of	O
the	O
drug	O
formulation	O
and/or	O
poor	O
compliance	O
might	O
have	O
contributed	O
to	O
the	O
decreased	O
cyclosporin	Pharmacological
blood	O
levels	O
in	O
the	O
patient	O
withdrawn	O
from	O
this	O
study	O
and	O
in	O
previous	O
uncontrolled	O
studies	O
.	O

CONCLUSION	O
Cyclosporin	O
bioavailability	O
was	O
not	O
clearly	O
modified	O
by	O
a	O
half	O
dosage	O
of	O
ticlopidine	Pharmacological
in	O
this	O
study	O
.	O

We	O
,	O
however	O
,	O
recommend	O
closely	O
monitoring	O
cyclosporin	O
blood	O
levels	O
when	O
prescribing	O
ticlopidine	Pharmacological
.	O

Further	O
studies	O
will	O
be	O
needed	O
with	O
new	O
formulations	O
of	O
cyclosporin	Pharmacological
or	O
when	O
using	O
the	O
full	O
dosage	O
of	O
ticlopidine	Pharmacological
.	O

Comparative	O
evaluation	O
of	O
percutaneous	Surgical
laser	Surgical
and	O
radiofrequency	Surgical
ablation	Surgical
in	O
patients	O
with	O
HCC	O
smaller	O
than	O
4	O
cm	O
.	O

OBJECTIVE	O
This	O
study	O
was	O
done	O
to	O
compare	O
percutaneous	Surgical
laser	Surgical
ablation	Surgical
(	Surgical
PLA	Surgical
)	Surgical
and	O
radiofrequency	Surgical
thermoablation	Surgical
(	Surgical
RFA	Surgical
)	Surgical
for	O
the	O
treatment	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
?	O
4	O
cm	O
,	O
in	O
patients	O
with	O
liver	O
cirrhosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
Thirty	O
patients	O
with	O
single	O
HCC	O
?	O
4	O
cm	O
in	O
diameter	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatments	O
:	O
15	O
patients	O
were	O
treated	O
with	O
PLA	O
,	O
using	O
a	O
multifibre	O
system	O
connected	O
to	O
a	O
neodymium	O
yttrium-aluminium-garnet	O
laser	O
source	O
;	O
15	O
patients	O
were	O
treated	O
with	O
RFA	O
,	O
using	O
an	O
expandable	O
needle	O
electrode	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
up	O
to	O
12	O
months	O
.	O

RESULTS	O
A	O
complete	O
response	O
was	O
obtained	O
in	O
87	O
%	O
lesions	O
treated	O
with	O
PLA	O
and	O
in	O
93	O
%	O
lesions	O
treated	O
with	O
RFA	O
(	O
p	O
=	O
ns	O
)	O
.	O

The	O
overall	O
local	O
recurrence-free	O
survival	O
rates	O
at	O
3	O
,	O
6	O
and	O
12	O
months	O
were	O
comparable	O
.	O

However	O
,	O
a	O
higher	O
rate	O
of	O
recurrence	O
was	O
observed	O
in	O
the	O
PLA	O
group	O
for	O
lesions	O
?	O
21	O
mm	O
(	O
p	O
=	O
0.0081	O
)	O
.	O

A	O
postablation	O
syndrome	O
was	O
documented	O
in	O
13	O
patients	O
(	O
1	O
PLA	O
;	O
12	O
RFA	O
)	O
.	O

Tumour	O
necrosis	O
factor-?	O
was	O
significantly	O
higher	O
in	O
the	O
RFA	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
RFA	O
is	O
more	O
effective	O
in	O
the	O
treatment	O
of	O
HCC	O
compared	O
to	O
PLA	O
for	O
lesions	O
?	O
21	O
mm	O
.	O

However	O
,	O
PLA	O
should	O
be	O
considered	O
a	O
viable	O
treatment	O
option	O
for	O
HCC	O
?	O
20	O
mm	O
,	O
in	O
view	O
of	O
the	O
lower	O
incidence	O
of	O
complications	O
.	O

Gabapentin	O
but	O
not	O
vigabatrin	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
acquired	O
nystagmus	O
in	O
multiple	O
sclerosis	O
:	O
How	O
valid	O
is	O
the	O
GABAergic	O
hypothesis	O
?	O
Acquired	O
nystagmus	O
occurs	O
frequently	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
is	O
often	O
the	O
cause	O
of	O
illusory	O
motion	O
of	O
the	O
environment	O
(	O
oscillopsia	O
)	O
,	O
and	O
blurring	O
of	O
vision	O
.	O

Based	O
primarily	O
on	O
the	O
beneficial	O
effect	O
of	O
gabapentin	O
on	O
acquired	O
pendular	O
nystagmus	O
(	O
APN	O
)	O
,	O
a	O
GABAergic	O
mechanism	O
in	O
controlling	O
nystagmus	O
has	O
been	O
hypothesised	O
.	O

If	O
increasing	O
GABA	O
concentrations	O
in	O
the	O
CNS	O
are	O
critical	O
for	O
the	O
treatment	O
of	O
nystagmus	O
,	O
then	O
a	O
selective	O
GABAergic	O
drug	O
should	O
be	O
highly	O
successful	O
.	O

However	O
,	O
as	O
gabapentin	O
is	O
not	O
a	O
selective	O
GABAergic	O
agent	O
,	O
vigabatrin	O
,	O
a	O
pure	O
GABAergic	O
medication	O
,	O
and	O
gabapentin	O
,	O
were	O
compared	O
in	O
a	O
single	O
blind	O
cross	O
over	O
trial	O
in	O
eight	O
patients	O
with	O
definite	O
multiple	O
sclerosis	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
begin	O
with	O
gabapentin	Pharmacological
(	Pharmacological
1200	Pharmacological
mg	Pharmacological
daily	Pharmacological
)	Pharmacological
or	Pharmacological
vigabatrin	Pharmacological
(	Pharmacological
2000	Pharmacological
mg	Pharmacological
daily	Pharmacological
)	Pharmacological
.	O

Neuro-ophthalmological	O
and	O
electro-oculographic	O
(	O
EOG	O
)	O
evaluations	O
were	O
performed	O
four	O
and	O
three	O
times	O
,	O
respectively	O
.	O

Treatment	O
efficacy	O
was	O
based	O
on	O
improving	O
visual	O
acuity	O
and	O
EOG	O
indices	O
(	O
amplitude	O
or	O
frequency	O
of	O
nystagmus	O
,	O
or	O
both	O
)	O
by	O
at	O
least	O
50	O
%	O
of	O
pretreatment	O
values	O
.	O

Three	O
out	O
of	O
eight	O
patients	O
dropped	O
out	O
due	O
to	O
adverse	O
effects	O
.	O

In	O
the	O
remaining	O
five	O
patients	O
gabapentin	O
improved	O
symptomatic	O
pendular	O
or	O
gaze	O
evoked	O
jerk	O
nystagmus	O
in	O
four	O
.	O

Three	O
patients	O
decided	O
to	O
continue	O
gabapentin	O
therapy	O
.	O

Importantly	O
,	O
vigabatrin	O
proved	O
useful	O
in	O
only	O
one	O
out	O
of	O
five	O
patients	O
,	O
suggesting	O
that	O
gabapentin	O
effectiveness	O
may	O
be	O
related	O
to	O
additional	O
non-GABAergic	O
mechanisms	O
of	O
action	O
.	O

Interaction	O
with	O
cerebral	O
glutamate	O
transmission	O
by	O
inhibition	O
of	O
NMDA	O
receptor	O
might	O
be	O
an	O
alternative	O
hypothesis	O
for	O
the	O
therapeutic	O
action	O
of	O
gabapentin	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
the	O
Korean	O
version	O
of	O
the	O
PEERS	O
(	O
?	O
)	O
parent-assisted	O
social	O
skills	O
training	O
program	O
for	O
teens	O
with	O
ASD	O
.	O

Impaired	O
social	O
functioning	O
is	O
a	O
hallmark	O
feature	O
of	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
often	O
requiring	O
treatment	O
throughout	O
the	O
life	O
span	O
.	O

PEERS	O
(	O
?	O
)	O
(	O
Program	O
for	O
the	O
Education	O
and	O
Enrichment	O
of	O
Relational	O
Skills	O
)	O
is	O
a	O
parent-assisted	O
social	O
skills	O
training	O
for	O
teens	O
with	O
ASD	O
.	O

Although	O
PEERS	O
(	O
?	O
)	O
has	O
an	O
established	O
evidence	O
base	O
in	O
improving	O
the	O
social	O
skills	O
of	O
adolescents	O
and	O
young	O
adults	O
with	O
ASD	O
in	O
North	O
America	O
,	O
the	O
efficacy	O
of	O
this	O
treatment	O
has	O
yet	O
to	O
be	O
established	O
in	O
cross-cultural	O
validation	O
trials	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
feasibility	O
and	O
treatment	O
efficacy	O
of	O
a	O
Korean	O
version	O
of	O
PEERS	O
(	O
?	O
)	O
for	O
enhancing	O
social	O
skills	O
through	O
a	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
.The	O
English	O
version	O
of	O
the	O
PEERS	O
(	O
?	O
)	O
Treatment	O
Manual	O
(	O
Laugeson	O
&	O
Frankel	O
,	O
2010	O
)	O
was	O
translated	O
into	O
Korean	O
and	O
reviewed	O
by	O
21	O
child	O
mental	O
health	O
professionals	O
.	O

Items	O
identified	O
as	O
culturally	O
sensitive	O
were	O
surveyed	O
by	O
447	O
middle	O
school	O
students	O
,	O
and	O
material	O
was	O
modified	O
accordingly	O
.	O

Participants	O
included	O
47	O
teens	O
between	O
12	O
and	O
18	O
years	O
of	O
age	O
with	O
a	O
diagnosis	O
of	O
ASD	O
and	O
a	O
verbal	O
intelligence	O
quotient	O
(	O
IQ	O
)	O
?	O
65	O
.	O

Eligible	O
teens	O
were	O
randomly	O
assigned	O
to	O
a	O
treatment	O
group	O
(	O
TG	O
)	O
or	O
delayed	O
treatment	O
control	O
group	O
(	O
CG	O
)	O
.	O

Primary	O
outcome	O
measures	O
included	O
questionnaires	O
and	O
direct	O
observations	O
quantifying	O
social	O
ability	O
and	O
problems	O
directly	O
related	O
to	O
ASD	O
.	O

Secondary	O
outcome	O
measures	O
included	O
scales	O
for	O
depressive	O
symptoms	O
,	O
anxiety	O
,	O
and	O
other	O
behavioral	O
problems	O
.	O

Rating	O
scales	O
for	O
parental	O
depressive	O
symptoms	O
and	O
anxiety	O
were	O
examined	O
to	O
detect	O
changes	O
in	O
parental	O
psychosocial	O
functioning	O
throughout	O
the	O
PEERS	O
(	O
?	O
)	O
treatment	O
.	O

Independent	O
samples	O
t-tests	O
revealed	O
no	O
significant	O
differences	O
at	O
baseline	O
across	O
the	O
TG	O
and	O
CG	O
conditions	O
with	O
regard	O
to	O
age	O
(	O
14.04	O
?	O
1.64	O
and	O
13.54	O
?	O
1.50	O
years	O
)	O
,	O
IQ	O
(	O
99.39	O
?	O
18.09	O
&	O
100.67	O
?	O
16.97	O
)	O
,	O
parental	O
education	O
,	O
socioeconomic	O
status	O
,	O
or	O
ASD	O
symptoms	O
(	O
p	O
<	O
0.05	O
)	O
,	O
respectively	O
.	O

Results	O
for	O
treatment	O
outcome	O
suggest	O
that	O
the	O
TG	O
showed	O
significant	O
improvement	O
in	O
communication	O
and	O
social	O
interaction	O
domain	O
scores	O
on	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
,	O
interpersonal	O
relationship	O
and	O
play/leisure	O
time	O
on	O
the	O
subdomain	O
scores	O
of	O
the	O
Korean	O
version	O
of	O
the	O
Vineland	O
Adaptive	O
Behavior	O
Scale	O
(	O
p	O
's	O
<	O
0.01	O
)	O
,	O
social	O
skills	O
knowledge	O
total	O
scores	O
on	O
the	O
Test	O
of	O
Adolescent	O
Social	O
Skills	O
Knowledge-Revised	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
decreased	O
depressive	O
symptoms	O
on	O
the	O
Child	O
Depression	O
Inventory	O
following	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Analyses	O
of	O
parental	O
outcome	O
reveal	O
a	O
significant	O
decrease	O
in	O
maternal	O
state	O
anxiety	O
in	O
the	O
TG	O
after	O
controlling	O
for	O
potential	O
confounding	O
variables	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Despite	O
cultural	O
and	O
linguistic	O
differences	O
,	O
the	O
PEERS	O
(	O
?	O
)	O
social	O
skills	O
intervention	O
appears	O
to	O
be	O
efficacious	O
for	O
teens	O
with	O
ASD	O
in	O
Korea	O
with	O
modest	O
cultural	O
adjustment	O
.	O

In	O
an	O
RCT	O
,	O
participants	O
receiving	O
the	O
PEERS	O
(	O
?	O
)	O
treatment	O
showed	O
significant	O
improvement	O
in	O
social	O
skills	O
knowledge	O
,	O
interpersonal	O
skills	O
,	O
and	O
play/leisure	O
skills	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
depressive	O
symptoms	O
and	O
ASD	O
symptoms	O
.	O

This	O
study	O
represents	O
one	O
of	O
only	O
a	O
few	O
cross-cultural	O
validation	O
trials	O
of	O
an	O
established	O
evidence-based	O
treatment	O
for	O
adolescents	O
with	O
ASD	O
.	O

Rotigotine	Pharmacological
transdermal	Pharmacological
patch	Pharmacological
enables	O
rapid	O
titration	O
to	O
effective	O
doses	O
in	O
advanced-stage	O
idiopathic	O
Parkinson	O
disease	O
:	O
subanalysis	O
of	O
a	O
parallel	O
group	O
,	O
open-label	O
,	O
dose-escalation	O
study	O
.	O

OBJECTIVE	O
Rotigotine	Pharmacological
(	Pharmacological
Neupro	Pharmacological
)	Pharmacological
is	O
formulated	O
as	O
a	O
transdermal	O
delivery	O
system	O
designed	O
to	O
provide	O
a	O
selective	O
,	O
non-ergot	O
D3/D2/D1	O
agonist	O
to	O
the	O
systemic	O
blood	O
flow	O
over	O
a	O
24-hour	O
period	O
.	O

In	O
clinical	O
trials	O
,	O
patches	Pharmacological
were	O
applied	O
once	O
daily	O
and	O
uptitrated	O
to	O
the	O
individual	O
effective	O
dose	O
in	O
increments	O
of	O
2	O
mg/24	O
h	O
every	O
week	O
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
the	O
safety	O
of	O
a	O
more	O
rapid	O
titration	O
of	O
rotigotine	Pharmacological
by	O
assessing	O
the	O
tolerability	O
of	O
escalating	O
transdermal	O
doses	O
of	O
rotigotine	Pharmacological
given	O
in	O
2	O
different	O
titration	O
schemes	O
.	O

METHODS	O
We	O
analyzed	O
the	O
safety	O
of	O
rotigotine	Pharmacological
in	O
2	O
groups	O
of	O
patients	O
with	O
advanced	O
stage	O
Parkinson	O
Disease	O
.	O

The	O
starting	O
dose	O
of	O
4	O
mg/24	O
h	O
was	O
increased	O
every	O
week	O
by	O
2	O
mg/24	O
h	O
in	O
the	O
slow-titration	O
group	O
and	O
4	O
mg/24	O
h	O
in	O
the	O
fast-titration	O
group	O
.	O

The	O
primary	O
focus	O
of	O
this	O
subanalysis	O
was	O
the	O
separate	O
tolerability	O
of	O
rotigotine	Pharmacological
in	O
each	O
randomized	O
treatment	O
arm	O
,	O
during	O
the	O
dose-escalation	O
period	O
.	O

However	O
,	O
the	O
2	O
titration	O
schemes	O
were	O
also	O
compared	O
with	O
each	O
other	O
.	O

RESULTS	O
The	O
dose	O
of	O
first	O
reported	O
nausea	O
and/or	O
vomiting	O
was	O
8	O
mg/24	O
h	O
for	O
the	O
fast-titration	O
group	O
and	O
4	O
mg/	O
24	O
h	O
for	O
the	O
slow-titration	O
group	O
.	O

There	O
were	O
no	O
remarkable	O
differences	O
concerning	O
the	O
side-effect	O
profile	O
between	O
the	O
2	O
different	O
titration	O
schemes	O
.	O

CONCLUSIONS	O
The	O
fast-titration	O
regimen	O
had	O
a	O
similar	O
adverse	O
event	O
profile	O
to	O
slower	O
titration	O
,	O
and	O
allowed	O
rotigotine	Pharmacological
to	O
be	O
introduced	O
quickly	O
.	O

This	O
subanalysis	O
suggests	O
that	O
rotigotine	Pharmacological
may	O
be	O
uptitrated	O
more	O
rapidly	O
.	O

Evaluation	O
of	O
masking	O
study	O
participants	O
to	O
intravitreal	O
injections	O
in	O
a	O
randomized	O
clinical	O
trial	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
success	O
of	O
masking	O
study	O
participants	O
to	O
treatment	O
allocation	O
using	O
sham	Pharmacological
intravitreal	Pharmacological
injections	Pharmacological
.	O

METHODS	O
Eyes	O
were	O
randomized	O
to	O
receive	O
sham	Pharmacological
injections	Pharmacological
plus	Pharmacological
prompt	Physical
laser	Physical
,	O
intravitreal	Pharmacological
ranibizumab	Pharmacological
injections	Pharmacological
plus	Pharmacological
prompt	Physical
laser	Physical
,	O
intravitreal	Pharmacological
ranibizumab	Pharmacological
injections	Pharmacological
plus	Pharmacological
deferred	Physical
laser	Physical
,	O
or	O
intravitreal	Pharmacological
triamcinolone	Pharmacological
acetonide	Pharmacological
injections	Pharmacological
plus	Pharmacological
prompt	Physical
laser	Physical
up	O
to	O
every	O
16	O
weeks	O
with	O
sham	O
injections	O
intermittently	O
.	O

All	O
eyes	O
could	O
receive	O
treatment	O
or	O
sham	O
as	O
often	O
as	O
every	O
4	O
weeks	O
.	O

Participants	O
with	O
2	O
study	O
eyes	O
had	O
1	O
eye	O
randomized	O
to	O
sham	Physical
plus	Physical
prompt	Physical
laser	Physical
and	O
1	O
eye	O
randomized	O
to	O
a	O
real	Pharmacological
injection	Pharmacological
group	O
.	O

Sham	O
injections	O
were	O
performed	O
by	O
pressing	O
the	O
syringe	O
hub	O
against	O
the	O
conjunctiva	O
to	O
mimic	O
a	O
real	O
injection	O
.	O

Laser	Physical
treatment	Physical
was	O
not	O
masked	O
.	O

At	O
the	O
1-year	O
visit	O
,	O
participants	O
were	O
asked	O
if	O
they	O
believed	O
that	O
the	O
injections	O
received	O
during	O
the	O
study	O
were	O
real	O
,	O
sham	Physical
,	O
or	O
sometimes	Physical
real	Physical
and	Physical
sometimes	Physical
sham	Physical
.	O

RESULTS	O
Among	O
423	O
participants	O
with	O
1	O
study	O
eye	O
,	O
the	O
correct	O
assignment	O
was	O
stated	O
by	O
9.9	O
%	O
of	O
the	O
sham	Physical
plus	Physical
prompt	Physical
laser	Physical
group	O
,	O
88.0	O
%	O
of	O
the	O
ranibizumab	Physical
plus	Physical
prompt	Physical
laser	Physical
group	O
,	O
89.6	O
%	O
of	O
the	O
unmasked	O
ranibizumab	Physical
plus	Physical
deferred	Physical
laser	Physical
group	O
,	O
and	O
44.0	O
%	O
of	O
the	O
triamcinolone	Pharmacological
plus	Pharmacological
prompt	Pharmacological
laser	Pharmacological
group	O
.	O

Among	O
112	O
participants	O
with	O
2	O
study	O
eyes	O
,	O
the	O
correct	O
assignment	O
was	O
stated	O
for	O
24.1	O
%	O
of	O
the	O
sham	O
plus	O
prompt	O
laser	O
eyes	O
.	O

CONCLUSIONS	O
Successful	O
masking	O
of	O
an	O
intravitreal	O
injection	O
can	O
be	O
accomplished	O
when	O
a	O
sham	Pharmacological
injection	Pharmacological
procedure	O
carefully	O
mimics	O
a	O
real	Pharmacological
injection	Pharmacological
procedure	O
.	O

Masking	O
seems	O
less	O
successful	O
when	O
one	O
eye	O
is	O
receiving	O
a	O
real	O
injection	O
and	O
the	O
other	O
eye	O
is	O
receiving	O
a	O
sham	O
injection	O
or	O
when	O
an	O
individual	O
eye	O
receives	O
both	O
real	O
and	O
sham	O
injections	O
.	O

Effect	O
of	O
exercise	Physical
,	Physical
training	Physical
,	O
and	O
glycogen	Physical
availability	Physical
on	O
IL-6	O
receptor	O
expression	O
in	O
human	O
skeletal	O
muscle	O
.	O

The	O
cytokine	O
interleukin-6	O
(	O
IL-6	O
)	O
exerts	O
it	O
actions	O
via	O
the	O
IL-6	O
receptor	O
(	O
IL-6R	O
)	O
in	O
conjunction	O
with	O
the	O
ubiquitously	O
expressed	O
gp130	O
receptor	O
.	O

IL-6	O
is	O
tightly	O
regulated	O
in	O
response	O
to	O
exercise	Physical
,	O
being	O
affected	O
by	O
factors	O
such	O
as	O
exercise	O
intensity	O
and	O
duration	O
,	O
as	O
well	O
as	O
energy	O
availability	O
.	O

Although	O
the	O
IL-6	O
response	O
to	O
exercise	O
has	O
been	O
extensively	O
studied	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
the	O
IL-6R	O
response	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
exercise	Physical
,	Physical
training	Physical
,	O
and	O
glycogen	Physical
availability	Physical
,	O
factors	O
known	O
to	O
affect	O
IL-6	O
,	O
on	O
the	O
regulation	O
of	O
gene	O
expression	O
of	O
the	O
IL-6R	O
in	O
human	O
skeletal	O
muscle	O
.	O

Human	O
subjects	O
performed	O
either	O
10	Physical
wk	Physical
of	Physical
training	Physical
with	Physical
an	Physical
acute	Physical
exercise	Physical
bout	Physical
before	Physical
and	Physical
after	Physical
the	Physical
training	Physical
period	Physical
,	O
or	O
a	O
low-glycogen	Pharmacological
vs.	O
normal-glycogen	Physical
acute	Physical
exercise	Physical
trial	Physical
.	O

The	O
IL-6R	O
mRNA	O
response	O
was	O
evaluated	O
in	O
both	O
trials	O
.	O

In	O
response	O
to	O
acute	O
exercise	O
,	O
an	O
increase	O
in	O
IL-6R	O
mRNA	O
levels	O
was	O
observed	O
.	O

Neither	O
training	O
nor	O
intramuscular	O
glycogen	O
levels	O
had	O
an	O
effect	O
on	O
the	O
IL-6R	O
mRNA	O
response	O
to	O
exercise	O
.	O

However	O
,	O
after	O
10	O
wk	O
of	O
training	O
,	O
the	O
skeletal	O
muscle	O
expressed	O
a	O
higher	O
mRNA	O
level	O
of	O
IL-6R	O
compared	O
with	O
before	O
training	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
the	O
IL-6R	O
gene	O
expression	O
levels	O
in	O
skeletal	O
muscle	O
are	O
increased	O
in	O
response	O
to	O
acute	O
exercise	O
,	O
a	O
response	O
that	O
is	O
very	O
well	O
conserved	O
,	O
being	O
affected	O
by	O
neither	O
training	Physical
status	O
nor	O
intramuscular	O
glycogen	O
levels	O
,	O
as	O
opposed	O
to	O
IL-6	O
.	O

However	O
,	O
after	O
the	O
training	O
period	O
,	O
IL-6R	O
mRNA	O
production	O
was	O
increased	O
in	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
sensitization	O
of	O
skeletal	O
muscle	O
to	O
IL-6	O
at	O
rest	O
.	O

A	O
comparison	O
of	O
human	O
papillomavirus	O
testing	O
of	O
clinician-collected	Physical
and	Physical
self-collected	Physical
samples	Physical
during	O
follow-up	O
after	O
screen-and-treat	O
.	O

Screen-and-treat	O
cervical	O
cancer	O
prevention	O
programs	O
based	O
on	O
high-risk	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
testing	O
and	O
cryotherapy	O
have	O
been	O
shown	O
to	O
be	O
effective	O
in	O
resource-limited	O
settings	O
.	O

However	O
,	O
because	O
cryotherapy	O
is	O
not	O
100	O
%	O
effective	O
,	O
follow-up	O
is	O
needed	O
after	O
treatment	O
to	O
detect	O
post-treatment	O
failures	O
.	O

We	O
compared	O
the	O
test	O
performances	O
of	O
high-risk	O
HPV	O
testing	O
(	O
Hybrid	O
Capture	O
2	O
)	O
using	O
self-collected	Physical
and	Physical
clinician-collected	Physical
samples	Physical
as	O
well	O
as	O
cervical	Physical
cytology	Physical
for	O
identifying	O
cervical	O
intraepithelial	O
neoplasia	O
grades	O
2	O
or	O
3	O
or	O
invasive	O
cervical	O
cancer	O
(	O
CIN2+	O
)	O
among	O
women	O
who	O
did	O
(	O
n=812	O
)	O
and	O
did	O
not	O
(	O
n=1858	O
)	O
undergo	O
cryotherapy	O
in	O
a	O
South	O
African	O
screen-and-treat	O
trial	O
.	O

At	O
6	O
months	O
after	O
enrolment	O
(	O
and	O
after	O
cryotherapy	Physical
,	O
if	O
performed	O
)	O
,	O
women	O
were	O
tested	O
using	O
all	O
three	O
screening	O
methods	O
and	O
then	O
underwent	O
colposcopy/biopsy	Physical
.	O

A	O
predefined	O
subset	O
of	O
women	O
(	O
n=1,455	O
)	O
had	O
extended	O
follow-up	O
with	O
colposcopy/biopsy	Physical
at	O
12	O
months	O
.	O

A	O
total	O
of	O
33	O
and	O
91	O
cases	O
of	O
CIN2+	O
were	O
detected	O
among	O
treated	O
and	O
untreated	O
women	O
,	O
respectively	O
.	O

The	O
sensitivity	O
of	O
HPV	O
testing	O
using	O
clinician-collected	Physical
samples	Physical
and	O
cervical	O
cytology	O
did	O
not	O
differ	O
by	O
treatment	O
status	O
.	O

HPV	O
testing	O
of	O
clinician-collected	Physical
samples	Physical
detected	O
the	O
most	O
cases	O
of	O
CIN2+	O
among	O
both	O
treated	O
(	O
85	O
%	O
)	O
and	O
untreated	O
(	O
91	O
%	O
)	O
women	O
(	O
p=0.31	O
)	O
.	O

Cytology	O
(	O
at	O
a	O
cutoff	O
of	O
atypical	O
squamous	O
cells	O
of	O
undetermined	O
significance	O
or	O
greater	O
)	O
detected	O
76	O
%	O
of	O
cases	O
among	O
both	O
treated	O
and	O
untreated	O
women	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
HPV	O
testing	O
using	O
self-collected	Physical
samples	Physical
was	O
significantly	O
lower	O
among	O
treated	O
versus	O
untreated	O
women	O
(	O
55	O
%	O
vs.	O
78	O
%	O
,	O
p=0.01	O
)	O
.	O

HPV	O
testing	O
using	O
self-collected	Physical
vaginal	Physical
specimens	Physical
may	O
be	O
useful	O
in	O
primary	O
screening	O
but	O
performs	O
poorly	O
for	O
detecting	O
post-treatment	O
failures	O
.	O

[	O
Neoton	Pharmacological
and	O
thrombolytic	Pharmacological
therapy	Pharmacological
of	O
myocardial	O
infarction	O
]	O
.	O

AIM	O
To	O
evaluate	O
neoton	Pharmacological
therapy	Pharmacological
effects	O
in	O
acute	O
myocardial	O
infarction	O
(	O
MI	O
)	O
on	O
systolic	O
function	O
of	O
the	O
left	O
ventricle	O
,	O
arrhythmia	O
and	O
clinical	O
symptoms	O
in	O
patients	O
on	O
thrombolytic	Pharmacological
therapy	Pharmacological
(	Pharmacological
TLT	Pharmacological
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
106	O
males	O
with	O
Q-MI	O
entered	O
the	O
study	O
.	O

47	O
received	O
treatment	Control
without	Control
TLT	Control
and	Control
neoton	Control
,	O
30	O
patients	O
received	O
TLT	Pharmacological
with	Pharmacological
streptokinase	Pharmacological
preparations	Pharmacological
,	O
29	O
patients	O
were	O
given	O
streptokinase	Pharmacological
preparations	Pharmacological
and	O
neoton	Pharmacological
.	O

Left	O
ventricular	O
systolic	O
function	O
was	O
measured	O
by	O
echocardiography	O
on	O
day	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
21	O
and	O
28	O
;	O
arrhythmia	O
was	O
analysed	O
at	O
Holter	O
monitoring	O
in	O
day	O
1	O
and	O
2	O
of	O
MI	O
.	O

RESULTS	O
TLT	O
failed	O
to	O
arrest	O
progression	O
of	O
left	O
ventricular	O
dilation	O
by	O
the	O
end	O
of	O
the	O
hospital	O
stay	O
.	O

Patients	O
given	O
neoton	Pharmacological
in	O
acute	O
period	O
of	O
MI	O
had	O
no	O
increase	O
in	O
the	O
end	O
systolic	O
and	O
diastolic	O
volumes	O
of	O
the	O
left	O
ventricle	O
in	O
the	O
course	O
of	O
the	O
first	O
months	O
after	O
MI	O
onset	O
.	O

Antiarrhythmic	O
action	O
of	O
neoton	Pharmacological
manifested	O
on	O
MI	O
day	O
2	O
.	O

CONCLUSION	O
Neoton	Pharmacological
given	O
to	O
MI	O
patients	O
receiving	O
TLT	O
prevents	O
progression	O
of	O
left	O
ventricular	O
systolic	O
dysfunction	O
and	O
establishment	O
of	O
predictors	O
of	O
unfavourable	O
outcome	O
.	O

Effect	O
of	O
rosuvastatin	O
monotherapy	O
or	O
in	O
combination	O
with	O
fenofibrate	O
or	O
?-3	O
fatty	O
acids	O
on	O
lipoprotein	O
subfraction	O
profile	O
in	O
patients	O
with	O
mixed	O
dyslipidaemia	O
and	O
metabolic	O
syndrome	O
.	O

BACKGROUND	O
Raised	O
triglycerides	O
(	O
TG	O
)	O
,	O
decreased	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
)	O
levels	O
and	O
a	O
predominance	O
of	O
small	O
dense	O
low	O
density	O
lipoproteins	O
(	O
sdLDL	O
)	O
are	O
characteristics	O
of	O
the	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effect	O
of	O
high-dose	O
rosuvastatin	O
monotherapy	O
with	O
moderate	O
dosing	O
combined	O
with	O
fenofibrate	O
or	O
?-3	O
fatty	O
acids	O
on	O
the	O
lipoprotein	O
subfraction	O
profile	O
in	O
patients	O
with	O
mixed	O
dyslipidaemia	O
and	O
MetS	O
.	O

METHODS	O
We	O
previously	O
randomised	O
patients	O
with	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
LDL-C	O
)	O
>	O
160	O
and	O
TG	O
>	O
200	O
mg/dl	O
to	O
rosuvastatin	O
monotherapy	O
40	O
mg/day	O
(	O
R	O
group	O
,	O
n	O
=	O
30	O
)	O
or	O
rosuvastatin	O
10	O
mg/day	O
combined	O
with	O
fenofibrate	O
200	O
mg/day	O
(	O
RF	O
group	O
,	O
n	O
=	O
30	O
)	O
or	O
?-3	O
fatty	O
acids	O
2	O
g/day	O
(	O
R?	O
group	O
,	O
n	O
=	O
30	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
only	O
patients	O
with	O
MetS	O
were	O
included	O
(	O
24	O
,	O
23	O
and	O
24	O
in	O
the	O
R	O
,	O
RF	O
and	O
R?	O
groups	O
respectively	O
)	O
.	O

At	O
baseline	O
and	O
after	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
lipoprotein	O
subfraction	O
profile	O
was	O
determined	O
by	O
polyacrylamide	O
3	O
%	O
gel	O
electrophoresis	O
.	O

RESULTS	O
The	O
mean	O
LDL	O
size	O
was	O
significantly	O
increased	O
in	O
all	O
groups	O
.	O

This	O
change	O
was	O
more	O
prominent	O
with	O
RF	O
than	O
with	O
other	O
treatments	O
in	O
parallel	O
with	O
its	O
greater	O
hypotriglyceridemic	O
capacity	O
(	O
p	O
<	O
0.05	O
compared	O
with	O
R	O
and	O
R?	O
)	O
.	O

A	O
decrease	O
in	O
insulin	O
resistance	O
by	O
RF	O
was	O
also	O
noted	O
.	O

Only	O
RF	O
significantly	O
raised	O
HDL-C	O
levels	O
(	O
by	O
7.7	O
%	O
,	O
p	O
<	O
0.05	O
)	O
by	O
increasing	O
the	O
cholesterol	O
of	O
small	O
HDL	O
particles	O
.	O

The	O
cholesterol	O
of	O
larger	O
HDL	O
subclasses	O
was	O
significantly	O
increased	O
by	O
R	O
and	O
R?	O
.	O

CONCLUSIONS	O
All	O
regimens	O
increased	O
mean	O
LDL	O
size	O
;	O
RF	O
was	O
the	O
most	O
effective	O
.	O

A	O
differential	O
effect	O
of	O
treatments	O
was	O
noted	O
on	O
the	O
HDL	O
subfraction	O
profile	O
.	O

Randomised	O
,	O
parallel-group	O
,	O
multicentre	O
,	O
multinational	O
phase	O
2	O
study	O
comparing	O
edoxaban	Pharmacological
,	O
an	O
oral	O
factor	O
Xa	O
inhibitor	O
,	O
with	O
warfarin	Pharmacological
for	O
stroke	O
prevention	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
of	O
four	O
fixed-dose	O
regimens	O
of	O
edoxaban	Pharmacological
with	Pharmacological
warfarin	Pharmacological
in	O
patients	O
with	O
non-valvular	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
.	O

In	O
this	O
12-week	O
,	O
parallel-group	O
,	O
multicentre	O
,	O
multinational	O
study	O
,	O
1,146	O
patients	O
with	O
AF	O
and	O
risk	O
of	O
stroke	O
were	O
randomised	O
to	O
edoxaban	Pharmacological
30	O
mg	O
qd	O
,	O
30	O
mg	O
bid	O
,	O
60	O
mg	O
qd	O
,	O
or	O
60	O
mg	O
bid	O
or	Pharmacological
warfarin	Pharmacological
dose-adjusted	O
to	O
a	O
target	O
international	O
normalised	O
ratio	O
of	O
2.0-3.0	O
.	O

The	O
study	O
was	O
double-blind	O
to	O
edoxaban	Pharmacological
dose	O
,	O
but	O
open-label	O
to	O
warfarin	Pharmacological
.	Pharmacological

Primary	O
outcomes	O
were	O
occurrence	O
of	O
major	O
and/or	O
clinically	O
relevant	O
non-major	O
bleeding	O
and	O
elevated	O
hepatic	O
enzymes	O
and/or	O
bilirubin	O
.	O

Mean	O
age	O
was	O
65	O
+/-	O
8.7	O
years	O
and	O
64.4	O
%	O
were	O
warfarin-na?ve	O
.	O

Whereas	O
major	O
plus	O
clinically	O
relevant	O
non-major	O
bleeding	O
occurred	O
in	O
3.2	O
%	O
of	O
patients	O
randomised	O
to	O
warfarin	O
,	O
the	O
incidence	O
of	O
bleeding	O
was	O
significantly	O
higher	O
with	O
the	O
edoxaban	O
60	O
mg	O
bid	O
(	O
10.6	O
%	O
;	O
p=0.002	O
)	O
and	O
30	O
mg	O
bid	O
regimens	O
(	O
7.8	O
%	O
;	O
p=0.029	O
)	O
,	O
but	O
not	O
with	O
the	O
edoxaban	O
60	O
mg	O
qd	O
(	O
3.8	O
%	O
)	O
or	O
30	O
mg	O
qd	O
regimens	O
(	O
3.0	O
%	O
)	O
.	O

For	O
the	O
same	O
total	O
daily	O
dose	O
of	O
60	O
mg	O
,	O
both	O
bleeding	O
frequency	O
and	O
trough	O
edoxaban	O
concentrations	O
were	O
higher	O
in	O
the	O
30-mg	O
bid	O
group	O
than	O
in	O
the	O
60-mg	O
qd	O
group	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
hepatic	O
enzyme	O
elevations	O
or	O
bilirubin	O
values	O
among	O
the	O
groups	O
.	O

The	O
safety	O
profiles	O
of	O
edoxaban	O
30	O
and	O
60	O
mg	O
qd	O
in	O
patients	O
with	O
AF	O
were	O
similar	O
to	O
warfarin	O
.	O

In	O
contrast	O
,	O
the	O
edoxaban	O
bid	O
regimens	O
were	O
associated	O
with	O
more	O
bleeding	O
than	O
warfarin	O
.	O

These	O
results	O
suggest	O
that	O
in	O
this	O
three-month	O
study	O
,	O
edoxaban	O
30	O
or	O
60	O
mg	O
qd	O
are	O
safe	O
and	O
well-tolerated	O
.	O

Community-based	Educational
treatment	Educational
for	O
opioid	O
dependent	O
offenders	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
Primary	Educational
care	Educational
opioid	Educational
substitution	Educational
treatment	Educational
(	Educational
OST	Educational
)	Educational
has	O
not	O
been	O
compared	O
to	O
program-based	O
OST	Pharmacological
for	O
community-supervised	O
offenders	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
project	O
was	O
to	O
compare	O
primary	O
care	O
to	O
specialist	O
supervised	O
OST	O
for	O
opioid	O
dependent	O
offenders	O
in	O
terms	O
of	O
substance	O
use	O
and	O
HIV	O
risk	O
outcomes	O
.	O

METHODS	O
This	O
project	O
randomly	O
assigned	O
15	O
jail	O
diversion	O
participants	O
to	O
either	O
:	O
(	O
i	O
)	O
primary	Educational
care	Educational
buprenorphine	Other
OST	Educational
,	O
(	O
ii	O
)	O
specialist	Educational
facility	Educational
buprenorphine	Other
OST	Educational
,	O
or	O
(	O
iii	O
)	O
specialist	Educational
facility	Educational
methadone	Other
OST	Educational
.	O

Participation	O
lasted	O
13.5	O
months	O
(	O
12-month	O
active	O
treatment	O
plus	O
a	O
post-participation	O
visit	O
)	O
.	O

RESULTS	O
All	O
subjects	O
endorsed	O
0	O
days	O
of	O
opioid	O
use	O
in	O
the	O
previous	O
14	O
at	O
follow-up	O
.	O

Specialty	O
care	O
reduced	O
HIV	O
risk	O
(	O
Risk	O
Assessment	O
Battery	O
composite	O
score	O
)	O
over	O
6	O
months	O
(	O
-.24	O
?	O
.17	O
)	O
compared	O
to	O
primary	O
care	O
(	O
.02	O
?	O
.14	O
;	O
p	O
=	O
.032	O
)	O
.	O

CONCLUSION	O
Findings	O
support	O
primary	O
care	O
OST	O
feasibility	O
for	O
a	O
community-supervised	O
offender	O
sample	O
.	O

Specialist	O
care	O
may	O
facilitate	O
improvements	O
in	O
secondary	O
outcomes	O
,	O
such	O
as	O
HIV	O
risk	O
behaviors	O
.	O

SCIENTIFIC	O
SIGNIFICANCE	O
Further	O
research	O
is	O
needed	O
to	O
clarify	O
(	O
i	O
)	O
the	O
role	O
of	O
primary	O
care	O
in	O
addicted	O
offender	O
management	O
,	O
and	O
(	O
ii	O
)	O
the	O
matching	O
of	O
offenders	O
,	O
based	O
upon	O
history	O
and	O
co-morbidity	O
,	O
to	O
care	O
coordination	O
conditions	O
.	O

Short-term	O
metabolic	O
effects	O
of	O
prednisone	Pharmacological
administration	O
in	O
healthy	O
subjects	O
.	O

AIMS	O
Supraphysiologic	O
glucocorticoid	O
activity	O
is	O
well	O
established	O
to	O
cause	O
impaired	O
glucose	O
tolerance	O
and	O
insulin	O
resistance	O
,	O
yet	O
no	O
study	O
has	O
evaluated	O
dose-dependent	O
effects	O
of	O
low-dose	O
prednisone	Pharmacological
during	O
short-term	O
oral	O
administration	O
.	O

METHODS	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
quantify	O
the	O
effects	O
of	O
daily	O
10	Pharmacological
or	Pharmacological
25	Pharmacological
mg	Pharmacological
prednisone	Pharmacological
administration	O
for	O
one	O
week	O
on	O
insulin	O
sensitivity	O
by	O
employing	O
a	O
two-step	Pharmacological
hyperinsulinemic	Pharmacological
euglycemic	Pharmacological
glucose	Pharmacological
clamp	Pharmacological
(	O
Step	O
1	O
:	O
insulin	O
infusion	O
=	O
20	O
mU/m?/min	O
;	O
Step	O
2	O
:	O
insulin	O
infusion	O
=	O
80	O
mU/m?/min	O
)	O
in	O
healthy	O
,	O
lean	O
males	O
.	O

The	O
amount	O
of	O
glucose	O
infused	O
at	O
steady-state	O
to	O
maintain	O
stable	O
blood	O
glucose	O
[	O
90	O
mg/dl	O
(	O
4.95	O
mmol/l	O
)	O
]	O
was	O
used	O
to	O
calculate	O
several	O
indices	O
of	O
insulin	O
sensitivity	O
.	O

RESULTS	O
During	O
Step	O
1	O
of	O
the	O
clamp	O
,	O
whole	O
body	O
glucose	O
disposal	O
(	O
M	O
)	O
was	O
reduced	O
by	O
35	O
%	O
(	O
p	O
=	O
0.003	O
)	O
and	O
M/I	O
was	O
reduced	O
by	O
29	O
%	O
(	O
p	O
=	O
0.025	O
)	O
for	O
25	O
mg	O
prednisone	O
compared	O
to	O
placebo	O
.	O

No	O
appreciable	O
effect	O
of	O
10	O
mg	O
prednisone	O
was	O
observed	O
.	O

During	O
Step	O
2	O
,	O
M	O
was	O
reduced	O
by	O
33	O
%	O
(	O
p	O
=	O
0.001	O
)	O
and	O
15	O
%	O
(	O
p	O
=	O
0.006	O
)	O
for	O
25	O
and	O
10	O
mg	O
prednisone	O
compared	O
to	O
placebo	O
;	O
and	O
M/I	O
ratio	O
was	O
reduced	O
by	O
31	O
%	O
(	O
p	O
<	O
0.001	O
)	O
and	O
13	O
%	O
(	O
p	O
=	O
0.026	O
)	O
,	O
respectively	O
.	O

The	O
insulin	O
sensitivity	O
index	O
,	O
Si	O
,	O
calculated	O
as	O
the	O
quotient	O
of	O
augmentation	O
of	O
M/I	O
between	O
Step	O
1	O
and	O
2	O
,	O
was	O
reduced	O
by	O
35.3	O
%	O
(	O
p	O
<	O
0.01	O
)	O
and	O
23.5	O
%	O
(	O
p	O
<	O
0.05	O
)	O
for	O
25	O
and	O
10	O
mg	O
prednisone	O
,	O
respectively	O
.	O

CONCLUSION	O
Administration	O
of	O
relatively	O
low	O
pharmacological	O
doses	O
of	O
prednisone	O
for	O
one	O
week	O
impaired	O
insulin	O
sensitivity	O
in	O
a	O
dose-dependent	O
manner	O
in	O
healthy	O
males	O
.	O

These	O
observed	O
changes	O
in	O
insulin	O
sensitivity	O
are	O
likely	O
to	O
be	O
clinically	O
relevant	O
,	O
especially	O
in	O
individuals	O
predisposed	O
to	O
develop	O
glucose	O
intolerance	O
.	O

Human	O
achaete-scute	O
homologue	O
(	O
hASH1	O
)	O
mRNA	O
level	O
as	O
a	O
diagnostic	O
marker	O
to	O
distinguish	O
esthesioneuroblastoma	O
from	O
poorly	O
differentiated	O
tumors	O
arising	O
in	O
the	O
sinonasal	O
tract	O
.	O

Distinction	O
of	O
high-grade	O
esthesioneuroblastomas	O
from	O
other	O
poorly	O
differentiated	O
tumors	O
arising	O
in	O
the	O
nasal	O
cavity	O
is	O
an	O
important	O
diagnostic	O
challenge	O
because	O
it	O
determines	O
patient	O
management	O
and	O
prognosis	O
.	O

The	O
human	O
achaete-scute	O
homologue	O
(	O
hASH1	O
)	O
gene	O
is	O
critical	O
in	O
olfactory	O
neuronal	O
differentiation	O
and	O
is	O
expressed	O
in	O
immature	O
olfactory	O
cells	O
;	O
therefore	O
,	O
it	O
could	O
have	O
potential	O
use	O
as	O
a	O
diagnostic	O
marker	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
value	O
of	O
hASH1	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
in	O
differentiating	O
esthesioneuroblastoma	O
from	O
other	O
poorly	O
differentiated	O
tumors	O
.	O

A	O
real-time	Physical
polymerase	Physical
chain	Physical
reaction	Physical
assay	Physical
was	O
developed	O
,	O
permitting	O
the	O
comparative	O
determination	O
of	O
hASH1	O
mRNA	O
levels	O
in	O
triplicate	O
in	O
a	O
double-blind	O
pilot	O
study	O
including	O
24	O
frozen	O
cases	O
of	O
esthesioneuroblastoma	O
and	O
poorly	O
differentiated	O
tumors	O
.	O

All	O
4	O
positive	O
cases	O
were	O
esthesioneuroblastomas	O
,	O
and	O
all	O
19	O
poorly	O
differentiated	O
tumors	O
were	O
negative	O
.	O

In	O
addition	O
,	O
there	O
was	O
an	O
inverse	O
association	O
between	O
the	O
grade	O
of	O
esthesioneuroblastomas	O
and	O
hASH1	O
mRNA	O
levels	O
.	O

The	O
hASH1	O
mRNA	O
level	O
might	O
represent	O
a	O
useful	O
tool	O
for	O
distinguishing	O
esthesioneuroblastoma	O
from	O
poorly	O
differentiated	O
tumors	O
of	O
the	O
sinonasal	O
region	O
.	O

Pre-operative	Physical
short-term	Physical
pulmonary	Physical
rehabilitation	Physical
for	Physical
patients	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
undergoing	O
coronary	Surgical
artery	Surgical
bypass	Surgical
graft	Surgical
surgery	Surgical
.	O

The	O
role	O
of	O
pre-operative	Physical
short-term	Physical
pulmonary	Physical
rehabilitation	Physical
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
who	O
undergo	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
has	O
been	O
assessed	O
for	O
the	O
first	O
time	O
prospectively	O
.	O

Forty-five	O
patients	O
posted	O
for	O
coronary	Surgical
artery	Surgical
bypass	O
graft	O
surgery	O
were	O
randomised	O
to	O
receive	O
either	O
short-term	Physical
pulmonary	Physical
rehabilitation	Physical
(	O
group	O
I	O
)	O
or	O
no	Control
such	Control
programme	Control
(	O
group	O
II	O
)	O
.	O

Patients	O
of	O
both	O
the	O
groups	O
were	O
evenly	O
matched	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
body	O
surface	O
area	O
,	O
duration	O
and	O
severity	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
coronary	O
artery	O
disease	O
.	O

Normal	O
individuals	O
who	O
evenly	O
matched	O
with	O
the	O
study	O
group	O
were	O
assessed	O
for	O
normal	O
respiratory	O
function	O
parameters	O
.	O

Pre-operative	O
and	O
post-operative	O
peak	O
expiratory	O
flow	O
rate	O
,	O
inspiratory	O
capacity	O
,	O
post-operative	O
ventilation	O
time	O
,	O
post-operative	O
pulmonary	O
complication	O
and	O
hospital	O
stay	O
were	O
determined	O
in	O
both	O
the	O
groups	O
.	O

Peak	O
expiratory	O
flow	O
rate	O
(	O
220.0	O
+/-	O
12.9	O
and	O
324.3	O
+/-	O
84.3	O
in	O
group	O
I	O
,	O
218.0	O
+/-	O
16.4	O
and	O
260.5	O
+/-	O
35.2	O
in	O
group	O
II	O
)	O
and	O
inspiratory	O
capacity	O
(	O
844.0	O
+/-	O
147.4	O
and	O
1100.0	O
+/-	O
158.1	O
in	O
group	O
I	O
,	O
830.0	O
+/-	O
117.4	O
and	O
1090	O
+/-	O
137	O
in	O
group	O
II	O
)	O
were	O
significantly	O
lower	O
before	O
and	O
after	O
surgery	O
respectively	O
in	O
both	O
groups	O
compared	O
to	O
normal	O
values	O
.	O

Even	O
though	O
both	O
groups	O
showed	O
a	O
significant	O
rise	O
in	O
post-operative	O
peak	O
expiratory	O
flow	O
rate	O
and	O
inspiratory	O
capacity	O
after	O
surgery	O
,	O
the	O
post-operative	O
peak	O
expiratory	O
flow	O
rate	O
and	O
inspiratory	O
capacity	O
in	O
group	O
I	O
was	O
significantly	O
higher	O
than	O
in	O
group	O
II	O
.	O

In	O
group	O
I	O
,	O
the	O
post-operative	O
ventilation	O
time	O
(	O
24.5	O
+/-	O
6.00	O
hours	O
)	O
,	O
post-operative	O
complications	O
(	O
n	O
=	O
4	O
)	O
and	O
hospital	O
stay	O
(	O
12.4	O
+/-	O
3.6	O
days	O
)	O
were	O
significantly	O
lower	O
than	O
in	O
group	O
II	O
(	O
35.2	O
+/-	O
22.3	O
hours	O
,	O
n	O
=	O
11	O
,	O
18.8	O
+/-	O
6.6	O
days	O
respectively	O
)	O
.	O

These	O
data	O
suggest	O
that	O
short-term	O
pulmonary	O
rehabilitation	O
is	O
feasible	O
and	O
effective	O
in	O
improving	O
pulmonary	O
functions	O
before	O
and	O
after	O
surgery	O
and	O
in	O
reducing	O
surgical	O
morbidity	O
and	O
cost	O
of	O
medical	O
care	O
significantly	O
.	O

Comparing	O
microvascular	O
alterations	O
during	O
minimal	O
extracorporeal	Surgical
circulation	Surgical
and	O
conventional	O
cardiopulmonary	Surgical
bypass	Surgical
in	O
coronary	Surgical
artery	Surgical
bypass	Surgical
graft	Surgical
surgery	Surgical
:	O
a	O
prospective	O
,	O
randomized	O
study	O
.	O

OBJECTIVES	O
Minimal	Physical
extracorporeal	Physical
circulation	Physical
(	Physical
MECC	Physical
)	Physical
has	O
been	O
introduced	O
in	O
coronary	Surgical
artery	Surgical
bypass	Surgical
graft	Surgical
(	Surgical
CABG	Surgical
)	Surgical
surgery	Surgical
,	O
offering	O
clinical	O
benefits	O
owing	O
to	O
reduced	O
hemodilution	O
and	O
no	O
blood-air	O
interface	O
.	O

Yet	O
,	O
the	O
effects	O
of	O
MECC	Surgical
on	O
the	O
intraoperative	O
microvascular	O
perfusion	O
in	O
comparison	O
with	O
conventional	Physical
extracorporeal	Physical
circulation	Physical
(	Physical
CECC	Physical
)	Physical
have	O
not	O
been	O
studied	O
so	O
far	O
.	O

METHODS	O
The	O
current	O
study	O
aimed	O
to	O
analyze	O
alterations	O
in	O
microvascular	O
perfusion	O
at	O
4	O
predefined	O
time	O
points	O
(	O
T1-T4	O
)	O
during	O
on-pump	O
CABG	O
using	O
orthogonal	O
polarization	O
spectral	O
imaging	O
.	O

Forty	O
patients	O
were	O
randomized	O
for	O
being	O
operated	O
on	O
with	O
either	O
MECC	Surgical
or	O
CECC	Surgical
.	O

Changes	O
in	O
functional	O
capillary	O
density	O
(	O
FCD	O
)	O
,	O
blood	O
flow	O
velocity	O
,	O
and	O
vessel	O
diameter	O
were	O
analyzed	O
by	O
a	O
blinded	O
investigator	O
.	O

RESULTS	O
After	O
start	O
of	O
extracorporeal	O
circulation	O
(	O
ECC	O
)	O
and	O
aortic	O
crossclamping	O
(	O
T2	O
)	O
,	O
both	O
groups	O
showed	O
a	O
significant	O
drop	O
of	O
FCD	O
,	O
with	O
a	O
significantly	O
higher	O
FCD	O
in	O
the	O
MECC	O
group	O
(	O
206.8	O
?	O
33.6	O
cm/cm?	O
in	O
CECC	O
group	O
versus	O
217.8	O
?	O
35.3	O
cm/cm?	O
in	O
MECC	O
group	O
;	O
P	O
=	O
.034	O
)	O
.	O

In	O
the	O
late	O
phase	O
of	O
the	O
ECC	O
(	O
T3	O
)	O
,	O
FCD	O
in	O
the	O
MECC	O
group	O
was	O
already	O
recovered	O
,	O
whereas	O
FCD	O
in	O
the	O
CECC	O
group	O
was	O
still	O
significantly	O
depressed	O
(	O
223.1	O
?	O
35.6	O
cm/cm?	O
in	O
MECC	O
group	O
;	O
P	O
=	O
.100	O
vs	O
T1	O
;	O
211.1	O
?	O
36.9	O
cm/cm?	O
in	O
CECC	O
group	O
;	O
P	O
=	O
.017	O
vs	O
T1	O
)	O
.	O

After	O
termination	O
of	O
ECC	O
(	O
T4	O
)	O
,	O
FCD	O
recovered	O
in	O
both	O
groups	O
to	O
baseline	O
.	O

Blood	O
flow	O
velocity	O
tended	O
to	O
be	O
higher	O
in	O
the	O
MECC	O
group	O
,	O
with	O
a	O
significant	O
intergroup	O
difference	O
after	O
aortic	O
crossclamping	O
(	O
T2	O
)	O
.	O

CONCLUSIONS	O
Orthogonal	O
polarization	O
spectral	O
imaging	O
data	O
reveal	O
an	O
impairment	O
of	O
microvascular	O
perfusion	O
during	O
on-pump	O
CABG	O
.	O

Changes	O
in	O
FCD	O
indicate	O
a	O
faster	O
recovery	O
of	O
the	O
microvascular	O
perfusion	O
in	O
MECC	O
during	O
the	O
reperfusion	O
period	O
.	O

Beneficial	O
recovery	O
of	O
microvascular	O
organ	O
perfusion	O
could	O
partly	O
explain	O
the	O
perioperative	O
advantages	O
reported	O
for	O
MECC	O
.	O

Efficacy	O
and	O
safety	O
of	O
timolol/pilocarpine	Pharmacological
combination	O
drops	O
in	O
glaucoma	O
patients	O
.	O

The	O
aim	O
of	O
this	O
randomized	O
,	O
double-blind	O
study	O
with	O
two	O
parallel	O
groups	O
was	O
to	O
examine	O
the	O
safety	O
,	O
efficacy	O
and	O
tolerability	O
of	O
two	O
combination	O
eye	O
drops	O
containing	O
0.5	O
%	O
timolol	Pharmacological
and	O
2	O
%	O
pilocarpine	Pharmacological
(	O
Fotil	O
,	O
Leiras	O
,	O
Finland	O
,	O
and	O
Timpilo	O
,	O
MSD	O
,	O
USA	O
)	O
in	O
patients	O
with	O
glaucoma	O
or	O
ocular	O
hypertension	O
.	O

Efficacy	O
was	O
determined	O
based	O
on	O
daytime	O
intraocular	O
pressure	O
curve	O
and	O
safety	O
by	O
examining	O
visual	O
fields	O
,	O
visual	O
acuity	O
,	O
optic	O
discs	O
,	O
by	O
determining	O
blood	O
pressure	O
and	O
pulse	O
rate	O
,	O
and	O
by	O
performing	O
Schirmer	O
and	O
fluorescein	O
tests	O
.	O

A	O
total	O
of	O
89	O
patients	O
were	O
enrolled	O
,	O
and	O
71	O
completed	O
the	O
10-week	O
treatment	O
period	O
.	O

This	O
study	O
showed	O
that	O
the	O
two	O
combinations	O
of	O
0.5	O
%	O
timolol	Pharmacological
maleate	Pharmacological
and	O
2	O
%	O
pilocarpine	Pharmacological
HCl	Pharmacological
compared	O
in	O
this	O
study	O
were	O
equally	O
effective	O
in	O
reducing	O
intraocular	O
pressure	O
.	O

The	O
decrease	O
in	O
mean	O
daily	O
intraocular	O
pressure	O
from	O
0	O
to	O
10	O
weeks	O
was	O
7.48	O
mmHg	O
for	O
Fotil	O
,	O
and	O
6.31	O
for	O
Timpilo	O
.	O

The	O
mean	O
decrease	O
in	O
mean	O
daily	O
intraocular	O
pressure	O
was	O
29.3	O
%	O
for	O
Fotil	O
,	O
and	O
26.0	O
%	O
for	O
Timpilo	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
.	O

Adverse	O
event	O
were	O
reported	O
by	O
70	O
out	O
of	O
89	O
patients	O
by	O
the	O
end	O
of	O
2	O
weeks	O
,	O
but	O
were	O
severe	O
enough	O
only	O
in	O
11	O
for	O
the	O
treatment	O
to	O
be	O
discontinued	O
.	O

In	O
all	O
others	O
,	O
adverse	O
events	O
were	O
of	O
transient	O
nature	O
and	O
considered	O
mild	O
.	O

In	O
general	O
,	O
adverse	O
events	O
were	O
similar	O
in	O
both	O
study	O
groups	O
.	O

However	O
,	O
burning	O
was	O
more	O
common	O
in	O
patients	O
on	O
Fotil	O
,	O
and	O
blurring	O
of	O
vision	O
and	O
light	O
sensitivity	O
were	O
more	O
common	O
in	O
patients	O
on	O
Timpilo	O
.	O

In	O
patients	O
with	O
no	O
contraindication	O
to	O
beta-blockers	O
,	O
these	O
drugs	O
appeared	O
to	O
be	O
safe	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
placebo-controlled	Control
trial	O
of	O
D-cycloserine	Pharmacological
added	O
to	O
conventional	O
neuroleptics	O
in	O
patients	O
with	O
schizophrenia	O
.	O

BACKGROUND	O
In	O
a	O
preliminary	O
dose-finding	O
study	O
,	O
D-cycloserine	Pharmacological
,	O
a	O
partial	O
agonist	O
at	O
the	O
glycine	O
modulatory	O
site	O
of	O
the	O
glutamatergic	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
receptor	O
,	O
improved	O
negative	O
symptoms	O
and	O
cognitive	O
function	O
when	O
added	O
to	O
conventional	O
neuroleptics	O
at	O
a	O
dose	O
of	O
50	O
mg/d	O
.	O

METHODS	O
Forty-seven	O
patients	O
with	O
schizophrenia	O
meeting	O
criteria	O
for	O
deficit	O
syndrome	O
were	O
randomized	O
to	O
D-cycloserine	Pharmacological
,	O
50	O
mg/d	O
(	O
n=23	O
)	O
or	O
placebo	Control
(	O
n=24	O
)	O
added	O
to	O
their	O
conventional	O
neuroleptic	O
for	O
an	O
8-week	O
,	O
double-blind	O
trial	O
.	O

Clinical	O
assessments	O
were	O
performed	O
at	O
baseline	O
and	O
at	O
weeks	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
8	O
.	O

Serum	O
concentrations	O
of	O
D-cycloserine	Pharmacological
,	O
relevant	O
amino	O
acids	O
,	O
and	O
homovanillic	O
acid	O
were	O
assayed	O
at	O
baseline	O
and	O
at	O
weeks	O
4	O
and	O
8	O
.	O

A	O
cognitive	O
battery	O
was	O
performed	O
at	O
baseline	O
and	O
at	O
week	O
8	O
.	O

RESULTS	O
Thirty-nine	O
patients	O
completed	O
the	O
8-week	O
trial	O
.	O

Seven	O
dropouts	O
occurred	O
in	O
the	O
D-cycloserine	Pharmacological
group	O
and	O
1	O
in	O
the	O
placebo	Control
group	O
.	O

The	O
mean	O
reduction	O
in	O
negative	O
symptoms	O
with	O
D-cycloserine	Pharmacological
(	O
23	O
%	O
)	O
was	O
significantly	O
greater	O
than	O
with	O
placebo	Control
(	O
7	O
%	O
)	O
as	O
calculated	O
by	O
slopes	O
representing	O
Scale	O
for	O
the	O
Assessment	O
of	O
Negative	O
Symptoms	O
(	O
SANS	O
)	O
total	O
scores	O
.	O

Improvement	O
of	O
negative	O
symptoms	O
was	O
predicted	O
by	O
low	O
neuroleptic	O
dose	O
and	O
low	O
baseline	O
SANS	O
total	O
score	O
.	O

No	O
differences	O
were	O
found	O
in	O
performance	O
on	O
any	O
cognitive	O
test	O
between	O
groups	O
or	O
in	O
changes	O
in	O
any	O
other	O
clinical	O
measure	O
.	O

Clinical	O
response	O
did	O
not	O
correlate	O
significantly	O
with	O
serum	O
amino	O
acid	O
concentrations	O
at	O
baseline	O
or	O
with	O
concentrations	O
of	O
D-cycloserine	Pharmacological
at	O
weeks	O
4	O
and	O
8	O
.	O

CONCLUSION	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
agents	O
acting	O
at	O
the	O
glycine	O
modulatory	O
site	O
of	O
the	O
NMDA	O
receptor	O
improve	O
primary	O
negative	O
symptoms	O
.	O

[	O
Evaluation	O
of	O
Stepping	O
Stones	O
Triple	O
P	O
:	O
Interims	O
analysis	O
of	O
the	O
Stepping-Stones-SPC-Multicentric	O
Study	O
]	O
.	O

Stepping	Educational
Stones	Educational
Triple	Educational
P	Educational
is	O
a	O
behavioural	O
parenting	O
training	O
for	O
families	O
with	O
a	O
handicapped	O
child	O
,	O
which	O
has	O
already	O
been	O
successfully	O
evaluated	O
in	O
its	O
country	O
of	O
origin	O
,	O
Australia	O
.	O

Within	O
a	O
multicentric	O
study	O
of	O
several	O
Social	O
Pediatric	O
Centers	O
(	O
SPCs	O
)	O
and	O
further	O
clinics/institutions	O
in	O
Germany	O
,	O
it	O
has	O
been	O
established	O
as	O
a	O
group	Educational
parenting	Educational
training	Educational
(	O
3-7	O
families	O
per	O
training	O
)	O
.	O

Statistical	O
analysis	O
proved	O
significant	O
effects	O
concerning	O
dysfunctional	O
parenting	O
,	O
parental	O
stress	O
and	O
child	O
behaviour	O
problems	O
as	O
well	O
as	O
little	O
side	O
effects	O
and	O
a	O
positive	O
acceptance	O
of	O
stepping	O
stones	O
by	O
the	O
families	O
.	O

Methotrexate	Pharmacological
in	O
the	O
treatment	O
of	O
steroid-dependent	O
asthma	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	Control
,	O
crossover	O
study	O
was	O
designed	O
to	O
compare	O
steroid	O
requirements	O
between	O
placebo	Control
and	O
methotrexate	Pharmacological
(	O
MTX	O
)	O
treatment	O
in	O
subjects	O
with	O
corticosteroid-requiring	O
asthma	O
.	O

Subjects	O
began	O
with	O
a	O
steroid	O
taper	O
and	O
then	O
were	O
randomized	O
to	O
a	O
3-month	O
trial	O
of	O
drug	O
or	O
placebo	Control
therapy	Control
.	Control

Subjects	O
received	O
15	O
mg	O
of	O
MTX	Pharmacological
a	O
week	O
or	O
identical	O
placebo	Control
.	Control

A	O
1-month	O
washout	O
period	O
was	O
completed	O
before	O
the	O
crossover	O
trial	O
.	O

Symptom	O
scores	O
,	O
peak	O
flow	O
rates	O
,	O
spirometry	O
,	O
and	O
beta-agonist	O
frequency	O
were	O
closely	O
monitored	O
.	O

Ten	O
subjects	O
completed	O
the	O
study	O
.	O

The	O
average	O
dose	O
of	O
prednisone	O
during	O
the	O
placebo-treatment	Control
period	O
was	O
11.97	O
mg/day	O
compared	O
to	O
8.37	O
mg/day	O
while	O
subjects	O
were	O
taking	O
MTX	Pharmacological
.	O

This	O
was	O
a	O
30	O
%	O
reduction	O
in	O
daily	O
steroid	O
requirement	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Symptom	O
scores	O
and	O
spirometry	O
did	O
not	O
differ	O
between	O
the	O
crossover	O
trials	O
,	O
and	O
overall	O
clinical	O
status	O
was	O
not	O
altered	O
.	O

Complications	O
from	O
MTX	Pharmacological
were	O
mild	O
and	O
included	O
anorexia	O
,	O
alopecia	O
,	O
and	O
stomatitis	O
.	O

All	O
complications	O
resolved	O
with	O
dose	O
reduction	O
or	O
when	O
MTX	Pharmacological
was	O
stopped	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

No	O
subjects	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
MTX	Pharmacological
complications	O
.	O

Low-dose	O
MTX	Pharmacological
significantly	O
reduced	O
the	O
steroid	O
requirement	O
in	O
this	O
group	O
of	O
subjects	O
with	O
steroid-dependent	O
asthma	O
.	O

This	O
reduction	O
in	O
steroid	O
requirement	O
was	O
obtained	O
without	O
altering	O
clinical	O
status	O
and	O
without	O
significant	O
complication	O
.	O

Different	Pharmacological
aprotinin	Pharmacological
applications	Pharmacological
influencing	O
hemostatic	O
changes	O
in	O
orthotopic	O
liver	O
transplantation	O
.	O

The	O
effect	O
of	O
different	O
aprotinin	Pharmacological
applications	Pharmacological
on	O
hemostatic	O
changes	O
and	O
blood	O
product	O
requirements	O
in	O
orthotopic	O
liver	O
transplantation	O
was	O
investigated	O
in	O
a	O
prospective	O
,	O
open	O
,	O
and	O
randomized	O
study	O
.	O

From	O
November	O
1989	O
to	O
June	O
1990	O
,	O
13	O
patients	O
received	O
aprotinin	Pharmacological
as	O
a	O
bolus	Pharmacological
of	Pharmacological
0.5	Pharmacological
Mill	Pharmacological
.	O

Kallikrein	O
inactivator	O
units	O
(	O
KIU	O
)	O
on	O
three	O
occasions	O
in	O
the	O
course	O
of	O
an	O
OLT	O
,	O
whereas	O
10	O
other	O
patients	O
were	O
treated	O
with	O
continuous	Pharmacological
aprotinin	Pharmacological
infusion	Pharmacological
of	Pharmacological
0.1-0.4	Pharmacological
Mill	Pharmacological
.	Pharmacological

KIU/hr	O
.	O

Before	O
and	O
after	O
reperfusion	O
of	O
the	O
graft	O
liver	O
,	O
signs	O
of	O
hyperfibrinolysis	O
,	O
measured	O
by	O
thrombelastography	O
,	O
were	O
significantly	O
lower	O
in	O
the	O
infusion	O
group	O
.	O

Tissue-type	O
plasminogen	O
activator	O
(	O
t-PA	O
)	O
activity	O
increased	O
during	O
the	O
anhepatic	O
phase	O
but	O
to	O
a	O
significantly	O
lesser	O
extent	O
in	O
the	O
infusion	O
group	O
.	O

Blood	O
product	O
requirements	O
during	O
OLT	O
were	O
tendentiously	O
higher	O
in	O
the	O
bolus	O
group	O
but	O
not	O
significantly	O
so	O
.	O

However	O
,	O
the	O
use	O
of	O
packed	O
red	O
blood	O
cells	O
was	O
significantly	O
lower	O
in	O
the	O
postoperative	O
period	O
,	O
whereas	O
there	O
was	O
no	O
significant	O
difference	O
in	O
fresh	O
frozen	O
plasma	O
requirements	O
between	O
the	O
two	O
groups	O
.	O

All	O
23	O
patients	O
have	O
survived	O
,	O
and	O
only	O
one	O
woman	O
of	O
each	O
group	O
required	O
retransplantation	O
due	O
to	O
severe	O
host-versus-graft	O
reactions	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
perfusate	O
of	O
the	O
graft	O
liver	O
in	O
both	O
groups	O
and	O
detected	O
signs	O
of	O
a	O
decreased	O
t-PA	O
release	O
in	O
the	O
infusion	O
group	O
.	O

Our	O
results	O
demonstrate	O
an	O
advantage	O
of	O
aprotinin	Pharmacological
given	O
as	O
continuous	O
infusion	O
over	O
bolus	O
application	O
in	O
OLT	O
.	O

Therapy	O
effect	O
of	O
either	O
paclitaxel	Control
or	O
cyclophosphamide	Control
combination	Control
treatment	O
in	O
patients	O
with	O
epithelial	O
ovarian	O
cancer	O
and	O
relation	O
to	O
TP53	O
gene	O
status	O
.	O

Cell	O
death	O
after	O
treatment	O
with	O
chemotherapy	Pharmacological
is	O
exerted	O
by	O
activation	O
of	O
apoptosis	O
,	O
and	O
the	O
p53	O
protein	O
has	O
been	O
shown	O
to	O
actively	O
participate	O
in	O
this	O
process	O
.	O

This	O
recent	O
focus	O
on	O
TP53	O
status	O
as	O
a	O
possible	O
determinant	O
of	O
cancer	O
therapy	O
response	O
has	O
raised	O
the	O
question	O
of	O
whether	O
or	O
not	O
mutations	O
in	O
the	O
TP53	O
gene	O
have	O
an	O
influence	O
on	O
paclitaxel	Pharmacological
therapy	O
.	O

The	O
TP53	O
status	O
has	O
been	O
analysed	O
at	O
the	O
DNA	O
level	O
in	O
tumours	O
from	O
45	O
ovarian	O
cancer	O
patients	O
randomized	O
to	O
treatment	O
with	O
paclitaxel	Pharmacological
and	O
cisplatin	O
or	O
cyclophosphamide	Pharmacological
and	O
cisplatin	Pharmacological
.	O

Therapy	O
response	O
was	O
obtained	O
for	O
38	O
patients	O
with	O
clinically	O
evaluable	O
disease	O
after	O
initial	O
surgery	O
.	O

The	O
positive	O
response	O
rate	O
to	O
the	O
paclitaxel/cisplatin	Pharmacological
therapy	O
was	O
85	O
%	O
vs	O
61	O
%	O
for	O
the	O
patients	O
who	O
received	O
the	O
cyclophosphamide/cisplatin	Pharmacological
regimen	O
.	O

A	O
significant	O
difference	O
in	O
relapse-free	O
survival	O
in	O
favour	O
of	O
paclitaxel/cisplatin	Pharmacological
chemotherapy	Pharmacological
was	O
found	O
(	O
P	O
=	O
0.001	O
)	O
.	O

A	O
total	O
of	O
33	O
tumour	O
samples	O
(	O
73	O
%	O
)	O
had	O
detectable	O
sequence	O
alterations	O
in	O
the	O
TP53	O
gene	O
.	O

When	O
relapse-free	O
survival	O
was	O
estimated	O
for	O
all	O
patients	O
with	O
TP53	O
alterations	O
in	O
their	O
tumours	O
,	O
a	O
significant	O
better	O
outcome	O
for	O
the	O
paclitaxel/cisplatin	Pharmacological
group	O
was	O
found	O
compared	O
with	O
the	O
patient	O
group	O
receiving	O
cyclophosphamide	Pharmacological
and	O
cisplatin	Pharmacological
therapy	O
(	O
P	O
=	O
0.002	O
)	O
.	O

We	O
did	O
not	O
observe	O
an	O
association	O
between	O
TP53	O
tumour	O
status	O
and	O
prognosis	O
for	O
patients	O
who	O
received	O
paclitaxel/cisplatin	Pharmacological
combination	O
treatment	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
this	O
therapy	O
is	O
not	O
influenced	O
by	O
this	O
parameter	O
.	O

Cognitive	O
performance	O
and	O
serotonergic	O
function	O
in	O
users	O
of	O
ecstasy	O
.	O

RATIONALE	O
(	O
+/-	O
)	O
3,4-Methylenedioxymethamphetamine	Pharmacological
(	Pharmacological
MDMA	Pharmacological
or	Pharmacological
ecstasy	Pharmacological
)	Pharmacological
has	O
been	O
shown	O
to	O
cause	O
long	O
term	O
damage	O
to	O
serotonergic	O
cerebral	O
neurons	O
in	O
animals	O
.	O

The	O
neurotoxic	O
effects	O
in	O
humans	O
are	O
less	O
clear	O
and	O
little	O
is	O
known	O
about	O
the	O
functional	O
consequences	O
,	O
although	O
some	O
studies	O
suggest	O
memory	O
impairment	O
.	O

Given	O
the	O
widespread	O
use	O
of	O
MDMA	Pharmacological
,	O
our	O
lack	O
of	O
knowledge	O
raises	O
concerns	O
.	O

OBJECTIVE	O
We	O
investigated	O
,	O
in	O
humans	O
,	O
the	O
relation	O
between	O
past	O
use	O
of	O
ecstasy	O
and	O
cognitive	O
performance	O
as	O
well	O
as	O
serotonergic	O
function	O
.	O

METHODS	O
Two	O
groups	O
of	O
21	O
males	O
with	O
moderate	O
and	O
heavy	O
recreational	O
use	O
of	O
MDMA	Pharmacological
,	O
respectively	O
,	O
and	O
a	O
control	O
group	O
of	O
20	O
males	O
without	O
use	O
of	O
MDMA	Pharmacological
were	O
compared	O
.	O

All	O
were	O
from	O
the	O
same	O
subculture	O
.	O

Reaction	O
time	O
,	O
direct	O
recall	O
,	O
and	O
recognition	O
were	O
assessed	O
.	O

Serotonergic	O
function	O
was	O
measured	O
by	O
the	O
neuro-endocrine	O
response	O
to	O
a	O
placebo-controlled	Control
,	O
crossover	O
challenge	O
with	O
dexfenfluramine	Pharmacological
.	O

RESULTS	O
Ecstasy	O
users	O
showed	O
a	O
broad	O
pattern	O
of	O
statistically	O
significant	O
,	O
but	O
clinically	O
small	O
,	O
impairment	O
of	O
memory	O
and	O
prolonged	O
reaction	O
times	O
.	O

Heavy	O
users	O
were	O
affected	O
stronger	O
than	O
moderate	O
users	O
.	O

Release	O
of	O
cortisol	O
but	O
not	O
of	O
prolactin	O
after	O
dexfenfluramine	Pharmacological
administration	O
was	O
significantly	O
reduced	O
in	O
both	O
groups	O
of	O
ecstasy	O
users	O
compared	O
with	O
the	O
controls	O
.	O

Analyses	O
of	O
covariance	O
showed	O
that	O
likely	O
confounding	O
variables	O
including	O
recent	O
exposure	O
to	O
ecstasy	O
,	O
psychosocial	O
profiles	O
and	O
use	O
of	O
other	O
drugs	O
did	O
not	O
explain	O
the	O
differences	O
found	O
between	O
the	O
groups	O
.	O

CONCLUSIONS	O
These	O
results	O
provide	O
further	O
evidence	O
that	O
use	O
of	O
ecstasy	O
may	O
be	O
associated	O
with	O
impairment	O
of	O
memory	O
and	O
of	O
serotonergic	O
function	O
.	O

These	O
findings	O
are	O
compatible	O
with	O
neurotoxicity	O
of	O
ecstasy	O
as	O
shown	O
in	O
animals	O
.	O

Nebulized	O
racemic	Pharmacological
epinephrine	Pharmacological
by	O
IPPB	O
for	O
the	O
treatment	O
of	O
croup	O
:	O
a	O
double-blind	O
study	O
.	O

Racemic	Pharmacological
epinephrine	Pharmacological
has	O
been	O
advocated	O
for	O
the	O
treatment	O
of	O
croup	O
,	O
but	O
controlled	O
studies	O
have	O
not	O
proved	O
it	O
more	O
effective	O
than	O
saline	O
.	O

Twenty	O
patients	O
(	O
aged	O
4	O
months	O
to	O
5	O
years	O
)	O
hospitalized	O
with	O
acute	O
croup	O
and	O
persistent	O
inspiratory	O
stridor	O
at	O
rest	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
saline	Pharmacological
or	Pharmacological
racemic	Pharmacological
epinephrine	Pharmacological
,	O
both	O
nebulized	O
and	O
delivered	O
by	O
intermittent	O
positive	O
pressure	O
breathing	O
.	O

Clinical	O
scores	O
were	O
significantly	O
improved	O
(	O
P	O
less	O
than	O
.01	O
)	O
at	O
ten	O
and	O
30	O
minutes	O
following	O
the	O
treatment	O
with	O
racemic	Pharmacological
epinephrine	Pharmacological
but	O
not	O
at	O
120	O
minutes	O
.	O

Racemic	Pharmacological
epinephrine	Pharmacological
was	O
significantly	O
more	O
effective	O
than	O
saline	O
at	O
10	O
(	O
P	O
less	O
than	O
.01	O
)	O
and	O
30	O
minutes	O
(	O
P	O
less	O
than	O
.05	O
)	O
but	O
not	O
at	O
120	O
minutes	O
after	O
the	O
treatment	O
.	O

We	O
conclude	O
that	O
nebulized	O
racemic	Pharmacological
epinephrine	Pharmacological
is	O
effective	O
treatment	O
for	O
the	O
acute	O
signs	O
of	O
croup	O
.	O

Skin	O
manifestations	O
of	O
inhaled	O
corticosteroids	Pharmacological
in	O
COPD	O
patients	O
:	O
results	O
from	O
Lung	O
Health	O
Study	O
II	O
.	O

OBJECTIVE	O
To	O
define	O
the	O
relationship	O
between	O
skin	O
bruising	O
(	O
as	O
well	O
as	O
other	O
cutaneous	O
manifestations	O
)	O
and	O
inhaled	O
corticosteroid	Pharmacological
(	Pharmacological
ICS	Pharmacological
)	Pharmacological
therapy	O
vs	O
placebo	O
in	O
subjects	O
with	O
COPD	O
who	O
were	O
participating	O
in	O
a	O
clinical	O
trial	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
easy	O
skin	O
bruising	O
and	O
other	O
systemic	O
effects	O
of	O
ICS	O
therapy	O
,	O
including	O
adrenal	O
suppression	O
and	O
loss	O
of	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
.	O

DESIGN	O
Double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
of	O
triamcinolone	Pharmacological
acetonide	Pharmacological
(	O
1200	O
microg	O
daily	O
)	O
vs	O
placebo	Control
in	O
participants	O
with	O
mild-to-moderate	O
COPD	O
.	O

SETTING	O
Lung	O
Health	O
Study	O
II	O
,	O
a	O
clinical	O
trial	O
to	O
assess	O
the	O
effect	O
of	O
ICS	Pharmacological
compared	O
to	O
placebo	O
in	O
1,116	O
participants	O
in	O
10	O
centers	O
over	O
>	O
3.5	O
to	O
4.5	O
years	O
.	O

PARTICIPANTS	O
A	O
total	O
of	O
1,116	O
smokers	O
or	O
recent	O
ex-smokers	O
with	O
mild-to-moderate	O
COPD	O
(	O
age	O
range	O
,	O
40	O
to	O
69	O
years	O
;	O
mean	O
age	O
,	O
56.3	O
years	O
;	O
37.2	O
%	O
female	O
)	O
.	O

MEASUREMENTS	O
AND	O
RESULTS	O
Every	O
6	O
months	O
,	O
a	O
structured	O
questionnaire	O
was	O
administered	O
to	O
elicit	O
reports	O
of	O
any	O
bruising	O
and/or	O
skin	O
rashes	O
,	O
slow	O
healing	O
of	O
cuts	O
or	O
sores	O
,	O
or	O
other	O
skin	O
changes	O
.	O

Compliance	O
with	O
inhaler	O
use	O
was	O
assessed	O
by	O
canister	O
weighing	O
.	O

A	O
significantly	O
higher	O
proportion	O
of	O
ICS	Pharmacological
than	O
placebo	O
participants	O
who	O
complied	O
with	O
using	O
their	O
inhaler	O
reported	O
easy	O
bruising	O
(	O
11.2	O
%	O
vs	O
3.5	O
%	O
,	O
respectively	O
)	O
and	O
the	O
slow	O
healing	O
of	O
skin	O
cuts	O
or	O
sores	O
(	O
2.4	O
%	O
vs	O
0.5	O
%	O
,	O
respectively	O
)	O
.	O

Older	O
men	O
in	O
the	O
ICS	Pharmacological
group	O
with	O
good	O
inhaler	O
compliance	O
appeared	O
to	O
be	O
at	O
the	O
greatest	O
risk	O
of	O
bruising	O
.	O

In	O
those	O
participants	O
undergoing	O
serial	O
measurements	O
of	O
adrenal	O
function	O
and	O
BMD	O
,	O
no	O
association	O
was	O
noted	O
between	O
skin	O
bruising	O
and	O
either	O
the	O
suppression	O
of	O
adrenal	O
function	O
or	O
the	O
loss	O
of	O
BMD	O
as	O
systemic	O
complications	O
of	O
ICS	O
use	O
.	O

CONCLUSION	O
These	O
findings	O
indicate	O
that	O
moderate-to-high	O
doses	O
of	O
ICSs	O
result	O
in	O
an	O
increased	O
incidence	O
of	O
easy	O
bruising	O
and	O
impairment	O
in	O
skin	O
healing	O
in	O
middle-aged	O
to	O
elderly	O
persons	O
with	O
COPD	O
.	O

No	O
association	O
was	O
noted	O
between	O
skin	O
bruising	O
and	O
other	O
markers	O
of	O
systemic	O
toxicity	O
from	O
the	O
use	O
of	O
ICSs	O
.	O

Comparison	O
of	O
intermittent	Pharmacological
or	Pharmacological
continuous	Pharmacological
methotrexate	Pharmacological
plus	O
6-mercaptopurine	Pharmacological
in	O
regimens	O
for	O
standard-risk	O
acute	O
lymphoblastic	O
leukemia	O
in	O
childhood	O
(	O
JCCLSG-S811	O
)	O
.	O

The	O
Japanese	O
Children	O
's	O
Cancer	O
and	O
Leukemia	O
Study	O
Group	O
.	O

From	O
1981	O
to	O
1983	O
,	O
131	O
previously	O
untreated	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
standard-risk	O
group	O
were	O
entered	O
to	O
the	O
protocol	O
JCCLSG-S811	O
.	O

Of	O
119	O
eligible	O
patients	O
,	O
115	O
(	O
96.6	O
%	O
)	O
attained	O
complete	O
remission	O
by	O
treatment	O
with	O
prednisone	Pharmacological
(	Pharmacological
PRD	Pharmacological
)	Pharmacological
plus	Pharmacological
vincristine	Pharmacological
(	Pharmacological
VCR	Pharmacological
)	Pharmacological
or	Pharmacological
vindesine	Pharmacological
(	Pharmacological
VDS	Pharmacological
)	Pharmacological
.	O

After	O
preventive	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
therapy	O
including	O
18	Physical
Gy	Physical
cranial	Physical
irradiation	Physical
and	O
three	O
doses	O
of	O
intrathecal	Pharmacological
methotrexate	Pharmacological
(	Pharmacological
MTX	Pharmacological
)	Pharmacological
,	O
the	O
patients	O
were	O
assigned	O
randomly	O
to	O
the	O
two	O
maintenance	O
chemotherapies	O
,	O
Regimen	O
A	O
and	O
Regimen	O
B	O
.	O

Regimen	O
A	O
(	O
intermittent	O
regimen	O
)	O
consisted	O
of	O
PRD	Pharmacological
(	O
120	O
mg/m2/day	O
by	O
mouth	O
for	O
5	O
days	O
)	O
plus	Pharmacological
6-mercaptopurine	Pharmacological
(	Pharmacological
6MP	Pharmacological
)	Pharmacological
(	O
175	O
mg/m2/day	O
by	O
mouth	O
for	O
5	O
days	O
)	O
plus	Pharmacological
VCR	Pharmacological
(	Pharmacological
2.0	Pharmacological
mg/m2	O
intravenously	O
)	O
alternating	O
biweekly	Pharmacological
with	Pharmacological
MTX	Pharmacological
(	O
225	O
mg/m2	O
intravenously	O
)	O
.	O

Regimen	O
B	O
(	O
continuous	O
regimen	O
)	O
consisted	O
of	O
6MP	Pharmacological
(	O
50	O
mg/m2/day	O
by	O
mouth	O
)	O
plus	Pharmacological
MTX	Pharmacological
(	O
20	O
mg/m2/week	O
by	O
mouth	O
)	O
combined	Pharmacological
with	Pharmacological
pulses	Pharmacological
of	Pharmacological
PRD	Pharmacological
and	Pharmacological
VCR	Pharmacological
(	O
the	O
same	O
dosages	O
as	O
Regimen	O
A	O
)	O
every	O
4	O
weeks	O
.	O

As	O
the	O
late	O
intensification	O
therapy	O
(	O
LIT	O
)	O
,	O
five	O
courses	O
of	O
high-dose	O
MTX	Pharmacological
(	O
2000	O
mg/m2	O
per	O
dose	O
per	O
week	O
intravenously	O
for	O
three	O
doses	O
every	O
12	O
weeks	O
)	O
with	O
leucovorin	O
rescue	O
were	O
administered	O
to	O
all	O
patients	O
who	O
were	O
in	O
continuous	O
complete	O
remission	O
(	O
CCR	O
)	O
for	O
more	O
than	O
2	O
years	O
.	O

Sixty	O
and	O
55	O
patients	O
,	O
respectively	O
,	O
were	O
registered	O
in	O
Regimen	O
A	O
and	O
B	O
.	O

The	O
CCR	O
rates	O
in	O
Regimen	O
A	O
and	O
B	O
were	O
75.1	O
%	O
+/-	O
5.8	O
%	O
(	O
mean	O
+/-	O
1	O
SE	O
)	O
and	O
49.7	O
%	O
+/-	O
7.3	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
at	O
4	O
years	O
,	O
and	O
72.1	O
%	O
+/-	O
6.3	O
%	O
and	O
49.7	O
%	O
+/-	O
7.3	O
%	O
(	O
P	O
less	O
than	O
0.05	O
)	O
at	O
5	O
years	O
,	O
respectively	O
.	O

In	O
Regimen	O
B	O
,	O
CNS	O
and	O
testicular	O
relapses	O
increased	O
after	O
3	O
years	O
of	O
CCR	O
.	O

In	O
addition	O
,	O
the	O
patients	O
in	O
Regimen	O
B	O
had	O
a	O
much	O
higher	O
incidence	O
of	O
infections	O
than	O
Regimen	O
A	O
.	O

The	O
LIT	O
did	O
not	O
seem	O
to	O
have	O
important	O
effects	O
on	O
the	O
duration	O
of	O
CCR	O
.	O

From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
intermittent	O
cyclic	O
regimen	O
of	O
6MP	O
and	O
MTX	Pharmacological
may	O
be	O
more	O
effective	O
as	O
compared	O
to	O
the	O
continuous	O
administration	O
of	O
these	O
drugs	O
in	O
the	O
maintenance	O
chemotherapy	O
.	O

Language	O
outcome	O
in	O
autism	O
:	O
randomized	O
comparison	O
of	O
joint	Physical
attention	Physical
and	Physical
play	Physical
interventions	Physical
.	O

This	O
study	O
reports	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
aimed	O
at	O
joint	Physical
attention	Physical
(	Physical
JA	Physical
)	Physical
and	Physical
symbolic	Physical
play	Physical
(	Physical
SP	Physical
)	Physical
in	O
preschool	O
children	O
with	O
autism	O
,	O
with	O
prediction	O
to	O
language	O
outcome	O
12	O
months	O
later	O
.	O

Participants	O
were	O
58	O
children	O
(	O
46	O
boys	O
)	O
with	O
autism	O
between	O
3	O
and	O
4	O
years	O
of	O
age	O
.	O

Children	O
were	O
randomized	O
to	O
a	O
JA	Educational
intervention	Educational
,	Educational
an	Educational
SP	Educational
intervention	Educational
,	O
or	O
control	Control
group	O
.	O

Interventions	O
were	O
conducted	O
30	O
min	O
daily	O
for	O
5-6	O
weeks	O
.	O

Assessments	O
of	O
JA	Educational
skills	O
,	O
SP	Physical
skills	O
,	O
mother-child	O
interactions	O
,	O
and	O
language	O
development	O
were	O
collected	O
at	O
4	O
time	O
points	O
:	O
pre-	O
and	O
postintervention	O
and	O
6	O
and	O
12	O
months	O
postintervention	O
by	O
independent	O
testers	O
.	O

Results	O
indicate	O
that	O
expressive	O
language	O
gains	O
were	O
greater	O
for	O
both	O
treatment	O
groups	O
compared	O
with	O
the	O
control	O
group	O
,	O
and	O
results	O
could	O
not	O
be	O
explained	O
by	O
differences	O
in	O
other	O
interventions	O
in	O
which	O
children	O
participated	O
.	O

For	O
children	O
beginning	O
treatment	O
with	O
the	O
lowest	O
language	O
levels	O
,	O
the	O
JA	Educational
intervention	Educational
improved	O
language	O
outcome	O
significantly	O
more	O
than	O
did	O
the	O
SP	Physical
or	O
control	O
interventions	O
.	O

These	O
findings	O
suggest	O
clinically	O
significant	O
benefits	O
of	O
actively	O
treating	O
JA	Educational
and	O
SP	Physical
skills	O
in	O
young	O
children	O
with	O
autism	O
.	O

Cholesterol-lowering	O
effect	O
of	O
stanol	Pharmacological
ester	Pharmacological
in	O
a	O
US	O
population	O
of	O
mildly	O
hypercholesterolemic	O
men	O
and	O
women	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
stanol	Pharmacological
esters	Pharmacological
in	O
lowering	O
cholesterol	O
in	O
a	O
US	O
population	O
.	O

SUBJECTS	O
AND	O
METHODS	O
After	O
a	O
run-in	O
phase	O
,	O
318	O
subjects	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	O
following	O
margarine-like	O
spreads	O
containing	O
stanol	Pharmacological
ester	Pharmacological
or	O
placebo	Physical
for	O
8	O
weeks	O
:	O
EU	O
3	O
G	O
:	O
1	O
g	O
of	O
stanol	Pharmacological
(	Pharmacological
ester	Pharmacological
form	Pharmacological
)	Pharmacological
per	O
8-g	O
serving	O
of	O
a	O
European	O
formula	O
3	O
times	O
a	O
day	O
;	O
US	O
3	O
G	O
:	O
1	O
g	O
of	O
stanol	Pharmacological
(	Pharmacological
ester	Pharmacological
form	Pharmacological
)	Pharmacological
per	O
8-g	O
serving	O
of	O
a	O
US	O
reformulation	O
3	O
times	O
a	O
day	O
;	O
US	O
2	O
G	O
:	O
0.67	O
g	O
of	O
stanol	Pharmacological
(	O
ester	O
form	O
)	O
per	O
8-g	O
serving	O
of	O
a	O
US	O
reformulation	O
3	O
times	O
a	O
day	O
;	O
or	O
placebo	Control
spread	O
.	O

RESULTS	O
Mean	O
+/-	O
SD	O
baseline	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
LDL-C	O
)	O
levels	O
were	O
233+/-20	O
and	O
153+21	O
mg+/-dL	O
,	O
respectively	O
.	O

In	O
the	O
US	O
3	O
G	O
group	O
,	O
3	O
g	O
daily	O
of	O
stanol	Pharmacological
esters	Pharmacological
lowered	O
TC	O
and	O
LDL-C	O
levels	O
by	O
6.4	O
%	O
and	O
10.1	O
%	O
,	O
respectively	O
.	O

There	O
was	O
a	O
dose-dependent	O
response	O
compared	O
with	O
2	O
g	O
daily	O
(	O
US	O
2	O
G	O
)	O
.	O

Triglyceride	O
and	O
high-density	O
lipoprotein	O
cholesterol	O
levels	O
were	O
unchanged	O
.	O

The	O
incidence	O
of	O
adverse	O
effects	O
was	O
not	O
different	O
from	O
placebo	Control
.	O

Serum	O
vitamin	O
A	O
and	O
25-hydroxyvitamin	O
D	O
levels	O
were	O
not	O
affected	O
.	O

CONCLUSIONS	O
Stanol	Pharmacological
esters	Pharmacological
lowered	O
TC	O
and	O
LDL-C	O
levels	O
in	O
a	O
mildly	O
hypercholesterolemic	O
US	O
population	O
without	O
evidence	O
of	O
adverse	O
effects	O
.	O

It	O
may	O
be	O
a	O
useful	O
dietary	O
adjunct	O
to	O
lower	O
cholesterol	O
.	O

Topical	Physical
anesthesia	Physical
during	O
infant	O
eye	O
examinations	O
:	O
does	O
it	O
reduce	O
stress	O
?	O
We	O
studied	O
the	O
effect	O
of	O
topical	Physical
anesthesia	Physical
on	O
infant	O
stress	O
and	O
corneal	O
haze	O
during	O
the	O
routine	O
eye	O
examination	O
for	O
retinopathy	O
of	O
prematurity	O
.	O

Using	O
a	O
double-blind	O
protocol	O
,	O
55	O
premature	O
infants	O
weighing	O
less	O
than	O
1501	O
g	O
at	O
birth	O
were	O
selected	O
randomly	O
to	O
receive	O
normal	Pharmacological
saline	Pharmacological
or	Pharmacological
proparacaine	Pharmacological
HCl	Pharmacological
0.5	Pharmacological
%	Pharmacological
eye	Pharmacological
drops	Pharmacological
as	O
a	O
corneal	O
wetting	O
agent	O
at	O
their	O
initial	O
eye	O
examination	O
.	O

Before	O
,	O
during	O
,	O
and	O
after	O
the	O
procedure	O
,	O
infant	O
stress	O
was	O
evaluated	O
by	O
heart	O
rate	O
,	O
respiration	O
rate	O
,	O
blood	O
pressure	O
,	O
and	O
transcutaneous	O
oxygen	O
saturation	O
.	O

Subjective	O
assessment	O
of	O
the	O
infant	O
's	O
cry	O
intensity	O
and	O
corneal	O
haze	O
also	O
were	O
recorded	O
.	O

Adequate	O
data	O
were	O
collected	O
on	O
42	O
patients	O
.	O

Using	O
analysis	O
of	O
variance	O
and	O
chi-square	O
tests	O
,	O
we	O
found	O
no	O
difference	O
in	O
any	O
of	O
these	O
parameters	O
between	O
the	O
two	O
patients	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
topical	O
anesthetic	Pharmacological
agents	O
offer	O
no	O
advantage	O
over	O
normal	O
saline	O
eye	O
drops	O
during	O
the	O
examination	O
of	O
premature	O
infants	O
.	O

Comparison	O
of	O
injection	O
comfort	O
of	O
a	O
new	O
category	O
of	O
cohesive	O
hyaluronic	Pharmacological
acid	Pharmacological
filler	Pharmacological
with	O
preincorporated	O
lidocaine	Pharmacological
and	O
a	O
hyaluronic	Pharmacological
acid	Pharmacological
filler	Pharmacological
alone	Pharmacological
.	O

BACKGROUND	O
A	O
smooth	O
,	O
cohesive	O
,	O
24-mg/mL	O
hyaluronic	Pharmacological
acid	Pharmacological
(	Pharmacological
HA	Pharmacological
)	Pharmacological
gel	Pharmacological
with	O
uniform	O
consistency	O
,	O
even	O
flow	O
characteristics	O
,	O
and	O
extended	O
duration	O
was	O
designed	O
for	O
injection	O
into	O
the	O
mid	O
to	O
deep	O
dermis	O
.	O

OBJECTIVE	O
To	O
compare	O
injection	O
pain	O
of	O
a	O
HA	Pharmacological
gel	Pharmacological
with	Pharmacological
preincorporated	Pharmacological
lidocaine	Pharmacological
with	O
that	O
with	O
a	O
non-lidocaine	O
formulation	O
.	O

METHODS	O
&	O
MATERIALS	O
This	O
double-blind	O
study	O
at	O
three	O
centers	O
enrolled	O
60	O
subjects	O
,	O
injected	O
with	O
both	O
products	O
,	O
randomly	O
assigned	O
to	O
left	O
or	O
right	O
nasolabial	O
fold	O
.	O

The	O
injecting	O
physician	O
assessed	O
severity	O
of	O
pain	O
and	O
ease	O
of	O
injection	O
.	O

Subjects	O
used	O
a	O
visual	O
analog	O
scale	O
(	O
0-10	O
)	O
for	O
pain	O
assessment	O
.	O

Adverse	O
events	O
were	O
recorded	O
.	O

RESULTS	O
Physician	O
assessment	O
of	O
injection	O
pain	O
was	O
none	O
or	O
mild	O
in	O
81	O
%	O
of	O
HA	O
gel	O
injections	O
with	O
preincorporated	O
lidocaine	Pharmacological
and	O
36	O
%	O
of	O
HA-alone	O
injections	O
(	O
p	O
<	O
.001	O
)	O
.	O

Mean	O
pain	O
assessment	O
by	O
subjects	O
was	O
3.6	O
for	O
HA+lidocaine	O
and	O
5.8	O
for	O
HA	O
alone	O
(	O
p	O
<	O
.001	O
)	O
.	O

Ninety-five	O
percent	O
of	O
the	O
injections	O
were	O
considered	O
easy	O
or	O
very	O
easy	O
;	O
a	O
greater	O
percentage	O
of	O
HA+lidocaine	O
injections	O
were	O
rated	O
very	O
easy	O
.	O

Mild	O
to	O
moderate	O
adverse	O
events	O
were	O
reported	O
for	O
both	O
products	O
.	O

CONCLUSION	O
The	O
smooth	O
,	O
cohesive	O
HA	O
gel	O
with	O
preincorporated	O
lidocaine	Pharmacological
increased	O
subject	O
comfort	O
during	O
treatment	O
and	O
improved	O
the	O
injection	O
experience	O
.	O

Tubeless	Surgical
percutaneous	Surgical
nephrolithotomy	Surgical
:	O
safe	O
even	O
in	O
supracostal	O
access	O
.	O

PURPOSE	O
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
outcome	O
and	O
safety	O
of	O
tubeless	Surgical
percutaneous	Surgical
nephrolithotomy	Surgical
(	Surgical
PCNL	Surgical
)	Surgical
in	O
the	O
treatment	O
of	O
renal	O
calculi	O
.	O

PATIENTS	O
AND	O
METHODS	O
Between	O
November	O
2005	O
and	O
March	O
2006	O
,	O
48	O
patients	O
were	O
randomized	O
to	O
either	O
an	O
18F	Surgical
Re-entry	Surgical
nephrostomy	Surgical
tube	Surgical
(	O
group	O
1	O
)	O
or	O
a	O
6F	Surgical
Double-J	Surgical
stent	Surgical
(	O
group	O
2	O
)	O
.	O

The	O
two	O
groups	O
were	O
well	O
matched	O
for	O
age	O
,	O
sex	O
,	O
stone	O
size	O
,	O
stone	O
laterality	O
,	O
and	O
number	O
of	O
previous	O
renal	O
procedures	O
.	O

All	O
PCNL	O
procedures	O
were	O
performed	O
by	O
the	O
same	O
surgeon	O
.	O

Postoperative	O
visual	O
analog	O
pain	O
scale	O
(	O
VAS	O
)	O
scores	O
at	O
8	O
and	O
24	O
hours	O
and	O
14	O
days	O
after	O
surgery	O
,	O
in-hospital	O
analgesic	O
use	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
success	O
rate	O
,	O
blood	O
transfusion	O
rate	O
,	O
and	O
postoperative	O
complications	O
were	O
compared	O
for	O
the	O
two	O
groups	O
.	O

RESULTS	O
The	O
mean	O
hospital	O
stays	O
in	O
groups	O
1	O
and	O
2	O
were	O
3.1	O
and	O
1.6	O
days	O
,	O
respectively	O
(	O
P	O
=	O
0.003	O
)	O
.	O

The	O
mean	O
VAS	O
scores	O
8	O
and	O
24	O
hours	O
after	O
surgery	O
were	O
significantly	O
lower	O
in	O
group	O
2	O
than	O
in	O
group	O
1	O
(	O
P	O
=	O
0.001	O
)	O
.	O

The	O
postoperative	O
analgesic	O
requirement	O
(	Pharmacological
diclofenac	Pharmacological
sodium	Pharmacological
)	Pharmacological
was	O
significantly	O
higher	O
in	O
group	O
1	O
(	O
263	O
mg	O
)	O
than	O
in	O
group	O
2	O
(	O
120	O
mg	O
;	O
P	O
=	O
0.02	O
)	O
.	O

The	O
rate	O
of	O
blood	O
transfusion	O
in	O
the	O
two	O
groups	O
was	O
similar	O
(	O
P	O
=	O
NS	O
)	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
VAS	O
scores	O
on	O
postoperative	O
day	O
14	O
.	O

The	O
number	O
of	O
supracostal	O
accesses	O
was	O
significantly	O
higher	O
in	O
group	O
2	O
than	O
in	O
group	O
1	O
(	O
P	O
=	O
0.02	O
)	O
.	O

The	O
stone-free	O
rates	O
and	O
the	O
numbers	O
of	O
patients	O
with	O
insignificant	O
residual	O
fragments	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
urine	O
leakage	O
or	O
formation	O
of	O
urinoma	O
in	O
patients	O
with	O
Double-J	O
stents	O
.	O

CONCLUSION	O
Tubeless	Surgical
PCNL	Surgical
is	O
safe	O
and	O
effective	O
even	O
after	O
supracostal	O
access	O
and	O
is	O
associated	O
with	O
less	O
postoperative	O
pain	O
and	O
a	O
shorter	O
hospital	O
stay	O
.	O

Relief	O
of	O
periorbital	O
pain	O
after	O
acute	O
angle	O
closure	O
glaucoma	O
attack	O
by	O
botulinum	Pharmacological
toxin	Pharmacological
type	Pharmacological
A	Pharmacological
.	Pharmacological

PURPOSE	O
To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
botulinum	Pharmacological
toxin	Pharmacological
type	Pharmacological
A	Pharmacological
(	Pharmacological
BoNT-A	Pharmacological
)	Pharmacological
injection	O
in	O
patients	O
suffering	O
from	O
intractable	O
periorbital	O
pain	O
after	O
acute	O
angle	O
closure	O
glaucoma	O
(	O
AACG	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
prospective	O
randomized	O
intervention	O
study	O
,	O
19	O
patients	O
suffering	O
from	O
periorbital	O
pain	O
after	O
an	O
AACG	O
attack	O
were	O
injected	Pharmacological
with	Pharmacological
BoNT-A	Pharmacological
or	O
placebo	Control
for	O
pain	O
relief	O
.	O

Patients	O
were	O
assessed	O
on	O
days	O
1	O
,	O
2	O
,	O
7	O
,	O
14	O
,	O
30	O
,	O
60	O
,	O
and	O
90	O
.	O

The	O
main	O
outcomes	O
were	O
mean	O
change	O
of	O
visual	O
analog	O
rating	O
scale	O
(	O
VARS	O
)	O
and	O
index	O
scores	O
measured	O
through	O
a	O
quality-of-life	O
questionnaire	O
(	O
EQ-5D	O
)	O
,	O
and	O
changes	O
in	O
the	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
,	O
all	O
of	O
which	O
were	O
assessed	O
at	O
each	O
visit	O
.	O

A	O
secondary	O
outcome	O
was	O
the	O
frequency	O
and	O
nature	O
of	O
adverse	O
events	O
and	O
the	O
number	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
as	O
a	O
result	O
.	O

RESULTS	O
In	O
the	O
treatment	O
group	O
(	O
n=10	O
)	O
,	O
the	O
mean	O
index	O
score	O
of	O
EQ-5D	O
and	O
VAS	O
changed	O
significantly	O
from	O
the	O
placebo	Control
group	O
(	O
by	O
0.299	O
and	O
2.61	O
,	O
respectively	O
)	O
from	O
day	O
2	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
VARS	O
of	O
EQ-5D	O
also	O
disclosed	O
significant	O
changes	O
from	O
day	O
2	O
(	O
17	O
,	O
P	O
<	O
0.01	O
)	O
.	O

In	O
addition	O
,	O
efficacy	O
was	O
maintained	O
mainly	O
between	O
days	O
2	O
and	O
60	O
but	O
declined	O
slightly	O
by	O
day	O
90	O
.	O

The	O
most	O
frequently	O
reported	O
treatment-related	O
adverse	O
events	O
in	O
the	O
treatment	O
and	O
placebo	O
groups	O
were	O
local	O
tenderness	O
(	O
21	O
%	O
)	O
,	O
subcutaneous	O
hemorrhage	O
(	O
10.5	O
%	O
)	O
,	O
and	O
conjunctivitis	O
(	O
10.5	O
%	O
)	O
.	O

No	O
severe	O
adverse	O
events	O
were	O
reported	O
during	O
the	O
study	O
or	O
follow-up	O
period	O
.	O

CONCLUSIONS	O
BoNT-A	Pharmacological
is	O
effective	O
and	O
well	O
tolerated	O
for	O
the	O
treatment	O
of	O
periorbital	O
pain	O
after	O
an	O
AACG	O
attack	O
.	O

Its	O
effects	O
may	O
be	O
maintained	O
for	O
3	O
months	O
.	O

A	O
study	O
of	O
a	O
Self-Care	Educational
Rehabilitation	Educational
Program	Educational
in	O
pediatric	O
asthma	O
.	O

The	O
Self-Care	Educational
Rehabilitation	Educational
in	O
Pediatric	O
Asthma	O
(	O
SCRPA	O
)	O
project	O
was	O
designed	O
to	O
ascertain	O
the	O
level	O
to	O
which	O
children	O
with	O
asthma	O
are	O
able	O
to	O
acquire	O
the	O
asthma	O
knowledge	O
and	O
skills	O
presented	O
in	O
a	O
self-management	O
training	O
program	O
conducted	O
by	O
the	O
American	O
Lung	O
Association	O
of	O
Utah	O
and	O
the	O
effect	O
of	O
such	O
training	O
on	O
the	O
asthma	O
experience	O
.	O

The	O
preschool	O
SCRPA	O
Curriculum	O
(	O
ages	O
2-5	O
)	O
consisted	O
of	O
six	Educational
1-hour	Educational
classes	Educational
scheduled	Educational
twice	Educational
a	Educational
week	Educational
for	Educational
3	Educational
weeks	Educational
.	O

The	O
first	O
and	O
last	O
classes	O
were	O
for	O
one	O
or	O
both	O
parents	O
only	O
,	O
and	O
the	O
middle	O
four	O
sessions	O
were	O
for	O
the	O
child	O
and	O
parent	O
(	O
s	O
)	O
.	O

The	O
school-age	O
SCRPA	O
curriculum	O
(	O
ages	O
6-14	O
)	O
consisted	O
of	O
eight	Educational
90-minute	Educational
classes	Educational
for	Educational
both	Educational
child	Educational
and	Educational
parent	Educational
(	Educational
s	Educational
)	Educational
scheduled	Educational
twice	O
a	O
week	O
for	O
4	O
weeks	O
.	O

Private	O
physicians	O
referred	O
21	O
preschool	O
children	O
and	O
38	O
school-age	O
children	O
into	O
the	O
program	O
.	O

The	O
school-age	O
children	O
were	O
randomly	O
assigned	O
to	O
a	O
study	O
or	O
control	O
group	O
,	O
and	O
the	O
preschool	O
children	O
served	O
as	O
their	O
own	O
controls	O
.	O

A	O
comparison	O
of	O
asthma	O
episodes	O
during	O
the	O
3	O
months	O
before	O
and	O
after	O
training	O
showed	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
number	O
of	O
episodes	O
but	O
no	O
change	O
in	O
severity	O
in	O
the	O
preschool	O
,	O
school	O
study	O
,	O
and	O
school	O
control	O
groups	O
.	O

The	O
decrease	O
in	O
episodes	O
for	O
the	O
control	O
groups	O
suggest	O
that	O
the	O
family	O
record	O
keeping	O
required	O
of	O
all	O
subjects	O
may	O
have	O
a	O
beneficial	O
effect	O
,	O
a	O
phenomenon	O
worth	O
further	O
investigation	O
.	O

Also	O
,	O
the	O
school-age	O
group	O
,	O
in	O
pre-	O
and	O
posttesting	O
,	O
demonstrated	O
that	O
the	O
SCRPA	Educational
curriculum	O
increased	O
knowledge	O
and	O
skills	O
in	O
the	O
study	O
group	O
,	O
changes	O
not	O
found	O
in	O
the	O
control	O
group	O
.	O

Antihypertensive	O
effect	O
of	O
single	O
doses	O
of	O
enalapril	Pharmacological
in	O
hypertensive	O
patients	O
treated	O
with	O
bendrofluazide	Pharmacological
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
then	O
current	O
recommendations	O
for	O
initiation	O
of	O
therapy	O
with	O
enalapril	Pharmacological
in	O
hypertensive	O
patients	O
on	O
treatment	O
with	O
a	O
diuretic	O
.	O

Enalapril	Pharmacological
in	O
single	O
doses	O
of	O
10	O
and	O
20	O
mg	O
was	O
given	O
to	O
13	O
hypertensive	O
patients	O
on	O
treatment	O
with	O
bendrofluazide	Pharmacological
5	O
mg	O
daily	O
in	O
a	O
randomised	O
,	O
crossover	O
,	O
placebo	Control
controlled	O
study	O
.	O

The	O
mean	O
maximal	O
reduction	O
in	O
blood	O
pressure	O
was	O
similar	O
with	O
both	O
doses	O
(	O
35/20	O
mmHg	O
supine	O
,	O
38/20	O
mmHg	O
standing	O
)	O
,	O
occurred	O
on	O
average	O
within	O
6	O
h	O
of	O
tablet	O
ingestion	O
,	O
and	O
was	O
not	O
accompanied	O
by	O
any	O
significant	O
change	O
in	O
heart	O
rate	O
.	O

Three	O
patients	O
experienced	O
symptomatic	O
hypotension	O
.	O

In	O
one	O
patient	O
this	O
was	O
incapacitating	O
after	O
10	O
mg	O
and	O
precluded	O
exposure	O
to	O
20	O
mg	O
.	O

This	O
study	O
shows	O
that	O
in	O
hypertensive	O
patients	O
receiving	O
treatment	O
with	O
diuretics	O
,	O
the	O
addition	O
of	O
enalapril	O
should	O
be	O
undertaken	O
with	O
caution	O
.	O

An	O
optimal	O
starting	O
dose	O
of	O
enalapril	O
in	O
such	O
patients	O
remains	O
to	O
be	O
confirmed	O
.	O

Effects	O
of	O
oral	Pharmacological
Lactobacillus	Pharmacological
GG	Pharmacological
on	O
enteric	O
microflora	O
in	O
low-birth-weight	O
neonates	O
.	O

BACKGROUND	O
Colonization	O
patterns	O
,	O
especially	O
by	O
anaerobic	O
flora	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
neonatal	O
gut	O
function	O
.	O

Probiotics	O
could	O
affect	O
disease	O
risk	O
either	O
directly	O
through	O
colonization	O
or	O
indirectly	O
by	O
promoting	O
changes	O
in	O
gut	O
microbial	O
ecology	O
.	O

METHODS	O
To	O
study	O
the	O
ability	O
of	O
Lactobacillus	Pharmacological
GG	Pharmacological
(	Pharmacological
LGG	Pharmacological
)	Pharmacological
to	O
colonize	O
the	O
neonatal	O
gut	O
and	O
modify	O
its	O
microbial	O
ecology	O
,	O
a	O
prospective	O
,	O
randomized	O
study	O
was	O
performed	O
in	O
71	O
preterm	O
infants	O
of	O
less	O
than	O
2000	O
g	O
birth	O
weight	O
.	O

Infants	O
less	O
than	O
1500	O
g	O
(	O
24	O
treated	O
,	O
15	O
control	O
)	O
received	O
10	O
(	O
9	O
)	O
LGG	Pharmacological
orally	O
twice	O
daily	O
for	O
21	O
days	O
.	O

Those	O
infants	O
weighing	O
1500	O
to	O
1999	O
g	O
(	O
23	O
treated	O
,	O
9	O
control	O
)	O
were	O
treated	O
for	O
8	O
days	O
.	O

Stools	O
were	O
collected	O
before	O
treatment	O
and	O
on	O
day	O
7	O
to	O
8	O
(	O
and	O
day	O
14	O
and	O
21	O
,	O
in	O
the	O
infants	O
weighing	O
less	O
than	O
1500	O
g	O
)	O
for	O
quantitative	O
aerobic	O
and	O
anaerobic	O
cultures	O
.	O

RESULTS	O
Colonization	O
with	O
LGG	O
occurred	O
in	O
5	O
of	O
24	O
(	O
21	O
%	O
)	O
infants	O
who	O
weighed	O
less	O
than	O
1500	O
g	O
versus	O
11	O
of	O
23	O
(	O
47	O
%	O
)	O
in	O
larger	O
infants	O
.	O

Colonization	O
was	O
limited	O
to	O
infants	O
who	O
were	O
not	O
on	O
antibiotics	Pharmacological
within	O
7	O
days	O
of	O
treatment	O
with	O
LGG	O
.	O

There	O
was	O
a	O
paucity	O
of	O
bacterial	O
species	O
at	O
baseline	O
,	O
although	O
larger	O
infants	O
had	O
more	O
bacterial	O
species	O
(	O
1.59	O
+/-	O
0.13	O
(	O
SEM	O
)	O
vs	O
1.11	O
+/-	O
0.12	O
;	O
P	O
<	O
0.03	O
)	O
and	O
higher	O
mean	O
log	O
colony	O
forming	O
units	O
(	O
CFU	O
)	O
(	O
8.79	O
+/-	O
0.43	O
vs	O
7.22	O
+/-	O
0.63	O
;	O
P	O
<	O
0.05	O
)	O
compared	O
with	O
infants	O
weighing	O
less	O
than	O
1500	O
g	O
LGG	O
.	O

Treatment	O
in	O
infants	O
weighing	O
less	O
than	O
1500	O
g	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
species	O
number	O
by	O
day	O
7	O
,	O
with	O
further	O
increases	O
by	O
day	O
21	O
.	O

This	O
increase	O
was	O
mainly	O
the	O
result	O
of	O
increased	O
Gram	O
(	O
+	O
)	O
and	O
anaerobic	O
species	O
.	O

No	O
difference	O
in	O
species	O
number	O
was	O
noted	O
in	O
controls	O
.	O

Mean	O
log	O
CFU	O
of	O
Gram	O
(	O
-	O
)	O
bacteria	O
did	O
not	O
change	O
in	O
treated	O
infants	O
weighing	O
less	O
than	O
1500	O
g.	O
However	O
,	O
Gram	O
(	O
+	O
)	O
mean	O
log	O
CFU	O
showed	O
a	O
significant	O
increase	O
on	O
day	O
21	O
(	O
6.1	O
+/-	O
0.9	O
)	O
compared	O
with	O
day	O
0	O
(	O
3.5	O
+/-	O
0.9	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

No	O
significant	O
changes	O
in	O
species	O
number	O
or	O
quantitative	O
counts	O
were	O
noted	O
after	O
LGG	O
treatment	O
in	O
the	O
infants	O
weighing	O
1500	O
to	O
1999	O
g	O
LGG	O
was	O
well	O
tolerated	O
in	O
all	O
infants	O
.	O

CONCLUSION	O
The	O
neonatal	O
response	O
to	O
a	O
probiotic	O
preparation	O
is	O
dependent	O
on	O
gestational	O
and	O
post-natal	O
age	O
and	O
prior	O
antibiotic	O
exposure	O
.	O

Although	O
LGG	O
is	O
a	O
relatively	O
poor	O
colonizer	O
in	O
infants	O
,	O
especially	O
those	O
infants	O
weighing	O
less	O
than	O
1500	O
g	O
at	O
birth	O
,	O
it	O
does	O
appear	O
to	O
affect	O
neonatal	O
intestinal	O
colonization	O
patterns	O
.	O

The	O
effect	O
of	O
two	O
types	O
of	O
teacher	Educational
training	Educational
on	O
implementation	O
of	O
Smart	Educational
Choices	Educational
:	O
a	O
tobacco	Educational
prevention	Educational
curriculum	Educational
.	O

This	O
study	O
examined	O
the	O
implementation	O
phase	O
of	O
a	O
four-year	O
research	O
project	O
to	O
test	O
the	O
effectiveness	O
of	O
strategies	O
to	O
increase	O
diffusion	O
of	O
Smart	O
Choices	O
,	O
a	O
school-based	Educational
tobacco	Educational
prevention	Educational
program	Educational
.	O

The	O
impact	O
on	O
curriculum	O
implementation	O
of	O
two	O
approaches	O
to	O
teacher	O
training	O
are	O
compared	O
.	O

School	O
districts	O
were	O
randomly	O
assigned	O
to	O
a	O
live	Educational
workshop	Educational
training	Educational
or	O
video	Educational
training	Educational
condition	Educational
.	O

The	O
outcome	O
of	O
the	O
evaluation	O
was	O
teachers	O
'	O
implementation	O
of	O
Smart	O
Choices	O
.	O

Results	O
show	O
a	O
lower	O
proportion	O
of	O
video-trained	Educational
teachers	O
implemented	O
the	O
curriculum	O
,	O
but	O
overall	O
completeness	O
and	O
fidelity	O
of	O
implementation	O
for	O
those	O
teachers	O
who	O
did	O
teach	O
the	O
curriculum	O
were	O
comparable	O
for	O
the	O
two	O
groups	O
.	O

Video-trained	Educational
teachers	O
,	O
however	O
,	O
were	O
less	O
likely	O
to	O
use	O
brainstorming	O
and	O
student	O
presentations/role	O
plays	O
,	O
two	O
of	O
the	O
methods	O
prescribed	O
by	O
the	O
curriculum	O
.	O

Implications	O
of	O
the	O
results	O
for	O
teacher	O
training	O
are	O
discussed	O
.	O

The	O
efficacy	O
of	O
a	O
herbal-based	Pharmacological
toothpaste	Pharmacological
on	O
the	O
control	O
of	O
plaque	O
and	O
gingivitis	O
.	O

A	O
double-blind	O
controlled	O
clinical	O
trial	O
with	O
parallel	O
groups	O
was	O
designed	O
to	O
investigate	O
the	O
effectiveness	O
of	O
a	O
herbal-based	Pharmacological
toothpaste	Pharmacological
in	O
the	O
control	O
of	O
plaque	O
and	O
gingivitis	O
as	O
compared	O
with	O
a	O
conventional	O
dentifrice	O
.	O

70	O
subjects	O
with	O
gingivitis	O
completed	O
the	O
6-week	O
study	O
.	O

All	O
participants	O
had	O
at	O
least	O
20	O
natural	O
teeth	O
with	O
no	O
probing	O
depths	O
greater	O
than	O
3	O
mm	O
and	O
a	O
plaque	O
index	O
of	O
2	O
or	O
more	O
at	O
baseline	O
.	O

At	O
baseline	O
,	O
both	O
groups	O
were	O
balanced	O
for	O
the	O
parameters	O
measured	O
:	O
plaque	O
index	O
,	O
plaque	O
vitality	O
,	O
gingival	O
index	O
,	O
bleeding	O
on	O
probing	O
and	O
gingival	O
crevicular	O
fluid	O
flow	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
there	O
were	O
reductions	O
within	O
both	O
groups	O
,	O
however	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

It	O
was	O
concluded	O
that	O
the	O
herbal	Pharmacological
based	Pharmacological
toothpaste	Pharmacological
was	O
as	O
effective	O
as	O
the	O
conventionally	Control
formulated	Control
dentifrice	Control
in	O
the	O
control	O
of	O
plaque	O
and	O
gingivitis	O
.	O

Feasibility	O
of	O
an	O
obesity	Educational
intervention	Educational
for	O
paediatric	O
primary	O
care	O
targeting	O
parenting	O
and	O
children	O
:	O
Helping	O
HAND	O
.	O

BACKGROUND	O
The	O
primary	O
care	O
setting	O
offers	O
the	O
opportunity	O
to	O
reach	O
children	O
and	O
parents	O
to	O
encourage	O
healthy	O
lifestyle	O
behaviours	O
,	O
and	O
improve	O
weight	O
status	O
among	O
children	O
.	O

OBJECTIVE	O
Test	O
the	O
feasibility	O
of	O
Helping	O
HAND	O
(	O
Healthy	O
Activity	O
and	O
Nutrition	O
Directions	O
)	O
,	O
an	O
obesity	O
intervention	O
for	O
5-	O
to	O
8-year-old	O
children	O
in	O
primary	O
care	O
clinics	O
.	O

METHODS	O
A	O
randomized	O
controlled	O
pilot	O
study	O
of	O
Helping	Educational
HAND	Educational
,	O
a	O
6-month	O
intervention	O
,	O
targeted	O
children	O
with	O
body	O
mass	O
index	O
85-99	O
%	O
tile	O
and	O
their	O
parents	O
.	O

Intervention	O
group	O
attended	O
monthly	Educational
sessions	Educational
and	Educational
self-selected	Educational
child	Educational
behaviours	Educational
and	Educational
parenting	Educational
practices	Educational
to	O
change	O
.	O

Control	O
group	O
received	O
regular	Educational
paediatric	Educational
care	Educational
and	Educational
was	Educational
wait-listed	Educational
for	Educational
Helping	Educational
HAND	Educational
.	O

Session	O
completion	O
,	O
participant	O
satisfaction	O
,	O
child	O
anthropometrics	O
,	O
dietary	O
intake	O
,	O
physical	O
activity	O
,	O
TV	O
viewing	O
and	O
behaviour-specific	O
parenting	O
practices	O
were	O
measured	O
pre	O
and	O
post	O
intervention	O
.	O

RESULTS	O
Forty	O
parent-child	O
dyads	O
enrolled	O
:	O
82.5	O
%	O
were	O
Hispanic	O
,	O
80	O
%	O
had	O
a	O
girl	O
and	O
65	O
%	O
reported	O
income	O
?	O
$	O
30	O
,	O
000/year	O
.	O

There	O
was	O
20	O
%	O
attrition	O
from	O
Helping	O
HAND	O
(	O
attended	O
<	O
4/6	O
sessions	O
)	O
.	O

Families	O
self-selected	O
4.35	O
(	O
SD	O
1.75	O
)	O
behaviours	O
to	O
target	O
during	O
the	O
6-month	O
programme	O
and	O
each	O
of	O
the	O
seven	O
behaviours	O
was	O
selected	O
by	O
45-80	O
%	O
of	O
the	O
families	O
.	O

There	O
were	O
no	O
between	O
group	O
differences	O
in	O
the	O
child	O
's	O
body	O
mass	O
index	O
z-score	O
,	O
dietary	O
intake	O
or	O
physical	O
activity	O
post	O
intervention	O
.	O

Intervention	O
group	O
viewed	O
14.9	O
(	O
SE	O
2.3	O
)	O
h/week	O
of	O
TV	O
post	O
intervention	O
versus	O
control	O
group	O
23.3	O
(	O
SE	O
2.4	O
)	O
h/week	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
Helping	O
HAND	O
is	O
feasible	O
,	O
due	O
to	O
low	O
attrition	O
,	O
good	O
programme	O
attendance	O
,	O
and	O
clinically	O
relevant	O
improvements	O
in	O
some	O
child	O
and	O
parenting	O
behaviours	O
.	O

Preliminary	O
findings	O
of	O
the	O
minimally-invasive	Surgical
surgery	Surgical
plus	Surgical
rtPA	Surgical
for	O
intracerebral	O
hemorrhage	O
evacuation	O
(	O
MISTIE	O
)	O
clinical	O
trial	O
.	O

INTRODUCTION	O
Compared	O
to	O
ischemic	O
stroke	O
,	O
intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
is	O
easily	O
and	O
rapidly	O
identified	O
,	O
occurs	O
in	O
younger	O
patients	O
,	O
and	O
produces	O
relatively	O
small	O
initial	O
injury	O
to	O
cerebral	O
tissues	O
--	O
all	O
factors	O
suggesting	O
that	O
interventional	O
amelioration	O
is	O
possible	O
.	O

Investigations	O
from	O
the	O
last	O
decade	O
established	O
that	O
extent	O
of	O
ICH-mediated	O
brain	O
injury	O
relates	O
directly	O
to	O
blood	O
clot	O
volume	O
and	O
duration	O
of	O
blood	O
exposure	O
to	O
brain	O
tissue	O
.	O

Using	O
minimally-invasive	Surgical
surgery	Surgical
plus	Surgical
recombinant	Surgical
tissue	Surgical
plasminogen	Surgical
activator	Surgical
(	Surgical
rtPA	Surgical
)	Surgical
,	O
MISTIE	O
investigators	O
explored	O
aggressive	O
avenues	O
to	O
treat	O
ICH	O
.	O

METHODS	O
We	O
investigated	O
the	O
difference	O
between	O
surgical	Surgical
intervention	Surgical
plus	Surgical
rtPA	Surgical
and	O
standard	O
medical	O
management	O
for	O
ICH	O
.	O

Subjects	O
in	O
both	O
groups	O
were	O
medically	O
managed	O
according	O
to	O
standard	O
ICU	O
protocols	O
.	O

Subjects	O
randomized	O
to	O
surgery	O
underwent	O
stereotactic	Surgical
catheter	Surgical
placement	Surgical
and	Surgical
clot	Surgical
aspiration	Surgical
.	O

Injections	Pharmacological
of	Pharmacological
rtPA	Pharmacological
were	O
then	O
given	O
through	O
hematoma	O
catheter	O
every	O
8	O
h	O
,	O
up	O
to	O
9	O
doses	O
,	O
or	O
until	O
a	O
clot-reduction	O
endpoint	O
.	O

After	O
each	O
injection	O
the	O
system	O
was	O
flushed	O
with	O
sterile	Pharmacological
saline	Pharmacological
and	O
closed	O
for	O
60	O
min	O
before	O
opening	O
to	O
spontaneous	O
drainage	O
.	O

RESULTS	O
Average	O
aspiration	O
of	O
clots	O
for	O
all	O
patients	O
randomized	O
to	O
surgery	O
plus	O
rtPA	O
was	O
20	O
%	O
of	O
mean	O
initial	O
clot	O
size	O
.	O

After	O
acute	O
treatment	O
phase	O
(	O
aspiration	O
plus	O
rtPA	O
)	O
,	O
clot	O
was	O
reduced	O
an	O
average	O
of	O
46	O
%	O
.	O

Recorded	O
adverse	O
events	O
were	O
within	O
safety	O
limits	O
,	O
including	O
30-day	O
mortality	O
,	O
8	O
%	O
;	O
symptomatic	O
re-bleeding	O
,	O
8	O
%	O
;	O
and	O
bacterial	O
ventriculitis	O
,	O
0	O
%	O
.	O

Patients	O
randomized	O
to	O
medical	O
management	O
showed	O
4	O
%	O
clot	O
resolution	O
in	O
a	O
similar	O
time	O
window	O
.	O

Preliminary	O
analysis	O
indicates	O
that	O
clot	O
resolution	O
rates	O
are	O
greatly	O
dependent	O
on	O
catheter	O
placement	O
.	O

Location	O
of	O
ICH	O
also	O
affects	O
efficacy	O
of	O
aggressive	O
treatment	O
of	O
ICH	O
.	O

CONCLUSION	O
There	O
is	O
tentative	O
indication	O
that	O
minimally-invasive	O
surgery	O
plus	O
rtPA	O
shows	O
greater	O
clot	O
resolution	O
than	O
traditional	O
medical	O
management	O
.	O

Effects	O
of	O
pentoxifylline	Pharmacological
administration	O
on	O
urinary	O
N-acetyl-beta-glucosaminidase	O
excretion	O
in	O
type	O
2	O
diabetic	O
patients	O
:	O
a	O
short-term	O
,	O
prospective	O
,	O
randomized	O
study	O
.	O

BACKGROUND	O
Tubulointerstitial	O
injury	O
is	O
a	O
major	O
feature	O
of	O
diabetic	O
nephropathy	O
and	O
an	O
important	O
predictor	O
of	O
renal	O
dysfunction	O
.	O

In	O
45	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
,	O
we	O
prospectively	O
analyzed	O
urinary	O
excretion	O
of	O
N-acetyl-beta-glucosaminidase	O
(	O
NAG	O
)	O
,	O
a	O
marker	O
of	O
tubular	O
renal	O
damage	O
;	O
the	O
potential	O
relationship	O
with	O
urinary	O
protein	O
excretion	O
;	O
and	O
effects	O
of	O
pentoxifylline	Pharmacological
(	Pharmacological
PTF	Pharmacological
)	Pharmacological
administration	O
.	O

METHODS	O
Forty-five	O
patients	O
with	O
type	O
2	O
DM	O
initially	O
were	O
compared	O
with	O
15	O
healthy	O
controls	O
matched	O
for	O
age	O
and	O
sex	O
.	O

After	O
randomization	O
,	O
PTF	Pharmacological
(	O
1,200	O
mg/d	O
)	O
was	O
administered	O
for	O
4	O
months	O
to	O
30	O
patients	O
and	O
results	O
were	O
compared	O
with	O
data	O
from	O
a	O
control	O
group	O
(	O
n	O
=	O
15	O
)	O
.	O

RESULTS	O
Proteinuria	O
and	O
urinary	O
NAG	O
excretion	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
DM	O
with	O
respect	O
to	O
healthy	O
controls	O
.	O

Before	O
PTF	O
administration	O
,	O
baseline	O
parameters	O
were	O
similar	O
in	O
both	O
groups	O
of	O
patients	O
with	O
DM	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
urinary	O
protein	O
excretion	O
and	O
NAG-creatinine	O
ratios	O
decreased	O
in	O
the	O
active	O
group	O
from	O
920	O
+/-	O
522	O
mg/d	O
and	O
14.3	O
+/-	O
16.9	O
U/g	O
to	O
803	O
+/-	O
523	O
mg/d	O
(	O
P	O
<	O
0.001	O
)	O
and	O
10.5	O
+/-	O
9.3	O
U/g	O
(	O
P	O
<	O
0.05	O
)	O
,	O
respectively	O
.	O

Conversely	O
,	O
proteinuria	O
and	O
urinary	O
NAG	O
excretion	O
did	O
not	O
change	O
in	O
the	O
control	Control
group	O
.	O

Regression	O
analysis	O
showed	O
that	O
urinary	O
NAG	O
excretion	O
was	O
significantly	O
associated	O
with	O
duration	O
of	O
DM	O
(	O
r	O
=	O
0.61	O
;	O
P	O
<	O
0.001	O
)	O
and	O
proteinuria	O
(	O
r	O
=	O
0.51	O
;	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
Urinary	O
NAG	O
excretion	O
is	O
elevated	O
in	O
patients	O
with	O
type	O
2	O
DM	O
compared	O
with	O
healthy	O
individuals	O
and	O
increases	O
as	O
nephropathy	O
progresses	O
.	O

PTF	Pharmacological
administration	O
is	O
effective	O
in	O
reducing	O
proteinuria	O
and	O
urinary	O
NAG	O
excretion	O
in	O
these	O
patients	O
.	O

These	O
findings	O
suggest	O
that	O
PTF	Pharmacological
may	O
have	O
beneficial	O
effects	O
on	O
tubulointerstitial	O
damage	O
in	O
diabetic	O
kidney	O
disease	O
.	O

Relationship	O
between	O
baseline	O
blood	O
pressure	O
parameters	O
(	O
including	O
mean	O
pressure	O
,	O
pulse	O
pressure	O
,	O
and	O
variability	O
)	O
and	O
early	O
outcome	O
after	O
stroke	O
:	O
data	O
from	O
the	O
Tinzaparin	Pharmacological
in	O
Acute	O
Ischaemic	O
Stroke	O
Trial	O
(	O
TAIST	O
)	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
High	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
acute	O
stroke	O
is	O
associated	O
independently	O
with	O
a	O
poor	O
outcome	O
.	O

Recent	O
evidence	O
suggests	O
that	O
other	O
hemodynamic	O
parameters	O
may	O
also	O
be	O
associated	O
with	O
outcomes	O
following	O
stroke	O
.	O

METHODS	O
The	O
relationship	O
between	O
baseline	O
BP	O
,	O
heart	O
rate	O
,	O
and	O
other	O
hemodynamic	O
parameters	O
,	O
and	O
early	O
outcomes	O
were	O
assessed	O
using	O
data	O
from	O
TAIST	O
trial	O
.	O

RESULTS	O
Death	O
or	O
neurological	O
deterioration	O
at	O
day	O
10	O
was	O
associated	O
,	O
both	O
in	O
unadjusted	O
and	O
adjusted	O
analyses	O
,	O
with	O
systolic	O
BP	O
(	O
adjusted	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
mean	O
arterial	O
pressure	O
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.04	O
)	O
,	O
pulse	O
pressure	O
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
and	O
BP	O
variability	O
(	O
OR	O
,	O
1.03	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.05	O
)	O
.	O

Similar	O
relationships	O
were	O
noted	O
for	O
deterioration	O
alone	O
,	O
and	O
recurrent	O
stroke	O
.	O

CONCLUSIONS	O
Early	O
death	O
or	O
neurologic	O
deterioration	O
,	O
deterioration	O
,	O
and	O
recurrent	O
stroke	O
are	O
associated	O
independently	O
with	O
high	O
systolic	O
BP	O
,	O
mean	O
arterial	O
pressure	O
,	O
pulse	O
pressure	O
,	O
and	O
BP	O
variability	O
.	O

These	O
measures	O
offer	O
potential	O
therapeutic	Physical
targets	Physical
for	O
improving	O
early	O
outcome	O
after	O
acute	O
ischemic	O
stroke	O
.	O

Topical	Pharmacological
anti-inflammatory	Pharmacological
drugs	Pharmacological
in	O
the	O
treatment	O
of	O
allergic	O
pollinosic	O
conjunctivitis	O
:	O
a	O
comparative	O
double-blind	O
study	O
.	O

Anti-inflammatory	O
drugs	O
,	O
i.e	O
.	O

glucocorticosteroids	Pharmacological
and	Pharmacological
NSAIDs	Pharmacological
(	O
nonsteroidal	Pharmacological
anti-inflammatory	Pharmacological
drugs	Pharmacological
)	O
,	O
are	O
often	O
included	O
in	O
the	O
treatment	O
of	O
allergic	O
conjunctivitis	O
.	O

The	O
present	O
study	O
compares	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
topical	O
hydrocortisone	Pharmacological
,	O
acetylsalicylic	Pharmacological
acid	Pharmacological
(	Pharmacological
ASA	Pharmacological
)	Pharmacological
and	O
piroxicam	Pharmacological
compared	O
to	O
placebo	Control
.	O

The	O
trial	O
,	O
designed	O
as	O
a	O
double-blind	O
,	O
randomized	O
and	O
parallel-group	O
treatment	O
,	O
was	O
carried	O
out	O
in	O
a	O
group	O
of	O
40	O
patients	O
suffering	O
from	O
seasonal	O
allergic	O
conjunctivitis	O
due	O
to	O
Parietaria	O
pollen	O
,	O
during	O
the	O
pollen	O
season	O
(	O
June-July	O
,	O
1990	O
)	O
.	O

Patients	O
received	O
hydrocortisone	Pharmacological
0.1	Pharmacological
%	Pharmacological
solution	Pharmacological
,	O
ASA	Pharmacological
1	Pharmacological
%	Pharmacological
solution	Pharmacological
,	O
piroxicam	Pharmacological
0.5	Pharmacological
%	Pharmacological
solution	Pharmacological
or	O
placebo	Control
as	O
eye	O
drops	O
,	O
all	O
one	O
drop	O
in	O
each	O
eye	O
q.i.d	O
.	O

for	O
14	O
days	O
.	O

The	O
symptoms	O
were	O
evaluated	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
treatment	O
by	O
the	O
clinician	O
and	O
by	O
patients	O
on	O
a	O
diary	O
card	O
.	O

The	O
hydrocortisone	O
group	O
showed	O
a	O
rapid	O
and	O
significant	O
improvement	O
during	O
the	O
first	O
week	O
of	O
treatment	O
,	O
while	O
ASA	O
and	O
piroxicam	O
reduced	O
symptomatology	O
during	O
the	O
second	O
week	O
of	O
treatment	O
;	O
this	O
difference	O
was	O
statistically	O
significant	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
the	O
active	O
drugs	O
were	O
comparable	O
with	O
regard	O
to	O
clinical	O
efficacy	O
.	O

A	O
statistically	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
active	O
drugs	O
and	O
placebo	O
,	O
while	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
among	O
the	O
three	O
drugs	O
.	O

No	O
serious	O
side-effects	O
were	O
observed	O
.	O

The	O
results	O
demonstrate	O
the	O
clinical	O
efficacy	O
of	O
anti-inflammatory	O
drugs	O
in	O
the	O
treatment	O
of	O
pollen-induced	O
allergic	O
conjunctivitis	O
;	O
they	O
also	O
suggest	O
the	O
use	O
of	O
NSAIDs	O
in	O
long-term	O
treatment	O
,	O
as	O
their	O
efficacy	O
has	O
been	O
shown	O
to	O
be	O
closely	O
comparable	O
to	O
that	O
of	O
steroids	O
,	O
while	O
avoiding	O
the	O
well-known	O
side-effects	O
of	O
the	O
latter	O
in	O
prolonged	O
treatment	O
.	O

Comparative	O
effectiveness	O
of	O
exercise	O
electrocardiography	O
with	O
or	O
without	O
myocardial	O
perfusion	O
single	O
photon	O
emission	O
computed	O
tomography	O
in	O
women	O
with	O
suspected	O
coronary	O
artery	O
disease	O
:	O
results	O
from	O
the	O
What	O
Is	O
the	O
Optimal	O
Method	O
for	O
Ischemia	O
Evaluation	O
in	O
Women	O
(	O
WOMEN	O
)	O
trial	O
.	O

BACKGROUND	O
There	O
is	O
a	O
paucity	O
of	O
randomized	O
trials	O
regarding	O
diagnostic	O
testing	O
in	O
women	O
with	O
suspected	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

It	O
remains	O
unclear	O
whether	O
the	O
addition	O
of	O
myocardial	O
perfusion	O
imaging	O
(	O
MPI	O
)	O
to	O
the	O
standard	O
ECG	O
exercise	O
treadmill	O
test	O
(	O
ETT	O
)	O
provides	O
incremental	O
information	O
to	O
improve	O
clinical	O
decision	O
making	O
in	O
women	O
with	O
suspected	O
CAD	O
.	O

METHODS	O
AND	O
RESULTS	O
We	O
randomized	O
symptomatic	O
women	O
with	O
suspected	O
CAD	O
,	O
an	O
interpretable	O
ECG	O
,	O
and	O
?5	O
metabolic	O
equivalents	O
on	O
the	O
Duke	O
Activity	O
Status	O
Index	O
to	O
1	O
of	O
2	O
diagnostic	O
strategies	O
:	O
ETT	O
or	O
exercise	O
MPI	O
.	O

The	O
primary	O
end	O
point	O
was	O
2-year	O
incidence	O
of	O
major	O
adverse	O
cardiac	O
events	O
,	O
defined	O
as	O
CAD	O
death	O
or	O
hospitalization	O
for	O
an	O
acute	O
coronary	O
syndrome	O
or	O
heart	O
failure	O
.	O

A	O
total	O
of	O
824	O
women	O
were	O
randomized	O
to	O
ETT	O
or	O
exercise	O
MPI	O
.	O

For	O
women	O
randomized	O
to	O
ETT	O
,	O
ECG	O
results	O
were	O
normal	O
in	O
64	O
%	O
,	O
indeterminate	O
in	O
16	O
%	O
,	O
and	O
abnormal	O
in	O
20	O
%	O
.	O

By	O
comparison	O
,	O
the	O
exercise	O
MPI	O
results	O
were	O
normal	O
in	O
91	O
%	O
,	O
mildly	O
abnormal	O
in	O
3	O
%	O
,	O
and	O
moderate	O
to	O
severely	O
abnormal	O
in	O
6	O
%	O
.	O

At	O
2	O
years	O
,	O
there	O
was	O
no	O
difference	O
in	O
major	O
adverse	O
cardiac	O
events	O
(	O
98.0	O
%	O
for	O
ETT	O
and	O
97.7	O
%	O
for	O
MPI	O
;	O
P=0.59	O
)	O
.	O

Compared	O
with	O
ETT	O
,	O
index	O
testing	O
costs	O
were	O
higher	O
for	O
exercise	O
MPI	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
downstream	O
procedural	O
costs	O
were	O
slightly	O
lower	O
(	O
P=0.0008	O
)	O
.	O

Overall	O
,	O
the	O
cumulative	O
diagnostic	O
cost	O
savings	O
was	O
48	O
%	O
for	O
ETT	O
compared	O
with	O
exercise	O
MPI	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
In	O
low-risk	O
,	O
exercising	O
women	O
,	O
a	O
diagnostic	O
strategy	O
that	O
uses	O
ETT	O
versus	O
exercise	O
MPI	O
yields	O
similar	O
2-year	O
posttest	O
outcomes	O
while	O
providing	O
significant	O
diagnostic	O
cost	O
savings	O
.	O

The	O
ETT	O
with	O
selective	O
follow-up	O
testing	O
should	O
be	O
considered	O
as	O
the	O
initial	O
diagnostic	O
strategy	O
in	O
symptomatic	O
women	O
with	O
suspected	O
CAD	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Unique	O
identifier	O
:	O
NCT00282711	O
.	O

Psychiatric	Psychological
treatment	Psychological
of	O
eczema	O
:	O
a	O
controlled	O
trial	O
.	O

Seventy-two	O
patients	O
with	O
eczema	O
were	O
randomly	O
allotted	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
A	O
,	O
those	O
receiving	O
dermatological	Physical
treatment	Physical
only	Physical
,	O
and	O
B	O
,	O
those	O
receiving	O
the	O
same	Educational
dermatological	Psychological
treatment	Psychological
plus	Psychological
psychiatric	Psychological
treatment	Psychological
,	O
limited	O
where	O
possible	O
to	O
four	O
months	O
.	O

Cases	O
were	O
followed	O
up	O
at	O
six-monthly	O
dermatological	O
assessments	O
,	O
57	O
(	O
79	O
%	O
)	O
for	O
18	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
in	O
the	O
presence	O
of	O
overt	O
emotional	O
disturbance	O
,	O
of	O
new	O
psychological	O
or	O
psychophysiological	O
symptoms	O
preceding	O
the	O
rash	O
by	O
up	O
to	O
a	O
year	O
,	O
and	O
of	O
high	O
motivation	O
for	O
it	O
,	O
brief	O
psychiatric	Psychological
treatment	Psychological
improves	O
the	O
outcome	O
in	O
eczema	O
(	O
the	O
proportion	O
clear	O
at	O
18	O
months	O
was	O
about	O
doubled	O
)	O
,	O
whereas	O
in	O
their	O
absence	O
such	O
treatment	O
may	O
worsen	O
it	O
,	O
especially	O
in	O
the	O
short	O
term	O
.	O

[	O
Clinical	O
observations	O
on	O
the	O
treatment	O
of	O
hookworm	O
,	O
Ascaris	O
and	O
Trichuris	O
infection	O
with	O
oxibendazole	Pharmacological
]	O
.	O

340	O
cases	O
of	O
hookworm	O
infection	O
,	O
196	O
cases	O
of	O
ascariasis	O
and	O
178	O
cases	O
of	O
trichuriasis	O
were	O
treated	O
with	O
an	O
anthelmintic	Pharmacological
,	Pharmacological
oxibendazole	Pharmacological
,	O
15mg/kg.d	O
x	O
3d	O
;	O
102	O
,	O
70	O
and	O
66	O
cases	O
of	O
respective	O
infections	O
were	O
treated	O
with	O
pyrantel	Pharmacological
10mg/kg.d	O
x	O
3d	O
and	O
108	O
,	O
74	O
and	O
63	O
cases	O
took	O
placebo	Control
for	O
comparison	O
and	O
as	O
control	O
under	O
double-blind	O
observations	O
.	O

Re-examinations	O
of	O
the	O
stool	O
were	O
performed	O
after	O
the	O
treatment	O
.	O

Among	O
the	O
cases	O
treated	O
with	O
oxibendazole	O
,	O
the	O
egg	O
negative	O
conversion	O
rates	O
of	O
hookworm	O
,	O
Ascaris	O
and	O
Trichuris	O
were	O
70.3-80.6	O
%	O
,	O
92.5-97.8	O
and	O
67.0-71.0	O
%	O
respectively	O
.	O

The	O
egg	O
reduction	O
rates	O
of	O
hookworm	O
were	O
98.1-98.6	O
%	O
.	O

The	O
larval	O
negative	O
conversion	O
rates	O
of	O
Ancylostoma	O
duodenale	O
and	O
Necator	O
americanus	O
were	O
77.7	O
and	O
83.2	O
%	O
respectively	O
.	O

Among	O
the	O
cases	O
treated	O
with	O
pyrantel	O
,	O
the	O
egg	O
negative	O
conversion	O
rates	O
of	O
the	O
three	O
above	O
mentioned	O
parasites	O
were	O
73.5	O
,	O
90.0	O
and	O
28.8	O
%	O
respectively	O
.	O

The	O
egg	O
reduction	O
rate	O
of	O
hookworm	O
was	O
98.8	O
%	O
.	O

Among	O
the	O
cases	O
treated	O
with	O
placebo	O
,	O
the	O
egg	O
negative	O
conversion	O
rates	O
of	O
the	O
three	O
above	O
mentioned	O
parasites	O
were	O
6.5	O
,	O
29.7	O
and	O
7.9	O
%	O
.	O

No	O
marked	O
adverse	O
reactions	O
were	O
observed	O
by	O
clinical	O
and	O
laboratory	O
examinations	O
.	O

Erythema	O
migrans	O
:	O
comparison	O
of	O
treatment	O
with	O
azithromycin	Pharmacological
,	O
doxycycline	Pharmacological
and	O
phenoxymethylpenicillin	Pharmacological
.	O

Azithromycin	Pharmacological
,	O
doxycycline	Pharmacological
and	O
phenoxymethylpenicillin	Pharmacological
were	O
compared	O
in	O
a	O
prospective	O
,	O
randomized	O
study	O
of	O
64	O
patients	O
with	O
typical	O
erythema	O
migrans	O
.	O

Twenty	O
patients	O
were	O
treated	O
with	O
oral	Pharmacological
azithromycin	Pharmacological
,	O
250	O
mg	O
bd	O
for	O
two	O
days	O
followed	O
by	O
250	O
mg	O
od	O
for	O
eight	O
days	O
,	O
21	O
patients	O
were	O
given	O
phenoxymethylpenicillin	Pharmacological
1	O
million	O
IU	O
tds	O
for	O
14	O
days	O
and	O
23	O
patients	O
received	O
doxycycline	Pharmacological
,	O
100	O
mg	O
bd	O
for	O
14	O
days	O
.	O

All	O
patients	O
were	O
followed	O
up	O
for	O
24	O
months	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
with	O
respect	O
to	O
the	O
persistence	O
of	O
cutaneous	O
lesions	O
after	O
starting	O
treatment	O
;	O
the	O
mean	O
durations	O
were	O
10.5	O
days	O
in	O
the	O
penicillin	Pharmacological
group	O
,	O
8.8	O
days	O
in	O
the	O
doxycycline	Pharmacological
group	O
and	O
8.6	O
days	O
in	O
the	O
azithromycin	Pharmacological
group	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
in	O
terms	O
of	O
the	O
resolution	O
of	O
associated	O
local	O
and/or	O
systemic	O
symptoms	O
.	O

The	O
response	O
time	O
was	O
shortest	O
in	O
patients	O
treated	O
with	O
azithromycin	Pharmacological
.	O

Two	O
patients	O
who	O
received	O
phenoxymethylpenicillin	Pharmacological
and	O
two	O
given	O
doxycycline	Pharmacological
subsequently	O
developed	O
major	O
manifestations	O
of	O
Lyme	O
borreliosis	O
;	O
these	O
did	O
not	O
occur	O
in	O
patients	O
receiving	O
azithromycin	Pharmacological
.	O

Although	O
azithromycin	Pharmacological
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
erythema	O
migrans	O
,	O
further	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
duration	O
of	O
therapy	O
.	O

Immediate	O
effects	O
of	O
a	O
tibiofibular	Physical
joint	Physical
manipulation	Physical
on	O
lower	O
extremity	O
H-reflex	O
measurements	O
in	O
individuals	O
with	O
chronic	O
ankle	O
instability	O
.	O

Persistent	O
muscle	O
inhibition	O
of	O
the	O
fibularis	O
longus	O
and	O
soleus	O
muscles	O
and	O
altered	O
joint	O
arthrokinematics	O
may	O
play	O
a	O
role	O
in	O
chronic	O
ankle	O
instability	O
(	O
CAI	O
)	O
.	O

Joint	O
mobilization	O
has	O
been	O
shown	O
to	O
improve	O
ankle	O
joint	O
motion	O
,	O
but	O
effects	O
on	O
surrounding	O
musculature	O
is	O
unknown	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
change	O
in	O
fibularis	O
longus	O
and	O
soleus	O
activation	O
following	O
tibiofibular	Physical
joint	Physical
manipulation	Physical
in	O
individuals	O
with	O
CAI	O
.	O

Forty-three	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
three	O
groups	O
(	O
proximal	Physical
tibiofibular	Physical
manipulation	Physical
,	O
distal	Physical
tibiofibular	Physical
manipulation	Physical
,	O
or	O
control	Control
)	O
.	O

A	O
two-way	O
mixed	O
model	O
ANOVA	O
was	O
used	O
to	O
compare	O
changes	O
in	O
the	O
ratio	O
of	O
the	O
maximum	O
H-reflex	O
and	O
maximum	O
M-wave	O
measurements	O
(	O
H/M	O
ratio	O
)	O
of	O
the	O
fibularis	O
longus	O
and	O
soleus	O
between	O
groups	O
over	O
time	O
(	O
pre	O
,	O
post	O
0	O
,	O
10	O
,	O
20	O
,	O
30	O
min	O
)	O
.	O

The	O
distal	O
tibiofibular	O
joint	O
manipulation	O
group	O
demonstrated	O
a	O
significant	O
increase	O
(	O
P	O
<	O
.05	O
)	O
in	O
soleus	O
H/M	O
ratio	O
at	O
all	O
post-intervention	O
time	O
periods	O
except	O
20	O
min	O
post-intervention	O
(	O
P=.48	O
)	O
.	O

The	O
proximal	O
tibiofibular	O
joint	O
manipulation	O
and	O
control	Control
groups	O
did	O
not	O
demonstrate	O
a	O
change	O
in	O
soleus	O
H/M	O
ratios	O
.	O

All	O
groups	O
demonstrated	O
a	O
decrease	O
(	O
P	O
<	O
.05	O
)	O
from	O
baseline	O
values	O
in	O
fibularis	O
longus	O
(	O
10-30	O
min	O
post-intervention	O
)	O
and	O
soleus	O
(	O
30	O
min	O
post-intervention	O
)	O
H/M	O
ratios	O
.	O

Interventions	O
directed	O
at	O
the	O
distal	O
tibiofibular	O
joint	O
acutely	O
increase	O
soleus	O
muscle	O
activation	O
.	O

Motion	O
aftereffects	O
with	O
horizontally	O
moving	O
sound	O
sources	O
in	O
the	O
free	O
field	O
.	O

A	O
horizontally	Other
moving	Other
sound	Other
was	O
presented	O
to	O
an	O
observer	O
seated	O
in	O
the	O
center	O
of	O
an	O
anechoic	O
chamber	O
.	O

The	O
sound	O
,	O
either	O
a	O
500-Hz	Other
low-pass	Other
noise	Other
or	O
a	O
6300-Hz	Other
high-pass	Other
noise	Other
,	O
repeatedly	O
traversed	O
a	O
semicircular	O
arc	O
in	O
the	O
observer	O
's	O
front	O
hemifield	O
at	O
ear	O
level	O
(	O
distance	O
:	O
1.5	O
m	O
)	O
.	O

At	O
10-sec	O
intervals	O
this	O
adaptor	O
was	O
interrupted	O
,	O
and	O
a	O
750-msec	O
moving	Other
probe	Other
(	O
a	O
500-Hz	O
low-pass	O
noise	O
)	O
was	O
presented	O
from	O
a	O
horizontal	O
arc	O
1.6	O
m	O
in	O
front	O
of	O
the	O
observer	O
.	O

During	O
a	O
run	O
,	O
the	O
adaptor	O
was	O
presented	O
at	O
a	O
constant	O
velocity	O
(	O
-200	O
degrees	O
to	O
+200	O
degrees/sec	O
)	O
,	O
while	O
probes	O
with	O
velocities	O
varying	O
from	O
-10	O
degrees	O
to	O
+10	O
degrees/sec	O
were	O
presented	O
in	O
a	O
random	O
order	O
.	O

Observers	O
judged	O
the	O
direction	O
of	O
motion	O
(	O
left	O
or	O
right	O
)	O
of	O
each	O
probe	O
.	O

As	O
in	O
the	O
case	O
of	O
stimuli	O
presented	O
over	O
headphones	O
(	O
Grantham	O
&	O
Wightman	O
,	O
1979	O
)	O
,	O
an	O
auditory	O
motion	O
aftereffect	O
(	O
MAE	O
)	O
occurred	O
:	O
subjects	O
responded	O
left	O
to	O
probes	O
more	O
often	O
when	O
the	O
adaptor	O
moved	O
right	O
than	O
when	O
it	O
moved	O
left	O
.	O

When	O
the	O
adaptor	O
and	O
probe	O
were	O
spectrally	O
the	O
same	O
,	O
the	O
MAE	O
was	O
greater	O
than	O
when	O
they	O
were	O
from	O
different	O
spectral	O
regions	O
;	O
the	O
magnitude	O
of	O
this	O
difference	O
depended	O
on	O
adaptor	O
speed	O
and	O
was	O
subject-dependent	O
.	O

It	O
is	O
proposed	O
that	O
there	O
are	O
two	O
components	O
underlying	O
the	O
auditory	O
MAE	O
:	O
(	O
1	O
)	O
a	O
generalized	O
bias	O
to	O
respond	O
that	O
probes	O
move	O
in	O
the	O
direction	O
opposite	O
to	O
that	O
of	O
the	O
adaptor	O
,	O
independent	O
of	O
their	O
spectra	O
;	O
and	O
(	O
2	O
)	O
a	O
loss	O
of	O
sensitivity	O
to	O
the	O
velocity	O
of	O
moving	O
sounds	O
after	O
prolonged	O
exposure	O
to	O
moving	O
sounds	O
having	O
the	O
same	O
spectral	O
content	O
.	O

Randomized	O
clinical	O
trial	O
of	O
radiofrequency	Physical
ablation	Physical
or	O
conventional	Surgical
high	Surgical
ligation	Surgical
and	O
stripping	O
for	O
great	O
saphenous	O
varicose	O
veins	O
.	O

BACKGROUND	O
This	O
randomized	O
clinical	O
trial	O
compared	O
early	O
outcomes	O
after	O
radiofrequency	Physical
ablation	Physical
(	Physical
RFA	Physical
)	Physical
and	O
conventional	O
surgery	O
for	O
varicose	O
veins	O
.	O

METHODS	O
Consecutive	O
patients	O
with	O
symptomatic	O
varicose	O
veins	O
due	O
to	O
isolated	O
great	O
saphenous	O
vein	O
(	O
GSV	O
)	O
incompetence	O
and	O
suitable	O
for	O
RFA	O
were	O
randomized	O
to	O
either	O
RFA	Physical
or	O
conventional	O
surgery	O
(	O
saphenofemoral	O
disconnection	O
and	O
stripping	O
)	O
.	O

Clinical	O
,	O
radiological	O
and	O
patient-based	O
outcomes	O
were	O
recorded	O
at	O
1	O
and	O
5	O
weeks	O
after	O
intervention	O
.	O

RESULTS	O
RFA	Physical
resulted	O
in	O
successful	O
obliteration	O
of	O
the	O
GSV	O
in	O
all	O
47	O
patients	O
.	O

Complete	O
above-knee	O
stripping	O
was	O
unsuccessful	O
in	O
seven	O
of	O
41	O
patients	O
.	O

RFA	O
took	O
longer	O
than	O
conventional	O
surgery	O
:	O
median	O
interquartile	O
range	O
76	O
(	O
67-84	O
)	O
versus	O
48	O
(	O
39-54	O
)	O
min	O
;	O
P	O
<	O
0.001	O
.	O

Patients	O
returned	O
to	O
their	O
normal	O
activities	O
significantly	O
earlier	O
after	O
RFA	Physical
(	O
median	O
3	O
(	O
2-5	O
)	O
versus	O
12.5	O
(	O
4-21	O
)	O
days	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Postoperative	O
pain	O
was	O
significantly	O
less	O
after	O
RFA	Physical
(	O
median	O
score	O
on	O
visual	O
analogue	O
scale	O
1.70	O
(	O
0.50-4.30	O
)	O
versus	O
4.0	O
(	O
2.35-6.05	O
)	O
;	O
P	O
=	O
0.001	O
)	O
.	O

Patient	O
satisfaction	O
,	O
quality	O
of	O
life	O
improvement	O
and	O
analgesic	O
requirements	O
significantly	O
favoured	O
RFA	Physical
.	O

CONCLUSION	O
RFA	O
took	O
longer	O
to	O
perform	O
but	O
resulted	O
in	O
a	O
significantly	O
better	O
early	O
outcome	O
than	O
conventional	O
surgery	O
in	O
suitable	O
patients	O
with	O
great	O
saphenous	O
varicose	O
veins	O
.	O

Primary	O
glaucoma	O
triple	O
procedure	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
:	O
the	O
effect	O
of	O
mitomycin	Pharmacological
C	Pharmacological
in	O
patients	O
with	O
and	O
without	O
prognostic	O
factors	O
for	O
filtration	O
failure	O
.	O

PURPOSE	O
To	O
investigate	O
the	O
effect	O
of	O
adjunctive	Pharmacological
mitomycin	Pharmacological
C	Pharmacological
on	O
primary	O
glaucoma	O
triple	O
procedure	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
with	O
and	O
without	O
one	O
or	O
more	O
of	O
the	O
prognostic	O
factors	O
for	O
filtration	O
failure	O
of	O
primary	O
glaucoma	O
triple	O
procedure	O
.	O

Those	O
factors	O
include	O
being	O
of	O
African-American	O
race	O
,	O
having	O
a	O
preoperative	O
intraocular	O
pressure	O
of	O
20	O
mm	O
Hg	O
or	O
more	O
on	O
maximum	O
tolerated	O
medications	O
,	O
and	O
being	O
on	O
two	O
or	O
more	O
medications	O
preoperatively	O
.	O

METHODS	O
Study	O
patients	O
consisted	O
of	O
197	O
consecutive	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
no	Control
adjunctive	Control
mitomycin	Control
C	Control
(	Control
101	Control
eyes	Control
of	Control
101	Control
patients	Control
)	Control
or	O
to	O
receive	Pharmacological
adjunctive	Pharmacological
subconjunctival	Pharmacological
mitomycin	Pharmacological
C	Pharmacological
(	Pharmacological
96	Pharmacological
eyes	Pharmacological
of	Pharmacological
96	Pharmacological
patients	Pharmacological
)	Pharmacological
during	Pharmacological
the	Pharmacological
primary	Pharmacological
glaucoma	Pharmacological
triple	Pharmacological
procedure	Pharmacological
.	O

Kaplan-Meier	O
survival	O
analysis	O
comparisons	O
were	O
made	O
between	O
respective	O
subgroups	O
with	O
and	O
without	O
prognostic	O
indicators	O
for	O
filtration	O
failures	O
using	O
a	O
relatively	O
stringent	O
set	O
of	O
criteria	O
for	O
filtration	O
success	O
of	O
primary	O
glaucoma	O
triple	O
procedure	O
.	O

RESULTS	O
There	O
was	O
no	O
statistically	O
significant	O
(	O
P	O
=	O
.117	O
)	O
difference	O
in	O
filtration	O
success	O
of	O
primary	O
glaucoma	O
triple	O
procedure	O
between	O
the	O
control	O
and	O
mitomycin	O
C	O
groups	O
.	O

Adjunctive	O
mitomycin	O
C	O
significantly	O
(	O
P	O
<	O
.05	O
)	O
improved	O
the	O
filtration	O
outcome	O
of	O
the	O
primary	O
glaucoma	O
triple	O
procedure	O
in	O
the	O
subgroups	O
with	O
each	O
of	O
the	O
three	O
prognostic	O
factors	O
for	O
filtration	O
failure	O
of	O
primary	O
glaucoma	O
triple	O
procedure	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
subgroups	O
without	O
the	O
prognostic	O
factors	O
,	O
adjunctive	O
mitomycin	O
C	O
did	O
not	O
significantly	O
(	O
P	O
>	O
.05	O
)	O
change	O
the	O
filtration	O
outcome	O
of	O
the	O
primary	O
glaucoma	O
triple	O
procedure	O
.	O

CONCLUSION	O
These	O
findings	O
establish	O
the	O
basis	O
for	O
selective	O
use	O
of	O
mitomycin	O
C	O
in	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
undergoing	O
primary	O
glaucoma	O
triple	O
procedure	O
.	O

The	O
addition	O
of	O
amifostine	Pharmacological
to	O
carboplatin	Pharmacological
and	O
paclitaxel	Pharmacological
based	O
chemoradiation	Physical
in	O
locally	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
:	O
long-term	O
follow-up	O
of	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(	O
RTOG	O
)	O
randomized	O
trial	O
9801	O
.	O

INTRODUCTION	O
We	O
report	O
the	O
long-term	O
results	O
of	O
RTOG	O
9801	O
,	O
a	O
randomized	O
trial	O
investigating	O
the	O
ability	O
of	O
amifostine	Pharmacological
,	O
a	O
radioprotector	O
,	O
to	O
reduce	O
chemoradiation-induced	O
esophagitis	O
.	O

METHODS	O
Patients	O
with	O
stages	O
II	O
and	O
IIIA/B	O
non-small-cell	O
lung	O
cancer	O
received	O
induction	O
paclitaxel	Pharmacological
225	O
mg/m2	O
intravenously	O
(	O
IV	O
)	O
and	O
carboplatin	Pharmacological
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
6	O
both	O
days	O
1	O
and	O
22	O
,	O
followed	O
by	O
concurrent	O
weekly	O
paclitaxel	Pharmacological
(	O
50	O
mg/m2	O
)	O
and	O
carboplatin	Pharmacological
(	O
AUC	O
2	O
)	O
,	O
with	O
hyperfractionated	Pharmacological
radiation	Pharmacological
therapy	Pharmacological
(	O
69.6	O
Gy	O
at	O
1.2	O
Gy	O
BID	O
)	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
amifostine	Pharmacological
(	O
AM	O
)	O
500	O
mg	O
IV	O
four	O
times	O
per	O
week	O
or	O
no-AM	O
during	O
chemoradiotherapy	O
.	O

Stratification	O
factors	O
included	O
age	O
(	O
<	O
70	O
vs.	O
?70	O
years	O
)	O
,	O
stage	O
and	O
performance	O
status	O
.	O

RESULTS	O
243	O
patients	O
(	O
pts	O
)	O
were	O
enrolled	O
;	O
120	O
received	O
AM	O
,	O
123	O
received	O
no-AM	O
.	O

Two	O
pts	O
on	O
each	O
arm	O
were	O
found	O
ineligible	O
.	O

Overall	O
,	O
85	O
%	O
of	O
patients	O
were	O
?70	O
years	O
;	O
75	O
%	O
had	O
a	O
KPS	O
?90	O
.	O

34	O
%	O
had	O
squamous	O
histology	O
.	O

With	O
median	O
follow-up	O
of	O
96.3	O
months	O
(	O
for	O
patients	O
still	O
alive	O
)	O
,	O
overall	O
survival	O
was	O
identical	O
(	O
hazard	O
ratio	O
1.03	O
(	O
0.79-1.34	O
)	O
,	O
NS	O
)	O
:	O
five-year	O
survival	O
17	O
%	O
in	O
both	O
arms	O
.	O

The	O
incidence	O
of	O
late	O
grade	O
3-5	O
toxicities	O
was	O
16	O
%	O
in	O
the	O
AM	O
arm	O
and	O
19	O
%	O
in	O
the	O
control	O
arm	O
(	O
hazard	O
ratio	O
1.24	O
(	O
0.66-2.32	O
)	O
,	O
NS	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
arms	O
regarding	O
overall	O
survival	O
,	O
disease-free	O
survival	O
or	O
long-term	O
toxicity	O
.	O

CONCLUSION	O
The	O
chemoradiation	O
regimen	O
of	O
carboplatin	O
and	O
paclitaxel	O
produced	O
long-term	O
results	O
in	O
the	O
multi-institutional	O
setting	O
comparable	O
to	O
other	O
regimens	O
.	O

Amifostine	O
did	O
not	O
appear	O
to	O
compromise	O
survival	O
.	O

As	O
done	O
in	O
RTOG	O
9801	O
,	O
more	O
consistent	O
reporting	O
of	O
long	O
term	O
toxicity	O
is	O
needed	O
for	O
comparison	O
of	O
different	O
chemoradiation	O
regimens	O
.	O

Dexamethasone	Pharmacological
effectively	O
reduces	O
postoperative	O
nausea	O
and	O
vomiting	O
in	O
a	O
general	O
surgical	O
adult	O
patient	O
population	O
.	O

BACKGROUND	O
Postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
is	O
still	O
a	O
common	O
and	O
major	O
complication	O
for	O
surgical	O
patients	O
,	O
which	O
may	O
delay	O
post-anesthetic	O
care	O
unit	O
discharge	O
,	O
prolong	O
hospital	O
stay	O
and	O
thus	O
increase	O
the	O
cost	O
of	O
hospitalization	O
.	O

It	O
is	O
understood	O
that	O
PONV	O
is	O
a	O
multi-factorial	O
outcome	O
and	O
occurs	O
more	O
often	O
with	O
general	O
anesthesia	O
than	O
with	O
other	O
anesthetic	O
methods	O
.	O

Prophylactic	O
administration	O
of	O
antihistamines	O
,	O
antidopaminergics	O
,	O
anticholinergics	O
,	O
phenothiazines	O
,	O
serotonin	O
antagonist	O
,	O
steroids	O
and	O
even	O
acupuncture	O
has	O
been	O
shown	O
to	O
be	O
effective	O
.	O

However	O
,	O
expenses	O
and	O
side	O
effects	O
of	O
these	O
agents	O
have	O
also	O
been	O
a	O
concern	O
for	O
clinical	O
doctors	O
.	O

The	O
aim	O
for	O
this	O
prospective	O
study	O
was	O
to	O
find	O
an	O
agent	O
that	O
is	O
cost	O
effective	O
and	O
side	O
effect	O
free	O
(	O
or	O
at	O
least	O
with	O
a	O
low	O
incidence	O
of	O
side	O
effects	O
)	O
for	O
the	O
prevention	O
of	O
PONV	O
.	O

METHODS	O
A	O
total	O
of	O
700	O
adult	O
surgical	O
patients	O
who	O
planned	O
to	O
have	O
surgery	O
under	O
general	O
anesthesia	O
were	O
enrolled	O
in	O
this	O
double-blinded	O
,	O
randomized	O
and	O
placebo-controlled	Pharmacological
study	O
.	O

Group	O
P	O
received	O
the	O
placebo	Control
(	O
0.9	O
%	O
normal	Control
saline	Control
2	O
ml	O
)	O
and	O
Group	O
D	O
received	O
10	O
mg	O
dexamethasone	Pharmacological
intravenously	O
right	O
before	O
the	O
induction	O
of	O
anesthesia	O
.	O

RESULTS	O
We	O
found	O
that	O
during	O
the	O
postoperative	O
period	O
of	O
1-8	O
h	O
,	O
patients	O
in	O
Group	O
D	O
reported	O
a	O
lower	O
incidence	O
of	O
PONV	O
(	O
24	O
%	O
)	O
than	O
those	O
in	O
Group	O
P	O
(	O
39	O
%	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Patients	O
in	O
Group	O
D	O
also	O
requested	O
less	O
rescue	O
anti-emetic	O
(	O
17	O
%	O
)	O
than	O
those	O
in	O
Group	O
P	O
(	O
30	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

The	O
same	O
phenomenon	O
was	O
also	O
noted	O
in	O
the	O
8-to-24-hour	O
interval	O
(	O
PONV	O
4	O
%	O
vs.	O
12	O
%	O
,	O
p	O
<	O
0.05	O
and	O
rescue	O
anti-emetic	O
3	O
%	O
vs.	O
9	O
%	O
,	O
p	O
<	O
0.05	O
in	O
Group	O
D	O
vs.	O
Group	O
P	O
,	O
respectively	O
.	O

)	O
CONCLUSIONS	O
We	O
conclude	O
that	O
the	O
prophylactic	O
intravenous	O
administration	O
of	O
10	O
mg	O
dexamethasone	O
immediately	O
before	O
the	O
induction	O
of	O
anesthesia	O
is	O
effective	O
in	O
preventing	O
PONV	O
in	O
the	O
general	O
surgical	O
adult	O
patient	O
population	O
.	O

Effects	O
of	O
captopril	Pharmacological
and	O
enalapril	Pharmacological
on	O
electroencephalogram	O
and	O
cognitive	O
performance	O
in	O
healthy	O
volunteers	O
.	O

OBJECTIVE	O
Captopril	Pharmacological
and	O
enalapril	Pharmacological
have	O
been	O
reported	O
to	O
influence	O
cognitive	O
functions	O
and	O
quality	O
of	O
life	O
in	O
hypertensive	O
patients	O
.	O

METHODS	O
The	O
effects	O
of	O
captopril	Pharmacological
(	O
12.5	O
mg	O
and	O
25	O
mg	O
)	O
and	O
enalapril	Pharmacological
(	O
5	O
mg	O
and	O
10	O
mg	O
)	O
administered	O
during	O
7-day	O
periods	O
on	O
electroencephalogram	Physical
(	O
EEG	O
)	O
,	O
cognitive	O
functions	O
,	O
and	O
subjective	O
assessments	O
were	O
investigated	O
in	O
healthy	O
males	O
.	O

RESULTS	O
Neither	O
captopril	O
nor	O
enalapril	O
influenced	O
EEG	O
and	O
cognitive	O
functions	O
compared	O
with	O
placebo	O
.	O

Captopril	Pharmacological
12.5	O
mg	O
decreased	O
subjective	O
activity	O
compared	O
with	O
placebo	Control
.	O

Enalapril	Pharmacological
did	O
not	O
alter	O
subjective	O
ratings	O
.	O

Both	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
were	O
significantly	O
lower	O
after	O
administration	O
of	O
captopril	Pharmacological
25	O
mg	O
,	O
whereas	O
blood	O
pressure	O
was	O
unaffected	O
by	O
enalapril	Pharmacological
compared	O
with	O
placebo	O
.	O

CONCLUSION	O
Our	O
results	O
suggest	O
that	O
central	O
effects	O
of	O
captopril	Pharmacological
and	O
enalapril	Pharmacological
were	O
minor	O
and	O
not	O
constant	O
in	O
young	O
healthy	O
men	O
.	O

Cognitive	O
effects	O
of	O
lithium	Pharmacological
carbonate	Pharmacological
and	Pharmacological
haloperidol	Pharmacological
in	O
treatment-resistant	O
aggressive	O
children	O
.	O

The	O
effects	O
of	O
lithium	Pharmacological
carbonate	Pharmacological
and	Pharmacological
haloperidol	Pharmacological
on	O
cognition	O
were	O
examined	O
in	O
a	O
placebo-controlled	Control
,	O
double-blind	O
study	O
of	O
61	O
treatment-resistant	O
,	O
hospitalized	O
school-aged	O
children	O
.	O

They	O
all	O
had	O
a	O
DSM-III	O
diagnosis	O
of	O
conduct	O
disorder	O
--	O
undersocialized	O
,	O
aggressive	O
,	O
with	O
a	O
profile	O
of	O
highly	O
explosive	O
and	O
aggressive	O
behavior	O
.	O

Children	O
were	O
assessed	O
at	O
the	O
end	O
of	O
a	O
two-week	O
placebo-baseline	Control
period	O
and	O
again	O
after	O
four	O
weeks	O
of	O
treatment	O
.	O

Drug	O
effects	O
on	O
cognition	O
were	O
mild	O
.	O

Haloperidol	Pharmacological
(	O
mean	O
dose	O
,	O
2.95	O
mg/day	O
)	O
caused	O
significant	O
decreases	O
in	O
Porteus	O
Maze	O
test	O
quotient	O
scores	O
and	O
a	O
slowing	O
of	O
reaction	O
time	O
(	O
RT	O
)	O
on	O
a	O
simple	O
RT	O
task	O
.	O

Lithium	Pharmacological
carbonate	Pharmacological
(	O
mean	O
dose	O
,	O
1,166	O
mg/day	O
)	O
adversely	O
affected	O
qualitative	O
scores	O
on	O
the	O
Porteus	O
Maze	O
test	O
.	O

No	O
significant	O
treatment	O
effects	O
were	O
found	O
for	O
the	O
Matching	O
Familiar	O
Figures	O
Test	O
,	O
short-term	O
recognition	O
memory	O
and	O
concept	O
attainment	O
tasks	O
,	O
or	O
the	O
Stroop	O
Test	O
.	O

Albumin-glutaraldehyde	Pharmacological
bioadhesive	Pharmacological
(	Pharmacological
Bioglue	Pharmacological
)	Pharmacological
for	O
prevention	O
of	O
postoperative	O
complications	O
after	O
stapled	O
hemorrhoidopexy	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Hemorrhoidopexy	O
using	O
the	O
circumferential	O
stapler	O
is	O
an	O
established	O
method	O
for	O
surgical	O
treatment	O
of	O
patients	O
with	O
prolapsing	O
hemorrhoids	O
.	O

Despite	O
its	O
advantages	O
,	O
complications	O
such	O
as	O
anal	O
canal	O
stenosis	O
,	O
hemorrhage	O
and	O
anastomosis	O
leak	O
with	O
eventual	O
intrapelvic	O
sepsis	O
can	O
cause	O
serious	O
postoperative	O
problems	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
utility	O
of	O
a	O
surgical	O
adhesive	O
,	O
the	O
biological	Pharmacological
albumin-glutaraldehyde	Pharmacological
glue	Pharmacological
Bioglue	Pharmacological
,	O
in	O
reduction	O
of	O
these	O
postoperative	O
complications	O
.	O

PATIENTS	O
AND	O
METHODS	O
Between	O
January	O
2002	O
and	O
November	O
2004	O
,	O
200	O
patients	O
undergoing	O
stapled	Surgical
hemorrhoidopexy	Surgical
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
.	O

One	O
hundred	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
control	Control
group	Control
;	Educational
the	O
study	O
group	O
consisted	O
of	O
100	O
patients	O
who	O
received	O
Bioglue	Pharmacological
in	Pharmacological
the	Pharmacological
mucosa	Pharmacological
anastomosis	Pharmacological
area	Pharmacological
.	O

All	O
patients	O
received	O
standardized	Pharmacological
postoperative	Pharmacological
analgesic	Pharmacological
,	Pharmacological
laxative	Pharmacological
and	Pharmacological
antibiotic	Pharmacological
treatment	Pharmacological
.	O

We	O
then	O
evaluated	O
the	O
two	O
groups	O
for	O
postoperative	O
complications	O
(	O
after	O
surgery	O
and	O
6	O
months	O
postoperatively	O
)	O
.	O

RESULTS	O
From	O
the	O
control	O
group	O
(	O
no	O
Bioglue	O
application	O
)	O
,	O
two	O
patients	O
presented	O
with	O
anal	O
stenosis	O
,	O
two	O
with	O
hemorrhage	O
,	O
three	O
had	O
anastomosis	O
leak	O
and	O
one	O
had	O
thrombosis	O
,	O
whereas	O
none	O
of	O
the	O
patients	O
from	O
the	O
Bioglue	O
group	O
had	O
any	O
of	O
these	O
complications	O
.	O

Both	O
groups	O
had	O
patients	O
with	O
severe	O
postoperative	O
pain	O
(	O
3	O
each	O
)	O
and	O
fecal	O
incontinence	O
(	O
1	O
patient	O
each	O
)	O
.	O

The	O
overall	O
difference	O
in	O
the	O
number	O
of	O
complications	O
in	O
the	O
two	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
In	O
this	O
first	O
study	O
using	O
Bioglue	O
in	O
patients	O
undergoing	O
circumferential	O
stapled	O
hemorrhoidopexy	O
we	O
have	O
shown	O
that	O
application	O
of	O
the	O
glue	O
is	O
effective	O
in	O
reducing	O
postoperative	O
complications	O
.	O

Nurse	O
and	O
patient	O
communication	O
profiles	O
in	O
a	O
home-based	O
telehealth	O
intervention	O
for	O
heart	O
failure	O
management	O
.	O

OBJECTIVE	O
This	O
study	O
compared	O
differences	O
in	O
nurse	O
and	O
patient	O
communication	O
profiles	O
between	O
two	O
telehealth	O
modes	O
:	O
telephone	Educational
and	O
videophone	Other
,	O
and	O
evaluated	O
longitudinal	O
changes	O
in	O
communication	O
,	O
nurse	O
perceptions	O
,	O
and	O
patient	O
satisfaction	O
.	O

METHODS	O
Subjects	O
were	O
enrolled	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
evaluating	O
a	O
90-day	O
home-based	O
intervention	O
for	O
heart	O
failure	O
.	O

Telephone	Educational
(	O
n=14	O
)	O
and	O
videophone	Other
(	O
n=14	O
)	O
interactions	O
were	O
audio	O
taped	O
and	O
analyzed	O
using	O
the	O
Roter	Other
Interaction	Other
Analysis	Other
System	Other
.	O

RESULTS	O
Nurses	O
were	O
more	O
likely	O
to	O
use	O
open-ended	O
questions	O
,	O
back-channel	O
responses	O
,	O
friendly	O
jokes	O
,	O
and	O
checks	O
for	O
understanding	O
on	O
the	O
telephone	Educational
compared	O
to	O
videophone	Other
.	O

Compliments	O
given	O
and	O
partnership	O
were	O
more	O
common	O
on	O
the	O
videophone	O
.	O

Patients	O
were	O
more	O
likely	O
to	O
give	O
lifestyle	O
information	O
and	O
approval	O
comments	O
on	O
the	O
telephone	Educational
,	O
and	O
used	O
more	O
closed-ended	O
questions	O
on	O
the	O
videophone	Other
.	O

Nurses	O
perceptions	O
of	O
the	O
interactions	O
were	O
not	O
different	O
between	O
the	O
telephone	O
and	O
videophone	Other
,	O
nor	O
did	O
their	O
perceptions	O
change	O
significantly	O
over	O
the	O
course	O
of	O
the	O
intervention	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
patient	O
satisfaction	O
between	O
the	O
telephone	O
and	O
videophone	Other
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
did	O
not	O
support	O
use	O
of	O
a	O
videophone	Other
over	O
the	O
telephone	Educational
.	O

PRACTICE	O
IMPLICATIONS	O
It	O
is	O
critical	O
to	O
match	O
technologies	O
to	O
patient	O
needs	O
and	O
use	O
the	O
least	O
complex	O
technology	O
possible	O
.	O

When	O
considering	O
use	O
a	O
videophone	Other
,	O
health	O
care	O
providers	O
should	O
critically	O
examine	O
the	O
trade-offs	O
between	O
additional	O
complexities	O
with	O
the	O
added	O
value	O
of	O
the	O
visual	O
interaction	O
.	O

Is	O
psychotherapy	Psychological
more	O
effective	O
when	O
therapists	O
disclose	O
information	O
about	O
themselves	O
?	O
Theorists	O
have	O
long	O
debated	O
the	O
wisdom	O
of	O
therapists	O
disclosing	O
personal	O
information	O
during	O
psychotherapy	Psychological
.	O

Some	O
observers	O
have	O
argued	O
that	O
such	O
therapist	O
self-disclosure	O
impedes	O
treatment	O
,	O
whereas	O
others	O
have	O
suggested	O
that	O
it	O
enhances	O
the	O
effectiveness	O
of	O
therapy	O
.	O

To	O
test	O
these	O
competing	O
positions	O
,	O
therapists	O
at	O
a	O
university	O
counseling	O
center	O
were	O
instructed	O
to	O
increase	Psychological
the	Psychological
number	Psychological
of	Psychological
self-disclosures	Psychological
they	O
made	O
during	O
treatment	Psychological
of	O
one	O
client	O
and	O
refrain	Psychological
from	Psychological
making	Psychological
self-disclosures	Psychological
during	Psychological
treatment	Psychological
of	O
another	O
client	O
.	O

Analyses	O
revealed	O
that	O
clients	O
receiving	O
psychotherapy	Psychological
under	O
conditions	O
of	O
heightened	O
therapist	Psychological
disclosure	Psychological
not	O
only	O
reported	O
lower	O
levels	O
of	O
symptom	O
distress	O
but	O
also	O
liked	O
their	O
therapist	O
more	O
.	O

Such	O
findings	O
suggest	O
that	O
self-disclosure	O
by	O
the	O
therapist	O
may	O
improve	O
both	O
the	O
quality	O
of	O
the	O
therapeutic	O
relationship	O
and	O
the	O
outcome	O
of	O
treatment	O
.	O

Pharmacokinetics	O
of	O
azithromycin	Pharmacological
in	O
lung	O
tissue	O
,	O
bronchial	O
washing	O
,	O
and	O
plasma	O
in	O
patients	O
given	O
multiple	O
oral	O
doses	O
of	O
500	O
and	O
1000	O
mg	O
daily	O
.	O

The	O
present	O
study	O
compares	O
the	O
pharmacokinetics	O
of	O
azithromycin	Pharmacological
in	O
plasma	O
,	O
lung	O
tissue	O
,	O
and	O
bronchial	O
washing	O
after	O
oral	O
administration	O
of	O
500	O
mg	O
(	O
standard	O
dose	O
)	O
versus	O
1000	O
mg	O
daily	O
for	O
3	O
days	O
.	O

Samples	O
were	O
taken	O
during	O
surgery	O
for	O
lung	O
resection	O
at	O
various	O
time	O
points	O
up	O
to	O
204	O
h	O
after	O
the	O
last	O
drug	O
dose	O
,	O
and	O
azithromycin	Pharmacological
levels	O
were	O
analyzed	O
by	O
HPLC	O
method	O
.	O

Azithromycin	Pharmacological
was	O
widely	O
distributed	O
within	O
the	O
lower	O
respiratory	O
tract	O
;	O
sustained	O
concentrations	O
of	O
the	O
drug	O
were	O
detectable	O
at	O
the	O
last	O
sampling	O
time	O
(	O
204	O
h	O
)	O
in	O
lung	O
tissue	O
and	O
bronchial	O
washing	O
,	O
with	O
long	O
terminal	O
half-lives	O
of	O
132.86	O
and	O
74.32	O
h	O
at	O
500	O
mg	O
daily	O
and	O
133.32	O
and	O
70.5	O
h	O
at	O
1000	O
mg	O
daily	O
,	O
respectively	O
.	O

Doubling	O
the	O
drug	O
dose	O
resulted	O
in	O
a	O
remarkable	O
increase	O
in	O
lung	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
,	O
1318	O
hx	O
microg	O
g	O
(	O
-1	O
)	O
vs	O
2502	O
hx	O
microg	O
g	O
(	O
-1	O
)	O
)	O
and	O
peak	O
tissue	O
concentration	O
(	O
9.13+/-0.53	O
microg	O
g	O
(	O
-1	O
)	O
vs	O
17.85+/-2.4	O
microg	O
g	O
(	O
-1	O
)	O
)	O
.	O

In	O
addition	O
to	O
this	O
,	O
enhanced	O
azithromycin	Pharmacological
penetration	O
from	O
plasma	O
into	O
bronchial	O
secretion	O
and	O
lung	O
tissue	O
was	O
evidenced	O
by	O
the	O
increase	O
in	O
the	O
ratio	O
of	O
AUC	O
(	O
bronchial	O
washing	O
)	O
versus	O
AUC	O
(	O
plasma	O
)	O
(	O
2.96	O
vs	O
5.27	O
at	O
500	O
and	O
1000	O
mg	O
,	O
respectively	O
)	O
and	O
AUC	O
(	O
lung	O
)	O
versus	O
AUC	O
(	O
plasma	O
)	O
(	O
64.35	O
vs	O
97.73	O
at	O
500	O
and	O
1000	O
mg	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
exposure	O
of	O
lung	O
and	O
bronchial	O
washing	O
to	O
azithromycin	Pharmacological
is	O
increased	O
by	O
doubling	O
the	O
dose	O
,	O
which	O
results	O
in	O
favorable	O
pharmacokinetic	O
profile	O
of	O
the	O
drug	O
in	O
the	O
lower	O
respiratory	O
tract	O
.	O

Increased	O
growth	O
hormone	O
response	O
to	O
sumatriptan	Pharmacological
challenge	O
in	O
adult	O
autistic	O
disorders	O
.	O

Serotonergic	O
(	O
5-HT	O
)	O
abnormalities	O
have	O
been	O
documented	O
in	O
autism	O
.	O

To	O
assess	O
sensitivity	O
of	O
the	O
5-HT1d	O
receptor	O
,	O
growth	O
hormone	O
response	O
to	O
the	O
5-HT1d	Pharmacological
receptor	Pharmacological
agonist	Pharmacological
sumatriptan	Pharmacological
was	O
studied	O
in	O
adult	O
autistic	O
patients	O
and	O
matched	O
normal	O
controls	O
.	O

In	O
this	O
study	O
,	O
11	O
adult	O
patients	O
with	O
autism	O
or	O
Asperger	O
's	O
disorder	O
were	O
compared	O
with	O
nine	O
matched	O
controls	O
.	O

All	O
subjects	O
were	O
randomized	O
to	O
single	Pharmacological
dose	Pharmacological
sumatriptan	Pharmacological
(	Pharmacological
6	Pharmacological
mg	Pharmacological
SQ	Pharmacological
)	Pharmacological
and	O
placebo	Control
challenges	Control
,	O
separated	O
by	O
a	O
1-week	O
interval	O
,	O
and	O
growth	Pharmacological
hormone	Pharmacological
was	Pharmacological
measured	Pharmacological
before	Pharmacological
and	Pharmacological
during	Pharmacological
the	Pharmacological
challenges	Pharmacological
.	O

The	O
results	O
showed	O
a	O
highly	O
significant	O
diagnosisxdrugxtime	O
interaction	O
on	O
repeated	O
measure	O
analysis	O
covaried	O
for	O
baseline	O
.	O

This	O
suggests	O
that	O
autistic	O
patients	O
had	O
significantly	O
greater	O
growth	O
hormone	O
response	O
to	O
sumatriptan	Pharmacological
than	O
normal	O
controls	O
,	O
independent	O
of	O
placebo	O
effects	O
.	O

Therefore	O
,	O
abnormalities	O
in	O
5-HT	O
regulation	O
in	O
autism	O
may	O
be	O
related	O
to	O
increased	O
sensitivity	O
of	O
the	O
5-HT1d	O
inhibitory	O
receptor	O
in	O
autism	O
.	O

Venlafaxine	Pharmacological
versus	O
clonidine	Pharmacological
for	O
the	O
treatment	O
of	O
hot	O
flashes	O
in	O
breast	O
cancer	O
patients	O
:	O
a	O
double-blind	O
,	O
randomized	O
cross-over	O
study	O
.	O

PURPOSE	O
Breast	O
cancer	O
patients	O
with	O
treatment-induced	O
menopause	O
experience	O
frequent	O
and	O
severe	O
hot	O
flashes	O
(	O
HF	O
)	O
.	O

We	O
compared	O
venlafaxine	Pharmacological
and	O
clonidine	Pharmacological
for	O
the	O
treatment	O
of	O
HF	O
with	O
regard	O
to	O
side	O
effects	O
,	O
efficacy	O
,	O
quality	O
of	O
life	O
and	O
sexual	O
functioning	O
.	O

METHODS	O
In	O
a	O
double-blind	O
,	O
cross-over	O
study	O
,	O
60	O
breast	O
cancer	O
patients	O
experiencing	O
HF	O
were	O
randomized	O
to	O
8	O
weeks	O
venlafaxine	Pharmacological
followed	O
by	O
2	O
weeks	O
wash-out	O
,	O
and	O
8	O
weeks	O
clonidine	Pharmacological
or	O
vice	O
versa	O
.	O

HF	O
frequency	O
and	O
severity	O
,	O
side	O
effects	O
,	O
quality	O
of	O
life	O
and	O
sexuality	O
were	O
assessed	O
.	O

RESULTS	O
Thirty	O
patients	O
started	O
with	O
venlafaxine	Pharmacological
and	O
30	O
with	O
clonidine	Pharmacological
.	O

Premature	O
discontinuation	O
for	O
toxicity	O
occurred	O
in	O
14/59	O
during	O
venlafaxine	Pharmacological
and	O
5/53	O
during	O
clonidine	Pharmacological
(	O
P	O
=	O
.038	O
)	O
.	O

Venlafaxine	Pharmacological
induced	O
more	O
side	O
effects	O
.	O

Median	O
reduction	O
in	O
HF	O
score	O
was	O
49	O
%	O
for	O
venlafaxine	Pharmacological
and	O
55	O
%	O
for	O
clonidine	Pharmacological
(	O
ns	O
)	O
.	O

CONCLUSION	O
Venlafaxine	Pharmacological
and	O
clonidine	Pharmacological
are	O
equally	O
,	O
but	O
moderately	O
effective	O
in	O
HF	O
reduction	O
.	O

Side	O
effects	O
are	O
the	O
main	O
reason	O
for	O
drug	O
discontinuation	O
,	O
occurring	O
more	O
often	O
with	O
venlafaxine	Pharmacological
.	O

Central	O
neuronal	O
mechanisms	O
of	O
gastric	Physical
electrical	Physical
stimulation	Physical
in	O
diabetic	O
gastroparesis	O
.	O

OBJECTIVE	O
The	O
mechanisms	O
underlying	O
symptom	O
improvement	O
in	O
gastric	Surgical
electrical	Surgical
stimulation	Surgical
(	Surgical
GES	Surgical
)	Surgical
are	O
not	O
fully	O
understood	O
.	O

Modulation	O
of	O
the	O
central	O
nervous	O
system	O
excitability	O
may	O
be	O
involved	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
central	O
effects	O
of	O
GES	Surgical
,	O
including	O
the	O
possible	O
modulation	O
of	O
the	O
visceral	O
sensory	O
nervous	O
system	O
.	O

MATERIAL	O
AND	O
METHODS	O
A	O
gastric	Surgical
electrical	Surgical
stimulator	Surgical
was	O
implanted	O
in	O
seven	O
diabetic	O
patients	O
with	O
medically	O
refractory	O
gastroparesis	Surgical
.	O

A	O
double-blinded	O
protocol	O
was	O
used	O
to	O
investigate	O
the	O
patients	O
at	O
baseline	O
and	O
one	O
month	O
after	O
recovery	O
with	O
the	O
stimulator	O
turned	O
on	O
and	O
off	O
(	O
1-month	O
periods	O
)	O
.	O

The	O
following	O
assessments	O
were	O
carried	O
out	O
:	O
mechanical	O
,	O
thermal	O
and	O
electrical	O
stimulations	O
with	O
sensory	O
recordings	O
in	O
the	O
esophagus	O
and	O
duodenum	O
,	O
and	O
standardized	O
,	O
self-administered	O
,	O
daily	O
symptom	O
questionnaires	O
.	O

RESULTS	O
No	O
difference	O
was	O
found	O
between	O
baseline	O
and	O
the	O
on-	O
and	O
off	O
periods	O
in	O
overall	O
gut	O
pain	O
thresholds	O
across	O
all	O
stimulus	O
modalities	O
in	O
the	O
esophagus	O
(	O
p=0.63	O
)	O
,	O
duodenum	O
(	O
p=0.19	O
)	O
or	O
esophagus	O
and	O
duodenum	O
combined	O
(	O
p=0.76	O
)	O
.	O

No	O
difference	O
in	O
the	O
sensory	O
response	O
to	O
mechanical	O
stimulation	O
was	O
found	O
in	O
the	O
esophagus	O
before	O
(	O
all	O
p	O
>	O
0.31	O
)	O
and	O
after	O
(	O
all	O
p	O
>	O
0.43	O
)	O
smooth	O
muscle	O
relaxation	O
with	O
butylscopolamine	Pharmacological
.	O

Similar	O
findings	O
were	O
observed	O
in	O
the	O
duodenum	O
.	O

No	O
differences	O
were	O
found	O
in	O
thermal	O
sensitivity	O
(	O
esophagus	O
(	O
p=0.67	O
)	O
and	O
duodenum	O
(	O
p=0.17	O
)	O
)	O
,	O
sensory	O
response	O
to	O
electrical	O
stimulation	O
(	O
esophagus	O
(	O
p=0.57	O
)	O
and	O
duodenum	O
(	O
p=0.52	O
)	O
)	O
or	O
induced	O
somatic	O
referred	O
pain	O
areas	O
(	O
esophagus	O
(	O
p=0.75	O
)	O
and	O
duodenum	O
(	O
p=0.51	O
)	O
)	O
.	O

No	O
difference	O
was	O
seen	O
in	O
the	O
induced	O
somatic	O
referred	O
pain	O
areas	O
or	O
self-reported	O
symptoms	O
.	O

CONCLUSIONS	O
No	O
evidence	O
was	O
found	O
for	O
GES-induced	Surgical
modulation	O
of	O
the	O
visceral	O
sensory	O
system	O
and	O
central	O
excitability	O
.	O

However	O
,	O
GES	Surgical
has	O
been	O
proven	O
to	O
modulate	O
the	O
central	O
nervous	O
system	O
in	O
animal	O
studies	O
,	O
necessitating	O
further	O
human	O
experiments	O
in	O
order	O
unambiguously	O
to	O
establish	O
the	O
possible	O
central	O
effects	O
of	O
GES	Surgical
.	O

Incidence	O
and	O
clinical	O
significance	O
of	O
false-negative	O
sextant	O
prostate	O
biopsies	O
.	O

PURPOSE	O
Since	O
most	O
patients	O
do	O
not	O
undergo	O
repeat	O
sextant	O
prostate	O
biopsies	O
after	O
a	O
biopsy	O
is	O
positive	O
for	O
prostate	O
cancer	O
,	O
the	O
true	O
incidence	O
of	O
false-negative	O
biopsies	O
is	O
not	O
well	O
defined	O
.	O

We	O
assess	O
the	O
incidence	O
and	O
clinical	O
significance	O
of	O
false-negative	O
sextant	O
prostate	O
biopsies	O
in	O
patients	O
undergoing	O
radical	Surgical
prostatectomy	Surgical
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
of	O
118	O
patients	O
with	O
biopsy	O
proved	O
prostate	O
cancer	O
underwent	O
repeat	Surgical
sextant	Surgical
prostate	Surgical
biopsy	Surgical
before	O
enrollment	O
in	O
a	O
prospective	O
randomized	O
trial	O
of	O
radical	Surgical
prostatectomy	Surgical
with	O
or	O
without	O
neoadjuvant	Physical
hormonal	Physical
therapy	Physical
.	O

Clinical	O
parameters	O
were	O
assessed	O
to	O
determine	O
potential	O
sources	O
of	O
bias	O
.	O

Pathological	O
parameters	O
and	O
prostate	O
specific	O
antigen	O
relapse-free	O
survival	O
rates	O
were	O
compared	O
to	O
determine	O
the	O
clinical	O
significance	O
of	O
false-negative	O
biopsies	O
.	O

RESULTS	O
Of	O
the	O
118	O
patients	O
27	O
(	O
23	O
%	O
)	O
had	O
a	O
negative	O
repeat	O
sextant	O
biopsy	O
.	O

Except	O
for	O
initial	O
clinical	O
stage	O
,	O
no	O
differences	O
were	O
noted	O
in	O
the	O
clinical	O
or	O
pathological	O
parameters	O
,	O
or	O
prostate	O
specific	O
antigen	O
relapse	O
rates	O
in	O
patients	O
with	O
negative	O
versus	O
positive	O
repeat	O
biopsies	O
.	O

CONCLUSIONS	O
Our	O
findings	O
suggest	O
that	O
this	O
23	O
%	O
incidence	O
of	O
false-negative	O
biopsies	O
represents	O
significant	O
cancer	O
.	O

This	O
relatively	O
high	O
incidence	O
is	O
important	O
to	O
consider	O
in	O
treatment	O
modalities	O
in	O
which	O
prostate	O
biopsy	O
may	O
be	O
performed	O
to	O
determine	O
response	O
to	O
therapy	O
.	O

Cholesterol-lowering	Physical
therapy	Physical
may	O
retard	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
.	O

There	O
is	O
experimental	O
evidence	O
to	O
suggest	O
that	O
hypercholesterolaemia	O
may	O
play	O
a	O
pathogenetic	O
role	O
in	O
progressive	O
glomerular	O
injury	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
cholesterol-lowering	O
therapy	O
on	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
in	O
34	O
patients	O
with	O
non-insulin-dependent	O
diabetes	O
mellitus	O
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
single-blind	O
fashion	O
to	O
treatment	O
with	O
either	O
lovastatin	Pharmacological
,	Pharmacological
an	Pharmacological
HMG	Pharmacological
CoA	Pharmacological
reductase	Pharmacological
inhibitor	Pharmacological
(	O
n	O
=	O
16	O
;	O
mean	O
dose	O
30.0	O
+/-	O
12.6	O
mg/day	O
)	O
or	O
placebo	Control
(	O
n	O
=	O
18	O
)	O
for	O
2	O
years	O
.	O

Renal	O
function	O
was	O
assessed	O
by	O
serially	O
measuring	O
the	O
serum	O
creatinine	O
,	O
glomerular	O
filtration	O
rate	O
(	O
using	O
Cr51-EDTA	O
)	O
,	O
and	O
24-h	O
urinary	O
protein	O
excretion	O
.	O

Lovastatin	Pharmacological
treatment	O
was	O
associated	O
with	O
significant	O
reductions	O
in	O
total	O
cholesterol	O
(	O
p	O
<	O
0.001	O
)	O
,	O
LDL-cholesterol	O
(	O
p	O
<	O
0.001	O
)	O
and	O
apo	O
B	O
(	O
p	O
<	O
0.01	O
)	O
,	O
the	O
reductions	O
at	O
24	O
months	O
being	O
26	O
,	O
30	O
and	O
18	O
%	O
,	O
respectively	O
.	O

Beneficial	O
effects	O
on	O
serum	O
triglyceride	O
,	O
HDL-cholesterol	O
and	O
apo	O
A1	O
levels	O
were	O
also	O
observed	O
.	O

Lp	O
(	O
a	O
)	O
showed	O
no	O
significant	O
change	O
in	O
both	O
groups	O
.	O

Glomerular	O
filtration	O
rate	O
deteriorated	O
significantly	O
in	O
the	O
placebo	O
group	O
after	O
24	O
months	O
(	O
p	O
<	O
0.025	O
)	O
but	O
showed	O
no	O
significant	O
change	O
in	O
the	O
lovastatin-treated	Pharmacological
patients	O
.	O

The	O
increase	O
in	O
serum	O
creatinine	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0.02	O
)	O
in	O
placebo-treated	O
patients	O
at	O
12	O
and	O
24	O
months	O
,	O
and	O
in	O
the	O
lovastatin	Pharmacological
group	O
after	O
24	O
months	O
.	O

Twenty-four	O
hour	O
urinary	O
protein	O
excretion	O
increased	O
in	O
both	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Lovastatin	Pharmacological
treatment	O
was	O
not	O
associated	O
with	O
significant	O
elevations	O
in	O
liver	O
or	O
muscle	O
enzymes	O
.	O

We	O
conclude	O
that	O
effective	O
normalisation	O
of	O
hypercholesterolaemia	O
may	O
retard	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
.	O

Do	O
heavier	O
women	O
benefit	O
from	O
a	O
higher	O
dose	O
of	O
leuprolide	Pharmacological
acetate	Pharmacological
for	O
suppression	O
of	O
serum	O
estradiol	O
?	O
OBJECTIVE	O
To	O
determine	O
if	O
heavier	O
women	O
benefit	O
from	O
a	O
higher	O
dose	O
of	O
the	O
gonadotropin-releasing	Pharmacological
hormone	Pharmacological
analogue	Pharmacological
leuprolide	Pharmacological
acetate	Pharmacological
(	Pharmacological
LA	Pharmacological
)	Pharmacological
depot	O
in	O
terms	O
of	O
suppression	O
of	O
serum	O
estradiol	O
.	O

METHODS	O
This	O
was	O
a	O
retrospective	O
analysis	O
of	O
the	O
effect	O
of	O
LA	Pharmacological
depot	Pharmacological
3.75	O
mg	O
and	O
7.5	O
mg	O
on	O
serum	Pharmacological
estradiol	Pharmacological
from	O
a	O
multicenter	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
12-week	O
study	O
of	O
women	O
with	O
anemia	O
due	O
to	O
bleeding	O
from	O
uterine	O
leiomyomata	O
.	O

Serum	O
estradiol	O
levels	O
were	O
obtained	O
at	O
baseline	O
and	O
at	O
week	O
12	O
.	O

Patients	O
were	O
divided	O
into	O
weight	O
quartiles	O
according	O
to	O
their	O
baseline	O
weight	O
in	O
kilograms	O
:	O
46-	O
<	O
64	O
,	O
64-	O
<	O
72	O
,	O
72-	O
<	O
89	O
,	O
89-159	O
(	O
pounds-102-	O
<	O
140	O
,	O
140-	O
<	O
159	O
,	O
159-	O
<	O
196	O
,	O
196-350	O
)	O
.	O

RESULTS	O
At	O
baseline	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
estradiol	O
level	O
between	O
groups	O
as	O
a	O
whole	O
or	O
within	O
weight	O
quartiles	O
.	O

Within	O
each	O
group	O
there	O
was	O
no	O
relationship	O
between	O
weight	O
and	O
baseline	O
estradiol	O
.	O

At	O
week	O
12	O
,	O
whereas	O
estradiol	O
levels	O
were	O
significantly	O
greater	O
in	O
the	O
heavier	O
patients	O
in	O
each	O
of	O
the	O
groups	O
(	O
LA	O
3.75	O
mg	O
,	O
p	O
=	O
0.044	O
;	O
LA	O
7.5	O
mg	O
,	O
p	O
=	O
0.002	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
estradiol	O
between	O
groups	O
as	O
a	O
whole	O
or	O
within	O
any	O
of	O
the	O
weight	O
quartiles	O
.	O

Moreover	O
,	O
at	O
week	O
12	O
there	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
estradiol	O
suppressed	O
to	O
the	O
menopausal	O
range	O
.	O

CONCLUSION	O
Heavier	O
women	O
do	O
not	O
benefit	O
from	O
a	O
higher	O
dose	O
of	O
LA	Pharmacological
depot	O
(	O
7.5	O
vs.	O
3.75	O
mg	O
)	O
for	O
suppression	O
of	O
serum	O
levels	O
of	O
estradiol	O
.	O

The	O
benefits	O
of	O
including	O
clinical	O
factors	O
in	O
rectal	O
normal	O
tissue	O
complication	Other
probability	Other
modeling	Other
after	O
radiotherapy	O
for	O
prostate	O
cancer	O
.	O

PURPOSE	O
To	O
study	O
the	O
impact	O
of	O
clinical	O
predisposing	O
factors	O
on	O
rectal	O
normal	O
tissue	O
complication	O
probability	O
modeling	O
using	O
the	O
updated	O
results	O
of	O
the	O
Dutch	O
prostate	O
dose-escalation	O
trial	O
.	O

METHODS	O
AND	O
MATERIALS	O
Toxicity	O
data	O
of	O
512	O
patients	O
(	O
conformally	O
treated	O
to	O
68	O
Gy	O
[	O
n	O
=	O
284	O
]	O
and	O
78	O
Gy	O
[	O
n	O
=	O
228	O
]	O
)	O
with	O
complete	O
follow-up	O
at	O
3	O
years	O
after	O
radiotherapy	Physical
were	O
studied	O
.	O

Scored	O
end	O
points	O
were	O
rectal	O
bleeding	O
,	O
high	O
stool	O
frequency	O
,	O
and	O
fecal	O
incontinence	O
.	O

Two	Other
traditional	Other
dose-based	Other
models	Other
(	Other
Lyman-Kutcher-Burman	Other
(	Other
LKB	Other
)	Other
and	Other
Relative	Other
Seriality	Other
(	Other
RS	Other
)	Other
and	Other
a	Other
logistic	Other
model	Other
were	O
fitted	O
using	O
a	O
maximum	O
likelihood	O
approach	O
.	O

Furthermore	O
,	O
these	O
model	O
fits	O
were	O
improved	O
by	O
including	O
the	O
most	O
significant	O
clinical	O
factors	O
.	O

The	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
)	O
was	O
used	O
to	O
compare	O
the	O
discriminating	O
ability	O
of	O
all	O
fits	O
.	O

RESULTS	O
Including	O
clinical	O
factors	O
significantly	O
increased	O
the	O
predictive	O
power	O
of	O
the	O
models	O
for	O
all	O
end	O
points	O
.	O

In	O
the	O
optimal	O
LKB	O
,	O
RS	O
,	O
and	O
logistic	O
models	O
for	O
rectal	O
bleeding	O
and	O
fecal	O
incontinence	O
,	O
the	O
first	O
significant	O
(	O
p	O
=	O
0.011-0.013	O
)	O
clinical	O
factor	O
was	O
previous	O
abdominal	O
surgery	O
.	O

As	O
second	O
significant	O
(	O
p	O
=	O
0.012-0.016	O
)	O
factor	O
,	O
cardiac	O
history	O
was	O
included	O
in	O
all	O
three	O
rectal	O
bleeding	O
fits	O
,	O
whereas	O
including	O
diabetes	O
was	O
significant	O
(	O
p	O
=	O
0.039-0.048	O
)	O
in	O
fecal	O
incontinence	O
modeling	O
but	O
only	O
in	O
the	O
LKB	O
and	O
logistic	O
models	O
.	O

High	O
stool	O
frequency	O
fits	O
only	O
benefitted	O
significantly	O
(	O
p	O
=	O
0.003-0.006	O
)	O
from	O
the	O
inclusion	O
of	O
the	O
baseline	O
toxicity	O
score	O
.	O

For	O
all	O
models	O
rectal	O
bleeding	O
fits	O
had	O
the	O
highest	O
AUC	O
(	O
0.77	O
)	O
where	O
it	O
was	O
0.63	O
and	O
0.68	O
for	O
high	O
stool	O
frequency	O
and	O
fecal	O
incontinence	O
,	O
respectively	O
.	O

LKB	O
and	O
logistic	O
model	O
fits	O
resulted	O
in	O
similar	O
values	O
for	O
the	O
volume	O
parameter	O
.	O

The	O
steepness	O
parameter	O
was	O
somewhat	O
higher	O
in	O
the	O
logistic	O
model	O
,	O
also	O
resulting	O
in	O
a	O
slightly	O
lower	O
D	O
(	O
50	O
)	O
.	O

Anal	O
wall	O
DVHs	O
were	O
used	O
for	O
fecal	O
incontinence	O
,	O
whereas	O
anorectal	O
wall	O
dose	O
best	O
described	O
the	O
other	O
two	O
endpoints	O
.	O

CONCLUSIONS	O
Comparable	O
prediction	O
models	O
were	O
obtained	O
with	O
LKB	O
,	O
RS	O
,	O
and	O
logistic	O
NTCP	O
models	O
.	O

Including	O
clinical	O
factors	O
improved	O
the	O
predictive	O
power	O
of	O
all	O
models	O
significantly	O
.	O

[	O
Long-term	O
effects	O
of	O
7-year	O
growth	Pharmacological
hormone	Pharmacological
substitution	Pharmacological
on	O
bone	O
metabolism	O
,	O
bone	O
density	O
,	O
and	O
bone	O
quality	O
in	O
growth	O
hormone-deficient	O
adults	O
]	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Subnormal	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
and	O
increased	O
fracture	O
risk	O
are	O
described	O
in	O
patients	O
with	O
growth	O
hormone	O
deficiency	O
(	O
GHD	O
)	O
.	O

Growth	Pharmacological
hormone	Pharmacological
(	Pharmacological
GH	Pharmacological
)	Pharmacological
has	O
been	O
reported	O
to	O
have	O
beneficial	O
effects	O
on	O
bone	O
in	O
GHD	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
long-term	O
effects	O
of	O
GH	Pharmacological
replacement	Pharmacological
therapy	Pharmacological
on	O
bone	O
metabolism	O
,	O
BMD	O
,	O
and	O
bone	O
quality	O
in	O
patients	O
with	O
GHD	O
.	O

PATIENTS	O
AND	O
METHODS	O
20	O
adult	O
patients	O
with	O
GHD	O
(	O
eleven	O
male	O
,	O
nine	O
female	O
,	O
mean	O
age	O
42.5	O
years	O
)	O
were	O
included	O
in	O
the	O
study	O
and	O
randomized	O
to	O
either	O
GH	Pharmacological
or	O
placebo	Control
in	O
a	O
dose	O
of	O
0.25	O
U/kg	O
body	O
weight/week	O
.	O

After	O
6	O
months	O
all	O
patients	O
received	O
GH	Pharmacological
.	O

After	O
a	O
1-year	O
double-blind	O
,	O
placebo-controlled	Control
study	O
the	O
patients	O
were	O
followed	O
for	O
another	O
72	O
months	O
in	O
an	O
open	O
study	O
.	O

The	O
patients	O
were	O
compared	O
to	O
20	O
age-	O
und	O
sex-matched	O
healthy	O
controls	O
.	O

Bone	O
turnover	O
was	O
determined	O
by	O
ICTP	O
(	O
type	O
I	O
collagen	O
carboxyterminal	O
cross-linked	O
telopeptide	O
)	O
as	O
parameter	O
of	O
bone	O
resorption	O
and	O
PICP	O
(	O
carboxyterminal	O
propeptide	O
of	O
type	O
I	O
procollagen	O
)	O
as	O
marker	O
of	O
bone	O
formation	O
.	O

BMD	O
was	O
measured	O
at	O
the	O
lumbar	O
spine	O
by	O
dual-photon	O
absorptiometry	O
(	O
DPA	O
)	O
and	O
at	O
the	O
forearm	O
by	O
single-photon	O
absorptiometry	O
(	O
SPA	O
)	O
.	O

Apparent	O
phalangeal	O
ultrasound	O
transmission	O
velocity	O
(	O
APU	O
)	O
was	O
assessed	O
as	O
parameter	O
of	O
bone	O
quality	O
independent	O
of	O
BMD	O
.	O

RESULTS	O
At	O
the	O
beginning	O
of	O
the	O
study	O
BMD	O
at	O
both	O
measuring	O
sites	O
was	O
lower	O
in	O
patients	O
with	O
GHD	O
than	O
in	O
healthy	O
controls	O
.	O

During	O
the	O
1st	O
year	O
of	O
GH	O
replacement	O
therapy	O
BMD	O
decreased	O
,	O
followed	O
by	O
a	O
continuous	O
increase	O
in	O
BMD	O
(	O
about	O
12	O
%	O
)	O
up	O
to	O
60	O
months	O
which	O
remained	O
unchanged	O
thereafter	O
,	O
building	O
up	O
a	O
plateau	O
.	O

After	O
72	O
months	O
no	O
significant	O
difference	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
controls	O
could	O
be	O
detected	O
.	O

Concerning	O
parameters	O
of	O
bone	O
turnover	O
,	O
first	O
ICTP	O
as	O
marker	O
of	O
bone	O
resorption	O
showed	O
a	O
significant	O
increase	O
,	O
later	O
on	O
the	O
marker	O
of	O
bone	O
formation	O
increased	O
as	O
well	O
.	O

APU	O
decreased	O
during	O
the	O
first	O
6	O
months	O
of	O
treatment	O
,	O
but	O
had	O
returned	O
to	O
its	O
baseline	O
value	O
after	O
24	O
months	O
and	O
remained	O
unchanged	O
throughout	O
the	O
rest	O
of	O
the	O
study	O
.	O

CONCLUSION	O
BMD	O
is	O
subnormal	O
in	O
adults	O
with	O
GHD	O
.	O

GH	Pharmacological
replacement	O
therapy	O
stimulates	O
bone	O
turnover	O
in	O
patients	O
with	O
GHD	O
and	O
in	O
the	O
long	O
term	O
such	O
stimulation	O
results	O
in	O
an	O
increased	O
BMD	O
.	O

Thereby	O
,	O
GH	Pharmacological
shows	O
a	O
triphasic	O
action	O
on	O
BMD	O
:	O
an	O
initial	O
decrease	O
in	O
BMD	O
during	O
the	O
1st	O
year	O
,	O
followed	O
by	O
a	O
continuous	O
increase	O
in	O
BMD	O
with	O
buildup	O
of	O
a	O
stable	O
plateau	O
after	O
60	O
months	O
.	O

The	O
newly	O
formed	O
bone	O
seems	O
to	O
have	O
normal	O
bone	O
elasticity	O
.	O

Efficacy	O
of	O
TeachTown	O
:	O
Basics	O
computer-assisted	Educational
intervention	Educational
for	O
the	O
Intensive	O
Comprehensive	O
Autism	O
Program	O
in	O
Los	O
Angeles	O
Unified	O
School	O
District	O
.	O

Computer	Educational
Assisted	Educational
Instruction	Educational
(	Educational
CAI	Educational
)	Educational
has	O
shown	O
increased	O
popularity	O
recently	O
and	O
there	O
are	O
many	O
studies	O
showing	O
promise	O
for	O
this	O
approach	O
for	O
children	O
with	O
Autism	O
Spectrum	O
Disorders	O
(	O
ASD	O
)	O
.	O

However	O
,	O
there	O
are	O
no	O
between-subject	O
studies	O
to	O
date	O
assessing	O
the	O
efficacy	O
of	O
CAI	Educational
with	O
this	O
population	O
.	O

In	O
this	O
study	O
,	O
47	O
preschool	O
and	O
K-1	O
students	O
in	O
ASD	O
classrooms	O
participated	O
from	O
Los	O
Angeles	O
Unified	O
School	O
District	O
.	O

TeachTown	Educational
:	Educational
Basics	Educational
,	Educational
a	Educational
CAI	Educational
program	Educational
which	Educational
also	Educational
includes	Educational
supplementary	Educational
off-computer	Educational
activities	Educational
,	O
was	O
implemented	O
over	O
3	O
months	O
for	O
approximately	O
20	O
minutes	O
per	O
day	O
on	O
the	O
computer	Educational
and	O
20	Educational
minutes	Educational
per	Educational
day	Educational
in	Educational
supplementary	Educational
TeachTown	Educational
:	Educational
Basics	Educational
activities	Educational
.	Educational

Compared	O
to	O
the	O
students	O
in	O
the	O
control	O
group	O
,	O
the	O
TeachTown	O
:	O
Basics	O
students	O
showed	O
more	O
improvement	O
overall	O
on	O
language	O
and	O
cognitive	O
outcome	O
measures	O
.	O

In	O
addition	O
,	O
students	O
who	O
used	O
TeachTown	O
:	O
Basics	O
demonstrated	O
significant	O
progress	O
overall	O
in	O
the	O
software	O
and	O
those	O
students	O
who	O
used	O
the	O
program	O
for	O
more	O
time	O
demonstrated	O
larger	O
gains	O
within	O
the	O
software	O
and	O
in	O
outcome	O
measures	O
.	O

Although	O
not	O
conclusive	O
,	O
these	O
findings	O
offer	O
possibilities	O
for	O
the	O
use	O
of	O
CAI	Other
for	O
remediating	O
many	O
deficits	O
for	O
children	O
with	O
ASD	O
and	O
other	O
special	O
needs	O
.	O

In	O
addition	O
,	O
CAI	Educational
may	O
offer	O
solutions	O
to	O
schools	O
and	O
parents	O
with	O
insufficient	O
funds	O
for	O
more	O
expensive	O
treatments	O
.	O

Treatment	O
of	O
acute	O
otitis	O
media	O
in	O
children	O
under	O
2	O
years	O
of	O
age	O
.	O

BACKGROUND	O
Recommendations	O
vary	O
regarding	O
immediate	Pharmacological
antimicrobial	Pharmacological
treatment	Pharmacological
versus	O
watchful	Physical
waiting	Physical
for	O
children	O
younger	O
than	O
2	O
years	O
of	O
age	O
with	O
acute	O
otitis	O
media	O
.	O

METHODS	O
We	O
randomly	O
assigned	O
291	O
children	O
6	O
to	O
23	O
months	O
of	O
age	O
,	O
with	O
acute	O
otitis	O
media	O
diagnosed	O
with	O
the	O
use	O
of	O
stringent	O
criteria	O
,	O
to	O
receive	O
amoxicillin-clavulanate	Pharmacological
or	O
placebo	Control
for	O
10	O
days	O
.	O

We	O
measured	O
symptomatic	O
response	O
and	O
rates	O
of	O
clinical	O
failure	O
.	O

RESULTS	O
Among	O
the	O
children	O
who	O
received	O
amoxicillin-clavulanate	Pharmacological
,	O
35	O
%	O
had	O
initial	O
resolution	O
of	O
symptoms	O
by	O
day	O
2	O
,	O
61	O
%	O
by	O
day	O
4	O
,	O
and	O
80	O
%	O
by	O
day	O
7	O
;	O
among	O
children	O
who	O
received	O
placebo	Control
,	O
28	O
%	O
had	O
initial	O
resolution	O
of	O
symptoms	O
by	O
day	O
2	O
,	O
54	O
%	O
by	O
day	O
4	O
,	O
and	O
74	O
%	O
by	O
day	O
7	O
(	O
P=0.14	O
for	O
the	O
overall	O
comparison	O
)	O
.	O

For	O
sustained	O
resolution	O
of	O
symptoms	O
,	O
the	O
corresponding	O
values	O
were	O
20	O
%	O
,	O
41	O
%	O
,	O
and	O
67	O
%	O
with	O
amoxicillin-clavulanate	Pharmacological
,	O
as	O
compared	O
with	O
14	O
%	O
,	O
36	O
%	O
,	O
and	O
53	O
%	O
with	O
placebo	Control
(	O
P=0.04	O
for	O
the	O
overall	O
comparison	O
)	O
.	O

Mean	O
symptom	O
scores	O
over	O
the	O
first	O
7	O
days	O
were	O
lower	O
for	O
the	O
children	O
treated	O
with	O
amoxicillin-clavulanate	Pharmacological
than	O
for	O
those	O
who	O
received	O
placebo	Control
(	O
P=0.02	O
)	O
.	O

The	O
rate	O
of	O
clinical	O
failure	O
--	O
defined	O
as	O
the	O
persistence	O
of	O
signs	O
of	O
acute	O
infection	O
on	O
otoscopic	O
examination	O
--	O
was	O
also	O
lower	O
among	O
the	O
children	O
treated	O
with	O
amoxicillin-clavulanate	Pharmacological
than	O
among	O
those	O
who	O
received	O
placebo	Control
:	O
4	O
%	O
versus	O
23	O
%	O
at	O
or	O
before	O
the	O
visit	O
on	O
day	O
4	O
or	O
5	O
(	O
P	O
<	O
0.001	O
)	O
and	O
16	O
%	O
versus	O
51	O
%	O
at	O
or	O
before	O
the	O
visit	O
on	O
day	O
10	O
to	O
12	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Mastoiditis	O
developed	O
in	O
one	O
child	O
who	O
received	O
placebo	Control
.	O

Diarrhea	O
and	O
diaper-area	O
dermatitis	O
were	O
more	O
common	O
among	O
children	O
who	O
received	O
amoxicillin-clavulanate	Pharmacological
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
either	O
group	O
in	O
the	O
rates	O
of	O
nasopharyngeal	O
colonization	O
with	O
nonsusceptible	O
Streptococcus	O
pneumoniae	O
.	O

CONCLUSIONS	O
Among	O
children	O
6	O
to	O
23	O
months	O
of	O
age	O
with	O
acute	O
otitis	O
media	O
,	O
treatment	O
with	O
amoxicillin-clavulanate	Pharmacological
for	O
10	O
days	O
tended	O
to	O
reduce	O
the	O
time	O
to	O
resolution	O
of	O
symptoms	O
and	O
reduced	O
the	O
overall	O
symptom	O
burden	O
and	O
the	O
rate	O
of	O
persistent	O
signs	O
of	O
acute	O
infection	O
on	O
otoscopic	O
examination	O
.	O

(	O
Funded	O
by	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
;	O
ClinicalTrials.gov	O
number	O
,	O
NCT00377260	O
.	O

)	O
.	O

Effect	O
of	O
reduced	O
alcohol	O
consumption	O
on	O
blood	O
pressure	O
in	O
untreated	O
hypertensive	O
men	O
.	O

Fifty-four	O
untreated	O
,	O
mildly	O
hypertensive	O
men	O
whose	O
daily	O
alcohol	O
consumption	O
was	O
>	O
or	O
=	O
28	O
ml	O
ethanol	O
and	O
who	O
drank	O
at	O
least	O
4	O
times	O
per	O
week	O
took	O
part	O
in	O
a	O
randomized	O
,	O
controlled	O
crossover	O
trial	O
.	O

The	O
purpose	O
of	O
the	O
trial	O
was	O
to	O
test	O
the	O
effects	O
of	O
alcohol	O
reduction	O
on	O
blood	O
pressure	O
.	O

After	O
a	O
2-week	O
familiarization	O
period	O
,	O
the	O
participants	O
were	O
assigned	O
to	O
either	O
a	O
reduced	Educational
alcohol	Educational
drinking	Educational
group	O
or	O
a	O
usual	Control
drinking	Control
group	Control
for	O
3	O
weeks	O
(	O
experimental	O
period	O
1	O
)	O
.	O

The	O
situation	O
was	O
then	O
reversed	O
for	O
the	O
next	O
3	O
weeks	O
(	O
experimental	O
period	O
2	O
)	O
.	O

The	O
participants	O
were	O
requested	O
to	O
limit	Educational
their	Educational
daily	Educational
alcohol	Educational
consumption	Educational
to	Educational
zero	Educational
or	O
reduce	Educational
it	Educational
as	Educational
much	Educational
as	Educational
possible	Educational
for	Educational
the	Educational
reduced	Educational
alcohol	Educational
consumption	Educational
period	Educational
.	O

The	O
self-reported	O
alcohol	O
consumption	O
was	O
56.1	O
+/-	O
3.6	O
(	O
SEM	O
)	O
ml/day	O
during	O
the	O
usual	O
alcohol	O
drinking	O
period	O
and	O
26.1	O
+/-	O
3.0	O
ml/day	O
during	O
the	O
period	O
of	O
reduced	O
alcohol	O
consumption	O
.	O

Systolic	O
and	O
diastolic	O
blood	O
pressures	O
in	O
the	O
intervention	O
group	O
were	O
found	O
by	O
analysis	O
of	O
variance	O
to	O
be	O
significantly	O
lower	O
(	O
2.6-4.8	O
and	O
2.2-3.0	O
mm	O
Hg	O
,	O
respectively	O
)	O
than	O
those	O
in	O
the	O
control	O
group	O
during	O
experimental	O
period	O
2	O
for	O
systolic	O
blood	O
pressure	O
and	O
experimental	O
period	O
1	O
for	O
diastolic	O
blood	O
pressure	O
.	O

Significant	O
(	O
3.6	O
mm	O
Hg	O
)	O
and	O
nonsignificant	O
(	O
1.9	O
mm	O
Hg	O
)	O
decreases	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
,	O
respectively	O
,	O
were	O
observed	O
.	O

The	O
method	O
of	O
Hills	O
and	O
Armitage	O
was	O
used	O
,	O
reducing	O
ethanol	O
in	O
daily	O
alcohol	O
consumption	O
by	O
28	O
ml	O
.	O

The	O
lowering	O
effect	O
of	O
reduced	O
alcohol	O
consumption	O
on	O
blood	O
pressure	O
was	O
independent	O
of	O
changes	O
in	O
salt	O
consumption	O
,	O
which	O
were	O
estimated	O
by	O
24-hour	O
urine	O
collection	O
and	O
body	O
weight	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Extra	Educational
prompts	Educational
versus	O
no	Educational
extra	Educational
prompts	Educational
in	O
self-care	O
training	O
of	O
autistic	O
children	O
and	O
adolescents	O
.	O

A	O
color-coded	Educational
extra	Educational
prompt	Educational
procedure	Educational
was	O
compared	Educational
to	Educational
a	Educational
no	Educational
extra	Educational
prompt	Educational
procedure	Educational
in	O
teaching	O
autistic	O
children	O
and	O
adolescents	O
how	O
to	O
lace	O
shoes	O
.	O

One	O
randomly	O
assigned	O
group	O
of	O
10	O
autistic	O
subjects	O
first	O
learned	Educational
to	Educational
lace	Educational
shoes	Educational
whose	Educational
laces	Educational
and	Educational
eyelets	Educational
were	Educational
color-coded	Educational
red	Educational
and	Educational
white	Educational
,	O
and	O
then	O
encountered	Educational
the	Educational
no	Educational
extra	Educational
prompt	Educational
condition	Educational
in	Educational
which	Educational
color	Educational
codes	Educational
could	Educational
no	Educational
longer	Educational
be	Educational
depended	Educational
upon	Educational
to	Educational
solve	Educational
the	Educational
position	Educational
discriminations	Educational
required	Educational
to	Educational
lace	Educational
properly	Educational
.	O

In	O
a	O
counterbalanced	O
fashion	O
,	O
the	O
other	O
group	O
of	O
10	O
autistic	O
subjects	O
reached	O
criterion	O
on	O
the	O
non-color-coded	O
,	O
naturalistic	O
shoe	O
before	O
experiencing	O
the	O
extra	O
prompt	O
condition	O
.	O

Analysis	O
of	O
variance	O
and	O
post-hoc	O
analyses	O
suggest	O
that	O
subjects	O
who	O
first	O
learned	O
under	O
the	O
color-coded	O
,	O
extra	O
prompt	O
condition	O
encountered	O
significant	O
difficulty	O
in	O
transferring	O
their	O
newly	O
acquired	O
skill	O
to	O
the	O
naturalistic	O
,	O
non-color-coded	O
condition	O
,	O
whereas	O
subjects	O
who	O
learned	O
initially	O
without	O
the	O
extra	O
prompts	O
had	O
little	O
difficulty	O
with	O
the	O
subsequent	O
color-coded	O
condition	O
.	O

A	O
follow-up	O
procedure	O
requiring	O
all	O
subjects	O
to	O
choose	O
between	O
the	O
color	O
prompt	O
and	O
the	O
position	O
cue	O
revealed	O
that	O
11	O
of	O
20	O
subjects	O
consistently	O
chose	O
the	O
color	O
cue	O
,	O
even	O
though	O
it	O
resulted	O
in	O
improper	O
lacing	O
.	O

It	O
is	O
recommended	O
that	O
clinicians	O
avoid	O
the	O
use	O
of	O
highly	O
salient	O
,	O
non-criterion-related	O
prompts	O
in	O
teaching	O
certain	O
types	O
of	O
adaptive	O
skills	O
to	O
autistic	O
children	O
.	O

Heparan	Pharmacological
sulfate	Pharmacological
in	O
the	O
treatment	O
of	O
intermittent	O
claudication	O
:	O
results	O
of	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
multicenter	O
trial	O
.	O

Peripheral	O
arterial	O
disease	O
(	O
PAD	O
)	O
is	O
by	O
far	O
the	O
most	O
common	O
cause	O
of	O
intermittent	O
claudication	O
.	O

This	O
disease	O
can	O
greatly	O
reduce	O
the	O
affected	O
individual	O
's	O
walking	O
capacity	O
and	O
can	O
seriously	O
affect	O
daily	O
life	O
activities	O
.	O

Few	O
therapeutic	O
options	O
are	O
aimed	O
at	O
improving	O
walking	O
capacity	O
.	O

This	O
was	O
a	O
randomized	O
,	O
doubleblind	O
,	O
placebo-controlled	O
,	O
multicenter	O
trial	O
,	O
performed	O
in	O
24	O
Italian	O
centers	O
.	O

Two	O
hundred	O
seventeen	O
patients	O
with	O
intermittent	O
claudication	O
(	O
stages	O
IIa	O
and	O
IIb	O
of	O
Fontaine	O
's	O
PAD	O
classification	O
)	O
were	O
randomly	O
assigned	O
to	O
heparan	Pharmacological
sulfate	Pharmacological
(	Pharmacological
40	Pharmacological
mg	Pharmacological
orally	Pharmacological
twice	Pharmacological
a	Pharmacological
day	Pharmacological
)	Pharmacological
or	O
placebo	Control
for	O
6	O
months	O
.	O

The	O
primary	O
end-point	O
was	O
an	O
increase	O
in	O
pain-free	O
walking	O
distance	O
[	O
initial	O
claudication	O
distance	O
(	O
ICD	O
)	O
]	O
during	O
the	O
24	O
weeks	O
of	O
treatment	O
.	O

The	O
pain-free	O
and	O
the	O
absolute	O
walking	O
distance	O
(	O
ACD	O
)	O
were	O
monitored	O
by	O
standardized	O
treadmill	O
test	O
at	O
baseline	O
and	O
at	O
4	O
,	O
12	O
and	O
24	O
weeks	O
.	O

The	O
change	O
in	O
initial	O
claudication	O
distance	O
during	O
treatment	O
,	O
expressed	O
as	O
integrated	O
change	O
over	O
time	O
,	O
was	O
significantly	O
greater	O
with	O
heparan	Pharmacological
sulfate	Pharmacological
than	O
with	O
placebo	O
(	O
306	O
+/-	O
494	O
vs.	O
250	O
+/-	O
510	O
meters	O
x	O
months	O
,	O
p	O
=	O
0.019	O
)	O
.	O

Significantly	O
fewer	O
treated	O
patients	O
worsened	O
during	O
treatment	O
(	O
decreased	O
initial	O
claudication	O
distance	O
)	O
compared	O
with	O
controls	O
(	O
9.1	O
%	O
vs.	O
19.6	O
%	O
;	O
p	O
=	O
0.027	O
)	O
.	O

Functional	O
recovery	O
in	O
the	O
most	O
severely	O
affected	O
subgroup	O
of	O
patients	O
(	O
stage	O
IIb	O
of	O
Fontaine	O
's	O
classification	O
)	O
was	O
more	O
clearly	O
detected	O
and	O
significantly	O
greater	O
among	O
treated	O
than	O
among	O
control	O
patients	O
(	O
absolute	O
increase	O
in	O
ICD	O
:	O
70	O
+/-	O
113	O
vs.	O
58	O
+/-	O
172	O
meters	O
,	O
p	O
=	O
0.028	O
;	O
integrated	O
increase	O
:	O
304	O
+/-	O
422	O
vs.	O
208	O
+/-	O
503	O
meters	O
x	O
months	O
;	O
p	O
=	O
0.004	O
)	O
.	O

Heparan	O
sulfate	O
appeared	O
to	O
increase	O
the	O
walking	O
capacity	O
of	O
patients	O
with	O
intermittent	O
claudication	O
to	O
a	O
significantly	O
greater	O
extent	O
than	O
did	O
placebo	O
.	O

The	O
treatment	O
was	O
well	O
tolerated	O
.	O

Response	O
to	O
tubular	Physical
airway	Physical
resistance	Physical
in	O
normal	O
subjects	O
and	O
postoperative	O
patients	O
.	O

Critically	O
ill	O
patients	O
must	O
often	O
breathe	O
spontaneously	O
through	O
an	O
endotracheal	Surgical
tube	Surgical
that	O
acts	O
as	O
a	O
fixed	O
inspiratory	O
and	O
expiratory	O
tubular	O
airway	O
resistor	O
.	O

Although	O
this	O
practice	O
is	O
common	O
,	O
its	O
effect	O
on	O
the	O
pattern	O
of	O
breathing	O
is	O
not	O
known	O
.	O

The	O
mean	O
breathing	O
patterns	O
of	O
seven	O
normal	O
,	O
healthy	O
male	O
subjects	O
and	O
eight	O
male	O
patients	O
who	O
had	O
undergone	O
upper	O
abdominal	O
surgery	O
2-4	O
days	O
previously	O
were	O
studied	O
breathing	O
through	O
a	O
mouthpiece	Physical
fitted	Physical
in	Physical
random	Physical
order	Physical
with	Physical
a	Physical
5	Physical
,	Physical
6	Physical
,	Physical
7	Physical
,	Physical
8	Physical
,	Physical
or	Physical
15	Physical
mm	Physical
diameter	Physical
(	Physical
17	Physical
mm	Physical
long	Physical
)	Physical
resistor	Physical
.	Physical

These	O
diameters	O
were	O
selected	O
because	O
they	O
simulate	O
the	O
pressure-flow	O
relationships	O
of	O
adult	O
endotracheal	O
tubes	O
.	O

With	O
the	O
15	O
mm	O
aperture	O
,	O
the	O
patients	O
had	O
a	O
greater	O
breathing	O
frequency	O
(	O
f	O
)	O
than	O
did	O
the	O
normal	O
subjects	O
(	O
21	O
+/-	O
5	O
[	O
SD	O
]	O
vs.	O
14	O
+/-	O
4	O
breaths/min	O
,	O
P	O
less	O
than	O
0.01	O
)	O
as	O
well	O
as	O
a	O
smaller	O
mean	O
tidal	O
volume	O
(	O
VT	O
)	O
.	O

In	O
both	O
groups	O
,	O
minute	O
ventilation	O
(	O
VE	O
)	O
and	O
f	O
progressively	O
decreased	O
as	O
resistance	O
was	O
increased	O
by	O
decreasing	O
the	O
aperture	O
size	O
from	O
15	O
to	O
16	O
mm	O
.	O

In	O
the	O
normal	O
subjects	O
but	O
not	O
the	O
patients	O
,	O
VT	O
also	O
progressively	O
decreased	O
.	O

When	O
the	O
diameter	O
was	O
decreased	O
from	O
6	O
mm	O
to	O
5	O
mm	O
,	O
there	O
were	O
increases	O
in	O
VT	O
and	O
decreases	O
in	O
f	O
that	O
were	O
more	O
marked	O
in	O
the	O
normal	O
subjects	O
.	O

In	O
both	O
groups	O
,	O
the	O
changes	O
in	O
VE	O
were	O
accompanied	O
by	O
decreases	O
in	O
mean	O
and	O
peak	O
inspiratory	O
and	O
expiratory	O
flow	O
rates	O
.	O

Throughout	O
the	O
study	O
,	O
oxygen	O
consumption	O
(	O
VO2	O
)	O
and	O
carbon	O
dioxide	O
production	O
(	O
VCO2	O
)	O
did	O
not	O
change	O
.	O

This	O
,	O
coupled	O
with	O
the	O
decreases	O
in	O
VE	O
resulted	O
in	O
decreases	O
in	O
the	O
ventilatory	O
equivalents	O
to	O
CO2	O
and	O
O2	O
(	O
VE/VCO2	O
,	O
VE/VO2	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Deleterious	O
effects	O
of	O
low-dose	Pharmacological
oestrogen	Pharmacological
therapy	Pharmacological
on	O
coronary	O
status	O
in	O
patients	O
with	O
prostatic	O
cancer	O
.	O

The	O
effects	O
of	O
oestrogen	Pharmacological
therapy	Pharmacological
and	O
of	O
orchidectomy	Surgical
on	O
coronary	O
status	O
,	O
as	O
reflected	O
by	O
exercise	O
ECG-testing	O
before	O
and	O
after	O
one	O
year	O
of	O
treatment	O
,	O
were	O
assessed	O
in	O
a	O
randomized	O
study	O
of	O
patients	O
(	O
N	O
=	O
100	O
)	O
with	O
prostatic	O
cancer	O
.	O

Oestrogen	Pharmacological
was	O
given	O
as	O
polyestradiol	Pharmacological
phosphate	Pharmacological
80	O
mg	O
i.m	O
.	O

per	O
month	O
in	O
combination	O
with	O
150	Pharmacological
micrograms	Pharmacological
ethinylestradiol	Pharmacological
p.o	O
.	O

per	O
day	O
.	O

There	O
were	O
no	O
significant	O
inter-group	O
differences	O
in	O
conventional	O
risk	O
factors	O
or	O
in	O
pre-treatment	O
exercise	O
test	O
results	O
.	O

Twelve	O
months	O
after	O
the	O
start	O
of	O
therapy	O
the	O
oestrogen	O
group	O
showed	O
a	O
significantly	O
greater	O
depression	O
of	O
the	O
ST-segment	O
during	O
maximal	O
exercise	O
in	O
leads	O
CH2	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
and	O
CH5	O
(	O
P	O
less	O
than	O
0.01	O
)	O
compared	O
with	O
the	O
pre-treatment	O
depression	O
.	O

Twenty-five	O
per	O
cent	O
(	O
N	O
=	O
13	O
)	O
of	O
the	O
patients	O
in	O
the	O
oestrogen	O
group	O
suffered	O
cardiovascular	O
complications	O
during	O
the	O
year	O
of	O
therapy	O
,	O
whereas	O
no	O
such	O
complications	O
were	O
observed	O
in	O
the	O
orchidectomy	O
group	O
.	O

However	O
,	O
even	O
the	O
patients	O
in	O
the	O
oestrogen	O
group	O
who	O
had	O
not	O
suffered	O
cardiovascular	O
complications	O
had	O
significantly	O
greater	O
depressions	O
of	O
the	O
ST-segment	O
during	O
exercise	O
both	O
in	O
lead	O
CH2	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
and	O
in	O
CH5	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
the	O
ST-segment	O
level	O
in	O
the	O
orchidectomy	O
group	O
twelve	O
months	O
after	O
surgery	O
.	O

In	O
summary	O
,	O
we	O
found	O
evidence	O
of	O
an	O
induction	O
of	O
myocardial	O
ischaemia	O
during	O
treatment	O
with	O
exogenous	Pharmacological
oestrogens	Pharmacological
at	O
low	O
dosage	O
in	O
patients	O
with	O
prostatic	O
cancer	O
.	O

This	O
deleterious	O
effect	O
of	O
oestrogen	Pharmacological
on	O
the	O
coronary	O
status	O
argues	O
against	O
oestrogen	O
therapy	O
,	O
since	O
oestrogen	Pharmacological
has	O
not	O
been	O
shown	O
to	O
be	O
more	O
beneficial	O
than	O
orchidectomy	O
against	O
prostatic	O
carcinoma	O
.	O

Virtual	Educational
reality	Educational
intervention	Educational
for	O
older	O
women	O
with	O
breast	O
cancer	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
a	O
virtual	Educational
reality	Educational
distraction	Educational
intervention	Educational
on	O
chemotherapy-related	O
symptom	O
distress	O
levels	O
in	O
16	O
women	O
aged	O
50	O
and	O
older	O
.	O

A	O
cross-over	O
design	O
was	O
used	O
to	O
answer	O
the	O
following	O
research	O
questions	O
:	O
(	O
1	O
)	O
Is	O
virtual	O
reality	O
an	O
effective	O
distraction	O
intervention	O
for	O
reducing	O
chemotherapy-related	O
symptom	O
distress	O
levels	O
in	O
older	O
women	O
with	O
breast	O
cancer	O
?	O
(	O
2	O
)	O
Does	O
virtual	Educational
reality	Educational
have	O
a	O
lasting	O
effect	O
?	O
Chemotherapy	O
treatments	O
are	O
intensive	O
and	O
difficult	O
to	O
endure	O
.	O

One	O
way	O
to	O
cope	O
with	O
chemotherapy-related	O
symptom	O
distress	O
is	O
through	O
the	O
use	O
of	O
distraction	O
.	O

For	O
this	O
study	O
,	O
a	O
head-mounted	O
display	O
(	O
Sony	O
PC	O
Glasstron	O
PLM	O
-	O
S700	O
)	O
was	O
used	O
to	O
display	O
encompassing	O
images	O
and	O
block	O
competing	O
stimuli	O
during	O
chemotherapy	O
infusions	O
.	O

The	O
Symptom	O
Distress	O
Scale	O
(	O
SDS	O
)	O
,	O
Revised	O
Piper	O
Fatigue	O
Scale	O
(	O
PFS	O
)	O
,	O
and	O
the	O
State	O
Anxiety	O
Inventory	O
(	O
SAI	O
)	O
were	O
used	O
to	O
measure	O
symptom	O
distress	O
.	O

For	O
two	O
matched	O
chemotherapy	O
treatments	O
,	O
one	O
pre-test	O
and	O
two	O
post-test	O
measures	O
were	O
employed	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
the	O
VR	Educational
distraction	Educational
intervention	Educational
during	Educational
one	Educational
chemotherapy	Psychological
treatment	Educational
and	O
received	O
no	Control
distraction	Control
intervention	Control
(	Control
control	Control
condition	Control
)	Control
during	O
an	O
alternate	O
chemotherapy	O
treatment	O
.	O

Analysis	O
using	O
paired	O
t-tests	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
SAI	O
(	O
p	O
=	O
0.10	O
)	O
scores	O
immediately	O
following	O
chemotherapy	O
treatments	O
when	O
participants	O
used	O
VR	O
.	O

No	O
significant	O
changes	O
were	O
found	O
in	O
SDS	O
or	O
PFS	O
values	O
.	O

There	O
was	O
a	O
consistent	O
trend	O
toward	O
improved	O
symptoms	O
on	O
all	O
measures	O
48	O
h	O
following	O
completion	O
of	O
chemotherapy	O
.	O

Evaluation	O
of	O
the	O
intervention	O
indicated	O
that	O
women	O
thought	O
the	O
head	O
mounted	O
device	O
was	O
easy	O
to	O
use	O
,	O
they	O
experienced	O
no	O
cybersickness	O
,	O
and	O
100	O
%	O
would	O
use	O
VR	O
again	O
.	O

Dose	O
dependent	O
response	O
of	O
symptoms	O
,	O
pituitary	O
,	O
and	O
bone	O
to	O
transdermal	O
oestrogen	O
in	O
postmenopausal	O
women	O
.	O

The	O
effect	O
of	O
the	O
plasma	O
oestradiol	O
concentration	O
on	O
climacteric	O
symptoms	O
,	O
gonadotrophin	O
release	O
,	O
and	O
bone	O
resorption	O
was	O
studied	O
in	O
three	O
groups	O
of	O
postmenopausal	O
women	O
given	O
0.025	O
mg	O
,	O
0.05	O
mg	O
,	O
or	O
0.1	O
mg	O
transdermal	Pharmacological
oestradiol	Pharmacological
daily	O
.	O

There	O
was	O
a	O
dose	O
related	O
reduction	O
in	O
symptoms	O
,	O
plasma	O
follicle	O
stimulating	O
hormone	O
concentration	O
,	O
and	O
urinary	O
calcium	O
and	O
hydroxyproline	O
excretion	O
.	O

The	O
relation	O
of	O
the	O
response	O
to	O
plasma	O
oestradiol	O
values	O
was	O
similar	O
for	O
each	O
variable	O
with	O
an	O
initial	O
large	O
reduction	O
and	O
little	O
change	O
in	O
response	O
to	O
increases	O
in	O
the	O
plasma	O
oestradiol	Pharmacological
concentration	O
above	O
150	O
pmol/l	O
(	O
41	O
pg/ml	O
)	O
.	O

Hormone	O
replacement	O
therapy	O
producing	O
an	O
effect	O
equivalent	O
to	O
higher	O
oestradiol	O
concentrations	O
is	O
likely	O
to	O
increase	O
the	O
risk	O
of	O
side	O
effects	O
without	O
conferring	O
any	O
additional	O
benefit	O
.	O

Adjuvant	O
subcutaneous	O
interleukin-2	Pharmacological
in	O
patients	O
with	O
resected	O
renal	O
cell	O
carcinoma	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
A	O
pilot	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
toxicity	O
and	O
tolerance	O
to	O
low-dose	O
subcutaneous	Pharmacological
interleukin-2	Pharmacological
(	Pharmacological
IL-2	Pharmacological
)	Pharmacological
for	O
patients	O
with	O
resected	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
at	O
high	O
risk	O
for	O
recurrent	O
disease	O
(	O
TNM	O
stages	O
III	O
and	O
IV	O
resected	O
distant	O
metastases	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
surgically	O
resected	O
locally	O
advanced	O
(	O
T3-4	O
or	O
N1-2	O
)	O
or	O
metastatic	O
RCC	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
4	O
treatment	O
groups	O
that	O
received	O
different	O
dose	O
levels	O
and	O
schedules	O
of	O
subcutaneous	O
IL-2	Pharmacological
as	O
follows	O
:	O
dose	O
level	O
1	O
,	O
4	O
MIU/m2	O
per	O
day	O
,	O
every	O
other	O
week	O
for	O
24	O
weeks	O
(	O
n	O
=	O
10	O
)	O
;	O
dose	O
level	O
2	O
,	O
8	O
MIU/m2	O
per	O
day	O
,	O
every	O
other	O
week	O
for	O
24	O
weeks	O
(	O
n	O
=	O
9	O
)	O
;	O
dose	O
level	O
3	O
,	O
4	O
MIU/m2	O
per	O
day	O
,	O
weeks	O
1-4	O
,	O
9-12	O
,	O
and	O
17-20	O
(	O
n	O
=	O
11	O
)	O
;	O
and	O
dose	O
level	O
4	O
,	O
8	O
MIU/m2	O
per	O
day	O
,	O
weeks	O
1-4	O
,	O
9-12	O
,	O
and	O
17-20	O
(	O
n	O
=	O
10	O
)	O
.	O

Interleukin-2	Pharmacological
was	O
administered	O
in	O
2	O
daily	O
doses	O
on	O
days	O
1-5	O
of	O
each	O
week	O
indicated	O
.	O

A	O
dose	O
level	O
was	O
considered	O
tolerable	O
if	O
no	O
more	O
than	O
2	O
patients	O
experienced	O
grade	O
3/4	O
toxicity	O
.	O

RESULTS	O
Forty-one	O
patients	O
were	O
entered	O
in	O
the	O
study	O
and	O
40	O
were	O
evaluable	O
for	O
toxicity	O
.	O

Therapy	O
was	O
well	O
tolerated	O
at	O
all	O
dose	O
levels	O
and	O
schedules	O
,	O
with	O
most	O
patients	O
(	O
98	O
%	O
)	O
experiencing	O
mild-to-moderate	O
constitutional	O
symptoms	O
.	O

Grade	O
3/4	O
toxicity	O
was	O
seen	O
in	O
8	O
patients	O
(	O
20	O
%	O
)	O
.	O

Interleukin-2	Pharmacological
dose	O
reductions	O
were	O
required	O
in	O
7	O
patients	O
,	O
and	O
no	O
patient	O
discontinued	O
therapy	O
secondary	O
to	O
toxicity	O
.	O

Of	O
39	O
patients	O
evaluable	O
for	O
efficacy	O
,	O
31	O
have	O
experienced	O
relapse	O
(	O
79	O
%	O
)	O
,	O
and	O
15	O
have	O
died	O
(	O
38	O
%	O
)	O
.	O

Median	O
survival	O
was	O
1.4	O
years	O
,	O
and	O
the	O
3-year	O
disease-free	O
survival	O
rate	O
was	O
33	O
%	O
.	O

Median	O
overall	O
survival	O
has	O
not	O
been	O
reached	O
;	O
however	O
,	O
the	O
3-year	O
survival	O
rate	O
was	O
70	O
%	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
any	O
of	O
the	O
treatment	O
arms	O
with	O
respect	O
to	O
disease-free	O
survival	O
or	O
3-year	O
survival	O
(	O
P	O
>	O
0.54	O
and	O
P	O
>	O
or=	O
0.09	O
for	O
all	O
pairwise	O
comparisons	O
)	O
,	O
schedules	O
(	O
dose	O
level	O
1/2	O
vs.	O
3/4	O
;	O
P	O
=	O
0.46	O
and	O
P	O
=	O
0.5	O
)	O
,	O
or	O
dose	O
of	O
IL-2	O
administered	O
(	O
dose	O
level	O
1/3	O
vs.	O
2/4	O
;	O
P	O
=	O
0.99	O
and	O
P	O
=	O
0.1	O
)	O
.	O

CONCLUSION	O
Subcutaneous	Pharmacological
IL-2	Pharmacological
was	O
well	O
tolerated	O
for	O
6	O
months	O
in	O
patients	O
with	O
surgically	O
resected	O
RCC	O
at	O
high	O
risk	O
of	O
recurrence	O
.	O

Future	O
adjuvant	O
trials	O
in	O
this	O
setting	O
are	O
not	O
likely	O
to	O
include	O
IL-2	Pharmacological
in	O
view	O
of	O
the	O
clinical	O
efficacy	O
and	O
favorable	O
toxicity	O
profiles	O
of	O
selected	O
multitargeted	O
kinase	O
inhibitors	O
.	O

PTK2	O
expression	O
and	O
immunochemotherapy	O
outcome	O
in	O
chronic	O
lymphocytic	O
leukemia	O
.	O

Addition	O
of	O
rituximab	Pharmacological
(	Pharmacological
R	Pharmacological
)	Pharmacological
to	Pharmacological
fludarabine	Pharmacological
and	Pharmacological
cyclophosphamide	Pharmacological
(	O
FC	O
)	O
has	O
significantly	O
improved	O
patient	O
outcomes	O
in	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
.	O

Whether	O
baseline	O
gene	O
expression	O
can	O
identify	O
patients	O
who	O
will	O
benefit	O
from	O
immunochemotherapy	O
over	O
chemotherapy	O
alone	O
has	O
not	O
been	O
determined	O
.	O

We	O
assessed	O
genome-wide	O
expression	O
of	O
300	O
pretreatment	O
specimens	O
from	O
a	O
subset	O
of	O
552	O
patients	O
in	O
REACH	O
,	O
a	O
study	O
of	O
FC	Pharmacological
or	O
R-FC	Pharmacological
in	O
relapsed	O
CLL	O
.	O

An	O
independent	O
test	O
set	O
was	O
derived	O
from	O
282	O
pretreatment	O
specimens	O
from	O
CLL8	O
,	O
a	O
study	O
of	O
FC	O
or	O
R-FC	O
in	O
treatment-na?ve	O
patients	O
.	O

Genes	O
specific	O
for	O
benefit	O
from	O
R-FC	O
were	O
determined	O
by	O
assessing	O
treatment-gene	O
interactions	O
in	O
Cox	O
proportional	O
hazards	O
models	O
.	O

REACH	O
patients	O
with	O
higher	O
pretreatment	O
protein	O
tyrosine	O
kinase	O
2	O
(	O
PTK2	O
)	O
messenger	O
RNA	O
levels	O
derived	O
greater	O
benefit	O
from	O
R-FC	O
,	O
with	O
significant	O
improvements	O
in	O
progression-free	O
survival	O
,	O
independent	O
of	O
known	O
prognostic	O
factors	O
in	O
a	O
multivariate	O
model	O
.	O

Examination	O
of	O
PTK2	O
gene	O
expression	O
in	O
CLL8	O
patients	O
yielded	O
similar	O
results	O
.	O

Furthermore	O
,	O
PTK2	O
inhibition	O
blunted	O
R-dependent	O
cell	O
death	O
in	O
vitro	O
.	O

This	O
retrospective	O
analysis	O
from	O
2	O
independent	O
trials	O
revealed	O
that	O
increased	O
PTK2	O
expression	O
is	O
associated	O
with	O
improved	O
outcomes	O
for	O
CLL	O
patients	O
treated	O
with	O
R-FC	O
vs	O
FC	O
.	O

PTK2	O
expression	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
patient	O
selection	O
in	O
future	O
trials	O
.	O

These	O
trials	O
were	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT00090051	O
(	O
REACH	O
)	O
and	O
#	O
NCT00281918	O
(	O
CLL8	O
)	O
.	O

Low-dose	O
versus	O
standard-dose	O
gemcitabine	Pharmacological
infusion	Pharmacological
and	O
cisplatin	Pharmacological
for	O
patients	O
with	O
advanced	O
bladder	O
cancer	O
:	O
a	O
randomized	O
phase	O
II	O
trial-an	O
update	O
.	O

Prolonged	O
infusion	O
of	O
low-dose	O
gemcitabine	Pharmacological
and	Pharmacological
cisplatin	Pharmacological
(	Pharmacological
GC	Pharmacological
)	Pharmacological
proved	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
patients	O
with	O
advanced	O
bladder	O
cancer	O
.	O

One	O
hundred	O
and	O
twenty	O
untreated	O
patients	O
with	O
stage	O
III/IV	O
bladder	O
cancer	O
were	O
randomized	O
to	O
receive	O
either	O
gemcitabine	Pharmacological
(	O
250	O
mg/m	O
(	O
2	O
)	O
)	O
6-h	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
and	O
cisplatin	Pharmacological
(	O
70	O
mg/m	O
(	O
2	O
)	O
)	O
on	O
day	O
2	O
every	O
21-day	O
cycle	O
(	O
arm	O
1	O
)	O
or	O
gemcitabine	Pharmacological
(	O
1,250	O
mg/m	O
(	O
2	O
)	O
)	O
30-min	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
with	O
the	O
same	O
dose	O
of	O
cisplatin	Pharmacological
(	O
arm	O
2	O
)	O
.	O

The	O
92	O
males	O
and	O
28	O
females	O
included	O
in	O
the	O
study	O
had	O
a	O
median	O
age	O
of	O
62	O
years	O
(	O
range	O
40-85	O
years	O
)	O
.	O

Among	O
the	O
120	O
patient	O
,	O
complete	O
response	O
was	O
achieved	O
in	O
11.7	O
%	O
(	O
7/60	O
patients	O
of	O
arm	O
1	O
)	O
and	O
5	O
%	O
(	O
3/60	O
patients	O
of	O
arm	O
2	O
)	O
.	O

Eighteen	O
patients	O
in	O
arm	O
1	O
(	O
30	O
%	O
)	O
and	O
17	O
patients	O
(	O
28.3	O
%	O
)	O
in	O
arm	O
2	O
had	O
partial	O
response	O
on	O
therapy	O
.	O

Thus	O
,	O
the	O
overall	O
response	O
rate	O
of	O
patients	O
in	O
arm	O
1	O
and	O
arm	O
2	O
was	O
41.7	O
%	O
(	O
25/60	O
patients	O
)	O
and	O
33.3	O
%	O
(	O
20/60	O
patients	O
)	O
,	O
respectively	O
(	O
p	O
=	O
0.37	O
)	O
.	O

No	O
significant	O
difference	O
in	O
median	O
time	O
to	O
disease	O
progression	O
(	O
26	O
vs.	O
24	O
months	O
,	O
p	O
=	O
0.4	O
)	O
,	O
median	O
survival	O
(	O
12	O
vs.	O
16	O
months	O
,	O
p	O
=	O
0.8	O
)	O
,	O
and	O
1-year	O
survival	O
(	O
49.9	O
vs.	O
54.7	O
%	O
,	O
p	O
=	O
0.8	O
)	O
was	O
detected	O
between	O
arms	O
1	O
and	O
2	O
,	O
respectively	O
.	O

Main	O
toxicities	O
were	O
similar	O
in	O
both	O
arms	O
with	O
no	O
statistically	O
significant	O
differences	O
.	O

Low-dose	O
,	O
prolonged	O
infusion	O
gemcitabine	Pharmacological
in	O
combination	O
with	O
cisplatin	Pharmacological
is	O
not	O
inferior	O
to	O
the	O
standard	Pharmacological
GC	Pharmacological
regimen	Pharmacological
with	O
favorable	O
toxicity	O
profile	O
and	O
less	O
financial	O
costs	O
.	O

Pulse	O
oximeter	O
perfusion	O
index	O
as	O
an	O
early	O
indicator	O
of	O
sympathectomy	O
after	O
epidural	O
anesthesia	O
.	O

BACKGROUND	O
The	O
pulse	O
oximeter	O
perfusion	O
index	O
(	O
PI	O
)	O
has	O
been	O
used	O
to	O
indicate	O
sympathectomy-induced	O
vasodilatation	O
.	O

We	O
hypothesized	O
that	O
pulse	O
oximeter	O
PI	O
provides	O
an	O
earlier	O
and	O
clearer	O
indication	O
of	O
sympathectomy	O
following	O
epidural	O
anesthesia	O
than	O
skin	O
temperature	O
and	O
arterial	O
pressure	O
.	O

METHODS	O
Forty	O
patients	O
received	O
lumbar	Physical
epidural	Physical
catheters	Physical
.	O

Patients	O
were	O
randomized	O
to	O
receive	Pharmacological
either	Pharmacological
10	Pharmacological
ml	Pharmacological
0.5	Pharmacological
%	Pharmacological
bupivacaine	Pharmacological
or	O
10	Pharmacological
ml	Pharmacological
0.25	Pharmacological
%	Pharmacological
bupivacaine	Pharmacological
.	O

PI	O
in	O
the	O
toe	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
and	O
toe	O
temperature	O
were	O
all	O
assessed	O
at	O
baseline	O
and	O
at	O
5	O
,	O
10	O
and	O
20	O
min	O
following	O
epidural	Pharmacological
anesthesia	Pharmacological
.	O

The	O
effect	O
of	O
epidural	Pharmacological
anesthesia	Pharmacological
over	O
time	O
was	O
assessed	O
by	O
repeated	O
measures	O
analysis	O
of	O
variance	O
.	O

Additionally	O
,	O
we	O
defined	O
clinically	O
evident	O
sympathectomy	O
criteria	O
(	O
a	O
100	O
%	O
increase	O
in	O
the	O
PI	O
,	O
a	O
15	O
%	O
decrease	O
in	O
MAP	O
and	O
a	O
1	O
degrees	O
C	O
increase	O
in	O
toe	O
temperature	O
)	O
.	O

The	O
numbers	O
of	O
patients	O
demonstrating	O
these	O
changes	O
for	O
each	O
test	O
were	O
compared	O
using	O
the	O
McNemar	O
test	O
for	O
each	O
time	O
point	O
.	O

RESULTS	O
Twenty-nine	O
subjects	O
had	O
photoplethysmography	O
signals	O
that	O
met	O
a	O
priori	O
signal	O
quality	O
criteria	O
for	O
analysis	O
.	O

By	O
20	O
min	O
,	O
PI	O
increased	O
by	O
326	O
%	O
,	O
compared	O
with	O
a	O
10	O
%	O
decrease	O
and	O
a	O
3	O
%	O
increase	O
in	O
MAP	O
and	O
toe	O
temperature	O
,	O
respectively	O
.	O

For	O
PI	O
15/29	O
,	O
26/29	O
and	O
29/29	O
of	O
the	O
subjects	O
met	O
the	O
sympathectomy	O
criteria	O
at	O
5	O
,	O
10	O
and	O
20	O
min	O
,	O
respectively	O
,	O
compared	O
with	O
4/29	O
,	O
6/29	O
and	O
18/29	O
for	O
MAP	O
changes	O
and	O
3/29	O
,	O
8/29	O
and	O
14/29	O
for	O
toe	O
temperature	O
changes	O
.	O

CONCLUSIONS	O
PI	O
was	O
an	O
earlier	O
,	O
clearer	O
and	O
more	O
sensitive	O
indicator	O
of	O
the	O
development	O
of	O
epidural-induced	O
sympathectomy	O
than	O
either	O
skin	O
temperature	O
or	O
MAP	O
.	O

14	O
day	O
endoscopy	O
study	O
comparing	O
risedronate	Pharmacological
and	O
alendronate	Pharmacological
in	O
postmenopausal	O
women	O
stratified	O
by	O
Helicobacter	O
pylori	O
status	O
.	O

OBJECTIVE	O
Bisphosphonates	Pharmacological
are	O
effective	O
treatment	O
for	O
osteoporosis	O
but	O
have	O
been	O
associated	O
with	O
gastrointestinal	O
(	O
GI	O
)	O
mucosal	O
injury	O
.	O

This	O
study	O
compared	O
the	O
incidence	O
of	O
gastric	O
ulcers	O
after	O
treatment	O
with	O
risedronate	Pharmacological
,	Pharmacological
a	Pharmacological
pyridinyl	Pharmacological
bisphosphonate	Pharmacological
,	O
or	O
alendronate	Pharmacological
,	Pharmacological
a	Pharmacological
primary	Pharmacological
amino	Pharmacological
bisphosphonate	Pharmacological
,	O
in	O
healthy	O
postmenopausal	O
women	O
stratified	O
by	O
Helicobacter	O
pylori	O
status	O
.	O

METHODS	O
Subjects	O
were	O
randomized	O
to	O
receive	O
risedronate	Pharmacological
5	O
mg	O
(	O
n	O
=	O
318	O
)	O
or	O
alendronate	Pharmacological
10	O
mg	O
(	O
n	O
=	O
317	O
)	O
daily	O
for	O
14	O
days	O
.	O

Endoscopy	Surgical
and	O
evaluator-blind	O
assessments	O
of	O
the	O
esophageal	O
,	O
gastric	O
,	O
and	O
duodenal	O
mucosa	O
were	O
performed	O
at	O
baseline	O
and	O
on	O
Days	O
8	O
and	O
15	O
.	O

RESULTS	O
Overall	O
,	O
gastric	O
ulcers	O
>	O
or	O
=	O
3	O
mm	O
were	O
observed	O
in	O
18	O
(	O
6.0	O
%	O
)	O
of	O
300	O
evaluable	O
subjects	O
in	O
the	O
risedronate	Pharmacological
group	O
and	O
36	O
(	O
12.1	O
%	O
)	O
of	O
297	O
in	O
the	O
alendronate	O
group	O
during	O
treatment	O
(	O
p	O
=	O
0.013	O
)	O
.	O

On	O
Day	O
8	O
,	O
the	O
incidences	O
of	O
gastric	O
ulcers	O
in	O
the	O
risedronate	Pharmacological
and	O
alendronate	Pharmacological
groups	O
were	O
3.6	O
%	O
and	O
6.6	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.133	O
)	O
,	O
and	O
on	O
Day	O
15	O
,	O
they	O
were	O
3.3	O
%	O
and	O
8.7	O
%	O
(	O
p	O
=	O
0.008	O
)	O
.	O

The	O
incidence	O
of	O
gastric	O
ulcers	O
was	O
not	O
affected	O
by	O
H.	O
pylori	O
status	O
.	O

Mean	O
gastric	O
endoscopy	O
scores	O
at	O
Days	O
8	O
and	O
15	O
were	O
significantly	O
lower	O
in	O
the	O
risedronate	Pharmacological
group	O
than	O
in	O
the	O
alendronate	Pharmacological
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Mean	O
esophageal	O
and	O
duodenal	O
endoscopy	O
scores	O
were	O
similar	O
in	O
the	O
2	O
groups	O
at	O
Days	O
8	O
and	O
15	O
.	O

When	O
the	O
treatment	O
groups	O
were	O
combined	O
,	O
gastric	O
endoscopy	O
scores	O
were	O
significantly	O
higher	O
among	O
H.	O
pylori	O
negative	O
than	O
H.	O
pylori	O
positive	O
subjects	O
at	O
Days	O
8	O
and	O
15	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Upper	O
GI	O
adverse	O
events	O
were	O
reported	O
by	O
18	O
(	O
5.7	O
%	O
)	O
subjects	O
in	O
the	O
risedronate	Pharmacological
group	O
(	O
19	O
events	O
)	O
and	O
28	O
(	O
8.8	O
%	O
)	O
subjects	O
in	O
the	O
alendronate	Pharmacological
group	O
(	O
32	O
events	O
)	O
.	O

Symptoms	O
did	O
not	O
predict	O
the	O
presence	O
of	O
mucosal	O
damage	O
.	O

CONCLUSION	O
Risedronate	Pharmacological
was	O
associated	O
with	O
a	O
significantly	O
lower	O
incidence	O
of	O
gastric	O
ulcers	O
than	O
alendronate	Pharmacological
.	O

H.	O
pylori	O
infection	O
did	O
not	O
increase	O
the	O
incidence	O
of	O
bisphosphonate	O
related	O
gastric	O
ulcers	O
.	O

The	O
findings	O
from	O
this	O
14	O
day	O
study	O
in	O
healthy	O
volunteers	O
support	O
the	O
hypothesis	O
that	O
bisphosphonates	O
may	O
differ	O
from	O
one	O
another	O
in	O
their	O
potential	O
to	O
produce	O
upper	O
GI	O
mucosal	O
damage	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	Control
trial	O
of	O
nefazodone	Pharmacological
in	O
the	O
treatment	O
of	O
patients	O
hospitalized	O
for	O
major	O
depression	O
.	O

BACKGROUND	O
There	O
are	O
few	O
published	O
placebo-controlled	Control
clinical	O
trials	O
demonstrating	O
the	O
efficacy	O
of	O
the	O
newer	O
antidepressants	O
in	O
markedly	O
or	O
severely	O
depressed	O
hospitalized	O
patients	O
.	O

This	O
study	O
demonstrates	O
the	O
efficacy	O
of	O
nefazodone	Pharmacological
compared	O
with	O
placebo	Control
in	O
the	O
treatment	O
of	O
patients	O
hospitalized	O
for	O
major	O
depression	O
.	O

METHOD	O
Nefazodone	Pharmacological
and	O
placebo	Control
treatment	O
were	O
compared	O
in	O
a	O
6-week	O
trial	O
of	O
120	O
patients	O
hospitalized	O
for	O
DSM-III-R	O
diagnosed	O
major	O
depression	O
(	O
without	O
psychosis	O
)	O
at	O
2	O
study	O
centers	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
standard	O
psychiatric	O
rating	O
scales	O
,	O
and	O
patients	O
were	O
monitored	O
for	O
safety	O
.	O

RESULTS	O
Nefazodone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
(	O
p	O
<	O
.01	O
)	O
of	O
the	O
17-item	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
(	O
HAM-D-17	O
)	O
total	O
score	O
compared	O
with	O
placebo	Control
from	O
the	O
end	O
of	O
the	O
first	O
treatment	O
week	O
through	O
the	O
end	O
of	O
the	O
study	O
(	O
-12.2	O
nefazodone	Pharmacological
vs.	O
-7.7	O
placebo	Control
)	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
significantly	O
more	O
nefazodone-treated	Pharmacological
patients	O
(	O
50	O
%	O
)	O
than	O
placebo-treated	Control
patients	O
(	O
29	O
%	O
)	O
had	O
responded	O
,	O
as	O
indicated	O
by	O
their	O
Clinical	O
Global	O
Impressions-Improvement	O
score	O
(	O
p	O
=	O
.021	O
)	O
or	O
by	O
a	O
>	O
or	O
=	O
50	O
%	O
reduction	O
in	O
their	O
HAM-D-17	O
scores	O
(	O
p	O
=	O
.017	O
)	O
.	O

Significantly	O
more	O
patients	O
treated	O
with	O
nefazodone	Pharmacological
(	O
36	O
%	O
)	O
than	O
placebo-treated	Control
patients	O
(	O
14	O
%	O
)	O
had	O
a	O
HAM-D-17	O
score	O
<	O
or	O
=	O
10	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
=	O
.004	O
)	O
.	O

Significant	O
treatment	O
differences	O
(	O
p	O
<	O
.01	O
)	O
in	O
favor	O
of	O
nefazodone	O
were	O
also	O
seen	O
in	O
the	O
Montgomery-Asberg	O
Depression	O
Rating	O
Scale	O
;	O
the	O
HAM-D	O
retardation	O
,	O
anxiety	O
,	O
and	O
sleep	O
disturbance	O
factors	O
;	O
and	O
HAM-D	O
item	O
1	O
(	O
depressed	O
mood	O
)	O
.	O

Patients	O
with	O
dysthymia	O
in	O
addition	O
to	O
major	O
depression	O
also	O
showed	O
significant	O
improvement	O
(	O
p	O
<	O
.05	O
)	O
when	O
treated	O
with	O
nefazodone	O
,	O
with	O
significant	O
differences	O
in	O
response	O
rates	O
seen	O
as	O
early	O
as	O
week	O
2	O
and	O
through	O
the	O
end	O
of	O
the	O
trial	O
.	O

The	O
mean	O
nefazodone	O
dose	O
was	O
491	O
mg/day	O
at	O
the	O
end	O
of	O
week	O
2	O
and	O
503	O
mg/day	O
at	O
the	O
end	O
of	O
treatment	O
.	O

Nefazodone	O
was	O
well	O
tolerated	O
,	O
and	O
the	O
number	O
of	O
patients	O
discontinuing	O
owing	O
to	O
adverse	O
events	O
was	O
small	O
,	O
with	O
no	O
significant	O
safety	O
issues	O
noted	O
in	O
either	O
treatment	O
group	O
.	O

Fewer	O
nefazodone-treated	Pharmacological
than	O
placebo-treated	Control
patients	O
discontinued	O
owing	O
to	O
lack	O
of	O
efficacy	O
.	O

CONCLUSION	O
Nefazodone	Pharmacological
was	O
superior	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
marked	O
to	O
severe	O
major	O
depression	O
in	O
patients	O
requiring	O
hospitalization	O
.	O

The	O
clinical	O
benefit	O
of	O
nefazodone	Pharmacological
was	O
evident	O
as	O
early	O
as	O
the	O
first	O
week	O
of	O
treatment	O
as	O
judged	O
by	O
several	O
measures	O
of	O
efficacy	O
,	O
with	O
significant	O
differences	O
from	O
placebo	O
sustained	O
throughout	O
the	O
trial	O
.	O

Penetration	O
and	O
accumulation	O
of	O
moxifloxacin	Pharmacological
in	O
uterine	O
tissue	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
moxifloxacin	Pharmacological
penetrates	O
the	O
uterine	O
tissue	O
and	O
accumulates	O
at	O
levels	O
sufficient	O
to	O
eradicate	O
the	O
major	O
pathogens	O
causing	O
pelvic	O
inflammatory	O
disease	O
(	O
PID	O
)	O
.	O

METHOD	O
In	O
a	O
prospective	O
,	O
multicenter	O
,	O
open-label	O
,	O
parallel-group	O
study	O
we	O
determined	O
the	O
concentration	O
of	O
moxifloxacin	O
in	O
plasma	O
and	O
uterine	O
tissue	O
after	O
a	O
single	O
,	O
400-mg	Pharmacological
intravenous	Pharmacological
dose	Pharmacological
of	Pharmacological
moxifloxacin	Pharmacological
.	O

Study	O
participants	O
were	O
randomized	O
for	O
time	O
of	O
tissue	O
sampling	O
,	O
which	O
was	O
performed	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
,	O
or	O
24	O
hours	O
following	O
the	O
moxifloxacin	Pharmacological
infusion	O
.	O

RESULTS	O
Of	O
43	O
participants	O
,	O
40	O
were	O
randomized	O
to	O
tissue	O
sampling	O
.	O

Moxifloxacin	O
accumulated	O
in	O
uterine	O
tissue	O
and	O
concentrations	O
were	O
highest	O
1	O
hour	O
after	O
infusion	O
in	O
both	O
plasma	O
and	O
tissue	O
.	O

Tissue	O
to	O
plasma	O
ratios	O
remained	O
between	O
1.7	O
and	O
2.1	O
for	O
24	O
hours	O
.	O

Moxifloxacin	O
was	O
found	O
to	O
be	O
safe	O
and	O
well	O
tolerated	O
.	O

CONCLUSION	O
Based	O
on	O
known	O
minimum	O
inhibitory	O
concentration	O
data	O
,	O
the	O
uterine	O
tissue	O
concentrations	O
of	O
moxifloxacin	O
achieved	O
over	O
24	O
hours	O
would	O
be	O
sufficient	O
to	O
eradicate	O
the	O
range	O
of	O
bacterial	O
pathogens	O
responsible	O
for	O
PID	O
.	O

A	O
first-in-man	O
,	O
randomized	O
,	O
placebo-controlled	Control
study	O
to	O
evaluate	O
the	O
safety	O
and	O
feasibility	O
of	O
autologous	Physical
delipidated	Physical
high-density	Physical
lipoprotein	Physical
plasma	Physical
infusions	Physical
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
.	O

OBJECTIVES	O
This	O
study	O
aimed	O
to	O
determine	O
whether	O
serial	Pharmacological
autologous	Pharmacological
infusions	Pharmacological
of	Pharmacological
selective	Pharmacological
high-density	Pharmacological
lipoprotein	Pharmacological
(	Pharmacological
HDL	Pharmacological
)	Pharmacological
delipidated	Physical
plasma	Physical
are	O
feasible	O
and	O
well	O
tolerated	O
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
.	O

BACKGROUND	O
Low	O
HDL	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

Plasma	O
selective	O
delipidation	O
converts	O
alphaHDL	O
to	O
prebeta-like	O
HDL	O
,	O
the	O
most	O
effective	O
form	O
of	O
HDL	O
for	O
lipid	O
removal	O
from	O
arterial	O
plaques	O
.	O

METHODS	O
ACS	O
patients	O
undergoing	O
cardiac	O
catheterization	O
with	O
>	O
or=1	O
nonobstructive	O
native	O
coronary	O
artery	O
atheroma	O
were	O
randomized	O
to	O
either	O
7	O
weekly	O
HDL	Physical
selective	Physical
delipidated	Physical
or	O
control	Control
plasma	Control
apheresis/reinfusions	Control
.	O

Patients	O
underwent	O
intravascular	Physical
ultrasound	Physical
(	O
IVUS	O
)	O
evaluation	O
of	O
the	O
target	O
vessel	O
during	O
the	O
catheterization	O
for	O
ACS	O
and	O
up	O
to	O
14	O
days	O
following	O
the	O
final	O
apheresis/reinfusion	Pharmacological
session	O
.	O

2-D	O
gel	O
electrophoresis	O
of	O
delipidated	O
plasmas	O
established	O
successful	O
conversion	O
of	O
alphaHDL	O
to	O
prebeta-like	O
HDL	O
.	O

The	O
trial	O
was	O
complete	O
with	O
28	O
patients	O
randomized	O
.	O

RESULTS	O
All	O
reinfusion	O
sessions	O
were	O
tolerated	O
well	O
by	O
all	O
patients	O
.	O

The	O
levels	O
of	O
prebeta-like	O
HDL	O
and	O
alphaHDL	O
in	O
the	O
delipidated	O
plasma	O
converted	O
from	O
5.6	O
%	O
to	O
79.1	O
%	O
and	O
92.8	O
%	O
to	O
20.9	O
%	O
,	O
respectively	O
.	O

The	O
IVUS	O
data	O
demonstrated	O
a	O
numeric	O
trend	O
toward	O
regression	O
in	O
the	O
total	O
atheroma	O
volume	O
of	O
-12.18	O
+/-	O
36.75	O
mm	O
(	O
3	O
)	O
in	O
the	O
delipidated	O
group	O
versus	O
an	O
increase	O
of	O
total	O
atheroma	O
volume	O
of	O
2.80	O
+/-	O
21.25	O
mm	O
(	O
3	O
)	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0.268	O
)	O
.	O

CONCLUSIONS	O
In	O
ACS	O
patients	O
,	O
serial	O
autologous	O
infusions	O
of	O
selective	Pharmacological
HDL	Pharmacological
delipidated	Pharmacological
plasma	Pharmacological
are	O
clinically	O
feasible	O
and	O
well	O
tolerated	O
.	O

This	O
therapy	O
may	O
offer	O
a	O
novel	O
adjunct	O
treatment	O
for	O
patients	O
presenting	O
with	O
ACS	O
.	O

Further	O
study	O
will	O
be	O
needed	O
to	O
determine	O
its	O
ability	O
to	O
reduce	O
clinical	O
cardiovascular	O
events	O
.	O

Phase	O
III	O
trial	O
of	O
gemcitabine	Pharmacological
plus	O
tipifarnib	Pharmacological
compared	O
with	O
gemcitabine	Pharmacological
plus	O
placebo	Control
in	O
advanced	O
pancreatic	O
cancer	O
.	O

PURPOSE	O
To	O
determine	O
whether	O
addition	O
of	O
the	O
farnesyltransferase	O
inhibitor	O
tipifarnib	Pharmacological
(	O
Zarnestra	O
,	O
R115777	O
;	O
Johnson	O
and	O
Johnson	O
Pharmaceutical	O
Research	O
and	O
Development	O
,	O
Beerse	O
,	O
Belgium	O
)	O
to	O
standard	O
gemcitabine	O
therapy	O
improves	O
overall	O
survival	O
in	O
advanced	O
pancreatic	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
This	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
compared	O
gemcitabine	Pharmacological
+	Pharmacological
tipifarnib	Pharmacological
versus	O
gemcitabine	O
+	O
placebo	O
in	O
patients	O
with	O
advanced	O
pancreatic	O
adenocarcinoma	O
previously	O
untreated	O
with	O
systemic	O
therapy	O
.	O

Tipifarnib	Pharmacological
was	Pharmacological
given	Pharmacological
at	Pharmacological
200	Pharmacological
mg	Pharmacological
bid	Pharmacological
orally	Pharmacological
continuously	Pharmacological
;	Pharmacological
gemcitabine	Pharmacological
was	Pharmacological
given	Pharmacological
at	Pharmacological
1,000	Pharmacological
mg/m	Pharmacological
(	Pharmacological
2	Pharmacological
)	Pharmacological
intravenously	Pharmacological
weekly	Pharmacological
x	Pharmacological
7	Pharmacological
for	Pharmacological
8	Pharmacological
weeks	Pharmacological
,	Pharmacological
then	Pharmacological
weekly	Pharmacological
x	Pharmacological
3	Pharmacological
every	Pharmacological
4	Pharmacological
weeks	Pharmacological
.	Pharmacological

The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
;	O
secondary	O
end	O
points	O
included	O
6-month	O
and	O
1-year	O
survival	O
rates	O
,	O
progression-free	O
survival	O
,	O
response	O
rate	O
,	O
safety	O
,	O
and	O
quality	O
of	O
life	O
.	O

RESULTS	O
Six	O
hundred	O
eighty-eight	O
patients	O
were	O
enrolled	O
.	O

Baseline	O
characteristics	O
were	O
well	O
balanced	O
between	O
the	O
two	O
treatment	O
arms	O
.	O

No	O
statistically	O
significant	O
differences	O
in	O
survival	O
parameters	O
were	O
observed	O
.	O

The	O
median	O
overall	O
survival	O
for	O
the	O
experimental	O
arm	O
was	O
193	O
v	O
182	O
days	O
for	O
the	O
control	O
arm	O
(	O
P	O
=.75	O
)	O
;	O
6-month	O
and	O
1-year	O
survival	O
rates	O
were	O
53	O
%	O
and	O
27	O
%	O
v	O
49	O
%	O
and	O
24	O
%	O
for	O
the	O
control	O
arm	O
,	O
respectively	O
;	O
median	O
progression-free	O
survival	O
was	O
112	O
v	O
109	O
days	O
for	O
the	O
control	O
arm	O
.	O

Ten	O
drug-related	O
deaths	O
were	O
reported	O
for	O
the	O
experimental	O
arm	O
and	O
seven	O
for	O
the	O
control	O
arm	O
.	O

Neutropenia	O
and	O
thrombocytopenia	O
grade	O
>	O
or	O
=	O
3	O
were	O
observed	O
in	O
40	O
%	O
and	O
15	O
%	O
in	O
the	O
experimental	O
arm	O
versus	O
30	O
%	O
and	O
12	O
%	O
in	O
the	O
control	O
arm	O
.	O

Incidences	O
of	O
nonhematologic	O
adverse	O
events	O
were	O
similar	O
in	O
two	O
groups	O
.	O

CONCLUSION	O
The	O
combination	O
of	O
gemcitabine	Pharmacological
and	Pharmacological
tipifarnib	Pharmacological
has	O
an	O
acceptable	O
toxicity	O
profile	O
but	O
does	O
not	O
prolong	O
overall	O
survival	O
in	O
advanced	O
pancreatic	O
cancer	O
compared	O
with	O
single-agent	O
gemcitabine	O
.	O

Zinc	Pharmacological
supplementation	Pharmacological
in	O
alcoholic	O
cirrhosis	O
.	O

A	O
double-blind	O
clinical	O
trial	O
.	O

A	O
double-blind	O
clinical	O
trial	O
with	O
zinc	Pharmacological
sulfate	Pharmacological
,	O
0.2	O
g	O
three	O
times	O
daily	O
,	O
and	O
a	O
placebo	Control
was	O
performed	O
in	O
30	O
patients	O
with	O
biopsy-proven	O
alcoholic	O
liver	O
cirrhosis	O
.	O

The	O
disease	O
was	O
in	O
a	O
stable	O
phase	O
,	O
and	O
none	O
of	O
the	O
patients	O
showed	O
evidence	O
of	O
a	O
decompensated	O
liver	O
function	O
.	O

Parameters	O
of	O
liver	O
function	O
,	O
taste	O
acuity	O
,	O
dark	O
adaptation	O
and	O
of	O
zinc	Pharmacological
and	O
vitamin	Pharmacological
A	Pharmacological
metabolism	Pharmacological
were	O
followed	O
for	O
six	O
weeks	O
.	O

In	O
the	O
zinc-treated	O
group	O
of	O
16	O
patients	O
,	O
serum	O
zinc	O
rose	O
from	O
a	O
normal	O
mean	O
value	O
of	O
13.3	O
to	O
17.4	O
mumol/l	O
,	O
whereas	O
the	O
mean	O
serum	O
vitamin	O
A	O
level	O
remained	O
practically	O
unaltered	O
within	O
the	O
normal	O
range	O
,	O
1.89	O
at	O
the	O
entry	O
and	O
1.83	O
mumol/l	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Plasma	O
prothrombin	O
and	O
serum	O
alkaline	O
phosphatase	O
levels	O
of	O
the	O
zinc	O
group	O
increased	O
and	O
serum	O
bilirubin	O
and	O
serum	O
carotene	O
decreased	O
significantly	O
.	O

The	O
dark	O
adaptation	O
did	O
not	O
change	O
,	O
but	O
the	O
taste	O
function	O
was	O
significantly	O
improved	O
during	O
zinc	O
treatment	O
.	O

The	O
results	O
indicate	O
that	O
zinc	Pharmacological
supplementation	Pharmacological
causes	O
alleviation	O
of	O
certain	O
abnormalities	O
of	O
cirrhotics	O
,	O
which	O
deserves	O
further	O
attention	O
.	O

Comparison	O
of	O
adaptive	Educational
pacing	Educational
therapy	Educational
,	O
cognitive	Educational
behaviour	Educational
therapy	Educational
,	O
graded	Educational
exercise	Educational
therapy	Educational
,	O
and	O
specialist	Other
medical	Other
care	Other
for	O
chronic	O
fatigue	O
syndrome	O
(	O
PACE	O
)	O
:	O
a	O
randomised	O
trial	O
.	O

BACKGROUND	O
Trial	O
findings	O
show	O
cognitive	O
behaviour	O
therapy	O
(	O
CBT	O
)	O
and	O
graded	O
exercise	O
therapy	O
(	O
GET	O
)	O
can	O
be	O
effective	O
treatments	O
for	O
chronic	O
fatigue	O
syndrome	O
,	O
but	O
patients	O
'	O
organisations	O
have	O
reported	O
that	O
these	O
treatments	O
can	O
be	O
harmful	O
and	O
favour	O
pacing	O
and	O
specialist	O
health	O
care	O
.	O

We	O
aimed	O
to	O
assess	O
effectiveness	O
and	O
safety	O
of	O
all	O
four	O
treatments	O
.	O

METHODS	O
In	O
our	O
parallel-group	O
randomised	O
trial	O
,	O
patients	O
meeting	O
Oxford	O
criteria	O
for	O
chronic	O
fatigue	O
syndrome	O
were	O
recruited	O
from	O
six	O
secondary-care	O
clinics	O
in	O
the	O
UK	O
and	O
randomly	O
allocated	O
by	O
computer-generated	O
sequence	O
to	O
receive	O
specialist	O
medical	O
care	O
(	O
SMC	O
)	O
alone	O
or	O
with	O
adaptive	Educational
pacing	Educational
therapy	Educational
(	Educational
APT	Educational
)	Educational
,	O
CBT	O
,	O
or	O
GET	O
.	O

Primary	O
outcomes	O
were	O
fatigue	O
(	O
measured	O
by	O
Chalder	O
fatigue	O
questionnaire	O
score	O
)	O
and	O
physical	O
function	O
(	O
measured	O
by	O
short	O
form-36	O
subscale	O
score	O
)	O
up	O
to	O
52	O
weeks	O
after	O
randomisation	O
,	O
and	O
safety	O
was	O
assessed	O
primarily	O
by	O
recording	O
all	O
serious	O
adverse	O
events	O
,	O
including	O
serious	O
adverse	O
reactions	O
to	O
trial	O
treatments	O
.	O

Primary	O
outcomes	O
were	O
rated	O
by	O
participants	O
,	O
who	O
were	O
necessarily	O
unmasked	O
to	O
treatment	O
assignment	O
;	O
the	O
statistician	O
was	O
masked	O
to	O
treatment	O
assignment	O
for	O
the	O
analysis	O
of	O
primary	O
outcomes	O
.	O

We	O
used	O
longitudinal	O
regression	O
models	O
to	O
compare	O
SMC	O
alone	O
with	O
other	O
treatments	O
,	O
APT	Educational
with	O
CBT	Educational
,	O
and	O
APT	O
with	O
GET	O
.	O

The	O
final	O
analysis	O
included	O
all	O
participants	O
for	O
whom	O
we	O
had	O
data	O
for	O
primary	O
outcomes	O
.	O

This	O
trial	O
is	O
registered	O
at	O
http	O
:	O
//isrctn.org	O
,	O
number	O
ISRCTN54285094	O
.	O

FINDINGS	O
We	O
recruited	O
641	O
eligible	O
patients	O
,	O
of	O
whom	O
160	O
were	O
assigned	O
to	O
the	O
APT	O
group	O
,	O
161	O
to	O
the	O
CBT	O
group	O
,	O
160	O
to	O
the	O
GET	O
group	O
,	O
and	O
160	O
to	O
the	O
SMC-alone	Physical
group	O
.	O

Compared	O
with	O
SMC	O
alone	O
,	O
mean	O
fatigue	O
scores	O
at	O
52	O
weeks	O
were	O
3?4	O
(	O
95	O
%	O
CI	O
1?8	O
to	O
5?0	O
)	O
points	O
lower	O
for	O
CBT	O
(	O
p	O
=	O
0?0001	O
)	O
and	O
3?2	O
(	O
1?7	O
to	O
4?8	O
)	O
points	O
lower	O
for	O
GET	O
(	O
p	O
=	O
0?0003	O
)	O
,	O
but	O
did	O
not	O
differ	O
for	O
APT	O
(	O
0?7	O
[	O
-0?9	O
to	O
2?3	O
]	O
points	O
lower	O
;	O
p	O
=	O
0?38	O
)	O
.	O

Compared	O
with	O
SMC	O
alone	O
,	O
mean	O
physical	O
function	O
scores	O
were	O
7?1	O
(	O
2?0	O
to	O
12?1	O
)	O
points	O
higher	O
for	O
CBT	O
(	O
p	O
=	O
0?0068	O
)	O
and	O
9?4	O
(	O
4?4	O
to	O
14?4	O
)	O
points	O
higher	O
for	O
GET	O
(	O
p	O
=	O
0?0005	O
)	O
,	O
but	O
did	O
not	O
differ	O
for	O
APT	O
(	O
3?4	O
[	O
-1?6	O
to	O
8?4	O
]	O
points	O
lower	O
;	O
p=0?18	O
)	O
.	O

Compared	O
with	O
APT	O
,	O
CBT	O
and	O
GET	O
were	O
associated	O
with	O
less	O
fatigue	O
(	O
CBT	O
p	O
=	O
0?0027	O
;	O
GET	O
p	O
=	O
0?0059	O
)	O
and	O
better	O
physical	O
function	O
(	O
CBT	O
p=0?0002	O
;	O
GET	O
p	O
<	O
0?0001	O
)	O
.	O

Subgroup	O
analysis	O
of	O
427	O
participants	O
meeting	O
international	O
criteria	O
for	O
chronic	O
fatigue	O
syndrome	O
and	O
329	O
participants	O
meeting	O
London	O
criteria	O
for	O
myalgic	O
encephalomyelitis	O
yielded	O
equivalent	O
results	O
.	O

Serious	O
adverse	O
reactions	O
were	O
recorded	O
in	O
two	O
(	O
1	O
%	O
)	O
of	O
159	O
participants	O
in	O
the	O
APT	O
group	O
,	O
three	O
(	O
2	O
%	O
)	O
of	O
161	O
in	O
the	O
CBT	O
group	O
,	O
two	O
(	O
1	O
%	O
)	O
of	O
160	O
in	O
the	O
GET	O
group	O
,	O
and	O
two	O
(	O
1	O
%	O
)	O
of	O
160	O
in	O
the	O
SMC-alone	O
group	O
.	O

INTERPRETATION	O
CBT	O
and	O
GET	O
can	O
safely	O
be	O
added	O
to	O
SMC	O
to	O
moderately	O
improve	O
outcomes	O
for	O
chronic	O
fatigue	O
syndrome	O
,	O
but	O
APT	O
is	O
not	O
an	O
effective	O
addition	O
.	O

FUNDING	O
UK	O
Medical	O
Research	O
Council	O
,	O
Department	O
of	O
Health	O
for	O
England	O
,	O
Scottish	O
Chief	O
Scientist	O
Office	O
,	O
Department	O
for	O
Work	O
and	O
Pensions	O
.	O

Effects	O
of	O
low	O
and	O
high	O
doses	O
of	O
atorvastatin	Pharmacological
on	O
arterial	O
compliance	O
.	O

At	O
the	O
beginning	O
of	O
atherosclerosis	O
before	O
evidence	O
of	O
morphological	O
lesions	O
or	O
plaques	O
,	O
vascular	O
distensibility	O
or	O
arterial	O
compliance	O
decreased	O
gradually	O
.	O

This	O
endothelial	O
dysfunction	O
is	O
regarded	O
as	O
an	O
early	O
feature	O
of	O
atherosclerosis	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
study	O
design	O
,	O
group	O
1	O
(	O
12	O
patients	O
;	O
7	O
males	O
,	O
5	O
females	O
)	O
with	O
serum	O
LDL-C	O
levels	O
higher	O
than	O
170	O
mg/dL	O
and	O
without	O
any	O
other	O
risk	O
factor	O
for	O
atherosclerosis	O
received	O
three	O
months	O
of	O
20	O
mg/day	O
atorvastatin	Pharmacological
treatment	Pharmacological
while	O
group	O
11	O
(	O
8	O
males	O
,	O
4	O
females	O
)	O
with	O
the	O
same	O
characteristics	O
received	O
80	O
mg/day	O
.	O

Baseline	O
and	O
posttreatment	O
serum	O
lipid	O
fractions	O
and	O
arterial	O
compliance	O
were	O
measured	O
.	O

Arterial	O
compliance	O
was	O
measured	O
noninvasively	O
in	O
the	O
left	O
common	O
carotid	O
artery	O
with	O
color	O
Doppler	O
ultrasound	O
.	O

Atorvastatin	Pharmacological
reduced	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
LDL-C	O
,	O
and	O
triglyceride	O
levels	O
by	O
32	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
40.8	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
19	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
and	O
increased	O
HDL-C	O
by	O
6.9	O
%	O
,	O
(	O
P	O
=	O
0.002	O
)	O
in	O
the	O
first	O
group	O
.	O

In	O
the	O
second	O
group	O
these	O
reductions	O
were	O
38.5	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
46.2	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
26.78	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
and	O
the	O
increase	O
in	O
HDL	O
was	O
7.8	O
%	O
(	O
P	O
=	O
0.03	O
)	O
.	O

It	O
was	O
observed	O
that	O
the	O
decrease	O
in	O
serum	O
TC	O
,	O
LDL-C	O
and	O
triglyceride	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
second	O
group	O
than	O
the	O
first	O
group	O
.	O

With	O
atorvastatin	Pharmacological
,	O
the	O
distensibility	O
coefficient	O
(	O
DC	O
)	O
and	O
compliance	O
coefficient	O
(	O
CC	O
)	O
increased	O
from	O
18.7	O
+/-	O
3.4	O
to	O
21.3	O
+/-	O
2.9	O
10	O
(	O
-3	O
)	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
and	O
from	O
0.69	O
+/-	O
0.05	O
to	O
0.77	O
+/-	O
0.03	O
mm2	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
first	O
group	O
while	O
they	O
changed	O
from	O
18.3	O
+/-	O
3.6	O
to	O
21.9	O
+/-	O
3.0	O
10	O
(	O
-3	O
)	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
and	O
from	O
0.70	O
+/-	O
0.04	O
to	O
0.81	O
+/-	O
0.01	O
mm2	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
respectively	O
,	O
in	O
the	O
second	O
group	O
.	O

DC	O
and	O
CC	O
increased	O
in	O
both	O
groups	O
,	O
but	O
the	O
differences	O
between	O
the	O
groups	O
were	O
not	O
significant	O
.	O

High	O
doses	O
of	O
atorvastatin	Pharmacological
reduce	O
blood	O
lipid	O
levels	O
more	O
than	O
conventional	O
doses	O
,	O
however	O
,	O
the	O
change	O
in	O
compliance	O
is	O
not	O
dose-dependent	O
.	O

As	O
endothelial	O
dysfunction	O
is	O
regarded	O
as	O
an	O
early	O
feature	O
of	O
atherosclerosis	O
,	O
there	O
would	O
be	O
no	O
need	O
to	O
administer	O
aggressive	O
doses	O
in	O
a	O
patient	O
without	O
any	O
risk	O
factors	O
other	O
than	O
hyperlipidemia	O
.	O

Onset	O
of	O
action	O
following	O
formoterol	Pharmacological
Turbuhaler	O
and	O
salbutamol	Pharmacological
pMDI	O
in	O
reversible	O
chronic	O
airway	O
obstruction	O
.	O

Short-acting	O
beta	O
(	O
2	O
)	O
-agonists	O
are	O
currently	O
recommended	O
for	O
symptom	O
relief	O
in	O
asthma	O
and	O
the	O
treatment	O
of	O
mild	O
,	O
acute	O
exacerbations	O
in	O
COPD	O
.	O

However	O
,	O
formoterol	Pharmacological
has	O
as	O
fast	O
an	O
onset	O
of	O
action	O
as	O
salbutamol	Pharmacological
with	O
the	O
additional	O
benefit	O
of	O
longer-lasting	O
bronchodilation	O
(	O
approximately	O
12	O
h	O
)	O
.	O

Furthermore	O
,	O
systemic	O
side	O
effects	O
observed	O
with	O
formoterol	Pharmacological
are	O
of	O
a	O
similar	O
duration	O
but	O
less	O
pronounced	O
than	O
with	O
short-acting	O
beta	O
(	O
2	O
)	O
-agonists	O
.	O

In	O
this	O
double-blind	O
,	O
randomized	O
,	O
cross-over	O
study	O
,	O
20	O
adult	O
patients	O
with	O
reversible	O
chronic	O
airway	O
obstruction	O
(	O
intrinsic	O
asthma	O
or	O
COPD	O
)	O
inhaled	O
single	O
doses	O
of	O
formoterol	Pharmacological
9	Pharmacological
microg	Pharmacological
or	O
salbutamol	Pharmacological
100	Pharmacological
microg	Pharmacological
(	Pharmacological
group	Pharmacological
A	Pharmacological
)	Pharmacological
or	O
formoterol	Pharmacological
18	Pharmacological
microg	Pharmacological
or	O
salbutamol	Pharmacological
200	Pharmacological
microg	Pharmacological
(	O
group	O
B	O
)	O
.	O

FEV	O
(	O
1	O
)	O
was	O
measured	O
prior	O
to	O
and	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
25	O
and	O
30	O
min	O
following	O
inhalation	O
of	O
study	O
drug	O
.	O

No	O
significant	O
differences	O
in	O
FEV	O
(	O
1	O
)	O
values	O
were	O
observed	O
between	O
group	O
A	O
(	O
P=0.704	O
)	O
or	O
group	O
B	O
(	O
P=0.270	O
)	O
at	O
baseline	O
,	O
or	O
at	O
5	O
(	O
Group	O
A	O
:	O
P=0.340	O
;	O
Group	O
B	O
:	O
P=0.559	O
)	O
and	O
15	O
min	O
(	O
Group	O
A	O
:	O
P=0.526	O
;	O
Group	O
B	O
:	O
P=0.818	O
)	O
post	O
dose	O
.	O

No	O
adverse	O
events	O
were	O
reported	O
during	O
the	O
study	O
.	O

Formoterol	Pharmacological
Turbuhaler	O
has	O
as	O
rapid	O
an	O
onset	O
of	O
action	O
as	O
salbutamol	Pharmacological
pMDI	O
when	O
given	O
at	O
the	O
recommended	O
doses	O
.	O

Aerobic	Physical
exercise	Physical
improves	O
self-reported	O
sleep	O
and	O
quality	O
of	O
life	O
in	O
older	O
adults	O
with	O
insomnia	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
efficacy	O
of	O
moderate	Physical
aerobic	Physical
physical	Physical
activity	Physical
with	O
sleep	O
hygiene	O
education	O
to	O
improve	O
sleep	O
,	O
mood	O
and	O
quality	O
of	O
life	O
in	O
older	O
adults	O
with	O
chronic	O
insomnia	O
.	O

METHODS	O
Seventeen	O
sedentary	O
adults	O
aged	O
>	O
or=55	O
years	O
with	O
insomnia	O
(	O
mean	O
age	O
61.6	O
[	O
SD?4.3	O
]	O
years	O
;	O
16	O
female	O
)	O
participated	O
in	O
a	O
randomized	O
controlled	O
trial	O
comparing	O
16	O
weeks	O
of	O
aerobic	O
physical	O
activity	O
plus	O
sleep	O
hygiene	O
to	O
non-physical	O
activity	O
plus	O
sleep	O
hygiene	O
.	O

Eligibility	O
included	O
primary	O
insomnia	O
for	O
at	O
least	O
3	O
months	O
,	O
habitual	O
sleep	O
duration	O
<	O
6.5h	O
and	O
a	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
(	O
PSQI	O
)	O
score	O
>	O
5	O
.	O

Outcomes	O
included	O
sleep	O
quality	O
,	O
mood	O
and	O
quality	O
of	O
life	O
questionnaires	O
(	O
PSQI	O
,	O
Epworth	O
Sleepiness	O
Scale	O
[	O
ESS	O
]	O
,	O
Short-form	O
36	O
[	O
SF-36	O
]	O
,	O
Center	O
for	O
Epidemiological	O
Studies	O
Depression	O
Scale	O
[	O
CES-D	O
]	O
)	O
.	O

RESULTS	O
The	O
physical	O
activity	O
group	O
improved	O
in	O
sleep	O
quality	O
on	O
the	O
global	O
PSQI	O
(	O
p	O
<	O
.0001	O
)	O
,	O
sleep	O
latency	O
(	O
p=.049	O
)	O
,	O
sleep	O
duration	O
(	O
p=.04	O
)	O
,	O
daytime	O
dysfunction	O
(	O
p=.027	O
)	O
,	O
and	O
sleep	O
efficiency	O
(	O
p=.036	O
)	O
PSQI	O
sub-scores	O
compared	O
to	O
the	O
control	O
group	O
.	O

The	O
physical	O
activity	O
group	O
also	O
had	O
reductions	O
in	O
depressive	O
symptoms	O
(	O
p=.044	O
)	O
,	O
daytime	O
sleepiness	O
(	O
p=.02	O
)	O
and	O
improvements	O
in	O
vitality	O
(	O
p=.017	O
)	O
compared	O
to	O
baseline	O
scores	O
.	O

CONCLUSION	O
Aerobic	O
physical	O
activity	O
with	O
sleep	O
hygiene	O
education	O
is	O
an	O
effective	O
treatment	O
approach	O
to	O
improve	O
sleep	O
quality	O
,	O
mood	O
and	O
quality	O
of	O
life	O
in	O
older	O
adults	O
with	O
chronic	O
insomnia	O
.	O

Association	O
of	O
severity	O
of	O
coexisting	O
patellofemoral	O
disease	O
with	O
increased	O
impairments	O
and	O
functional	O
limitations	O
in	O
patients	O
with	O
knee	O
osteoarthritis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
association	O
between	O
severity	O
of	O
coexisting	O
patellofemoral	O
(	O
PF	O
)	O
disease	O
with	O
lower	O
extremity	O
impairments	O
and	O
functional	O
limitations	O
in	O
patients	O
with	O
tibiofemoral	O
(	O
TF	O
)	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

METHODS	O
Radiographic	Physical
views	Physical
of	O
the	O
TF	O
and	O
PF	O
compartments	O
,	O
knee	Physical
extension	Physical
strength	Physical
,	O
and	O
knee	Physical
range	Physical
of	Physical
motion	Physical
were	O
obtained	O
for	O
167	O
patients	O
with	O
knee	O
OA	O
.	O

Additionally	O
,	O
knee-specific	O
symptoms	O
and	O
functional	O
limitations	O
were	O
assessed	O
using	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
Osteoarthritis	O
Index	O
(	O
WOMAC	O
)	O
and	O
the	O
Activities	O
of	O
Daily	O
Living	O
Scale	O
(	O
ADLS	O
)	O
.	O

RESULTS	O
Moderate/severe	O
PFOA	O
was	O
associated	O
with	O
lower	O
knee	O
extension	O
strength	O
(	O
mean	O
?	O
SD	O
1.4	O
?	O
0.5	O
Nm/body	O
weight	O
[	O
BW	O
]	O
)	O
compared	O
to	O
no	O
PFOA	O
(	O
mean	O
?	O
SD	O
1.8	O
?	O
0.5	O
Nm/BW	O
)	O
.	O

Additionally	O
,	O
total	O
knee	O
range	O
of	O
motion	O
was	O
significantly	O
lower	O
for	O
patients	O
with	O
moderate/severe	O
PFOA	O
(	O
mean	O
?	O
SD	O
120.8?	O
?	O
14.4?	O
)	O
compared	O
to	O
no	O
PFOA	O
(	O
mean	O
?	O
SD	O
133.5?	O
?	O
10.7?	O
)	O
and	O
mild	O
PFOA	O
(	O
mean	O
?	O
SD	O
125.8?	O
?	O
13.0?	O
)	O
.	O

Moderate/severe	O
PFOA	O
and	O
mild	O
PFOA	O
were	O
also	O
associated	O
with	O
less	O
pain	O
while	O
standing	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.2	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
0.1-0.7	O
and	O
OR	O
0.2	O
,	O
95	O
%	O
CI	O
0.1-0.6	O
,	O
respectively	O
)	O
on	O
the	O
WOMAC	O
,	O
and	O
moderate/severe	O
PFOA	O
was	O
associated	O
with	O
greater	O
difficulty	O
with	O
going	O
downstairs	O
(	O
OR	O
2.9	O
,	O
95	O
%	O
CI	O
1.0-8.1	O
)	O
on	O
the	O
ADLS	O
.	O

CONCLUSION	O
It	O
appears	O
that	O
knees	O
with	O
more	O
severe	O
coexisting	O
PF	O
disease	O
demonstrate	O
features	O
distinct	O
from	O
those	O
observed	O
in	O
TFOA	O
in	O
isolation	O
or	O
in	O
combination	O
with	O
mild	O
PF	O
disease	O
.	O

Treatment	O
strategies	O
targeting	O
the	O
PF	O
joint	O
may	O
be	O
warranted	O
to	O
mitigate	O
the	O
specific	O
lower	O
extremity	O
impairments	O
and	O
functional	O
problems	O
present	O
in	O
this	O
patient	O
population	O
.	O

Oral	O
desensitization	O
in	O
papular	O
urticaria	O
in	O
children	O
.	O

Papular	O
urticaria	O
(	O
PU	O
)	O
is	O
among	O
the	O
commonest	O
skin	O
ailments	O
in	O
children	O
.	O

Induced	O
specific	O
desensitization	O
to	O
insect	O
bites	O
is	O
theoretically	O
an	O
effective	O
means	O
of	O
prevention	O
of	O
PU	O
.	O

In	O
this	O
double	O
blind	O
placebo	Control
controlled	O
study	O
,	O
an	O
oral	Pharmacological
vaccine	Pharmacological
prepared	Pharmacological
from	Pharmacological
insect	Pharmacological
saliva	Pharmacological
was	O
compared	O
with	O
placebo	Control
(	Control
stable	Control
vaccine	Control
solvent	Control
)	Control
.	Control

Vaccine	Pharmacological
and	O
placebo	Control
effectiveness	O
were	O
tested	O
by	O
counting	O
active	O
PU	O
lesions	O
,	O
serum	O
eosinophils	O
,	O
and	O
IgE	O
,	O
before	O
and	O
after	O
4	O
months	O
of	O
treatment	O
.	O

Statistically	O
significant	O
differences	O
between	O
oral	O
vaccine	O
and	O
placebo	O
were	O
not	O
found	O
in	O
the	O
clinical	O
or	O
the	O
immunological	O
variables	O
tested	O
.	O

We	O
conclude	O
that	O
,	O
although	O
a	O
lack	O
of	O
oral	O
vaccine	O
efficacy	O
was	O
suspected	O
,	O
larger	O
study	O
samples	O
are	O
needed	O
to	O
strengthen	O
our	O
conclusion	O
.	O

Hypertension	O
and	O
non-insulin-dependent	O
diabetes	O
.	O

A	O
comparison	O
between	O
an	O
angiotensin-converting	Pharmacological
enzyme	Pharmacological
inhibitor	Pharmacological
and	O
a	O
calcium	Pharmacological
antagonist	Pharmacological
.	Pharmacological

The	O
effects	O
of	O
the	O
angiotensin-converting	Pharmacological
enzyme	Pharmacological
lisinopril	Pharmacological
were	O
compared	O
with	O
those	O
of	O
the	O
calcium	Pharmacological
antagonist	Pharmacological
nifedipine	Pharmacological
in	O
162	O
non-insulin-dependent	O
diabetic	O
hypertensive	O
patients	O
for	O
a	O
24-week	O
period	O
.	O

In	O
83	O
and	O
79	O
patients	O
,	O
respectively	O
,	O
lisinopril	Pharmacological
and	Pharmacological
slow-release	Pharmacological
nifedipine	Pharmacological
produced	O
similar	O
reductions	O
in	O
blood	O
pressure	O
(	O
systolic/diastolic	O
:	O
-16/-13	O
mmHg	O
supine	O
and	O
-14/-11	O
mmHg	O
standing	O
after	O
lisinopril	O
;	O
-15/-12	O
mmHg	O
supine	O
and	O
-14/-11	O
mmHg	O
standing	O
nifedipine	O
)	O
.	O

Fasting	O
and	O
post-prandial	O
plasma	O
glucose	O
,	O
glycosylated	O
haemoglobin	O
and	O
plasma	O
lipids	O
appeared	O
to	O
be	O
unaffected	O
by	O
either	O
agent	O
.	O

Also	O
,	O
28	O
%	O
of	O
the	O
patients	O
on	O
lisinopril	Pharmacological
and	O
30	O
%	O
of	O
those	O
on	O
nifedipine	Pharmacological
presented	O
microalbuminuria	O
.	O

Both	O
drugs	O
induced	O
a	O
reduction	O
in	O
the	O
albumin	O
excretion	O
rate	O
(	O
AER	O
)	O
.	O

The	O
geometric	O
mean	O
x	O
:	O
tolerance	O
factor	O
of	O
the	O
reduction	O
in	O
AER	O
among	O
the	O
23	O
microalbuminuric	O
patients	O
on	O
lisinopril	Pharmacological
(	O
-10.0	O
x:1.3	O
micrograms/min	O
)	O
was	O
greater	O
,	O
though	O
not	O
significantly	O
so	O
,	O
than	O
that	O
observed	O
in	O
the	O
26	O
on	O
nifedipine	Pharmacological
(	O
-0.9	O
x	O
1.2	O
micrograms/min	O
)	O
.	O

Moreover	O
,	O
lisinopril	Pharmacological
appeared	O
to	O
be	O
better	O
tolerated	O
than	O
nifedipine	Pharmacological
in	O
our	O
study	O
population	O
.	O

Microalbuminuria	O
is	O
an	O
important	O
risk	O
factor	O
for	O
cardiovascular	O
mortality	O
in	O
non-insulin-dependent	O
diabetic	O
patients	O
as	O
well	O
as	O
in	O
the	O
general	O
population	O
.	O

To	O
what	O
extent	O
a	O
reduction	O
in	O
the	O
AER	O
could	O
ameliorate	O
diabetic	O
patients	O
is	O
,	O
at	O
present	O
,	O
unknown	O
.	O

Finally	O
,	O
both	O
lisinopril	Pharmacological
and	O
nifedipine	Pharmacological
showed	O
a	O
similar	O
antihypertensive	O
effect	O
in	O
these	O
patients	O
which	O
was	O
not	O
associated	O
with	O
significant	O
differences	O
in	O
plasma	O
glucose	O
,	O
insulin	O
or	O
lipid	O
concentrations	O
.	O

The	O
clinical	O
consequences	O
of	O
the	O
insignificant	O
differences	O
in	O
AER	O
remain	O
unclear	O
.	O

A	O
prospective	O
randomized	O
study	O
of	O
amoxycillin	Pharmacological
and	Pharmacological
omeprazole	Pharmacological
with	O
and	O
without	O
metronidazole	Pharmacological
in	O
the	O
eradication	O
treatment	O
of	O
Helicobacter	O
pylori	O
.	O

A	O
combination	O
of	O
amoxycillin	Pharmacological
and	Pharmacological
omeprazole	Pharmacological
is	O
often	O
used	O
to	O
treat	O
Helicobacter	O
pylori	O
infection	O
.	O

A	O
three-drug	O
regimen	O
comprising	O
metronidazole	Pharmacological
,	Pharmacological
amoxycillin	Pharmacological
and	Pharmacological
omeprazole	Pharmacological
has	O
been	O
proposed	O
as	O
an	O
alternative	O
therapy	O
.	O

In	O
a	O
prospective	O
,	O
randomized	O
,	O
comparative	O
study	O
,	O
we	O
evaluated	O
these	O
two	O
regimens	O
with	O
respect	O
to	O
safety	O
and	O
efficacy	O
in	O
patients	O
with	O
H.	O
pylori	O
infection	O
.	O

Sixty	O
patients	O
with	O
peptic	O
ulcer	O
(	O
gastric	O
,	O
32	O
patients	O
;	O
duodenal	O
,	O
28	O
patients	O
)	O
who	O
had	O
a	O
history	O
of	O
ulcer	O
recurrence	O
were	O
randomly	O
assigned	O
to	O
dual	O
therapy	O
with	O
amoxycillin	Pharmacological
(	O
500	O
mg	O
three	O
times	O
daily	O
for	O
2	O
weeks	O
)	O
and	O
omeprazole	Pharmacological
(	O
20	O
mg	O
once	O
daily	O
for	O
8	O
weeks	O
)	O
or	O
to	O
triple	O
therapy	O
with	O
metronidazole	Pharmacological
(	O
500	O
mg	O
twice	O
daily	O
for	O
2	O
weeks	O
)	O
plus	O
amoxycillin	Pharmacological
and	Pharmacological
omeprazole	Pharmacological
,	O
given	O
in	O
the	O
same	O
dosages	O
as	O
dual	O
therapy	O
.	O

Forty-eight	O
patients	O
completed	O
the	O
protocol	O
;	O
treatment	O
was	O
discontinued	O
because	O
of	O
side	O
effects	O
in	O
nine	O
patients	O
,	O
and	O
three	O
patients	O
dropped	O
out	O
of	O
the	O
study	O
.	O

On	O
the	O
basis	O
of	O
all	O
patients	O
treated	O
,	O
the	O
rate	O
of	O
H.	O
pylori	O
eradication	O
was	O
significantly	O
higher	O
for	O
triple	O
therapy	O
20/23	O
cases	O
,	O
87.0	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.664-0.972	O
)	O
than	O
for	O
dual	O
therapy	O
13/25	O
,	O
52.0	O
%	O
;	O
0.313-0.722	O
;	O
P	O
<	O
0.05	O
)	O
.	O

On	O
an	O
intention-to-treat	O
basis	O
,	O
the	O
difference	O
between	O
the	O
groups	O
in	O
the	O
rate	O
of	O
H.	O
pylori	O
eradication	O
was	O
marginally	O
significant	O
(	O
P	O
=	O
0.06	O
[	O
0.028-0.512	O
]	O
)	O
.	O

Side	O
effects	O
were	O
reported	O
by	O
five	O
patients	O
receiving	O
triple	O
therapy	O
(	O
skin	O
rash	O
,	O
one	O
;	O
nausea	O
,	O
two	O
;	O
headache	O
,	O
one	O
;	O
abdominal	O
pain	O
,	O
one	O
)	O
,	O
and	O
four	O
patients	O
receiving	O
dual	O
therapy	O
(	O
skin	O
rash	O
,	O
two	O
;	O
abdominal	O
pain	O
,	O
one	O
;	O
diarrhoea	O
,	O
one	O
)	O
.	O

All	O
side	O
effects	O
resolved	O
spontaneously	O
after	O
termination	O
of	O
treatment	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
safety	O
between	O
the	O
two	O
regimens	O
.	O

Triple	O
therapy	O
with	O
metronidazole	Pharmacological
,	Pharmacological
amoxycillin	Pharmacological
,	Pharmacological
and	Pharmacological
omeprazole	Pharmacological
was	O
significantly	O
more	O
effective	O
for	O
the	O
eradication	O
of	O
H.	O
pylori	O
than	O
dual	O
therapy	O
with	O
amoxycillin	Pharmacological
and	Pharmacological
omeprazole	Pharmacological
alone	Pharmacological
.	O

The	O
safety	O
of	O
these	O
regimens	O
was	O
similar	O
,	O
and	O
triple	O
therapy	O
was	O
found	O
to	O
be	O
clinically	O
acceptable	O
.	O

Removal	O
of	O
humoral	O
mediators	O
and	O
the	O
effect	O
on	O
the	O
survival	O
of	O
septic	O
patients	O
by	O
hemoperfusion	Pharmacological
with	O
neutral	O
microporous	O
resin	O
column	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
impact	O
of	O
neutral	Pharmacological
microporous	Pharmacological
resin	Pharmacological
hemoperfusion	Pharmacological
on	O
hemodynamic	O
improvement	O
,	O
removal	O
of	O
inflammatory	O
cytokines	O
,	O
and	O
mortality	O
in	O
critical	O
care	O
patients	O
with	O
severe	O
sepsis	O
.	O

Forty-four	O
patients	O
with	O
severe	O
sepsis	O
or	O
septic	O
shock	O
were	O
randomized	O
to	O
HA	Pharmacological
type	Pharmacological
hemoperfusion	Pharmacological
treatment	Pharmacological
(	O
N=24	O
)	O
or	O
standard	O
therapy	O
(	O
N=20	O
)	O
.	O

Those	O
undergoing	O
hemoperfusion	O
treatment	O
received	O
HA330	Pharmacological
hemoperfusion	Pharmacological
.	O

We	O
measured	O
the	O
plasma	O
concentrations	O
of	O
IL-6	O
and	O
IL-8	O
at	O
the	O
start	O
of	O
every	O
hemoperfusion	O
treatment	O
,	O
and	O
the	O
following	O
parameters	O
were	O
compared	O
between	O
the	O
control	O
group	O
and	O
the	O
hemoperfusion	Pharmacological
group	O
on	O
days	O
3	O
,	O
7	O
,	O
and	O
14	O
:	O
hemodynamics	O
(	O
cardiac	O
index	O
,	O
systemic	O
vascular	O
resistance	O
index	O
,	O
heart	O
rate	O
,	O
and	O
mean	O
arterial	O
pressure	O
)	O
;	O
change	O
of	O
hematology	O
and	O
coagulation	O
function	O
;	O
organ	O
function	O
;	O
and	O
the	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
.	O

Hospital	O
,	O
28-day	O
,	O
and	O
ICU	O
mortality	O
were	O
also	O
observed	O
.	O

Patients	O
treated	O
with	O
HA	Pharmacological
hemoperfusion	Pharmacological
showed	O
a	O
significant	O
removal	O
of	O
plasma	O
IL-6	O
and	O
IL-8	O
over	O
time	O
while	O
in	O
the	O
study	O
.	O

Patients	O
in	O
the	O
HA	O
group	O
also	O
demonstrated	O
significant	O
increases	O
in	O
cardiac	O
index	O
,	O
systemic	O
vascular	O
resistant	O
index	O
,	O
fast	O
withdrawal	O
of	O
vasoactive	O
agents	O
and	O
decreases	O
in	O
heart	O
rate	O
compared	O
with	O
the	O
controls	O
at	O
days	O
3	O
and	O
7	O
.	O

Although	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
in	O
organ	O
dysfunction	O
as	O
assessed	O
by	O
SOFA	O
scores	O
from	O
day	O
0	O
(	O
baseline	O
)	O
to	O
day	O
7	O
,	O
significant	O
improvement	O
can	O
be	O
demonstrated	O
in	O
the	O
hemoperfusion	O
group	O
at	O
day	O
14	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
in	O
28-day	O
mortality	O
,	O
hospital	O
mortality	O
,	O
or	O
length	O
of	O
hospital	O
stay	O
,	O
but	O
ICU	O
mortality	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
in	O
the	O
HA	O
group	O
were	O
markedly	O
reduced	O
.	O

Hemoperfusion	O
treatment	O
using	O
the	O
HA	O
type	O
cartridge	O
in	O
sepsis	O
is	O
safe	O
and	O
it	O
may	O
improve	O
organ	O
dysfunction	O
,	O
ICU	O
mortality	O
,	O
and	O
shorten	O
the	O
length	O
of	O
ICU	O
stay	O
.	O

Clinical	O
significant	O
removal	O
of	O
inflammatory	O
cytokines	O
such	O
as	O
IL-6	O
and	O
IL-8	O
from	O
circulation	O
by	O
hemoperfusion	Pharmacological
may	O
contribute	O
to	O
improving	O
a	O
patient	O
's	O
outcome	O
in	O
an	O
ICU	O
.	O

Dexamethasone	Pharmacological
phosphate	Pharmacological
in	O
antibiotic	Pharmacological
ear	Pharmacological
drops	Pharmacological
for	O
the	O
treatment	O
of	O
acute	O
bacterial	O
otitis	O
externa	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
polymyxin	Pharmacological
sulfate	Pharmacological
7500	Pharmacological
IU/neomycin	Pharmacological
sulfate	Pharmacological
3500	Pharmacological
IU/dexamethasone	Pharmacological
phosphate	Pharmacological
0.1	Pharmacological
%	Pharmacological
(	Pharmacological
PN+Dx	Pharmacological
)	Pharmacological
otic	Pharmacological
solution	Pharmacological
with	O
polymyxin	Pharmacological
sulfate	Pharmacological
7500	Pharmacological
IU/neomycin	Pharmacological
sulfate	Pharmacological
3500	Pharmacological
IU	Pharmacological
(	Pharmacological
PN-Dx	Pharmacological
)	Pharmacological
in	O
patients	O
with	O
acute	O
bacterial	O
otitis	O
externa	O
(	O
AOE	O
)	O
,	O
in	O
order	O
to	O
determine	O
the	O
possible	O
benefit	O
of	O
the	O
addition	O
of	O
dexamethasone	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
Active	O
controlled	O
,	O
double-blind	O
,	O
randomized	O
,	O
parallel	O
group	O
,	O
multi-center	O
clinical	O
trial	O
in	O
ear	O
,	O
nose	O
,	O
and	O
throat	O
(	O
ENT	O
)	O
specialist	O
practices	O
with	O
a	O
planned	O
interim	O
analysis	O
for	O
sample	O
size	O
adaptation	O
.	O

In	O
total	O
,	O
338	O
patients	O
aged	O
18-76	O
who	O
had	O
a	O
previous	O
episode	O
of	O
otitis	O
externa	O
within	O
the	O
last	O
year	O
were	O
randomized	O
to	O
receive	O
10	O
+/-	O
2	O
days	O
of	O
treatment	O
with	O
two	O
drops	O
,	O
three	O
times	O
daily	O
,	O
of	O
either	O
PN+Dx	Pharmacological
or	O
PN-Dx	Control
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Change	O
in	O
the	O
clinical	O
symptom	O
score	O
(	O
consisting	O
of	O
the	O
subscores	O
redness	O
,	O
swelling	O
,	O
pain	O
,	O
and	O
secretion	O
)	O
and	O
of	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
rating	O
for	O
pain	O
from	O
Visit	O
1	O
(	O
Day	O
1	O
)	O
to	O
Visit	O
2	O
(	O
Day	O
4	O
+/-	O
1	O
)	O
,	O
patient	O
's	O
assessment	O
of	O
efficacy	O
at	O
Visit	O
3	O
(	O
Day	O
10	O
+/-	O
2	O
)	O
,	O
and	O
the	O
frequency	O
and	O
type	O
of	O
adverse	O
events	O
.	O

RESULTS	O
There	O
was	O
a	O
significantly	O
greater	O
reduction	O
of	O
swelling	O
from	O
Visit	O
1	O
to	O
Visit	O
2	O
with	O
PN+Dx	O
,	O
and	O
more	O
patients	O
rated	O
the	O
efficacy	O
of	O
PN+Dx	O
as	O
'very	O
good	O
'	O
or	O
'good	O
'	O
at	O
Visit	O
3	O
(	O
p	O
=	O
0.03	O
)	O
.	O

There	O
was	O
also	O
a	O
significantly	O
greater	O
decrease	O
in	O
the	O
clinical	O
symptom	O
score	O
from	O
Visit	O
1	O
to	O
Visit	O
2	O
in	O
the	O
PN+Dx	O
group	O
in	O
patients	O
who	O
had	O
at	O
least	O
a	O
moderately	O
severe	O
symptom	O
score	O
with	O
more	O
than	O
seven	O
points	O
at	O
Visit	O
1	O
(	O
p	O
=	O
0.01	O
)	O
and	O
in	O
patients	O
suffering	O
from	O
their	O
current	O
episode	O
of	O
otitis	O
externa	O
for	O
more	O
than	O
2	O
days	O
(	O
p	O
=	O
0.02	O
)	O
.	O

In	O
total	O
,	O
14	O
adverse	O
events	O
were	O
reported	O
during	O
the	O
study	O
period	O
with	O
no	O
related	O
adverse	O
drug	O
reactions	O
for	O
PN+Dx	O
.	O

CONCLUSIONS	O
The	O
addition	O
of	O
dexamethasone	Pharmacological
phosphate	Pharmacological
to	O
polymyxin	Pharmacological
B/neomycin	Pharmacological
significantly	O
reduces	O
swelling	O
in	O
patients	O
with	O
AOE	O
and	O
leads	O
to	O
significantly	O
higher	O
patient	O
's	O
ratings	O
of	O
treatment	O
efficacy	O
.	O

It	O
especially	O
leads	O
to	O
an	O
overall	O
reduction	O
of	O
symptoms	O
in	O
cases	O
of	O
moderately	O
or	O
more	O
severe	O
otitis	O
externa	O
and	O
cases	O
lasting	O
for	O
more	O
than	O
2	O
days	O
.	O

New	Pharmacological
introducer	Pharmacological
PEG	Pharmacological
gastropexy	Pharmacological
does	O
not	O
require	O
prophylactic	O
antibiotics	O
:	O
multicenter	O
prospective	O
randomized	O
double-blind	O
placebo-controlled	O
study	O
.	O

BACKGROUND	O
Peristomal	O
infections	O
are	O
the	O
most	O
common	O
complications	O
of	O
PEG	O
,	O
despite	O
prophylactic	O
antibiotics	O
.	O

The	O
introducer	O
PEG-placement	O
technique	O
avoids	O
the	O
sojourn	O
of	O
a	O
PEG	O
catheter	O
through	O
the	O
oropharynx	O
,	O
and	O
hence	O
minimizes	O
the	O
chances	O
of	O
infectious	O
complications	O
.	O

Despite	O
the	O
obvious	O
potential	O
advantage	O
,	O
this	O
technique	O
failed	O
to	O
gain	O
popularity	O
,	O
mainly	O
as	O
a	O
result	O
of	O
other	O
associated	O
risks	O
and	O
complications	O
.	O

Recently	O
,	O
a	O
modified	O
introducer	O
endoscopic	O
PEG-gastropexy	O
technique	O
was	O
shown	O
to	O
be	O
quite	O
safe	O
.	O

The	O
present	O
study	O
is	O
the	O
first	O
study	O
that	O
evaluated	O
the	O
need	O
of	O
prophylactic	O
antibiotics	O
for	O
introducer	O
PEG	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
incidence	O
of	O
peristomal	O
wound	O
infections	O
during	O
the	O
immediate	O
7-day	O
postprocedure	O
follow-up	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

SETTINGS	O
Multicenter	O
;	O
a	O
university	O
tertiary-care	O
hospital	O
and	O
a	O
private	O
practice	O
endoscopy	O
clinic	O
.	O

PATIENTS	O
A	O
total	O
of	O
633	O
patients	O
undergoing	O
PEG	O
were	O
assessed	O
for	O
inclusion	O
.	O

Ninety-seven	O
patients	O
who	O
had	O
malignant	O
stenotic	O
oropharyngeal	O
stricture	O
were	O
randomized	O
:	O
group	O
I	O
(	O
49	O
patients	O
)	O
received	O
prophylactic	Pharmacological
ceftriaxone	Pharmacological
,	O
and	O
group	O
II	O
(	O
48	O
patients	O
)	O
received	O
a	O
placebo	Control
.	O

Both	O
groups	O
were	O
similar	O
in	O
patient	O
characteristics	O
.	O

INTERVENTIONS	O
Introducer	O
PEG	Pharmacological
was	O
performed	O
by	O
using	O
the	O
Freka	O
Pexact-15	O
CH/FR	O
,	O
with	O
the	O
gastric	O
wall	O
nonsurgically	O
sutured	O
to	O
the	O
anterior	O
abdominal	O
wall	O
by	O
use	O
of	O
an	O
endoscope	O
.	O

MAIN	O
OUTCOME	O
MEASUREMENTS	O
The	O
peristomal	O
area	O
was	O
assessed	O
daily	O
for	O
7	O
days	O
by	O
using	O
2	O
different	O
types	O
of	O
infection	O
scores	O
.	O

RESULTS	O
Clinically	O
significant	O
wound	O
reaction	O
was	O
observed	O
in	O
1	O
patient	O
in	O
each	O
group	O
.	O

Wound	O
infection	O
scores	O
were	O
marginally	O
higher	O
in	O
the	O
placebo	Control
group	O
,	O
but	O
the	O
differences	O
in	O
the	O
values	O
of	O
infection	O
scores	O
between	O
both	O
the	O
groups	O
were	O
not	O
statistically	O
significant	O
during	O
the	O
7-day	O
post-PEG	O
follow-up	O
.	O

LIMITATIONS	O
The	O
introducer	O
gastropexy	O
kit	O
is	O
5	O
times	O
more	O
expensive	O
than	O
the	O
pull	O
PEG	O
.	O

CONCLUSIONS	O
The	Pharmacological
new	Pharmacological
introducer	Pharmacological
PEG-gastropexy	Pharmacological
technique	Pharmacological
can	O
be	O
performed	O
safely	O
,	O
without	O
prophylactic	O
antibiotics	O
in	O
patients	O
potentially	O
at	O
high	O
risk	O
of	O
peristomal	O
infectious	O
complications	O
(	O
those	O
with	O
advanced	O
oropharyngeal	O
malignancy	O
)	O
(	O
ClinicalTrials.gov	O
identifier	O
NCT00375414	O
)	O
.	O

Treatment	O
of	O
canine	O
parvoviral	O
enteritis	O
with	O
interferon-omega	Pharmacological
in	O
a	O
placebo-controlled	O
challenge	O
trial	O
.	O

Canine	O
parvoviral	O
enteritis	O
continues	O
to	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
dogs	O
worldwide	O
,	O
and	O
efficacious	O
antiviral	Pharmacological
therapies	Pharmacological
are	O
lacking	O
.	O

The	O
present	O
trial	O
was	O
aimed	O
at	O
evaluating	O
the	O
therapeutic	O
efficacy	O
of	O
a	O
recombinant	Pharmacological
feline	Pharmacological
interferon	Pharmacological
(	Pharmacological
type	Pharmacological
omega	Pharmacological
)	Pharmacological
preparation	O
in	O
the	O
treatment	O
of	O
parvoviral	O
enteritis	O
in	O
dogs	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
challenge	O
trial	O
was	O
performed	O
in	O
beagle	O
pups	O
(	O
8-9	O
weeks	O
)	O
;	O
clinical	O
signs	O
,	O
body	O
weight	O
,	O
hematologic	O
parameters	O
,	O
and	O
mortality	O
were	O
monitored	O
for	O
a	O
period	O
of	O
14	O
days	O
after	O
challenge	O
.	O

Fourteen	O
animals	O
were	O
inoculated	Pharmacological
with	Pharmacological
virulent	Pharmacological
canine	Pharmacological
parvovirus	Pharmacological
;	O
10	O
animals	O
that	O
developed	O
clinical	O
signs	O
thereby	O
meeting	O
the	O
inclusion	O
criteria	O
were	O
admitted	O
to	O
the	O
treatment	O
phase	O
in	O
two	O
randomly	O
selected	O
groups	O
(	O
placebo	Control
and	O
IFN	Pharmacological
)	O
of	O
equal	O
size	O
.	O

The	O
IFN	O
group	O
received	O
daily	O
intravenous	O
injections	O
of	O
rFeIFN-omega	Pharmacological
(	O
2.5	O
MU/kg	O
)	O
for	O
three	O
consecutive	O
days	O
.	O

The	O
placebo	Control
group	O
received	O
daily	O
injections	O
of	O
saline	Pharmacological
without	O
IFN	O
.	O

Both	O
groups	O
of	O
animals	O
received	O
individual	O
supportive	O
treatment	O
consisting	O
of	O
adjusted	O
diet	O
and	O
electrolyte	O
solution	O
.	O

All	O
five	O
dogs	O
in	O
the	O
placebo	O
group	O
developed	O
fulminating	O
enteritis	O
with	O
typical	O
clinical	O
signs	O
and	O
died	O
within	O
10	O
days	O
post-inoculation	O
(	O
or	O
6	O
days	O
post-treatment	O
)	O
.	O

In	O
the	O
IFN-treated	O
group	O
,	O
one	O
animal	O
died	O
on	O
day	O
2	O
after	O
the	O
treatment	O
was	O
started	O
,	O
whereas	O
the	O
other	O
four	O
dogs	O
survived	O
the	O
challenge	O
and	O
gradually	O
recovered	O
.	O

Our	O
data	O
confirm	O
that	O
the	O
rFeIFN-omega	Pharmacological
can	O
exert	O
a	O
significant	O
therapeutic	O
effect	O
on	O
dogs	O
with	O
parvoviral	O
enteritis	O
by	O
improving	O
clinical	O
signs	O
and	O
reducing	O
mortality	O
.	O

Exemestane	Pharmacological
for	O
breast-cancer	O
prevention	O
in	O
postmenopausal	O
women	O
.	O

BACKGROUND	O
Tamoxifen	O
and	O
raloxifene	O
have	O
limited	O
patient	O
acceptance	O
for	O
primary	O
prevention	O
of	O
breast	O
cancer	O
.	O

Aromatase	O
inhibitors	O
prevent	O
more	O
contralateral	O
breast	O
cancers	O
and	O
cause	O
fewer	O
side	O
effects	O
than	O
tamoxifen	O
in	O
patients	O
with	O
early-stage	O
breast	O
cancer	O
.	O

METHODS	O
In	O
a	O
randomized	O
,	O
placebo-controlled	Control
,	O
double-blind	O
trial	O
of	O
exemestane	Pharmacological
designed	O
to	O
detect	O
a	O
65	O
%	O
relative	O
reduction	O
in	O
invasive	O
breast	O
cancer	O
,	O
eligible	O
postmenopausal	O
women	O
35	O
years	O
of	O
age	O
or	O
older	O
had	O
at	O
least	O
one	O
of	O
the	O
following	O
risk	O
factors	O
:	O
60	O
years	O
of	O
age	O
or	O
older	O
;	O
Gail	O
5-year	O
risk	O
score	O
greater	O
than	O
1.66	O
%	O
(	O
chances	O
in	O
100	O
of	O
invasive	O
breast	O
cancer	O
developing	O
within	O
5	O
years	O
)	O
;	O
prior	O
atypical	O
ductal	O
or	O
lobular	O
hyperplasia	O
or	O
lobular	O
carcinoma	O
in	O
situ	O
;	O
or	O
ductal	O
carcinoma	O
in	O
situ	O
with	O
mastectomy	O
.	O

Toxic	O
effects	O
and	O
health-related	O
and	O
menopause-specific	O
qualities	O
of	O
life	O
were	O
measured	O
.	O

RESULTS	O
A	O
total	O
of	O
4560	O
women	O
for	O
whom	O
the	O
median	O
age	O
was	O
62.5	O
years	O
and	O
the	O
median	O
Gail	O
risk	O
score	O
was	O
2.3	O
%	O
were	O
randomly	O
assigned	O
to	O
either	O
exemestane	Pharmacological
or	O
placebo	Control
.	O

At	O
a	O
median	O
follow-up	O
of	O
35	O
months	O
,	O
11	O
invasive	O
breast	O
cancers	O
were	O
detected	O
in	O
those	O
given	O
exemestane	Pharmacological
and	O
in	O
32	O
of	O
those	O
given	O
placebo	Control
,	O
with	O
a	O
65	O
%	O
relative	O
reduction	O
in	O
the	O
annual	O
incidence	O
of	O
invasive	O
breast	O
cancer	O
(	O
0.19	O
%	O
vs.	O
0.55	O
%	O
;	O
hazard	O
ratio	O
,	O
0.35	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.18	O
to	O
0.70	O
;	O
P=0.002	O
)	O
.	O

The	O
annual	O
incidence	O
of	O
invasive	O
plus	O
noninvasive	O
(	O
ductal	O
carcinoma	O
in	O
situ	O
)	O
breast	O
cancers	O
was	O
0.35	O
%	O
on	O
exemestane	O
and	O
0.77	O
%	O
on	O
placebo	Control
(	O
hazard	O
ratio	O
,	O
0.47	O
;	O
95	O
%	O
CI	O
,	O
0.27	O
to	O
0.79	O
;	O
P=0.004	O
)	O
.	O

Adverse	O
events	O
occurred	O
in	O
88	O
%	O
of	O
the	O
exemestane	O
group	O
and	O
85	O
%	O
of	O
the	O
placebo	O
group	O
(	O
P=0.003	O
)	O
,	O
with	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
terms	O
of	O
skeletal	O
fractures	O
,	O
cardiovascular	O
events	O
,	O
other	O
cancers	O
,	O
or	O
treatment-related	O
deaths	O
.	O

Minimal	O
quality-of-life	O
differences	O
were	O
observed	O
.	O

CONCLUSIONS	O
Exemestane	Pharmacological
significantly	O
reduced	O
invasive	O
breast	O
cancers	O
in	O
postmenopausal	O
women	O
who	O
were	O
at	O
moderately	O
increased	O
risk	O
for	O
breast	O
cancer	O
.	O

During	O
a	O
median	O
follow-up	O
period	O
of	O
3	O
years	O
,	O
exemestane	O
was	O
associated	O
with	O
no	O
serious	O
toxic	O
effects	O
and	O
only	O
minimal	O
changes	O
in	O
health-related	O
quality	O
of	O
life	O
.	O

(	O
Funded	O
by	O
Pfizer	O
and	O
others	O
;	O
NCIC	O
CTG	O
MAP.3	O
ClinicalTrials.gov	O
number	O
,	O
NCT00083174	O
.	O

)	O
.	O

Hodgkin	O
's	O
disease	O
in	O
childhood	O
and	O
adolescence	O
:	O
results	O
of	O
chemotherapy-radiotherapy	O
in	O
clinical	O
stages	O
IA-IIB	O
.	O

From	O
April	O
1972	O
to	O
May	O
1980	O
,	O
72	O
children	O
and	O
adolescents	O
(	O
aged	O
5	O
to	O
19	O
years	O
old	O
,	O
median	O
16	O
)	O
with	O
Hodgkin	O
's	O
disease	O
,	O
clinical	O
stages	O
IA-IIB	O
(	O
IA	O
,	O
18	O
;	O
II2A	O
,	O
two	O
areas	O
involved	O
on	O
the	O
same	O
side	O
of	O
the	O
diaphragm	O
,	O
23	O
;	O
II3+A	O
,	O
three	O
areas	O
or	O
more	O
,	O
16	O
;	O
IIB	O
,	O
15	O
)	O
were	O
prospectively	O
treated	O
in	O
two	O
successive	O
clinical	O
trials	O
(	O
H	O
72	O
and	O
H	O
77	O
)	O
.	O

Clinical	O
stages	O
IA	O
and	O
II2A	O
received	O
three	O
courses	O
of	O
mechlorethamine	Physical
,	Physical
Oncovin	Physical
,	Physical
procarbazine	Physical
,	Physical
and	Physical
prednisone	Physical
(	Physical
MOPP	Physical
)	Physical
and	O
supradiaphragmatic	Physical
radiotherapy	Physical
(	Physical
40	Physical
Gy	Physical
)	Physical
,	O
and	O
no	Physical
laparotomy	Physical
was	O
performed	O
.	O

Clinical	O
stages	O
II3+A	O
and	O
IIB	O
received	O
either	O
six	O
cycles	O
of	O
MOPP	Pharmacological
(	O
H	O
72	O
)	O
,	O
three	O
cycles	O
of	O
MOPP	O
,	O
or	O
three	O
cycles	O
of	O
CCNU	Pharmacological
,	Pharmacological
vinblastine	Pharmacological
,	Pharmacological
procarbazine	Pharmacological
,	O
and	O
prednisone	Pharmacological
(	O
CVPP	O
)	O
(	O
H	O
77	O
)	O
and	O
subsequently	O
had	O
a	O
laparotomy	Surgical
followed	O
by	O
supradiaphragmatic	Physical
radiotherapy	Physical
and	O
a	O
lumboaortic	O
field	O
if	O
results	O
of	O
laparotomy	O
were	O
positive	O
.	O

Patients	O
without	O
evidence	O
of	O
mediastinal	O
involvement	O
did	O
not	O
have	O
mediastinal	O
radiotherapy	O
.	O

At	O
the	O
completion	O
of	O
therapy	O
,	O
the	O
disease	O
in	O
70	O
of	O
72	O
patients	O
was	O
in	O
complete	O
remission	O
(	O
one	O
failure	O
,	O
one	O
death	O
during	O
treatment	O
)	O
.	O

Eight	O
patients	O
relapsed	O
(	O
in	O
situ	O
,	O
1	O
;	O
marginal	O
,	O
1	O
;	O
nonirradiated	O
subdiaphragmatic	O
area	O
,	O
6	O
)	O
after	O
three	O
to	O
57	O
months	O
of	O
complete	O
remission	O
(	O
median	O
20	O
months	O
)	O
;	O
one	O
patient	O
died	O
after	O
relapse	O
.	O

There	O
were	O
three	O
deaths	O
after	O
complete	O
remission	O
of	O
the	O
disease	O
(	O
infection	O
,	O
two	O
;	O
acute	O
nonlymphocytic	O
leukemia	O
[	O
ANLL	O
]	O
,	O
one	O
)	O
.	O

As	O
of	O
June	O
1984	O
the	O
median	O
follow-up	O
was	O
82	O
months	O
(	O
range	O
,	O
49	O
to	O
145	O
months	O
)	O
,	O
the	O
actuarial	O
probabilities	O
for	O
survival	O
and	O
freedom	O
from	O
relapse	O
for	O
all	O
patients	O
being	O
91.6	O
%	O
and	O
87.6	O
%	O
,	O
respectively	O
.	O

There	O
was	O
no	O
statistical	O
difference	O
according	O
to	O
clinical	O
stage	O
,	O
age	O
(	O
greater	O
than	O
15	O
or	O
less	O
than	O
15	O
years	O
)	O
,	O
sex	O
,	O
or	O
number	O
of	O
cycles	O
of	O
chemotherapy	O
(	O
six	O
or	O
three	O
)	O
.	O

Bone	O
growth	O
defects	O
related	O
to	O
radiotherapy	O
were	O
reduced	O
particularly	O
in	O
the	O
29	O
patients	O
who	O
did	O
not	O
receive	O
mediastinal	O
radiotherapy	O
.	O

None	O
of	O
these	O
patients	O
had	O
a	O
mediastinal	O
relapse	O
.	O

Azoospermia	O
was	O
the	O
rule	O
for	O
the	O
male	O
patients	O
studied	O
,	O
but	O
young	O
girls	O
and	O
young	O
women	O
retained	O
reproductive	O
integrity	O
.	O

Treatments	O
of	O
preterm	O
premature	O
rupture	O
of	O
the	O
membranes	O
:	O
a	O
meta-analysis	O
.	O

The	O
objective	O
of	O
this	O
overview	O
was	O
to	O
critically	O
evaluate	O
published	O
randomized	O
controlled	O
trials	O
on	O
treatments	O
in	O
preterm	O
premature	O
rupture	O
of	O
the	O
membranes	O
.	O

The	O
Oxford	O
data	O
base	O
on	O
perinatal	O
trials	O
,	O
MEDLINE	O
,	O
Excerpta	O
Medica	O
,	O
and	O
Index	O
Medicus	O
were	O
searched	O
.	O

Through	O
primary	O
and	O
secondary	O
review	O
with	O
preset	O
inclusion	O
criteria	O
,	O
two	O
independent	O
judges	O
identified	O
27	O
randomized	O
controlled	O
trials	O
,	O
of	O
which	O
13	O
met	O
inclusion	O
criteria	O
.	O

The	O
quality	O
of	O
these	O
randomized	O
controlled	O
trials	O
was	O
scored	O
.	O

Five	O
randomized	O
controlled	O
trials	O
regarding	O
antenatal	O
use	O
of	O
corticosteroids	Pharmacological
to	O
prevent	O
respiratory	O
distress	O
syndrome	O
could	O
be	O
combined	O
meta-analytically	O
and	O
showed	O
a	O
reduction	O
in	O
respiratory	O
distress	O
syndrome	O
in	O
the	O
treatment	O
group	O
(	O
p	O
=	O
0.001	O
)	O
.	O

However	O
,	O
no	O
significant	O
reduction	O
in	O
respiratory	O
distress	O
syndrome	O
(	O
p	O
=	O
0.286	O
)	O
was	O
found	O
after	O
one	O
study	O
,	O
with	O
the	O
lowest	O
quality	O
score	O
,	O
was	O
excluded	O
.	O

A	O
significant	O
increase	O
in	O
endometritis	O
and	O
a	O
trend	O
toward	O
an	O
increase	O
in	O
neonatal	O
infections	O
and	O
cesarean	O
section	O
rates	O
were	O
noted	O
with	O
treatment	O
.	O

Tocolysis	Pharmacological
,	Pharmacological
prophylactic	Pharmacological
antibiotics	Pharmacological
,	O
and	O
other	O
interventions	O
studied	O
were	O
not	O
found	O
to	O
be	O
of	O
proved	O
benefit	O
and	O
therefore	O
should	O
not	O
be	O
used	O
outside	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

Atrial	O
natriuretic	O
factor	O
inhibits	O
metoclopramide	Pharmacological
stimulated	O
aldosterone	O
release	O
in	O
man	O
.	O

1	O
.	O

Atrial	O
natriuretic	O
factor	O
(	O
ANF	O
)	O
has	O
an	O
inhibitory	O
effect	O
on	O
angiotensin	O
II	O
and	O
ACTH	O
stimulated	O
aldosterone	O
secretion	O
in	O
man	O
.	O

The	O
selectivity	O
of	O
this	O
aldosterone	O
suppressing	O
effect	O
of	O
ANF	O
is	O
unclear	O
in	O
man	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
ANF	O
on	O
the	O
increase	O
in	O
plasma	O
aldosterone	O
due	O
to	O
metoclopramide	O
in	O
man	O
.	O

2	O
.	O

Eight	O
normal	O
male	O
volunteers	O
were	O
studied	O
on	O
three	O
occasions	O
.	O

Metoclopramide	Pharmacological
(	O
10	O
mg	O
slow	O
i.v	O
.	O

)	O
was	O
given	O
on	O
all	O
study	O
days	O
and	O
each	O
volunteer	O
was	O
randomised	O
to	O
receive	O
45	O
min	O
infusion	O
of	O
either	Pharmacological
5	Pharmacological
%	Pharmacological
D-glucose	Pharmacological
(	Pharmacological
placebo	Control
)	Pharmacological
or	Pharmacological
ANF	Pharmacological
(	O
99-126	O
)	O
3	O
or	O
15	O
pmol	Pharmacological
kg-1	O
min-1	O
.	O

3	O
.	O

Metoclopramide	Pharmacological
increased	O
plasma	O
aldosterone	O
to	O
approximately	O
170	O
%	O
of	O
baseline	O
levels	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Concomitant	O
infusion	O
of	O
ANF	Pharmacological
3	Pharmacological
pmol	O
kg-1	O
min-1	O
and	O
15	O
pmol	O
kg-1	O
min-1	O
significantly	O
attenuated	O
this	O
rise	O
in	O
plasma	O
aldosterone	O
to	O
approximately	O
130	O
%	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
110	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
of	O
baseline	O
values	O
respectively	O
.	O

4	O
.	O

It	O
is	O
suggested	O
,	O
in	O
the	O
light	O
of	O
previous	O
findings	O
,	O
that	O
the	O
inhibitory	O
effect	O
of	O
ANF	O
represents	O
a	O
non-selective	O
action	O
of	O
ANF	O
on	O
aldosterone	O
release	O
.	O

Ventilator-delivered	Physical
mask	Physical
ventilation	Physical
compared	O
with	O
three	O
standard	O
methods	O
of	O
mask	O
ventilation	O
in	O
a	O
manikin	O
model	O
.	O

BACKGROUND	O
Little	O
is	O
known	O
regarding	O
the	O
variations	O
in	O
effective	O
ventilation	O
during	O
bag	Other
and	Other
mask	Other
resuscitation	Other
with	O
standard	O
methods	O
compared	O
with	O
that	O
delivered	O
by	O
ventilator-delivered	Physical
mask	Physical
ventilation	Physical
(	Physical
VDMV	Physical
)	Physical
.	O

AIM	O
To	O
measure	O
the	O
variations	O
in	O
delivered	O
airway	O
pressure	O
,	O
tidal	O
volume	O
(	O
TV	O
)	O
,	O
minute	O
ventilation	O
(	O
MV	O
)	O
and	O
inspiratory	O
time	O
during	O
a	O
3-min	O
period	O
of	O
mask	O
ventilation	O
comparing	O
VDMV	Physical
with	O
three	O
commonly	O
used	O
hand-delivered	O
methods	O
of	O
bag	O
and	O
mask	O
ventilation	O
:	O
Laerdal	Other
self-inflating	Other
bag	Other
(	Other
SIB	Other
)	Other
;	O
anaesthetic	Other
bag	Other
and	O
T-piece	Other
Neopuff	Other
.	O

METHODS	O
A	O
modified	O
resuscitation	O
manikin	O
was	O
used	O
to	O
measure	O
variation	O
in	O
mechanical	O
ventilation	O
during	O
3-min	O
periods	O
of	O
mask	Other
ventilation	Other
.	O

Thirty-six	O
experienced	O
practitioners	O
gave	O
positive	O
pressure	O
mask	Other
ventilation	Other
targeting	O
acceptable	O
chest	O
wall	O
movement	O
with	O
a	O
rate	O
of	O
60	O
inflations/min	O
and	O
when	O
pressures	O
could	O
be	O
targeted	O
or	O
set	O
,	O
a	O
peak	O
inspiratory	O
pressure	O
(	O
PIP	O
)	O
of	O
18	O
cm	O
water	O
,	O
positive	O
end-expiratory	O
pressure	O
(	O
PEEP	O
)	O
of	O
5	O
cm	O
water	O
,	O
for	O
3	O
min	O
with	O
each	O
of	O
the	O
four	O
mask	O
ventilation	O
methods	O
.	O

Each	O
mode	O
was	O
randomly	O
sequenced	O
.	O

RESULTS	O
A	O
total	O
of	O
21	O
136	O
inflations	O
were	O
recorded	O
and	O
analysed	O
.	O

VDMV	Physical
achieved	O
PIP	O
and	O
PEEP	O
closest	O
to	O
that	O
targeted	O
and	O
significantly	O
lower	O
variation	O
in	O
all	O
measured	O
parameters	O
(	O
p	O
<	O
0.001	O
)	O
other	O
than	O
with	O
PIP	O
.	O

SIB	O
delivered	O
TV	O
and	O
MV	O
over	O
twice	O
that	O
delivered	O
by	O
VDMV	Physical
and	O
Neopuff	Other
.	O

CONCLUSION	O
During	O
3-min	O
periods	O
of	O
mask	O
ventilation	O
on	O
a	O
manikin	O
,	O
VDMV	Physical
produced	O
the	O
least	O
variation	O
in	O
delivered	O
ventilation	O
.	O

SIB	O
produced	O
wide	O
variation	O
and	O
unacceptably	O
high	O
TV	O
and	O
MV	O
in	O
experienced	O
hands	O
.	O

Prospective	O
randomized	O
trial	O
of	O
short-term	Physical
neoadjuvant	Physical
chemotherapy	Physical
for	O
advanced	O
gastric	O
cancer	O
.	O

BACKGROUND	O
We	O
performed	O
short-term	Physical
neoadjuvant	Physical
chemotherapy	Physical
(	Physical
s-NAC	Physical
)	Physical
to	O
examine	O
whether	O
anticancer	O
drugs	O
can	O
change	O
the	O
proliferative	O
ability	O
of	O
cancer	O
cells	O
in	O
gastric	O
cancer	O
patients	O
.	O

METHODS	O
Chemotherapy	O
was	O
performed	O
for	O
72	O
h	O
before	O
gastrectomy	O
in	O
63	O
gastric	O
cancer	O
patients	O
.	O

Patients	O
were	O
classed	O
into	O
four	O
groups	O
:	O
Group	O
F	O
,	O
16	O
cases	O
who	O
received	O
a	O
single	O
administration	O
of	O
5-fluorouracil	Pharmacological
(	Pharmacological
5-FU	Pharmacological
)	Pharmacological
;	O
Group	O
C	O
,	O
15	O
cases	O
who	O
received	O
a	O
single	O
administration	O
of	O
cis-diamminedichloroplatinum	Pharmacological
(	Pharmacological
CDDP	Pharmacological
;	Pharmacological
cisplatin	Pharmacological
)	Pharmacological
;	O
Group	O
FC	O
,	O
16	O
cases	O
who	O
received	O
both	O
5-FU+CDDP	Pharmacological
;	O
and	O
a	O
Control	O
group	O
,	O
16	O
cases	O
who	O
did	O
not	Control
receive	Control
chemotherapy	Control
.	O

We	O
reviewed	O
neoadjuvant	O
biopsy	O
tissue	O
and	O
gastric	O
cancer	O
tissue	O
delivered	O
by	O
operation	O
in	O
these	O
cases	O
.	O

The	O
TUNEL	O
method	O
and	O
immunohistochemistry	O
with	O
an	O
anti-MIB-1	O
antibody	O
were	O
used	O
to	O
evaluate	O
cellular	O
apoptosis	O
and	O
proliferative	O
ability	O
,	O
respectively	O
.	O

The	O
apoptotic	O
index	O
(	O
AI	O
)	O
and	O
an	O
MIB-1	O
index	O
(	O
MI	O
)	O
were	O
also	O
calculated	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
in	O
AI	O
or	O
MI	O
in	O
biopsy	O
tissue	O
between	O
the	O
groups	O
.	O

The	O
AI	O
of	O
gastric	O
cancer	O
tissue	O
in	O
Group	O
FC	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
MI	O
of	O
Group	O
FC	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
after	O
s-NAC	Pharmacological
operation	O
there	O
was	O
a	O
significant	O
inhibition	O
of	O
proliferative	O
potency	O
and	O
an	O
induction	O
of	O
apoptosis	O
in	O
Group	O
FC	O
.	O

CONCLUSION	O
Combination	Pharmacological
of	Pharmacological
CDDP	Pharmacological
and	Pharmacological
5-FU	Pharmacological
reduced	O
proliferative	O
potency	O
and	O
increased	O
cellular	O
apoptosis	O
in	O
gastric	O
cancer	O
cells	O
.	O

Transcutaneous	O
electrical	O
nerve	O
stimulation	O
for	O
postoperative	O
pain	O
relief	O
after	O
total	O
knee	O
arthroplasty	O
.	O

Transcutaneous	Control
electrical	Control
nerve	Control
stimulation	Control
(	Control
TENS	Control
)	Control
has	O
been	O
used	O
to	O
treat	O
chronic	O
pain	O
syndromes	O
and	O
has	O
been	O
reported	O
to	O
be	O
of	O
some	O
utility	O
in	O
the	O
treatment	O
of	O
postsurgical	O
pain	O
.	O

A	O
randomized	O
,	O
blinded	O
,	O
placebo-controlled	O
trial	O
was	O
designed	O
to	O
evaluate	O
the	O
utility	O
of	O
TENS	O
after	O
total	O
knee	O
arthroplasty	O
.	O

Patients	O
were	O
randomly	O
enrolled	O
into	O
patient-controlled	O
anesthesia	O
(	O
PCA	O
)	O
alone	O
,	O
PCA	O
plus	O
TENS	O
,	O
or	O
PCA	O
plus	O
sham	O
TENS	O
.	O

The	O
cumulative	O
dose	O
of	O
morphine	O
by	O
PCA	O
for	O
each	O
group	O
was	O
used	O
as	O
the	O
end-point	O
of	O
the	O
study	O
.	O

There	O
was	O
no	O
significant	O
reduction	O
in	O
the	O
requirement	O
for	O
patient-controlled	O
analgesia	O
with	O
or	O
without	O
TENS	O
.	O

We	O
conclude	O
that	O
there	O
is	O
no	O
utility	O
for	O
TENS	O
in	O
the	O
postoperative	O
management	O
of	O
pain	O
after	O
knee	O
arthroplasty	O
.	O

The	O
efficacy	O
of	O
audiotapes	Educational
in	O
promoting	O
psychological	O
well-being	O
in	O
cancer	O
patients	O
:	O
a	O
randomised	O
,	O
controlled	O
trial	O
.	O

Open	O
or	O
uncontrolled	O
studies	O
have	O
suggested	O
that	O
providing	O
cancer	O
patients	O
with	O
audiotapes	Educational
of	O
their	O
clinical	O
interviews	O
can	O
improve	O
information	O
recall	O
and	O
reduce	O
psychological	O
distress	O
.	O

We	O
tested	O
these	O
hypotheses	O
in	O
a	O
'clinician-blind	O
'	O
,	O
prospective	O
,	O
randomised	O
controlled	O
trial	O
.	O

A	O
total	O
of	O
117	O
patients	O
newly	O
referred	O
to	O
a	O
medical	O
oncology	O
clinic	O
who	O
were	O
to	O
be	O
given	O
'bad	O
news	O
'	O
had	O
their	O
consultations	O
audiotaped	Educational
.	O

Blind	O
to	O
the	O
clinician	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
a	O
copy	Educational
of	Educational
the	Educational
tape	Educational
to	Educational
play	Educational
at	Educational
home	Educational
or	Educational
not	Educational
(	Educational
control	Educational
group	Educational
)	Educational
.	O

At	O
6	O
months	O
follow-up	O
,	O
tape	O
group	O
patients	O
reported	O
positive	O
attitudes	O
to	O
the	O
audiotape	Educational
and	O
were	O
shown	O
to	O
recall	O
significantly	O
more	O
information	O
about	O
their	O
illness	O
than	O
did	O
controls	O
.	O

Overall	O
improvement	O
in	O
psychological	O
distress	O
at	O
1	O
and	O
6	O
months	O
follow-up	O
,	O
as	O
measured	O
with	O
the	O
30-item	O
General	O
Health	O
Questionnaire	O
and	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
was	O
no	O
different	O
in	O
the	O
two	O
groups	O
.	O

However	O
,	O
a	O
second-order	O
interaction	O
suggested	O
that	O
poor-prognosis	O
patients	O
were	O
disadvantaged	O
specifically	O
by	O
access	O
to	O
the	O
audiotape	O
,	O
with	O
less	O
improvement	O
in	O
psychological	O
distress	O
at	O
6	O
months	O
follow-up	O
than	O
non-tape	O
controls	O
.	O

Patient	O
access	O
to	O
audiotapes	Educational
of	O
clinical	O
interviews	O
promotes	O
factual	O
retention	O
but	O
does	O
not	O
reliably	O
reduce	O
psychological	O
distress	O
and	O
may	O
be	O
actively	O
unhelpful	O
in	O
some	O
subgroups	O
of	O
patients	O
.	O

Cognitive	O
effects	O
of	O
risperidone	Pharmacological
in	O
children	O
with	O
autism	O
and	O
irritable	O
behavior	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
this	O
research	O
was	O
to	O
explore	O
the	O
effects	O
of	O
risperidone	Pharmacological
on	O
cognitive	O
processes	O
in	O
children	O
with	O
autism	O
and	O
irritable	O
behavior	O
.	O

METHOD	O
Thirty-eight	O
children	O
,	O
ages	O
5-17	O
years	O
with	O
autism	O
and	O
severe	O
behavioral	O
disturbance	O
,	O
were	O
randomly	O
assigned	O
to	O
risperidone	Pharmacological
(	O
0.5	O
to	O
3.5	O
mg/day	O
)	O
or	O
placebo	Control
for	O
8	O
weeks	O
.	O

This	O
sample	O
of	O
38	O
was	O
a	O
subset	O
of	O
101	O
subjects	O
who	O
participated	O
in	O
the	O
clinical	O
trial	O
;	O
63	O
were	O
unable	O
to	O
perform	O
the	O
cognitive	O
tasks	O
.	O

A	O
double-blind	O
placebo-controlled	O
parallel	O
groups	O
design	O
was	O
used	O
.	O

Dependent	O
measures	O
included	O
tests	O
of	O
sustained	O
attention	O
,	O
verbal	O
learning	O
,	O
hand-eye	O
coordination	O
,	O
and	O
spatial	O
memory	O
assessed	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
8-week	O
treatment	O
.	O

Changes	O
in	O
performance	O
were	O
compared	O
by	O
repeated	O
measures	O
ANOVA	O
.	O

RESULTS	O
Twenty-nine	O
boys	O
and	O
9	O
girls	O
with	O
autism	O
and	O
severe	O
behavioral	O
disturbance	O
and	O
a	O
mental	O
age	O
>	O
or=18	O
months	O
completed	O
the	O
cognitive	O
part	O
of	O
the	O
study	O
.	O

No	O
decline	O
in	O
performance	O
occurred	O
with	O
risperidone	O
.	O

Performance	O
on	O
a	O
cancellation	O
task	O
(	O
number	O
of	O
correct	O
detections	O
)	O
and	O
a	O
verbal	O
learning	O
task	O
(	O
word	O
recognition	O
)	O
was	O
better	O
on	O
risperidone	Pharmacological
than	O
on	O
placebo	Control
(	O
without	O
correction	O
for	O
multiplicity	O
)	O
.	O

Equivocal	O
improvement	O
also	O
occurred	O
on	O
a	O
spatial	O
memory	O
task	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
treatment	O
conditions	O
on	O
the	O
Purdue	O
Pegboard	O
(	O
hand-eye	O
coordination	O
)	O
task	O
or	O
the	O
Analog	O
Classroom	O
Task	O
(	O
timed	O
math	O
test	O
)	O
.	O

CONCLUSION	O
Risperidone	Pharmacological
given	O
to	O
children	O
with	O
autism	O
at	O
doses	O
up	O
to	O
3.5	O
mg	O
for	O
up	O
to	O
8	O
weeks	O
appears	O
to	O
have	O
no	O
detrimental	O
effect	O
on	O
cognitive	O
performance	O
.	O

Cryotherapy	O
does	O
not	O
affect	O
peroneal	O
reaction	O
following	O
sudden	O
inversion	O
.	O

CONTEXT	O
If	O
ankle	O
joint	O
cryotherapy	O
impairs	O
the	O
ability	O
of	O
the	O
ankle	O
musculature	O
to	O
counteract	O
potentially	O
injurious	O
forces	O
,	O
the	O
ankle	O
is	O
left	O
vulnerable	O
to	O
injury	O
.	O

OBJECTIVE	O
To	O
compare	O
peroneal	O
reaction	O
to	O
sudden	O
inversion	O
following	O
ankle	O
joint	O
cryotherapy	O
.	O

DESIGN	O
Repeated	O
measures	O
design	O
with	O
independent	O
variables	O
,	O
treatment	O
(	O
cryotherapy	Physical
and	O
control	Control
)	O
,	O
and	O
time	O
(	O
baseline	O
,	O
immediately	O
post	O
treatment	O
,	O
15	O
minutes	O
post	O
treatment	O
,	O
and	O
30	O
minutes	O
post	O
treatment	O
)	O
.	O

SETTING	O
University	O
research	O
laboratory	O
.	O

PATIENTS	O
OR	O
OTHER	O
PARTICIPANTS	O
Twenty-seven	O
healthy	O
volunteers	O
.	O

INTERVENTION	O
(	O
S	O
)	O
An	O
ice	O
bag	O
was	O
secured	O
to	O
the	O
lateral	O
ankle	O
joint	O
for	O
20	O
minutes	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
onset	O
and	O
average	O
root	O
mean	O
square	O
amplitude	O
of	O
EMG	O
activity	O
in	O
the	O
peroneal	O
muscles	O
was	O
calculated	O
following	O
the	O
release	O
of	O
a	O
trap	O
door	O
mechanism	O
causing	O
inversion	O
.	O

RESULTS	O
There	O
was	O
no	O
statistically	O
significant	O
change	O
from	O
baseline	O
for	O
peroneal	O
reaction	O
time	O
or	O
average	O
peroneal	O
muscle	O
activity	O
at	O
any	O
post	O
treatment	O
time	O
.	O

CONCLUSIONS	O
Cryotherapy	O
does	O
not	O
affect	O
peroneal	O
muscle	O
reaction	O
following	O
sudden	O
inversion	O
perturbation	O
.	O

A	O
web-based	Educational
patient	Educational
activation	Educational
intervention	Educational
to	O
improve	O
hypertension	O
care	O
:	O
study	O
design	O
and	O
baseline	O
characteristics	O
in	O
the	O
web	O
hypertension	O
study	O
.	O

BACKGROUND	O
Despite	O
the	O
known	O
health	O
risks	O
of	O
hypertension	O
,	O
many	O
hypertensive	O
patients	O
still	O
have	O
uncontrolled	O
blood	O
pressure	O
.	O

Clinical	O
inertia	O
,	O
the	O
tendency	O
of	O
physicians	O
not	O
to	O
intensify	O
treatment	O
,	O
is	O
a	O
common	O
barrier	O
in	O
controlling	O
chronic	O
diseases	O
.	O

This	O
trial	O
is	O
aimed	O
at	O
determining	O
the	O
impact	O
of	O
activating	O
patients	O
to	O
ask	O
providers	O
to	O
make	O
changes	O
to	O
their	O
care	O
through	O
tailored	O
feedback	O
.	O

METHODS	O
Diagnosed	O
hypertensive	O
patients	O
were	O
enrolled	O
in	O
this	O
RCT	O
and	O
randomized	O
to	O
one	O
of	O
two	O
study	O
groups	O
:	O
(	O
1	O
)	O
the	Educational
intervention	Educational
condition	Educational
--	Educational
Web-based	Educational
hypertension	Educational
feedback	Educational
,	Educational
based	Educational
on	Educational
the	Educational
individual	Educational
patient	Educational
's	Educational
self-report	Educational
of	Educational
health	Educational
variables	Educational
and	Educational
previous	Educational
BP	Educational
measurements	Educational
,	Educational
to	Educational
prompt	Educational
them	Educational
to	Educational
ask	Educational
questions	Educational
during	Educational
their	Educational
next	Educational
physician	Educational
's	Educational
visit	Educational
about	Educational
hypertension	Educational
care	Educational
(	O
2	O
)	O
the	Educational
control	Educational
condition	Educational
--	Educational
Web-based	Educational
preventive	Educational
health	Educational
feedback	Educational
,	Educational
based	Educational
on	Educational
the	Educational
individual	Educational
's	Educational
self-report	Educational
of	Educational
receiving	Educational
preventive	Educational
care	Educational
(	O
e.g.	O
,	O
pap	O
testing	O
)	O
,	O
to	Educational
prompt	Educational
them	Educational
to	Educational
ask	Educational
questions	Educational
during	Educational
their	Educational
next	Educational
physician	Educational
's	Educational
visit	Educational
about	Educational
preventive	Educational
care	Educational
.	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
is	O
change	O
in	O
blood	O
pressure	O
and	O
change	O
in	O
the	O
percentage	O
of	O
patients	O
in	O
each	O
group	O
with	O
controlled	O
blood	O
pressure	O
.	O

CONCLUSION	O
Five	O
hundred	O
participants	O
were	O
enrolled	O
and	O
baseline	O
characteristics	O
include	O
a	O
mean	O
age	O
of	O
60.0	O
years	O
;	O
57.6	O
%	O
female	O
;	O
and	O
77.6	O
%	O
white	O
.	O

Overall	O
37.7	O
%	O
participants	O
had	O
uncontrolled	O
blood	O
pressure	O
;	O
the	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
in	O
the	O
obese	O
range	O
(	O
32.4	O
)	O
and	O
21.8	O
%	O
had	O
diabetes	O
.	O

By	O
activating	O
patients	O
to	O
become	O
involved	O
in	O
their	O
own	O
care	O
,	O
we	O
believe	O
the	O
addition	O
of	O
the	O
web-based	O
intervention	O
will	O
improve	O
blood	O
pressure	O
control	O
compared	O
to	O
a	O
control	O
group	O
who	O
receive	O
web-based	O
preventive	O
messages	O
unrelated	O
to	O
hypertension	O
.	O

Intra-articular	O
hyaluronic	Pharmacological
acid	Pharmacological
compared	O
to	O
exercise	Physical
therapy	Physical
in	O
osteoarthritis	O
of	O
the	O
ankle	O
.	O

A	O
prospective	O
randomized	O
trial	O
with	O
long-term	O
follow-up	O
.	O

OBJECTIVE	O
The	O
goal	O
of	O
this	O
study	O
has	O
been	O
to	O
determine	O
whether	O
hyaluronic	Pharmacological
acid	Pharmacological
(	Pharmacological
HA	Pharmacological
)	Pharmacological
or	O
exercise	Physical
therapy	Physical
can	O
improve	O
functional	O
parameters	O
in	O
patients	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
of	O
the	O
ankle	O
.	O

METHODS	O
In	O
a	O
prospective	O
clinical	O
trial	O
,	O
43	O
ankles	O
(	O
30	O
patients	O
)	O
with	O
radiographic	O
Kellgren	O
Lawrence	O
grade	O
III	O
OA	O
were	O
randomized	O
to	O
receive	O
three	Pharmacological
intra-articular	Pharmacological
HA	Pharmacological
injections	Pharmacological
,	O
with	O
one-week	O
interval	O
of	O
or	O
exercise	Physical
therapy	Physical
for	O
six	O
weeks	O
.	O

Patients	O
were	O
evaluated	O
by	O
the	O
American	O
Orthopaedic	O
Foot	O
and	O
Ankle	O
Society	O
(	O
AOFAS	O
)	O
Ankle-Hindfoot	O
Scale	O
and	O
followed-up	O
after	O
12	O
months	O
.	O

RESULTS	O
Total	O
AOFAS	O
Ankle-Hindfoot	O
score	O
of	O
OA	O
patients	O
has	O
improved	O
in	O
both	O
groups	O
,	O
varying	O
from	O
61.6+/-16.8	O
to	O
90.1+/-9.7	O
with	O
HA	Pharmacological
treatment	O
and	O
from	O
72.1+/-16.6	O
to	O
87.5+/-17.5	O
using	O
exercise	Physical
therapy	Physical
at	O
the	O
end	O
of	O
the	O
trial	O
(	O
p	O
<	O
0.01	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

CONCLUSION	O
This	O
prospective	O
randomized	O
trial	O
confirmed	O
that	O
,	O
both	O
HA	Pharmacological
injections	O
and	O
exercise	Physical
therapy	Physical
provide	O
functional	O
improvement	O
.	O

However	O
,	O
larger	O
trials	O
with	O
longer	O
follow-up	O
are	O
necessary	O
for	O
more	O
definite	O
conclusions	O
.	O

Combination	Pharmacological
peel	Pharmacological
with	Pharmacological
incorporated	Pharmacological
fractional	Pharmacological
prickle	Pharmacological
coral	Pharmacological
calcium	Pharmacological
for	O
the	O
treatment	O
of	O
keratosis	O
pilaris	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
Keratosis	O
pilaris	O
(	O
KP	O
)	O
is	O
a	O
common	O
condition	O
of	O
follicular	O
plugging	O
with	O
variable	O
erythema	O
.	O

There	O
is	O
a	O
lack	O
of	O
reliable	O
response	O
to	O
the	O
treatment	O
of	O
KP	O
.	O

OBJECTIVE	O
We	O
evaluated	O
the	O
effect	O
and	O
safety	O
of	O
combination	O
peel	O
with	O
fractional	O
prickle	O
coral	O
calcium	O
(	O
FCR?	O
)	O
in	O
the	O
treatment	O
of	O
KP	O
.	O

MATERIALS	O
AND	O
METHODS	O
Sixteen	O
Korean	O
patients	O
were	O
treated	O
with	O
FCR?	O
on	O
both	O
upper	O
arms	O
for	O
five	O
sessions	O
at	O
2-week	O
intervals	O
.	O

Clinical	O
evaluations	O
,	O
mexameter	O
measurements	O
,	O
and	O
assessment	O
of	O
patients	O
'	O
satisfaction	O
and	O
adverse	O
events	O
were	O
performed	O
at	O
baseline	O
and	O
every	O
visit	O
.	O

RESULTS	O
After	O
treatments	O
,	O
statistically	O
significant	O
improvements	O
in	O
the	O
baseline	O
KP	O
were	O
observed	O
in	O
erythema	O
and	O
melanin	O
index	O
of	O
mexameter	O
on	O
treated	O
upper	O
arms	O
.	O

Both	O
the	O
physicians	O
'	O
and	O
patients	O
'	O
assessments	O
correlate	O
with	O
the	O
results	O
of	O
mexameter	O
scores	O
.	O

CONCLUSION	O
Our	O
results	O
suggest	O
FCR?	O
should	O
be	O
considered	O
as	O
an	O
effective	O
and	O
safe	O
treatment	O
option	O
for	O
the	O
patients	O
with	O
KP	O
.	O

The	O
sequencing	O
of	O
chemotherapy	O
and	O
radiation	O
therapy	O
after	O
conservative	O
surgery	O
for	O
early-stage	O
breast	O
cancer	O
.	O

BACKGROUND	O
Patients	O
with	O
early-stage	O
breast	O
cancer	O
who	O
are	O
at	O
substantial	O
risk	O
for	O
systemic	O
metastases	O
are	O
increasingly	O
treated	O
with	O
breast-conserving	Pharmacological
therapy	Pharmacological
and	O
adjuvant	Pharmacological
chemotherapy	Pharmacological
.	O

However	O
,	O
the	O
optimal	O
sequencing	O
of	O
chemotherapy	Pharmacological
and	O
radiation	Pharmacological
therapy	Pharmacological
is	O
not	O
clear	O
.	O

METHODS	O
Two	O
hundred	O
forty-four	O
patients	O
with	O
stage	O
I	O
or	O
II	O
breast	O
cancer	O
who	O
were	O
at	O
substantial	O
risk	O
for	O
distant	O
metastases	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
12-week	Pharmacological
course	Pharmacological
of	Pharmacological
chemotherapy	Pharmacological
either	Pharmacological
before	Pharmacological
or	Pharmacological
after	Pharmacological
radiation	Pharmacological
therapy	Pharmacological
.	O

All	O
had	O
had	O
breast-conserving	O
surgery	O
.	O

The	O
median	O
length	O
of	O
follow-up	O
in	O
surviving	O
patients	O
was	O
58	O
months	O
(	O
range	O
,	O
10	O
to	O
124	O
)	O
.	O

RESULTS	O
The	O
five-year	O
actuarial	O
rates	O
of	O
cancer	O
recurrence	O
at	O
any	O
site	O
and	O
of	O
distant	O
metastases	O
in	O
the	O
radiotherapy-first	Pharmacological
group	O
and	O
the	O
chemotherapy-first	Pharmacological
group	O
were	O
38	O
percent	O
and	O
31	O
percent	O
(	O
P	O
=	O
0.17	O
)	O
and	O
36	O
percent	O
and	O
25	O
percent	O
(	O
P	O
=	O
0.05	O
)	O
,	O
respectively	O
.	O

Overall	O
survival	O
was	O
73	O
percent	O
and	O
81	O
percent	O
(	O
P	O
=	O
0.11	O
)	O
,	O
respectively	O
.	O

The	O
five-year	O
crude	O
rates	O
of	O
first	O
recurrence	O
according	O
to	O
site	O
in	O
the	O
radiotherapy-first	Pharmacological
and	O
chemotherapy-first	Pharmacological
groups	O
,	O
respectively	O
,	O
were	O
5	O
percent	O
and	O
14	O
percent	O
for	O
local	O
recurrence	O
and	O
32	O
percent	O
and	O
20	O
percent	O
for	O
distant	O
or	O
regional	O
recurrence	O
or	O
both	O
.	O

This	O
difference	O
in	O
the	O
pattern	O
of	O
recurrence	O
was	O
of	O
borderline	O
statistical	O
significance	O
(	O
P	O
=	O
0.07	O
)	O
.	O

CONCLUSIONS	O
This	O
study	O
suggests	O
that	O
for	O
patients	O
ar	O
substantial	O
risk	O
for	O
systemic	O
metastases	O
,	O
it	O
is	O
preferable	O
to	O
give	O
a	O
12-week	O
course	O
of	O
chemotherapy	O
followed	O
by	O
radiation	Pharmacological
therapy	Pharmacological
,	O
rather	O
than	O
radiation	Pharmacological
therapy	Pharmacological
followed	Pharmacological
by	Pharmacological
chemotherapy	Pharmacological
.	O

Prognostic	O
value	O
of	O
postoperative	Surgical
CEA	Surgical
clearance	Surgical
in	O
rectal	O
cancer	O
patients	O
with	O
high	O
preoperative	O
CEA	O
levels	O
.	O

PURPOSE	O
We	O
determined	O
the	O
prognostic	O
value	O
of	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
clearance	O
after	O
tumor	Surgical
resection	Surgical
with	O
serial	O
evaluation	O
of	O
postoperative	O
CEA	O
levels	O
in	O
rectal	O
cancer	O
.	O

METHODS	O
Between	O
1994	O
and	O
2004	O
,	O
we	O
retrospectively	O
reviewed	O
122	O
patients	O
with	O
rectal	O
cancer	O
whose	O
serum	O
CEA	O
levels	O
were	O
measured	O
on	O
the	O
preoperative	O
day	O
and	O
postoperative	O
days	O
7	O
and	O
30	O
.	O

Patients	O
with	O
preoperative	O
CEA	O
levels	O
<	O
5.0	O
ng/ml	O
were	O
excluded	O
.	O

An	O
exponential	O
trend	O
line	O
was	O
drawn	O
using	O
the	O
three	O
CEA	O
values	O
.	O

Patients	O
were	O
categorized	O
into	O
three	O
groups	O
based	O
on	O
R	O
(	O
2	O
)	O
values	O
calculated	O
through	O
trend	O
line	O
,	O
which	O
indicates	O
the	O
correlation	O
coefficient	O
between	O
exponential	O
graph	O
and	O
measured	O
CEA	O
values	O
:	O
exponential	O
decrease	O
group	O
(	O
group	O
1	O
:	O
0.9	O
<	O
R	O
(	O
2	O
)	O
<	O
or	O
=	O
1.0	O
)	O
,	O
nearly	O
exponential	O
decrease	O
group	O
(	O
group	O
2	O
:	O
0.5	O
<	O
R	O
(	O
2	O
)	O
<	O
or	O
=	O
0.9	O
)	O
,	O
and	O
randomized	O
clearance	O
group	O
(	O
group	O
3	O
:	O
0.5	O
<	O
or	O
=	O
R	O
(	O
2	O
)	O
)	O
.	O

We	O
then	O
analyzed	O
the	O
CEA	O
clearance	O
pattern	O
as	O
a	O
prognostic	O
indicator	O
.	O

RESULTS	O
With	O
a	O
median	O
follow-up	O
of	O
57	O
months	O
,	O
the	O
5-year	O
overall	O
survival	O
was	O
62.3	O
%	O
vs.	O
48.1	O
%	O
vs.	O
25	O
%	O
and	O
the	O
5-year	O
disease-free	O
survival	O
was	O
58.6	O
%	O
vs.	O
52.7	O
%	O
vs.	O
25	O
%	O
among	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
(	O
P	O
=	O
0.014	O
,	O
P	O
=	O
0.027	O
,	O
respectively	O
)	O
in	O
patients	O
with	O
stage	O
III	O
rectal	O
cancer	O
.	O

For	O
those	O
with	O
stage	O
II	O
rectal	O
cancer	O
,	O
the	O
5-year	O
overall	O
survival	O
rate	O
of	O
group	O
1	O
was	O
significantly	O
better	O
than	O
groups	O
2	O
and	O
3	O
(	O
88.8	O
%	O
vs.	O
74.1	O
%	O
,	O
respectively	O
,	O
P	O
=	O
0.021	O
)	O
.	O

CONCLUSIONS	O
The	O
postoperative	Surgical
pattern	Surgical
of	Surgical
CEA	Surgical
clearance	Surgical
is	O
a	O
useful	O
prognostic	O
determinant	O
in	O
patients	O
with	O
rectal	O
cancer	O
.	O

Patients	O
with	O
a	O
randomized	O
pattern	O
of	O
CEA	O
clearance	O
after	O
tumor	O
resection	O
should	O
be	O
regarded	O
as	O
having	O
the	O
possibility	O
of	O
a	O
persistent	O
CEA	O
source	O
and	O
may	O
require	O
consideration	O
of	O
intensive	O
follow-up	O
or	O
adjuvant	O
therapy	O
.	O

Improved	O
local	O
control	O
of	O
invasive	O
bladder	O
cancer	O
by	O
concurrent	Physical
cisplatin	Physical
and	O
preoperative	Physical
or	Physical
definitive	Physical
radiation	Physical
.	O

The	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
.	O

PURPOSE	O
A	O
prospective	O
randomized	O
trial	O
was	O
conducted	O
to	O
determine	O
whether	O
the	O
addition	O
of	O
concurrent	Physical
cisplatin	Physical
to	Physical
preoperative	Physical
or	O
definitive	O
radiation	O
therapy	O
in	O
patients	O
with	O
muscle-invasive	O
bladder	O
cancer	O
improved	O
local	O
control	O
or	O
survival	O
.	O

PATIENTS	O
AND	O
METHODS	O
Ninety-nine	O
eligible	O
patients	O
with	O
T2	O
to	O
T4b	O
transitional	O
cell	O
bladder	O
cancer	O
participated	O
,	O
64	O
%	O
with	O
cT3b	O
or	O
cT4	O
.	O

Patients	O
and	O
their	O
physicians	O
selected	O
either	O
definitive	O
radiotherapy	Physical
or	O
precystectomy	Physical
radiotherapy	Physical
;	O
patients	O
were	O
then	O
randomly	O
allocated	O
to	O
receive	O
intravenous	Pharmacological
cisplatin	Pharmacological
100	O
mg/m2	O
at	O
2-week	O
intervals	O
for	O
three	O
cycles	O
concurrent	Physical
with	Physical
pelvic	Physical
radiation	Physical
,	O
or	O
to	O
receive	Physical
radiation	Physical
without	Physical
chemotherapy	Physical
.	O

Patients	O
were	O
stratified	O
by	O
clinical	O
tumor	O
stage	O
and	O
by	O
radiation	O
plan	O
.	O

The	O
median	O
follow-up	O
duration	O
is	O
6.5	O
years	O
.	O

RESULTS	O
The	O
occurrence	O
of	O
distant	O
metastases	O
was	O
the	O
same	O
in	O
both	O
study	O
arms	O
.	O

However	O
,	O
25	O
of	O
48	O
control	O
patients	O
have	O
had	O
a	O
first	O
recurrence	O
in	O
the	O
pelvis	O
,	O
compared	O
with	O
15	O
of	O
51	O
cisplatin-treated	Pharmacological
patients	O
(	O
P	O
=	O
.036	O
)	O
.	O

The	O
pelvic	O
relapse	O
rate	O
in	O
the	O
two	O
groups	O
was	O
significantly	O
reduced	O
by	O
concurrent	Pharmacological
cisplatin	Pharmacological
(	O
P	O
=	O
.038	O
,	O
log-rank	O
test	O
)	O
and	O
this	O
effect	O
was	O
preserved	O
in	O
a	O
stepwise	O
Cox	O
regression	O
model	O
of	O
prognostic	O
factors	O
(	O
hazards	O
ratio	O
,	O
0.50	O
;	O
90	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.29	O
to	O
0.86	O
;	O
P	O
=	O
.036	O
)	O
.	O

The	O
hazard	O
reduction	O
was	O
similar	O
for	O
both	O
radiation	O
plans	O
.	O

Pretreatment	O
leukocytosis	O
and	O
high	O
clinical	O
stage	O
were	O
independent	O
adverse	O
factors	O
in	O
a	O
Cox	O
model	O
of	O
overall	O
survival	O
,	O
but	O
the	O
effect	O
of	O
cisplatin	Pharmacological
was	O
not	O
significant	O
.	O

CONCLUSION	O
Concurrent	Pharmacological
cisplatin	Pharmacological
may	O
improve	O
pelvic	O
control	O
of	O
locally	O
advanced	O
bladder	O
cancer	O
with	O
preoperative	Physical
or	Physical
definitive	Physical
radiation	Physical
,	O
but	O
has	O
not	O
been	O
shown	O
to	O
improve	O
overall	O
survival	O
.	O

The	O
use	O
of	O
concurrent	Pharmacological
cisplatin	Pharmacological
had	O
no	O
detectable	O
effect	O
on	O
distant	O
metastases	O
.	O

[	O
Intra-arterial	Pharmacological
chemotherapy	Pharmacological
in	O
advanced	O
ovarian	O
cancers	O
.	O

2	O
.	O

Therapeutic	O
results	O
in	O
relation	O
to	O
prognostic	O
factors	O
]	O
.	O

85	O
patients	O
with	O
advanced	O
ovarian	O
carcinomas	O
were	O
treated	O
either	O
intra-arterially	Pharmacological
with	Pharmacological
MTX	Pharmacological
and	O
5-FU	Pharmacological
,	O
later	O
systemically	Pharmacological
with	Pharmacological
the	Pharmacological
CMFV-combination	Pharmacological
(	O
therapy	O
arm	O
A	O
)	O
or	O
only	Physical
systemically	Physical
(	O
therapy	O
arm	O
B	O
)	O
after	O
randomization	O
.	O

The	O
achieved	O
rates	O
of	O
remission	O
and	O
survival	O
time	O
showed	O
an	O
obvious	O
dependence	O
on	O
the	O
histological	O
type	O
of	O
tumor	O
and	O
on	O
the	O
degree	O
of	O
differentiation	O
.	O

Whereas	O
the	O
results	O
of	O
the	O
treatment	O
were	O
nearly	O
identical	O
in	O
both	O
groups	O
of	O
treatment	O
with	O
badly	O
differentiated	O
carcinomas	O
,	O
a	O
significant	O
improvement	O
could	O
be	O
achieved	O
by	O
the	O
initial	O
local	O
treatment	O
of	O
well	O
and	O
moderately	O
differentiated	O
malignancies	O
.	O

More	O
than	O
one	O
third	O
of	O
the	O
cases	O
of	O
advanced	O
tumors	O
were	O
operable	O
by	O
local	O
chemotherapy	O
.	O

Thus	O
the	O
survival	O
time	O
could	O
be	O
extended	O
.	O

The	O
intra-arterial	Pharmacological
chemotherapy	Pharmacological
represents	O
an	O
expensive	O
,	O
but	O
effective	O
method	O
of	O
treatment	O
of	O
advanced	O
ovarian	O
carcinomas	O
.	O

A	O
comparative	O
efficacy	O
and	O
safety	O
study	O
of	O
clarithromycin	Pharmacological
,	O
roxithromycin	Pharmacological
and	O
erythromycin	Pharmacological
stearate	Pharmacological
in	O
mild	O
pneumonia	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
clarithromycin	Pharmacological
,	O
roxithromycin	Pharmacological
and	O
erythromycin	Pharmacological
stearate	Pharmacological
in	O
mild	O
pneumonia	O
were	O
compared	O
in	O
an	O
open	O
randomized	O
trial	O
.	O

Eighty-six	O
male	O
patients	O
,	O
doing	O
their	O
obligatory	O
military	O
service	O
,	O
ranging	O
between	O
19	O
and	O
24	O
years	O
of	O
age	O
(	O
mean	O
20	O
)	O
,	O
were	O
randomly	O
treated	O
:	O
29	O
with	O
clarithromycin	Pharmacological
500	Pharmacological
mg	Pharmacological
12-hourly	Pharmacological
,	O
30	O
with	O
roxithromycin	Pharmacological
150	O
mg	O
12-hourly	O
,	O
and	O
27	O
with	O
erythromycin	Pharmacological
stearate	O
500	O
mg	O
6-hourly	O
,	O
each	O
course	O
being	O
administered	O
for	O
10	O
days	O
.	O

Seventy-eight	O
patients	O
were	O
able	O
to	O
be	O
evaluated	O
for	O
efficacy	O
,	O
28	O
receiving	O
clarithromycin	Pharmacological
,	O
28	O
roxithromycin	Pharmacological
,	O
and	O
22	O
erythromycin	Pharmacological
stearate	Pharmacological
.	O

There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
groups	O
in	O
terms	O
of	O
clinical	O
success	O
rates	O
(	O
clinical	O
cure	O
or	O
improvement	O
:	O
89	O
%	O
for	O
clarithromycin	Pharmacological
,	O
82	O
%	O
for	O
roxithromycin	Pharmacological
,	O
and	O
73	O
%	O
for	O
erythromycin	Pharmacological
stearate	Pharmacological
,	O
p	O
=	O
0.32	O
)	O
.	O

However	O
,	O
we	O
found	O
that	O
there	O
were	O
significant	O
differences	O
among	O
the	O
groups	O
in	O
terms	O
of	O
clinical	O
cure	O
rates	O
(	O
75	O
%	O
for	O
clarithromycin	Pharmacological
,	O
64	O
%	O
for	O
roxithromycin	Pharmacological
,	O
and	O
41	O
%	O
for	O
erythromycin	Pharmacological
stearate	Pharmacological
,	O
p	O
=	O
0.04	O
)	O
.	O

Adverse	O
events	O
,	O
mostly	O
gastrointestinal	O
,	O
caused	O
discontinuation	O
of	O
treatment	O
in	O
3.4	O
%	O
of	O
the	O
patients	O
in	O
the	O
clarithromycin	Pharmacological
group	O
,	O
in	O
6.6	O
%	O
of	O
the	O
patients	O
in	O
the	O
roxithromycin	Pharmacological
group	O
,	O
and	O
in	O
18.5	O
%	O
of	O
the	O
patients	O
in	O
the	O
erythromycin	Pharmacological
stearate	Pharmacological
group	O
.	O

The	O
results	O
indicate	O
that	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
among	O
the	O
three	O
treatment	O
groups	O
in	O
terms	O
of	O
clinical	O
success	O
rates	O
,	O
but	O
that	O
clarithromycin	Pharmacological
and	O
roxithromycin	Pharmacological
were	O
better	O
tolerated	O
.	O

Tomato	Pharmacological
paste	Pharmacological
rich	Pharmacological
in	Pharmacological
lycopene	Pharmacological
protects	O
against	O
cutaneous	O
photodamage	O
in	O
humans	O
in	O
vivo	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Previous	O
epidemiological	O
,	O
animal	O
and	O
human	O
data	O
report	O
that	O
lycopene	O
has	O
a	O
protective	O
effect	O
against	O
ultraviolet	O
radiation	O
(	O
UVR	O
)	O
-induced	O
erythema	O
.	O

OBJECTIVES	O
We	O
examined	O
whether	O
tomato	Pharmacological
paste	Pharmacological
--	Pharmacological
rich	Pharmacological
in	Pharmacological
lycopene	Pharmacological
,	O
a	O
powerful	O
antioxidant	O
--	O
can	O
protect	O
human	O
skin	O
against	O
UVR-induced	O
effects	O
partially	O
mediated	O
by	O
oxidative	O
stress	O
,	O
i.e	O
.	O

erythema	O
,	O
matrix	O
changes	O
and	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
damage	O
.	O

METHODS	O
In	O
a	O
randomized	O
controlled	O
study	O
,	O
20	O
healthy	O
women	O
(	O
median	O
age	O
33	O
years	O
,	O
range	O
21-47	O
;	O
phototype	O
I/II	O
)	O
ingested	O
55	Physical
g	Physical
tomato	Physical
paste	Physical
(	Physical
16	Physical
mg	Physical
lycopene	Physical
)	Physical
in	Physical
olive	Physical
oil	Physical
,	Physical
or	Physical
olive	Physical
oil	Physical
alone	Physical
,	Physical
daily	Physical
for	Physical
12	Physical
weeks	Physical
.	Physical

Pre-	O
and	O
postsupplementation	O
,	O
UVR	O
erythemal	O
sensitivity	O
was	O
assessed	O
visually	O
as	O
the	O
minimal	O
erythema	O
dose	O
(	O
MED	O
)	O
and	O
quantified	O
with	O
a	O
reflectance	O
instrument	O
.	O

Biopsies	O
were	O
taken	O
from	O
unexposed	O
and	O
UVR-exposed	O
(	O
3	O
?	O
MED	O
24	O
h	O
earlier	O
)	O
buttock	O
skin	O
pre-	O
and	O
postsupplementation	O
,	O
and	O
analysed	O
immunohistochemically	O
for	O
procollagen	O
(	O
pC	O
)	O
I	O
,	O
fibrillin-1	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-1	O
,	O
and	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
for	O
mtDNA	O
3895-bp	O
deletion	O
.	O

RESULTS	O
Mean	O
?	O
SD	O
erythemal	O
D	O
(	O
30	O
)	O
was	O
significantly	O
higher	O
following	O
tomato	O
paste	O
vs.	O
control	O
(	O
baseline	O
,	O
26?5	O
?	O
7?5	O
mJ	O
cm	O
(	O
-2	O
)	O
;	O
control	O
,	O
23	O
?	O
6?6	O
mJ	O
cm	O
(	O
-2	O
)	O
;	O
tomato	O
paste	O
,	O
36?6	O
?	O
14?7	O
mJ	O
cm	O
(	O
-2	O
)	O
;	O
P	O
=	O
0?03	O
)	O
,	O
while	O
the	O
MED	O
was	O
not	O
significantly	O
different	O
between	O
groups	O
(	O
baseline	O
,	O
35?1	O
?	O
9?9	O
mJ	O
cm	O
(	O
-2	O
)	O
;	O
control	O
,	O
32?6	O
?	O
9?6	O
mJ	O
cm	O
(	O
-2	O
)	O
;	O
tomato	O
paste	O
,	O
42?2	O
?	O
11?3	O
mJ	O
cm	O
(	O
-2	O
)	O
)	O
.	O

Presupplementation	O
,	O
UVR	O
induced	O
an	O
increase	O
in	O
MMP-1	O
(	O
P	O
=	O
0?01	O
)	O
and	O
a	O
reduction	O
in	O
fibrillin-1	O
(	O
P	O
=	O
0?03	O
)	O
.	O

Postsupplementation	O
,	O
UVR-induced	O
MMP-1	O
was	O
reduced	O
in	O
the	O
tomato	O
paste	O
vs.	O
control	O
group	O
(	O
P	O
=	O
0?04	O
)	O
,	O
while	O
the	O
UVR-induced	O
reduction	O
in	O
fibrillin-1	O
was	O
similarly	O
abrogated	O
in	O
both	O
groups	O
,	O
and	O
an	O
increase	O
in	O
pCI	O
deposition	O
was	O
seen	O
following	O
tomato	O
paste	O
(	O
P	O
=	O
0?05	O
)	O
.	O

mtDNA	O
3895-bp	O
deletion	O
following	O
3	O
?	O
MED	O
UVR	O
was	O
significantly	O
reduced	O
postsupplementation	O
with	O
tomato	O
paste	O
(	O
P	O
=	O
0?01	O
)	O
.	O

CONCLUSIONS	O
Tomato	O
paste	O
containing	O
lycopene	O
provides	O
protection	O
against	O
acute	O
and	O
potentially	O
longer-term	O
aspects	O
of	O
photodamage	O
.	O

[	O
Results	O
of	O
three-year	O
clinical	O
study	O
of	O
prostamol	Pharmacological
uno	Pharmacological
efficacy	O
and	O
safety	O
in	O
patients	O
with	O
initial	O
symptoms	O
of	O
prostatic	O
adenoma	O
and	O
risk	O
of	O
its	O
progression	O
]	O
.	O

Prostamol	Pharmacological
Uno	Pharmacological
(	Pharmacological
PU	Pharmacological
)	Pharmacological
efficacy	O
and	O
safety	O
were	O
studied	O
in	O
a	O
multicenter	O
,	O
open-population	O
,	O
randomized	O
and	O
comparative	O
trial	O
.	O

PU	Pharmacological
was	O
given	O
in	O
a	O
single	O
daily	O
dose	O
320	O
mg	O
for	O
36	O
months	O
to	O
50	O
patients	O
with	O
initial	O
symptoms	O
of	O
prostatic	O
adenoma	O
(	O
PA	O
)	O
in	O
comparison	O
with	O
50	O
matched	O
controls	O
.	O

The	O
trial	O
evaluated	O
PU	Pharmacological
action	O
on	O
the	O
symptoms	O
progression	O
and	O
quality	O
of	O
life	O
with	O
application	O
of	O
questionnaires	O
IPSS	O
and	O
QoL	O
(	O
BS	O
)	O
.	O

It	O
was	O
found	O
that	O
PU	O
treatment	O
relieved	O
PA	O
symptoms	O
by	O
IPSS	O
,	O
while	O
these	O
symptoms	O
progressed	O
in	O
the	O
controls	O
.	O

QoL	O
improved	O
in	O
the	O
study	O
group	O
and	O
deteriorated	O
in	O
the	O
control	O
one	O
.	O

Administration	O
of	O
PU	O
significantly	O
increased	O
urinary	O
flow	O
rate	O
though	O
in	O
the	O
controls	O
urinary	O
flow	O
rate	O
decreased	O
,	O
size	O
of	O
the	O
prostate	O
diminished	O
and	O
increased	O
,	O
respectively	O
.	O

Changes	O
in	O
the	O
PSA	O
were	O
not	O
seen	O
and	O
were	O
insignificant	O
,	O
respectively	O
.	O

The	O
results	O
of	O
the	O
study	O
say	O
that	O
prostamol	O
Uno	O
in	O
a	O
dose	O
320	O
mg/day	O
can	O
prevent	O
PA	O
progression	O
without	O
side	O
effects	O
.	O

Effect	O
of	O
2	O
weeks	O
of	O
theophylline	O
on	O
glucose	O
counterregulation	O
in	O
patients	O
with	O
type	O
1	O
diabetes	O
and	O
unawareness	O
of	O
hypoglycemia	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
A	O
single	O
dose	O
of	O
theophylline	O
improves	O
hypoglycemia	O
unawareness	O
in	O
type	O
1	O
diabetic	O
patients	O
.	O

Prolonged	O
theophylline	O
use	O
is	O
,	O
however	O
,	O
associated	O
with	O
emergence	O
of	O
tolerance	O
.	O

This	O
study	O
investigated	O
whether	O
prolonged	O
use	O
of	O
theophylline	O
retains	O
efficacy	O
for	O
counterregulatory	O
defects	O
in	O
patients	O
with	O
type	O
1	O
diabetes	O
and	O
hypoglycemia	O
unawareness	O
.	O

METHODS	O
Experiments	O
were	O
performed	O
with	O
12	O
subjects	O
with	O
type	O
1	O
diabetes	O
and	O
hypoglycemia	O
unawareness	O
.	O

All	O
subjects	O
participated	O
in	O
a	O
crossover	O
study	O
of	O
2	O
randomly	O
scheduled	O
15-day	O
study	O
periods	O
during	O
which	O
250	Pharmacological
mg	Pharmacological
theophylline	Pharmacological
twice	Pharmacological
daily	Pharmacological
or	O
matching	Control
placebo	Control
was	O
used	O
.	O

On	O
the	O
final	O
day	O
of	O
each	O
period	O
,	O
hyperinsulinemic	O
(	O
360	O
pmol	O
x	O
m	O
(	O
-2	O
)	O
x	O
min	O
(	O
-1	O
)	O
)	O
hypoglycemic	O
(	O
5.0	O
,	O
3.5	O
,	O
2.5	O
mmol	O
x	O
L	O
(	O
-1	O
)	O
)	O
glucose	O
clamps	O
were	O
used	O
to	O
assess	O
counterregulatory	O
and	O
cardiovascular	O
responses	O
.	O

RESULTS	O
Under	O
normoglycemic	O
conditions	O
,	O
there	O
were	O
no	O
differences	O
between	O
theophylline	O
and	O
placebo	O
.	O

Under	O
hypoglycemic	O
conditions	O
,	O
theophylline	O
enhanced	O
responses	O
of	O
growth	O
hormone	O
,	O
symptoms	O
,	O
heart	O
rate	O
,	O
and	O
pulse	O
pressure	O
(	O
all	O
P	O
<	O
.05	O
)	O
,	O
induced	O
sweating	O
at	O
higher	O
plasma	O
glucose	O
levels	O
(	O
P	O
=.039	O
)	O
,	O
and	O
reduced	O
exogenous	O
glucose	O
requirements	O
(	O
P	O
=.018	O
)	O
.	O

Hypoglycemia-induced	O
responses	O
of	O
epinephrine	O
,	O
norepinephrine	O
,	O
and	O
cortisol	O
were	O
not	O
enhanced	O
by	O
theophylline	O
.	O

CONCLUSIONS	O
Prolonged	O
use	O
of	O
theophylline	O
has	O
a	O
sustained	O
effect	O
on	O
cardiovascular	O
,	O
metabolic	O
,	O
and	O
symptom	O
responses	O
to	O
hypoglycemia	O
in	O
patients	O
with	O
type	O
1	O
diabetes	O
and	O
hypoglycemia	O
unawareness	O
.	O

Whether	O
these	O
results	O
translate	O
into	O
clinical	O
benefit	O
remains	O
to	O
be	O
determined	O
.	O

Rapid	O
injection	O
of	O
propofol	Pharmacological
reduces	O
vascular	O
pain	O
and	O
facilitates	O
Laryngeal	O
Mask	O
Airway	O
insertion	O
.	O

STUDY	O
OBJECTIVE	O
To	O
compare	O
the	O
clinical	O
efficacy	O
of	O
a	O
rapid	O
injection	O
of	O
propofol	Pharmacological
in	O
regard	O
to	O
pain	O
and	O
ability	O
to	O
facilitate	O
Laryngeal	O
Mask	O
Airway	O
(	O
LMA	O
)	O
insertion	O
.	O

DESIGN	O
Randomized	O
,	O
single-blinded	O
,	O
placebo-controlled	Control
study	O
.	O

SETTING	O
University	O
hospital	O
.	O

PATIENTS	O
120	O
ASA	O
physical	O
status	O
1	O
and	O
2	O
patients	O
undergoing	O
elective	O
orthopedic	O
surgeries	O
.	O

INTERVENTIONS	O
Patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
4	O
groups	O
.	O

Group	O
A	O
patients	O
were	O
pretreated	O
with	O
normal	Pharmacological
saline	Pharmacological
followed	Pharmacological
by	Pharmacological
propofol	Pharmacological
2.0	Pharmacological
mg/kg	Pharmacological
at	Pharmacological
3.3	Pharmacological
mg/sec	Pharmacological
.	Pharmacological

Group	O
B	O
patients	O
were	O
pretreated	O
with	O
lidocaine	Pharmacological
0.5	Pharmacological
mg/kg	Pharmacological
followed	Pharmacological
by	Pharmacological
propofol	Pharmacological
2.0	Pharmacological
mg/kg	Pharmacological
at	Pharmacological
3.3	Pharmacological
mg/sec	Pharmacological
.	Pharmacological

In	O
Group	O
C	O
,	O
patients	O
were	O
pretreated	O
with	O
lidocaine	Pharmacological
1.0	Pharmacological
mg/kg	Pharmacological
followed	Pharmacological
by	Pharmacological
propofol	Pharmacological
2.0	Pharmacological
mg/kg	Pharmacological
at	Pharmacological
3.3	Pharmacological
mg/sec	Pharmacological
.	Pharmacological

In	O
Group	O
D	O
,	O
patients	O
were	O
pretreated	O
with	O
normal	Pharmacological
saline	Pharmacological
followed	Pharmacological
by	Pharmacological
propofol	Pharmacological
2.0	Pharmacological
mg/kg	Pharmacological
at	Pharmacological
50	Pharmacological
mg/sec	Pharmacological
.	Pharmacological

MEASUREMENTS	O
Pain	O
on	O
injection	O
was	O
measured	O
using	O
a	O
4-point	O
scale	O
.	O

Scale	O
and	O
success	O
rate	O
of	O
smooth	O
LMA	O
insertion	O
also	O
were	O
recorded	O
.	O

MAIN	O
RESULTS	O
Rapid	Physical
injection	Physical
was	O
less	O
painful	O
than	O
after	O
pretreatment	O
with	O
lidocaine	Pharmacological
0.5	O
mg/kg	O
,	O
but	O
was	O
similar	O
to	O
slow	Physical
injection	Physical
after	O
pretreatment	Pharmacological
with	Pharmacological
lidocaine	Pharmacological
1.0	O
mg/kg	O
.	O

Rapid	Physical
injection	Physical
facilitated	O
LMA	O
insertion	O
,	O
unlike	O
slow	Physical
injection	Physical
with	O
lidocaine	Pharmacological
0.5	O
mg/kg	O
pretreatment	O
,	O
and	O
was	O
similarly	O
successful	O
to	O
slow	Physical
injection	Physical
after	Pharmacological
pretreatment	Pharmacological
with	Pharmacological
lidocaine	Pharmacological
1.0	O
mg/kg	O
.	O

CONCLUSIONS	O
The	O
rapid	Physical
administration	Physical
of	O
propofol	Pharmacological
reduces	O
pain	O
and	O
facilitates	O
LMA	O
insertion	O
versus	O
slow	Physical
administration	Physical
of	O
propofol	Pharmacological
.	O

Effects	O
of	O
single	O
dose	O
intranasal	O
oxytocin	Pharmacological
on	O
social	O
cognition	O
in	O
schizophrenia	O
.	O

Deficits	O
in	O
social	O
cognition	O
are	O
common	O
in	O
schizophrenia	O
and	O
predict	O
poor	O
community	O
functioning	O
.	O

Given	O
the	O
current	O
limitations	O
of	O
psychosocial	O
treatments	O
and	O
the	O
lack	O
of	O
pharmacological	O
treatments	O
for	O
social	O
cognitive	O
deficits	O
,	O
the	O
development	O
of	O
novel	O
therapeutic	O
agents	O
could	O
greatly	O
enhance	O
functional	O
recovery	O
in	O
schizophrenia	O
.	O

This	O
study	O
evaluated	O
whether	O
a	O
single	O
dose	O
of	O
intranasal	O
oxytocin	Pharmacological
acutely	O
improves	O
social	O
cognitive	O
functioning	O
in	O
schizophrenia	O
.	O

Twenty-three	O
male	O
veterans	O
with	O
schizophrenia	O
completed	O
baseline	O
assessments	O
of	O
social	O
cognition	O
that	O
were	O
divided	O
into	O
lower-level	O
(	O
facial	O
affect	O
perception	O
,	O
social	O
perception	O
,	O
detection	O
of	O
lies	O
)	O
and	O
higher-level	O
(	O
detection	O
of	O
sarcasm	O
and	O
deception	O
,	O
empathy	O
)	O
processes	O
.	O

One	O
week	O
later	O
,	O
patients	O
received	O
the	O
same	O
battery	O
after	O
being	O
randomized	O
to	O
a	O
single	O
dose	O
of	O
40	O
IU	O
intranasal	Pharmacological
oxytocin	Pharmacological
or	O
placebo	Control
.	O

Though	O
the	O
groups	O
did	O
not	O
differ	O
significantly	O
on	O
the	O
social	O
cognition	O
composite	O
score	O
,	O
oxytocin	O
improved	O
performance	O
for	O
the	O
higher-level	O
social	O
cognitive	O
tasks	O
(	O
Cohen	O
's	O
d=1.0	O
,	O
p=0.045	O
)	O
.	O

Subjects	O
were	O
unable	O
to	O
accurately	O
guess	O
which	O
treatment	O
they	O
had	O
received	O
.	O

The	O
improvements	O
found	O
in	O
higher-level	O
social	O
cognition	O
encourage	O
further	O
studies	O
into	O
the	O
therapeutic	O
potential	O
of	O
oxytocin	O
in	O
schizophrenia	O
.	O

Quantifying	O
the	O
extent	O
of	O
osteonecrosis	O
of	O
the	O
femoral	O
head	O
.	O

A	O
new	O
method	O
using	O
MRI	Physical
.	O

In	O
a	O
randomised	O
trial	O
comparing	O
core	O
decompression	O
with	O
conservative	O
treatment	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
extent	O
of	O
necrosis	O
at	O
the	O
initial	O
MRI	Physical
predicts	O
the	O
subsequent	O
risk	O
of	O
collapse	O
of	O
the	O
femoral	O
head	O
.	O

After	O
the	O
initial	O
clinical	O
evaluation	O
,	O
including	O
plain	Physical
radiography	Physical
and	O
MRI	Physical
,	O
37	O
hips	O
with	O
early-stage	O
osteonecrosis	O
(	O
ON	O
)	O
in	O
33	O
patients	O
were	O
randomly	O
assigned	O
to	O
a	O
core-decompression	Physical
group	O
or	O
a	O
conservatively-treated	Physical
group	O
.	O

All	O
were	O
followed	O
regularly	O
by	O
clinical	O
evaluation	O
,	O
plain	Physical
radiography	Physical
and	O
MRI	Physical
at	O
intervals	O
of	O
three	O
months	O
.	O

The	O
extent	O
of	O
ON	O
was	O
estimated	O
on	O
the	O
basis	O
of	O
abnormal	O
signal	O
intensity	O
in	O
the	O
weight-bearing	O
portion	O
of	O
the	O
femoral	O
head	O
as	O
determined	O
from	O
a	O
combination	O
of	O
coronal	O
and	O
sagittal	O
MRIs	O
.	O

The	O
arc	O
of	O
the	O
necrotic	O
portion	O
in	O
the	O
mid-coronal	O
image	O
(	O
A	O
)	O
and	O
that	O
in	O
the	O
mid-sagittal	O
image	O
(	O
B	O
)	O
were	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
necrosis	O
by	O
the	O
formula	O
:	O
(	O
A/180	O
)	O
x	O
(	O
B/180	O
)	O
x	O
100	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
this	O
index	O
and	O
the	O
risk	O
of	O
collapse	O
before	O
and	O
after	O
adjustment	O
for	O
age	O
,	O
gender	O
,	O
stage	O
and	O
treatment	O
group	O
.	O

We	O
conclude	O
that	O
the	O
extent	O
of	O
the	O
necrotic	O
portion	O
ascertain	O
by	O
this	O
method	O
is	O
a	O
major	O
predictor	O
of	O
future	O
collapse	O
.	O

We	O
propose	O
a	O
systematic	O
method	O
of	O
determining	O
the	O
index	O
of	O
the	O
necrotic	O
portion	O
which	O
may	O
be	O
clinically	O
useful	O
in	O
the	O
management	O
of	O
early-stage	O
ON	O
of	O
the	O
femoral	O
head	O
.	O

Central	O
5-HT4	O
receptor	O
binding	O
as	O
biomarker	O
of	O
serotonergic	O
tonus	O
in	O
humans	O
:	O
a	O
[	O
11C	O
]	O
SB207145	O
PET	O
study	O
.	O

Identification	O
of	O
a	O
biomarker	O
that	O
can	O
inform	O
on	O
extracellular	O
serotonin	O
(	O
5-HT	O
)	O
levels	O
in	O
the	O
brains	O
of	O
living	O
humans	O
would	O
enable	O
greater	O
understanding	O
of	O
the	O
way	O
brain	O
circuits	O
are	O
modulated	O
by	O
serotonergic	O
neurotransmission	O
.	O

Substantial	O
evidence	O
from	O
studies	O
in	O
animals	O
and	O
humans	O
indicates	O
an	O
inverse	O
relationship	O
between	O
central	O
5-HT	O
tonus	O
and	O
5-HT	O
type	O
4	O
receptor	O
(	O
5-HT4R	O
)	O
density	O
,	O
suggesting	O
that	O
5-HT4R	O
receptor	O
density	O
may	O
be	O
a	O
biomarker	O
marker	O
for	O
5-HT	O
tonus	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
a	O
3-week	O
administration	O
of	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
,	O
expected	O
to	O
increase	O
brain	O
5-HT	O
levels	O
,	O
is	O
associated	O
with	O
a	O
decline	O
in	O
brain	O
5-HT4R	O
binding	O
.	O

A	O
total	O
of	O
35	O
healthy	O
men	O
were	O
studied	O
in	O
a	O
placebo-controlled	Control
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

Participants	O
were	O
assigned	O
to	O
receive	O
3	O
weeks	O
of	O
oral	Control
dosing	Control
with	Control
placebo	Control
or	O
fluoxetine	Pharmacological
,	Pharmacological
40	Pharmacological
mg	Pharmacological
per	Pharmacological
day	Pharmacological
.	O

Brain	O
5-HT4R	O
binding	O
was	O
quantified	O
at	O
baseline	O
and	O
at	O
follow-up	O
with	O
[	O
(	Physical
11	Physical
)	Physical
C	Physical
]	Physical
SB207145	Physical
positron	Physical
emission	Physical
tomography	Physical
(	Physical
PET	Physical
)	Physical
.	O

Three	O
weeks	O
of	O
intervention	O
with	O
fluoxetine	O
was	O
associated	O
with	O
a	O
5.2	O
%	O
reduction	O
in	O
brain	O
5-HT4R	O
binding	O
(	O
P=0.017	O
)	O
,	O
whereas	O
placebo	O
intervention	O
did	O
not	O
change	O
5-HT4R	O
binding	O
(	O
P=0.52	O
)	O
.	O

Our	O
findings	O
are	O
consistent	O
with	O
a	O
model	O
,	O
wherein	O
the	O
5-HT4R	O
density	O
adjusts	O
to	O
changes	O
in	O
the	O
extracellular	O
5-HT	O
tonus	O
.	O

Our	O
data	O
demonstrate	O
for	O
the	O
first	O
time	O
in	O
humans	O
that	O
the	O
imaging	O
of	O
central	O
5-HT4R	O
binding	O
may	O
be	O
used	O
as	O
an	O
in	O
vivo	O
biomarker	O
of	O
the	O
central	O
5-HT	O
tonus	O
.	O

Transcutaneous	Physical
electrical	Physical
nerve	Physical
stimulation	Physical
after	O
thoracotomy	O
.	O

Pain	O
relief	O
and	O
peak	O
expiratory	O
flow	O
rate	O
--	O
a	O
trial	O
of	O
transcutaneous	Physical
electrical	Physical
nerve	Physical
stimulation	Physical
.	O

Forty	O
patients	O
scheduled	O
to	O
undergo	O
thoracotomy	O
were	O
randomly	Physical
allocated	Physical
to	Physical
receive	Physical
either	Physical
transcutaneous	Physical
electrical	Physical
nerve	Physical
stimulation	Physical
with	Physical
intramuscular	Physical
papaveretum	Physical
(	Physical
20	Physical
patients	Physical
)	Physical
or	O
intramuscular	Physical
papaveretum	Physical
alone	Physical
(	Physical
20	Physical
patients	Physical
)	Physical
for	Physical
postoperative	Physical
pain	Physical
relief	Physical
.	Physical

Total	O
intramuscular	O
analgesic	O
requirements	O
in	O
the	O
first	O
24	O
hours	O
,	O
time	O
to	O
satisfactory	O
transfer	O
to	O
oral	O
analgesia	O
,	O
antiemetic	O
requirements	O
and	O
length	O
of	O
stay	O
in	O
hospital	O
postoperatively	O
were	O
noted	O
.	O

Peak	O
expiratory	O
flow	O
rate	O
was	O
compared	O
pre-	O
and	O
postoperatively	O
in	O
the	O
two	O
groups	O
.	O

Use	O
of	O
nerve	O
stimulation	O
did	O
not	O
significantly	O
alter	O
the	O
requirements	O
for	O
analgesia	O
although	O
there	O
was	O
a	O
reduction	O
in	O
postoperative	O
nausea	O
and	O
vomiting	O
in	O
the	O
nerve	O
stimulation	O
group	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
changes	O
in	O
peak	O
expiratory	O
flow	O
rate	O
.	O

Cross-over	O
trial	O
of	O
intensive	O
monotherapy	O
with	O
atorvastatin	Pharmacological
and	O
combined	O
therapy	O
with	O
atorvastatin	Pharmacological
and	O
colestimide	Pharmacological
for	O
Japanese	O
familial	O
hypercholesterolemia	O
.	O

BACKGROUND	O
In	O
familial	O
hypercholesterolemia	O
(	O
FH	O
)	O
,	O
low-density	O
lipoprotein-cholesterol	O
(	O
LDL-C	O
)	O
-lowering	O
therapy	O
is	O
important	O
to	O
avoid	O
predisposition	O
to	O
coronary	O
artery	O
disease	O
.	O

This	O
study	O
investigated	O
the	O
advantages	O
of	O
combined	O
therapy	O
with	O
atorvastatin	Pharmacological
and	O
colestimide	Pharmacological
vs	O
intensive	O
monotherapy	O
with	O
atorvastatin	Pharmacological
.	O

METHODS	O
AND	O
RESULTS	O
The	O
trial	O
used	O
a	O
randomized	O
cross-over	O
design	O
consisting	O
of	O
2	O
16-week	O
periods	O
of	O
open-label	O
drug	O
therapy	O
.	O

Among	O
the	O
24	O
initial	O
patients	O
,	O
17	O
heterozygous	O
FH	O
patients	O
(	O
age	O
:	O
54.1	O
years	O
;	O
5	O
males	O
)	O
were	O
enrolled	O
after	O
20	Pharmacological
mg/day	Pharmacological
atorvastatin	Pharmacological
failed	O
to	O
achieve	O
their	O
target	O
level	O
.	O

The	O
patients	O
received	O
20	O
mg/day	O
atorvastatin	Pharmacological
and	O
3	O
g/day	O
colestimide	Pharmacological
or	O
40	O
mg/day	O
atorvastatin	Pharmacological
.	O

Fifteen	O
patients	O
completed	O
the	O
trial	O
and	O
their	O
LDL-C	O
reduced	O
from	O
5.07	O
+/-	O
1.10	O
mmol/L	O
to	O
3.76	O
+/-	O
0.90	O
mmol/L	O
with	O
the	O
combined	O
therapy	O
and	O
to	O
3.81	O
+/-	O
0.50	O
mmol/L	O
with	O
the	O
intensive	O
monotherapy	O
.	O

Although	O
the	O
2	O
therapies	O
showed	O
comparable	O
mean	O
effects	O
for	O
decreasing	O
LDL-C	O
,	O
similar	O
adverse	O
reaction	O
and	O
cost	O
,	O
each	O
therapy	O
was	O
predominantly	O
more	O
effective	O
in	O
some	O
patients	O
than	O
in	O
others	O
.	O

The	O
triglyceride	O
and	O
high-density	O
lipoprotein	O
cholesterol	O
levels	O
were	O
similar	O
in	O
both	O
therapies	O
.	O

CONCLUSIONS	O
To	O
achieve	O
the	O
therapeutic	O
target	O
of	O
LDL-C	O
level	O
for	O
refractory	O
FH	O
,	O
the	O
LDL-C-lowering	O
therapy	O
selected	O
can	O
be	O
either	O
intensive	O
monotherapy	O
or	O
combined	O
therapy	O
as	O
the	O
next	O
to	O
standard	O
statin	O
therapy	O
.	O

Acute	O
and	O
short-term	O
effects	O
of	O
secondhand	O
smoke	O
on	O
lung	O
function	O
and	O
cytokine	O
production	O
.	O

RATIONALE	O
The	O
acute	O
effect	O
of	O
secondhand	O
smoke	O
(	O
SHS	O
)	O
on	O
lung	O
function	O
and	O
the	O
duration	O
of	O
system	O
disruption	O
remain	O
unknown	O
.	O

OBJECTIVES	O
To	O
assess	O
the	O
SHS	O
effects	O
and	O
their	O
duration	O
on	O
lung	O
function	O
and	O
inflammatory	O
markers	O
.	O

METHODS	O
In	O
a	O
randomized	O
single-blind	O
crossover	O
experiment	O
data	O
were	O
obtained	O
from	O
16	O
(	O
8	O
women	O
)	O
nonsmoking	O
adults	O
at	O
baseline	Physical
and	Physical
at	Physical
0	Physical
,	Physical
1	Physical
,	Physical
and	Physical
3	Physical
hours	Physical
after	Physical
a	Physical
1-hour	Physical
SHS	Physical
exposure	Physical
set	Physical
at	Physical
bar/restaurant	Physical
SHS	Physical
levels	Physical
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Serum	O
and	O
urine	O
cotinine	O
,	O
lung	O
function	O
,	O
and	O
cytokines	Pharmacological
IL-4	Pharmacological
,	Pharmacological
IL-5	Pharmacological
,	Pharmacological
IL-6	Pharmacological
,	O
tumor	Pharmacological
necrosis	Pharmacological
factor	Pharmacological
(	Pharmacological
TNF	Pharmacological
)	Pharmacological
-alpha	Pharmacological
,	O
and	O
IFN-gamma	Pharmacological
.	O

At	O
0	O
hours	O
most	O
lung	O
function	O
parameters	O
were	O
significantly	O
reduced	O
(	O
indicative	O
:	O
FEV	O
(	O
1	O
)	O
,	O
4.3	O
+/-	O
0.4	O
vs.	O
3.8	O
+/-	O
0.3	O
L	O
;	O
FEV	O
(	O
1	O
)	O
/FVC	O
,	O
0.9	O
+/-	O
0.1	O
vs.	O
0.8	O
+/-	O
0.1	O
;	O
P	O
<	O
0.05	O
)	O
but	O
at	O
3	O
hours	O
they	O
were	O
at	O
baseline	O
levels	O
.	O

In	O
contrast	O
,	O
cotinine	O
(	O
serum	O
,	O
8.9	O
+/-	O
3.2	O
vs.	O
35.5	O
+/-	O
10.2	O
ng	O
x	O
ml	O
(	O
-1	O
)	O
)	O
,	O
IL-4	O
(	O
41.3	O
+/-	O
5.8	O
vs.	O
44.2	O
+/-	O
4.5	O
pg	O
x	O
ml	O
(	O
-1	O
)	O
)	O
,	O
IL-5	O
(	O
36.1	O
+/-	O
3.2	O
vs.	O
60.1	O
+/-	O
7.0	O
pg	O
x	O
ml	O
(	O
-1	O
)	O
)	O
,	O
IL-6	O
(	O
2.5	O
+/-	O
0.3	O
vs.	O
7.6	O
+/-	O
1.4	O
pg	O
x	O
ml	O
(	O
-1	O
)	O
)	O
and	O
IFN-gamma	O
(	O
0.3	O
+/-	O
0.2	O
vs.	O
0.6	O
+/-	O
0.2	O
IU	O
x	O
ml	O
(	O
-1	O
)	O
)	O
at	O
3	O
hours	O
were	O
higher	O
than	O
at	O
baseline	O
(	O
P	O
<	O
0.05	O
)	O
.	O

IL-4	O
and	O
TNF-alpha	O
increased	O
only	O
in	O
men	O
,	O
whereas	O
IL-5	O
,	O
IL-6	O
,	O
and	O
IFN-gamma	O
were	O
different	O
between	O
sexes	O
after	O
exposure	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Regression	O
analyses	O
revealed	O
inverse	O
associations	O
of	O
FEV	O
(	O
1	O
)	O
and	O
FEV	O
(	O
1	O
)	O
/FVC	O
ratio	O
with	O
IL-5	O
(	O
P	O
<	O
0.05	O
)	O
in	O
men	O
and	O
with	O
IL-5	O
(	O
P	O
=	O
0.01	O
)	O
,	O
IL-6	O
(	O
P	O
<	O
0.001	O
)	O
,	O
IFN-gamma	O
(	O
P	O
=	O
0.034	O
)	O
and	O
serum	O
cotinine	O
(	O
P	O
<	O
0.001	O
)	O
in	O
women	O
.	O

CONCLUSIONS	O
We	O
conclude	O
that	O
1	O
hour	O
of	O
SHS	O
exposure	O
at	O
bar/restaurant	O
levels	O
is	O
accompanied	O
by	O
significant	O
decrements	O
on	O
lung	O
function	O
and	O
marked	O
increases	O
in	O
inflammatory	O
cytokines	O
,	O
particularly	O
in	O
men	O
.	O

More	O
importantly	O
,	O
whereas	O
most	O
smoke-induced	O
effects	O
on	O
lung	O
function	O
appear	O
to	O
recede	O
within	O
60	O
minutes	O
,	O
inflammatory	O
cytokines	O
remain	O
elevated	O
for	O
at	O
least	O
3	O
hours	O
after	O
exposure	O
to	O
SHS	O
.	O

In	O
vivo	O
effect	O
of	O
clarithromycin	Pharmacological
on	O
multiple	O
cytochrome	O
P450s	O
.	O

The	O
in	O
vivo	O
effects	O
of	O
oral	O
clarithromycin	Pharmacological
administration	O
on	O
the	O
in	O
vivo	O
activity	O
of	O
cytochrome	O
P450	O
1A2	O
,	O
2C9	O
,	O
and	O
2D6	O
were	O
determined	O
.	O

The	O
cytochrome	O
P450	O
probes	O
caffeine	Pharmacological
(	O
CYP1A2	O
)	O
,	O
tolbutamide	Pharmacological
(	O
CYP2C9	O
)	O
,	O
and	O
dextromethorphan	Pharmacological
(	O
CYP2D6	O
)	O
were	O
administered	O
as	O
an	O
oral	O
cocktail	O
prior	O
to	O
and	O
7	O
days	O
after	O
oral	O
clarithromycin	Pharmacological
(	O
500	O
mg	O
twice	O
daily	O
)	O
administration	O
to	O
12	O
healthy	O
male	O
subjects	O
.	O

Blood	O
and	O
urine	O
samples	O
were	O
collected	O
and	O
assayed	O
for	O
each	O
of	O
the	O
compounds	O
and	O
their	O
metabolites	O
using	O
high-performance	O
liquid	O
chromatography	O
.	O

The	O
CYP1A2	O
indices	O
,	O
oral	O
caffeine	O
clearance	O
(	O
6.2	O
+/-	O
3.3	O
l/h	O
before	O
and	O
5.7	O
+/-	O
4.2	O
l/h	O
after	O
,	O
p	O
>	O
0.05	O
)	O
and	O
the	O
6-h	O
paraxanthine	O
to	O
caffeine	O
serum	O
concentration	O
ratio	O
(	O
0.49	O
+/-	O
0.3	O
before	O
and	O
0.44	O
+/-	O
0.3	O
after	O
,	O
p	O
>	O
0.05	O
)	O
,	O
were	O
unchanged	O
following	O
clarithromycin	O
dosing	O
.	O

Neither	O
the	O
tolbutamide	Pharmacological
oral	O
clearance	O
(	O
0.77	O
+/-	O
0.28	O
l/h	O
before	O
and	O
0.72	O
+/-0.24	O
l/h	O
after	O
,	O
p	O
>	O
0.05	O
)	O
nor	O
the	O
tolbutamide	Pharmacological
urinary	O
metabolic	O
ratio	O
(	O
779	O
+/-	O
294	O
before	O
and	O
681	O
+/-	O
416	O
after	O
,	O
p	O
>	O
0.05	O
)	O
indices	O
of	O
CYP2C9	O
were	O
altered	O
by	O
clarithromycin	Pharmacological
administration	O
.	O

In	O
the	O
case	O
of	O
CYP2D6	O
,	O
the	O
dextromethorphan	Pharmacological
to	O
dextrorphan	O
urinary	O
ratio	O
was	O
not	O
significantly	O
different	O
before	O
(	O
0.021	O
+/-	O
0.04	O
)	O
and	O
after	O
(	O
0.024	O
+/-	O
0.06	O
)	O
clarithromycin	Pharmacological
dosing	O
.	O

In	O
conclusion	O
,	O
clarithromycin	Pharmacological
does	O
not	O
appear	O
to	O
alter	O
the	O
in	O
vivo	O
catalytic	O
activity	O
of	O
CYP1A2	O
,	O
CYP2C9	O
,	O
and	O
CYP2D6	O
in	O
healthy	O
individuals	O
as	O
assessed	O
by	O
caffeine	O
,	O
tolbutamide	O
,	O
and	O
dextromethorphan	O
,	O
respectively	O
.	O

Once-daily	O
versus	O
twice-daily	O
intravenous	O
administration	O
of	O
vancomycin	Pharmacological
for	O
infections	O
in	O
hospitalized	O
patients	O
.	O

The	O
efficacy	O
and	O
toxicity	O
of	O
once-daily	O
(	O
od	O
)	O
versus	O
twice-daily	O
(	O
bd	O
)	O
dosing	O
of	O
vancomycin	Pharmacological
was	O
compared	O
in	O
121	O
hospitalized	O
patients	O
.	O

Eighteen	O
patients	O
were	O
then	O
withdrawn	O
from	O
the	O
study	O
.	O

Clinical	O
and	O
bacteriological	O
responses	O
were	O
evaluated	O
in	O
all	O
patients	O
(	O
n	O
=	O
103	O
)	O
.	O

Nephrotoxicity	O
was	O
assessed	O
in	O
patients	O
who	O
did	O
not	O
receive	O
nephrotoxic	O
agents	O
(	O
n	O
=	O
76	O
)	O
.	O

Ototoxicity	O
was	O
assessed	O
in	O
patients	O
who	O
completed	O
two	O
audiograms	O
and	O
were	O
not	O
receiving	O
ototoxic	O
agents	O
(	O
n	O
=	O
63	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
groups	O
for	O
favourable	O
clinical	O
response	O
:	O
47/51	O
(	O
92.1	O
%	O
)	O
and	O
49/52	O
(	O
94.2	O
%	O
)	O
in	O
the	O
od	O
and	O
bd	O
groups	O
,	O
respectively	O
.	O

In	O
34	O
patients	O
vancomycin	Pharmacological
was	O
the	O
only	O
effective	O
antibiotic	O
.	O

Fifteen	O
of	O
18	O
(	O
83.3	O
%	O
)	O
evaluated	O
episodes	O
in	O
the	O
od	O
and	O
12/16	O
(	O
75.0	O
%	O
)	O
evaluated	O
episodes	O
in	O
the	O
bd	O
group	O
showed	O
a	O
favourable	O
bacteriological	O
response	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
od	O
and	O
bd	O
groups	O
for	O
all	O
adverse	O
events	O
.	O

Nephrotoxicity	O
developed	O
in	O
4/37	O
(	O
10.8	O
%	O
)	O
and	O
3/39	O
(	O
7.7	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Hearing	O
loss	O
developed	O
in	O
1/31	O
(	O
3.2	O
%	O
)	O
and	O
5/32	O
(	O
15.6	O
%	O
)	O
.	O

Phlebitis	O
occurred	O
in	O
7/51	O
(	O
13.7	O
%	O
)	O
and	O
12/52	O
(	O
23.0	O
%	O
)	O
.	O

Red	O
man	O
syndrome	O
occurred	O
in	O
7/51	O
(	O
13.7	O
%	O
)	O
and	O
5/52	O
(	O
9.6	O
%	O
)	O
in	O
od	O
and	O
bd	O
groups	O
,	O
respectively	O
.	O

The	O
efficacy	O
and	O
safety	O
profile	O
of	O
od	O
administration	O
of	O
vancomycin	Pharmacological
is	O
similar	O
to	O
that	O
of	O
the	O
customary	O
,	O
but	O
less	O
convenient	O
,	O
bd	O
administration	O
.	O

A	O
comparison	O
of	O
a	O
non-ionic	Pharmacological
dimer	Pharmacological
,	O
iodixanol	Pharmacological
with	O
a	Pharmacological
non-ionic	Pharmacological
monomer	Pharmacological
,	Pharmacological
iohexol	Pharmacological
in	O
low	O
dose	O
intravenous	O
urography	O
.	O

A	O
prospective	O
,	O
double-blind	O
study	O
of	O
392	O
patients	O
randomized	O
into	O
four	O
groups	O
was	O
performed	O
to	O
establish	O
whether	O
diagnostic	O
intravenous	O
urograms	O
could	O
be	O
obtained	O
with	O
a	O
lower	O
dose	O
of	O
iodine	O
when	O
using	O
the	O
dimeric	O
,	O
non-ionic	Pharmacological
contrast	Pharmacological
medium	Pharmacological
iodixanol	Pharmacological
compared	O
with	O
the	O
monomeric	Pharmacological
,	Pharmacological
non-ionic	Pharmacological
iohexol	Pharmacological
.	O

Patients	O
received	O
iodixanol	Pharmacological
or	Pharmacological
iohexol	Pharmacological
containing	O
either	O
9	O
or	O
12	O
g	O
of	O
iodine	Pharmacological
(	O
gI	O
)	O
.	O

The	O
primary	O
parameter	O
was	O
the	O
diagnostic	O
quality	O
of	O
the	O
6	O
min	O
film	O
,	O
assessed	O
in	O
a	O
blinded	O
fashion	O
,	O
by	O
consensus	O
,	O
by	O
four	O
radiologists	O
.	O

Iodixanol	Pharmacological
at	O
both	O
doses	O
was	O
diagnostic	O
in	O
over	O
90	O
%	O
of	O
cases	O
.	O

Iohexol	Pharmacological
was	O
only	O
diagnostic	O
in	O
74	O
%	O
(	O
9	O
gI	O
)	O
and	O
81.8	O
%	O
(	O
12	O
gI	O
)	O
.	O

Pairwise	O
comparisons	O
revealed	O
that	O
iodixanol	O
9	O
gI	O
was	O
significantly	O
better	O
than	O
both	O
iohexol	Pharmacological
9	O
gI	O
(	O
p	O
=	O
0.0005	O
)	O
and	O
12	O
gI	O
(	O
p	O
=	O
0.014	O
)	O
.	O

No	O
significant	O
difference	O
was	O
present	O
for	O
different	O
doses	O
within	O
the	O
same	O
contrast	O
medium	O
group	O
.	O

Iodixanol	Pharmacological
resulted	O
in	O
poorer	O
bladder	O
distension	O
than	O
iohexol	Pharmacological
.	Pharmacological

Iodixanol	Pharmacological
caused	O
significantly	O
less	O
discomfort	O
than	O
iohexol	Pharmacological
.	Pharmacological

Effectiveness	O
of	O
sensory	Surgical
integration	Surgical
interventions	Surgical
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
:	O
a	O
pilot	O
study	O
.	O

The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
establish	O
a	O
model	O
for	O
randomized	O
controlled	O
trial	O
research	O
,	O
identify	O
appropriate	O
outcome	O
measures	O
,	O
and	O
address	O
the	O
effectiveness	O
of	O
sensory	Surgical
integration	Surgical
(	Surgical
SI	Surgical
)	Surgical
interventions	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
.	O

Children	O
ages	O
6-12	O
with	O
ASD	O
were	O
randomly	O
assigned	O
to	O
a	O
fine	Surgical
motor	Surgical
or	O
SI	Physical
treatment	Physical
group	O
.	O

Pretests	O
and	O
posttests	O
measured	O
social	O
responsiveness	O
,	O
sensory	O
processing	O
,	O
functional	O
motor	O
skills	O
,	O
and	O
social-emotional	O
factors	O
.	O

Results	O
identified	O
significant	O
positive	O
changes	O
in	O
Goal	O
Attainment	O
Scaling	O
scores	O
for	O
both	O
groups	O
;	O
more	O
significant	O
changes	O
occurred	O
in	O
the	O
SI	O
group	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
autistic	O
mannerisms	O
occurred	O
in	O
the	O
SI	O
group	O
.	O

No	O
other	O
results	O
were	O
significant	O
.	O

The	O
study	O
discusses	O
considerations	O
for	O
designing	O
future	O
outcome	O
studies	O
for	O
children	O
with	O
ASD	O
.	O

Multiple	O
doses	O
of	O
secretin	Pharmacological
in	O
the	O
treatment	O
of	O
autism	O
:	O
a	O
controlled	O
study	O
.	O

UNLABELLED	O
Dramatic	O
effects	O
on	O
autistic	O
behaviour	O
after	O
repeated	O
injections	O
of	O
the	O
gastrointestinal	O
hormone	O
secretin	Pharmacological
have	O
been	O
referred	O
in	O
a	O
number	O
of	O
case	O
reports	O
.	O

In	O
the	O
absence	O
of	O
curative	O
and	O
effective	O
treatments	O
for	O
this	O
disabling	O
condition	O
,	O
this	O
information	O
has	O
created	O
new	O
hope	O
among	O
parents	O
.	O

Although	O
controlled	O
studies	O
on	O
the	O
effect	O
of	O
mainly	O
one	O
single	O
dose	O
have	O
not	O
documented	O
any	O
effect	O
,	O
many	O
children	O
still	O
continue	O
to	O
receive	O
secretin	Pharmacological
.	O

Six	O
children	O
enrolled	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
in	O
which	O
each	O
child	O
was	O
its	O
own	O
control	O
.	O

Human	Pharmacological
synthetic	Pharmacological
secretin	Pharmacological
,	O
mean	O
dose	O
3.4	O
clinical	O
units	O
,	O
and	O
placebo	Control
were	O
administered	O
intravenously	O
in	O
randomized	O
order	O
every	O
4th	O
wk	O
,	O
on	O
three	O
occasions	O
each	O
.	O

The	O
measurement	O
instruments	O
were	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
the	O
aberrant	O
behaviour	O
checklist	O
(	O
ABC	O
)	O
.	O

Statistically	O
significant	O
differences	O
were	O
found	O
for	O
placebo	O
in	O
3	O
out	O
of	O
6	O
children	O
and	O
for	O
secretin	Pharmacological
in	O
one	O
child	O
,	O
using	O
parental	O
ratings	O
only	O
(	O
VAS	O
scores	O
)	O
.	O

Differences	O
were	O
small	O
and	O
lacked	O
clinical	O
significance	O
,	O
which	O
was	O
in	O
accordance	O
with	O
the	O
overall	O
impression	O
of	O
the	O
parents	O
and	O
teachers	O
and	O
visual	O
inspection	O
of	O
graphs	O
.	O

CONCLUSION	O
In	O
this	O
placebo-controlled	O
study	O
,	O
multiple	O
doses	O
of	O
secretin	O
did	O
not	O
produce	O
any	O
symptomatic	O
improvement	O
.	O

Correlation	O
between	O
in	O
vivo	O
humoral	O
and	O
in	O
vitro	O
cellular	O
immune	O
responses	O
following	O
immunization	O
with	O
hepatitis	Pharmacological
B	Pharmacological
surface	Pharmacological
antigen	Pharmacological
(	Pharmacological
HBsAg	Pharmacological
)	Pharmacological
vaccines	Pharmacological
.	Pharmacological

To	O
study	O
the	O
regulation	O
of	O
the	O
human	O
immune	O
response	O
to	O
hepatitis	Pharmacological
B	Pharmacological
surface	Pharmacological
antigen	Pharmacological
(	Pharmacological
HBsAg	Pharmacological
)	Pharmacological
we	O
have	O
carefully	O
monitored	O
the	O
in	O
vivo	O
humoral	O
and	O
in	O
vitro	O
cellular	O
immune	O
responses	O
to	O
HBsAg	O
in	O
50	O
subjects	O
receiving	O
four	O
doses	O
of	O
hepatitis	Pharmacological
B	Pharmacological
vaccine	Pharmacological
according	O
to	O
a	O
0	O
,	O
1	O
,	O
2	O
,	O
12	O
month	O
vaccination	O
scheme	O
.	O

Twenty-three	O
subjects	O
were	O
given	O
a	O
plasma-derived	Pharmacological
vaccine	Pharmacological
(	Pharmacological
Hevac	Pharmacological
B	Pharmacological
)	Pharmacological
and	O
27	O
received	O
a	O
recombinant	Pharmacological
HBsAg	Pharmacological
vaccine	Pharmacological
(	Pharmacological
yeast-derived	Pharmacological
;	Pharmacological
Engerix-B	Pharmacological
)	Pharmacological
.	Pharmacological

The	O
humoral	O
and	O
cellular	O
immune	O
responses	O
were	O
measured	O
before	O
vaccination	O
(	O
day	O
0	O
)	O
;	O
6	O
days	O
after	O
the	O
second	O
dose	O
(	O
day	O
36	O
)	O
;	O
6	O
days	O
(	O
day	O
66	O
)	O
,	O
2	O
months	O
(	O
day	O
120	O
)	O
and	O
10	O
months	O
(	O
day	O
365	O
)	O
after	O
the	O
third	O
dose	O
and	O
1	O
month	O
after	O
the	O
fourth	O
dose	O
(	O
day	O
395	O
)	O
.	O

Based	O
on	O
the	O
kinetics	O
of	O
the	O
humoral	O
immune	O
responses	O
,	O
the	O
vaccinees	O
could	O
be	O
classified	O
into	O
fast	O
,	O
intermediate	O
and	O
slow/non-responders	O
.	O

Based	O
on	O
the	O
magnitude	O
of	O
the	O
immune	O
response	O
(	O
anti-HBs	O
titre	O
)	O
on	O
day	O
395	O
,	O
the	O
vaccinees	O
could	O
be	O
divided	O
into	O
high	O
(	O
>	O
or	O
=	O
2000	O
U	O
l-1	O
)	O
and	O
low	O
(	O
<	O
or	O
=	O
2000	O
U	O
l-1	O
)	O
responders	O
.	O

A	O
close	O
correlation	O
between	O
the	O
kinetics	O
and	O
the	O
magnitude	O
of	O
the	O
humoral	O
immune	O
response	O
was	O
observed	O
.	O

The	O
in	O
vivo	O
anti-HBs	O
response	O
was	O
measured	O
using	O
commercially	O
available	O
immunoradiometric	O
assays	O
.	O

The	O
in	O
vitro	O
cellular	O
immune	O
response	O
was	O
measured	O
using	O
an	O
HBsAg-specific	O
lymphoproliferation	O
assay	O
.	O

Because	O
of	O
interassay	O
variability	O
the	O
results	O
were	O
considered	O
as	O
dichotomous	O
variables	O
(	O
proliferation	O
versus	O
non-proliferation	O
)	O
for	O
further	O
data	O
analysis	O
.	O

A	O
statistically	O
significant	O
correlation	O
was	O
observed	O
between	O
the	O
kinetics	O
and	O
magnitude	O
of	O
the	O
humoral	O
immune	O
response	O
on	O
the	O
one	O
hand	O
and	O
the	O
in	O
vitro	O
anti-HBs	O
response	O
on	O
the	O
other	O
hand	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Clinical	O
effects	O
of	O
root	O
instrumentation	O
using	O
conventional	O
steel	O
or	O
non-tooth	O
substance	O
removing	O
plastic	O
curettes	O
during	O
supportive	O
periodontal	O
therapy	O
(	O
SPT	O
)	O
.	O

Although	O
root	O
instrumentation	O
has	O
been	O
accepted	O
as	O
the	O
most	O
important	O
cause-related	O
treatment	O
of	O
periodontal	O
diseases	O
,	O
repeated	O
scaling	O
and	O
root	O
planing	O
may	O
over	O
time	O
result	O
in	O
substantive	O
loss	O
of	O
tooth	O
substance	O
and	O
increased	O
sensitivity	O
of	O
the	O
teeth	O
.	O

In	O
an	O
effort	O
to	O
minimize	O
these	O
side	O
effects	O
of	O
therapy	O
,	O
non-root	O
substance	O
removing	O
curettes	O
have	O
been	O
developed	O
.	O

However	O
,	O
the	O
clinical	O
effects	O
of	O
such	O
plastic	O
curettes	O
with	O
regard	O
to	O
the	O
control	O
of	O
the	O
periodontal	O
infection	O
has	O
not	O
yet	O
been	O
established	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
,	O
therefore	O
,	O
to	O
compare	O
the	O
effects	O
of	O
root	O
instrumentation	O
using	O
plastic	Other
curettes	Other
(	O
Universal	O
Perio	O
Soft	O
Scaler	O
,	O
Hawe-Neos	O
Dental	O
,	O
Bioggio	O
,	O
TI	O
,	O
Switzerland	O
)	O
versus	O
conventional	Other
steel	Other
curettes	Other
on	O
the	O
periodontal	O
conditions	O
during	O
supportive	O
periodontal	O
therapy	O
.	O

40	O
subjects	O
participated	O
in	O
this	O
parallel	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
prospective	O
longitudinal	O
clinical	O
study	O
following	O
active	O
peridontal	O
therapy	O
.	O

20	O
subjects	O
served	O
as	O
a	O
control	Control
group	Control
and	O
were	O
treated	O
with	O
conventional	Other
steel	Other
curettes	Other
during	O
a	O
supportive	O
periodontal	O
care	O
visit	O
(	O
SPT	O
)	O
.	O

The	O
other	O
20	O
subjects	O
,	O
the	O
experimental	O
group	O
,	O
were	O
treated	O
using	O
plastic	Other
curettes	Other
during	O
a	O
similar	O
SPT	O
visit	O
.	O

Clinical	O
parameters	O
,	O
such	O
as	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
and	O
probing	O
pocket	O
depth	O
(	O
PPD	O
)	O
,	O
were	O
assessed	O
at	O
baseline	O
and	O
3-6	O
months	O
later	O
at	O
the	O
next	O
regular	O
SPT	O
visit	O
.	O

In	O
addition	O
,	O
the	O
BOP	O
percentage	O
was	O
determined	O
10	O
days	O
following	O
baseline	O
.	O

The	O
results	O
showed	O
that	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
2	O
treatment	O
modalities	O
regarding	O
BOP	O
and	O
PPD	O
at	O
any	O
observation	O
time	O
.	O

Both	O
treatments	O
were	O
effective	O
in	O
reducing	O
the	O
BOP	O
percentage	O
which	O
ranged	O
from	O
17-42	O
%	O
at	O
baseline	O
by	O
about	O
40	O
%	O
after	O
10	O
days	O
(	O
mean	O
BOP	O
baseline	O
:	O
26	O
%	O
,	O
mean	O
BOP	O
after	O
10	O
days	O
:	O
16	O
%	O
)	O
.	O

This	O
clinical	O
study	O
suggests	O
that	O
non-root	Other
substance	Other
removing	Other
curettes	Other
may	O
be	O
valuable	O
instruments	O
for	O
periodontally	O
treated	O
patients	O
during	O
maintenance	O
care	O
,	O
thus	O
minimizing	O
trauma	O
on	O
the	O
hard	O
structures	O
of	O
the	O
teeth	O
.	O

Differential	O
effects	O
of	O
two	O
dihydropyridine	Pharmacological
calcium	Pharmacological
antagonists	Pharmacological
in	O
humans	O
.	O

We	O
studied	O
the	O
effects	O
after	O
single	O
doses	O
of	O
niguldipine	Pharmacological
(	O
0.3	O
,	O
0.6	O
,	O
and	O
0.9	O
mg	O
intravenously	O
;	O
8	O
and	O
16	O
mg	O
orally	O
)	O
and	O
nifedipine	Pharmacological
(	O
2	O
mg	O
intravenously	O
;	O
20	O
mg	O
orally	O
)	O
in	O
healthy	O
male	O
volunteers	O
in	O
randomized	O
placebo-controlled	Control
experiments	O
.	O

Total	O
peripheral	O
resistance	O
(	O
TPR	O
)	O
,	O
heart	O
rate-corrected	O
electromechanical	O
systole	O
(	O
QS2c	O
)	O
,	O
and	O
preejection	O
period	O
(	O
PEPc	O
)	O
were	O
assessed	O
noninvasively	O
.	O

Both	O
drugs	O
induced	O
a	O
similar	O
pronounced	O
decreased	O
in	O
TRP	O
,	O
indicating	O
peripheral	O
vasodilation	O
,	O
followed	O
by	O
increasing	O
heart	O
rate	O
and	O
cardiac	O
output	O
,	O
a	O
decrease	O
in	O
diastolic	O
blood	O
pressure	O
,	O
and	O
a	O
shortening	O
of	O
the	O
PEPc	O
.	O

QS2c	O
was	O
unchanged	O
after	O
niguldipine	O
.	O

The	O
prolongation	O
of	O
QS2c	O
after	O
oral	O
nifedipine	Pharmacological
is	O
suggestive	O
of	O
a	O
negative	O
inotropic	O
effect	O
.	O

We	O
conclude	O
that	O
the	O
vasodilatory	O
effects	O
of	O
dihydropyridines	Pharmacological
may	O
(	O
as	O
for	O
nifedipine	Pharmacological
)	O
or	O
may	O
not	O
(	O
as	O
for	O
niguldipine	Pharmacological
)	O
be	O
associated	O
with	O
changes	O
that	O
are	O
suggestive	O
of	O
negative	O
inotropic	O
effects	O
,	O
and	O
that	O
this	O
difference	O
is	O
detectable	O
by	O
noninvasive	O
methods	O
in	O
healthy	O
subjects	O
.	O

Adjvant	Pharmacological
treatment	Pharmacological
of	O
tongue	O
and	O
floor	O
of	O
the	O
mouth	O
cancers	O
.	O

Since	O
January	O
1974	O
,	O
95	O
patients	O
with	O
anterior	O
tongue	O
and	O
floor	O
of	O
the	O
mouth	O
cancers	O
were	O
included	O
in	O
a	O
randomized	O
trial	O
.	O

After	O
stratification	O
according	O
to	O
staging	O
and	O
initial	O
treatment	O
,	O
one-third	O
of	O
the	O
patients	O
received	O
chemotherapy	Pharmacological
for	Pharmacological
2	Pharmacological
years	Pharmacological
(	Pharmacological
methotrexate	Pharmacological
400	Pharmacological
mg	Pharmacological
followed	Pharmacological
by	Pharmacological
citrovorum	Pharmacological
factor	Pharmacological
100	Pharmacological
mg	Pharmacological
+	Pharmacological
bleomycin	Pharmacological
60	Pharmacological
mg/week	Pharmacological
,	Pharmacological
during	Pharmacological
the	Pharmacological
first	Pharmacological
15	Pharmacological
weeks	Pharmacological
)	Pharmacological
,	O
one-third	Pharmacological
of	Pharmacological
the	Pharmacological
patients	Pharmacological
received	Pharmacological
immunotherapy	Pharmacological
with	Pharmacological
weekly	Pharmacological
C.	Pharmacological
parvum	O
injections	O
during	O
2	O
years	O
,	O
while	O
the	O
remaining	Control
third	Control
did	Control
not	Control
receive	Control
any	Control
treatment	Control
.	O

If	O
adjuvant	O
treatment	O
seems	O
to	O
delay	O
recurrence	O
it	O
did	O
not	O
significantly	O
decrease	O
the	O
recurrence	O
rate	O
.	O

Survival	O
is	O
also	O
not	O
signigicantly	O
modified	O
by	O
adjuvant	Pharmacological
treatment	O
and	O
was	O
better	O
for	O
patients	O
with	O
small	O
tumors	O
.	O

Patients	O
who	O
previously	O
received	O
radiotherapy	Physical
did	O
not	O
benefit	O
from	O
adjuvant	Pharmacological
therapy	Pharmacological
.	O

Desmopressin	Pharmacological
in	O
the	O
treatment	O
of	O
nocturia	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

OBJECTIVES	O
To	O
investigate	O
efficacy	O
,	O
safety	O
,	O
and	O
impact	O
on	O
quality	O
of	O
sleep	O
of	O
desmopressin	Pharmacological
in	O
the	O
treatment	O
of	O
nocturia	O
.	O

METHODS	O
Adults	O
aged	O
>	O
or	O
=18	O
yr	O
with	O
nocturia	O
(	O
>	O
or	O
=2	O
voids/night	O
)	O
received	O
desmopressin	Pharmacological
tablets	O
(	O
0.1	O
,	O
0.2	O
,	O
or	O
0.4	O
mg	O
)	O
during	O
a	O
3-wk	O
dose-titration	O
period	O
.	O

Patients	O
should	O
show	O
sufficient	O
response	O
during	O
the	O
dose-titration	O
period	O
(	O
>	O
or	O
=20	O
%	O
reduction	O
in	O
nocturnal	O
diuresis	O
)	O
and	O
a	O
return	O
of	O
nocturnal	O
diuresis	O
to	O
>	O
or	O
=80	O
%	O
of	O
baseline	O
levels	O
during	O
washout	O
.	O

Eligible	O
patients	O
then	O
entered	O
a	O
3-wk	O
double-blind	O
treatment	O
period	O
and	O
received	O
either	O
desmopressin	Pharmacological
or	O
placebo	Control
.	O

RESULTS	O
127	O
patients	O
were	O
randomised	O
to	O
either	O
desmopressin	Pharmacological
(	O
n=61	O
)	O
or	O
placebo	Pharmacological
(	O
n=66	O
)	O
.	O

Twenty	O
(	O
33	O
%	O
)	O
desmopressin-treated	Control
patients	O
compared	O
with	O
seven	O
(	O
11	O
%	O
)	O
placebo-treated	Control
patients	O
showed	O
a	O
clinical	O
response	O
,	O
defined	O
as	O
a	O
>	O
or	O
=50	O
%	O
reduction	O
in	O
the	O
number	O
of	O
nocturnal	O
voids	O
compared	O
with	O
baseline	O
(	O
p=0.0014	O
)	O
.	O

Compared	O
with	O
placebo	O
,	O
desmopressin	Pharmacological
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
mean	O
number	O
of	O
nocturnal	O
voids	O
(	O
39	O
%	O
reduction	O
with	O
desmopressin	Pharmacological
vs.	O
15	O
%	O
with	O
placebo	Pharmacological
;	O
absolute	O
difference	O
-0.84	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
duration	O
of	O
the	O
first	O
sleep	O
period	O
(	O
prolonged	O
by	O
108	O
min	O
with	O
desmopressin	Pharmacological
vs.	O
41	O
min	O
with	O
placebo	Pharmacological
;	O
p	O
<	O
0.0001	O
)	O
.	O

Quality	O
of	O
sleep	O
was	O
also	O
improved	O
with	O
desmopressin	Pharmacological
versus	O
placebo	Pharmacological
(	O
statistically	O
significant	O
for	O
one	O
of	O
the	O
two	O
parameters	O
evaluated	O
)	O
.	O

Adverse	O
events	O
were	O
mainly	O
mild	O
.	O

CONCLUSIONS	O
Oral	O
desmopressin	Pharmacological
tablets	O
provide	O
an	O
effective	O
and	O
well-tolerated	O
treatment	O
for	O
nocturia	O
.	O

Compared	O
with	O
placebo	Pharmacological
,	O
nocturnal	O
voiding	O
frequency	O
is	O
reduced	O
,	O
duration	O
of	O
the	O
first	O
sleep	O
period	O
is	O
increased	O
,	O
and	O
sleep	O
quality	O
may	O
be	O
improved	O
.	O

A	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
comparing	O
standard	Educational
wound	Educational
care	Educational
with	O
adjunctive	Physical
hyperbaric	Physical
oxygen	Physical
therapy	Physical
(	Physical
HBOT	Physical
)	Physical
to	O
standard	O
wound	O
care	O
only	O
for	O
the	O
treatment	O
of	O
chronic	O
,	O
non-healing	O
ulcers	O
of	O
the	O
lower	O
limb	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
:	O
a	O
study	O
protocol	O
.	O

BACKGROUND	O
It	O
has	O
been	O
suggested	O
that	O
the	O
use	O
of	O
adjunctive	Physical
hyperbaric	Physical
oxygen	Physical
therapy	Physical
improves	O
the	O
healing	O
of	O
diabetic	O
foot	O
ulcers	O
,	O
and	O
decreases	O
the	O
risk	O
of	O
lower	O
extremity	O
amputations	O
.	O

A	O
limited	O
number	O
of	O
studies	O
have	O
used	O
a	O
double	O
blind	O
approach	O
to	O
evaluate	O
the	O
efficacy	O
of	O
hyperbaric	Physical
oxygen	Physical
therapy	Physical
in	O
the	O
treatment	O
of	O
diabetic	O
ulcers	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
efficacy	O
of	O
hyperbaric	Physical
oxygen	Physical
therapy	Physical
plus	Physical
standard	Physical
wound	Physical
care	Physical
compared	O
with	O
standard	Physical
wound	Physical
care	Physical
alone	O
in	O
preventing	O
the	O
need	O
for	O
major	O
amputation	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
chronic	O
ulcers	O
of	O
the	O
lower	O
limb	O
.	O

METHODS/DESIGN	O
One	O
hundred	O
and	O
eighteen	O
(	O
59	O
patients	O
per	O
arm	O
)	O
patients	O
with	O
non-healing	O
diabetic	O
ulcers	O
of	O
the	O
lower	O
limb	O
,	O
referred	O
to	O
the	O
Judy	O
Dan	O
Research	O
and	O
Treatment	O
Centre	O
are	O
being	O
recruited	O
if	O
they	O
are	O
at	O
least	O
18	O
years	O
of	O
age	O
,	O
have	O
either	O
Type	O
1	O
or	O
2	O
diabetes	O
with	O
a	O
Wagner	O
grading	O
of	O
foot	O
lesions	O
2	O
,	O
3	O
or	O
4	O
on	O
lower	O
limb	O
not	O
healing	O
for	O
at	O
least	O
4	O
weeks	O
.	O

Patients	O
receive	O
hyperbaric	Physical
oxygen	Physical
therapy	Physical
every	O
day	O
for	O
6	O
weeks	O
during	O
the	O
treatment	O
phase	O
and	O
are	O
provided	O
ongoing	Educational
wound	Educational
care	Educational
and	O
weekly	O
assessments	O
.	O

Patients	O
are	O
required	O
to	O
return	O
to	O
the	O
study	O
centre	O
every	O
week	O
for	O
an	O
additional	O
6	O
weeks	O
of	O
follow-up	O
for	O
wound	O
evaluation	O
and	O
management	O
.	O

The	O
primary	O
outcome	O
is	O
freedom	O
from	O
having	O
,	O
or	O
meeting	O
the	O
criteria	O
for	O
,	O
a	O
major	O
amputation	O
(	O
below	O
knee	O
amputation	O
,	O
or	O
metatarsal	O
level	O
)	O
up	O
to	O
12	O
weeks	O
after	O
randomization	O
.	O

The	O
decision	O
to	O
amputate	O
is	O
made	O
by	O
a	O
vascular	O
surgeon	O
.	O

Other	O
outcomes	O
include	O
wound	O
healing	O
,	O
effectiveness	O
,	O
safety	O
,	O
healthcare	O
resource	O
utilization	O
,	O
quality	O
of	O
life	O
,	O
and	O
cost-effectiveness	O
.	O

The	O
study	O
will	O
run	O
for	O
a	O
total	O
of	O
about	O
3	O
years	O
.	O

DISCUSSION	O
The	O
results	O
of	O
this	O
study	O
will	O
provide	O
detailed	O
information	O
on	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
for	O
the	O
treatment	O
of	O
non-healing	O
ulcers	O
of	O
the	O
lower	O
limb	O
.	O

This	O
will	O
be	O
the	O
first	O
double-blind	O
randomized	O
controlled	O
trial	O
for	O
this	O
health	O
technology	O
which	O
evaluates	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
in	O
prevention	O
of	O
amputations	O
in	O
diabetic	O
patients	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00621608	O
.	O

Allelic	O
imbalance	O
in	O
the	O
clonal	O
evolution	O
of	O
prostate	O
carcinoma	O
.	O

BACKGROUND	O
To	O
understand	O
better	O
the	O
genetic	O
basis	O
of	O
the	O
clonal	O
evolution	O
of	O
prostate	O
carcinoma	O
,	O
the	O
authors	O
analyzed	O
the	O
pattern	O
of	O
allelic	O
loss	O
in	O
25	O
matched	O
primary	O
and	O
metastatic	O
prostate	O
tumors	O
.	O

METHODS	O
Twenty-five	O
cases	O
were	O
selected	O
from	O
the	O
surgical	O
pathology	O
files	O
of	O
the	O
Mayo	O
Clinic	O
from	O
patients	O
who	O
had	O
undergone	O
radical	Surgical
retropubic	Surgical
prostatectomy	Surgical
and	O
bilateral	Surgical
lymphadenectomy	Surgical
between	O
1987-1991	O
.	O

All	O
patients	O
had	O
regional	O
lymph	O
node	O
metastases	O
at	O
the	O
time	O
of	O
surgery	O
.	O

DNA	O
samples	O
for	O
the	O
analysis	O
of	O
allelic	O
loss	O
pattern	O
were	O
prepared	O
from	O
primary	O
tumors	O
and	O
matched	O
synchronous	O
lymph	O
node	O
metastases	O
by	O
tissue	O
microdissection	O
.	O

The	O
oligonucleotide	O
primer	O
pairs	O
for	O
the	O
microsatellite	O
DNA	O
markers	O
were	O
D8S133	O
,	O
D8S136	O
,	O
D8S137	O
,	O
ANK1	O
on	O
chromosome	O
8p12-21	O
,	O
LPLTET	O
on	O
chromosome	O
8p22	O
,	O
and	O
D17S855	O
(	O
intragenic	O
to	O
the	O
BRCA1	O
gene	O
)	O
on	O
chromosome	O
17q21	O
.	O

One	O
case	O
was	O
not	O
informative	O
at	O
any	O
of	O
the	O
loci	O
tested	O
and	O
was	O
excluded	O
from	O
further	O
analysis	O
.	O

RESULTS	O
The	O
overall	O
frequency	O
of	O
allelic	O
imbalance	O
was	O
79	O
%	O
in	O
primary	O
tumors	O
and	O
88	O
%	O
in	O
paired	O
metastases	O
.	O

Of	O
24	O
informative	O
cases	O
,	O
14	O
patients	O
(	O
58	O
%	O
)	O
showed	O
the	O
same	O
pattern	O
of	O
allelic	O
loss	O
or	O
retention	O
in	O
matched	O
primary	O
and	O
metastatic	O
tumors	O
at	O
all	O
marker	O
locus	O
;	O
discordant	O
allelic	O
loss	O
was	O
observed	O
in	O
the	O
remaining	O
10	O
patients	O
(	O
42	O
%	O
)	O
.	O

Four	O
patients	O
showed	O
loss	O
of	O
the	O
same	O
allele	O
at	O
one	O
or	O
more	O
marker	O
loci	O
in	O
both	O
primary	O
and	O
metastatic	O
tumors	O
,	O
but	O
discordant	O
allelic	O
loss	O
was	O
observed	O
at	O
other	O
marker	O
loci	O
.	O

Five	O
patients	O
showed	O
allelic	O
loss	O
in	O
at	O
least	O
one	O
genetic	O
marker	O
in	O
the	O
metastatic	O
tumor	O
but	O
not	O
in	O
its	O
matched	O
primary	O
tumor	O
.	O

Five	O
patients	O
displayed	O
loss	O
of	O
one	O
allele	O
at	O
one	O
or	O
more	O
marker	O
loci	O
in	O
a	O
primary	O
tumor	O
but	O
not	O
in	O
the	O
matched	O
metastases	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
allelic	O
imbalance	O
between	O
primary	O
and	O
metastatic	O
tumors	O
at	O
any	O
marker	O
analyzed	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSIONS	O
These	O
data	O
suggest	O
that	O
different	O
patterns	O
of	O
allelic	O
deletion	O
may	O
be	O
acquired	O
during	O
cancer	O
progression	O
to	O
metastases	O
.	O

The	O
differences	O
in	O
genetic	O
composition	O
between	O
primary	O
prostate	O
carcinoma	O
and	O
its	O
metastases	O
may	O
be	O
related	O
to	O
intrinsic	O
cancer	O
heterogeneity	O
,	O
overall	O
genetic	O
instability	O
,	O
and	O
clonal	O
divergence	O
.	O

Activator	Pharmacological
protein-1	Pharmacological
(	Pharmacological
AP-1	Pharmacological
)	Pharmacological
signalling	O
in	O
human	O
atherosclerosis	O
:	O
results	O
of	O
a	O
systematic	O
evaluation	O
and	O
intervention	O
study	O
.	O

Animal	O
studies	O
implicate	O
the	O
AP-1	Pharmacological
(	Pharmacological
activator	Pharmacological
protein-1	Pharmacological
)	Pharmacological
pro-inflammatory	O
pathway	O
as	O
a	O
promising	O
target	O
in	O
the	O
treatment	O
of	O
atherosclerotic	O
disease	O
.	O

It	O
is	O
,	O
however	O
,	O
unclear	O
whether	O
these	O
observations	O
apply	O
to	O
human	O
atherosclerosis	O
.	O

Therefore	O
we	O
evaluated	O
the	O
profile	O
of	O
AP-1	Pharmacological
activation	Pharmacological
through	O
histological	O
analysis	O
and	O
tested	O
the	O
potential	O
benefit	O
of	O
AP-1	Pharmacological
inhibition	Pharmacological
in	O
a	O
clinical	O
trial	O
.	O

AP-1	Pharmacological
activation	Pharmacological
was	O
quantified	O
by	O
phospho-c-Jun	O
nuclear	O
translocation	O
(	O
immunohistochemistry	O
)	O
on	O
a	O
biobank	O
of	O
aortic	O
wall	O
samples	O
from	O
organ	O
donors	O
.	O

The	O
effect	O
of	O
AP-1	Pharmacological
inhibition	Pharmacological
on	O
vascular	O
parameters	O
was	O
tested	O
through	O
a	O
double	O
blind	O
placebo-controlled	O
cross-over	O
study	O
of	O
28	O
days	O
doxycycline	O
or	O
placebo	O
in	O
patients	O
with	O
symptomatic	O
peripheral	O
artery	O
disease	O
.	O

Vascular	O
function	O
was	O
assessed	O
by	O
brachial	O
dilation	O
as	O
well	O
as	O
by	O
plasma	O
samples	O
analysed	O
for	O
hs-CRP	O
(	O
high-sensitivity	O
C-reactive	O
protein	O
)	O
,	O
IL-6	O
(	O
interleukin-6	O
)	O
,	O
IL-8	O
,	O
ICAM-1	O
(	O
intercellular	O
adhesion	O
molecule-1	O
)	O
,	O
vWF	O
(	O
von	O
Willebrand	O
factor	O
)	O
,	O
MCP-1	O
(	O
monocyte	O
chemoattractant	O
protein-1	O
)	O
,	O
PAI-1	O
(	O
plasminogen	O
activator	O
inhibitor-1	O
)	O
and	O
fibrinogen	O
.	O

Histological	O
evaluation	O
of	O
human	O
atherosclerosis	O
showed	O
minimal	O
AP-1	O
activation	O
in	O
non-diseased	O
arterial	O
wall	O
(	O
i.e	O
.	O

vessel	O
wall	O
without	O
any	O
signs	O
of	O
atherosclerotic	O
disease	O
)	O
.	O

A	O
gradual	O
increase	O
of	O
AP-1	O
activation	O
was	O
found	O
in	O
non-progressive	O
and	O
progressive	O
phases	O
of	O
atherosclerosis	O
respectively	O
(	O
P	O
<	O
0.044	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
progressive	O
and	O
vulnerable	O
lesions	O
.	O

The	O
expression	O
of	O
phospho-c-Jun	O
diminished	O
as	O
the	O
lesion	O
stabilized	O
(	O
P	O
<	O
0.016	O
)	O
and	O
does	O
not	O
significantly	O
differ	O
from	O
the	O
normal	O
aortic	O
wall	O
(	O
P	O
<	O
0.33	O
)	O
.	O

Evaluation	O
of	O
the	O
doxycycline	O
intervention	O
only	O
revealed	O
a	O
borderline-significant	O
reduction	O
of	O
circulating	O
hs-CRP	O
levels	O
(	O
-0.51	O
?g/ml	O
,	O
P=0.05	O
)	O
and	O
did	O
not	O
affect	O
any	O
of	O
the	O
other	O
markers	O
of	O
systemic	O
inflammation	O
and	O
vascular	O
function	O
.	O

Our	O
studies	O
do	O
not	O
characterize	O
AP-1	O
as	O
a	O
therapeutic	O
target	O
for	O
progressive	O
human	O
atherosclerotic	O
disease	O
.	O

Sedation	O
depth	O
during	O
spinal	Pharmacological
anesthesia	Pharmacological
and	O
survival	O
in	O
elderly	O
patients	O
undergoing	O
hip	O
fracture	O
repair	O
.	O

Low	O
intraoperative	O
Bispectral	O
Index	O
(	O
BIS	O
)	O
values	O
may	O
be	O
associated	O
with	O
increased	O
mortality	O
.	O

In	O
a	O
previously	O
reported	O
trial	O
to	O
prevent	O
delirium	O
,	O
we	O
randomized	O
patients	O
undergoing	O
hip	O
fracture	O
repair	O
under	O
spinal	Pharmacological
anesthesia	Pharmacological
to	O
light	Pharmacological
(	Pharmacological
BIS	Pharmacological
>	Pharmacological
80	Pharmacological
)	Pharmacological
or	O
deep	Pharmacological
(	Pharmacological
BIS	Pharmacological
approximately	Pharmacological
50	Pharmacological
)	Pharmacological
sedation	O
.	O

We	O
analyzed	O
survival	O
of	O
patients	O
in	O
the	O
original	O
trial	O
.	O

Among	O
all	O
patients	O
,	O
mortality	O
was	O
equivalent	O
across	O
sedation	O
groups	O
.	O

However	O
,	O
among	O
patients	O
with	O
serious	O
comorbidities	O
(	O
Charlson	O
score	O
>	O
4	O
)	O
,	O
1-year	O
mortality	O
was	O
reduced	O
in	O
the	O
light	Other
(	O
22.2	O
%	O
)	O
vs	O
deep	Other
(	O
43.6	O
%	O
)	O
sedation	Pharmacological
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.43	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.19-0.97	O
;	O
P	O
=	O
0.04	O
)	O
during	O
spinal	O
anesthesia	O
.	O

Similarly	O
,	O
among	O
patients	O
with	O
Charlson	O
score	O
>	O
6	O
,	O
1-year	O
mortality	O
was	O
reduced	O
in	O
the	O
light	Pharmacological
(	O
28.6	O
%	O
)	O
vs	O
deep	Pharmacological
(	O
52.6	O
%	O
)	O
sedation	Pharmacological
group	O
(	O
HR	O
0.33	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.12-0.94	O
;	O
P	O
=	O
0.04	O
)	O
during	O
spinal	Pharmacological
anesthesia	Pharmacological
.	O

Further	O
research	O
on	O
reduced	O
mortality	O
after	O
light	Pharmacological
sedation	Pharmacological
during	O
spinal	Pharmacological
anesthesia	Pharmacological
is	O
needed	O
.	O

Superior	O
survival	O
with	O
capecitabine	Pharmacological
plus	O
docetaxel	Pharmacological
combination	Pharmacological
therapy	Pharmacological
in	O
anthracycline-pretreated	O
patients	O
with	O
advanced	O
breast	O
cancer	O
:	O
phase	O
III	O
trial	O
results	O
.	O

PURPOSE	O
Docetaxel	Pharmacological
and	O
capecitabine	Pharmacological
,	O
a	O
tumor-activated	O
oral	O
fluoropyrimidine	O
,	O
show	O
high	O
single-agent	O
efficacy	O
in	O
metastatic	O
breast	O
cancer	O
(	O
MBC	O
)	O
and	O
synergy	O
in	O
preclinical	O
studies	O
.	O

This	O
international	O
phase	O
III	O
trial	O
compared	O
efficacy	O
and	O
tolerability	O
of	O
capecitabine/docetaxel	Pharmacological
therapy	Pharmacological
with	O
single-agent	Pharmacological
docetaxel	Pharmacological
in	O
anthracycline-pretreated	O
patients	O
with	O
MBC	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
were	O
randomized	O
to	O
21-day	O
cycles	O
of	O
oral	O
capecitabine	Pharmacological
1,250	O
mg/m	O
(	O
2	O
)	O
twice	O
daily	O
on	O
days	O
1	O
to	O
14	O
plus	O
docetaxel	Pharmacological
75	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
255	O
)	O
or	O
to	O
docetaxel	Pharmacological
100	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
256	O
)	O
.	O

RESULTS	O
Capecitabine/docetaxel	Pharmacological
resulted	O
in	O
significantly	O
superior	O
efficacy	O
in	O
time	O
to	O
disease	O
progression	O
(	O
TTP	O
)	O
(	O
hazard	O
ratio	O
,	O
0.652	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.545	O
to	O
0.780	O
;	O
P	O
=.0001	O
;	O
median	O
,	O
6.1	O
v	O
4.2	O
months	O
)	O
,	O
overall	O
survival	O
(	O
hazard	O
ratio	O
,	O
0.775	O
;	O
95	O
%	O
CI	O
,	O
0.634	O
to	O
0.947	O
;	O
P	O
=.0126	O
;	O
median	O
,	O
14.5	O
v	O
11.5	O
months	O
)	O
,	O
and	O
objective	O
tumor	O
response	O
rate	O
(	O
42	O
%	O
v	O
30	O
%	O
,	O
P	O
=.006	O
)	O
compared	O
with	O
docetaxel	Pharmacological
.	O

Gastrointestinal	O
side	O
effects	O
and	O
hand-foot	O
syndrome	O
were	O
more	O
common	O
with	O
combination	Pharmacological
therapy	Pharmacological
,	O
whereas	O
myalgia	O
,	O
arthralgia	O
,	O
and	O
neutropenic	O
fever/sepsis	O
were	O
more	O
common	O
with	O
single-agent	Pharmacological
docetaxel	Pharmacological
.	O

More	O
grade	O
3	O
adverse	O
events	O
occurred	O
with	O
combination	O
therapy	O
(	O
71	O
%	O
v	O
49	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
grade	O
4	O
events	O
were	O
slightly	O
more	O
common	O
with	O
docetaxel	Pharmacological
(	O
31	O
%	O
v	O
25	O
%	O
with	O
combination	O
)	O
.	O

CONCLUSION	O
The	O
significantly	O
superior	O
TTP	O
and	O
survival	O
achieved	O
with	O
the	O
addition	Pharmacological
of	Pharmacological
capecitabine	Pharmacological
to	Pharmacological
docetaxel	Pharmacological
75	O
mg/m	O
(	O
2	O
)	O
,	O
with	O
the	O
manageable	O
toxicity	O
profile	O
,	O
indicate	O
that	O
this	O
combination	O
provides	O
clear	O
benefits	O
over	O
single-agent	Pharmacological
docetaxel	Pharmacological
100	O
mg/m	O
(	O
2	O
)	O
.	O

Docetaxel/capecitabine	Pharmacological
therapy	Pharmacological
is	O
an	O
important	O
treatment	O
option	O
for	O
women	O
with	O
anthracycline-pretreated	O
MBC	O
.	O

Antihypertensive	O
efficacy	O
of	O
cetamolol	Pharmacological
:	O
a	O
dose-titrated	O
study	O
.	O

This	O
double-blind	O
,	O
placebo-controlled	Control
,	O
randomized	O
multicenter	O
study	O
evaluated	O
the	O
antihypertensive	O
efficacy	O
and	O
safety	O
of	O
cetamolol	Pharmacological
hydrochloride	Pharmacological
in	O
108	O
patients	O
diagnosed	O
as	O
having	O
mild	O
to	O
moderate	O
hypertension	O
.	O

After	O
a	O
placebo	Control
lead-in	O
period	O
,	O
patients	O
received	O
either	O
cetamolol	Pharmacological
5-10-15	O
mg/d	O
(	O
low	O
dose	O
)	O
,	O
cetamolol	Pharmacological
15-25-50	Pharmacological
mg/d	Pharmacological
(	O
high	O
dose	O
)	O
,	O
or	O
placebo	Control
,	O
once	O
daily	O
for	O
four	O
weeks	O
.	O

Patients	O
began	O
at	O
the	O
lowest	O
dose	O
and	O
were	O
titrated	O
to	O
higher	O
doses	O
based	O
on	O
the	O
first	O
two	O
assessments	O
of	O
diastolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
,	O
which	O
were	O
conducted	O
each	O
week	O
after	O
double-blind	O
treatment	O
was	O
dispensed	O
.	O

After	O
four	O
weeks	O
of	O
treatment	O
82.4	O
%	O
,	O
81.3	O
%	O
,	O
and	O
93.3	O
%	O
of	O
the	O
low-dose	Pharmacological
group	O
,	O
high-dose	Pharmacological
group	O
,	O
and	O
placebo	Control
group	O
,	O
respectively	O
,	O
were	O
titrated	O
to	O
the	O
maximum	O
dose	O
level	O
.	O

After	O
four	O
weeks	O
of	O
treatment	O
and	O
24	O
hours	O
since	O
the	O
patient	O
's	O
last	O
dose	O
,	O
both	O
cetamolol	Pharmacological
groups	O
showed	O
a	O
significantly	O
greater	O
(	O
P	O
less	O
than	O
or	O
equal	O
to	O
.05	O
)	O
reduction	O
in	O
supine	O
systolic/diastolic	O
blood	O
pressure	O
(	O
-18.1	O
+/-	O
2.3/-9.2	O
+/-	O
1.5	O
mm	O
Hg	O
[	O
low	O
dose	O
]	O
and	O
-17.3	O
+/-	O
2.3/-8.3	O
+/-	O
1.6	O
mm	O
Hg	O
[	O
high	O
dose	O
]	O
)	O
than	O
the	O
placebo	O
group	O
(	O
-9.9	O
+/-	O
2.5/-3.5	O
+/-	O
1.7	O
mm	O
Hg	O
)	O
.	O

In	O
general	O
,	O
the	O
changes	O
in	O
standing	O
(	O
stabilized	O
)	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
were	O
similar	O
to	O
those	O
seen	O
in	O
supine	O
measurements	O
.	O

Significantly	O
more	O
patients	O
receiving	O
cetamolol	O
than	O
those	O
receiving	O
placebo	O
showed	O
a	O
good	O
response	O
(	O
a	O
decrease	O
in	O
diastolic	O
blood	O
pressure	O
of	O
10	O
mm	O
Hg	O
or	O
more	O
or	O
measuring	O
less	O
than	O
90	O
mm	O
Hg	O
with	O
a	O
decrease	O
of	O
at	O
least	O
4	O
mm	O
Hg	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Developing	O
the	O
Ho'ouna	Educational
Pono	Educational
substance	Educational
use	Educational
prevention	Educational
curriculum	Educational
:	O
collaborating	O
with	O
Hawaiian	O
youth	O
and	O
communities	O
.	O

This	O
article	O
briefly	O
outlines	O
a	O
collaboration	O
among	O
communities	O
on	O
Hawai'i	O
Island	O
and	O
a	O
university-based	O
research	O
team	O
to	O
develop	O
,	O
implement	O
,	O
and	O
evaluate	O
a	O
school-based	Educational
substance	Educational
use	Educational
prevention	Educational
curriculum	Educational
called	Educational
Ho'ouna	Educational
Pono	Educational
.	O

In	O
addition	O
to	O
providing	O
a	O
rationale	O
for	O
the	O
project	O
,	O
the	O
goal	O
of	O
this	O
paper	O
is	O
fourfold	O
.	O

First	O
,	O
an	O
overview	O
of	O
the	O
Ho'ouna	Educational
Pono	Educational
research	O
results	O
to	O
date	O
(	O
2007-2013	O
)	O
is	O
provided	O
.	O

Second	O
,	O
within	O
this	O
overview	O
,	O
the	O
ways	O
in	O
which	O
selected	O
results	O
informed	O
program	O
development	O
are	O
highlighted	O
.	O

Third	O
,	O
the	O
curriculum	O
is	O
briefly	O
described	O
,	O
and	O
finally	O
,	O
the	O
role	O
of	O
the	O
students	O
and	O
community	O
in	O
the	O
video	O
production	O
is	O
described	O
.	O

Resource	O
utilization	O
and	O
economic	O
costs	O
of	O
care	O
based	O
on	O
a	O
randomized	O
trial	O
of	O
vacuum-assisted	Physical
closure	Physical
therapy	Physical
in	O
the	O
treatment	O
of	O
diabetic	O
foot	O
wounds	O
.	O

BACKGROUND	O
To	O
evaluate	O
resource	O
utilization	O
and	O
direct	O
economic	O
costs	O
of	O
care	O
for	O
patients	O
treated	O
with	O
negative-pressure	Physical
wound	Physical
therapy	Physical
(	Physical
NPWT	Physical
)	Physical
,	O
using	O
the	Physical
Vacuum-Assisted	Physical
Closure	Physical
(	Physical
V.A.C	Physical
.	Physical

)	Physical
system	Physical
,	O
compared	O
to	O
standard	Physical
moist	Physical
wound	Physical
therapy	Physical
(	Physical
MWT	Physical
)	Physical
.	O

METHODS	O
A	O
total	O
of	O
162	O
diabetic	O
patients	O
with	O
post-amputation	O
wounds	O
(	O
up	O
to	O
the	O
trans-metatarsal	O
level	O
)	O
entered	O
a	O
16-week	O
,	O
randomized	O
clinical	O
trial	O
.	O

Patients	O
randomized	O
to	O
V.A.C	Physical
.	Physical

(	O
n	O
=	O
77	O
)	O
received	O
therapy	Physical
with	Physical
dressing	Physical
changes	Physical
every	O
48	O
hours	O
.	O

Control	O
patients	O
(	O
n	O
=	O
85	O
)	O
received	O
standard	O
MWT	Physical
.	O

Resource	O
utilization	O
,	O
procedures	O
,	O
and	O
direct	O
costs	O
were	O
calculated	O
and	O
analyzed	O
in	O
this	O
post	O
hoc	O
retrospective	O
study	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
between	O
groups	O
for	O
in-patient	O
hospital	O
stay	O
(	O
number	O
of	O
admissions	O
or	O
length	O
of	O
stay	O
)	O
.	O

More	O
surgical	O
procedures	O
(	O
including	O
debridement	O
)	O
were	O
required	O
in	O
the	O
MWT	Physical
group	O
(	O
120	O
vs	O
43	O
NPWT	Physical
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
average	O
number	O
of	O
dressing	O
changes	O
performed	O
per	O
patient	O
was	O
118.0	O
(	O
range	O
12-226	O
)	O
for	O
MWT	Physical
versus	O
41	O
(	O
6-140	O
)	O
for	O
NPWT	Physical
(	O
P	O
=	O
.0001	O
)	O
.	O

The	O
MWT	Physical
group	O
had	O
11	O
(	O
range	O
0-106	O
)	O
outpatient	O
treatment	O
visits	O
during	O
the	O
study	O
versus	O
4	O
(	O
range	O
0-47	O
)	O
in	O
the	O
NPWT	Physical
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
average	O
direct	O
cost	O
per	O
patient	O
treated	O
for	O
8	O
weeks	O
or	O
longer	O
(	O
independent	O
of	O
clinical	O
outcome	O
)	O
was	O
$	O
27,270	O
and	O
$	O
36,096	O
in	O
the	O
NPWT	O
and	O
MWT	O
groups	O
,	O
respectively	O
.	O

The	O
average	O
total	O
cost	O
to	O
achieve	O
healing	O
was	O
$	O
25,954	O
for	O
patients	O
treated	O
with	O
NPWT	Physical
(	O
n	O
=	O
43	O
)	O
compared	O
with	O
$	O
38,806	O
for	O
the	O
MWT	Physical
group	O
(	O
n	O
=	O
33	O
)	O
.	O

CONCLUSION	O
Treatment	O
of	O
diabetic	O
patients	O
with	O
post	O
amputation	O
wounds	O
using	O
NPWT	Physical
resulted	O
in	O
lower	O
resource	O
utilization	O
and	O
a	O
greater	O
proportion	O
of	O
patients	O
obtaining	O
wound	O
healing	O
at	O
a	O
lower	O
overall	O
cost	O
of	O
care	O
when	O
compared	O
to	O
MWT	Physical
.	O

Triple	Pharmacological
antiretroviral	Pharmacological
compared	O
with	O
zidovudine	Pharmacological
and	O
single-dose	O
nevirapine	Pharmacological
prophylaxis	Pharmacological
during	O
pregnancy	O
and	O
breastfeeding	O
for	O
prevention	O
of	O
mother-to-child	O
transmission	O
of	O
HIV-1	O
(	O
Kesho	O
Bora	O
study	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Breastfeeding	O
is	O
essential	O
for	O
child	O
health	O
and	O
development	O
in	O
low-resource	O
settings	O
but	O
carries	O
a	O
significant	O
risk	O
of	O
transmission	O
of	O
HIV-1	O
,	O
especially	O
in	O
late	O
stages	O
of	O
maternal	O
disease	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
triple	O
antiretroviral	O
compared	O
with	O
zidovudine	O
and	O
single-dose	O
nevirapine	O
prophylaxis	O
in	O
pregnant	O
women	O
infected	O
with	O
HIV	O
.	O

METHODS	O
Pregnant	O
women	O
with	O
WHO	O
stage	O
1	O
,	O
2	O
,	O
or	O
3	O
HIV-1	O
infection	O
who	O
had	O
CD4	O
cell	O
counts	O
of	O
200-500	O
cells	O
per	O
?L	O
were	O
enrolled	O
at	O
five	O
study	O
sites	O
in	O
Burkina	O
Faso	O
,	O
Kenya	O
,	O
and	O
South	O
Africa	O
to	O
start	O
study	O
treatment	O
at	O
28-36	O
weeks	O
'	O
gestation	O
.	O

Women	O
were	O
randomly	O
assigned	O
(	O
1:1	O
)	O
by	O
a	O
computer	O
generated	O
random	O
sequence	O
to	O
either	O
triple	O
antiretroviral	O
prophylaxis	O
(	O
a	O
combination	O
of	O
300	O
mg	O
zidovudine	O
,	O
150	O
mg	O
lamivudine	O
,	O
and	O
400	O
mg	O
lopinavir	O
plus	O
100	O
mg	O
ritonavir	O
twice	O
daily	O
until	O
cessation	O
of	O
breastfeeding	O
to	O
a	O
maximum	O
of	O
6?5	O
months	O
post	O
partum	O
)	O
or	O
zidovudine	O
and	O
single-dose	O
nevirapine	O
(	O
300	O
mg	O
zidovudine	O
twice	O
daily	O
until	O
delivery	O
and	O
a	O
dose	O
of	O
600	O
mg	O
zidovudine	O
plus	O
200	O
mg	O
nevirapine	O
at	O
the	O
onset	O
of	O
labour	O
and	O
,	O
after	O
a	O
protocol	O
amendment	O
in	O
December	O
,	O
2006	O
,	O
1	O
week	O
post-partum	O
zidovudine	O
300	O
mg	O
twice	O
daily	O
and	O
lamivudine	O
150	O
mg	O
twice	O
daily	O
)	O
.	O

All	O
infants	O
received	O
a	O
0?6	O
mL	O
dose	O
of	O
nevirapine	O
at	O
birth	O
and	O
,	O
from	O
December	O
,	O
2006	O
,	O
4	O
mg/kg	O
twice	O
daily	O
of	O
zidovudine	O
for	O
1	O
week	O
after	O
birth	O
.	O

Patients	O
and	O
investigators	O
were	O
not	O
masked	O
to	O
treatment	O
.	O

The	O
primary	O
endpoints	O
were	O
HIV-free	O
infant	O
survival	O
at	O
6	O
weeks	O
and	O
12	O
months	O
;	O
HIV-free	O
survival	O
at	O
12	O
months	O
in	O
infants	O
who	O
were	O
ever	O
breastfed	O
;	O
AIDS-free	O
survival	O
in	O
mothers	O
at	O
18	O
months	O
;	O
and	O
serious	O
adverse	O
events	O
in	O
mothers	O
and	O
babies	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
trial	O
is	O
registered	O
with	O
Current	O
Controlled	O
Trials	O
,	O
ISRCTN71468401	O
.	O

FINDINGS	O
From	O
June	O
,	O
2005	O
,	O
to	O
August	O
,	O
2008	O
,	O
882	O
women	O
were	O
enrolled	O
,	O
824	O
of	O
whom	O
were	O
randomised	O
and	O
gave	O
birth	O
to	O
805	O
singleton	O
or	O
first	O
,	O
liveborn	O
infants	O
.	O

The	O
cumulative	O
rate	O
of	O
HIV	O
transmission	O
at	O
6	O
weeks	O
was	O
3?3	O
%	O
(	O
95	O
%	O
CI	O
1?9-5?6	O
%	O
)	O
in	O
the	O
triple	O
antiretroviral	O
group	O
compared	O
with	O
5?0	O
%	O
(	O
3?3-7?7	O
%	O
)	O
in	O
the	O
zidovudine	O
and	O
single-dose	O
nevirapine	O
group	O
,	O
and	O
at	O
12	O
months	O
was	O
5?4	O
%	O
(	O
3?6-8?1	O
%	O
)	O
in	O
the	O
triple	O
antiretroviral	O
group	O
compared	O
with	O
9?5	O
%	O
(	O
7?0-12?9	O
%	O
)	O
in	O
the	O
zidovudine	O
and	O
single-dose	O
nevirapine	O
group	O
(	O
p=0?029	O
)	O
.	O

The	O
cumulative	O
rate	O
of	O
HIV	O
transmission	O
or	O
death	O
at	O
12	O
months	O
was	O
10?2	O
%	O
(	O
95	O
%	O
CI	O
7?6-13?6	O
%	O
)	O
in	O
the	O
triple	O
antiretroviral	O
group	O
compared	O
with	O
16?0	O
%	O
(	O
12?7-20?0	O
%	O
)	O
in	O
the	O
zidovudine	O
and	O
single-dose	O
nevirapine	O
group	O
(	O
p=0?017	O
)	O
.	O

In	O
infants	O
whose	O
mothers	O
declared	O
they	O
intended	O
to	O
breastfeed	O
,	O
the	O
cumulative	O
rate	O
of	O
HIV	O
transmission	O
at	O
12	O
months	O
was	O
5?6	O
%	O
(	O
95	O
%	O
CI	O
3?4-8?9	O
%	O
)	O
in	O
the	O
triple	O
antiretroviral	O
group	O
compared	O
with	O
10?7	O
%	O
(	O
7?6-14?8	O
%	O
)	O
in	O
the	O
zidovudine	O
and	O
single-dose	O
nevirapine	O
group	O
(	O
p=0?02	O
)	O
.	O

AIDS-free	O
survival	O
in	O
mothers	O
at	O
18	O
months	O
will	O
be	O
reported	O
in	O
a	O
different	O
publication	O
.	O

The	O
incidence	O
of	O
laboratory	O
and	O
clinical	O
serious	O
adverse	O
events	O
in	O
both	O
mothers	O
and	O
their	O
babies	O
was	O
similar	O
between	O
groups	O
.	O

INTERPRETATION	O
Triple	O
antiretroviral	O
prophylaxis	O
during	O
pregnancy	O
and	O
breastfeeding	O
is	O
safe	O
and	O
reduces	O
the	O
risk	O
of	O
HIV	O
transmission	O
to	O
infants	O
.	O

Revised	O
WHO	O
guidelines	O
now	O
recommend	O
antiretroviral	O
prophylaxis	O
(	O
either	O
to	O
the	O
mother	O
or	O
to	O
the	O
baby	O
)	O
during	O
breastfeeding	O
if	O
the	O
mother	O
is	O
not	O
already	O
receiving	O
antiretroviral	O
treatment	O
for	O
her	O
own	O
health	O
.	O

FUNDING	O
Agence	O
nationale	O
de	O
recherches	O
sur	O
le	O
sida	O
et	O
les	O
h?patites	O
virales	O
,	O
Department	O
for	O
International	O
Development	O
,	O
European	O
and	O
Developing	O
Countries	O
Clinical	O
Trials	O
Partnership	O
,	O
Thrasher	O
Research	O
Fund	O
,	O
Belgian	O
Directorate	O
General	O
for	O
International	O
Cooperation	O
,	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
Eunice	O
Kennedy	O
Shriver	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
,	O
and	O
UNDP/UNFPA/World	O
Bank/WHO	O
Special	O
Programme	O
of	O
Research	O
,	O
Development	O
and	O
Research	O
Training	O
in	O
Human	O
Reproduction	O
.	O

Feedlot	O
performance	O
and	O
carcass	O
characteristics	O
of	O
Holstein	O
steers	O
as	O
affected	O
by	O
source	O
of	O
dietary	O
protein	O
and	O
level	O
of	O
ruminally	O
protected	O
lysine	O
and	O
methionine	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
source	O
of	O
dietary	O
CP	O
and	O
level	O
of	O
ruminally	O
protected	O
lysine	O
and	O
methionine	O
(	O
RPLM	O
)	O
on	O
feedlot	O
performance	O
and	O
carcass	O
characteristics	O
of	O
Holstein	O
steers	O
during	O
a	O
growing-finishing	O
trial	O
(	O
266	O
d	O
)	O
.	O

A	O
total	O
of	O
168	O
Holstein	O
steers	O
(	O
182.7	O
+/-	O
27.5	O
kg	O
)	O
were	O
used	O
in	O
a	O
completely	O
randomized	O
design	O
experiment	O
(	O
eight	O
treatments	O
;	O
three	O
pens	O
of	O
seven	O
steers/treatment	O
)	O
.	O

Steers	O
were	O
given	O
ad	Physical
libitum	Physical
access	Physical
to	Physical
high-concentrate	Physical
diets	Physical
(	Pharmacological
13	Pharmacological
%	Pharmacological
CP	Pharmacological
)	Pharmacological
containing	O
71	O
%	O
whole	O
shelled	O
corn	O
,	O
10	O
%	O
corn	O
silage	O
,	O
4	O
%	O
condensed	O
distillers	O
solubles	O
,	O
and	O
15	O
%	O
protein	O
supplements	O
(	O
DM	O
basis	O
)	O
.	O

Treatments	O
were	O
arranged	O
as	O
a	O
2	O
x	O
4	O
factorial	O
.	O

The	O
main	O
factors	O
were	O
two	O
sources	O
of	O
dietary	O
CP	O
and	O
four	O
levels	O
of	O
RPLM	O
.	O

The	O
sources	O
of	O
dietary	O
CP	O
were	O
soybean	O
meal	O
(	O
SBM	O
)	O
or	O
SBM	O
and	O
urea	O
(	O
SBM-U	O
)	O
.	O

Urea-N	O
replaced	O
50	O
%	O
of	O
SBM-N	O
in	O
the	O
SBM-U	O
diet	O
.	O

The	O
levels	O
of	O
RPLM	O
were	O
0	O
,	O
5	O
,	O
10	O
,	O
and	O
15	O
g	O
per	O
steer	O
daily	O
.	O

No	O
interactions	O
(	O
P	O
>	O
.10	O
)	O
between	O
source	O
of	O
dietary	O
CP	O
and	O
level	O
of	O
RPLM	O
were	O
observed	O
for	O
feedlot	O
performance	O
or	O
carcass	O
characteristics	O
.	O

Feedlot	O
performance	O
showed	O
an	O
advantage	O
(	O
P	O
<	O
.10	O
)	O
to	O
feeding	O
SMB	O
during	O
the	O
first	O
84	O
d	O
of	O
the	O
trial	O
and	O
an	O
advantage	O
to	O
feeding	O
SBM-U	O
during	O
the	O
last	O
98	O
d	O
of	O
the	O
trial	O
.	O

However	O
,	O
feedlot	O
performance	O
for	O
the	O
whole	O
trial	O
and	O
carcass	O
characteristics	O
(	O
except	O
for	O
fat	O
thickness	O
)	O
were	O
not	O
affected	O
(	O
P	O
>	O
.10	O
)	O
by	O
the	O
source	O
of	O
dietary	O
CP	O
.	O

Steers	O
fed	O
diets	O
containing	O
SBM-U	O
had	O
12	O
%	O
less	O
(	O
P	O
<	O
.10	O
)	O
fat	O
thickness	O
than	O
those	O
fed	O
diets	O
containing	O
SBM	O
.	O

Supplementation	O
of	O
diets	O
with	O
increasing	O
levels	O
of	O
RPLM	O
did	O
not	O
affect	O
(	O
P	O
>	O
.10	O
)	O
ADG	O
or	O
carcass	O
characteristics	O
.	O

However	O
,	O
DMI	O
and	O
gain	O
:	O
feed	O
showed	O
cubic	O
(	O
P	O
<	O
.10	O
)	O
responses	O
to	O
increasing	O
dietary	O
level	O
of	O
RPLM	O
.	O

Supplementation	O
of	O
RPLM	O
at	O
the	O
10	O
g/d	O
level	O
improved	O
gain	O
:	O
feed	O
by	O
12	O
%	O
during	O
the	O
last	O
98	O
d	O
of	O
the	O
trial	O
,	O
and	O
this	O
was	O
a	O
direct	O
response	O
to	O
the	O
cubic	O
effects	O
of	O
RPLM	O
on	O
DMI	O
.	O

Results	O
suggest	O
a	O
cost	O
advantage	O
for	O
replacing	O
50	O
%	O
of	O
SBM-N	O
with	O
that	O
from	O
urea	O
in	O
high-corn	O
diets	O
without	O
negative	O
effects	O
on	O
feedlot	O
performance	O
or	O
carcass	O
characteristics	O
of	O
growing-finishing	O
Holstein	O
steers	O
with	O
extended	O
feeding	O
periods	O
(	O
266	O
d	O
)	O
.	O

These	O
types	O
of	O
diets	O
seem	O
to	O
meet	O
the	O
amino	O
acid	O
requirements	O
and	O
are	O
not	O
limiting	O
in	O
lysine	O
and	O
methionine	O
.	O

A	O
randomized	O
comparison	O
of	O
the	O
effect	O
of	O
two	O
prelinguistic	Educational
communication	Educational
interventions	Educational
on	O
the	O
acquisition	O
of	O
spoken	O
communication	O
in	O
preschoolers	O
with	O
ASD	O
.	O

PURPOSE	O
This	O
randomized	O
group	O
experiment	O
compared	O
the	O
efficacy	O
of	O
2	O
communication	Educational
interventions	Educational
(	O
Responsive	O
Education	O
and	O
Prelinguistic	O
Milieu	O
Teaching	O
[	O
RPMT	O
]	O
and	O
the	O
Picture	Educational
Exchange	Educational
Communication	Educational
System	Educational
[	O
PECS	O
]	O
)	O
on	O
spoken	O
communication	O
in	O
36	O
preschoolers	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
.	O

METHOD	O
Each	O
treatment	O
was	O
delivered	O
to	O
children	O
for	O
a	O
maximum	O
total	O
of	O
24	O
hr	O
over	O
a	O
6-month	O
period	O
.	O

Spoken	O
communication	O
was	O
assessed	O
in	O
a	O
rigorous	O
test	O
of	O
generalization	O
at	O
pretreatment	O
,	O
posttreatment	O
,	O
and	O
6-month	O
follow-up	O
periods	O
.	O

RESULTS	O
PECS	O
was	O
more	O
successful	O
than	O
RPMT	O
in	O
increasing	O
the	O
number	O
of	O
nonimitative	O
spoken	O
communication	O
acts	O
and	O
the	O
number	O
of	O
different	O
nonimitative	O
words	O
used	O
at	O
the	O
posttreatment	O
period	O
.	O

Considering	O
growth	O
over	O
all	O
3	O
measurement	O
periods	O
,	O
an	O
exploratory	O
analysis	O
showed	O
that	O
growth	O
rate	O
of	O
the	O
number	O
of	O
different	O
nonimitative	O
words	O
was	O
faster	O
in	O
the	O
PECS	O
group	O
than	O
in	O
the	O
RPMT	O
group	O
for	O
children	O
who	O
began	O
treatment	O
with	O
relatively	O
high	O
object	O
exploration	O
.	O

In	O
contrast	O
,	O
analogous	O
slopes	O
were	O
steeper	O
in	O
the	O
RPMT	O
group	O
than	O
in	O
the	O
PECS	O
group	O
for	O
children	O
who	O
began	O
treatment	O
with	O
relatively	O
low	O
object	O
exploration	O
.	O

Evaluation	O
of	O
a	O
new	Educational
computer	Educational
intervention	Educational
to	O
teach	O
people	O
with	O
autism	O
or	O
Asperger	O
syndrome	O
to	O
recognize	O
and	O
predict	O
emotions	O
in	O
others	O
.	O

This	O
randomized	O
controlled	O
trial	O
looked	O
at	O
the	O
effect	O
of	O
a	O
new	Educational
computer	Educational
program	Educational
designed	O
to	O
teach	O
people	O
with	O
autistic	O
spectrum	O
disorders	O
to	O
better	O
recognize	O
and	O
predict	O
emotional	O
responses	O
in	O
others	O
.	O

Two	O
groups	O
of	O
11	O
children	O
(	O
age	O
12-18	O
)	O
with	O
autism	O
or	O
Asperger	O
syndrome	O
at	O
two	O
special	O
schools	O
participated	O
:	O
one	Educational
group	Educational
used	Educational
the	Educational
computer	Educational
program	Educational
for	Educational
10	Educational
half-hour	Educational
sessions	Educational
over	Educational
2	Educational
weeks	Educational
.	O

Within-program	O
data	O
showed	O
a	O
significant	O
reduction	O
in	O
errors	O
made	O
from	O
first	O
to	O
last	O
use	O
.	O

Students	O
were	O
assessed	O
pre-	O
and	O
post-intervention	O
using	O
facial	O
expression	O
photographs	O
,	O
cartoons	O
depicting	O
emotion-laden	O
situations	O
,	O
and	O
non-literal	O
stories	O
.	O

Scores	O
were	O
not	O
related	O
to	O
age	O
or	O
verbal	O
ability	O
.	O

The	O
experimental	O
group	O
made	O
gains	O
relative	O
to	O
the	O
control	O
group	O
on	O
all	O
three	O
measures	O
.	O

Gains	O
correlated	O
significantly	O
with	O
the	O
number	O
of	O
times	O
the	O
computer	Educational
program	Educational
was	O
used	O
and	O
results	O
suggest	O
positive	O
effects	O
.	O

Further	O
research	O
could	O
assess	O
whether	O
these	O
gains	O
generalized	O
into	O
real	O
life	O
or	O
improved	O
performance	O
on	O
theory	O
of	O
mind	O
measures	O
.	O

Capsular	O
contracture	O
around	O
saline-filled	Pharmacological
fine	Pharmacological
textured	Pharmacological
and	O
smooth	Pharmacological
mammary	Pharmacological
implants	Pharmacological
:	O
a	O
prospective	O
7.5-year	O
follow-up	O
.	O

In	O
a	O
previous	O
prospective	O
randomized	O
clinical	O
study	O
comparing	O
in	O
the	O
same	O
patient	O
textured	O
and	O
smooth	O
saline-filled	Pharmacological
mammary	Pharmacological
implants	Pharmacological
(	Pharmacological
Biocell	Pharmacological
)	Pharmacological
with	O
large	O
pore	O
size	O
(	O
300	O
to	O
600	O
microm	O
)	O
,	O
we	O
saw	O
no	O
difference	O
in	O
capsular	O
contracture	O
.	O

This	O
study	O
was	O
undertaken	O
in	O
a	O
similar	O
way	O
to	O
compare	O
capsular	O
contracture	O
around	O
smooth	O
and	O
textured	O
saline-filled	Pharmacological
prostheses	Pharmacological
with	O
pores	O
of	O
small	O
size	O
.	O

During	O
a	O
period	O
of	O
7.5	O
years	O
,	O
the	O
breast	O
hardness	O
was	O
followed	O
up	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
patient	O
satisfaction	O
was	O
evaluated	O
.	O

Twenty	O
healthy	O
women	O
with	O
a	O
mean	O
age	O
of	O
30	O
years	O
were	O
operated	O
on	O
for	O
breast	O
augmentation	O
.	O

Two	O
surgeons	O
performed	O
all	O
operations	O
in	O
a	O
standardized	O
way	O
.	O

Each	O
patient	O
received	O
subglandularly	Pharmacological
a	Pharmacological
Siltex	Pharmacological
textured	Pharmacological
saline-filled	Pharmacological
prosthesis	Pharmacological
with	O
a	O
pore	O
size	O
of	O
30	O
to	O
70	O
microm	O
in	O
one	O
breast	O
,	O
and	O
a	O
smooth	Pharmacological
saline-filled	Pharmacological
prosthesis	Pharmacological
in	Pharmacological
the	Pharmacological
other	Pharmacological
.	O

The	O
hardness	O
of	O
the	O
breasts	O
was	O
evaluated	O
after	O
0.5	O
,	O
1	O
,	O
and	O
7.5	O
years	O
using	O
Baker	O
grading	O
and	O
applanation	O
tonometry	O
.	O

Eighteen	O
patients	O
completed	O
1-year	O
and	O
7.5-year	O
follow-up	O
.	O

Two	O
breasts	O
with	O
smooth	O
prostheses	O
were	O
contracted	O
after	O
6	O
months	O
(	O
Baker	O
III	O
or	O
IV	O
)	O
.	O

After	O
1	O
year	O
,	O
four	O
patients	O
with	O
smooth	O
prostheses	O
and	O
one	O
with	O
a	O
textured	O
prosthesis	O
had	O
capsular	O
contracture	O
(	O
p	O
=	O
0.34	O
)	O
.	O

Seven	O
and	O
one-half	O
years	O
after	O
surgery	O
,	O
six	O
patents	O
with	O
smooth	O
and	O
four	O
with	O
textured	O
implants	Physical
had	O
contracture	O
(	O
p	O
=	O
0.66	O
)	O
.	O

On	O
two	O
patients	O
with	O
smooth	O
prostheses	O
and	O
one	O
patient	O
with	O
a	O
textured	O
prosthesis	O
,	O
the	O
capsule	O
around	O
the	O
implant	O
hardened	O
between	O
6	O
and	O
12	O
months	O
.	O

Between	O
1	O
year	O
and	O
7.5	O
years	O
,	O
three	O
breasts	O
with	O
smooth	O
and	O
textured	O
implants	O
contracted	O
and	O
one	O
with	O
a	O
textured	O
implant	O
softened.The	O
patients	O
reported	O
on	O
a	O
Visual	O
Analogue	O
Scale	O
(	O
1	O
to	O
10	O
)	O
the	O
impact	O
of	O
the	O
augmentation	O
on	O
their	O
quality	O
of	O
life	O
to	O
be	O
9	O
+/-	O
1	O
.	O

Four	O
patients	O
preferred	O
the	O
breast	O
with	O
the	O
smooth	O
prosthesis	O
,	O
three	O
preferred	O
the	O
breast	O
with	O
the	O
textured	O
prosthesis	O
,	O
and	O
the	O
others	O
found	O
both	O
breasts	O
equal	O
.	O

This	O
study	O
showed	O
no	O
significant	O
difference	O
of	O
contracture	O
with	O
smooth	O
versus	O
fine	O
textured	O
implants	O
.	O

The	O
majority	O
of	O
the	O
patients	O
preferred	O
the	O
smooth	O
implants	O
.	O

The	O
patients	O
reported	O
that	O
the	O
breast	O
augmentation	O
had	O
had	O
an	O
extremely	O
high	O
impact	O
on	O
their	O
quality	O
of	O
life	O
.	O

Remifentanil	O
with	O
morphine	O
transitional	O
analgesia	O
shortens	O
neurological	O
recovery	O
compared	O
to	O
fentanyl	O
for	O
supratentorial	O
craniotomy	O
.	O

PURPOSE	O
To	O
compare	O
the	O
recovery	O
profiles	O
,	O
efficacy	O
and	O
safety	O
of	O
remifentanil	O
and	O
morphine	O
for	O
transitional	O
analgesia	O
with	O
fentanyl	O
in	O
patients	O
undergoing	O
elective	O
craniotomy	O
for	O
supratentorial	O
mass	O
lesions	O
.	O

METHODS	O
Ninety-one	O
patients	O
were	O
enrolled	O
in	O
this	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
study	O
.	O

Anesthesia	Pharmacological
was	O
induced	O
with	O
thiopental	O
and	O
remifentanil	Pharmacological
(	Pharmacological
1.0	Pharmacological
micro	Pharmacological
g	Pharmacological
x	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
bolus	Pharmacological
and	O
a	O
1	Pharmacological
micro	Pharmacological
g	Pharmacological
x	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
x	Pharmacological
min	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
infusion	Pharmacological
)	Pharmacological
or	O
fentanyl	Pharmacological
(	Pharmacological
1	Pharmacological
micro	Pharmacological
g	Pharmacological
x	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
bolus	Pharmacological
and	O
a	O
1.0	Pharmacological
micro	Pharmacological
g	Pharmacological
x	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
x	Pharmacological
min	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
infusion	Pharmacological
)	O
.	O

The	O
opioid	Pharmacological
infusion	Pharmacological
continued	O
until	O
the	O
level	O
of	O
anesthesia	Pharmacological
was	O
deemed	O
appropriate	O
for	O
intubation	O
.	O

Anesthesia	Pharmacological
was	O
maintained	O
with	O
N	O
(	O
2	O
)	O
O/O	O
(	O
2	O
)	O
,	O
isoflurane	Pharmacological
0.5	Pharmacological
MAC	Pharmacological
and	O
remifentanil	Pharmacological
0.2	Pharmacological
micro	Pharmacological
g	Pharmacological
x	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
x	Pharmacological
min	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
or	O
fentanyl	Pharmacological
0.04	Pharmacological
micro	Pharmacological
g	Pharmacological
x	Pharmacological
kg	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
x	Pharmacological
min	Pharmacological
(	Pharmacological
-1	Pharmacological
)	Pharmacological
.	O

At	Physical
bone	Physical
flap	Physical
replacement	Physical
,	O
either	Pharmacological
morphine	Pharmacological
0.08	Pharmacological
mg	Pharmacological
x	O
kg	O
(	O
-1	O
)	O
(	O
remifentanil	Pharmacological
group	Pharmacological
)	Pharmacological
or	O
saline	Pharmacological
(	O
fentanyl	O
group	O
)	O
was	O
given	O
.	O

RESULTS	O
Systolic	O
blood	O
pressure	O
was	O
greater	O
in	O
those	O
receiving	O
fentanyl	O
during	O
induction	O
(	O
145.6	O
+/-17.5	O
mmHg	O
vs	O
128.8	O
+/-18.3	O
mmHg	O
;	O
P	O
=	O
0.006	O
)	O
and	O
intubation	O
(	O
126.9	O
+/-17.1	O
vs	O
110.9	O
+/-16.5	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Median	O
time	O
to	O
tracheal	O
extubation	O
was	O
similar	O
but	O
less	O
variable	O
in	O
the	O
remifentanil	O
group	O
(	O
remifentanil	O
=	O
8	O
min	O
:	O
range	O
=	O
2-44	O
min	O
;	O
fentanyl	O
=	O
8	O
min	O
:	O
range	O
=	O
1-732	O
min	O
)	O
.	O

The	O
fentanyl	O
patients	O
required	O
a	O
longer	O
time	O
to	O
achieve	O
the	O
first	O
normal	O
neurological	O
score	O
(	O
fentanyl	O
=	O
38.0	O
min	O
;	O
remifentanil	O
=	O
26.0	O
min	O
;	O
P	O
=	O
0.035	O
)	O
.	O

Both	O
the	O
anesthesiologists	O
and	O
the	O
recovery	O
room	O
nurses	O
rated	O
remifentanil	O
better	O
with	O
respect	O
to	O
level	O
of	O
consciousness	O
.	O

Analgesics	O
were	O
required	O
earlier	O
in	O
patients	O
receiving	O
remifentanil	O
;	O
median	O
time	O
0.5	O
vs	O
1.08	O
hr	O
,	O
P	O
<	O
0.001	O
.	O

CONCLUSIONS	O
Remifentanil	O
is	O
a	O
suitable	O
alternative	O
to	O
fentanyl	O
in	O
supratentorial	O
craniotomy	O
.	O

Time	O
to	O
preoperative	O
neurological	O
recovery	O
is	O
faster	O
and	O
morphine	O
provides	O
some	O
transitional	O
analgesia	O
without	O
compromising	O
the	O
quality	O
of	O
recovery	O
.	O

[	O
Intra-arterial	Pharmacological
(	Pharmacological
5-FU/FA	Pharmacological
and	Physical
FUDR	Pharmacological
)	Physical
versus	O
systemic	Pharmacological
chemotherapy	Pharmacological
(	Pharmacological
5-FU/FA	Pharmacological
)	Pharmacological
of	O
non-resectable	O
colorectal	O
liver	O
metastases	O
]	O
.	O

The	O
relative	O
efficacy	O
of	O
HAI	Pharmacological
FUDR	Pharmacological
,	Physical
HAI	Pharmacological
5-FU/FA	Pharmacological
,	Physical
and	Physical
i.v	Physical
.	Physical

5-FU/FA	O
chemotherapy	O
for	O
the	O
treatment	O
of	O
unresectable	O
colorectal	O
liver	O
metastases	O
was	O
compared	O
in	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

The	O
response	O
rate	O
after	O
HAI	Pharmacological
treatment	O
was	O
significantly	O
higher	O
as	O
compared	O
to	O
i.v	O
.	O

treatment	O
with	O
no	O
statistical	O
benefit	O
regarding	O
survival	O
and	O
time	O
to	O
progression	O
.	O

HAI	Pharmacological
FUDR	Pharmacological
treatment	O
was	O
inferior	O
as	O
compared	O
to	O
HAI	Pharmacological
or	O
i.v	O
.	O

5-FU/FA	Pharmacological
.	Pharmacological

i.v	O
.	O

5-FU/FA-therapy	Pharmacological
is	O
therefore	O
the	O
method	O
of	O
choice	O
outside	O
clinical	O
trials	O
.	O

Treatment	O
of	O
sperm	O
with	O
platelet-activating	Pharmacological
factor	Pharmacological
does	O
not	O
improve	O
intrauterine	Physical
insemination	Physical
outcome	O
in	O
unselected	O
cases	O
of	O
mild	O
male	O
factor	O
infertility	O
:	O
a	O
prospective	O
double-blind	O
randomized	O
crossover	O
study	O
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
effect	O
of	O
sperm	O
treatment	O
with	O
exogenous	Pharmacological
platelet-activating	Pharmacological
factor	Pharmacological
(	Pharmacological
PAF	Pharmacological
)	Pharmacological
on	O
intrauterine	Physical
insemination	Physical
(	Physical
IUI	Physical
)	Physical
clinical	O
pregnancy	O
rate	O
in	O
cases	O
of	O
mild	O
male	O
factor	O
infertility	O
.	O

PAF	O
is	O
a	O
phospholipid	O
mediator	O
,	O
which	O
is	O
present	O
in	O
human	O
sperm	O
.	O

METHODS	O
The	O
study	O
was	O
performed	O
in	O
the	O
Assisted	O
Reproduction	O
Unit	O
of	O
the	O
2nd	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
University	O
of	O
Athens	O
,	O
Aretaieion	O
Hospital	O
,	O
Athens	O
,	O
Greece	O
,	O
and	O
included	O
92	O
couples	O
who	O
presented	O
with	O
mild	O
male	O
factor	O
infertility-all	O
candidates	O
for	O
IUI	O
.	O

A	O
maximum	O
of	O
4	O
IUI	Physical
cycles	O
per	O
couple	O
with	O
or	O
without	O
exogenous	Pharmacological
PAF	Pharmacological
treatment	Pharmacological
were	O
performed	O
and	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
clinical	O
pregnancy	O
rate	O
(	O
pregnancies	O
confirmed	O
by	O
ultrasonography	O
per	O
100	O
cycles	O
)	O
.	O

RESULTS	O
The	O
overall	O
clinical	O
pregnancy	O
rate	O
after	O
a	O
maximum	O
of	O
4	O
IUI	Physical
cycles	O
was	O
comparable	O
in	O
cases	O
with	O
and	O
without	O
sperm	Pharmacological
treatment	Pharmacological
with	Pharmacological
PAF	Pharmacological
(	O
12.24	O
%	O
vs	O
11.11	O
%	O
)	O
.	O

Addition	O
or	O
exclusion	O
of	O
PAF	Pharmacological
sperm	Pharmacological
treatment	Pharmacological
in	O
the	O
same	O
patients	O
did	O
not	O
significantly	O
alter	O
the	O
outcome	O
.	O

CONCLUSIONS	O
The	O
generalized	O
use	O
of	O
exogenous	Pharmacological
PAF	Pharmacological
for	O
the	O
preparation	O
of	O
sperm	O
in	O
unselected	O
cases	O
of	O
mild	O
male	O
infertility	O
does	O
not	O
improve	O
the	O
clinical	O
outcome	O
of	O
IUI	O
.	O

Effects	O
of	O
preoperative	O
intentional	Physical
hemodilution	Physical
on	O
the	O
extravasation	O
rate	O
of	O
albumin	O
and	O
fluid	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
preoperative	O
intentional	O
hemodilution	O
with	O
4	O
%	O
albumin	Pharmacological
solution	O
on	O
the	O
extravasation	O
rate	O
of	O
intravascular	O
albumin	O
and	O
fluid	O
in	O
surgical	O
patients	O
.	O

DESIGN	O
A	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
.	O

SETTING	O
University	O
teaching	O
hospital	O
.	O

PATIENTS	O
Two	O
groups	O
(	O
control	O
group	O
[	O
group	O
1	O
]	O
and	O
hemodiluted	O
group	O
[	O
group	O
2	O
]	O
)	O
of	O
13	O
healthy	O
patients	O
were	O
studied	O
during	O
a	O
long-term	O
(	O
>	O
4	O
hrs	O
)	O
surgical	O
procedure	O
.	O

INTERVENTIONS	O
Autologous	Pharmacological
technetium-99m	Pharmacological
(	Pharmacological
99mTc	Pharmacological
)	Pharmacological
-labeled	Pharmacological
red	Pharmacological
blood	Pharmacological
cells	Pharmacological
and	O
indium-oxine	Pharmacological
(	Pharmacological
(	Pharmacological
111	Pharmacological
)	Pharmacological
In	Pharmacological
)	Pharmacological
-labeled	Pharmacological
human	Pharmacological
serum	Pharmacological
albumin	Pharmacological
were	Pharmacological
injected	Pharmacological
intravenously	Pharmacological
during	O
anesthesia	O
at	O
T	O
=	O
0	O
min	O
in	O
the	O
two	O
groups	O
for	O
the	O
determination	O
of	O
total	O
blood	O
volume	O
and	O
albumin	O
diffusion	O
space	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
body	O
tetrapolar	O
electrical	O
impedance	O
was	O
used	O
to	O
assess	O
extracellular	O
fluid	O
volume	O
.	O

In	O
the	O
hemodiluted	O
group	O
(	O
group	O
2	O
)	O
,	O
15	O
mL/kg	O
of	O
blood	O
was	O
withdrawn	O
over	O
30	O
mins	O
(	O
T	O
=	O
20	O
mins	O
to	O
T	O
=	O
50	O
mins	O
)	O
and	O
simultaneously	O
replaced	O
by	O
an	O
equal	O
volume	O
of	O
4	O
%	O
albumin	O
solution	O
(	O
0.6	O
g/kg	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
The	O
albumin	O
diffusion	O
space	O
,	O
the	O
colloid	O
oncotic	O
pressure	O
,	O
the	O
plasma	O
albumin	O
concentration	O
and	O
the	O
electrical	O
impedance	O
were	O
measured	O
before	O
(	O
T	O
=	O
10	O
mins	O
)	O
and	O
after	O
(	O
T	O
=	O
60	O
,	O
120	O
,	O
and	O
240	O
mins	O
)	O
hemodilution	O
.	O

Urine	O
was	O
collected	O
from	O
T	O
=	O
10	O
mins	O
to	O
T	O
=	O
240	O
mins	O
.	O

The	O
total	O
blood	O
volume	O
was	O
calculated	O
at	O
T	O
=	O
10	O
mins	O
.	O

No	O
differences	O
in	O
the	O
initial	O
values	O
were	O
found	O
between	O
the	O
two	O
groups	O
.	O

In	O
group	O
2	O
,	O
hemodilution	O
(	O
hematocrit	O
30	O
+/-	O
3	O
%	O
)	O
resulted	O
in	O
a	O
steeper	O
increase	O
in	O
the	O
albumin	O
diffusion	O
space	O
(	O
p	O
<	O
.05	O
)	O
and	O
a	O
progressive	O
decrease	O
in	O
the	O
body	O
electrical	O
impedance	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
extravasation	O
rate	O
of	O
albumin	O
was	O
0.052	O
+/-	O
0.007	O
mL/kg/min	O
in	O
group	O
2	O
vs.	O
0.038	O
+/-	O
0.020	O
mL/kg/min	O
in	O
group	O
1	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
value	O
of	O
calculated	O
plasma	O
volume	O
at	O
T	O
=	O
0	O
min	O
did	O
not	O
shown	O
any	O
difference	O
between	O
the	O
two	O
groups	O
.	O

This	O
value	O
was	O
then	O
lower	O
than	O
expected	O
in	O
group	O
2	O
,	O
corresponding	O
to	O
a	O
loss	O
of	O
plasma	O
volume	O
of	O
>	O
3	O
mL/kg	O
.	O

Urine	O
output	O
was	O
significantly	O
lower	O
in	O
group	O
2	O
than	O
in	O
group	O
1	O
(	O
0.7	O
+/-	O
0.4	O
vs.	O
1.4	O
+/-	O
1.0	O
mL/min	O
,	O
respectively	O
;	O
p	O
<	O
.05	O
)	O
.	O

A	O
comparable	O
decrease	O
in	O
colloid	O
oncotic	O
pressure	O
and	O
in	O
plasma	O
albumin	O
concentration	O
was	O
observed	O
in	O
both	O
groups	O
.	O

CONCLUSIONS	O
These	O
results	O
suggest	O
that	O
preoperative	O
hemodilution	O
using	O
4	O
%	O
albumin	O
on	O
a	O
1:1	O
volume	O
basis	O
for	O
blood	O
substitution	O
during	O
a	O
prolonged	O
surgical	O
procedure	O
with	O
reduced	O
blood	O
losses	O
enhances	O
the	O
extravasation	O
rate	O
of	O
albumin	O
and	O
fluid	O
to	O
the	O
interstitial	O
tissues	O
,	O
impeding	O
the	O
maintenance	O
of	O
isovolemia	O
.	O

These	O
findings	O
support	O
the	O
use	O
of	O
a	O
volume	O
of	O
infused	O
colloid	O
solution	O
higher	O
than	O
that	O
of	O
withdrawn	O
blood	O
during	O
preoperative	O
hemodilution	O
.	O

Safety	O
,	O
pharmacokinetics	O
and	O
pharmocodynamics	O
of	O
recombinant	Pharmacological
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
in	O
healthy	O
subjects	O
and	O
asymptomatic	O
carriers	O
of	O
the	O
acute	O
intermittent	O
porphyria	O
gene	O
who	O
have	O
increased	O
porphyrin	O
precursor	O
excretion	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
Acute	O
intermittent	O
porphyria	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
third	O
enzyme	O
in	O
the	O
haem	O
biosynthetic	O
pathway	O
,	O
porphobilinogen	O
deaminase	O
.	O

It	O
is	O
characterised	O
by	O
acute	O
,	O
potentially	O
life-threatening	O
neurological	O
attacks	O
that	O
are	O
precipitated	O
by	O
various	O
drugs	O
,	O
reproductive	O
hormones	O
and	O
other	O
factors	O
.	O

During	O
acute	O
attacks	O
,	O
the	O
porphyrin	O
precursors	O
5-aminolevulinic	O
acid	O
and	O
porphobilinogen	O
accumulate	O
and	O
are	O
excreted	O
at	O
high	O
concentrations	O
in	O
the	O
urine	O
.	O

Current	O
treatment	O
is	O
based	O
on	O
glucose	O
loading	O
and	O
parenteral	O
haem	O
replenishment	O
,	O
which	O
reduce	O
the	O
accumulation	O
of	O
5-aminolevulinic	O
acid	O
and	O
porphobilinogen	O
.	O

Recently	O
,	O
a	O
new	O
form	O
of	O
treatment	O
based	O
on	O
porphobilinogen	Pharmacological
deaminase	Pharmacological
enzyme	Pharmacological
replacement	Pharmacological
therapy	Pharmacological
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
an	O
acute	O
intermittent	O
porphyria	O
mouse	O
model	O
which	O
,	O
during	O
phenobarbital	O
(	O
phenobarbitone	O
)	O
induction	O
of	O
haem	O
biosynthesis	O
,	O
mimics	O
the	O
biochemical	O
pattern	O
of	O
acute	O
porphyric	O
attacks	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
,	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
recombinant	Pharmacological
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
(	O
P	O
9808	O
)	O
,	O
administered	O
to	O
healthy	O
subjects	O
and	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
with	O
high	O
concentrations	O
of	O
porphobilinogen	O
,	O
the	O
substrate	O
of	O
porphobilinogen	O
deaminase	O
.	O

STUDY	O
DESIGN	O
Forty	O
individuals	O
participated	O
in	O
this	O
two-part	O
study	O
:	O
20	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
(	O
both	O
male	O
and	O
female	O
)	O
with	O
>	O
or	O
=4	O
times	O
the	O
upper	O
reference	O
urinary	O
porphobilinogen	O
level	O
,	O
and	O
20	O
healthy	O
male	O
subjects	O
.	O

Four	O
different	O
doses	O
of	O
recombinant	Pharmacological
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
were	O
studied	O
(	O
0.5	O
,	O
1	O
,	O
2	O
and	O
4	O
mg/kg	O
bodyweight	O
)	O
.	O

Part	O
A	O
included	O
12	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
,	O
and	O
the	O
enzyme	O
was	O
administered	O
in	O
an	O
open-label	O
,	O
single-dose	O
design	O
.	O

Part	O
B	O
included	O
20	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
and	O
20	O
healthy	O
subjects	O
.	O

The	O
same	O
enzyme	O
dosages	O
were	O
administered	O
as	O
divided	O
doses	O
every	O
12	O
hours	O
for	O
4	O
consecutive	O
days	O
in	O
a	O
randomised	O
,	O
double-blinded	O
,	O
placebo-controlled	O
design	O
.	O

The	O
washout	O
period	O
between	O
Parts	O
A	O
and	O
B	O
was	O
2	O
weeks	O
.	O

METHODS	O
The	O
concentrations	O
of	O
recombinant	O
human	O
porphobilinogen	Pharmacological
deaminase	Pharmacological
and	O
titres	O
of	O
antibodies	O
against	O
recombinant	O
human	O
porphobilinogen	O
deaminase	O
were	O
analysed	O
by	O
ELISA	O
.	O

Plasma	O
porphobilinogen	O
and	O
5-aminolevulinic	O
acid	O
concentrations	O
were	O
analysed	O
using	O
a	O
novel	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
method	O
.	O

Urinary	O
porphobilinogen	O
,	O
5-aminolevulinic	O
acid	O
and	O
porphyrin	O
concentrations	O
,	O
as	O
well	O
as	O
plasma	O
porphyrin	O
concentrations	O
,	O
were	O
analysed	O
using	O
standard	O
methods	O
.	O

The	O
pharmacodynamic	O
effect	O
of	O
the	O
enzyme	O
was	O
studied	O
through	O
changes	O
in	O
plasma	O
porphobilinogen	O
concentrations	O
.	O

RESULTS	O
No	O
serious	O
adverse	O
events	O
were	O
observed	O
.	O

Seven	O
subjects	O
(	O
four	O
healthy	O
men	O
and	O
three	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
)	O
developed	O
antibodies	O
against	O
recombinant	O
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
but	O
did	O
not	O
experience	O
allergic	O
manifestations	O
.	O

The	O
mean	O
elimination	O
half-lives	O
of	O
the	O
highest	O
doses	O
of	O
recombinant	O
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
ranged	O
between	O
1.7	O
and	O
2.5	O
hours	O
for	O
both	O
healthy	O
men	O
and	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
.	O

The	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
was	O
proportional	O
to	O
the	O
respective	O
dose	O
.	O

In	O
asymptomatic	O
porphobilinogen	O
deaminase-deficient	O
subjects	O
,	O
plasma	O
porphobilinogen	O
concentrations	O
decreased	O
below	O
measurable	O
levels	O
almost	O
instantaneously	O
after	O
administration	O
of	O
any	O
dose	O
of	O
the	O
enzyme	O
.	O

The	O
effect	O
lasted	O
for	O
approximately	O
2	O
hours	O
,	O
after	O
which	O
the	O
plasma	O
porphobilinogen	O
concentration	O
slowly	O
increased	O
,	O
reaching	O
about	O
70	O
%	O
of	O
the	O
initial	O
values	O
12	O
hours	O
after	O
administration	O
.	O

There	O
was	O
no	O
effect	O
on	O
plasma	O
5-aminolevulinic	O
acid	O
concentrations	O
,	O
and	O
there	O
was	O
a	O
transitory	O
increment	O
in	O
porphyrin	O
concentrations	O
.	O

The	O
corresponding	O
concentrations	O
of	O
metabolites	O
in	O
the	O
urine	O
reflected	O
the	O
pattern	O
observed	O
in	O
the	O
plasma	O
.	O

CONCLUSIONS	O
The	O
recombinant	Pharmacological
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
enzyme	Pharmacological
preparation	Pharmacological
was	O
found	O
to	O
be	O
safe	O
to	O
administer	O
and	O
effective	O
for	O
removal	O
of	O
the	O
accumulated	O
metabolite	O
porphobilinogen	O
from	O
plasma	O
and	O
urine	O
.	O

The	O
pharmacokinetic	O
profile	O
of	O
recombinant	Pharmacological
human	Pharmacological
porphobilinogen	Pharmacological
deaminase	Pharmacological
showed	O
dose	O
proportionality	O
,	O
and	O
the	O
elimination	O
half-life	O
was	O
about	O
2.0	O
hours	O
for	O
the	O
two	O
highest	O
doses	O
.	O

Thus	O
,	O
clinical	O
grounds	O
were	O
established	O
for	O
investigation	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
enzyme	O
during	O
periods	O
of	O
overt	O
disease	O
in	O
patients	O
with	O
acute	O
intermittent	O
porphyria	O
.	O

Randomised	O
controlled	O
trial	O
of	O
graded	Physical
exercise	Physical
in	O
patients	O
with	O
the	O
chronic	O
fatigue	O
syndrome	O
.	O

OBJECTIVE	O
To	O
test	O
the	O
efficacy	O
of	O
a	O
graded	Physical
aerobic	Physical
exercise	Physical
programme	Physical
in	O
the	O
chronic	O
fatigue	O
syndrome	O
.	O

DESIGN	O
Randomised	O
controlled	O
trial	O
with	O
control	O
treatment	O
crossover	O
after	O
the	O
first	O
follow	O
up	O
examination	O
.	O

SETTING	O
Chronic	O
fatigue	O
clinic	O
in	O
a	O
general	O
hospital	O
department	O
of	O
psychiatry	O
.	O

SUBJECTS	O
66	O
patients	O
with	O
the	O
chronic	O
fatigue	O
syndrome	O
who	O
had	O
neither	O
a	O
psychiatric	O
disorder	O
nor	O
appreciable	O
sleep	O
disturbance	O
.	O

INTERVENTIONS	O
Random	O
allocation	O
to	O
12	O
weeks	O
of	O
either	O
graded	Physical
aerobic	Physical
exercise	Physical
or	O
flexibility	Physical
exercises	Physical
and	O
relaxation	Physical
therapy	Physical
.	O

Patients	O
who	O
completed	O
the	O
flexibility	Physical
programme	Physical
were	O
invited	O
to	O
cross	O
over	O
to	O
the	O
exercise	Physical
programme	Physical
afterwards	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
The	O
self	O
rated	O
clinical	O
global	O
impression	O
change	O
score	O
,	O
very	O
much	O
better	O
or	O
much	O
better	O
being	O
considered	O
as	O
clinically	O
important	O
.	O

RESULTS	O
Four	O
patients	O
receiving	O
exercise	Physical
and	O
three	O
receiving	O
flexibility	Control
treatment	Control
dropped	O
out	O
before	O
completion	O
.	O

15	O
of	O
29	O
patients	O
rated	O
themselves	O
as	O
better	O
after	O
completing	O
exercise	Physical
treatment	Physical
compared	O
with	O
eight	O
of	O
30	O
patients	O
who	O
completed	O
flexibility	Control
treatment	Control
.	O

Analysis	O
by	O
intention	O
to	O
treat	O
gave	O
similar	O
results	O
(	O
17/33	O
v	O
9/33	O
patients	O
better	O
)	O
.	O

Fatigue	O
,	O
functional	O
capacity	O
,	O
and	O
fitness	O
were	O
significantly	O
better	O
after	O
exercise	Physical
than	O
after	O
flexibility	Control
treatment	Control
.	O

12	O
of	O
22	O
patients	O
who	O
crossed	O
over	O
to	O
exercise	Physical
after	O
flexibility	O
treatment	O
rated	O
themselves	O
as	O
better	O
after	O
completing	O
exercise	O
treatment	O
32	O
of	O
47	O
patients	O
rated	O
themselves	O
as	O
better	O
three	O
months	O
after	O
completing	O
supervised	O
exercise	Physical
treatment	Physical
35	O
of	O
47	O
patients	O
rated	O
themselves	O
as	O
better	O
one	O
year	O
after	O
completing	O
supervised	Physical
exercise	Physical
treatment	Physical
.	O

CONCLUSION	O
These	O
findings	O
support	O
the	O
use	O
of	O
appropriately	O
prescribed	O
graded	Physical
aerobic	Physical
exercise	Physical
in	O
the	O
management	O
of	O
patients	O
with	O
the	O
chronic	O
fatigue	O
syndrome	O
.	O

Two	O
randomized	O
studies	O
demonstrate	O
the	O
efficacy	O
and	O
safety	O
of	O
dapsone	Pharmacological
gel	Pharmacological
,	O
5	O
%	O
for	O
the	O
treatment	O
of	O
acne	O
vulgaris	O
.	O

BACKGROUND	O
A	O
new	O
aqueous	O
gel	O
formulation	O
of	O
dapsone	Pharmacological
has	O
been	O
developed	O
that	O
allows	O
clinically-effective	O
doses	O
of	O
dapsone	Pharmacological
to	O
be	O
administered	O
topically	O
with	O
minimal	O
systemic	O
absorption	O
.	O

OBJECTIVES	O
The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
dapsone	Pharmacological
gel	Pharmacological
,	O
5	O
%	O
in	O
the	O
treatment	O
of	O
acne	O
.	O

METHODS	O
Patients	O
12	O
years	O
of	O
age	O
and	O
older	O
with	O
acne	O
vulgaris	O
(	O
N	O
=	O
3010	O
)	O
participated	O
in	O
two	O
identically-designed	O
12-week	O
,	O
randomized	O
,	O
double-blind	O
studies	O
of	O
twice-daily	O
monotherapy	Pharmacological
with	Pharmacological
dapsone	Pharmacological
gel	Pharmacological
,	Pharmacological
5	Pharmacological
%	O
,	O
versus	O
a	O
vehicle	Pharmacological
gel	Pharmacological
.	O

RESULTS	O
Dapsone	Pharmacological
gel-treated	Pharmacological
patients	O
achieved	O
superior	O
results	O
in	O
terms	O
of	O
the	O
investigator	O
's	O
global	O
acne	O
assessment	O
(	O
P	O
<	O
.001	O
)	O
and	O
the	O
mean	O
percentage	O
reduction	O
in	O
inflammatory	O
,	O
noninflammatory	O
,	O
and	O
total	O
lesion	O
counts	O
(	O
all	O
,	O
P	O
<	O
.001	O
)	O
at	O
week	O
12	O
.	O

Reductions	O
in	O
inflammatory	O
lesion	O
counts	O
favoring	O
dapsone	Pharmacological
gel	Pharmacological
over	O
vehicle	O
were	O
apparent	O
as	O
early	O
as	O
2	O
weeks	O
and	O
reached	O
statistical	O
significance	O
by	O
4	O
weeks	O
.	O

No	O
clinically	O
significant	O
changes	O
in	O
laboratory	O
parameters	O
,	O
including	O
hemoglobin	O
,	O
even	O
among	O
glucose-6-phosphate	O
dehydrogenase-deficient	O
patients	O
,	O
were	O
observed	O
.	O

Adverse	O
events	O
were	O
comparable	O
between	O
the	O
treatment	O
groups	O
and	O
rarely	O
led	O
to	O
discontinuation	O
.	O

LIMITATIONS	O
Adjunctive	O
topical	O
treatments	O
and	O
their	O
impact	O
on	O
acne	O
were	O
not	O
studied	O
in	O
this	O
trial	O
.	O

CONCLUSIONS	O
Dapsone	Pharmacological
gel	Pharmacological
,	O
5	O
%	O
appears	O
to	O
be	O
an	O
effective	O
,	O
safe	O
,	O
and	O
well-tolerated	O
treatment	O
for	O
acne	O
vulgaris	O
,	O
with	O
a	O
rapid	O
onset	O
of	O
action	O
.	O

Effect	O
of	O
mild	Physical
endurance	Physical
exercise	Physical
training	Physical
and	O
pravastatin	Pharmacological
on	O
peripheral	O
vasodilatation	O
of	O
forearm	O
resistance	O
vessels	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

BACKGROUND	O
Improved	O
endothelial	O
function	O
may	O
contribute	O
to	O
the	O
beneficial	O
effects	O
of	O
cholesterol	O
lowering	O
therapy	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
,	O
but	O
results	O
of	O
the	O
effect	O
of	O
statin	O
therapy	O
on	O
endothelial	O
function	O
are	O
disparate	O
in	O
these	O
patients	O
.	O

Exercise	Physical
training	Physical
has	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
of	O
patients	O
at	O
risk	O
of	O
or	O
with	O
established	O
CAD	O
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
mild	Physical
exercise	Physical
training	Physical
or	O
statin	Pharmacological
therapy	Pharmacological
on	O
forearm	O
endothelial	O
function	O
in	O
CAD	O
patients	O
with	O
average	O
cholesterol	O
levels	O
.	O

DESIGN	O
AND	O
METHODS	O
Twenty-eight	O
sedentary	O
male	O
patients	O
with	O
angiographically	O
documented	O
CAD	O
and	O
average	O
pretreatment	O
total	O
plasma	O
cholesterol	O
levels	O
(	O
5.1+/-0.9	O
mmol/l	O
)	O
aged	O
42-75	O
years	O
were	O
included	O
.	O

They	O
were	O
randomly	O
assigned	O
in	O
a	O
2	O
:	O
1	O
order	O
to	O
either	O
statin	Pharmacological
therapy	Pharmacological
(	Pharmacological
pravastatin	Pharmacological
,	O
40	O
mg	O
daily	O
)	O
or	O
exercise	Physical
training	Physical
therapy	Physical
(	O
mild	O
endurance	O
exercise	O
three	O
or	O
more	O
times	O
a	O
week	O
)	O
.	O

The	O
effects	O
of	O
10	O
weeks	O
of	O
either	O
treatment	O
on	O
endothelium-dependent	O
and	O
independent	O
vasodilation	O
of	O
forearm	O
resistance	O
vessels	O
was	O
assessed	O
by	O
plethysmography	O
.	O

Cardiopulmonary	Physical
exercise	Physical
testing	O
was	O
performed	O
at	O
baseline	O
and	O
after	O
10	O
weeks	O
.	O

RESULTS	O
Ten	O
weeks	O
of	O
pravastatin	Pharmacological
therapy	O
significantly	O
reduced	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
from	O
3.8+/-0.6	O
to	O
3.1+/-0.6	O
mmol/l	O
at	O
study	O
end	O
,	O
P=0.04	O
)	O
and	O
the	O
ratio	O
of	O
total	O
to	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
from	O
4.9+/-0.8	O
to	O
3.7+/-0.7	O
mmol/l	O
,	O
P=0.002	O
)	O
.	O

Exercise	Physical
training	Physical
did	O
not	O
significantly	O
modify	O
the	O
lipid	O
profile	O
.	O

Peak	O
oxygen	O
consumption	O
,	O
maximal	O
achieved	O
workload	O
and	O
exercise	O
duration	O
tended	O
to	O
improve	O
in	O
the	O
exercise	O
training	O
group	O
but	O
remained	O
unchanged	O
in	O
the	O
pravastatin-treated	Pharmacological
group	O
.	O

Neither	O
10	O
weeks	O
of	O
pravastatin	Pharmacological
nor	O
mild	Physical
endurance	Physical
exercise	Physical
training	Physical
improved	O
endothelium-dependent	O
or	O
independent	O
vasomotor	O
function	O
in	O
forearm	O
resistance	O
vessels	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
CAD	O
and	O
average	O
cholesterol	O
levels	O
,	O
10	O
weeks	O
of	O
treatment	O
with	O
mild	Physical
endurance	Physical
exercise	Physical
training	Physical
or	O
with	O
pravastatin	Pharmacological
failed	O
to	O
improve	O
endothelium-dependent	O
or	O
independent	O
vasomotor	O
function	O
in	O
forearm	O
resistance	O
vessels	O
.	O

Metabolic	O
and	O
ventilatory	O
responses	O
during	O
very	Physical
low	Physical
level	Physical
exercise	Physical
.	O

1	O
.	O

Nine	O
male	O
and	O
six	O
female	O
healthy	O
subjects	O
were	O
studied	O
during	O
supine	Physical
bicycle	Physical
exercise	Physical
at	O
workloads	O
of	O
12	O
and	O
37	O
W	O
;	O
pedalling	O
rates	O
varied	O
between	O
30	O
and	O
50	O
cycles/min	O
at	O
each	O
workload	O
.	O

Measurements	O
were	O
made	O
of	O
oxygen	O
consumption	O
(	O
VO2	O
)	O
,	O
carbon	O
dioxide	O
production	O
(	O
VCO2	O
)	O
,	O
minute	O
ventilation	O
(	O
VE	O
)	O
,	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
respiratory	O
frequency	O
(	O
fR	O
)	O
,	O
inspiratory	O
and	O
expiratory	O
time	O
(	O
TI	O
,	O
TE	O
)	O
and	O
mean	O
inspiratory	O
flow	O
(	O
VT/TI	O
)	O
using	O
a	O
non-invasive	O
canopy-computer-spirometer	O
system	O
.	O

2	O
.	O

At	O
rest	O
,	O
males	O
had	O
greater	O
values	O
of	O
VE	O
,	O
VT	O
,	O
TI	O
,	O
inspiratory	O
duty	O
cycle	O
(	O
TI/TTOT	O
)	O
,	O
VCO2	O
and	O
VO2	O
,	O
and	O
a	O
lower	O
fR	O
,	O
than	O
females	O
.	O

3	O
.	O

At	O
the	O
lower	O
workload	O
,	O
VO2	O
,	O
VCO2	O
,	O
VE	O
,	O
VT	O
and	O
VT/TI	O
increased	O
linearly	O
with	O
increasing	O
pedalling	O
rate	O
,	O
whereas	O
at	O
the	O
higher	O
workload	O
there	O
was	O
a	O
decrease	O
in	O
VO2	O
and	O
little	O
or	O
no	O
change	O
in	O
ventilatory	O
parameters	O
from	O
30	O
to	O
50	O
cycles/min	O
except	O
for	O
an	O
increase	O
in	O
fR	O
in	O
females	O
.	O

4	O
.	O

While	O
performing	O
supine	Physical
exercise	Physical
,	O
there	O
was	O
an	O
effect	O
of	O
pedalling	O
rate	O
on	O
ventilatory	O
and	O
metabolic	O
parameters	O
at	O
the	O
low	O
workload	O
(	O
12	O
W	O
)	O
which	O
diminished	O
at	O
the	O
higher	O
workload	O
(	O
37	O
W	O
)	O
.	O

An	O
increase	O
in	O
pedalling	O
rate	O
appears	O
to	O
enhance	O
efficiency	O
at	O
these	O
low	O
workloads	O
.	O

5	O
.	O

Differences	O
between	O
the	O
sexes	O
during	O
exercise	O
generally	O
include	O
:	O
(	O
a	O
)	O
a	O
higher	O
breathing	O
frequency	O
,	O
(	O
b	O
)	O
a	O
greater	O
mechanical	O
efficiency	O
,	O
and	O
(	O
c	O
)	O
lower	O
ventilatory	O
equivalents	O
of	O
O2	O
and	O
CO2	O
(	O
VE/VO2	O
and	O
VE/VCO2	O
)	O
during	O
the	O
higher	O
workload	O
in	O
females	O
than	O
males	O
.	O

Neurophysiological	O
double-blind	O
trial	O
of	O
a	O
botulinum	Pharmacological
neurotoxin	Pharmacological
type	Pharmacological
a	Pharmacological
free	O
of	O
complexing	O
proteins	O
.	O

OBJECTIVE	O
Safety	O
and	O
efficacy	O
of	O
botulinum	Pharmacological
neurotoxin	Pharmacological
type	Pharmacological
A	Pharmacological
preparation	Pharmacological
NT	Pharmacological
201	Pharmacological
(	O
Xeomin	O
,	O
Merz	O
Pharmaceuticals	O
GmbH	O
,	O
Frankfurt	O
am	O
Main	O
,	O
Germany	O
)	O
were	O
investigated	O
over	O
52	O
weeks	O
in	O
a	O
double-blind	O
,	O
randomized	O
trial	O
with	O
32	O
male	O
volunteers	O
.	O

METHODS	O
Electroneurographic	O
assessments	O
with	O
surface	O
electrodes	O
were	O
performed	O
after	O
single	Pharmacological
injections	Pharmacological
of	Pharmacological
NT	Pharmacological
201	Pharmacological
(	O
2	O
,	O
4	O
,	O
16	O
,	O
or	O
32	O
units	O
)	O
into	O
the	O
extensor	Pharmacological
digitorum	Pharmacological
brevis	Pharmacological
(	O
EDB	O
)	O
muscle	O
and	O
the	O
same	Pharmacological
dose	Pharmacological
(	O
Botox	O
;	O
Allergan	O
Pharmaceuticals	O
(	O
Ireland	O
)	O
Ltd.	O
Westport	O
,	O
Ireland	O
)	O
into	Pharmacological
the	Pharmacological
contralateral	Pharmacological
EDB	Pharmacological
.	O

RESULTS	O
All	O
NT	Pharmacological
201	Pharmacological
and	Pharmacological
BTXCo	Pharmacological
doses	O
achieved	O
a	O
statistically	O
significant	O
reduction	O
of	O
the	O
compound	O
muscle	O
action	O
potential	O
M-wave	O
amplitude	O
in	O
the	O
EDB	O
muscle	O
.	O

At	O
week	O
4	O
,	O
the	O
highest	O
dose	O
was	O
statistically	O
significantly	O
more	O
effective	O
than	O
the	O
lowest	O
dose	O
(	O
NT	O
201	O
,	O
P	O
=	O
0.019	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.195-1.370	O
;	O
and	O
BTXCo	O
,	O
P	O
=	O
0.002	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.309-1.167	O
)	O
.	O

Duration	O
of	O
effect	O
was	O
dose	O
dependent	O
.	O

The	O
mean	O
values	O
of	O
compound	O
muscle	O
action	O
potential	O
M-wave	O
amplitudes	O
in	O
the	O
adjacent	O
muscles	O
(	O
abductor	O
digiti	O
quinti	O
and	O
abductor	O
hallucis	O
)	O
were	O
above	O
the	O
predefined	O
threshold	O
of	O
effect	O
,	O
indicating	O
that	O
there	O
was	O
no	O
relevant	O
diffusion-induced	O
reduction	O
of	O
muscle	O
activity	O
.	O

NT	Pharmacological
201	Pharmacological
and	O
BTXCo	Pharmacological
were	O
well	O
tolerated	O
.	O

CONCLUSIONS	O
NT	Pharmacological
201	Pharmacological
is	O
effective	O
and	O
safe	O
in	O
inducing	O
the	O
desired	O
paretic	O
effect	O
.	O

Randomized	O
controlled	O
study	O
of	O
chemoimmunotherapy	Pharmacological
with	Pharmacological
bestatin	Pharmacological
of	O
acute	O
nonlymphocytic	O
leukemia	O
in	O
adults	O
.	O

A	O
new	O
immunomodulating	Pharmacological
agent	Pharmacological
,	Pharmacological
bestatin	Pharmacological
(	O
INN	O
:	O
Ubenimex	Pharmacological
has	O
low	O
toxicity	O
even	O
after	O
long-term	O
oral	O
administration	O
and	O
has	O
significant	O
modifications	O
in	O
immunological	O
response	O
.	O

A	O
cooperative	O
randomized	O
controlled	O
study	O
of	O
bestatin	Pharmacological
immunotherapy	Pharmacological
in	O
combination	O
with	O
remission	Pharmacological
maintenance	Pharmacological
chemotherapy	Pharmacological
for	O
adult	O
acute	O
nonlymphocytic	O
leukemia	O
(	O
ANLL	O
)	O
was	O
performed	O
.	O

After	O
induction	O
of	O
complete	O
remission	O
,	O
patients	O
were	O
randomized	O
to	O
the	O
bestatin	Pharmacological
group	Pharmacological
(	O
30	O
mg/bw	O
per	O
os	O
(	O
po	O
)	O
daily	O
)	O
and	O
the	O
control	Control
group	Control
.	Control

The	O
101	O
eligible	O
cases	O
(	Pharmacological
bestatin	Pharmacological
:	Pharmacological
48	O
,	O
control	O
:	O
53	O
)	O
were	O
analyzed	O
;	O
the	O
bestatin	Pharmacological
group	O
achieved	O
longer	O
remission	O
than	O
the	O
control	O
group	O
and	O
a	O
statistically	O
significant	O
longer	O
survival	O
.	O

Though	O
this	O
prolongation	O
of	O
remission	O
was	O
not	O
significant	O
in	O
the	O
bestatin	Pharmacological
group	O
compared	O
to	O
the	O
control	O
group	O
in	O
the	O
15-49	O
yr	O
age	O
group	O
,	O
in	O
the	O
50-65	O
yr	O
age	O
group	O
it	O
was	O
significantly	O
longer	O
.	O

Bestatin	Pharmacological
is	O
shown	O
to	O
be	O
a	O
clinically	O
useful	O
drug	O
for	O
immunotherapy	Pharmacological
of	O
adult	O
ANLL	O
,	O
since	O
it	O
has	O
prolonged	O
survival	O
and	O
remission	O
especially	O
in	O
elderly	O
patients	O
,	O
with	O
few	O
side-effects	O
.	O

The	O
role	O
of	O
the	O
MA-sensitive	O
leukocyte	O
chemotaxis	O
in	O
rheumatoid	O
arthritis	O
.	O

A	O
randomized	O
double-blind	O
clinical	O
trial	O
of	O
griseofulvin	Pharmacological
treatment	O
.	O

Polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
chemotaxis	O
is	O
thought	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O

PMN	O
chemotaxis	O
is	O
in	O
part	O
sensitive	O
to	O
microtubule	O
antagonists	O
(	O
MAs	O
)	O
,	O
e.g	O
.	O

colchicine	O
.	O

The	O
antimycotic	O
antibiotic	O
griseofulvin	Pharmacological
inhibits	O
the	O
MA-sensitive	O
PMN	O
chemotaxis	O
in	O
vitro	O
in	O
concentrations	O
far	O
below	O
those	O
obtained	O
in	O
serum	O
during	O
antimycotic	Physical
therapy	Physical
.	Pharmacological

The	O
role	O
of	O
the	O
MA-sensitive	O
chemotaxis	O
in	O
rheumatoid	O
arthritis	O
could	O
thus	O
be	O
elucidated	O
by	O
a	O
clinical	O
trial	O
of	O
griseofulvin	Educational
treatment	O
.	O

Griseofulvin	Pharmacological
(	O
n	O
=	O
20	O
)	O
was	O
tested	O
in	O
a	O
randomized	O
double-blind	O
study	O
versus	O
placebo	Control
(	O
m	O
=	O
19	O
)	O
during	O
one	O
year	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
of	O
mild-moderate	O
activity	O
.	O

No	O
beneficial	O
effect	O
of	O
griseofulvin	Pharmacological
treatment	O
was	O
noted	O
on	O
clinical	O
symptoms	O
or	O
laboratory	O
parameters	O
of	O
rheumatoid	O
arthritis	O
.	O

Moreover	O
,	O
the	O
placebo-treated	Control
patients	O
showed	O
more	O
improvement	O
than	O
the	O
griseofulvin-treated	Pharmacological
patients	O
.	O

It	O
is	O
therefore	O
suggested	O
that	O
the	O
MA-sensitive	O
chemotaxis	O
plays	O
a	O
reparative	O
role	O
in	O
the	O
inflammatory	O
lesions	O
of	O
rheumatoid	O
arthritis	O
.	O

The	O
effect	O
of	O
risedronate	Pharmacological
treatment	O
on	O
serum	O
cytokines	O
in	O
postmenopausal	O
osteoporosis	O
:	O
a	O
6-month	O
randomized	O
and	O
controlled	O
study	O
.	O

There	O
is	O
much	O
evidence	O
suggesting	O
that	O
the	O
decline	O
in	O
ovarian	O
function	O
after	O
menopause	O
is	O
associated	O
with	O
spontaneous	O
increases	O
in	O
proinflammatory	O
cytokines	O
.	O

Treatment	O
with	O
risedronate	Pharmacological
is	O
accompanied	O
by	O
significant	O
changes	O
in	O
bone	O
turnover	O
and	O
bone	O
mineral	O
density	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
risedronate	Pharmacological
treatment	O
on	O
the	O
level	O
of	O
serum	O
cytokines	O
including	O
receptor	O
activator	O
of	O
nuclear	O
factor-kappaB	O
ligand	O
(	O
RANKL	O
)	O
and	O
osteoprotegerin	O
among	O
postmenopausal	O
women	O
with	O
osteoporosis	O
.	O

The	O
study	O
group	O
consisted	O
of	O
61	O
postmenopausal	O
women	O
with	O
osteoporosis	O
.	O

Patients	O
were	O
randomly	O
divided	O
in	O
two	O
groups	O
:	O
In	O
group	O
1	O
(	O
n	O
=	O
41	O
)	O
postmenopausal	O
women	O
received	O
oral	Pharmacological
risedronate	Pharmacological
(	O
35	O
mg/week	O
)	O
,	O
calcium	Pharmacological
(	O
1,000	O
mg/day	O
)	O
,	O
and	O
vitamin	Pharmacological
D	Pharmacological
(	O
400	O
IU/day	O
)	O
for	O
12	O
months	O
.	O

In	O
group	O
2	O
(	O
control	O
group	O
;	O
n	O
=	O
20	O
)	O
patients	O
received	O
only	O
oral	Pharmacological
calcium	Pharmacological
(	O
1,000	O
mg/day	O
)	O
and	O
vitamin	Pharmacological
D	Pharmacological
(	O
400	O
IU/day	O
)	O
.	O

Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
of	O
lumbar	O
spine	O
(	O
L1-L4	O
)	O
and	O
proximal	O
femur	O
were	O
determined	O
using	O
dual	O
X-ray	O
absorptiometry	O
at	O
baseline	O
and	O
after	O
one	O
year	O
.	O

Venous	O
blood	O
samples	O
were	O
obtained	O
for	O
determination	O
of	O
serum	O
cytokines	O
including	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
,	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
,	O
RANKL	O
,	O
osteoprotegerin	O
,	O
and	O
markers	O
of	O
bone	O
formation	O
and	O
resorption	O
.	O

Levels	O
of	O
serum	O
cytokines	O
were	O
measured	O
before	O
therapy	O
and	O
after	O
three	O
and	O
6	O
months	O
.	O

Markers	O
of	O
bone	O
metabolism	O
were	O
studied	O
before	O
therapy	O
and	O
after	O
6	O
months	O
.	O

In	O
group	O
1	O
(	O
risedronate	O
plus	O
calcium/vitamin	O
D-treated	O
patients	O
)	O
,	O
serum	O
levels	O
of	O
RANKL	O
and	O
IL-1beta	O
significantly	O
decreased	O
and	O
the	O
level	O
of	O
osteoprotegerin	O
significantly	O
increased	O
after	O
three	O
and	O
6	O
months	O
,	O
but	O
no	O
significant	O
difference	O
was	O
found	O
in	O
TNF-alpha	O
level	O
.	O

In	O
group	O
2	O
,	O
however	O
,	O
the	O
level	O
of	O
serum	O
cytokines	O
did	O
not	O
change	O
after	O
three	O
and	O
6	O
months	O
.	O

In	O
cases	O
of	O
bone	O
turnover	O
,	O
both	O
markers	O
of	O
bone	O
resorption	O
and	O
formation	O
significantly	O
decreased	O
after	O
6	O
months	O
in	O
group	O
1	O
.	O

In	O
conclusion	O
risedronate	O
could	O
improve	O
osteoporosis	O
by	O
increasing	O
osteoprotegerin	O
and	O
reducing	O
RANKL	O
and	O
IL-1beta	O
.	O

Leucocyte	O
depletion	O
of	O
perioperative	Pharmacological
blood	Pharmacological
transfusion	Pharmacological
does	O
not	O
affect	O
long-term	O
survival	O
and	O
recurrence	O
in	O
patients	O
with	O
gastrointestinal	O
cancer	O
.	O

BACKGROUND	O
Perioperative	Pharmacological
red	Pharmacological
blood	Pharmacological
cell	Pharmacological
(	Pharmacological
RBC	Pharmacological
)	Pharmacological
transfusion	Pharmacological
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
cancer	O
surgery	O
.	O

Allogeneic	O
leucocytes	O
are	O
assumed	O
to	O
play	O
a	O
causal	O
role	O
.	O

This	O
study	O
evaluated	O
the	O
long-term	O
effect	O
of	O
transfusion	Pharmacological
with	Pharmacological
leucocyte-depleted	Pharmacological
(	O
LD	O
)	O
blood	O
in	O
patients	O
with	O
gastrointestinal	O
cancer	O
.	O

METHODS	O
The	O
Transfusion	O
Associated	O
Complications	O
=	O
Transfusion	O
Induced	O
Complications	O
?	O
(	O
TACTIC	O
)	O
study	O
is	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
short-term	O
benefits	O
of	O
LD	Pharmacological
versus	Pharmacological
non-LD	Physical
RBC	Physical
transfusions	Physical
.	O

The	O
present	O
study	O
evaluated	O
5-year	O
survival	O
and	O
cancer	O
recurrence	O
among	O
512	O
patients	O
with	O
gastrointestinal	O
cancer	O
included	O
in	O
the	O
TACTIC	O
study	O
.	O

RESULTS	O
Some	O
89.2	O
per	O
cent	O
of	O
patients	O
had	O
a	O
primary	O
tumour	O
and	O
79.7	O
per	O
cent	O
underwent	O
surgery	Surgical
with	O
curative	O
intent	O
;	O
243	O
patients	O
received	O
perioperative	Physical
RBC	Physical
transfusion	Physical
(	O
median	O
3	O
units	O
)	O
.	O

The	O
5-year	O
overall	O
survival	O
rate	O
of	O
patients	O
with	O
any	O
type	O
of	O
gastrointestinal	O
cancer	O
was	O
50.8	O
per	O
cent	O
in	O
the	O
LD	O
group	O
and	O
45.8	O
per	O
cent	O
in	O
the	O
non-LD	O
group	O
(	O
P	O
=	O
0.191	O
)	O
.	O

Corresponding	O
5-year	O
disease-free	O
survival	O
rates	O
were	O
60.0	O
and	O
56.6	O
per	O
cent	O
(	O
P	O
=	O
0.482	O
)	O
,	O
and	O
recurrence	O
rates	O
32.9	O
and	O
34.3	O
per	O
cent	O
(	O
P	O
=	O
0.864	O
)	O
.	O

CONCLUSION	O
Leucocyte	O
depletion	O
is	O
not	O
associated	O
with	O
better	O
long-term	O
survival	O
and	O
lower	O
recurrence	O
rates	O
in	O
patients	O
with	O
gastrointestinal	O
cancer	O
.	O

The	O
peroxisome	O
proliferator-activated	O
receptor-gamma	O
agonist	O
pioglitazone	Pharmacological
increases	O
number	O
and	O
function	O
of	O
endothelial	O
progenitor	O
cells	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
and	O
normal	O
glucose	O
tolerance	O
.	O

OBJECTIVE	O
Peroxisome	O
proliferator-activated	O
receptor-gamma	O
(	O
PPAR	O
gamma	O
)	O
agonists	O
(	O
thiazolidinediones	Pharmacological
[	Pharmacological
TZDs	Pharmacological
]	O
)	O
are	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O

Bone	O
marrow-derived	O
endothelial	O
progenitor	O
cells	O
(	O
EPCs	O
)	O
improve	O
vascular	O
function	O
and	O
predict	O
cardiovascular	O
risk	O
.	O

The	O
effect	O
of	O
pioglitazone	Pharmacological
therapy	O
on	O
EPCs	O
was	O
examined	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
AND	O
RESULTS	O
We	O
performed	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
on	O
patients	O
with	O
documented	O
stable	O
coronary	O
artery	O
disease	O
and	O
normal	O
glucose	O
tolerance	O
.	O

Of	O
54	O
patients	O
with	O
normal	O
fasting	O
glucose	O
levels	O
,	O
18	O
showed	O
impaired	O
glucose	O
tolerance	O
and	O
36	O
patients	O
with	O
normal	O
glucose	O
tolerance	O
were	O
randomized	O
to	O
30-day	O
treatment	O
with	O
pioglitazone	Pharmacological
(	O
45	O
mg	O
)	O
or	O
placebo	O
in	O
addition	O
to	O
optimal	O
medical	O
therapy	O
.	O

All	O
patients	O
in	O
the	O
TZD	Pharmacological
group	O
showed	O
an	O
increase	O
of	O
adiponectin	O
levels	O
as	O
an	O
indicator	O
of	O
compliance	O
(	O
11.4	O
+/-	O
1.1	O
to	O
36.8	O
+/-	O
2.1	O
microg/ml	O
;	O
P	O
<	O
0.001	O
)	O
.	O

TZD	Pharmacological
,	O
but	O
not	O
placebo	O
,	O
decreased	O
mean	O
high-sensitivity	O
C-reactive	O
protein	O
to	O
43	O
+/-	O
19	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pioglitazone	O
increased	O
CD34	O
(	O
+	O
)	O
/kinase	O
insert	O
domain	O
receptor	O
(	O
+	O
)	O
EPCs	O
to	O
142	O
+/-	O
9	O
%	O
and	O
cultured	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	O
acetylated	O
LDL	O
(	O
+	O
)	O
/lectin	O
(	O
+	O
)	O
EPCs	O
to	O
180	O
+/-	O
3	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

EPC	O
numbers	O
were	O
not	O
changed	O
in	O
the	O
placebo	O
group	O
.	O

TZD	O
increased	O
the	O
SDF-1-induced	O
migratory	O
capacity	O
to	O
146	O
+/-	O
9	O
%	O
per	O
EPC	O
number	O
(	O
P	O
<	O
0.05	O
)	O
and	O
upregulated	O
the	O
clonogenic	O
potential	O
of	O
EPCs	O
,	O
increasing	O
the	O
colony-forming	O
units	O
to	O
172	O
+/-	O
12	O
%	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
cultured	O
human	O
EPCs	O
,	O
TZD	Pharmacological
increased	O
EPC	O
numbers	O
and	O
migration	O
and	O
reduced	O
NADPH-oxidase	O
activity	O
.	O

The	O
TZD	Pharmacological
effect	O
was	O
reversed	O
by	O
the	O
PPAR	O
gamma	O
antagonist	O
GW9662	O
and	O
mimicked	O
by	O
treatment	O
with	O
adiponectin	O
.	O

CONCLUSIONS	O
The	O
PPAR	O
gamma	O
agonist	O
pioglitazone	Pharmacological
increases	O
the	O
number	O
and	O
function	O
of	O
EPCs	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

The	O
effect	O
represents	O
a	O
potential	O
regenerative	O
mechanism	O
in	O
atherosclerosis	O
and	O
is	O
observed	O
in	O
normoglycemic	O
individuals	O
with	O
stable	O
coronary	O
artery	O
disease	O
.	O

Preoperative	O
beta-blocker	Pharmacological
usage	Pharmacological
:	O
is	O
it	O
really	O
worthy	O
of	O
being	O
a	O
quality	O
indicator	O
?	O
BACKGROUND	O
Since	O
2007	O
,	O
the	O
use	O
of	O
preoperative	O
?-blockers	O
has	O
been	O
used	O
as	O
a	O
quality	O
standard	O
for	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
.	O

Recent	O
studies	O
have	O
called	O
into	O
question	O
of	O
the	O
benefit	O
of	O
empiric	O
preoperative	O
?-blocker	O
use	O
.	O

METHODS	O
Data	O
were	O
extracted	O
from	O
our	O
Society	O
of	O
Thoracic	O
Surgeons	O
certified	O
database	O
for	O
patients	O
undergoing	O
isolated	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
from	O
2000	O
to	O
2008	O
.	O

We	O
compared	O
the	O
outcomes	O
for	O
patients	O
who	O
received	O
preoperative	O
?-blockers	O
with	O
those	O
of	O
patients	O
who	O
did	O
not	O
.	O

RESULTS	O
The	O
study	O
group	O
had	O
12,855	O
patients	O
,	O
of	O
whom	O
7,967	O
(	O
62.0	O
%	O
)	O
were	O
treated	O
preoperatively	O
with	O
?-blockers	O
.	O

Using	O
propensity	O
matching	O
,	O
we	O
selected	O
two	O
matched	O
groups	O
of	O
4,474	O
patients	O
with	O
preoperative	O
?-blocker	O
use	O
and	O
4,474	O
not	O
using	O
preoperative	O
?-blockers	O
.	O

In	O
the	O
unmatched	O
cohort	O
,	O
only	O
deep	O
sternal	O
infection	O
(	O
0.3	O
%	O
versus	O
0.5	O
%	O
without	O
?-blockers	O
;	O
p=0.032	O
)	O
,	O
pneumonia	O
(	O
1.9	O
%	O
versus	O
2.4	O
%	O
without	O
?-blockers	O
;	O
p=0.039	O
)	O
,	O
and	O
intraoperative	O
blood	O
usage	O
(	O
37.2	O
%	O
versus	O
34.1	O
%	O
without	O
?-blockers	O
;	O
p	O
<	O
0.001	O
)	O
reached	O
statistically	O
significant	O
difference	O
.	O

In	O
the	O
matched	O
groups	O
,	O
there	O
was	O
no	O
difference	O
between	O
adverse	O
event	O
rates	O
in	O
patients	O
treated	O
with	O
?-blockers	O
and	O
those	O
who	O
were	O
not	O
.	O

The	O
number	O
of	O
patients	O
requiring	O
intraoperative	O
blood	O
product	O
use	O
was	O
significantly	O
higher	O
among	O
?-blocker-treated	O
patients	O
(	O
p=0.004	O
)	O
.	O

Calculating	O
the	O
adjusted	O
odds	O
ratios	O
showed	O
that	O
in	O
the	O
matched	O
groups	O
,	O
the	O
preoperative	O
use	O
of	O
?-blockers	O
was	O
not	O
an	O
independent	O
predictor	O
of	O
mortality	O
.	O

CONCLUSIONS	O
A	O
rational	O
for	O
preoperative	O
?-blockade	O
exists	O
.	O

However	O
,	O
as	O
with	O
any	O
medical	O
intervention	O
,	O
its	O
application	O
should	O
be	O
tailored	O
to	O
specific	O
clinical	O
scenarios	O
.	O

With	O
no	O
differences	O
in	O
mortality	O
or	O
morbidity	O
,	O
our	O
findings	O
do	O
not	O
support	O
preoperative	O
?-blockade	O
as	O
a	O
useful	O
quality	O
indicator	O
for	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
.	O

The	O
effect	O
of	O
Naftidrofuryl	Pharmacological
on	O
ethanol-induced	O
liver	O
damage	O
in	O
chronic	O
alcoholic	O
patients	O
.	O

A	O
prospective	O
double-blind	O
placebo-controlled	Control
trial	O
of	O
intramuscular	O
Naftidrofuryl	Pharmacological
was	O
carried	O
out	O
on	O
32	O
randomly	O
selected	O
hospitalized	O
male	O
alcoholic	O
patients	O
with	O
clinical	O
,	O
biochemical	O
and	O
histological	O
evidence	O
of	O
hepatic	O
damage	O
.	O

Seventeen	O
patients	O
received	O
the	O
drug	O
(	O
40	O
mg	O
in	O
5	O
ml	O
i.m	O
.	O

three	O
times	O
daily	O
for	O
6	O
days	O
)	O
and	O
15	O
patients	O
received	O
a	O
placebo	Pharmacological
(	O
5	O
ml	O
in	O
normal	O
saline	O
i.m	O
.	O

three	O
times	O
daily	O
for	O
6	O
days	O
)	O
.	O

The	O
drug	O
was	O
well	O
tolerated	O
and	O
there	O
were	O
no	O
adverse	O
side-effects	O
.	O

Naftidrofuryl	O
significantly	O
improved	O
the	O
physiological	O
function	O
of	O
the	O
liver	O
cells	O
as	O
reflected	O
by	O
indocyanine	O
green	O
(	O
ICG	O
)	O
clearance	O
by	O
the	O
liver	O
(	O
t	O
=	O
2.61	O
;	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.02	O
)	O
and	O
also	O
caused	O
a	O
larger	O
fall	O
in	O
raised	O
serum	O
levels	O
of	O
gamma	O
glutamyl	O
transpeptidase	O
(	O
GGT	O
)	O
than	O
did	O
the	O
placebo	O
injections	O
.	O

Overall	O
clinical	O
improvement	O
(	O
e.g	O
.	O

appetite	O
,	O
body	O
weight	O
,	O
reduced	O
liver	O
size	O
,	O
general	O
sense	O
of	O
well-being	O
)	O
was	O
more	O
clearly	O
evident	O
in	O
patients	O
of	O
the	O
treated	O
group	O
than	O
in	O
those	O
of	O
the	O
placebo	O
group	O
.	O

Naftidrofuryl	Pharmacological
,	O
therefore	O
,	O
appears	O
to	O
be	O
of	O
benefit	O
in	O
ethanol-induced	O
liver	O
damage	O
and	O
more	O
extensive	O
long-term	O
trials	O
are	O
suggested	O
in	O
patients	O
with	O
alcoholic	O
liver	O
disease	O
(	O
ALD	O
)	O
.	O

[	O
Efficacy	O
of	O
immunomodulating	Pharmacological
treatment	Pharmacological
in	O
patients	O
with	O
different	O
degrees	O
of	O
immunosuppression	O
]	O
.	O

Immunodepression	O
is	O
a	O
common	O
condition	O
in	O
patients	O
undergoing	O
elective	O
operations	O
and	O
it	O
constitutes	O
a	O
high	O
risk	O
for	O
the	O
onset	O
of	O
postoperative	O
infective	O
complications	O
.	O

The	O
use	O
of	O
immunomodulatory	Pharmacological
drugs	Pharmacological
has	O
proved	O
useful	O
in	O
the	O
prophylaxis	O
of	O
these	O
complications	O
,	O
although	O
the	O
precise	O
indications	O
for	O
each	O
drug	O
have	O
not	O
yet	O
been	O
clearly	O
codified	O
.	O

The	O
present	O
study	O
aimed	O
to	O
assess	O
the	O
effects	O
of	O
thymostimulin	Pharmacological
in	O
patients	O
with	O
different	O
degrees	O
of	O
immunodepression	O
,	O
by	O
evaluating	O
both	O
the	O
incidence	O
of	O
postoperative	O
infections	O
and	O
the	O
changes	O
induced	O
in	O
various	O
immunological	O
parameters	O
.	O

The	O
results	O
obtained	O
indicated	O
that	O
those	O
subjects	O
with	O
the	O
highest	O
degree	O
of	O
immunodepression	O
(	O
hypo-anergic	O
)	O
benefited	O
most	O
from	O
drug	Pharmacological
therapy	Pharmacological
in	O
comparison	O
to	O
those	O
with	O
a	O
lesser	O
degree	O
of	O
immunodepression	O
(	O
relatively	O
hypo-ergic	O
)	O
.	O

The	O
advantages	O
were	O
evident	O
in	O
hypo-anergic	O
subjects	O
both	O
with	O
regard	O
to	O
the	O
frequency	O
of	O
early	O
postoperative	O
infections	O
,	O
and	O
with	O
regard	O
to	O
immunological	O
parameters	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
relatively	O
hypo-ergic	O
subjects	O
,	O
benefits	O
were	O
limited	O
to	O
the	O
improvement	O
of	O
some	O
immunological	O
parameters	O
.	O

In	O
our	O
opinion	O
,	O
the	O
use	O
of	O
thymostimulin	Pharmacological
is	O
of	O
particular	O
use	O
only	O
in	O
those	O
subjects	O
with	O
marked	O
immunodepression	O
since	O
the	O
incidence	O
of	O
post-operative	O
sepsis	O
is	O
highest	O
in	O
this	O
group	O
.	O

[	O
The	O
anti-ischemic	O
effect	O
of	O
phosphodiesterase	O
III	O
inhibitors	O
]	O
.	O

When	O
enoximone	Pharmacological
is	O
acutely	O
administered	O
to	O
patients	O
with	O
stable	O
angina	O
and	O
angiographically	O
proven	O
relevant	O
coronary	O
stenosis	O
i.v	O
.	O

application	O
of	O
0.75	O
mg/kg	O
exhibits	O
pronounced	O
antiischemic	O
effects	O
.	O

This	O
could	O
be	O
observed	O
in	O
patients	O
during	O
exercise	O
and	O
in	O
those	O
in	O
whom	O
the	O
ischemia	O
was	O
provoked	O
by	O
rapid	O
cardiac	O
stimulation	O
.	O

The	O
antiischemic	O
effects	O
were	O
documented	O
by	O
relief	O
of	O
symptoms	O
,	O
reduction	O
of	O
ST-depression	O
,	O
improvement	O
of	O
impaired	O
myocardial	O
wall	O
motion	O
,	O
decrease	O
to	O
normalization	O
of	O
pathologically	O
elevated	O
filling	O
pressure	O
,	O
amelioration	O
of	O
coronary	O
blood	O
flow	O
as	O
evidenced	O
by	O
myocard	O
scintigraphy	O
and	O
washout	O
time	O
of	O
an	O
intracoronarily	O
injected	O
echo-contrast	O
medium	O
.	O

There	O
was	O
also	O
a	O
definite	O
improvement	O
of	O
ischemia-caused	O
mitral	O
regurgitation	O
.	O

Similar	O
observations	O
were	O
found	O
when	O
the	O
drug	O
was	O
injected	O
in	O
the	O
diseased	O
coronary	O
arteries	O
in	O
a	O
small	O
dose	O
(	O
0.075	O
mg/kg	O
)	O
so	O
that	O
peripheral	O
effects	O
were	O
not	O
present	O
.	O

In	O
comparison	O
to	O
the	O
Ca	O
(	O
++	O
)	O
-blocker	O
Gallopamil	Pharmacological
the	O
antiischemic	O
effects	O
of	O
Enoximone	Pharmacological
were	O
more	O
pronounced	O
,	O
a	O
synergistic	O
action	O
was	O
,	O
however	O
,	O
observed	O
.	O

Negative	O
dromotropic	O
effects	O
of	O
Gallopamil	Pharmacological
could	O
be	O
abolished	O
by	O
Enoximone	Pharmacological
.	O

With	O
oral	O
administration	O
of	O
the	O
drug	O
over	O
a	O
period	O
of	O
one	O
week	O
antiischemic	O
effects	O
could	O
also	O
be	O
documented	O
with	O
Holter	O
monitoring	O
as	O
well	O
as	O
during	O
exercise	O
.	O

There	O
was	O
a	O
reduction	O
of	O
ST-depression	O
both	O
at	O
spontaneously	O
occurring	O
ischemic	O
episodes	O
and	O
during	O
exercise	O
,	O
in	O
the	O
number	O
and	O
duration	O
of	O
episodes	O
of	O
silent	O
ischemia	O
,	O
particularly	O
,	O
however	O
,	O
a	O
decrease	O
in	O
symptomatic	O
episodes	O
.	O

In	O
none	O
of	O
the	O
patients	O
under	O
study	O
proarrhythmic	O
effects	O
were	O
observed	O
.	O

Management	O
of	O
unstable	O
angina	O
at	O
rest	O
by	O
verapamil	Pharmacological
.	O

A	O
double-blind	O
cross-over	O
study	O
in	O
coronary	O
care	O
unit	O
.	O

A	O
therapeutic	O
trial	O
with	O
verapamil	Pharmacological
,	O
a	O
calcium-antagonist	Pharmacological
drug	Pharmacological
,	O
was	O
performed	O
in	O
12	O
patients	O
admitted	O
to	O
our	O
coronary	O
care	O
unit	O
because	O
of	O
frequent	O
daily	O
attacks	O
of	O
angina	O
at	O
rest	O
attributed	O
to	O
coronary	O
vasospasm	O
.	O

After	O
a	O
48-hour	O
run-in	O
period	O
,	O
oral	Pharmacological
verapamil	Pharmacological
480	Pharmacological
mg/day	Pharmacological
and	O
placebo	Control
were	O
administered	O
alternately	O
during	O
4	O
randomised	O
48-hour	O
periods	O
.	O

Transient	O
ischaemic	O
attacks	O
with	O
ST	O
segment	O
elevation	O
or	O
depression	O
,	O
with	O
or	O
without	O
pain	O
,	O
were	O
documented	O
by	O
continuous	O
electrocardiographic	O
monitoring	O
.	O

The	O
number	O
of	O
attacks	O
during	O
the	O
run-in	O
and	O
2	O
placebo	Control
periods	O
were	O
128	O
,	O
123	O
,	O
and	O
130	O
,	O
respectively	O
,	O
and	O
31	O
and	O
23	O
during	O
the	O
2	O
treatment	O
periods	O
(	O
P	O
less	O
than	O
0.006	O
and	O
P	O
less	O
than	O
0.003	O
)	O
.	O

This	O
drug	O
therefore	O
appears	O
to	O
be	O
effective	O
in	O
the	O
management	O
of	O
patients	O
with	O
frequent	O
attacks	O
of	O
angina	O
at	O
rest	O
.	O

Treatment	O
of	O
adult	O
asthma	O
:	O
controlled	O
double-blind	O
clinical	O
trial	O
of	O
oxitropium	Pharmacological
bromide	Pharmacological
.	O

Sixteen	O
young	O
adult	O
sufferers	O
from	O
extrinsic	O
paroxysmal	O
asthma	O
with	O
pollen	O
hypersensitivity	O
took	O
part	O
in	O
a	O
therapeutic	O
trial	O
of	O
the	O
synthetic	Pharmacological
anticholinergic	Pharmacological
agent	Pharmacological
oxitropium	Pharmacological
bromide	Pharmacological
administered	O
by	O
a	O
metered	O
dose	O
inhaler	O
.	O

The	O
study	O
comprised	O
three	O
3-week	O
periods	O
.	O

The	O
first	O
,	O
run-in	O
period	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
ability	O
of	O
the	O
patients	O
to	O
maintain	O
a	O
daily	O
record	O
of	O
symptoms	O
.	O

During	O
the	O
second	O
and	O
third	O
periods	O
,	O
the	O
patient	O
received	O
3	O
X	O
2	O
inhalations	O
of	O
drug	O
or	O
placebo	Control
in	O
a	O
cross-over	O
design	O
.	O

The	O
medical	O
staff	O
was	O
blind	O
to	O
the	O
nature	O
of	O
the	O
aerosol	O
(	O
drug	Pharmacological
or	O
placebo	Control
)	Control
,	O
which	O
was	O
given	O
in	O
random	O
order	O
.	O

The	O
run-in	O
clinical	O
score	O
was	O
high	O
.	O

Asymptomatic	O
days	O
were	O
relatively	O
infrequent	O
and	O
daily	O
drug	O
consumption	O
was	O
high	O
.	O

Functional	O
studies	O
between	O
the	O
cross-over	O
periods	O
showed	O
flow-rate	O
values	O
close	O
to	O
normal	O
,	O
with	O
an	O
increase	O
in	O
residual	O
volume	O
and	O
functional	O
residual	O
capacity	O
.	O

During	O
treatment	O
either	O
with	O
placebo	Control
or	O
oxitropium	Pharmacological
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
clinical	O
scores	O
.	O

Results	O
for	O
oxitropium	Pharmacological
bromide	Pharmacological
treatment	O
were	O
significantly	O
better	O
than	O
the	O
run-in	O
values	O
(	O
p	O
less	O
than	O
0.005	O
)	O
and	O
the	O
placebo	Control
period	O
(	O
p	O
less	O
than	O
0.02	O
)	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
non-trial	O
drug	O
consumption	O
.	O

Functional	O
values	O
showed	O
no	O
difference	O
in	O
terms	O
of	O
flow	O
rate	O
,	O
although	O
oxitropium	O
did	O
cause	O
a	O
significant	O
improvement	O
in	O
the	O
RV/TLC	O
ratio	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

No	O
adverse	O
reactions	O
were	O
reported	O
.	O

[	O
Comparison	O
of	O
complications	O
after	O
intra-	Physical
and	Physical
extracapsular	Physical
cataract	Physical
extraction	Physical
with	Physical
lens	Physical
implantation	Physical
.	O

Results	O
of	O
a	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
]	O
.	O

BACKGROUND	O
The	O
postoperative	O
complications	O
of	O
ICCE	Physical
with	Physical
ACL	Physical
implantation	Physical
are	O
compared	O
with	O
those	O
of	O
ECCE	Physical
and	Physical
PCL	Physical
.	Physical

Our	O
clinical	O
experience	O
with	O
ICCE	Physical
and	Physical
ACL	Physical
implantation	Physical
can	O
not	O
confirm	O
the	O
widespread	O
rejection	O
of	O
this	O
method	O
.	O

PATIENTS	O
AND	O
METHOD	O
A	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
with	O
participation	O
of	O
medical	O
statisticians	O
was	O
performed	O
.	O

A	O
total	O
of	O
190	O
patients	O
with	O
ICCE	Physical
and	Physical
ACL	Physical
and	O
170	O
patients	O
with	O
ECCE	Physical
and	Physical
PCL	Physical
were	O
followed	O
up	O
for	O
2	O
years	O
.	O

The	O
follow-up	O
examinations	O
were	O
performed	O
upon	O
dismission	O
from	O
the	O
hospital	O
,	O
after	O
6	O
,	O
12	O
and	O
24	O
months	O
.	O

The	O
data	O
were	O
compiled	O
in	O
a	O
computer	O
program	O
designed	O
for	O
this	O
study	O
and	O
evaluated	O
by	O
the	O
statisticians	O
.	O

The	O
surgical	O
procedures	O
and	O
the	O
surgeons	O
were	O
defined	O
prior	O
to	O
the	O
beginning	O
of	O
patient	O
recruitment	O
.	O

RESULTS	O
ICCE	Physical
with	Physical
ACL	Physical
shows	O
much	O
less	O
postoperative	O
complications	O
as	O
usually	O
emphasized	O
.	O

There	O
were	O
only	O
2	O
(	O
1.2	O
%	O
)	O
of	O
retinal	O
detachment	O
and	O
no	O
case	O
of	O
corneal	O
decompensation	O
.	O

Cystoid	O
macular	O
edema	O
8	O
(	O
4.7	O
%	O
)	O
,	O
postoperative	O
vitreous	O
prolaps	O
into	O
the	O
anterior	O
chamber	O
4	O
(	O
2.3	O
%	O
)	O
and	O
spontaneous	O
complaints	O
of	O
pain	O
16	O
(	O
9.4	O
%	O
)	O
occurred	O
in	O
a	O
low	O
percentage	O
after	O
ICCE	Physical
with	Physical
ACL	Physical
.	O

These	O
complications	O
did	O
not	O
occur	O
after	O
ECCE	Physical
with	Physical
PCL	Physical
.	O

The	O
patients	O
with	O
ECCE	Physical
and	Physical
PCL	Physical
showed	O
capsular	O
fibrosis	O
in	O
48	O
(	O
28	O
%	O
)	O
making	O
it	O
the	O
most	O
frequent	O
complication	O
of	O
the	O
whole	O
study	O
.	O

33	O
%	O
of	O
these	O
patients	O
required	O
YAG-laser	Surgical
capsulotomy	Surgical
.	O

Since	O
retinal	O
detachment	O
occurs	O
in	O
2.5	O
%	O
after	O
YAG-laser	Surgical
capsulotomy	Surgical
we	O
can	O
not	O
regard	O
capsular	O
fibrosis	O
as	O
a	O
totally	O
harmless	O
complication	O
.	O

It	O
is	O
noteworthy	O
that	O
visual	O
acuity	O
is	O
almost	O
identical	O
1	O
year	O
after	O
surgery	O
in	O
both	O
methods	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
the	O
evaluation	O
of	O
ICCE	Physical
with	Physical
ACL	Physical
is	O
too	O
negative	O
.	O

The	O
elimination	O
of	O
postoperative	O
complications	O
in	O
this	O
method	O
is	O
more	O
difficult	O
.	O

ECCE	Surgical
with	Surgical
PCL	Surgical
is	O
burdened	O
by	O
frequent	O
capsular	O
fibrosis	O
.	O

Visual	O
acuity	O
is	O
almost	O
the	O
same	O
in	O
both	O
methods	O
1	O
years	O
after	O
the	O
operation	O
.	O

ACL-implantation	Surgical
remains	O
our	O
method	O
of	O
choice	O
for	O
secondary	O
implantation	O
in	O
patients	O
with	O
an	O
intact	O
iris	O
diaphragm	O
.	O

Problem-solving	Educational
counseling	Educational
for	O
caregivers	O
of	O
the	O
cognitively	O
impaired	O
:	O
effective	O
for	O
whom	O
?	O
BACKGROUND	O
Individualized	O
problem-solving	Educational
counseling	Educational
for	O
caregivers	O
of	O
cognitively	O
impaired	O
relatives	O
is	O
thought	O
to	O
help	O
caregivers	O
cope	O
with	O
the	O
stress	O
and	O
burden	O
of	O
caregiving	O
.	O

Few	O
studies	O
have	O
shown	O
the	O
effectiveness	O
of	O
counseling	O
for	O
these	O
caregivers	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
effectiveness	O
of	O
individualized	Educational
problem-solving	Educational
counseling	Educational
by	Educational
nurses	Educational
for	O
caregivers	O
and	O
the	O
expenditures	O
of	O
health	O
care	O
utilization	O
.	O

METHOD	O
Caregivers	O
(	O
n	O
=	O
77	O
)	O
of	O
the	O
cognitively	O
impaired	O
living	O
at	O
home	O
were	O
randomized	O
to	O
receive	O
nurse	Educational
counseling	Educational
or	Educational
not	Control
.	O

Psychosocial	O
adjustment	O
to	O
their	O
relative	O
's	O
illness	O
,	O
psychological	O
distress	O
,	O
burden	O
,	O
coping	O
skills	O
,	O
and	O
expenditures	O
were	O
measured	O
after	O
6	O
months	O
and	O
1	O
year	O
.	O

RESULTS	O
Although	O
on	O
average	O
,	O
all	O
caregivers	O
receiving	O
nurse	Educational
counseling	Educational
indicated	O
no	O
improvement	O
in	O
psychosocial	O
adjustment	O
to	O
their	O
relative	O
's	O
illness	O
,	O
psychological	O
distress	O
,	O
or	O
caregiver	O
burden	O
,	O
they	O
found	O
counseling	O
very	O
helpful	O
and	O
it	O
was	O
effective	O
for	O
a	O
subgroup	O
of	O
caregivers	O
.	O

Those	O
with	O
poor	O
logical	O
analysis	O
coping	O
skills	O
at	O
baseline	O
had	O
decreased	O
psychological	O
distress	O
(	O
F	O
(	O
1,53	O
)	O
=	O
9.7	O
,	O
p	O
=	O
.003	O
)	O
and	O
improved	O
psychosocial	O
adjustment	O
(	O
F	O
(	O
1,53	O
)	O
=	O
4.7	O
,	O
p	O
=	O
.035	O
)	O
after	O
1	O
year	O
.	O

Caregivers	O
in	O
control	Control
and	O
counseling	Educational
groups	O
whose	O
relatives	O
entered	O
a	O
nursing	O
home	O
improved	O
their	O
psychosocial	O
adjustment	O
23	O
%	O
on	O
average	O
whereas	O
those	O
continuing	O
to	O
live	O
in	O
the	O
community	O
decreased	O
by	O
8	O
%	O
.	O

Almost	O
half	O
as	O
many	O
relatives	O
entered	O
nursing	O
homes	O
in	O
the	O
counseling	Educational
group	O
(	O
n	O
=	O
9	O
vs.	O
n	O
=	O
5	O
)	O
but	O
these	O
compared	O
to	O
control	Control
group	O
relatives	O
had	O
greater	O
annualized	O
per	O
person	O
expenditures	O
for	O
health	O
and	O
social	O
services	O
(	O
Cdn	O
$	O
23,437	O
vs.	O
Cdn	O
$	O
15,151	O
)	O
.	O

CONCLUSIONS	O
Caregivers	O
found	O
nurse	Educational
counseling	Educational
most	O
helpful	O
.	O

Those	O
indicating	O
infrequent	O
use	O
of	O
logical	O
analysis	O
coping	O
skills	O
showed	O
benefits	O
.	O

Reversal	O
of	O
skeletal	O
effects	O
of	O
endocrine	O
treatments	O
in	O
the	O
Intergroup	O
Exemestane	O
Study	O
.	O

The	O
adjuvant	O
use	O
of	O
aromatase	Pharmacological
inhibitors	Pharmacological
in	O
breast	O
cancer	O
is	O
associated	O
with	O
adverse	O
effects	O
on	O
bone	O
health	O
.	O

We	O
previously	O
reported	O
a	O
decline	O
in	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
following	O
the	O
switch	O
from	O
tamoxifen	Pharmacological
to	O
exemestane	Pharmacological
in	O
the	O
Intergroup	O
Exemestane	O
Study	O
(	O
IES	O
)	O
.	O

Here	O
we	O
report	O
effects	O
of	O
endocrine	Pharmacological
treatment	Pharmacological
withdrawal	O
on	O
BMD	O
,	O
bone	O
turnover	O
markers	O
(	O
BTM	O
)	O
and	O
fracture	O
rates	O
.	O

4,724	O
patients	O
took	O
part	O
in	O
IES	O
,	O
and	O
206	O
patients	O
were	O
included	O
in	O
a	O
bone	O
sub-study	O
.	O

BMD	O
and	O
BTM	O
were	O
assessed	O
pre-randomization	O
,	O
during	O
and	O
after	O
the	O
end	O
of	O
treatment	O
(	O
EOT	O
)	O
.	O

To	O
evaluate	O
treatment	O
withdrawal	O
effects	O
,	O
12-	O
and	O
24-month	O
post	O
EOT	O
BMD	O
results	O
are	O
available	O
for	O
122	O
and	O
126	O
patients	O
,	O
respectively	O
.	O

Similar	O
patient	O
numbers	O
had	O
BTM	O
measured	O
post	O
EOT	O
.	O

Following	O
treatment	O
withdrawal	O
,	O
the	O
differences	O
in	O
BMD	O
observed	O
between	O
the	O
two	O
endocrine	O
strategies	O
were	O
partially	O
reversed	O
.	O

At	O
24	O
months	O
from	O
EOT	O
,	O
spine	O
BMD	O
increased	O
by	O
1.53	O
%	O
(	O
95	O
%	O
CI	O
0.63-2.43	O
;	O
p	O
=	O
0.001	O
)	O
after	O
stopping	O
exemestane	O
and	O
fell	O
by	O
1.93	O
%	O
(	O
95	O
%	O
CI	O
-2.91	O
to	O
0.95	O
;	O
p	O
=	O
0.0002	O
)	O
following	O
tamoxifen	Pharmacological
withdrawal	O
.	O

A	O
similar	O
pattern	O
of	O
changes	O
was	O
observed	O
at	O
the	O
hip	O
.	O

At	O
2	O
years	O
post	O
EOT	O
,	O
BMD	O
changes	O
from	O
baseline	O
were	O
similar	O
with	O
both	O
treatment	O
strategies	O
.	O

Corresponding	O
inverse	O
changes	O
in	O
BTM	O
were	O
seen	O
,	O
with	O
an	O
increase	O
following	O
tamoxifen	O
withdrawal	O
and	O
a	O
reduction	O
after	O
exemestane	O
.	O

A	O
higher	O
number	O
of	O
fractures	O
occurred	O
during	O
exemestane	Pharmacological
treatment	O
,	O
but	O
fracture	O
rates	O
were	O
similar	O
after	O
treatment	O
withdrawal	O
.	O

With	O
the	O
switch	O
strategy	O
used	O
in	O
IES	O
,	O
the	O
on	O
treatment	O
adverse	O
bone	O
effects	O
of	O
exemestane	Pharmacological
are	O
reversed	O
.	O

Ongoing	O
monitoring	O
of	O
BMD	O
is	O
therefore	O
not	O
routinely	O
required	O
.	O

Influence	O
of	O
SNPs	O
in	O
nutrient-sensitive	O
candidate	O
genes	O
and	O
gene-diet	O
interactions	O
on	O
blood	O
lipids	O
:	O
the	O
DiOGenes	O
study	O
.	O

Blood	O
lipid	O
response	O
to	O
a	O
given	Physical
dietary	Physical
intervention	Physical
could	O
be	O
determined	O
by	O
the	O
effect	O
of	O
diet	O
,	O
gene	O
variants	O
or	O
gene-diet	O
interactions	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
variants	O
in	O
presumed	O
nutrient-sensitive	O
genes	O
involved	O
in	O
lipid	O
metabolism	O
modified	O
lipid	O
profile	O
after	O
weight	O
loss	O
and	O
in	O
response	O
to	O
a	O
given	Pharmacological
diet	Pharmacological
,	O
among	O
overweight	O
European	O
adults	O
participating	O
in	O
the	O
Diet	O
Obesity	O
and	O
Genes	O
study	O
.	O

By	O
multiple	O
linear	O
regressions	O
,	O
240	O
SNPs	O
in	O
twenty-four	O
candidate	O
genes	O
were	O
investigated	O
for	O
SNP	O
main	O
and	O
SNP-diet	O
interaction	O
effects	O
on	O
total	O
cholesterol	O
,	O
LDL-cholesterol	O
,	O
HDL-cholesterol	O
and	O
TAG	O
after	O
an	Physical
8-week	Physical
low-energy	Physical
diet	Physical
(	O
only	O
main	O
effect	O
)	O
,	O
and	O
a	O
6-month	Pharmacological
ad	Pharmacological
libitum	Pharmacological
weight	Pharmacological
maintenance	Pharmacological
diet	Pharmacological
,	O
with	O
different	O
contents	O
of	O
dietary	Pharmacological
protein	Pharmacological
or	O
glycaemic	Pharmacological
index	Pharmacological
.	O

After	O
adjusting	O
for	O
multiple	O
testing	O
,	O
a	O
SNP-dietary	O
protein	O
interaction	O
effect	O
on	O
TAG	O
was	O
identified	O
for	O
lipin	O
1	O
(	O
LPIN1	O
)	O
rs4315495	O
,	O
with	O
a	O
decrease	O
in	O
TAG	O
of	O
20.26	O
mmol/l	O
per	O
A-allele/protein	O
unit	O
(	O
95	O
%	O
CI	O
20.38	O
,	O
20.14	O
,	O
P=0.000043	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
investigated	O
SNP-diet	Pharmacological
interactions	Pharmacological
for	O
blood	O
lipid	O
profiles	O
for	O
240	O
SNPs	O
in	O
twenty-four	O
candidate	O
genes	O
,	O
selected	O
for	O
their	O
involvement	O
in	O
lipid	O
metabolism	O
pathways	O
,	O
and	O
identified	O
one	O
significant	O
interaction	O
between	O
LPIN1	O
rs4315495	O
and	O
dietary	O
protein	O
for	O
TAG	O
concentration	O
.	O

Intranasal	O
recombinant	O
alfa-2b	Pharmacological
interferon	Pharmacological
treatment	O
of	O
naturally	O
occurring	O
common	O
colds	O
.	O

In	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
,	O
patients	O
with	O
naturally	O
occurring	O
common	O
colds	O
of	O
less	O
than	O
or	O
equal	O
to	O
48	O
h	O
duration	O
were	O
randomly	O
assigned	O
to	O
receive	O
nasal	O
sprays	O
of	O
recombinant	Pharmacological
alfa-2b	Pharmacological
interferon	Pharmacological
at	O
10	O
or	O
20	O
MU/day	O
or	O
placebo	Control
four	O
times	O
per	O
day	O
for	O
5	O
days	O
.	O

The	O
10-MU	O
(	O
n	O
=	O
74	O
)	O
,	O
20-MU	O
(	O
n	O
=	O
74	O
)	O
,	O
and	O
placebo	Control
(	O
n	O
=	O
72	O
)	O
groups	O
had	O
comparable	O
frequencies	O
of	O
documented	O
rhinovirus	O
colds	O
(	O
50	O
to	O
65	O
%	O
)	O
and	O
mean	O
durations	O
of	O
pretreatment	O
symptoms	O
(	O
26	O
to	O
27	O
h	O
)	O
.	O

The	O
median	O
duration	O
of	O
colds	O
tended	O
to	O
be	O
longer	O
in	O
the	O
20-MU	O
group	O
(	O
10	O
days	O
)	O
than	O
the	O
10-MU	O
group	O
(	O
8	O
days	O
)	O
or	O
placebo	Control
group	O
(	O
8	O
days	O
)	O
(	O
P	O
=	O
0.06	O
)	O
.	O

In	O
those	O
with	O
proven	O
rhinovirus	O
colds	O
treated	O
within	O
24	O
h	O
,	O
the	O
median	O
duration	O
was	O
significantly	O
longer	O
in	O
the	O
20-MU	O
group	O
(	O
9	O
days	O
)	O
than	O
in	O
the	O
placebo	Control
group	O
(	O
6	O
days	O
)	O
.	O

No	O
differences	O
favoring	O
interferon	O
treatment	O
were	O
found	O
in	O
respiratory	O
symptom	O
scores	O
or	O
resolution	O
of	O
specific	O
symptoms	O
.	O

On	O
days	O
5	O
and	O
7	O
,	O
nasal	Physical
washings	Physical
from	O
compliant	O
subjects	O
with	O
proven	O
rhinovirus	O
colds	O
yielded	O
rhinoviruses	O
more	O
often	O
in	O
placebo	Control
(	O
47	O
and	O
48	O
%	O
,	O
respectively	O
)	O
than	O
in	O
interferon	Pharmacological
(	O
15	O
and	O
16	O
%	O
,	O
respectively	O
)	O
recipients	O
(	O
P	O
less	O
than	O
0.02	O
)	O
,	O
but	O
no	O
differences	O
in	O
new	O
respiratory	O
illness	O
occurrence	O
were	O
observed	O
in	O
household	O
contacts	O
.	O

Interferon	Pharmacological
recipients	O
had	O
significantly	O
higher	O
frequencies	O
of	O
blood	O
in	O
nasal	O
mucus	O
(	O
16	O
to	O
18	O
%	O
)	O
than	O
did	O
placebo	Control
recipients	O
(	O
4	O
%	O
)	O
during	O
treatment	O
.	O

Antibiotics	Pharmacological
for	O
presumed	O
secondary	O
infections	O
were	O
given	O
more	O
often	O
in	O
the	O
20-MU	O
group	O
(	O
11	O
%	O
)	O
than	O
in	O
the	O
placebo	Control
group	O
(	O
0	O
%	O
)	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Nasal	O
sprays	O
of	O
recombinant	O
alfa-2b	Pharmacological
interferon	Pharmacological
were	O
not	O
an	O
effective	O
treatment	O
for	O
natural	O
colds	O
and	O
were	O
associated	O
with	O
toxicity	O
.	O

Sorafenib	Pharmacological
dose	O
escalation	O
is	O
not	O
uniformly	O
associated	O
with	O
blood	O
pressure	O
elevations	O
in	O
normotensive	O
patients	O
with	O
advanced	O
malignancies	O
.	O

Hypertension	O
after	O
treatment	O
with	O
vascular	Physical
endothelial	Physical
growth	Physical
factor	Physical
(	Physical
VEGF	Physical
)	Physical
receptor	O
inhibitors	O
is	O
associated	O
with	O
superior	O
treatment	O
outcomes	O
for	O
advanced	O
cancer	O
patients	O
.	O

To	O
determine	O
whether	O
increased	O
sorafenib	Pharmacological
doses	O
cause	O
incremental	O
increases	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
we	O
measured	O
12-h	O
ambulatory	O
BP	O
in	O
41	O
normotensive	O
advanced	O
solid	O
tumor	O
patients	O
in	O
a	O
randomized	O
dose-escalation	O
study	O
.	O

After	O
7	O
days	O
'	O
treatment	O
(	O
400	O
mg	O
b.i.d	O
.	O

)	O
,	O
mean	O
diastolic	O
BP	O
(	O
DBP	O
)	O
increased	O
in	O
both	O
study	O
groups	O
.	O

After	O
dose	O
escalation	O
,	O
group	O
A	O
(	O
400	O
mg	O
t.i.d	O
.	O

)	O
had	O
marginally	O
significant	O
further	O
increase	O
in	O
12-h	O
mean	O
DBP	O
(	O
P	O
=	O
0.053	O
)	O
,	O
but	O
group	O
B	O
(	O
600	O
mg	O
b.i.d	O
.	O

)	O
did	O
not	O
achieve	O
statistically	O
significant	O
increases	O
(	O
P	O
=	O
0.25	O
)	O
.	O

Within	O
groups	O
,	O
individuals	O
varied	O
in	O
BP	O
response	O
to	O
sorafenib	O
dose	O
escalation	O
,	O
but	O
these	O
differences	O
did	O
not	O
correlate	O
with	O
changes	O
in	O
steady-state	O
plasma	O
sorafenib	O
concentrations	O
.	O

These	O
findings	O
in	O
normotensive	O
patients	O
suggest	O
BP	O
is	O
a	O
complex	O
pharmacodynamic	O
biomarker	O
of	O
VEGF	O
inhibition	O
.	O

Patients	O
have	O
intrinsic	O
differences	O
in	O
sensitivity	O
to	O
sorafenib	O
's	O
BP-elevating	O
effects	O
.	O

Randomized	O
trial	O
of	O
a	O
stage-of-change	Educational
oriented	Educational
smoking	Educational
cessation	Educational
intervention	Educational
in	O
infertile	O
and	O
pregnant	O
women	O
.	O

OBJECTIVE	O
To	O
assess	O
a	O
stage-of-change	Educational
oriented	Educational
smoking	Educational
cessation	Educational
intervention	Educational
for	O
infertile	O
and	O
pregnant	O
women	O
,	O
compared	O
with	O
standard	O
of	O
care	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Three	O
university	O
teaching	O
hospitals	O
in	O
Hamilton	O
,	O
Ontario	O
,	O
Canada	O
.	O

PATIENT	O
(	O
S	O
)	O
Infertile	O
women	O
at	O
their	O
first	O
visit	O
to	O
a	O
tertiary	O
referral	O
infertility	O
clinic	O
(	O
n	O
=	O
94	O
)	O
and	O
new	O
patients	O
seeking	O
pre-natal	O
care	O
(	O
n	O
=	O
110	O
)	O
who	O
had	O
smoked	O
>	O
/=	O
3	O
cigarettes	O
in	O
the	O
past	O
six	O
months	O
.	O

INTERVENTION	O
(	O
S	O
)	O
A	O
three	Educational
to	Educational
five	Educational
minute	Educational
scripted	Educational
intervention	Educational
and	Educational
booklet	Educational
specific	Educational
to	Educational
the	Educational
woman	Educational
's	Educational
stage-of-change	Educational
in	Educational
the	Educational
smoking	Educational
continuum	Educational
,	Educational
versus	Educational
standard	Other
of	Other
care	Other
.	O

Exhaled	Physical
carbon-monoxide	Physical
(	Physical
CO	Physical
)	Physical
monitoring	O
was	O
used	O
to	O
validate	O
exposure	O
in	O
both	O
groups	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Delta	O
stage-of-change	O
and	O
rate	O
of	O
maintained	O
cessation	O
at	O
12	O
months	O
post	O
follow-up	O
.	O

RESULT	O
(	O
S	O
)	O
Intervention	O
and	O
control	O
were	O
similarly	O
effective	O
for	O
infertile	O
women	O
:	O
the	O
rate	O
of	O
maintained	O
cessation	O
rose	O
significantly	O
from	O
4	O
%	O
to	O
24	O
%	O
over	O
twelve	O
months	O
,	O
with	O
a	O
mean	O
delta	O
stage-of-change	O
0.28	O
.	O

In	O
prenatal	O
women	O
,	O
neither	O
approach	O
was	O
effective	O
.	O

Maintained	O
cessation	O
did	O
not	O
significantly	O
change	O
from	O
0	O
to	O
12	O
months	O
(	O
19	O
%	O
to	O
18	O
%	O
)	O
.	O

Mean	O
delta	O
stage-of-change	O
declined	O
by	O
-0.62	O
.	O

CONCLUSION	O
(	O
S	O
)	O
For	O
infertile	O
women	O
,	O
basic	O
information	O
describing	O
the	O
impact	O
of	O
smoking	O
on	O
fertility	O
,	O
along	O
with	O
exhaled	O
CO	O
monitoring	O
and	O
a	O
more	O
intensive	O
intervention	O
were	O
both	O
highly	O
effective	O
.	O

In	O
pregnant	O
women	O
neither	O
approach	O
was	O
beneficial	O
,	O
with	O
some	O
evidence	O
of	O
post-partum	O
relapse	O
.	O

